PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Chin, EY; Nelson, LD; Barr, WB; McCrory, P; McCrea, MA				Chin, Esther Y.; Nelson, Lindsay D.; Barr, William B.; McCrory, Paul; McCrea, Michael A.			Reliability and Validity of the Sport Concussion Assessment Tool-3 (SCAT3) in High School and Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussions; clinical assessments; grading scales; athletic training; Sport Concussion Assessment Tool-3 (SCAT3)	TRAUMATIC BRAIN-INJURY; LINE TEST-PERFORMANCE; BASE-LINE; NEUROPSYCHOLOGICAL ASSESSMENT; INTERNATIONAL-CONFERENCE; STANDARDIZED ASSESSMENT; NORMATIVE DATA; CONSENSUS STATEMENT; POSTURAL STABILITY; SYMPTOMS	Background: The Sport Concussion Assessment Tool-3 (SCAT3) facilitates sideline clinical assessments of concussed athletes. Yet, there is little published research on clinically relevant metrics for the SCAT3 as a whole. Purpose: We documented the psychometric properties of the major SCAT3 components (symptoms, cognition, balance) and derived clinical decision criteria (ie, reliable change score cutoffs and normative conversation tables) for clinicians to apply to cases with and without available preinjury baseline data. Study Design: Cohort study (diagnosis); Level of evidence, 2. Methods: High school and collegiate athletes (N = 2018) completed preseason baseline evaluations including the SCAT3. Re-evaluations of 166 injured athletes and 164 noninjured controls were performed within 24 hours of injury and at 8, 15, and 45 days after injury. Analyses focused on predictors of baseline performance, test-retest reliability, and sensitivity and specificity of the SCAT3 using either single postinjury cutoffs or reliable change index (RCI) criteria derived from this sample. Results: Athlete sex, level of competition, attention-deficit/hyperactivity disorder (ADHD), learning disability (LD), and estimated verbal intellectual ability (but not concussion history) were associated with baseline scores on 1 SCAT3 components (small to moderate effect sizes). Female sex, high school level of competition (vs college), and ADHD were associated with higher baseline symptom ratings (d = 0.25-0.32). Male sex, ADHD, and LD were associated with lower baseline Standardized Assessment of Concussion (SAC) scores (d = 0.28-0.68). Male sex, high school level of competition, ADHD, and LD were associated with poorer baseline Balance Error Scoring System (BESS) performance (d = 0.14-0.26). After injury, the symptom checklist manifested the largest effect size at the 24-hour assessment (d = 1.52), with group differences diminished but statistically significant at day 8 (d = 0.39) and nonsignificant at day 15. Effect sizes for the SAC and BESS were small to moderate at 24 hours (SAC: d = -0.36; modified BESS: d = 0.46; full BESS: d = 0.51) and became nonsignificant at day 8 (SAC) and day 15 (BESS). Receiver operating characteristic curve analyses demonstrated a stronger discrimination for symptoms (area under the curve [AUC] = 0.86) than cognitive and balance measures (AUCs = 0.58 and 0.62, respectively), with comparable discrimination of each SCAT3 component using postinjury scores alone versus baseline-adjusted scores (P = .71-.90). Normative conversion tables and RCI criteria were created to facilitate the use of the SCAT3 both with and without baseline test results. Conclusion: Individual predictors should be taken into account when interpreting the SCAT3. The normative conversion tables and RCIs presented can be used to help interpret concussed athletes' performance both with and without baseline data, given the comparability of the 2 interpretative approaches.	[Chin, Esther Y.; Nelson, Lindsay D.; Barr, William B.; McCrory, Paul; McCrea, Michael A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Chin, Esther Y.] AMITA Hlth, Alexian Bros Neurosci Inst, Elk Grove Village Hoffman Estates, Hoffman Estates, IL USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, 8701 West Watertown Planck Rd, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, 8701 West Watertown Planck Rd, Milwaukee, WI 53226 USA; [Barr, William B.] NYU, Sch Med, Dept Neurol, New York, NY USA; [McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia	Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 West Watertown Planck Rd, Milwaukee, WI 53226 USA.; Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurol, 8701 West Watertown Planck Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568; Barr, William/0000-0001-7711-7758	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973(-01)]; National Center for Advancing Translational Sciences/National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8UL1TR000055]; International Olympic Committee; Axon Sports (US); Cogstate Inc.; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	This work was supported by the US Army Medical Research and Materiel Command under award number W81XWH-12-1-0004. This publication was also supported by the Clinical and Translational Science Institute grant 1UL1-RR031973(-01) and by the National Center for Advancing Translational Sciences/National Institutes of Health grant 8UL1TR000055. P.M. is a co-investigator, collaborator, or consultant on grants relating to mild traumatic brain injuries (TBIs) funded by several governmental organizations. He is directly employed by the National Health and Medical Research Council of Australia and is based at the Florey Institute of Neuroscience and Mental Health. He is a co-chair of the Australian Centre for Research into Injury in Sport and its Prevention, which is one of the Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee. He is a co-chair of the International Concussion in Sport Group. He has a clinical and consulting practice in general and sports neurology. He receives book royalties from McGraw-Hill and was employed in an editorial capacity by the British Medical Journal Publishing Group (2001-2008). He has been reimbursed by the government, professional scientific bodies, and sporting bodies for travel costs related to presenting research on mild TBIs and sport-related concussions at meetings, scientific conferences, and symposiums. He received consultancy fees in 2010 from Axon Sports (US) for the development of educational material (which was not renewed) and has received research funding since 2001 from Cogstate Inc. He has not received any research funding, salary, or other monies from the Australian Football League (AFL), Federation Internationale de Football Association, or National Football League. The AFL funds research at the Florey Institute under a legal memorandum; P.M. does not receive any money from this industry-funded research. P.M. serves on the AFL Concussion Working Group in an honorary capacity. He is a co-founder and shareholder in 2 biomedical companies (involved in eHealth and compression garment technologies) but does not hold any individual shares in any company related to concussion or brain injury assessments or technologies. He did not receive any form of financial support directly related to this article.	[Anonymous], 2000, Am J Sports Med, V28, P440; Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brown CN, 2007, J ATHL TRAINING, V42, P515; Bruce JM, 2004, NEUROLOGY, V63, P1516; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; DeRight J, 2015, CHILD NEUROPSYCHOL, V21, P1, DOI 10.1080/09297049.2013.864383; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Griffin LY, 2003, MED SCI SPORT EXER, V35, P1785; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Helmick K, 2006, DEFENSE VETERANS BRA; Herring SA, 2002, MED SCI SPORT EXER, V34, P1212; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2015, BRAIN INJURY, V29, P263, DOI 10.3109/02699052.2014.965214; Jerrell JM, 2015, EUR CHILD ADOLES PSY, V24, P65, DOI 10.1007/s00787-014-0541-z; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maassen GH, 2004, J INT NEUROPSYCH SOC, V10, P888, DOI 10.1017/S1355617704106097; Margari L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-198; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Moser RS, 2015, APPL NEUROPSYCH-CHIL, V4, P41, DOI 10.1080/21622965.2013.791825; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Parisi P, 2014, EPILEPSY BEHAV, V32, P72, DOI 10.1016/j.yebeh.2013.12.028; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Rahn C, 2015, CLIN J SPORT MED, V25, P248, DOI 10.1097/JSM.0000000000000141; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2014, ARCH CLIN NEUROPSYCH, V29, P625, DOI 10.1093/arclin/acu041; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Susco TM, 2004, J ATHL TRAINING, V39, P241; Zottoli TM, 2015, CLIN NEUROPSYCHOL, V29, P678, DOI 10.1080/13854046.2015.1062562; 2001, MED SCI SPORTS EXERC, V33, P846	58	105	105	0	43	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP	2016	44	9					2276	2285		10.1177/0363546516648141			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DV6CU	WOS:000383019300016	27281276				2021-06-18	
J	Vespa, P; Tubi, M; Claassen, J; Buitrago-Blanco, M; McArthur, D; Velazquez, AG; Tu, B; Prins, M; Nuwer, M				Vespa, Paul; Tubi, Meral; Claassen, Jan; Buitrago-Blanco, Manuel; McArthur, David; Velazquez, Angela G.; Tu, Bin; Prins, Mayumi; Nuwer, Marc			Metabolic crisis occurs with seizures and periodic discharges after brain trauma	ANNALS OF NEUROLOGY			English	Article							CEREBRAL PERFUSION-PRESSURE; SUBARACHNOID HEMORRHAGE; NONCONVULSIVE SEIZURES; STATUS EPILEPTICUS; INJURY; MICRODIALYSIS; ELECTROENCEPHALOGRAPHY; ISCHEMIA; INCREASE	ObjectiveTraumatic brain injury (TBI) results in persistent disruption of brain metabolism that has yet to be mechanistically defined. Early post-traumatic seizures are one potential mechanism for metabolic crisis and hence could be a therapeutic target. We hypothesized that seizures and pseudoperiodic discharges (PDs) may be mechanistically linked to metabolic crisis as measured by cerebral microdialysis. MethodsA prospective multicenter study of surface and intracortical depth electroencephalography (EEG) was performed in conjunction with cerebral microdialysis in a cohort of severe TBI patients with time-locked analysis of the neurochemical response to seizures and pseudoperiodic discharges. ResultsSeizures or PDs occurred in 61% of 34 subjects, with 42.9% of these seizures noted only on intracortical depth EEG and in some cases lasting for many hours. Metabolic crisis as measured by elevated cerebral microdialysis lactate/pyruvate ratio occurred during seizures or PDs but not during electrically nonepileptic epochs. InterpretationIn TBI patients, seizures and periodic discharges are one mechanism for metabolic crisis, and hence represent a therapeutic target for future study. Ann Neurol 2016;79:579-590	[Vespa, Paul; Tubi, Meral; McArthur, David; Prins, Mayumi] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA; [Claassen, Jan; Velazquez, Angela G.; Tu, Bin] Columbia Univ, New York, NY USA; [Buitrago-Blanco, Manuel] Univ Calif Los Angeles, Med Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA; [Nuwer, Marc] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA	Vespa, P (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, 757 Westwood Blvd,Room 6236A, Los Angeles, CA 90095 USA.	PVespa@mednet.ucla.edu	Claassen, Jan/AAA-5451-2020	Tubi, Meral/0000-0003-0435-8352	NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS03039, NS058489, PT074268, NS049471]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049471, P01NS058489] Funding Source: NIH RePORTER	This study was funded by the NIH National Institute of Neurological Disorders and Stroke (NS03039, NS058489, PT074268, NS049471).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Claassen J, 2014, ANN NEUROL, V75, P771, DOI 10.1002/ana.24166; Claassen J, 2013, ANN NEUROL, V74, P53, DOI 10.1002/ana.23859; Dreier JP, 2013, ACTA NEUROCHIR SUPPL, V115, P125, DOI 10.1007/978-3-7091-1192-5_26; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Ko SB, 2011, ARCH NEUROL-CHICAGO, V68, P1323, DOI 10.1001/archneurol.2011.240; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721	17	105	108	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	APR	2016	79	4					579	590		10.1002/ana.24606			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DJ2AM	WOS:000374006100008	26814699				2021-06-18	
J	Akhtar, A				Akhtar, Aysha			The Flaws and Human Harms of Animal Experimentation	CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS			English	Article						animal research; medical testing; human health; human ethics; drug development; animal ethics	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; CLINICAL-TRIALS; POSTMENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; MODELS; STROKE; MOUSE; DRUGS; TRANSLATION	Nonhuman animal ("animal") experimentation is typically defended by arguments that it is reliable, that animals provide sufficiently good models of human biology and diseases to yield relevant information, and that, consequently, its use provides major human health benefits. I demonstrate that a growing body of scientific literature critically assessing the validity of animal experimentation generally (and animal modeling specifically) raises important concerns about its reliability and predictive value for human outcomes and for understanding human physiology. The unreliability of animal experimentation across a wide range of areas undermines scientific arguments in favor of the practice. Additionally, I show how animal experimentation often significantly harms humans through misleading safety studies, potential abandonment of effective therapeutics, and direction of resources away from more effective testing methods. The resulting evidence suggests that the collective harms and costs to humans from animal experimentation outweigh potential benefits and that resources would be better invested in developing human-based testing methods.	Oxford Ctr Anim Eth, Oxford, England	Akhtar, A (corresponding author), Oxford Ctr Anim Eth, Oxford, England.						Akhtar A, 2012, ANIMALS PUBLIC HLTH; Akhtar AZ, 2008, REV NEUROSCIENCE, V19, P47; Akhtar AZ, 2009, ATLA-ALTERN LAB ANIM, V37, P43, DOI 10.1177/026119290903700108; Allen A., 2006, SLATE; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 2003, NAT REV DRUG DISCOV, V2, P167; Attarwala H, 2010, J Young Pharm, V2, P332, DOI 10.4103/0975-1483.66810; Bailey J, 2008, ATLA-ALTERN LAB ANIM, V36, P381, DOI 10.1177/026119290803600403; Bailey Jarrod, 2005, Biogenic Amines, V19, P235, DOI 10.1163/156939105774647385; Balcombe JP, 2004, CONTEMP TOP LAB ANIM, V43, P42; Baldwin A, 2007, NEW SCI, V194, P24, DOI 10.1016/S0262-4079(07)61358-X; Benatar M, 2007, NEUROBIOL DIS, V26, P1, DOI 10.1016/j.nbd.2006.12.015; Blander J., 2002, DRUG DISCOVERY W FAL, P33; Cavanaugh S, 2014, ALTEX; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; Curry SH, 2003, ANN NY ACAD SCI, V993, P69, DOI 10.1111/j.1749-6632.2003.tb07512.x; DeGrazia D, 1996, TAKING ANIMALS SERIO, P116; Degryse AL, 2011, AM J MED SCI, V341, P444, DOI 10.1097/MAJ.0b013e31821aa000; Dirnagl U, 2006, J CEREBR BLOOD F MET, V26, P1465, DOI 10.1038/sj.jcbfm.9600298; Farber N, DRUG DEV BRAIN INJUR; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; FLETCHER AP, 1978, J ROY SOC MED, V71, P693, DOI 10.1177/014107687807100915; Flow BL, 1997, CONTEMP TOP LAB ANIM, V36, P65; Gawrylewski A, 2007, SCIENTIST, V21, P44; Godlee F., 2014, BMJ-BRIT MED J, V348, pg3719, DOI DOI 10.1136/BMJ.G3719; Greek R, 2000, JAMA-J AM MED ASSOC, V283, P743, DOI 10.1001/jama.283.6.743; Greek Ray, 2010, Philos Ethics Humanit Med, V5, P14, DOI 10.1186/1747-5341-5-14; Guttman-Yassky E, 2007, BRIT J DERMATOL, V157, P1103, DOI 10.1111/j.1365-2133.2007.08135.x; Harding A., 2004, SCIENTIST; Hart PC, 2010, NEUROSCI RES PROG SE, P71; Hartung T, 2012, ALTEX-ALTERN ANIM EX, V29, P251, DOI 10.14573/altex.2012.3.251; Hartung T, 2009, ATLA-ALTERN LAB ANIM, V37, P45, DOI 10.1177/026119290903702S10; HEYWOOD R, 1981, TOXICOL LETT, V8, P349, DOI 10.1016/0378-4274(81)90125-9; Hogan RJ, 2006, PLOS MED, V3, P1656, DOI 10.1371/journal.pmed.0030411; Horrobin DF, 2003, NAT REV DRUG DISCOV, V2, P151, DOI 10.1038/nrd1012; Institute of Medicine, 2013, IMPR UT TRANSL AN MO; Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267; Jucker M, 2010, NAT MED, V16, P1210, DOI 10.1038/nm.2224; KOPPANYI T, 1966, CLIN PHARMACOL THER, V7, P250; LaFollette H., 2011, OXFORD HDB ANIMAL ET, P812; Lane E, 2008, PSYCHOPHARMACOLOGY, V199, P303, DOI 10.1007/s00213-007-0931-8; Leist M, 2013, ARCH TOXICOL, V87, P563, DOI 10.1007/s00204-013-1038-0; Lemere CA, 2009, PROG BRAIN RES, V175, P83, DOI 10.1016/S0079-6123(09)17506-4; Lemon R, 2005, BMJ-BRIT MED J, V330, P977, DOI 10.1136/bmj.330.7498.977; Lonjon N, 2009, J NEUROSCI RES, V87, P403, DOI 10.1002/jnr.21871; Lutz C, 2003, AM J PRIMATOL, V60, P1, DOI 10.1002/ajp.10075; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Macleod MR, 2004, STROKE, V35, P1203, DOI 10.1161/01.STR.0000125719.25853.20; Mak IWY, 2014, AM J TRANSL RES, V6, P114; Matthews RAJ, 2008, J ROY SOC MED, V101, P95, DOI 10.1258/jrsm.2007.070164; Mogil JS, 1999, PAIN, V80, P67, DOI 10.1016/S0304-3959(98)00197-3; Monastersky R., 2008, CHRON HIGHER EDUC, P54; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morgan KN, 2007, APPL ANIM BEHAV SCI, V102, P262, DOI 10.1016/j.applanim.2006.05.032; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; O'Neil BJ, 1999, ACAD EMERG MED, V6, P75, DOI 10.1111/j.1553-2712.1999.tb00099.x; Odom DT, 2007, NAT GENET, V39, P730, DOI 10.1038/ng2047; Perel P, 2007, BMJ-BRIT MED J, V334, P197, DOI 10.1136/bmj.39048.407928.BE; Perrin S, 2014, NATURE, V507, P423, DOI 10.1038/507423a; Pippin JJ, 2013, S TEXAS LAW REV, V54, P469; Pound P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3387; Roberts I, 2002, BRIT MED J, V324, P474, DOI 10.1136/bmj.324.7335.474; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sams-Dodd F, 2006, DRUG DISCOV TODAY, V11, P355, DOI 10.1016/j.drudis.2006.02.005; Schneider LS, 2014, J INTERN MED, V275, P251, DOI 10.1111/joim.12191; SCHNEIERSON SS, 1956, P SOC EXP BIOL MED, V91, P229, DOI 10.3181/00379727-91-22221; Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Shanks Niall, 2009, Philos Ethics Humanit Med, V4, P2, DOI 10.1186/1747-5341-4-2; Sinha G, 2013, NAT BIOTECHNOL, V31, P185; Suckow MA, 2006, LAB RAT, P323; Tator CH, 2012, J NEUROSURG-SPINE, V17, P157, DOI 10.3171/2012.5.AOSPINE12116; Taylor K, 2008, ATLA-ALTERN LAB ANIM, V36, P327, DOI 10.1177/026119290803600310; Tonks A, 2007, BMJ-BRIT MED J, V334, P1346, DOI 10.1136/bmj.39240.416968.AD; Traynor BJ, 2006, NEUROLOGY, V67, P20, DOI 10.1212/01.wnl.0000223353.34006.54; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245; Vassilopoulos S, 2009, SCIENCE, V324, P1192, DOI 10.1126/science.1171529; Wadman M., 2012, NATURE NEWS BLOG; Wall RJ, 2008, THERIOGENOLOGY, V69, P2, DOI 10.1016/j.theriogenology.2007.09.030; Wang MM, 2013, TRANSL STROKE RES, V4, P3, DOI 10.1007/s12975-012-0219-0; WIEBERS DO, 1990, STROKE, V21, P1; Wilkins HM, 2011, HORIZONS NEUROSC RES, V5, P1; Woodroofe A, 2007, GENETIC ENG BIOTECHN, V27, P18; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zurlo J, 2012, HASTINGS CENT REP, V42, pS23, DOI 10.1002/hast.104	85	105	106	10	121	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0963-1801	1469-2147		CAMB Q HEALTHC ETHIC	Camb. Q. Healthc. Ethics	OCT	2015	24	4					407	419		10.1017/S0963180115000079			13	Health Care Sciences & Services; Health Policy & Services; Social Sciences, Biomedical	Health Care Sciences & Services; Biomedical Social Sciences	CR7YX	WOS:000361569300004	26364776	Green Published, Bronze	Y	N	2021-06-18	
J	Mobashsher, AT; Abbosh, AM; Wang, YF				Mobashsher, Ahmed Toaha; Abbosh, Amin M.; Wang, Yifan			Microwave System to Detect Traumatic Brain Injuries Using Compact Unidirectional Antenna and Wideband Transceiver With Verification on Realistic Head Phantom	IEEE TRANSACTIONS ON MICROWAVE THEORY AND TECHNIQUES			English	Article						Directional antenna; head imaging; head phantom; microwave imaging	MODELING HUMAN HEAD; DIRECTIONAL ANTENNA; RADAR; TISSUES; SENSOR; BODY	A portable microwave system to detect traumatic brain injuries is described. The wideband system utilizes a unidirectional antenna, microwave transceiver, and processing and image reconstruction algorithms. The utilized antenna is designed to have a compact three-dimensional (3-D) structure using a slotted dipole element and a folded parasitic structure. It attains directional radiation patterns with an average 9-dB front-to-back ratio and 102.2% fractional bandwidth covering the band 1.1-3.4 GHz, which is suitable for head imaging. To test the system, a realistic head phantom, which attains accurate internal and external anatomical structure and electrical properties, is fabricated by a 3-D printer using a detailed numerical model. Targets imitating the properties of bleeding are inserted at different positions in the fabricated head phantom to emulate brain injury scenarios. The integrated system is used in a virtual arrayed monostatic radar approach to detect the injuries. Using data sets recorded at 32 antenna positions around the head, a back projection algorithm is used to generate images of the scanned head. The achieved results demonstrate the feasibility of such a system as a portable module for brain injuries detection.	[Mobashsher, Ahmed Toaha; Abbosh, Amin M.; Wang, Yifan] Univ Queensland, Sch ITEE, Brisbane, Qld 4072, Australia	Mobashsher, AT (corresponding author), Univ Queensland, Sch ITEE, Brisbane, Qld 4072, Australia.	a.mobashsher@uq.edu.au	Abbosh, Amin/C-3944-2009; Mobashsher, Ahmed Toaha/H-6341-2019	Abbosh, Amin/0000-0002-8015-5883; Mobashsher, Ahmed Toaha/0000-0002-6351-8136	ARCAustralian Research Council [DP120101214]	This work was supported by ARC Discovery under Grant DP120101214. This paper is an expanded version from the IEEE MTT-S International Microwave Workshop Series on RF and Wireless Technologies for Biomedical and Healthcare Applications, Singapore, Dec. 9-11, 2013.	Akter M, 2007, ACAD RADIOL, V14, P1011, DOI 10.1016/j.acra.2007.05.013; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Bassi M, 2013, IEEE T MICROW THEORY, V61, P2108, DOI 10.1109/TMTT.2013.2247052; Bialkowski M, 2010, ASIA PACIF MICROWAVE, P267; Callaway J., 2013, RISK, V29, P72; Coronado VG, 2011, SURVEILLANCE TRAUMAT; Fhager A., 2012, Proceedings of the 2012 6th European Conference on Antennas and Propagation (EuCAP), P1796, DOI 10.1109/EuCAP.2012.6206715; Gabriel S, 1996, PHYS MED BIOL, V41, P2271, DOI 10.1088/0031-9155/41/11/003; Guarnieri Massimo, 2010, 2010 14th Biennial IEEE Conference on Electromagnetic Field Computation (CEFC 2010), DOI 10.1109/CEFC.2010.5481709; Hofmann M, 2013, IEEE T MICROW THEORY, V61, P2195, DOI 10.1109/TMTT.2013.2250516; Ireland D, 2013, IEEE T ANTENN PROPAG, V61, P2352, DOI 10.1109/TAP.2013.2242037; Jalilvand M, 2014, ELECTRON LETT, V50, P255, DOI 10.1049/el.2013.4078; Jalilvand M, 2011, IEEE NATL RADAR CONF, P956; Karanasiou IS, 2004, IEEE T MICROW THEORY, V52, P1898, DOI 10.1109/TMTT.2004.831999; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Klemm M, 2005, IEEE T ANTENN PROPAG, V53, P3884, DOI 10.1109/TAP.2005.859906; Li XY, 2014, IEEE T ANTENN PROPAG, V62, P1808, DOI 10.1109/TAP.2013.2297158; Li YT, 2011, IEEE ANTENN WIREL PR, V10, P1397, DOI 10.1109/LAWP.2011.2178810; Meng X, 2013, IEEE T MICROW THEORY, V61, P316, DOI 10.1109/TMTT.2012.2224361; Mercuri M, 2013, IEEE T MICROW THEORY, V61, P2061, DOI 10.1109/TMTT.2013.2247619; Mobashsher AT, 2014, ELECTRON LETT, V50, P850, DOI 10.1049/el.2014.0616; Mobashsher AT, 2014, ELECTRON LETT, V50, P246, DOI 10.1049/el.2013.3909; Mobashsher AT, 2014, IET MICROW ANTENNA P, V8, P171, DOI 10.1049/iet-map.2013.0374; Mobashsher AT, 2013, P IEEE MTT S INT MIC, P1, DOI DOI 10.1109/IMWS-BIO.2013.6756149; Mohammed B, 2012, P INT C DIG IM COMP, P1; Mohammed B. J., 2011, Proceedings of the 2011 Seventh International Conference on Intelligent Sensors, Sensor Networks and Information Processing (ISSNIP), P17, DOI 10.1109/ISSNIP.2011.6146567; Mohammed BJ, 2014, MICROW OPT TECHN LET, V56, P979, DOI 10.1002/mop.28229; Mohammed BJ, 2014, IEEE T INSTRUM MEAS, V63, P117, DOI 10.1109/TIM.2013.2277562; Mustafa S, 2013, IEEE ANTENN WIREL PR, V12, P460, DOI 10.1109/LAWP.2013.2255095; Mustafa S, 2014, IEEE T ANTENN PROPAG, V62, P1354, DOI 10.1109/TAP.2013.2296323; Mustafa S, 2012, CAIRO INT BIOM ENG, P194, DOI 10.1109/CIBEC.2012.6473328; Park SW, 2013, IEEE T MICROW THEORY, V61, P2153, DOI 10.1109/TMTT.2013.2247211; Scapaticci R., 2012, Progress In Electromagnetics Research B, V40, P305; Schwerdt HN, 2013, IEEE T MICROW THEORY, V61, P2170, DOI 10.1109/TMTT.2013.2252916; Semenov SY, 2008, INT J ANTENN PROPAG, V2008, DOI 10.1155/2008/254830; Sperandio M, 2012, IEEE T BIO-MED ENG, V59, P383, DOI 10.1109/TBME.2011.2173197; Thotahewa KMS, 2013, IEEE T MICROW THEORY, V61, P2161, DOI 10.1109/TMTT.2013.2250515; Wang YF, 2014, IEEE T ANTENN PROPAG, V62, P698, DOI 10.1109/TAP.2013.2289355; Yarovoy AG, 2007, IEEE T MICROW THEORY, V55, P1288, DOI 10.1109/TMTT.2007.896791	39	105	105	6	25	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9480	1557-9670		IEEE T MICROW THEORY	IEEE Trans. Microw. Theory Tech.	SEP	2014	62	9			SI		1826	1836		10.1109/TMTT.2014.2342669			11	Engineering, Electrical & Electronic	Engineering	AT5NU	WOS:000344990400002					2021-06-18	
J	Alali, AS; Fowler, RA; Mainprize, TG; Scales, DC; Kiss, A; de Mestral, C; Ray, JG; Nathens, AB				Alali, Aziz S.; Fowler, Robert A.; Mainprize, Todd G.; Scales, Damon C.; Kiss, Alexander; de Mestral, Charles; Ray, Joel G.; Nathens, Avery B.			Intracranial Pressure Monitoring in Severe Traumatic Brain Injury: Results from the American College of Surgeons Trauma Quality Improvement Program	JOURNAL OF NEUROTRAUMA			English	Article						head injury; intracranial pressure; multilevel analysis; traumatic brain injury	BRIEF CONCEPTUAL TUTORIAL; SOCIAL EPIDEMIOLOGY; MULTILEVEL ANALYSIS; HEAD TRAUMA; MORTALITY; OUTCOMES; CARE; MANAGEMENT; HEALTH; TRIALS	Although existing guidelines support the utilization of intracranial pressure (ICP) monitoring in patients with traumatic brain injury (TBI), the evidence suggesting benefit is limited. To evaluate the impact on outcome, we determined the relationship between ICP monitoring and mortality in centers participating in the American College of Surgeons Trauma Quality Improvement Program (TQIP). Data on 10,628 adults with severe TBI were derived from 155 TQIP centers over 2009-2011. Random-intercept multilevel modeling was used to evaluate the association between ICP monitoring and mortality after adjusting for important confounders. We evaluated this relationship at the patient level and at the institutional level. Overall mortality (n=3769) was 35%. Only 1874 (17.6%) patients underwent ICP monitoring, with a mortality of 32%. The adjusted odds ratio (OR) for mortality was 0.44 [95% confidence interval (CI), 0.31-0.63], when comparing patients with ICP monitoring to those without. It is plausible that patients receiving ICP monitoring were selected because of an anticipated favorable outcome. To overcome this limitation, we stratified hospitals into quartiles based on ICP monitoring utilization. Hospitals with higher rates of ICP monitoring use were associated with lower mortality: The adjusted OR of death was 0.52 (95% CI, 0.35-0.78) in the quartile of hospitals with highest use, compared to the lowest. ICP monitoring utilization rates explained only 9.9% of variation in mortality across centers. Results were comparable irrespective of the method of case-mix adjustment. In this observational study, ICP monitoring utilization was associated with lower mortality. However, variability in ICP monitoring rates contributed only modestly to variability in institutional mortality rates. Identifying other institutional practices that impact on mortality is an important area for future research.	[Alali, Aziz S.; Fowler, Robert A.; Scales, Damon C.; Kiss, Alexander; de Mestral, Charles; Nathens, Avery B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Fowler, Robert A.; Scales, Damon C.; Kiss, Alexander; Ray, Joel G.; Nathens, Avery B.] Univ Toronto, Clin Epidemiol Program, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Alali, Aziz S.] Univ Ottawa, Div Neurosurg, Ottawa, ON, Canada; [Fowler, Robert A.; Scales, Damon C.] Sunnybrook Hlth Sci Ctr, Dept Crit Care, Toronto, ON M4N 3M5, Canada; [Fowler, Robert A.; Scales, Damon C.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Mainprize, Todd G.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Neurosurg, Toronto, ON, Canada; [Kiss, Alexander] Sunnybrook Hlth Sci Ctr, Dept Res Design & Biostat, Toronto, ON M4N 3M5, Canada; [Ray, Joel G.; Nathens, Avery B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Ray, Joel G.] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; [de Mestral, Charles; Nathens, Avery B.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON, Canada	Alali, AS (corresponding author), Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, 2075 Bayview Ave,Room D-574, Toronto, ON M4N 3M5, Canada.	aziz.alali@mail.utoronto.ca			Physicians' Services Inc. Foundation; Canada Research Chair Program in Systems of Trauma Care; Heart and Stroke Foundation Clinician Scientist Award; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This work was supported, in part, by funds from the Physicians' Services Inc. Foundation (to A. S. A.) and a Canada Research Chair Program in Systems of Trauma Care (to A.B.N.). R. A. F. was supported by a Heart and Stroke Foundation Clinician Scientist Award. D. C. S. was supported by a New Investigator Award from the Canadian Institutes of Health Research.	Akopian G, 2007, AM SURGEON, V73, P447; Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Carney N, 2012, J NEUROTRAUM, V29, P2022, DOI 10.1089/neu.2011.2019; Chesnut R, 2011, J NEUROTRAUM, V28, pA111; Chesnut RM, 2008, J TRAUMA, V65, P500, DOI 10.1097/TA.0b013e31818020b3; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chesnut RM, 2012, NEUROSURGERY, V71, P1055, DOI 10.1227/NEU.0b013e31827276b7; Citerio G, 2008, INTENS CARE MED, V34, P1173, DOI 10.1007/s00134-008-1080-1; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Coronado V. G., 2012, EPIDEMIOLOG IN PRESS; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Finney JW, 2011, AM J PUBLIC HEALTH, V101, P1635, DOI 10.2105/AJPH.2011.300153; GUILLAUME J, 1951, REV NEUROL, V84, P131; Harris OA, 2008, J NEUROSURG, V109, P433, DOI 10.3171/JNS/2008/109/9/0433; Hemmila MR, 2010, J TRAUMA, V68, P253, DOI 10.1097/TA.0b013e3181cfc8e6; Lane PL, 2000, CAN J SURG, V43, P442; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; Lingsma HF, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-201; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P729, DOI 10.1136/jech.2004.023929; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Mittlbock M, 1996, STAT MED, V15, P1987, DOI 10.1002/(SICI)1097-0258(19961015)15:19<1987::AID-SIM318>3.0.CO;2-9; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Salim A, 2008, AM SURGEON, V74, P1088; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shafi S, 2009, J AM COLL SURGEONS, V209, P521, DOI 10.1016/j.jamcollsurg.2009.07.001; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Wijeysundera DN, 2012, ANESTHESIOLOGY, V116, P25, DOI 10.1097/ALN.0b013e31823cfc03; Yang D., 2012, 3352012 SAS	50	105	110	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1737	1746		10.1089/neu.2012.2802			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000006	23731257	Green Published			2021-06-18	
J	Cao, T; Thomas, TC; Ziebell, JM; Pauly, JR; Lifshitz, J				Cao, T.; Thomas, T. C.; Ziebell, J. M.; Pauly, J. R.; Lifshitz, J.			MORPHOLOGICAL AND GENETIC ACTIVATION OF MICROGLIA AFTER DIFFUSE TRAUMATIC BRAIN INJURY IN THE RAT	NEUROSCIENCE			English	Article						classical activation; alternate activation; anti-inflammatory; neuroplasticity	CLOSED-HEAD INJURY; NEURONAL INJURY; NEUTROPHIL INFILTRATION; ALTERNATIVE ACTIVATION; AXON REGENERATION; MYELOID CELLS; SPINAL-CORD; LATE-ONSET; EXPRESSION; MACROPHAGES	Traumatic brain injury (TBI) survivors experience long-term post-traumatic morbidities. In diffuse brain-injured rats, a chronic sensory sensitivity to whisker stimulation models the agitation of TBI survivors and provides anatomical landmarks across the whisker-barrel circuit to evaluate post-traumatic neuropathology. As a consequence of TBI, acute and chronic microglial activation can contribute to degenerative and reparative events underlying post-traumatic morbidity. Here we hypothesize that a temporal sequence of microglial activation states contributes to the circuit pathology responsible for post-traumatic morbidity, and test the hypothesis by examining microglial morphological activation and neuroinflammatory markers for activation states through gene expression and receptor-binding affinity. Adult male, Sprague-Dawley rats were subjected to a single moderate midline fluid percussion injury (FPI) or sham injury. Microglial activation was determined by immunohistochemistry, quantitative real-time PCR and receptor autoradiography in the primary somatosensory barrel field (S1BF) and ventral posterior medial nucleus (VPM) of the thalamus at 7 and 28 days following FPI. Morphological changes indicative of microglial activation, including swollen cell body with thicker, shrunken processes, were evident in S1BF and VPM at 7 and 28 days post-injury. Principally at 7 days post-injury in VPM, general inflammatory gene expression (major histocompatibility complex I, major histocompatibility complex II, translocator protein 18 kDa [TSPO]) is increased above sham level and TSPO gene expression confirmed by receptor autoradiography. Further, CD45, a marker of classical activation, and TGF-beta I, an acquired deactivation marker, were elevated significantly above sham at 7 days post-injury. Daily administration of the anti-inflammatory ibuprofen (20 mg/kg, i.p.) significantly reduced the expression of these genes. Evidence for alternative activation (arginase 1) was not observed. Thus, these data demonstrate concomitant classical activation and acquired deactivation phenotypes of microglia in diffuse TBI in the absence of overt contusion or cavitation. Antiinflammatory treatment may further alleviate the neuropathological burden of post-traumatic inflammation. (C) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Cao, T.] Univ Kentucky, Coll Art & Sci, Dept Biol, Lexington, KY USA; [Cao, T.; Thomas, T. C.; Ziebell, J. M.; Pauly, J. R.; Lifshitz, J.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Pauly, J. R.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA; [Lifshitz, J.] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Lifshitz, J.] Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Lexington, KY USA	Lifshitz, J (corresponding author), Univ Arizona, Phoenix Childrens Hosp, Phoenix VA Hlth Care Syst, Barrow Neurol Inst,Dept Child Hlth,Coll Med Phoen, 3rd Floor,Ambulatory B Bldg,1919 E Thomas Rd, Phoenix, AZ 85016 USA.	JLifshitz@email.arizona.edu	Ziebell, Jenna/Y-4496-2019; Thomas, Theresa Currier/K-1979-2019	Thomas, Theresa Currier/0000-0002-9619-7666; Ziebell, Jenna/0000-0003-2497-4347	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065052, P30 NS051220]; NIH NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD061996]; Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) [7-11]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, P30NS051220] Funding Source: NIH RePORTER	With generous thanks to Amanda M. Lisembee for preparing the diffuse brain-injured rats; Deanne Hopkins for conducting the radioligand binding experiments; and Kelley D. Hall for assistance with the ibuprofen administration. Supported, in part, by NIH NINDS R01 NS065052, NIH NICHD R01 HD061996, Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) 7-11 and NIH NINDS P30 NS051220.	Benowitz LI, 2007, DEV NEUROBIOL, V67, P1148, DOI 10.1002/dneu.20515; Boekhoff TMA, 2012, J NEUROTRAUM, V29, P1000, DOI 10.1089/neu.2011.1821; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cook NL, 2009, J NEUROSCI RES, V87, P34, DOI 10.1002/jnr.21846; Cullheim S, 2007, BRAIN RES REV, V55, P89, DOI 10.1016/j.brainresrev.2007.03.012; del Zoppo GJ, 2007, STROKE, V38, P646, DOI 10.1161/01.STR.0000254477.34231.cb; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Farfara D, 2008, J CELL MOL MED, V12, P762, DOI 10.1111/j.1582-4934.2008.00314.x; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fu Q, 2007, J NEUROSCI, V27, P4154, DOI 10.1523/JNEUROSCI.4353-06.2007; Gao JJ, 2002, J LEUKOCYTE BIOL, V72, P1234; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham DI, 2002, GREENFIELDS NEUROP E, P823; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Harris JL, 2009, J NEUROTRAUM, V26, P1669, DOI [10.1089/neu.2009.0875, 10.1089/neu.2009-0875]; Henkel JS, 2009, J NEUROIMMUNE PHARM, V4, P389, DOI 10.1007/s11481-009-9171-5; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Ling ZD, 2006, EXP NEUROL, V199, P499, DOI 10.1016/j.expneurol.2006.01.010; Little KY, 1998, ARCH GEN PSYCHIAT, V55, P793, DOI 10.1001/archpsyc.55.9.793; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Park EM, 2005, NEUROSCIENCE, V132, P625, DOI 10.1016/j.neuroscience.2005.01.021; PATEL PM, 1993, BRAIN RES, V614, P315, DOI 10.1016/0006-8993(93)91050-3; Perry VH, 2010, ASN NEURO, V2, P281, DOI 10.1042/AN20100024; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Ross SM, 2003, J ENG TECHNOL, V20, P38; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Soares HD, 1995, J NEUROSCI, V15, P8223; Thomas TC, 2012, J NEUROTRAUM, V29, P187, DOI 10.1089/neu.2011.2091; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wang XX, 2009, J NEUROTRAUM, V26, P81, DOI 10.1089/neu.2007.0464; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Yeates GN, 2008, NEUROPSYCHOL REHABIL, V18, P566, DOI 10.1080/09602010802151532; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	72	105	108	1	27	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 6	2012	225						65	75		10.1016/j.neuroscience.2012.08.058			11	Neurosciences	Neurosciences & Neurology	039SP	WOS:000311267100007	22960311	Green Accepted			2021-06-18	
J	Nakase-Richardson, R; Whyte, J; Giacino, JT; Pavawalla, S; Barnett, SD; Yablon, SA; Sherer, M; Kalmar, K; Hammond, FM; Greenwald, B; Horn, LJ; Seel, R; McCarthy, M; Tran, J; Walker, WC				Nakase-Richardson, Risa; Whyte, John; Giacino, Joseph T.; Pavawalla, Shital; Barnett, Scott D.; Yablon, Stuart A.; Sherer, Mark; Kalmar, Kathleen; Hammond, Flora M.; Greenwald, Brian; Horn, Lawrence J.; Seel, Ron; McCarthy, Marissa; Tran, Johanna; Walker, William C.			Longitudinal Outcome of Patients with Disordered Consciousness in the NIDRR TBI Model Systems Programs	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; DOC; outcome; rehabilitation; TBI	PROLONGED UNCONSCIOUS STATE; SEVERE BRAIN-INJURY; INPATIENT REHABILITATION; GALVESTON ORIENTATION; VEGETATIVE STATE; RATING-SCALE; YOUNG-ADULTS; RECOVERY; CHILDREN; VALIDITY	Few studies address the course of recovery from prolonged disorders of consciousness (DOC) after severe traumatic brain injury (TBI). This study examined acute and long-term outcomes of persons with DOC admitted to acute inpatient rehabilitation within the National Institute on Disability and Rehabilitation Research (NIDRR) TBI Model Systems Programs (TBIMS). Of 9028 persons enrolled from 1988 to 2009, 396 from 20 centers met study criteria. Participants were primarily male (73%), Caucasian (67%), injured in motor vehicle collision (66%), with a median age of 28, and emergency department Glasgow Coma Scale (GCS) score of 3. Participant status was evaluated at acute rehabilitation admission and discharge and at 1, 2, and 5 years post-injury. During inpatient rehabilitation, 268 of 396 (68%) regained consciousness and 91 (23%) emerged from post-traumatic amnesia (PTA). Participants demonstrated significant improvements on GCS (z = 16.135, p <= 0.001) and Functional Independence Measure (FIM) (z = 15.584, p <= 0.001) from rehabilitation admission (median GCS = 9; FIM = 18) to discharge (median GCS = 14; FIM = 43). Of 337 with at least one follow-up visit, 28 (8%) had died by 2.1 years (mean) after discharge. Among survivors, 66 (21%) improved to become capable of living without in-house supervision, and 63 demonstrated employment potential using the Disability Rating Scale (DRS). Participants with follow-up data at 1, 2, and 5 years post-injury (n = 108) demonstrated significant improvement across all follow-up evaluations on the FIM Cognitive and Supervision Rating Scale (p < 0.01). Significant improvements were observed on the DRS and FIM Motor at 1 and 2 years post-injury (p < 0.01). Persons with DOC at the time of admission to inpatient rehabilitation showed functional improvement throughout early recovery and in years post-injury.	[Nakase-Richardson, Risa; Pavawalla, Shital; Barnett, Scott D.; McCarthy, Marissa; Tran, Johanna] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Nakase-Richardson, Risa; Barnett, Scott D.] Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL USA; [Nakase-Richardson, Risa] Univ S Florida, Tampa, FL USA; [Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Giacino, Joseph T.] Spaulding Rehabil Hosp, Boston, MA USA; [Yablon, Stuart A.] Baylor Inst Rehabil, Dallas, TX USA; [Sherer, Mark] Baylor Coll Med, TIRR Mem Hermann, Houston, TX 77030 USA; [Kalmar, Kathleen] JFK Johnson Rehabil Inst, Edison, NJ USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ, Indianapolis, IN 46204 USA; [Greenwald, Brian] Mt Sinai Sch Med, New York, NY USA; [Horn, Lawrence J.] Wayne State Univ, Detroit, MI USA; [Seel, Ron] Shepherd Ctr, Atlanta, GA USA; [Walker, William C.] Virginia Commonwealth Univ, Richmond, VA USA	Nakase-Richardson, R (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd,Route 116B, Tampa, FL 33612 USA.	Risa.Richardson@va.gov	Giacino, Joseph/AAF-1952-2021; Walker, William C/N-3162-2014	Giacino, Joseph/0000-0002-7916-9698; Whyte, John/0000-0002-4381-1474; Tran, Johanna/0000-0001-6231-5620	National Institute on Disability and Rehabilitation Research, Department of Education [H133A060038, H133A070043, H133A070040, H133A-080044, H133A070036, H133A070027, H133A070042, H133A031713, H133A070030, H133A070033]; HSR&D/RR&D Center of Excellence for Maximizing Rehabilitation Outcomes [COE-HFP 09-156]	The contents of this manuscript were developed under grants from the National Institute on Disability and Rehabilitation Research, Department of Education (H133A060038 [TBI Model System National Data and Statistical Center], H133A070043 [Texas TBI Model System of TIRR], H133A070040 [Moss TBI Model System], H133A-080044 [Southeastern Michigan TBI System], H133A070036 [Virginia Commonwealth TBI Model System], H133A070027 [North Texas TBI Model System], H133A070042 [Carolinas Traumatic Brain Injury Rehabilitation and Research System] H133A031713, H133A070030, H133A070033). However, those contents do not necessarily represent the policy of the Department of Education, and endorsement by the federal government should not be assumed. Statistical support was provided by the HSR&D/RR&D Center of Excellence for Maximizing Rehabilitation Outcomes [COE-HFP 09-156].	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; Centers for Medicare and Medicaid Services, 2004, FED REGISTER, V69, P25; DUBROJA I, 1995, J NEUROL NEUROSUR PS, V58, P465, DOI 10.1136/jnnp.58.4.465; Eilander HJ, 2007, BRAIN INJURY, V21, P53, DOI 10.1080/02699050601151795; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; FIELDS AI, 1993, CRIT CARE MED, V21, P1890, DOI 10.1097/00003246-199312000-00016; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Ng YS, 2005, NEUROREHABILITATION, V20, P97; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; TEASDALE G, 1974, LANCET, V2, P81	31	105	105	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					59	65		10.1089/neu.2011.1829			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300006	21663544				2021-06-18	
J	Leventhal, JM; Martin, KD; Asnes, AG				Leventhal, John M.; Martin, Kimberly D.; Asnes, Andrea G.			Incidence of fractures attributable to abuse in young hospitalized children: Results from analysis of a United States database	PEDIATRICS			English	Article						fracture; incidence; abuse	TRAUMATIC BRAIN-INJURY; INFANTS	OBJECTIVE. The goal was to assess the proportion of children with fractures attributable to abuse and the incidence of fractures caused by abuse among children <36 months of age who were hospitalized in the United States. METHODS. We used the Kids' Inpatient Database, which has discharge data on 80% of acute pediatric hospitalizations in the United States, for 3 time periods (1997, 2000, and 2003). Fractures attributable to abuse in children <36 months of age were identified by both an International Classification of Diseases, Ninth Revision, Clinical Modification code for fracture and a diagnosis external-cause-of-injury code for abuse. Weighted estimates of the incidence were calculated. RESULTS. Among children <36 months of age who were hospitalized with fractures, the proportions of cases attributable to abuse were 11.9% in 1997, 11.9% in 2000, and 12.1% in 2003. The proportions of cases attributable to abuse decreased with increasing age; for example, in 2003, the proportions attributable to abuse were 24.9% for children <12 months of age, 7.2% for children 12 to 23 months of age, and 2.9% for children 24 to 35 months of age. In 2003, the incidence of fractures caused by abuse was 15.3 cases per 100 000 children <36 months of age. The incidence was 36.1 cases per 100 000 among children <12 months of age; this decreased to 4.8 cases per 100 000 among 12-to 23-month-old children and 4.8 cases per 100 000 among 24-to 35-month-old children. CONCLUSIONS. The Kids' Inpatient Database can be used to provide reasonable estimates of the incidence of hospitalization with fractures attributable to child abuse. For children <12 months of age, the incidence was 36.1 cases per 100 000, a rate similar to that of inflicted traumatic brain injury (25-32 cases per 100 000).	[Leventhal, John M.; Asnes, Andrea G.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; [Martin, Kimberly D.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Leventhal, JM (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu					Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project, OV KIDS INP DAT KID; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barnes PM, 2005, LANCET, V366, P234, DOI 10.1016/S0140-6736(05)66913-9; Brown D, 2004, AM J PUBLIC HEALTH, V94, P558, DOI 10.2105/AJPH.94.4.558; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Leventhal JM, 2005, CHILD ABUSE NEGLECT, V29, P209, DOI 10.1016/j.chiabu.2005.02.008; LEVENTHAL JM, 1993, AM J DIS CHILD, V147, P87, DOI 10.1001/archpedi.1993.02160250089028; Leventhal JM, 2007, CHILD ABUSE NEGLECT, V31, P311, DOI 10.1016/j.chiabu.2006.07.004; National Center for Health Statistics Centers for Medicare and Medicaid Services, 1999, INT CLASS DIS 9 REV; REWERS A, 2005, PEDIATRICS, V115; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277	15	105	105	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	SEP	2008	122	3					599	604		10.1542/peds.2007-1959			6	Pediatrics	Pediatrics	342ZR	WOS:000258822600017	18762531				2021-06-18	
J	Davis, LM; Pauly, JR; Readnower, RD; Rho, JM; Sullivan, PG				Davis, Laurie M.; Pauly, James R.; Readnower, Ryan D.; Rho, Jong M.; Sullivan, Patrick G.			Fasting is neuroprotective following traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						acute caloric reduction; fasting; ketone bodies; mitochondria; reactive oxygen species; trauma	PENTOSE-PHOSPHATE PATHWAY; BETA-HYDROXYBUTYRATE; UNITED-STATES; KETONE-BODIES; MITOCHONDRIAL; METABOLISM; PROTECTS; GLUCOSE; DAMAGE; ACETOACETATE	To determine the neuroprotective effect of fasting after traumatic brain injury (TBI) and to elucidate the potential underlying mechanisms, we used a controlled cortical impact (CCI) injury model to induce either a moderate or a severe injury to adult male Sprague Dawley rats. Tissue-sparing assessments were used to determine the level of neuroprotection of fasting, hypoglycemia (insulin 10 U), or ketone (1.66 mmoles/kg/day or 0.83 mmoles/kg/day; D-beta-hydroxtbutyrate) administration. Mitochondrial isolation and respiratory studies were utilized to determine the functionality of mitochondria at the site of injury. We also investigated biomarkers of oxidative stress, such as lipid/protein oxidation, reactive oxygen species (ROS) production, and intramitochondrial calcium load, as a secondary measure of mitochondrial homeostasis. We found that fasting animals for 24 hr, but not 48 hr, after a moderate (1.5 mm), but not severe (2.0 mm), CCI resulted in a significant increase in tissue sparing. This 24-hr fast also decreased biomarkers of oxidative stress and calcium loading and increased mitochondrial oxidative phosphorylation in mitochondria isolated from the site of injury. Insulin administration, designed to mimic the hypoglycemic effect seen during fasting did not result in significant tissue sparing after moderate CCI injury and in fact induced increased mortality at some injection time points. However, the administration of ketones resulted in increased tissue sparing after moderate injury. Fasting for 24 hr confers neuroprotection, maintains cognitive function, and improves mitochondrial function after moderate (1.5 mm) TBI. The underlying mechanism appears to involve ketosis rather than hypoglycemia. (c) 2008 Wiley-Liss, Inc.	[Davis, Laurie M.; Readnower, Ryan D.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Davis, Laurie M.; Readnower, Ryan D.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA; [Rho, Jong M.] Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Rho, Jong M.] St Joseph Hosp, Phoenix, AZ 85013 USA; [Rho, Jong M.] Med Ctr, Phoenix, AZ 85013 USA	Sullivan, PG (corresponding author), 741 S Limestone,375 BBSRB, Lexington, KY 40536 USA.	patsullivan@uky.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS044846, NS48191, NS42196] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS044846, R01NS048191, R01NS042196] Funding Source: NIH RePORTER		Alquier T, 2001, NEUROSCI LETT, V308, P75, DOI 10.1016/S0304-3940(01)01936-X; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; Bough KJ, 2003, EPILEPSIA, V44, P752, DOI 10.1046/j.1528-1157.2003.55502.x; Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528-1167.2007.00915.x; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; BURGE MR, 1993, J CLIN ENDOCR METAB, V76, P1192, DOI 10.1210/jc.76.5.1192; Caron M J, 1991, Neurosurg Clin N Am, V2, P483; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; El Messari S, 1998, J COMP NEUROL, V399, P492, DOI 10.1002/(SICI)1096-9861(19981005)399:4<492::AID-CNE4>3.0.CO;2-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fromenty B, 2004, DIABETES METAB, V30, P121, DOI 10.1016/S1262-3636(07)70098-8; Greene AE, 2003, J NEUROCHEM, V86, P529, DOI 10.1046/j.1471-4159.2003.01862.x; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; Kim DY, 2007, J NEUROCHEM, V101, P1316, DOI 10.1111/j.1471-4159.2007.04483.x; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; McKee T., 2003, BIOCH MOL BASIS LIFE; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Morris AAM, 2005, J INHERIT METAB DIS, V28, P109, DOI 10.1007/s10545-005-5518-0; Nehlig A, 2004, PROSTAG LEUKOTR ESS, V70, P265, DOI 10.1016/j.plefa.2003.07.006; Nicholls D. G., 2002, BIOENERGETICS, V3; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nicholls DG, 2003, CELL CALCIUM, V34, P407, DOI 10.1016/S0143-4160(03)00144-1; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; Nukala VN, 2006, J NEUROSCI METH, V152, P48, DOI 10.1016/j.jneumeth.2005.08.017; Pan JW, 2000, J CEREBR BLOOD F MET, V20, P1502, DOI 10.1097/00004647-200010000-00012; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Rho JM, 2002, EPILEPSIA, V43, P358, DOI 10.1046/j.1528-1157.2002.47901.x; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Smith SL, 2005, CNS DRUG REV, V11, P113; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Totland GK, 2000, BIOL CELL, V92, P317, DOI 10.1016/S0248-4900(00)01077-7; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; YAGER JY, 1992, PEDIATR RES, V31, P138, DOI 10.1203/00006450-199202000-00009; Yamada KA, 2005, NEUROSCI LETT, V385, P210, DOI 10.1016/j.neulet.2005.05.038	68	105	108	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2008	86	8					1812	1822		10.1002/jnr.21628			11	Neurosciences	Neurosciences & Neurology	312CJ	WOS:000256646400014	18241053				2021-06-18	
J	Garay, L; Deniselle, MCG; Lima, A; Roig, P; De Nicola, AR				Garay, Laura; Gonzalez Deniselle, Maria Claudia; Lima, Analia; Roig, Paulina; De Nicola, Alejandro R.			Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						EAE; multiple sclerosis; progesterone; myelination; neuroprotection	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MESSENGER-RNA EXPRESSION; TRAUMATIC BRAIN-INJURY; STEROID-HORMONES; DOWN-REGULATION; NITRIC-OXIDE; RAT-BRAIN; PROTEIN; DISEASE	The spinal cord is a target of progesterone (PROG), as demonstrated by the expression of intracellular and membrane PROG receptors and by its myelinating and neuroprotective effects in trauma and neurodegeneration. Here we studied PROG effects in mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis characterized by demyelination and immune cell infiltration in the spinal cord. Female C57BL/6 mice were immunized with a myelin oligodendrocyte glycoprotein peptide (MOG(40-54)). One week before EAE induction, mice received single pellets of PROG weighing either 20 or 100 mg or remained free of steroid treatment. On average, mice developed clinical signs of EAE 9-10 days following MOG administration. The spinal cord white matter of EAE mice showed inflammatory cell infiltration and circumscribed demyelinating areas, demonstrated by reductions of luxol fast blue (LFB) staining, myelin basic protein (MBP) and proteolipid protein (PLP) immunoreactivity (IR) and PLP mRNA expression. In motoneurons, EAE reduced the expression of the alpha 3 subunit of Na,K-ATPase mRNA. In contrast, EAE mice receiving PROG showed less inflammatory cell infiltration, recovery of myelin proteins and normal grain density of neuronal Na,K-ATPase mRNA. Clinically, PROG produced a moderate delay of disease onset and reduced the clinical scores. Thus, PROG attenuated disease severity, and reduced the inflammatory response and the occurrence of demyelination in the spinal cord during the acute phase of EAE. (c) 2007 Elsevier Ltd. All rights reserved.	Inst & Biol Med Exp, Biochem Neuroendocrinol Lab, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Human Biochem, Buenos Aires, DF, Argentina; Inst Univ Ciencias & Salud, Fundac Barcelo, Buenos Aires, DF, Argentina	De Nicola, AR (corresponding author), Inst & Biol Med Exp, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar					Ayers MM, 2004, NEUROCHEM INT, V45, P409, DOI 10.1016/j.neuint.2003.08.018; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Cowden WB, 1998, J NEUROIMMUNOL, V88, P1, DOI 10.1016/S0165-5728(98)00040-X; Deniselle MCG, 2005, EXP NEUROL, V195, P518, DOI 10.1016/j.expneurol.2005.06.015; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; Druckmann R, 2005, J STEROID BIOCHEM, V97, P389, DOI 10.1016/j.jsbmb.2005.08.010; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; ELLIOTT GA, 1973, ACTA NEUROPATHOL, V23, P95, DOI 10.1007/BF00685763; Elloso MM, 2005, J ENDOCRINOL, V185, P243, DOI 10.1677/joe.1.06063; FERRINI M, 1995, LIFE SCI, V57, P2403, DOI 10.1016/0024-3205(95)02236-3; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; GARAY L, 2005, MULT SCLER, V11, P43; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Giardino L, 2004, NEUROPATH APPL NEURO, V30, P522, DOI 10.1111/j.1365-2990.2004.00559.x; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gonzalez S, 1996, NEUROREPORT, V7, P1041, DOI 10.1097/00001756-199604100-00017; Gonzalez-Rey E, 2006, AM J PATHOL, V168, P1179, DOI 10.2353/ajpath.2006.051081; GRILLO C, 1994, BRAIN RES, V657, P83, DOI 10.1016/0006-8993(94)90956-3; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; Hughes MD, 2004, NEUROL CLIN, V22, P757, DOI 10.1016/j.ncl.2004.06.004; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Jones KJ, 1997, NEUROCHEM RES, V22, P1367, DOI 10.1023/A:1022071123255; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kim S, 1999, NEUROLOGY, V52, P1230, DOI 10.1212/WNL.52.6.1230; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; LEES GJ, 1994, BRAIN RES, V649, P225, DOI 10.1016/0006-8993(94)91068-5; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li XB, 2006, ARCH IMMUNOL THER EX, V54, P51, DOI 10.1007/s00005-006-0005-3; Liu YR, 2006, FREE RADICAL BIO MED, V40, P960, DOI 10.1016/j.freeradbiomed.2005.07.021; Mason C., 1999, VENTURE CAPITAL, V1, P1, DOI DOI 10.1080/136910699295974; Mathisen PM, 2001, J NEUROSCI RES, V64, P542, DOI 10.1002/jnr.1106; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; Merrill JE, 1999, NEUROPATH APPL NEURO, V25, P435; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Nicot A, 2003, BRAIN, V126, P398, DOI 10.1093/brain/awg041; Offner H, 2000, J CLIN INVEST, V105, P1465, DOI 10.1172/JCI9213; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Onuki I, 2001, MICROSC RES TECHNIQ, V52, P731; Palaszynski KM, 2004, J NEUROIMMUNOL, V149, P84, DOI 10.1016/j.jneuroim.2003.12.015; Palladino MJ, 2003, J NEUROSCI, V23, P1276; Papadopoulos D, 2006, EXP NEUROL, V197, P373, DOI 10.1016/j.expneurol.2005.10.033; PAXINOS G, 1983, RAT BRAIN STEREOTAXI; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; PICCINNI MP, 1995, J IMMUNOL, V155, P128; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; PRUDHOMME GJ, 1993, CLIN IMMUNOL IMMUNOP, V66, P185, DOI 10.1006/clin.1993.1024; RAINE CS, 1993, J NEUROPATH EXP NEUR, V52, P199, DOI 10.1097/00005072-199305000-00003; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schilling S, 2006, CLIN EXP IMMUNOL, V145, P101, DOI 10.1111/j.1365-2249.2006.03094.x; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Sim FJ, 2000, NEUROSCIENCE, V100, P131, DOI 10.1016/S0306-4522(00)00252-9; STAHL WL, 1984, ANN NEUROL, V16, pS121, DOI 10.1002/ana.410160718; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Sun DM, 2003, INT IMMUNOL, V15, P261, DOI 10.1093/intimm/dxg023; Svensson L, 2002, EUR J IMMUNOL, V32, P1939, DOI 10.1002/1521-4141(200207)32:7<1939::AID-IMMU1939>3.0.CO;2-S; SzekeresBartho J, 1996, J REPROD IMMUNOL, V31, P81, DOI 10.1016/0165-0378(96)00964-3; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vizioli N M, 1999, J Capill Electrophor Microchip Technol, V6, P109; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23	65	105	108	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	NOV-DEC	2007	107	3-5					228	237		10.1016/j.jsbmb.2007.03.040			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	220UU	WOS:000250183600012	17692515				2021-06-18	
J	Loy, DN; Kim, JH; Xie, M; Schmidt, RE; Trinkaus, K; Song, SK				Loy, David N.; Kim, Joong Hee; Xie, Mingqiang; Schmidt, Robert E.; Trinkaus, Kathryn; Song, Sheng-Kwei			Diffusion tensor Imaging predicts hyperacute spinal cord injury severity	JOURNAL OF NEUROTRAUMA			English	Article						anisotropy; axial diffusion; diffusion tensor imaging; hyperacute; ischemia; magnetic resonance; mouse; radial diffusion; spinal cord injury	WHITE-MATTER TRACTS; IN-VIVO; CONTUSION INJURY; MOUSE; MRI; ISCHEMIA; RECOVERY; BRAIN; AXON; DTI	Experimental strategies that focus on ventral white matter (VWM) preservation during the hyperacute phase hold great potential for our improved understanding of functional recovery following traumatic spinal cord injury (SCI). Critical comparisons of human SCI to rapidly accumulating data derived from rodent models are limited by a basic lack of in vivo measures of subclinical pathophysiologic changes and white matter damage in the spinal cord. Spinal cord edema and intra-parenchymal hemorrhage demonstrated with routine MR sequences have limited value for predicting functional outcomes in SCI animal models and in human patients. We recently demonstrated that in vivo derived diffusion tensor imaging (DTI) parameters are sensitive and specific biomarkers for spinal cord white matter damage. In this study, non-invasive in vivo DTI was utilized to evaluate the white matter of C57BL/6 mice 3 h after mild (0.3 mm), moderate (0.6 mm), or severe (0.9 mm) contusive SCI. In the hyperacute phase, relative anisotropy maps provided excellent gray-white matter contrast in all degrees of injury. In vivo DTI-derived measurements of axial diffusion differentiated between mild, moderate, and severe contusive SCI with good histological correlation. Cross-sectional regional measurements of white matter injury severity between dorsal columns and VWM varied with increasing cord displacement in a pattern consistent with spinal cord viscoelastic properties.	Washington Univ, Dept Radiol, St Louis, MO USA; Washington Univ, Dept Pathol, St Louis, MO USA; Washington Univ, Dept Biostat, St Louis, MO USA	Song, SK (corresponding author), Washington Univ, Sch Med, Biomed Mr Lab, Campus Box 8227,Rm 2313,4525 Scott Ave, St Louis, MO 63110 USA.	ssong@wustl.edu			NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24CA083060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK019645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010299] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24-CA83060] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG10299] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01-DK19645] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS047592] Funding Source: Medline		Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bilgen M, 2005, MAGN RESON MED, V54, P1226, DOI 10.1002/mrm.20672; Bilgen M, 2000, MAGN RESON MED, V43, P594; Blight A, 1988, J Am Paraplegia Soc, V11, P26; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Boldin C, 2006, SPINE, V31, P554, DOI 10.1097/01.brs.0000201274.59427.a4; Bonny JM, 2004, NEUROBIOL DIS, V15, P474, DOI 10.1016/j.nbd.2003.11.026; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; EDELSTEIN WA, 1984, MED PHYS, V11, P180, DOI 10.1118/1.595484; Gallyas F, 2002, ACTA NEUROPATHOL, V103, P36, DOI 10.1007/s004010100424; Garbow JR, 2004, CONCEPT MAGN RESON B, V21B, P40, DOI 10.1002/cmr.b.20010; Gullapalli J, 2006, J MAGN RESON IMAGING, V24, P231, DOI 10.1002/jmri.20622; Hasan KM, 2006, MAGN RESON MED, V56, P130, DOI 10.1002/mrm.20935; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Madi S, 2005, MAGN RESON MED, V53, P118, DOI 10.1002/mrm.20304; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; Schwartz ED, 2003, EXP NEUROL, V184, P570, DOI 10.1016/S0014-4886(03)00295-4; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun SW, 2003, MAGNET RESON MED, V49, P271, DOI 10.1002/mrm.10362; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thurnher MM, 2006, NEURORADIOLOGY, V48, P795, DOI 10.1007/s00234-006-0130-z; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287	29	105	112	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					979	990		10.1089/neu.2006.0253			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700006	17600514				2021-06-18	
J	Witting, A; Chen, LF; Cudaback, E; Straiker, A; Walter, L; Rickman, B; Moller, T; Brosnan, C; Stella, N				Witting, A; Chen, LF; Cudaback, E; Straiker, A; Walter, L; Rickman, B; Moller, T; Brosnan, C; Stella, N			Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						cannabinoid; microglia; purinergic; multiple sclerosis	MULTIPLE-SCLEROSIS MODEL; FOCAL CEREBRAL-ISCHEMIA; CANNABINOID RECEPTORS; CONTROL SPASTICITY; EXTRACELLULAR ATP; GLIAL-CELLS; VIRAL MODEL; SPINAL-CORD; SYSTEM; P2X(7)	Focal cerebral ischemia and traumatic brain injury induce an escalating amount of cell death because of harmful mediators diffusing from the original lesion site. Evidence suggests that healthy cells surrounding these lesions attempt to protect themselves by producing endocannabinoids (eCBs) and activating cannabinoid receptors, the molecular target for marijuana-derived compounds. Indeed, activation of cannabinoid receptors reduces the production and diffusion of harmful mediators. Here, we provide evidence that an exception to this pattern is found in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. We show that cell damage induced by EAE does not lead to increase in eCBs, even though cannabinoid receptors are functional because synthetic cannabinoid agonists are known to confine EAE-induced lesions. This lack of eCB increase is likely due to IFN-gamma, which is released by primed T cells invading the CNS. We show that IFN-gamma disrupts the functionality of purinergic P2X(7) receptors, a key step controlling eCB production by microglia, the main source of eCBs in brain. Accordingly, induction of EAE in P2X(7)(-/-) mice results in even lower eCB levels and more pronounced cell damage than in wild-type mice. Our data suggest that the high level of CNS IFN-gamma associated with EAE disrupts eCB-mediated neuroprotection while maintaining functional cannabinoid receptors, thus providing additional support for the use of cannabinoid-based medicine to treat multiple sclerosis.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Inst Stem Cell & Regenerat med, Seattle, WA 98195 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Stella, N (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	nstella@u.washington.edu	Chen, Lanfen/B-7975-2016	Chen, Lanfen/0000-0002-9413-1284; Walter, Lisa/0000-0003-3421-2362			Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Bianco F, 2005, BRAIN RES REV, V48, P144, DOI 10.1016/j.brainresrev.2004.12.004; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Cabranes A, 2005, NEUROBIOL DIS, V20, P207, DOI 10.1016/j.nbd.2005.03.002; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; Ferrer B, 2003, EUR J NEUROSCI, V18, P1607, DOI 10.1046/j.1460-9568.2003.02896.x; Franklin A, 2003, J NEUROSCI, V23, P7767; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Juedes AE, 2000, J IMMUNOL, V164, P419, DOI 10.4049/jimmunol.164.1.419; Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Mestre L, 2005, J NEUROCHEM, V92, P1327, DOI 10.1111/j.1471-4159.2004.02979.x; Nagayama T, 1999, J NEUROSCI, V19, P2987; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Pertwee RG, 2002, PHARMACOL THERAPEUT, V95, P165, DOI 10.1016/S0163-7258(02)00255-3; Pryce G, 2005, TRENDS NEUROSCI, V28, P272, DOI 10.1016/j.tins.2005.03.006; Stella N, 2004, GLIA, V48, P267, DOI 10.1002/glia.20084; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Walter L, 2003, J NEUROSCI, V23, P1398; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Witting A, 2004, J NEUROCHEM, V89, P1555, DOI 10.1111/j.1471-4159.2004.02544.x; Witting A, 2004, P NATL ACAD SCI USA, V101, P3214, DOI 10.1073/pnas.0306707101	28	105	109	0	4	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	APR 18	2006	103	16					6362	6367		10.1073/pnas.0510418103			6	Multidisciplinary Sciences	Science & Technology - Other Topics	035KF	WOS:000236999000055	16571660	Bronze, Green Published			2021-06-18	
B	Sharma, HS; Ali, SF		Ali, SF; Fornai, F		Sharma, Hari Shanker; Ali, Syed F.			Alterations in blood-brain barrier function by morphine and methamphetamine	CELLULAR AND MOLECULAR MECHANISMS OF DRUGS OF ABUSE AND NEUROTOXICITY: COCAINE, GHB, AND SUBSTITUTED AMPHETAMINES	Annals of the New York Academy of Sciences-Series		English	Article; Proceedings Paper	Satellite Meeting on Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity - Cocaine, GHB and Substituted Amphetamines	AUG 16-19, 2005	Venice Int Univ, Venice, ITALY	Int Soc Neurochem, Neuromed Pozzilli, FDA, Natl Ctr Toxicol Res	Venice Int Univ	morphine; methamphetamine; rats; mice; stress; blood-brain barrier; brain dysfunction; heat shock protein; glial cells; nerve cells; Evans blue; radioiodine	SEROTONIN SYNTHESIS INHIBITOR; PITUITARY-ADRENAL RESPONSES; SHOCK-PROTEIN RESPONSE; SPINAL-CORD-INJURY; NITRIC-OXIDE; HEAT-STRESS; INDUCED PATHOPHYSIOLOGY; P-CHLOROPHENYLALANINE; TRAUMATIC INJURY; 5-HT LEVEL	The possibility that stress associated with morphine and amphetamine administration or withdrawal will influence the blood-brain barrier (BBB) and brain dysfunction was examined in a rodent model. Repeated daily administration of morphine (10 mg/kg, i.p.) resulted in drug dependence in rats on the sixth-day and onwards. Measurement of the BBB permeability to large molecule tracers normally bound to proteins, e.g., Evans blue albumin and radioiodine (([131])Iodine) did not show any leakage on the 12th day of drug dependence. On the other hand, spontaneous withdrawal of morphine on day 1 resulted in profound stress symptoms. These symptoms were much more intense on the second day of morphine withdrawal. Alterations in the BBB to protein tracers were seen in several regions of the brain. This increase in BBB to protein tracers was most pronounced on the second day of morphine withdrawal. These rats also exhibited abnormal neuronal, glial and stress protein, the heat-shock protein 72 kD (HSP-72 kD) response. On the other hand, acute administration of methamphetamine (40 mg/kg, i.p.) in mice resulted in marked extravasation of endogenous serum protein as seen with increased expression of albumin immunohistochemistry. These observations suggest that psychostimulants and associated stress are capable to influence the brain function, probably through modifying the BBB function, not reported earlier.	Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden; US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Neurochem Lab, Jefferson, AR 72079 USA	Sharma, HS (corresponding author), Frodingsgatan 12-28, SE-75421 Uppsala, Sweden.	Sharma@surgsci.uu.se					Ali S F, 1995, Ann N Y Acad Sci, V765, P338, DOI 10.1111/j.1749-6632.1995.tb16610.x; ANDERSSON K, 1993, EUR J PHARM-ENVIRON, V228, P305, DOI 10.1016/0926-6917(93)90065-X; BHARGAVA HN, 1994, PHARMACOL REV, V46, P293; BHATNAGAR S, 1995, PHYSIOL BEHAV, V57, P633, DOI 10.1016/0031-9384(94)00161-8; Bhatnagar S, 1998, NEUROSCIENCE, V84, P1025, DOI 10.1016/S0306-4522(97)00577-0; BUCKINGHAM JC, 1984, NEUROENDOCRINOLOGY, V38, P411, DOI 10.1159/000123927; CHILDRESS AR, 1994, J SUBST ABUSE TREAT, V11, P17, DOI 10.1016/0740-5472(94)90060-4; DALLMAN MJ, 1991, J EXP MED, V173, P79, DOI 10.1084/jem.173.1.79; GIANUTSOS G, 1975, PSYCHOPHARMACOLOGIA, V43, P43, DOI 10.1007/BF00437613; GIANUTSOS G, 1975, METHODS NARCOTIC RES, P293; Himmelsbach CK, 1943, FED PROC, V2, P201; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P862, DOI 10.1046/j.1365-2826.2001.00713.x; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P875, DOI 10.1046/j.1365-2826.2001.00714.x; Itzhak Y, 2002, ANN NY ACAD SCI, V965, P127; KOSTEN TR, 1986, BIOL PSYCHIAT, V21, P217, DOI 10.1016/0006-3223(86)90150-2; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; MARTI O, 1994, NEUROENDOCRINOLOGY, V60, P1, DOI 10.1159/000126713; Mitchell JM, 2000, NAT NEUROSCI, V3, P47; Nag Sukriti, 2003, Methods Mol Med, V89, P133; ODOHERTY F, 1991, DRUG ALCOHOL DEPEN, V29, P97, DOI 10.1016/0376-8716(91)90026-U; Olsson Y, 1995, PROG BRAIN RES, V104, P381; OLSSON Y, 1990, ACTA NEUROPATHOL, V79, P595, DOI 10.1007/BF00294236; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; RAY AK, 1980, ARCH INT PHARMACOD T, V246, P108; Sharma, 2004, BLOOD SPINAL CORD BR, P437; SHARMA H S, 1984, Indian Journal of Physiology and Pharmacology, V28, P259; SHARMA H S, 1981, Indian Journal of Physiology and Pharmacology, V25, P111; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P299; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P231; Sharma H. S., 1982, THESIS BANARAS HINDU, P1; SHARMA HS, 1995, NEUROSCI RES, V21, P241, DOI 10.1016/0168-0102(94)00855-A; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P422, DOI 10.1196/annals.1344.037; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; Sharma HS, 2003, INT J HYPERTHER, V19, P325, DOI 10.1080/0265673021000054621; Sharma HS, 1998, PROG BRAIN RES, V115, P297; SHARMA HS, 1993, ACTA NEUROPATHOL, V86, P422; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Sharma HS, 1998, NEW FRONTIERS IN STRESS RESEARCH: MODULATION OF BRAIN FUNCTION, P259; SHARMA HS, 1990, ACT NEUR S, V51, P383; SHARMA HS, 1994, ACT NEUR S, V60, P65; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1992, NEUROSCIENCE, V48, P889, DOI 10.1016/0306-4522(92)90277-9; SHARMA HS, 1987, BRAIN RES, V424, P153, DOI 10.1016/0006-8993(87)91205-4; Sharma HS, 1997, ACT NEUR S, V70, P269; Sharma HS, 1996, BEHAV BRAIN RES, V72, P189; SHARMA HS, 1987, MATH NATURWISSENSCHA, V36, P104; Sharma HS, 1999, ACTA U UPSAL, V830, P1; SHARMA HS, 2002, ENDOTHELIUM, V8, P302; Song P, 2001, NEUROSCI RES, V39, P281, DOI 10.1016/S0168-0102(00)00226-1; Westman J, 1998, PROG BRAIN RES, V115, P207; Williams JT, 2001, PHYSIOL REV, V81, P299; YOUNG E, 1985, NEUROPEPTIDES, V5, P545, DOI 10.1016/0143-4179(85)90075-7; Zea-Aragon Z, 2004, J NEUROSCI METH, V138, P89, DOI 10.1016/j.jneumeth.2004.03.018	58	105	105	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER STREET, HOBOKEN, NJ, UNITED STATES			1-57331-629-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2006	1074						198	224		10.1196/annals.1369.020			27	Cell Biology; Substance Abuse; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Cell Biology; Substance Abuse; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BFJ04	WOS:000242168100020	17105918				2021-06-18	
J	Ware, ML; Nemani, VM; Meeker, M; Lee, C; Morabito, DJ; Manley, GT				Ware, ML; Nemani, VM; Meeker, M; Lee, C; Morabito, DJ; Manley, GT			Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: A preliminary study	NEUROSURGERY			English	Article						hypertonic saline; intracranial hypertension; traumatic brain injury	HYPERTONIC SALINE RESUSCITATION; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; CEREBRAL EDEMA; BLOOD-FLOW; HYPERTENSION; MANAGEMENT; HYPOTENSION; MANNITOL; DEXTRAN	OBJECTIVE: Mannitol is the standard of care for patients with increased intracranial pressure (ICP), but multiple administrations of mannitol risk renal toxicity and fluid accumulation in the brain parenchyma with consequent worsening of cerebral edema. This preliminary study assessed the safety and efficacy of small-volume injections of 23.4% sodium chloride solution for the treatment of intracranial hypertension in patients with traumatic brain injury who became tolerant to mannitol. METHODS: We retrospectively reviewed the charts of 13 adult patients with traumatic brain injury who received mannitol and 23.49% sodium chloride independently for the treatment of intracranial hypertension at San Francisco General Hospital between January and October 2003. Charts were reviewed to determine ICP, cerebral perfusion pressure, mean arterial pressure, serum sodium values, and serum osmolarity before and after treatment with 23.4% sodium chloride and mannitol. Complications were noted. RESULTS: The mean reductions in ICP after treatment were significant for both mannitol (P < 0.001) and hypertonic saline (P < 0.001); there were no significant differences between reductions in ICP when comparing the two agents (P = 0.174). The ICP reduction observed for hypertonic saline was durable, and its mean duration of effect (96 min) was significantly longer than that of mannitol treatment (59 min) (P = 0.016). No complications were associated with treatment with hypertonic saline. CONCLUSION: This study suggests that 23.4% hypertonic saline is a safe and effective treatment for elevated ICP in patients after traumatic brain injury. These results warrant a rigorous evaluation of its efficacy as compared to mannitol in a prospective randomized controlled trial.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94110 USA; Univ Illinois, Sch Med, Chicago, IL USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Box 0899, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu	Ware, Marcus/E-4981-2011	Nemani, Venu/0000-0001-8895-7090	ODCDC CDC HHS [R49 CCR903697] Funding Source: Medline		BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BITTERMAN H, 1987, CIRC SHOCK, V21, P271; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; DEFELIPPE J, 1980, LANCET, V2, P1002; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Hartl R, 1997, ACT NEUR S, V70, P126; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KREIMEIER U, 1990, CIRC SHOCK, V32, P83; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629; MESSMER K, 1989, RESUSCITATION, V18, pS51, DOI 10.1016/0300-9572(89)90053-1; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; Shackford SR, 1996, CRIT CARE MED, V24, P1933, DOI 10.1097/00003246-199611000-00031; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHACKFORD SR, 1992, CRIT CARE MED, V20, P160; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soupart A, 1996, CLIN NEPHROL, V46, P149; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1990, ACT NEUR S, V51, P324	40	105	108	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2005	57	4					727	735		10.1227/01.NEU.0000175726.08903.OA			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	031CK	WOS:000236681500034	16239885				2021-06-18	
J	Anderson, V; Catroppa, C				Anderson, V; Catroppa, C			Recovery of executive skills following paediatric traumatic brain injury (TBI): A 2 year follow-up	BRAIN INJURY			English	Article						TBI; children; recovery	CLOSED HEAD-INJURY; ATTENTIONAL DEFICITS; CHILDREN; CHILDHOOD; METACOGNITION; ADOLESCENCE; ABILITY; MEMORY	Primary objective: Disruptions to executive function (EF) may occur as a result of traumatic brain injury (TBI), in the context of direct damage to frontal regions or in association with disruption of connections between these areas and other brain regions. Little investigation of EF has occurred following TBI during childhood and there is little evidence of possible recovery trajectories in the years post-injury. The present study aimed to (i) examine whether a dose-response relationship exists between injury severity and EF; (ii) document recovery of EF in the 2 years post-injury and (iii) determine any additional predictors of outcome in the domain of EF. Research design: The study employed a prospective, longitudinal design, with participants recruited at time of injury and followed over a 2-year period. Methods and procedures: The study examined EF in a group of 69 children who had sustained a mild, moderate or severe TBI. Four components of EF were assessed: (i) attentional control; (ii) planning, goal setting and problem solving; (iii) cognitive flexibility; and (iv) abstract reasoning. Outcomes and results: Results showed that, while children with severe TBI performed most poorly during the acute stage post-injury, they exhibited greatest recovery of EF over a 24-month period. Regardless, functional deficits remained most severe for this group 2 years post-injury. Results demonstrated the multi-dimensional nature of EF and the differential recovery of skills, following childhood TBI. Pre-injury ability and age at injury were identified as significant predictors of EF and functional skills. Conclusions: Children sustaining severe TBI at a young age are particularly vulnerable to impairments in EF. While these difficulties do show some recovery with time since injury, long-term deficits remain and may impact on ongoing development.	Univ Melbourne, Royal Childrens Hosp, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	v.anderson@psych.unimelb.edu.au					Anderson P, 2001, CLIN NEUROPSYCHOL, V15, P81, DOI 10.1076/clin.15.1.81.1905; Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; ANDERSON V, 2001, PEDIAT NEUROPSYCHOLO; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; FENNELL EB, 1992, ADV CHILD NEUROPSYCH, V1; GADDES WH, 1973, RES MONOGRAPH U VICT, V25; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Goldstein FC, 1992, COGNITIVE DISORDERS; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HYND GW, 1988, INTERCRANIAL INJURIE; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEZAK MD, 1993, NEUROPSYCHOLOGICAL A; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MILLER JD, 1991, NEUROPSYCHOLOGY, V5, P235; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROWE JK, 1995, ROWE BEHAV RATING IN; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; TEASDALE G, 1974, LANCET, V2, P81; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; WALSH K, 1978, NEUROPSYCHOLOGY CLIN; Wechsler D., 1992, MANUAL WECHSLER INTE; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WEYANDT LL, 1994, DEV NEUROPSYCHOL, V10, P27, DOI 10.1080/87565649409540564	44	105	106	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2005	19	6					459	470		10.1080/02699050400004823			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	932JI	WOS:000229549600007	16101268				2021-06-18	
J	Shiozaki, T; Hayakata, T; Tasaki, O; Hosotubo, H; Fuijita, K; Mouri, T; Tajima, G; Kajino, K; Nakae, H; Tanaka, H; Shimazu, T; Sugimoto, H				Shiozaki, T; Hayakata, T; Tasaki, O; Hosotubo, H; Fuijita, K; Mouri, T; Tajima, G; Kajino, K; Nakae, H; Tanaka, H; Shimazu, T; Sugimoto, H			Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury	SHOCK			English	Article						IL-1ra; sTNFr-I; IL-10; cerebrospinal fluid; head injury	INTERLEUKIN-1 RECEPTOR ANTAGONIST; NECROSIS-FACTOR RECEPTORS; MULTIPLE INJURIES; PRACTICAL SCALE; RELEASE; SERUM; BARRIER; PATTERN; ALPHA; SCORE	In our previous study of patients with early-phase severe traumatic brain injury (TBI), the anti-inflammatory interleukin (IL)-10 concentration was lower in cerebrospinal fluid (CSF) than in serum, whereas proinflammatory IL-1&beta; and tumor necrosis factor (TNF)-&alpha; concentrations were higher in CSF than in serum. To clarify the influence of additional injury on this disproportion between proinflammatory and anti-inflammatory mediators, we compared their CSF and serum concentrations in patients with severe TBI with and without additional injury. All 35 study patients (18 with and 17 without additional injury) had a Glasgow Coma Scale score of 8 or less upon admission. With the exception of additional injury, clinical characteristics did not differ significantly between groups. CSF and serum concentrations of two proinflammatory mediators (IL-1&beta; and TNF-&alpha;,) and three anti-inflammatory mediators (IL-1 receptor antagonist [IL-1ra], soluble TNF receptor-I [sTNFr-1], and IL-10) were measured and compared at 6 h after injury. CSF concentrations of proinflammatory mediators were much higher than the corresponding serum concentrations in both patient groups (P &LT; 0.001). In contrast, serum concentrations of anti-inflammatory mediators were much higher than the paired CSF concentrations in patients with additional injury (P&LT; 0.001), but serum concentrations were lower than or equal to the corresponding CSF concentrations in patients without additional injury. CSF concentrations of IL-10, IL-1ra, sTNFr-1, and IL-10 were significantly higher (P&LT; 0.01 for all) in patients with high intracranial pressure (ICP; n = 11) than in patients with low ICP (n = 24), and were also significantly higher (P &LT; 0.05 for all) in patients with an unfavorable outcome (n = 14) than in patients with a favorable outcome (n = 21). These findings indicate that increased serum concentrations of anti-inflammatory mediators after severe TBI are mainly due to additional extracranial injury. We conclude that anti-inflammatory mediators in CSF may be useful indicators of the severity of brain damage in terms of ICP as well as overall prognosis of patients with severe TBI.	Osaka Univ, Grad Sch Med, Dept Traumatol, Suita, Osaka 5650871, Japan	Shiozaki, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	shiozaki@hp-emerg.med.osaka-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15390545] Funding Source: KAKEN		AREND WP, 1991, J IMMUNOL, V147, P1530; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHRISTIAN S, 2005, SHOCK, V23, P30; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; Gruber A, 2000, J NEUROSURG ANESTH, V12, P297, DOI 10.1097/00008506-200010000-00001; GUTIERREZ EG, 1994, J NEUROIMMUNOL, V55, P153, DOI 10.1016/0165-5728(94)90005-1; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; JENNETT B, 1975, LANCET, V1, P480; Lanzrein AS, 1998, ALZ DIS ASSOC DIS, V12, P215, DOI 10.1097/00002093-199809000-00016; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Partrick DA, 1999, AM J SURG, V178, P564, DOI 10.1016/S0002-9610(99)00240-8; POUTSIAKA DD, 1991, BLOOD, V78, P1275; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Tarkowski E, 2003, BRAIN RES BULL, V61, P255, DOI 10.1016/S0361-9230(03)00088-1; TEASDALE G, 1974, LANCET, V2, P81	20	105	109	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	MAY	2005	23	5					406	410		10.1097/01.shk.0000161385.62758.24			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	923MH	WOS:000228913500003	15834305				2021-06-18	
J	Chamelian, L; Reis, M; Feinstein, A				Chamelian, L; Reis, M; Feinstein, A			Six-month recovery from mild to moderate Traumatic Brain Injury: the role of APOE-epsilon 4 allele	BRAIN			English	Article						APOE-epsilon 4 allele; cognitive testing; mood; psychosocial outcome; head injury	APOLIPOPROTEIN-E POLYMORPHISM; ROUTINE FOLLOW-UP; HEAD-INJURY; ALZHEIMERS-DISEASE; RANDOMIZED-TRIAL; RISK-FACTORS; E EPSILON-4; APOE; ASSOCIATION; DEPRESSION	The possession of at least one APOE-epsilon4 allele may be linked to poor outcome in patients with predominantly severe traumatic brain injury (TBI). In mild TBI, which accounts for approximately 85% of all cases, the role of the APOE-epsilon4 allele is less clear. Studies completed to date have relied on brief cognitive assessments or coarse measures of global functioning, thereby limiting their conclusions. Our study investigated the influence of the APOE-epsilon4 allele in a prospective sample of 90 adults with mild to moderate TBI in whom neuropsychiatric outcome 6 months after injury was assessed as follows: (i) a detailed neuropsychological battery; (ii) an index of emotional distress (General Health Questionnaire); (iii) a diagnosis of major depression (Structured Clinical Interview for DSM-IV); (iv) a measure of global functioning (Glasgow Outcome Scale); (v) an index of psychosocial outcome (Rivermead Head Injury Follow-up Questionnaire); and (vi) symptoms of persistent post-concussion disorder (Rivermead Post-Concussion Symptoms Questionnaire). No association was found between the presence of the APOE-epsilon4 allele and poor outcome across all measures. Given the homogeneous nature of our sample (mild to moderate injury severity), the uniform follow-up period (6 months) and the comprehensive markers of recovery used, our data suggest that the APOE-epsilon4 allele does not adversely impact outcome in this group of TBI patients.	Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Traumat Brain Injury Clin, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Clin Pathol, Toronto, ON, Canada	Feinstein, A (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Traumat Brain Injury Clin, FG08,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	loricham@yahoo.com; antfeinstein@aol.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bachman DL, 2003, NEUROLOGY, V60, P1372, DOI 10.1212/01.WNL.0000058751.43033.4D; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Benedict R., 1997, BRIEF VISUOSPATIAL M; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Delis DC, 2000, CALIFORNIA VERBAL LE; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; FEINSTEIN A, 1992, BRAIN, V115, P1403, DOI 10.1093/brain/115.5.1403; First M., 1994, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Heaton R., 1993, WISCONSIN CARD SORTI; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; JENNETT B, 1975, LANCET, V1, P480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Katzman R, 1996, NEUROLOGY, V46, P889; Keppel G., 1982, DESIGN ANAL RES HDB, V2nd; Kerr ME, 1999, ADV EXP MED BIOL, V471, P117; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lopez-Figueroa AL, 2004, BIOL PSYCHIAT, V55, P225, DOI 10.1016/j.biopsych.2003.09.017; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Roth BL, 2004, PSYCHOPHARMACOLOGY, V174, P17, DOI 10.1007/s00213-003-1683-8; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Spreen O, 1969, NEUROSENSORY CTR COM; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wechsler D., 1999, WECHSLER ABBREVATED; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weiner MF, 1999, BIOL PSYCHIAT, V45, P633, DOI 10.1016/S0006-3223(98)00222-4; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Zekraoui L, 1997, HUM BIOL, V69, P575	62	105	107	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	DEC	2004	127		12				2621	2628		10.1093/brain/awh296			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	874PE	WOS:000225361500008	15496436	Bronze			2021-06-18	
J	Tomaiuolo, F; Carlesimo, GA; Di Paola, M; Petrides, M; Fera, F; Bonanni, R; Formisano, R; Pasqualetti, P; Caltagirone, C				Tomaiuolo, F; Carlesimo, GA; Di Paola, M; Petrides, M; Fera, F; Bonanni, R; Formisano, R; Pasqualetti, P; Caltagirone, C			Gross morphology and morphometric sequelae in the hippocampus, fornix, and corpus callosum of patients with severe non-missile traumatic brain injury without macroscopically detectable lesions: a T1 weighted MRI study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD-INJURY; VOLUME MEASUREMENT; AXONAL INJURY; ATROPHY; MEMORY; AMYGDALA; SIZE	Objective: The gross morphology and morphometry of the hippocampus, fornix, and corpus callosum in patients with severe non-missile traumatic brain injury (nmTBI) without obvious neuroradiological lesions was examined and the volumes of these structures were correlated with performance on memory tests. In addition, the predictability of the length of coma from the selected anatomical volumes was examined. Method: High spatial resolution T1 weighted MRI scans of the brain (1 mm(3)) and neuropsychological evaluations with standardised tests were performed at least 3 months after trauma in 19 patients. Results: In comparison with control subjects matched in terms of gender and age, volume reduction in the hippocampus, fornix, and corpus callosum of the nmTBI patients was quantitatively significant. The length of coma correlated with the volume reduction in the corpus callosum. Immediate free recall of word lists correlated with the volume of the fornix and the corpus callosum. Delayed recall of word lists and immediate recall of the Rey figure both correlated with the volume of the fornix. Delayed recall of the Rey figure correlated with the volume of the fornix and the right hippocampus. Conclusion: These findings demonstrate that in severe nmTBI without obvious neuroradiological lesions there is a clear hippocampal, fornix, and callosal volume reduction. The length of coma predicts the callosal volume reduction, which could be considered a marker of the severity of axonal loss. A few memory test scores correlated with the volumes of the selected anatomical structures. This relationship with memory performance may reflect the diffuse nature of the damage, leading to the disruption of neural circuits at multiple levels and the progressive neural degeneration occurring in TBI.	IRCCS Santa Lucia, I-00179 Rome, Italy; Univ Roma Tor Vergata, Neurol Clin, I-00173 Rome, Italy; McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; CNR, IMSEB, Cosenza, Italy; AFaR Osped Fatebenefratelli, Rome, Italy	Tomaiuolo, F (corresponding author), IRCCS Santa Lucia, Via Ardeatina 309, I-00179 Rome, Italy.	tomaiuolo@hsantalucia.it	Caltagirone, Carlo/B-4930-2013; Pasqualetti, Patrizio/D-4496-2013; Di Paola, Margherita/A-8480-2010; Tomaiuolo, Francesco/AAC-1534-2019	Pasqualetti, Patrizio/0000-0001-5560-1979; Tomaiuolo, Fancesco/0000-0003-1230-2770			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adams JH, 1990, HDB CLIN NEUROLOGY, P43; Adams JH, 1994, INTRO NEUROPATHOLOGY; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Azouvi P., 1993, ANN READAPTATION MED, V36, P1; Bermudez P, 2001, NEUROIMAGE, V13, P1121, DOI 10.1006/nimg.2001.0772; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; CAPITANI E, 1987, J NEUROL SCI S, V8, P14; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Carlesimo G.A., 2002, NUOVA RIV NEUROLOGIA, V12, P1, DOI DOI 10.1080/17408989.2016.1268591; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Jancke J, 1999, NEUROREPORT, V10, P2981; Jancke L, 1997, CEREB CORTEX, V7, P48, DOI 10.1093/cercor/7.1.48; Kilpatrick C, 1997, SEIZURE, V6, P213, DOI 10.1016/S1059-1311(97)80008-8; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P191, DOI 10.1016/0028-3932(68)90019-5; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; Paus T, 1996, J COMP NEUROL, V376, P664, DOI 10.1002/(SICI)1096-9861(19961223)376:4<664::AID-CNE12>3.0.CO;2-M; Penhune VB, 1996, CEREB CORTEX, V6, P661, DOI 10.1093/cercor/6.5.661; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Rey A., 1968, REATTIVO FIGURA COMP; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; SALAT D, SEX DIFFERENCES CORP; Schmitt JE, 2001, DEV MED CHILD NEUROL, V43, P155, DOI 10.1017/S0012162201000305; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Spiers HJ, 2001, NEUROCASE, V7, P357, DOI 10.1076/neur.7.5.357.16245; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 1999, EUR J NEUROSCI, V11, P3033, DOI 10.1046/j.1460-9568.1999.00718.x; Tomaiuolo F, 2002, NEUROREPORT, V13, P2281, DOI 10.1097/00001756-200212030-00022; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WECHSLER DA, 1981, SCALA INTELLIGENZA A; Wilson JTL, 1990, NEUROPSYCHOLOGY, V4, P261, DOI 10.1037/0894-4105.4.4.261; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799	48	105	108	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2004	75	9					1314	1322		10.1136/jnnp.2003.017046			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	846QM	WOS:000223330700020	15314123	Bronze, Green Published			2021-06-18	
J	Andreasen, JO; Andreasen, FM; Mejare, I; Cvek, M				Andreasen, JO; Andreasen, FM; Mejare, I; Cvek, M			Healing of 400 intra-alveolar root fractures. 1. Effect of pre-injury and injury factors such as sex, age, stage of root development, fracture type, location of fracture and severity of dislocation	DENTAL TRAUMATOLOGY			English	Article						root fractures; pulp healing; periodontal healing; sex; age; stage of root development; fracture type; location of fracture; severity of dislocation	PERMANENT ANTERIOR TEETH; DENTAL INJURIES; PROGNOSIS; INCISORS; CHILDREN	This retrospective study consisted of 400 root-fractured, splinted or non-splinted incisors in young individuals aged 7-17 years (mean = 11.5 +/- 2.7 SD) who were treated in the period 1959-1995 at the Department of Pediatric Dentistry, Eastman Dental Institute, Stockholm. Four hundred of these root fractures were diagnosed at the time of injury; and 344 teeth were splinted with either cap-splints, orthodontic appliances, bonded metal wires, proximal bonding with composite resin or bonding with a Kevlar(R) or glass fiber splint. In 56 teeth, no splinting was carried out for various reasons. In the present study, only pre-injury and injury factors were analyzed. In a second study, treatment variables will be analyzed. The average observation period was 3.1 years +/- 2.6 SD. The clinical and radiographic findings showed that 120 teeth out of 400 teeth (30%) had healed by hard tissue fusion of the fragments. Interposition of periodontal ligament (PDL) and bone between fragments was found in 22 teeth (5%), whereas interposition of PDL alone was found in 170 teeth (43%). Finally, non-healing, with pulp necrosis and inflammatory changes between fragments, was seen in 88 teeth (22%). In a univariate and multivariate stratified analysis, a series of clinical factors were analyzed for their relation to the healing outcome with respect to pulp healing vs. pulp necrosis and type of healing (hard tissue vs. interposition of bone and/or PDL or pulp necrosis). Young age, immature root formation and positive pulp sensibility at the time of injury were found to be significantly and positively related to both pulpal healing and hard tissue repair of the fracture. The same applied to concussion or subluxation (i.e. no displacement) of the coronal fragment compared to extrusion or lateral luxation (i.e. displacement). Furthermore, no mobility vs. mobility of the coronal fragment. Healing was progressively worsened with increased millimeter diastasis between fragments. Sex was a significant factor, as girls showed more frequent hard tissue healing than boys. This relationship could possibly be explained by the fact that girls experienced trauma at an earlier age (i.e. with more immature root formation) and their traumas were of a less severe nature. Thus, the pre-injury or injury factors which had the greatest influence upon healing (i.e. whether hard tissue fusion or pulp necrosis) were age, stage of root development (i.e. the size of the pulpal lumen at the fracture site) and mobility of the coronal fragment, dislocation of the coronal fragment and diastasis between fragments (i.e. rupture or stretching of the pulp at the fracture site).	Univ Hosp, Rigshosp, Dept Oral & Maxillofacial Surg, DK-2200 Copenhagen N, Denmark; Eastman Dent Inst, Dept Pedodont, Stockholm, Sweden	Andreasen, JO (corresponding author), Univ Hosp, Rigshosp, Dept Oral & Maxillofacial Surg, 9 Blegdamsvej, DK-2200 Copenhagen N, Denmark.	rh11323@rh.dk					ANDREASEN F M, 1985, Endodontics and Dental Traumatology, V1, P207; ANDREASEN F M, 1986, Endodontics and Dental Traumatology, V2, P90; ANDREASEN FM, 1988, ENDOD DENT TRAUMATOL, V4, P202; ANDREASEN FM, 1989, ENDOD DENT TRAUMATOL, V5, P11; ANDREASEN FM, 1994, TXB COLOR ATLAS TRAU, P279; ANDREASEN JO, 1967, J ORAL SURG, V25, P414; Andreasen JO, 2004, DENT TRAUMATOL, V20, P203, DOI 10.1111/j.1600-9657.2004.00278.x; Andreasen JO, 2001, OPER DENT, V26, P328; BIRCH R, 1986, BRIT DENT J, V160, P119, DOI 10.1038/sj.bdj.4805786; Cvek M, 2002, DENT TRAUMATOL, V18, P57, DOI 10.1034/j.1600-9657.2002.180202.x; Cvek M, 2001, DENT TRAUMATOL, V17, P53, DOI 10.1034/j.1600-9657.2001.017002053.x; DE S, 1987, J ORAL MAXILLOFAC SU, V45, P111; DEAN AG, 2000, EPI INFO 2000; Feely L, 2003, DENT TRAUMATOL, V19, P52, DOI 10.1034/j.1600-9657.2003.00119.x; Glendor U, 1996, SWED DENT J, V20, P15; GROVE GL, 1982, ARCH DERMATOL RES, V272, P381, DOI 10.1007/BF00509069; Hedegard B, 1973, Sven Tandlak Tidskr, V66, P431; HOLM-PEDERSEN P, 1971, Scandinavian Journal of Dental Research, V79, P40; JACOBSEN I, 1975, SCAND J DENT RES, V83, P355; Lentner C, 1981, GEIGY SCI TABLES, V1; MANTEL N, 1959, J NATL CANCER I, V22, P719; MOORREES COENRAAD F.A., 1963, JOUR DENT RES, V42, P1490, DOI 10.1177/00220345630420062701; RAVN JJ, 1974, COMMUNITY DENT ORAL, V2, P231, DOI 10.1111/j.1600-0528.1974.tb01658.x; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; Welbury R, 2002, Pediatr Dent, V24, P98; ZACHRISSON BU, 1975, SCAND J DENT RES, V83, P345	26	105	108	3	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	AUG	2004	20	4					192	202		10.1111/j.1600-9657.2004.00279.x			11	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	841MU	WOS:000222935300002	15245518				2021-06-18	
J	Borg, J; Holm, L; Peloso, PM; Cassidy, JD; Carroll, LJ; von Holst, H; Paniak, C; Yates, D				Borg, J; Holm, L; Peloso, PM; Cassidy, JD; Carroll, LJ; von Holst, H; Paniak, C; Yates, D			Non-surgical intervention and cost for mild traumatic brain injury: Results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; treatment; economic cost	ROUTINE FOLLOW-UP; HEAD TRAUMA; RANDOMIZED-TRIAL; HOME	We examined the evidence for non-surgical interventions and for economic costs for mild traumatic brain injury patients by a systematic search of the literature and a best-evidence synthesis. After screening 38,806 abstracts, we critically reviewed 45 articles on intervention and accepted 16 (36%). We reviewed 16 articles on economic costs and accepted 7 (44%). We found some evidence that early educational information can reduce long-term complaints and that this early intervention need not be intensive. Most cost studies were performed more than a decade ago. Indirect costs are probably higher than direct costs. Studies comparing costs for routine hospitalized observation vs the use of computerized tomography scan examination for selective hospital admission indicate that the latter policy reduces costs, but comparable clinical outcome of these policies has not been demonstrated. The sparse scientific literature in these areas reflects both conceptual confusion and limited knowledge of the natural history of mild traumatic brain injury.	Univ Uppsala Hosp, Dept Neurosci, SE-78185 Uppsala, Sweden; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Univ Iowa, Ctr Hlth, Dept Internal Med, Iowa City, IA USA; Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Glenrose Rehabil Hosp, Edmonton, AB, Canada; Univ Alberta, Edmonton, AB T6G 2M7, Canada; Univ Manchester, Hope Hosp, Dept Emergency, Manchester M13 9PL, Lancs, England	Borg, J (corresponding author), Univ Uppsala Hosp, Dept Neurosci, SE-78185 Uppsala, Sweden.	jorgen.borg@rehab.uu.se		Borg, Jorgen/0000-0002-2372-7478; Carroll, Linda/0000-0003-0876-2336			Bergman DA, 1999, PEDIATRICS, V104, P1407; BOHNEN NI, 1993, NEUROLOGY, V43, P103, DOI 10.1212/WNL.43.1_Part_1.103; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BRITTON M, 2000, 153 SBU SWED COUNC T; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; CASEY R, 1987, PEDIATRICS, V80, P159; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; CLINE DM, 1988, ANN EMERG MED, V17, P127, DOI 10.1016/S0196-0644(88)80297-X; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kyle J M, 1988, W V Med J, V84, P283; LOWDON IMR, 1989, INJURY, V20, P193, DOI 10.1016/0020-1383(89)90109-5; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; ROBERTS CJ, 1981, LANCET, V2, P791; SAUNDERS CE, 1986, ANN EMERG MED, V15, P160, DOI 10.1016/S0196-0644(86)80012-9; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	27	105	105	0	4	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			76	83		10.1080/16501960410023840			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	800QR	WOS:000220043300009	15083872	DOAJ Gold			2021-06-18	
J	Ingebrigtsen, T; Romner, B				Ingebrigtsen, T; Romner, B			Biochemical serum markers for brain damage: A short review with emphasis on clinical utility in mild head injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	International Symposium on Molecular Markers of Brain Damage - Current State and Future Perspectives	JUN 13-15, 2002	BREMEN, GERMANY			head injury; biochemical markers; creatine kinase; neuron specific enolase; S-100B protein; glial fibrillary acidic protein	NEURON-SPECIFIC ENOLASE; S-100 PROTEIN MEASUREMENTS; CREATINE-KINASE-BB; CEREBROSPINAL-FLUID; TRAUMA PATIENTS; OUTCOME PREDICTION; PROGNOSTIC VALUE; S100B LEVELS; ELIMINATION; MANAGEMENT	Purpose. To provide an overview of clinical research on the use of biochemical serum markers for traumatic brain injury (TRI) in the evaluation of patients with mild head injuries (MHI). Methods. The MEDLINE database was searched for publications on biochemical serum markers of TBI until August 2002. Clinical studies addressing their use in MHI were reviewed. Results. Desirable characteristics for biochemical serum markers of TBI were identified. Creatine kinase isoenzyme 1313 (CK-BB), neuron specific enolase (NSE) and S-100B protein have been most extensively studied. The sensitivity and specificity of CK-BB is inadequate for use as an indicator of traumatic brain injury. Serum levels of NSE do not correspond to the amount of TBI, probably because of its long (20 h) half-life. S-100B serum levels are correlated to both clinical measures of injury severity, neuroradiological findings and outcomes in several studies from different authors. Conclusion. Currently, S-100B protein is the most promising marker for evaluation of TBI in patients with MHI.	Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway; Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden	Ingebrigtsen, T (corresponding author), Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway.			Ingebrigtsen, Tor/0000-0001-5966-9786			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; BAKAY RAE, 1986, NEUROSURGERY, V18, P376, DOI 10.1227/00006123-198603000-00026; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Biberthaler P, 2000, ACT NEUR S, V76, P177; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Ergun R, 1998, NEUROL RES, V20, P418; FRIDRIKSSON T, 2001, ACAD EMERG MED, V7, P404; GRAEBER GM, 1990, CHEST, V97, P521, DOI 10.1378/chest.97.3.521; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2001, NEUROSURGERY, V49, P1272, DOI 10.1097/00006123-200111000-00058; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Missler U, 1999, CLIN CHEM, V45, P138; Mussack T, 2000, ACT NEUR S, V76, P393; Nygaard O, 1997, CLIN CHEM, V43, P541; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055; ROGULJIC A, 1989, TUMORI J, V75, P537; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wiesmann M, 1998, CLIN CHEM, V44, P1056; WONG SS, 1987, CLIN CHEM, V33, P809; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217	43	105	120	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2003	21	3-4					171	176					6	Neurosciences	Neurosciences & Neurology	745LV	WOS:000186690900009	14530579				2021-06-18	
J	Deniselle, MCG; Lopez-Costa, JJ; Saavedra, JP; Pietranera, L; Gonzalez, SL; Garay, L; Guennoun, R; Schumacher, M; De Nicola, AF				Deniselle, MCG; Lopez-Costa, JJ; Saavedra, JP; Pietranera, L; Gonzalez, SL; Garay, L; Guennoun, R; Schumacher, M; De Nicola, AF			Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease	NEUROBIOLOGY OF DISEASE			English	Article						neuroprotection; progesterone; spinal cord; neurodegeneration; Wobbler mice; amyotrophic lateral sclerosis	TRAUMATIC BRAIN-INJURY; MURINE MUTANT WOBBLER; NITRIC-OXIDE SYNTHASE; NERVOUS-SYSTEM; DEGENERATING MOTONEURONS; SUPEROXIDE-DISMUTASE; NADPH-DIAPHORASE; TRANSGENIC MODEL; MESSENGER-RNA; CELL-DEATH	Motor neuron degeneration characterizes the spinal cord of patients with amyotrophic lateral sclerosis and the Wobbler mouse mutant. Considering that progesterone (PROG) provides neuroprotection in experimental ischemia and injury, its potential role in neurodegeneration was studied in the murine model. Two-month-old symptomatic Wobbler mice were left untreated or received sc a 20-mg PROG implant for 15 days. Both light and electron microscopy of Wobbler mice spinal cord showed severely affected motor neurons with profuse cytoplasmic vacuolation of the endoplasmic reticulum and/or Golgi apparatus and ruptured mitochondria with damaged cristae, a profile indicative of a type II cytoplasmic form of cell death. In contrast to untreated mice, neuropathology was less severe in Wobbler mice receiving PROG; including a reduction of vacuolation and of the number of vacuolated cells and better conservation of the mitochondrial ultrastructure. In biochemical studies, we determined the mRNA for the alpha3 subunit of Na,K-ATPase, a neuronal enzyme controlling ion fluxes, neurotransmission, membrane potential, and nutrient uptake. In untreated Wobbler mice, mRNA levels in motor neurons were reduced by half compared to controls, whereas PROG treatment of Wobbler mice restored the expression of a3 subunit Na,K-ATPase mRNA. Therefore, PROG was able to rescue motor neurons from degeneration, based on recovery of histopathological abnormalities and of mRNA levels of the sodium pump. However, because the gene mutation in Wobbler mice is still unknown, further studies are needed to unveil the action of PROG and the mechanism of neuronal death in this genetic model of neurodegeneration. (C) 2003 Elsevier Science (USA).	Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Bioquim Humana, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencias Prof E De Rober, RA-1121 Buenos Aires, DF, Argentina; INSERM, U488, Le Kremlin Bicetre, France	De Nicola, AF (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300			Abe K, 1997, J NEUROSCI RES, V48, P63; Azcoitia I, 1999, J NEUROCYTOL, V28, P699, DOI 10.1023/A:1007025219044; BAULAC M, 1983, NEUROSCI LETT, V37, P99, DOI 10.1016/0304-3940(83)90511-6; Blondet B, 2001, NEUROSCI LETT, V305, P202, DOI 10.1016/S0304-3940(01)01741-4; Boillee S, 2001, GLIA, V33, P277, DOI 10.1002/1098-1136(20010315)33:4<277::AID-GLIA1026>3.0.CO;2-Y; Boillee S, 2002, NEUROSCIENCE, V113, P825, DOI 10.1016/S0306-4522(02)00235-X; Brinton RD, 2001, LEARN MEMORY, V8, P121, DOI 10.1101/lm.39601; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; CHUWANG IW, 1978, J COMP NEUROL, V177, P33, DOI 10.1002/cne.901770105; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Clowry GJ, 1996, NEUROSCI LETT, V215, P177, DOI 10.1016/0304-3940(96)12971-2; Coulpier M, 1996, J NEUROSCI, V16, P5897; CUDKOWICZ ME, 1998, PRINCIPLES MOL MED, P907; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Deniselle MCG, 2001, CELL MOL NEUROBIOL, V21, P237, DOI 10.1023/A:1010943104315; Deniselle MCG, 1999, NEUROCHEM RES, V24, P1, DOI 10.1023/A:1020918310281; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; DESPORTES V, 1994, NEUROREPORT, V5, P1861, DOI 10.1097/00001756-199410000-00005; Dikranian K, 2001, NEUROBIOL DIS, V8, P359, DOI 10.1006/nbdi.2001.0411; Dockery P, 1997, J ANAT, V191, P89, DOI 10.1046/j.1469-7580.1997.19110089.x; DUCHEN LW, 1968, J NEUROL NEUROSUR PS, V31, P535, DOI 10.1136/jnnp.31.6.535; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; Gonzalez S, 1996, NEUROREPORT, V7, P1041, DOI 10.1097/00001756-199604100-00017; GUANGPING X, 2001, NEUROSCI LETT, V300, P141; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Gurney ME, 2000, BIOESSAYS, V22, P297, DOI 10.1002/(SICI)1521-1878(200003)22:3<297::AID-BIES12>3.0.CO;2-I; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; HALL ED, 1982, J NEUROSURG, V49, P563; Henderson JT, 1996, J NEUROSCI, V16, P7574; Henderson VW, 1997, NEUROLOGY, V48, pS27, DOI 10.1212/WNL.48.5_Suppl_7.27S; Ikeda K, 1998, J NEUROL SCI, V160, P9, DOI 10.1016/S0022-510X(98)00224-X; Ikeda K, 2000, BRAIN RES, V858, P84, DOI 10.1016/S0006-8993(99)02427-0; IKEDA K, 1995, J NEUROSCI RES, V48, P63; JUNIER MP, 1994, J NEUROSCI, V14, P4206; Junier MP, 1998, MOL CELL NEUROSCI, V12, P168, DOI 10.1006/mcne.1998.0708; KAUPMANN K, 1992, GENOMICS, V13, P39, DOI 10.1016/0888-7543(92)90199-3; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kong JM, 1998, J NEUROSCI, V18, P3241; KRIEGER C, 1992, CAN J NEUROL SCI, V19, P462, DOI 10.1017/S0317167100041652; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; McEwen BS, 1999, J CLIN ENDOCR METAB, V84, P1790, DOI 10.1210/jc.84.6.1790; MEIRI H, 1986, BRAIN RES, V385, P193, DOI 10.1016/0006-8993(86)91566-0; Migheli A, 1999, NAT MED, V5, P966, DOI 10.1038/12381; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; Morrison BM, 1998, J COMP NEUROL, V391, P64, DOI 10.1002/(SICI)1096-9861(19980202)391:1<64::AID-CNE6>3.0.CO;2-P; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Pernas-Alonso R, 2001, NEUROBIOL DIS, V8, P581, DOI 10.1006/nbdi.2001.0403; POLLIN MM, 1990, J NEUROCYTOL, V19, P29, DOI 10.1007/BF01188437; Popper P, 1997, EXP NEUROL, V143, P246, DOI 10.1006/exnr.1996.6364; Price D L, 1994, Neurobiol Dis, V1, P3, DOI 10.1006/nbdi.1994.0002; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Spooren WPJM, 2000, CELL MOL BIOL, V46, P63; STAHL WL, 1986, NEUROCHEM INT, V8, P449, DOI 10.1016/0197-0186(86)90179-8; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Toran-Allerand C D, 2000, Novartis Found Symp, V230, P56, DOI 10.1002/0470870818.ch6; Tsuzaka K, 2001, MUSCLE NERVE, V24, P474, DOI 10.1002/mus.1029; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; WONG PC, 1995, SCIENCE, V271, P515; YU WHA, 1989, BRAIN RES, V491, P379, DOI 10.1016/0006-8993(89)90075-9; YUNG KKL, 1992, NEUROSCIENCE, V50, P209, DOI 10.1016/0306-4522(92)90393-G	74	105	106	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2002	11	3					457	468		10.1006/nbdi.2002.0564			12	Neurosciences	Neurosciences & Neurology	643NC	WOS:000180866500009	12586554				2021-06-18	
J	Yogev-Falach, M; Amit, T; Bar-Am, O; Weinstock, M; Youdim, MBH				Yogev-Falach, M; Amit, T; Bar-Am, O; Weinstock, M; Youdim, MBH			The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline	FASEB JOURNAL			English	Article						alpha-secretase; acetylcholinesterase inhibitors; signal transduction; Alzheimer's disease	ALPHA-SECRETASE CLEAVAGE; OXIDASE-B INHIBITOR; ANTI-PARKINSON DRUG; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; BETA-PROTEIN; CONVERTING-ENZYME; BRAIN; PHOSPHORYLATION; RIVASTIGMINE	Two novel neuroprotective cholinesterase (ChE) inhibitors, TV3326, (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate, and TV3279, (N-propargyl-(3S) aminoindan-5-yl)ethyl methyl carbamate, were derived from rasagiline for the treatment of Alzheimer's disease (AD). TV3326 also inhibits monoamine oxidase (MAO)-A and -B, whereas its S-isomer, TV3279, lacks MAO inhibitory activity. The action of these drugs in the regulation of amyloid precursor protein (APP) processing, using rat PC12 and human SH-SY5Y neuroblastoma cells, was examined. Both isomers stimulated the release of the non-amyloidogenic alpha-secretase form of soluble APP (sAPP) from these cell lines. The increases in sAPP induced by TV3326 and TV3279, were dose-dependent (0.1-100 muM) and blocked by the hydroxamic acid-based metalloprotease inhibitor, Ro31-9790, suggesting mediation via alpha-secretase activity. Using several signal transduction inhibitors, we identified the involvement of protein kinase C (PKC), mitogen-activated protein (MAP) kinase, and tyrosine kinase-dependent pathways in the enhancement of sAPP release by TV3326 and TV3279. In addition, both drugs directly induced the phosphorylation of p44 and p42 MAP kinase, which was abolished by the specific inhibitors of MAP kinase activation, PD98059 and U0126. These data suggest a novel pharmacological mechanism whereby these ChE inhibitors regulate the secretory processes of APP via activation of the MAP kinase pathway.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf Ctr Neurodegenerat Dis, Haifa, Israel; Technion Israel Inst Technol, Fac Med, NPF Ctr Neurodegenerat Dis, Haifa, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il					Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAVIES B, 1993, CANCER RES, V53, P2087; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; Desai A, 2001, Expert Opin Pharmacother, V2, P653, DOI 10.1517/14656566.2.4.653; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finberg J P, 1999, Adv Neurol, V80, P495; Finberg JPM, 1998, NEUROREPORT, V9, P703; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giacobini E, 1998, NEUROCHEM INT, V32, P413, DOI 10.1016/S0197-0186(97)00124-1; Giacobini E, 1996, ANN NY ACAD SCI, V777, P393, DOI 10.1111/j.1749-6632.1996.tb34451.x; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Krall WJ, 1999, ANN PHARMACOTHER, V33, P441, DOI 10.1345/aph.18211; Lamb HM, 2001, PHARMACOECONOMICS, V19, P303, DOI 10.2165/00019053-200119030-00008; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MARUYAMA W, 2002, IN PRESS NEUROSCI LE; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Mills J, 1997, J NEUROSCI, V17, P9415; MORI F, 1995, NEUROREPORT, V6, P633, DOI 10.1097/00001756-199503000-00012; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; NITSCH RM, 1993, ANN NY ACAD SCI, V695, P122, DOI 10.1111/j.1749-6632.1993.tb23039.x; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pakaski M, 2001, NEUROCHEM INT, V38, P219, DOI 10.1016/S0197-0186(00)00091-7; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Racchi M, 2001, MOL PSYCHIATR, V6, P520, DOI 10.1038/sj.mp.4000878; Rossner S, 2000, EUR J NEUROSCI, V12, P3191, DOI 10.1046/j.1460-9568.2000.00211.x; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1994, J NEUROSCI, V14, P2117; Solano DC, 2000, FASEB J, V14, P1015; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.0.CO;2-Z; Weinstock M, 2001, ANN NY ACAD SCI, V939, P148; WEINSTOCK M, 2000, J NEURAL TRANSM-SUPP, V60, pS157; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45	80	105	106	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1674	+		10.1096/fj.02-0198fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	WOS:000177814000010	12206996				2021-06-18	
J	Noshita, N; Lewen, A; Sugawara, T; Chan, PH				Noshita, N; Lewen, A; Sugawara, T; Chan, PH			Akt phosphorylation and neuronal survival after traumatic brain injury in mice	NEUROBIOLOGY OF DISEASE			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; MITOCHONDRIAL CYTOCHROME-C; CONTROLLED CORTICAL IMPACT; TRANSIENT FOCAL ISCHEMIA; DNA FRAGMENTATION; CELL-DEATH; PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; ACTIVATION	The serine-threonine kinase, Akt, is involved in the survival signaling pathways in many cell systems. The present study examined phosphorylation of Akt at serine-473 and DNA fragmentation after traumatic brain injury (TBI) in mice. Immunohistochemistry showed phospho-Akt was decreased in the injured cortex 1 h after TBI, whereas it was temporally increased at 4 h in the perifocal damaged cortex. In the CA1 region of the hippocampus, phospho-Akt was increased after TBI. Western blot analysis showed that Akt was significantly decreased as early as 1 h after trauma; however, the phosphorylation was accelerated at 4 h. Double staining with phospho-Akt and phospho-BAD or phospho-GSK-3beta revealed the colocalization of phospho-Akt and downstream elements. Double staining with phospho-Akt and terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling showed different cellular distributions after TBI. The present study implicates Akt phosphorylation in the signaling pathways that are involved in cell survival after TBI. (C) 2002 Elsevier Science (USA).	Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA	Noshita, N (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036147, R01NS025372, R01NS038653] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 36147, NS 38653, NS 25372, NS 14534] Funding Source: Medline		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Enari M, 1998, NATURE, V391, P43; Frank J., 1997, RETINOIDS, V13, P88; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujimura M, 1999, J CEREBR BLOOD F MET, V19, P495, DOI 10.1097/00004647-199905000-00003; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Janelidze S, 2001, NEUROBIOL DIS, V8, P147, DOI 10.1006/nbdi.2000.0325; KERR LE, 2001, J CEREB BLOOD FLOW S, V21, pS44; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Namikawa K, 2000, J NEUROSCI, V20, P2875; Namura S, 2000, J CEREBR BLOOD F MET, V20, P1301, DOI 10.1097/00004647-200009000-00004; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; RINK A, 1995, AM J PATHOL, V147, P1575; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Springer JE, 2000, J NEUROSCI, V20, P7246; Srivastava AK, 1998, MOL CELL BIOCHEM, V182, P135, DOI 10.1023/A:1006857527588; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	105	108	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	APR	2002	9	3					294	304		10.1006/nbdi.2002.0482			11	Neurosciences	Neurosciences & Neurology	545AF	WOS:000175193500003	11950275				2021-06-18	
J	Fichtenberg, NL; Zafonte, RD; Putnam, S; Mann, NR; Millard, AE				Fichtenberg, NL; Zafonte, RD; Putnam, S; Mann, NR; Millard, AE			Insomnia in a post-acute brain injury sample	BRAIN INJURY			English	Article							MINOR HEAD-INJURIES; SLEEP DISTURBANCES; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; DISORDERS; COMPLAINTS; PREVALENCE; CONCUSSION; SYMPTOMS; QUALITY	Objective: The purpose was to establish the frequency of insomnia within the post-acute TBI population and compare it with insomnia rates among other rehabilitation outpatients. Design: A prospective study was undertaken of 50 consecutive post-acute TBI admissions and a comparison group of 50 rehabilitation outpatients evenly divided between spinal cord injury (SCI) and musculoskeletal (MSK) cases. Setting: Subjects were recruited at various outpatient clinics of a major rehabilitation hospital. Patients: Among the TBI subjects, the predominant cause of injury was motor vehicle accident; both mild and severe injuries were well represented in the sample; and, on average, patients were almost 4 months post-injury. The comparison and TBI groups did not differ significantly with respect to education or marital status. However, the MSK group was older and a higher proportion of the SCI group was female. Measures: The Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and sleep diaries were administered to the TBI group. Only the PSQI and BDI were completed by the comparison group. Results: Thirty per cent of the patients were found to suffer from insomnia. Sleep initiation was a problem almost twice as often as sleep duration. An additional 12% did not meet the DSM-IV criteria for insomnia but, nevertheless, experienced a degradation of sleep quality, as measured by the PSQI. Conversely, only slightly more than half (58%) of the TBI sample reported sleep to be relatively normal and satisfactory. Insomnia was also commonly reported by the patients in the rehabilitation comparison groups. They generated significantly higher mean PSQI Global Scores relative to the TBI group and the frequency of poor sleep quality was elevated significantly above the TBI rate. Relative to the TBI cases, twice as many comparison group patients were classified by the PSQI as insomniacs. Conclusion: Poor sleep quality and insomnia were definitely problems for the TBI group, although the magnitude of these problems was much greater for the rehabilitation comparison group. Degraded and disordered sleep may represent widespread challenges within the rehabilitation population in general.	Rehabil Inst Michigan, Novi Ctr, Novi, MI 48337 USA; Wayne State Univ, Sch Med, Detroit, MI 48202 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; Univ Michigan Hosp & Hlth Care Ctrs, Ann Arbor, MI USA	Fichtenberg, NL (corresponding author), Rehabil Inst Michigan, Novi Ctr, 42005 W 12 Mile Rd, Novi, MI 48337 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CLARK CM, 1992, ARCH NEUROL-CHICAGO, V49, P641, DOI 10.1001/archneur.1992.00530300077013; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; FACTOR SA, 1990, MOVEMENT DISORD, V5, P280, DOI 10.1002/mds.870050404; FERINISTRAMBI L, 1994, J NEUROL SCI, V125, P194, DOI 10.1016/0022-510X(94)90035-3; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; GISLASON T, 1987, ACTA MED SCAND, V221, P475; Hagen C, 1979, REHABILITATION HEAD, P87; HOLLEY JL, 1992, AM J KIDNEY DIS, V19, P156, DOI 10.1016/S0272-6386(12)70125-7; HYPPA MT, 1989, J CLIN EPIDEMIOL, V42, P633; JANSON C, 1995, SLEEP, V18, P589; JANSON C, 1990, RESP MED, V84, P37, DOI 10.1016/S0954-6111(08)80092-3; JENNUM P, 1993, J RHEUMATOL, V20, P1756; KALES A, 1971, CLIN PHARMACOL THER, V12, P397; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KRUPP LB, 1993, J PSYCHOSOM RES, V37, P325, DOI 10.1016/0022-3999(93)90134-2; LAVERDIERE M, 1984, SLEEP RES, V13, P177; LEES AJ, 1988, CLIN NEUROPHARMACOL, V11, P512, DOI 10.1097/00002826-198812000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHIAVI RC, 1993, BIOL PSYCHIAT, V34, P171, DOI 10.1016/0006-3223(93)90388-T; SHAPIRO CM, 1993, BRIT MED J, V306, P1532, DOI 10.1136/bmj.306.6891.1532; SRIDHAR GR, 1994, DIABETES RES CLIN PR, V23, P183, DOI 10.1016/0168-8227(94)90103-1; TACHIBANA N, 1994, EUR NEUROL, V34, P320, DOI 10.1159/000117070; VANKEIMPEMA ARJ, 1995, J ASTHMA, V32, P69, DOI 10.3109/02770909509089502; VERMA NP, 1991, J EPILEPSY, V4, P217, DOI 10.1016/0896-6974(91)90079-X; WITTIG RM, 1982, J NERV MENT DIS, V170, P429, DOI 10.1097/00005053-198207000-00011; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304	36	105	108	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2002	16	3					197	206		10.1080/02699050110103940			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	526HP	WOS:000174124800002	11874613				2021-06-18	
J	Shibuya, S; Miyamoto, O; Auer, RN; Itano, T; Mori, S; Norimatsu, H				Shibuya, S; Miyamoto, O; Auer, RN; Itano, T; Mori, S; Norimatsu, H			Embryonic intermediate filament, nestin, expression following traumatic spinal cord injury in adult rats	NEUROSCIENCE			English	Article						glial fibrillary acidic protein; subpial astrocyte; radial glia; pial surface; immunohistochemistry; neural regeneration	CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; GROWTH-FACTOR; BRAIN INJURY; WALLERIAN DEGENERATION; SUBEPENDYMAL CELLS; PROGENITOR CELLS; PYRAMIDAL TRACT; MESSENGER-RNA; ASTROCYTES	Precursor cells in the ependyma of the lateral ventricles of adult mammalian brain have been reported in brain, and also in the spinal cord. The present study used antibody to the intermediate filament protein (nestin) as an immunohistochemical marker for neural stem cells and precursor cells in a rat model of spinal cord trauma. Male Sprague-Dawley rats (n = 25) had a laminectomy at Th11-Th12, and spinal cord contusion was created by compression with 30 g of force for 10 min. The rats were killed at 24 h, 1 week and 4 weeks after injury, and four levels of the spinal cord were examined: 5 mm and 10 mm, both rostral and caudal region to the injury center. Time- and region-dependent alterations of nestin immunoreactivity were analyzed. Revealed at 24 h post-injury, 5 min rostral and caudal to the lesions, nestin expression was observed in ependymal cells and around the hemorrhagic and necrotic lesion located in dorsal spinal cord, peaking at 1 week after injury. Moreover, nestin expression was also observed in the white matter of ventral spinal cord, extending into arborizing processes centripetally from the pial surface toward the central canal. At 4 weeks after injury, nestin expression in ependyma decreased 10 min from the injury site. But nestin expression in white matter increased dramatically with a 100-fold increase in nestin originating from the pial surface, and extension now to all the white matter. The latter was accompanied by glial fibrillary acidic protein positivity into very long arborizing processes, morphologically compatible with radial glia. The findings suggest two possible sources of precursor cells in adult mammalian spinal cord; ependyma of the central canal and subpial astrocytes. Subpial astrocytes may be associated with neural repair and regeneration after spinal cord injury. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Kagawa Med Univ, Dept Biol, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Orthopaed Surg, Miki, Kagawa 7610793, Japan; Univ Calgary, Fac Med, Neurosci Res Grp, Dept Pathol & Lab Med, Calgary, AB T2N 4N1, Canada	Itano, T (corresponding author), Kagawa Med Univ, Dept Biol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	toshi@kms.ac.jp	Auer, Roland/G-7164-2011	Auer, Roland/0000-0001-9044-3419	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [14571383] Funding Source: KAKEN		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Ajtai BM, 2000, ANAT EMBRYOL, V202, P313, DOI 10.1007/s004290000117; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; CHOI BH, 1978, BRAIN RES, V148, P295, DOI 10.1016/0006-8993(78)90721-7; COLLINS GH, 1986, J NEUROPATH EXP NEUR, V45, P742, DOI 10.1097/00005072-198611000-00010; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; FUJITA S, 1964, J COMP NEUROL, V122, P311, DOI 10.1002/cne.901220303; FUJITA S, 1962, EXP CELL RES, V28, P52, DOI 10.1016/0014-4827(62)90311-7; FUJITA S, 1963, J COMP NEUROL, V120, P37, DOI 10.1002/cne.901200104; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gritti A, 1996, J NEUROSCI, V16, P1091; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; Horner PJ, 2000, J NEUROSCI, V20, P2218; Inoue T, 1998, NEUROSCI LETT, V247, P151, DOI 10.1016/S0304-3940(98)00297-3; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVINE JM, 1994, J NEUROSCI, V14, P4716; LEVITT P, 1980, J COMP NEUROL, V193, P815, DOI 10.1002/cne.901930316; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LUDWIN SK, 1990, ACTA NEUROPATHOL, V80, P184, DOI 10.1007/BF00308922; LUDWIN SK, 1984, NATURE, V308, P274, DOI 10.1038/308274a0; Matsuda M, 1996, BRAIN RES, V723, P177, DOI 10.1016/0006-8993(96)00243-0; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; MILLER RH, 1984, J NEUROSCI, V4, P585; MITSUHASHI T, 1994, PARAPLEGIA, V32, P524, DOI 10.1038/sc.1994.84; Mokry J, 1999, Gen Physiol Biophys, V18 Suppl 1, P25; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; PUCHALA E, 1977, EXP NEUROL, V55, P1, DOI 10.1016/0014-4886(77)90155-8; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Salgado-Ceballos H, 1998, BRAIN RES, V782, P126; SASAKI H, 1989, BRAIN RES, V501, P339, DOI 10.1016/0006-8993(89)90651-3; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; Shibasaki K, 1981, Nihon Seikeigeka Gakkai Zasshi, V55, P1693; SMITH AJK, 1978, J NEUROSURG, V48, P239, DOI 10.3171/jns.1978.48.2.0239; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TOHYAMA T, 1992, LAB INVEST, V66, P303; TOLBERT DL, 1987, J COMP NEUROL, V260, P299, DOI 10.1002/cne.902600210; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Umeoka S, 2001, EPILEPSY RES, V43, P249, DOI 10.1016/S0920-1211(00)00200-X; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Weiss S, 1996, J NEUROSCI, V16, P7599; Whittemore SR, 1999, EXP CELL RES, V252, P75, DOI 10.1006/excr.1999.4621	67	105	112	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2002	114	4					905	916	PII S0306-4522(02)00323-8	10.1016/S0306-4522(02)00323-8			12	Neurosciences	Neurosciences & Neurology	613LZ	WOS:000179134900009	12379246				2021-06-18	
J	Van Landeghem, FKH; Stover, JF; Bechmann, I; Bruck, W; Unterberg, A; Buhrer, C; Von Deimling, A				Van Landeghem, FKH; Stover, JF; Bechmann, I; Bruck, W; Unterberg, A; Buhrer, C; Von Deimling, A			Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat	GLIA			English	Article						astrocytes; controlled cortical impact injury; glutamate; glutamate transporter; glutamate uptake; microglia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMINO-ACID TRANSPORTER; RELEASE; LOCALIZATION; GLT-1; EXCITOTOXICITY; INHIBITION; INCREASES; NEURONS; MODEL	Traumatic brain injury is followed by increased extracellular glutamate concentration. Uptake of glutamate is mainly mediated by the glial glutamate transporters GLAST and GLT-1. Extent and distribution of GLAST and GLT-1 were studied in a rat model of controlled cortical impact injury (CCH). Western Blot analysis revealed lowest levels of GLAST and GLT-1 with a decrease by 40%-54% and 42%-49% between 24 and 72 h posttrauma. By 8 h after CCll, CSF glutamate levels were increased (10.5 muM vs. 2.56 VM in controls; P < 0.001), reaching maximum values by 48 h. A significant increase in de novo GLAST and GLT-1 expressing ramified microglia was observed within 4 h, reached a stable level by 48 li, and remained high up to 72 h after CCH. Furthermore, ramified microglia de novo expressed the neuronal glutamate transporter EAAC1 after CCII Following CCII, GLAST/GLT-1 and GFAP coexpressing astrocytes were immediately reduced, reaching minimum levels within 8 h. This reduction of expression could be either due to protein downregulation or loss of astrocytes. At 72 h, a marked population of GLAST- and GLT-1-positive reactive astrocytes appeared. These results support the hypothesis that reduced astrocytic GLAST and GLT-1 protein levels following MI contribute to evolving secondary injury. Microglia are capable of de novo expressing glutamate transporter proteins, indicating that the expression of glial and neuronal glutamate transporters is not restricted to a specific glial or neuronal lineage. Ramified microglia may play an important compensatory role in the early regulation of extracellular glutamate after CCII. (C) 2001 Wiley-Liss, Inc.	Humboldt Univ, Inst Neuropathol, Charite, D-13353 Berlin, Germany; Humboldt Univ, Dept Neurosurg, Charite, D-13353 Berlin, Germany; Humboldt Univ, Inst Anat, Dept Cell & Neurobiol, Charite, D-13353 Berlin, Germany; Humboldt Univ, Dept Neonatol, Charite, D-13353 Berlin, Germany	Van Landeghem, FKH (corresponding author), Humboldt Univ, Inst Neuropathol, Charite, Charite Campus Virchow Klinikum,Augustenburger Pl, D-13353 Berlin, Germany.	frank.van_landeghem@charite.de	; von Deimling, Andreas/F-7774-2013	van Landeghem, Frank/0000-0002-9404-7031; von Deimling, Andreas/0000-0002-5863-540X			Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BALEAR VJ, 1972, J NEUROCHEM, V19, P2657; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; JOHNSTON GAR, 1981, GLUTAMATE TRANSMITTE, P77; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; Klose J, 1999, METH MOL B, V112, P67; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEVY LM, 1993, FEBS LETT, V317, P79, DOI 10.1016/0014-5793(93)81495-L; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; Li S, 1999, J NEUROSCI, V19, P1; LOGAN WJ, 1972, BRAIN RES, V42, P413, DOI 10.1016/0006-8993(72)90540-9; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; Rutledge EM, 1996, J NEUROSCI, V16, P7803; Rutledge EM, 1998, AM J PHYSIOL-CELL PH, V274, pC1511; SCHNEIDER GH, 1992, CAN J PHYSIOL PHARM, V70, pS334, DOI 10.1139/y92-280; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; STREIT WJ, 1985, J HISTOCHEM CYTOCHEM, V33, P1042, DOI 10.1177/33.10.4045182; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Swanson RA, 1997, J NEUROSCI, V17, P932; TANAKA H, 1994, ACTA NEUROCHIR, P524; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x	48	105	106	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	SEP	2001	35	3					167	179		10.1002/glia.1082			13	Neurosciences	Neurosciences & Neurology	470TB	WOS:000170886300001	11494408				2021-06-18	
J	McIntosh, AS; McCrory, P; Comerford, J				McIntosh, AS; McCrory, P; Comerford, J			The dynamics of concussive head impacts in rugby and Australian rules football	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						biomechanics; head injury		A study was commenced in 1998 at the University of New South Wales (UNSW) to investigate the dynamics of head impacts in football which resulted in concussion. Sixty-eight cases of medically verified concussion from Australian Rules Football and 32 from Rugby Union and Rugby League were analyzed. Video of each injury event was analyzed to obtain descriptive data regarding the head impact site and striking object. The video was analyzed quantitatively to obtain estimates of the closing speeds. A secondary analysis was undertaken using the conservation of momentum and energy relationships to estimate the change in velocity of the head during the impact, the change in momentum of the head, and the energy imparted to the head. Ninety-seven cases involved direct head contact, whereas three cases involved impulsive loading via the trunk. The majority of impacts were to the tempero-parietal region, and the striking body segment was commonly the ann or shoulder/thorax. The mean change in velocity of the head and head impact energy for all 97 cases of direct head impact were 4 m.s(-1) and 56 J, respectively. Head impact energy can be used as a performance criteria for testing and developing headgear for rugby and Australian rules football.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Dept Neurol, Austin & Repatriat Med Ctr, Heidelberg, Vic 3084, Australia	McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.		McCrory, Paul/Q-8688-2019				*AUSTR NAT HLTH ME, 1994, FOOTB INJ HEAD NECK, P78; ENOUEN S, 1986, P 37 STAPP CAR CRASH, P199; McCrory P, 1998, SPORTS NEUROLOGY, P441; McIntosh A. S., 1992, P 1992 INT C BIOM IM, P51; MCINTOSH AS, 1993, P 37 STAPP CAR CRASH, P43; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; SEWARD H, 1986, 3 YEAR SURVEY VICTOR, P11; Winter DA, 1990, BIOMECHANICS MOTOR C, P56	8	105	106	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2000	32	12					1980	1984		10.1097/00005768-200012000-00002			5	Sport Sciences	Sport Sciences	380BG	WOS:000165678000002	11128839				2021-06-18	
J	Kaya, SS; Mahmood, A; Li, Y; Yavuz, E; Goksel, M; Chopp, M				Kaya, SS; Mahmood, A; Li, Y; Yavuz, E; Goksel, M; Chopp, M			Apoptosis and expression of p53 response proteins and cyclin D1 after cortical impact in rat brain	BRAIN RESEARCH			English	Article						apoptosis; DNA fragmentation; DNA repair; cortical impact; temporal profile; rat; hippocampus	PROGRAMMED CELL-DEATH; CEREBRAL-ARTERY OCCLUSION; SPATIAL MEMORY DEFICITS; FLUID-PERCUSSION MODEL; DNA-DAMAGE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ISCHEMIC-INJURY; GRANULE CELLS; FRAGMENTATION	We measured the temporal profile and cellular identification of apoptosis in rat brain after cortical contusion injury. Double staining immunohistochemistry was also used to investigate the relationship between apoptotic cell death and selective protein expression associated with DNA damage and repair (p53, Bar, MDM2, WAF1, Gadd45, PCNA) and cell cycle protein, Cyclin D1, in male Wistar rats 48 h after injury. Cortical contusion was induced in male Wistar rats with a pneumatic impactor device. The animals were sacrificed at different times after trauma (1, 2, and 14 h and 1, 2, 4, 7 and 14 days; n = 4 per time point). Sham-operated rats (a = 4) and normal rats not subjected to any surgical procedure (n = 4) were used as controls for temporal profile determination Additional 11 rats were used for study of protein expression. Coronal brain sections were analyzed using an in situ terminal deoxynucleotdyl transferase-mediated biotinylated deoxyuridine triphosphate nick end labeling (TUNEL), hematoxylin, and immunohistochemical double staining methods. Apoptotic cells were observed as early as 2 h after the impact. Apoptotic cell death peaked at 2 days, gradually tapering off afterward, although scattered apoptotic cells were detected at 2 weeks after the impact. The number of apoptotic cells at 2 days far exceeded their number at other times (p = 0.009). Apoptotic cells were observed primarily in the cortex adjacent to the site of injury. In addition, apoptotic cells in conjunction with few injured cells were present in the ipsilateral hippocampus and localized to the granule layer of dentate gyrus. Our data indicate that DNA fragmentation is present in nearly all neurons subacutely after cortical contusion and persists for at least 2 weeks thereafter. Apoptosis is also present in neurons localized to the hilus of the dentate gyrus at a site remote from the area of injury suggesting a selective role for apoptosis in promoting secondary brain damage and dysfunction after traumatic brain injury. Using double staining, we were able to show that a great majority of apoptotic cells (> 95%) were neurons and the rest were astrocytes and endothelial cells. Proteins associated with DNA damage and repair (p53, Bar, MDM2, WAF1, Gadd 45, PCNA) were expressed in the cytoplasm of normal cells of naive and sham rats. These proteins were translocated to the nuclei of apoptotic and injured cells at 48 h after cortical contusion. Cyclin D1 was not present in apoptotic cells. The differential expression of proteins associated with DNA damage, repair and the cell cycle protein Cyclin D1 in the contused brain suggest a potential role for these proteins in cell survival and apoptosis after cortical contusion. (C) 1999 Published by Elsevier Science B.V. All rights reserved.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035504, P01NS023393] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS35504, P01 NS23393] Funding Source: Medline		BABB L, 1991, ADV NEUROL, V44, P949; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BREDESEN DE, 1994, APOPTOSIS 2, V1, P397; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CALNE DB, 1994, NEUROLOGY, V44, P5; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DASH PK, 1995, J NEUROSCI, V15, P2030; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; Duchen L. W., 1992, GREENFIELDS NEUROPAT, P1; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GARCIA JH, 1993, AM J PATHOL, V142, P623; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; GU Y, 1993, NATURE, V366, P701; GUDAS M, 1994, CELL GROWTH DIFFER, V5, P294; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P557; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASTAN MB, 1991, CANCER RES, V51, P6304; KENR SE, 1991, SCIENCE, V252, P1608; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LI Y, 1995, AM J PATHOL, V146, P1045; Liu XZ, 1997, J NEUROSCI, V17, P5395; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LUNA RMD, 1995, NATURE, V378, P203; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARTIN DP, 1991, BIOL BASIS CELL DEAT, V3, P247; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLNEY JW, 1983, BRAIN RES BULL, V10, P699, DOI 10.1016/0361-9230(83)90038-2; PAXINOS G, 1986, RAT BRAIN STREEOTAXI; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; POSMANTUR R, 1997, NEUROSCIENCE, V77, P765; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cellbio.8.1.529; RINK A, 1995, AM J PATHOL, V147, P1; ROSE CD, 1993, NEURODEGENERATION, V2, P2878; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SCHREIBER SS, 1994, EXP NEUROL, V130, P368, DOI 10.1006/exnr.1994.1216; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; SELVAKUMARAN M, 1994, ONCOGENE, V9, P179; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TOMINAGA T, 1993, BRAIN RES, V608, P21, DOI 10.1016/0006-8993(93)90768-I; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; WYLIE AH, 1980, INT REV CYTOL, V68, P251; WYLIE AH, 1980, NATURE, V284, P555	78	105	118	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 6	1999	818	1					23	33		10.1016/S0006-8993(98)01204-9			11	Neurosciences	Neurosciences & Neurology	163BC	WOS:000078381500003	9914434				2021-06-18	
J	BRYAN, RM; CHERIAN, L; ROBERTSON, C				BRYAN, RM; CHERIAN, L; ROBERTSON, C			REGIONAL CEREBRAL BLOOD-FLOW AFTER CONTROLLED CORTICAL IMPACT INJURY IN RATS	ANESTHESIA AND ANALGESIA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; ARTERY OCCLUSION; HEAD-INJURY; ISCHEMIA; CIRCULATION; THRESHOLDS	Regional cerebral blood flow (rCBF) and laser-Doppler perfusion were measured in rats after controlled cortical impact injury (CCII), a model of traumatic brain injury. Male Long-Evans rats were anesthetized with isoflurane and surgically prepared with arterial and venous cannulae. CCII was induced after a craniectomy by deforming the right parietal cortex to a depth of 2 mm with a metal cylinder traveling at a velocity of 5.2 m/s. Laser-Doppler perfusion was monitored from the surface of the left frontal cortex. rCBF, using C-14-isopropyliodoamphetamine, and laser-Doppler perfusion were measured in three groups of rats consisting of a sham group (n = 6), a group 30 min after CCII (n = 6), and a group 4 h after CCII (n = 5). CCII was characterized by cortical ischemia (rCBF < 20 mL.100 g(-1).min(-1)) surrounding the site of impact. The occipital cortex, a cortical region distant from the impact site, was also ischemic in some, but not all, injured rats. In the 30-min group, the ischemic zone showed very sharp boundaries with cortical areas of hyperperfusion surrounding the ischemic zone. In the 4-h group, the ischemic boundaries were not as sharp and the hyperperfusion surrounding the ischemic zone was no longer present. The caudate-putamen, hippocampus, and thalamus showed significant reductions in rCBF ranging from 50% to 30% of control 30 min and 4 h postinjury, respectively. We conclude that complex changes in rCBF occur shortly after CCII and persist for at least 4 h. During this time several brain regions, especially the cortical areas, may suffer damage due to the ischemia.	BAYLOR COLL MED,DEPT NEUROSURG,HOUSTON,TX 77030	BRYAN, RM (corresponding author), BAYLOR COLL MED,DEPT ANESTHESIOL,ROOM 434D,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL041960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [NIHLB-41960] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		ADAMS H, 1972, SCI F NEUROLOGY, P478; BLAIR RDG, 1970, NEUROLOGY, V20, P802, DOI 10.1212/WNL.20.8.802; BOLANDER HG, 1989, STROKE, V20, P930, DOI 10.1161/01.STR.20.7.930; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRYAN RM, 1988, AM J PHYSIOL, V255, pR295; BRYAN RM, 1986, J NEUROSCI METH, V17, P311, DOI 10.1016/0165-0270(86)90132-9; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRAHAM DI, 1971, LANCET, V1, P265; HARRIS RJ, 1984, J CEREBR BLOOD F MET, V4, P178, DOI 10.1038/jcbfm.1984.26; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOEDTRASMUSSEN K, 1967, ARCH NEUROL-CHICAGO, V17, P271, DOI 10.1001/archneur.1967.00470270049007; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NARITOMI H, 1988, J CEREBR BLOOD F MET, V8, P16, DOI 10.1038/jcbfm.1988.3; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P414, DOI 10.1038/jcbfm.1986.74; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; Palkovits M., 1988, MAPS GUIDE MICRODISS; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SHIGENO T, 1985, SURG NEUROL, V24, P47, DOI 10.1016/0090-3019(85)90063-1; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P61, DOI 10.1038/jcbfm.1981.7; YAMAGUCHI T, 1971, NEUROLOGY, V21, P565, DOI 10.1212/WNL.21.6.565; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	41	105	106	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	1995	80	4					687	695		10.1097/00000539-199504000-00007			9	Anesthesiology	Anesthesiology	QP462	WOS:A1995QP46200007	7893019				2021-06-18	
J	GRAY, BG; ICHISE, M; CHUNG, DG; KIRSH, JC; FRANKS, W				GRAY, BG; ICHISE, M; CHUNG, DG; KIRSH, JC; FRANKS, W			TECHNETIUM-99M-HMPAO SPECT IN THE EVALUATION OF PATIENTS WITH A REMOTE HISTORY OF TRAUMATIC BRAIN INJURY - A COMPARISON WITH X-RAY COMPUTED-TOMOGRAPHY	JOURNAL OF NUCLEAR MEDICINE			English	Article							CLOSED HEAD-INJURY; MAGNETIC-RESONANCE; TRAUMA; LESIONS; MILD; MR; CT	The functional imaging modality has potential for demonstrating parenchymal abnormalities not detectable by traditional morphological imaging. Fifty-three patients with a remote history of traumatic brain injury (TBI) were studied with SPECT using Tc-99m-hexamethylpropyleneamineoxime (HMPAO) and x-ray computed tomography (CT). Overall, 42 patients (80%) showed regional cerebral blood flow (rCBF) deficits by HMPAO SPECT, whereas 29 patients (55%) showed morphological abnormalities by CT. Out of 20 patients with minor head injury, 12 patients (60%) showed rCBF deficits and 5 patients (25%) showed CT abnormalities. Of 33 patients with major head injury, 30 patients (90%) showed rCBF deficits and 24 patients (72%) showed CT abnormalities. Thus, HMPAO SPECT was more sensitive than CT in detecting abnormalities in patients with a history of TBI, particularly in the minor head injury group. In the major head injury group, three patients showed localized cortical atrophy by CT and normal rCBF by HMPAO SPECT. In the evaluation of TBI patients, HMPAO SPECT is a useful technique to demonstrate regional brain dysfunction in the presence of morphological integrity as assessed by CT.	MT SINAI HOSP, DEPT RADIOL, ROOM 635, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; W PK HOSP, DEPT REHABIL MED, TORONTO, ONTARIO, CANADA							ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; CHANG LT, 1978, IEEE T NUCL SCI, V25, P638, DOI 10.1109/TNS.1978.4329385; FISHER JM, 1985, SEMIN NEUROL, V5, P197, DOI 10.1055/s-2008-1041516; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GEORGE J K, 1989, Journal of Nuclear Medicine, V30, P802; GRAY B, 1990, Journal of Nuclear Medicine, V31, P936; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1979, CENTRAL NERVOUS SYST, P204; JOLLES PR, 1989, J NUCL MED, V30, P1589; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRELINA M, 1989, CAN J NEUROL SCI, V2, P279; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; NEWTON MR, 1989, NUCL MED COMMUN, V10, P254; NIMMON C C, 1989, European Journal of Nuclear Medicine, V15, P507; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF RM, 1990, NEUROPSYCHOLOGICAL F, P161; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; SOUDER E, 1990, Journal of Nuclear Medicine, V31, P876; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	39	105	107	0	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	JAN	1992	33	1					52	58					7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	GY676	WOS:A1992GY67600017	1730996				2021-06-18	
J	TAKAHASHI, H; MANAKA, S; SANO, K				TAKAHASHI, H; MANAKA, S; SANO, K			CHANGES IN EXTRACELLULAR POTASSIUM CONCENTRATION IN CORTEX AND BRAIN-STEM DURING THE ACUTE PHASE OF EXPERIMENTAL CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article										TAKAHASHI, H (corresponding author), UNIV TOKYO HOSP,DEPT NEUROSURG,BUNKYO KU,TOKYO,JAPAN.						AOYAGI N, 1979, CLIN ELECTROENCEPHAL, V21, P482; ASTRUP J, 1980, BRAIN RES, V199, P161, DOI 10.1016/0006-8993(80)90238-3; BOURKE RS, 1979, NEURAL TRAUMA, P95; BURES J, 1958, J COMP PHYSIOL PSYCH, V51, P263, DOI 10.1037/h0048462; BURES J, 1975, EPILEPSIA, V16, P111, DOI 10.1111/j.1528-1157.1975.tb04727.x; BURESOVA O, 1979, PHYSIOL BOHEMOSLOV, V28, P243; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DUDEL J, 1978, FUNDAMENTALS NEUROPH, P19; Eidelberg E, 1975, Surg Neurol, V3, P317; FOLTZ EL, 1953, J NEUROSURG, V10, P342, DOI 10.3171/jns.1953.10.4.0342; GURDJIAN ES, 1975, IMPACT HEAD INJURY, P139; Hashimoto I, 1979, Neurol Res, V1, P39; HUBSCHMANN OR, 1980, J NEUROSURG, V52, P456, DOI 10.3171/jns.1980.52.4.0456; HUBSCHMANN OR, 1980, J NEUROSURG, V53, P272; KIMELBERG HK, 1979, NEURAL TRAUMA, P137; KONIG JFR, 1963, RAT BRAIN STEREOTAXI; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LUX HD, 1976, ARCH PSYCHIAT NERVEN, V221, P227, DOI 10.1007/BF00418482; MANAKA S, 1977, J JPN ACCIDENT MED A, V28, P202; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; PORTNOY HD, 1980, J NEUROSURG, V53, P272; SEKINO H, 1980, Neurologia Medico-Chirurgica, V20, P127; SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822; WALKER EA, 1944, J NEUROSURG, V1, P103; WALKER JL, 1971, ANAL CHEM, V43, pA89, DOI 10.1021/ac60298a039	25	105	106	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1981	55	5					708	717		10.3171/jns.1981.55.5.0708			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MN520	WOS:A1981MN52000006	7310492				2021-06-18	
J	Schinke, RJ; Stambulova, NB; Si, GY; Moore, Z				Schinke, Robert J.; Stambulova, Natalia B.; Si, Gangyan; Moore, Zella			International society of sport psychology position stand: Athletes' mental health, performance, and development	INTERNATIONAL JOURNAL OF SPORT AND EXERCISE PSYCHOLOGY			English	Article						mental health; elite athletes; career stressors; holistic development	BRUNEL MOOD SCALE; ELITE; MINDFULNESS; PREVALENCE; TRANSITIONS; CONCUSSION; DEPRESSION; SYMPTOMS; CAREERS; INJURY	Mental health is a major resource for athletes in relation to their performance and development. Concurrently, athletes experience additional mental health risk factors compared to non-athletic population, such as high training loads, tough competitions, and a stressful lifestyle. Contemporary statistics demonstrate a substantial growth in athletes' mental health-related problems, such as concussion, overtraining, and identity crisis. Therefore, the International Society of Sport Psychology through this Position Stand provides support to sport psychology researchers, practitioners, sport participants, and stakeholders in understanding: (a) mental health phenomenon based on continuum-type models outlining mental illness (prevalence vs. absence) and mental health in association with peak performance, (b) major findings of research dealing with athletes' performance, career and personal (e.g. identity) development in relation to mental health issues, and (c) interventions aimed at monitoring and maintaining athletes' mental health as well as preventing various forms of mental ill-being. Five major sections reflect the logic outlined above (i.e. from definitions and theories to research and practice), complemented by 10 postulates summarising the International Society of Sport Psychology message intended to spur further discussions on how to make athletes healthier and, thus, more resourceful for (and through) sport.	[Schinke, Robert J.] Laurentian Univ, Sch Human Kinet, Sudbury, ON, Canada; [Stambulova, Natalia B.] Halmstad Univ, Sch Hlth & Welf, Halmstad, Sweden; [Si, Gangyan] Hong Kong Inst Educ, Dept Hlth & Phys Educ, Hong Kong, Peoples R China; [Moore, Zella] Manhattan Coll, Dept Psychol, Bronx, NY 10471 USA	Schinke, RJ (corresponding author), Laurentian Univ, Sch Human Kinet, Sudbury, ON, Canada.	rschinke@laurentian.ca	Schinke, Robert/AAS-2966-2020	Schinke, Robert J./0000-0002-4432-0730; Stambulova, Natalia/0000-0001-6198-0784			American Sports Data Inc, 2006, COMPR STUD SPORTS IN; Appaneal R. N, 2013, PSYCHOL SPORT INJURY, P117; Australian Institute of Health and Welfare , 2014, INJURY RES STAT SERI, V92; Bapat S, 2009, AUSTRALAS PSYCHIATRY, V17, P475, DOI 10.1080/10398560902964586; Battochio RC, 2013, INT J SPORT EXERC PS, V11, P101, DOI 10.1080/1612197X.2013.748996; Blodgett AT, 2015, PSYCHOL SPORT EXERC, V21, P115, DOI 10.1016/j.psychsport.2015.03.001; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Boffano P, 2011, J CRANIOFAC SURG, V22, P2053, DOI 10.1097/SCS.0b013e318231988d; Brannon L., 2014, HLTH PSYCHOL INTRO B; BUDGETT R, 1994, BRIT MED J, V309, P465, DOI 10.1136/bmj.309.6952.465; Budgett R, 1998, BRIT J SPORT MED, V32, P107, DOI 10.1136/bjsm.32.2.107; Campbell E.E, 2009, ATHLETIC INSIGHT, V11, pXXX; Creswell JD, 2014, CURR DIR PSYCHOL SCI, V23, P401, DOI 10.1177/0963721414547415; Davydov DM, 2010, CLIN PSYCHOL REV, V30, P479, DOI 10.1016/j.cpr.2010.03.003; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Dworkin SL, 1998, SOCIOL SPORT J, V15, P1, DOI 10.1123/ssj.15.1.1; Brandao MRF, 2013, INT PER KEY ISS SPO, P43; Foot J., 2012, WHAT MAKES US HLTH A; Franck A, 2018, INT J SPORT EXERC PS, V16, P398, DOI [10.1080/1612197x.2016.1256339, 10.1080/1612197X.2016.1256339]; Gardner F., 2007, PSYCHOL ENHANCING HU; Gardner F, 2001, ANN C ASS ADV APPL S; Gardner F., 2006, CLIN SPORT PSYCHOL; Gardner FL, 2004, BEHAV THER, V35, P707, DOI 10.1016/S0005-7894(04)80016-9; Gardner FL, 2012, CAN PSYCHOL, V53, P309, DOI 10.1037/a0030220; Gastin PB, 2013, J STRENGTH COND RES, V27, P2518, DOI 10.1519/JSC.0b013e31827fd600; Gill D., 2010, CULTURAL TURN SPORT, P53; Gordon S, 1986, SPORT SCI PERIODICAL, P1; Gouttebarge V, 2015, OCCUP MED-OXFORD, V65, P190, DOI 10.1093/occmed/kqu202; Gouttebarge V, 2017, J SPORT SCI, V35, P2148, DOI 10.1080/02640414.2016.1258485; Gouttebarge V, 2016, KNEE SURG SPORT TR A, V24, P3934, DOI 10.1007/s00167-015-3729-y; Gouttebarge V, 2016, EUR J SPORT SCI, V16, P595, DOI 10.1080/17461391.2015.1086819; Gross M., 2016, INT J SPORT EXERCISE; Guignon C., 2015, INT S NAT OL COMM NA; Gulliver A, 2015, J SCI MED SPORT, V18, P255, DOI 10.1016/j.jsams.2014.04.006; Gulliver A, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-157; Gulliver Amelia, 2012, J Med Internet Res, V14, pe69, DOI 10.2196/jmir.1864; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Gustafsson H, 2015, J CLIN SPORT PSYCHOL, V9, P263, DOI 10.1123/jcsp.2014-0051; Hammond T, 2013, CLIN J SPORT MED, V23, P273, DOI 10.1097/JSM.0b013e318287b870; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hendry L. B., 2002, LIFESPAN DEV RESOURC; Henriksen K, 2010, PSYCHOL SPORT EXERC, V11, P212, DOI 10.1016/j.psychsport.2009.10.005; Hughes L, 2012, BRIT J PSYCHIAT, V200, P95, DOI 10.1192/bjp.bp.111.095976; Ivarsson A, 2018, INT J SPORT EXERC PS, V16, P365, DOI 10.1080/1612197X.2016.1242149; Ivarsson A, 2013, J SPORT REHABIL, V22, P19, DOI 10.1123/jsr.22.1.19; Ivarsson A, 2010, J SPORT SCI MED, V9, P347; Kentta G, 1998, SPORTS MED, V26, P1; Keyes CLM, 2002, J HEALTH SOC BEHAV, V43, P207, DOI 10.2307/3090197; Kontos A. P., 2016, ROUTLEDGE INT HDB SP, P204; Kontos A.P., 2009, CULTURAL SPORT PSYCH, P103; Koutedakis Y, 1990, Br J Sports Med, V24, P248; Krane V., 2010, CULTURAL TURN SPORT, P153; Krane V., 2000, OLYMPICS MILLENNIUM, P147; Krane V, 2015, INT PER KEY ISS SPO, P48; Kubler-Ross E., 1969, DEATH DYING; Lan MF, 2012, J SPORT SCI MED, V11, P131; Lardon MT, 2013, CLINICAL SPORTS PSYCHIATRY: AN INTERNATIONAL PERSPECTIVE, P132; Lavallee D, 2005, SPORT PSYCHOL, V19, P193, DOI 10.1123/tsp.19.2.193; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Main L, 2009, EUR J SPORT SCI, V9, P195, DOI 10.1080/17461390902818260; Markser VZ, 2011, EUR ARCH PSY CLIN N, V261, P182, DOI 10.1007/s00406-011-0239-x; Matos NF, 2011, MED SCI SPORT EXER, V43, P1287, DOI 10.1249/MSS.0b013e318207f87b; Meeusen R, 2006, EUR J SPORT SCI, V6, P1, DOI 10.1080/17461390600617717; Moore Z. E., 2011, NEW SPORT EXERCISE P, P381; Moore Z. E., 2012, OXFORD HDB SPORT PER; Moore Z. E, 2016, ROUTLEDGE COMPANION, P51; Murphy S., 2012, OXFORD HDB SPORT PER; NCAA (Author), 2014, NCAA STUD ATHL SUBST; NCAA Sport Science Institute, 2016, MENT HLTH LANDSC SPO; Oltmanns TF., 2013, PSYCHOPATHOLOGY SCI; Pedersen P, 1986, ATHLETIC TRAINING, V21, P1; Peluso Marco Aurélio Monteiro, 2005, Clinics, V60, P61, DOI 10.1590/S1807-59322005000100012; Poczwardowski A, 2014, J APPL SPORT PSYCHOL, V26, P33, DOI 10.1080/10413200.2013.773950; Podlog L., 2016, ROUTLEDGE INT HDB SP, P167; Raglin JS, 2001, SPORTS MED, V31, P875, DOI 10.2165/00007256-200131120-00004; Raglin JS, 2000, EMOTIONS SPORT, P191; Reints A., 2011, THESIS; Rice SM, 2016, SPORTS MED, V46, P1333, DOI 10.1007/s40279-016-0492-2; ROSE J, 1993, SPORT PSYCHOL, V7, P309, DOI 10.1123/tsp.7.3.309; Ryba TV, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00427; Ryba TV, 2013, INT J SPORT EXERC PS, V11, P123, DOI 10.1080/1612197X.2013.779812; Ryba TV, 2005, QUEST, V57, P192, DOI 10.1080/00336297.2005.10491853; Samuel RD, 2015, J SPORT PSYCHOL ACTI, V6, P99, DOI 10.1080/21520704.2015.1012249; Samuel RD, 2013, SPORT PSYCHOL, V27, P78, DOI 10.1123/tsp.27.1.78; Samuel RD, 2011, SPORT PSYCHOL, V25, P233, DOI 10.1123/tsp.25.2.233; Schaal K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019007; Schinke RJ, 2006, SPORT PSYCHOL, V20, P435, DOI 10.1123/tsp.20.4.435; Schinke RJ, 2016, PSYCHOL SPORT EXERC, V25, P36, DOI 10.1016/j.psychsport.2016.04.001; Schinke RJ, 2015, INT J SPORT EXERC PS, V13, P74, DOI 10.1080/1612197X.2014.959982; Schinke RJ, 2015, PSYCHOL SPORT EXERC, V17, P45, DOI 10.1016/j.psychsport.2014.10.010; Schinke RJ, 2014, INT J SPORT EXERC PS, V12, P64, DOI 10.1080/1612197X.2013.785093; Schwenk TL, 2000, BRIT J SPORT MED, V34, P4, DOI 10.1136/bjsm.34.1.4; Si GY, 2008, INT J SPORT EXERC PS, V6, P319, DOI 10.1080/1612197X.2008.9671876; Stambulova N., 2009, PSYCHOL SPORT EXCELL, P63; Stambulova N., 2003, SVENSK IDROTTSPSYKOL, P97; Stambulova N, 2014, ROUTLEDGE COMPANION, P605; Stambulova N. B., 2016, ROUTLEDGE INT HDB SP, P519; Stambulova N, 2009, INT J SPORT EXERC PS, V7, P395, DOI 10.1080/1612197X.2009.9671916; Stambulova NB, 2014, INT REV SPORT EXER P, V7, P1, DOI 10.1080/1750984X.2013.851727; Stambulova NB, 2000, INT J SPORT PSYCHOL, V31, P584; Taylor K.-L., 2012, J AUSTR STRENGTH CON, V20, P12, DOI DOI 10.1017/CB09781107415324.004; Terry PC, 2003, PSYCHOL SPORT EXERC, V4, P125, DOI 10.1016/S1469-0292(01)00035-8; Uphill M, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00935; US Department of Health and Human Services, 1999, MENT HLTH REP SURG G; Watson JC, 2005, J COLL STUDENT DEV, V46, P442, DOI 10.1353/csd.2005.0044; Wiese-Bjornstal D. M., 1995, ATHLETIC TRAINING, V1, P17; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wolanin A, 2015, CURR SPORT MED REP, V14, P56, DOI 10.1249/JSR.0000000000000123; World Health Organization, 2007, NEUR DIS PUBL HLTH C; Wylleman P., 2013, MANAGING HIGH PERFOR, P159; Wylleman P., 2015, HIGH PERF TEAM TEAM; Wylleman P., 2014, ENCY SPORT EXERCISE, P105; Wylleman P, 2015, ROUTL RES SPORT CULT, V38, P99; Wylleman P, 2012, PSYCHOL SPORT EXERC, V13, P687, DOI 10.1016/j.psychsport.2012.04.005; Zhang CQ, 2014, J SPORT SCI, V32, P1465, DOI 10.1080/02640414.2014.898184	116	104	108	15	55	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1612-197X	1557-251X		INT J SPORT EXERC PS	Int. J. Sport Exerc. Psychol.		2018	16	6					622	639		10.1080/1612197X.2017.1295557			18	Hospitality, Leisure, Sport & Tourism; Psychology, Applied	Social Sciences - Other Topics; Psychology	IA9LI	WOS:000469878300004			Y	N	2021-06-18	
J	van der Naalt, J; Timmerman, ME; de Koning, ME; van der Horn, HJ; Scheenen, ME; Jacobs, B; Hageman, G; Yilmaz, T; Roks, G; Spikman, JM				van der Naalt, Joukje; Timmerman, Marieke E.; de Koning, Myrthe E.; van der Horn, Harm J.; Scheenen, Myrthe E.; Jacobs, Bram; Hageman, Gerard; Yilmaz, Tansel; Roks, Gerwin; Spikman, Jacoba M.			Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study	LANCET NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION SYNDROME; SYMPTOMS; DEPRESSION; COMPLAINTS; HEALTH; IMPACT; SCALE; AGE	Background Mild traumatic brain injury (mTBI) accounts for most cases of TBI, and many patients show incomplete long-term functional recovery. We aimed to create a prognostic model for functional outcome by combining demographics, injury severity, and psychological factors to identify patients at risk for incomplete recovery at 6 months. In particular, we investigated additional indicators of emotional distress and coping style at 2 weeks above early predictors measured at the emergency department. Methods The UPFRONT study was an observational cohort study done at the emergency departments of three level-1 trauma centres in the Netherlands, which included patients with mTBI, defined by a Glasgow Coma Scale score of 13-15 and either post-traumatic amnesia lasting less than 24 h or loss of consciousness for less than 30 min. Emergency department predictors were measured either on admission with mTBI-comprising injury severity (GCS score, post-traumatic amnesia, and CT abnormalities), demographics (age, gender, educational level, pre-injury mental health, and previous brain injury), and physical conditions (alcohol use on the day of injury, neck pain, headache, nausea, dizziness)-or at 2 weeks, when we obtained data on mood (Hospital Anxiety and Depression Scale), emotional distress (Impact of Event Scale), coping (Utrecht Coping List), and post-traumatic complaints. The functional outcome was recovery, assessed at 6 months after injury with the Glasgow Outcome Scale Extended (GOSE). We dichotomised recovery into complete (GOSE=8) and incomplete (GOSE <= 7) recovery. We used logistic regression analyses to assess the predictive value of patient information collected at the time of admission to an emergency department (eg, demographics, injury severity) alone, and combined with predictors of outcome collected at 2 weeks after injury (eg, emotional distress and coping). Findings Between Jan 25, 2013, and Jan 6, 2015, data from 910 patients with mTBI were collected 2 weeks after injury; the final date for 6-month follow-up was July 6, 2015. Of these patients, 764 (84%) had post-traumatic complaints and 414 (45%) showed emotional distress. At 6 months after injury, outcome data were available for 671 patients; complete recovery (GOSE=8) was observed in 373 (56%) patients and incomplete recovery (GOSE <= 7) in 298 (44%) patients. Logistic regression analyses identified several predictors for 6-month outcome, including education and age, with a clear surplus value of indicators of emotional distress and coping obtained at 2 weeks (area under the curve [AUC] = 0.79, optimism 0.02; Nagelkerke R-2 = 0.32, optimism 0.05) than only emergency department predictors at the time of admission (AUC= 0.72, optimism 0.03; Nagelkerke R-2 = 0.19, optimism 0.05). Interpretation Psychological factors (ie, emotional distress and maladaptive coping experienced early after injury) in combination with pre-injury mental health problems, education, and age are important predictors for recovery at 6 months following mTBI. These findings provide targets for early interventions to improve outcome in a subgroup of patients at risk of incomplete recovery from mTBI, and warrant validation.	[van der Naalt, Joukje; de Koning, Myrthe E.; van der Horn, Harm J.; Jacobs, Bram; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 GZ Groningen, Netherlands; [Timmerman, Marieke E.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychometr & Stat, Groningen, Netherlands; [Scheenen, Myrthe E.; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Neuropsychol, Groningen, Netherlands; [Hageman, Gerard] Hosp Med Spectrum Twente Enschede, Dept Neurol, Enschede, Netherlands; [Yilmaz, Tansel; Roks, Gerwin] Elisabeth Hosp Tilburg, Dept Neurol, Tilburg, Netherlands	van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 GZ Groningen, Netherlands.	j.van.der.naalt@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763	Dutch Brain Foundation	Dutch Brain Foundation.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; de Koning ME, 2016, INJURY, V47, P2041, DOI 10.1016/j.injury.2016.04.036; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Gregorio GW, 2016, J NEUROTRAUM, V33, P696, DOI 10.1089/neu.2015.3900; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Maestas KL, 2014, J HEAD TRAUMA REHAB, V29, P407, DOI 10.1097/HTR.0b013e31828654b4; McIntyre A, 2013, NEUROREHABILITATION, V32, P409, DOI 10.3233/NRE-130862; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; SCHREURS PJG, 1984, GEDRAG GEZOND, V12, P101; Shin SS, 2017, BRAIN IMAGING BEHAV, V11, P591, DOI 10.1007/s11682-017-9684-0; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696	36	104	104	2	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2017	16	7					532	540		10.1016/S1474-4422(17)30117-5			9	Clinical Neurology	Neurosciences & Neurology	EX4MH	WOS:000403208400016	28653646				2021-06-18	
J	Hay, JR; Johnson, VE; Young, AMH; Smith, DH; Stewart, W				Hay, Jennifer R.; Johnson, Victoria E.; Young, Adam M. H.; Smith, Douglas H.; Stewart, William			Blood-Brain Barrier Disruption Is an Early Event That May Persist for Many Years After Traumatic Brain Injury in Humans	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Blood-brain barrier; Chronic traumatic encephalopathy; Fibrinogen; Traumatic brain injury	RECEPTOR-RELATED PROTEIN-1; ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; CEREBRAL MICROVASCULATURE; PERMEABILITY; INFLAMMATION; MICROVESSELS; PATHOLOGY; DYSFUNCTION	Traumatic brain injury (TBI) is a risk factor for dementia. Mixed neurodegenerative pathologies have been described in late survivors of TBI, but the mechanisms driving post-TBI neurodegeneration remain elusive. Increasingly, blood-brain barrier (BBB) disruption has been recognized in a range of neurologic disorders including dementias, but little is known of the consequences of TBI on the BBB. Autopsy cases of single moderate or severe TBI from the Glasgow TBI Archive (n = 70) were selected to include a range from acute (10 hours-13 days) to long-term (1-47 years) survival, together with age-matched uninjured controls (n = 21). Multiple brain regions were examined using immunohistochemistry for the BBB integrity markers fibrinogen and immunoglobulin G. After TBI, 40% of patients dying in the acute phase and 47% of those surviving a year or more from injury showed multifocal, abnormal, perivascular, and parenchymal fibrinogen and immunoglobulin G immunostaining localized to the gray matter, with preferential distribution toward the crests of gyri and deep neocortical layers. In contrast, when present, controls showed only limited localized immunostaining. These preliminary data demonstrate evidence of widespread BBB disruption in a proportion of TBI patients emerging in the acute phase and, intriguingly, persisting in a high proportion of late survivors.	[Hay, Jennifer R.; Stewart, William] Univ Glasgow, Glasgow, Lanark, Scotland; [Hay, Jennifer R.; Young, Adam M. H.; Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Perelman Sch Med, Philadelphia, PA 19104 USA; [Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA	Stewart, W (corresponding author), Queen Elizabeth Univ Hosp, Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	William.Stewart@glasgow.ac.uk		Stewart, William/0000-0003-2199-2582	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104, NS056202]; US Department of DefenseUnited States Department of Defense [PT110785]; Sackler Institute Endowment Fund, Department of Neurology, Queen Elizabeth University Hospital, Glasgow, United Kingdom; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202, R01NS038104] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grants NS038104 and NS056202; US Department of Defense Grant PT110785; and The Sackler Institute Endowment Fund, Department of Neurology, Queen Elizabeth University Hospital, Glasgow, United Kingdom.	Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bell RD, 2009, ACTA NEUROPATHOL, V118, P103, DOI 10.1007/s00401-009-0522-3; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Brown WR, 2011, NEUROPATH APPL NEURO, V37, P56, DOI 10.1111/j.1365-2990.2010.01139.x; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Eisele YS, 2010, SCIENCE, V330, P980, DOI 10.1126/science.1194516; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Grammas P, 1999, AM J PATHOL, V154, P337, DOI 10.1016/S0002-9440(10)65280-7; Grammas P, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-26; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hirao K, 2005, NEUROIMAGE, V28, P1014, DOI 10.1016/j.neuroimage.2005.06.066; Ho KM, 2014, J NEUROSURG, V121, P674, DOI 10.3171/2014.6.JNS132838; Jaeger LB, 2009, BRAIN BEHAV IMMUN, V23, P507, DOI 10.1016/j.bbi.2009.01.017; Johnson NA, 2005, RADIOLOGY, V234, P851, DOI 10.1148/radiol.2343040197; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kirk J, 2003, J PATHOL, V201, P319, DOI 10.1002/path.1434; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; Paul J, 2007, J EXP MED, V204, P1999, DOI 10.1084/jem.20070304; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Povlishock J T, 1980, Adv Exp Med Biol, V131, P227; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Saw MM, 2014, NEUROCRIT CARE, V20, P209, DOI 10.1007/s12028-013-9933-z; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Starr JM, 2009, PSYCHIAT RES-NEUROIM, V171, P232, DOI 10.1016/j.pscychresns.2008.04.003; Sutcliffe JG, 2011, J NEUROSCI RES, V89, P808, DOI 10.1002/jnr.22603; Tomkins Oren, 2011, Cardiovasc Psychiatry Neurol, V2011, P765923, DOI 10.1155/2011/765923; Ujiie M, 2003, MICROCIRCULATION, V10, P463, DOI 10.1038/sj.mn.7800212; van Oijen M, 2005, STROKE, V36, P2637, DOI 10.1161/01.STR.0000189721.31432.26; Vaz R, 1998, ACTA NEUROCHIR, V140, P76, DOI 10.1007/s007010050061; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; Viggars AP, 2011, NEUROSCI LETT, V505, P25, DOI 10.1016/j.neulet.2011.09.049; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Xu G, 2008, INT J CLIN PRACT, V62, P1070, DOI 10.1111/j.1742-1241.2007.01268.x; Zhang Y, 2001, J NEUROIMMUNOL, V114, P168, DOI 10.1016/S0165-5728(01)00242-9; Zipser BD, 2007, NEUROBIOL AGING, V28, P977, DOI 10.1016/j.neurobiolaging.2006.05.016; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114; Zlokovic BV, 2010, J NEUROCHEM, V115, P1077, DOI 10.1111/j.1471-4159.2010.07002.x	72	104	105	0	26	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2015	74	12					1147	1157		10.1093/jnen/74.12.1147			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CX3PB	WOS:000365610200004	26574669	Green Accepted, Bronze			2021-06-18	
J	Faden, AI; Loane, DJ				Faden, Alan I.; Loane, David J.			Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation?	NEUROTHERAPEUTICS			English	Article						Traumatic brain injury; Neurodegeneration; Concussion; Repetitive mild TBI; Alzheimer disease; Chronic traumatic encephalopathy; Microglial activation; Chronic traumatic brain inflammation	AMYLOID-BETA-PROTEIN; INTRACEREBRAL INFLAMMATORY RESPONSE; LONG-TERM ACCUMULATION; HEAD-INJURY; MICROGLIAL ACTIVATION; DIFFUSION-TENSOR; AXONAL INJURY; RISK-FACTOR; LONGITUDINAL CHANGES; SYNAPTIC PLASTICITY	It has long been suggested that prior traumatic brain injury (TBI) increases the subsequent incidence of chronic neurodegenerative disorders, including Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis. Among these, the association with Alzheimer disease has the strongest support. There is also a long-recognized association between repeated concussive insults and progressive cognitive decline or other neuropsychiatric abnormalities. The latter was first described in boxers as dementia pugilistica, and has received widespread recent attention in contact sports such as professional American football. The term chronic traumatic encephalopathy was coined to attempt to define a "specific" entity marked by neurobehavioral changes and the extensive deposition of phosphorylated tau protein. Nearly lost in the discussions of post-traumatic neurodegeneration after traumatic brain injury has been the role of sustained neuroinflammation, even though this association has been well established pathologically since the 1950s, and is strongly supported by subsequent preclinical and clinical studies. Manifested by extensive microglial and astroglial activation, such chronic traumatic brain inflammation may be the most important cause of post-traumatic neurodegeneration in terms of prevalence. Critically, emerging preclinical studies indicate that persistent neuroinflammation and associated neurodegeneration may be treatable long after the initiating insult(s).	[Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol & Shock, Trauma & Anesthesiol Res STAR Ctr,Hlth Sci Facil, Baltimore, MD 21201 USA	Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol & Shock, Trauma & Anesthesiol Res STAR Ctr,Hlth Sci Facil, S247 20,Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu		Faden, Alan I./0000-0003-0128-2348; Loane, David/0000-0003-0393-3503	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS037313, R01NS052568, R01NS082308]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS052568, R01NS082308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants R01NS037313 and R01NS052568 (A.I. Faden), and R01NS082308 (D.J. Loane).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Eikelenboom P, 2010, NEURODEGENER DIS, V7, P38, DOI 10.1159/000283480; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Faden AI, 2011, ANN NEUROL, V70, P345, DOI 10.1002/ana.22555; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Juengst SB, 2014, BRAIN BEHAV IMMUN, V41, P134, DOI 10.1016/j.bbi.2014.05.020; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kumar R., 2014, J HEAD TRAUMA REHABI; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lewis KM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/578480; Leypoldt F, 2014, CLIN EXP IMMUNOL, V175, P336, DOI 10.1111/cei.12185; Leypoldt F, 2014, ANN N Y ACAD SCI; Lindqvist D, 2014, BRAIN BEHAV IMMUN; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nath S, 2012, J NEUROSCI, V32, P8767, DOI 10.1523/JNEUROSCI.0615-12.2012; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Roberts G, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rodgers KM, 2014, J NEUROTRAUM, V31, P487, DOI [10.1089/NEU.2013.3090, 10.1089/neu.2013.3090]; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	99	104	107	2	44	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JAN	2015	12	1					143	150		10.1007/s13311-014-0319-5			8	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CB3PX	WOS:000349541800016	25421001	Green Published, Bronze			2021-06-18	
J	Gotzl, JK; Mori, K; Damme, M; Fellerer, K; Tahirovic, S; Kleinberger, G; Janssens, J; van der Zee, J; Lang, CM; Kremmer, E; Martin, JJ; Engelborghs, S; Kretzschmar, HA; Arzberger, T; Van Broeckhoven, C; Haass, C; Capell, A				Goetzl, Julia K.; Mori, Kohji; Damme, Markus; Fellerer, Katrin; Tahirovic, Sabina; Kleinberger, Gernot; Janssens, Jonathan; van der Zee, Julie; Lang, Christina M.; Kremmer, Elisabeth; Martin, Jean-Jacques; Engelborghs, Sebastiaan; Kretzschmar, Hans A.; Arzberger, Thomas; Van Broeckhoven, Christine; Haass, Christian; Capell, Anja			Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis	ACTA NEUROPATHOLOGICA			English	Article						Frontotemporal lobar degeneration (FTLD); Progranulin (GRN); TDP-43; Neuronal ceroid lipofuscinosis (NCL); Cathepsin D; Lysosome; Neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; MITOCHONDRIAL ATP SYNTHASE; PROTEIN-DEGRADATION PATHWAYS; TRAUMATIC BRAIN-INJURY; D-DEFICIENT MICE; CATHEPSIN-D; MUTATION CARRIERS; KNOCKOUT MICE; CELL-DEATH; SUBUNIT-C	Heterozygous loss-of-function mutations in the progranulin (GRN) gene and the resulting reduction of GRN levels is a common genetic cause for frontotemporal lobar degeneration (FTLD) with accumulation of TAR DNA-binding protein (TDP)-43. Recently, it has been shown that a complete GRN deficiency due to a homozygous GRN loss-of-function mutation causes neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disorder. These findings suggest that lysosomal dysfunction may also contribute to some extent to FTLD. Indeed, Grn(-/-) mice recapitulate not only pathobiochemical features of GRN-associated FTLD-TDP (FTLD-TDP/GRN), but also those which are characteristic for NCL and lysosomal impairment. In Grn(-/-) mice the lysosomal proteins cathepsin D (CTSD), LAMP (lysosomal-associated membrane protein) 1 and the NCL storage components saposin D and subunit c of mitochondrial ATP synthase (SCMAS) were all found to be elevated. Moreover, these mice display increased levels of transmembrane protein (TMEM) 106B, a lysosomal protein known as a risk factor for FTLD-TDP pathology. In line with a potential pathological overlap of FTLD and NCL, Ctsd(-/-) mice, a model for NCL, show elevated levels of the FTLD-associated proteins GRN and TMEM106B. In addition, pathologically phosphorylated TDP-43 occurs in Ctsd(-/-) mice to a similar extent as in Grn(-/-) mice. Consistent with these findings, some NCL patients accumulate pathologically phosphorylated TDP-43 within their brains. Based on these observations, we searched for pathological marker proteins, which are characteristic for NCL or lysosomal impairment in brains of FTLD-TDP/GRN patients. Strikingly, saposin D, SCMAS as well as the lysosomal proteins CTSD and LAMP1/2 are all elevated in patients with FTLD-TDP/GRN. Thus, our findings suggest that lysosomal storage disorders and GRN-associated FTLD may share common features.	[Goetzl, Julia K.; Mori, Kohji; Fellerer, Katrin; Kleinberger, Gernot; Lang, Christina M.; Haass, Christian; Capell, Anja] Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; [Goetzl, Julia K.] Tech Univ Munich, Inst Neurosci, D-80802 Munich, Germany; [Damme, Markus] Univ Kiel, Dept Biochem, D-20498 Kiel, Germany; [Tahirovic, Sabina; Kremmer, Elisabeth; Arzberger, Thomas; Haass, Christian] German Ctr Neurodegenerat Dis DZNE Munich, D-80336 Munich, Germany; [Kleinberger, Gernot; Janssens, Jonathan; van der Zee, Julie; Van Broeckhoven, Christine] VIB, Neurodegenerat Brain Dis Grp, Dept Mol Genet, B-2610 Antwerp, Belgium; [Kleinberger, Gernot; Janssens, Jonathan; van der Zee, Julie; Martin, Jean-Jacques; Engelborghs, Sebastiaan; Van Broeckhoven, Christine] Univ Antwerp, Inst Born Bunge, B-2610 Antwerp, Belgium; [Kleinberger, Gernot; Haass, Christian] Munich Cluster Syst Neurol SyNergy, D-80336 Munich, Germany; [Kremmer, Elisabeth] German Res Ctr Environm Hlth GmbH, Helmholtz Ctr Munich, Inst Mol Immunol, D-81377 Munich, Germany; [Kretzschmar, Hans A.; Arzberger, Thomas] Univ Munich, Ctr Neuropathol & Prion Res, D-81377 Munich, Germany; [Arzberger, Thomas] Univ Munich, Dept Psychiat & Psychotherapy, D-80336 Munich, Germany	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	christian.haass@dzne.lmu.de; anja.capell@dzne.lmu.de	Van Broeckhoven, Christine/G-8362-2017; Mori, Kohji/AAM-8471-2020; Van Broeckhoven, Christine/M-7853-2019	Van Broeckhoven, Christine/0000-0003-0183-7665; Mori, Kohji/0000-0003-2629-0723; Van Broeckhoven, Christine/0000-0003-0183-7665	European Research Council under European UnionEuropean Research Council (ERC) [321366]; Competence Network for Neurodegenerative Diseases (KNDD) of the Bundesministerium fur Bildung und Forschung (BMBF)Federal Ministry of Education & Research (BMBF); DFGGerman Research Foundation (DFG)European Commission [RTG1373]; Hans & Ilse Breuer foundation; MetLife Foundation Award; Belgian Science Policy Office Interuniversity Attraction Poles Program; Medical Foundation Queen Elisabeth; Foundation for Alzheimer Research (SAO/FRA); Flemish Government initiated Methusalem Excellence program; Agency for Innovation by Science and Technology (IWT) FlandersInstitute for the Promotion of Innovation by Science and Technology in Flanders (IWT); Research Foundation Flanders (FWO)FWO; University of Antwerp Research Fund; IWTInstitute for the Promotion of Innovation by Science and Technology in Flanders (IWT); London Neurodegenerative Disease Brain Bank and Brains for Dementia Research; Human Brain and Spinal Fluid Resource Center, VA West Los Angeles Healthcare Center, Los Angeles [CA 90073]; NINDS/NIMH, National Multiple Sclerosis Society	We thank Paul Saftig (Christian-Albrechts University of Kiel) for providing the Ctsd knockout mouse strain, Masugi Nishihara (University of Tokyo) for the Grn knockout mouse strain, Konrad Sandhoff (University of Bonn, Kekule-Institut fur Organische Chemie und Biochemie) for the saposin D antibody, Elizabeth Neufeld (University of California Los Angeles) for the SCMAS antibody and Virginia Lee and Alice Chen-Plotkin (University of Pennsylvania) for the TMEM106B antibody clone N2077. We are grateful to Andrea Wenninger-Weinzierl and Brigitte Kraft for excellent technical assistance and to Dorothee Dormann for critical reading of the manuscript and valuable comments. This work was supported by the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC Grant Agreement No. 321366-Amyloid (advanced grant to C. H.) and the Competence Network for Neurodegenerative Diseases (KNDD) of the Bundesministerium fur Bildung und Forschung (BMBF to C. H.). J.K.G. is supported by the RTG1373 (DFG) and C. M. L. by the Hans & Ilse Breuer foundation. The Antwerp site was in part funded by the MetLife Foundation Award (to C. V. B.), the Belgian Science Policy Office Interuniversity Attraction Poles Program, the Medical Foundation Queen Elisabeth, the Foundation for Alzheimer Research (SAO/FRA), Flemish Government initiated Methusalem Excellence program, the Agency for Innovation by Science and Technology (IWT) Flanders, the Research Foundation Flanders (FWO) and the University of Antwerp Research Fund. We acknowledge the contribution of genetic data by I. Gijselinck and M. Cruts, clinical and pathological data by the neurologists T. Van Langenhove, P. Cras, P.P. De Deyn and immunohistochemical data, autopsy brain samples and sections by the neuropathologist by A. Sieben. We are also grateful for the support by the research nurses at VIB, the personnel at the neurological departments at the Antwerp University Hospital and ZNA Middelheim, the Antwerp Biobank at the Institute Born-Bunge and the Genetic Service Facility at VIB. J.J. receives a Ph.D. fellowship of the IWT. We acknowledge the London Neurodegenerative Disease Brain Bank and Brains for Dementia Research, the Human Brain and Spinal Fluid Resource Center, VA West Los Angeles Healthcare Center, Los Angeles, CA 90073, which is sponsored by NINDS/NIMH, National Multiple Sclerosis Society and the Veterans Affairs West Los Angeles Healthcare Center for providing brain tissue. We thank the Batten Disease Registry, Genetic Services and Specialty Clinical Laboratories, NYS Institute for Basic Research in Developmental Disabilities.	Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Amritraj A, 2013, J BIOL CHEM, V288, P3136, DOI 10.1074/jbc.M112.412460; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Benussi L, 2008, NEUROBIOL AGING, V29, P427, DOI 10.1016/j.neurobiolaging.2006.10.028; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Brady OA, 2013, HUM MOL GENET, V22, P685, DOI 10.1093/hmg/dds475; Brouwers N, 2007, ARCH NEUROL-CHICAGO, V64, P1436, DOI 10.1001/archneur.64.10.1436; Busch JI, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-36; Butler D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020501; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; Chen-Plotkin AS, 2012, J NEUROSCI, V32, P11213, DOI 10.1523/JNEUROSCI.0521-12.2012; Cluzeau CVM, 2012, HUM MOL GENET, V21, P3632, DOI 10.1093/hmg/dds193; Cruchaga C, 2011, ARCH NEUROL-CHICAGO, V68, P581, DOI 10.1001/archneurol.2010.350; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Cruts M, 2012, HUM MUTAT, V33, P1340, DOI 10.1002/humu.22117; Ebrahimi-Fakhari D, 2012, ACTA NEUROPATHOL, V124, P153, DOI 10.1007/s00401-012-1004-6; Elleder M, 1997, ACTA NEUROPATHOL, V93, P379, DOI 10.1007/s004010050629; Finch N, 2011, NEUROLOGY, V76, P467, DOI 10.1212/WNL.0b013e31820a0e3b; Finch N, 2009, BRAIN, V132, P583, DOI 10.1093/brain/awn352; Fritchie K, 2009, ACTA NEUROPATHOL, V117, P201, DOI 10.1007/s00401-008-0426-7; Gallagher MD, 2014, ACTA NEUROPATHOL, V127, P407, DOI 10.1007/s00401-013-1239-x; Gass J, 2006, HUM MOL GENET, V15, P2988, DOI 10.1093/hmg/ddl241; Ghidoni R, 2008, NEUROLOGY, V71, P1235, DOI 10.1212/01.wnl.0000325058.10218.fc; Ghoshal N, 2012, NEUROBIOL DIS, V45, P395, DOI 10.1016/j.nbd.2011.08.029; Gijselinck I, 2008, HUM MUTAT, V29, P1373, DOI 10.1002/humu.20785; Graff-Radford NR, 2007, SEMIN NEUROL, V27, P48, DOI 10.1055/s-2006-956755; HALL NA, 1991, BIOCHEM J, V275, P269, DOI 10.1042/bj2750269; Harris H, 2012, NAT REV NEUROL, V8, P108, DOI 10.1038/nrneurol.2011.200; Hasegawa M, 2008, ANN NEUROL, V64, P60, DOI 10.1002/ana.21425; Hiraiwa M, 1997, ARCH BIOCHEM BIOPHYS, V341, P17, DOI 10.1006/abbi.1997.9958; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Jabs S, 2008, J NEUROCHEM, V106, P1415, DOI 10.1111/j.1471-4159.2008.05497.x; Jalanko A, 2009, BBA-MOL CELL RES, V1793, P697, DOI 10.1016/j.bbamcr.2008.11.004; Janssens J, 2013, HUM MOL GENET, V22, pR77, DOI 10.1093/hmg/ddt349; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Lang CM, 2012, J BIOL CHEM, V287, P19355, DOI 10.1074/jbc.M112.365098; Le Ber I, 2008, BRAIN, V131, P732, DOI 10.1093/brain/awn012; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; Mackenzie IRA, 2009, ACTA NEUROPATHOL, V117, P15, DOI 10.1007/s00401-008-0460-5; Martin JJ, 1997, ACTA NEUROL BELG, V97, P85; Mori K, 2013, SCIENCE, V339, P1335, DOI 10.1126/science.1232927; Mukherjee O, 2008, HUM MUTAT, V29, P512, DOI 10.1002/humu.20681; Nakanishi H, 2001, J NEUROSCI, V21, P7526; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Neumann M, 2009, ACTA NEUROPATHOL, V117, P137, DOI 10.1007/s00401-008-0477-9; Nijssen PCG, 2003, BRAIN PATHOL, V13, P574; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Nixon RA, 2011, NEUROBIOL DIS, V43, P38, DOI 10.1016/j.nbd.2011.01.021; Partanen S, 2008, J NEUROPATH EXP NEUR, V67, P16, DOI 10.1097/nen.0b013e31815f3899; Petkau TL, 2012, NEUROBIOL DIS, V45, P711, DOI 10.1016/j.nbd.2011.10.016; Petkau TL, 2010, J COMP NEUROL, V518, P3931, DOI 10.1002/cne.22430; Qiao LY, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-17; Repnik U, 2012, BBA-PROTEINS PROTEOM, V1824, P22, DOI 10.1016/j.bbapap.2011.08.016; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Ryazantsev S, 2007, MOL GENET METAB, V90, P393, DOI 10.1016/j.ymgme.2006.11.006; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Seelaar H, 2011, J NEUROL NEUROSUR PS, V82, P476, DOI 10.1136/jnnp.2010.212225; Shankaran SS, 2008, J BIOL CHEM, V283, P1744, DOI 10.1074/jbc.M705115200; Sieben A, 2012, ACTA NEUROPATHOL, V124, P353, DOI 10.1007/s00401-012-1029-x; Siintola E, 2006, BRAIN, V129, P1438, DOI 10.1093/brain/awl107; Skibinski G, 2005, NAT GENET, V37, P806, DOI 10.1038/ng1609; Sleegers K, 2009, ANN NEUROL, V65, P603, DOI 10.1002/ana.21621; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Tofaris GK, 2012, MOVEMENT DISORD, V27, P1364, DOI 10.1002/mds.25136; Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014; TYYNELA J, 1993, FEBS LETT, V330, P8, DOI 10.1016/0014-5793(93)80908-D; Urwin H, 2010, HUM MOL GENET, V19, P2228, DOI 10.1093/hmg/ddq100; van Blitterswijk M, 2014, ACTA NEUROPATHOL, V127, P397, DOI 10.1007/s00401-013-1240-4; Van Deerlin VM, 2010, NAT GENET, V42, P234, DOI 10.1038/ng.536; van der Zee J, 2007, HUM MUTAT, V28, P416, DOI 10.1002/humu.9484; van der Zee J, 2011, BRAIN, V134, P808, DOI 10.1093/brain/awr007; Vitner EB, 2010, HUM MOL GENET, V19, P3583, DOI 10.1093/hmg/ddq273; Wang J, 2010, J NEUROCHEM, V112, P1305, DOI 10.1111/j.1471-4159.2009.06546.x; Watts GDJ, 2007, CLIN GENET, V72, P420, DOI 10.1111/j.1399-0004.2007.00887.x; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Wils H, 2012, J PATHOL, V228, P67, DOI 10.1002/path.4043; Yang DS, 2011, BRAIN, V134, P258, DOI 10.1093/brain/awq341; Yin FF, 2010, FASEB J, V24, P4639, DOI 10.1096/fj.10-161471; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Yu CE, 2010, ARCH NEUROL-CHICAGO, V67, P161, DOI 10.1001/archneurol.2009.328	87	104	106	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2014	127	6					845	860		10.1007/s00401-014-1262-6			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	AH6WO	WOS:000336273100005	24619111				2021-06-18	
J	Dewan, Y; Komolafe, EO; Mejia-Mantilla, JH; Perel, P; Roberts, I; Shakur, H				Dewan, Yashbir; Komolafe, Edward O.; Mejia-Mantilla, Jorge H.; Perel, Pablo; Roberts, Ian; Shakur, Haleema		CRASH-3 Collaborators	CRASH-3-tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial	TRIALS			English	Article						Antifibrinolytic; Clinical trial; Emergency care; Intracranial bleeding; Tranexamic acid; Traumatic brain injury	CLINICAL-TRIALS; EDEMA FORMATION; HEMORRHAGE; EQUIPOISE	Background: Worldwide, over 10 million people are killed or hospitalized because of traumatic brain injury each year. About 90% of deaths occur in low- and middle-income countries. The condition mostly affects young adults, and many experience long lasting or permanent disability. The social and economic burden is considerable. Tranexamic acid (TXA) is commonly given to surgical patients to reduce bleeding and the need for blood transfusion. It has been shown to reduce the number of patients receiving a blood transfusion by about a third, reduces the volume of blood transfused by about one unit, and halves the need for further surgery to control bleeding in elective surgical patients. Methods/design: The CRASH-3 trial is an international, multicenter, pragmatic, randomized, double-blind, placebo-controlled trial to quantify the effects of the early administration of TXA on death and disability in patients with traumatic brain injury. Ten thousand adult patients who fulfil the eligibility criteria will be randomized to receive TXA or placebo. Adults with traumatic brain injury, who are within 8 h of injury and have any intracranial bleeding on computerized tomography (CT scan) or Glasgow Coma Score (GCS) of 12 or less can be included if the responsible doctor is substantially uncertain as to whether or not to use TXA in this patient. Patients with significant extracranial bleeding will be excluded since there is evidence that TXA improves outcome in these patients. Treatment will entail a 1 g loading dose followed by a 1 g maintenance dose over 8 h. The main analyses will be on an 'intention-to-treat' basis, irrespective of whether the allocated treatment was received. Results will be presented as appropriate effect estimates with a measure of precision (95% confidence intervals). Subgroup analyses for the primary outcome will be based on time from injury to randomization, the severity of the injury, location of the bleeding, and baseline risk. Interaction tests will be used to test whether the effect of treatment differs across these subgroups. A study with 10,000 patients will have approximately 90% power to detect a 15% relative reduction from 20% to 17% in all-cause mortality.	[Perel, Pablo; Roberts, Ian; Shakur, Haleema] Univ London London Sch Hyg & Trop Med, Clin Trials Unit, London WC1E 7HT, England; [Dewan, Yashbir] FLT Lt Rajan Dhall Fortis Hosp, Dept Neurosci, Delhi 110070, Ncr New Delhi, India; [Komolafe, Edward O.] Obafemi Awolowo Univ, Dept Surg, Ife 20022, Osun State, Nigeria; [Mejia-Mantilla, Jorge H.] Dept Anaesthesia & Resuscitat Fdn Valle del Lili, Cali, Colombia	Shakur, H (corresponding author), Univ London London Sch Hyg & Trop Med, Clin Trials Unit, Keppel St, London WC1E 7HT, England.	Haleema.Shakur@Lshtm.ac.uk		Shakur-Still, Haleema/0000-0002-6511-109X; /0000-0002-2342-301X			[Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Edwards P, 2005, LANCET, V365, P1957; Figueroa BE, 1998, STROKE, V29, P1202, DOI 10.1161/01.STR.29.6.1202; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Gebel JM, 2002, STROKE, V33, P2636, DOI 10.1161/01.STR.0000035283.34109.EA; Guerriero C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018987; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Henry DA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub4; HORROW JC, 1995, ANESTHESIOLOGY, V82, P383, DOI 10.1097/00000542-199502000-00009; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Peden M., 2004, WORLD REPORT ROAD TR; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Roberts I, 2011, LANCET, V377, P1071, DOI 10.1016/S0140-6736(11)60317-6; Rubin DB, 2006, STAT SCI, V21, P299, DOI 10.1214/088342306000000114; Shakur H, 2010, LANCET, V376, P1051; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Thiex R, 2004, EXP NEUROL, V189, P25, DOI 10.1016/j.expneurol.2004.05.021; Thiex R, 2003, NEUROL RES, V25, P254, DOI 10.1179/016164103101201463; Weijer C, 2000, BMJ-BRIT MED J, V321, P756, DOI 10.1136/bmj.321.7263.756; Yutthakasemsunt S, 2010, NAT NEUR S	29	104	108	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	JUN 21	2012	13								87	10.1186/1745-6215-13-87			14	Medicine, Research & Experimental	Research & Experimental Medicine	028VP	WOS:000310452600001	22721545	DOAJ Gold, Green Published			2021-06-18	
J	Avery, MA; Rooney, TM; Pandya, JD; Wishart, TM; Gillingwater, TH; Geddes, JW; Sullivan, PG; Freeman, MR				Avery, Michelle A.; Rooney, Timothy M.; Pandya, Jignesh D.; Wishart, Thomas M.; Gillingwater, Thomas H.; Geddes, James W.; Sullivan, Patrick G.; Freeman, Marc R.			Wld(S) Prevents Axon Degeneration through Increased Mitochondrial Flux and Enhanced Mitochondrial Ca2+ Buffering	CURRENT BIOLOGY			English	Article							SLOW WALLERIAN DEGENERATION; TRAUMATIC BRAIN-INJURY; C57BL/OLA MICE; MECHANISMS	Wld(S) (slow Wallerian degeneration) is a remarkable protein that can suppress Wallerian degeneration of axons and synapses [1], but how it exerts this effect remains unclear [2]. Here, using Drosophila and mouse models, we identify mitochondria as a key site of action for Wd(S) neuroprotective function. Targeting the NAD(+) biosynthetic enzyme Nmnat to mitochondria was sufficient to fully phenocopy Wld(S), and Wld(S) was specifically localized to mitochondria in synaptic preparations from mouse brain. Axotomy of live wild-type axons induced a dramatic spike in axoplasmic Ca2+ and termination of mitochondrial movement-Wld(S) potently suppressed both of these events. Surprisingly, Wld(S) also promoted increased basal mitochondrial motility in axons before injury, and genetically suppressing mitochondrial motility in vivo dramatically reduced the protective effect of Wld(S). Intriguingly, purified mitochondria from Wld(S) mice exhibited enhanced Ca2+ buffering capacity. We propose that the enhanced Ca2+ buffering capacity of Wld(S+) mitochondria leads to increased mitochondrial motility, suppression of axotomy-induced Ca2+ elevation in axons, and thereby suppression of Wallerian degeneration.	[Avery, Michelle A.; Rooney, Timothy M.; Freeman, Marc R.] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA; [Avery, Michelle A.; Rooney, Timothy M.; Freeman, Marc R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; [Wishart, Thomas M.; Gillingwater, Thomas H.] Univ Edinburgh, Euan MacDonald Ctr Motor Neurone Dis Res, Edinburgh EH8 9XD, Midlothian, Scotland; [Wishart, Thomas M.; Gillingwater, Thomas H.] Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; [Pandya, Jignesh D.; Geddes, James W.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Freeman, MR (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.	marc.freeman@umassmed.edu		Gillingwater, Thomas/0000-0002-0306-5577; Freeman, Marc/0000-0003-3481-3715; wishart, thomas/0000-0002-1973-6654	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS062993, NS059991]; Wellcome TrustWellcome TrustEuropean Commission; Department of DefenseUnited States Department of Defense [BC093796]; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BBS/E/D/20251969] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059991, R01NS062993] Funding Source: NIH RePORTER	All animal procedures were carried out in accordance with National Institutes of Health (NIH) guidelines and the Institutional Animal Care and Use Committee regulations of the University of Kentucky and the University of Edinburgh. This work was supported by NIH grant NS062993 (J.W.G. and P.G.S.), the Wellcome Trust (T.H.G. and M.R.F.), and NIH grant NS059991 (to M.R.F.). M.R.F. is an Early Career Scientist with the Howard Hughes Medical Institute. T.M.R. was supported by a grant from the Department of Defense (BC093796). We thank Vimala Bondada and Dingyuan Lou for preliminary work on the mitochondrial Ca<SUP>2+</SUP> dynamics and all members of the laboratories for helpful discussions.	Avery MA, 2009, J CELL BIOL, V184, P501, DOI 10.1083/jcb.200808042; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Chang DTW, 2006, NEUROBIOL DIS, V22, P388, DOI 10.1016/j.nbd.2005.12.007; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; De Vos KJ, 2007, HUM MOL GENET, V16, P2720, DOI 10.1093/hmg/ddm226; Ganitkevich VY, 2003, EXP PHYSIOL, V88, P91, DOI 10.1113/eph8802504; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Gillingwater TH, 2006, BRAIN, V129, P1546, DOI 10.1093/brain/awl101; GLASS JD, 1993, J NEUROCYTOL, V22, P311, DOI 10.1007/BF01195555; Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x; Russo GJ, 2009, J NEUROSCI, V29, P5443, DOI 10.1523/JNEUROSCI.5417-08.2009; Santo-Domingo J, 2010, BBA-BIOENERGETICS, V1797, P907, DOI 10.1016/j.bbabio.2010.01.005; Sasaki Y, 2010, J BIOL CHEM, V285, P41211, DOI 10.1074/jbc.C110.193904; Schon EA, 2011, NEURON, V70, P1033, DOI 10.1016/j.neuron.2011.06.003; Shi P, 2010, BBA-MOL BASIS DIS, V1802, P707, DOI 10.1016/j.bbadis.2010.05.008; Sievers C, 2003, NEUROSCI RES, V46, P161, DOI 10.1016/S0168-0102(03)00039-7; Sunio A, 1997, EXP NEUROL, V146, P46, DOI 10.1006/exnr.1997.6484; Wang XL, 2009, J NEUROCHEM, V109, P153, DOI 10.1111/j.1471-4159.2009.05867.x; Wang XN, 2009, CELL, V136, P163, DOI 10.1016/j.cell.2008.11.046; Yahata N, 2009, J NEUROSCI, V29, P6276, DOI 10.1523/JNEUROSCI.4304-08.2009; Yi MQ, 2004, J CELL BIOL, V167, P661, DOI 10.1083/jcb.200406038	30	104	104	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0960-9822	1879-0445		CURR BIOL	Curr. Biol.	APR 10	2012	22	7					596	600		10.1016/j.cub.2012.02.043			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	926QC	WOS:000302844900021	22425157	Green Published, Green Accepted			2021-06-18	
J	Byrnes, KR; Loane, DJ; Stoica, BA; Zhang, JY; Faden, AI				Byrnes, Kimberly R.; Loane, David J.; Stoica, Bogdan A.; Zhang, Jiangyang; Faden, Alan I.			Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; microglia; metabotropic glutamate receptor 5; delayed treatment; neuroprotection	METABOTROPIC GLUTAMATE RECEPTORS; AUTOMATED IMAGE REGISTRATION; CONTROLLED CORTICAL IMPACT; DIFFUSION-TENSOR; LONGITUDINAL CHANGES; PROGRESSIVE ATROPHY; NEURONAL APOPTOSIS; MICROGLIA; NEUROTOXICITY; INFLAMMATION	Background: Traumatic brain injury initiates biochemical processes that lead to secondary neurodegeneration. Imaging studies suggest that tissue loss may continue for months or years after traumatic brain injury in association with chronic microglial activation. Recently we found that metabotropic glutamate receptor 5 (mGluR5) activation by (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) decreases microglial activation and release of associated pro-inflammatory factors in vitro, which is mediated in part through inhibition of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Here we examined whether delayed CHPG administration reduces chronic neuroinflammation and associated neurodegeneration after experimental traumatic brain injury in mice. Methods: One month after controlled cortical impact traumatic brain injury, C57Bl/6 mice were randomly assigned to treatment with single dose intracerebroventricular CHPG, vehicle or CHPG plus a selective mGluR5 antagonist, 3(( 2-Methyl-4-thiazolyl)ethynyl) pyridine. Lesion volume, white matter tract integrity and neurological recovery were assessed over the following three months. Results: Traumatic brain injury resulted in mGluR5 expression in reactive microglia of the cortex and hippocampus at one month post-injury. Delayed CHPG treatment reduced expression of reactive microglia expressing NADPH oxidase subunits; decreased hippocampal neuronal loss; limited lesion progression, as measured by repeated T2-weighted magnetic resonance imaging (at one, two and three months) and white matter loss, as measured by high field ex vivo diffusion tensor imaging at four months; and significantly improved motor and cognitive recovery in comparison to the other treatment groups. Conclusion: Markedly delayed, single dose treatment with CHPG significantly improves functional recovery and limits lesion progression after experimental traumatic brain injury, likely in part through actions at mGluR5 receptors that modulate neuroinflammation.	[Byrnes, Kimberly R.; Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Natl Study Ctr Trauma, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, EMS, Baltimore, MD 21201 USA; [Zhang, Jiangyang] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734; Zhang, Jiangyang/0000-0003-4146-8163; Zhang, Jiangyang/0000-0003-0740-2662; Loane, David/0000-0003-0393-3503	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS037313, NS NS059529]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568, R01NS037313, R21NS059529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	We would like to thank Nicole Hockenbury, Rainier Cabatbat, Kelly Wilson and Stephanie Custer for expert technical assistance. We thank Dr. Chunshu Piao for help with MRI analysis and Dr. Shruti Kabadi for helpful discussion. This work was supported by grants from the NIH/NINDS to AIF (5R01NS037313) and to JZ (NS NS059529).	Aggarwal M, 2009, NEUROSCIENCE, V162, P1339, DOI 10.1016/j.neuroscience.2009.05.070; Aggarwal M, 2010, MAGN RESON MED, V64, P249, DOI 10.1002/mrm.22426; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Byrnes KR, 2009, NEUROTHERAPEUTICS, V6, P94, DOI 10.1016/j.nurt.2008.10.038; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; Deng WB, 2004, P NATL ACAD SCI USA, V101, P7751, DOI 10.1073/pnas.0307850101; Drouin-Ouellet J, 2011, GLIA, V59, P188, DOI 10.1002/glia.21086; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kabadi SV, 2012, J NEUROTRAUMA; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nicoletti E, 2011, NEUROPHARMACOLOGY, V60, P1017, DOI 10.1016/j.neuropharm.2010.10.022; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Zhan XH, 2008, BRAIN RES, V1234, P183, DOI 10.1016/j.brainres.2008.07.094	60	104	104	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 28	2012	9								43	10.1186/1742-2094-9-43			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	917IT	WOS:000302168100001	22373400	DOAJ Gold, Green Published			2021-06-18	
J	Korkmaz, B				Korkmaz, Bars			Theory of Mind and Neurodevelopmental Disorders of Childhood	PEDIATRIC RESEARCH			English	Article							SOCIAL COGNITIVE NEUROSCIENCE; EXECUTIVE FUNCTION; EMPATHIC ACCURACY; MENTAL STATES; FUNCTIONAL CONNECTIVITY; INDIVIDUAL-DIFFERENCES; ASPERGER-SYNDROME; CHILDREN; AUTISM; LANGUAGE	To a large extent, the human infant is socialized through the acquisition of a specific cognitive mechanism known as theory of mind (ToM), a term which is currently used to explain a related set of intellectual abilities that enable us to understand that others have beliefs, desires, plans, hopes, information, and intentions that may differ from our own. Various neurodevelopmental disorders, such as autism spectrum disorders, attention deficit hyperactivity disorder, developmental language disorders, and schizophrenia, as well as acquired disorders of the right brain (and traumatic brain injury) impair ToM. ToM is a composite function, which involves memory, joint attention, complex perceptual recognition (such as face and gaze processing), language, executive functions (such as tracking of intentions and goals and moral reasoning), emotion processing-recognition, empathy, and imitation. Hence, ToM development is dependent on the maturation of several brain systems and is shaped by parenting, social relations, training, and education; thus, it is an example of the dense interaction that occurs between brain development and (social) environment. (Pediatr Res 69: 101R-108R, 2011)	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurol, Div Child Neurol, TR-34301 Istanbul, Turkey	Korkmaz, B (corresponding author), Istanbul Univ, Cerrahpasa Med Fac, Dept Neurol, Div Child Neurol, TR-34301 Istanbul, Turkey.	bkorkmaz@istanbul.edu.tr	Korkmaz, Baris/AAE-4742-2021				Akhutina T.V, 2003, J RUSSIAN E EUROPEAN, V41, P159, DOI [DOI 10.2753/RP01061-0405410304159, DOI 10.2753/RPO1061-0405410304159]; Allman JM, 2005, TRENDS COGN SCI, V9, P367, DOI 10.1016/j.tics.2005.06.008; Ang GK, 2009, AUSTRALAS PSYCHIATRY, V17, P117, DOI 10.1080/10398560802375982; Apperly IA, 2008, COGNITION, V107, P266, DOI 10.1016/j.cognition.2007.07.019; Apperly IA, 2006, SOC NEUROSCI-UK, V1, P334, DOI 10.1080/17470910601038693; Apperly IA, 2009, PSYCHOL REV, V116, P953, DOI 10.1037/a0016923; Apperly IA, 2009, DEV PSYCHOL, V45, P190, DOI 10.1037/a0014098; Assaf M, 2010, NEUROIMAGE, V53, P247, DOI 10.1016/j.neuroimage.2010.05.067; Astington JW, 1999, DEV PSYCHOL, V35, P1311, DOI 10.1037/0012-1649.35.5.1311; Back E, 2010, COGNITION, V115, P54, DOI 10.1016/j.cognition.2009.11.008; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S., 1992, MIND LANG, V7, P172, DOI [10.1111/j.1468-0017.1992.tb00203.x, DOI 10.1111/J.1468-0017.1992.TB00203.X]; BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; BaronCohen S, 1995, MINDBLINDNESS ESSAY, P1; Bedny M, 2009, P NATL ACAD SCI USA, V106, P11312, DOI 10.1073/pnas.0900010106; Begeer S, 2003, J AUTISM DEV DISORD, V33, P479, DOI 10.1023/A:1025875311062; Begeer S, 2010, EUR J DEV PSYCHOL, V7, P104, DOI 10.1080/17405620903024263; Blair RJR, 2008, Q J EXP PSYCHOL, V61, P157, DOI 10.1080/17470210701508855; Blakemore SJ, 2004, TRENDS COGN SCI, V8, P216, DOI 10.1016/j.tics.2004.03.012; Bora E, 2005, ACTA PSYCHIAT SCAND, V112, P110, DOI 10.1111/j.1600-0447.2005.00570.x; Brothers L., 1990, CONCEPT NEUROSCI, V1, P27, DOI DOI 10.1093/SCHBUL/SBQ012; Brune M, 2006, NEUROSCI BIOBEHAV R, V30, P437, DOI 10.1016/j.neubiorev.2005.08.001; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Burnett S, 2009, EUR J NEUROSCI, V29, P1294, DOI 10.1111/j.1460-9568.2009.06674.x; Call J, 2008, TRENDS COGN SCI, V12, P187, DOI 10.1016/j.tics.2008.02.010; Camaioni L, 2004, INFANCY, V5, P291, DOI 10.1207/s15327078in0503_3; CAPPS L, 1993, AUTISM, V2, P325; Carlson SM, 2004, DEV PSYCHOL, V40, P1105, DOI 10.1037/0012-1649.40.6.1105; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Chakrabarti S, 2005, AM J PSYCHIAT, V162, P1133, DOI 10.1176/appi.ajp.162.6.1133; CONNOLLY JA, 1984, DEV PSYCHOL, V20, P797, DOI 10.1037/0012-1649.20.5.797; Cutting AL, 1999, CHILD DEV, V70, P853, DOI 10.1111/1467-8624.00061; Dahlgren SO, 1996, J CHILD PSYCHOL PSYC, V37, P759, DOI 10.1111/j.1469-7610.1996.tb01469.x; Dale N, 2008, BRIT J VISUAL IMPA, V26, P135, DOI 10.1177/0264619607088282; de Villiers P. A., 2005, WHY LANGUAGE MATTERS, P266, DOI DOI 10.1093/ACPROF:OSO/9780195159912.003.0013; Decety J, 2006, BRAIN RES, V1079, P4, DOI 10.1016/j.brainres.2005.12.115; DODGE KA, 1993, ANNU REV PSYCHOL, V44, P559, DOI 10.1146/annurev.ps.44.020193.003015; Doherty MJ, 1999, COGNITIVE DEV, V14, P549, DOI 10.1016/S0885-2014(99)00019-2; DOHERTY MJ, 2008, THEORY MIND CHILDREN, P1; Dolan M, 2004, PSYCHOL MED, V34, P1093, DOI 10.1017/S0033291704002028; Dumontheil I, 2010, NEUROIMAGE, V52, P1574, DOI 10.1016/j.neuroimage.2010.05.056; Egeth M, 2009, CONSCIOUS COGN, V18, P244, DOI 10.1016/j.concog.2008.07.005; Farrar M. J., 2002, FIRST LANG, V22, P197, DOI DOI 10.1177/014272370202206504; Farrar MJ, 2009, J COMMUN DISORD, V42, P428, DOI 10.1016/j.jcomdis.2009.07.001; Farroni T, 2002, P NATL ACAD SCI USA, V99, P9602, DOI 10.1073/pnas.152159999; Fine C, 2001, BRAIN, V124, P287, DOI 10.1093/brain/124.2.287; Fonagy P, 1989, B A FREUD CTR, V12, P91; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; FRITH CD, 1992, COGNITIVE NEUROPSYCH, P124; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gillott A., 2004, CHILD LANGUAGE TEACH, V20, P1, DOI [DOI 10.1191/0265659004CT260OA, 10.1191/0265659004ct260oa]; Hamilton AFD, 2009, J CHILD PSYCHOL PSYC, V50, P881, DOI 10.1111/j.1469-7610.2009.02098.x; Happe F, 1996, BRAIN, V119, P1377, DOI 10.1093/brain/119.4.1377; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Hobson RP, 1999, J AUTISM DEV DISORD, V29, P45; Hobson RP, 2003, PHILOS T R SOC B, V358, P335, DOI 10.1098/rstb.2002.1201; Hughes C, 2005, CHILD DEV, V76, P356, DOI 10.1111/j.1467-8624.2005.00850_a.x; Hughes C, 2007, DEV PSYCHOL, V43, P1447, DOI 10.1037/0012-1649.43.6.1447; Jenkins JM, 2003, CHILD DEV, V74, P905, DOI 10.1111/1467-8624.00575; Jenkins JM, 1996, DEV PSYCHOL, V32, P70, DOI 10.1037/0012-1649.32.1.70; Keysar B, 2003, COGNITION, V89, P25, DOI 10.1016/S0010-0277(03)00064-7; Klein KJK, 2001, PERS SOC PSYCHOL B, V27, P720, DOI 10.1177/0146167201276007; KNUPPEL A, 2007, LANG ACQ WORKSH SCL, V34, P110; Kushalnagar P, 2010, J CLIN ETHIC, V21, P143; Leslie AM, 2004, TRENDS COGN SCI, V8, P528, DOI 10.1016/j.tics.2004.10.001; Lewis C, 1996, CHILD DEV, V67, P2930, DOI 10.1111/j.1467-8624.1996.tb01896.x; LEWIS V, 1988, BRIT J DEV PSYCHOL, V6, P325, DOI 10.1111/j.2044-835X.1988.tb01105.x; Lieberman M. D., 2010, HDB SOCIAL PSYCHOL, P143, DOI [10.1002/9780470561119.socpsy001005, DOI 10.1002/9780470561119.SOCPSY001005]; Lin SH, 2010, J EXP SOC PSYCHOL, V46, P551, DOI 10.1016/j.jesp.2009.12.019; Liu D, 2008, DEV PSYCHOL, V44, P523, DOI 10.1037/0012-1649.44.2.523; Lu HJ, 2008, DEV PSYCHOL, V44, P1726, DOI 10.1037/a0013074; Malle BF, 2008, HANDBOOK OF MOTIVATION AND COGNITION ACROSS CULTURES, P267, DOI 10.1016/B978-0-12-373694-9.00012-X; McAlister A, 2007, COGNITIVE DEV, V22, P258, DOI [10.1016/j.cogdev.2006.10.009, 10.1111/cdev.12043]; Meins E, 2002, CHILD DEV, V73, P1715, DOI 10.1111/1467-8624.00501; Mitchell P, 2009, BRIT J DEV PSYCHOL, V27, P513, DOI 10.1348/026151008X334737; Modinos G, 2009, J NEUROPSYCH CLIN N, V21, P100, DOI 10.1176/appi.neuropsych.21.1.100; Nelson KD, 2004, PSYCHOL REV, V111, P486, DOI 10.1037/0033-295X.111.2.486; Nettle, 2006, J CULTURAL EVOLUTION, V4, P231, DOI [10.1556/JCEP.4.2006.3-4.3, DOI 10.1556/JCEP.4.2006.3-4.3]; Nielsen M, 2004, INFANT BEHAV DEV, V27, P342, DOI 10.1016/j.infbeh.2003.12.006; Onishi KH, 2005, SCIENCE, V308, P255, DOI 10.1126/science.1107621; Ontai LL, 2008, SOC DEV, V17, P47, DOI 10.1111/j.1467-9507.2007.00414.x; Paynter J, 2010, RES AUTISM SPECT DIS, V4, P377, DOI 10.1016/j.rasd.2009.10.005; Pears KC, 2005, DEV PSYCHOPATHOL, V17, P47, DOI 10.1017/S0954579405050030; Pellicano E, 2010, CHILD DEV, V81, P1400, DOI 10.1111/j.1467-8624.2010.01481.x; PEREZPEREIRA M, 1994, J CHILD LANG, V21, P317, DOI 10.1017/S0305000900009296; Perkins T, 2010, J CLIN NEUROSCI, V17, P1239, DOI 10.1016/j.jocn.2010.01.026; Perner J, 2002, INFANT CHILD DEV, V11, P141, DOI 10.1002/icd.302; Peterson CC, 2000, MIND LANG, V15, P123, DOI 10.1111/1468-0017.00126; Ponnet K, 2005, J AUTISM DEV DISORD, V35, P585, DOI 10.1007/s10803-005-0003-z; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Press C, 2010, NEUROPSYCHOLOGIA, V48, P3291, DOI 10.1016/j.neuropsychologia.2010.07.012; Qureshi AW, 2010, COGNITION, V117, P230, DOI 10.1016/j.cognition.2010.08.003; Redmond SM, 1998, J SPEECH LANG HEAR R, V41, P688, DOI 10.1044/jslhr.4103.688; Richell RA, 2003, NEUROPSYCHOLOGIA, V41, P523, DOI 10.1016/S0028-3932(02)00175-6; Rieffe C, 2000, J CHILD PSYCHOL PSYC, V41, P601, DOI 10.1111/1469-7610.00647; Rieffe C, 2005, INFANT CHILD DEV, V14, P259, DOI 10.1002/icd.391; Rizzolatti G, 2008, CURR OPIN NEUROBIOL, V18, P179, DOI 10.1016/j.conb.2008.08.001; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Rosenbaum RS, 2007, SCIENCE, V318, P1257, DOI 10.1126/science.1148763; Samson D, 2007, NEUROPSYCHOLOGIA, V45, P2561, DOI 10.1016/j.neuropsychologia.2007.03.013; SCAIFE M, 1975, NATURE, V253, P265, DOI 10.1038/253265a0; Schick B, 2007, CHILD DEV, V78, P376, DOI 10.1111/j.1467-8624.2007.01004.x; Spence SA, 2004, PHILOS T R SOC B, V359, P1755, DOI 10.1098/rstb.2004.1555; Surian L, 2007, PSYCHOL SCI, V18, P580, DOI 10.1111/j.1467-9280.2007.01943.x; Tager-Flusberg H, 1999, INT REV PSYCHIATR, V11, P325, DOI 10.1080/09540269974203; Teufel C, 2010, TRENDS COGN SCI, V14, P376, DOI 10.1016/j.tics.2010.05.005; Uddin LQ, 2007, TRENDS COGN SCI, V11, P153, DOI 10.1016/j.tics.2007.01.001; Uekermann J, 2010, NEUROSCI BIOBEHAV R, V34, P734, DOI 10.1016/j.neubiorev.2009.10.009; Varga S, 2011, PSYCHOPATHOLOGY, V44, P46, DOI 10.1159/000317777; Vecera S. P., 1995, Visual Cognition, V2, P59, DOI 10.1080/13506289508401722; Verbeke E, 2005, BEHAV BRAIN SCI, V28, P718, DOI 10.1017/S0140525X05510124; Vygotski LS, 1929, PEDAGOG SEMIN J GEN, V36, P415; VYGOTSKY LS, 1965, NEUROPSYCHOLOGIA, V3, P381, DOI 10.1016/0028-3932(65)90011-4; Watson AC, 1999, DEV PSYCHOL, V35, P386, DOI 10.1037/0012-1649.35.2.386; Wellman HM, 2008, HUM DEV, V51, P105, DOI 10.1159/000115958; WELLMAN HM, 1995, COGNITION EMOTION, V9, P117, DOI 10.1080/02699939508409005; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Woolfe T., 2003, J DEAF STUD DEAF EDU, V8, P340, DOI [10.1093/deafed/eng023, DOI 10.1093/DEAFED/ENG023]; Yagmurlu B, 2005, J APPL DEV PSYCHOL, V26, P521, DOI 10.1016/j.appdev.2005.06.004; ZAITCHIK D, 1990, COGNITION, V35, P41, DOI 10.1016/0010-0277(90)90036-J; Zaitchik D, 2010, NEUROPSYCHOLOGIA, V48, P2528, DOI 10.1016/j.neuropsychologia.2010.04.031	123	104	105	2	97	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	MAY	2011	69	5	2				101R	108R		10.1203/PDR.0b013e318212c177			8	Pediatrics	Pediatrics	753WO	WOS:000289811100015	21289541	Bronze			2021-06-18	
J	Lange, RT; Iverson, GL; Rose, A				Lange, Rael T.; Iverson, Grant L.; Rose, Alice			Depression Strongly Influences Postconcussion Symptom Reporting Following Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; mild traumatic brain injury; postconcussion symptoms	POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; COMPLAINT BASE RATES; GOOD OLD DAYS; MAJOR DEPRESSION; HEAD-INJURY; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; CHRONIC PAIN; EXPECTATION	Objective: To examine the influence of depression on postconcussion symptom reporting in patients following mild traumatic brain injury (MTBI). Participants: Sixty patients referred to a specialty clinic following MTBI, 58 outpatients with Structured Clinical Interview for DSM-diagnosed depression, and 72 healthy community control participants. Procedure: Participants with MTBI were divided into 2 subgroups on the basis of self-reported symptoms of depression (23 MTBI-depressed, 37 MTBI-not depressed). All participants completed a postconcussion symptom questionnaire. Main outcome measure: British Columbia Post-concussion Symptom Inventory. Results: There were significant differences in total reported postconcussion symptoms among all 4 groups (all P < .002; Cohen's d = 0.68-3.24, large to very large effect sizes; MTBI-depressed > depressed outpatients > MTBI-no depression > healthy controls). There were significant differences in the number of symptoms endorsed (P < .05), with the highest number of symptoms endorsed by the MTBI-depressed group, followed by depressed outpatients, MTBI-no depression, and healthy controls. Conclusions: Patients who experience MTBIs and who have a postinjury recovery course complicated by significant depression report more postconcussion symptoms, and more severe symptoms, than (a) outpatients with depression, and (b) patients with MTBIs who do not have significant symptoms of depression.	[Lange, Rael T.; Iverson, Grant L.] PHSA Res & Networks, British Columbia Mental Hlth & Addict Serv, Vancouver, BC V5Z 4C2, Canada; [Rose, Alice] Univ British Columbia, GF Strong Rehab Ctr, Vancouver, BC V5Z 1M9, Canada	Lange, RT (corresponding author), PHSA Res & Networks, British Columbia Mental Hlth & Addict Serv, Ste 201,601 W Broadway St, Vancouver, BC V5Z 4C2, Canada.	rael.lange@gmail.com		Iverson, Grant/0000-0001-7348-9570			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ATKINSON JH, 1991, PAIN, V45, P111, DOI 10.1016/0304-3959(91)90175-W; Bockting CLH, 2005, J CONSULT CLIN PSYCH, V73, P647, DOI 10.1037/0022-006X.73.4.647; Breslau N, 2000, NEUROLOGY, V54, P308, DOI 10.1212/WNL.54.2.308; Campbell LC, 2003, BIOL PSYCHIAT, V54, P399, DOI 10.1016/S0006-3223(03)00545-6; Channon S, 1999, J NEUROL NEUROSUR PS, V66, P162, DOI 10.1136/jnnp.66.2.162; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; First M.B., 1998, STRUCTURED CLIN INTE; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; Franklin CL, 2001, J NERV MENT DIS, V189, P548, DOI 10.1097/00005053-200108000-00008; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hung CI, 2006, CEPHALALGIA, V26, P26, DOI 10.1111/j.1468-2982.2005.00985.x; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2004, PSYCHOL REP, V95, P1241, DOI 10.2466/pr0.95.3f.1241-1247; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; IVERSON GL, BLACK BOOK IN PRESS; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; KELLER MB, 1992, ARCH GEN PSYCHIAT, V49, P809; Kessing LV, 2004, ACTA PSYCHIAT SCAND, V109, P339, DOI 10.1046/j.1600-0447.2003.00266.x; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Merriam EP, 1999, AM J PSYCHIAT, V156, P780; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mulder RT, 2006, AM J PSYCHIAT, V163, P95, DOI 10.1176/appi.ajp.163.1.95; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nunes EV, 2004, JAMA-J AM MED ASSOC, V291, P1887, DOI 10.1001/jama.291.15.1887; Pettit JW, 2006, PSYCHIAT RES, V141, P271, DOI 10.1016/j.psychres.2005.07.022; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Solomon DA, 2000, AM J PSYCHIAT, V157, P229, DOI 10.1176/appi.ajp.157.2.229; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Williams JMG, 2006, J AFFECT DISORDERS, V91, P189, DOI 10.1016/j.jad.2006.01.002; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002; World Health Organization, 1992, ICD 10 INT STAT CLAS; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111	66	104	105	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2011	26	2					127	137		10.1097/HTR.0b013e3181e4622a			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	732OR	WOS:000288197200003	20631632				2021-06-18	
J	Ferguson, PL; Smith, GM; Wannamaker, BB; Thurman, DJ; Pickelsimer, EE; Selassie, AW				Ferguson, Pamela L.; Smith, Gigi M.; Wannamaker, Braxton B.; Thurman, David J.; Pickelsimer, E. Elisabeth; Selassie, Anbesaw W.			A population-based study of risk of epilepsy after hospitalization for traumatic brain injury	EPILEPSIA			English	Article						Posttraumatic epilepsy; Traumatic brain injuries; Incidence cohort studies; Population surveillance; Depressive disorder	LATE POSTTRAUMATIC SEIZURES; UNPROVOKED SEIZURES; MAJOR DEPRESSION; SOUTH-CAROLINA; HEAD-INJURY; HIPPOCAMPAL VOLUME; ADULTS; PREVALENCE; COMMUNITY; EPIDEMIOLOGY	P>Purpose: This study was undertaken to determine the risk of developing posttraumatic epilepsy (PTE) within 3 years after discharge among a population-based sample of older adolescents and adults hospitalized with traumatic brain injury (TBI) in South Carolina. It also identifies characteristics related to development of PTE within this population. Methods: A stratified random sample of persons aged 15 and older with TBI was selected from the South Carolina nonfederal hospital discharge dataset for four consecutive years. Medical records of recruits were reviewed, and they participated in up to three yearly follow-up telephone interviews. Results: The cumulative incidence of PTE in the first 3 years after discharge, after adjusting for loss to follow-up, was 4.4 per 100 persons over 3 years for hospitalized mild TBI, 7.6 for moderate, and 13.6 for severe. Those with severe TBI, posttraumatic seizures prior to discharge, and a history of depression were most at risk for PTE. This higher risk group also included persons with three or more chronic medical conditions at discharge. Discussion: These results raise the possibility that although some of the characteristics related to development of PTE are nonmodifiable, other factors, such as depression, might be altered with intervention. Further research into factors associated with developing PTE could lead to risk-reducing treatments.	[Ferguson, Pamela L.; Pickelsimer, E. Elisabeth; Selassie, Anbesaw W.] Med Univ S Carolina, Div Biostat & Epidemiol, Dept Med, Charleston, SC 29425 USA; [Smith, Gigi M.; Wannamaker, Braxton B.] Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; [Smith, Gigi M.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA; [Thurman, David J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA	Ferguson, PL (corresponding author), Med Univ S Carolina, Div Biostat & Epidemiol, Dept Med, 135 Cannon St,Suite 303,MSC 835, Charleston, SC 29425 USA.	ferguspl@musc.edu	Cusco, Xavier Garcia/S-7576-2019	Cusco, Xavier Garcia/0000-0001-7199-6931; Thurman, David/0000-0002-0533-7062; Smith, Gigi/0000-0002-0921-7498	Division of Injury Response, National Center for Injury Prevention and Control (NCIPC) [U17/CCU421926]; National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	This study was supported by cooperative agreement U17/CCU421926 (PI: Anbesaw W. Selassie) from the Division of Injury Response, National Center for Injury Prevention and Control (NCIPC), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC). The study was performed pursuant to a jointly financed cooperative arrangement between the NCPIC, the NCCDPHP, CDC, and the Social Security Administration (SSA), Office of Disability Income and Support Programs. The opinions and conclusions expressed are solely the authors' and should not be construed as representing the opinions or policy of CDC, SSA, or any agency of the federal government.We would like to thank the individuals at the SC Office of Research and Statistics and the SC Department of Health and Environmental Control who were invaluable in collecting data for this study, and Monica Gardner, who read and answered questions on a cited article published in German.We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.Disclosure: None of the authors has any conflict of interest to disclose.	Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Annegers JF, 1999, EPILEPSIA, V40, P502, DOI 10.1111/j.1528-1157.1999.tb00748.x; ARMITAGE P, 2002, STAT METHODS MED RES, P568; ARMSTRONG KK, 1990, ARCH PHYS MED REHAB, V71, P156; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Berg AT, 1996, NEUROL CLIN, V14, P383, DOI 10.1016/S0733-8619(05)70263-2; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Corrigan J., 2003, TECHN REP PROBL SUBS; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; DESAI BT, 1983, ANN EMERG MED, V12, P543, DOI 10.1016/S0196-0644(83)80294-7; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Ettinger A, 2004, NEUROLOGY, V63, P1008, DOI 10.1212/01.WNL.0000138430.11829.61; Expert Group on Injury Severity Measurement in Administrative Datasets, 2004, DISC DOC INJ SEV MEA; Ferguson PL, 2008, EPILEPSY BEHAV, V13, P529, DOI 10.1016/j.yebeh.2008.05.005; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; FORSGREN L, 1990, EPILEPSY RES, V6, P66, DOI 10.1016/0920-1211(90)90010-S; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gaitatzis A, 2002, EPILEPSY RES, V50, P233, DOI 10.1016/S0920-1211(02)00031-1; HAERER AF, 1986, EPILEPSIA, V27, P66, DOI 10.1111/j.1528-1157.1986.tb03503.x; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Heaney DC, 2002, BMJ-BRIT MED J, V325, P1013, DOI 10.1136/bmj.325.7371.1013; Hermann BP, 2000, EPILEPSIA, V41, pS31, DOI 10.1111/j.1528-1157.2000.tb01522.x; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Hesdorffer DC, 2000, ANN NEUROL, V47, P246, DOI 10.1002/1531-8249(200002)47:2<246::AID-ANA17>3.0.CO;2-E; Hillbom E., 1959, ACTA PSYCHIAT NEUROL, V34, P7; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; *J HOPK U TRIAN IN, 1998, ICDMAP 90 US GUID; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kotsopoulos I, 2005, SEIZURE-EUR J EPILEP, V14, P175, DOI 10.1016/j.seizure.2005.01.005; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; Malberg JE, 2003, NEUROPSYCHOPHARMACOL, V28, P1562, DOI 10.1038/sj.npp.1300234; Mensah SA, 2006, EPILEPSY BEHAV, V8, P213, DOI 10.1016/j.yebeh.2005.09.014; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; *SAS I INC, 2002, SAS HELP DOC COCHR A; Schmitz EB, 1999, EPILEPSY RES, V35, P59, DOI 10.1016/S0920-1211(98)00129-6; Schutze M, 1999, ZBL NEUROCHIR, V60, P163; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Sheline YI, 1999, J NEUROSCI, V19, P5034; Singer R B, 2001, J Insur Med, V33, P42; STOKES ME, 2000, CATEGORICAL DATA ANA, P349; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Szklo M, 2000, EPIDEMIOLOGY BASICS, P55; Thurman DJ., 1995, GUIDELINES SURVEILLA; Timmons S, 2002, Ir Med J, V95, P47; *US CENS BUR, 2007, INC 2007 MED HOUS IN; Wallace H, 1998, LANCET, V352, P1970, DOI 10.1016/S0140-6736(98)04512-7; Wang HC, 2008, J TRAUMA, V64, P883, DOI 10.1097/TA.0b013e31804a7fa4; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Wiebe S, 1999, CAN J NEUROL SCI, V26, P263, DOI 10.1017/S0317167100000354; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594	59	104	108	2	12	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia	MAY	2010	51	5					891	898		10.1111/j.1528-1167.2009.02384.x			8	Clinical Neurology	Neurosciences & Neurology	587OA	WOS:000277000900023	19845734	Bronze			2021-06-18	
J	Vinchon, M; de Foort-Dhellemmes, S; Desurmont, M; Delestret, I				Vinchon, Matthieu; de Foort-Dhellemmes, Sabine; Desurmont, Marie; Delestret, Isabelle			Confessed abuse versus witnessed accidents in infants: comparison of clinical, radiological, and ophthalmological data in corroborated cases	CHILDS NERVOUS SYSTEM			English	Article						Subdural hematoma; Infant; Inflicted head injury; Shaken baby syndrome; Accidental trauma	SHAKEN BABY SYNDROME; TRAUMATIC BRAIN-INJURY; INFLICTED HEAD-INJURY; YOUNG-CHILDREN; HEMORRHAGES; PATTERNS; CANADA; FALLS	The diagnosis of inflicted head injury (IHI) or accidental trauma (AT) in infants is based on clinical, radiological, and/or ophthalmological findings such as subdural hematoma (SDH), encephalopathy, retinal hemorrhage (RH), and signs of impact. As a consequence, the diagnostic value of these criteria is difficult to assess because of a circularity bias. In order to assess the predictive value of these diagnostic criteria avoiding circularity, we studied prospectively corroborated cases of head injuries in infants, comparing IHI with AT. We selected 45 cases of confessed IHI and 39 cases of AT having occurred in public places. Patients were systematically evaluated clinically, with computed tomography scanner and ophthalmological evaluation by a trained ophthalmologist. RH was rated as absent, mild, and severe, according to the depth and extent of the RH. Brain ischemia was found in 26.7% of IHI; the most prominent elements in favor of IHI were SDH, severe RH, and absence of signs of impact; the predictive diagnostic values of these three features were 0.685, 0.961, and 0.830, respectively; however, only severe RH in the absence of ocular impact was specific of IHI. When all three features were combined, the specificity was 100%, but the sensitivity was only 24.4%. Our study confirms the high diagnostic value of RH, SDH, and signs of impact for the differential diagnosis between AT and IHI. The evaluation of head injuries in infants requires a high level of awareness and thorough and systematic examination by a trained multidisciplinary team.	[Vinchon, Matthieu] CHRU Lille, Serv Neurochirurg Pediat, F-59037 Lille, France; [Desurmont, Marie] Lille Univ Hosp, Dept Forens Med, Lille, France; [de Foort-Dhellemmes, Sabine] Lille Univ Hosp, Dept Neuroophthalmol, Lille, France; [Vinchon, Matthieu; Delestret, Isabelle] Lille Univ Hosp, Dept Pediat Neurosurg, Lille, France	Vinchon, M (corresponding author), CHRU Lille, Serv Neurochirurg Pediat, F-59037 Lille, France.	m-vinchon@chru-lille.fr		Vinchon, Matthieu/0000-0002-9122-6165			Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; GARDNER HB, 2005, PEDIATR NEUROSURG, V43, P433; Geddes JF, 2004, BMJ-BRIT MED J, V328, P719, DOI 10.1136/bmj.328.7442.719; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; HARWOODNASH DC, 1992, AM J NEURORADIOL, V13, P569; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; King WJ, 2003, CAN MED ASSOC J, V168, P155; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Leestma J. E., 2006, J AM PHYS SURG, V11, P14; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Oehmichen M, 2005, NEUROPEDIATRICS, V36, P240, DOI 10.1055/s-2005-872812; Piatt J H Jr, 1999, Neurosurg Focus, V7, pe4; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Pollanen MS, 2002, FORENSIC SCI INT, V126, P101, DOI 10.1016/S0379-0738(02)00008-7; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11	27	104	105	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAY	2010	26	5					637	645		10.1007/s00381-009-1048-7			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	582NV	WOS:000276605600010	19946688				2021-06-18	
J	Pietrzak, RH; Johnson, DC; Goldstein, MB; Malley, JC; Southwick, SM				Pietrzak, Robert H.; Johnson, Douglas C.; Goldstein, Marc B.; Malley, James C.; Southwick, Steven M.			Posttraumatic Stress Disorder Mediates the Relationship Between Mild Traumatic Brain Injury and Health and Psychosocial Functioning in Veterans of Operations Enduring Freedom and Iraqi Freedom	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						Veterans; combat; soldiers; posttraumatic stress disorder; mild traumatic brain injury; psychosocial; functioning; barriers to care	POSTCONCUSSIVE SYMPTOMS; AFGHANISTAN; DEPLOYMENT; BARRIERS; WAR	This study evaluated whether posttraumatic stress disorder (PTSD) mediated the relationship between mild traumatic brain injury (MTBI) and general health ratings, psychosocial functioning, and perceived barriers to receiving mental healthcare 2 years following return from deployment in veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF). A total of 277 OEF/OIF veterans completed the Connecticut OEF/OIF Veterans Needs Assessment Survey; 18.8% of the sample screened positive for MTBI. Compared with respondents who screened negative for MTBI, respondents who screened positive for MTBI were younger, more likely to have PTSD, more likely to report fair/poor overall health and unmet medical and psychological needs, and scored higher on measures of psychosocial difficulties and perceived barriers to mental healthcare. Injuries involving loss of consciousness were associated with greater work-related difficulties and unmet psychological needs. PTSD mediated the relationship between MTBI and all of these outcomes. These results underscore the importance of assessing PTSD in OEF/OIF veterans who screen positive for MTBI.	[Pietrzak, Robert H.] Yale Univ, Sch Med, Natl Ctr PTSD, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA; [Pietrzak, Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Johnson, Douglas C.] Univ Calif San Diego, Dept Psychiat, Sch Med, San Diego, CA 92103 USA; [Johnson, Douglas C.] VA San Diego Healthcare Syst, San Diego, CA USA; [Goldstein, Marc B.] Cent Connecticut State Univ, Dept Psychol, New Britain, CT 06050 USA; [Malley, James C.] Cent Connecticut State Univ, Dept Counseling & Family Therapy, New Britain, CT 06050 USA	Pietrzak, RH (corresponding author), Yale Univ, Sch Med, Natl Ctr PTSD, VA Connecticut Healthcare Syst, 950 Campbell Ave 151E, West Haven, CT 06516 USA.	robert.pietrzak@yale.com			State of Connecticut; National Center for PTSD; private donation	Supported by the State of Connecticut. the National Center for PTSD, and a private donation.	BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Britt TW, 2008, J SOC CLIN PSYCHOL, V27, P317, DOI 10.1521/jscp.2008.27.4.317; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; *GOV ACC OFF, 2008, GAO08276; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Tate AR, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-51; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Weathers F., 1991, PTSD CHECKLIST MILIT; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314	20	104	105	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3018	1539-736X		J NERV MENT DIS	J. Nerv. Ment. Dis.	OCT	2009	197	10					748	753		10.1097/NMD.0b013e3181b97a75			6	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	507CZ	WOS:000270829900006	19829203				2021-06-18	
J	Pitkanen, A; Immonen, RJ; Grohn, OHJ; Kharatishvili, I				Pitkanen, Asla; Immonen, Riikka J.; Grohn, Olli H. J.; Kharatishvili, Irina			From traumatic brain injury to posttraumatic epilepsy: What animal models tell us about the process and treatment options	EPILEPSIA			English	Article						Antiepileptic drug; Epileptogenesis; Fluid-percussion injury; Recovery; Surrogate marker	FLUID PERCUSSION INJURY; TEMPORAL-LOBE EPILEPSY; DENTATE GYRUS; HIPPOCAMPAL CA1; CELL-DEATH; RAT; HYPEREXCITABILITY; EPILEPTOGENESIS; VULNERABILITY; EPIDEMIOLOGY	A large number of animal models of traumatic brain injury (TBI) are already available for studies on mechanisms and experimental treatments of TBI. Immediate and early seizures have been described in many of these models with focal or mixed type (both gray and white matter damage) injury. Recent long-term video-electroencephalography (EEG) monitoring studies have demonstrated that TBI produced by lateral fluid-percussion injury in rats results in the development of late seizures, that is, epilepsy. These animals develop hippocampal alterations that are well described in status epilepticus-induced spontaneous seizure models and human posttraumatic epilepsy (PTE). In addition, these rats have damage ipsilaterally in the cortical injury site and thalamus. Although studies in the trauma field provide a large amount of information about the molecular and cellular alterations corresponding to the immediate and early phases of PTE, chronic studies relevant to the epileptogenesis phase are sparse. Moreover, despite the multiple preclinical pharmacologic and cell therapy trials, there is no information available describing whether these therapeutic approaches aimed at improving posttraumatic recovery would also affect the development of lowered seizure threshold and epilepsy. To make progress, there is an obvious need for information exchange between the trauma and epilepsy fields. In addition, the inclusion of epilepsy as an outcome measure in preclinical trials aiming at improving somatomotor and cognitive recovery after TBI would provide valuable information about possible new avenues for antiepileptogenic interventions and disease modification after TBI.	[Pitkanen, Asla; Kharatishvili, Irina] Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; [Immonen, Riikka J.; Grohn, Olli H. J.] Univ Kuopio, Biomed NMR Res Grp, Biomed Imaging Unit, Dept Neurobiol,AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uku.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE; Finnish Technological Fund	This study was supported by the Academy of Finland, the Sigrid Juselius Foundation, CURE, and the Finnish Technological Fund. We thank Nick Hayward, M.Sc., for checking the English language.	Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Golarai G, 2001, J NEUROSCI, V21, P8523; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Keck CA, 2007, RESTOR NEUROL NEUROS, V25, P77; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J., 2006, P 7 EUR C EP, P87; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2006, DRUG DISCOV TODAY, V2, P409; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; WILLMORE LJ, 1978, SCIENCE, V200, P501; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	44	104	107	0	15	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia		2009	50						21	29		10.1111/j.1528-1167.2008.02007.x			9	Clinical Neurology	Neurosciences & Neurology	399VN	WOS:000262827500005	19187291	Bronze			2021-06-18	
J	Marcoux, J; McArthur, DA; Miller, C; Glenn, TC; Villablanca, P; Martin, NA; Hovda, DA; Alger, JR; Vespa, PM				Marcoux, Judith; McArthur, David A.; Miller, Chad; Glenn, Thomas C.; Villablanca, Pablo; Martin, Neil A.; Hovda, David A.; Alger, Jeffry R.; Vespa, Paul M.			Persistent metabolic crisis as measured by elevated cerebral microdialysis lactate-pyruvate ratio predicts chronic frontal lobe brain atrophy after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain trauma; microdialysis; lactate; pyruvate; MRI; atrophy; outcome; biomarker	POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD-INJURY; PERFUSION-PRESSURE; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; EXTRACELLULAR GLUTAMATE; LACTATE/PYRUVATE RATIO; QUANTITATIVE-ANALYSIS; ENERGY-METABOLISM; GLUCOSE	Objective: To determine whether persistent metabolic dysfunction in normal-appearing frontal lobe tissue is correlated with long-term tissue atrophy. Design: Prospective monitoring with retrospective data analysis. Setting: Single-center academic neurointensive care unit. Patients: Fifteen patients with moderate to severe traumatic brain injury (Glasgow Coma Scale score 3-12). Interventions: None. Measurements and Main Results: Hourly cerebral microdialysis was performed for the initial 96 hrs after trauma to determine extracellular levels of glucose, glutamate, glycerol, lactate, and pyruvate in normal appearing frontal lobes. Six months after injury, the anatomical outcome was assessed by measures of global and regional cerebral atrophy using volumetric brain magnetic resonance imaging. The lactate/pyruvate ratio was elevated >40 after traumatic brain injury in most patients, with a mean percent time of 32 +/- 29% of hours monitored. At 6 months after traumatic brain injury, there was a mean frontal lobe atrophy of 12 +/- 11% and global brain atrophy of 8.5 +/- 4.5%. The percentage of time of elevated lactate/pyruvate ratio correlated with the extent of frontal lobe brain atrophy (r = -.56, p < 0.01), but not global brain atrophy (r = -.31, p = 0.20). The predictive effect of lactate/pyruvate ratio was independent of patient age, Glasgow Coma Scale score, and volume of frontal lobe contusion. Conclusion: Persistent metabolic crisis, as reflected by an elevated lactate/pyruvate ratio, in normal appearing posttraumatic frontal lobe, is predictive of the degree of tissue atrophy at 6 months.	[Marcoux, Judith] McGill Univ, Montreal Neurol Inst, Dept Neurosurg, Montreal, PQ, Canada; [McArthur, David A.; Miller, Chad; Glenn, Thomas C.; Martin, Neil A.; Hovda, David A.; Vespa, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg Neurosurg, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Vespa, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Villablanca, Pablo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA	Marcoux, J (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurosurg, Montreal, PQ, Canada.	PVespa@mednet.ucla.edu		Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408	 [NS049471];  [NS02089]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002089, R01NS049471] Funding Source: NIH RePORTER	Supported in part by grants NS049471 and NS02089.	Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gopinath SP, 2000, ACT NEUR S, V76, P437; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Verger K, 2001, BRAIN INJURY, V15, P211; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	29	104	106	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	OCT	2008	36	10					2871	2877		10.1097/CCM.0b013e318186a4a0			7	Critical Care Medicine	General & Internal Medicine	356GF	WOS:000259766000022	18766106				2021-06-18	
J	de la Plata, CAM; Hart, T; Hammond, FH; Frol, AB; Hudak, A; Harper, CR; O'Neil-Pirozzi, TM; Whyte, J; Carlile, M; Diaz-Arrastia, R				de la Plata, Carlos A. Marquez; Hart, Tessa; Hammond, Flora H.; Frol, Alan B.; Hudak, Anne; Harper, Caryn R.; O'Neil-Pirozzi, Therese M.; Whyte, John; Carlile, Mary; Diaz-Arrastia, Ramon			Impact of age on long-term recovery from traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; disabled persons; rehabilitation	DIFFUSE AXONAL INJURY; HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTOR; SYSTEMATIC BIAS; FOLLOW-UP; PREDICTORS; DISABILITY; ASSOCIATION; INDUCTION	Objective: To determine whether older persons are at increased risk for progressive functional decline after traumatic brain injury (TBI). Design: Longitudinal cohort Study. Setting: Traumatic Brain Injury Model Systems (TBIMS) rehabilitation centers. Participants: Subjects enrolled in the TBIMS national dataset. Interventions: Not applicable. Main Outcome Measures: Disability Rating Scale (DRS), FIM instrument cognitive items, and the Glasgow Outcome Scale-Extended. Results: Participants were separated into 3 age tertiles: youngest (16-26y), intermediate (27-39y), and oldest (>= 40y). DRS scores were comparable across age groups at admission to,I rehabilitation center. The oldest group was slightly more disabled at discharge from rehabilitation despite having less severe acute injury severity than the younger groups. Although DRS scores for the 2 younger groups improved significantly from year 1 to year 5, the greatest magnitude of improvement in disability was seen among the youngest group. In addition, after dividing patients into groups according to whether their DRS scores improved (13%), declined (10%), or remained stable (77%) over time, the likelihood of decline was found to be greater for the 2 older groups than for the youngest group. A multiple regression model showed that age has a significant negative influence on DRS score 5 years post-TBI after accounting for the effects of covariates. Conclusions: This study supported our primary hypothesis that older patients show greater decline over the first 5 years after TBI than Younger patients. In addition, the greatest amount of improvement in disability was observed among the Youngest group of survivors. These results suggest that TBI Survivors. especially older patients, may be candidates for neuroprotective therapies after TBI.	[de la Plata, Carlos A. Marquez; Frol, Alan B.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [de la Plata, Carlos A. Marquez; Harper, Caryn R.; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Hudak, Anne] Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; [Carlile, Mary] Baylor Inst Rehabil, Dallas, TX USA; [Hart, Tessa; Whyte, John] Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; [Hart, Tessa; Whyte, John] Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19107 USA; [Hammond, Flora H.] Carolinas Rehabil, Charlotte, NC USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Spaulding Rehabil Hosp, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA	Diaz-Arrastia, R (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ramon.diaz-arrastia@utsoutinvestern.edu		Whyte, John/0000-0002-4381-1474; Diaz-Arrastia, Ramon/0000-0001-6051-3594	National Institutes of Health, U.S. Department of EducationUS Department of EducationUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [H133 A020526, R01 HD48179, U01 HD42652]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	Supported by the National Institutes of Health, U.S. Department of Education (grant nos. H133 A020526, R01 HD48179, U01 HD42652).	Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Corrada MM, 1997, NEUROLOGY, V48, P5054; Corrigan J, 2003, TECHNICAL REPORT PRO; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Ge YL, 2002, AM J NEURORADIOL, V23, P1327; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hillbom M, 1999, J CARDIOVASC RISK, V6, P223; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAKIER A, 2002, ANN NEUROL, V9, P187; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Sapoznik S, 2006, LEARN MEMORY, V13, P719, DOI 10.1101/lm.351706; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Sherer M, 1999, BRAIN INJURY, V13, P973; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; VERMA NP, 1992, CLIN ELECTROENCEPHAL, V23, P147, DOI 10.1177/155005949202300310; WALBRAN BB, 1981, ALCOHOL CLIN EXP RES, V5, P531, DOI 10.1111/j.1530-0277.1981.tb05355.x; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; ZABAR Y, 2000, NEURODEGENERATIVE DE, P79	53	104	108	1	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					896	903		10.1016/j.apmr.2007.12.030			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900016	18452739	Green Accepted			2021-06-18	
J	Shafi, S; de la Plata, CM; Diaz-Arrastia, R; Bransky, A; Frankel, H; Elliott, AC; Parks, J; Gentilello, LM				Shafi, Shahid; de la Plata, Carlos Marquez; Diaz-Arrastia, Ramon; Bransky, Aaron; Frankel, Heidi; Elliott, Alan C.; Parks, Jennifer; Gentilello, Larry M.			Ethnic disparities exist in trauma care	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma		ethnic disparities; rehabilitation; trauma care; TBI	ACUTE MYOCARDIAL-INFARCTION; SPANISH-SPEAKING PATIENTS; BRAIN-INJURY; UNITED-STATES; HEALTH-CARE; OUTCOMES; IMPACT; RACE; EMERGENCY; MORTALITY	Background: An estimated 5.3 million people in the United States live with permanent disability related to traumatic brain injury (TBI). Access to rehabilitation after TBI is important in minimizing these disabilities. Ethnic disparities in access to health care have been documented in other diseases, but have not been studied in trauma care. We hypothesized that access to rehabilitation after TBI is influenced by race or ethnicity. Methods: Retrospective analysis of the National Trauma Data Bank patients with severe blunt TBI (head abbreviated injury score 3-5, n = 58,729) who survived the initial hospitalization was performed. Placement into rehabilitation after discharge was studied in three groups: non-Hispanic white (NHW 77%), African American (14%), and Hispanic (9%). The two minority groups were compared with NHW patients using logistic regression to control for differences in age, gender, overall injury severity (injury severity score), TBI severity (head abbreviated injury score and Glasgow Coma Scale score), associated injuries, and insurance status. Results: The three groups were similar in injury severity score, TBI severity, and associated injuries. After accounting for differences in potential confounders, including injury severity and insurance status, minority patients were 15% less likely to be placed in rehabilitation (odds ratio 0.85, 95% confidence interval 0.8-0.9, p < 0.0001). Conclusions: Ethnic minority patients are less likely to be placed in rehabilitation than NHW` patients are, even after accounting for insurance status, suggesting existence of systematic inequalities in access. Such inequalities may have a disproportionate impact on long-term functional outcomes of African American and Hispanic TBI patients, and suggest the need for an in-depth analysis of this disparity at a health policy level.	Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Clin Sci, Dallas, TX USA	Shafi, S (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shahid.shafi@uthsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594			BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Baker DW, 1998, MED CARE, V36, P1461, DOI 10.1097/00005650-199810000-00004; Baker DW, 1996, JAMA-J AM MED ASSOC, V275, P783, DOI 10.1001/jama.275.10.783; Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Barnhart JM, 2003, ARCH INTERN MED, V163, P461, DOI 10.1001/archinte.163.4.461; Bertoni AG, 2005, J NATL MED ASSOC, V97, P317; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; Carrasquillo O, 1999, J GEN INTERN MED, V14, P82, DOI 10.1046/j.1525-1497.1999.00293.x; COLLINS K, 1999, HLTH CHARTBOOK; ERZINGER S, 1991, CULT MED PSYCHIAT, V15, P91, DOI 10.1007/BF00050829; Flattery Maureen P, 2004, J Cult Divers, V11, P25; FRANKOWSKI RAJ, 1985, DESCRIPTIVE EPIDEMIO; Franks P, 2002, MED CARE, V40, P717, DOI 10.1097/00005650-200208000-00011; Greenwood RJ, 2004, BRIT J NEUROSURG, V18, P462, DOI 10.1080/02688690400012327; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lucas FL, 2006, ANN SURG, V243, P281, DOI 10.1097/01.sla.0000197560.92456.32; Mochari Heidi, 2006, Prev Cardiol, V9, P8, DOI 10.1111/j.1520-037X.2005.3703.x; *NAT CTR INJ PREV, 2002, CDC INJ RES AG; Perez-Stable EJ, 1997, MED CARE, V35, P1212, DOI 10.1097/00005650-199712000-00005; Reid AE, 2004, LIVER TRANSPLANT, V10, P834, DOI 10.1002/lt.20174; SEIJO R, 1991, HISPANIC J BEHAV SCI, V13, P363, DOI 10.1177/07399863910134001; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28; Underwood W, 2006, J AM COLL SURGEONS, V202, P284, DOI 10.1016/j.jamcollsurg.2005.09.009; *US DEP HHS, 2000, HLTH PEOP 2010; US Department of Health and Human Services, 2005, NAT HEALTHC DISP REP; Venkat A, 2003, ACAD EMERG MED, V10, P1199, DOI 10.1197/S1069-6563(03)00490-1; Weinick RM, 2000, MED CARE RES REV, V57, P36, DOI 10.1177/107755800773743592; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09	33	104	105	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2007	63	5					1138	1142		10.1097/TA.0b013e3181568cd4			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	232BX	WOS:000250994200033	17993963				2021-06-18	
J	Pieracci, FM; Eachempati, SR; Shou, J; Hydo, LJ; Barie, PS				Pieracci, Fredric M.; Eachempati, Soumitra R.; Shou, Jian; Hydo, Lynn J.; Barie, Philip S.			Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		warfarin; intracranial hemorrhage; traumatic brain injury; geriatrics; anticoagulation	PREINJURY WARFARIN; ATRIAL-FIBRILLATION; INTRACRANIAL HEMORRHAGE; ANTITHROMBOTIC THERAPY; METAANALYSIS; MORTALITY; REVERSAL; STROKE; IMPACT; RISK	Background: The relationship between preinjury warfarin use and outcomes after traumatic brain injury in elderly trauma patients remains controversial. We hypothesized that, among elderly warfarin users, the degree of anticoagulation, rather than warfarin therapy itself, would predict the severity of traumatic brain injury. Methods: Retrospective study (20042006) of all elderly trauma patients (age a:65 years) who were evaluated by the trauma service at a Level I trauma center and underwent computed tomography of the head for suspicion of an intracranial injury was performed. Three cohorts were grouped: (1) warfarin users with an admission International Normalized Ratio >= 2 (therapeutic group), (2) warfarin users with an admission International Normalized Ratio < 2 (nontherapeutic group), and (3) warfarin nonusers. Main outcome variables were presenting with a Glasgow Coma Scale (GCS) score :513 points, intracranial hemorrhage (ICH), overall mortality, and mortality after ICH. Results: A total of 225 trauma patients were studied, including 40 warfarin users (17.3%), of whom 22 (55.0%) were in the therapeutic group. Age, gender, and mechanism of injury were similar among groups. Likelihood of Glasgow Coma Scale score <= 13 (odds ratio [OR] = 5.13, 95% confidence interval [CI] 1.97-13.39, p = 0.001), ICH (OR = 2.59, 95% CI 0.92-7.32, p = 0.07), overall mortality (OR = 4.48, 95% CI 1.60-12.50, p = 0.004), and mortality after ICH (OR = 3.42, 95% CI 1.09-10.76, p = 0.03) was increased in the therapeutic as compared with the nonuser group. There was no difference in any measured outcome between the nonuser and nontherapeutic groups. Conclusions: Therapeutic anticoagulation with warfarin, rather than warfarin use itself, is associated with adverse outcomes after traumatic brain injury in elderly patients.	Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA	Pieracci, FM (corresponding author), Cornell Univ, Weill Med Coll, Dept Surg, 411 E 69th St,KB-220, New York, NY 10021 USA.	frp9005@med.cornell.edu	Barie, Philip/AAN-8811-2020				Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Coimbra R, 2005, J TRAUMA, V59, P374, DOI 10.1097/01.ta.000174728.46883.a4; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; SCHWAB CW, 2000, TRAUMA, P1099; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	14	104	106	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2007	63	3					525	530		10.1097/TA.0b013e31812e5216			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	211DA	WOS:000249503300008	18073596				2021-06-18	
J	Ono, K; Wada, K; Takahara, T; Shirotani, T				Ono, Kenichiro; Wada, Kojiro; Takahara, Takashi; Shirotani, Toshiki			Indications for computed tomography in patients with mild head injury	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						mild head injury; intracranial lesion; indications for computed tomography; Japan Coma Scale; Glasgow Coma Scale; risk factor	TRAUMATIC BRAIN INJURY; GLASGOW COMA SCALE; INITIAL MANAGEMENT; RISK; DIAGNOSIS; RECOMMENDATIONS; RELIABILITY; VALIDATION; PREDICTORS; HEMORRHAGE	The factors affecting outcome were analyzed in 1,064 patients, 621 males and 443 females aged 10 to 104 years (mean 46 23 years), with mild head injury (Glasgow Coma Scale [GCS] score +/- 14) but no neurological signs presenting within 6 hours after injury. Intracranial lesion was found in 4.7% (50/1,064), and 0.66% (7/1,064) required surgical treatment. The Japan Coma Scale (JCS) and GCS assessments were well correlated (r = 0.797). Multivariate analysis revealed significant correlations between computed tomography (CT) abnormality and age >= 60 years, male sex, JCS score >= 1, alcohol consumption, headache, nausea/vomiting, and transient loss of consciousness (LOC)/amnesia. Univariate analysis revealed that pedestrian in a motor vehicle accident, falling from height, and mechanisms of injuries except blows were correlated to intracranial injury. No significant correlations were found between craniofacial soft tissue injury and intracranial injury. Patients with occipital impact, nonfrontal impact, or skull fracture were more likely have intracranial lesions. Bleeding tendency was not correlated with CT abnormality. The following indications were proposed for CT: JCS score > 0, presence of accessory symptoms (headache, nausea/vomiting, LOC/amnesia), and age >= 60 years. These criteria would reduce the frequency of CT by 29% (309/1,064). Applying these indications to subsequent patients with GCS scores 14-15, 114 of 168 patients required CT, and intracranial lesions were found in 13. Two refused CT. Fifty-four of the 168 patients did not need CT according to the indications, but 38 of the 54 patients actually underwent CT because of social reasons (n = 21) or patient request (n = 17). These indications for CT including JCS may be useful in the management of patients with mild head injury.	Japan Self Def Forces Cent Hosp, Dept Neurosurg, Tokyo, Japan	Ono, K (corresponding author), Ground Self Def Force 7th Div Headquarters, Camp Higashichitose 1016 Shukubai, Chitose, Hokkaido 0668577, Japan.						Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; GOTOH O, NO TO SHINKEI, V47, P49; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; *JAP SOC NEUR, 2006, SHINKEL GAISHI S1, V29, P1; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Katada Kazuhiro, 2006, Nihon Hoshasen Gijutsu Gakkai Zasshi, V62, P649; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Ohta T., 1985, SOGO RINSHO, V34, P477; *SCOTT INT GUID NE, 2000, EARL MAN PAT HEAD IN, P7; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shiomi N, 2004, NEUROL SURG TOKYO, V32, P465; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Takagi K, 1998, NEUROL SURG TOKYO, V26, P509; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TOMEI G, 1996, J NEUROSURG SCI, V40, P11; Volans AP, 1998, J ACCID EMERG MED, V15, P159; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	34	104	107	0	3	JAPAN NEUROSURGICAL SOC	TOKYO	C/O AKAMON-MAE IWATA BLDG, 5-27-8 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105			NEUROL MED-CHIR	Neurol. Med.-Chir.	JUL	2007	47	7					291	297		10.2176/nmc.47.291			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	191LH	WOS:000248132200001	17652914	Bronze			2021-06-18	
J	Jagannathan, J; Okonkwo, DO; Dumont, AS; Ahmed, H; Bahari, A; Prevedello, DM; Jane, JA; Jane, JA				Jagannathan, Jay; Okonkwo, David O.; Dumont, Aaron S.; Ahmed, Hazem; Bahari, Abbas; Prevedello, Daniel M.; Jane, John A., Sr.; Jane, John A., Jr.			Outcome following decompressive craniectomy in children with severe traumatic brain injury: a 10-year single-center experience with long-term follow up	JOURNAL OF NEUROSURGERY			English	Article						trauma; brain injury; craniectomy; outcome; pediatric neurosurgery	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; INTRACRANIAL HYPERTENSION; EDEMA; PRESSURE; ADOLESCENTS; CRANIOTOMY; THERAPY; ADULTS; TRIAL	Object. The authors examine the indications for and outcomes following decompressive craniectomy in a single-center pediatric patient population with traumatic brain injury (TBI). Methods. A retrospective review of data was performed using a prospectively acquired database of patients who underwent decompressive craniectomy at the authors' institution between January 1995 and April 2006. The patients' neuroimages were examined to evaluate the extent of intracranial injury, and the patients' records were reviewed to determine the admission Glasgow Coma Scale (GCS) score, the extent of systemic injuries, the time to craniectomy, and the indications for craniectomy. Long-term functional outcome and independence levels were evaluated using the Glasgow Outcome Scale (GOS) and a Likert patient quality-of-life rating scale. Twenty-three craniectomies were performed in children during the study period. The mean patient age at craniectomy was 11.9 years (range 2-19 years). In all patients, the computed tomography scans obtained at presentation revealed pathological findings, with diffuse axonal injury and traumatic contusions being the most common abnormalities. The median presenting GCS score was 4.6 (range 3-9). Nineteen patients (83%) suffered from other systemic injuries. One patient (4%) died intraoperatively and six patients (26%) died postoperatively. Postoperative intracranial pressure (ICP) control was obtained in 19 patients (83%); an ICP greater than 20 mm Hg was found to have the strongest correlation with subsequent brain death (p = 0.001). The mean follow-up duration was 63 months (range 11-126 months, median 49 months). The mean GOS score at the 2-year follow-up examination was 4.2 (median 5). At the most recent follow-up examination, 13 (81%) of 16 survivors had returned to school and only three survivors (18%) were dependent on caregivers. Conclusions. Although the mortality rate for children with severe TBI remains high, decompressive craniectomy is effective in reducing ICP and is associated with good outcomes in surviving patients.	Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22908 USA	Jagannathan, J (corresponding author), Univ Virginia Hlth Syst, Dept Neurol Surg, POB 800212, Charlottesville, VA 22908 USA.	jj5a@virginia.edu					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARIE PS, 1993, J TRAUMA, V35, P88, DOI 10.1097/00005373-199307000-00015; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CALEY DW, 1970, J COMP NEUROL, V138, P31, DOI 10.1002/cne.901380104; Chambers IR, 2005, ACT NEUR S, V95, P21; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; EVANS CAN, 1974, J PHYSIOL-LONDON, V238, P371, DOI 10.1113/jphysiol.1974.sp010530; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kirkness CJ, 2005, ACTA NEUROCHIR SUPPL, V95, P13; KITA H, 1994, ACTA NEUROCHIR, P452; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; Paolin A, 1998, J TRAUMA, V44, P495, DOI 10.1097/00005373-199803000-00012; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; YOSHINO E, 1985, J NEUROSURG, V63, P830, DOI 10.3171/jns.1985.63.6.0830	36	104	110	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2007	106	4		S			268	275		10.3171/ped.2007.106.4.268			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	172UO	WOS:000246830200003	17465359				2021-06-18	
J	Ciriza, I; Carrero, P; Frye, CA; Garcia-Segura, LM				Ciriza, Iratxe; Carrero, Paloma; Frye, Cheryl A.; Garcia-Segura, Luis M.			Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective	JOURNAL OF NEUROBIOLOGY			English	Article						dihydroprogesterone; finasteride; indomethacin; kainic acid; tetrahydroprogesterone	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; 4-DAY ESTROUS-CYCLE; SPINAL-CORD TRAUMA; GABA-A RECEPTOR; CELL-DEATH; NEUROACTIVE STEROIDS; FEMALE RATS; KAINIC ACID; PREFRONTAL CORTEX	The ovarian hormone progesterone is neuroprotective in different experimental models of neuro-degeneration. In the nervous system, progesterone is metabolized to 5 alpha-dihydroprogesterone (DHP) by the enzyme 5 alpha-reductase. DHP is subsequently reduced to 3 alpha,5 alpha-tetrahydroprogesterone (THP) by a reversible reaction catalyzed by the enzyme 3 alpha-hydroxysteroid dehydrogenase. In this study we have analyzed whether progesterone metabolism is involved in the neuroprotective effect of the hormone in the hilus of the hippocampus of ovariectomized rats injected with kainic acid, an experimental model of excitotoxic cell death. Progesterone increased the levels of DHP and THP in plasma and hippocampus and prevented kainic-acid-induced neuronal loss. In contrast to progesterone, the synthetic progestin medroxyprogesterone acetate (NIPA, Provera) did not increase DHP and THP levels and did not prevent kainic-acid-induced neuronal loss. The administration of the 5m-reductase inhibitor finasteride prevented the increase in the levels of DHP and THP in plasma and hippocampus as a result of progesterone administration and abolished the neuroprotective effect of progesterone. Both DHP and THP were neuroprotective against kainic acid. However, the administration of indomethacin, a 3 alpha-hydroxysteroid dehydrogenase inhibitor, blocked the neuroprotective effect of both DHP and THP, suggesting that both metabolites are necessary for the neuroprotective effect of progesterone. In conclusion, our findings indicate that progesterone is neuroprotective against kainic acid excitotoxicity in vivo while the synthetic progestin MPA is not and suggest that progesterone metabolism to its reduced derivatives DHP and THP is necessary for the neuroprotective effect of the hormone. (c) 2006 Wiley Periodicals, Inc.	CSIC, Inst Cajal, E-28002 Madrid, Spain; SUNY Albany, Univ Albany, Dept Psychol, Dept Biol, Albany, NY 12222 USA; SUNY Albany, Univ Albany, Ctr Res Neurosci, Albany, NY 12222 USA	Garcia-Segura, LM (corresponding author), CSIC, Inst Cajal, Ave Doctor Arce 37, E-28002 Madrid, Spain.	lmgs@cajal.csic.es	Garcia-Segura, Luis M/U-3711-2017	Garcia-Segura, Luis M/0000-0002-2450-2916			Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Baulieu EE, 2000, STEROIDS, V65, P605, DOI 10.1016/S0039-128X(00)00173-2; BELANGER A, 1981, BIOL REPROD, V24, P591, DOI 10.1095/biolreprod24.3.591; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Belelli D, 2003, J NEUROSCI, V23, P10013; Bentel JM, 1999, MOL CELL ENDOCRINOL, V154, P11, DOI 10.1016/S0303-7207(99)00109-4; Beyer C, 1999, HORM BEHAV, V35, P1, DOI 10.1006/hbeh.1998.1457; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; CELOTTI F, 1992, FRONT NEUROENDOCRIN, V13, P163; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Follesa P, 2001, BRAIN RES REV, V37, P81, DOI 10.1016/S0165-0173(01)00125-4; Frank C, 2000, PROG NEURO-PSYCHOPH, V24, P1117, DOI 10.1016/S0278-5846(00)00124-X; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Frye CA, 1999, J NEUROENDOCRINOL, V11, P839; Frye CA, 2000, PHARMACOL BIOCHEM BE, V67, P587, DOI 10.1016/S0091-3057(00)00392-0; FRYE CA, 1995, BRAIN RES, V696, P113, DOI 10.1016/0006-8993(95)00793-P; Frye CA, 1998, BRAIN RES, V808, P72, DOI 10.1016/S0006-8993(98)00764-1; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Guerra-Araiza C, 2003, J NEUROENDOCRINOL, V15, P984, DOI 10.1046/j.1365-2826.2003.01088.x; GUO Q, 2006, IN PRESS EXP NEUROL; Hapgood JP, 2004, TRENDS PHARMACOL SCI, V25, P554, DOI 10.1016/j.tips.2004.09.005; Hatton WJ, 1999, J COMP NEUROL, V409, P169; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; HORIKOSHI H, 1974, ENDOCRINOL JAPON, V21, P69; HOWARD CV, 1998, UNBIASED STEREOLOGY; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; Littleton-Kearney MT, 2005, J CEREBR BLOOD F MET, V25, P421, DOI 10.1038/sj.jcbfm.9600052; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Maki PM, 2005, ANN NY ACAD SCI, V1052, P182, DOI 10.1196/annals.1347.012; Matsumoto K, 2005, STRESS, V8, P85, DOI 10.1080/10253890500159022; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Melcangi RC, 1999, J NEUROBIOL, V40, P471, DOI 10.1002/(SICI)1097-4695(19990915)40:4<471::AID-NEU5>3.3.CO;2-G; Melcangi RC, 2005, BRAIN RES REV, V48, P328, DOI 10.1016/j.brainresrev.2004.12.021; Melcangi RC, 2003, PROG NEUROBIOL, V71, P57, DOI 10.1016/j.pneurobio.2003.09.003; Melcangi RC, 2001, INT REV NEUROBIOL, V46, P145; Mellon SH, 2001, BRAIN RES REV, V37, P3, DOI 10.1016/S0165-0173(01)00109-6; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756-200205070-00018; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Palumbo MA, 1995, J ENDOCRINOL INVEST, V18, P853, DOI 10.1007/BF03349832; Patte-Mensah C, 2005, P NATL ACAD SCI USA, V102, P9044, DOI 10.1073/pnas.0502968102; Paxinos G, 1986, RAT BRAIN STEROTAXIC; Petralia SM, 2005, J NEUROENDOCRINOL, V17, P545, DOI 10.1111/j.1365-2826.2005.01342.x; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; PURDY RH, 1990, STEROIDS, V55, P290, DOI 10.1016/0039-128X(90)90031-6; Rhodes ME, 2004, EPILEPSIA, V45, P1531, DOI 10.1111/j.0013-9580.2004.16504.x; Rhodes ME, 2004, PHARMACOL BIOCHEM BE, V78, P505, DOI 10.1016/j.pbb.2004.04.021; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; RODBARD D, 1974, CLIN CHEM, V20, P1255; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; SHAIKH AA, 1975, ENDOCRINOLOGY, V96, P37, DOI 10.1210/endo-96-1-37; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Singh M, 2005, ANN NY ACAD SCI, V1052, P145, DOI 10.1196/annals.1347.010; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stoffel-Wagner B, 1998, J CLIN ENDOCR METAB, V83, P3636, DOI 10.1210/jc.83.10.3636; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; WALF AA, 2006, IN PRESS PSYCHOPHARM; Wiegratz I, 2004, TRENDS ENDOCRIN MET, V15, P277, DOI 10.1016/j.tem.2004.06.006; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; YU WHA, 1989, BRAIN RES, V491, P379, DOI 10.1016/0006-8993(89)90075-9; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100	89	104	105	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0022-3034			J NEUROBIOL	J. Neurobiol.	AUG	2006	66	9					916	928		10.1002/neu.20293			13	Neurosciences	Neurosciences & Neurology	070SS	WOS:000239544900002	16758493				2021-06-18	
J	Hiler, M; Czosnyka, M; Hutchinson, P; Balestreri, M; Smielewski, P; Matta, B; Pickard, JD				Hiler, M; Czosnyka, M; Hutchinson, P; Balestreri, M; Smielewski, P; Matta, B; Pickard, JD			Predictive value of initial computerized tomography scan, intracranial pressure, and state of autoregulation in patients with traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; intracranial pressure; computerized tomography; outcome	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; UNITED-KINGDOM; CARE; CLASSIFICATION; HYPERTENSION; THRESHOLDS; REACTIVITY; MANAGEMENT	Object. The authors explored the relationship between computerized tomography (CT) scan findings and intracranial pressure (ICP) measurements obtained in the first 24 hours of monitoring to identify parameters predicting outcome in patients with severe traumatic brain injury (TBI). Methods. Intracranial pressure, mean arterial blood pressure, cerebral perfusion pressure (CPP), and pressure reactivity index were measured continuously in 126 patients with severe TBI who were admitted to a neuroscience critical care unit. Mean values in the initial 24 hours of monitoring and in the total period of monitoring were compared with types of injury categorized on the basis of the initial CT scan according to the classification of Marshall, et al., and with Glasgow Outcome Scale scores. The initial CT scan classification correlated significantly but weakly with ICP measured during the first 24 hours of monitoring (p = 0.036) but not with mean ICP over the total time of intensive care. Both midline shift and the ratio of frontal horn diameter to internal diameter correlated with ICP in the first 24 hours (p < 0.007) and with ICP over the total monitoring period (p < 0.03). Outcome score correlated with initial CT scan findings (p = 0.018), ICP over the total monitoring period (p < 0.0023), pressure reactivity over the total monitoring period (p < 0.0002), and pressure reactivity in the first 24 hours (p < 0.0001) but not with ICP in the first 24 hours. Patients with disturbed pressure reactivity in the first 24 hours after injury had a significantly higher mortality rate than patients with intact pressure reactivity (28.6% compared with 9.5%; p < 0.001). Conclusions. Patients with severe TBI who have early loss of autoregulation have a worse prognosis. Mean ICP values in patients with diffuse TBI cannot be predicted by using the Marshall CT scan classification.	Univ Cambridge, Dept Clin Neurosci, Acad Neurosurg Unit, Cambridge, England; Addenbrookes NHS Trust, Dept Anaesthet, Cambridge CB2 2QQ, England	Czosnyka, M (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, Box 167,Hills Rd, Cambridge CB2 2QQ, England.	mc141@medschl.cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G9439390, G0001237] Funding Source: Medline		Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; EDDY VA, 1995, AM SURGEON, V61, P24; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; HOLLIDAY PO, 1982, NEUROSURGERY, V10, P25, DOI 10.1227/00006123-198201000-00005; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Lubillo S, 2000, ACT NEUR S, V76, P415; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Poca MA, 1998, ACT NEUR S, V71, P27; Ropper AH, 2004, NEUROLOGICAL NEUROSU; Smielewski P, 1997, INT J CLIN MONIT COM, V14, P185, DOI 10.1023/A:1016901710584; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002	23	104	110	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2006	104	5					731	737		10.3171/jns.2006.104.5.731			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	041CD	WOS:000237429800007	16703877				2021-06-18	
J	Delaney, A; Bagshaw, SM; Ferland, A; Manns, B; Laupland, KB; Doig, CJ				Delaney, A; Bagshaw, SM; Ferland, A; Manns, B; Laupland, KB; Doig, CJ			A systematic evaluation of the quality of meta-analyses in the critical care literature	CRITICAL CARE			English	Article							RANDOMIZED CONTROLLED-TRIALS; EVIDENCE-BASED MEDICINE; TRAUMATIC BRAIN-INJURY; CRITICAL-APPRAISAL; ILL PATIENTS; REVIEWS; HYPOTHERMIA; STATEMENT; ARTICLES; ALBUMIN	Introduction Meta-analyses have been suggested to be the highest form of evidence available to clinicians to guide clinical practice in critical care. The purpose of this study was to systematically evaluate the quality of meta-analyses that address topics pertinent to critical care. Methods To identify potentially eligible meta-analyses for inclusion, a systematic search of Medline, EMBASE and the Cochrane Database of Systematic Reviews was undertaken, using broad search terms relevant to intensive care, including: intensive care, critical care, shock, resuscitation, inotropes and mechanical ventilation. Predetermined inclusion criteria were applied to each identified meta-analysis independently by two authors. To assess report quality, the included meta-analyses were assessed using the component and overall scores from the Overview Quality Assessment Questionnaire (OQAQ). The quality of reports published before and after the publication of the QUOROM statement was compared. Results A total of 139 reports of meta-analyses were included ( kappa = 0.93). The overall quality of reports of meta-analyses was found to be poor, with an estimated mean overall OQAQ score of 3.3 (95% CI; 3.0 - 3.6). Only 43 (30.9%) were scored as having minimal or minor flaws (> 5). We noted problems with the reporting of key characteristics of meta-analyses, such as performing a thorough literature search, avoidance of bias in the inclusion of studies and appropriately referring to the validity of the included studies. After the release of the QUOROM statement, however, an improvement in the overall quality of published meta-analyses was noted. Conclusion The overall quality of the reports of meta-analyses available to critical care physicians is poor. Physicians should critically evaluate these studies prior to considering applying the results of these studies in their clinical practice.	Royal N Shore Hosp, Dept Intens Care Med, Sydney, NSW, Australia; Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada	Delaney, A (corresponding author), Royal N Shore Hosp, Dept Intens Care Med, Sydney, NSW, Australia.	adelaney@med.usyd.edu.au	Laupland, Kevin/AAG-3656-2020; Manns, Braden J/I-8942-2012; Doig, Christopher/AAC-7949-2020; Laupland, kevin/AAJ-6339-2020; Delaney, Anthony/AAE-3365-2019	Doig, Christopher/0000-0002-8576-9139; Laupland, kevin/0000-0002-1205-5354; 			ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; Celermajer DS, 2001, MED J AUSTRALIA, V174, P293, DOI 10.5694/j.1326-5377.2001.tb143274.x; Choi PTL, 2001, ANESTH ANALG, V92, P700; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook DJ, 1996, CRIT CARE MED, V24, P1757, DOI 10.1097/00003246-199610000-00026; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Dixon E, 2005, ANN SURG, V241, P450, DOI 10.1097/01.sla.0000154258.30305.df; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Flather MD, 1997, CONTROL CLIN TRIALS, V18, P568, DOI 10.1016/S0197-2456(97)00024-X; Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hunt DL, 1997, ANN INTERN MED, V126, P532, DOI 10.7326/0003-4819-126-7-199704010-00006; Jadad AR, 1997, CAN MED ASSOC J, V156, P1411; Kelly KD, 2001, ANN EMERG MED, V38, P518, DOI 10.1067/mem.2001.115881; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Shojania K G, 2001, Eff Clin Pract, V4, P157; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0	26	104	110	0	6	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care	OCT	2005	9	5					R575	R582		10.1186/cc3803			8	Critical Care Medicine	General & Internal Medicine	976JE	WOS:000232728800036	16277721	DOAJ Gold, Green Published			2021-06-18	
J	Mihalik, JP; Stump, JE; Collins, MW; Lovell, MR; Field, M; Maroon, JC				Mihalik, JP; Stump, JE; Collins, MW; Lovell, MR; Field, M; Maroon, JC			Posttraumatic migraine characteristics in athletes following sports-related concussion	JOURNAL OF NEUROSURGERY			English	Article						concussion; headache; ImPACT; neuropsychological testing; mild traumatic brain injury; high-school athlete	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURY; UNITED-STATES; MILD; EPIDEMIOLOGY; RECOVERY; PATHOGENESIS; PERFORMANCE; SEVERITY	Object. The object of this study was to compare symptom status and neurocognitive functioning in athletes with no headache (non-HA group), athletes complaining of headache (HA group), and athletes with characteristics of posttraumatic migraine (PTM group). Methods. Neurocognitive tests were undertaken by 261 high-school and collegiate athletes with a mean age of 16.36 +/- 2.6 years. Athletes were separated into three groups: the PTM group (74 athletes with a mean age of 16.39 +/- 3.06 years), the HA group (124 athletes with a mean age of 16.44 +/- 2.51 years), and the non-HA group (63 patients with a mean age of 16.14 +/- 2.18 years). Neurocognitive summary scores (outcome measures) for verbal and visual memory, visual motor speed, reaction time, and total symptom scores were collected using ImPACT, a computer software program designed to assess sports-related concussion. Significant differences existed among the three groups for all outcome measures. The PTM group demonstrated significantly greater neurocognitive deficits when compared with the HA and non-HA groups. The PTM group also exhibited the greatest amount of departure from baseline scores. Conclusions. The differences among these groups can be used as a basis to argue that PTM characteristics triggered by sports-related concussion are related to increased neurocognitive dysfunction following mild traumatic brain injury. Thus, athletes suffering a concussion accompanied by PTM should be examined in a setting that includes symptom status and neurocognitive testing to address their recovery more fully. Given the increased impairments observed in the PTM group, in this population clinicians should exercise increased caution in decisions about treatment and when the athlete should be allowed to return to play.	Univ Pittsburgh, Sch Hlth & Rehabil Sci, Ctr Med, Dept Sports Med & Nutr,Dept Orthopaed Surg, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA USA; Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Chapel Hill, NC USA; Florida Hosp, Inst Neurosci, Dept Neurosurg, Orlando, FL USA; Ctr Sports Related Craniospinal Injuries, Orlando, FL USA	Lovell, MR (corresponding author), Univ Pittsburgh, Ctr Med, Sports Med Concuss Program, 3200 S Water St, Pittsburgh, PA 15203 USA.	lovellmr@upmc.edu	Mihalik, Jason P/E-7059-2010	Mihalik, Jason/0000-0001-6085-8322			Amer Assoc Study Headache, 1998, HEADACHE, V38, P736; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DENNYBRO.D, 1973, BRAIN, V96, P783, DOI 10.1093/brain/96.4.783; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Haas David C., 1993, P629; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; LARSSON LI, 1976, BRAIN RES, V113, P400, DOI 10.1016/0006-8993(76)90951-3; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MANDEL S, 1989, POSTGRAD MED, V85, P213; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PERNOW B, 1983, PHARMACOL REV, V35, P85; Soloman S, 1998, HEADACHE, V38, P772, DOI 10.1046/j.1526-4610.1998.3810772.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; SPEED WG, 1986, PRACTICING PHYSICIAN, P113; TAYLOR AR, 1966, LANCET, V2, P178; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Triplett G, 1996, PERCEPT MOTOR SKILL, V83, P1344, DOI 10.2466/pms.1996.83.3f.1344; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	44	104	104	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2005	102	5					850	855		10.3171/jns.2005.102.5.0850			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	954KO	WOS:000231154200008	15926709				2021-06-18	
J	Pellman, EJ; Lovell, MR; Viano, DC; Casson, IR; Tucker, AM				Pellman, EJ; Lovell, MR; Viano, DC; Casson, IR; Tucker, AM			Concussion in professional football: Neuropsychological testing - Part 6	NEUROSURGERY			English	Article						concussion; neuropsychological testing; sport injury; traumatic brain injury	HIGH-SCHOOL; HEAD-INJURY; SPORTS; RECOVERY; PERFORMANCE; PLAYERS; IMPACTS	OBJECTIVE: The National Football League (NFL) neuropsychological testing program is reviewed, and neuropsychological test data are presented on various samples of NFL athletes who sustained concussion (mild traumatic brain injury, MTBI). METHODS: This study evaluated post-MTBI neuropsychological testing of NFL players from 1996 to 2001. All athletes completed a standardized battery of neuropsychological tests and underwent postinjury neuropsychological testing within a few days after concussion. Test scores were compared with baselines using analysis of variance for athletes having on-field memory dysfunction, three or more concussions, or 7+ days out from practice and play. RESULTS: The MTBI group did not display significant neuropsychological dysfunction relative to baseline scores within a few days of injury. However, a subsample of the injured athletes who displayed on-field memory dysfunction performed significantly more poorly on two of the memory tests. The neuropsychological test results of a group of athletes with a history of three or more MTBIs did not differ significantly compared with a group who had fewer than three concussions or compared with league-wide normative data. The neuropsychological performance of athletes who were out from full participation 7+ days was not significantly different from the group who returned to play within 7 days or the norms. CONCLUSION: Neuropsychological testing is used within the overall medical evaluation and care of NFL athletes. Players who experience MTBI generally demonstrate rapid recovery of neuropsychological performance, although poorer neuropsychological test results were related to on-field memory dysfunction. NFL players did not demonstrate evidence of neurocognitive decline after multiple (three or more) MTBIs or in those players out 7+ days. The data show that MTBI in this population is characterized by a rapid return of neuropsychological function in the days after injury.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; ProHEALTH Care Associates LLP, Lake Success, NY USA; Univ Pittsburgh, Med Ctr, Dept Orthopaed & Sports Med, Pittsburgh, PA USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Univ Maryland, Sch Med, Lutherville Timonium, MD USA	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT, 1989, MILD HEAD INJURY; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benton AL, 1978, MULTILINGUAL APHASIA; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; LOVELL MR, 1996, 1 ANN SPORTS REL MIL; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; OLVEY S, 2002, NEW DEV SPORTS REL C; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Smith A., 1982, SYMBOL DIGIT MODALIT; *STATS INC, 2001, STAT; SYMONDS C, 1962, LANCET, V1, P1; Wechsler D, 1997, WAIS 3 ADM SCORING M; YARNELL PR, 1970, LANCET, V1, P863	45	104	104	0	25	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2004	55	6					1290	1305		10.1227/01.NEU.0000149244.97560.91			16	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	878CB	WOS:000225623000008	15574211				2021-06-18	
J	Sewell, DL; Nacewicz, B; Liu, F; Macvilay, S; Erdei, A; Lambris, JD; Sandor, M; Fabry, Z				Sewell, DL; Nacewicz, B; Liu, F; Macvilay, S; Erdei, A; Lambris, JD; Sandor, M; Fabry, Z			Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist	JOURNAL OF NEUROIMMUNOLOGY			English	Article						inflammation; neutrophil; cryoinjury; trauma; CNS; cytokines; chemokines	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ALZHEIMERS-DISEASE BRAINS; MEMBRANE ATTACK COMPLEX; MULTIPLE-SCLEROSIS; LIVER-REGENERATION; CEREBRAL-ISCHEMIA; ANAPHYLATOXIN C5A; HUMAN ASTROCYTES; MESSENGER-RNA	The role of complement components in traumatic brain injury is poorly understood. Here we show that secondary damage after acute cryoinjury is significantly reduced in C3(-/-) or C5(-/-) mice or in mice treated with C5a receptor antagonist peptides. Injury sizes and neutrophil extravasation were compared. While neutrophil density increased following traumatic brain injury in wild type (C57BL/6) mice, C3-deficient mice demonstrated lower neutrophil extravasation and injury sizes in the brain. RNase protection assay indicated that C3 contributes to the induction of brain inflammatory mediators, MIF, RANTES (CCL5) and MCP-1 (CCL2). Intracranial C3 injection induced neutrophil extravasation in injured brains of C3(-/-) mice suggesting locally produced C3 is important in brain inflammation. We show that neutrophil extravasation is significantly reduced in both C5(-/-) mice and C5a receptor antagonist treated cryoinjured mice suggesting that one of the possible mechanisms of C3 effect on neutrophil extravasation is mediated via downstream complement activation products such as C5a. Our data indicates that complement inhibitors may ameliorate traumatic brain injury. (C) 2004 Elsevier B.V. All rights reserved.	Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA; Eotvos Lorand Univ, Dept Immunol, Budapest, Hungary; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol, 1300 Univ Ave, Madison, WI 53706 USA.	zfabry@facstaff.wisc.edu	Lambris, John D./O-8507-2019; Erdei, Anna/AAN-5988-2020	Lambris, John D./0000-0002-9370-5776; Erdei, Anna/0000-0002-3622-6680	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI030040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM062135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI030040] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM062135, GM-62135] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037570, R01-NS 37570-01A2] Funding Source: Medline		BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301; Bergamaschini L, 1999, CLIN EXP IMMUNOL, V115, P526; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; Cancilla P A, 1980, Adv Exp Med Biol, V131, P257; CANCILLA PA, 1972, LAB INVEST, V26, P376; CANCILLA PA, 1979, LAB INVEST, V40, P74; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; Cooper NR, 2000, IMMUNOL RES, V21, P159, DOI 10.1385/IR:21:2-3:159; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; FISCHER B, 1995, J MOL MED, V73, P465; Gasque P, 1998, J IMMUNOL, V160, P3543; GASQUE P, 1995, J IMMUNOL, V155, P4882; Girardi G, 2003, J CLIN INVEST, V112, P1644, DOI 10.1172/JCI18817; Glass WG, 2004, J IMMUNOL, V172, P4018, DOI 10.4049/jimmunol.172.7.4018; Glass WG, 2001, VIROLOGY, V288, P8, DOI 10.1006/viro.2001.1050; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Lane TE, 2000, J VIROL, V74, P1415, DOI 10.1128/JVI.74.3.1415-1424.2000; Lew SM, 1999, BRAIN RES BULL, V48, P325, DOI 10.1016/S0361-9230(99)00004-0; Ling CY, 2003, J NEUROIMMUNOL, V141, P90, DOI 10.1016/S0165-5728(03)00249-2; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; Nadeau S, 2001, FASEB J, V15, P1410, DOI 10.1096/fj.00-0709fje; Niculescu T, 2004, J IMMUNOL, V172, P5702, DOI 10.4049/jimmunol.172.9.5702; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Schafer MKH, 2000, J IMMUNOL, V164, P5446, DOI 10.4049/jimmunol.164.10.5446; Shen Y, 1998, BRAIN RES, V796, P187, DOI 10.1016/S0006-8993(98)00346-1; Speth C, 2001, J VIROL, V75, P2604, DOI 10.1128/JVI.75.6.2604-2516.2001; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; VANDENBERG CW, 1989, J IMMUNOL METHODS, V122, P73, DOI 10.1016/0022-1759(89)90336-0; Veerhuis R, 1996, ACTA NEUROPATHOL, V91, P53; VEERHUIS R, 1995, VIRCHOWS ARCH, V426, P603, DOI 10.1007/BF00192116; WALKER DG, 1992, MOL BRAIN RES, V14, P109, DOI 10.1016/0169-328X(92)90017-6; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Weerth SH, 2003, AM J PATHOL, V163, P1069, DOI 10.1016/S0002-9440(10)63466-9; Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199; Yasojima K, 1999, AM J PATHOL, V154, P927, DOI 10.1016/S0002-9440(10)65340-0	45	104	109	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	OCT	2004	155	1-2					55	63		10.1016/j.jneuroim.2004.06.003			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	855VV	WOS:000224003900006	15342196	Green Accepted			2021-06-18	
J	Conte, V; Uryu, K; Fujimoto, S; Yao, Y; Rokach, J; Longhi, L; Trojanowski, JQ; Lee, VMY; McIntosh, TK; Pratico, D				Conte, V; Uryu, K; Fujimoto, S; Yao, Y; Rokach, J; Longhi, L; Trojanowski, JQ; Lee, VMY; McIntosh, TK; Pratico, D			Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; amyloidosis; head trauma; oxidative stress; vitamin E	CONTROLLED CORTICAL IMPACT; TRANSGENIC MOUSE MODEL; A-BETA DEPOSITION; ALZHEIMERS-DISEASE; HEAD-INJURY; APOLIPOPROTEIN-E; LIPID-PEROXIDATION; OXIDATIVE STRESS; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN	Traumatic brain injury is a well-recognized environmental risk factor for developing Alzheimer's disease. Repetitive concussive brain injury (RCBI) exacerbates brain lipid peroxidation, accelerates amyloid (Abeta) formation and deposition, as well as cognitive impairments in Tg2576 mice. This study evaluated the effects of vitamin E on these four parameters in Tg2576 mice following RCBI. Eleven-month-old mice were randomized to receive either regular chow or chow-supplemented with vitamin E for 4 weeks, and subjected to RCBI (two injuries, 24 h apart) using a modified controlled cortical impact model of closed head injury. The same dietary regimens were maintained up to 8 weeks post-injury, when the animals were killed for biochemical and immunohistochemical analyses after behavioral evaluation. Vitamin E-treated animals showed a significant increase in brain vitamin E levels and a significant decrease in brain lipid peroxidation levels. After RBCI, compared with the group on regular chow, animals receiving vitamin E did not show the increase in Abeta peptides, and had a significant attenuation of learning deficits. This study suggests that the exacerbation of brain oxidative stress following RCBI plays a mechanistic role in accelerating Abeta accumulation and behavioral impairments in the Tg2576 mice.	Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Philadelphia, PA 19104 USA; Florida Inst Technol, Dept Chem, Claude Pepper Inst, Melbourne, FL 32901 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Aging, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Osped Maggiore, Policlin IRCCS, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Milan, Italy; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Head Injury Ctr, Philadelphia, PA 19104 USA	Pratico, D (corresponding author), Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, BRB 2-3,Room 812,421 Curie Blvd, Philadelphia, PA 19104 USA.	domenico@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020	Rokach, Joshu/0000-0003-1814-7505	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL69835] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG11542] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40978, NS08803] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL069835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011542] Funding Source: NIH RePORTER		Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lee EB, 2003, J BIOL CHEM, V278, P4458, DOI 10.1074/jbc.M210105200; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Misonou H, 2000, BIOCHEMISTRY-US, V39, P6951, DOI 10.1021/bi000169p; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Parks E, 2000, ANTIOXID REDOX SIGN, V2, P405, DOI 10.1089/15230860050192189; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pratico D, 2001, Ital Heart J, V2, P878; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Pratico D, 1998, FASEB J, V12, P1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2002, BIOCHEM PHARMACOL, V63, P563, DOI 10.1016/S0006-2952(01)00919-4; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.3.CO;2-0; Raby CA, 1998, J NEUROCHEM, V71, P2505; Ritchie K, 2002, LANCET, V360, P1759, DOI 10.1016/S0140-6736(02)11667-9; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Veinbergs I, 2000, EUR J NEUROSCI, V12, P4541, DOI 10.1111/j.1460-9568.2000.01308.x; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085	53	104	108	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2004	90	3					758	764		10.1111/j.1471-4159.2004.02560.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	838NQ	WOS:000222720500027	15255955	Bronze			2021-06-18	
J	Franulic, A; Carbonell, CG; Pinto, P; Sepulveda, I				Franulic, A; Carbonell, CG; Pinto, P; Sepulveda, I			Psychosocial adjustment and employment outcome 2, 5 and 10 years after TBI	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; HEAD-INJURY; DEPRESSION; REHABILITATION; PREDICTORS; RECOVERY; MODERATE; SCALE	Objective: A patient's return to work has been considered a good indicator of his/her overall adaptation after suffering from TBI. A study has been designed at the Hospital del Trabajador to evaluate patients' psycho-pathological and social situations and to describe evolution and return-to-work predictors. Particular attention was paid to subjects' employment situations 2, 5 and 10 years after TBI. Method: TBI patients who had also suffered spinal cord injuries, amputations and other physical impairments were excluded. A total of 202 individuals were evaluated by a psychologist and an occupational therapist during clinical interviews using the Hamilton Anxiety and Depression Rating Scale and the Neurobehavioural Rating Scale (NRS-R). Work situations were evaluated by interviewing the subjects and family members and, whenever possible, a patient's immediate supervisor at his or her place of employment. Results: Unemployed patients presented more severe symptoms of anxiety and depression than those who were working. Significant differences were observed in the NRS-R between employed and unemployed patients. There was no change in the marital status for at least 10 years after TBI. Conclusion: Factors determining a poor prognosis for adaptation and re-insertion into the workplace are age, a low educational level, a lack of job qualifications and greater cognitive impairments. The significant differences found between the NRS-R of employed and unemployed patients suggest that this variable may be used to predict a subject's ability to return to work.	Hosp Trabajador Santiago, Santiago, Chile	Franulic, A (corresponding author), Hosp Trabajador Santiago, Ramon Carnicer 185, Santiago, Chile.	ghtrae@gw.achs.cl		Carbonell, Carmen Gloria/0000-0001-9279-1847			Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Cespedes JMM, 2000, PSICOTHEMA, V12, P99; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Eames PG, 2001, BRAIN DAM B, P29; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; Franulic A, 2000, BRAIN INJURY, V14, P431; FRASER R, 1999, REPORT RECOMMENDATIO, P12; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoofien D, 2001, BRAIN INJURY, V15, P189; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Novack TA, 2000, BRAIN INJURY, V14, P987; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; WEST M, 2001, BRAIN INJURY SOURCE, V5, P24	31	104	105	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2004	18	2					119	129		10.1080/0269905031000149515			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000002	14660225				2021-06-18	
J	Brown, AW; Leibson, CL; Malec, JF; Perkins, PK; Diehl, NN; Larson, DR				Brown, AW; Leibson, CL; Malec, JF; Perkins, PK; Diehl, NN; Larson, DR			Long-term survival after traumatic brain injury: A population-based analysis	NEUROREHABILITATION			English	Article						brain injuries; head trauma; longevity; mortality	LIFE EXPECTANCY; HEAD-INJURY; EPIDEMIOLOGY; CHILDREN; TRENDS; SEIZURES; DEATH	This population-based retrospective cohort study identified all Olmsted County, MN residents with any diagnosis indicative of potential traumatic brain injury (TBI) during the years 1985 to 2000. The complete community-based medical records of a random sample (n = 7,175) were reviewed to confirm and characterize the event, and to determine vital status through 2002. The review identified 1,448 confirmed incident cases; 164 (11%) were moderate to severe; 1,284 were mild. The estimated 30-day case fatality rate was 29% for moderate to severe cases and 0.2% for mild cases. Comparison of observed mortality over the full period of follow-up with that expected revealed a risk ratio (95% CI) of 5.29 (4.11-6.71) for moderate to severe cases and 1.33 (1.05-1.65) for mild cases. Proportional hazards modeling showed the adjusted hazard of all-cause mortality for moderate to severe cases relative to mild cases was 5.18 (3.65-7.3) within six months of the event and 1.04 (0.57-1.88) for the remaining follow-up period. This analysis indicates that persons who experience mild TBI exhibit a small but statistically significant reduction in long-term survival compared to the general population. The case fatality rate for persons with moderate to severe TBI is very high, but among six-month survivors, long-term survival is similar to that for persons with mild TBI.	Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA	Brown, AW (corresponding author), Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA.	brown.allen@mayo.edu		Brown, Allen W./0000-0001-7228-3351			ADEKOYA N, 2002, SURVEILLANCE SUMMARI, V51, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Baguley I, 2000, BRAIN INJURY, V14, P505; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LCGARRY LJ, 2002, J TRAUMA INJURY INFE, V53, P1152; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001	24	104	107	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	1					37	43					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	777KA	WOS:000189176500005	14988586				2021-06-18	
J	Millar, K; Nicoll, JAR; Thornhill, S; Murray, GD; Teasdale, GM				Millar, K; Nicoll, JAR; Thornhill, S; Murray, GD; Teasdale, GM			Long term neuropsychological outcome after head injury: relation to APOE genotype	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; PRACTICAL SCALE; RISK-FACTORS; EPSILON-4; ASSOCIATION; REANALYSIS; ADULTHOOD; ALLELE	Background: Existing evidence suggests that some patients who sustain a head injury suffer cognitive decline many years later, and that head injury and possession of the APOE epsilon4 allele are each risk factors for Alzheimer's disease. Objective: To determine whether late cognitive decline after head injury is more prevalent among carriers of APOE epsilon4. Methods: A database of head injured patients was used. Initial assessment was at the time of their injury, between 1968 and 1985, and outcome data at six months were available. Their ages at the time of injury ranged between 2 and 70 years. A cohort of 396 subjects was reassessed at a mean of 18 years later, with determination of APOE genotype and detailed neuropyschological testing. Results: Judging by the Glasgow outcome scale, twice as many patients had deteriorated as improved between six months after injury and the late assessment; 22.2% of APOE epsilon4 carriers had a good late outcome compared with 30.5% of non-carriers (95% confidence interval for the difference, -0.7% to 17.2%; p = 0.084). There were no clear differences between e 4 carriers and non-carriers in detailed neuropsychological assessments. Conclusions: Although this study provides additional evidence that a late decline may occur after head injury, there was no clear relation to APOE genotype. Despite the follow up interval of 15 to 25 years, the cohort is still too young ( mean age 42.1 years) to assess the risk of Alzheimer's disease.	Univ Glasgow, Div Behav Med, Dept Psychol Med, Gartnavel Royal Hosp, Glasgow, Lanark, Scotland; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton, Hants, England; Univ Glasgow, Dept Neurosurg, So Gen Hosp, Glasgow, Lanark, Scotland; Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh, Midlothian, Scotland	Nicoll, JAR (corresponding author), Southampton Gen Hosp, Mailpoint 813,Level E, Southampton SO16 6YD, Hants, England.		; Nicoll, James/I-9253-2017	Murray, Gordon/0000-0001-9866-4734; Nicoll, James/0000-0002-9444-7246			CORKIN S, 1989, J NEUROSCI, V9, P3876; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; Fox NC, 1998, BRAIN, V121, P1631, DOI 10.1093/brain/121.9.1631; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; JENNETT B, 1975, LANCET, V1, P480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millar K, 2001, BRIT J ANAESTH, V86, P63, DOI 10.1093/bja/86.1.63; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newcombe F, 1996, J CLIN EXP NEUROPSYC, V18, P1, DOI 10.1080/01688639608408258; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; VANDUIJN CM, 1994, GENET EPIDEMIOL, V11, P539, DOI 10.1002/gepi.1370110609; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	30	104	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2003	74	8					1047	1052		10.1136/jnnp.74.8.1047			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	703MJ	WOS:000184283100011	12876232	Green Published, Bronze			2021-06-18	
J	Yune, TY; Chang, MJ; Kim, SJ; Lee, YB; Shin, SW; Rhim, HW; Kim, YC; Shin, ML; Oh, YJ; Han, CT; Markelonis, GJ; Oh, TH				Yune, TY; Chang, MJ; Kim, SJ; Lee, YB; Shin, SW; Rhim, HW; Kim, YC; Shin, ML; Oh, YJ; Han, CT; Markelonis, GJ; Oh, TH			Increased production of tumor necrosis factor-alpha induces apoptosis after traumatic spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; iNOS; NO; NOS inhibitors; spinal cord injury; TNF-alpha; TUNEL	NITRIC-OXIDE SYNTHASE; CENTRAL-NERVOUS-SYSTEM; CELL-DEATH; TNF-ALPHA; BRAIN-INJURY; FUNCTIONAL RECOVERY; NEURONAL APOPTOSIS; GLIAL APOPTOSIS; GENE-EXPRESSION; TRANSGENIC MICE	We showed previously that, after spinal cord injury (SCI), tumor necrosis factor-alpha (TNF-alpha) may serve as an external signal, initiating apoptosis in neurons and oligodendrocytes. To further characterize the apoptotic cascade initiated by TNF-alpha after SCI, we examined the expression of TNF-alpha, inducible nitric oxide (NO) synthase (iNOS), and the level of NO after SCI. Western blots and reverse transcription polymerase chain reactions showed an early upregulation of TNF-a after injury. A peak TNF-alpha expression was observed within 1 h of injury. By 4 h after injury, the expression of MOS and the level of NO were markedly increased in the injured spinal cord. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL)positive cells were also first observed in the lesioned area 4 h after SCI. The largest number of TUNEL-positive cells was observed between 24-48 h after SCI. Injecting a neutralizing antibody against TNF-alpha into the lesion site after injury significantly reduced the expression of MOS, the level of NO and the number of TUNEL-positive cells in the injured spinal cord. Injecting the NOS inhibitors, N-G-monomethyl-L-arginine monoacetate and S-methylisothiourea sulfate, or an NO scavenger, carboxy-PTIO, into the lesion site also significantly reduced the level of NO and the degree of DNA laddering in the injured spinal cord. These data suggest that after SCI, apoptosis induced by TNF-alpha may be mediated in part by NO via upregulation of MOS, induced in response to TNF-alpha.	Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; KIST, Ctr Biomed Res, Seoul, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; Sogang Univ, Dept Life Sci, Seoul, South Korea	Oh, TH (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, 685 W Baltimore St, Baltimore, MD 21201 USA.	toh@umaryland.edu					Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; Ankarcrona M, 1998, PROG BRAIN RES, V116, P265, DOI 10.1016/S0079-6123(08)60442-2; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BALENTINE JD, 1978, LAB INVEST, V39, P236; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bhat NR, 1999, J NEUROCHEM, V72, P472, DOI 10.1046/j.1471-4159.1999.0720472.x; BROSNAN JP, 1998, BIOCHEM SOC T, V25, P679; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Cohen TI, 1996, J NEUROTRAUM, V13, P361, DOI 10.1089/neu.1996.13.361; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Coyle PK, 1996, ADV NEUROIMMUNOL, V6, P143, DOI 10.1016/0960-5428(96)00013-7; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; DSOUZA S, 1995, J NEUROSCI, V15, P7293; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; ENG LF, 1992, PROG BRAIN RES, V94, P353; ESTLER HC, 1992, BIOL CHEM H-S, V373, P271, DOI 10.1515/bchm3.1992.373.1.271; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Kim GM, 2001, J NEUROSCI, V21, P6617; KIM HK, 1995, J IMMUNOL, V154, P4741; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LIPTON SA, 1994, PROG BRAIN RES, V103, P359; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; MincGolomb D, 1996, J NEUROCHEM, V66, P1504; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nakajima W, 2000, J NEUROSCI, V20, P7994; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; Sasaki S, 2002, ACTA NEUROPATHOL, V103, P421, DOI 10.1007/s00401-001-0484-6; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sato I, 1996, NEUROSCI LETT, V205, P45, DOI 10.1016/0304-3940(96)12377-6; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SELINA CC, 1989, BRAIN RES, V482, P271; SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Sipe KJ, 1996, MOL BRAIN RES, V38, P222, DOI 10.1016/0169-328X(95)00310-O; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1994, NEUROREPORT, V5, P585, DOI 10.1097/00001756-199401000-00013; Wang CX, 2002, NEUROREPORT, V13, P1391, DOI 10.1097/00001756-200208070-00008; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhao XR, 2001, J NEUROSCI RES, V64, P121, DOI 10.1002/jnr.1059; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	65	104	118	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2003	20	2					207	219		10.1089/08977150360547116			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	652XV	WOS:000181406900007	12675973				2021-06-18	
J	Hawley, CA; Ward, AB; Magnay, AR; Long, J				Hawley, CA; Ward, AB; Magnay, AR; Long, J			Parental stress and burden following traumatic brain injury amongst children and adolescents	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; FAMILY; ADAPTATION; DISTRESS; CARERS; NEEDS	Primary objectives: To assess parental stress following paediatric traumatic brain injury (TBI), and examine the relationship between self-reported problems, parental stress and general health. Research design: Parents of 97 children admitted with a TBI (49 mild, 19 moderate, 29 severe) to North Staffordshire National Health Service Trust, and parents of 31 uninjured children were interviewed and assessed. Methods and procedures: Structured interviews were carried out with families, and parents assessed on the Parenting Stress Index (PSI/SF) and General Health Questionnaire (GHQ-12) at recruitment, and repeated 12 months later. Main outcomes and results: Forty parents (41.2%) of children with TBI exhibited clinically significant stress. Regardless of injury severity, parents of injured children suffered greater stress than control parents as measured by the PSI/SF (p=0.001). There was a highly significant relationship between number of problems reported and level of parental stress (p=0.001). Financial burden was related to severity of TBI. At follow-up, one third of parents of children with severe TBI scored 18 on the GHQ-12, signifying poor psychological health. Conclusions: The parents of a child with serious TBI should be screened for abnormal levels of stress. Parental stress and family burden may be alleviated by improved information, follow-up and support.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent, Staffs, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England		c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				Abidin RR., 1995, PARENTING STRESS IND; Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Goldberg D., 1991, USERS GUIDE GEN HLTH; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; McPherson KM, 2000, INT J REHABIL RES, V23, P295, DOI 10.1097/00004356-200023040-00005; *N STAFF HLTH AUTH, 1994, HLTH N STAFF ANN REP; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Parmelee D X, 1989, Psychiatr Med, V7, P11; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1993, ARCH PHYSICAL MED RE, V74, P1947; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; TAYLOR GH, 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Townsend P, 1986, INEQUALITIES HLTH NO; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; World Health Organization, 1980, INT CLASS IMP DIS HA	33	104	106	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	1					1	23		10.1080/0269905021000010096			23	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600001	12519644				2021-06-18	
J	Simpson, G; Tate, R				Simpson, G; Tate, R			Suicidality after traumatic brain injury: demographic, injury and clinical correlates	PSYCHOLOGICAL MEDICINE			English	Article							HEAD-INJURY; IDEATION; HOPELESSNESS; BEHAVIOR; MODEL	Background. In spite of the high frequency of emotional distress after traumatic brain injury (TBI), few investigations have examined the extreme of such distress, namely, suicidality, and no large scale surveys have been conducted. The current study examined both the prevalence and demographic, injury, and clinical correlates of hopelessness, suicidal ideation and suicide attempts after TBI. Methods. Out-patients (N = 172) with TBI were screened for suicidal ideation and hopelessness using the Beek Scale for Suicide Ideation and the Beck Hopelessness Scale. Data were also collected on demographic, injury, pre-morbid and post-injury psychosocial variables and included known risk factors for suicide. Results. A substantial proportion of participants had clinically significant levels of hopelessness (35%) and suicide ideation (23%), and 18% had made a suicide attempt post-injury, There was a high degree of co-morbidity between suicide attempts and emotional/psychiatric disturbance. Results from regression analyses indicated that a high level of hopelessness was the most significant association of suicide ideation and a high level of suicide ideation, along with occurrence of post-injury emotional/psychiatric disturbance, were the most significant associations of post-injury suicide attempts. Neither injury severity nor the presence of pre-morbid suicide risk factors contributed to elevated levels of suicidality post-injury. Conclusions. Suicidality is a common psychological reaction to TBI among out-patient populations. Management should involve careful history taking of previous post-injury suicidal behaviour, assessment of post-injury adjustment to TBI with particular focus on the degree of emotional/psychiatric disturbance, and close monitoring of those individuals with high levels of hopelessness and suicide ideation.	Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool BC, NSW 1871, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia	Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool BC, NSW 1871, Australia.		Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060			BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1985, AM J PSYCHIAT, V142, P559; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; BERNARD, 2000, HEADING NEWSLETTER S, P2; Bongar B., 1989, J INTEGRATIVE ECLECT, V8, P53; BONGAT B, 1991, SUICIDAL PATIENT CLI; BONNER RL, 1987, SUICIDE LIFE-THREAT, V17, P50; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Deb S, 1999, AM J PSYCHIAT, V156, P374; DICKSTRA RF, 1995, SUICIDE PREVENTION Y, P36; EAMES P, 1990, REHABILITATION ADULT, P410; Graham A, 2000, AUST PSYCHOL, V35, P1, DOI 10.1080/00050060008257463; HIRSCHFIELD R, 1988, AM PSYCHIAT PRESS VI, P307; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KIENHORST CWM, 1990, SUICIDE LIFE-THREAT, V20, P101; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Leon-Carrion J, 1997, NEUROPSYCHOL REHABIL, P415; MARIS RW, 1981, PATHWAYS SUICIDE SUR; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOTTO JA, 1977, SUICIDE LIFE-THREAT, V7, P236; Parmelee D X, 1989, Brain Inj, V3, P295, DOI 10.3109/02699058909029642; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Robins E., 1986, SUICIDE, P123; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHOTTE DE, 1982, J CONSULT CLIN PSYCH, V50, P690, DOI 10.1037/0022-006X.50.5.690; SCHWEITZER R, 1995, AUST NZ J PSYCHIAT, V29, P473, DOI 10.3109/00048679509064956; SHAFFER D, 1988, J AM ACAD CHILD PSY, V27, P675, DOI 10.1097/00004583-198811000-00001; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436	34	104	106	2	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	MAY	2002	32	4					687	697		10.1017/S0033291702005561			11	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	552VD	WOS:000175640000013	12102383				2021-06-18	
J	Liberman, JN; Stewart, WF; Wesnes, K; Troncoso, J				Liberman, JN; Stewart, WF; Wesnes, K; Troncoso, J			Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury	NEUROLOGY			English	Article							SEVERE HEAD-INJURY; PROTEIN; CONCUSSION; EXPRESSION; PREDICTION; DEPOSITION; MODERATE; ALLELE; APOE; RAT	Objective: To determine whether APOE genotype explained variability in short-term recovery from predominantly mild traumatic brain injury (TBI). Methods: A total of 87 adult patients presenting with mild or moderate TBI to a shock trauma center were enrolled prospectively. A battery of 13 neuropsychological tests was administered twice, at approximately 3 and 6 weeks after injury. Eighty of 87 patients were successfully genotyped for APOE using a buccal swab technique. Results: Ninety percent of study patients had mild TBI (Glasgow Coma Scale score of 13 to 15); 18 (22.5%) had one APOE epsilon4 and none had two epsilon4 alleles. After adjusting for potential confounders, patients positive for the APOE epsilon4 allele had lower mean scores on 12 of 13 neuropsychological outcomes at visit I compared with APOE epsilon4-negative patients. Two of the differences were significant (grooved pegboard test, p = 0.005; paced auditory serial addition task 2.8-second trial, p = 0.004). At visit 2, APOE epsilon4-positive patients had lower adjusted mean scores on 11 of the 13 neuropsychological outcomes. None of the differences was significant. Conclusions: APOE genotype may influence the severity of the acute injury. However, with no consistent pattern to the recovery curves, it is not clear if APOE genotype influences the rate of recovery.	Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; Cognit Drug Res Ltd, Reading, Berks, England	Liberman, JN (corresponding author), IMR Inc, 11350 McCormack Rd,Execut Pl 2,Suite1000, Hunt Valley, MD 21031 USA.	jliberman@imrinc.com	Wesnes, Keith A/D-7148-2018	Wesnes, Keith/0000-0002-4498-8511			Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GRONWALL D, 1975, LANCET, V2, P995; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAYNEY MS, 1995, MAYO CLIN PROC, V70, P951, DOI 10.4065/70.10.951; HIXSON JE, 1990, J LIPID RES, V31, P545; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Keith MS, 1998, BRAIN INJURY, V12, P1037, DOI 10.1080/026990598121945; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KlOve H, 1963, MED CLIN N AM; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marques M, 1997, ALZHEIMER RES, V3, P1; Matthews C, 1964, INSTRUCTION MANUAL A; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; Pierce JES, 1996, J NEUROSCI, V16, P1083; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRICH SJ, 1969, LATE EFFECTS HEAD IN, P501; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sun YL, 1998, J NEUROSCI, V18, P3261; TSUBOKAWA T, 1975, Neurologia Medico-Chirurgica, V15, P57, DOI 10.2176/nmc.15pt1.57; UNTERHARNSCHEID.F, 1966, HEAD INJURY C P, P321; Wesnes KA, 1999, DIAGNOSIS MANAGEMENT, P124	38	104	110	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 9	2002	58	7					1038	1044		10.1212/WNL.58.7.1038			7	Clinical Neurology	Neurosciences & Neurology	539JC	WOS:000174865900010	11940689				2021-06-18	
J	Bleiberg, J; Kane, RL; Reeves, DL; Garmoe, WS; Halpern, E				Bleiberg, J; Kane, RL; Reeves, DL; Garmoe, WS; Halpern, E			Factor analysis of computerized and traditional tests used in mild brain injury research	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; PERFORMANCE; CONCUSSION; CONSISTENCY; DEFICITS; PLAYERS	The present study examines the relation between a set of computerized neuropsychological measures, Automated Neuropsychological Assessment Metrics (ANAM), acid a set of traditional clinical neuropsychological tests. Both sets of tests have been employed in recent studies of mild brain injury. Factor analysis and stepwise regression indicate that both sets of tests measure similar underlying constructs of cognitive processing speed, resistance to interference, and working memory. The present findings indicate strong concordance between computerized and traditional neuropsychological measures and support the construct validity of ANAM and similar procedures.	Natl Rehabil Hosp, Washington, DC 20010 USA; Univ Maryland, College Pk, MD 20742 USA	Bleiberg, J (corresponding author), Natl Rehabil Hosp, 102 Irving St NW, Washington, DC 20010 USA.			Bleiberg, Joseph/0000-0003-0867-5494			Benton AL, 1978, MULTILINGUAL APHASIA; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DELIS C, 1987, CALIFORNIA VERBAL LE; Golden C., 1978, STROOP COLOR WORD TE; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KANE RL, 1997, NEUROPSYCHOLOGY HDB, V2; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McDiarmid MA, 2000, ENVIRON RES, V82, P168, DOI 10.1006/enrs.1999.4012; Milner B, 1972, Clin Neurosurg, V19, P421; Reitan RM., 1985, HALSTEAD REITAN NEUR; STARBUCK VN, 1995, NEUROPSY NEUROPSY BE, V8, P189; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	26	104	108	0	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2000	14	3					287	294		10.1076/1385-4046(200008)14:3;1-P;FT287			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	392FV	WOS:000166401600004	11262703				2021-06-18	
J	Medd, J; Tate, RL				Medd, J; Tate, RL			Evaluation of an anger management therapy programme following acquired brain injury: A preliminary study	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							ABUSE SCREENING-TEST; GENERAL ANGER; RELAXATION; REHABILITATION; DISTURBANCE; REDUCTION; DISORDERS; SKILLS	Problems with anger management after traumatic brain injury are one of the most frequent changes in the long term reported by relatives of injured people. In spite of their impact there have been few reports either describing therapy procedures for this disorder or examining their efficacy. The present study evaluated a cognitive-behavioural intervention for anger management difficulties following acquired brain injury. Participants were screened and randomly allocated to either a Treatment Group (TREAT) or Waiting List Group (WAIT). Each participant in TREAT received approximately six, hourly individual sessions of anger-management therapy while those in WAIT monitored their anger daily. Sixteen participants proceeded through to the final stages of the study. A significant decrease in anger on the State-Trait Anger Expression Inventory (STAXI) was found for TREAT in comparison with WAIT at pout-treatment. Repeated-measures analyses for TREAT showed significant improvements between pre-treatment and post-treatment measures (immediate and 2-month follow-up) on the STAXI. No significant generalisation of treatment effects to self-esteem, anxiety, depression, or degree of self-awareness were found.	Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia							ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; ALDERMAN N, 1990, COGNITIVE REHABILITA, P204; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bedian A, 1977, PSYCHOL REP, V41, P1041; Burgess P. W., 1990, COGNITIVE REHABILITA, P183; Butler G., 1989, COGNITIVE BEHAV THER, P97; COOPERSMITH S, 1975, SEI SELF ESTEEM INVE; DAWSON H, ANGER MANAGEMENT MAN; DEFFENBACHER JL, 1986, BEHAV RES THER, V24, P481, DOI 10.1016/0005-7967(86)90014-8; DEFFENBACHER JL, 1987, J COUNS PSYCHOL, V34, P171; DEFFENBACHER JL, 1992, J COUNS PSYCHOL, V39, P158, DOI 10.1037/0022-0167.39.2.158; DEFFENBACHER JL, 1990, J COLL STUDENT DEV, V31, P351; DELIS D, 1987, CALIFORNIA VERBAL LE; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; GOULD RA, 1993, CLIN PSYCHOL REV, V13, P169, DOI 10.1016/0272-7358(93)90039-O; HAZALEUS SL, 1986, J CONSULT CLIN PSYCH, V54, P222, DOI 10.1037/0022-006X.54.2.222; HEATON RK, 1993, WISCONSN CARD SORTIN; Heppner PP., 1988, PROBLEM SOLVING INVE; JACOBS HE, 1987, J HEAD TRAUMA REHAB, V2, P37; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LIRA FT, 1983, INT J CLIN NEUROPSYC, V5, P159; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; LOPEZ FG, 1986, COGNITIVE THER RES, V10, P245, DOI 10.1007/BF01173729; Luria A. R, 1973, WORKING BRAIN; LUSSICK S, 1993, UNPUB ANGER CONTROL; Manchester D, 1997, BRAIN INJURY, V11, P605, DOI 10.1080/026990597123296; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; Miller L., 1990, COGN REHABIL, V8, P14; Novaco R.W., 1975, ANGER CONTROL DEV EV; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Spielberger CD., 1988, STATE TRAIT ANGER EX; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 1981, APPL CONDITIONING TH, P81; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	104	105	0	14	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR	2000	10	2					185	201		10.1080/096020100389246			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	295HK	WOS:000085960500005					2021-06-18	
J	Dash, PK; Mach, SA; Moore, AN				Dash, PK; Mach, SA; Moore, AN			Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						celecoxib; cyclooxygenase; hippocampus; inflammation; rat; trauma	ENDOPEROXIDE SYNTHASE-2 GENE; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; MESSENGER-RNA; RAT-BRAIN; PROSTAGLANDIN SYNTHASE; GRANULOSA-CELLS; AXONAL INJURY; PROMOTER; DAMAGE	Prostaglandins, potent mediators of inflammation, are generated from arachidonic acid (AA) via the action of cyclooxygenase-1 and -2 (COX-1 and COX-2), In this study, we report that lateral cortical impact injury in rats significantly increases COX-2 protein levels both in the cortex surrounding the injury site and the ipsilateral hippocampus. COX-2 protein level was elevated as early as 3 h postinjury and persisted for up to 3 days. Increases in immunoreactivity were detected not only in the adjacent cortex and hippocampus, but were also observed in the contralateral cortex and hippocampus, the ipsilateral piriform cortex and the ipsilateral amygdaloid complex. COX-2 immunoreactive cells appear morphologically normal and do not present any of the characteristic features of apoptosis. Double immunostaining experiments using either a neuron-specific or an astroglial-specific marker show that the expression of COX-2 is localized almost exclusively in neuronal cells. Administration of the COX-2 inhibitor 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-H-1-pyrazol-1-yl]benzenesulfonamide (celecoxib, marketed as Celebrex) worsens motor, but not cognitive, performance, suggesting that COX-2 induction following traumatic brain injury may play a protective role.	Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, POB 20708, Houston, TX 77225 USA.	pdash@nba19.med.uth.tmc.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49662] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS23327, NS3545] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH049662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327] Funding Source: NIH RePORTER		ARIASNEGRETE S, 1995, BIOCHEM BIOPH RES CO, V208, P582, DOI 10.1006/bbrc.1995.1378; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; Bauer MKA, 1997, EUR J BIOCHEM, V243, P726, DOI 10.1111/j.1432-1033.1997.00726.x; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; DASH PK, 1995, J NEUROSCI, V15, P2030; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dubois RN, 1998, FASEB J, V12, P1063; FADEN AI, 1996, PHARMACOL TOXICOL, V78, P21; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayaishi O, 1997, ADV EXP MED BIOL, V433, P347; Hayaishi O, 1996, ADV EXP MED BIOL, V398, P3; Homayoun P, 1997, J NEUROCHEM, V69, P199; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KLEIN J, 1995, J NEUROCHEM, V65, P1445; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nogawa S, 1997, J NEUROSCI, V17, P2746; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	48	104	111	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2000	17	1					69	81		10.1089/neu.2000.17.69			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	278WR	WOS:000085012400006	10674759				2021-06-18	
J	Fontaine, A; Azouvi, P; Remy, P; Bussel, B; Samson, Y				Fontaine, A; Azouvi, P; Remy, P; Bussel, B; Samson, Y			Functional anatomy of neuropsychological deficits after severe traumatic brain injury	NEUROLOGY			English	Article; Proceedings Paper	5th Conference of the International-Association-for-the-Study-of-Traumatic-Brain-Injury	NOV 15-18, 1996	MELBOURNE, AUSTRALIA	Int Assoc Study Traumat Brain Injury		traumatic brain injury; PET; neuropsychological deficits	CLOSED-HEAD-INJURY; POSITRON EMISSION TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; GLUCOSE METABOLIC-RATE; VERBAL MEMORY; HUMANS; SPECT; PET; ATTENTION; BEHAVIOR	Background: Neurobehavioral disorders after Severe traumatic brain injury (TBI) are poorly correlated with focal lesions detected by structural neuroimaging techniques such as CT scan or MRI. Objective: To explore the relationships between regional cerebral glucose metabolism at rest, as measured by PET, and neurobehavioral status after severe TBI at the subacute stage. Methods: Thirteen patients without focal structural lesion on MRI were studied. Neuropsychological assessment included tests of memory, attention and speed of information processing, and executive functions, and a global neurobehavioral assessment. Regional cerebral glucose metabolism at rest was measured with (F-18)-fluorodeoxyglucose and PET. Results: A close link was found between cognitive and behavioral disorders and decreased cortical metabolism in prefrontal and cingulate cortex. Tests of memory and executive functions significantly correlated with regional metabolism in the mesial and lateral prefrontal cortex and the cingulate gyrus. Behavioral disorders correlated significantly with mesial prefrontal and cingulate metabolisms. Conclusion: These results suggest a predominant role of prefrontal and cingulate dysfunction in cognitive and behavioral disorders of patients with severe traumatic brain injury, even in the absence of focal structural lesion of the brain. Further cognitive functional activation research using PET or functional MRI might help clarify the relative contributions of both areas to dysfunction.	Univ Paris 05, Hosp Raymond Poincare AP HP, Serv Reeduc Neurol, Format Rech Claude Bernard,UFR Paris Ouest, Garches, France; Hop Orsay, CEA, Dept Biol, Serv Hosp Frederic Joliot, Orsay, France	Azouvi, P (corresponding author), Reymond Poincare Hosp, Dept Neurol Rehabil, F-92380 Garches, France.		samson, yves/C-5647-2013	samson, yves/0000-0002-8080-1427; Remy, Philippe/0000-0003-2150-2563			ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Azouvi P., 1993, Annales de Readaptation et de Medecine Physique, V36, P157; BENES FM, 1993, SCHIZOPHRENIA BULL, V19, P537, DOI 10.1093/schbul/19.3.537; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; JENNETT B, 1975, LANCET, V1, P480; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LAPLANE D, 1981, J NEUROL SCI, V51, P289, DOI 10.1016/0022-510X(81)90107-6; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOCKWOOD AH, 1993, HEPATOLOGY, V18, P1061; MANGIN JF, 1994, J CEREBR BLOOD F MET, V14, P749, DOI 10.1038/jcbfm.1994.96; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PENNIELLO MJ, 1995, BRAIN, V118, P697, DOI 10.1093/brain/118.3.697; PERANI D, 1993, BRAIN, V116, P903, DOI 10.1093/brain/116.4.903; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; REIVICH M, 1985, J CEREBR BLOOD F MET, V5, P179, DOI 10.1038/jcbfm.1985.24; Sarazin M, 1998, NEUROLOGY, V51, P142, DOI 10.1212/WNL.51.1.142; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; SIGNORET JL, 1991, BATTERIE EVALUATION, V144; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; Talairach J., 1988, COPLANAR STEREOTAXIC; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y	41	104	107	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 10	1999	53	9					1963	1968		10.1212/WNL.53.9.1963			6	Clinical Neurology	Neurosciences & Neurology	265QR	WOS:000084255300012	10599766				2021-06-18	
J	Cifu, DX; Kreutzer, JS; Marwitz, JH; Rosenthal, M; Englander, J; High, W				Cifu, DX; Kreutzer, JS; Marwitz, JH; Rosenthal, M; Englander, J; High, W			Functional outcomes of older adults with traumatic brain injury: A prospective, multicenter analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; STROKE REHABILITATION; EARLY INTERVENTION; PREDICTORS; ALCOHOL; PATIENT	Objective: To investigate improvement rates and medical services costs in older brain injured adults relative to younger patients. Design: Descriptive statistics were computed in a prospective comparative study of 50 patients 55 years and older and 50 patients 18 to 54 years old matched for gender and injury severity (number of days in coma, admission Glasgow Coma Score, intracranial pressure). Independent t tests were performed to examine differences between the two samples on specific variables. Setting: Five medical centers in the federally sponsored Traumatic Brain Injury Model Systems Project that provide emergency medical services, intensive and acute medical care, inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Patients were selected from a national database of 531 rehabilitation inpatients admitted to acute care within 8 hours of traumatic brain injury between 1989 and 1994. Main Outcome Measures: Disability Rating Scale, Functional Independence Measure, Rancho Los Amigos Levels of Cognitive Functioning Scale, length of stay, acute care and rehabilitation charges, and discharge disposition. Results: Older persons averaged a significantly longer rehabilitation length of stay, higher total rehabilitation charges, and a lower rate of change on functional measures. No significant differences between groups were found for acute care length of stay, daily rehabilitation charges, acute care charges (daily or total), or discharge disposition. Conclusions: Although older persons demonstrated functional changes, the cost of change was substantially higher than for younger patients, coincident with longer lengths of stay. These higher overall charges and slower rates of change may effect changes in referral and management patterns. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA 23298; WAYNE STATE UNIV,DEPT PHYS MED & REHABIL,DETROIT,MI 48202; SANTA CLARA VALLEY MED CTR,DEPT REHABIL,SANTA CLARA,CA; BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030				Cifu, David/0000-0003-1600-9387			AMACHER AL, 1979, NEUROSURGERY, V20, P954; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Cifu D X, 1993, Clin Geriatr Med, V9, P473; Cifu D X, 1993, Arch Phys Med Rehabil, V74, pS406; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; FEIGENSON JS, 1977, STROKE, V8, P657, DOI 10.1161/01.STR.8.6.657; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALBRAITH S, 1987, BRIT MED J, V294, P294; Gershkoff A M, 1993, Arch Phys Med Rehabil, V74, pS402; GOODMAN H, 1992, PHYS MED REH CLIN N, V3, P441; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GRANGER CV, 1992, STROKE, V23, P978, DOI 10.1161/01.STR.23.7.978; GRANGER CV, 1994, TOP GERIATR REHABIL, V9, P72; Granger CV, 1986, TOPICS GERIATRIC REH; HAGEN C, 1982, COGNITIVE REHABILITA, P131; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HAYES SH, 1986, ARCH PHYS MED REHAB, V67, P319; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JENNET B, 1981, MANAGEMENT HEAD INJU, P1; JENNETT B, 1976, LANCET, V1, P1031; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; KALRA L, 1993, POSTGRAD MED J, V69, P33, DOI 10.1136/pgmj.69.807.33; KATZ DI, 1990, NEUROLOGY S, V40, pS276; KEITH RA, 1995, ARCH PHYS MED REHAB, V76, P495, DOI 10.1016/S0003-9993(95)80501-X; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MALKMUS D, 1979, REHABILITATION HEAD; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; SCHWARTZ RH, 1986, PEDIATRICS, V78, P1169; SHAH S, 1989, STROKE, V21, P766; SOSIN DN, 1989, JAMA-J AM MED ASSOC, V282, P2251; STEWART DG, 1994, J BACK MUSCULOSKELET, V4, P135, DOI 10.3233/BMR-1994-4211	40	104	105	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1996	77	9					883	888		10.1016/S0003-9993(96)90274-9			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	VG419	WOS:A1996VG41900007	8822678				2021-06-18	
J	Allen, K; Blascovich, J				Allen, K; Blascovich, J			The value of service dogs for people with severe ambulatory disabilities - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOCIAL ACKNOWLEDGMENTS; DEPRESSION; STRESS; CHILDREN; SUPPORT	Objective.-To assess the value of service dogs for people with ambulatory disabilities. Design.-Randomized, controlled clinical trial. Setting.-Environments of study participants. Participants.-Forty-eight individuals with severe and chronic ambulatory disabilities requiring use of wheelchairs who were recruited from advocacy and support groups for persons with muscular dystrophy, multiple sclerosis, traumatic brain injury, and spinal cord injury. Participants were matched on age, sex, marital status, race, and the nature and severity of the disability in order to create 24 pairs. Within each pair, participants were randomly assigned to either the experimental group or a wait-list control group. Intervention.-Experimental group members received trained-service dogs 1 month after the study began, and subjects in the wait-list control group received dogs in month 13 of the study. Main Outcome Measures.-Dependent variables evaluated were self-reported assessments of psychological well-being, internal locus of control, community integration, school attendance, part-time work status, self-esteem, marital status, living arrangements, and number of biweekly paid and unpaid assistance hours. Data collection occurred every 6 months over a 2-year period, resulting in five data collection points for all subjects. Results.-Significant positive changes in all but two dependent measures were associated with the presence of a service dog both between and within groups (P<.001). Psychologically, all participants showed substantial improvements in self-esteem, internal locus of control, and psychological well-being within 6 months after receiving their service dog. Socially, all participants showed similar improvements in community integration. Demographically, all participants showed increases in school attendance and/or part-time employment. Economically, all participants showed dramatic decreases in the number of both paid and unpaid assistance hours. Conclusions.-Trained service dogs can be highly beneficial and potentially cost-effective components of independent living for people with physical disabilities.	SUNY BUFFALO,DEPT MED,BUFFALO,NY; UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106							ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; BATAVIA AI, 1991, J HEALTH POLIT POLIC, V16, P523, DOI 10.1215/03616878-16-3-523; Bradburn NM, 1969, STRUCTURE PSYCHOL WE; *CAN COMP IND, 1994, CAN COMP IND PROGR I; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EATON L, 1994, NY TIMES        0911, P1; EDDY J, 1988, J PSYCHOL, V122, P39, DOI 10.1080/00223980.1988.10542941; EISENBERG MG, 1982, DISABLED PEOPLE 2 CL; FITZPATRICK R, 1991, SOC SCI MED, V33, P605, DOI 10.1016/0277-9536(91)90218-2; FRIEDLAND J, 1992, SOC SCI MED, V34, P395, DOI 10.1016/0277-9536(92)90299-6; HARTMANN C, 1988, Biofactors, V1, P41; KEENAN MP, 1989, CHANGING NEEDS LONG; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Kirk RE., 1982, EXPT DESIGN PROCEDUR, V2; LAPLANTE MP, 1989, 1 U CAL I HLTH AG; LITVAK S, 1987, ATTENDING AM PERSONA; MADER B, 1989, CHILD DEV, V60, P1529, DOI 10.2307/1130941; MARINELLI RP, 1977, PSYCHOL SOCIAL IMPAC; PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; VALENTINE DP, 1993, SOC WORK HEALTH CARE, V19, P109, DOI 10.1300/J010v19n01_07; VARNI JW, 1991, ARCH PHYS MED REHAB, V72, P1053; West J, 1991, AM DISABILITIES ACT; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; *WORLD I DIS, 1988, REP NAT COUNC HAND M	27	104	105	1	50	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1001	1006		10.1001/jama.275.13.1001			6	Medicine, General & Internal	General & Internal Medicine	UC123	WOS:A1996UC12300027	8596231				2021-06-18	
J	REEVES, TM; LYETH, BG; POVLISHOCK, JT				REEVES, TM; LYETH, BG; POVLISHOCK, JT			LONG-TERM POTENTIATION DEFICITS AND EXCITABILITY CHANGES FOLLOWING TRAUMATIC BRAIN INJURY	EXPERIMENTAL BRAIN RESEARCH			English	Article						LONG-TERM POTENTIATION; TRAUMATIC BRAIN INJURY; EXCITABILITY; HIPPOCAMPUS; RAT	EXCITATORY AMINO-ACIDS; RAT HIPPOCAMPUS; MECHANISMS; RELEASE; RECEPTORS; NEURONS; MEMORY; MODEL	The effects of traumatic brain injury (TBI) on hippocampal long-term potentiation (LTP) and cellular excitability were assessed at postinjury days 2, 7, and 15. TBI was induced using a well-characterized central fluid-percussion model. LTP of the Schaffer collateral/commissural system was assessed in vivo in urethane-anesthetized rats. Significant LTP of the population excitatory postsynaptic potential (EPSP) slope was found only in controls, and no recovery to control levels was observed for any postinjury time point. Four measurement parameters reflecting pyramidal cell discharges (population spike) indicated that TBI significantly increased cellular excitability, at postinjury day 2: (1) pretetanus baseline recording showed that TBI reduced population spike threshold and latency; (2) tetanic stimulation (400 Hz) increased population spike amplitudes to a greater degree in injured animals than in control animals; (3) tetanus-induced population spike latency shifts were greater in injured cases; and (4) tetanic stimulation elevated EPSP to spike ratios (E-S potentiation) to a greater degree in injured animals. These parameters returned to control levels, as measured on postinjury days 7 and 15. These results suggest that TBI induced excitability changes persist at least through 2 days postinjury and involve a differential impairment of mechanisms subserving LTP of synaptic efficacy and mechanisms related to action potential generation	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA	REEVES, TM (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT ANAT, BOX 709, RICHMOND, VA 23298 USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, K17NS001750, P01NS012587, R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 12587, NS 01750] Funding Source: Medline		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Burke RE, 1977, HDB PHYSL NERVOUS SY, VI, P877; CHAVEZNORIEGA LE, 1989, NEUROSCI LETT, V104, P58, DOI 10.1016/0304-3940(89)90329-7; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; ILLES P, 1986, NEUROSCIENCE, V17, P909, DOI 10.1016/0306-4522(86)90071-0; JEFFERY KJ, 1993, HIPPOCAMPUS, V3, P133, DOI 10.1002/hipo.450030205; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH G, 1991, Brain Research Reviews, V16, P204; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Reeves T. M., 1994, Society for Neuroscience Abstracts, V20, P425; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TAUBE JS, 1988, J NEUROSCI, V8, P1632; WILSON R C, 1981, Journal of Neurophysiology (Bethesda), V46, P339	30	104	106	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	OCT	1995	106	2					248	256					9	Neurosciences	Neurosciences & Neurology	TB527	WOS:A1995TB52700008	8566189				2021-06-18	
J	IP, RY; DORNAN, J; SCHENTAG, C				IP, RY; DORNAN, J; SCHENTAG, C			TRAUMATIC BRAIN INJURY - FACTORS PREDICTING RETURN TO WORK OR SCHOOL	BRAIN INJURY			English	Article							HEAD-INJURY; REHABILITATION	Prediction of outcome for brain-injured individuals will facilitate effective rehabilitation programme planning which will ultimately improve the patient's quality of life. A sample of traumatic brain-injured subjects who had completed their rehabilitation were contacted post-discharge to identify predictive factors for return to work/school. Subjects were given a telephone interview and their charts were examined retrospectively along five subsets of variables in the predictive matrix: sociodemographics, chronicity, indices of severity, physical impairment, and cognitive functioning. Forty-five subjects were used as the study sample to investigate their vocational and educational outcome, and to generate the best predictive model for return to work/school. Twenty subjects made up the test sample used to evaluate the generalizability of the predictive model. Performance IQ score of the Wechsler Adult Intelligence Scale-Revised emerged as the most significant predictor of return to work/school. Implications of these findings for treatment and rehabilitation are discussed.		IP, RY (corresponding author), QUEEN ELIZABETH HOSP,ACQUIRED BRAIN INJURY PROGRAM,550 UNIV AVE,TORONTO,ON M5G 2A2,CANADA.						BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; BRENNAN MA, 1981, IRISH MED J, V74, P5; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; DIKMEN S, 1988, REHABILITATION COUNS, V31, P276; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1975, LANCET, V1, P480; JOHNSON R, 1987, INT DISABILITY STUDI, V9, P45; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MEIER MJ, 1974, APA CONVENTION NEW O; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; REITAN RM, 1978, REITAN NEUROLOGICAL; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; STAMBROOK M, BRAIN INJURY, V4, P183; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; 1991, CANADIAN YB MINISTRY	24	104	106	0	5	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1995	9	5					517	532		10.3109/02699059509008211			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100010	7550223				2021-06-18	
J	HOLMES, B; HARBAUGH, RE				HOLMES, B; HARBAUGH, RE			TRAUMATIC INTRACRANIAL ANEURYSMS - A CONTEMPORARY REVIEW	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							INTERNAL CAROTID-ARTERY; PERIPHERAL CEREBRAL-ARTERIES; BALLOON EMBOLIZATION; WOUNDS; COMPLICATIONS; BRAIN; ANGIOGRAPHY; MANAGEMENT; CHILDHOOD; PATIENT	Intracranial aneurysms are rare complications of head injury. Clinical and pathologic features as well as the surgical treatment of patients harboring traumatic intracranial aneurysms are presented. The latest neuroradiologic procedures as they relate to traumatic aneurysms are discussed. An illustrative case report is followed by a review of the literature.	DARTMOUTH HITCHCOCK MED CTR,DEPT SURG,NEUROSURG SECT,LEBANON,NH				Harbaugh, Robert/0000-0003-3607-7926			AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ALMEIDA GM, 1977, CHILD BRAIN, V3, P193; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BERGSTROM K, 1973, ACTA RADIOL DIAGN, V14, P657, DOI 10.1177/028418517301400604; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; COCKRILL HH, 1977, J NEUROSURG, V46, P377, DOI 10.3171/jns.1977.46.3.0377; CRESSMAN MR, 1966, J NEUROSURG, V24, P102, DOI 10.3171/jns.1966.24.1.0102; DEGOS JD, 1987, BRAIN, V110, P1155, DOI 10.1093/brain/110.5.1155; DIAL DL, 1937, AM J SURG, V35, P2; EDELMAN RR, 1990, AM J ROENTGENOL, V154, P937, DOI 10.2214/ajr.154.5.2108568; ELGINDI S, 1979, ACTA NEUROCHIR, V48, P237, DOI 10.1007/BF02056972; Endo S, 1974, No Shinkei Geka, V2, P329; FEIN JM, 1979, NEUROSURGERY, V5, P254, DOI 10.1227/00006123-197908000-00010; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FOX JL, 1983, INTRACRANIAL ANEURYS, V3, P1453; Funahashi K, 1977, No Shinkei Geka, V5, P619; GIANNOTTA SL, 1982, CLIN NEUR, V29, P288; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Handa J, 1976, Surg Neurol, V5, P241; HARBAUGH RE, 1992, J NEUROSURG, V76, P408, DOI 10.3171/jns.1992.76.3.0408; HIGASHIDA RT, 1990, J NEUROSURG, V72, P857, DOI 10.3171/jns.1990.72.6.0857; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; HODES JE, 1990, J NEUROSURG, V72, P567, DOI 10.3171/jns.1990.72.4.0567; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; KUHN RA, 1964, J NEUROSURG, V21, P92, DOI 10.3171/jns.1964.21.2.0092; LASSMAN LP, 1974, VASCULAR SURG, V8, P1; LEE JP, 1990, J TRAUMA, V30, P619, DOI 10.1097/00005373-199005000-00017; MANI RL, 1978, AM J ROENTGENOL, V131, P871, DOI 10.2214/ajr.131.5.871; MASANA Y, 1992, J NEUROSURG, V76, P524, DOI 10.3171/jns.1992.76.3.0524; MAURER JJ, 1961, J NEUROSURG, V18, P837, DOI 10.3171/jns.1961.18.6.0837; MORARD M, 1991, NEUROSURGERY, V29, P438, DOI 10.1227/00006123-199109000-00018; NOV AA, 1984, J NEURORADIOLOGY, V11, P3; OVERTON MC, 1966, J NEUROSURG, V24, P672, DOI 10.3171/jns.1966.24.3.0672; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PATEL AN, 1971, J NEUROSURG, V35, P571, DOI 10.3171/jns.1971.35.5.0571; PAUL GA, 1980, J NEUROSURG, V53, P101, DOI 10.3171/jns.1980.53.1.0101; RUMBAUGH CL, 1970, RADIOLOGY, V96, P49, DOI 10.1148/96.1.49; SEKHAR LN, 1986, NEUROSURGERY, V19, P967, DOI 10.1227/00006123-198612000-00012; SENEGOR M, 1991, J NEUROSURG, V75, P475, DOI 10.3171/jns.1991.75.3.0475; SHALLAT RF, 1981, NEUROSURGERY, V8, P569, DOI 10.1227/00006123-198105000-00010; SMITH DR, 1970, J NEUROSURG, V32, P357, DOI 10.3171/jns.1970.32.3.0357; SMITH KR, 1968, J NEUROSURG, V29, P551, DOI 10.3171/jns.1968.29.5.0551; STEHBENS WE, 1972, PATHOLOGY CEREBRAL B, P452; TEAL JS, 1973, J NEUROSURG, V38, P568, DOI 10.3171/jns.1973.38.5.0568; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163; WANG AN, 1986, SURG NEUROL, V25, P77, DOI 10.1016/0090-3019(86)90120-5	51	104	109	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1993	35	6					855	860		10.1097/00005373-199312000-00009			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	MP518	WOS:A1993MP51800009	8263982				2021-06-18	
J	LIEHLAI, MW; THEODOROU, AA; SARNAIK, AP; MEERT, KL; MOYLAN, PM; CANADY, AI				LIEHLAI, MW; THEODOROU, AA; SARNAIK, AP; MEERT, KL; MOYLAN, PM; CANADY, AI			LIMITATIONS OF THE GLASGOW COMA SCALE IN PREDICTING OUTCOME IN CHILDREN WITH TRAUMATIC BRAIN INJURY	JOURNAL OF PEDIATRICS			English	Article							CLOSED-HEAD-INJURY; MANAGEMENT	Objective: To study the hypothesis that, in the absence of an ischemic-hypoxic state, children with severe traumatic brain injury and with unfavorable Glasgow Coma Scale scores may have good recovery. Design: Retrospective, observational, cross-sectional study with factorial design. Setting: Inpatient population in a university hospital. Patients: Seventy-nine children with traumatic brain injury admitted to the intensive care unit. Interventions: All patients received close monitoring and strict control of intracranial pressure (< 20 mm Hg) and cerebral perfusion pressure (> 60 mm Hg). Measurements and results: Admission Glasgow Coma Scale score, survival, need for cardiopulmonary resuscitation, presence of shock, peak intracranial pressure, duration of coma, Glasgow Outcome Scale score, and the results of neuropsychologic tests were analyzed. Of 79 children, 70 (89%) survived. Although the mortality rate was higher among patients with Glasgow Coma Scale scores of 3 to 5,14 (64%) of 22 of these children survived. Nonsurvivors had a significantly higher incidence of shock and need for cardiopulmonary resuscitation. Except for two patients who had prolonged hypoxemia, all children, including those with Glasgow Coma Scale scores of 3 to 5, had a satisfactory outcome (Glasgow Outcome Scale scores of 4 or 5). Neuropsychologic outcome was not significantly different in the survivors with Glasgow Coma Scale scores of 3 to 5 and those with Glasgow Coma Scale scores of 6 or more. Conclusions: A low Glasgow Coma Scale score does not always accurately predict the outcome of severe traumatic brain injury; in the absence of hypoxic-ischemic injury, children with traumatic brain injury and Glasgow Coma Scale scores of 3 to 5 can recover independent function.	WAYNE STATE UNIV, CHILDRENS HOSP MICHIGAN, SCH MED, DIV PEDIAT NEUROSURG, DETROIT, MI 48201 USA	LIEHLAI, MW (corresponding author), WAYNE STATE UNIV, CHILDRENS HOSP MICHIGAN, SCH MED, DIV CRIT CARE MED, DETROIT, MI 48201 USA.						BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BIJUR PE, 1990, PEDIATRICS, V86, P337; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1979, CHILD BRAIN, V5, P174; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Gerring J P, 1986, Pediatr Rev, V8, P115, DOI 10.1542/pir.8-4-115; GIBSON RM, 1989, LANCET, V2, P369; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAYER T, 1981, CHILD BRAIN, V8, P189; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; SARNAIK AP, 1989, J TRAUMA, V29, P1434, DOI 10.1097/00005373-198910000-00023	19	104	105	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	FEB	1992	120	2	1				195	199		10.1016/S0022-3476(05)80426-3			5	Pediatrics	Pediatrics	HC901	WOS:A1992HC90100005	1735814				2021-06-18	
J	Mountjoy, M; Sundgot-Borgen, JK; Burke, LM; Ackerman, KE; Blauwet, C; Constantini, N; Lebrun, C; Lundy, B; Melin, AK; Meyer, NL; Sherman, RT; Tenforde, AS; Torstveit, MK; Budgett, R				Mountjoy, Margo; Sundgot-Borgen, Jorunn Kaiander; Burke, Louise M.; Ackerman, Kathryn E.; Blauwet, Cheri; Constantini, Naama; Lebrun, Constance; Lundy, Bronwen; Melin, Anna Katarina; Meyer, Nanna L.; Sherman, Roberta T.; Tenforde, Adam S.; Torstveit, Monica Klungland; Budgett, Richard			IOC consensus statement on relative energy deficiency in sport (RED-S): 2018 update	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						relative energy deficiency in sport (RED-S); low energy availability; female athlete triad; disordered eating; amenorrhea; low testosterone; low bone mineral density	FEMALE ATHLETE TRIAD; BONE-MINERAL DENSITY; FUNCTIONAL HYPOTHALAMIC AMENORRHEA; SPINAL-CORD-INJURY; CLINICAL-PRACTICE GUIDELINE; EATING-DISORDER SYMPTOMATOLOGY; RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; ELITE KENYAN RUNNERS; HIGH-SCHOOL COACHES		[Mountjoy, Margo] McMaster Univ, Michael G DeGroote Sch Med, Dept Family Med, Hamilton, ON N2G 1C5, Canada; [Sundgot-Borgen, Jorunn Kaiander] Norwegian Sch Sport Sci, Dept Sports Med, Oslo, Norway; [Burke, Louise M.; Lundy, Bronwen] Australian Inst Sport, Sports Nutr, Beclonnen, Australia; [Burke, Louise M.] Mary MacKillop Inst Hlth Res, Ctr Exercise & Nutr, Melbourne, Vic, Australia; [Ackerman, Kathryn E.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Ackerman, Kathryn E.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA; [Ackerman, Kathryn E.] Harvard Med Sch, Massachuetts Gen Hosp, Neuroendocrine Unit, Boston, MA USA; [Blauwet, Cheri] Harvard Med Sch, Spaulding Rehabil Hosp, Brigham & Womens Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Constantini, Naama] Hebrew Univ Jerusalem, Heidi Rothberg Sport Med Ctr, Shaare Zedek Med Ctr, Jerusalem, Israel; [Lebrun, Constance] Univ Alberta, Fac Med & Dent, Dept Family Med, Glen Sather Sports Med Clin, Edmonton, AB, Canada; [Melin, Anna Katarina] Univ Copenhagen, Dept Nutr Exercise & Sport, Frederiksberg, Denmark; [Meyer, Nanna L.] Univ Colorado, Hlth Sci Dept Colorado Springs, Denver, CO 80202 USA; [Tenforde, Adam S.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA; [Torstveit, Monica Klungland] Univ Agder, Fac Hlth & Sport Sci, Kristiansand, Norway; [Budgett, Richard] IOC Med & Sci Dept, Lausanne, Switzerland	Mountjoy, M (corresponding author), McMaster Univ, Michael G DeGroote Sch Med, Dept Family Med, Hamilton, ON N2G 1C5, Canada.	mmsportdoc@mcmaster.ca	Burke, Louise/X-3127-2019; Burke, Louise/ABC-5691-2020; Melin, Anna/E-5380-2017	Burke, Louise/0000-0001-8866-5637; Melin, Anna/0000-0002-8249-1311			Ackerman KE, 2015, MED SCI SPORT EXER, V47, P1577, DOI 10.1249/MSS.0000000000000574; Ackerman KE, 2012, BONE, V51, P680, DOI 10.1016/j.bone.2012.07.019; Ackerman KE, 2011, J CLIN ENDOCR METAB, V96, P3123, DOI 10.1210/jc.2011-1614; Ackerman KE, 2018, BR J SPORTS MED; Ackerman KE, 2017, TRANSDERMAL 17 ESTRA; Allaway HCM, 2016, HORM MOL BIOL CLIN I, V25, P91, DOI 10.1515/hmbci-2015-0053; American Academy of Family Physicians, 2010, PREP PHYS EV; Andreoli A, 2001, MED SCI SPORT EXER, V33, P507; Aparicio-Ugarriza R, 2015, NUTR HOSP, V31, P219, DOI 10.3305/nh.2015.31.sup3.8769; Arends JC, 2012, INT J SPORT NUTR EXE, V22, P98, DOI 10.1123/ijsnem.22.2.98; Areta JL, 2014, AM J PHYSIOL-ENDOC M, V306, pE989, DOI 10.1152/ajpendo.00590.2013; Arthur-Cameselle J, 2017, EAT DISORD, V25, P199, DOI 10.1080/10640266.2016.1258940; Arthur-Cameselle JN, 2014, EAT DISORD, V22, P50, DOI 10.1080/10640266.2014.857518; Bar RJ, 2016, EUR J SPORT SCI, V16, P325, DOI 10.1080/17461391.2015.1013995; Barrack MT, 2017, BRIT J SPORT MED, V51, P200, DOI 10.1136/bjsports-2016-096698; Barrack MT, 2014, AM J SPORT MED, V42, P949, DOI 10.1177/0363546513520295; Barrack MT, 2008, MED SCI SPORT EXER, V40, P2015, DOI 10.1249/MSS.0b013e3181822ea0; Barron E, 2016, J ACAD NUTR DIET, V116, P481, DOI 10.1016/j.jand.2015.10.022; Baskaran C, 2017, PSYCHIAT RES, V258, P605, DOI 10.1016/j.psychres.2016.12.054; Becker CB, 2012, BODY IMAGE, V9, P31, DOI 10.1016/j.bodyim.2011.09.005; Beis LY, 2011, J INT SOC SPORT NUTR, V8, DOI 10.1186/1550-2783-8-7; Berga SL, 2006, ANN NY ACAD SCI, V1092, P114, DOI 10.1196/annals.1365.010; Berkovich BE, 2016, INT J SPORT NUTR EXE, V26, P276, DOI 10.1123/ijsnem.2015-0196; Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354; BILANIN JE, 1989, MED SCI SPORT EXER, V21, P66, DOI 10.1249/00005768-198902000-00012; Blauwet CA, 2017, SPORTS MED, V47, P1697, DOI 10.1007/s40279-017-0696-0; Bomba M, 2007, FERTIL STERIL, V87, P876, DOI 10.1016/j.fertnstert.2006.09.011; Bomba M, 2014, EAT WEIGHT DISORD-ST, V19, P41, DOI 10.1007/s40519-013-0056-5; Brown KN, 2014, J PEDIATR ADOL GYNEC, V27, P278, DOI 10.1016/j.jpag.2013.11.014; Brown KN, 2016, WOMEN SPORT PHYS ACT, V24, P1, DOI [10. 1123/wspaj. 2014-0058, DOI 10.1123/WSPAJ.2014-0058]; Buchholz AC, 2004, CURR OPIN CLIN NUTR, V7, P635, DOI 10.1097/00075197-200411000-00008; Burden RJ, 2015, BRIT J SPORT MED, V49, P1389, DOI 10.1136/bjsports-2014-093624; Burke L., 2015, CLIN SPORTS NUTR, V5th; Burke LM, 2018, INT J SPORT NUTR EXE; Cialdella-Kam L, 2014, NUTRIENTS, V6, P3018, DOI 10.3390/nu6083018; Clausen L, 2013, INT J EAT DISORDER, V46, P755, DOI 10.1002/eat.22156; Cobb KL, 2007, MED SCI SPORT EXER, V39, P1464, DOI 10.1249/mss.0b013e318074e532; Colantonio A, 2010, J WOMENS HEALTH, V19, P1109, DOI 10.1089/jwh.2009.1740; Constantini N, 2011, IMS WORLD C SPORTS M; Crosland J., 2014, SPORTS NUTR PARALYMP, P91, DOI DOI 10.1201/B16375-6; Curry EJ, 2015, SPORTS MED-OPEN, V1, DOI 10.1186/s40798-015-0037-5; de Bruin AP, 2017, CURR OPIN PSYCHOL, V16, P148, DOI 10.1016/j.copsyc.2017.05.009; De Souza MJ, 2008, BONE, V43, P140, DOI 10.1016/j.bone.2008.03.013; De Souza MJ, 2007, APPETITE, V48, P359, DOI 10.1016/j.appet.2006.10.009; De Souza MJ, 2014, BRIT J SPORT MED, V48, P1461, DOI 10.1136/bjsports-2014-093958; De Souza MJ, 2014, BRIT J SPORT MED, V48, DOI 10.1136/bjsports-2013-093218; Drew M, 2018, BRIT J SPORT MED, V52, DOI 10.1136/bjsports-2017-098208; Drew MK, 2017, J SCI MED SPORT, V20, P745, DOI 10.1016/j.jsams.2017.02.010; DSM-V American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; Ducher G, 2011, SPORTS MED, V41, P587, DOI 10.2165/11588770-000000000-00000; Dueck CA, 1996, INT J SPORT NUTR, V6, P24, DOI 10.1123/ijsn.6.1.24; El Ghoch M, 2013, NUTRIENTS, V5, P5140, DOI 10.3390/nu5125140; Fagerberg P, 2018, INT J SPORT NUTR EXE, V28, P385, DOI 10.1123/ijsnem.2016-0332; Fairburn C., 2008, COGNITIVE BEHAV THER, DOI [10.1037/t03975-000, DOI 10.1037/T03975-000]; FAIRBURN CG, 1994, INT J EAT DISORDER, V16, P363; Fazeli PK, 2014, J CLIN ENDOCR METAB, V99, P1322, DOI 10.1210/jc.2013-4105; Fazeli PK, 2014, J ENDOCRINOL, V220, pR56, DOI 10.1530/JOE-13-0477; Feldmann JM, 2011, J PEDIATR ADOL GYNEC, V24, P311, DOI 10.1016/j.jpag.2011.05.011; FOGELHOLM M, 1994, SPORTS MED, V18, P249, DOI 10.2165/00007256-199418040-00004; Fredericson M, 2007, BRIT J SPORT MED, V41, P664, DOI 10.1136/bjsm.2006.030783; GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6; GARNER DM, 1979, PSYCHOL MED, V9, P273, DOI 10.1017/S0033291700030762; Gaskins AJ, 2009, AM J CLIN NUTR, V90, P1061, DOI 10.3945/ajcn.2009.27990; Geesmann B, 2017, INT J SPORT PHYSIOL, V12, P984, DOI 10.1123/ijspp.2016-0061; Gibbs JC, 2013, MED SCI SPORT EXER, V45, P985, DOI 10.1249/MSS.0b013e31827e1bdc; Gibbs JC, 2011, INT J SPORT NUTR EXE, V21, P280, DOI 10.1123/ijsnem.21.4.280; Giel KE, 2016, INT J EAT DISORDER, V49, P553, DOI 10.1002/eat.22511; Goktepe AS, 2004, AM J PHYS MED REHAB, V83, P279, DOI 10.1097/01.PHM.0000118036.20170.6C; Golden Neville H, 2016, Adolesc Med State Art Rev, V27, P125; GONZALEZ EG, 1974, ARCH PHYS MED REHAB, V55, P111; Gordon CM, 2017, J CLIN ENDOCR METAB, V102, P1413, DOI 10.1210/jc.2017-00131; Hackney A. C., 2005, Acta Physiologica Hungarica, V92, P121, DOI 10.1556/APhysiol.92.2005.2.3; HACKNEY AC, 1988, MED SCI SPORT EXER, V20, P60, DOI 10.1249/00005768-198802000-00009; Hagmar M, 2013, CLIN J SPORT MED, V23, P197, DOI 10.1097/JSM.0b013e31827a8809; Harber VJ, 1998, CAN J APPL PHYSIOL, V23, P293, DOI 10.1139/h98-017; Heikura IA, 2018, INT J SPORT NUTR EXE, V28, P403, DOI 10.1123/ijsnem.2017-0313; Hill LS, 2010, INT J EAT DISORDER, V43, P344, DOI 10.1002/eat.20679; Hind K, 2006, BONE, V39, P880, DOI 10.1016/j.bone.2006.03.012; Hinton PS, 2005, J AM COLL HEALTH, V54, P149, DOI 10.3200/JACH.54.3.149-156; Hoch Anne Z, 2007, WMJ, V106, P301; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Hooper DR, 2017, EUR J APPL PHYSIOL, V117, P1349, DOI 10.1007/s00421-017-3623-z; Ihle R, 2004, J BONE MINER RES, V19, P1231, DOI 10.1359/JBMR.040410; Iwamoto J, 2011, WORLD J ORTHOP, V2, P7, DOI 10.5312/wjo.v2.i1.7; Jasienska G, 2003, ACTA BIOTHEOR, V51, P1, DOI 10.1023/A:1023035321162; Joy E, 2016, BRIT J SPORT MED, V50, P154, DOI 10.1136/bjsports-2015-095735; Kilpela LS, 2016, INT J EAT DISORDER, V49, P591, DOI 10.1002/eat.22562; Kim BY, 2016, CLIN J SPORT MED, P26; Koehler K, 2017, EUR J CLIN NUTR, V71, P365, DOI 10.1038/ejcn.2016.203; Koehler K, 2016, J SPORT SCI, V34, P1921, DOI 10.1080/02640414.2016.1142109; Kong PL, 2015, J PSYCHOL, V149, P141, DOI 10.1080/00223980.2013.846291; Kopp-Woodroffe SA, 1999, INT J SPORT NUTR, V9, P70, DOI 10.1123/ijsn.9.1.70; Krempien JL, 2011, INT J SPORT NUTR EXE, V21, P417, DOI 10.1123/ijsnem.21.5.417; Krempien JL, 2012, EAT BEHAV, V13, P36, DOI 10.1016/j.eatbeh.2011.11.005; Krentz EM, 2013, SCAND J MED SCI SPOR, V23, P303, DOI 10.1111/j.1600-0838.2011.01380.x; Kroshus E, 2015, J SCH NURS, V31, P272, DOI 10.1177/1059840514563760; Kroshus E, 2014, EAT DISORD, V22, P193, DOI 10.1080/10640266.2013.874827; Lantzouni E, 2002, J ADOLESCENT HEALTH, V31, P162, DOI 10.1016/S1054-139X(02)00342-7; Lappe JM, 2001, OSTEOPOROSIS INT, V12, P35, DOI 10.1007/s001980170155; Laughlin GA, 1996, J CLIN ENDOCR METAB, V81, P4301, DOI 10.1210/jc.81.12.4301; Levine JA, 2005, PUBLIC HEALTH NUTR, V8, P1123, DOI 10.1079/PHN2005800; Lieberman JL, 2018, MED SCI SPORT EXER, V50, P551, DOI 10.1249/MSS.0000000000001451; Ljungqvist A, 2009, BRIT J SPORT MED, V43, P631, DOI 10.1136/bjsm.2009.064394; Logue D, 2018, SPORTS MED, V48, P73, DOI 10.1007/s40279-017-0790-3; Lopez LM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006033.pub5; Lopez LM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009849.pub3; LOUCKS AB, 1994, AM J PHYSIOL, V266, pR817; Loucks AB, 2003, J CLIN ENDOCR METAB, V88, P297, DOI 10.1210/jc.2002-020369; Loucks AB, 2007, SPORTS MED, V37, P348, DOI 10.2165/00007256-200737040-00019; Loucks AB, 2011, J SPORT SCI, V29, pS7, DOI 10.1080/02640414.2011.588958; MACCONNIE SE, 1986, NEW ENGL J MED, V315, P411, DOI 10.1056/NEJM198608143150702; Mallinson RJ, 2013, J INT SOC SPORT NUTR, V10, DOI 10.1186/1550-2783-10-34; Manore MM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040350; Marcus MD, 2001, FERTIL STERIL, V76, P310, DOI 10.1016/S0015-0282(01)01921-5; Martinsen M, 2010, BRIT J SPORT MED, V44, P70, DOI 10.1136/bjsm.2009.068668; Martinsen M, 2015, MED SCI SPORT EXER, V47, P1070, DOI 10.1249/MSS.0000000000000489; Martinsen M, 2014, MED SCI SPORT EXER, V46, P435, DOI 10.1249/MSS.0b013e3182a702fc; Martinsen M, 2013, MED SCI SPORT EXER, V45, P1188, DOI 10.1249/MSS.0b013e318281a939; MCCOLL EM, 1989, CLIN ENDOCRINOL, V31, P617, DOI 10.1111/j.1365-2265.1989.tb01286.x; McNulty KY, 2001, J AM DIET ASSOC, V101, P886, DOI 10.1016/S0002-8223(01)00218-8; Melin A, 2016, SCAND J MED SCI SPOR, V26, P1060, DOI 10.1111/sms.12516; Melin A, 2015, SCAND J MED SCI SPOR, V25, P610, DOI 10.1111/sms.12261; Melin A., 2015, CLIN SPORTS NUTR, P146; Melin A, 2014, BRIT J SPORT MED, V48, P540, DOI 10.1136/bjsports-2013-093240; Michopoulos V, 2013, FERTIL STERIL, V99, P2084, DOI 10.1016/j.fertnstert.2013.02.036; Miller SM, 2012, INT J SPORT NUTR EXE, V22, P131, DOI 10.1123/ijsnem.22.2.131; Misra M, 2014, HAND CLINIC, V124, P373, DOI 10.1016/B978-0-444-59602-4.00025-3; Misra M, 2011, J BONE MINER RES, V26, P2430, DOI 10.1002/jbmr.447; Modan-Moses D, 2003, PEDIATRICS, V111, P270, DOI 10.1542/peds.111.2.270; Modan-Moses D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045504; Mooses M, 2017, INT J SPORT PHYSIOL, V12, P422, DOI 10.1123/ijspp.2016-0408; Moreira CA, 2017, J CLIN ENDOCR METAB, V102, P525, DOI 10.1210/jc.2016-2720; Morel J, 2001, OSTEOPOROSIS INT, V12, P152, DOI 10.1007/s001980170148; Mountjoy M, 2018, BRIT J SPORT MED, V52, DOI 10.1136/bjsports-2017-097900; Mountjoy Margo, 2015, Br J Sports Med, V49, P421; Mountjoy M, 2015, BRIT J SPORT MED, V49, P417, DOI 10.1136/bjsports-2014-094371; Mountjoy M, 2014, BRIT J SPORT MED, V48, P491, DOI 10.1136/bjsports-2014-093502; Muia EN, 2016, J SPORT SCI, V34, P598, DOI 10.1080/02640414.2015.1065340; MUKESHI M, 1993, WORLD REV NUTR DIET, V72, P218; Mukherjee S, 2016, INT J SPORTS SCI COA, V11, P545, DOI 10.1177/1747954116654781; MYBURGH KH, 1990, ANN INTERN MED, V113, P754, DOI 10.7326/0003-4819-113-10-754; Nattiv Aurelia, 2007, Med Sci Sports Exerc, V39, P1867; Nichols JF, 2011, J STRENGTH COND RES, V25, P727, DOI 10.1519/JSC.0b013e3181c6a116; Nieves JW, 2010, PM&R, V2, P740, DOI 10.1016/j.pmrj.2010.04.020; Norris ML, 2016, INT J EAT DISORDER, V49, P216, DOI 10.1002/eat.22462; O'Donnell E, 2015, HYPERTENSION, V65, P1089, DOI 10.1161/HYPERTENSIONAHA.114.04976; O'Donnell E, 2011, J CLIN ENDOCR METAB, V96, P3638, DOI 10.1210/jc.2011-1223; Pantano KJ, 2017, J PEDIATR ADOL GYNEC, V30, P540, DOI 10.1016/j.jpag.2016.09.013; Pantano Kathleen J, 2006, N Am J Sports Phys Ther, V1, P195; Papageorgiou M, 2018, EUR J NUTR, V57, P847, DOI 10.1007/s00394-017-1498-8; Papageorgiou M, 2017, BONE, V105, P191, DOI 10.1016/j.bone.2017.08.019; Pernick Y, 2006, J ADOLESCENT HEALTH, V38, P689, DOI 10.1016/j.jadohealth.2005.07.003; Petkus DL, 2017, SPORTS MED, V47, P1721, DOI 10.1007/s40279-017-0706-2; Petrie T, 2014, PSYCHOL SPORT EXERC, V15, P680, DOI 10.1016/j.psychsport.2013.09.002; Volp ACP, 2011, NUTR HOSP, V26, P430, DOI [10.1590/S0212-16112011000300002, 10.3305/nh.2011.26.3.5181]; Plateau C. R., 2013, APPETITE, V71, P483, DOI [10.1016/j.appet.2013.06.052, DOI 10.1016/J.APPET.2013.06.052]; Plateau CR, 2017, EAT DISORD, V25, P273, DOI 10.1080/10640266.2016.1269551; Price M, 2010, SPORTS MED, V40, P681, DOI 10.2165/11531960-000000000-00000; Quah YV, 2009, ASIA PAC J CLIN NUTR, V18, P200; Ranganathan P, 2016, BRAIN INJURY, V30, P452, DOI 10.3109/02699052.2016.1144081; Rauh MJ, 2010, J ATHL TRAINING, V45, P243, DOI 10.4085/1062-6050-45.3.243; Reed JL, 2015, J INT SOC SPORT NUTR, V12, DOI 10.1186/s12970-015-0072-0; Reed JL, 2014, J SPORT SCI, V32, P1499, DOI 10.1080/02640414.2014.908321; Rhea DJ, 1999, J ADOLESCENCE, V22, P379, DOI 10.1006/jado.1999.0229; Rickenlund A, 2005, J CLIN ENDOCR METAB, V90, P1354, DOI 10.1210/jc.2004-1286; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; Ruohola JP, 2006, J BONE MINER RES, V21, P1483, DOI 10.1359/JBMR.060607; Sacheck JM, 2017, J CLIN ENDOCR METAB, V102, P4496, DOI 10.1210/jc.2017-01179; Sansone R. A., 2007, CLIN MANUAL EATING D, P79; Shanmugam V, 2014, SCAND J MED SCI SPOR, V24, P469, DOI 10.1111/sms.12109; Sherk V, 2008, J BONE MINER RES, V23, P1449, DOI 10.1359/JBMR.080402; Shimizu K, 2012, J STRENGTH COND RES, V26, P1402, DOI 10.1519/JSC.0b013e31822e7a6c; Silva MRG, 2016, EUR J SPORT SCI, V16, P726, DOI 10.1080/17461391.2015.1103316; Spaulding-Barclay MA, 2016, CARDIOL YOUNG, V26, P623, DOI 10.1017/S104795111500267X; Steiner H, 2003, CHILD PSYCHIAT HUM D, V34, P97, DOI 10.1023/A:1027389923666; Stewart AD, 2000, MED SCI SPORT EXER, V32, P1373, DOI 10.1097/00005768-200008000-00003; Stice E, 2012, J CLIN CHILD ADOLESC, V41, P845, DOI 10.1080/15374416.2012.728156; Stirling A, 2012, EUR J SPORT SCI, V12, P262, DOI 10.1080/17461391.2011.586437; Sundgot-Borgen J, 2004, CLIN J SPORT MED, V14, P25, DOI 10.1097/00042752-200401000-00005; SUNDGOTBORGEN J, 1993, INT J SPORT NUTR, V3, P29, DOI 10.1123/ijsn.3.1.29; SUNDGOTBORGEN J, 1994, MED SCI SPORT EXER, V26, P414; SYKORA C, 1993, INT J EAT DISORDER, V14, P203, DOI 10.1002/1098-108X(199309)14:2&lt;203::AID-EAT2260140210&gt;3.0.CO;2-V; Tam N, 2018, J SPORT SCI, V36, P456, DOI 10.1080/02640414.2017.1313998; Tarnopolsky MA, 2001, J APPL PHYSIOL, V91, P225; Temme KE, 2013, CURR SPORT MED REP, V12, P190, DOI 10.1249/JSR.0b013e318296190b; Temme KE, 2013, CLIN J SPORT MED, V23, P134; Tenforde AS, 2017, AM J SPORT MED, V45, P302, DOI 10.1177/0363546516676262; Tenforde AS, 2016, SPORTS MED, V46, P171, DOI 10.1007/s40279-015-0411-y; Tenforde AS, 2015, AM J SPORT MED, V43, P1494, DOI 10.1177/0363546515572142; Thein-Nissenbaum JM, 2014, SPORTS HEALTH, V6, P313, DOI 10.1177/1941738113498852; Thiemann P, 2015, EUR EAT DISORD REV, V23, P269, DOI 10.1002/erv.2360; Thompson RA, 2011, EATING DISORDERS SPO; Thralls KJ, 2016, INT J SPORT NUTR EXE, V26, P17, DOI 10.1123/ijsnem.2015-0072; Tornberg AB, 2017, MED SCI SPORT EXER, V49, P2478, DOI 10.1249/MSS.0000000000001383; Torres-McGehee TM, 2012, J ATHL TRAINING, V47, P205; Troy Kate, 2006, WMJ, V105, P21; U.S. Department of Agriculture Agricultural Research Service, 2011, USDA NAT NUTR DAT ST; US Department of Health and Human Services, 2015, 2015 2020 DIET GUID; Valliant MW, 2012, NUTRIENTS, V4, P506, DOI 10.3390/nu4060506; VanHeest JL, 2014, MED SCI SPORT EXER, V46, P156, DOI 10.1249/MSS.0b013e3182a32b72; Viner RT, 2015, INT J SPORT NUTR EXE, V25, P594, DOI 10.1123/ijsnem.2015-0073; Vo M, 2017, INT J EAT DISORDER, V50, P578, DOI 10.1002/eat.22628; Wade GN, 2004, AM J PHYSIOL-REG I, V287, pR1277, DOI 10.1152/ajpregu.00475.2004; Waters DL, 2001, J CLIN ENDOCR METAB, V86, P1013, DOI 10.1210/jc.86.3.1013; Williams NI, 2015, AM J PHYSIOL-ENDOC M, V308, pE29, DOI 10.1152/ajpendo.00386.2013; Wilson G, 2015, APPL PHYSIOL NUTR ME, V40, P1318, DOI 10.1139/apnm-2015-0354; Wilson G, 2014, J SPORT SCI, V32, P383, DOI 10.1080/02640414.2013.825732; Woods AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173807	208	103	103	5	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2018	52	11					687	697		10.1136/bjsports-2018-099193			11	Sport Sciences	Sport Sciences	GH2KX	WOS:000433231900001	29773536	Bronze	Y	N	2021-06-18	
J	Kumar, A; Stoica, BA; Loane, DJ; Yang, M; Abulwerdi, G; Khan, N; Kumar, A; Thom, SR; Faden, AI				Kumar, Alok; Stoica, Bogdan A.; Loane, David J.; Yang, Ming; Abulwerdi, Gelareh; Khan, Niaz; Kumar, Asit; Thom, Stephen R.; Faden, Alan I.			Microglial-derived microparticles mediate neuroinflammation after traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Microparticles; Microglia; Neuroinflammation; Traumatic brain injury; Interleukin-1 beta; miR-155	NANOPARTICLE TRACKING ANALYSIS; INDUCED NEUTROPHIL ACTIVATION; IMPROVES FUNCTIONAL RECOVERY; IN-VIVO; EXTRACELLULAR VESICLES; VASCULAR INJURY; PLATELET MICROPARTICLES; INFLAMMATORY RESPONSE; ALZHEIMERS-DISEASE; OXIDATIVE STRESS	Background: Local and systemic inflammatory responses are initiated early after traumatic brain injury (TBI), and may play a key role in the secondary injury processes resulting in neuronal loss and neurological deficits. However, the mechanisms responsible for the rapid expansion of neuroinflammation and its long-term progression have yet to be elucidated. Here, we investigate the role of microparticles (MP), a member of the extracellular vesicle family, in the exchange of pro-inflammatory molecules between brain immune cells, as well as their transfer to the systemic circulation, as key pathways of inflammation propagation following brain trauma. Methods: Adult male C57BL/6 mice were subjected to controlled cortical impact TBI for 24 h, and enriched MP were isolated in the blood, while neuroinflammation was assessed in the TBI cortex. MP were characterized by flow cytometry, and MP content was assayed using gene and protein markers for pro-inflammatory mediators. Enriched MP co-cultured with BV2 or primary microglial cells were used for immune propagation assays. Enriched MP from BV2 microglia or CD11b-positive microglia from the TBI brain were stereotactically injected into the cortex of uninjured mice to evaluate MP-related seeding of neuroinflammation in vivo. Results: As the neuroinflammatory response is developing in the brain after TBI, microglial-derived MP are released into the circulation. Circulating enriched MP from the TBI animals can activate microglia in vitro. Lipopolysaccharide stimulation increases MP release from microglia in vitro and enhances their content of pro-inflammatory mediators, interleukin-1 beta and microRNA-155. Enriched MP from activated microglia in vitro or CD11b-isolated microglia/macrophage from the TBI brain ex vivo are sufficient to initiate neuroinflammation following their injection into the cortex of naive (uninjured) animals. Conclusions: These data provide further insights into the mechanisms underlying the development and dissemination of neuroinflammation after TBI. MP loaded with pro-inflammatory molecules initially released by microglia following trauma can activate additional microglia that may contribute to progressive neuroinflammatory response in the injured brain, as well as stimulate systemic immune responses. Due to their ability to independently initiate inflammatory responses, MP derived from activated microglia may provide a potential target for other neurological disorders in which neuroinflammation may be a contributing factor.	[Kumar, Alok; Stoica, Bogdan A.; Loane, David J.; Abulwerdi, Gelareh; Khan, Niaz; Kumar, Asit; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Kumar, Alok; Stoica, Bogdan A.; Loane, David J.; Abulwerdi, Gelareh; Khan, Niaz; Kumar, Asit; Faden, Alan I.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Hlth Sci Facil 2, S247 20 Penn St, Baltimore, MD 21201 USA; [Yang, Ming; Thom, Stephen R.] Univ Maryland, Sch Med, Dept Emergency Med, Baltimore, MD 21201 USA	Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.; Faden, AI (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Hlth Sci Facil 2, S247 20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	Kumar, Asit/AAG-3916-2021; STOICA, BOGDAN/H-9782-2013	Kumar, Asit/0000-0003-1735-7033; STOICA, BOGDAN/0000-0002-2501-6434; Faden, Alan I./0000-0003-0128-2348; Vinueza, Gelareh/0000-0002-1036-6378; Loane, David/0000-0003-0393-3503	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568, R01NS037313, R01NS082308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052568, R01 NS082308, R01 NS037313] Funding Source: Medline		An K, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-47; Andrews AM, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00043; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Basso M, 2013, J BIOL CHEM, V288, P15699, DOI 10.1074/jbc.M112.425066; Bhullar J, 2016, FREE RADICAL BIO MED, V101, P154, DOI 10.1016/j.freeradbiomed.2016.10.010; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Bohman LE, 2016, J NEUROTRAUM, V33, P168, DOI 10.1089/neu.2015.3885; Burnier L, 2009, THROMB HAEMOSTASIS, V101, P439, DOI 10.1160/TH08-08-0521; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Pena-Philippides JC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0753-x; Castro-Seoane R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002538; Chan HC, 2013, BLOOD, V122, P3632, DOI 10.1182/blood-2013-05-504639; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davizon P, 2010, SEMIN THROMB HEMOST, V36, P857, DOI 10.1055/s-0030-1267039; Dinkins MB, 2014, NEUROBIOL AGING, V35, P1792, DOI 10.1016/j.neurobiolaging.2014.02.012; Dragovic RA, 2011, NANOMED-NANOTECHNOL, V7, P780, DOI 10.1016/j.nano.2011.04.003; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; French SL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165565; Gachet C, 2012, PURINERG SIGNAL, V8, P609, DOI 10.1007/s11302-012-9303-x; Grad LI, 2015, NEUROBIOL DIS, V77, P257, DOI 10.1016/j.nbd.2015.02.009; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Klohn PC, 2013, J INFECTION, V67, P359, DOI 10.1016/j.jinf.2013.07.024; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lawrie AS, 2009, VOX SANG, V96, P206, DOI 10.1111/j.1423-0410.2008.01151.x; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mause SF, 2010, CIRCULATION, V122, P495, DOI 10.1161/CIRCULATIONAHA.109.909473; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Nie DM, 2016, AM J PHYSIOL-CELL PH, V310, pC821, DOI 10.1152/ajpcell.00372.2015; Oosthuyzen W, 2013, J PHYSIOL-LONDON, V591, P5833, DOI 10.1113/jphysiol.2013.264069; Perez-Pujol S, 2007, CYTOM PART A, V71A, P38, DOI 10.1002/cyto.a.20354; Porro C, 2013, J CYST FIBROS, V12, P721, DOI 10.1016/j.jcf.2013.03.002; Qu Y, 2009, J IMMUNOL, V182, P5052, DOI 10.4049/jimmunol.0802968; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Rozmyslowicz T, 2003, AIDS, V17, P33, DOI 10.1097/00002030-200301030-00006; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; Su W, 2016, BRAIN BEHAV IMMUN, V52, P1, DOI 10.1016/j.bbi.2015.07.003; Takeshita J, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000507; Thom SR, 2014, J BIOL CHEM, V289, P18831, DOI 10.1074/jbc.M113.543702; Thom SR, 2013, J APPL PHYSIOL, V114, P550, DOI 10.1152/japplphysiol.01386.2012; Thom SR, 2011, J APPL PHYSIOL, V110, P340, DOI 10.1152/japplphysiol.00811.2010; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Verderio C, 2012, ANN NEUROL, V72, P610, DOI 10.1002/ana.23627; Xu JJ, 2013, TOXICOL APPL PHARM, V273, P410, DOI 10.1016/j.taap.2013.09.019; Yang M, 2015, J APPL PHYSIOL, V119, P219, DOI 10.1152/japplphysiol.00384.2015; Yang M, 2015, J APPL PHYSIOL, V119, P77, DOI 10.1152/japplphysiol.00183.2015; Yang M, 2013, J APPL PHYSIOL, V115, P1481, DOI 10.1152/japplphysiol.00745.2013; Yuyama K, 2014, J BIOL CHEM, V289, P24488, DOI 10.1074/jbc.M114.577213; Zappulli V, 2016, J CLIN INVEST, V126, P1198, DOI 10.1172/JCI81134; Zhang YQ, 2016, J MOL CELL BIOL, V8, P505, DOI 10.1093/jmcb/mjw040	64	103	105	0	21	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 15	2017	14								47	10.1186/s12974-017-0819-4			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	EP1NK	WOS:000397151400001	28292310	DOAJ Gold, Green Published			2021-06-18	
J	Pollack, MM; Holubkov, R; Funai, T; Berger, JT; Clark, AE; Meert, K; Berg, RA; Carcillo, J; Wessel, DL; Moler, F; Dalton, H; Newth, CJL; Shanley, T; Harrison, RE; Doctor, A; Jenkins, TL; Tamburro, R; Dean, JM				Pollack, Murray M.; Holubkov, Richard; Funai, Tomohiko; Berger, John T.; Clark, Amy E.; Meert, Kathleen; Berg, Robert A.; Carcillo, Joseph; Wessel, David L.; Moler, Frank; Dalton, Heidi; Newth, Christopher J. L.; Shanley, Thomas; Harrison, Rick E.; Doctor, Allan; Jenkins, Tammara L.; Tamburro, Robert; Dean, J. Michael		Eunice Kennedy Shriver Natl Inst C	Simultaneous Prediction of New Morbidity, Mortality, and Survival Without New Morbidity From Pediatric Intensive Care: A New Paradigm for Outcomes Assessment	CRITICAL CARE MEDICINE			English	Article						critical care; functional status; functional status score; intensive care; morbidity; outcome prediction; pediatric critical care; pediatric intensive care; pediatrics; severity of illness	CHRONIC HEALTH EVALUATION; MULTIPLE ORGAN DYSFUNCTION; NEONATAL ACUTE PHYSIOLOGY; HOSPITAL-WIDE MORTALITY; FUNCTIONAL STATUS SCALE; CRITICALLY-ILL PATIENTS; VERMONT OXFORD NETWORK; TRAUMATIC BRAIN-INJURY; CARDIAC-ARREST; PERFORMANCE CATEGORY	Objectives: Assessments of care including quality assessments adjusted for physiological status should include the development of new morbidities as well as mortalities. We hypothesized that morbidity, like mortality, is associated with physiological dysfunction and could be predicted simultaneously with mortality. Design: Prospective cohort study from December 4, 2011, to April 7, 2013. Setting: General and cardiac/cardiovascular PICUs at seven sites. Patients: Randomly selected PICU patients from their first PICU admission. Interventions: None. Measurements and Main Results: Among 10,078 admissions, the unadjusted morbidity rates (measured with the Functional Status Scale and defined as an increase of >= 3 from preillness to hospital discharge) were 4.6% (site range, 2.6-7.7%) and unadjusted mortality rates were 2.7% (site range, 1.3-5.0%). Morbidity and mortality were significantly (p < 0.001) associated with physiological instability (measured with the Pediatric Risk of Mortality III score) in dichotomous (survival and death) and trichotomous (survival without new morbidity, survival with new morbidity, and death) models without covariate adjustments. Morbidity risk increased with increasing Pediatric Risk of Mortality III scores and then decreased at the highest Pediatric Risk of Mortality III values as potential morbidities became mortalities. The trichotomous model with covariate adjustments included age, admission source, diagnostic factors, baseline Functional Status Scale, and the Pediatric Risk of Mortality III score. The three-level goodness-of-fit test indicated satisfactory performance for the derivation and validation sets (p > 0.20). Predictive ability assessed with the volume under the surface was 0.50 +/- 0.019 (derivation) and 0.50 +/- 0.034 (validation) (vs chance performance = 0.17). Site-level standardized morbidity ratios were more variable than standardized mortality ratios. Conclusions: New morbidities were associated with physiological status and can be modeled simultaneously with mortality. Trichotomous outcome models including both morbidity and mortality based on physiological status are suitable for research studies and quality and other outcome assessments. This approach may be applicable to other assessments presently based only on mortality.	[Pollack, Murray M.; Berger, John T.; Wessel, David L.] Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA; [Pollack, Murray M.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Pollack, Murray M.; Dalton, Heidi] Phoenix Childrens Hosp, Dept Child Hlth, Phoenix, AZ USA; [Pollack, Murray M.] Univ Arizona, Sch Med, Phoenix, AZ USA; [Holubkov, Richard; Funai, Tomohiko; Clark, Amy E.; Dean, J. Michael] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; [Meert, Kathleen] Childrens Hosp Michigan, Dept Pediat, Washington, DC USA; [Berg, Robert A.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Carcillo, Joseph] Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Moler, Frank; Shanley, Thomas] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Dalton, Heidi] Univ Arizona, Coll Med, Phoenix, AZ USA; [Newth, Christopher J. L.] Childrens Hosp Los Angeles, Dept Anesthesiol & Crit Care Med, Los Angeles, CA 90027 USA; [Harrison, Rick E.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Doctor, Allan] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Doctor, Allan] Washington Univ, Sch Med, Dept Biochem, St Louis, MO 63110 USA; [Jenkins, Tammara L.; Tamburro, Robert] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Trauma & Crit Illness Branch, NIH, Bethesda, MD USA	Pollack, MM (corresponding author), Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA.	mpollack@childrensnational.org		Holubkov, Richard/0000-0003-0431-3381; Shanley, Thomas/0000-0001-8936-377X	Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human ServicesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD050096, U10HD049981, U10HD049983, U10HD050012, U10HD063108, U10HD063106, U10HD063114, U01HD049934]; National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Association for Pediatric Pulmonary Hypertension; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); NIH/NICHD (Collaborative Pediatric Critical Care Research Network); NICHD (Collaborative Pediatric Critical Care Research Network [CPCCRN] grant); NIH (Clinical and Translational Science Award grant); NICHD (CPCCRN grant); NIH (CPCCRN); NIH (Therapeutic Hypothermia for Pediatric Cardiac Arrest); American Hospital Association; Children's Discovery Institute; U.S. Food and Drug Administration Office of Orphan Product Development Grant; Health Services and Resources Administration; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [UG1HD063108, UG1HD049983, U10HD050096, U10HD063108, U01HD049934, U10HD050012, UG1HD050096, U10HD063114, UG1HD050012, U10HD049983, U10HD063106, U10HD049981, UG1HD049981] Funding Source: NIH RePORTER	Supported, in part, by the following cooperative agreements from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services: U10HD050096, U10HD049981, U10HD049983, U10HD050012, U10HD063108, U10HD063106, U10HD063114, and U01HD049934.; Dr. Pollack received grant support from the National Institute of Child Health and Human Development (NICHD), has planned patents through Children's National Medical Center (his not-for-profit employer), and received support for article research from the National Institutes of Health (NIH). Dr. Holubkov served as a board member for Pfizer, the National Burn Association, and Fibrocell (Data Safety Board Membership); consulted for St. Jude Medical, Physicians Committee for Responsible Medicine, and Covidien (Biostatistical Consulting); received support for article research from the NIH. Dr. Holubkov and his institution received grant support (Salary support [biostatistician]) and support for travel (Steering Committee Meeting Travel) from the NIH. Dr. Funai received support for article research from the NIH. Dr. Funai and his institution received grant support from the NIH (salaries support Biostatistician). Dr. Berger received support for article research from the NIH. His institution received grant support from the NIH and the Association for Pediatric Pulmonary Hypertension. Dr. Clark received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Meert received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Berg received grant support from the NICHD and received support for article research from the NIH. Dr. Carcillo received support for article research from the NIH. His institution received grant support and support for travel. Dr. Wessel received support for article research from the NIH. His institution received grant support from the NIH (ongoing). Dr. Moler received support for article research from the NIH. His institution received grant support and support for travel from the NICHD. Dr. Dalton lectured for rEVO Biologics, received royalties from the Society of Critical Care Medicine (SCCM) for Pediatric Multidisciplinary Board Review Book, and received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Newth received support for article research from the NIH. His institution received grant support from the NIH/NICHD (Collaborative Pediatric Critical Care Research Network). Dr. Shanley received support for article research from the NIH and served as a board member for International Pediatric Research Foundation (Society for Pediatric Research Representative on Executive Committee). His institution received grant support from the NICHD (Collaborative Pediatric Critical Care Research Network [CPCCRN] grant) and the NIH (Clinical and Translational Science Award grant) and received support for travel from the NICHD (CPCCRN grant). Dr. Harrison lectured for the SCCM (board review lectures for my professional society) and received support for article research from the NIH. His institution received grant support from the NIH (CPCCRN funding and Therapeutic Hypothermia for Pediatric Cardiac Arrest trial funding via NIH). Dr. Doctor consulted for the NICHD/CPCCRN (honorarium to serve as Steering Committee chairperson), Terumo, BCT, iNO Therapeutics, Novartis, and Galleon Pharmaceuticals; received support for travel from the NICHD/CPCCRN; and lectured for Terumo, BCT. His institution received grant support from the NIH, the American Hospital Association, and the Children's Discovery Institute. Dr. Jenkins received support for article research from the NIH and disclosed government work. Dr. Tamburro received grant support from the U.S.; Food and Drug Administration Office of Orphan Product Development Grant to study calfactant in pediatric stem cell transplant patients (No longer co-principal investigator on the trial secondary to accepting a new position), received royalties from Springer Publisher (received royalties for serving as an associate editor on a pediatric critical care textbook and study guide), received support for article research from the NIH, and disclosed government work. Dr. Dean received support for article research from the NIH. His institution received grant support from the NIH and Health Services and Resources Administration.	Black N, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2066; Borzecki AM, 2010, MED CARE, V48, P1117, DOI 10.1097/MLR.0b013e3181ef9d53; Borzecki AM, 2010, MED CARE, V48, P694, DOI 10.1097/MLR.0b013e3181e419e3; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Burstein DS, 2011, PEDIATRICS, V127, pE1482, DOI 10.1542/peds.2010-2796; Checkley W, 2014, CRIT CARE MED, V42, P344, DOI 10.1097/CCM.0b013e3182a275d7; Cook R, 2001, CRIT CARE MED, V29, P2046, DOI 10.1097/00003246-200111000-00002; Cook SF, 2002, CRIT CARE MED, V30, P2765, DOI 10.1097/00003246-200212000-00024; Daily OP, 2004, TRANSPLANTATION, V77, P1309, DOI 10.1097/01.TP.0000120943.94789.E4; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Donnino MW, 2013, RESUSCITATION, V84, P651, DOI 10.1016/j.resuscitation.2012.10.024; Elixhauser A, 2005, JT COMM J QUAL PATIE, V31, P533, DOI 10.1016/S1553-7250(05)31069-5; Fagerland MW, 2008, STAT MED, V27, P4238, DOI 10.1002/sim.3202; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Forthman M Thane, 2010, Qual Manag Health Care, V19, P265, DOI 10.1097/QMH.0b013e3181eb143d; Graf J, 2003, CRIT CARE MED, V31, P2163, DOI 10.1097/01.CCM.0000079607.87009.3A; Horbar JD, 2012, PEDIATRICS, V129, P1019, DOI 10.1542/peds.2011-3028; Horbar JD, 2010, CLIN PERINATOL, V37, P29, DOI 10.1016/j.clp.2010.01.003; Hussey PS, 2013, JT COMM J QUAL PATIE, V39, P177, DOI 10.1016/S1553-7250(13)39024-2; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kerlin MP, 2013, NEW ENGL J MED, V368, P2201, DOI 10.1056/NEJMoa1302854; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Knoester H, 2008, INTENS CARE MED, V34, P1076, DOI 10.1007/s00134-008-1061-4; Kramer AA, 2014, CRIT CARE MED, V42, P544, DOI 10.1097/CCM.0b013e3182a66a49; LEGALL JR, 1984, CRIT CARE MED, V12, P975; Li JL, 2008, BIOSTATISTICS, V9, P566, DOI 10.1093/biostatistics/kxm050; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marshall JC, 2005, CRIT CARE MED, V33, P1708, DOI 10.1097/01.CCM.0000174478.70338.03; Mayr VD, 2006, CRIT CARE, V10, DOI 10.1186/cc5086; Mentzelopoulos SD, 2013, JAMA-J AM MED ASSOC, V310, P270, DOI 10.1001/jama.2013.7832; Mossman D, 1999, MED DECIS MAKING, V19, P78, DOI 10.1177/0272989X9901900110; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Ferreira AMP, 2011, SEMIN RESP CRIT CARE, V32, P543, DOI 10.1055/s-0031-1287862; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Pollack MM, 2014, PEDIATR CRIT CARE ME, V15, P821, DOI 10.1097/PCC.0000000000000250; Pollack MM, 2014, JAMA PEDIATR, V168, P671, DOI 10.1001/jamapediatrics.2013.5316; Pollack MM, 2013, PEDIATR CRIT CARE ME, V14, P448, DOI 10.1097/PCC.0b013e31828a7270; Pollack MM, 2009, PEDIATRICS, V124, pE18, DOI 10.1542/peds.2008-1987; Proulx F, 2009, PEDIATR CRIT CARE ME, V10, P12, DOI 10.1097/PCC.0b013e31819370a9; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Shahian DM, 2012, AM J MED QUAL, V27, P112, DOI 10.1177/1062860611412358; Shahian DM, 2010, NEW ENGL J MED, V363, P2530, DOI 10.1056/NEJMsa1006396; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Shann F, 1997, INTENS CARE MED, V23, P201, DOI 10.1007/s001340050317; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; Stausberg Jurgen, 2011, Qual Manag Health Care, V20, P198, DOI 10.1097/QMH.0b013e318223d00a; TERES D, 1987, CRIT CARE MED, V15, P208, DOI 10.1097/00003246-198703000-00005; Waegeman W, 2008, PATTERN RECOGN LETT, V29, P1, DOI 10.1016/j.patrec.2007.07.019; Wetzel RC, 2001, PEDIATR CLIN N AM, V48, P795, DOI 10.1016/S0031-3955(05)70340-0; WILKINSON JD, 1986, CRIT CARE MED, V14, P271, DOI 10.1097/00003246-198604000-00002; Willson DF, 2010, PEDIATR CRIT CARE ME, V11, P1, DOI 10.1097/PCC.0b013e3181c01302; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0; Zupancic JAF, 2007, PEDIATRICS, V119, pE156, DOI 10.1542/peds.2005-2957	58	103	106	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2015	43	8					1699	1709		10.1097/CCM.0000000000001081			11	Critical Care Medicine	General & Internal Medicine	DC5JA	WOS:000369256100036	25985385	Green Accepted			2021-06-18	
J	Togher, L; Wiseman-Hakes, C; Douglas, J; Stergiou-Kita, M; Ponsford, J; Teasell, R; Bayley, M; Turkstra, LS				Togher, Leanne; Wiseman-Hakes, Catherine; Douglas, Jacinta; Stergiou-Kita, Mary; Ponsford, Jennie; Teasell, Robert; Bayley, Mark; Turkstra, Lyn S.		INCOG Expert Panel	INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part IV: Cognitive Communication	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive communication; cognitive rehabilitation; guidelines; rehabilitation; traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; PRACTICE GUIDELINES; REHABILITATION; PEOPLE; DEFICITS; INDIVIDUALS; DISCOURSE; ADULTS; SKILLS; CONVERSATIONS	Introduction: Cognitive-communication disorders are common in individuals with traumatic brain injury (TBI) and can have a major impact on long-term outcome. Guidelines for evidence-informed rehabilitation are needed, thus an international group of researchers and clinicians (known as INCOG) convened to develop recommendations for assessment and intervention. Methods: An expert panel met to select appropriate recommendations for assessment and treatment of cognitive-communication disorders based on available literature. To promote implementation, the team developed decision algorithms incorporating the recommendations, based on inclusion and exclusion criteria of published trials, and then prioritized recommendations for implementation and developed audit criteria to evaluate adherence to best practice recommendations. Results: Rehabilitation of individuals with cognitive-communication disorders should consider premorbid communication status; be individualized to the person's needs, goals, and skills; provide training in use of assistive technology where appropriate; include training of communication partners; and occur in context to minimize the need for generalization. Evidence supports treatment of social communication problems in a group format. Conclusion: There is strong evidence for person-centered treatment of cognitive-communication disorders and use of instructional strategies such as errorless learning, metacognitive strategy training, and group treatment. Future studies should include tests of alternative service delivery models and development of participation-level outcome measures.	[Togher, Leanne] Univ Sydney, Fac Hlth Sci, Lidcombe, NSW, Australia; [Wiseman-Hakes, Catherine] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Douglas, Jacinta] La Trobe Univ, Dept Human Commun Sci, Bundoora, Vic 3086, Australia; [Stergiou-Kita, Mary] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [Teasell, Robert] Parkwood Hosp, Lawson Hlth Res Inst, Aging Rehabil & Geriatr Care Program, London, ON, Canada; [Teasell, Robert] Univ Western Ontario, Schulich Sch Med, Dept Phys Med & Rehabil, London, ON, Canada; [Bayley, Mark] Univ Toronto, UHN Toronto Rehabil Inst, Toronto, ON, Canada; [Bayley, Mark] Univ Toronto, Div Phys Med & Rehabil, Toronto, ON, Canada; [Turkstra, Lyn S.] Univ Wisconsin Madison, Dept Commun Sci & Disorders, Madison, WI USA	Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, Rm 155,75 East St, Lidcombe, NSW, Australia.	Leanne.togher@sydney.edu.au	Wiseman-Hakes, Catherine/AAC-8303-2021; Togher, Leanne/AAC-7083-2019	Wiseman-Hakes, Catherine/0000-0001-8441-884X; Togher, Leanne/0000-0002-4518-6748; Douglas, Jacinta/0000-0003-0940-6624; Bayley, Mark/0000-0001-7860-9463	Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University; Ontario Neurotrauma Foundation (ONF)	The authors gratefully acknowledge the support of the Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University, and the Ontario Neurotrauma Foundation (ONF) for their support of this project.	ABIKUS Guideline Development Group, 2007, ABIKUS EV BAS REC RE; American Speech-Language-Hearing Association, 2004, ROL SPEECH LANG PATH; [Anonymous], 2014, AGREE ADV SCI PRACT; BALANDIN S, 1998, AUGMENTATIVE ALTERNA, V14, P239, DOI DOI 10.1080/07434619812331278416; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Behn N, 2012, BRAIN INJURY, V26, P1702, DOI 10.3109/02699052.2012.722258; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bogart E, 2012, BRAIN INJURY, V26, P221, DOI 10.3109/02699052.2011.648711; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Campbell L, 2002, ADV SPEECH LANG PATH, V4, P89; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; College of Audiologists and Speech-Language Pathologists of On- tario, 2002, PREF PRACT GUID COGN; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Deruyter F, 1988, J HEAD TRAUMA REHAB, V3, P35; DeRuyter F, 1991, COMMUNICATION DISORD, P317; Douglas JM, 2010, BRAIN IMPAIR, V11, P171, DOI 10.1375/brim.11.2.171; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Doyle M, 2000, AUG ALTER COMMUN SER, P271; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Fager S, 2006, AUGMENT ALTERN COMM, V22, P37, DOI 10.1080/07434610500243990; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Fried-Oken M, 1992, J HEAD TRAUMA REHAB, V7, P59, DOI DOI 10.1097/00001199-199209000-00008; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Golper L, 2001, ACAD NEUROL COMMUN D; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Holland A., 1982, CLIN APH P C, P345; Hoofien D, 2001, BRAIN INJURY, V15, P189; Ivers N, 2012, COCHRANE DATABASE SY, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Katz R, 2002, J MED SPEECH-LANG PA, V10, pix; Kertesz A., 2006, W APHASIA BATTERY RE; Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; Larkins BM, 2004, BRAIN INJURY, V18, P691, DOI 10.1080/02699050310001617389; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; MacDonald S, 1998, FUNCTIONAL ASSESSMEN; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; McDonald S, 2013, NEUROPSYCHOL REHABIL, V23, P267, DOI 10.1080/09602011.2012.751340; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; Milton S. B., 1986, CLIN NEUROPSYCHOLOGY, P223, DOI [10.1007/978-1-4613-2291-7_11, DOI 10.1007/978-1-4613-2291-7_11]; New Zealand Guidelines Group, 2006, GUIDE, P244; Ownsworth T, 2008, J REHABIL MED, V40, P81, DOI 10.2340/16501977-0124; Parente R, 1999, NEUROREHABILITATION, V13, P13; Powell LE, 2012, NEUROPSYCHOL REHABIL, V22, P85, DOI 10.1080/09602011.2011.640466; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Rietdijk R, 2013, BRAIN INJURY, V27, P812, DOI 10.3109/02699052.2013.775491; Rietdijk R, 2012, J REHABIL MED, V44, P913, DOI 10.2340/16501977-1058; Rosewilliam S, 2011, CLIN REHABIL, V25, P501, DOI 10.1177/0269215510394467; *ROY COLL PHYS, 2003, REH FOLL ACQ BRAIN I; Russell A, 1995, AUGMENTATIVE ALTERNA, V11, P138; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Schrijnemaekers AC, 2014, J HEAD TRAUMA REHAB, V29, pE9, DOI 10.1097/01.HTR.0000438117.63852.b4; Snow P, 1997, BRAIN INJURY, V11, P409; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; Sohlberg MM., 2011, OPTIMIZING COGNITIVE; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; The ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Togher L, 2013, J REHABIL MED, V45, P637, DOI 10.2340/16501977-1173; Togher L, 2009, BRAIN IMPAIR, V10, P188, DOI 10.1375/brim.10.2.188; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra Lyn S, 2005, Semin Speech Lang, V26, P213, DOI 10.1055/s-2005-922100; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Turner BJ, 2008, AUST OCCUP THER J, V55, P96, DOI 10.1111/j.1440-1630.2007.00660.x; Valitchka L, 2013, SEMIN SPEECH LANG, V34, P142, DOI 10.1055/s-0033-1358371; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	87	103	104	0	43	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					353	368		10.1097/HTR.0000000000000071			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300011	24984097				2021-06-18	
J	Maegele, M; Schochl, H; Cohen, MJ				Maegele, Marc; Schoechl, Herbert; Cohen, Mitchell J.			AN UPDATE ON THE COAGULOPATHY OF TRAUMA	SHOCK			English	Article						Trauma; hemorrhage; coagulopathy; mechanisms	ENDOTHELIAL GLYCOCALYX DEGRADATION; PROTEIN-C; PLATELET DYSFUNCTION; GLOBAL BURDEN; FACTOR VIIA; INJURY; TEMPERATURE; HYPOTHERMIA; DEATH; HYPERFIBRINOLYSIS	Trauma remains the leading cause of death with bleeding as the primary cause of preventable mortality during the first 24 h following trauma. When death occurs, it happens quickly, typically within the first 6 h after injury. One of four patients to arrive in the emergency department after trauma is already in the state of acute traumatic coagulopathy and shock. The principal drivers of acute traumatic coagulopathy have been characterized by tissue hypoperfusion, inflammation, and the acute activation of the neurohumoral system. Hypoperfusion leads to an activation of protein C with cleavage of activated factors V and VIII and the inhibition of plasminogen activator inhibitor 1 with subsequent hyperfibrinolysis. Endothelial damage and activation result in Weibel-Palade body degradation and glycocalyx shedding associated with autoheparinization. In contrast, there is an iatrogenic coagulopathy that occurs secondary to uncritical volume therapy leading to acidosis, hypothermia, and hemodilution. This coagulopathy then may be an integral part of the "vicious cycle" when combined with acidosis and hypothermia. The present article summarizes an update on the principal mechanisms and triggers of the coagulopathy of trauma including traumatic brain injury.	[Maegele, Marc] Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Traumatol Orthoped Surg & Sportsmed, D-51109 Cologne, Germany; [Maegele, Marc] Univ Witten Herdecke, Inst Res Operat Med, D-51109 Cologne, Germany; [Schoechl, Herbert] Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria; [Schoechl, Herbert] AUVA Trauma Hosp, Dept Anaesthesiol & Intens Care, Salzburg, Austria; [Cohen, Mitchell J.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA	Maegele, M (corresponding author), Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Traumatol Orthoped Surg & Sportsmed, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de					BELLAMY RF, 1984, MIL MED, V149, P55; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESPOSITO TJ, 1995, J TRAUMA, V39, P955, DOI 10.1097/00005373-199511000-00022; Floccard B, 2012, INJURY, V43, P26, DOI 10.1016/j.injury.2010.11.003; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Gonzalez E, 2006, SHOCK, V25, P88, DOI 10.1097/00024382-200606001-00264; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Hoyt DB, 2004, SEMIN HEMATOL, V41, P40, DOI 10.1053/j.seminhematol.2003.11.009; Ives C, 2012, J AM COLL SURGEONS, V215, P496, DOI 10.1016/j.jamcollsurg.2012.06.005; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Kermode JC, 1999, BLOOD, V94, P199, DOI 10.1182/blood.V94.1.199.413k14_199_207; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P1389, DOI 10.1097/TA.0b013e318270d595; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P87, DOI 10.1097/TA.0b013e3182598c70; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2006, SHOCK, V25, P56, DOI 10.1097/00024382-200606001-00170; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Maegele M, 2012, SHOCK, V38, P450, DOI 10.1097/SHK.0b013e31826dbd23; Martini WZ, 2009, J TRAUMA, V67, P202, DOI 10.1097/TA.0b013e3181a602a7; Meng ZH, 2003, J TRAUMA, V55, P886, DOI 10.1097/01.TA.0000066184.20808.A5; Monroe DM, 2008, THROMB RES, V122, pS7, DOI 10.1016/S0049-3848(08)70010-0; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nieuwdorp M, 2005, CURR OPIN LIPIDOL, V16, P507, DOI 10.1097/01.mol.0000181325.08926.9c; Noel P, 2013, SEMIN HEMATOL, V50, P259, DOI 10.1053/j.seminhematol.2013.06.009; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Raza I, 2013, J THROMB HAEMOST, V11, P307, DOI 10.1111/jth.12078; Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852; Rezaie AR, 2010, CURR MED CHEM, V17, P2059, DOI 10.2174/092986710791233706; Rourke C, 2012, J THROMB HAEMOST, V10, P1342, DOI 10.1111/j.1538-7836.2012.04752.x; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schochl H, 2009, J TRAUMA, V67, P125, DOI 10.1097/TA.0b013e31818b2483; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053	50	103	115	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	MAY	2014	41			1			21	25		10.1097/SHK.0000000000000088			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	AI6EX	WOS:000336965100004	24192549				2021-06-18	
J	Naviaux, RK				Naviaux, Robert K.			Metabolic features of the cell danger response	MITOCHONDRION			English	Article						Oxidative stress; Oxidative shielding; Innate immunity; Inflammation; Purinergic signaling; Mitochondria	CYSTINE/GLUTAMATE ANTIPORTER; MOLECULAR-MECHANISMS; IMPROVES RECOVERY; STRESS-RESPONSE; ATP RELEASE; KAPPA-B; RECEPTOR; SURAMIN; MITOCHONDRIA; DISEASE	The cell danger response (CDR) is the evolutionarily conserved metabolic response that protects cells and hosts from harm. It is triggered by encounters with chemical, physical, or biological threats that exceed the cellular capacity for homeostasis. The resulting metabolic mismatch between available resources and functional capacity produces a cascade of changes in cellular electron flow, oxygen consumption, redox, membrane fluidity, lipid dynamics, bioenergetics, carbon and sulfur resource allocation, protein folding and aggregation, vitamin availability, metal homeostasis, indole, pterin, 1-carbon and polyamine metabolism, and polymer formation. The first wave of danger signals consists of the release of metabolic intermediates like ATP and ADP, Krebs cycle intermediates, oxygen, and reactive oxygen species (ROS), and is sustained by purinergic signaling. After the danger has been eliminated or neutralized, a choreographed sequence of anti-inflammatoty and regenerative pathways is activated to reverse the CDR and to heal. When the CDR persists abnormally, whole body metabolism and the gut microbiome are disturbed, the collective performance of multiple organ systems is impaired, behavior is changed, and chronic disease results. Metabolic memory of past stress encounters is stored in the form of altered mitochondrial and cellular macromolecule content, resulting in an increase in functional reserve capacity through a process known as mitocellular hormesis. The systemic form of the CDR, and its magnified form, the purinergic life-threat response (PLTR), are under direct control by ancient pathways in the brain that are ultimately coordinated by centers in the brainstem. Chemosensory integration of whole body metabolism occurs in the brainstem and is a prerequisite for normal brain, motor, vestibular, sensory, social, and speech development. An understanding of the CDR permits us to reframe old concepts of pathogenesis for a broad array of chronic, developmental, autoimmune, and degenerative disorders. These disorders include autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), asthma, atopy, gluten and many other food and chemical sensitivity syndromes, emphysema, Tourette's syndrome, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), chronic traumatic encephalopathy (CTE), traumatic brain injury (TB!), epilepsy, suicidal ideation, organ transplant biology, diabetes, kidney, liver, and heart disease, cancer, Alzheimer and Parkinson disease, and autoimmune disorders like lupus, rheumatoid arthritis, multiple sclerosis, and primary sclerosing cholangitis. (C) 2013 The Author. Published by Elsevier B.V. and Mitochondria Research Society. All rights reserved.	[Naviaux, Robert K.] Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, Dept Med, San Diego, CA 92103 USA; [Naviaux, Robert K.] Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, Dept Pediat, San Diego, CA 92103 USA; [Naviaux, Robert K.] Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, Dept Pathol, San Diego, CA 92103 USA; [Naviaux, Robert K.] Vet Affairs Ctr Excellence Stress & Mental Hlth C, La Jolla, CA USA	Naviaux, RK (corresponding author), Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, 214 Dickinson St,Bldg CTF,Rm C102, San Diego, CA 92103 USA.	Naviaux@ucsd.edu			UCSD Christini Fund; Jane Botsford Johnson Foundation; Wright Foundation; Lennox Foundation; Takes Guts Foundation; UCSD Mitochondrial Disease Research Foundation; Hailey's Wish Foundation	RKN thanks Jane Naviaux, Will Alaynick, Jim Adams, Steve Edelson, Kate Crowley, and Vicki Kobliner for helpful comments on the manuscript. This work was made possible by support from the UCSD Christini Fund, the Jane Botsford Johnson Foundation, the Wright Foundation, the Lennox Foundation, the It Takes Guts Foundation, the UCSD Mitochondrial Disease Research Foundation, and the Hailey's Wish Foundation.	Ajioka RS, 2006, BBA-MOL CELL RES, V1763, P723, DOI 10.1016/j.bbamcr.2006.05.005; Angata T, 2012, ANN NY ACAD SCI, V1253, P159, DOI 10.1111/j.1749-6632.2012.06469.x; Arispe N, 2002, FASEB J, V16, P1526, DOI 10.1096/fj.02-0829com; Arnoult D, 2011, EMBO REP, V12, P901, DOI 10.1038/embor.2011.157; Bachrach U, 2007, AMINO ACIDS, V33, P267, DOI 10.1007/s00726-007-0535-y; Ballok DA, 2008, BRAIN BEHAV IMMUN, V22, P1208, DOI 10.1016/j.bbi.2008.06.002; Bernstein HG, 2012, NEUROPHARMACOLOGY, V62, P237, DOI 10.1016/j.neuropharm.2011.07.012; Bezvenyuk Z, 2000, NEUROSCI LETT, V292, P111, DOI 10.1016/S0304-3940(00)01453-1; Blumberg Stephen J, 2013, Natl Health Stat Report, P1; Bours Martijn Jan Leo, 2011, Front Biosci (Schol Ed), V3, P1443; Bridges RJ, 2012, BRIT J PHARMACOL, V165, P20, DOI 10.1111/j.1476-5381.2011.01480.x; BURNSTOCK G, 1972, BRIT J PHARMACOL, V44, P451, DOI 10.1111/j.1476-5381.1972.tb07283.x; Burnstock G, 2012, CURR OPIN PHARMACOL, V12, P80, DOI 10.1016/j.coph.2011.10.008; Burnstock G, 2010, ACTA PHYSIOL, V199, P93, DOI 10.1111/j.1748-1716.2010.02114.x; Burnstock G, 2009, ACTA PHYSIOL, V195, P415, DOI 10.1111/j.1748-1716.2009.01957.x; Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006; Caccamo D, 2012, AMINO ACIDS, V42, P1037, DOI 10.1007/s00726-011-1018-8; Cantin LD, 2012, BIOORG MED CHEM LETT, V22, P2565, DOI 10.1016/j.bmcl.2012.01.124; Cervelli M, 2012, AMINO ACIDS, V42, P441, DOI 10.1007/s00726-011-1014-z; Choo AM, 2013, BRAIN, V136, P65, DOI 10.1093/brain/aws286; Cicko S, 2010, J IMMUNOL, V185, P688, DOI 10.4049/jimmunol.0904042; Corcoran JA, 2009, J VIROL, V83, P2601, DOI 10.1128/JVI.02087-08; Darwin C.R., 1839, C DARWIN AUSTR, P30; De Clercq E, 2009, MED RES REV, V29, P611, DOI 10.1002/med.20153; de Oliveira Moreira D., 2013, MUSCLE NERVE; Degtyar E, 2009, CELL MICROBIOL, V11, P1219, DOI 10.1111/j.1462-5822.2009.01328.x; DiNatale BC, 2010, TOXICOL SCI, V115, P89, DOI 10.1093/toxsci/kfq024; Dreifus Claudia, 1998, NY TIMES; Edmonds JL, 2002, ARCH OTOLARYNGOL, V128, P355, DOI 10.1001/archotol.128.4.355; Ehlert U., 2013, PSYCHONEUROENDOCRINO; Eisner V, 2010, CELL CALCIUM, V48, P358, DOI 10.1016/j.ceca.2010.11.001; Engel T, 2012, FASEB J, V26, P1616, DOI 10.1096/fj.11-196089; Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035; Fulkerson PC, 2013, NAT REV DRUG DISCOV, V12, P117, DOI 10.1038/nrd3838; Garrod AE, 1902, LANCET, V2, P1616; Gray TJ, 1999, J CARDIOVASC PHARM, V33, P960, DOI 10.1097/00005344-199906000-00018; Gunderson LH, 2000, ANNU REV ECOL SYST, V31, P425, DOI 10.1146/annurev.ecolsys.31.1.425; Halassa MM, 2011, SEMIN CELL DEV BIOL, V22, P245, DOI 10.1016/j.semcdb.2011.02.008; Haynes CM, 2013, TRENDS CELL BIOL, V23, P311, DOI 10.1016/j.tcb.2013.02.002; He SQ, 2013, J PHARMACOL EXP THER, V344, P417, DOI 10.1124/jpet.112.199919; HeberKatz E, 2013, CURR TOP MICROBIOL, V367, P1, DOI 10.1007/978-3-642-35810-4; Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005; HSU HC, 1994, AUTOIMMUNITY, V19, P253, DOI 10.3109/08916939409071351; Hultqvist M, 2009, TRENDS IMMUNOL, V30, P201, DOI 10.1016/j.it.2009.03.004; Ibrahim D, 2006, CLIN LAB MED, V26, P67, DOI 10.1016/j.cll.2006.02.003; Jacobs SA, 2007, MED HYPOTHESES, V68, P308, DOI 10.1016/j.mehy.2006.07.023; Jiang XM, 2012, IMMUNITY, V36, P959, DOI 10.1016/j.immuni.2012.03.022; Jin S, 2009, CURR ATHEROSCLER REP, V11, P220, DOI 10.1007/s11883-009-0034-6; Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938; Kannan KB, 2007, J IMMUNOL, V178, P5253, DOI 10.4049/jimmunol.178.8.5253; KAWAMURA M, 1991, JPN J PHARMACOL, V56, P543, DOI 10.1254/jjp.56.543; Kharlamov A, 2002, EXP BRAIN RES, V147, P353, DOI 10.1007/s00221-002-1251-1; Kim HP, 2006, EXPERT OPIN THER TAR, V10, P759, DOI 10.1517/14728222.10.5.759; Kim HJ, 2012, BBA-MOL CELL RES, V1823, P1604, DOI 10.1016/j.bbamcr.2012.04.008; Kivity S, 2011, CELL MOL IMMUNOL, V8, P243, DOI 10.1038/cmi.2010.73; Knight JC, 2013, TRENDS GENET, V29, P74, DOI 10.1016/j.tig.2012.10.006; Kobayashi S, 2012, FREE RADICAL BIO MED, V53, P2197, DOI 10.1016/j.freeradbiomed.2012.09.040; Korrapati MC, 2012, J PHARMACOL EXP THER, V343, P34, DOI 10.1124/jpet.112.196964; Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262; Kuijpers T, 2012, CELL MOL LIFE SCI, V69, P7, DOI 10.1007/s00018-011-0834-z; Landrigan PJ, 2012, ENVIRON HEALTH PERSP, V120, pA258, DOI 10.1289/ehp.1104285; Lee AH, 2009, CELL MOL LIFE SCI, V66, P2835, DOI 10.1007/s00018-009-0049-8; LESCH M, 1964, AM J MED, V36, P561, DOI 10.1016/0002-9343(64)90104-4; Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391; Liu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052703; Liu GG, 2008, BIOCHEM BIOPH RES CO, V370, P651, DOI 10.1016/j.bbrc.2008.04.031; Liu GW, 2010, NAT IMMUNOL, V11, P1047, DOI 10.1038/ni.1939; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lucki NC, 2012, ANNU REV PHYSIOL, V74, P131, DOI 10.1146/annurev-physiol-020911-153321; Lushchak VI, 2011, COMP BIOCHEM PHYS C, V153, P175, DOI 10.1016/j.cbpc.2010.10.004; MacLennan AJ, 2006, HEARING RES, V220, P38, DOI 10.1016/j.heares.2006.06.016; Mahankali M, 2011, P NATL ACAD SCI USA, V108, P19617, DOI 10.1073/pnas.1114692108; Mandi Y, 2012, J NEURAL TRANSM, V119, P197, DOI 10.1007/s00702-011-0681-y; Marina N, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-012-0317-x; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2011, NAT REV IMMUNOL, V11, P221, DOI 10.1038/nri2940; McLain AL, 2013, FREE RADICAL BIO MED, V61, P161, DOI 10.1016/j.freeradbiomed.2013.03.020; Micheli V, 2011, CURR TOP MED CHEM, V11, P923, DOI 10.2174/156802611795347645; Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320; Naviaux RK, 2008, CANCER BIOL THER, V7, P1191, DOI 10.4161/cbt.7.8.6741; Naviaux RK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057380; Naviaux RK, 2012, J PHARMACOL EXP THER, V342, P608, DOI 10.1124/jpet.112.192120; Nie XW, 2013, INT J BIOCHEM CELL B, V45, P964, DOI 10.1016/j.biocel.2013.01.017; Nielsen MJ, 2012, NAT REV GASTRO HEPAT, V9, P345, DOI 10.1038/nrgastro.2012.76; NovalesLi P, 1996, IMMUNOPHARMACOLOGY, V35, P155, DOI 10.1016/S0162-3109(96)00141-5; Novgorodov Sergei A, 2011, Int J Biochem Mol Biol, V2, P347; Nyhan WL, 2005, MOL GENET METAB, V86, P25, DOI 10.1016/j.ymgme.2005.07.027; NYHAN WL, 1969, J PEDIATR, V74, P20, DOI 10.1016/S0022-3476(69)80004-1; Oguma T, 2007, CLIN EXP ALLERGY, V37, P893, DOI 10.1111/j.1365-2222.2007.02719.x; Ohta A, 2011, MITOCHONDRION, V11, P1, DOI 10.1016/j.mito.2010.08.006; Ong WY, 2010, CURR MED CHEM, V17, P2746, DOI 10.2174/092986710791859289; Panossian A, 2009, CURR CLIN PHARMACOL, V4, P198, DOI 10.2174/157488409789375311; Pastural E, 2009, PROSTAG LEUKOTR ESS, V81, P253, DOI 10.1016/j.plefa.2009.06.003; Paul L, 2013, NUTR REV, V71, P239, DOI 10.1111/nure.12014; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Peng X, 2012, ACTA PHYSIOL, V204, P219, DOI 10.1111/j.1748-1716.2011.02298.x; Pimentel VC, 2013, NEUROCHEM RES, V38, P886, DOI 10.1007/s11064-013-0994-3; Rabiet MJ, 2005, EUR J IMMUNOL, V35, P2486, DOI 10.1002/eji.200526338; Riegl B, 2009, ANN NY ACAD SCI, V1162, P136, DOI 10.1111/j.1749-6632.2009.04493.x; Riteau N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.144; Romero P, 2005, GENOME BIOL, V6; Sahu D, 2012, INT IMMUNOPHARMACOL, V12, P288, DOI 10.1016/j.intimp.2011.12.003; Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005; Scott I, 2010, MITOCHONDRION, V10, P316, DOI 10.1016/j.mito.2010.02.005; Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shanmugasundaram R, 2012, POULTRY SCI, V91, P1819, DOI 10.3382/ps.2011-02129; Silva JM, 2009, NEUROBIOL DIS, V34, P357, DOI 10.1016/j.nbd.2009.02.005; Smriga M, 2003, P NATL ACAD SCI USA, V100, P15370, DOI 10.1073/pnas.2436556100; Stipanuk MH, 2011, J INHERIT METAB DIS, V34, P17, DOI 10.1007/s10545-009-9006-9; SUTTON RAL, 1993, MINER ELECTROL METAB, V19, P232; Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113; Thompson CR, 2005, J IMMUNOL, V174, P3551, DOI 10.4049/jimmunol.174.6.3551; West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975; Williams BL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024585; Wood JH, 2010, CURR OPIN PEDIATR, V22, P315, DOI 10.1097/MOP.0b013e328338da48; Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983; Yang Z, 2012, OBES REV, V13, P58, DOI 10.1111/j.1467-789X.2012.01038.x; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Zamek-Gliszczynski MJ, 2006, EUR J PHARM SCI, V27, P447, DOI 10.1016/j.ejps.2005.12.007; Zhang XY, 2011, AM J PHYSIOL-CELL PH, V301, pC451, DOI 10.1152/ajpcell.00458.2010; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	125	103	106	0	89	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1567-7249	1872-8278		MITOCHONDRION	Mitochondrion	MAY	2014	16				SI		7	17		10.1016/j.mito.2013.08.006			11	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	AH9OP	WOS:000336472000003	23981537	Other Gold			2021-06-18	
J	Figley, SA; Khosravi, R; Legasto, JM; Tseng, YF; Fehlings, MG				Figley, Sarah A.; Khosravi, Ramak; Legasto, Jean M.; Tseng, Yun-Fan; Fehlings, Michael G.			Characterization of Vascular Disruption and Blood-Spinal Cord Barrier Permeability following Traumatic Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						vascular permeability; blood-spinal cord barrier; vascular injury; spinal cord injury; endogenous angiogenesis	FUNCTIONAL RECOVERY; CONTUSION INJURY; TIME COURSE; EVANS BLUE; RAT; MECHANISMS; BRAIN; APOPTOSIS; ANGIOGENESIS; TRANSECTION	Significant vascular changes occur subsequent to spinal cord injury (SCI), which contribute to progressive pathophysiology. In the present study, we used female Wistar rats (300-350 g) and a 35-g clip-compression injury at T6 to T7 to characterize the spatial and temporal vascular changes that ensue post-SCI. Before sacrifice, animals were injected with vascular tracing dyes (2% Evans Blue (EB) or fluorescein isothiocyanate/Lycopersicon esculentum agglutinin [FITC-LEA]) to assess blood-spinal cord barrier (BSCB) integrity or vascular architecture, respectively. Spectrophotometry of EB tissue showed maximal BSCB disruption at 24 h postinjury, with significant disruption observed until 5 days postinjury (p<0.01). FITC-LEA-identified functional vasculature was dramatically reduced by 24 h. Similarly, RECA-1 immunohistochemistry showed a significant decrease in the number of vessels at 24 h postinjury, compared to uninjured animals (p<0.01), with slight increases in endogenous revascularization by 10 days postinjury. White versus gray matter (GM) quantification showed that GM vessels are more susceptible to SCI. Finally, we observed an endogenous angiogenic response between 3 and 7 days postinjury: maximal endothelial cell proliferation was observed at day 5. These data indicate that BSCB disruption and endogenous revascularization occur at specific time points after injury, which may be important for developing effective therapeutic interventions for SCI.	[Figley, Sarah A.; Fehlings, Michael G.] Univ Hlth Network, Krembil Neurosci Ctr, Toronto Western Res Inst, Dept Genet & Dev, Toronto, ON M5T 2S8, Canada; [Figley, Sarah A.; Fehlings, Michael G.] Univ Hlth Network, Krembil Neurosci Ctr, Spinal Program, Toronto, ON M5T 2S8, Canada; [Figley, Sarah A.; Khosravi, Ramak; Legasto, Jean M.; Tseng, Yun-Fan; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Fehlings, Michael G.] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada	Fehlings, MG (corresponding author), Univ Hlth Network, Toronto Western Hosp, Div Neurosurg, 399 Bathurst St,4WW-449, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.on.ca		Khosravi, Ramak/0000-0002-4181-3679; Fehlings, Michael/0000-0002-5722-6364	Gerald and Tootsie Halbert Chair in Neural Repair and Regeneration; Krembil Foundation	The authors express their gratitude to Eunice Cho and Sofia Khan for their help with tissue extraction, tissue processing, immunohistochemistry, and cell counting. The authors also thank Jared Wilcox, Behzad Azad, Yang Liu, and other members of the Fehlings' lab who assisted with postoperative animal care. This study was supported by the Gerald and Tootsie Halbert Chair in Neural Repair and Regeneration (held by Dr. Michael G. Fehlings) and by a grant received from the Krembil Foundation.	Aoki T, 2002, STROKE, V33, P2711, DOI 10.1161/01.STR.0000033932.34467.97; Bearden SE, 2004, MICROCIRCULATION, V11, P633, DOI 10.1080/10739680490517659; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; Benton RL, 2003, NEUROCHEM RES, V28, P1693, DOI 10.1023/A:1026013106016; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Engelhardt B, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-4; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Furlan JC, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E13; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; IKEDA Y, 1994, ACTA NEUROCHIR, P119; Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505; Kaya M, 2011, METHODS MOL BIOL, V763, P369, DOI 10.1007/978-1-61779-191-8_25; Ling X, 2007, J NEUROSCI RES, V85, P2175, DOI 10.1002/jnr.21362; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; NOBLE LJ, 1988, EXP NEUROL, V99, P567, DOI 10.1016/0014-4886(88)90173-2; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Raab S, 2007, ACTA NEUROPATHOL, V113, P607, DOI 10.1007/s00401-007-0228-3; Ribatti D, 2001, MECH DEVELOP, V100, P157, DOI 10.1016/S0925-4773(00)00522-0; SARIA A, 1983, J NEUROSCI METH, V8, P41, DOI 10.1016/0165-0270(83)90050-X; Saunders NR, 1999, CLIN EXP PHARMACOL P, V26, P11, DOI 10.1046/j.1440-1681.1999.02986.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; vonEuler M, 1997, EXP NEUROL, V145, P502, DOI 10.1006/exnr.1997.6481; Yoshihara T, 2007, J NEUROTRAUM, V24, P1026, DOI 10.1089/neu.2007.132R	36	103	114	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2014	31	6					541	552		10.1089/neu.2013.3034			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AC3WV	WOS:000332453000002	24237182	Green Published			2021-06-18	
J	Okonkwo, DO; Yue, JK; Puccio, AM; Panczykowski, DM; Inoue, T; McMahon, PJ; Sorani, MD; Yuh, EL; Lingsma, HF; Maas, AIR; Valadka, AB; Manley, GT; Casey, SS; Cheong, M; Cooper, SR; Dams-O'Connor, K; Gordon, WA; Hricik, AJ; Hochberger, K; Menon, DK; Mukherjee, P; Sinha, TK; Schnyer, DM; Vassar, MJ				Okonkwo, David O.; Yue, John K.; Puccio, Ava M.; Panczykowski, David M.; Inoue, Tomoo; McMahon, Paul J.; Sorani, Marco D.; Yuh, Esther L.; Lingsma, Hester F.; Maas, Andrew I. R.; Valadka, Alex B.; Manley, Geoffrey T.; Casey, Scott S.; Cheong, Maxwell; Cooper, Shelly R.; Dams-O'Connor, Kristen; Gordon, Wayne A.; Hricik, Allison J.; Hochberger, Kerri; Menon, David K.; Mukherjee, Pratik; Sinha, Tuhin K.; Schnyer, David M.; Vassar, Mary J.		Transforming Res Clinical Knowledg	GFAP-BDP as an Acute Diagnostic Marker in Traumatic Brain Injury: Results from the Prospective Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study	JOURNAL OF NEUROTRAUMA			English	Article						clinical trial; health-related quality of life; outcome; post-concussion syndrome; TBI	FIBRILLARY ACIDIC PROTEIN; COMMON DATA ELEMENTS; INTRACRANIAL LESIONS; CARDIAC TROPONIN; SERUM-LEVELS; MILD; BIOMARKERS; BLOOD; S100B	Reliable diagnosis of traumatic brain injury (TBI) is a major public health need. Glial fibrillary acidic protein (GFAP) is expressed in the central nervous system, and breakdown products (GFAP-BDP) are released following parenchymal brain injury. Here, we evaluate the diagnostic accuracy of elevated levels of plasma GFAP-BDP in TBI. Participants were identified as part of the prospective Transforming Research And Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Study. Acute plasma samples (<24 h post-injury) were collected from patients presenting with brain injury who had CT imaging. The ability of GFAP-BDP level to discriminate patients with demonstrable traumatic lesions on CT, and with failure to return to pre-injury baseline at 6 months, was evaluated by the area under the receiver operating characteristic curve (AUC). Of the 215 patients included for analysis, 83% had mild, 4% had moderate, and 13% had severe TBI; 54% had acute traumatic lesions on CT. The ability of GFAP-BDP level to discriminate patients with traumatic lesions on CT as evaluated by AUC was 0.88 (95% confidence interval [CI], 0.84-0.93). The optimal cutoff of 0.68 ng/mL for plasma GFAP-BDP level was associated with a 21.61 odds ratio for traumatic findings on head CT. Discriminatory ability of unfavorable 6 month outcome was lower, AUC 0.65 (95% CI, 0.55-0.74), with a 2.07 odds ratio. GFAP-BDP levels reliably distinguish the presence and severity of CT scan findings in TBI patients. Although these findings confirm and extend prior studies, a larger prospective trial is still needed to validate the use of GFAP-BDP as a routine diagnostic biomarker for patient care and clinical research. The term "mild'' continues to be a misnomer for this patient population, and underscores the need for evolving classification strategies for TBI targeted therapy. (ClinicalTrials.gov number NCT01565551; NIH Grant 1RC2 NS069409)	[Okonkwo, David O.; Puccio, Ava M.; Panczykowski, David M.; McMahon, Paul J.; Hricik, Allison J.; Hochberger, Kerri] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Yue, John K.; Inoue, Tomoo; Sorani, Marco D.; Manley, Geoffrey T.; Casey, Scott S.; Cooper, Shelly R.; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yuh, Esther L.; Cheong, Maxwell; Mukherjee, Pratik; Sinha, Tuhin K.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Lingsma, Hester F.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Cooper, Shelly/0000-0003-0026-6688; Mukherjee, Pratik/0000-0001-7473-7409; Schnyer, David/0000-0002-7472-2853	National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RC2 NS069409] Funding Source: Medline		Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Peacock WF, 2008, NEW ENGL J MED, V358, P2117, DOI 10.1056/NEJMoa0706824; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Reichlin T, 2009, NEW ENGL J MED, V361, P858, DOI 10.1056/NEJMoa0900428; Reinsfelt B, 2012, ANN THORAC SURG, V94, P549, DOI 10.1016/j.athoracsur.2012.04.044; Savage WJ, 2011, AM J HEMATOL, V86, P427, DOI 10.1002/ajh.21995; Seco M, 2012, ANN THORAC SURG, V94, P1026, DOI 10.1016/j.athoracsur.2012.04.142; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vissers JLM, 2006, CLIN CHIM ACTA, V366, P336, DOI 10.1016/j.cca.2005.11.017; Vos PE, 2006, EUR J NEUROL, V13, P632, DOI 10.1111/j.1468-1331.2006.01332.x; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yue J.K., 2013, J NEUROTRAUMA; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	31	103	105	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1490	1497		10.1089/neu.2013.2883			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800004	23489259	Green Published			2021-06-18	
J	Castile, L; Collins, CL; McIlvain, NM; Comstock, RD				Castile, Lianne; Collins, Christy L.; McIlvain, Natalie M.; Comstock, R. Dawn			The epidemiology of new versus recurrent sports concussions among high school athletes, 2005-2010	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; SEX-DIFFERENCES; FOOTBALL; COLLEGIATE; RECOVERY; PLAY	Objectives To compare new versus recurrent concussions with respect to constellation of symptoms, symptom severity, symptom resolution; evaluate potential subset differences with respect to gender and sport; and to compare mechanisms and activities associated with new versus recurrent concussions. Methods Sports-related injury and exposure data were collected for nine sports from 2005 to 2010 from 100 nationally representative US high schools. Results Nationally, an estimated 732,805 concussions occurred. Of these reported concussions, 13.2% were recurrent. The rate of new concussions was 22.2 per 100,000 athletic exposures while the rate of recurrent concussions was 3.1 per 100,000 athletic exposures (RR 7.23, 95% CI 6.39 to 8.17, p<0.001). While 0.6% of new concussion symptoms took >1 month to resolve, 6.5% of recurrent concussion symptoms took >1 month to resolve (IPR 10.35; 95% CI 4.62 to 23.16; p<0.001). Loss of consciousness was reported more often with recurrent (7.7%) than new concussions (4.4%) (IPR 1.76; 95% CI 1.02 to 3.03; p=0.043). A greater proportion of athletes sustaining recurrent concussions returned to play in >3 weeks (7.5%) or were medically disqualified (16.2%) than athletes sustaining new concussions (3.8%; IPR 1.95; 95% CI 1.01 to 3.77; p=0.047 and 2.9%; IPR 5.58; 95% CI 3.50 to 8.88; p<0.001, respectively). The majority of new and recurrent concussions resulted from contact with another person (73.4% and 77.9%, respectively). Conclusions Athletes sustaining recurrent concussions had longer symptom resolution times, were kept out of play longer and reported loss of consciousness more frequently than athletes sustaining new concussions. With the possibility of long-term impairment and other negative sequelae, proper management and prevention of concussions at the high school level is imperative.	[Castile, Lianne; Collins, Christy L.; McIlvain, Natalie M.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA	Collins, CL (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	christy.collins@nationwidechildrens.org			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations (NFHS); EyeBlack and DonJoy Orthotics; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674, R49CE001172] Funding Source: NIH RePORTER	The content of this report was funded in part by the Centers for Disease Control and Prevention (CDC) grants # R49/CE000674-01 and # R49/CE001172-01. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the CDC. The authors acknowledge the generous research funding contributions of the National Federation of State High School Associations (NFHS), EyeBlack and DonJoy Orthotics.	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; National Federation of State High School Associations, 2009, 2009 10 HIGH SCH ATH; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Swenson DM, 2009, AM J SPORT MED, V37, P1586, DOI 10.1177/0363546509332500; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; United States Census Bureau, CENS REG US; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	34	103	103	2	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2012	46	8					603	610		10.1136/bjsports-2011-090115			8	Sport Sciences	Sport Sciences	959AB	WOS:000305281000012	22144000				2021-06-18	
J	Denning, JH				Denning, John H.			The Efficiency and Accuracy of The Test of Memory Malingering Trial 1, Errors on the First 10 Items of The Test of Memory Malingering, and Five Embedded Measures in Predicting Invalid Test Performance	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Test of Memory Malingering; Medical Symptom Validity Test; symptom validity testing; Malingering; Veterans; Neuropsychology	SYMPTOM VALIDITY TESTS; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; SELF-REPORTED SYMPTOMS; CLASSIFICATION ACCURACY; TOMM PERFORMANCE; CLINICAL-SAMPLE; RESPONSE BIAS; TEST FAILURE; DISABILITY CLAIMANTS	The current study attempted to improve upon the efficiency and accuracy of one of the most frequently administered measures of test validity, the Test of Memory Malingering (TOMM) by utilizing two short forms (TOMM trial 1 or TOMM1; and errors on the first 10 items of TOMM1 or TOMMe10). In addition, we cross-validated the accuracy of five embedded measures frequently used in malingering research. TOMM1 and TOMMe10 were highly accurate in predicting test validity (area under the curve [AUC] 92 and 87, respectively; TOMM1 40 and TOMMe10 epsilon 1; sensitivities 70 and specificities 90). A logistic regression of five embedded measures showed better accuracy compared with any individual embedded measure alone or in combination (AUC 87). TOMM1 and TOMMe10 provide evidence of greater sensitivity to invalid test performance compared with the standard TOMM administration and the use of regression improved the accuracy of the five embedded cognitive measures.	Alvin C York Vet Affairs Hosp, Tennessee Valley Healthcare Syst, Dept Psychol, Murfreesboro, TN 37129 USA	Denning, JH (corresponding author), Alvin C York Vet Affairs Hosp, Tennessee Valley Healthcare Syst, Dept Psychol, Murfreesboro, TN 37129 USA.	john.denning@va.gov			Department of Veterans Affairs, Veterans Health AdministrationUS Department of Veterans Affairs; Office of Research and Development	This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development.	Armistead-Jehle P, 2011, APPL NEUROPSYCHOL, V18, P284, DOI 10.1080/09084282.2011.595455; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Batt K, 2008, J INT NEUROPSYCH SOC, V14, P1074, DOI 10.1017/S135561770808137X; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Benedict R., 1997, BRIEF VISUOSPATIAL M; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brooks BL, 2012, ARCH CLIN NEUROPSYCH, V27, P23, DOI 10.1093/arclin/acr086; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Delis DC, 2000, CALIFORNIA VERBAL LE; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; Green, 2004, GREENS MED SYMPTOM V; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P., 2008, MANUAL NONVERBAL MED; Green P., 2006, INT J FORENSIC PSYCH, V1, P1; Green P., 2007, ASSESSMENT FEIGNED C; Green P, 2011, APPL NEUROPSYCHOL, V18, P18, DOI 10.1080/09084282.2010.523365; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Guilmette TJ, 1996, PERCEPT MOTOR SKILL, V83, P1007, DOI 10.2466/pms.1996.83.3.1007; Gunner JH, 2012, ARCH CLIN NEUROPSYCH, V27, P1, DOI 10.1093/arclin/acr089; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hill SK, 2003, J FORENSIC NEUROPSYC, V3, P1; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Horner MD, 2006, INT J NEUROSCI, V116, P1181, DOI 10.1080/00207450500514029; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; Jasinski LJ, 2011, CLIN NEUROPSYCHOL, V25, P1415, DOI 10.1080/13854046.2011.630024; Kaufmann PM, 2009, CLIN NEUROPSYCHOL, V23, P1130, DOI 10.1080/13854040903107809; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kirk JW, 2011, CHILD NEUROPSYCHOL, V17, P242, DOI 10.1080/09297049.2010.533166; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Li, 2004, APPL LINEAR REGRESSI; Lindstrom WA, 2009, ARCH CLIN NEUROPSYCH, V24, P659, DOI 10.1093/arclin/acp071; Locke DEC, 2008, NEUROREHABILITATION, V23, P273; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; McCaffrey R. J., 2003, J FORENSIC NEUROPSYC, V3, P45, DOI [10.1300/J151v03n03_03, DOI 10.1300/J151V03N03_03]; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morel KR, 2009, ARCH CLIN NEUROPSYCH, V24, P635, DOI 10.1093/arclin/acp062; Morgan J. E., 2009, NEUROPSYCHOLOGY MALI; Musso MW, 2011, ARCH CLIN NEUROPSYCH, V26, P756, DOI 10.1093/arclin/acr078; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; O'Bryant SE, 2008, APPL NEUROPSYCHOL, V15, P113, DOI 10.1080/09084280802083921; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Pella RD, 2012, ARCH CLIN NEUROPSYCH, V27, P45, DOI 10.1093/arclin/acr090; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Ruocco AC, 2008, CLIN NEUROPSYCHOL, V22, P547, DOI 10.1080/13854040701336444; Ryan JJ, 2010, APPL NEUROPSYCHOL, V17, P246, DOI 10.1080/09084282.2010.499802; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; SCHROEDER R, 2011, ARCH CLIN NEUROPSYCH, V26, P564; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Shandera AL, 2010, PSYCHOL ASSESSMENT, V22, P50, DOI 10.1037/a0016585; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Sollman MJ, 2010, PSYCHOL ASSESSMENT, V22, P325, DOI 10.1037/a0018857; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vanderslice-Barr JL, 2011, APPL NEUROPSYCHOL, V18, P34, DOI 10.1080/09084282.2010.523377; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481; Whiteside D, 2011, CLIN NEUROPSYCHOL, V25, P287, DOI 10.1080/13854046.2010.538436; Whiteside DM, 2009, CLIN NEUROPSYCHOL, V23, P523, DOI 10.1080/13854040802389169; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Wisdom NM, 2012, ARCH CLIN NEUROPSYCH, V27, P208, DOI 10.1093/arclin/acr107; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009	102	103	103	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2012	27	4					417	432		10.1093/arclin/acs044			16	Psychology, Clinical; Psychology	Psychology	944JX	WOS:000304198300005	22543569				2021-06-18	
J	Wolff, EF; Gao, XB; Yao, KV; Andrews, ZB; Du, HL; Elsworth, JD; Taylor, HS				Wolff, Erin F.; Gao, Xiao-Bing; Yao, Katherine V.; Andrews, Zane B.; Du, Hongling; Elsworth, John D.; Taylor, Hugh S.			Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE			English	Article						stem cells; adult stem cells; MSC; endometrium; Parkinson's disease; transplantation	MARROW STROMAL CELLS; TRAUMATIC BRAIN-INJURY; STEM/PROGENITOR CELLS; FUNCTIONAL RECOVERY; MOUSE MODEL; RATS; MICE; MICROCHIMERISM; IDENTIFICATION; MIGRATE	Parkinson's disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons. Adult human endometrial derived stem cells (HEDSC), a readily obtainable type of mesenchymal stem-like cell, were used to generate dopaminergic cells and for transplantation. Cells expressing CD90, platelet derived growth factor (PDGF)-R beta and CD146 but not CD45 or CD31 were differentiated in vitro into dopaminergic neurons that exhibited axon projections, pyramidal cell bodies and dendritic projections that recapitulate synapse formation; these cells also expressed the neural marker nestin and tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Whole cell patch clamp recording identified G-protein coupled inwardly rectifying potassium current 2 channels characteristic of central neurons. A 1-methyl 4-phenyl 1,2,3,6-tetrahydro pyridine induced animal model of PD was used to demonstrate the ability of labelled HEDSC to engraft, migrate to the site of lesion, differentiate in vivo and significantly increase striatal dopamine and dopamine metabolite concentrations. HEDSC are a highly inducible source of allogenic stem cells that rescue dopamine concentrations in an immunocompetent PD mouse model.	[Wolff, Erin F.; Gao, Xiao-Bing; Yao, Katherine V.; Andrews, Zane B.; Du, Hongling; Taylor, Hugh S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; [Elsworth, John D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; [Taylor, Hugh S.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Taylor, HS (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,POB 208063, New Haven, CT 06520 USA.	hugh.taylor@yale.edu	Gao, Xiao-Bing/C-3121-2011	Gao, Xiao-Bing/0000-0002-2035-4936; Andrews, Zane B./0000-0002-9097-7944	Reproductive Scientist Development Program [NIH K12HD00849]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD000849] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD052668] Funding Source: NIH RePORTER	This study was supported by the Reproductive Scientist Development Program (Berlex Foundation and NIH K12HD00849) and Specialized Cooperative Centers Program in Reproduction and Infertility Research (NIH U54 HD052668).	BERNSTEIN DC, 1988, ANN NY ACAD SCI, V532, P207, DOI 10.1111/j.1749-6632.1988.tb36339.x; Blondheim NR, 2006, STEM CELLS DEV, V15, P141, DOI 10.1089/scd.2006.15.141; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cipriani S, 2007, CELL BIOL INT, V31, P845, DOI 10.1016/j.cellbi.2007.01.037; Dimitrov R, 2008, REPRODUCTION, V135, P551, DOI 10.1530/REP-07-0428; Elsworth JD, 1996, CELL TRANSPLANT, V5, P315, DOI 10.1016/0963-6897(95)02034-9; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gargett B E, 2006, Minerva Ginecol, V58, P511; Gargett CE, 2008, MOL CELL ENDOCRINOL, V288, P22, DOI 10.1016/j.mce.2008.02.026; Gargett CE, 2007, REPROD SCI, V14, P405, DOI 10.1177/1933719107306231; Gargett CE, 2009, BIOL REPROD, V80, P1136, DOI 10.1095/biolreprod.108.075226; Gargett CE, 2006, AUST NZ J OBSTET GYN, V46, P250, DOI 10.1111/j.1479-828X.2006.00582.x; Hellmann MA, 2006, NEUROSCI LETT, V395, P124, DOI 10.1016/j.neulet.2005.10.097; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Lapaire O, 2007, J MATERN-FETAL NEO M, V20, P1, DOI 10.1080/14767050601144834; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu LL, 2005, BRAIN RES PROTOC, V15, P46, DOI 10.1016/j.brainresprot.2005.03.002; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mansilla E, 2005, TRANSPL P, V37, P292, DOI 10.1016/j.transproceed.2005.01.070; Mouiseddine M, 2007, BRIT J RADIOL, V80, pS49, DOI 10.1259/bjr/25927054; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Rakic P, 2002, NAT REV NEUROSCI, V3, P65, DOI 10.1038/nrn700; Sasson IE, 2008, ANN NY ACAD SCI, V1127, P106, DOI 10.1196/annals.1434.014; Schwab KE, 2008, HUM REPROD, V23, P934, DOI 10.1093/humrep/den051; Schwab KE, 2007, HUM REPROD, V22, P2903, DOI 10.1093/humrep/dem265; Waldorf KMA, 2008, IMMUNOL INVEST, V37, P631, DOI 10.1080/08820130802205886; Wolff EF, 2007, REPROD SCI, V14, P524, DOI 10.1177/1933719107306896; Xu GW, 2007, CELL RES, V17, P240, DOI 10.1038/cr.2007.4; Ye M, 2007, BRAIN RES, V1142, P206, DOI 10.1016/j.brainres.2006.12.061; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	37	103	114	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA		1582-4934		J CELL MOL MED	J. Cell. Mol. Med.	APR	2011	15	4					747	755		10.1111/j.1582-4934.2010.01068.x			9	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	760GL	WOS:000290312700004	20406327	Green Accepted, Green Published			2021-06-18	
J	Leddy, JJ; Baker, JG; Kozlowski, K; Bisson, L; Willer, B				Leddy, John J.; Baker, John G.; Kozlowski, Karl; Bisson, Leslie; Willer, Barry			Reliability of a Graded Exercise Test for Assessing Recovery From Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						traumatic brain injury; treadmill; symptoms; physiology; heart rate	TRAUMATIC BRAIN-INJURY; VALIDITY; SYMPTOMS; SPORTS	Objective: To evaluate a graded treadmill test for retest reliability (RTR) and interrater reliability (IRR) in the evaluation of the physiologic effects of symptom exacerbation from concussion. Design: Prospective case series (RTR) and blinded rater assessment of 10 actors portraying patients with and without symptom exacerbation (IRR). Setting: University Sports Medicine Concussion Clinic. Participants: For RTR, 21 refractory concussed patients (11 athletes and 10 nonathletes) and 10 healthy subjects; for IRR, 32 raters representing a variety of health care disciplines. Intervention: For RTR, a Balke protocol treadmill test to symptom exacerbation before and after 2 to 3 weeks. For IRR, video recordings of actors during the treadmill test viewed by raters blinded to condition. Main Outcome Measures: For RTR, agreement of the tests for maximal heart rate (HR), systolic blood pressure, diastolic blood pressure, and rating of perceived exertion. For IRR, presence or absence of symptom exacerbation and the symptom exacerbation HR. Results: Raters achieved a sensitivity of 99% for identifying actors with symptom exacerbation and a specificity of 89% for ruling out concussion symptoms and agreed on 304 of 320 observations (accuracy of 95%). The intraclass correlation coefficient for the symptom exacerbation HR was large at 0.90 (95% confidence interval, 0.78-0.98). The treadmill test had good RTR for maximum HR (intraclass correlation coefficient, 0.79) but not for systolic blood pressure, diastolic blood pressure, or rating of perceived exertion. Conclusions: The Balke exercise treadmill protocol has very good IRR and sufficient RTR for identifying patients with symptom exacerbation from concussion.	[Leddy, John J.; Bisson, Leslie] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14260 USA; [Leddy, John J.; Bisson, Leslie] SUNY Buffalo, Sports Med Inst, Buffalo, NY 14260 USA; [Baker, John G.] SUNY Buffalo, Dept Rehabil Med & Nucl Med, Buffalo, NY 14260 USA; [Kozlowski, Karl] SUNY Buffalo, Dept Exercise & Nutr Sci, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA	Leddy, JJ (corresponding author), Univ Sports Med, 160 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	leddy@buffalo.edu	Kozlowski, Karl/H-5253-2019		Robert Rich Family Foundation; Buffalo Sabres Foundation; New York State Athletic Trainers' Association	The authors are very appreciative of the financial assistance of the Robert Rich Family Foundation, the Buffalo Sabres Foundation and the New York State Athletic Trainers' Association.	ADES PA, 1990, AM HEART J, V120, P585, DOI 10.1016/0002-8703(90)90015-P; Atkinson G, 1998, SPORTS MED, V26, P217, DOI 10.2165/00007256-199826040-00002; Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; FERNHALL B, 1990, ARCH PHYS MED REHAB, V71, P1065; Fielding RA, 1997, MED SCI SPORT EXER, V29, P1109, DOI 10.1097/00005768-199708000-00018; Finch LE, 2004, AM J PHYS MED REHAB, V83, P613, DOI 10.1097/01.phm.0000133501.62602.3f; Gaetz MB, 2009, BRIT J SPORT MED, V43, P508, DOI 10.1136/bjsm.2008.051748; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; HAGBERG JM, 1994, BAILLIERE CLIN RHEUM, V8, P29, DOI 10.1016/S0950-3579(05)80223-7; Lamb KL, 1999, BRIT J SPORT MED, V33, P336, DOI 10.1136/bjsm.33.5.336; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; PALATINI P, 1990, EUR HEART J, V11, P348, DOI 10.1093/oxfordjournals.eurheartj.a059709; Rosengren DB, 2008, DRUG ALCOHOL DEPEN, V97, P130, DOI 10.1016/j.drugalcdep.2008.03.018; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; TONINO RP, 1988, J GERONTOL, V43, pM101, DOI 10.1093/geronj/43.4.M101	21	103	104	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2011	21	2					89	94		10.1097/JSM.0b013e3181fdc721			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	728AB	WOS:000287844100003	21358497				2021-06-18	
J	McGrath, N				McGrath, Neal			Supporting the Student-Athlete's Return to the Classroom After a Sport-Related Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; mild traumatic brain injuries; academic accommodations; school concussion programs	SCHOOL FOOTBALL PLAYERS; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; COLLEGIATE; STATEMENT; RECOVERY; INJURY; RISK	Objective: This article provides a framework for school athletic trainers to use in advising colleagues about the health and academic needs of student-athletes presenting with concussions. Background: Management of sport-related concussions has been an area of growing concern for school athletic programs. Recent work in this area has highlighted significant risks for student-athletes presenting with these mild traumatic brain injuries. Description: Topics covered include general teaching points for the athletic trainer to use with school colleagues. Anintegrated model for school management of sport concussion injuries is presented that includes involvement of the student's athletic trainer, school nurse, guidance counselor, teachers, social worker, psychologist, physicians, and parents. Clinical Advantages: Academic accommodations for specific postconcussion symptoms are proposed that may help the student-athlete strike an optimum balance between rest and continued academic progress during recovery.	Sports Concuss New England, Brookline, MA 02446 USA	McGrath, N (corresponding author), Sports Concuss New England, 1368 Beacon St,Suite 116, Brookline, MA 02446 USA.	dr.neal@sportsconcussion.net					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bleiberg J., 2006, SPORTS NEUROPSYCHOLO, P263; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kaushik T., 2006, SPORTS NEUROPSYCHOLO, P216; Lovell M.R., 2006, SPORTS NEUROPSYCHOLO, P193; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; WEBBE FM, 2006, SPORTS NEUROPSYCHOLO, P45; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	103	103	0	38	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2010	45	5					492	498		10.4085/1062-6050-45.5.492			7	Sport Sciences	Sport Sciences	654GZ	WOS:000282157800011	20831397	Green Published			2021-06-18	
J	McCrea, M; Prichep, L; Powell, MR; Chabot, R; Barr, WB				McCrea, Michael; Prichep, Leslie; Powell, Matthew R.; Chabot, Robert; Barr, William B.			Acute Effects and Recovery After Sport-Related Concussion: A Neurocognitive and Quantitative Brain Electrical Activity Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; concussion; electroencephalography; neuropsychological tests	FOOTBALL PLAYERS; INJURY; EEG; COLLEGIATE; PERFORMANCE; SYMPTOMS; DEFICITS; INDEX; QEEG	Objective: To investigate the clinical utility and sensitivity of a portable, automatic, frontal quantitative electroencephalographic (QEEG) acquisition device currently in development in detecting abnormal brain electrical activity after sport-related concussion. Design: This was a prospective, non-randomized study of 396 high school and college football players, including cohorts of 28 athletes with concussion and 28 matched controls. All subjects underwent preseason baseline testing on measures of postconcussive symptoms, postural stability, and cognitive functioning, as well as QEEG. Clinical testing and QEEG were repeated on day of injury and days 8 and 45 postinjury for the concussion and control groups. Main Outcomes and Results: The injured group reported more significant postconcussive symptoms during the first 3 days postinjury, which resolved by days 5 and 8. Injured subjects also performed poorer than controls on neurocognitive testing on the day of injury, but no differences were evident on day 8 or day 45. QEEG studies revealed significant abnormalities in electrical brain activity in the injured group on day of injury and day 8 postinjury, but not on day 45. Conclusions: Results from the current study on clinical recovery after sport-related concussion are consistent with early reports indicating a typical course of full recovery in symptoms and cognitive dysfunction within the first week of injury. QEEG results, however, suggest that the duration of physiological recovery after concussion may extend longer than observed clinical recovery. Further study is required to replicate and extend these findings in a larger clinical sample, and further demonstrate the utility of QEEG as a marker of recovery after sport-related concussion.	[McCrea, Michael; Powell, Matthew R.] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI 53188 USA; [Prichep, Leslie] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY USA; [Barr, William B.] NYU, Sch Med, Dept Neurol, New York, NY USA; [Prichep, Leslie; Chabot, Robert] Nathan S Kline Inst Psychiat Res, New York State Dept Mental Hlth, Orangeburg, NY 10962 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA	McCrea, M (corresponding author), Waukesha Mem Hosp, Ctr Neurosci, 721 Amer Ave,Ste 406, Waukesha, WI 53188 USA.	michael.mccrea@phci.org		Barr, William/0000-0001-7711-7758	BrainScope, Inc	This research was supported by a clinical research grant from BrainScope, Inc, as an investigator-initiated study, with Drs McCrea and Barr as principal investigators. The investigators thank the certified athletic trainers and student athletes from those high schools and colleges that participated. We also acknowledge the insights of E. Roy John, PhD, in the concept and design of this study. Drs McCrea and Barr had full access to all of the clinical data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; Dr Prichep holds the same responsibility for the integrity and accuracy of the electrophysiological data. Drs Barr, Prichep, and Chabot serve as consultants to BrainScope, Inc, and Dr Prichep holds financial interest in BrainScope, Inc, through patented technology. None of the other authors has any conflict of interest to declare with respect to this study or article. The authors have no other personal financial or institutional interest in any of the drugs, materials, or devices described in the article. Aside from the author-investigators, representatives from BrainScope, Inc, did not play a role in the design or execution of the study beyond funding, and had no involvement in the preparation of this article.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Chen Xi-Ping, 2006, Neurosci Bull, V22, P165; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gurdjian ES, 1975, IMPACT HEAD INJURY; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kondacs A, 1999, CLIN NEUROPHYSIOL, V110, P1708, DOI 10.1016/S1388-2457(99)00122-4; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Malloy P.F., 1998, SEMIN CLIN NEUROPSYC, V3, P186; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	51	103	105	1	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					283	292		10.1097/HTR.0b013e3181e67923			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900006	20611046				2021-06-18	
J	Alcala-Barraza, SR; Lee, MS; Hanson, LR; McDonald, AA; Frey, WH; McLoon, LK				Alcala-Barraza, Sandra R.; Lee, Michael S.; Hanson, Leah R.; McDonald, Abby A.; Frey, William H., II; McLoon, Linda K.			Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS	JOURNAL OF DRUG TARGETING			English	Article						Nasal drug delivery; protein delivery; central nervous system (CNS); blood-brain barrier; distribution; neurotrophic factor; ciliary neurotrophic factor; brain-derived neurotrophic factor; insulin growth factor-1; erythropoietin; neurotrophin-4/5; intranasal delivery; brain injury; Akt	NERVE GROWTH-FACTOR; BLOOD-BRAIN-BARRIER; IN-VIVO; DRUG-DELIVERY; INDUCED NEUROTOXICITY; AXONAL REGENERATION; CHOLINERGIC NEURONS; SPINAL-CORD; RAT RETINA; INSULIN	Injury to the central nervous system (CNS) generally results in significant neuronal death and functional loss. In vitro experiments have demonstrated that neurotrophic factors such as brain-derived neurotrophic factor ( BDNF), ciliary neurotrophic factor ( CNTF), and neurotrophin-4/5 (NT-4/5) can promote neuronal survival. However, delivery to the injured CNS is difficult as these large protein molecules do not efficiently cross the blood-brain barrier. Intranasal delivery of 70 mu g [I-125]-radiolabeled BDNF, CNTF, NT-4, or erythropoietin (EPO) resulted in 0.1-1.0 nM neurotrophin concentrations within 25 min in brain parenchyma. In addition, not only did these neurotrophic factors reach the CNS, they were present in sufficient concentrations to activate the prosurvival PI3Kinase/Akt pathway, even where lower levels of neurotrophic factors were measured. Currently traumatic, ischemic and compressive injuries to the CNS have no effective treatment. There is potential clinical relevancy of this method for rescuing injured CNS tissues in order to maintain CNS function in affected patients. The intranasal delivery method has great clinical potential due to ( 1) simplicity of administration, ( 2) noninvasive drug administration, ( 3) relatively rapid CNS delivery, ( 4) ability to repeat dosing easily, ( 5) no requirement for drug modification, and ( 6) minimal systemic exposure.	[Alcala-Barraza, Sandra R.; Lee, Michael S.; McDonald, Abby A.; McLoon, Linda K.] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA; [McLoon, Linda K.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; [Hanson, Leah R.; Frey, William H., II; McLoon, Linda K.] Reg Hosp, Alzheimers Res Ctr, HealthPartners Res Fdn, St Paul, MN USA	McLoon, LK (corresponding author), Univ Minnesota, Dept Ophthalmol, 2001 6th St SE, Minneapolis, MN 55455 USA.	mcloo001@umn.edu		Frey II, William/0000-0002-6373-0794	National Eye Institute, Prevent Blindness AmericaUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI); Glaucoma Foundation; Minnesota Lions and Lionesses; Wasserman Mid-Career Merit Award from Research to Prevent Blindness (RPB)Research to Prevent Blindness (RPB); RPB Inc; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY011374, P30EY001730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008471] Funding Source: NIH RePORTER	This work was supported by EY11374 from the National Eye Institute, Prevent Blindness America, the Glaucoma Foundation, the Minnesota Lions and Lionesses, the Lew Wasserman Mid-Career Merit Award from Research to Prevent Blindness (RPB), and an unrestricted grant to the Department of Ophthalmology from RPB Inc.	Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Anderson KD, 1996, P NATL ACAD SCI USA, V93, P7346, DOI 10.1073/pnas.93.14.7346; Arancibia S, 2008, NEUROBIOL DIS, V31, P316, DOI 10.1016/j.nbd.2008.05.012; Azadi S, 2007, BRAIN RES, V1129, P116, DOI 10.1016/j.brainres.2006.10.031; Azoulay D, 2008, J NEUROIMMUNOL, V195, P186, DOI 10.1016/j.jneuroim.2008.01.010; Benedict C, 2004, PSYCHONEUROENDOCRINO, V29, P1326, DOI 10.1016/j.psyneuen.2004.04.003; Benedict C, 2008, J CLIN ENDOCR METAB, V93, P1339, DOI 10.1210/jc.2007-2606; Benedict C, 2007, NEUROENDOCRINOLOGY, V86, P136, DOI 10.1159/000106378; Blitts B, 2003, NEUROSCIENCE, V118, P271, DOI 10.1016/S0306-4522(02)00970-3; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Canals JM, 2004, J NEUROSCI, V24, P7727, DOI 10.1523/JNEUROSCI.1197-04.2004; Capsoni S, 2002, P NATL ACAD SCI USA, V99, P12432, DOI 10.1073/pnas.192442999; Chen Xue-Qing, 1998, J Alzheimers Dis, V1, P35; Chu K, 2008, EPILEPSIA, V49, P1723, DOI 10.1111/j.1528-1167.2008.01644.x; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; Danielyan L, 2005, EUR J CELL BIOL, V84, P907, DOI 10.1016/j.ejcb.2005.07.001; De Rosa R, 2005, P NATL ACAD SCI USA, V102, P3811, DOI 10.1073/pnas.0500195102; DECKNER ML, 1993, NEUROREPORT, V5, P301, DOI 10.1097/00001756-199312000-00030; Diem R, 2005, BRAIN, V128, P375, DOI 10.1093/brain/awh365; Digicaylioglu M, 2004, P NATL ACAD SCI USA, V101, P9855, DOI 10.1073/pnas.0403172101; Emerich DF, 1997, CELL TRANSPLANT, V6, P249, DOI 10.1016/S0963-6897(97)00035-3; Endres M, 2003, J CEREBR BLOOD F MET, V23, P150, DOI 10.1097/01.WCB.0000043949.67811.C6; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Fischer AJ, 2004, MOL CELL NEUROSCI, V27, P531, DOI 10.1016/j.mcn.2004.08.007; Francis G, 2009, DIABETES, V58, P934, DOI 10.2337/db08-1287; Francis GJ, 2008, BRAIN, V131, P3311, DOI 10.1093/brain/awn288; Frey WH, 1997, DRUG DELIV, V4, P87, DOI 10.3109/10717549709051878; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hallschmid M, 2008, INT J OBESITY, V32, P275, DOI 10.1038/sj.ijo.0803722; Hallschmid M, 2004, PHYSIOL BEHAV, V83, P55, DOI 10.1016/j.physbeh.2004.07.023; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Ikeda K, 2004, CURR EYE RES, V29, P349, DOI 10.1080/02713680490516279; Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022539; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LEE MY, 1997, NEUROSCIENCE, V68, P979; LEFEBVRE PP, 1994, NEUROREPORT, V5, P865, DOI 10.1097/00001756-199404000-00003; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; Liu Xin-Feng, 2004, J Stroke Cerebrovasc Dis, V13, P16, DOI 10.1016/j.jstrokecerebrovasdis.2004.01.005; MAGAL E, 1993, NEUROREPORT, V4, P779, DOI 10.1097/00001756-199306000-00046; Mandel RJ, 1999, EXP NEUROL, V155, P59, DOI 10.1006/exnr.1998.6961; Merkus Frans W H M, 2007, Drugs R D, V8, P133, DOI 10.2165/00126839-200708030-00001; Merkus P, 2003, NEUROLOGY, V60, P1669, DOI 10.1212/01.WNL.0000067993.60735.77; Misra A, 2003, J PHARM PHARM SCI, V6, P252; Nowis D, 2007, INT J ONCOL, V31, P1547; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Pietrowsky R, 1996, BIOL PSYCHIAT, V39, P332, DOI 10.1016/0006-3223(95)00180-8; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Qu HY, 2008, EUR J PHARMACOL, V594, P93, DOI 10.1016/j.ejphar.2008.06.109; Rabacchi SA, 1999, J NEUROBIOL, V40, P254, DOI 10.1002/(SICI)1097-4695(199908)40:2<254::AID-NEU11>3.3.CO;2-W; Rami A, 2008, PROG NEUROBIOL, V85, P273, DOI 10.1016/j.pneurobio.2008.04.003; Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36; Reger MA, 2006, NEUROBIOL AGING, V27, P451, DOI 10.1016/j.neurobiolaging.2005.03.016; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Sadick MD, 1997, EXP CELL RES, V234, P354, DOI 10.1006/excr.1997.3614; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Samelson L. E., 2001, CURR PROTOC IMMUNOL; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; SKAPER SD, 1992, J NEUROSCI RES, V33, P330, DOI 10.1002/jnr.490330217; Sun XM, 2008, INT J DEV NEUROSCI, V26, P363, DOI 10.1016/j.ijdevneu.2007.11.005; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Thorne RG, 2008, NEUROSCIENCE, V152, P785, DOI 10.1016/j.neuroscience.2008.01.013; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; THORNE RG, 1995, BRAIN RES, V692, P278, DOI 10.1016/0006-8993(95)00637-6; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; van Wijngaarden P, 2007, MOL VIS, V13, P1508; WAJCHENBERG BL, 1978, J NUCL MED, V19, P900; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; WIDMER HR, 1993, NEUROREPORT, V4, P363, DOI 10.1097/00001756-199304000-00005; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Yamada K, 2007, J DRUG TARGET, V15, P59, DOI 10.1080/10611860601029496; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; Yu YP, 2005, NEUROSCI LETT, V387, P5, DOI 10.1016/j.neulet.2005.07.008; Zhang QZ, 2006, J DRUG TARGET, V14, P281, DOI 10.1080/10611860600721051; Zuccato C, 2007, PROG NEUROBIOL, V81, P294, DOI 10.1016/j.pneurobio.2007.01.003	78	103	114	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1061-186X	1029-2330		J DRUG TARGET	J. Drug Target.	APR	2010	18	3					179	190		10.3109/10611860903318134			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	577ZN	WOS:000276262800003	19807216	Green Accepted			2021-06-18	
J	Reiber, GE; McFarland, LV; Hubbard, S; Maynard, C; Blough, DK; Gambel, JM; Smith, DG				Reiber, Gayle E.; McFarland, Lynne V.; Hubbard, Sharon; Maynard, Charles; Blough, David K.; Gambel, Jeffrey M.; Smith, Douglas G.			Servicemembers and veterans with major traumatic limb loss from Vietnam war and OIF/OEF conflicts: Survey methods, participants, and summary findings	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						benefits; combat; limb loss; OIF/OEF; prosthetic devices; traumatic amputation; veterans; Vietnam war; wounded servicemembers; wounded warriors	POSTTRAUMATIC-STRESS-DISORDER; OPERATIONS ENDURING FREEDOM; LOWER-EXTREMITY AMPUTATION; HEALTH-CARE UTILIZATION; PROSTHETIC-DEVICE USE; QUALITY-OF-LIFE; SKIN PROBLEMS; PSYCHOSOCIAL ADJUSTMENT; PHANTOM PAIN; AMPUTEES	Care of veterans and servicemembers with major traumatic limb loss from combat theaters is one of the highest priorities of the Department of Veteran Affairs. We achieved a 62% response rate in our Survey for Prosthetic Use from 298 Vietnam war veterans and 283 servicemembers/veterans from Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) who sustained major traumatic limb loss. Participants reported their combat injuries; health status; quality of life; and prosthetic device use, function, rejection, and satisfaction. Despite the serious injuries experienced, health status was rated excellent, very good, or good by 70.7% of Vietnam war and 85.5% of OIF/OEF survey participants. However, many health issues persist for Vietnam war and OIF/OEF survey participants (respectively): phantom limb pain (72.2%/76.0%), chronic back pain (36.2%/42.1%), residual-limb pain (48.3%/62.9%), prosthesis-related skin problems (51.0%/58.0%), hearing loss (47.0%/47.0%), traumatic brain injury (3.4%/33.9%), depression (24.5%/24.0%), and posttraumatic stress disorder (37.6%/58.7%). Prosthetic devices are currently used by 78.2% of Vietnam war and 90.5% of OIF/OEF survey participants to improve function and mobility. On average, the annual rate for prosthetic device receipt is 10.7-fold higher for OIF/OEF than for Vietnam war survey participants. Findings from this cross-conflict survey identify many strengths in prosthetic rehabilitation for those with limb loss and several areas for future attention.	[Reiber, Gayle E.; McFarland, Lynne V.; Maynard, Charles] Hlth Serv Res & Dev, Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98101 USA; [Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; [Hubbard, Sharon] Prosthet Res Study, Seattle, WA USA; [Blough, David K.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA; [Gambel, Jeffrey M.] Walter Reed Army Med Ctr, Armed Forces Amputee Patient Care Program, Washington, DC 20307 USA; [Smith, Douglas G.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Smith, Douglas G.] Univ Washington, Dept Orthoped, Seattle, WA 98195 USA	Reiber, GE (corresponding author), Hlth Serv Res & Dev, Dept Vet Affairs Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.	Gayle.Reiber@va.gov	Maynard, Charles/N-3906-2015	Maynard, Charles/0000-0002-1644-7814	VA Health Services Research and DevelopmentUS Department of Veterans Affairs [IIR 05-244]; Senior Career Scientist Award [RCS 98-353]	This material is based on work supported by VA Health Services Research and Development (grant IIR 05-244) and a Senior Career Scientist Award to Dr. Reiber (grant RCS 98-353).	American Association for Public Opinion Research, 2008, STAND DEF FIN DISP C, V5th; Andersson GBJ, 1991, OCCUPATIONAL LOW BAC, P95; Behel JM, 2002, REHABIL PSYCHOL, V47, P92, DOI 10.1037/0090-5550.47.1.92; Bellamy RF, 2007, MIL MED, V172, p[i, 1023]; BERKE GM, 2010, CURRENT, V47, P361; Blough DK, 2010, J REHABIL RES DEV, V47, P387, DOI 10.1682/JRRD.2009.04.0037; BRADWAY JK, 1984, ORTHOTICS PROSTHET, V38, P46; Bui KM, 2009, J REHABIL RES DEV, V46, P1085, DOI 10.1682/JRRD.2009.04.0052; Burger H, 2007, DISABIL REHABIL, V29, P1323, DOI 10.1080/09638280701320797; Carlson K, 2009, ASSESSMENT TREATMENT; Chan D, 2009, PSYCHIAT SERV, V60, P1612, DOI 10.1176/ps.2009.60.12.1612; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Collins Diane M., 2006, Critical Reviews in Biomedical Engineering, V34, P379; CUMMING JC, 2006, COCHRANE DB SYST REV, V11; Davidson JRT, 2004, J NEUROPSYCH CLIN N, V16, P135, DOI 10.1176/appi.neuropsych.16.2.135; DeSalvo KB, 2005, HEALTH SERV RES, V40, P1234, DOI 10.1111/j.1475-6773.2005.00404.x; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; Devlin M, 2004, ARCH PHYS MED REHAB, V85, P1339, DOI 10.1016/j.apmr.2003.09.025; DILLINGHAM TR, 1994, MIL MED, V159, P635; Dillingham TR, 2001, AM J PHYS MED REHAB, V80, P563, DOI 10.1097/00002060-200108000-00003; Dillman DA., 1999, MAIL INTERNET SURVEY; Dougherty PJ, 2010, J REHABIL RES DEV, V47, P333, DOI 10.1682/JRRD.2009.04.0043; Dougherty PJ, 2003, J TRAUMA, V54, P718, DOI 10.1097/01.TA.0000046260.16866.A9; Dougherty PJ, 2001, J BONE JOINT SURG AM, V83A, P383, DOI 10.2106/00004623-200103000-00010; Dunn DS, 1996, REHABIL PSYCHOL, V41, P285, DOI 10.1037/0090-5550.41.4.285; Ebrahimzadeh Mohammad H, 2007, J Foot Ankle Surg, V46, P429, DOI 10.1053/j.jfas.2007.08.011; Edwards P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000008.pub3; Ehde DM, 2000, ARCH PHYS MED REHAB, V81, P1039, DOI 10.1053/apmr.2000.7583; Ephraim PL, 2005, ARCH PHYS MED REHAB, V86, P1910, DOI 10.1016/j.apmr.2005.03.031; Epstein RA, 2010, J REHABIL RES DEV, V47, P373, DOI 10.1682/JRRD.2009.03.0023; Esquenazi A, 2004, DISABIL REHABIL, V26, P831, DOI 10.1080/09638280410001708850; Fowler F. J., 1993, SURVEY RES METHODS; Gailey R, 2010, J REHABIL RES DEV, V47, P317, DOI 10.1682/JRRD.2009.04.0039; Gallagher P, 1999, BEHAV MED, V25, P117, DOI 10.1080/08964289909596741; Gauthier-Gagnon C, 1999, ARCH PHYS MED REHAB, V80, P706, DOI 10.1016/S0003-9993(99)90177-6; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hagberg K, 2004, J REHABIL RES DEV, V41, P695, DOI 10.1682/JRRD.2003.11.0167; Heikkinen M, 2007, PROSTHET ORTHOT INT, V31, P277, DOI 10.1080/03093640601040244; Heinemann AW, 2003, PROSTHET ORTHOT INT, V27, P191, DOI 10.1080/03093640308726682; Highsmith James T, 2007, JAAPA, V20, P33; Hofmann SG, 2003, J ANXIETY DISORD, V17, P573, DOI 10.1016/S0887-6185(02)00227-X; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Horgan O, 2004, DISABIL REHABIL, V26, P837, DOI 10.1080/09638280410001708869; Jensen MP, 2002, PAIN, V95, P133, DOI 10.1016/S0304-3959(01)00390-6; Kerkovich DM, 2004, J REHABIL RES DEV, V41, pXI; KESSLER LG, 1987, AM J PUBLIC HEALTH, V77, P18, DOI 10.2105/AJPH.77.1.18; Ketz AK, 2008, ARCH PHYS MED REHAB, V89, P1127, DOI 10.1016/j.apmr.2007.11.037; KISHBAUGH D, 1995, MIL MED, V160, P82; Kulkarni J, 1998, CLIN REHABIL, V12, P348, DOI 10.1191/026921598672367610; Laferrier JZ, 2010, J REHABIL RES DEV, V47, P349, DOI 10.1682/JRRD.2009.03.0022; Legro MW, 1998, ARCH PHYS MED REHAB, V79, P931, DOI 10.1016/S0003-9993(98)90090-9; Legro MW, 1999, J REHABIL RES DEV, V36, P155; LIVEH H, 1999, INT J REHABIL RES, V22, P21; Maconochie N, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-4; Marshall RP, 2000, AUST NZ J PSYCHIAT, V34, P954, DOI 10.1080/000486700269; Maynard C, 2010, J REHABIL RES DEV, V47, P403, DOI 10.1682/JRRD.2009.02.0016; McFarland LV, 2010, J REHABIL RES DEV, V47, P299, DOI 10.1682/JRRD.2009.03.0027; Meatherall BL, 2005, ARCH PHYS MED REHAB, V86, P1594, DOI 10.1016/j.apmr.2004.11.026; Meulenbelt HEJ, 2007, J EUR ACAD DERMATOL, V21, P147, DOI 10.1111/j.1468-3083.2006.01936.x; Meulenbelt HEJ, 2006, DISABIL REHABIL, V28, P603, DOI 10.1080/09638280500277032; MULROW CD, QUALITY LIFE CHANGES; Murray CD, 2007, DISABIL REHABIL, V29, P1465, DOI 10.1080/09638280601107385; Nehler MR, 2003, J VASC SURG, V38, P7, DOI 10.1016/S0741-5214(03)00092-2; Norvell DC, 2005, ARCH PHYS MED REHAB, V86, P487, DOI 10.1016/j.apmr.2004.04.034; Ostojic L, 2001, CROAT MED J, V42, P535; Pasquina PF, 2008, J REHABIL RES DEV, V45, P953, DOI 10.1682/JRRD.2007.10.0163; Pasquina PF, 2006, ARCH PHYS MED REHAB, V87, pS34, DOI 10.1016/j.apmr.2005.11.026; Pasquina PF, 2004, J REHABIL RES DEV, V41, pVII; Peake JB, 2005, NEW ENGL J MED, V352, P219, DOI 10.1056/NEJMp048312; *PORTL DEP VET AFF, 2008, PAIN PAT POL SYST RE; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Reed AB, 2008, ANN VASC SURG, V22, P335, DOI 10.1016/j.avsg.2007.07.039; Reiber GE, 2010, J REHABIL RES DEV, V47, pXXIX, DOI 10.1682/JRRD.2010.03.0031; RYBARCZYK B, 1995, REHABIL PSYCHOL, V40, P95; Sigford BJ, 2010, J REHABIL RES DEV, V47, pXV, DOI 10.1682/JRRD.2009.02.0020; Singh R, 2007, CLIN REHABIL, V21, P754, DOI 10.1177/0269215507077361; Spiro A, 2006, J AMBUL CARE MANAG, V29, P71; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Van der Linde H, 2007, DISABIL REHABIL, V29, P1049, DOI 10.1080/09638280600948375; VANDER L, 2003, J REHABIL RES DEV, V41, P555; *VET BEN ADM, 2008, ANN BENEFITS REPORT; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; WARE JE, 1993, NEW ENGLAND MEDICAL; Webster Lynn R, 2008, Am J Manag Care, V14, pS116; WEED R, 1997, J REHABILITATION OUT, V1, P35; Williams RM, 2006, ARCH PHYS MED REHAB, V87, P989, DOI 10.1016/j.apmr.2006.03.006; WILLIAMSON GM, 1994, J SOC BEHAV PERS, V9, P249; 2010, J REHABIL RES DEV, V47, P409; 2007, MAJOR LIMB AMPUTEE S	91	103	107	0	22	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	4					275	297		10.1682/JRRD.2010.01.0009			23	Rehabilitation	Rehabilitation	623ZK	WOS:000279785700006	20803399	Bronze			2021-06-18	
J	Gosselin, N; Lassonde, M; Petit, D; Leclerc, S; Mongrain, V; Collie, A; Montplaisir, J				Gosselin, Nadia; Lassonde, Maryse; Petit, Dominique; Leclerc, Suzanne; Mongrain, Valerie; Collie, Alex; Montplaisir, Jacques			Sleep following sport-related concussions	SLEEP MEDICINE			English	Article						Concussion; Traumatic brain injury; Quantitative EEG; Sleep; Sport; Athletes; Delta activity; Spectral analysis	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; SCHOOL FOOTBALL PLAYERS; POSTCONCUSSION SYNDROME; PATIENT COMPLAINTS; SECONDARY INSOMNIA; SPECTRAL-ANALYSIS; RISK-FACTORS; TIME-COURSE; EEG	Objectives: Sleep and vigilance disorders Lire among the most commonly reported symptoms following a concussion. The aim of the Study was thus to investigate the effects of sport-related concussions oil subjective and objective sleep quality. Methods: Ten concussed athletes and 11 non-concussed athletes were included. Concussed athletes had a history of 4.6 +/- 2.1 concussions with at least one concussion during the last year. They were recorded for two consecutive nights in the laboratory and during a 10-min period of wakefulness. They completed questionnaires related to sleep quality and symptoms as well as neuropsychological tests anti the CogSport computer battery. Results: Concussed athletes reported more symptoms and worse sleep quality than control athletes, but no between-group differences were found oil polysomnographic variables or on REM and NREM sleep quantitative EEG variables. However, concussed athletes showed significantly more delta activity and less alpha activity during wakefulness than did control athletes. Conclusion: In spite of the subjective complaints in sleep quality of concussed athletes, no change was observed in objective sleep characteristics. However, concussions were associated with,in increase in delta and a reduction in alpha power in the waking EEG. Sport-related concussions are thus associated with wakefulness problems rather than sleep disturbances. (C) 2007 Elsevier B.V. All rights reserved.	[Gosselin, Nadia; Petit, Dominique; Mongrain, Valerie; Montplaisir, Jacques] Hop Sacre Coeur, Res Ctr Sleep & Biol Rhythms, Montreal, PQ H4J 1C5, Canada; [Gosselin, Nadia; Lassonde, Maryse] Univ Montreal, Res Ctr Neuropsychol & Cognit, Montreal, PQ, Canada; [Leclerc, Suzanne; Mongrain, Valerie; Montplaisir, Jacques] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; [Collie, Alex] Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; [Collie, Alex] CogState Ltd, Melbourne, Vic, Australia	Montplaisir, J (corresponding author), Hop Sacre Coeur, Res Ctr Sleep & Biol Rhythms, 5400 Boul, Montreal, PQ H4J 1C5, Canada.	jy.montplaisir@umontreal.ca	Mongrain, Valerie/A-3931-2012	Collie, Alex/0000-0003-2617-9339	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds pour la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This research was supported by the Canadian Institutes of Health Research (J.M. and N.G.), by the Fonds pour la Recherche en Sante du Quebec (M.L. and N.G.) and by the Natural Sciences and Engineering Research Council of Canada (V.M.). J.M. holds a Canada Research Chair in Sleep Disorders and M.L., a Canada Research Chair in Developmental Neuropsychology. The authors are grateful to Emmanuelle Baron, MD, Jimmy Gosselin, B.Sc., and Sylvie Rompre for their assistance.	Achermann P, 1995, ARCH ITAL BIOL, V134, P109; AESCHBACH D, 1993, J SLEEP RES, V2, P70, DOI 10.1111/j.1365-2869.1993.tb00065.x; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Beck AT., 1987, DEPRESSION INVENTORY; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Besset A, 1998, ELECTROEN CLIN NEURO, V107, P122, DOI 10.1016/S0013-4694(98)00048-0; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; De Gennaro L, 2004, PSYCHIAT RES, V128, P253, DOI 10.1016/j.psychres.2004.05.023; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ferrara M, 2006, BEHAV BRAIN RES, V167, P237, DOI 10.1016/j.bbr.2005.09.012; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; JENNETT B, 1975, LANCET, V1, P480; Jewett ME, 1999, J SLEEP RES, V8, P1, DOI 10.1111/j.1365-2869.1999.00128.x; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Mongrain V, 2006, EUR J NEUROSCI, V23, P497, DOI 10.1111/j.1460-9568.2005.04561.x; Motulsky H.J., 2003, FITTING MODELS BIOL; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PARSONS LC, 1982, NURS RES, V31, P260; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Perlis ML, 2001, J SLEEP RES, V10, P93, DOI 10.1046/j.1365-2869.2001.00247.x; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Perlis ML, 2001, SLEEP, V24, P110, DOI 10.1093/sleep/24.1.110; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6	48	103	106	5	32	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	JAN	2009	10	1					35	46		10.1016/j.sleep.2007.11.023			12	Clinical Neurology	Neurosciences & Neurology	407XN	WOS:000263397700008	18226956				2021-06-18	
J	DeKosky, ST; Abrahamson, EE; Ciallella, JR; Paljug, WR; Wisniewski, SR; Clark, RSB; Ikonomovic, MD				DeKosky, Steven T.; Abrahamson, Eric E.; Ciallella, John R.; Paljug, William R.; Wisniewski, Stephen R.; Clark, Robert S. B.; Ikonomovic, Milos D.			Association of increased cortical soluble A beta(42) levels with diffuse plaques after severe brain injury in humans	ARCHIVES OF NEUROLOGY			English	Article							AMYLOID-BETA-PROTEIN; HEAD-INJURY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; NEURONS; EXPRESSION; DEPOSITION; A-BETA-40; CORTEX	Background: Traumatic brain injury (TBI) is an environmental risk factor for developing Alzheimer disease. This may be due, in part, to changes associated with beta-amyloid (A beta) plaque formation, which can occur within hours after injury, regardless of the patient's age. In addition to being precursors of toxic fibrils that deposit into plaques, soluble (nonfibrillar) A beta peptides are posited to disrupt synaptic function and are associated with cognitive decline in Alzheimer disease. Changes in soluble A beta levels and their relationship to A beta plaque formation following TBI are unknown. Objective: To quantify brain tissue levels of soluble A beta peptides and their precursor protein in relation to A beta plaque formation after TBI in humans. Design: Surgically resected temporal cortex tissue from patients with severe TBI was processed for biochemical assays of soluble A beta peptides with COOH-termini ending in amino acid 40 (A beta(40)) or 42 (A beta(42)) and A beta precursor protein to compare patients with cortical A beta plaques and those without. Patients: Nineteen subjects admitted to the University of Pittsburgh Medical Center for treatment of severe closed head injury. Results: Patients with severe TBI and cortical plaques had higher levels of soluble A beta(1-42) but not A beta(1-40); half of them were apolipoprotein E (APOE) epsilon 4 allele carriers. The lowest A beta levels were in 1 patient without plaques who was the only subject with an APOE epsilon 2 allele. beta-Amyloid precursor protein levels were comparable in the 2 TBI groups. Conclusions: Selective increases in soluble A beta(1-42) after TBI may predispose individuals with a brain injury to Alzheimer disease pathology. This may be influenced by the APOE genotype, and it may confer increased risk for developing Alzheimer disease later in life.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA 15213 USA	DeKosky, ST (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 3471 5th Ave,Suite 811, Pittsburgh, PA 15213 USA.	dekoskyst@upmc.edu		Wisniewski, Stephen/0000-0002-3877-9860; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; Fagan AM, 2006, ANN NEUROL, V59, P512, DOI 10.1002/ana.20730; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Maier M, 2006, J NEUROSCI, V26, P4717, DOI 10.1523/JNEUROSCI.0381-06.2006; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rockenstein E, 2006, J NEUROSCI RES, V83, P1252, DOI 10.1002/jnr.20818; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085	26	103	104	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	APR	2007	64	4					541	544		10.1001/archneur.64.4.541			4	Clinical Neurology	Neurosciences & Neurology	155AG	WOS:000245549300011	17420316	Bronze			2021-06-18	
J	Anstey, KJ; Butterworth, P; Jorm, AF; Christensen, H; Rodgers, B; Windsor, TD				Anstey, KJ; Butterworth, P; Jorm, AF; Christensen, H; Rodgers, B; Windsor, TD			A population survey found an association between self-reports of traumatic brain injury and increased psychiatric symptoms	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						traumatic brain injury; depression; anxiety; suicide; epidemiology	ALCOHOL-CONSUMPTION; HEAD-INJURY; COLLEGE-STUDENTS; DEPRESSION; PREVALENCE; DISORDERS; COMMUNITY; ANXIETY; HEALTH; ADULTS	Objective: This study determined whether self-reported Traumatic Brain Injury (TBI), identified in a community sample and occurring up to 60 years previously, is associated with current psychiatric symptoms, suicidality, and psychologic well-being. Study Design and Setting: Three age cohorts (20-24, 40-44, 60-64) were randomly sampled from the cities of Canberra and Queanbeyan, Australia, yielding a total of 7,485 participants. The samples were administered scales measuring anxiety, depression, suicidality, positive and negative affect, personality traits, and physical health status. Results: Of the total sample, 5.7% reported history of TBI involving loss of consciousness for at least 15 min, occurring an average of 22 years previously. History of TBI was associated with increased symptoms of depression, anxiety, negative affect, and suicidal ideation. Conclusion: History of TBI is a risk factor for psychiatric morbidity. The effect is greatest in young adults, and occurs up to several decades subsequent to the occurrence of TBI. (C) 2004 Elsevier Inc. All rights reserved.	Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia	Anstey, KJ (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia.	kaarin.anstey@anu.edu.au	Anstey, Kaarin J/A-3852-2008; Christensen, Helen/F-5053-2012; Rodgers, Bryan/B-2090-2013; Anstey, Kaarin/AAB-4870-2020; Jorm, Anthony F/B-5555-2009	Christensen, Helen/0000-0003-0435-2065; Rodgers, Bryan/0000-0002-2863-3737; Jorm, Anthony F/0000-0002-1424-4116; Butterworth, Peter/0000-0002-1531-3881; Windsor, Tim/0000-0003-3725-2730; Anstey, Kaarin/0000-0002-9706-9316			BROOKS N, 1984, CLOSED HEAD INJURY P, P123; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; BUTTERWORTH P, IN PRESS J CLIN EPID; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P21, DOI 10.1016/0191-8869(85)90026-1; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FROOM P, 1992, THEOR MED, V13, P255, DOI 10.1007/BF00489202; GOLDBERG D, 1988, BRIT MED J, V297, P897, DOI 10.1136/bmj.297.6653.897; HOLMES CB, 1991, PERCEPT MOTOR SKILL, V73, P497, DOI 10.2466/PMS.73.5.497-498; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lindelow M, 1997, J EPIDEMIOL COMMUN H, V51, P549, DOI 10.1136/jech.51.5.549; MacCallum H, 2000, J EPIDEMIOL COMMUN H, V54, P77, DOI 10.1136/jech.54.1.77; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; REDMAN S, 1987, J STUD ALCOHOL, V48, P104, DOI 10.15288/jsa.1987.48.104; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Shakeshaft AP, 1999, ALCOHOL ALCOHOLISM, V34, P636, DOI 10.1093/alcalc/34.4.636; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thomas CS, 2002, BRIT J PSYCHIAT, V180, P392, DOI 10.1192/bjp.180.5.392; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Triplett G, 1996, PERCEPT MOTOR SKILL, V83, P1344, DOI 10.2466/pms.1996.83.3f.1344; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Watson D., 1994, PANASX MANUAL POSITI; Willer B, 1996, NEUROREHABILITATION, V6, P219, DOI 10.3233/NRE-1996-6308	32	103	103	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0895-4356			J CLIN EPIDEMIOL	J. Clin. Epidemiol.	NOV	2004	57	11					1202	1209		10.1016/j.jclinepi.2003.11.011			8	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	878UO	WOS:000225672800015	15567638				2021-06-18	
J	Engberg, AW; Teasdale, TW				Engberg, AW; Teasdale, TW			Psychosocial outcome following traumatic brain injury in adults: a long-term population-based follow-up	BRAIN INJURY			English	Article							HEAD-INJURY; EPIDEMIOLOGY; IMPAIRMENT; DISABILITY	Primary objective: On a national basis to conduct a 5, 10 and 15 year follow-up study of representative samples of survivors after traumatic brain injury (TBI) and to identify factors of importance for long-term survival and life satisfaction after TBI occurring in 1982, 1987 or 1992. Research design: Epidemiological, register-based questionnaire survey. Main outcomes, result and conclusions: Out of 389 survivors randomly chosen from a national complete hospital register, 173 had suffered a cranial fracture, 186 a cerebral lesion (brain contusion or traumatic haemorrhage) and 30 patients a chronic subdural haematoma. Out of 337 survivors found eligible for a questionnaire, 76% responded. Among the data registered according to the above mentioned areas, the main findings were that 23-31% of the cerebral lesion responders were unable to maintain earlier work/education at pre-injury level, against up to 14% of cranial fracture patients. Significantly more cerebral lesion patients than cranial fracture patients found emotional control more difficult, as well as increased difficulties with memory and concentration, maintenance of leisure time interests and general life satisfaction. In the long run, an important factor influencing survival among cerebral lesion patients seemed to be whether relations with family and friends could be maintained at the pre-injury level.	Copenhagen Univ Hosp, Hvidovre Hosp, Div Neurol Rehabil, DK-2650 Hvidovre, Denmark; Univ Copenhagen, Dept Psychol, DK-1168 Copenhagen, Denmark	Engberg, AW (corresponding author), Copenhagen Univ Hosp, Hvidovre Hosp, Div Neurol Rehabil, DK-2650 Hvidovre, Denmark.	aase.engberg@hh.hosp.dk					Andersen TF, 1999, DAN MED BULL, V46, P263; Brooks N., 1984, CLOSED HEAD INJURY P; Enevoldsen B, 1980, Ugeskr Laeger, V142, P544; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Haase J, 1992, Acta Neurochir Suppl (Wien), V55, P75; Hillier SL, 1997, BRAIN INJURY, V11, P661; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; LUNDHOLM J, 1975, SCAND J REHABIL MED, V7, P97; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; 1994, NYT DANMARKS STAT, P179	22	103	103	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2004	18	6					533	545		10.1080/02699050310001645829			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	811DX	WOS:000220753700002	15204335				2021-06-18	
J	Stein, SC; Chen, XH; Sinson, GP; Smith, DH				Stein, SC; Chen, XH; Sinson, GP; Smith, DH			Intravascular coagulation: a major secondary insult in nonfatal traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; thrombosis; disseminated intravascular coagulation; secondary insult; rat; pig	SEVERE HEAD-INJURY; BLOOD; COAGULOPATHY; CONTUSION; DAMAGE; RAT; DISTURBANCES; HYPEREMIA; VASOSPASM; ISCHEMIA	Object. The goal of this study was to determine the frequency with which cerebral intravascular coagulation (IC) complicates traumatic brain injury (TBI). The authors also investigated the incidence of IC in relation to varying mechanisms, time courses, and severities of TBI and in different species. Methods. Tissue was sampled from surgical specimens of human cerebral contusions, from rats with lateral fluid-percussion injuries, and from pigs with head rotational acceleration injuries. Immunohistochemical fluorescent staining for antithrombin III was performed to detect cerebral intravascular microthrombi. Abundant IC was found in all specimens, and microthrombi had formed in arterioles and venules of all sizes, ranging from 10 to 600 mum. Although it was more pronounced in focal lesions and more severe injuries, considerable IC was also observed in mild and diffuse injuries. The authors found a strong association between the severity of coagulopathy and the density of IC. Conclusions. These results strongly support the contention that IC is a universal response to TBI and an important secondary cerebral insult.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007				ATTAR S, 1969, J TRAUM, V9, P939, DOI 10.1097/00005373-196911000-00004; AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; Bostrom K, 1986, Acta Neurochir Suppl (Wien), V36, P51; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BREDBACKA S, 1992, J NEUROSURG ANESTH, V4, P128, DOI 10.1097/00008506-199204000-00008; Cortiana M, 1986, J Neurosurg Sci, V30, P133; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HOOTS K, 1983, BLOOD S, V62, pA275; HOOTS WK, 1996, NEUROTRAUMA, P673; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KAUFMAN HH, 1985, CENTRAL NERVOUS SYST, P187; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; May AK, 1997, AM SURGEON, V63, P233; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; SUZUKI M, 1994, THROMB HAEMOSTASIS, V71, P155; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Tikk A, 1979, Acta Neurochir Suppl (Wien), V28, P96; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; 1989, LANCET, V2, P957	42	103	110	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2002	97	6					1373	1377		10.3171/jns.2002.97.6.1373			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	626YG	WOS:000179901000018	12507136				2021-06-18	
J	Kinoshita, K; Chatzipanteli, K; Vitarbo, E; Truettner, JS; Alonso, OF; Dietrich, WD				Kinoshita, K; Chatzipanteli, K; Vitarbo, E; Truettner, JS; Alonso, OF; Dietrich, WD			Interleukin-1 beta messenger ribonucleic acid and protein levels after fluid-percussion brain injury in rats: Importance of injury severity and brain temperature	NEUROSURGERY			English	Article						hyperthermia; hypothermia; inflammation and secondary injury; interleukin-1 beta; traumatic brain injury	TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONIST; ADHESION MOLECULES; FACTOR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; SUBARACHNOID HEMORRHAGE; MODERATE HYPOTHERMIA; PERMEABILITY CHANGES; CEREBROSPINAL-FLUID; TNF-ALPHA	OBJECTIVE: Posttraumatic temperature. manipulations have been reported to significantly influence the inflammatory traumatic brain injury (TBI). The purpose of this study was to determine the temporal and regional profiles of messenger ribonucleic acid (mRNA) expression-and protein levels for the proinflammatory cytokine interleukin-1beta (IL-1beta), after moderate or severe TBI. The effects of posttraumatic hypothermia (33degreesC) or hyperthermia (39.5degreesC) on these consequences of TBI were then determined. METHODS: Male Sprague-Dawley rat underwent fluid-percussion brain injury. In the first,phase of the study, rats were killed 15 minutes or 1, 3, or 24 hours after moderate TBI (1.8-2.2 atmospheres), for reverse transcription-polymerase chain reaction analysis. other groups of rats were killed 1, 3, 24, or 72 hours after moderate, or severe TB,l (2.4-27 atmospheres), for protein analysis. In the second phase, rats underwent moderate fluid-percussion brain injury, followed immediately by 3 hours of posttraumatic normothermia (37degreesC), hyperthermia (39.5degreesC), or hypothermia (33degreesC), and were then killed, for analyses of protein levels and mRNA expression. Brain samples, including cerebral cortex,, hippocampus, thalamus, and cerebellum, were dissected. and stored at -80degreesC until analyzed. RESULTS: The findings indicated that mRNA levels were increased (P<0.05) as early as 1 hour after TBI and remained elevated up to 3 hours after moderate TBI. Although I both, moderate and severe TBI induced increased levels of IL-1 beta (P < 0.05), increased protein levels were also noted in remote brain structures after severe TBI. Posttraumatic hypothermia attenuated IL-1beta protein levels, compared with hormothermia (P< 0.05), although the levels remained elevated in comparison with sham values. In contrast, hyperthermia had no significant effect on, IL-1 beta levels, compared with normothermic values. Posttraumatic temperature manipulations had no significant effect on IL-1 beta mRNA levels. CONCLUSION: Injury severity determines the degree of IL-1 beta protein level elevation after TBI. The effects of posttraumatic hypothermia on IL-1 beta protein levels (an important mediator of neurodegeneration after TBI) may partly explain the established effects of posttraumatic temperature manipulations on inflammatory processes after TBI.	Univ Miami, Sch Med, Lois Pope LIFE Ctr,Dept Neurol Surg, Miami Project Cure Paralysis R48,Neurotrauma Res, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Lois Pope LIFE Ctr,Dept Neurol Surg, Miami Project Cure Paralysis R48,Neurotrauma Res, 2nd Floor,1095 NW 14 Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42133-01, 5P50-NS30291-11, T32-NS07459-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007459, P50NS030291, R01NS042133] Funding Source: NIH RePORTER		ALBELDA SM, 1994, FASEB J, V8, P504; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; Blasi F, 1999, BIOL CHEM, V380, P259, DOI 10.1515/BC.1999.034; Boutin H, 2001, J NEUROSCI, V21, P5528; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; Chao CC, 1998, BIOCHEM PHARMACOL, V56, P397, DOI 10.1016/S0006-2952(98)00161-0; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DESIMONI MG, 1993, AM J PHYSIOL, V265, pR739; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; FAN L, 1995, MOL BRAIN RES, V30, P125; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GERMANO A, 1992, NEUROSURGERY, V30, P882, DOI 10.1227/00006123-199206000-00011; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GORDON CR, 1990, ACT NEUR S, V51, P268; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hays SJ, 1998, CURR PHARM DESIGN, V4, P335; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; JOHANSEN KS, 1983, ACTA PATH MICRO IM C, V91, P355; Kataoka K, 1998, NEUROSCI RES, V32, P103, DOI 10.1016/S0168-0102(98)00076-5; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; LIU LX, 1993, INFECT MED, V10, P24; MAIMONE D, 1993, J NEUROIMMUNOL, V47, P73, DOI 10.1016/0165-5728(93)90286-8; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McIntosh TK, 1996, LAB INVEST, V74, P315; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; NORRIS JG, 1994, J IMMUNOL, V152, P841; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.0.CO;2-E; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Romero LI, 1996, AM J PHYSIOL-REG I, V270, pR518; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Soares HD, 1995, J NEUROSCI, V15, P8223; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TONNESEN MG, 1988, MOL CELLULAR BIOL WO, P149; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; UTOH J, 1992, ARTIF ORGANS, V16, P377; Vitkovic L, 2000, MOL PSYCHIATR, V5, P604, DOI 10.1038/sj.mp.4000813; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Whalen MJ, 1997, ACT NEUR S, V70, P260; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; YAMASAKI Y, 1994, ACTA NEUROCHIR, P300; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2; ZILLES KJL, 1985, CORTEX BRAIN STEREOT	77	103	107	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2002	51	1					195	203		10.1097/00006123-200207000-00027			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	569PU	WOS:000176611700041	12182417				2021-06-18	
J	Donders, J; Tulsky, DS; Zhu, JJ				Donders, J; Tulsky, DS; Zhu, JJ			Criterion validity of new WAIS-III subtest scores after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	Annual Meeting of the American-Psychological-Association	AUG 24-28, 2001	San Francisco, CA	Amer Psychol Assoc		WAIS-III; traumatic brain injury; criterion validity	MEMORY MALINGERING TOMM; VERBAL-LEARNING TEST; TEST-PERFORMANCE; HEAD-INJURY; EDUCATION; REITAN; NORMS; AGE	The criterion validity of the new subtests from the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III Wechsler, 1997) was evaluated in a sample of 100 patients with traumatic brain injury (TBI). Letter-Number Sequencing and Symbol Search, but not Matrix Reasoning, yielded statistically significant differences, in performance between patients with moderate-severe TBI, patient with mild TBI, and demographically matched controls. Level of education accounted for a statistically significant amount of variance in the performance of patients with TBI, in addition to that explained by injury severity variable. It is concluded that Letter-Number Sequencing and Symbol Search have e satisfactory, criterion validity. but that they need to he supplemented with other measure in the context of neuropsychological evaluations. Matrix Reasoning, on the other hand, is not sensitive to the sequelae of TBI and more studies are needed to determine ho it can he used for neuropsychological assessment purposes.	Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, Grand Rapids, MI USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Psychol Corp, San Antonio, TX USA	Donders, J (corresponding author), Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, 235 Wealthy,SE, Grand Rapids, MI USA.	jdonders@mfbrc.com		Tulsky, David/0000-0002-4335-4509			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CHARTER RA, 1994, J CLIN EXP NEUROPSYC, V16, P744, DOI 10.1080/01688639408402687; Crosson B., 1990, CLIN NEUROPSYCHOL, V4, P253, DOI 10.1080/13854049008401908; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dugbartey AT, 1999, CLIN NEUROPSYCHOL, V13, P396, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT396; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; HEATON RK, 2000, C NAT AC NEUR ORL FL; IVERSON G, 2000, C AM PSYCH ASS WASH; Jones R. D., 1996, P395; Kaufman AS, 1999, ESSENTIALS WAIS 3 AS; MANLY J, 2000, C AM PSYCH ASS WASH; Manly JJ, 1998, NEUROLOGY, V50, P1238, DOI 10.1212/WNL.50.5.1238; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; MILLIS SR, 1997, M INT NEUR SOC BERG; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Moses JA, 1999, ARCH CLIN NEUROPSYCH, V14, P445, DOI 10.1016/S0887-6177(98)00030-4; Naglieri JA, 1997, GEN ABILITY MEASURE; Norman MA, 2000, J CLIN EXP NEUROPSYC, V22, P80, DOI 10.1076/1380-3395(200002)22:1;1-8;FT080; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Reinecke MA, 1999, J AM ACAD CHILD PSY, V38, P322, DOI 10.1097/00004583-199903000-00020; Reitan R M, 1997, Appl Neuropsychol, V4, P16, DOI 10.1207/s15324826an0401_3; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P151, DOI 10.1080/13854049508401597; Reynolds CR, 1997, ARCH CLIN NEUROPSYCH, V12, P29, DOI 10.1016/S0887-6177(96)00015-7; SATTLER JM, 1999, ASSESSMENT CHILDREN; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vanderploeg RD, 1997, CLIN NEUROPSYCHOL, V11, P210, DOI 10.1080/13854049708407054; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler, 1997, WAIS 3 WMS 3 TECHNIC; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]	40	103	103	0	23	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2001	7	7					892	898		10.1017/S1355617701777132			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	496YV	WOS:000172426700013	11771633				2021-06-18	
J	Bryant, RA				Bryant, RA			Posttraumatic stress disorder and traumatic brain injury: Can they co-exist?	CLINICAL PSYCHOLOGY REVIEW			English	Article						posttraumatic stress disorder; brain injury; memory	MOTOR-VEHICLE ACCIDENTS; CLOSED-HEAD-INJURY; ROAD TRAFFIC ACCIDENTS; 2-YEAR PROSPECTIVE EVALUATION; PSYCHOLOGICAL CONSEQUENCES; NONSEXUAL ASSAULT; PTSD; SYMPTOMS; VICTIMS; MEMORY	The possibility that posttraumatic stress disorder (PTSD) can develop following traumatic brain injury (TBI) has been the subject of considerable debate. The traditional view has held that impaired consciousness that occurs with TBI precludes encoding of the traumatic experience, and this prevents subsequent reexperiencing symptoms. This paper critically reviews available empirical studies on PTSD in TBI populations and suggests that these two conditions can co-exist. The various mechanisms that may mediate PTSD following TBI are discussed, and special attention is given to issues that recognize the distinctive features of PTSD following TBI. These processes include implicit processing,, biologically mediated fear conditioning, and,reconstruction of trauma memories. Finally, implications for assessment, treatment, and forensic investigation of PTSD in TBI populations are addressed. This review concludes that TBI populations provide a useful means by which the role of traumatic memories (and impaired memories) in posttraumatic adjustment can be studied. (C) 2001 Elsevier Science Ltd. All rights reserved.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Bell P., 1993, INT HDB TRAUMATIC ST, P377; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; BRYANT RA, 1995, AUST J PUBLIC HEALTH, V19, P185; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; DALTON JE, 1989, INT J CLIN NEUROPSYC, V11, P121; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEITZ J, 1992, J AM ACAD PSYCHOAN, V20, P277, DOI 10.1521/jaap.1.1992.20.2.277; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; DiGallo A, 1997, BRIT J PSYCHIAT, V171, P393; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, P807, DOI 10.2466/pms.1989.68.3.807; Fearnley D, 1997, BRIT J PSYCHIAT, V171, P393; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; FOA EB, 1995, AM J PSYCHIAT, V152, P116; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRIGSBY JP, 1986, INT J CLIN NEUROPSYC, V8, P65; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1996, COGNITIVE THER RES, V20, P613, DOI 10.1007/BF02227964; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P500, DOI 10.1037/0022-006X.66.3.500; Harvey AG, 1999, J NERV MENT DIS, V187, P443, DOI 10.1097/00005053-199907000-00009; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; HARVEY AG, IN PRESS J TRAUMATIC; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Jennett B, 1981, MANAGEMENT HEAD INJU; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King SM, 1996, VISUAL NEUROSCI, V13, P1, DOI 10.1017/S0952523800007082; KOCH WJ, 1995, COGN BEHAV PRACT, V2, P327, DOI 10.1016/S1077-7229(95)80016-6; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; Kraus Jess F., 1994, P3; KRYSTAL JH, 1989, BEHAV THER, V20, P177, DOI 10.1016/S0005-7894(89)80068-1; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Ledoux J E, 1989, J Cogn Neurosci, V1, P238, DOI 10.1162/jocn.1989.1.3.238; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG C, 1983, PSYCHIAT MED, V1, P33; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Middelboe T., 1992, European Psychiatry, V7, P183; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Orr Scott P., 1997, P69; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Price K. P., 1994, DEF LAW J, V43, P113; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; RIGGS DS, 1995, J INTERPERS VIOLENCE, V10, P201, DOI 10.1177/0886260595010002005; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; RUTHERFORD WH, 1989, NEUROBEHAVIORAL RECO, P217; SALMON K, IN PRESS CLIN PSYCHO; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SBORDONE RJ, 1992, NEUROLAW LETT, V3; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; SIVEC HJ, 1995, CLIN PSYCHOL REV, V15, P297, DOI 10.1016/0272-7358(95)00012-E; SOLOMON SD, 1990, COMPR PSYCHIAT, V31, P227, DOI 10.1016/0010-440X(90)90006-E; Tarrier N, 1999, J CONSULT CLIN PSYCH, V67, P13, DOI 10.1037/0022-006X.67.1.13; Taylor S, 1995, CLIN PSYCHOL REV, V15, P721, DOI 10.1016/0272-7358(95)00043-7; Valentiner DP, 1996, J ABNORM PSYCHOL, V105, P455, DOI 10.1037/0021-843X.105.3.455; Van Der Kolk Bessel A., 1996, P214; Warda G, 1998, BEHAV RES THER, V36, P1171, DOI 10.1016/S0005-7967(98)00082-5; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P	98	103	107	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358	1873-7811		CLIN PSYCHOL REV	Clin. Psychol. Rev.	AUG	2001	21	6					931	948					18	Psychology, Clinical	Psychology	458AC	WOS:000170170300005	11497213				2021-06-18	
J	Movsesyan, VA; O'Leary, DM; Fan, L; Bao, WL; Mullins, PGM; Knoblach, SM; Faden, AI				Movsesyan, VA; O'Leary, DM; Fan, L; Bao, WL; Mullins, PGM; Knoblach, SM; Faden, AI			mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; BRAIN INJURY; NMDA-RECEPTORS; AMINO-ACIDS; CELL-DEATH; IN-VITRO; RAT; NEUROTOXICITY; ACTIVATION; MK801	The effect of selective group I metabotropic glutamate receptor subtype 5 (mGluR5) antagonists 2-methyl-6-(phenylethynyl) pyridine (MPEP) and (E)-2-methyl-6-(2-phenylethenyl)-pyridine (SIB-1893) on neuronal cell survival and post-traumatic recovery was examined using rat in vitro and in vivo trauma models. Treatment with MPEP and SIB-1893 showed significant neuroprotective effects in rat cortical neuronal cultures subjected to mechanical injury. Application of the antagonists also attenuated glutamate- and N-methyl-D-aspartate (NMDA)-induced neuronal cell death in vitro. Intracerebroventricular administration of MPEP to rats markedly improved motor recovery and reduced deficits of spatial learning after lateral fluid percussion-induced traumatic brain injury. Lesion volumes as assessed by magnetic resonance imaging were also substantially reduced by MPEP treatment. Although we show that MPEP acts as a potent mGluR5 antagonist in our culture system, where it completely blocks agonist-induced phosphoinositide hydrolysis, electrophysiological and pharmacological studies indicate that MPEP and SIB-1893 also inhibit NMDA receptor activity at higher concentrations that are neuroprotective. Taken together, these data suggest that MPEP and SIB-1893 may have therapeutic potential in brain injury, although the mechanisms of neuroprotective action for these drugs may reflect their ability to modulate NMDA receptor activity.	Georgetown Univ, Med Ctr, Dept Neurosci, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Georgetown Inst Cognit & Computat Sci, 3900 Reservoir Rd NW,Res Bldg,Rm EP12, Washington, DC 20007 USA.			Mullins, Paul/0000-0002-1339-6361	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37313] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; BAGETTA G, 1990, BRIT J PHARMACOL, V101, P776, DOI 10.1111/j.1476-5381.1990.tb14156.x; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; DOBERTY AJ, 1997, NEUROPHARMACOLOGY, V36, P265; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Haghighi SS, 1996, NEUROL RES, V18, P509; HOCKINGS PD, 1995, JMRI-J MAGN RESON IM, V5, P437, DOI 10.1002/jmri.1880050412; Holscher C, 1999, NEUROSCI BIOBEHAV R, V23, P399, DOI 10.1016/S0149-7634(98)00045-1; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KNOPFEL T, 1995, J MED CHEM, V38, P1417; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; OLEARY DM, 2001, IN PRESS BR J PHARM; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RINK A, 1995, AM J PATHOL, V147, P1575; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1111/j.1460-9568.1998.00291.x; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; UEDA Y, 1995, NEUROSCI LETT, V185, P107, DOI 10.1016/0304-3940(94)11236-C; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	36	103	105	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JAN	2001	296	1					41	47					7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	384NM	WOS:000165951800006	11123360				2021-06-18	
J	Beschorner, R; Adjodah, D; Schwab, JM; Mittelbronn, M; Pedal, I; Mattern, R; Schluesener, HJ; Meyermann, R				Beschorner, R; Adjodah, D; Schwab, JM; Mittelbronn, M; Pedal, I; Mattern, R; Schluesener, HJ; Meyermann, R			Long-term expression of heme oxygenase-1 (HO-1, HSP-32) following focal cerebral infarctions and traumatic brain injury in humans	ACTA NEUROPATHOLOGICA			English	Article						heme oxygenase-1; heat shock protein-32; traumatic brain injury; cerebral infarction; immunohistochemistry	TRANSIENT FOREBRAIN ISCHEMIA; RAT-BRAIN; MESSENGER-RNA; OXIDATIVE STRESS; HEAT-SHOCK; PROVIDES PROTECTION; CARBON-MONOXIDE; NITRIC-OXIDE; INDUCTION; PROTEIN	Extracellular heme derived from hemoglobin following hemorrhage or released from dying cells induces the expression of heme oxygenase-1 (HO-1, HSP-32) which metabolizes heme to the gaseous mediator carbon monoxide (CO), iron (Fe) and biliverdin. Biliverdin and its product bilirubin are powerful antioxidants. Thus, expression of HO-1 is considered to be a protective mechanism against oxidative stress and has been described in microglia, astrocytes and neurons following distinct experimental models of pathological alterations to the brain such as subarachnoidal hemorrhage, ischemia and traumatic brain injury (TBI) and in human neurodegenerative diseases. We have now analyzed the expression of HO-1 in human brains following TBI (n = 28; survival times: few minutes up to 6 months) and focal cerebral infarctions (FCI; n = 17; survival time: < 1 day up to months) by immunohistochemistry. Follwing TBI, accumulation of HO-1(+) microglia/macrophages at the hemorrhagic lesion was detected as early as 6 h post trauma and was still pronounced after 6 months. In contrast, after FCI HO-1(+) microglia/macrophages accumulated within focal hemorrhages only and were absent in non-hemorrhagic regions. Further, HO-1 was weakly expressed in astrocytes in the perifocal penumbra. In contrast to experimental data derived from rat focal ischemia, these results indicate a prolonged HO-1 expression in humans after brain injury.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Heidelberg Univ, Inst Legal Med, Heidelberg, Germany	Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X; Schwab, Jan/0000-0001-6784-4919; Mittelbronn, Michel/0000-0002-2998-052X			ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; AMIT Y, 1993, EXP NEUROL, V121, P248, DOI 10.1006/exnr.1993.1092; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; Bergeron M, 1997, J CEREBR BLOOD F MET, V17, P647; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CASTELLANI R, 1995, BRAIN RES, V696, P268, DOI 10.1016/0006-8993(95)00535-X; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438; Ewing JF, 1997, BRAIN RES PROTOC, V1, P165, DOI 10.1016/S1385-299X(96)00027-X; FORESTI R, 1999, J NEUROSCI RES, V56, P652; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hara E, 1996, BIOCHEM BIOPH RES CO, V224, P153, DOI 10.1006/bbrc.1996.0999; Heye N, 1996, STROKE, V27, P431, DOI 10.1161/01.STR.27.3.431; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Koistinaho J, 1996, EUR J NEUROSCI, V8, P2265, DOI 10.1111/j.1460-9568.1996.tb01190.x; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Panahian N, 1999, J NEUROCHEM, V72, P1187; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SIESJO BK, 1995, J NEUROSURG ANESTH, V7, P47, DOI 10.1097/00008506-199501000-00009; Snyder SH, 1998, BRAIN RES REV, V26, P167, DOI 10.1016/S0165-0173(97)00032-5; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Suttner DM, 1999, FASEB J, V13, P1800; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1970, J LAB CLIN MED, V75, P410; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; WEBER CM, 1994, J NEUROCHEM, V63, P953; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	51	103	105	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	OCT	2000	100	4					377	384		10.1007/s004010000202			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	341KW	WOS:000088590400005	10985695				2021-06-18	
J	Wagner, KR; Hua, Y; De Courten-Myers, GM; Broderick, JP; Nishimura, RN; Lu, SY; Dwyer, BE				Wagner, KR; Hua, Y; De Courten-Myers, GM; Broderick, JP; Nishimura, RN; Lu, SY; Dwyer, BE			Tin-mesoporphyrin, a potent heme oxygenase inhibitor, for treatment of intracerebral hemorrhage: In vivo and in vitro studies	CELLULAR AND MOLECULAR BIOLOGY			English	Article						edema; while matter; pigs; iron	LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; RAT ASTROGLIAL CELLS; LIPID-PEROXIDATION; HEAT-SHOCK; BILIRUBIN PRODUCTION; HYDROGEN-PEROXIDE; SN-MESOPORPHYRIN; BRAIN; IRON	Spontaneous intracerebral hemorrhage (ICH) is the stroke subtype with highest mortality and morbidity. ICH can also occur following traumatic brain injury and thrombolysis for ischemic stroke and myocardial infarction. Development of ICH-induced hemispheric edema can elevate intracranial pressure and cause death. In survivors, edema-related white matter injury can lead to life-long neurological deficits. At present, there are no scientifically proven treatments for ICH. Heme oxygenase products, particularly iron and bilirubin, can be toxic to cells. In cerebral ischemia models, metalloporphyrins that are potent heme oxygenase inhibitors, reduce edema and infarct size. Tin-mesoporphyrin (SnMP) is a neuroprotectant that has also been used clinically to treat hyperbilirubinemia. Presently, we tested the hypothesis that SnMP treatment would reduce edema development following experimental ICH. We produced hematomas in pentobarbital-anesthetized pigs (9-11 kg) by infusing autologous blood into the frontal white matter. To maximize tissue concentrations, SnMP (87.5 mu M in DMSO) or DMSO (vehicle controls) was included in the infused blood. Pig brains were frozen in situ at 24 hrs. following ICH and hematoma acid edema volumes were determined on coronal sections by computer-assisted image analysis. We also examined the effects of SnMP in vitro on ferritin iron release, the formation of iron-induced thiobarbituric acid reactive substances (TBARS) and initial clot formation and hemolysis. SnMP treatment significantly reduced intracerebral mass following ICH. This was due to significant decreases in hematoma (0.68 +/- 0.08 vs. 1.39 +/- 0.30 cc, vehicle controls p<0.025) and edema volumes (edema = 1.16 +/- 0.33 vs. 1.77 +/- 0.31 cc, p<0.05). In vitro, SnMP did not stabilize ferritin iron against reductive release nor did it decrease iron-induced TBARS formation in brain homogenates. SnMP or DMSO added to pig blood did not alter clot weights. In conclusion, SnMP reduced intracerebral mass in an ICH model by decreasing both hematoma and edema volumes SnMP's mechanism of action is presently unknown but may involve its potent inhibition of heme oxygenase activity. SnMP's effect appears unrelated to ferritin iron release, antioxidant activity or initial clot formation. Since SnMP treatment could be brain protective following ICH, further investigations into neurological and neuropathological outcomes and as well as into its mechanism of action are warranted.	Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Vet Affairs Med Ctr, Med Res Serv, Cincinnati, OH 45220 USA; Vet Affairs Med Ctr, Dept Neurol 111N1, Sepulveda, CA USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA; Vet Affairs Med Ctr, Res Serv 151, White River Jct, VT USA; Dartmouth Med Sch, Dept Med Neurol, Hanover, NH USA	Wagner, KR (corresponding author), Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA.	wagnerkr@email.uc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030652] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30652] Funding Source: Medline		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; Appleton SD, 1999, DRUG METAB DISPOS, V27, P1214; BABBS CF, 1990, METHOD ENZYMOL, V186, P464; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Crow JP, 1999, ARCH BIOCHEM BIOPHYS, V371, P41, DOI 10.1006/abbi.1999.1414; daSilva JL, 1996, J LAB CLIN MED, V128, P290, DOI 10.1016/S0022-2143(96)90030-X; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; DRUMMOND GS, 1987, ARCH BIOCHEM BIOPHYS, V255, P64, DOI 10.1016/0003-9861(87)90294-3; Dul K, 1994, INTRACEREBRAL HEMORR, P73; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; Dwyer BE, 1998, J NEUROCHEM, V71, P2497; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; Gebel JM, 1998, STROKE, V29, P563, DOI 10.1161/01.STR.29.3.563; Giandomenico AR, 1997, FREE RADICAL BIO MED, V23, P426, DOI 10.1016/S0891-5849(97)00113-5; GREEN D, 1990, J LAB CLIN MED, V115, P144; Hall N, 1999, J NEUROCHEM, V72, pS33; Hall N, 1998, STROKE, V29, P273; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; KASE CCL, 1994, INTRACEREBRAL HEMORR; Lamb NJ, 1999, BIOCHEM J, V344, P153, DOI 10.1042/0264-6021:3440153; Lin T. N., 1999, Society for Neuroscience Abstracts, V25, P1587; LISK DR, 1994, NEUROLOGY, V44, P133, DOI 10.1212/WNL.44.1.133; LO YK, 1994, ACTA NEUROL SCAND, V90, P83; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557; Martinez JC, 1999, PEDIATRICS, V103, P1, DOI 10.1542/peds.103.1.1; Matsuoka Y, 1999, J CEREBR BLOOD F MET, V19, P1247, DOI 10.1097/00004647-199911000-00009; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; MAYER SA, 1994, NEUROLOGY, V44, P1379, DOI 10.1212/WNL.44.8.1379; McCord JM, 1998, SEMIN HEMATOL, V35, P5; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Packard B. A., 1999, Society for Neuroscience Abstracts, V25, P1849; Panahian N, 1999, J NEUROCHEM, V72, P1187; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Peeling J, 1998, BRAIN RES, V795, P63, DOI 10.1016/S0006-8993(98)00253-4; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; Richmon JD, 1998, BRAIN RES, V780, P108, DOI 10.1016/S0006-8993(97)01314-0; SCHIPPER HM, 1991, J NEUROSCI, V11, P2170; SCHIPPER HM, 1993, J NEUROPATH EXP NEUR, V52, P399, DOI 10.1097/00005072-199307000-00007; Schipper HM, 1999, J NEUROCHEM, V72, P1802, DOI 10.1046/j.1471-4159.1999.0721802.x; Schmidt J, 1999, MOL BRAIN RES, V73, P50, DOI 10.1016/S0169-328X(99)00231-4; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Suttner DM, 1999, FASEB J, V13, P1800; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; VALAES T, 1994, PEDIATRICS, V93, P1; Wagner K, 1998, STROKE, V29, P332; Wagner K. R., 1998, Society for Neuroscience Abstracts, V24, P1230; WAGNER KR, 1985, EXP NEUROL, V89, P146, DOI 10.1016/0014-4886(85)90272-9; Wagner KR, 1997, STROKE, V28, P170; Wagner KR, 1998, J NEUROSURG, V88, P1058, DOI 10.3171/jns.1998.88.6.1058; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wagner KR, 1999, J NEUROSURG, V90, P491, DOI 10.3171/jns.1999.90.3.0491; WAGNER KR, 1995, J CEREB BLOOD FLO S1, V15, pS28; WEBER CM, 1994, J NEUROCHEM, V63, P953; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; YAGI K, 1984, METHOD ENZYMOL, V105, P328; Yoo JH, 1998, STROKE, V29, P2478, DOI 10.1161/01.STR.29.12.2478	73	103	110	0	0	C M B  ASSOC	POITIERS	34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE	0145-5680	1165-158X		CELL MOL BIOL	Cell. Mol. Biol.	MAY	2000	46	3					597	608					12	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	324QV	WOS:000087633600011	10872746				2021-06-18	
J	Benson, BW; Mohtadi, NGH; Rose, MS; Meeuwisse, WH				Benson, BW; Mohtadi, NGH; Rose, MS; Meeuwisse, WH			Head and neck injuries among ice hockey players wearing full face shields vs half face shields	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPINAL-INJURIES	Context Speculation exists that use of a full face shield by ice hockey players may increase their risk of concussions and neck injuries, offsetting the benefits of protection from dental, facial, and ocular injuries, but, to our knowledge, no data exist regarding this possibility. Objective To determine the risk of sustaining a head or neck injury among intercollegiate ice hockey players wearing full face shields compared with those wearing half shields. Design, Setting, and Participants Prospective cohort study conducted during the 1997-1998 Canadian Inter-University Athletics Union hockey season of 642 male hockey players (mean age, 22 years) from 22 teams. Athletes from 11 teams wore full face shields and athletes from 11 teams wore half face shields during play. Main Outcome Measure Reportable injury, defined as any event requiring assessment or treatment by a team therapist or physician or any mild traumatic brain injury or brachial plexus stretch, categorized by time lost from subsequent participation and compared by type of face shield. Results Of 379 athletes who wore full face shields, 195 (61.6%) had at least 1 injury during the study season, whereas of 323 who wore half lace shields, 204 (63.2%) were injured. The risk of sustaining a facial laceration and dental injury was 2.31 (95% confidence interval [CI], 1.53-3.48; P < .001) and 9.90 (95% CI, 1.88-52.1; P = .007) times greater, respectively, for players wearing half vs full face shields. No statistically significant risk differences were found for neck injuries, concussion, or other injuries, although time lost from participation because of concussion was significantly greater in the half shield group (P < .001), than in the group wearing full shields. Conclusions These data provide evidence that the use of full face shields is associated with significantly reduced risk of sustaining facial and dental injuries without an increase in the risk of neck injuries, concussions, or other injuries.	Univ Calgary, Ctr Sports Med, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Calgary, AB T2N 1N4, Canada	Meeuwisse, WH (corresponding author), Univ Calgary, Ctr Sports Med, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	meeuwiss@ucalgary.ca					Bishop P J, 1983, Can J Appl Sport Sci, V8, P19; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; Brukner P, 1996, Aust Fam Physician, V25, P1445; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Deady B, 1996, J Emerg Med, V14, P645, DOI 10.1016/S0736-4679(96)00134-5; GOODWINGERBERIC.S, 1987, CHILD NERV SYST, V3, P59; Kleinbaum D, 1982, EPIDEMIOLOGIC RES PR; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MONTELPARE WJ, 1996, EPIDEMIOLOGY SPORTS, P247; PASHBY T, 1987, CAN J OPHTHALMOL, V22, P293; PASHBY T, 1985, CAN J OPHTHALMOL, V20, P2; PASHBY T, 1993, SAFETY ICE HOCKEY, P159; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; REILLY M, 1982, ATHL TRAIN, V17, P88; SIM FH, 1987, AM J SPORT MED, V15, P30, DOI 10.1177/036354658701500105; Smith A W, 1985, Can J Appl Sport Sci, V10, P68; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1984, CAN J NEUROL SCI, V11, P34, DOI 10.1017/S0317167100045297; TATOR CH, 1991, CAN J SURG, V34, P63; TATOR CH, 1982, CAN MED ASSOC J, V127, P1077; Voaklander DC, 1996, CLIN J SPORT MED, V6, P15, DOI 10.1097/00042752-199601000-00005; WALSH S, 1989, SAFETY ICE HOCKEY, P55; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	27	103	103	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2328	2332		10.1001/jama.282.24.2328			5	Medicine, General & Internal	General & Internal Medicine	265TK	WOS:000084261700026	10612320	Bronze			2021-06-18	
J	Dahiya, R; Keller, JD; Litofsky, NS; Bankey, PE; Bonassar, LJ; Megerian, CA				Dahiya, R; Keller, JD; Litofsky, NS; Bankey, PE; Bonassar, LJ; Megerian, CA			Temporal bone fractures: Otic capsule sparing versus otic capsule violating clinical and radiographic considerations	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						temporal bone fractures; otic capsule sparing fractures; otic capsule violating fractures; intracranial complications; otologic complications	TRAUMA	Objective: To assess the practicality and utility of the traditional classification system for temporal bone fracture (transverse vs, longitudinal) in the modern Level I trauma setting and to determine whether a newer system of designation (otic capsule sparing vs. otic capsule violating fracture) is practical from a clinical and radiographic standpoint, Methods: The University of Massachusetts Medical Center Trauma Registry was reviewed for the years 1995 to 1997. Patients identified as sustaining closed head injury were reviewed for basilar skull fracture and temporal bone fracture. Clinical and radiographic records were evaluated by using the two classification schemes. Results: A total of 2,977 patients were treated at the trauma center during this time, Ninety (3%) patients sustained a temporal bone fracture. The classic characterization of transverse versus longitudinal fracture (20% vs. 80%, respectively) was unable to be determined in this group; therefore, clinical correlation to complications using that paradigm was not possible. By using the otic capsule violating versus sparing designation, an important difference in clinical sequelae and intracranial complications became apparent, Compared with otic capsule sparing fractures, patients with otic capsule violating fractures were approximately two times more likely to develop facial paralysis, four times more likely to develop CSF leak, and seven times more likely to experience profound hearing loss, as well as more likely to sustain intracranial complications including epidural hematoma and subarachnoid hemorrhage, Conclusion: The use of a classification system for temporal bone fractures that emphasizes violation or lack of violation of the otic capsule seems to offer the advantage of radiographic utility and stratification of clinical severity, including severity of Glasgow Coma Scale scores and intracranial complications such as subarachnoid hemorrhage and epidural hematoma.	Univ Massachusetts, Sch Med, Dept Otolaryngol HNS, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Surg, Div Neurosurg, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Div Trauma Surg, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Anesthesiol, Worcester, MA 01655 USA	Megerian, CA (corresponding author), Univ Massachusetts, Sch Med, Dept Otolaryngol HNS, 55 Lake Ave N, Worcester, MA 01655 USA.		Bonassar, Lawrence J/C-2103-2016	Bonassar, Lawrence J/0000-0003-1094-6433			BARRS DM, 1991, LARYNGOSCOPE, V101, P835; Brodie HA, 1997, AM J OTOL, V18, P188; GHORAYEB BY, 1992, LARYNGOSCOPE, V102, P129; GURDJIAN ES, 1946, SURG GYNECOL OBSTET, V83, P219; LIEBETRAU R, 1993, J OTOLARYNGOL, V22, P249; LYOS AT, 1995, ARCH OTOLARYNGOL, V121, P795; MCKENNAN KX, 1992, AM J OTOL, V13, P1167; NAGERIS B, 1995, AM J EMERG MED, V13, P211, DOI 10.1016/0735-6757(95)90096-9; Nosan DK, 1997, OTOLARYNG HEAD NECK, V117, P67, DOI 10.1016/S0194-5998(97)70209-2; SOFFERMAN RA, 1993, SURG EAR TEMPORAL BO, P333; TRAVIS LV, 1997, J TRAUMA, V17, P761; WENNMO C, 1993, AM J OTOLARYNG, V14, P38, DOI 10.1016/0196-0709(93)90008-U; Yanagihara N, 1997, Ear Nose Throat J, V76, P79	13	103	107	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1999	47	6					1079	1083		10.1097/00005373-199912000-00014			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	266JD	WOS:000084296100019	10608536				2021-06-18	
J	Cattelani, R; Lombardi, F; Brianti, R; Mazzucchi, A				Cattelani, R; Lombardi, F; Brianti, R; Mazzucchi, A			Traumatic brain injury in childhood: intellectual, behavioural and social outcome into adulthood	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; YOUNG-ADULTS; CHILDREN; SEQUELAE; REHABILITATION	In order to obtain indicative data regarding intellectual, behavioural and social outcome into adulthood of subjects with a history of childhood head injury (CHI), twenty adults were selected who had been referred to the Neuropsychology Unit at the University of Parma at the: time of a traumatic brain injury (TBI) at an age between 8 and 14 years. The level of intellectual and behavioural impairment was determined and rated by WISC and WAIS IQa and by the frequency of maladjustive behaviour. GOS score and Barthel index were used to detect the level of disability. Social adjustment and community integration were determined by the Social Adjustment Scale (SAS) and the Community Integration Questionnaire (CIQ) respectively. Results indicate that (1) subjects who suffer a severe CHI present a higher pre-injury incidence of character disturbances than the normal population and injury-related difficulties to socialize which persist long-term and add to other problems; (2) even though intellectual and functional sequelae are frequent in these children in adulthood and do not improve in their correlation to age, these do not appear to be the prevailing problems and (3) the prevailing problems seem to be social maladjustment and poor quality of life, which art: still present several years post-injury and seem to be related to behavioural and psychosocial disorders in spite of an increased ADL-functioning. This has already been clearly demonstrated in the case of adulthood trauma.	Univ Parma, Dept Neurol, Neuropsychol Unit, I-43100 Parma, Italy	Cattelani, R (corresponding author), Univ Parma, Ist Neurol, Sez Neuropsicol, Str Quartiere 4, I-43100 Parma, Italy.		Brianti, Rodolfo/H-2152-2013	Brianti, Rodolfo/0000-0001-8069-3502; LOMBARDI, Francesco/0000-0002-7184-6391			Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; BOND MR, 1990, REHABILITATION ADULT, P59; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUZY S, 1996, J HEAD TRAUMA REHAB, V11, P74; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DAVIDSON LL, 1988, PEDIATRICS, V82, P644; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; GOODMAN R, 1989, CHILDRENS HEAD INJUR, P12; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; JAFFE KM, 1994, ARCH PHYSICAL MED RE, V75, P733; JENNETT B, 1975, LANCET, V1, P480; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LANGLEY J, 1983, Journal of Pediatric Psychology, V8, P181, DOI 10.1093/jpepsy/8.2.181; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; LOMBARDI F, 1996, INT C REC ADV NEUR R, P521; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAHONEY F I, 1965, Md State Med J, V14, P61; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MANHEIMER DI, 1967, CHILD DEV, V38, P491, DOI 10.1111/j.1467-8624.1967.tb04358.x; MATHENY AP, 1971, J PEDIATR-US, V79, P122, DOI 10.1016/S0022-3476(71)80071-9; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PARTINGTON MW, 1960, ARCH DIS CHILD, V35, P215, DOI 10.1136/adc.35.181.215; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Rimel RW, 1990, REHABILITATION ADULT, P8; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; TATE RL, 1971, J MENTAL NERVOUS DIS, V179, P117; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEISSMAN MM, 1975, ARCH GEN PSYCHIAT, V32, P357; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	39	103	104	0	12	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1998	12	4					283	296		10.1080/026990598122584			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZF942	WOS:000072948700004	9562911				2021-06-18	
J	LaPlaca, MC; Lee, VMY; Thibault, LE				LaPlaca, MC; Lee, VMY; Thibault, LE			An in vitro model of traumatic neuronal injury: Loading rate-dependent changes in acute cytosolic calcium and lactate dehydrogenase release	JOURNAL OF NEUROTRAUMA			English	Article						cellular injury; intracellular free calcium; lactate dehydrogenase; mechanical injury; NT2-N cells; traumatic brain injury models	EXPERIMENTAL BRAIN INJURY; NTERA-2 CELLS; INVITRO; CULTURE; ANTAGONISTS; RESPONSES; CONTUSION; PROTEINS; PRIMATE; DAMAGE	We developed a new in vitro model of neuronal injury using NT2-N cells to examine the effects of hydrodynamic loading rate on intraneuronal calcium dynamics and lactate dehydrogenase (LDH) release, Our apparatus consisted of a parallel disk viscometer which induced fluid shear stress with well-defined magnitudes and loading rates to cultured cells, We found that the deformation response of the cells was dependent on the severity of the insult, with increased cellular strains generated for higher shear stresses at a constant loading rate, Peak intracellular free calcium concentration correlated with strain, suggesting that mechanical deformation may regulate calcium response, Slowly applied fluid shear stress elicited no response, whereas high loading rates resulted in peak calcium increases 2.9 to 3.6 times baseline values as injury severity was increased, LDH release measured within 5 min after the insult correlated with loading rate, Zn addition, LDH release continued to increase out to 24 h following high loading rate conditions, demonstrating that the application of fluid shear stress led to prolonged cell damage, The acute response in NT2-N cells subjected to an insult with the CSID is dependent on the loading rate, and these results suggest that initial membrane deformation may trigger subsequent events.	UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; ALLEGHENY UNIV HLTH SCI, DEPT NEUROSURG, DIV BIOENGN, PHILADELPHIA, PA 19102 USA	LaPlaca, MC (corresponding author), UNIV PENN, DIV NEUROSURG, DEPT BIOENGN, 102B HAYDEN HALL, 3320 SMITH WALK, PHILADELPHIA, PA 19104 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R491CCR304684] Funding Source: Medline		BALENTINE JD, 1988, LAB INVEST, V58, P93; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1990, FID RES FDN, V4, P235; *DEP HLTH HUM SERV, 1989, INT HEAD INJ TASK FO; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1984, CENTRAL NERVOUS SYST; GENNARELLI TA, 1972, 16 STAPP CAR CRASH C; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOLDSTEIN DM, 1994, J NEUROTRAUM, V11, P110; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GROSS GW, 1983, J NEUROSCI, V3, P1979; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LEE VMY, 1986, J NEUROSCI, V6, P514; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCINTOSH TK, 1989, NEUROSCI; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SAATMAN KE, 1994, J NEUROTRAUMA, V11, P125; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMON SI, 1990, BIOPHYS J, V58, P319, DOI 10.1016/S0006-3495(90)82379-1; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SOMERSON SK, 1987, EXP NEUROL, V96, P82, DOI 10.1016/0014-4886(87)90170-1; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THIBAULT LE, 1993, ACCIDENTAL INJURY BI, P512; THIBAULT LE, 1985, BIOMECHANICS DIFFUSE; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; TYMNAISKI M, 1993, NEURON, V11, P221; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1	50	103	108	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1997	14	6					355	368		10.1089/neu.1997.14.355			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XJ836	WOS:A1997XJ83600001	9219851				2021-06-18	
J	Jaicks, RR; Cohn, SM; Moller, BA				Jaicks, RR; Cohn, SM; Moller, BA			Early fracture fixation may be deleterious after head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head trauma; secondary brain injury; fracture fixation	MULTIPLE TRAUMA PATIENTS; LONG-BONE FRACTURES; FEMUR FRACTURES; PULMONARY; OSTEOSYNTHESIS; MANAGEMENT; STATE	Objective: To determine the neurologic risks associated with early fracture fixation (FF) in multitrauma patients with head injuries. Methods: We reviewed 33 blunt trauma patients with significant closed head injuries (Abbreviated Injury Scale (AIS) score greater than or equal to 2) requiring operative FF. Nineteen patients underwent early FF defined as less than or equal to 24 hours after injury, and 14 patients underwent late FF defined as >24 hours after injury, The two groups were well matched in regards to age, 40.3 years (range, 8-88 years) versus 36.4 Sears (range, 8-75 Sears), admission Glasgow Coma Scale score (12 +/- 4 vs. 11 +/- 5), and Injury Severity Score (25 +/- 10 vs. 27 +/- 12). Additionally, the groups had similar neurologic and orthopedic injury scores (AIS-CNS score = 3.3 +/- 0.9 vs. 3.1 +/- 0.9, AIS-Ortho score = 3.0 +/- 0.9 vs. 2.9 +/- 0.7), Data were collected concerning the volume of fluid resuscitation, neurologic complications, and clinical outcomes. Results: The early FF group received significantly more fluids in the first 48 hours (14.0 +/- 10.2 vs. 8.7 +/- 3.5 liters, p < 0.05). The early group trended towards a higher rate of intraoperative hypotension (systolic blood pressure < 90 mm Hg, 16% vs. 7%) and intraoperative hypoxia (O-2-Saturation less than or equal to 90, 11% vs. 7%), The neurologic complication rate was similar in the two groups (early FF = 16% vs. late FF = 21%), but the average discharge Glasgow Coma Scale score was lower in the early group (13.5 +/- 3.7) when compared with the late FF patient group (15.0 +/- 0.0). Conclusions: Early FF leads to greater fluid administration in patients with head injuries, Hypoxemia and hypotension, risk factors for secondary brain injury, may contribute to a poor neurologic outcome after early fixation, Prospective studies evaluating the impact of the timing of FF on head injury are indicated.	YALE UNIV,SCH MED,DEPT SURG,SECT TRAUMA & SURG CRIT CARE,NEW HAVEN,CT 06520							BECKMAN SB, 1989, AM SURGEON, V56, P356; BEHRMAN SW, 1990, J TRAUMA, V30, P792, DOI 10.1097/00005373-199007000-00005; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BONE LB, 1994, J TRAUMA, V37, P262, DOI 10.1097/00005373-199408000-00019; CHARASH WE, 1994, J TRAUMA, V37, P667, DOI 10.1097/00005373-199410000-00023; Chesnut R M, 1995, New Horiz, V3, P366; FAKHRY SM, 1994, J TRAUMA, V37, P255, DOI 10.1097/00005373-199408000-00018; GORIS RJA, 1982, J TRAUMA, V22, P895, DOI 10.1097/00005373-198211000-00002; HOFMAN PAM, 1991, J TRAUMA, V31, P261, DOI 10.1097/00005373-199131020-00020; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; KOTWICA Z, 1990, ACTA NEUROCHIR, V102, P19, DOI 10.1007/BF01402180; LOZMAN J, 1986, ARCH SURG-CHICAGO, V121, P992; PAPE HC, 1993, J TRAUMA, V34, P540, DOI 10.1097/00005373-199304000-00010; PELIAS ME, 1992, SURGERY, V111, P576; POOLE GV, 1992, J TRAUMA, V32, P654, DOI 10.1097/00005373-199205000-00019; REYNOLDS MA, 1995, ANN SURG, V222, P470; RISKA EB, 1977, J TRAUMA, V17, P111, DOI 10.1097/00005373-197702000-00005; ROGERS FB, 1994, J TRAUMA, V36, P774, DOI 10.1097/00005373-199406000-00004; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; VANOS JP, 1994, J TRAUMA, V37, P262	20	103	106	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1997	42	1					1	5		10.1097/00005373-199701000-00001			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	WD269	WOS:A1997WD26900001	9003250				2021-06-18	
J	Fukuda, K; Richmon, JD; Sato, M; Sharp, FR; Panter, SS; Noble, LJ				Fukuda, K; Richmon, JD; Sato, M; Sharp, FR; Panter, SS; Noble, LJ			Induction of heme oxygenase-1 (HO-1) in glia after traumatic brain injury	BRAIN RESEARCH			English	Article						heme oxygenase; astrocyte; microglia; macrophage; Bergmann glia; heat shock protein	HEAT-SHOCK PROTEIN; MESSENGER-RNA; RAT-BRAIN; LIPID-PEROXIDATION; RAPID INDUCTION; EXPRESSION; ANTIOXIDANT; MECHANISMS; HYPERTHERMIA; MICROGLIA	In this study we examined the induction of heme oxygenase-1 (HO-1) in glia in the traumatized rat brain. HO-1 was immunolocalized in fixed sections of brain 3 h to 5 days after injury. Induction of this enzyme in astrocytes, microglia/macrophages, and oligodendrocytes was evaluated using immunofluorescent double labeling with monoclonal antibodies to glial fibrillary acidic protein, complement C3bi receptor, and myelin basic protein. Induction of HO-1 was apparent in the injured hemisphere and cerebellum as early as 24 h postinjury. The protein was likewise noted in similar regions of the brain at 72 h postinjury but appeared to be more widespread in its distribution. At 5 days postinjury, there was a notable decline in the degree of immunostaining for HO-1. HO-1 was typically induced in astrocytes in the cerebral cortex at the site of impact, in the deep cortical layers adjacent to the hemorrhagic lesions, and in the hippocampus. HO-1 was induced in Bergmann glia in the vermis of cerebellum. In addition, HO-1 was also induced in microglia/macrophages scattered throughout the ipsilateral cerebral cortex, cerebellum and subarachnoid space. These findings demonstrate prolonged glial induction of HO-1 in the traumatized brain. Such a response may reflect a protective role of these cells against secondary insults including oxidative stress.	SAN FRANCISCO GEN HOSP,DEPT NEUROSURG,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121			Richmon, Jeremy/ABI-4295-2020	Richmon, Jeremy/0000-0002-6588-6549	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL53040] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543, NS28167] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL053040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, R01NS028167, P50NS014543] Funding Source: NIH RePORTER		APPLEGATE LA, 1991, CANCER RES, V51, P974; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177; MAINES MD, 1988, FASEB J, V2, P2557; MATZ P, 1996, MOL BRAIN RES, V713, P211; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; PASCHEN W, 1994, NEUROSCI LETT, V180, P5, DOI 10.1016/0304-3940(94)90900-8; PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399; SCHIPPER HM, 1995, ANN NEUROL, V37, P758, DOI 10.1002/ana.410370609; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; THOMAS WE, 1992, BRAIN RES REV, V17, P61; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; TURNER CP, 1995, SOC NEUR ABSTR, V25, P496; WHITE BC, 1993, ANN EMERG MED, V22, P970, DOI 10.1016/S0196-0644(05)82737-4	29	103	105	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 14	1996	736	1-2					68	75		10.1016/0006-8993(96)00680-4			8	Neurosciences	Neurosciences & Neurology	VR613	WOS:A1996VR61300009	8930310				2021-06-18	
J	SERVADEI, F; NANNI, A; NASI, MT; ZAPPI, D; VERGONI, G; GIULIANI, G; ARISTA, A				SERVADEI, F; NANNI, A; NASI, MT; ZAPPI, D; VERGONI, G; GIULIANI, G; ARISTA, A			EVOLVING BRAIN-LESIONS IN THE FIRST 12 HOURS AFTER HEAD-INJURY - ANALYSIS OF 37 COMATOSE PATIENTS	NEUROSURGERY			English	Article						COMATOSE PATIENTS; EVOLVING INTRACRANIAL LESIONS; SUBDURAL, EXTRADURAL, AND INTRACEREBRAL HEMATOMAS; SURGICAL INDICATIONS; TIMING OF COMPUTED TOMOGRAPHIC SCAN	ACUTE SUBDURAL-HEMATOMA; ACUTE EXTRADURAL HEMATOMA; EPIDURAL HEMATOMAS; MANAGEMENT; TRAUMA; RESOLUTION; TOMOGRAPHY; MORTALITY	FROM JANUARY 1, 1990, to April 30, 1994, 412 patients were admitted to our intensive care unit in coma after head injuries. Our study group consisted of 37 patients who were retrospectively identified as harboring lesions or developing new lesions within a 12-hour period from the time of admission. We defined the evolution of a lesion as an increase or decrease in the size of an already present hematoma or as the appearance of a totally new lesion. There were 25 male and 12 female patients (mean age, 34.9 yr), and the cause of trauma was road traffic accidents in 32 patients. Nine patients presented with shock, and six had evidence of abnormal coagulation at admission, Patients were divided into two different groups. In Group 1, 15 patients harbored lesions that evolved toward reabsorption. In Group 2, 22 patients harbored hematomas that evolved toward lesions requiring surgical removal. Fifteen of these patients had initial diagnoses of diffuse injury that evolved in this manner, whereas the remaining seven patients had already been operated upon and had developed second, noncontiguous, surgical lesions. Patients with lesions that required surgical evacuation had their computed tomographic (CT) scans obtained earlier and had a higher incidence of clinical deterioration. There was a significant difference in the evolution of the different lesions (P < 0.001), with subdural hematomas being more prone to reabsorption and intracerebral and extradural hematomas being more likely to increase in size or to appear as new lesions. Second CT scans were obtained because of clinical deterioration in 10 patients and because of increase in intracranial pressure in 5 patients. Scheduled CT scans were obtained in 13 patients, whereas in the remaining 9 patients, the diagnosis emerged from a combination of scheduled CT scans and intracranial pressure monitoring. There was a trend toward a poorer result among the patients with clinical deterioration, which, however, was not significant. A significant proportion of post-traumatic patients, particularly those who are unconscious, harbor early evolving intracranial lesions. When the first CT scan is performed within 3 hours after injury, a CT scan should be repeated within 12 hours.	OSPED GEN PROVINCIALE M BUFALINI, INTENS CARE UNIT, I-47023 CESENA, ITALY; OSPED GEN PROVINCIALE M BUFALINI, SERV NEURORADIOL, I-47023 CESENA, ITALY	SERVADEI, F (corresponding author), OSPED GEN PROVINCIALE M BUFALINI, DIV NEUROSURG, I-47023 CESENA, ITALY.			Servadei, Franco/0000-0002-3595-3464			AOKI N, 1986, J NEUROSURG, V65, P555, DOI 10.3171/jns.1986.65.4.0555; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; BULLOCK R, 1990, HDB CLIN NEUROLOGY H, V13, P249; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Cooper PR, 1993, HEAD INJURY, P275; CROCE MA, 1994, J TRAUMA, V36, P820, DOI 10.1097/00005373-199406000-00012; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; JENNETT B, 1975, LANCET, V1, P480; KATAYAMA Y, 1993, INTRACRANIAL PRESSUR, V8, P678; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MILLER JD, 1987, ACTA NEUROCHIR, V85, P80, DOI 10.1007/BF01456102; NAGAO T, 1986, NEUROSURGERY, V19, P465, DOI 10.1227/00006123-198609000-00024; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; POLMAN CH, 1986, NEUROSURGERY, V19, P446, DOI 10.1227/00006123-198609000-00019; POON WS, 1992, NEUROSURGERY, V30, P681; REALE F, 1985, SURG NEUROL, V24, P260, DOI 10.1016/0090-3019(85)90034-5; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1989, J TRAUMA, V29, P880, DOI 10.1097/00005373-198906000-00030; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	31	103	108	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	1995	37	5					899	906		10.1227/00006123-199511000-00008			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TC381	WOS:A1995TC38100023	8559338				2021-06-18	
J	KAUFMANN, PM; FLETCHER, JM; LEVIN, HS; MINER, ME; EWINGCOBBS, L				KAUFMANN, PM; FLETCHER, JM; LEVIN, HS; MINER, ME; EWINGCOBBS, L			ATTENTIONAL DISTURBANCE AFTER PEDIATRIC CLOSED-HEAD INJURY	JOURNAL OF CHILD NEUROLOGY			English	Article							CHILDREN; ADOLESCENTS; MEMORY	The influence of severity of closed head injury and age on attentional functioning was prospectively investigated in 36 children (age range, 7 to 16 years) 6 months after injury. Children were placed into mild, moderate, and severe injury groups using established neurologic criteria. Each child received the Wechsler Intelligence Scale for Children-Revised Digit Span subtest and a continuous performance test. Children with severe closed head injury demonstrated significantly poorer continuous performance test scores than mildly or moderately injured children. Injury severity had no effect on Digit Span scores. Younger children exhibited more pronounced impairment on the continuous performance test relative to uninjured age peers. These results extend the persistence of attentional impairments beyond those of previous reports. Closed head injury is not associated with preferential sparing of sustained attention in younger children 6 months after injury. Brain injury earlier in life may result in delayed vulnerability of information processing skills.	UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77025; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; OHIO STATE UNIV HOSP,DIV NEUROSURG,COLUMBUS,OH 43210	KAUFMANN, PM (corresponding author), UNIV ARIZONA,COLL MED,DEPT PEDIAT,PEDIAT NEUROL SECT,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD027597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [NICHD HD-27597] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NINCDS NS-21889] Funding Source: Medline		Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; KAUFMANN PM, 1989, J CLIN EXP NEUROPSYC, V11, P367; KAUFMANN PM, 1989, J CLIN EXP NEUROPSYC, V11, P33; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; MURPHYBERMAN V, 1987, PERCEPT MOTOR SKILL, V64, P1139, DOI 10.2466/pms.1987.64.3c.1139; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Sattler J.M., 1988, ASSESSMENT CHILDRENS, V3rd; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	18	103	103	0	1	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	OCT	1993	8	4					348	353		10.1177/088307389300800410			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	MA260	WOS:A1993MA26000010	8228030				2021-06-18	
J	DEWITT, DS; PROUGH, DS; TAYLOR, CL; WHITLEY, JM				DEWITT, DS; PROUGH, DS; TAYLOR, CL; WHITLEY, JM			REDUCED CEREBRAL BLOOD-FLOW, OXYGEN DELIVERY, AND ELECTROENCEPHALOGRAPHIC ACTIVITY AFTER TRAUMATIC BRAIN INJURY AND MILD HEMORRHAGE IN CATS	JOURNAL OF NEUROSURGERY			English	Article						CEREBRAL BLOOD FLOW; HEAD INJURY; SHOCK; HEMORRHAGE; CAT	FLUID-PERCUSSION INJURY; HEAD-INJURY; ISOVOLEMIC HEMODILUTION; HYPERTONIC SALINE; RESUSCITATION; SHOCK; HYPOTENSION; METABOLISM; HEMODYNAMICS; ISCHEMIA	The authors investigated the effects of transient, mild hemorrhagic hypotension after fluid-percussion traumatic brain injury on intracranial pressure, cerebral blood flow (CBF), cerebral oxygen delivery (CBF x arterial O2 content), and electroencephalographic (EEG) activity. Adult mongrel cats were anesthetized with 1.6% isoflurane in N2O:O2 (70:30) and prepared for trauma and for radioactive microsphere CBF measurement. Isoflurane concentration was decreased to 0.8%, and the cats were randomly assigned to one of four control groups or to an experimental group. Animals in the four control groups underwent either mild hemorrhage (18 ml . kg-1) immediately followed by resuscitation with equal volumes of 10% Hetastarch (eight cats), mild hemorrhage followed by replacement of shed blood (six cats), isovolemic hemodilution with 18 ml . kg-1 of Hetastarch (six cats), or moderate (2.2 atm) trauma alone (eight cats). The experimental group received a combination of trauma and mild hemorrhage followed by resuscitation with Hetastarch (eight cats). Mild hemorrhage produced no significant changes in CBF, renal blood flow, or cardiac output. Following resuscitation from mild hemorrhage, mean arterial blood pressure, cardiac output, renal blood flow, and CBF were not significantly different from baseline; cardiac output and renal blood flow did not differ significantly from baseline 2 hours after Hetastarch resuscitation. Neither hemorrhage nor trauma alone produced significant decreases in CBF or in EEG activity, but trauma followed by hemorrhage and resuscitation produced significant (p < 0.01) decreases in CBF, cerebral oxygen delivery, and EEG score. These data demonstrate that, following traumatic brain injury, even mild hemorrhagic hypotension is associated with significant deficits in cerebral oxygen availability and neurological function.	WAKE FOREST UNIV,MED CTR,DEPT ANAT,WINSTON SALEM,NC 27109; WAKE FOREST UNIV,MED CTR,DEPT NEUROL,WINSTON SALEM,NC 27109; WAKE FOREST UNIV,MED CTR,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27109	DEWITT, DS (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT ANESTHESIA,WINSTON SALEM,NC 27157, USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [19355] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; CHEN RYZ, 1984, STROKE, V15, P343, DOI 10.1161/01.STR.15.2.343; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COKER LH, 1989, ANESTHESIOLOGY, V71, P108; COLE JWL, 1966, BIOMETRICS, V22, P810, DOI 10.2307/2528076; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; EMERSON TE, 1981, CEREBRAL MICROCIRCUL, P379; FIESCHI C, 1972, EUR NEUROL, V8, P192, DOI 10.1159/000114577; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENBERG RP, 1981, SURG FORUM, V32, P492; GREGORY PC, 1979, STROKE, V10, P719, DOI 10.1161/01.STR.10.6.719; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOFFBRAND BI, 1969, CARDIOVASC RES, V3, P426, DOI 10.1093/cvr/3.4.426; HOLM S, 1979, SCAND J STAT, V6, P65; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KONG DL, 1991, CRIT CARE MED, V19, P532, DOI 10.1097/00003246-199104000-00013; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCNAMARA JJ, 1983, J TRAUMA, V23, P552, DOI 10.1097/00005373-198307000-00002; MICHENFELDER JD, 1969, ANESTHESIOLOGY, V31, P449, DOI 10.1097/00000542-196911000-00017; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NEES JE, 1978, SURGERY, V83, P639; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; POOLE GV, 1986, CRIT CARE MED, V14, P629, DOI 10.1097/00003246-198607000-00009; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRIOR PF, 1978, BRIT J ANAESTH, V50, P993, DOI 10.1093/bja/50.10.993; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEASDALE G, 1974, LANCET, V2, P81; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	46	103	103	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1992	76	5					812	821		10.3171/jns.1992.76.5.0812			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HQ269	WOS:A1992HQ26900013	1564544				2021-06-18	
J	Shively, SB; Horkayne-Szakaly, I; Jones, RV; Kelly, JP; Armstrong, RC; Perl, DP				Shively, Sharon Baughman; Horkayne-Szakaly, Iren; Jones, Robert V.; Kelly, James P.; Armstrong, Regina C.; Perl, Daniel P.			Characterisation of interface astroglial scarring in the human brain after blast exposure: a post-mortem case series	LANCET NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; POSTTRAUMATIC-STRESS-DISORDER; U.S. MILITARY PERSONNEL; HEAD-INJURY; EXPLOSIVE BLAST; MODEL; PATHOLOGY; IRAQ	Background No evidence-based guidelines are available for the definitive diagnosis or directed treatment of most blast-associated traumatic brain injuries, partly because the underlying pathology is unknown. Moreover, few neuropathological studies have addressed whether blast exposure produces unique lesions in the human brain, and if those lesions are comparable with impact-induced traumatic brain injury. We aimed to test the hypothesis that blast exposure produces unique patterns of damage, differing from that associated with impact-induced, non-blast traumatic brain injuries. Methods In this post-mortem case series, we investigated several features of traumatic brain injuries, using clinical histopathology techniques and markers, in brain specimens from male military service members with chronic blast exposures and from those who had died shortly after severe blast exposures. We then compared these results with those from brain specimens from male civilian (ie, non-military) cases with no history of blast exposure, including cases with and without chronic impact traumatic brain injuries and cases with chronic exposure to opiates, and analysed the limited associated clinical histories of all cases. Brain specimens had been archived in tissue banks in the USA. Findings We analysed brain specimens from five cases with chronic blast exposure, three cases with acute blast exposure, five cases with chronic impact traumatic brain injury, five cases with exposure to opiates, and three control cases with no known neurological disorders. All five cases with chronic blast exposure showed prominent astroglial scarring that involved the subpial glial plate, penetrating cortical blood vessels, grey white matter junctions, and structures lining the ventricles; all cases of acute blast exposure showed early astroglial scarring in the same brain regions. All cases of chronic blast exposure had an antemortem diagnosis of post traumatic stress disorder. The civilian cases, with or without history of impact traumatic brain injury or a history of opiate use, did not have any astroglial scarring in the brain regions analysed. Interpretation The blast exposure cases showed a distinct and previously undescribed pattern of interface astroglial scarring at boundaries between brain parenchyma and fluids, and at junctions between grey and white matter. This distinctive pattern of scarring may indicate specific areas of damage from blast exposure consistent with the general principles of blast biophysics, and further, could account for aspects of the neuropsychiatric clinical sequelae reported. The generalisability of these findings needs to be explored in future studies, as the number of cases, clinical data, and tissue availability were limited.	[Shively, Sharon Baughman; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pathol, Bethesda, MD 20814 USA; [Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Shively, Sharon Baughman; Armstrong, Regina C.; Perl, Daniel P.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Horkayne-Szakaly, Iren; Jones, Robert V.] Def Hlth Agcy, Joint Pathol Ctr, Silver Spring, MD USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO USA; [Shively, Sharon Baughman] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA	Perl, DP (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Ctr Neurosci & Regenerat Med, Dept Pathol, Bethesda, MD 20814 USA.	daniel.perl@usuhs.edu			Defense Health Program of the United States Department of Defense	This study was funded by the Defense Health Program of the United States Department of Defense. This study utilized neuropathology core facilities of the Center for Neuroscience and Regenerative Medicine (CNRM), Uniformed Services University of the Health Sciences (USUHS), and The Joint Pathology Center (JPC), within the US Department of Defense. We thank Charles Rice, Thomas Baker, Arthur Kellermann, and Steven Kaminsky for their continuous encouragement and support; and Patricia Lee for histotechnology support and Leslie Sawyers for administrative support. Human tissue for most civilian cases was obtained from University of Maryland Brain and Tissue Bank (UMB BTB), which is a Brain and Tissue Repository of the NIH NeuroBioBank. The opinions expressed herein are those of the authors and are not necessarily representative of those of the Uniformed Services University of the Health Sciences (USUHS), the Department of Defense (DOD); or, the United States Army, Navy, or Air Force.	Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Benzinger T., 1950, GERMAN AVIATION MED, V2, P1225; Cameron KL, 2012, J NEUROTRAUM, V29, P1313, DOI 10.1089/neu.2011.2168; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; COHEN H, 1946, ARCH PATHOL, V42, P12; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mott F. N., 1919, WAR NEUROSES SHELL S; Mott F W, 1917, Br Med J, V2, P612; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Stahl S.M., 2008, STAHLS ESSENTIAL PSY, V3rd; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224	41	102	102	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2016	15	9					944	953		10.1016/S1474-4422(16)30057-6			10	Clinical Neurology	Neurosciences & Neurology	DT1YY	WOS:000381279200014	27291520	Bronze			2021-06-18	
J	Xu, JG; Wang, HD; Ding, K; Zhang, L; Wang, CX; Li, T; Wei, WT; Lu, XY				Xu, Jianguo; Wang, Handong; Ding, Ke; Zhang, Li; Wang, Chunxi; Li, Tao; Wei, Wuting; Lu, Xinyu			Luteolin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE pathway	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Luteolin; Neuroprotection; Traumatic brain injury; Nrf2	TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; ANTIOXIDANT THERAPIES; SELECTIVE AUTOPHAGY; IN-VITRO; EXPRESSION; PROTECTS; CELLS; P62/SQSTM1; MODULATION	Luteolin has recently been proven to exert neuroprotection in a variety of neurological diseases; however, its roles and the underlying mechanisms in traumatic brain injury are not fully understood. The present study was aimed to investigate the neuroprotective effects of luteolin in models of traumatic brain injury (TBI) and the possible role of the Nrf2-ARE pathway in the putative neuroprotection. A modified Marmarou's weight-drop model in mice and the scratch model in mice primary cultured neurons were used to induce TBI. We determined that luteolin significantly ameliorated secondary brain injury induced by TBI, including neurological deficits, brain water content, and neuronal apoptosis. Furthermore, the level of malondialdehyde (MDA) and the activity of glutathione peroxidase (GPx) were restored in the group with luteolin treatment. in vitro studies showed that luteolin administration lowered the intracellular reactive oxygen species (ROS) level and increased the neuron survival. Moreover, luteolin enhanced the translocation of Nrf2 to the nucleus both in vivo and in vitro, which was proved by the results of Western blot, immunohistochemistry, and electrophoretic mobility shift assay (EMSA). Subsequently upregulation of the expression of the downstream factors such as heme oxygenase 1 (HO1) and NAD(P)H:quinone oxidoreductase 1 (NQO1) was also examined. However, luteolin treatment failed to provide neuroprotection after TBI in Nrf2(-/-) mice. Taken together, these in vivo and in vitro data demonstrated that luteolin provided neuroprotective effects in the models of TBI, possibly through the activation of the Nrf2-ARE pathway. (C) 2014 Elsevier Inc. All rights reserved.	[Xu, Jianguo; Wang, Handong; Ding, Ke; Zhang, Li; Wang, Chunxi; Li, Tao; Lu, Xinyu] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Wei, Wuting] Southern Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357]	The authors thank Dr. Jin He and Dr. Bo Yu for their technical assistance on histochemistry. This work was supported by grants from the National Natural Science Foundation of China (No. 81371357).	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Coleta M, 2008, BEHAV BRAIN RES, V189, P75, DOI 10.1016/j.bbr.2007.12.010; Copple IM, 2010, J BIOL CHEM, V285, P16782, DOI 10.1074/jbc.M109.096545; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dajas Federico, 2013, Central Nervous System Agents in Medicinal Chemistry, V13, P30; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Siraichi JTG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072733; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hendricks JJA, 2004, J EXP MED, V200, P1667, DOI 10.1084/jem.20040819; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Huang CS, 2013, ARCH TOXICOL, V87, P167, DOI 10.1007/s00204-012-0913-4; Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005; Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jang S, 2008, P NATL ACAD SCI USA, V105, P7534, DOI 10.1073/pnas.0802865105; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Park CM, 2013, NUTR RES PRACT, V7, P423, DOI 10.4162/nrp.2013.7.6.423; Park SH, 2013, FOOD CHEM TOXICOL, V56, P100, DOI 10.1016/j.fct.2013.02.022; Povlishock J T, 1992, Hum Cell, V5, P345; Qiao HM, 2012, NEUROCHEM RES, V37, P2014, DOI 10.1007/s11064-012-0822-1; Qiao HM, 2012, BRAIN RES, V1448, P71, DOI 10.1016/j.brainres.2012.02.003; Rodriguez-Rodriguez A., 2013, CURR MED CHEM; Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200; Sawmiller D, 2014, INT J MOL SCI, V15, P895, DOI 10.3390/ijms15010895; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Sun M., 2013, J NEUROTRAUMA; Tang XW, 2011, FREE RADICAL BIO MED, V50, P1599, DOI 10.1016/j.freeradbiomed.2011.03.008; Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wruck CJ, 2007, J NEURAL TRANSM-SUPP, P57; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang YC, 2013, FOOD CHEM TOXICOL, V59, P272, DOI 10.1016/j.fct.2013.05.058; Zhao G, 2011, J NUTR BIOCHEM, V22, P929, DOI 10.1016/j.jnutbio.2010.07.014; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	51	102	105	2	54	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUN	2014	71						186	195		10.1016/j.freeradbiomed.2014.03.009			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AI5FP	WOS:000336891100017	24642087				2021-06-18	
J	Turtzo, LC; Lescher, J; Janes, L; Dean, DD; Budde, MD; Frank, JA				Turtzo, L. Christine; Lescher, Jacob; Janes, Lindsay; Dean, Dana D.; Budde, Matthew D.; Frank, Joseph A.			Macrophagic and microglial responses after focal traumatic brain injury in the female rat	JOURNAL OF NEUROINFLAMMATION			English	Article						Controlled cortical impact; Inflammation; Macrophage; Microglia; MRI; Rat; Traumatic brain injury	TUMOR-ASSOCIATED MACROPHAGES; SPINAL-CORD-INJURY; CYTOKINE EXPRESSION; NERVOUS-SYSTEM; ESTROUS-CYCLE; PROGESTERONE; ACTIVATION; RECOVERY; NEUROINFLAMMATION; POLARIZATION	Background: After central nervous system injury, inflammatory macrophages (M1) predominate over anti-inflammatory macrophages (M2). The temporal profile of M1/M2 phenotypes in macrophages and microglia after traumatic brain injury (TBI) in rats is unknown. We subjected female rats to severe controlled cortical impact (CCI) and examined the postinjury M1/M2 time course in their brains. Methods: The motor cortex (2.5 mm left laterally and 1.0 mm anteriorly from the bregma) of anesthetized female Wistar rats (ages 8 to 10 weeks; N = 72) underwent histologically moderate to severe CCI with a 5-mm impactor tip. Separate cohorts of rats had their brains dissociated into cells for flow cytometry, perfusion-fixed for immunohistochemistry (IHC) and ex vivo magnetic resonance imaging or flash-frozen for RNA and protein analysis. For each analytical method used, separate postinjury times were included for 24 hours; 3 or 5 days; or 1, 2, 4 or 8 weeks. Results: By IHC, we found that the macrophagic and microglial responses peaked at 5 to 7 days post-TBI with characteristics of mixed populations of M1 and M2 phenotypes. Upon flow cytometry examination of immunological cells isolated from brain tissue, we observed that peak M2-associated staining occurred at 5 days post-TBI. Chemokine analysis by multiplex assay showed statistically significant increases in macrophage inflammatory protein 1 alpha and keratinocyte chemoattractant/growth-related oncogene on the ipsilateral side within the first 24 hours after injury relative to controls and to the contralateral side. Quantitative RT-PCR analysis demonstrated expression of both M1- and M2-associated markers, which peaked at 5 days post-TBI. Conclusions: The responses of macrophagic and microglial cells to histologically severe CCI in the female rat are maximal between days 3 and 7 postinjury. The response to injury is a mixture of M1 and M2 phenotypes.	[Turtzo, L. Christine; Lescher, Jacob; Janes, Lindsay; Frank, Joseph A.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Turtzo, L. Christine; Lescher, Jacob; Janes, Lindsay; Dean, Dana D.; Budde, Matthew D.; Frank, Joseph A.] NIH, Frank Lab, Bethesda, MD 20814 USA; [Frank, Joseph A.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20814 USA; [Dean, Dana D.] Baylor Univ, Dept Environm Sci, Waco, TX 76798 USA; [Budde, Matthew D.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA	Turtzo, LC (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	turtzolc@mail.nih.gov	Frank, Joseph/W-2021-2019		US Department of Defense Center for Neuroscience and Regenerative Medicine under Henry M. Jackson Foundation for the Advancement of Military Medicine award [300604-13.01-60855]; National Institutes of Health Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; CLINICAL CENTER [ZIACL090020] Funding Source: NIH RePORTER	These studies were supported by the US Department of Defense Center for Neuroscience and Regenerative Medicine under Henry M. Jackson Foundation for the Advancement of Military Medicine award 300604-13.01-60855 and by the National Institutes of Health Intramural Research Program. We would also like to thank Aneeka Chaudhry, Tiziana Coppola and Eric Gold for their invaluable technical assistance with these studies.	Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bonecchi R, 2000, J IMMUNOL, V164, P3862, DOI 10.4049/jimmunol.164.7.3862; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; DEGREEF WJ, 1974, ENDOCRINOLOGY, V95, P565, DOI 10.1210/endo-95-2-565; DING AH, 1988, J IMMUNOL, V141, P2407; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Khaksari M, 2013, CAN J PHYSIOL PHARM, V91, P700, DOI 10.1139/cjpp-2012-0359; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Liu L, 2014, NEUROBIOL AGING, V35, P309, DOI 10.1016/j.neurobiolaging.2013.08.016; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; McKimmie CS, 2010, BIOCHEM BIOPH RES CO, V394, P1006, DOI 10.1016/j.bbrc.2010.03.111; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Ydens E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-176; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038	57	102	104	0	27	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 24	2014	11								82	10.1186/1742-2094-11-82			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AG6IW	WOS:000335523300001	24761998	DOAJ Gold, Green Published			2021-06-18	
J	Talving, P; Karamanos, E; Teixeira, PG; Skiada, D; Lam, L; Belzberg, H; Inaba, K; Demetriades, D				Talving, Peep; Karamanos, Efstathios; Teixeira, Pedro G.; Skiada, Dimitra; Lam, Lydia; Belzberg, Howard; Inaba, Kenji; Demetriades, Demetrios			Intracranial pressure monitoring in severe head injury: compliance with Brain Trauma Foundation guidelines and effect on outcomes: a prospective study Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure monitoring; mortality; brain herniation; Brain Trauma Foundation guidelines; traumatic brain injury	INTENSIVE-CARE; UNITED-STATES; MANAGEMENT	Object. The Brain Trauma Foundation (BTF) has established guidelines for intracranial pressure (ICP) monitoring in severe traumatic brain injury (TBI). This study assessed compliance with these guidelines and the effect on outcomes. Methods. This is a prospective, observational study including patients with severe blunt TBI (Glasgow Coma Scale score <= 8, head Abbreviated Injury Scale score a 3) between January 2010 and December 2011. Demographics, clinical characteristics, laboratory profile, head CT scans, injury severity indices, and interventions were collected. The study population was stratified into 2 study groups: ICP monitoring and no ICP monitoring. Primary outcomes included compliance with BTF guidelines, overall in-hospital mortality, and mortality due to brain herniation. Secondary outcomes were ICU and hospital lengths of stay. Multiple regression analyses were deployed to determine the effect of ICP monitoring on outcomes. Results. A total of 216 patients met the BTF guideline criteria for ICP monitoring. Compliance with BTF guidelines was 46.8% (101 patients). Patients with subarachnoid hemorrhage and those who underwent craniectomy/craniotomy were significantly more likely to undergo ICP monitoring. Hypotension, coagulopathy, and increasing age were negatively associated with the placement of ICP monitoring devices. The overall in-hospital mortality was significantly higher in patients who did not undergo ICP monitoring (53.9% vs 32.7%, adjusted p = 0.019). Similarly, mortality due to brain herniation was significantly higher for the group not undergoing ICP monitoring (21.7% vs 12.9%, adjusted p = 0.046). The ICU and hospital lengths of stay were significantly longer in patients subjected to ICP monitoring. Conclusions. Compliance with BTF ICP monitoring guidelines in our study sample was 46.8%. Patients managed according to the BTF ICP guidelines experienced significantly improved survival.	[Talving, Peep; Karamanos, Efstathios; Teixeira, Pedro G.; Skiada, Dimitra; Lam, Lydia; Belzberg, Howard; Inaba, Kenji; Demetriades, Demetrios] Los Angeles Cty Univ Southern Calif Med Ctr, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Dept Surg, Los Angeles, CA USA	Talving, P (corresponding author), LAC USC Med Ctr, Keck Sch Med, Dept Surg, Div Acute Care Surg, 2051 Marengo St,Rm IPT C5L100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Talving, Peep/G-8621-2015; Teixeira, Pedro/H-2239-2011; Talving, Peep/E-6015-2013; INABA, KENJI/AAC-8532-2020; Karamanos, Efstathios/AAU-8082-2020	Talving, Peep/0000-0002-9741-2073; Teixeira, Pedro/0000-0002-7258-7977; Karamanos, Efstathios/0000-0002-5118-4642			Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Idris Z, 2007, ASIAN J SURG, V30, P200, DOI 10.1016/S1015-9584(08)60023-8; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Lane PL, 2000, CAN J SURG, V43, P442; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Poca MA, 1998, ACT NEUR S, V71, P27; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wilkins IA, 2001, ANAESTHESIA, V56, P350, DOI 10.1046/j.1365-2044.2001.01708.x	23	102	109	0	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2013	119	5					1248	1254		10.3171/2013.7.JNS122255			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	238OB	WOS:000325956200031	23971954				2021-06-18	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Dual-Task Effect on Gait Balance Control in Adolescents With Concussion	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Attention; Brain concussion; Brain injuries; Gait; Postural balance; Rehabilitation	STATES HIGH-SCHOOL; ATTENTIONAL DEFICITS; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; SPORT CONCUSSION; MOTOR FUNCTION; RECOVERY; EPIDEMIOLOGY; PERFORMANCE; MANAGEMENT	Objective: To prospectively and longitudinally examine how concussion affects gait balance control in adolescents during single- and dual-task walking. Design: Cohort, prospective, repeated-measures design. Setting: Motion analysis laboratory. Participants: Adolescents (N=20) identified as suffering a concussion were matched with healthy control subjects (N=20) and tested 5 times across a 2-month period after injury. Interventions: Not applicable. Main Outcome Measures: Gait temporal-distance parameters included average walking speed, step length, and step width; whole body center of mass (COM) parameters included medial/lateral displacement and peak COM medial/lateral and anterior velocities; dual-task cost, which was defined as percent change from single- to dual-task conditions; and Stroop test accuracy. Results: No between-group differences were observed for step length and step width. The dual-task cost for average walking speed for subjects with concussion was greater than control subjects across the 2-month testing period (main effect of group P=.019), as was the dual-task costs for peak anterior COM velocity (main effect of group P=.017) and total COM medial/lateral displacement (main effect of group P=.013). The total COM medial/lateral displacement (group x task interaction P=.006) and peak COM medial/lateral velocity (main effect of group P=.027; main effect of task P=.01) were significantly greater in subjects with concussion compared with control subjects during dual-task walking. Subjects with concussion were significantly less accurate than controls on the Stroop test (main effect of group P=.004). Conclusions: The findings suggest that concussion affects the ability of adolescents to control body posture during gait up to 2 months after injury. Furthermore, dual-task paradigms may provide additional useful information in the clinical assessment and recovery of concussion. Archives of Physical Medicine and Rehabilitation 2013;94:1513-20 (C) 2013 by the American Congress of Rehabilitation Medicine	[Howell, David R.; Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA	Chou, LS (corresponding author), Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Department of Defense-Telemedicine Advanced Technology Research Center [W81XWH-11-1-0717]; University of Oregon and Peace Health Oregon Region	Supported by the Veterans Administration (subcontract awards nos. A4842C8 and A4843C); Department of Defense-Telemedicine Advanced Technology Research Center (award no. W81XWH-11-1-0717); and a translational research award from the University of Oregon and Peace Health Oregon Region.	Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Fait P, J HEAD TRAU IN PRESS; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Goethals I, 2004, EUR J NUCL MED MOL I, V31, P408, DOI 10.1007/s00259-003-1382-z; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marchetti GF, 2008, PHYS THER, V88, P640, DOI 10.2522/ptj.20070130; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Register-Mihalik JK, J HEAD TRAU IN PRESS; Ridderinkhof KR, 2004, BRAIN COGNITION, V56, P129, DOI 10.1016/j.bandc.2004.09.016; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Spreen O., 1995, DEV NEUROPSYCHOLOGY; Springer S, 2006, MOVEMENT DISORD, V21, P950, DOI 10.1002/mds.20848; Stuss DT, 2006, ANN NY ACAD SCI, V769, P191; Tomei KL, 2012, NEUROSURG FOCUS, V33; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Winter D. A., 2009, BIOMECHANICS MOTOR C, V4th; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	42	102	104	0	46	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2013	94	8					1513	1520		10.1016/j.apmr.2013.04.015			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	196TZ	WOS:000322801600011	23643687				2021-06-18	
J	Kontos, AP; Elbin, RJ; Lau, B; Simensky, S; Freund, B; French, J; Collins, MW				Kontos, Anthony P.; Elbin, R. J.; Lau, Brian; Simensky, Steven; Freund, Brin; French, Jonathan; Collins, Michael W.			Posttraumatic Migraine as a Predictor of Recovery and Cognitive Impairment After Sport-Related Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; headache; migraine; mild traumatic brain injury; sports; symptoms	BRAIN-STEM ACTIVATION; MILD HEAD TRAUMA; HIGH-SCHOOL; PROTRACTED RECOVERY; DEPRESSION; OUTCOMES; INJURY; RISK	Background: Although previous research has demonstrated that patients with posttraumatic migraine (PTM) after concussion report more symptoms and cognitive deficits after injury than do those without PTM, it is not known whether these effects persist beyond the first week of injury or whether PTM predicts recovery time. Purpose: To determine whether PTM during the first week after injury predicts (1) cognitive impairment and symptoms in the second week after injury and (2) overall recovery time. Study Design: Cohort study; Level of evidence, 2. Methods: Participants were 138 male high school football players with a mean age of 15.96 years (SD, 1.18 years; range, 13-19 years). They were classified into 3 groups: PTM (headache, nausea, and photosensitivity or phonosensitivity), headache (headache without the other PTM symptoms), or no headache (no headache or PTM symptoms). The Immediate Post-concussion Assessment and Cognitive Test (ImPACT) was used to assess cognitive performance and symptoms at baseline, postinjury days 1-7, and postinjury days 8-14. Recovery time data were collected from medical records. Results: The PTM group performed worse on verbal memory than did the headache group at 8-14 days after injury. The PTM group performed worse on visual memory, reaction time, and symptoms than did the other groups at 1-7 days and 8-14 days after injury. The PTM group was 7.3 times (95% confidence interval, 1.80-29.91) more likely to have protracted recovery (>20 days) than the no headache group and 2.6 times (95% confidence interval, 1.10-6.54) more likely than the headache group. Conclusion: Results suggest that PTM is associated with cognitive impairments and protracted recovery and that headache alone is not a good predictor of recovery.	Univ Pittsburgh, Pittsburgh, PA USA; Humboldt State Univ, Arcata, CA 95521 USA	Kontos, AP (corresponding author), Univ Pittsburgh, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310			Bahra A, 2001, LANCET, V357, P1016, DOI 10.1016/S0140-6736(00)04250-1; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Etminan M, 2005, BMJ-BRIT MED J, V330, P63, DOI 10.1136/bmj.38302.504063.8F; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LARSSON LI, 1976, BRAIN RES, V113, P400, DOI 10.1016/0006-8993(76)90951-3; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Neinstein L, 2000, J ADOLESCENT HEALTH, V27, P119, DOI 10.1016/S1054-139X(99)00099-3; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; TAYLOR AR, 1966, LANCET, V2, P178; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658	27	102	102	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2013	41	7					1497	1504		10.1177/0363546513488751			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	301HS	WOS:000330524000010	23698389				2021-06-18	
J	Kleber, C; Giesecke, MT; Tsokos, M; Haas, NP; Buschmann, CT				Kleber, C.; Giesecke, M. T.; Tsokos, M.; Haas, N. P.; Buschmann, C. T.			Trauma-related Preventable Deaths in Berlin 2010: Need to Change Prehospital Management Strategies and Trauma Management Education	WORLD JOURNAL OF SURGERY			English	Article							ROAD TRAFFIC FATALITIES; SYSTEM; CARE; MORTALITY; QUALITY; AUDIT; INJURIES; VICTORIA	Fatal trauma is one of the leading causes of death in Western industrialized countries. The aim of the present study was to determine the preventability of traumatic deaths, analyze the medical measures related to preventable deaths, detect management failures, and reveal specific injury patterns in order to avoid traumatic deaths in Berlin. In this prospective observational study all autopsied, direct trauma fatalities in Berlin in 2010 were included with systematic data acquisition, including police files, medical records, death certificates, and autopsy records. An interdisciplinary expert board judged the preventability of traumatic death according to the classification of non-preventable (NP), potentially preventable (PP), and definitively preventable (DP) fatalities. Of the fatalities recorded, 84.9 % (n = 224) were classified as NP, 9.8 % (n = 26) as PP, and 5.3 % (n = 14) as DP. The incidence of severe traumatic brain injury (sTBI) was significantly lower in PP/DP than in NP, and the incidence of fatal exsanguinations was significantly higher. Most PP and NP deaths occurred in the prehospital setting. Notably, no PP or DP was recorded for fatalities treated by a HEMS crew. Causes of DP deaths consisted of tension pneumothorax, unrecognized trauma, exsanguinations, asphyxia, and occult bleeding with a false negative computed tomography scan. The trauma mortality in Berlin, compared to worldwide published data, is low. Nevertheless, 15.2 % (n = 40) of traumatic deaths were classified as preventable. Compulsory training in trauma management might further reduce trauma-related mortality. The main focus should remain on prevention programs, as the majority of the fatalities occurred as a result of non-survivable injuries.	[Kleber, C.; Giesecke, M. T.; Haas, N. P.] Charite, AG Polytrauma, Ctr Musculoskeletal Surg, D-13353 Berlin, Germany; [Kleber, C.] Charite, Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany; [Tsokos, M.; Buschmann, C. T.] Charite, Inst Legal Med & Forens Sci, D-10559 Berlin, Germany	Kleber, C (corresponding author), Charite, AG Polytrauma, Ctr Musculoskeletal Surg, Augustenburger Pl 1, D-13353 Berlin, Germany.	christian.kleber@charite.de			Berlin-Brandenburg School for Regenerative Therapies [GSC 203]	Contributions were made possible by DFG funding through the Berlin-Brandenburg School for Regenerative Therapies GSC 203. The authors are grateful to Dr. Paul Bedford for his contribution to the manuscript.	ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; Arnold JL, 1999, ANN EMERG MED, V33, P97, DOI 10.1016/S0196-0644(99)70424-5; Ashour A, 2007, EMERG MED AUSTRALAS, V19, P163, DOI 10.1111/j.1742-6723.2007.00948.x; Bakke HK, 2011, WORLD J SURG, V35, P1615, DOI 10.1007/s00268-011-1102-y; Buschmann CT, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-55; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Davies GE, 2011, J TRAUMA, V70, pE75, DOI 10.1097/TA.0b013e3181f6f72f; DAVIS JW, 1992, J TRAUMA, V32, P660, DOI 10.1097/00005373-199205000-00020; Dick WF, 2003, PREHOSP DISASTER MED, V18, P35; Dick Wolfgang F, 2003, Prehosp Disaster Med, V18, P29; DRAAISMA JMT, 1989, J TRAUMA, V29, P1552; ESPOSITO TJ, 1995, J TRAUMA, V39, P955, DOI 10.1097/00005373-199511000-00022; Frink M, 2007, UNFALLCHIRURG, V110, P334, DOI 10.1007/s00113-006-1222-2; HAAS NP, 1995, CLIN ORTHOP RELAT R, P25; Jat Afzal Ali, 2004, Asian J Surg, V27, P58, DOI 10.1016/S1015-9584(09)60247-5; Kleber C, 2013, UNFALLCHIRURG, V116, P345, DOI 10.1007/s00113-011-2132-5; Kleber C, 2012, WORLD J SURG, V36, P2125, DOI 10.1007/s00268-012-1650-9; Limb D, 1996, J ACCID EMERG MED, V13, P248; MACKENZIE EJ, 1992, J TRAUMA, V33, P292, DOI 10.1097/00005373-199208000-00021; Maio RF, 1996, J TRAUMA, V41, P83, DOI 10.1097/00005373-199607000-00013; McDermott FT, 2005, PREHOSP DISASTER MED, V20, P219, DOI 10.1017/S1049023X00002570; McDermott FT, 1996, J TRAUMA, V40, P520, DOI 10.1097/00005373-199604000-00003; Mock C, 2004, LANCET, V363, P2172, DOI 10.1016/S0140-6736(04)16510-0; Mock CN, 1998, J TRAUMA, V44, P804, DOI 10.1097/00005373-199805000-00011; OTTOSSON A, 1984, JAMA-J AM MED ASSOC, V251, P2668, DOI 10.1001/jama.251.20.2668; Papadopoulos IN, 1996, J TRAUMA, V41, P864, DOI 10.1097/00005373-199611000-00018; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Probst C, 2009, INJURY, V40, P77, DOI 10.1016/j.injury.2008.10.004; Roy MS, 2004, BRAIN DEV-JPN, V26, P197, DOI 10.1016/S0387-7604(03)00147-5; Sanddal TL, 2011, J TRAUMA, V70, P970, DOI 10.1097/TA.0b013e3181fec9ba; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; STOCCHETTI N, 1994, J TRAUMA, V36, P401, DOI 10.1097/00005373-199403000-00022; VAN WAGONER F H, 1961, J Trauma, V1, P401; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455; ZOLLINGER RW, 1955, ARCH SURG-CHICAGO, V70, P694, DOI 10.1001/archsurg.1955.01270110066010	36	102	106	0	10	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	MAY	2013	37	5					1154	1161		10.1007/s00268-013-1964-2			8	Surgery	Surgery	123AU	WOS:000317361200033	23430005				2021-06-18	
J	Beckwith, JG; Greenwald, RM; Chu, JJ; Crisco, JJ; Rowson, S; Duma, SM; Broglio, SP; Mcallister, TW; Guskiewicz, KM; Mihalik, JP; Anderson, S; Schnebel, B; Brolinson, PG; Collins, MW				Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.; Crisco, Joseph J.; Rowson, Steven; Duma, Stefan M.; Broglio, Steven P.; Mcallister, Thomas W.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Anderson, Scott; Schnebel, Brock; Brolinson, P. Gunnar; Collins, Michael W.			Head Impact Exposure Sustained by Football Players on Days of Diagnosed Concussion	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HIT SYSTEM; SPORT; IMPACT BIOMECHANICS; mTBI; TBI; INJURY THRESHOLD	HIGH-SCHOOL FOOTBALL; DIFFUSE AXONAL INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; COLLEGIATE; RISK; ACCELERATION; ASSOCIATION; EPIDEMIOLOGY; KINEMATICS	BECKWITH, J. G., R. M. GREENWALD, J. J. CHU, J. J. CRISCO, S. ROWSON, S. M. DUMA, S. P. BROGLIO, T. W. MCALLISTER, K. M. GUSKIEWICZ, J. P. MIHALIK, S. ANDERSON, B. SCHNEBEL, P. G. BROLINSON, and M. W. COLLINS. Head Impact Exposure Sustained by Football Players on Days of Diagnosed Concussion. Med. Sci. Sports Exerc., Vol. 45, No. 4, pp. 737-746, 2013. Purpose: This study compares the frequency and severity of head impacts sustained by football players on days with and without diagnosed concussion and to identify the sensitivity and specificity of single-impact severity measures to diagnosed injury. Methods: One thousand two hundred eight players from eight collegiate football teams and six high school football teams wore instrumented helmets to measure head impacts during all team sessions, of which 95 players were diagnosed with concussion. Eight players sustained two injuries and one sustained three, providing 105 injury cases. Measures of head kinematics (peak linear and rotational acceleration, Gadd severity index, head injury criteria (HIC15), and change in head velocity (Delta v)) and the number of head impacts sustained by individual players were compared between days with and without diagnosed concussion. Receiver operating characteristic curves were generated to evaluate the sensitivity and specificity of each kinematic measure to diagnosed concussion using only those impacts that directly preceded diagnosis. Results: Players sustained a higher frequency of impacts and impacts with more severe kinematic properties on days of diagnosed concussion than on days without diagnosed concussion. Forty-five injury cases were immediately diagnosed after head impact. For these cases, peak linear acceleration and HIC15 were most sensitive to immediately diagnosed concussion (area under the curve = 0.983). Peak rotational acceleration was less sensitive to diagnosed injury than all other kinematic measures (P = 0.01), which are derived from linear acceleration (peak linear, HIC15, Gadd severity index, and Delta v). Conclusions: Players sustained more impacts and impacts of higher severity on days of diagnosed concussion than on days without diagnosed concussion. In addition, of historical measures of impact severity, those associated with peak linear acceleration are the best predictors of immediately diagnosed concussion.	[Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.] Simbex, Lebanon, NH 03766 USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Crisco, Joseph J.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI USA; [Broglio, Steven P.] Michigan NeuroSport, Ann Arbor, MI USA; [Mcallister, Thomas W.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA; [Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Anderson, Scott] Univ Oklahoma, Dept Intercollegiate Athlet, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Orthoped, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Athlet, Norman, OK 73019 USA; [Brolinson, P. Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Pittsburgh, PA USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA	Beckwith, JG (corresponding author), Simbex, 10 Water St,Suite 410, Lebanon, NH 03766 USA.	jbeckwith@simbex.com	Lang, Steven/AAE-8102-2021; Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Lang, Steven/0000-0003-1669-9146; Rowson, Steven/0000-0002-3227-0596; Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, R01NS055020]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, 5R49CE000196]; NOCSAE [07-04, 14-19)]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, R49CE000196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported in part by award R01HD048638 and R01NS055020 from the National Institute of Health, R01CE001254 and 5R49CE000196 from the Centers for Disease Control and Prevention, and NOCSAE (07-04, 14-19). HIT System technology was developed in part under NIH R44HD40473 and research and development support from Riddell, Inc. (Chicago, IL).	Beckwith JG, 2010, 8 WORLD C BRAIN INJ, P446; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick R, 2007, J ATHL TRAINING, V42, P221; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hodgson VR, 1970, 700901 SAE, DOI [10.4271/700901, DOI 10.4271/700901]; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moon D W, 1971, Med Sci Sports, V3, P44; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Talavage T. M., 2010, J NEUROTRAUMA; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	102	102	0	42	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2013	45	4					737	746		10.1249/MSS.0b013e3182792ed7			10	Sport Sciences	Sport Sciences	109ZK	WOS:000316410600017	23135363	Green Accepted, Green Published			2021-06-18	
J	Ojo, JO; Mouzon, B; Greenberg, MB; Bachmeier, C; Mullan, M; Crawford, F				Ojo, Joseph-Olubunmi; Mouzon, Benoit; Greenberg, M. Banks; Bachmeier, Corbin; Mullan, Mike; Crawford, Fiona			Repetitive Mild Traumatic Brain Injury Augments Tau Pathology and Glial Activation in Aged hTau Mice	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Aging; Chronic traumatic encephalopathy; Glia; Human tau; Mild traumatic brain injury; Phospho-tau	FOOTBALL-LEAGUE PLAYER; MOUSE MODEL; ALZHEIMERS-DISEASE; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; CEREBRAL-CORTEX; PHOSPHATASE-ACTIVITY; PHYSICAL DEVELOPMENT; REACTIVE ASTROCYTES; HIV-1 ENCEPHALITIS	Extensive tau-immunoreactive neurons and glial cells associated with chronic traumatic encephalopathy (CTE) have been documented in the brains of some professional athletes and others with a history of repetitive mild traumatic brain injury (r-mTBI). The neuropathology and tau involvement in mTBI have not been extensively studied in animal models, particularly in aged animals. We investigated the effects of single mTBI (s-mTBI) and r-mTBI in 18-month-old hTau mice, which express wild-type human tau isoforms on a null murine tau background (n = 3-5 per group). At this age, hTau mice already demonstrate tau pathology, but there was a significant increase in phospho-tau immunoreactivity in response to r-mTBI, but not to s-mTBI, as determined using multiple phospho-tau-specific antibodies. Repetitive mTBI also resulted in a marked increase in astrocyte/microglia activation notably in the superficial layer of the motor/somatosensory cortex and the corpus callosum. We did not observe the perivascular tau pathology, neuritic threads, or astrocytic tangles that are commonly found in human CTE. The increase in phosphotau in the r-mTBI mice suggests that this may be a useful model for investigating further the link between mTBI, particularly r-mTBI, and tau pathobiology in CTE and in understanding responses of the aged brain to mTBI.	[Ojo, Joseph-Olubunmi; Mouzon, Benoit; Greenberg, M. Banks; Bachmeier, Corbin; Mullan, Mike; Crawford, Fiona] Roskamp Inst, Sarasota, FL 34243 USA	Ojo, JO (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	bojo@roskampinstitute.net		Mullan, Michael/0000-0002-1473-7527	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation	This work was supported by Department of Defense award W81XWH-10-1-0759 (to Fiona Crawford) and by the Roskamp Foundation.	Alldred MJ, 2012, NEUROBIOL DIS, V45, P751, DOI 10.1016/j.nbd.2011.10.022; Amenta F, 1998, MICROSC RES TECHNIQ, V43, P29, DOI 10.1002/(SICI)1097-0029(19981001)43:1<29::AID-JEMT5>3.0.CO;2-H; Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Blau CW, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.09.035; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Cosenza MA, 2002, BRAIN PATHOL, V12, P442, DOI 10.1111/j.1750-3639.2002.tb00461.x; Cosenza-Nashat MA, 2006, BRAIN PATHOL, V16, P256, DOI 10.1111/j.1750-3639.2006.00027.x; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Dilger RN, 2008, J LEUKOCYTE BIOL, V84, P932, DOI 10.1189/jlb.0208108; Duff K, 2000, NEUROBIOL DIS, V7, P87, DOI 10.1006/nbdi.1999.0279; Eckenhoff RG, 2012, ANESTHESIOLOGY, V116, P751, DOI 10.1097/ALN.0b013e31824be8e1; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P57; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P1; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GEINISMAN Y, 1978, AM J ANAT, V153, P537, DOI 10.1002/aja.1001530405; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Harris FM, 2004, J BIOL CHEM, V279, P44795, DOI 10.1074/jbc.M408127200; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwakiri M, 2009, NEUROPATHOLOGY, V29, P263, DOI 10.1111/j.1440-1789.2008.00978.x; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kimura T, 1996, DEMENTIA, V7, P177, DOI 10.1159/000106875; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mavrogiorgou P, 2011, PSYCHIAT DANUB, V23, P334; Mazanetz MP, 2007, NAT REV DRUG DISCOV, V6, P464, DOI 10.1038/nrd2111; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nowinski C, 2006, HEAD GAMES FOOTBALLS; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ojo B, 2011, EXP NEUROL, V232, P318, DOI 10.1016/j.expneurol.2011.09.025; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Papon MA, 2011, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00272; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Yao XL, 2008, J NEUROCHEM, V104, P353, DOI 10.1111/j.1471-4159.2007.04970.x; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	69	102	102	0	42	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	2013	72	2					137	151		10.1097/NEN.0b013e3182814cdf			15	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	079HE	WOS:000314160400006	23334597	Bronze			2021-06-18	
J	Gysland, SM; Mihalik, JP; Register-Mihalik, JK; Trulock, SC; Shields, EW; Guskiewicz, KM				Gysland, Sonia M.; Mihalik, Jason P.; Register-Mihalik, Johna K.; Trulock, Scott C.; Shields, Edgar W.; Guskiewicz, Kevin M.			The Relationship Between Subconcussive Impacts and Concussion History on Clinical Measures of Neurologic Function in Collegiate Football Players	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion history; Cumulative exposure; Subconcussive impacts; Mild traumatic brain injury	HIGH-SCHOOL; HEAD IMPACTS; BRAIN-INJURY; STANDARDIZED ASSESSMENT; PROFESSIONAL FOOTBALL; SPORTS CONCUSSION; POSTURAL CONTROL; NCAA CONCUSSION; UNITED-STATES; EPIDEMIOLOGY	Concussions sustained during college and professional football careers have been associated with both acute and chronic neurologic impairment. The contribution of subconcussive impacts to this impairment has not been adequately studied. Therefore, we investigated the relationship between subconcussive impacts and concussion history on clinical measures of neurologic function. Forty-six collegiate football players completed five clinical measures of neurologic function commonly employed in the evaluation of concussion before and after a single season. These tests included the Automated Neuropsychological Assessment Metrics, Sensory Organization Test, Standardized Assessment of Concussion, Balance Error Scoring System, and Graded Symptom Checklist. The Head Impact Telemetry (HIT) System recorded head impact data including the frequency, magnitude, and location of impacts. College football players sustain approximately 1,000 subconcussive impacts to the head over the course of a season, but for the most part, do not demonstrate any clinically meaningful changes from preseason to postseason on measures of neurologic function. Changes in performance were mostly independent of prior concussion history, and the total number, magnitude and location of sustained impacts over one season as observed R-2 values ranged between 0.30 and 0.35. Repetitive subconcussive head impacts over a single season do not appear to result in short-term neurologic impairment, but these relationships should be further investigated for a potential dose-response over a player's career.	[Gysland, Sonia M.; Mihalik, Jason P.; Register-Mihalik, Johna K.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Trulock, Scott C.] Univ N Carolina, Campus Hlth Serv, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, 2207 Stallings Evans Sports Med Complex,Campus Bo, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Register-Mihalik, Johna/0000-0002-4229-4743; Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; National Operating Committee on Standards for Athletic Equipment	This study was supported in part by the Centers for Disease Control and Prevention and the National Operating Committee on Standards for Athletic Equipment.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Delaney JS, 2005, CLIN J SPORT MED, V15, P212; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Riemann BL, 1999, J SPORT REHABIL, V8, P171, DOI 10.1123/jsr.8.3.171; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Talavage T. M., 2010, J NEUROTRAUMA; Valovich TC, 2003, J ATHL TRAINING, V38, P51	35	102	102	0	39	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		14	22		10.1007/s10439-011-0421-3			9	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700002	21994067				2021-06-18	
J	Fazel, S; Lichtenstein, P; Grann, M; Langstrom, N				Fazel, Seena; Lichtenstein, Paul; Grann, Martin; Langstrom, Niklas			Risk of Violent Crime in Individuals with Epilepsy and Traumatic Brain Injury: A 35-Year Swedish Population Study	PLOS MEDICINE			English	Article							NATIONAL INPATIENT REGISTER; ACUTE MYOCARDIAL-INFARCTION; HEAD-INJURY; AGGRESSIVE-BEHAVIOR; SUBSTANCE-ABUSE; SCHIZOPHRENIA; COHORT; PREVALENCE; PRISONERS; REHABILITATION	Background: Epilepsy and traumatic brain injury are common neurological conditions, with general population prevalence estimates around 0.5% and 0.3%, respectively. Although both illnesses are associated with various adverse outcomes, and expert opinion has suggested increased criminality, links with violent behaviour remain uncertain. Methods and Findings: We combined Swedish population registers from 1973 to 2009, and examined associations of epilepsy (n = 22,947) and traumatic brain injury (n = 22,914) with subsequent violent crime (defined as convictions for homicide, assault, robbery, arson, any sexual offense, or illegal threats or intimidation). Each case was age and gender matched with ten general population controls, and analysed using conditional logistic regression with adjustment for socio-demographic factors. In addition, we compared cases with unaffected siblings. Among the traumatic brain injury cases, 2,011 individuals (8.8%) committed violent crime after diagnosis, which, compared with population controls (n = 229,118), corresponded to a substantially increased risk (adjusted odds ratio [aOR] = 3.3, 95% CI: 3.1-3.5); this risk was attenuated when cases were compared with unaffected siblings (aOR = 2.0, 1.8-2.3). Among individuals with epilepsy, 973 (4.2%) committed a violent offense after diagnosis, corresponding to a significantly increased odds of violent crime compared with 224,006 population controls (aOR = 1.5, 1.4-1.7). However, this association disappeared when individuals with epilepsy were compared with their unaffected siblings (aOR = 1.1, 0.9-1.2). We found heterogeneity in violence risk by age of disease onset, severity, comorbidity with substance abuse, and clinical subgroups. Case ascertainment was restricted to patient registers. Conclusions: In this longitudinal population-based study, we found that, after adjustment for familial confounding, epilepsy was not associated with increased risk of violent crime, questioning expert opinion that has suggested a causal relationship. In contrast, although there was some attenuation in risk estimates after adjustment for familial factors and substance abuse in individuals with traumatic brain injury, we found a significantly increased risk of violent crime. The implications of these findings will vary for clinical services, the criminal justice system, and patient charities.	[Fazel, Seena] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England; [Fazel, Seena; Grann, Martin; Langstrom, Niklas] Karolinska Inst, Ctr Violence Prevent, Stockholm, Sweden; [Lichtenstein, Paul; Grann, Martin; Langstrom, Niklas] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Grann, Martin; Langstrom, Niklas] Swedish Prison & Probat Serv, Norrkoping, Sweden	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England.	seena.fazel@psych.ox.ac.uk	Fazel, Seena/B-5307-2008; Langstrom, Niklas/C-5615-2009	Fazel, Seena/0000-0002-5383-5365; Langstrom, Niklas/0000-0002-2686-6799; lichtenstein, paul/0000-0003-3037-5287	Swedish Research Council - MedicineSwedish Research Council; Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); National Prison and Probation Administration RD	Funded by the Swedish Research Council - Medicine, Swedish Council for Working Life and Social Research, and the National Prison and Probation Administration R&D. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2004, PRACT GUID TREATM PA; Amoroso C, 2006, LANCET, V367, P1143, DOI 10.1016/S0140-6736(06)68503-6; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Arseneault L, 2000, ARCH GEN PSYCHIAT, V57, P979, DOI 10.1001/archpsyc.57.10.979; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Butler T, 2004, AUST NZ J PUBL HEAL, V28, P344, DOI 10.1111/j.1467-842X.2004.tb00442.x; Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8; Dalman C, 2002, SOC PSYCH PSYCH EPID, V37, P527, DOI 10.1007/s00127-002-0582-3; Damasio AR, 2000, ARCH GEN PSYCHIAT, V57, P128, DOI 10.1001/archpsyc.57.2.128; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; de Boer HM, 2002, EPILEPSIA, V43, P7, DOI 10.1046/j.1528-1157.43.s.6.4.x; Dolmen L, 2001, BROTTSLIGHETEN I OLI; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Ekholm B, 2005, NORD J PSYCHIAT, V59, P457, DOI 10.1080/08039480500360906; ELLIOTT FA, 1992, ARCH NEUROL-CHICAGO, V49, P595, DOI 10.1001/archneur.1992.00530300027006; Farrington DP, 2004, CROSS NATL STUDIES C; Fazel S, 2002, BRIT MED J, V324, P1495, DOI 10.1136/bmj.324.7352.1495; Fazel S, 2006, AM J PSYCHIAT, V163, P1397, DOI 10.1176/appi.ajp.163.8.1397; Fazel S, 2010, ARCH GEN PSYCHIAT, V67, P931, DOI 10.1001/archgenpsychiatry.2010.97; Fazel S, 2009, J NEUROL, V256, P1591, DOI 10.1007/s00415-009-5134-2; Fazel S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000120; Fazel S, 2009, JAMA-J AM MED ASSOC, V301, P2016, DOI 10.1001/jama.2009.675; Filley CM, 2001, NEUROPSY NEUROPSY BE, V14, P1; Forsgren L, 2005, EUR J NEUROL, V12, P245, DOI 10.1111/j.1468-1331.2004.00992.x; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Greve KW, 2001, BRAIN INJURY, V15, P255; GUNN J, 1971, BRIT J PSYCHIAT, V118, P337, DOI 10.1192/bjp.118.544.337; Hammar N, 2001, INT J EPIDEMIOL, V30, pS30, DOI 10.1093/ije/30.suppl_1.S30; Hjern A, 2002, LANCET, V360, P443, DOI 10.1016/S0140-6736(02)09674-5; Huband N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003499.pub3; JIANG GX, 1995, ACTA NEUROL SCAND, V91, P109; Kale R, 1997, BRIT MED J, V315, P2, DOI 10.1136/bmj.315.7099.2; Klein-Geltink JE, 2007, J CLIN EPIDEMIOL, V60, P766, DOI 10.1016/j.jclinepi.2006.11.008; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lambert M, 2003, NEUROPSYCHIATRY; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LINDBLAD U, 1993, SCAND J SOC MED, V21, P3, DOI 10.1177/140349489302100102; LIVINGSTON S, 1964, JAMA-J AM MED ASSOC, V188, P172; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Maudsley Henry, 1870, BODY MIND; National Institute for Health and Clinical Excellence, 2007, HEAD INJ TRAIG ASS I; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Raine A, 2005, J ABNORM PSYCHOL, V114, P38, DOI 10.1037/0021-843X.114.1.38; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; Reuber M, 2008, EPILEPSIA, V49, P138, DOI 10.1111/j.1528-1167.2007.01269.x; Shih JJ, 2009, NEUROLOGY, V73, P1804, DOI 10.1212/WNL.0b013e3181c2933f; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Statistics Sweden, 2005, FLERG 2004 BESKR INN; STEIN SC, 1995, PEDIATR SURG INT, V10, P465; Swedish National Board of Health and Welfare, 2011, PAT PAT REG; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tardiff K., 2003, TXB CLIN PSYCHIAT; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Toone B, 2009, NEW OXFORD TXB PSYCH, P1076; TREIMAN DM, 1986, EPILEPSIA, V27, pS77, DOI 10.1111/j.1528-1157.1986.tb05742.x; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Wallace C, 1998, BRIT J PSYCHIAT, V172, P477, DOI 10.1192/bjp.172.6.477; WHITMAN S, 1984, NEUROLOGY, V34, P775, DOI 10.1212/WNL.34.6.775; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Wood RL, 2006, J NEUROPSYCH CLIN N, V18, P333, DOI 10.1176/appi.neuropsych.18.3.333	65	102	104	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	DEC	2011	8	12							e1001150	10.1371/journal.pmed.1001150			7	Medicine, General & Internal	General & Internal Medicine	870KM	WOS:000298668100015	22215988	DOAJ Gold, Green Published			2021-06-18	
J	Wang, X; Sirianni, A; Pei, ZJ; Cormier, K; Smith, K; Jiang, JY; Zhou, SH; Wang, H; Zhao, R; Yano, H; Kim, JE; Li, W; Kristal, BS; Ferrante, RJ; Friedlander, RM				Wang, Xin; Sirianni, Ana; Pei, Zhijuan; Cormier, Kerry; Smith, Karen; Jiang, Jiying; Zhou, Shuanhu; Wang, Hui; Zhao, Rong; Yano, Hiroko; Kim, Jeong Eun; Li, Wei; Kristal, Bruce S.; Ferrante, Robert J.; Friedlander, Robert M.			The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity	JOURNAL OF NEUROSCIENCE			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; OXIDATIVE DAMAGE; DOUBLE-BLIND; NEURONAL DYSFUNCTION; COENZYME Q(10); DISEASE; INHIBITION	Melatonin mediates neuroprotection in several experimental models of neurodegeneration. It is not yet known, however, whether melatonin provides neuroprotection in genetic models of Huntington's disease (HD). We report that melatonin delays disease onset and mortality in a transgenic mouse model of HD. Moreover, mutant huntingtin (htt)-mediated toxicity in cells, mice, and humans is associated with loss of the type 1 melatonin receptor (MT1). We observe high levels of MT1 receptor in mitochondria from the brains of wild-type mice but much less in brains from HD mice. Moreover, we demonstrate that melatonin inhibits mutant htt-induced caspase activation and preserves MT1 receptor expression. This observation is critical, because melatonin-mediated protection is dependent on the presence and activation of the MT1 receptor. In summary, we delineate a pathologic process whereby mutant htt-induced loss of the mitochondrial MT1 receptor enhances neuronal vulnerability and potentially accelerates the neurodegenerative process.	[Yano, Hiroko; Friedlander, Robert M.] Univ Pittsburgh, Dept Neurol Surg, Sch Med, Neuroapoptosis Lab, Pittsburgh, PA 15213 USA; [Wang, Xin; Sirianni, Ana; Pei, Zhijuan; Jiang, Jiying; Wang, Hui; Zhao, Rong; Yano, Hiroko; Kim, Jeong Eun; Li, Wei] Harvard Univ, Sch Med, Brigham & Womens Hosp, Neuroapoptosis Lab, Boston, MA 02115 USA; [Wang, Xin; Sirianni, Ana; Pei, Zhijuan; Jiang, Jiying; Wang, Hui; Zhao, Rong; Yano, Hiroko; Kim, Jeong Eun; Li, Wei; Kristal, Bruce S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Zhou, Shuanhu] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA; [Cormier, Kerry; Smith, Karen; Ferrante, Robert J.] Bedford Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA; [Cormier, Kerry; Smith, Karen; Ferrante, Robert J.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Cormier, Kerry; Smith, Karen; Ferrante, Robert J.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Cormier, Kerry; Smith, Karen; Ferrante, Robert J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA	Friedlander, RM (corresponding author), Univ Pittsburgh, Med Ctr, Presbyterian Hosp, Dept Neurol Surg,Sch Med, Suite 449,200 Lothrop St, Pittsburgh, PA 15213 USA.	xwang@rics.bwh.harvard.edu; friedlanderr@upmc.edu	Kim, Jeong Eun/J-5434-2012; Zhou, Shuanhu/Q-7137-2019; Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219; Zhou, Shuanhu/0000-0003-4745-5347	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Muscular Dystrophy AssociationMuscular Dystrophy Association; Huntington's Disease Society of America; Veterans AdministrationUS Department of Veterans Affairs; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK040561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051756, R01NS039324] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (R. M. F., X. W., R.J.F.), the Muscular Dystrophy Association (X. W.), the Huntington's Disease Society of America (R. M. F.,) and the Veterans Administration (R.J.F.). We thank Dr. Ethan M. Shimony and Dr. Diane Carlisle for editorial assistance, Dr. Irina Stavrovskaya, Jennifer Moody, and Diane Sheldon for experimental assistance, and Dr. Ahmad Aziz for insightful discussion.	Adamczyk A, 2005, J Physiol Pharmacol, V56 Suppl 2, P5; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Aziz NA, 2009, J NEUROL, V256, P1961, DOI 10.1007/s00415-009-5196-1; Bennett EJ, 2007, NATURE, V448, P704, DOI 10.1038/nature06022; Blazejova K, 2000, Sb Lek, V101, P347; Brydon L, 2001, ENDOCRINOLOGY, V142, P4264, DOI 10.1210/en.142.10.4264; Caballero B, 2008, J PINEAL RES, V45, P302, DOI 10.1111/j.1600-079X.2008.00591.x; Carranza-Lira S, 2000, Med Sci Monit, V6, P1209; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chopra V, 2007, P NATL ACAD SCI USA, V104, P16685, DOI 10.1073/pnas.0707842104; COGBURN LA, 1987, GEN COMP ENDOCR, V68, P343, DOI 10.1016/0016-6480(87)90073-6; Das A, 2008, J PINEAL RES, V45, P117, DOI 10.1111/j.1600-079X.2008.00582.x; Dominguez-Rodriguez A, 2007, CONTEMP CLIN TRIALS, V28, P532, DOI 10.1016/j.cct.2006.10.007; Drew JE, 2001, J NEUROENDOCRINOL, V13, P453, DOI 10.1046/j.1365-2826.2001.00651.x; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; Franklin K.B., 2000, MOUSE BRAIN STEREOTA; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Gupta M, 2004, EPILEPSY BEHAV, V5, P316, DOI 10.1016/j.yebeh.2004.01.012; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Kasahara T, 2010, P NATL ACAD SCI USA, V107, P6412, DOI 10.1073/pnas.0914399107; Kiechle T, 2002, NEUROMOL MED, V1, P183; Kilic E, 2004, J PINEAL RES, V36, P171, DOI 10.1046/j.1600-079X.2003.00115.x; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; Krasnikov BF, 2005, BBA-BIOENERGETICS, V1708, P375, DOI 10.1016/j.bbabio.2005.05.009; Lena PJ, 2003, POL J PHARMACOL, V55, P1031; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XJ, 1999, MOL NEUROBIOL, V20, P111, DOI 10.1007/BF02742437; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin M, 2000, FASEB J, V14, P1677; Masuda N, 2008, NEUROBIOL DIS, V30, P293, DOI 10.1016/j.nbd.2008.01.014; Medeiros CAM, 2007, J NEUROL, V254, P459, DOI 10.1007/s00415-006-0390-x; MOCCHEGIANI E, 1994, J NEUROIMMUNOL, V53, P189, DOI 10.1016/0165-5728(94)90029-9; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; Niles LP, 1999, MOL CELL ENDOCRINOL, V156, P107, DOI 10.1016/S0303-7207(99)00135-5; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Ozcankaya R, 2002, CROAT MED J, V43, P28; Ozdemir D, 2005, PHYSIOL RES, V54, P631; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Ravindra T, 2006, Indian J Med Sci, V60, P523; Reiter RJ, 2002, J PINEAL RES, V33, P61, DOI 10.1034/j.1600-079X.2002.2e001.x; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; Sanchez-Hidalgo M, 2009, J PINEAL RES, V46, P29, DOI 10.1111/j.1600-079X.2008.00604.x; Savaskan E, 2002, J HISTOCHEM CYTOCHEM, V50, P519, DOI 10.1177/002215540205000408; Savaskan E, 2007, CURR ALZHEIMER RES, V4, P47, DOI 10.2174/156720507779939823; Savina TA, 2006, B EXP BIOL MED+, V142, P601, DOI 10.1007/s10517-006-0429-0; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Southgate G, 1999, METAB BRAIN DIS, V14, P165, DOI 10.1023/A:1020610708637; Srinivasan V, 2006, Behav Brain Funct, V2, P15, DOI 10.1186/1744-9081-2-15; Stack EC, 2006, BBA-MOL BASIS DIS, V1762, P373, DOI 10.1016/j.bbadis.2005.11.002; Stavrovskaya IG, 2005, FREE RADICAL BIO MED, V38, P687, DOI 10.1016/j.freeradbiomed.2004.11.032; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Tunez I, 2004, J PINEAL RES, V37, P252, DOI 10.1111/j.1600-079X.2004.00163.x; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; WALDHAUSER F, 1984, NEUROENDOCRINOLOGY, V39, P307, DOI 10.1159/000123997; Wang X, 2005, J NEUROSCI, V25, P11645, DOI 10.1523/JNEUROSCI.4181-05.2005; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wang X, 2008, J NEUROSCI, V28, P9473, DOI 10.1523/JNEUROSCI.1867-08.2008; Wang X, 2009, STROKE, V40, P1877, DOI 10.1161/STROKEAHA.108.540765; Weishaupt JH, 2006, J PINEAL RES, V41, P313, DOI 10.1111/j.1600-079X.2006.00377.x; Willis GL, 1999, PHYSIOL BEHAV, V66, P785, DOI 10.1016/S0031-9384(99)00023-2; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zhang Y, 2003, J NEUROCHEM, V87, P1184, DOI 10.1046/j.1471-4159.2003.02105.x; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	68	102	104	1	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 12	2011	31	41					14496	14507		10.1523/JNEUROSCI.3059-11.2011			12	Neurosciences	Neurosciences & Neurology	835FB	WOS:000296019600007	21994366	Green Published, Bronze, Green Accepted			2021-06-18	
J	Matthews, SC; Strigo, IA; Simmons, AN; O'Connell, RM; Reinhardt, LE; Moseley, SA				Matthews, Scott C.; Strigo, Irina A.; Simmons, Alan N.; O'Connell, Ryan M.; Reinhardt, Lindsay E.; Moseley, Suzanne A.			A multimodal imaging study in US veterans of Operations Iraqi and Enduring Freedom with and without major depression after blast-related concussion	NEUROIMAGE			English	Article						Depression; Concussion; Traumatic brain injury; Combat; Emotion processing; Amygdala; fMRI; Diffusion tensor imaging; Fractional anisotropy	TRAUMATIC BRAIN-INJURY; LATE-LIFE DEPRESSION; EVENT-RELATED FMRI; WHITE-MATTER; HUMAN AMYGDALA; MICROSTRUCTURAL ABNORMALITIES; DISORDER; INDIVIDUALS; ASSOCIATION; AFGHANISTAN	Although the exact number of affected individuals is unknown, it has been estimated that approximately 20% of U. S. veterans of Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF) have experienced mild traumatic brain injury (mTBI) (i.e., concussion), which is defined as a brief loss or alteration of consciousness from a blow or jolt to the head. Blast exposure is among the most common causes of concussion in OEF-OIF warriors. Although the mechanism is unknown, major depressive disorder (MDD) after head injury is common. The purpose of this study was to use diffusion tensor imaging (DTI) and functional magnetic resonance imaging (fMRI) to examine the structural and functional neural correlates of MDD in OEF-OIF combat veterans with a self-reported history of blast-related concussion. We hypothesized that subjects in the MDD group (i.e., individuals with a history of blast-related concussion who were experiencing current MDD) relative to individuals in the non-MDD group (i.e., individuals with a history of blast-related concussion but no current or lifetime history of MDD) would show amygdala hyperactivity and disruption of white matter tracts connecting prefrontal and limbic brain regions. To test these hypotheses, 11 MDD and 11 non-MDD individuals underwent DTI and performed a validated emotional face matching task during fMRI. MDD relative to non-MDD individuals showed greater activity during fear matching trials in the amygdala and other emotion processing structures, lower activity during fear matching trials in emotional control structures such as the dorsolateral prefrontal cortex and lower fractional anisotropy (FA) in several white matter tracts including the superior longitudinal fasciculus (SLF). Greater depressive symptom severity correlated negatively with FA in the SLF. These results suggest a biological basis of MDD in OEF-OIF veterans who have experienced blast-related concussion, and may contribute to the development of treatments aimed at improving the clinical care of this unique population of wounded warriors. Published by Elsevier Inc.	[Matthews, Scott C.; O'Connell, Ryan M.; Reinhardt, Lindsay E.; Moseley, Suzanne A.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Matthews, Scott C.; Strigo, Irina A.; Simmons, Alan N.; O'Connell, Ryan M.; Reinhardt, Lindsay E.; Moseley, Suzanne A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA	Matthews, SC (corresponding author), 3350 La Jolla Village Dr,116-A, San Diego, CA 92161 USA.	scmatthews@ucsd.edu	strigo, irina A/L-9882-2016; Simmons, Alan N/A-9815-2008	strigo, irina A/0000-0002-8799-716X; Simmons, Alan N/0000-0003-3963-2112	Veterans AdministrationUS Department of Veterans Affairs; Congressionally Directed Medical Research ProgramUnited States Department of Defense	The authors are grateful to Martin Paulus, M. D., Dean Delis, Ph.D. and Larry Frank, Ph.D. for their contributions to this research, which was supported by grants from the Veterans Administration and the Congressionally Directed Medical Research Program.	Adolphs R, 1998, NATURE, V393, P470, DOI 10.1038/30982; Alexopoulos GS, 2002, AM J PSYCHIAT, V159, P1929, DOI 10.1176/appi.ajp.159.11.1929; Baldwin RC, 2000, INT J GERIATR PSYCH, V15, P1097, DOI 10.1002/1099-1166(200012)15:12<1097::AID-GPS251>3.0.CO;2-N; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1963, ARCH GEN PSYCHIAT, V9, P324; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CASTRO CA, 2006, M P RTO MP HFM 134 N; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; First MB., 1997, STRUCTURED CLIN INTE; Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; JOHNSON S, 2009, INT STAT OF THE SCI; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; Lacerda ALT, 2005, J PSYCHIATR RES, V39, P347, DOI 10.1016/j.jpsychires.2004.10.004; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; LeDoux J, 1996, PROG BRAIN RES, V107, P437; LeDoux J., 1996, EMOTIONAL BRAIN; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Liberzon I, 2003, NEUROPSYCHOPHARMACOL, V28, P726, DOI 10.1038/sj.npp.1300113; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Matthews SC, 2008, J AFFECT DISORDERS, V111, P13, DOI 10.1016/j.jad.2008.05.022; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Mollica RF, 2009, ARCH GEN PSYCHIAT, V66, P1221, DOI 10.1001/archgenpsychiatry.2009.127; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Nobuhara K, 2006, J NEUROL NEUROSUR PS, V77, P120, DOI 10.1136/jnnp.2004.055129; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schwab KA, 2006, NEUROLOGY, V66, pA235; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Siegle GJ, 2002, BIOL PSYCHIAT, V51, P693, DOI 10.1016/S0006-3223(02)01314-8; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Strigo IA, 2008, ARCH GEN PSYCHIAT, V65, P1275, DOI 10.1001/archpsyc.65.11.1275; TALAIRACH J, 1998, COPLANAR STEREOTAXI; Taylor WD, 2004, AM J PSYCHIAT, V161, P1293, DOI 10.1176/appi.ajp.161.7.1293; TEASDALE G, 1974, LANCET, V2, P81; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Yang Q, 2007, INT PSYCHOGERIATR, V19, P757, DOI 10.1017/S1041610207004875; Zald DH, 2003, BRAIN RES REV, V41, P88, DOI 10.1016/S0165-0173(02)00248-5; Zou K, 2008, J PSYCHIATR NEUROSCI, V33, P525	56	102	103	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN	2011	54			1			S69	S75		10.1016/j.neuroimage.2010.04.269			7	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600010	20451622				2021-06-18	
J	Sosnoff, JJ; Broglio, SP; Shin, S; Ferrara, MS				Sosnoff, Jacob J.; Broglio, Steven P.; Shin, Sunghoon; Ferrara, Michael S.			Previous Mild Traumatic Brain Injury and Postural-Control Dynamics	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; balance; complexity analysis; long-term effects; nonlinear dynamics	PROFESSIONAL FOOTBALL PLAYERS; CEREBRAL CONCUSSION; RECURRENT CONCUSSION; APPROXIMATE ENTROPY; LEAGUE PLAYER; STABILITY; COMPLEXITY; ENCEPHALOPATHY; RECOVERY; SPORTS	Context: Postural control and cognitive function are adversely affected by acute mild traumatic brain injury (mTBI). Whether postural-control deficits persist beyond the acute stage in individuals with a history of mTBI is unclear. Objective: To determine if postural-control deficits persist in individuals with a history of mTBI. Design: Retrospective cross-sectional study. Setting: University research laboratory. Patients or Other Participants: As part of an ongoing investigation examining cognitive and motor deficits associated with mTBI, 224 individuals participated in the study. Of these, 62 participants self-reported at least 1 previous physician-diagnosed mTBI. Intervention(s): Postural control was assessed using the NeuroCom Sensory Organization Test (SOT) postural-assessment battery. Main Outcome Measure(s): The SOT postural assessment yields 4 indices of postural control: a composite balance score, a visual ratio score, a somatosensory score, and a vestibular score. Postural dynamics were also examined by calculating approximate entropy of center-of-pressure excursions in the anteroposterior and mediolateral axis for each test condition. Results: Minimal differences in the SOT indices were noted among individuals with and without a history of previous mTBI (P > .05). In the group with a history of mTBI, anteroposterior postural irregularity decreased as postural difficulty increased. In contrast, the group without a history of mTBI displayed increased postural irregularity in the mediolateral direction. Conclusions: Individuals with a history of mTBI exhibited altered postural dynamics compared with individuals without a history of mTBI. These findings support the notion that changes in cerebral functioning that affect postural control may persist long after acute injury resolution.	[Sosnoff, Jacob J.; Broglio, Steven P.; Shin, Sunghoon] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Ferrara, Michael S.] Univ Georgia, Dept Exercise Sci, Athens, GA 30602 USA	Sosnoff, JJ (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	jsosnoff@illinois.edu	Sosnoff, Jacob/P-3397-2019; Shin, Sunghoon/O-2070-2019	Sosnoff, Jacob/0000-0002-0286-9207; Shin, Sunghoon/0000-0001-5355-2157			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Keselman HJ, 1998, PSYCHOPHYSIOLOGY, V35, P470, DOI 10.1111/1469-8986.3540470; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Nashner LM., 1997, HDB BALANCE FUNCTION, P280; NeuroCom International Inc, 2001, NEUROCOM SYST OP MAN; Newell KM, 1998, APPLICATIONS OF NONLINEAR DYNAMICS TO DEVELOPMENTAL PROCESS MODELING, P63; Newell KM., 2006, J GERONTOL B-PSYCHOL, V6, P163, DOI [10.1016/B978-012101264-9/50011-2, DOI 10.1016/B978-012101264-9/50011-2]; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piirtola M, 2006, GERONTOLOGY, V52, P1, DOI 10.1159/000089820; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Vaillancourt DE, 2002, NEUROBIOL AGING, V23, P1, DOI 10.1016/S0197-4580(01)00247-0; Winter D.A., 1990, BIOMECHANICS MOTOR C, V2nd	34	102	102	0	21	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2011	46	1					85	91		10.4085/1062-6050-46.1.85			7	Sport Sciences	Sport Sciences	704SZ	WOS:000286074000011	21214355	Bronze, Green Published			2021-06-18	
J	Unden, J; Romner, B				Unden, Johan; Romner, Bertil			Can Low Serum Levels of S100B Predict Normal CT Findings After Minor Head Injury in Adults?: An Evidence-Based Review and Meta-Analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						evidence; guidelines; head injury; management; meta-analysis; MHI; mild; minor; TBI; S100/S-100/S100B	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; S-100 PROTEIN MEASUREMENTS; CLINICAL DECISION INSTRUMENTS; FIBRILLARY ACIDIC PROTEIN; COMPUTED-TOMOGRAPHY; URINARY S100B; EMERGENCY-DEPARTMENT; MILD; CHILDREN	Objective: To determine whether low levels of S100B in serum can predict normal computed tomography (CT) findings after minor head injury (MHI) in adults. Participants: Not applicable. Design: Systematic evidence-based review of the peer-reviewed literature with meta-analytical interpretation. Primary Measures: Not applicable. Results: We identified 12 eligible articles that specifically studied adult MHI patients with S100B and cranial CT scans in the acute phase after injury, comprising a total of 2466 separate patients. Individual negative predictive values of 90% to 100% were found for the ability of a negative (under cutoff) S100B level to predict a normal CT scan. A total of 6 patients included in the studies had low S100B levels and positive CT scans (0.26%) and only 1 of these patients (0.04%) had a clinically relevant CT finding. The pooled negative predictive value for all studies was more than 99% (95% CI 98%-100%), with an average prevalence for any CT finding at 8%. The studies are consistently classed as level 2 and level 3 grades of evidence, suggesting a grade B recommendation. Conclusion: Low serum S100B levels accurately predict normal CT findings after MHI in adults. S100B sampling should be considered in MHI patients with no focal neurological deficit, an absence of significant extracerebral injury, should be taken within 3 hours of injury, and the cutoff for omitting CT set at less than 0.10 mu g/L. Care givers should also be aware of other clinical factors predictive of intracranial complications after MHI.	[Unden, Johan] Halmstad Reg Hosp, Dept Anaesthesia & Intens Care, S-30185 Halmstad, Sweden; [Romner, Bertil] Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark	Unden, J (corresponding author), Halmstad Reg Hosp, Dept Anaesthesia & Intens Care, S-30185 Halmstad, Sweden.	johan.unden@Ithalland.se			Vetenskapliga Radet/Landstinget i Halland; Region Skane and Sodra Sjukvardsregionen	JU has received funding from the following noncommercial sources: Vetenskapliga Radet/Landstinget i Halland, Region Skane and Sodra Sjukvardsregionen.	AFGEIJERSTAM JL, BMJ, V333, P465; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 2006, RESTOR NEUROL NEUROS, V24, P163; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Bouvier D, 2009, ANN BIOL CLIN-PARIS, V67, P425, DOI 10.1684/abc.2009.0347; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; Corwin MT, 2009, AM J ROENTGENOL, V192, P1319, DOI 10.2214/AJR.08.1346; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Enochsson L, 2005, EUR J NEUROL, V12, P445, DOI 10.1111/j.1468-1331.2005.00996.x; Gazzolo D, 2004, CRIT CARE MED, V32, P131, DOI 10.1097/01.CCM.0000104116.91462.CD; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; HALL EJ, 2008, BRIT J RADIOL, V81, P1148; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; Heneghan Carl, 2009, Evid Based Med, V14, P67, DOI 10.1136/ebm.14.3.67; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KANNER AA, 2003, CANCER, V1, P97; Keller T, 2009, NEW ENGL J MED, V361, P868, DOI 10.1056/NEJMoa0903515; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Oh EJ, 2007, J CLIN LAB ANAL, V21, P387, DOI 10.1002/jcla.20201; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI [10.1089/neu.2009.0928, 10.1089/neu.2009-0928]; Schultke E, 2009, CAN J NEUROL SCI, V36, P612, DOI 10.1017/S031716710000812X; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; STEINER J, BMC NEUROSCI, V8, P2; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Wells PS, 2006, JAMA-J AM MED ASSOC, V295, P199, DOI 10.1001/jama.295.2.199; Whiting Penny F, 2006, BMC Med Res Methodol, V6, P9, DOI 10.1186/1471-2288-6-9; WIESMANN M, 2009, ACTA NEUROL SCAND, V5, P178; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117	83	102	107	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					228	240		10.1097/HTR.0b013e3181e57e22			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900002	20611042				2021-06-18	
J	Mihalik, JP; Blackburn, JT; Greenwald, RM; Cantu, RC; Marshall, SW; Guskiewicz, KM				Mihalik, Jason P.; Blackburn, J. Troy; Greenwald, Richard M.; Cantu, Robert C.; Marshall, Stephen W.; Guskiewicz, Kevin M.			Collision Type and Player Anticipation Affect Head Impact Severity Among Youth Ice Hockey Players	PEDIATRICS			English	Article						child; concussion; injury; physical activity; sports; trauma	SEGMENT DYNAMIC STABILIZATION; TRAUMATIC UNCONSCIOUSNESS; CEREBRAL CONCUSSION; FOOTBALL PLAYERS; INJURIES; ACCELERATION; CHIMPANZEE; MILD	OBJECTIVE: The objective was to determine how body collision type and player anticipation affected the severity of head impacts sustained by young athletes. For anticipated collisions, we sought to evaluate different body position descriptors during delivery and receipt of body collisions and their effects on head impact severity. We hypothesized that head impact biomechanical features would be more severe in unanticipated collisions and open-ice collisions, compared with anticipated collisions and collisions along the playing boards, respectively. METHODS: Sixteen ice hockey players (age: 14.0 +/- 0.5 years) wore instrumented helmets from which biomechanical measures (ie, linear acceleration, rotational acceleration, and severity profile) associated with head impacts were computed. Body collisions observed in video footage captured over a 54-game season were evaluated for collision type (open ice versus along the playing boards), level of anticipation (anticipated versus unanticipated), and relative body positioning by using a new tool developed for this purpose. RESULTS: Open-ice collisions resulted in greater head linear (P = .036) and rotational (P = .003) accelerations, compared with collisions along the playing boards. Anticipated collisions tended to result in less-severe head impacts than unanticipated collisions, especially for medium-intensity impacts (50th to 75th percentiles of severity scores). CONCLUSION: Our data underscore the need to provide players with the necessary technical skills to heighten their awareness of imminent collisions and to mitigate the severity of head impacts in this sport. Pediatrics 2010; 125: e1394-e1401	[Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, Chapel Hill, NC 27599 USA; [Blackburn, J. Troy] Univ N Carolina, Dept Exercise & Sport Sci, Neuromuscular Res Lab, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Blackburn, J. Troy; Guskiewicz, Kevin M.] Univ N Carolina, Curriculum Human Movement Sci, Sch Med, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Sport Med, Concord, MA USA	Mihalik, JP (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, 209 Fetzer Gymnasium,South Rd, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu	Mihalik, Jason P/E-7059-2010	Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233	HIT System technology; Ontario Neurotrauma Foundation; National Operating Committee on Standards for Athletic Equipment; USA Hockey Foundation	FINANCIAL DISCLOSURE: Dr Greenwald has a financial interest in the HIT System technology used to collect data in this study.; Funding for this research was obtained from the Ontario Neurotrauma Foundation, the National Operating Committee on Standards for Athletic Equipment, and the USA Hockey Foundation.	Bailes JE, 2001, J ATHL TRAINING, V36, P236; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Demidenko E., 2004, MIXED MODELS THEORY; Finkelstein EA., 2006, INCIDENCE EC BURDEN; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; Mansell J, 2005, J ATHL TRAINING, V40, P310; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; *US HOCK, 2009, HEADS HOCK PROGR GUI	25	102	103	1	20	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2010	125	6					E1394	E1401		10.1542/peds.2009-2849			8	Pediatrics	Pediatrics	604GX	WOS:000278268600044	20478933				2021-06-18	
J	Fremont, RD; Koyama, T; Calfee, CS; Wu, W; Dossett, LA; Bossert, FR; Mitchell, D; Wickersham, N; Bernard, GR; Matthay, MA; May, AK; Ware, LB				Fremont, Richard D.; Koyama, Tatsuki; Calfee, Carolyn S.; Wu, William; Dossett, Lesly A.; Bossert, Fred R.; Mitchell, Daphne; Wickersham, Nancy; Bernard, Gordon R.; Matthay, Michael A.; May, Addison K.; Ware, Lorraine B.			Acute Lung Injury in Patients With Traumatic Injuries: Utility of a Panel of Biomarkers for Diagnosis and Pathogenesis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	104th International Conference of the American-Thoracic-Society	MAY 16-21, 2008	Toronto, CANADA	Amer Thorac Soc		Acute respiratory distress syndrome; Acute pulmonary edema; Pulmonary contusion; Alveolar epithelium	RESPIRATORY-DISTRESS-SYNDROME; INTRAVASCULAR VOLUME STATUS; III PROCOLLAGEN PEPTIDE; GLYCATION END-PRODUCTS; CRITICALLY-ILL TRAUMA; PULMONARY-EDEMA FLUID; BRONCHOALVEOLAR LAVAGE; CLINICAL-OUTCOMES; VASCULAR PEDICLE; MORTALITY	Background: The diagnosis of acute lung injury (ALI) is based on a consensus clinical definition. Despite the simplicity of this definition, ALI remains underdiagnosed and undertreated. Severe trauma is a well-described cause of ALI that represents a relatively homogeneous subset of patients with ALI. The aims of this study were to develop a panel of plasma biomarkers to facilitate diagnosis of trauma-induced ALI and to enhance our understanding of the pathogenesis of human ALI. Methods: A retrospective nested case control of 192 patients admitted to the trauma intensive care unit at a university hospital between 2002 and 2006. We compared 107 patients with ALI to 85 patients without ALI. Plasma was collected within 72 hours of intensive care unit admission. Twenty-one plasma biomarkers were measured in duplicate in each plasma sample. Results: Patients with ALI had higher severity of illness scores, more days of mechanical ventilation, longer hospital stays, and higher mortality versus controls. Seven biomarkers (receptor for advanced glycation end products, procollagen peptide III, brain natriuretic peptide, angiopoietin-2, interleukin-10, tumor necrosis factor alpha, and interleukin-8) had a high diagnostic accuracy as reflected by the area under the receiver operating characteristic curve of 0.86 (95% confidence interval, 0.82-0.92) in differentiating ALI from controls. Conclusions: A model using seven plasma biomarkers had a high diagnostic accuracy in differentiating patients with trauma-induced ALI from trauma patients without ALI. In addition, use of a panel of biomarkers provides insight into the likely importance of alveolar epithelial injury in the pathogenesis of early ALI.	[Fremont, Richard D.; Bossert, Fred R.; Mitchell, Daphne; Wickersham, Nancy; Bernard, Gordon R.; Ware, Lorraine B.] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Koyama, Tatsuki; Wu, William] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Dossett, Lesly A.; May, Addison K.] Vanderbilt Univ, Dept Surg, Div Trauma & Surg Crit Care, Nashville, TN 37232 USA; [Calfee, Carolyn S.; Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Calfee, Carolyn S.; Matthay, Michael A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Calfee, Carolyn S.; Matthay, Michael A.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA	Ware, LB (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, T1218 MCN,1161 21st Ave St, Nashville, TN 37232 USA.	lorraine.ware@vanderbilt.edu	Ware, Lorraine/AAJ-9307-2021; Dossett, Lesly/I-8881-2019	Ware, Lorraine/0000-0002-9429-4702; Dossett, Lesly/0000-0001-8060-1073	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL090833, R37HL051856, R01HL051856, K24HL103836, U01HL081332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI049989] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K24 HL103836, U01 HL081332, HL081332, K23 HL090833, HL51856, HL 090833] Funding Source: Medline; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI49989] Funding Source: Medline		*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Calfee CS, 2008, THORAX, V63, P1083, DOI 10.1136/thx.2008.095588; Calfee CS, 2007, CRIT CARE MED, V35, P2243, DOI 10.1097/01.CCM.0000280434.33451.87; Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124; CLARK JG, 1995, ANN INTERN MED, V122, P17, DOI 10.7326/0003-4819-122-1-199501010-00003; Cohn SM, 1997, J TRAUMA, V42, P973, DOI 10.1097/00005373-199705000-00033; Dicker RA, 2004, J TRAUMA, V57, P522, DOI 10.1097/01.TA.0000135749.64867.06; Dossett LA, 2008, CHEST, V134, P974, DOI 10.1378/chest.08-0079; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; Effron B., 1993, INTRO BOOTSTRAP; Eisner MD, 2001, AM J RESP CRIT CARE, V164, P231, DOI 10.1164/ajrccm.164.2.2011093; Eisner MD, 2003, THORAX, V58, P983, DOI 10.1136/thorax.58.11.983; Ely EW, 2002, CHEST, V121, P942, DOI 10.1378/chest.121.3.942; Ely EW, 2001, CRIT CARE MED, V29, P1502; Estenssoro E, 2002, CRIT CARE MED, V30, P2450, DOI 10.1097/00003246-200211000-00008; Frank JA, 2002, AM J RESP CRIT CARE, V165, P242, DOI 10.1164/ajrccm.165.2.2108087; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; Harrell Frank E., 2001, REGRESSION MODELING; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Laffon M, 1999, AM J PHYSIOL-LUNG C, V277, pL760; LOW RB, 1983, LAB INVEST, V48, P755; LOW RB, 1992, AM REV RESPIR DIS, V146, P701, DOI 10.1164/ajrccm/146.3.701; Luchette FA, 2004, J TRAUMA, V57, P526; Marshall RP, 2000, AM J RESP CRIT CARE, V162, P1783, DOI 10.1164/ajrccm.162.5.2001061; Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; McClintock D, 2008, CRIT CARE, V12, DOI 10.1186/cc6846; Meduri GU, 1998, AM J RESP CRIT CARE, V158, P1432; MILNE ENC, 1984, RADIOLOGY, V152, P1; Modelska K, 1999, AM J PHYSIOL-LUNG C, V276, pL844; MODELSKA K, 1998, AM J RESP CRIT CARE, V157, pA350; Prabhakaran P, 2003, AM J PHYSIOL-LUNG C, V285, pL20, DOI 10.1152/ajplung.00312.2002; RAEDSCH R, 1983, GASTROENTEROLOGY, V85, P1265; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; Salim A, 2008, INJURY, V39, P30, DOI 10.1016/j.injury.2007.06.015; Salim A, 2006, ARCH SURG-CHICAGO, V141, P655, DOI 10.1001/archsurg.141.7.655; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; Treggiari MM, 2004, CRIT CARE MED, V32, P327, DOI 10.1097/01.CCM.0000108870.09693.42; Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Ware LB, 2005, NEW ENGL J MED, V353, P2788, DOI 10.1056/NEJMcp052699; Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; WAYDHAS C, 1993, CRIT CARE MED, V21, P240, DOI 10.1097/00003246-199302000-00016; Weber KT, 1997, CIRCULATION, V96, P2488; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	58	102	113	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2010	68	5					1121	1127		10.1097/TA.0b013e3181c40728			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	595MQ	WOS:000277615200017	20038857	Green Accepted			2021-06-18	
J	Schnakers, C; Chatelle, C; Vanhaudenhuyse, A; Majerus, S; Ledoux, D; Boly, M; Bruno, MA; Boveroux, P; Demertzi, A; Moonen, G; Laureys, S				Schnakers, Caroline; Chatelle, Camille; Vanhaudenhuyse, Audrey; Majerus, Steve; Ledoux, Didier; Boly, Melanie; Bruno, Marie-Aurulie; Boveroux, Pierre; Demertzi, Athena; Moonen, Gustave; Laureys, Steven			The Nociception Coma scale: A new tool to assess nociception in disorders of consciousness	PAIN			English	Article						Nociception; Behavioral assessment; Brain injury; Consciousness; Vegetative state; Minimally conscious state	PAIN ASSESSMENT; STIMULI; STATE	Assessing behavioral responses to nociception is difficult in severely brain-injured patients recovering from coma. We here propose a new scale developed for assessing nociception in vegetative (VS) and minimally conscious (MCS) coma survivors, the Nociception Coma Scale (NCS), and explore its concurrent validity, inter-rater agreement and sensitivity. Concurrent validity was assessed by analyzing behavioral responses of 48 post-comatose patients to a noxious stimulation (pressure applied to the fingernail) (28 VS and 20 MCS; age range 20-82 years; 17 of traumatic etiology). Patients' were assessed using the NCS and four other scales employed in non-communicative patients: the 'Neonatal Infant Pain Scale' (NIPS) and the 'Faces, Legs, Activity, Cry, Consolability' (FLACC) used in newborns; and the 'Pain Assessment In Advanced Dementia Scale' (PAINAD) and the 'Checklist of Non-verbal Pain Indicators' (CNPI) used in dementia. For the establishment of inter-rater agreement, fifteen patients were concurrently assessed by two examiners. Concurrent validity, assessed by Spearman rank order correlations between the NCS and the four other validated scales, was good. Cohen's kappa analyses revealed a good to excellent inter-rater agreement for the NCS total and subscore measures, indicating that the scale yields reproducible findings across examiners. Finally, a significant difference between NCS total scores was observed as a function of diagnosis (i.e., VS or MCS). The NCS constitutes a sensitive clinical tool for assessing nociception in severely brain-injured patients. This scale constitutes the first step to a better management of patients recovering from coma. (C) 2009 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.	[Schnakers, Caroline; Chatelle, Camille; Vanhaudenhuyse, Audrey; Boly, Melanie; Bruno, Marie-Aurulie; Boveroux, Pierre; Demertzi, Athena; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Majerus, Steve] Univ Liege, Dept Cognit Sci, B-4000 Liege, Belgium; [Ledoux, Didier] CHU Sart Tilman, Dept Intens Care, B-4000 Liege, Belgium; [Boly, Melanie; Moonen, Gustave; Laureys, Steven] CHU Sart Tilman, Dept Neurol, B-4000 Liege, Belgium; [Boveroux, Pierre] Univ Liege, CHU Sart Tilman Hosp, Dept Anesthesia, B-4000 Liege, Belgium	Schnakers, C (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, Sart Tilman B30, B-4000 Liege, Belgium.	C.Schnakers@ulg.ac.be; steven.laureys@ulg.ac.be	Laureys, Steven/A-3349-2011; Majerus, Steve/D-4678-2009; Laureys, Steven/AAN-2097-2021; Demertzi, Athena/I-1251-2019; Vanhaudenhuyse, Audrey/AAP-2455-2020	Laureys, Steven/0000-0002-3096-3807; Demertzi, Athena/0000-0001-8021-3759; Chatelle, Camille/0000-0002-7526-2107; Majerus, Steve/0000-0002-8206-8097; Boly, Melanie/0000-0001-9584-0907; Ledoux, Didier/0000-0002-9314-6564	Belgian Fund for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation; Mind Science Foundation; French Speaking Community Concerted Research Action [ARC-06/11-340]; Fondation Medicale Reine Elisabeth, University of LiegeUniversity of Liege; CNRS/FNRS-CGRI collaboration fundsCentre National de la Recherche Scientifique (CNRS)Fonds de la Recherche Scientifique - FNRS	This research was funded by the Belgian Fund for Scientific Research (FNRS), European Commission, James McDonnell Foundation, Mind Science Foundation, French Speaking Community Concerted Research Action (ARC-06/11-340), Fondation Medicale Reine Elisabeth, University of Liege and the CNRS/FNRS-CGRI collaboration funds.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Chatelle C, 2008, Rev Med Liege, V63, P429; Feldt K S, 2000, Pain Manag Nurs, V1, P13, DOI 10.1053/jpmn.2000.5831; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Halliburton J R, 1998, CRNA, V9, P39; Herr K, 2006, PAIN MANAG NURS, V7, P44, DOI 10.1016/j.pmn.2006.02.003; Hummel P, 2006, SEMIN FETAL NEONAT M, V11, P237, DOI 10.1016/j.siny.2006.02.004; *IASP, 1994, CLASS CHRON PAIN D S, V3; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2007, CURR OPIN NEUROL, V20, P609, DOI 10.1097/WCO.0b013e3282f1d6dd; Lawrence J, 1993, Neonatal Netw, V12, P59; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Merkel S I, 1997, Pediatr Nurs, V23, P293; SCHNAKERS C, 2009, ENCY CONSCIOUSNESS, V1, P243; Schnakers C, 2007, CURR OPIN NEUROL, V20, P620, DOI 10.1097/WCO.0b013e3282f169d9; Stevens RD, 2006, CRIT CARE CLIN, V22, P787, DOI 10.1016/j.ccc.2006.11.006; TEASDALE G, 1974, LANCET, V2, P81; Treede RD, 1999, PAIN, V79, P105, DOI 10.1016/S0304-3959(98)00184-5; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1016/S1525-8610(04)70258-3	27	102	109	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	FEB	2010	148	2					215	219		10.1016/j.pain.2009.09.028			5	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	547MV	WOS:000273894600009	19854576				2021-06-18	
J	Yard, EE; Schroeder, MJ; Fields, SK; Collins, CL; Comstock, RD				Yard, Ellen E.; Schroeder, Matthew J.; Fields, Sarah K.; Collins, Christy L.; Comstock, R. Dawn			The epidemiology of United States high school soccer injuries, 2005-2007	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						high school; soccer; injury; gender; epidemiology; surveillance	CRUCIATE LIGAMENT INJURIES; FOOTBALL INJURIES; DESCRIPTIVE EPIDEMIOLOGY; EMERGENCY-DEPARTMENTS; SURVEILLANCE SYSTEM; SPORTS; CONCUSSIONS; POPULATION; MECHANISMS; PATTERNS	Background: United States high school soccer participation increased 5 fold over the last 30 years. With increased participation comes increased injury incidence. Hypothesis: High school soccer injury patterns will vary by gender and type of exposure. Study Design: Descriptive epidemiologic study. Methods: Soccer-related injury data were collected over the 2005-2006 and 2006-2007 school years from 100 nationally representative United States high schools via Reporting Information Online (RIO, an Internet-based sports-related injury surveillance system). Results: Participating certified athletic trainers reported 1524 soccer injuries during 637 446 athlete exposures (AEs), for an injury rate of 2.39 per 1000 AEs, corresponding to a nationally estimated 807 492 soccer-related injuries during the 2005-2006 and 2006-2007 seasons. The injury rate per 1000 AEs was greater during competition (4.77) than practice (1.37) (rate ratio [RR] = 3.49; 95% confidence interval [CI], 3.15-3.87). Overall, the most frequent diagnoses were incomplete ligament sprains (26.8%), incomplete muscle strains (17.9%), contusions (13.8%), and concussions (10.8%). The most commonly injured body sites were the ankle (23.4%), knee (18.7%), head/face (13.7%), and thigh/upper leg (13.1%). Similar proportions of boys (57.9%) and girls (53.9%) returned to activity in <1 week. During competition, girls sustained complete knee ligament sprains requiring surgery at a rate of 26.4 per 100 000 AEs, higher than the rate among boys during competition (1.98 per 100 000 AEs) (RR = 13.3; 95% CI, 3.15-56.35) and among girls during practice (2.34 per 100 000 AEs) (RR = 11.3; 95% CI, 4.31-29.58). Player-to-player contact was more common among competition injuries (injury proportion ratio [IPR] = 2.42; 95% CI, 2.01-2.92), while noncontact mechanisms were more common among practice injuries (IPR = 2.39; 95% CI, 1.90-3.01). Conclusions: High school soccer injury patterns vary by gender and type of exposure. Identifying such differences in injury patterns is the important first step in the development of evidence-based, targeted injury prevention efforts.	[Yard, Ellen E.; Collins, Christy L.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Schroeder, Matthew J.; Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Fields, Sarah K.] Ohio State Univ, Sch Phys Activ & Educ Serv, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA	Yard, EE (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	Ellen.Yard@NationwideChildrens.org			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01]; National Athletic Trainers' Association (NATA) Research; Education Foundation [905GGP008]	This research was in part funded by the Centers for Disease Control and Prevention (CDC), grant #R49/CE000674-01, and the National Athletic Trainers' Association (NATA) Research and Education Foundation, grant #905GGP008. The content of this report is solely the responsibility of the authors and does not necessarily represent the official view of the CDC or the NATA.	Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; Agel J, 2007, J ATHL TRAINING, V42, P270; Anderson SJ, 2000, PEDIATRICS, V105, P659, DOI 10.1542/peds.105.3.640; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Boden BP, 2000, ORTHOPEDICS, V23, P573, DOI 10.3928/0147-7447-20000601-15; Bonsell S, 2000, Proc (Bayl Univ Med Cent), V13, P327; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Covassin T, 2003, J ATHL TRAINING, V38, P238; Delaney JS, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.015735; Dick R, 2007, J ATHL TRAINING, V42, P278; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Elias SR, 2001, MED SCI SPORT EXER, V33, P359, DOI 10.1097/00005768-200103000-00004; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; *FED INT FOOTB ASS, FOOTB WORLDW 2000 OF; Fernandez WG, 2007, ACAD EMERG MED, V14, P641, DOI [10.1197/j.aem.2007.03.1354, 10.1111/j.1553-2712.2007.tb01851.x]; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza E, 2005, BRIT J SPORT MED, V39, P212, DOI 10.1136/bjsm.2004.011973; Giza Eric, 2005, Med Sport Sci, V49, P140, DOI 10.1159/000085395; Hewett TE, 2006, AM J SPORT MED, V34, P490, DOI 10.1177/0363546505282619; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; HUTCHINSON MR, 1995, SPORTS MED, V19, P288, DOI 10.2165/00007256-199519040-00006; Kakavelakis KN, 2003, SCAND J MED SCI SPOR, V13, P175, DOI 10.1034/j.1600-0838.2003.00294.x; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; Marchi AG, 1999, ARCH DIS CHILD, V81, P324, DOI 10.1136/adc.81.4.324; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Metzl JD, 1999, PEDIATR EMERG CARE, V15, P130, DOI 10.1097/00006565-199904000-00013; *NAT FED STAT HIGH, 2006 07 HIGH SCH ATH; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; Peterson L, 2000, AM J SPORT MED, V28, pS51; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Simon TD, 2004, ACAD EMERG MED, V11, P1042, DOI 10.1197/j.aem.2004.04.013; United States Census Bureau, CENS REG DIV US; Walden M, 2005, BRIT J SPORT MED, V39, P542, DOI 10.1136/bjsm.2004.014571; Wong P, 2005, BRIT J SPORT MED, V39, P473, DOI 10.1136/bjsm.2004.015511; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	45	102	106	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2008	36	10					1930	1937		10.1177/0363546508318047			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	354MA	WOS:000259642500009	18628486				2021-06-18	
J	Laupland, KB; Shahpori, R; Kirkpatrick, AW; Ross, T; Gregson, DB; Stelfox, HT				Laupland, Kevin B.; Shahpori, Reza; Kirkpatrick, Andrew W.; Ross, Terry; Gregson, Daniel B.; Stelfox, H. Thomas			Occurrence and outcome of fever in critically ill adults	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	37th Critical Care Congress of the Society-of-Critical-Care-Medicine	FEB 02-08, 2008	Honolulu, HI	Soc Crit Care Med		fever; mortality; intensive care unit; outcome; adult	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; RISK-FACTORS; INFECTION; SYSTEM; MORTALITY; SINUSITIS; PROGRESS; SEPSIS	Objective., Although fever is common in the critically ill, only a small number of studies have specifically investigated its epidemiology in the intensive care unit (ICU). The objective of this study was to describe the occurrence of fever in the critically ill and assess its effect on ICU outcome. Design: Retrospective cohort. Fever was defined by temperature >= 38.3 degrees C and high fever by >= 39.5 degrees C. Setting. Calgary Health Region during 2000-2006. Patients. All adults ( >= 18 yrs) admitted to ICUs. Interventions: None. Measurements and Main Results: A total of 24,204 ICU admission episodes occurred among 20,466 patients; 35% were classified as medical, 33% as cardiac surgical, 16% as other surgical, and 15% as trauma/neurologic. The cumulative incidence of fever and high fever was 44% and 8% and the incidence density was 24.3 and 2.7 per 100 days of ICU admission, respectively. The incidence density of fever was higher in trauma/neuro patients, males, younger patients, and was lower in those with admission Acute Physiology and Chronic Health Evaluation 11 scores >= 25. Seventeen percent and 31% of patients with fever and high fever had associated positive cultures. Resolution of fever and high fever occurred in 27% and 53% of patients before ICU discharge and prolonged fever and high fever lasting for 5 or more days in the ICU occurred in 18% and 11% of febrile patients, respectively. Although the presence of fever was not associated with increased ICU mortality (13% vs. 12%; p =.08), high fever was associated with significantly increased risk for death (20.3% vs. 12%, p <.0001). After controlling for confounding factors using multivariable logistic regression models, the influence of fever on the ICU mortality varied significantly according to its timing of onset, degree, and main admission category. Conclusions. Fever is common in patients admitted to the ICU and its occurrence and impact on outcome varies among defined patient populations.	[Laupland, Kevin B.; Gregson, Daniel B.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Laupland, Kevin B.] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Laupland, Kevin B.; Shahpori, Reza; Kirkpatrick, Andrew W.; Gregson, Daniel B.; Stelfox, H. Thomas] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Kirkpatrick, Andrew W.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Laupland, Kevin B.; Ross, Terry] Univ Calgary, Ctr Antimicrobial Resistance, Calgary, AB, Canada; Calgary Lab Serv, Calgary, AB, Canada	Laupland, KB (corresponding author), Univ Calgary, Dept Med, Calgary, AB, Canada.	kevin.laupland@calgaryhealthregion.ca	Laupland, kevin/AAJ-6339-2020; Laupland, Kevin/AAG-3656-2020; Viani, Rafael/V-1196-2018	Laupland, kevin/0000-0002-1205-5354; Stelfox, Henry/0000-0003-1231-1490			Andrews Peter J D, 2004, Curr Opin Crit Care, V10, P110, DOI 10.1097/00075198-200404000-00006; Barie Philip S, 2004, Surg Infect (Larchmt), V5, P145, DOI 10.1089/1096296041839534; BORMAN KR, 1992, AM J SURG, V164, P412, DOI 10.1016/S0002-9610(05)81171-7; Bota DP, 2004, INTENS CARE MED, V30, P811, DOI 10.1007/s00134-004-2166-z; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; CHIN R, 1991, CRIT CARE CLIN, V7, P23; Circiumaru B, 1999, INTENS CARE MED, V25, P668, DOI 10.1007/s001340050928; CLARKE DE, 1991, CHEST, V100, P213, DOI 10.1378/chest.100.1.213; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; Cunha BA, 1999, INTENS CARE MED, V25, P648, DOI 10.1007/s001340050925; Cunha BA, 1996, INFECT DIS CLIN N AM, V10, P185, DOI 10.1016/S0891-5520(05)70294-4; Cunningham JA, 2005, ANAESTH INTENS CARE, V33, P534, DOI 10.1177/0310057X0503300421; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Gozzoli V, 2001, ARCH INTERN MED, V161, P121, DOI 10.1001/archinte.161.1.121; Hebbar Kiran, 2005, Pediatr Crit Care Med, V6, P557, DOI 10.1097/01.PCC.0000163671.69197.16; Hebert PC, 2003, JAMA-J AM MED ASSOC, V289, P1941, DOI 10.1001/jama.289.15.1941; Jaber S, 2005, CHEST, V127, P233, DOI 10.1378/chest.127.1.233; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kluger MJ, 1996, INFECT DIS CLIN N AM, V10, P1, DOI 10.1016/S0891-5520(05)70282-8; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Laupland KB, 2006, CHEST, V129, P954, DOI 10.1378/chest.129.4.954; Laupland KB, 2005, CRIT CARE, V9, pR60, DOI 10.1186/cc3023; Laupland KB, 2004, CRIT CARE, V8, pR431, DOI 10.1186/cc2947; Laupland KB, 2004, CRIT CARE MED, V32, P992, DOI 10.1097/01.CCM.0000119424.31648.1E; Laupland KB, 2002, J CRIT CARE, V17, P50, DOI 10.1053/jcrc.2002.33029; Laupland KB, 2005, INTENS CARE MED, V31, P213, DOI 10.1007/s00134-004-2544-6; Leon C, 2005, J CRIT CARE, V20, P106, DOI 10.1016/j.jcrc.2004.08.011; O'Grady NP, 1998, CLIN INFECT DIS, V26, P1042, DOI 10.1086/520308; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Rizoli SB, 2002, LANCET INFECT DIS, V2, P137, DOI 10.1016/S1473-3099(02)00220-7; Ryan M, 2003, CRIT CARE, V7, P221, DOI 10.1186/cc1879; Schulman Carl I, 2005, Surg Infect (Larchmt), V6, P369; Singh N, 1999, CLIN TRANSPLANT, V13, P504, DOI 10.1034/j.1399-0012.1999.130611.x; SMEGO RA, 1982, ARCH INTERN MED, V142, P1183, DOI 10.1001/archinte.142.6.1183; Thong WY, 2002, ANESTH ANALG, V95, P1489, DOI 10.1097/00000539-200212000-00006; Toltzis P, 2001, INFECT CONT HOSP EP, V22, P499, DOI 10.1086/501940; van Zanten ARH, 2005, CRIT CARE, V9, pR583, DOI 10.1186/cc3805; Zygun DA, 2003, CAN J NEUROL SCI, V30, P307, DOI 10.1017/S0317167100003000; Zygun D, 2006, CRIT CARE, V10, DOI 10.1186/cc5007	40	102	105	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2008	36	5					1531	1535		10.1097/CCM.0b013e318170efd3			5	Critical Care Medicine	General & Internal Medicine	297NJ	WOS:000255623100021	18434882				2021-06-18	
J	Tsenter, J; Beni-Adani, L; Assaf, Y; Alexandrovich, AG; Trembovler, V; Shohami, E				Tsenter, Jeanna; Beni-Adani, Liana; Assaf, Yaniv; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther			Dynamic changes in the recovery after traumatic brain injury in mice: Effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions	JOURNAL OF NEUROTRAUMA			English	Article						closed head injury; memory; object recognition; outcome measures	CLOSED-HEAD INJURY; OBJECT RECOGNITION MEMORY; LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; ONE-TRIAL TEST; PERIRHINAL CORTEX; DOPAMINE-D4 RECEPTORS; FORNIX TRANSECTION; NEUROTOXIC LESIONS; WORKING-MEMORY	Memory and neurobehavioral dysfunctions are among the sequelae of traumatic brain injury (TBI). The Neurological Severity Score (NSS) includes 10 tasks and was previously designed to assess the functional status of mice after TBI. The object recognition task (ORT) measures specific episodic memory and is expressed by the percent time spent by an animal at a novel, unfamiliar object (Discrimination Index [DI]). It is an ideal tool for evaluating cognitive function after TBI. The present study sought to validate the use of the NSS and ORT in severe and mild focal TBI in mice, and to confirm that the spontaneous recovery and the radiological abnormalities, shown by T2-weighted magnetic resonance imaging (MRI), are dependent upon injury severity. Mice were subjected to severe and mild closed head injury (NSS at 1 h 7.52 +/- 0.34 and 4.62 +/- 0.14, respectively). NSS was evaluated for 25 days and showed a decrease by 3.86 +/- 0.26 and 2.54 +/- 0.35 units in the severely and mildly injured mice, respectively. ORT revealed DI in severely injured group of 51.7 +/- 6.15%, (vs similar to 75-80% in uninjured animal) on day 3 and 66.2 +/- 6.81% on day 21. In contrast, the mildly injured mice did not show cognitive impairment throughout the same period. The damage seen by MRI at 24 h after injury, strongly correlated with NSS(1h) (R = 0.87, p < 0.001). We conclude that NSS is a reliable tool for evaluation of neurological damage in head-injured mice, NSS(1h) predicts the motor dysfunction, cognitive damage, and brain-damage characteristics as depicted by T2-weighted MRI. The combined assessment of neurobehavioral and cognitive function along with MRI is most useful in evaluating recovery from injury, especially when testing effectiveness of novel treatments or genetic manipulations.	[Tsenter, Jeanna; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Tsenter, Jeanna] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Rehabil, Jerusalem, Israel; [Beni-Adani, Liana] Dana Childrens Hosp, Dept Neurosurg & Pediat Neurosurg, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; [Assaf, Yaniv] Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il		assaf, yaniv/0000-0001-6828-7595			Albensi BC, 2000, J NEUROSCI RES, V62, P177, DOI 10.1002/1097-4547(20001015)62:2&lt;177::AID-JNR3&gt;3.0.CO;2-D; Ariano MA, 1997, BRAIN RES, V752, P26, DOI 10.1016/S0006-8993(96)01422-9; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Baker KB, 2002, LEARN MEMORY, V9, P58, DOI 10.1101/lm.46102; Barker GRI, 2007, J NEUROSCI, V27, P2948, DOI 10.1523/JNEUROSCI.5289-06.2007; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; BONTKE CF, 1996, NEUROTRAUMA, P841; Chen GQ, 2000, NATURE, V408, P975; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Eichenbaum H, 1999, BEHAV BRAIN RES, V103, P123, DOI 10.1016/S0166-4328(99)00044-3; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; ENNACEUR A, 1992, BEHAV BRAIN RES, V51, P83, DOI 10.1016/S0166-4328(05)80315-8; Ennaceur A, 1996, BEHAV BRAIN RES, V80, P9, DOI 10.1016/0166-4328(96)00006-X; Ennaceur A, 1997, BEHAV BRAIN RES, V88, P181, DOI 10.1016/S0166-4328(97)02297-3; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Kornecook TJ, 1999, BEHAV BRAIN RES, V98, P67; Lee Bruce, 2005, NeuroRx, V2, P372; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Marciano D, 2007, J NEUROTRAUM, V24, P1378, DOI 10.1089/neu.2007.0318; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McIntosh TK, 1996, LAB INVEST, V74, P315; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paschen W, 2004, J NEUROCHEM, V88, P983, DOI 10.1046/j.1471-4159.2003.02218.x; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Roach JT, 2004, BRAIN RES, V1015, P161, DOI 10.1016/j.brainres.2004.05.004; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Steckler T, 1998, PROG NEUROBIOL, V54, P313, DOI 10.1016/S0301-0082(97)00061-0; Ullman S, 1996, HIGH LEVEL VISION OB; Vaucher E, 2002, EXP NEUROL, V175, P398, DOI 10.1006/exnr.2002.7915; Wedzony K, 2000, J PHYSIOL PHARMACOL, V51, P205; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; YOUNG B, 1996, NEUROTRAUMA, P352	51	102	106	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2008	25	4					324	333		10.1089/neu.2007.0452			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	282PL	WOS:000254579600005	18373482				2021-06-18	
J	Bettger, JAP; Stineman, MG				Bettger, Janet A. Prvu; Stineman, Margaret G.			Effectiveness of multidisciplinary rehabilitation services in postacute care: State-of-the-science. A review	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Symposium on Post-Acute Rehabilitation	FEB 12-13, 2007	Arlington, VA			evidence-based medicine; rehabilitation; review [publication type]	HIP FRACTURE PATIENTS; STROKE REHABILITATION; INPATIENT REHABILITATION; PARKINSONS-DISEASE; SYSTEMATIC REVIEWS; CLINICAL-TRIALS; OUTCOMES; QUALITY; METAANALYSIS; POPULATION	Objectives: To summarize the efficacy of postacute rehabilitation and to outline future research strategies for increasing knowledge of its effectiveness. Data Sources: English-language systematic reviews that examined multidisciplinary therapy-based rehabilitation services for adults, published in the last 25 years and available through Cochrane, Medline, or CINAHL databases. We excluded multidisciplinary biopsychosocial rehabilitation prograins and mental health services. Study Selection: Using the search term rehabilitation, 167 records were identified in the Cochrane database. 1163 meta-analyses and reviews were identified in Medline, and 226 in CINAHL. The Medline and CINAHL search was further refined with 3 additional search terms: therapy, multidisciplinary v, and interdisciplinary. In summary, we used 12 reviews to summarize the efficacy of multidisciplinary, therapy-based postacute rehabilitation; the 12 covered only 5 populations. Data Extraction: Two reviewers extracted information about study populations, sample sizes, study designs, the settings and timing of rehabilitation, interventions, and findings. Data Synthesis: Based on systematic reviews, the evidence for efficacy of postacute rehabilitation services across the continuum was strongest for stroke. There was also strong evidence supporting multidisciplinary inpatient rehabilitation for patients with rheumatoid arthritis, moderate to severe acquired brain injury, including traumatic etiologies, and for older adults. Heterogeneity limited our ability to conclude a benefit or a lack of a benefit for rehabilitation in other postacute settings for the other conditions in which systematic reviews had been completed. The efficacy of multidisciplinary rehabilitation services has not been systematically reviewed for many of the diagnostic conditions treated in rehabilitation. We did not complete a summary of findings from individual studies. Conclusions: Given the limitations and paucity of systematic reviews, information from carefully designed nonrandomn ized studies could be used to complement randomized controlled trials in the study of the effectiveness of postacute rehabilitation. Consequently, a stronger evidence base would become available with which to inform policy decisions, guide the use of services, and improve patient access and outcomes.	Univ Penn, Dept Phys Med & Rehabil, Sch Med, Philadelphia, PA 19104 USA	Stineman, MG (corresponding author), Univ Penn, Dept Phys Med & Rehabil, Sch Med, 3615 Chestnut St,101 Ralston Penn Ctr, Philadelphia, PA 19104 USA.	mstinema@mail.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042588] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007425] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042588, R01 HD042588-05A2, T32 HD007425, T32-HD-007425] Funding Source: Medline		Adunsky A, 2003, J GERONTOL A-BIOL, V58, P542; *AG HEALTHC RES QU, 2006, NEXT STEPS YOUR DIAG; Anderson C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub2; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; AZIZ NA, 2006, COCHRANE DB SYST REV, P5952; Beaupre LA, 2005, J GEN INTERN MED, V20, P1019, DOI 10.1111/j.1525-1497.2005.00219.x; CAMERON ID, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000106; COOK RJ, 1995, PLANT PHYSIOL, V108, P4; COUNSELL C, 1995, STROKE, V26, P498, DOI 10.1161/01.STR.26.3.498; Coyte PC, 2000, J HEALTH ECON, V19, P907, DOI 10.1016/S0167-6296(00)00041-2; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; Dekker R, 1998, SCAND J REHABIL MED, V30, P87; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Di Fabio RP, 1998, ARCH PHYS MED REHAB, V79, P141, DOI 10.1016/S0003-9993(98)90290-8; Esselman PC, 2004, JAMA-J AM MED ASSOC, V292, P1746, DOI 10.1001/jama.292.14.1746; EVANS RL, 1995, SOC SCI MED, V40, P1699, DOI 10.1016/0277-9536(94)00286-3; Evans RL, 1998, DISABIL REHABIL, V20, P298, DOI 10.3109/09638289809166085; Freeman JA, 1997, ANN NEUROL, V42, P236, DOI 10.1002/ana.410420216; Freeman JA, 1999, NEUROLOGY, V52, P50, DOI 10.1212/WNL.52.1.50; GREEN SB, 1984, STAT MED, V3, P361, DOI 10.1002/sim.4780030413; Greener J, 2002, CLIN REHABIL, V16, P69, DOI 10.1191/0269215502cr469oa; GROTZINGER KM, 1994, MED CARE, V32, P989, DOI 10.1097/00005650-199410000-00002; Huusko TM, 2002, ACTA ORTHOP SCAND, V73, P425, DOI 10.1080/00016470216324; Inman C, 1999, CLIN REHABIL, V13, P25, DOI 10.1191/026921599674943310; KANE RL, 1990, MEASURING EFFECTIVEN, P429; Khan F, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006036.pub2; KHAN F, 2005, COCHRANE DB SYST REV, P4957; Klienbaum DG, 1982, EPIDEMIOLOGIC RES PR; Ko CK, 1999, CLIN REHABIL, V13, P33, DOI 10.1191/026921599669648143; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Langhorne P, 2001, STROKE, V32, P268, DOI 10.1161/01.STR.32.1.268; Lytle BW, 1999, J THORAC CARDIOV SUR, V117, P855, DOI 10.1016/S0022-5223(99)70365-X; Mechanic D, 2001, MILBANK Q, V79, P459, DOI 10.1111/1468-0009.00215; Moher D, 2005, EXPLORE-NY, V1, P40, DOI 10.1016/j.explore.2004.11.001; *MOR CO, 2006, UT TRENDS INP REH; Nagi S.Z., 1991, DISABILITY AM NATL A, P309, DOI DOI 10.17226/1579; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; *OUTP SERV TRIAL, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002925; Ozdemir F, 2001, ARCH PHYS MED REHAB, V82, P1375, DOI 10.1053/apmr.2001.25973; Patton MQ, 1997, EVAL PRACT, V18, P147, DOI 10.1016/S0886-1633(97)90019-2; Pezzin LE, 2000, ARCH PHYS MED REHAB, V81, P292, DOI 10.1053/apmr.2000.0810292; Plint AC, 2006, MED J AUSTRALIA, V185, P263, DOI 10.5694/j.1326-5377.2006.tb00557.x; Rice-Oxley M, 1999, CLIN REHABIL, V13, P7, DOI 10.1191/026921599668051623; Robinson JC, 2001, MILBANK Q, V79, P149, DOI 10.1111/1468-0009.00202; ROSENBAUM P, 2002, OVERT BIAS OBSERVATI, pCH3; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Ryan T, 2006, CLIN REHABIL, V20, P123, DOI 10.1191/0269215506cr933oa; Shyu YIL, 2005, J AM GERIATR SOC, V53, P811, DOI 10.1111/j.1532-5415.2005.53253.x; Stineman MG, 2007, DISABIL REHABIL, V29, P1165, DOI 10.1080/09638280600976145; Stineman MG, 2001, AM J PHYS MED REHAB, V80, P147, DOI 10.1097/00002060-200102000-00016; STINEMAN MG, 2000, DISABIL STUD Q, V20, P11; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; Thompson AJ, 2000, J REHABIL RES DEV, V37, P455; Trend P, 2002, CLIN REHABIL, V16, P717, DOI 10.1191/0269215502cr545oa; Turner-Stokes L, 1999, CLIN REHABIL, V13, P83; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Vlieland TPMV, 1997, SEMIN ARTHRITIS RHEU, V27, P110, DOI 10.1016/S0049-0172(97)80011-X; Vogel WB, 2002, J REHABIL RES DEV, V39, P367; Wade DT, 2003, J NEUROL NEUROSUR PS, V74, P158, DOI 10.1136/jnnp.74.2.158; WARD D, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003164; Whyte J, 2003, AM J PHYS MED REHAB, V82, pS16, DOI 10.1097/01.PHM.0000086992.95121.C2; World Health Organization, 2001, INT CLASS FUNCT DIS	64	102	105	1	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2007	88	11					1526	1534		10.1016/j.apmr.2007.06.768			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	229AT	WOS:000250774400026	17964900	Green Accepted			2021-06-18	
J	Lu, DY; Mahmood, A; Qu, CS; Hong, X; Kaplan, D; Chopp, M				Lu, Dunyue; Mahmood, Asirn; Qu, Changsheng; Hong, Xin; Kaplan, David; Chopp, Michael			Collagen scaffolds populated with human marrow stromal cells reduce lesion volume and improve functional outcome after traumatic brain injury	NEUROSURGERY			English	Article						human marrow stromal cells; Lesion volume; Scaffold; traumatic brain injury	STEM-CELLS; RAT MODEL; TRANSPLANTATION; GROWTH	OBJECTIVE: Traumatic brain injury (TBI) causes extensive loss of cerebral parenchyma; however, no strategy for reconstruction has been clinically effective. Our group and others have used human marrow stromal cells (hMSCs) to treat rats subjected to TBI and found no significant changes in the lesion volume, although functional outcome was improved significantly. To identify new ways of delivering hMSCs into the injured brain and to maximize the therapeutic benefits of hMSC treatment, we investigated the use of Collagen scaffolds implanted with hMSCs as a cell delivery system for treatment of TBI. METHODS: Collagen scaffolds populated with 3 X 106 hMSCs were transplanted into the lesion cavity of the injured cortex 4 days after TBI, and the rats were euthanized 35 days after TBI. We measured sensorimotor function and spatial learning using an array of function tests, and the brain tissue was processed for histopathology analysis. CONCLUSION: The data show that scaffolds populated by hMSCs improve spatial learning and sensorimotor function, reduce the lesion volume, and foster the migration of hMSCs into the lesion boundary zone after TBI in rats. hMSC-populated scaffolds may be a new way to reconstruct the injured brain and improve neurological function after TBI.	Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA; Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41 EB002520] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40225, R01 NS052280-01A1, P01 NS42345, P01 NS042345] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280, P01NS042345] Funding Source: NIH RePORTER		Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4; Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Kempermann G, 2000, Prog Brain Res, V127, P35; Kim HJ, 2005, BIOMATERIALS, V26, P4442, DOI 10.1016/j.biomaterials.2004.11.013; Kim UJ, 2005, BIOMATERIALS, V26, P2775, DOI 10.1016/j.biomaterials.2004.07.044; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Meinel L, 2005, BONE, V37, P688, DOI 10.1016/j.bone.2005.06.010; Meinel L, 2004, BIOTECHNOL BIOENG, V88, P379, DOI 10.1002/bit.20252; Meinel L, 2004, J BIOMED MATER RES A, V71A, P25, DOI 10.1002/jbm.a.30117; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; Wang YZ, 2005, BIOMATERIALS, V26, P7082, DOI 10.1016/j.biomaterials.2005.05.022; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008	23	102	108	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2007	61	3					596	602		10.1227/01.NEU.0000290908.38438.B2			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	214FE	WOS:000249720600050	17881974	Green Accepted			2021-06-18	
J	Tavazzi, B; Vagnozzi, R; Signoretti, S; Amorini, AM; Belli, A; Cimatti, M; Delfini, R; Di Pietro, V; Finocchiaro, A; Lazzarino, G				Tavazzi, Barbara; Vagnozzi, Roberto; Signoretti, Stefano; Amorini, Angela M.; Belli, Antonio; Cimatti, Marco; Delfini, Roberto; Di Pietro, Valentina; Finocchiaro, Antonino; Lazzarino, Giuseppe			Temporal window of metabolic brain vulnerability to concussions: Oxidative and nitrosative stresses - Part II	NEUROSURGERY			English	Article						brain vulnerability; concussion; multiple concussions; nitrosative stress; oxidative stress; repeat concussions; repeat mild traumatic brain injury	NITRIC-OXIDE SYNTHASE; LIPID-PEROXIDATION; ASCORBIC-ACID; HEAD-INJURY; MITOCHONDRIAL DYSFUNCTION; PROFESSIONAL FOOTBALL; CEREBROSPINAL-FLUID; ENERGY-METABOLISM; MOUSE MODEL; PEROXYNITRITE	OBJECTIVE: In the present study, we investigated the occurrence of oxidative and nitrosative stresses in rats undergoing repeat mild traumatic brain injury (mTBI) delivered with increasing time intervals. METHODS: Rats were subjected to two diffuse mTBIs (450 g/1 m height), with the second mTBI delivered after 1 (n = 6), 2 (n = 6), 3 (n = 6), 4 (n = 6), or 5 days (n = 6). The rats were sacrificed 48 hours after the last mTBI. Sham-operated animals were used as controls (n = 6). Concentrations of biochemical indices of oxidative stress (malondialdehyde, ascorbic acid, reduced and oxidized glutathione) and nitrosative stress (nitrite, nitrate) were synchronously measured by high-performance liquid chromatography in deproteinized tissue extracts (three right + three left hemispheres for each group of animals). RESULTS: Increase of malondialdehyde, reduced/oxidized glutathione ratio, nitrite, nitrate, and decrease of ascorbic acid and glutathione were dependent on the interval between impacts with maximal changes recorded when mTBIs were spaced by 3 days. Biochemical markers of oxidative and nitrosative stresses were near control levels only in animals receiving mTBIs 5 days apart. CONCLUSION: This Study shows the remarkable negative contribution of reactive oxygen species overproduction and activation of inducible nitric oxide synthase in repeat mTBI. Because these effects were maximal when mTBIs were spaced by 3 days, it can be inferred that occurrence of a second mTBI within the temporal window of brain vulnerability not only causes profound derangement of mitochondrial functions, but also induces sustained oxidative and nitrosative stresses. Both phenomena certainly play a major role in the overall brain tissue damage occurring under these pathological conditions.	Univ Catania, Biochem Lab, Dept Chem Sci, I-95125 Catania, Italy; Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00173 Rome, Italy; San Camillo Hosp, Div Neurosurg, Rome, Italy; Univ Southampton, Div Clin Neurosci, Southampton SO9 5NH, Hants, England; Univ Roma La Sapienza, Dept Neurol Sci Neurosurg, Rome, Italy	Lazzarino, G (corresponding author), Univ Catania, Biochem Lab, Dept Chem Sci, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; Belli, Antonio/I-3799-2015; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; Belli, Antonio/0000-0002-3211-9933; lazzarino, giuseppe/0000-0002-5917-7279; Di Pietro, Valentina/0000-0001-9430-4723; AMORINI, Angela Maria/0000-0003-3525-9955			Angelow S, 2003, BRAIN RES, V988, P105, DOI 10.1016/S0006-8993(03)03350-X; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Chan TS, 2005, FREE RADICAL BIO MED, V38, P867, DOI 10.1016/j.freeradbiomed.2004.12.006; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Donzelli S, 2006, FREE RADICAL BIO MED, V40, P1056, DOI 10.1016/j.freeradbiomed.2005.10.058; Donzelli S, 2006, ANTIOXID REDOX SIGN, V8, P1363, DOI 10.1089/ars.2006.8.1363; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; Kaminski KA, 2002, INT J CARDIOL, V86, P41, DOI 10.1016/S0167-5273(02)00189-4; Kikugawa K, 2004, BIOL PHARM BULL, V27, P17, DOI 10.1248/bpb.27.17; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mendez DR, 2004, J TRAUMA, V56, P1235, DOI 10.1097/01.TA.0000130759.62286.0E; Mun GH, 2006, J NEUROSCI RES, V83, P919, DOI 10.1002/jnr.20751; Nojiri H, 2006, J BIOL CHEM, V281, P33789, DOI 10.1074/jbc.M602118200; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Sawa T, 2006, NITRIC OXIDE-BIOL CH, V14, P91, DOI 10.1016/j.niox.2005.06.005; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Sotiriou S, 2002, NAT MED, V8, P514, DOI 10.1038/nm0502-514; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Wilson JX, 2002, J NEUROSURG ANESTH, V14, P66, DOI 10.1097/00008506-200201000-00014; Ziylan YZ, 2006, INT J NEUROSCI, V116, P25, DOI 10.1080/00207450690962262	45	102	102	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2007	61	2					390	395		10.1227/01.NEU.0000255525.34956.3F			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400038	17806141				2021-06-18	
J	Staab, JP; Ruckenstein, MJ				Staab, Jeffrey P.; Ruckenstein, Michael J.			Expanding the differential diagnosis of chronic dizziness	ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY			English	Article							ANXIETY; MIGRAINE; VERTIGO; DISORDERS; 1ST	Objective: To improve treatment outcomes for patients with chronic dizziness by identifying clinical conditions associated with persistent symptoms and delineating key diagnostic features that differentiate its causes and direct attention to specific treatments. Design: Prospective cohort study from 1998 to 2004. Setting: Tertiary care balance center. Patients: A total of 345 men and women, aged 15 to 89 years, referred for evaluation of chronic dizziness (duration of :3 months) of uncertain cause. Interventions: Patients were systematically directed through multiple specialty examinations until definitive diagnoses were made. Main Outcome Measure: Final diagnoses associated with dizziness. Results: Nearly all patients with chronic subjective dizziness were diagnosed with psychiatric or neurologic illnesses. These included primary and secondary anxiety disorders (n = 206 [59.7%]) and central nervous system conditions (n = 133 [38.6%]), specifically migraine headaches, mild traumatic brain injuries, and neurally mediated dysautonomias. A small number of patients (6 [1.7%]) had dysrhythmias. Four of 5 patients with migraine or dysrhythmias had comorbid anxiety. Conclusions: Chronic dizziness has several common causes, including anxiety disorders, migraine, traumatic brain injuries, and dysautonomia, that require different treatments. Key features of the clinical history distinguish these illnesses from one another and from active neurotologic conditions. The high prevalence of secondary anxiety may give a false impression of psycho-gehicity.	Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; Univ Penn, Balance Ctr, Philadelphia, PA 19104 USA	Staab, JP (corresponding author), Univ Penn, Dept Psychiat, 3535 Market St Room 677, Philadelphia, PA 19104 USA.	jeffrey.staab@uphs.upenn.edu	Staab, Jeffrey/B-8792-2015	Staab, Jeffrey/0000-0002-1516-3131			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baloh RW, 2002, CURR OPIN NEUROL, V15, P17, DOI 10.1097/00019052-200202000-00004; Baloh RW, 1999, POSTGRAD MED, V105, P161, DOI 10.3810/pgm.1999.02.555; Brignole M, 2004, EUROPACE, V6, P467, DOI 10.1016/j.eupc.2004.08.008; Cass SP, 1997, ANN OTO RHINOL LARYN, V106, P182, DOI 10.1177/000348949710600302; Eckhardt-Henn A, 2003, J ANXIETY DISORD, V17, P369, DOI 10.1016/S0887-6185(02)00226-8; First M., 1994, STRUCTURED CLIN INTE; Furman JM, 2005, J NEUROL NEUROSUR PS, V76, P1, DOI 10.1136/jnnp.2004.048926; Godemann F, 2005, J PSYCHIATR RES, V39, P529, DOI 10.1016/j.jpsychires.2004.12.006; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Lin J K, 1993, Zhonghua Yi Xue Za Zhi (Taipei), V51, P289; Lipton RB, 2002, NEUROLOGY, V58, P885, DOI 10.1212/WNL.58.6.885; Pollak L, 2003, OTOLARYNG HEAD NECK, V128, P829, DOI 10.1016/S0194-5998(03)00454-6; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Staab JP, 2005, ARCH OTOLARYNGOL, V131, P675, DOI 10.1001/archotol.131.8.675; Staab JP, 2004, LARYNGOSCOPE, V114, P1637, DOI 10.1097/00005537-200409000-00025; Staab JP, 2003, LARYNGOSCOPE, V113, P1714, DOI 10.1097/00005537-200310000-00010; Staab JP, 2002, LARYNGOSCOPE, V112, P1346, DOI 10.1097/00005537-200208000-00005; World Health Organization, 1994, INT STAT CLASS DIS R	21	102	114	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0886-4470	1538-361X		ARCH OTOLARYNGOL	Arch. Otolaryngol. Head Neck Surg.	FEB	2007	133	2					170	176		10.1001/archotol.133.2.170			7	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	135TM	WOS:000244176400013	17309987	Bronze			2021-06-18	
J	Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M				Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M			Long-term recovery after bone marrow stromal cell treatment of traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; bone marrow stromal cell; growth factor; rat	RANDOMIZED CONTROLLED-TRIAL; SPINAL-CORD-INJURY; ADULT RATS; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR; TIRILAZAD MESYLATE; GENE-EXPRESSION; TRANSPLANTATION; HIPPOCAMPUS; DEFICITS	Object. This study was designed to follow the effects of bone marrow stromal cell (BMSC) administration in rats after traumatic brain injury (TBI) for a 3-month period. Methods. Forty adult female Wistar rats were injured by a controlled cortical impact and, I week later, were injected intravenously with one of three different doses of BMSCs (2 X 10(6), 4 X 10(6), or 8 X 10(6) cells per animal) obtained in male rats. Control rats received phosphate-buffered saline (PBS). Neurological function in these rats was studied using a neurological severity scale (NSS). The rats were killed 3 months after injury, and immunohistochemical stains were applied to brain samples to study the distribution of the BMSCs. Additional brain samples were analyzed by quantitative enzyme-linked immunosorbent assays to measure the expression of the growth factors brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Three months after injury, BMSCs were present in the injured brain and their number was significantly greater in animals that received 4 X 10(6) or 8 X 10(6) BMSCs than in animals that received 2 X 106 BMSCs, The cells were primarily distributed around the lesion boundary zone. Functional outcome was significantly better in rats that received 4 X 10(6) or 8 X 10(6) BMSCs, compared with control animals, although no improvement was seen in animals that received 2 X 10(6) BMSCs. All doses of BMSCs significantly increased the expression of BDNF but not that of NGF; however, this increase was significantly larger in animals that received 4 X 10(6) or 8 X 10(6) BMSCs than in controls or animals that received 2 X 10(6) BMSCs. Conclusions. In summary, when injected in rats after TBI, BMSCs are present in the brain 3 months later and significantly improve functional outcome.	Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu					Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LIAU LM, 1996, NEUROLOGICAL SURG, P1549; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MEMBERG SP, 1995, MOL CELL NEUROSCI, V6, P323, DOI 10.1006/mcne.1995.1025; Newman MP, 2000, NEUROSCIENCE, V99, P343, DOI 10.1016/S0306-4522(00)00194-9; Pencea V, 2001, J NEUROSCI, V21, P6706; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Seil FJ, 2000, J NEUROSCI, V20, P5367, DOI 10.1523/JNEUROSCI.20-14-05367.2000; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Snider WD, 1996, MOL CELL NEUROSCI, V7, P433, DOI 10.1006/mcne.1996.0031; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	35	102	125	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2006	104	2					272	277		10.3171/jns.2006.104.2.272			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	009CY	WOS:000235090000015	16509501				2021-06-18	
J	Parcell, DL; Ponsford, JL; Rajaratnam, SM; Redman, JR				Parcell, DL; Ponsford, JL; Rajaratnam, SM; Redman, JR			Self-reported changes to nighttime sleep after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						anxiety; brain injuries; depression; rehabilitation; sleep	EXCESSIVE DAYTIME SLEEPINESS; LATENCY TEST MSLT; DEPRESSION SCALE; HOSPITAL ANXIETY; INSOMNIA; VALIDATION; DISORDERS; APNEA; POPULATIONS; RELIABILITY	Objectives: To explore subjective sleep reports from people in the chronic stages of traumatic brain injury (TBI) and to examine the extent and nature of sleep complaints in this population. Design: Survey. Setting: All participants were community based at the time of data collection. Participants: Sixty-three subjects with TBI consecutively recruited after discharge from rehabilitation and 63 age- and sex-matched controls from the general community. Interventions: Not applicable. Main Outcome Measures: A 7-day self-reported sleep-wake diary assessing sleep and wake times, sleep onset latency, frequency, and duration of nocturnal awakenings and daytime naps; a general sleep questionnaire used to evaluate sleep changes and quality; and the Epworth Sleepiness Scale to measure daytime sleepiness. Results: Group-wise comparisons showed a significantly higher frequency of reported sleep changes after TBI (80%) relative to the control group (23%), supporting previous findings. The TBI group reported more nighttime awakenings and longer sleep onset latency; these changes were more frequently reported by participants with TBI with milder injuries. Increased levels of anxiety and depression were associated with increased reporting of sleep changes. Conclusions: These findings confirm the experience of changes to sleep after TBI and may at least in part account for the reported increased daytime sleepiness in this population. Sleep disturbance should be addressed during rehabilitation. Treatments need to focus on correcting the underlying cause of the sleep problem and to address patients' subjective experiences of their sleep, possibly through education and mood stabilization.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, POB 17, Melbourne, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au	Sanguansri, Luz/B-6630-2011; Rajaratnam, Shantha/D-8144-2012	Sanguansri, Luz/0000-0003-1908-7604; Rajaratnam, Shantha/0000-0001-7527-8558			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anch AM, 1988, SLEEP SCI PERSPECTIV; Armitage R, 2001, SLEEP MED REV, V5, P237, DOI 10.1053/smrv.2000.0144; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Benca R. M., 2000, PRINCIPLES PRACTICE, P1140; Bilwise D. L., 2000, PRINCIPLES PRACTICE, P26; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Braekeland F, 1971, ARCH GEN PSYCHIAT, V24, P548; Briones B, 1996, SLEEP, V19, P583, DOI 10.1093/sleep/19.7.583; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Dement, 2000, PRINCIPLES PRACTICE, P1123; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Hauri P., 1977, CURRENT CONCEPTS SLE; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; Lockley SW, 1999, J SLEEP RES, V8, P175, DOI 10.1046/j.1365-2869.1999.00155.x; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCCALL WV, 1995, SLEEP, V18, P646, DOI 10.1093/sleep/18.8.646; Means MK, 2003, SLEEP MED, V4, P285, DOI 10.1016/S1389-9457(03)00057-1; Monk TH, 2000, CHRONOBIOL INT, V17, P49, DOI 10.1081/CBI-100101031; MONROE LJ, 1967, J ABNORM PSYCHOL, V72, P255, DOI 10.1037/h0024563; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parkes JD, 1998, J SLEEP RES, V7, P41, DOI 10.1046/j.1365-2869.1998.00093.x; PARSONS LC, 1982, NURS RES, V31, P260; Phipps-Nelson J, 2003, SLEEP, V26, P695; Ponsford J., 1995, TRAUMATIC BRAIN INJU, P1; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Riemann D, 2001, BIOL PSYCHOL, V57, P67, DOI 10.1016/S0301-0511(01)00090-4; ROGERS AE, 1993, NURS RES, V42, P368; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SALINPASCUAL RJ, 1992, AM J PSYCHIAT, V149, P904; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Shiffman S., 2001, APPL CLIN TRIALS, V10, P46; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Stone AA, 2002, BMJ-BRIT MED J, V324, P1193, DOI 10.1136/bmj.324.7347.1193; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Vanable PA, 2000, SLEEP, V23, P71; Voderholzer U, 2003, DEPRESS ANXIETY, V17, P162, DOI 10.1002/da.10101; WIGGINS CL, 1990, SLEEP, V13, P245, DOI 10.1093/sleep/13.3.245; Wilson KG, 1998, PAIN, V75, P75, DOI 10.1016/S0304-3959(97)00207-8; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	63	102	103	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2006	87	2					278	285		10.1016/j.apmr.2005.10.024			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	013CJ	WOS:000235386900021	16442985				2021-06-18	
J	Mendez, MF				Mendez, Mario F.			The accurate diagnosis of early-onset dementia	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						dementia; Alzheimer's disease; vascular dementia; frontotemporal dementia; traumatic brain injury	ALZHEIMERS-DISEASE; PRESENILE-DEMENTIA; VASCULAR DEMENTIA; FRONTOTEMPORAL DEMENTIA; PREVALENCE; FEATURES; POPULATION; HEALTH; ASCERTAINMENT; IMPAIRMENT	Early-onset dementia (EOD, < 65 years at onset) is a relatively common and frequently misdiagnosed condition. One reason for misdiagnosis is that EOD has a more varied differential diagnosis than late-onset dementia (LOD). For example, Alzheimer's disease (AD), the preponderant LOD, makes up only about one-third of EODs; the rest are due to vascular dementias, frontotemporal lobar degenerations, traumatic head injury, alcohol-related dementia, and a great many other conditions. Another reason for misdiagnosis is that early-onset AD may have predominant cognitive deficits other than memory loss and a potential familial inheritance with spastic paraparesis, seizures, or myoclonus. A third reason is that EOD often presents with neuropsychiatric features out-of-proportion to any cognitive deficits. Despite these obstacles, it is important to accurately diagnose EODs, particularly because they differ in management and course. Clinicians can successfully diagnose most EODs with careful cognitive and family histories, mental status and neurological examinations, and neuroimaging.	VA Greater Los Angeles Healthcare Syst, Neurobiol Unit, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA	Mendez, MF (corresponding author), VA Greater Los Angeles Healthcare Syst, Neurobiol Unit, 116AF,Bldg 500,3S,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	mmendez@ucla.edu					BICKEL H, 2005, NERVENARZT      0615; Caine D, 2001, NEUROPSYCHOLOGY, V15, P155, DOI 10.1037/0894-4105.15.2.155; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; DELANY N, 1995, INT J GERIATR PSYCH, V10, P597, DOI 10.1002/gps.930100710; Elberling TV, 2002, NEUROLOGY, V59, P1259, DOI 10.1212/WNL.59.8.1259; Forman MS, 2006, ANN NEUROL, V59, P952, DOI 10.1002/ana.20873; Frisoni GB, 2005, J NEUROL NEUROSUR PS, V76, P112, DOI 10.1136/jnnp.2003.029876; Fujihara S, 2004, ARQ NEURO-PSIQUIAT, V62, P592, DOI 10.1590/S0004-282X2004000400005; Harvey RJ, 2003, J NEUROL NEUROSUR PS, V74, P1206, DOI 10.1136/jnnp.74.9.1206; Hodges JR, 2004, ANN NEUROL, V56, P399, DOI 10.1002/ana.20203; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P736, DOI 10.1093/ije/20.3.736; JACOBS D, 1994, NEUROLOGY, V44, P1215, DOI 10.1212/WNL.44.7.1215; Kemp PM, 2003, J NEUROL NEUROSUR PS, V74, P715, DOI 10.1136/jnnp.74.6.715; Knopman DS, 2003, ARCH NEUROL-CHICAGO, V60, P569, DOI 10.1001/archneur.60.4.569; KOKMEN E, 1989, NEUROLOGY, V39, P773, DOI 10.1212/WNL.39.6.773; Kono I, 2004, GERONTOLOGY, V50, P242, DOI 10.1159/000078353; KONO K, 1994, J GERIATR PSYCH NEUR, V7, P39, DOI 10.1177/089198879400700108; Lopez OL, 2005, NEUROLOGY, V64, P1539, DOI 10.1212/01.WNL.0000159860.19413.C4; LORING DW, 1985, NEUROPSYCHOLOGIA, V23, P351, DOI 10.1016/0028-3932(85)90021-1; MCGONIGAL G, 1993, BRIT MED J, V306, P680, DOI 10.1136/bmj.306.6879.680; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McMurtray A, 2006, DEMENT GERIATR COGN, V21, P59, DOI 10.1159/000089546; Mendez M. F., 2003, DEMENTIA CLIN APPROA; Mendez MF, 1997, BRAIN COGNITION, V34, P301, DOI 10.1006/brcg.1997.0923; Mendez MF, 2005, DEMENT GERIATR COGN, V20, P99, DOI 10.1159/000086474; Mendez MF, 1996, NEUROLOGY, V47, P1189, DOI 10.1212/WNL.47.5.1189; Mendez MF, 2002, J NEUROPSYCH CLIN N, V14, P424, DOI 10.1176/appi.neuropsych.14.4.424; Mendez MF, 1999, DEMENT GERIATR COGN, V10, P518, DOI 10.1159/000017199; MENDEZ MF, IN PRESS AM J GERIAT; MENDEZ MF, IN PRESS ALZHEIMER D; Mendible M, 2002, CRITIQUE-ST CONTEMP, V43, P289, DOI 10.1080/00111610209602186; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; NEWENS AJ, 1993, PSYCHOL MED, V23, P631, DOI 10.1017/S0033291700025411; Panegyres PK, 2000, MED J AUSTRALIA, V173, P279, DOI 10.5694/j.1326-5377.2000.tb125651.x; Passant U, 2005, ALZ DIS ASSOC DIS, V19, pS15, DOI 10.1097/01.wad.0000183084.22562.5a; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Raux G, 2000, NEUROLOGY, V55, P1577, DOI 10.1212/WNL.55.10.1577; Reed BR, 2004, CLIN NEUROPSYCHOL, V18, P63, DOI 10.1080/13854040490507163; Roman GC, 2002, LANCET NEUROL, V1, P426, DOI 10.1016/S1474-4422(02)00190-4; Sakamoto S, 2002, J NEUROL SCI, V200, P27, DOI 10.1016/S0022-510X(02)00114-4; Sampson EL, 2004, POSTGRAD MED J, V80, P125, DOI 10.1136/pgmj.2003.011171; SELTZER B, 1983, ARCH NEUROL-CHICAGO, V40, P143, DOI 10.1001/archneur.1983.04050030037006; Smith DM, 1995, INT J ADDICT, V30, P1843, DOI 10.3109/10826089509071058; TREVES T, 1986, ARCH NEUROL-CHICAGO, V43, P26, DOI 10.1001/archneur.1986.00520010022014; Wen HM, 2004, STROKE, V35, P1826, DOI 10.1161/01.STR.0000133686.29320.58; Woodburn K, 1999, INT J GERIATR PSYCH, V14, P362, DOI 10.1002/(SICI)1099-1166(199905)14:5<362::AID-GPS914>3.3.CO;2-L; World Health Organization, 1992, INT CLASS DIS; Yokota O, 2005, EUR J NEUROL, V12, P782, DOI 10.1111/j.1468-1331.2005.01072.x	50	102	102	0	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2174	1541-3527		INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		2006	36	4					401	412		10.2190/Q6J4-R143-P630-KW41			12	Psychiatry	Psychiatry	150VY	WOS:000245248900002	17407994				2021-06-18	
J	Max, JE; Schachar, RJ; Levin, HS; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Saunders, A; Landis, J				Max, JE; Schachar, RJ; Levin, HS; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Saunders, A; Landis, J			Predictors of secondary attention-deficit/hyperactivity disorder in children and adolescents 6 to 24 months after traumatic brain injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children and adolescents; secondary attention-deficit/hyperactivity disorder; adaptive function	CLOSED-HEAD INJURY; DEFICIT HYPERACTIVITY DISORDER; RELIABILITY; VALIDITY; SCHEDULE; ADHD	Objective: To assess the phenomenology and predictive factors of attention-deficit/hyperactivity disorder (ADHD) after traumatic brain injury (TBI), also called secondary ADHD (SADHD). Method: Children without preinjury ADHD 5-14 years old with TBI from consecutive admissions (n = 143) to five trauma centers were observed prospectively from 6 to 12 months (12-month assessment) and from 12 to 24 months (24-month assessment) postinjury with semistructured psychiatric interviews. Injury and preinjury psychosocial variables were assessed. Results: SADHD occurred in 15 of 103 (15%) of participants between 6 and 12 months after injury and 17 of 82 (21%) in the second year after injury. SADHD was significantly (p < .05) comorbid with personality change due to TBI and new-onset disruptive behavior disorders. Preinjury adaptive function was a consistent predictor of SADHD. Regression analyses revealed that preinjury psychosocial adversity was an independent predictor of SADHD in the second year after injury. Neither severity of injury nor lesion location predicted SADHD from 6 to 24 months postinjury. Conclusions: Determination of preinjury psychosocial adversity and the child's preinjury functioning during the index hospitalization would improve identification of children at highest risk of development of SADHD.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Psychol, Brain & Behav Program, Res Inst, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat, Houston, TX USA; Univ Texas, Ctr Brain Hlth, Dallas, TX 75230 USA; Univ Houston, Dept Educ Psychol, Houston, TX 77004 USA	Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5033, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Biederman J, 1997, J AFFECT DISORDERS, V44, P177, DOI 10.1016/S0165-0327(97)00043-8; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Castellanos FX, 2001, ARCH GEN PSYCHIAT, V58, P289, DOI 10.1001/archpsyc.58.3.289; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MAX JE, IN PRESS J AM ACAD C; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	23	102	103	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	OCT	2005	44	10					1041	1049		10.1097/01.chi.0000173292.05817.f8			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	967GD	WOS:000232078600015	16175109				2021-06-18	
J	Anderson, KJ; Miller, KM; Fugaccia, I; Scheff, SW				Anderson, KJ; Miller, KM; Fugaccia, I; Scheff, SW			Regional distribution of Fluoro-Jade B staining in the hippocampus following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						cell death; cortical contusion; Fluoro-Jade; hippocampus; stereology	ACUTE NEURONAL DEGENERATION; CONTROLLED CORTICAL IMPACT; LATERAL FLUID PERCUSSION; STEREOLOGICAL ESTIMATION; BEHAVIORAL DEFICITS; AGED RATS; ASTROCYTES; NUMBER; LOCALIZATION; FRACTIONATOR	Fluoro-Jade B (FJB) is an anionic fluorescein derivative that has been reported to specifically stain degenerating neurons. We were interested in applying FJB staining in a well-characterized model of traumatic brain injury (TBI) in order to estimate the total number of neurons in different regions of the hippocampus that die after a mild or moderate injury. Rats were subjected to a mild or moderate unilateral cortical contusion (1.0- or 1.5-min displacement from the cortical surface) with a controlled cortical impacting device. Animals were allowed to survive for 1, 2, or 7 days and the total number of FJB-positive neurons in hippocampal areas CA1, CA3, and the dentate gyrus granule layer was estimated using sterological methods. The region that had the highest number of FJP-positive neurons after TBI was the dentate gyrus. In both 1- and 1.5-mm injuries, 17,FJB-positive granule cells were observed throughout the rostro-caudal extent of the dentate. In contrast, labeled pyramidal neurons of area CA3 were most numerous after the 1.5-min injury. The area that had the fewest number of FJB-labeled cells was area CAI with only scattered neurons seen in the 1.5-inin group. In both injury groups and in all hippocampal regions, more FJB-positive neurons were seen at the earlier times post injury (1 and 2 days) than at 7 days. FJB appears to be a reliable marker for neuronal vulnerability following TB1. (c) 2004 Elsevier Inc. All rights reserved.	Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA; Univ Kentucky, Sanders Brown Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Anderson, KJ (corresponding author), Univ Florida, Dept Physiol Sci, POB 100144, Gainesville, FL 32610 USA.	kanders@ufbi.ufl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21981] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39828] Funding Source: Medline		Amaral David G., 1995, P443; Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hopkins KJ, 2000, BRAIN RES, V864, P69, DOI 10.1016/S0006-8993(00)02137-5; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MADEIRA MD, 1988, J HIRNFORSCH, V29, P643; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MITCHELL Y, 2002, NEUROPATHOL APPL NEU, V28, P160; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1111/j.1530-0277.2002.tb02573.x; Rapp PR, 1996, P NATL ACAD SCI USA, V93, P9926, DOI 10.1073/pnas.93.18.9926; Rasmussen T, 1996, NEUROBIOL AGING, V17, P143, DOI 10.1016/0197-4580(95)02032-2; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Xavier GF, 1999, HIPPOCAMPUS, V9, P668, DOI 10.1002/(SICI)1098-1063(1999)9:6<668::AID-HIPO8>3.0.CO;2-9; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	38	102	105	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2005	193	1					125	130		10.1016/j.expneurol.2004.11.025			6	Neurosciences	Neurosciences & Neurology	916VB	WOS:000228413300012	15817271				2021-06-18	
J	Giacino, J				Giacino, J			The vegetative and minimally conscious states - Current knowledge and remaining questions	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; COMA SCALE; RECOVERY; DISABILITY; PREDICTION; PROGNOSIS; LIFE; NEUROPATHOLOGY; INTERVENTION	In the last 2 decades, the minimally conscious state has been distinguished conceptually from the vegetative state and operational criteria for these diagnoses have been published. Standardized and individualized assessment tools have been developed to assist with the diagnosis of severe disorders of consciousness and the measurement of clinical improvement. The natural course of recovery and the importance of key prognostic predictors have been elucidated. Important advances have also been made in defining the similarities and differences in the pathophysiology of these two states, and functional imaging modalities have begun to explicate the neural substrate underlying the behavioral features of these disorders. Research on the efficacy of treatments for severe disorders of consciousness lags behind, due to the practical and ethical difficulties in executing large rigorously controlled clinical trials. The past and future scientific developments in this area provide an important background for continuing discussions of the ethical controversies surrounding end-of-life decision making and resource allocation.	JFK Johnson Rehabil Inst, Edison, NJ USA; Moss Rehabil Res Inst, Philadelphia, PA USA	Giacino, J (corresponding author), JFK Johnson Rehabil Inst, 65 James St, Edison, NJ USA.	jgiacino@solarishs.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Whyte, John/0000-0002-4381-1474	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A031713] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ARNOULD M, 1963, NEUROCHIRURGICA STUT, V6, P1; ARRILLAGE P, 2000, DETROIT NEWS    0312; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Ashwal Stephen, 2002, Semin Pediatr Neurol, V9, P19, DOI 10.1053/spen.2002.30334; BECK M, 1996, NEWSWEEK        0226, P56; BERROLL S, 1986, J HEAD TRAUMA REHAB, P1; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; *CATH BISH PENNS, 1999, STAT NUTR HYDR REV M; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman D, 2002, NEUROLOGY, V58, P506, DOI 10.1212/WNL.58.3.506; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DiPasquale MC, 1996, J HEAD TRAUMA REHAB, V11, P9, DOI 10.1097/00001199-199612000-00004; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; GIACINO J, 2003, 15 ANN JKF MED CTR C; GIACINO J, 2004, INT C LIF SUST TREAT; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2004, J HEAD TRAUMA REHAB, V19, P254, DOI 10.1097/00001199-200405000-00006; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GIACINO JT, IN PRESS REHABILITAT; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; HAGAN C, 1979, LEVELS COGNITIVE FUN; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HANS P, 1989, J NEUROSURG, V71, P54, DOI 10.3171/jns.1989.71.1.0054; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; HIRSCH J, 2001, SOC NEUR ABSTR, V529, P14; HORN S, 1992, Brain Injury, V6, P321, DOI 10.3109/02699059209034946; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; JOHNPAUL II, 2004, LIFE SUSTAINING TREA; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Majerus S, 2000, NEUROPSYCHOL REHABIL, V10, P167, DOI 10.1080/096020100389237; McMillan TM, 1997, BRAIN INJURY, V11, P483, DOI 10.1080/713802184; McMillan TM, 2000, BRAIN INJURY, V14, P197, DOI 10.1080/026990500120853; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Phipps E, 1999, AM J PHYS MED REHAB, V78, P77, DOI 10.1097/00002060-199901000-00020; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Plum F, 1982, DIAGNOSIS STUPOR COM; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; RADER MA, 1994, BRAIN INJURY, V8, P309, DOI 10.3109/02699059409150982; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Sackett D.L., 2000, PRACTICE TEACH EBM; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shewmon DA, 2002, NEUROLOGY, V58, P506; SHIN DY, 1989, ARCH PHYS MED REHAB, V70, P189; Showalter PEC, 2000, BRAIN INJURY, V14, P997; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; TALBOT LR, 1994, BRAIN INJURY, V8, P689, DOI 10.3109/02699059409151023; TEASDALE G, 1974, LANCET, V2, P81; Tsubokawa T, 1990, Brain Inj, V4, P315; VAPALAHTI M, 1971, BMJ-BRIT MED J, V3, P404, DOI 10.1136/bmj.3.5771.404; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; WHYTE J, IN PRESS ARCH PHYS M; Whyte J., 1999, REHABILITATION ADULT, P435; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; Wilson SL, 2000, BRAIN INJURY, V14, P319; Yamamoto T, 2002, ACT NEUR S, V79, P79	93	102	107	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2005	20	1					30	50		10.1097/00001199-200501000-00005			21	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	894AT	WOS:000226762900004	15668569				2021-06-18	
J	Stone, JR; Okonkwo, DO; Dialo, AO; Rubin, DG; Mutlu, LK; Povlishock, JT; Helm, GA				Stone, JR; Okonkwo, DO; Dialo, AO; Rubin, DG; Mutlu, LK; Povlishock, JT; Helm, GA			Impaired axonal transport and altered axolemmal permeability occur in distinct populations of damaged axons following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic axonal injury; diffuse axonal injury; traumatic brain injury; axolemmal permeability; impaired axonal transport; impact acceleration; dextran; rat	AMYLOID PRECURSOR PROTEIN; NEUROFILAMENT COMPACTION; RETROGRADE CONVERSION; CYCLOSPORINE-A; PROTEOLYSIS; MARKER; APP	Traumatic axonal injury (TAI) evolves within minutes to hours following traumatic brain injury (TBI). Previous studies have identified axolemmal disruption and impaired axonal transport (AxT) as key mechanisms in the evolution of TAL While initially hypothesized that axolemmal disruption culminates in impaired AxT, previous studies employed single-label methodologies that did not allow for a full determination of the spatial-temporal relationships of these two events. To explore directly the relationship between impaired AxT and altered axolemmal permeability, the current investigation employed 40, 10, and 3 kDa fluorescently conjugated dextrans as markers of axolemmal integrity, with antibodies targeting the anterogradely transported amyloid precursor protein (APP) utilized as a marker of impaired AxT. Rats underwent impact acceleration TBI and were intrathecally administered 40 kDa, 40 + 10 kDa or 40 + 3 kDa fluorescently tagged dextrans, with brains subsequently prepared for APP immunofluorescence. Brainstem corticospinal tracts (CSpT), medial lemnisci (ML), and medial longitudinal fasciculi were examined for evidence of TAL APP and all dextrans consistently localized to distinct classes of TAL Dextrans were noted as early as 5 min following injury within axonal segments demonstrating an irregular/tortuous appearance, and were seen within thin and elongate/vacuolated axons by 30 min-6 h following injury. APP, first noted within swollen axons at 30 min following injury, was found within progressively swollen axons that showed no dextran colocalization within 3 h of injury. However, by 6 h, dextrans colocalized in disconnected axonal bulbs. At this time-point, dextrans also persisted within single-labeled, highly vacuolated/thin, and elongate axons. These studies confirm that axolemmal disruption and impaired AxT occur as distinct non-related events early in the pathogenesis of TAL Further, these studies provide evidence that the process of impaired axonal transport and subsequent axonal disconnection leads to delayed axolemmal instability, rather than proceeding as a consequence of initial axolemmal failure. This finding underscores the need of multiple approaches to fully assess the axonal response to TBI. (C) 2004 Elsevier Inc. All rights reserved.	Univ Virginia, Dept Neurosurg, Charlottesville, VA 22908 USA; Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA	Stone, JR (corresponding author), Univ Virginia Hlth Syst, Dept Neurosurg, POB 800212, Charlottesville, VA 22908 USA.	jrs7r@virginia.edu					Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	28	102	104	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2004	190	1					59	69		10.1016/j.expneurol.2004.05.022			11	Neurosciences	Neurosciences & Neurology	867DJ	WOS:000224822100005	15473980				2021-06-18	
J	Hansson, MJ; Mattiasson, G; Mansson, R; Karlsson, J; Keep, MF; Waldmeier, P; Ruegg, UT; Dumont, JM; Besseghir, K; Elmer, E				Hansson, MJ; Mattiasson, G; Mansson, R; Karlsson, J; Keep, MF; Waldmeier, P; Ruegg, UT; Dumont, JM; Besseghir, K; Elmer, E			The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article; Proceedings Paper	Mitochondria and Neuroprotection Symposium	APR 16-19, 2004	Ft Lauderdale, FL			cell death; apoptosis; neuron; ischemia; neurodegeneration; traumatic brain injury; amyotrophic lateral sclerosis; cyclophilin; mitochondrial permeability transition; flow cytometry	DOSE-RESPONSE; CELL-DEATH; INJURY; PORE; RAT; CYCLOPHILIN; INHIBITION; ACTIVATION; APOPTOSIS; ISCHEMIA	CyclosporinA(CsA) is highly neuroprotective in several animal models of acute neurological damage and neurodegenerative disease with inhibition of the mitochondrial permeability transition (mPT) having emerged as a possible mechanism for the observed neuroprotection. In the present study, we have evaluated two new nonimmunosuppressive cyclosporin analogs NIM811 (Novartis) and UNIL025 (Debiopharm) for their ability to inhibit mPT in rat brain-derived mitochondria. Both NIM811 and UNIL025 were found to be powerful inhibitors of calcium-induced mitochondrial swelling under energized and deenergized conditions, and the maximal effects were identical to those of native CsA. The potencies of mPT inhibition by NIM811 and UNIL025 were stronger, with almost one order of magnitude higher potency for UNIL025 compared to CsA, correlating to their respective inhibitory action of cyclophilin activity. These compounds will be instrumental in the evaluation of mPT as a central target for neuroprotection in vivo.	Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, SE-22184 Lund, Sweden; Ryhov Hosp, Dept Internal Med, Jonkoping, Sweden; Malmo Univ Hosp, Dept Neurol, Malmo, Sweden; Univ New Mexico, Dept Internal Med, Community Environm Hlth Program, Albuquerque, NM 87131 USA; Univ New Mexico, Div Neurosurg, Albuquerque, NM 87131 USA; Novartis Inst Biomed Res, Dept Neurosci, Basel, Switzerland; Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland; Debiopharm SA, Lausanne, Switzerland	Elmer, E (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, SE-22184 Lund, Sweden.		Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638; RUEGG, Urs/0000-0001-6078-8280			Alves O, 2003, J NEUROTRAUM, V20, P1125; Bambrick L, 2004, NEUROCHEM RES, V29, P601, DOI 10.1023/B:NERE.0000014830.06376.e6; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; Brophy GM, 2003, J NEUROTRAUM, V20, P1125; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Keep Marcus F., 2003, P3; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Mattiasson G, 2003, J NEUROCHEM, V87, P532, DOI 10.1046/j.1471-4159.2003.02026.x; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	28	102	104	0	8	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X			J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	AUG	2004	36	4					407	413		10.1023/B:JOBB.0000041776.31885.45			7	Biophysics; Cell Biology	Biophysics; Cell Biology	854PR	WOS:000223916300025	15377880				2021-06-18	
J	Nimmo, AJ; Cernak, I; Heath, DL; Hu, X; Bennett, CJ; Vink, R				Nimmo, AJ; Cernak, I; Heath, DL; Hu, X; Bennett, CJ; Vink, R			Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats	NEUROPEPTIDES			English	Article						neurotrauma; capsaicin; diffuse brain injury; edema; magnesium; neuropeptides	PRIMARY SENSORY NEURONS; SUBSTANCE-P; CAPSAICIN TREATMENT; BINDING-SITES; RECEPTOR NK1; SPINAL-CORD; HEAD-INJURY; TIME-COURSE; ADULT-RAT; NEUROPEPTIDES	The present study has used capsaicin-induced neuropeptide depletion to examine the role of neurogenic inflammation in the development of edema and functional deficits following traumatic brain injury (TBI). Adult, male rats were treated with capsaicin (neuropeptide-depleted) or equal volume vehicle (controls) 14 days prior to induction of moderate/severe diffuse TBI. Injury in vehicle treated control animals resulted in acute (4-5 h) edema formation, which was confirmed as being vasogenic in origin by diffusion weighted magnetic resonance imaging and the presence of increased permeability of the blood-brain barrier (BBB) to Evans blue dye. There was also a significant decline in brain magnesium concentration, as assessed by phosphorus magnetic resonance spectroscopy, and the development of profound motor and cognitive deficits. In contrast, capsaicin pre-treatment resulted in a significant reduction in post-traumatic edema formation (p < 0.001), BBB permeability (p < 0.001), free magnesium decline (p < 0.01) and both motor and cognitive deficits (p < 0.001). We conclude that neurogenic inflammation may play an integral role in the development of edema and functional deficits following TBI, and that neuropeptides may be a novel target for development of interventional pharmacological strategies. (C) 2004 Elsevier Ltd. All rights reserved.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia; Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia	Vink, R (corresponding author), Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA.	robert.vink@adelaide.edu.au	Vink, Robert/J-7351-2012; Cernak, Ibolja/A-6399-2008; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Nimmo, Alan/0000-0002-0718-7934; Ibolja, Cernak/0000-0003-3214-698X			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; Bracci-Laudiero L, 1999, NEUROSCI LETT, V275, P57, DOI 10.1016/S0304-3940(99)00737-5; CADIEUX A, 1986, NEUROSCIENCE, V19, P605, DOI 10.1016/0306-4522(86)90285-X; CERNAK I, 2001, J NEUROTRAUM, V19, P1397; CUELLO AC, 1981, N-S ARCH PHARMACOL, V315, P185, DOI 10.1007/BF00499834; DRAY A, 1992, BIOCHEM PHARMACOL, V44, P611, DOI 10.1016/0006-2952(92)90393-W; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; GAUMANN DM, 1990, NEUROSCIENCE, V39, P761, DOI 10.1016/0306-4522(90)90259-7; Geraghty DP, 2003, BRAIN RES, V979, P230, DOI 10.1016/S0006-8993(03)02871-3; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HUSTON JP, 1995, BEHAV BRAIN RES, V66, P117, DOI 10.1016/0166-4328(94)00132-Y; Kashiba H, 1997, NEUROSCIENCE, V76, P299; KITA H, 1994, ACTA NEUROCHIR, P452; Leroy V, 2000, EXPERT OPIN INV DRUG, V9, P735, DOI 10.1517/13543784.9.4.735; LEVASSEUR JE, 1993, J NEUROSURG, V78, P610, DOI 10.3171/jns.1993.78.4.0610; Lin RCS, 1995, NEUROREPORT, V7, P310, DOI 10.1097/00001756-199512290-00074; Malcangio M, 2000, EUR J NEUROSCI, V12, P397, DOI 10.1046/j.1460-9568.2000.00946.x; MANTYH PW, 1989, P NATL ACAD SCI USA, V86, P5193, DOI 10.1073/pnas.86.13.5193; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; NEWBOLD P, 1995, BRIT J PHARMACOL, V114, P570, DOI 10.1111/j.1476-5381.1995.tb17177.x; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Parsadaniantz SM, 2000, J NEUROENDOCRINOL, V12, P766, DOI 10.1046/j.1365-2826.2000.00517.x; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; Stumm RK, 2001, J NEUROSCI, V21, P798; Tjen-A-Looi S, 1998, REGUL PEPTIDES, V74, P1, DOI 10.1016/S0167-0115(98)00007-X; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; VINK R, 2002, ABSTR BRAIN EDEMA S, P57; WOIE K, 1993, CIRC RES, V73, P839, DOI 10.1161/01.RES.73.5.839	41	102	108	0	11	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4179	1532-2785		NEUROPEPTIDES	Neuropeptides	FEB	2004	38	1					40	47		10.1016/j.npep.2003.12.003			8	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	806WK	WOS:000220463800006	15003715				2021-06-18	
J	Alessandri, B; Rice, AC; Levasseur, J; DeFord, M; Hamm, RJ; Bullock, MR				Alessandri, B; Rice, AC; Levasseur, J; DeFord, M; Hamm, RJ; Bullock, MR			Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						behavior; cyclosporin A; fluid percussion injury; rat	MITOCHONDRIAL PERMEABILITY TRANSITION; MUSCARINIC ACETYLCHOLINE-RECEPTORS; TRANSIENT FOREBRAIN ISCHEMIA; GERBIL HIPPOCAMPUS; MEMORY FORMATION; AXONAL DAMAGE; CELL-DEATH; CALCIUM; METABOLISM; ACTIVATION	Traumatic brain injury (TBI) triggers a complex pathophysiological cascade, leading to cell death. A major factor in the pathogenesis of TBI is neuronal overloading with calcium, causing the opening of mitochondrial permeability transition pores (MPTP), which consequently inhibit normal mitochondrial function. The immunosuppressant Cyclosporin A (CsA) has been shown to block MPTPs, and to be neuroprotective in ischemia and TBI. However, the translation of these effects on mitochondrial function, into behavioral endpoints has not been investigated thoroughly. Therefore, we tested the effect of a low, clinically evaluated, CsA dose of 0.125 mg/kg (infused for 3 h) and a higher "known" neuroprotective dose of 18.75 mg/kg on brain tissue O-2 consumption, and on motor and cognitive performance following lateral fluid percussion injury (FPI) in rats. CsA at both concentrations abolished the 25% decrease in O-2 consumption (VO2), seen in saline-treated animals at 5 h post-FPI. Furthermore, the lower dose of CsA also ameliorated acute motor deficits (days 1-5 post-FPI) and learning and memory impairments in a Morris water maze test on days 11-15 post-FPI. Although, the higher dose of CsA improved cognitive performance, it worsened acute motor functional recovery. These results suggest, that the CsA-induced preservation of mitochondrial function, as assessed by tissue O-2 consumption, directly translated into improvements in motor and cognitive behavior.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA	Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631,1200 E Broad St, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; ALESSANDRI B, 1998, PROGR BRAIN RES, P311; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Bennett PC, 1998, FEBS LETT, V431, P386, DOI 10.1016/S0014-5793(98)00795-9; Bennett PC, 1996, BRAIN RES, V730, P107; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Borlongan CV, 1998, NEUROSCI RES, V32, P195, DOI 10.1016/S0168-0102(98)00088-1; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; Di X, 2000, ACT NEUR S, V76, P379; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; FAYNOR SM, 1984, MAYO CLIN PROC, V59, P571, DOI 10.1016/S0025-6196(12)61496-7; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 1998, J NEUROSCI, V18, P5151; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Gijtenbeek JMM, 1999, J NEUROL, V246, P339, DOI 10.1007/s004150050360; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, V1, P86; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kondo Y, 1999, NEUROCHEM RES, V24, P9, DOI 10.1023/A:1020915727119; KONDO Y, 1995, NEUROSCI RES, V22, P123, DOI 10.1016/0168-0102(95)00878-W; Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; RINK A, 1995, AM J PATHOL, V147, P1575; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; SIGNORETTI S, 2000, RESTOR NEUROL NEUROS, V16, P218; STEINER R, 1996, EARTH ISL J, V11, P2; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; SZABO I, 1991, J BIOL CHEM, V266, P3376; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	65	102	104	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2002	19	7					829	841		10.1089/08977150260190429			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	577JL	WOS:000177057700003	12184853				2021-06-18	
J	Norwood, SH; McAuley, CE; Berne, JD; Vallina, VL; Kerns, DB; Grahm, TW; Short, K; McLarty, MW				Norwood, SH; McAuley, CE; Berne, JD; Vallina, VL; Kerns, DB; Grahm, TW; Short, K; McLarty, MW			Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	109th Scientific Session of the Western-Surgical-Association	NOV 12-14, 2001	SAN ANTONIO, TEXAS	Western Surg Assoc			MOLECULAR-WEIGHT HEPARIN; LOW-DOSE HEPARIN; TRAUMA PATIENTS; MAJOR TRAUMA; COMPRESSION STOCKINGS; PREVENTION; NEUROSURGERY; THROMBOSIS	Background: Patients with traumatic intracranial hemorrhagic injuries (lHIs) are at high risk for venous thromboembolism (VTE). The safety of early anticoagulation for IHI has not been established. Hypothesis: Enoxaparin can be safely administered to most patients with IHI for VTE prophylaxis. Setting: Level I trauma center. Design: Prospective, single-cohort, observational study Patients and Methods: One hundred fifty (85%) of 177 patients with blunt IHI received enoxaparin beginning approximately 24 hours after hospital admission until discharge. Brain computed tomographic (CT) scans were performed at admission, 24 hours after admission, and at variable intervals thereafter based on clinical course. Patients were excluded for coagulopathy, heparin allergy, expected brain death or discharge within 48 hours, and age younger than 14 years. Complications of enoxaparin prophylaxis were defined as Marshall CT grade progression of IHI expansion of an existing IHI, or development of a new hemorrhagic lesion on follow-up CT after beginning enoxaparin use. Results: Thirty-four patients (23%) had CT progression of IHI. Twenty-eight CT scans (19%) worsened before enoxaparin therapy and 6 (4%) worsened after beginning enoxaparin use. No differences between operative patient (2/24, 8%) and nonoperative patient (4/126, 3%) complications were identified (P=.23). Study group mortality was 7% (10/150). All 6 patients who developed progression of IHI after initiation of enoxaparin therapy survived hospitalization. A deep vein thrombosis was identified in 2 (2%) of 106 patients. Conclusion: Enoxaparin can be safely used for VTE prophylaxis in trauma patients with IHI when started 24 hours after hospital admission or after craniotomy.	E Texas Med Ctr, Dept Surg, Tyler, TX 75701 USA; E Texas Med Ctr, Dept Neurosurg, Tyler, TX 75701 USA; E Texas Med Ctr, Dept Radiol, Tyler, TX 75701 USA; Univ Texas Hlth Ctr, Dept Epidemiol Biomath, Tyler, TX USA	Norwood, SH (corresponding author), E Texas Med Ctr, Dept Surg, 1020 E Idel St, Tyler, TX 75701 USA.						Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; Brasel KJ, 1997, J TRAUMA, V42, P456, DOI 10.1097/00005373-199703000-00013; CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378; Devlin JW, 1998, PHARMACOTHERAPY, V18, P1335; Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Greenfield LJ, 2000, J VASC SURG, V32, P490, DOI 10.1067/mva.2000.108636; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; JENNETT B, 1975, LANCET, V1, P480; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Wojcik R, 2000, J TRAUMA, V49, P839, DOI 10.1097/00005373-200011000-00008	19	102	109	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	JUN	2002	137	6					696	701		10.1001/archsurg.137.6.696			6	Surgery	Surgery	559VF	WOS:000176045500018	12049541	Bronze			2021-06-18	
J	Chiaretti, A; Piastra, M; Pulitano, S; Pietrini, D; De Rosa, G; Barbaro, R; Di Rocco, C				Chiaretti, A; Piastra, M; Pulitano, S; Pietrini, D; De Rosa, G; Barbaro, R; Di Rocco, C			Prognostic factors and outcome of children with severe head injury: an 8-year experience	CHILDS NERVOUS SYSTEM			English	Article						severe head injury; childhood; Glasgow outcome score; prognostic factors; therapeutic algorithms	TRAUMATIC BRAIN INJURY; DISSEMINATED INTRAVASCULAR COAGULATION; GLASGOW COMA SCALE; EARLY POSTTRAUMATIC SEIZURES; MANAGEMENT; GUIDELINES; HYPERGLYCEMIA; HYPOTENSION; PREDICTION; HYPOXIA	Objectives: Our aim was to analyze prognostic factors and their association with outcome among children with severe head injury. Methods: We conducted a retrospective study among children with severe head injury admitted to our Pediatric Intensive Care Unit (PICU) from November 1992 to December 2000. The patients were immediately evaluated for the severity of head injury (Glasgow Coma Score, GCS), clinical presentation, cerebral axial tomography, early complications (hypoxia and hypotension), metabolic and hematological alterations and early post-traumatic seizures. Six months after injury we applied the Glasgow Outcome Score (GOS). Correlations with GOS were evaluated using univariate and multivariate logistic models. Results: In all, 122 children with severe head injury were identified. The patients presented the following scores: 18 (14.7.0%) children had a GOS of 1; 2 had a GOS of 2 (1.6%); 27 (22.2%) a GOS of 3 and 75 (61.5%) a GOS of 4 or 5. A low GOS was significantly and independently associated with low GCS, multiple trauma, the presence of hypoxia and hypotension, disseminated intravascular coagulation (DIC), hyperglycemia and early post-traumatic seizures. Hematological alterations (white blood cells) were also associated with a low GOS, though not significantly. Conclusion: In addition to GCS, types of trauma and brain lesion, hypoxia and hypotension, hemocoagulative disorders (DIC), hyperglycemia and early post-traumatic seizures are predictors of GOS. A knowledge of these prognostic factors and the correct management of children with severe head injury helps clinicians to improve outcome and to reduce morbidity and mortality.	Gemelli Hosp, Pediat Intens Care Unit, I-00168 Rome, Italy; Gemelli Hosp, Dept Anesthesiol, I-00168 Rome, Italy	Chiaretti, A (corresponding author), Gemelli Hosp, Pediat Intens Care Unit, I-00168 Rome, Italy.	chiarant@katamail.com					Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BRUCE DA, 1999, PEDIAT NEUROSURGERY, P355; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; GHAJAR J, 1992, PEDIATR CLIN N AM, V39, P1093; Glasgow JF, 1997, CURR PEDIAT, V7, P187; Gordini G, 1992, Minerva Anestesiol, V58, P217; GREWAL M, 1991, J PEDIATR SURG, V26, P1161, DOI 10.1016/0022-3468(91)90323-L; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; JENNETT B, 1975, LANCET, V1, P480; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; KUSHNER M, 1990, ANN NEUROL, V28, P129, DOI 10.1002/ana.410280204; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; MORONT ML, 1994, PEDIATR CLIN N AM, V41, P1201; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Paret Gideon, 1999, Harefuah, V136, P677; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; Rivara FP, 1999, PEDIATRICS, V103, P883; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Tikk A, 1979, Acta Neurochir Suppl (Wien), V28, P96; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Wright M M, 1999, AACN Clin Issues, V10, P32, DOI 10.1097/00044067-199902000-00004; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	49	102	106	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	APR	2002	18	3-4					129	136		10.1007/s00381-002-0558-3			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	555LU	WOS:000175796200006	11981619				2021-06-18	
J	Moser, RS; Schatz, P				Moser, RS; Schatz, P			Enduring effects of concussion in youth athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Annual Conference on Sports Related Concussion and Nervous System Injuries	1999	ORLANDO, FL			concussion; youth sports; neuropsychological testing; baseline screening; mild head injury	TRAUMATIC BRAIN-INJURY	The purpose of this study was to explore the mild, enduring effects of concussion in otherwise healthy youth athletes. Reported history of concussion and cognitive functioning was examined in an initial sample of 35 youth athletes, 21 of whom were considered healthy volunteers (No Recent Concussion within the past 6 months) with no identified medical or neuropsychological difficulties related to concussion. The remaining 14 volunteers had each sustained a concussion within I week of testing (Recent Concussion). Significant differences in performances on a general cognitive measure, and specifically in the area of attention, were found as a function of number of concussions reported by the No Recent Concussion athletes. Furthermore, on some of the measures, No Recent Concussion athletes with a history of two or more concussions appeared to resemble Recent Concussion athletes more so than No Recent Concussion athletes with a history of one or no concussion. The importance of assessment of youth concussion and the use of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) for this purpose are discussed. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	RSM Psychol Ctr LLC, Lawrenceville, NJ 08648 USA; St Josephs Univ, Philadelphia, PA 19131 USA	Moser, RS (corresponding author), RSM Psychol Ctr LLC, 3131 Princeton Pike,Bldg 5, Lawrenceville, NJ 08648 USA.	r.moser@rcn.com		Schatz, Philip/0000-0002-6222-6545			Barth JT., 1989, MILD HEAD INJURY, P257; BARTH JT, 1998, RECOVERY, V9, P30; CANTU R, 1998, CLIN SPORTS MED, P27; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; ECHEMENDIA R, 1999, ANN SPORTS REL CONC; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GRADY D, 1998, NY TIMES        0501, pA18; GRONWALL D, 1976, NZ PSYCHOL, V5, P72; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KUTNER K, 1998, NAN B, V13, P19; LAPOINTE J, 1998, NY TIMES        0322, pL3; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; *QUAL STAND SUBC, 1997, NEUROLOGY, V48, P481; Randolph C, 1998, REPEATABLE BATTERY A; ROOS R, 1996, PHYSICIAN SPORTSMED, V24, P1	21	102	104	0	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2002	17	1					91	100		10.1016/S0887-6177(01)00108-1			10	Psychology, Clinical; Psychology	Psychology	504XD	WOS:000172880700008	14589756	Bronze			2021-06-18	
J	Masel, BE; Scheibel, RS; Kimbark, T; Kuna, ST				Masel, BE; Scheibel, RS; Kimbark, T; Kuna, ST			Excessive daytime sleepiness in adults with brain injuries	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	50th Annual Meeting of the American-Academy-of-Neurology	APR 25-MAY 02, 1998	MINNEAPOLIS, MINNESOTA	Amer Acad Neurol		Xbrain injuries; disorders of excessive somnolence; rehabilitation; sleep apnea syndromes; sleep disorders	CLOSED-HEAD-INJURY; LATENCY TEST; SCALE; POPULATION; PREVALENCE	Objectives: To determine the prevalence, demographics, and causes of excessive daytime sleepiness in adults with brain injuries after the acute phase of their injury and to investigate the relations between self-report and objective measures of hypersomnolence. Design: A case series of patients enrolled consecutively into a residential rehabilitation program. Setting: University sleep laboratory, live-in rehabilitation center. Patients: Adults with brain injuries (n = 71); mean time +/- standard deviation from injury to study, 38 +/- 60 months. Interventions: A polysomnogram and Multiple Sleep Latency Test (MSLT) were performed in each subject. Each subject also completed the Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI) questionnaires. Main Outcome Measures: Sleep patterns, by polysomnogram. Daytime hypersomnolence, diagnosed by mean sleep latency on the MSLT less than or equal to 10 minutes. Sleep apnea-hypopnea syndrome, diagnosed by Apnea-Hypopnea Index greater than 10 events/hr. Periodic limb movement disorder, diagnosed by a Periodic Leg Movement Index greater than 10 events/hr. Results: Mean sleep latency was : 10 minutes in 47% of the cohort and less than or equal to 5 minutes in 18.3%. Subjects were classified into 3 groups: nonhypersomnolent (n = 38, 53%), hypersomnolent with abnormal indices (n = 12, 17%), or hypersomnolent with normal indices (n = 21, 30%). Among the 3 groups, no significant differences were present in Glasgow Coma Scale score, length of coma, or time since brain injury. No differences across groups were found in nature of the injury, gender, or medications. No significant correlation existed between the ESS or PSQI results and mean sleep latency on the MSLT. Conclusions: Hypersomnia is common in adults with brain injuries, with a relatively high prevalence of sleep apnea-hypopnea syndrome, periodic limb movement disorder, and posttraurnatic hypersomnia. Subjects with objectively measured sleepiness were not identified on self-reporting questionnaires, suggesting their inability to perceive their hypersomnolence. (C) 2001 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Transit Learning Ctr Galveston, Galveston, TX 77550 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	Masel, BE (corresponding author), Transit Learning Ctr Galveston, 1528 PO, Galveston, TX 77550 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-73] Funding Source: Medline		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Sleep Disorders Association, 1997, INT CLASS SLEEP DIS; ANCOLIISRAEL S, 1991, SLEEP, V14, P496, DOI 10.1093/sleep/14.6.496; Benbadis SR, 1999, NEUROLOGY, V52, P209, DOI 10.1212/WNL.52.1.209; Benbadis SR, 1999, ANN INTERN MED, V130, P289, DOI 10.7326/0003-4819-130-4-199902160-00014; Benton A. L., 1994, CONTRIBUTIONS NEUROP; BIXLER EO, 1982, RES COMMUN CHEM PATH, V36, P129; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DALESSANDRO R, 1995, SLEEP, V18, P389; Dorsey CM, 1996, NEUROPSYCHOPHARMACOL, V14, P437, DOI 10.1016/0893-133X(95)00148-7; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; GUILLEMINAULT C, 1976, ACTA NEUROL SCAND, V54, P71, DOI 10.1111/j.1600-0404.1976.tb07621.x; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Harada M, 1976, Kumamoto Med J, V29, P110; Heaton R. K, 1981, WISCONSIN CARD SORTI; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; MANN MR, 1997, ARCH PHYS MED REHAB, V78, P1086; MANN NR, 1997, ARCH PHYS MED REHAB, V78, P1055; MILLON T, 1987, MANUAL MCMI II; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SCHEIBEL RS, 1997, J NEUROPSYCHOL CLIN, V9, P673; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	31	102	103	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2001	82	11					1526	1532		10.1053/apmr.2001.26093			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	488WK	WOS:000171959600004	11689971				2021-06-18	
J	Strauss, KI; Barbe, MF; Marshall, RM; Raghupathi, R; Mehta, S; Narayan, RK				Strauss, KI; Barbe, MF; Marshall, RM; Raghupathi, R; Mehta, S; Narayan, RK			Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						neural gene expression; quantitative mRNA measurements; hippocampus; parietal cortex; perirhinal cortex; piriform cortex	CEREBRAL BLOOD-FLOW; LONG-TERM POTENTIATION; HEAD-INJURY; MESSENGER-RNA; INDUCIBLE CYCLOOXYGENASE; HIPPOCAMPAL-FORMATION; ENDOTHELIAL-CELLS; FEBRILE RESPONSE; ARACHIDONIC-ACID; GENE-EXPRESSION	Cyclooxygenase-2 (COX2) is a primary inflammatory mediator that converts arachidonic acid into precursors of vasoactive prostaglandins, producing reactive oxygen species in the process. Under normal conditions COX2 is not detectable, except at low abundance in the brain. This study demonstrates a distinctive pattern of COX2 increases in the brain over time following traumatic brain injury (TBI). Quantitative lysate ribonuclease protection assays indicate acute and sustained increases in COX2 mRNA in two rat models of TBI. In the lateral fluid percussion model, COX2 mRNA is significantly elevated (>twofold, p < 0.05, Dunnett) at 1 day postinjury in the injured cortex and bilaterally in the hippocampus, compared to sham-injured controls. In the lateral cortical impact model (LCI), COX2 mRNA peaks around 6 h postinjury in the ipsilateral cerebral cortex (fivefold induction, p < 0.05, Dunnett) and in the ipsilateral and contralateral hippocampus (two- and sixfold induction, respectively, p < 0.05, Dunnett). Increases are sustained out to 3 days postinjury in the injured cortex in both models. Further analyses use the LCI model to evaluate COX2 induction. Immunoblot analyses confirm increased levels of COX2 protein in the cortex and hippocampus. Profound increases in COX2 protein are observed in the cortex at 1-3 days, that return to sham levels by 7 days postinjury (p < 0.05, Dunnett). The cellular pattern of COX2 induction following TBI has been characterized using immunohistochemistry. COX2-immunoreactivity (-ir) rises acutely (cell numbers and intensity) and remains elevated for several days following TBI. Increases in COX2-ir colocalize with neurons (MAP2-ir) and glia (GFAP-ir). Increases in COX2-ir are observed in cerebral cortex and hippocampus, ipsilateral and contralateral to injury as early as 2 h postinjury. Neurons in the ipsilateral parietal, perirhinal and piriform cortex become intensely COX2-ir from 2 h to at least 3 days postinjury. In agreement with the mRNA and immunoblot results, COX2-ir appears greatest in the contralateral hippocampus. Hippocampal COX2-ir progresses from the pyramidal cell layer of the CA1 and CA2 region at 2 h, to the CA3 pyramidal cells and dentate polymorphic and granule cell layers by 24 h postinjury. These increases are distinct from those observed following inflammatory challenge, and correspond to brain areas previously identified with the neurological and cognitive deficits associated with TBI. While COX2 induction following TBI may result in selective beneficial responses, chronic COX2 production may contribute to free radical mediated cellular damage, vascular dysfunction, and alterations in cellular metabolism. These may cause secondary injuries to the brain that promote neuropathology and worsen behavioral outcome.	Temple Univ, Sch Med, Dept Neurosurg, Philadelphia, PA 19122 USA; Temple Univ, Dept Phys Therapy, Philadelphia, PA 19122 USA; Temple Univ, Dept Anat & Cell Biol, Philadelphia, PA 19122 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA USA	Strauss, KI (corresponding author), Temple Neurotrauma Res Lab, 3420 N Broad St,MRB 711, Philadelphia, PA 19140 USA.	kstrauss@thunder.temple.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038654, R01 NS38654] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038654] Funding Source: NIH RePORTER		Adams J, 1996, J NEUROCHEM, V66, P6; AMARAL DG, 1984, J COMP NEUROL, V224, P307, DOI 10.1002/cne.902240302; BABB TL, 1988, J COMP NEUROL, V278, P121, DOI 10.1002/cne.902780108; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; BREDER CD, 1992, J COMP NEUROL, V322, P409, DOI 10.1002/cne.903220309; Busija David W., 1996, Microcirculation (Philadelphia), V3, P379, DOI 10.3109/10739689609148310; Caggiano AO, 1996, J COMP NEUROL, V376, P447, DOI 10.1002/(SICI)1096-9861(19961216)376:3<447::AID-CNE7>3.0.CO;2-2; CAJAL SRY, 1995, HISTOLOGY NERVOUS SY, P638; Cao CY, 1997, ANN NY ACAD SCI, V813, P307, DOI 10.1111/j.1749-6632.1997.tb51710.x; CAO CY, 1995, BRAIN RES, V697, P187, DOI 10.1016/0006-8993(95)00839-I; Cao CY, 1999, J NEUROSCI, V19, P716; CHEN J, 1995, NEUROREPORT, V6, P245; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Conti AC, 1998, J NEUROSCI, V18, P5663; Dahl B, 1996, ACTA NEUROCHIR, V138, P265, DOI 10.1007/BF01411736; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397; ELLIS EF, 1979, AM J PHYSIOL, V237, pH381; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FU JY, 1990, J BIOL CHEM, V265, P16737; GRAHAM SH, 1996, J NEUROTRAUM, V13, pA620; GRAHAM SH, 1996, NEUROLOGY S, V46, pA406; Ho L, 1998, J NEUROIMMUNOL, V89, P142, DOI 10.1016/S0165-5728(98)00132-5; Ino T, 1998, NEUROSCI RES, V32, P241, DOI 10.1016/S0168-0102(98)00093-5; ISAACS KR, 1995, CELL TISSUE RES, V280, P639, DOI 10.1007/s004410050391; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; KEMPSKI O, 1987, STROKE, V18, P111, DOI 10.1161/01.STR.18.1.111; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kong D. L., 1997, Society for Neuroscience Abstracts, V23, P2181; Kontos H A, 1980, Adv Exp Med Biol, V131, P243; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; Lacroix S, 1998, J NEUROCHEM, V70, P452, DOI 10.1046/j.1471-4159.1998.70020452.x; LERANTH C, 1987, J COMP NEUROL, V261, P33, DOI 10.1002/cne.902610104; LEWEN A, 1996, J NEUROTRAUM, V13, pA600; LI DY, 1993, J PHARMACOL EXP THER, V267, P1292; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Marcheselli VL, 1996, J BIOL CHEM, V271, P24794, DOI 10.1074/jbc.271.40.24794; MARKLUND N, 1996, J NEUROTRAUM, V13, pA600; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore S. A., 1997, Society for Neuroscience Abstracts, V23, P1166; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nakayama M., 1996, Society for Neuroscience Abstracts, V22, P1670; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; NISHIHARA I, 1995, NEUROSCI LETT, V196, P57, DOI 10.1016/0304-3940(95)11839-O; Nishizaki T, 1999, BIOCHEM BIOPH RES CO, V254, P446, DOI 10.1006/bbrc.1998.9961; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; PRASAD MR, 1994, J NEUROCHEM, V63, P773; RAZ A, 1988, J BIOL CHEM, V263, P3022; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Sanz O, 1997, NEUROSCIENCE, V80, P221, DOI 10.1016/S0306-4522(97)00089-4; SAPER CB, 1992, PROG BRAIN RES, V93, P419; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SEVANIAN A, 1985, Journal of Free Radicals in Biology and Medicine, V1, P263, DOI 10.1016/0748-5514(85)90130-8; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; STRAUSS KI, 1993, MOL BRAIN RES, V20, P229, DOI 10.1016/0169-328X(93)90045-Q; STRAUSS KI, 1997, J NEUROTRAUM, V14, pA794; STRAUSS KI, 1998, J NEUROTRAUM, V15, pA898; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TSUBOKURA S, 1991, BRAIN RES, V543, P15, DOI 10.1016/0006-8993(91)91043-Z; VanDam AM, 1996, FASEB J, V10, P351; VANGROEN T, 1990, J COMP NEUROL, V302, P515, DOI 10.1002/cne.903020308; vanHaeften T, 1997, J NEUROSCI, V17, P862; VANSTUCK SL, 1996, J NEUROTRAUM, V13, pA618; Wallace CS, 1998, J NEUROSCI, V18, P26; Walton M, 1997, MOL BRAIN RES, V50, P165, DOI 10.1016/S0169-328X(97)00181-2; WEI EP, 1980, AM J PHYSIOL, V238, pH226; WEST JR, 1979, BRAIN RES, V160, P203, DOI 10.1016/0006-8993(79)90419-0; Wolf MJ, 1995, FEBS LETT, V377, P358, DOI 10.1016/0014-5793(95)01371-7; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG B, 1996, NEUROTRAUMA, P345	95	102	112	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2000	17	8					695	711		10.1089/089771500415436			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	347WF	WOS:000088951600006	10972245	Green Accepted			2021-06-18	
J	Kaya, SS; Mahmood, A; Li, Y; Yavuz, E; Chopp, M				Kaya, SS; Mahmood, A; Li, Y; Yavuz, E; Chopp, M			Expression of nestin after traumatic brain injury in rat brain	BRAIN RESEARCH			English	Article						nestin; traumatic brain injury; astrocyte; microglia; plasticity	NERVE GROWTH-FACTOR; RADIAL GLIA; ASTROCYTES; CELLS; CNS; CORTEX	We tested the hypothesis that traumatic brain injury upregulates expression of nestin, an embryonic cell intermediate filament protein. Brain from rats (n = 24) subjected to controlled cortical impact injury and sham operated (n = 3) and normal(n = 3) rats were processed for dual label immunohistochemical study to identify cellular expression of nestin. Our results show that in normal noninjured animals, nestin is expressed slightly and localized only in a few endothelial and subventricular cells. In contrast, at 1-4 weeks postinjury nestin is strongly expressed in astrocytes and microglia. The expression of nestin in astrocytes and microglia after traumatic brain injury support the hypothesis that injured cerebral tissue expresses developmental proteins, and that these proteins may promote recovery after injury. (C) 1999 Elsevier Science B.V. All rights reserved.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI 48202 USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA	Mahmood, A (corresponding author), Henry Ford Hlth Sci Ctr, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035504, P01NS023393] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS23393, R01 NS35504] Funding Source: Medline		BARRES BA, 1991, J NEUROSCI, V11, P3685; BIGNAMI A, 1974, NATURE, V252, P55, DOI 10.1038/252055a0; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; CULICAN SM, 1990, J NEUROSCI, V10, P684; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GALLO V, 1995, J NEUROSCI, V15, P394; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; ISHIKAWA R, 1991, NEUROSCI LETT, V127, P70, DOI 10.1016/0304-3940(91)90897-3; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Schmitt A, 1997, J NEUROSCI, V17, P1, DOI 10.1523/jneurosci.17-01-00001.1997; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623	20	102	107	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 4	1999	840	1-2					153	157		10.1016/S0006-8993(99)01757-6			5	Neurosciences	Neurosciences & Neurology	234GY	WOS:000082477300017	10517963				2021-06-18	
J	Hoffmann, GF; Zschocke, J				Hoffmann, GF; Zschocke, J			Glutaric aciduria type I: From clinical, biochemical and molecular diversity to successful therapy	JOURNAL OF INHERITED METABOLIC DISEASE			English	Article; Proceedings Paper	36th Annual Symposium of the SSIEM	1998	YORK, ENGLAND	Soc Study Inborn Errors Metabolism			COA-DEHYDROGENASE-DEFICIENCY; ACIDEMIA TYPE-I; DIAGNOSIS; MUTATIONS; GENE; ENCEPHALOPATHY; EXPRESSION; KINDREDS; DISORDER; COENZYME	The biochemical hallmark of glutaric aciduria type I (GA I) due to glutaryl-CoA dehydrogenase deficiency is the accumulation of glutaric acid, and to a lesser degree of 3-hydroxyglutaric and glutaconic acids. Abnormal metabolites vary from gross organic aciduria to only slightly or intermittently elevated or even normal excretion of glutaric acid, making the diagnosis sometimes difficult. Close to 100 pathogenic mutations have been identified in the gene encoding glutaryl-CoA dehydrogenase. Specific mutations correlate with low or no excretion of glutaric acid, but there appears to be no correlation between genotype and clinical phenotype. GA I causes unique age- and location-specific neuropathological sequelae. Starting in the second half of gestation, maturation of the frontal and temporal cortex is hindered, leading to the characteristic appearance of frontotemporal atrophy. Between 6 and 18 months of age, relatively mild neurological symptoms may become exacerbated by fever or a catabolic state in the course of common infections or routine immunizations, by fasts required for surgery, or by minor head injuries. Putamen and caudate are destroyed, resulting in a permanent movement disorder that is similar to cerebral palsy and ranges from extreme hypotonia to choreoathetosis to rigidity with spasticity. Recently, the underlying pathophysiology could be delineated to an environmentally triggered age- and location-specific overstimulation of the NMDA 2B receptor subtype. Current therapy prevents brain degeneration in more than 90% of affected infants who are treated prospectively. Without treatment, more than 90% of affected children will develop severe neurological disabilities. Recognition of this disorder before the brain has been injured is essential to treatment. GA I may be recognized in routine neonatal screening performed with tandem mass spectrometry by an elevation of glutarylcarnitine. Where this is not done, timely diagnosis depends on the recognition of relatively nonspecific physical findings such as hypotonia, irritability, macrocephaly, on the detection of suggestive abnormalities in neuroimaging and on quantitative urinary organic acid analysis by gas chromatography - mass spectrometry.	Univ Marburg, Dept Neuropaediat & Metab Dis, Marburg, Germany	Hoffmann, GF (corresponding author), Univ Childrens Hosp, Dept Neuropaediat & Metab Dis, Deutschhausstr 12, D-35033 Marburg, Germany.		Zschocke, Johannes/C-5885-2013	Zschocke, Johannes/0000-0002-0046-8274			AMIR N, 1989, J PEDIATR-US, V114, P983, DOI 10.1016/S0022-3476(89)80442-1; Baric I, 1998, J INHERIT METAB DIS, V21, P326, DOI 10.1023/A:1005390105171; Baric I., 1997, Journal of Inherited Metabolic Disease, V20, P34; BARIC I, 1997, 7 INT C INB ERR MET; BENNETT MJ, 1991, J INHERIT METAB DIS, V14, P165, DOI 10.1007/BF01800589; BERGMAN I, 1989, PEDIATRICS, V83, P228; Biery BJ, 1996, AM J HUM GENET, V59, P1006; CAMPISTOL J, 1992, J PEDIATR-US, V121, P83, DOI 10.1016/S0022-3476(05)82548-X; CHRISTENSEN E, 1993, CLIN CHIM ACTA, V220, P71, DOI 10.1016/0009-8981(93)90007-Q; Christensen E, 1997, J INHERIT METAB DIS, V20, P383, DOI 10.1023/A:1005390214391; FLORET D, 1979, ARCH FR PEDIATR, V36, P462; FlottRahmel B, 1997, J INHERIT METAB DIS, V20, P387, DOI 10.1023/A:1005342331229; GOODMAN SI, 1975, BIOCHEM MED METAB B, V12, P12, DOI 10.1016/0006-2944(75)90091-5; GOODMAN SI, 1995, HUM MOL GENET, V4, P1493; Goodman SI, 1998, HUM MUTAT, V12, P141, DOI 10.1002/(SICI)1098-1004(1998)12:3<141::AID-HUMU1>3.0.CO;2-K; GOODMAN SI, 1977, J PEDIATR-US, V90, P746, DOI 10.1016/S0022-3476(77)81240-7; GOODMAN SI, 1995, METABOLIC MOL BASES, P1451; Greene JG, 1998, NEUROSCIENCE, V84, P503, DOI 10.1016/S0306-4522(97)00389-8; HAWORTH JC, 1991, J PEDIATR-US, V118, P52, DOI 10.1016/S0022-3476(05)81843-8; Hoffmann GF, 1996, NEUROPEDIATRICS, V27, P115, DOI 10.1055/s-2007-973761; HOFFMANN GF, 1991, PEDIATRICS, V88, P1194; Kolker S, 1999, J INHERIT METAB DIS, V22, P259; Liesert M, 1999, J INHERIT METAB DIS, V22, P256, DOI 10.1023/A:1005525903207; McDonald JW, 1997, BRAIN RES, V759, P228, DOI 10.1016/S0006-8993(97)00248-5; MERINERO B, 1995, NEUROPEDIATRICS, V26, P238, DOI 10.1055/s-2007-979763; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORTON DH, 1991, AM J MED GENET, V41, P89, DOI 10.1002/ajmg.1320410122; Muntau AC, 1997, MONATSSCHR KINDERH, V145, P646, DOI 10.1007/s001120050166; Schwartz M, 1998, HUM GENET, V102, P452, DOI 10.1007/s004390050720; ZIADEH R, 1994, 6 INT C INB ERR MET	30	102	110	0	10	KLUWER ACADEMIC PUBL	DORDRECHT	SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS	0141-8955			J INHERIT METAB DIS	J. Inherit. Metab. Dis.	JUN	1999	22	4					381	391		10.1023/A:1005543904484			11	Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental	Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine	204CG	WOS:000080744900006	10407775				2021-06-18	
J	D'Ambrosio, R; Maris, DO; Grady, MS; Winn, HR; Janigro, D				D'Ambrosio, R; Maris, DO; Grady, MS; Winn, HR; Janigro, D			Selective loss of hippocampal long-term potentiation, but not depression, following fluid percussion injury	BRAIN RESEARCH			English	Article						brain injury; glia/neuronal interaction; swelling; synaptic plasticity; sprouting	TRAUMATIC BRAIN INJURY; NITRIC-OXIDE SYNTHASE; DENTATE GYRUS; SYNAPTIC TRANSMISSION; RAT-BRAIN; NEURONS; POTASSIUM; LTP; DYSFUNCTION; GLUTAMATE	We investigated the early effects of in vivo fluid percussion injury (FPI) on hippocampal synaptic potentials and excitability. In vitro field potential recordings and immunocytochemistry were performed in the CA1 region in slices from naive, post-FPI, or sham-operated rats. The following electrophysiological and morphological parameters were affected following FPI: (1) threshold for population spike generation was increased suggesting that post-FPI neurons were hypoexcitable; (2) long-term potentiation (LTP) could not be induced in injured hippocampi; (3) GFAP and inducible NO synthase (iNOS) immunoreactivity were enhanced post-FPI; and (4) following injury, synaptophysin immunoreactivity was enhanced in CAI stratum radiatum. The effects of FPI on synaptic plasticity were LTP-specific, since long-term depression (LTD) could be equally induced and maintained in post-FPI, sham-operated and control slices. Sham-operated slices were characterized by synaptic excitability indistinguishable from naive controls, but displayed decreased ability for LTP production and expressed high levels of iNOS. We conclude that FPI causes a selective loss of LTP, possibly due to a previous potentiation induced by trauma as reflected by the increased expression of synaptic proteins. Sham surgical procedures were, however, not without effects on long-term potentiation itself; the latter effects appear to be mediated by an increased production of NO. Our study demonstrates for the first time that hippocampal slices can be used to investigate the correlates of in vivo FPI. Furthermore, we describe LTP-specific deficits in post-traumatic brain injury, suggesting that FPI can selectively erase one of the two main NMDA-dependent forms of synaptic plasticity in the hippocampus. (C) 1998 Elsevier Science B.V.	Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Sch Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Environm Hlth, Seattle, WA 98104 USA	Janigro, D (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Sch Med, 325 9Th Ave,Box 359914, Seattle, WA 98104 USA.	ciao@u.washington.edu		Janigro, Damir/0000-0003-2165-5826	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [NHLB 51614] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES 07033] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21076] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL051614, R29HL051614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021076] Funding Source: NIH RePORTER		ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Barth A, 1997, BRAIN RES, V762, P79, DOI 10.1016/S0006-8993(97)00348-X; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BENARI Y, 1990, NEUROSCIENCE, V37, P55, DOI 10.1016/0306-4522(90)90191-6; CASULLO J, 1987, CAN J PHYSIOL PHARM, V65, P847, DOI 10.1139/y87-136; CONTZEN R, 1994, BRAIN RES, V340, P340; CREPEL V, 1993, J NEUROPHYSIOL, V69, P494; Dawson VL, 1996, J NEUROSCI, V16, P2479; FLECK MW, 1992, BRAIN RES, V580, P100, DOI 10.1016/0006-8993(92)90931-X; GALLUCI E, 1997, IN PRESS J NEUROTRAU; HARRISON CM, 1993, BRAIN RES, V602, P175, DOI 10.1016/0006-8993(93)90261-K; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holscher C, 1997, TRENDS NEUROSCI, V20, P298, DOI 10.1016/S0166-2236(97)01065-5; Hoque AM, 1996, SHOCK, V6, P365, DOI 10.1097/00024382-199611000-00011; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JANIGRO D, 1988, BRAIN RES, V453, P265, DOI 10.1016/0006-8993(88)90166-7; Janigro D, 1997, J NEUROSCI, V17, P2813; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kimelberg H K, 1987, Cent Nerv Syst Trauma, V4, P3; KOMBIAN SB, 1994, NATURE, V368, P242, DOI 10.1038/368242a0; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; Largo C, 1996, NEUROL RES, V18, P445; Largo C, 1996, J NEUROSCI, V16, P1219; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Linden DJ, 1997, NEURON, V18, P983, DOI 10.1016/S0896-6273(00)80337-2; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYNCH MA, 1994, NEUROSCIENCE, V60, P1, DOI 10.1016/0306-4522(94)90197-X; MACCAFERRI G, 1994, NEUROREPORT, V5, P1813, DOI 10.1097/00001756-199409080-00032; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Nakanishi H, 1996, BRAIN RES, V732, P232, DOI 10.1016/0006-8993(96)00689-0; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Sastry B R, 1990, Adv Exp Med Biol, V268, P377; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; WENZEL J, 1991, BRAIN RES, V560, P122, DOI 10.1016/0006-8993(91)91222-M; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	40	102	103	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 9	1998	786	1-2					64	79		10.1016/S0006-8993(97)01412-1			16	Neurosciences	Neurosciences & Neurology	ZJ738	WOS:000073248000008	9554957				2021-06-18	
J	Kelly, DF; Martin, NA; Kordestani, R; Counelis, G; Hovda, DA; Bergsneider, M; McBride, DQ; Shalmon, E; Herman, D; Becker, DP				Kelly, DF; Martin, NA; Kordestani, R; Counelis, G; Hovda, DA; Bergsneider, M; McBride, DQ; Shalmon, E; Herman, D; Becker, DP			Cerebral blood flow as a predictor of outcome following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral blood flow; cerebral metabolism cerebral vasoreactivity; hyperemia; intracranial hypertension	SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; GLUCOSE-UTILIZATION; SUBDURAL-HEMATOMA; PROTEIN-SYNTHESIS; METABOLISM; CIRCULATION; THRESHOLDS; ISCHEMIA; STATE	As part of a prospective study of the cerebrovascular effects of head injury, 54 moderate and severely injured patients underwent 184 Xe-133-cerebral blood flow (CBF) studies to determine the relationship between the period of maximum blood flow and outcome. The lowest blood flows were observed on the day of injury (Day 0) and the highest CBFs were documented on postinjury Days 1 to 5. Patients were divided into three groups based on CBF values obtained during this period of maximum flow: Group 1 (seven patients), CBF less than 33 ml/100 g/minute on all determinations; Group 2 (13 patients), CBF both less than and greater than or equal to 33 ml/100 g/minute; and Group 3 (34 patients), CBF greater than or equal to 33 ml/100 g/minute on all measurements. For Groups 1, 2, and 3, mean CBF during Days 1 to 5 postinjury was 25.7 +/- 4, 36.5 +/- 4.2, and 49.4 +/- 9.3 ml/100 g/minute, respectively, and PaCO2 at the time of the CBF study was 31.4 +/- 6, 32.7 +/- 2.9, and 33.4 +/- 4.7 mm Hg, respectively. There were significant differences across Groups 1, 2, and 3 regarding mean age, percentage of individuals younger than 35 years of age (42.9%, 23.1%, and 76.5%, respectively), incidence of patients requiring evacuation of intradural hematomas (57.1%, 38.5%, and 17.6%, respectively) and incidence of abnormal pupils (57.1%, 61.5%, and 32.4%, respectively). Favorable neurological outcome at 6 months postinjury in Groups 1, 2, and 3 was 0%, 46.2%, and 58.8%, respectively (p < 0.05). Further analysis of patients in Group 3 revealed that of 14 with poor outcomes, six had one or more episodes of hyperemia-associated intracranial hypertension (simultaneous CBF > 55 ml/100 g/minute and ICP > 20 mm Hg). These six patients were unique in having the highest CBFs for postinjury Days 1 to 5 (mean 59.8 ml/100 g/minute) and the most severe degree of intracranial hypertension and reduced cerebral perfusion pressure (p < 0.0001). These results indicate that a phasic elevation in CBF acutely after head injury is a necessary condition for achieving functional recovery. It is postulated that for the majority of patients, this rise in blood flow results from an increase in metabolic demands in the setting of intact vasoreactivity. In a minority of individuals, however, the constellation of supranormal CBF, severe intracranial hypertension, and poor outcome indicates a state of grossly impaired vasoreactivity with uncoupling between blood flow and metabolism.	UNIV CALIF LOS ANGELES, CEREBRAL BLOOD FLOW LAB, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA 90024 USA	Kelly, DF (corresponding author), UNIV CALIF LOS ANGELES, DIV NEUROSURG, BRAIN INJURY RES CTR, ROOM 18-218A NPI, BOX 957039, LOS ANGELES, CA 90024 USA.			Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30308] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERTSNEIDER M, 1995, J CEREB BLOOD FLO S1, V15, pS26; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LEE SM, 1995, J CEREB BLOOD FLO S1, V15, pS722; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; MELAMED E, 1980, STROKE, V11, P31, DOI 10.1161/01.STR.11.1.31; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63; NARITOMI H, 1979, ARCH NEUROL-CHICAGO, V36, P410, DOI 10.1001/archneur.1979.00500430040005; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Ritter A M, 1994, Neurosurg Clin N Am, V5, P633; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SALVANT JB, 1993, NEUROSURGERY, V33, P387; STEWART L, 1994, ACTA NEUROCHIR, P544; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	48	102	105	1	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	1997	86	4					633	641		10.3171/jns.1997.86.4.0633			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WP020	WOS:A1997WP02000009	9120627				2021-06-18	
J	Li, GH; Keyl, PM; Smith, GS; Baker, SP				Li, GH; Keyl, PM; Smith, GS; Baker, SP			Alcohol and injury severity: Reappraisal of the continuing controversy	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	56th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 19-21, 1996	HOUSTON, TX	Amer Assoc Surg Trauma		alcohol; epidemiology; injury; potentiating effect; trauma	TRAUMATIC BRAIN INJURY; HOSPITAL COURSE; ETHANOL; INTOXICATION; PERFORMANCE; DEPENDENCE; IMPACT; ABUSE; SCORE; ORDER	It is well recognized that alcohol increases the risk of injury, It is controversial, however, whether alcohol also has an effect on the degree and outcome of injury after controlling for the severity of impact, This review examines the evidence from experimental studies in animals regarding the potentiating effects of alcohol on trauma, and the methodologic issues that may have contributed to the contradictory findings of clinical and epidemiologic studies, Most experimental studies indicate that alcohol can adversely affect the degree and outcome of injury, In controlled laboratory conditions, alcohol is found to reduce cardiac output, to increase the susceptibility to hemorrhagic shock, and to increase the pulmonary vascular resistance after standardized experimental injuries, However, it is difficult to extrapolate these findings to humans, partly because the interactive effects of chronic and acute alcohol use on trauma are rarely considered in experimental studies, The conflicting results in studies involving trauma patients are due in part to the differences in study design, particularly selection of study populations, and in measuring and controlling for kinetic forces on the body, Studies indicating that alcohol is associated with an increased risk of serious or fatal injury are usually based on data from emergency departments or police departments, The alcohol-injury severity relationship reported in these studies is attributable to a great extent to the effects of correlates of alcohol, such as speeding and not wearing seat belts, rather than the biological effects of alcohol, Studies indicating that alcohol is not associated with the degree and outcomes of injury are mostly those involving patients who were admitted to hospitals or trauma centers, Methodologic issues concerning the alcohol-injury severity controversy, including conceptual models and future research needs, are discussed.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR INJURY RES & POLICY, BALTIMORE, MD USA	Li, GH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT EMERGENCY MED, 600 N WOLFE ST, MARBURG B194A, BALTIMORE, MD 21287 USA.			Smith, Gordon/0000-0002-2911-3071	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R29AA009963, R01AA007700] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA07700, R29AA09963] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR302486] Funding Source: Medline		ALTURA BM, 1995, ALCOHOL, V12, P433, DOI 10.1016/0741-8329(95)00026-N; ANDERSEN JA, 1990, J TRAUMA, V30, P415, DOI 10.1097/00005373-199030040-00007; Anderson T E, 1986, Cent Nerv Syst Trauma, V3, P183; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BALLIN JC, 1986, JAMA-J AM MED ASSOC, V255, P522; BLOMBERG RD, 1979, P AM ASS AUT MED, V26, P1; BLOMQVIST S, 1987, J TRAUMA, V27, P40, DOI 10.1097/00005373-198701000-00007; BRADBURY A, 1991, INJURY, V22, P132, DOI 10.1016/0020-1383(91)90074-O; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; BRODNER RA, 1981, J TRAUMA, V21, P124, DOI 10.1097/00005373-198102000-00005; Cherpitel CJ, 1996, ALCOHOL CLIN EXP RES, V20, P338, DOI 10.1111/j.1530-0277.1996.tb01649.x; CHERPITEL CJ, 1994, ALCOHOL ALCOHOLISM, V29, P211; CHIN JH, 1981, MOL PHARMACOL, V19, P425; DESIDERIO MA, 1986, J TRAUMA, V26, P467, DOI 10.1097/00005373-198605000-00011; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DISCHINGER PC, 1988, P AM ASS AUTOMOTIVE, V32, P299; ELMER O, 1985, ACTA CHIR SCAND, V151, P305; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FULLER MG, 1995, J ADDICT DIS, V14, P47, DOI 10.1300/J069v14n01_05; GARRISON HG, 1984, ANN EMERG MED, V13, P26, DOI 10.1016/S0196-0644(84)80379-0; GENTILELLO LM, 1993, J TRAUMA, V34, P669, DOI 10.1097/00005373-199305000-00009; GRANT BF, 1994, ALCOHOL HEALTH RES W, V18, P243; GRUBER J E, 1992, Journal of Emergency Medicine, V10, P545, DOI 10.1016/0736-4679(92)90134-F; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HADDON W, 1961, J CHRON DIS, V14, P655, DOI 10.1016/0021-9681(61)90122-9; HOEK JB, 1990, ALCOHOL ALCOHOLISM, V25, P143, DOI 10.1093/oxfordjournals.alcalc.a044989; HONKANEN R, 1991, INJURY, V22, P225, DOI 10.1016/0020-1383(91)90047-I; HONKANEN R, 1983, J STUD ALCOHOL, V44, P231, DOI 10.15288/jsa.1983.44.231; House EG, 1982, P AM ASS AUTOMOTIVE, V26, P349; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KIM K, 1995, ACCIDENT ANAL PREV, V27, P469, DOI 10.1016/0001-4575(95)00001-G; KNOTT DH, 1963, NEW ENGL J MED, V269, P292, DOI 10.1056/NEJM196308082690604; KNOTT DH, 1967, JAMA-J AM MED ASSOC, V84, P179; KOELEGA HS, 1995, PSYCHOPHARMACOLOGY, V118, P233, DOI 10.1007/BF02245951; Last J. M., 1995, DICT EPIDEMIOLOGY, P134; LIEDTKE AJ, 1975, AM J CARDIOL, V35, P243, DOI 10.1016/0002-9149(75)90008-9; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MCCALL D, 1989, BIOCHEM PHARMACOL, V38, P2593, DOI 10.1016/0006-2952(89)90543-1; MCCARROLL JR, 1962, J CHRON DIS, V15, P811, DOI 10.1016/0021-9681(62)90051-6; MENGERT P, 1992, US COAST GUARD PUBLI; MIDANIK LT, 1994, AM J PUBLIC HEALTH, V84, P1218, DOI 10.2105/AJPH.84.8.1218; MOSS LK, 1959, SURG FORUM, V10, P390; National Institute on Alcohol Abuse and Alcoholism, 1994, NIH PUBL, P233; NEWSOME HH, 1988, J TRAUMA, V28, P1, DOI 10.1097/00005373-198801000-00001; NICHOLAS GG, 1980, J TRAUMA, V20, P58, DOI 10.1097/00005373-198020010-00009; NIE Y, 1989, ARCH BIOCHEM BIOPHYS, V268, P349, DOI 10.1016/0003-9861(89)90596-1; NILSSEN O, 1994, J TRAUMA, V36, P784, DOI 10.1097/00005373-199406000-00006; OLKKONEN S, 1990, ACCIDENT ANAL PREV, V22, P89, DOI 10.1016/0001-4575(90)90010-I; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; PORTANS I, 1989, PSYCHOPHARMACOLOGY, V97, P365, DOI 10.1007/BF00439452; RAPPAPORT WD, 1990, J TRAUMA, V30, P1518, DOI 10.1097/00005373-199012000-00014; Ridella S A, 1986, Cent Nerv Syst Trauma, V3, P195; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; SCHUCKIT MA, 1991, NEUROPSYCHOPHARMACOL, V4, P157; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; STEWART JR, 1989, ACCIDENT ANAL PREV, V21, P575, DOI 10.1016/0001-4575(89)90071-7; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; TIKELLIS JI, 1986, AM SURGEON, V52, P53; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Vinson D C, 1995, Arch Fam Med, V4, P505, DOI 10.1001/archfami.4.6.505; WALLER JA, 1988, J TRAUMA, V28, P1632, DOI 10.1097/00005373-198812000-00003; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WALLER PF, 1989, P AM ASS AUTOMOTIVE, V33, P1; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Warren RA, 1981, P AM ASS AUTOMOTIVE, V28, P133; WECHSLER H, 1969, PUBLIC HEALTH REP, V84, P1043, DOI 10.2307/4593753; WINEK CL, 1984, FORENSIC SCI INT, V25, P159, DOI 10.1016/0379-0738(84)90189-0; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	74	102	103	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1997	42	3					562	569		10.1097/00005373-199703000-00032			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	WR152	WOS:A1997WR15200052	9095132				2021-06-18	
J	Kreutzer, JS; Marwitz, JH; Seel, R; Serio, CD				Kreutzer, JS; Marwitz, JH; Seel, R; Serio, CD			Validation of a neurobehavioral functioning inventory for adults with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							BLUNT HEAD-INJURY; RATING-SCALE; RELATIVES; PERFORMANCE; RECOVERY; PATIENT; TESTS	Objective: To examine the validity of a neurobehavioral inventory for adults with traumatic brain injury. Design: Construct validity was examined by applying principal components and confirmatory factor analytic procedures. internal consistency of factors was examined using Cronbach's alpha. Criterion-related validity was examined by comparing inventory scale scores with neuropsychological and personality test variables. Setting: Medical center outpatient clinic. Participants: 520 consecutive adult patients with traumatic brain injury were administered psychological and neuropsychological tests; 520 informants, primarily family members, completed the neurobehavioral inventory. Main Outcome Measure: Neurobehavioral inventory with items describing symptoms and daily living problems; scale scores were compared with a set of neuropsychological measures and Minnesota Multiphasic Personality Inventory scores. Results: Principal components and confirmatory factor analytic procedures identified six scales with a total of 70 items. The primary scale inclusion criterion required a minimum factor loading of .40. Chronbach's alpha analysis revealed acceptably high internal reliability for all scales ranging from .86 to .95. Scale scores were statistically compared with patients' scores on neuropsychological and personality tests. Poor neuropsychological test performance and greater levels of psychopathology were associated with greater frequency of perceived neurobehavioral problems. Conclusions: Findings suggest that the neurobehavioral inventory is a promising means of investigating informants' perceptions of outpatients' everyday problems. Such information can serve as a complement to historical information, test results, and information from standardized interviews to develop a holistic perspective of patients. Differential weighting of items, association of scales with other measures, and validation with other neurological patient populations are recommended avenues for future research. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation .		Kreutzer, JS (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, MCV BOX 980542, RICHMOND, VA 23298 USA.						ACKER MB, 1986, CLIN NEUROPSYCHOL IN, P85; Anastasi A., 1988, PSYCHOL TESTING; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; BECKER ME, 1993, BRAIN INJURY, V7, P515, DOI 10.3109/02699059309008179; Bentler P.M., 1992, EQS STRUCTURAL EQUAT; BLACK FW, 1975, PERCEPT MOTOR SKILL, V40, P87, DOI 10.2466/pms.1975.40.1.87; Bollen K.A., 1993, TESTING STRUCTURAL E; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BURKE J M, 1990, Brain Injury, V4, P223, DOI 10.3109/02699059009026171; Byrne B.M., 1994, STRUCTURAL EQUATION; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CHARTRAND JM, 1990, J COUNS PSYCHOL, V37, P491, DOI 10.1037/0022-0167.37.4.491; COLE DA, 1987, J CONSULT CLIN PSYCH, V55, P584, DOI 10.1037/0022-006X.55.4.584; COMREY AL, 1957, EDUC PSYCHOL MEAS, V17, P586, DOI 10.1177/001316445701700413; Dahlstrom W. G., 1972, MMPI HDB, V1; EAMES P, 1990, REHABILITATION ADULT, P410; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; FASSINGER RE, 1987, J COUNS PSYCHOL, V34, P425, DOI 10.1037/0022-0167.34.4.425; GILEWSKI MJ, 1986, HDB CLIN MEMORY ASSE, P93, DOI DOI 10.1037/10057-008; Graham J.R., 1987, MMPI PRACTICAL GUIDE, V2nd Ed.; GREENE RL, 1991, MMPI2MMPI INTERPRETI; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HARTLAGE LC, 1987, ESSENTIALS NEUROPSYC; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HOYLE RH, 1991, J CONSULT CLIN PSYCH, V59, P67, DOI 10.1037/0022-006X.59.1.67; KASZNIAK AW, 1986, CLIN MEMORY ASSESSME, P271; KAY T, 1988, J HEAD TRAUMA REHAB, V3, P65; KAY T, 1988, ADMINISTRATION MANUA; KEPPEL G, 1991, DESIGN ANAL RESEARCH; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KREUTZER JS, 1987, GENERAL HLTH HIST QU; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; KREUTZER JS, 1991, COGNITIVE REHABILITA, P55; LARZELERE RE, 1977, PSYCHOL BULL, V84, P557, DOI 10.1037/0033-2909.84.3.557; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; LEZAK MD, 1994, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Lynch W. J., 1990, REHABILITATION ADULT, P310; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; NROUSIS MJ, 1993, SPSS WINDOWS BASE SY; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Prigatano G. P., 1991, AWARENESS DEFICIT BR; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REISBERG B, 1986, HDB CLIN MEMORY ASSE, P108; Reitan RM., 1985, HALSTEAD REITAN NEUR; RYAN JJ, 1992, PSYCHOL ASSESSMENT, V4, P63; SILVER JM, 1994, J HEAD TRAUMA REHAB, V9, P61, DOI 10.1097/00001199-199409000-00006; Spreen O., 1991, COMPENDIUM NEUROPSYC; Tabachnick B.G., 1989, USING MULTIVARIATE S; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; WOOTEN AJ, 1983, J CLIN PSYCHOL, V39, P392, DOI 10.1002/1097-4679(198305)39:3<392::AID-JCLP2270390313>3.0.CO;2-H; 1985, STANDARDS ED PSYCHOL	67	102	105	0	19	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1996	77	2					116	124		10.1016/S0003-9993(96)90155-0			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TU541	WOS:A1996TU54100002	8607734				2021-06-18	
J	Maddocks, D; Saling, M				Maddocks, D; Saling, M			Neuropsychological deficits following concussion	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; MILD CONCUSSION	The term 'concussion' has been applied to head injuries of varying severity. Most studies have examined subjects suffering concussion of a severity requiring hospital observation, usually as a consequence of motor vehicle accidents. Milder concussive injuries such as those resulting from contact sport are often not reported in hospital-based studies. In this study, subjects with mild concussive injuries were studied with the aim of determining ifneuropsychological sequelae are detectable. The subjects received their injuries while playing Australian Rules Football. Baseline (pre-injury) measures on the Paced Auditory Serial Addition Test (PASAT), Digit Symbol Substitution Test (DSST) and Four-Choice Reaction time, involving measures of decision time (DT) and movement time (MT), were obtained in a sample of 130 players. Ten players subsequently concussed were re-tested at 5 days post-injury. A control group of age-matched umpires were assessed on two corresponding occasions. Analyses of covariance showed poorer performances following concussion on the DSST and DT measures. The results suggested that neuropsychological deficits are detectable after resolution of neurological symptoms in the early stages following mild concussive injury.	TRANSPORT ACCID COMMISS,REHABIL CTR,GLEN WAVERLEY,VIC,AUSTRALIA	Maddocks, D (corresponding author), UNIV MELBOURNE,DEPT PSYCHOL,SCH BEHAV SCI,PARKVILLE,VIC 3052,AUSTRALIA.						Barth JT., 1989, MILD HEAD INJURY, P257; Dicker G, 1986, Aust Fam Physician, V15, P455; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MADDOCKS D, 1988, ATHLETE MAXIMISING P, P235; MERRITT H, 1959, TXB NEUROLOGY; ROWLAND L, 1984, MERRITTS TXB NEUROLO, P281; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; 1966, CLIN NEUROSURG, V12, P386	15	102	102	0	10	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1996	10	2					99	103		10.1080/026990596124584			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UB726	WOS:A1996UB72600003	8696320				2021-06-18	
J	Levin, HS; Fletcher, JM; Kufera, JA; Harward, H; Lilly, MA; Mendelsohn, D; Bruce, D; Eisenberg, HM				Levin, HS; Fletcher, JM; Kufera, JA; Harward, H; Lilly, MA; Mendelsohn, D; Bruce, D; Eisenberg, HM			Dimensions of cognition measured by the Tower of London and other cognitive tasks in head-injured children and adolescents	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							LESIONS	To determine the factor structure of executive functioning in head-injured (n = 81) and normal children (n = 102), we administered tests of concept formation and problem solving, plus planning, verbal fluency, design fluency, memory (to evaluate semantic organization), and response modulation using a Go/No-Go task. The children who sustained closed head injury (CHI) were divided into subgroups who sustained severe (n = 39) and mild/moderate (n = 42) injury. The CHI groups and normal controls were also grouped according to age at the time of testing (6-8, 9-12, and 13-16). The principal components analysis disclosed a five-factor solution that accounted for 79% of the variance: Conceptual-Productivity (Factor 1), Planning (Factor 2), Schema (Factor 3), Cluster (Factor 4), and Inhibition (Factor 5). Age had a significant effect on Factors 1, 2, and 5, whereas severity of CHI affected Factors 1, 2, 4, and 5. Using hierarchial regression in which the Glasgow Coma Scale score, age, and their interaction were entered first, the volume of frontal lobe lesion contributed significantly to predicting Factors 1 (Conceptual-Productivity) and 2 (Planning), whereas the volume of left frontal lesions also predicted Factor 3 (Schema). The volume of extrafrontal lesions augmented the prediction of Factor 3, supporting the general relation of left hemisphere abnormality to the cognitive variables loading on this factor. Pending replication in a different sample of head-injured children, caution is advised in interpreting the findings due to potential instability of the factor structure.	UNIV TEXAS, SCH MED, DEPT PEDIAT, AUSTIN, TX USA; UNIV MARYLAND MED SYST, DIV NEUROSURG, COLLEGE PK, MD 20742 USA; UNIV TEXAS, MED BRANCH, DIV NEUROSURG, GALVESTON, TX 77550 USA; UNIV TEXAS, SW MED SCH, DEPT RADIOL, DALLAS, TX USA; UNIV TEXAS, SW MED SCH, DEPT NEUROSURG, DALLAS, TX USA	Levin, HS (corresponding author), BAYLOR COLL MED, COGNIT NEUROSCI LAB, A-205, 1333 MOURSUND, HOUSTON, TX 77030 USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019				BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; DELIS D, 1986, CALIFORNIA VERBAL LE; DENNEY DR, 1973, DEV PSYCHOL, V9, P275, DOI 10.1037/h0035092; DREWE E A, 1975, Cortex, V11, P8; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R., 1993, WISCONSIN CARD SORTI; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; PEENNINGTON BF, 1994, FUTURE ORIENTED PROC, P243; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; TEASDALE G, 1974, LANCET, V2, P81	16	102	102	1	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		1996	12	1					17	34		10.1080/87565649609540638			18	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	UM970	WOS:A1996UM97000003					2021-06-18	
J	KACZOROWSKI, SL; SCHIDING, JK; TOTH, CA; KOCHANEK, PM				KACZOROWSKI, SL; SCHIDING, JK; TOTH, CA; KOCHANEK, PM			EFFECT OF SOLUBLE COMPLEMENT RECEPTOR-1 ON NEUTROPHIL ACCUMULATION AFTER TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BRAIN; COMPLEMENT; NEUTROPHIL; RAT; TRAUMA	INFLAMMATION; TISSUE; TYPE-1; REPERFUSION; LEUKOCYTES; SYSTEM; ASSAY	As part of the acute inflammatory response, neutrophils accumulate in the central nervous system after injury. Recently, a soluble human recombinant complement receptor (sCR1; BRL 55730; T Cell Sciences, Inc., Cambridge, MA, U.S.A.) has been developed that inhibits the activation of both the classical and the alternative pathways of complement. sCR1 attenuates the effects of the acute inflammatory response in several models of injury outside the central nervous system. The role of complement in traumatic brain injury, however, remains undefined. We hypothesized that treatment with sCR1 would attenuate neutrophil accumulation in the brain after cerebral trauma. Using a randomized, blinded protocol, 18 anesthetized Sprague-Dawley rats were pretreated with sCR1 or saline (control) at both 2 h and 2 min before trauma (weight drop) to the exposed right parietal cortex. A third dose of sCR1 (or saline) was given 6 h after trauma. Coronal brain sections centered on the site of trauma were obtained at 24 h after trauma and analyzed for myeloperoxidase (MPO) activity as a marker of neutrophil accumulation. Complete blood counts with differential were obtained before treatment with sCR1 and at 24 h after trauma. At 24 h after trauma, brain MPO activity was reduced by 41% in sCR1-treated rats compared with control rats [0.1599 +/- 0.102 versus 0.2712 +/- 0.178 U/g (mean +/- SD); p = 0.02]. The neutrophil count in peripheral blood increased approximately twofold in both groups. Neutrophil accumulation occurring in the brain after trauma is inhibited by sCR1 treatment. This suggests that complement activation is involved in the local inflammatory response to traumatic brain injury and plays an important role in neutrophil accumulation in the injured brain.	UNIV PITTSBURGH,SCH MED,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261; T CELL SCI INC,CAMBRIDGE,MA			Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X			BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BECKER P, 1987, ANAESTHESIST, V36, P301; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CHOPP M, 1993, STROKE, V25, P869; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DAVIES CL, 1984, J TRAUMA, V24, P99, DOI 10.1097/00005373-198402000-00002; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; FEARON D T, 1991, Clinical and Experimental Immunology, V86, P43; FRIEDL HP, 1989, AM J PATHOL, V135, P203; GALLINARO R, 1992, SURG GYNECOL OBSTET, V174, P435; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HILL J, 1992, J IMMUNOL, V149, P1723; HORNER HC, 1992, SOC NEUR ABSTR, V8, P173; KATORI M, 1989, JPN J PHARMACOL, V50, P234, DOI 10.1254/jjp.50.234; MULLIGAN MS, 1992, J IMMUNOL, V148, P1479; NILSSON UR, 1967, J EXP MED, V125, P1, DOI 10.1084/jem.125.1.1; PASNINETTI GM, 1992, EXP NEUROL, V188, P117; REBHUN J, 1991, ANN ALLERGY, V66, P335; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; TUOMANEN E, 1986, MICROB PATHOGENESIS, V1, P15, DOI 10.1016/0882-4010(86)90028-8; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WILLIAMS CA, 1984, J NEUROIMMUNOL, V9, P29; YEH CG, 1991, J IMMUNOL, V146, P250	25	102	103	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	1995	15	5					860	864		10.1038/jcbfm.1995.107			5	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	RQ020	WOS:A1995RQ02000016	7673379	Bronze			2021-06-18	
J	DAWSON, DR; CHIPMAN, M				DAWSON, DR; CHIPMAN, M			THE DISABLEMENT EXPERIENCED BY TRAUMATICALLY BRAIN-INJURED ADULTS LIVING IN THE COMMUNITY	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; IMPAIRMENT; RECOVERY; DISABILITY; CONCUSSION; SKILLS; LONG	The disablement that occurs following traumatic brain injury (TBI) can be extensive and severe and consequently has been difficult to report on in a comprehensive and thorough manner. We were able to address this difficulty by analysing a sub group of data from the Canadian Health and Activity Limitation Survey (HALS) using the theoretical framework of disablement developed by the World Health Organization, the International Classification of Impairment, Disability and Handicap (ICIDH). There were 454 survey respondents (representing 12290 in the Canadian population) with disability resulting from a TBI and a mean time post-injury of 13 years. Three handicaps identified in the ICIDH were the focus of the study: physical independence, work, social integration. The prevalence of long term handicap was very high with 66% of the sample reporting the need for ongoing assistance with some activities of daily living, 75% not working, and 90% reporting some limitations or dissatisfaction with their social integration. Multivariate regression analysis was used to investigate the determinants of the handicaps. The determinants included: age, gender, level of education, living alone, physical environment, and specific disabilities. The implications of these findings are discussed in relation to rehabilitation issues, the usefulness of the ICIDH as a model to investigate outcomes, and directions for future research.	SUNNYBROOK HLTH SCI CTR,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA	DAWSON, DR (corresponding author), UNIV TORONTO,DEPT OCCUPAT THERAPY,256 MCCAUL ST,TORONTO,ON M5T 1W5,CANADA.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121			[Anonymous], 1980, INT CLASSIFICATION I; Asberg K H, 1988, Scand J Caring Sci, V2, P171; Badley E M, 1987, Int Disabil Stud, V9, P122; Badley E M, 1990, Int Disabil Stud, V12, P47; BERROL S, 1989, TRAUMATIC BRAIN INJU, V2, P31; Bryden J, 1989, MODELS BRAIN INJURY, P17; DAWSON DR, 1993, THESIS U TORONTO; DEATON A, 1993, BRAIN INJURY, V2, P99; DOLSON D, 1987, SUURVEY METHODOLOGY, V13, P93; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; FURRIE A, 1989, HLTH ACTIVITY LIMITA; Granger C V, 1985, Int Rehabil Med, V7, P45; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; HAFFEY W, 1989, MODELS BRAIN INJURY, P205; HAHN H, 1985, SOC SCI J, V22, P87; HERBERT R, 1988, AGE AGEING, V17, P293; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JOHNSON R, 1987, INJURY, V18, P7, DOI 10.1016/0020-1383(87)90374-3; JOHNSTON MV, 1991, AM J PHYS MED REHAB, V70, pS114; KAY T, 1986, MINOR HEAD INJURY IN; KLEIN RM, 1982, ARCH PHYS MED REHAB, V63, P335; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LAVIGNE M, 1991, 82615 MIN SUPPL SERV, V4; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MAHONEY F I, 1965, Md State Med J, V14, P61; MAURETTE P, 1992, J TRAUMA, V33, P728, DOI 10.1097/00005373-199211000-00023; MCDOWELL I, 1988, HLTH ADTIVITY LIMITA; Mckinnon A.L., 1992, CANADIAN J OCCUPATIO, DOI [10.1177/000841749205900206, DOI 10.1177/000841749205900206]; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PANIKOFF LB, 1983, AM J OCCUP THER, V37, P735, DOI 10.5014/ajot.37.11.735; PARKINSON D, 1985, CAN J SURG, V28, P79; POPE AM, 1991, DISABILITY AM, P309; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; 1989, UNPUB INTERAGENCY HE; 1991, SERVICES PROGRAMS AL; 1988, HLTH ACTIVITY LIMITA	52	102	102	0	8	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1995	9	4					339	353		10.3109/02699059509005774			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QY080	WOS:A1995QY08000002	7640680				2021-06-18	
J	DEKOSKY, ST; GOSS, JR; MILLER, PD; STYREN, SD; KOCHANEK, PM; MARION, D				DEKOSKY, ST; GOSS, JR; MILLER, PD; STYREN, SD; KOCHANEK, PM; MARION, D			UP-REGULATION OF NERVE GROWTH-FACTOR FOLLOWING CORTICAL TRAUMA	EXPERIMENTAL NEUROLOGY			English	Article							ADULT-RAT BRAIN; MESSENGER-RNA; HEAD-INJURY; CHOLINERGIC NEURONS; NEUROTROPHIC FACTOR; ASTROCYTE CULTURES; ASTROGLIAL CELLS; SYSTEM TRAUMA; INTERLEUKIN-1; EXPRESSION	As part of the inflammatory response to brain injury, CSF and tissue levels of interleukin-1 beta (IL-1 beta) are elevated after trauma. This elevation in IL-1 beta initiates a cascade of events among which may be an upregulation in nerve growth factor (NGF) in brain tissue. We infused IL-1 beta into the ventricle of adult rats and found a two- to fourfold increase in NGF in the cerebral cortex, hippocampus, and cerebellum, suggesting that IL-1 beta induced in vivo may also increase NGF in the brain. To test this hypothesis we utilized two models of traumatic brain injury (TBI) in the rat and examined NGF protein and RNA in the cortex over a period of several days. Both weight drop and controlled cortical contusion models of CNS trauma demonstrated large and significant increases in NGF protein in the cortex. NGF RNA was assessed in the controlled cortical contusion model and increased approximately fivefold by 1 day post-trauma. The remarkable elevation of NGF observed following TBI suggests that its role in response to injury may be other than as a target derived growth substance. We hypothesize that the elevation of NGF in trauma induces upregulation of enzymes which suppress free-radical formation after injury. (C) 1994 Academic Press, Inc.	UNIV PITTSBURGH,SCH MED,DEPT NEUROL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT NEUROBIOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT ANESTHESIOL,PITTSBURGH,PA 15261; WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA	DEKOSKY, ST (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,PITTSBURGH,PA, USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		BAKHIT C, 1991, BRAIN RES, V560, P76, DOI 10.1016/0006-8993(91)91217-O; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DREYFUS CF, 1989, TRENDS PHARMACOL SCI, V10, P145, DOI 10.1016/0165-6147(89)90166-1; FAN L, 1993, SOC NEUR ABSTR, V19; FARRAR WL, 1987, J IMMUNOL, V139, P459; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; GIULIAN D, 1988, J NEUROSCI, V8, P709; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HEFTI F, 1986, J NEUROSCI, V6, P2155; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; Lindholm D, 1990, Neuroreport, V1, P9; LINDSAY RM, 1982, BRAIN RES, V243, P329, DOI 10.1016/0006-8993(82)90257-8; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LOREZ H, 1989, NEUROSCI LETT, V98, P339, DOI 10.1016/0304-3940(89)90425-4; LOREZ HP, 1988, BRAIN RES, V454, P355, DOI 10.1016/0006-8993(88)90837-2; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; TAKAO T, 1990, NEUR ABSTR, V16, P1213; TIMMUSK T, 1992, SOC NEUR ABSTR, V18; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WETMORE C, 1992, SOC NEUR ABSTR, V18; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	45	102	106	1	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	1994	130	2					173	177		10.1006/exnr.1994.1196			5	Neurosciences	Neurosciences & Neurology	QJ162	WOS:A1994QJ16200001	7867748				2021-06-18	
J	JORGE, RE; ROBINSON, RG; ARNDT, SV; FORRESTER, AW; GEISLER, F; STARKSTEIN, SE				JORGE, RE; ROBINSON, RG; ARNDT, SV; FORRESTER, AW; GEISLER, F; STARKSTEIN, SE			COMPARISON BETWEEN ACUTE-ONSET AND DELAYED-ONSET DEPRESSION FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							SEVERE HEAD-INJURY; RELATIVES	Sixty-six patients admitted for the treatment of acute closed head injury were assessed for the presence of mood disorders during the in-hospital period and at 3-, 6-, and 12-month follow-ups. Diagnosis was made using a structured psychiatric interview and DSM-III criteria. A total of 28 patients had major depression at some time during the study: 17 had acute-onset depression and 11 had delayed-onset depression. Acute-onset depressions are related to lesion location and may have their etiology in biological responses of the injured brain, whereas delayed depressions may be mediated by psychosocial factors, suggesting psychological reaction as a possible mechanism.	UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; UNIV MARYLAND,DIV NEUROSURG,DEPT SURG,MARYLAND INST EMERGENCY MED SERV SYST,CTR SHOCK TRAUMA,BALTIMORE,MD 21201; INST NEUROL INVEST DR RAUL CARREA,DEPT BEHAV NEUROL,BUENOS AIRES,ARGENTINA			Robinson, Robert/AAF-6191-2021; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH00163, MH40355] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS151178] Funding Source: Medline		CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; JORGE R, IN PRESS J AFFECTIVE; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; RUTHERFORD WH, 1977, LANCET, V1, P1; Sartorius N, 1974, MEASUREMENT CLASSIFI; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; TEASDALE G, 1974, LANCET, V2, P81; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397	22	102	104	0	4	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1993	5	1					43	49					7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	KK041	WOS:A1993KK04100007	8428134				2021-06-18	
J	PANTER, SS; FADEN, AI				PANTER, SS; FADEN, AI			PRETREATMENT WITH NMDA ANTAGONISTS LIMITS RELEASE OF EXCITATORY AMINO-ACIDS FOLLOWING TRAUMATIC BRAIN INJURY	NEUROSCIENCE LETTERS			English	Article						CGS-19755; DEXTRORPHAN; EXTRACELLULAR EXCITATORY AMINO ACID; HIPPOCAMPUS; MICRODIALYSIS; N-METHYL-D-ASPARTATE ANTAGONIST; TRAUMATIC BRAIN INJURY	SPINAL-CORD INJURY; CEREBRAL-ISCHEMIA; INTRACEREBRAL MICRODIALYSIS; RECEPTOR ANTAGONIST; ASPARTATE; GLUTAMATE; RAT; CGS-19755	After central nervous system (CNS) trauma, there are marked elevations in the extracellular levels of excitatory amino acids (EAA), which are believed to contribute to delayed tissue damage. Administration of N-methyl-D-aspartate (NMDA) receptor antagonists reduces injury severity after brain or spinal cord trauma, presumably by blocking the postsynaptic NMDA receptor. In the present studies, levels of extracellular amino acids were monitored by microdialysis during, and after, a moderately severe fluid-percussion brain injury to rats. Pretreatment (15 min prior to injury) with the non-competitive NMDA antagonist dextrorphan or the competitive NMDA antagonist CGS 19755 significantly attenuated the post-traumatic increase in extracellular glutamate. Pretreatment with dextrorphan attenuated the post-traumatic increase in extracellular levels of aspartate; although these differences did not reach significance when examined as absolute values, they were significant when analyzed as percent increase over pre-trauma baseline levels. These results are consistent with recent experiments and suggest that NMDA antagonists may limit the release of glutamate and aspartate after trauma through a presynaptic mechanism.	LETTERMAN ARMY INST RES,DIV BLOOD RES,SAN FRANCISCO,CA 94129; GEORGETOWN UNIV,SCH MED,DEPT NEUROL & PHARMACOL,WASHINGTON,DC 20007					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [SR01NS27849-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; CRAWFORD D, 1989, SOC NEUR ABSTR, V15, P358; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; GROTTA JC, 1990, ANN NEUROL, V27, P612, DOI 10.1002/ana.410270605; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; LEHMANN J, 1988, J PHARMACOL EXP THER, V246, P65; LOBNER D, 1989, Society for Neuroscience Abstracts, V15, P358; MCBEAN GJ, 1981, NATURE, V291, P593, DOI 10.1038/291593a0; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MORIMOTO BH, 1990, P NATL ACAD SCI USA, V87, P3518, DOI 10.1073/pnas.87.9.3518; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANTER SS, 1990, ANN NEUROL, V28, P594, DOI 10.1002/ana.410280431; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; SIMON R, 1990, ANN NEUROL, V27, P606, DOI 10.1002/ana.410270604; SNEDECOR GW, 1980, STATISTICAL METHODS, P333; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	24	102	103	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAR 2	1992	136	2					165	168		10.1016/0304-3940(92)90040-E			4	Neurosciences	Neurosciences & Neurology	HG894	WOS:A1992HG89400008	1353624				2021-06-18	
J	NEWTON, MR; GREENWOOD, RJ; BRITTON, KE; CHARLESWORTH, M; NIMMON, CC; CARROLL, MJ; DOLKE, G				NEWTON, MR; GREENWOOD, RJ; BRITTON, KE; CHARLESWORTH, M; NIMMON, CC; CARROLL, MJ; DOLKE, G			A STUDY COMPARING SPECT WITH CT AND MRI AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CEREBRAL BLOOD-FLOW; TRAUMA	After closed head injury nineteen patients had single photon emission tomography (SPECT) using the lipophilic tracer 99m-Technetium hexamethyl-propylene-amineoxime (HMPAO) to compare the defects shown by CT and MRI. SPECT showed more focal cerebral lesions than either CT or MRI alone or in combination. Most lesions shown by SPECT were not shown by CT or MRI in the corresponding anatomical regions. The most severely disabled patients showed the highest number of SPECT lesions (average four per patient) and the lowest (mean, SE) cerebral blood flow (718, 69 ml/min) compared with the less disabled patients (two per patient and 1058, 51 ml/min, p < 0.05). There was a correlation between the Glasgow Outcome Scale grade and the global cerebral blood flow (r 0.74, p < 0.05). The perfusion defects may correlate with clinical signs that were not explained by CT or MRI findings. SPECT may complement the clinical evaluation in the assessment of outcome after head injury.	HOMERTON HOSP,REG NEUROL REHABIL UNIT,HOMERTON ROW,LONDON E9 6SR,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT NUCL MED,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT NEURORADIOL,LONDON EC1A 7BE,ENGLAND							ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; BRITTON KE, 1985, NUCL MED COMMUN, V6, P251, DOI 10.1097/00006231-198505000-00002; COSTA D C, 1987, Nuclear Medicine Communications, V8, P573; COSTA DC, 1986, NUCL MED COMMUN, V7, P647; ELL PJ, 1985, LANCET, V2, P50; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; NIMMON CC, 1985, 1983 P INT S MEAS CE, P214; NIMMON CC, 1986, NEUROLOGIJA, V35, P161; PODREKA I, 1987, Nuclear Medicine Communications, V8, P559	14	102	102	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	1992	55	2					92	94		10.1136/jnnp.55.2.92			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	HD380	WOS:A1992HD38000002	1538233	Bronze, Green Published			2021-06-18	
J	Stocchetti, N; Carbonara, M; Citerio, G; Ercole, A; Skrifvars, MB; Smielewski, P; Zoerle, T; Menon, DK				Stocchetti, Nino; Carbonara, Marco; Citerio, Giuseppe; Ercole, Ari; Skrifvars, Markus B.; Smielewski, Peter; Zoerle, Tommaso; Menon, David K.			Severe traumatic brain injury: targeted management in the intensive care unit	LANCET NEUROLOGY			English	Article							CEREBRAL PERFUSION-PRESSURE; GLASGOW COMA SCALE; WAKE-UP TEST; INTRACRANIAL-PRESSURE; TISSUE OXYGEN; DECOMPRESSIVE CRANIECTOMY; METABOLIC CRISIS; OLDER-ADULTS; HEAD-INJURY; NEUROLOGICAL DETERIORATION	Severe traumatic brain injury (TBI) is currently managed in the intensive care unit with a combined medical-surgical approach. Treatment aims to prevent additional brain damage and to optimise conditions for brain recovery. TBI is typically considered and treated as one pathological entity, although in fact it is a syndrome comprising a range of lesions that can require different therapies and physiological goals. Owing to advances in monitoring and imaging, there is now the potential to identify specific mechanisms of brain damage and to better target treatment to individuals or subsets of patients. Targeted treatment is especially relevant for elderly people-who now represent an increasing proportion of patients with TBI-as preinjury comorbidities and their therapies demand tailored management strategies. Progress in monitoring and in understanding pathophysiological mechanisms of TBI could change current management in the intensive care unit, enabling targeted interventions that could ultimately improve outcomes.	[Stocchetti, Nino; Carbonara, Marco; Zoerle, Tommaso] Fdn IRCCS CaGranda, Osped Maggiore Policlin, Dept Anaesthesia & Crit Care, Neurosci Intens Care Unit, I-20133 Milan, Italy; [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, Milan, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] San Gerardo Hosp, Neurointens Care, ASST, Monza, Italy; [Ercole, Ari; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Skrifvars, Markus B.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Skrifvars, Markus B.] Univ Helsinki, Helsinki, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Div Intens Care, Dept Anaesthesiol Intens Care & Pain Med, Helsinki, Finland; [Smielewski, Peter] Univ Cambridge, Brain Phys Lab, Dept Clin Neurosci, Div Neurosurg, Cambridge, England	Stocchetti, N (corresponding author), Fdn IRCCS CaGranda, Osped Maggiore Policlin, Dept Anaesthesia & Crit Care, Neurosci Intens Care Unit, I-20133 Milan, Italy.	nino.stocchetti@policlinico.mi.it	Ercole, Ari/B-6288-2009; Carbonara, Marco/N-3793-2015; Citerio, Giuseppe/B-1839-2015; Stocchetti, Nino/O-7444-2017	Ercole, Ari/0000-0001-8350-8093; Carbonara, Marco/0000-0002-1431-8322; Citerio, Giuseppe/0000-0002-5374-3161; Stocchetti, Nino/0000-0003-3250-6834; Zoerle, Tommaso/0000-0001-8713-8085; Smielewski, Peter/0000-0001-5096-3938	Helsinki University, Finland; Finska Lakaresallskapet; Svenska Kulturfonden; Stiftelsen for Perklens Minne; European UnionEuropean Commission; National Institute for Healthcare Research, UK; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish	MBS reports grants from Helsinki University, Finland, Finska Lakaresallskapet, Svenska Kulturfonden, and Stiftelsen for Perklens Minne during the preparation of this review. DKM reports grants from the European Union (FP7 grant for the CENTER-TBI study) and support from the National Institute for Healthcare Research, UK, during the preparation of this review.	Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Aries MJH, 2016, CRIT CARE MED, V44, pE996, DOI 10.1097/CCM.0000000000001816; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Bauer DF, 2011, NEUROSURGERY, V69, P255, DOI 10.1227/NEU.0b013e31821a45ba; Bragge P, 2016, J NEUROTRAUM, V33, P1461, DOI 10.1089/neu.2015.4233; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; Centers for Disease Control and Prevention, 2016, TBI DAT STAT; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Couret D, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1239-z; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; Depreitere B, 2012, Acta Neurochir Suppl, V114, P289, DOI 10.1007/978-3-7091-0956-4_56; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Flechet M, 2016, CURR OPIN CRIT CARE, V22, P87, DOI 10.1097/MCC.0000000000000287; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x; Gaist D, 2017, JAMA-J AM MED ASSOC, V317, P836, DOI 10.1001/jama.2017.0639; Gillespie LD, 2012, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD007146; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Helbok R, 2012, CRIT CARE, V16, DOI 10.1186/cc11880; Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226; Hollis S, 2006, J TRAUMA, V61, P1255, DOI 10.1097/01.ta.0000243889.07090.da; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Iaccarino C, 2014, J NEUROSURG, V120, P908, DOI 10.3171/2013.12.JNS131090; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kehoe A, 2016, EMERG MED J, V33, P381, DOI 10.1136/emermed-2015-205180; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kirkman MA, 2013, J NEUROTRAUM, V30, P1385, DOI 10.1089/neu.2013.2881; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Larson MD, 2015, ANESTH ANALG, V120, P1242, DOI 10.1213/ANE.0000000000000314; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Magnoni S, 2015, BRAIN, V138, P2263, DOI 10.1093/brain/awv152; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mathias JL, 2015, NEUROSCI BIOBEHAV R, V55, P573, DOI 10.1016/j.neubiorev.2015.06.001; McAllister Thomas W, 2015, Handb Clin Neurol, V128, P723, DOI 10.1016/B978-0-444-63521-1.00045-5; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Miley Jefferson T, 2008, J Vasc Interv Neurol, V1, P79; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Mrozek S, 2014, CRIT CARE, V18, DOI 10.1186/cc13841; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nangunoori R, 2012, NEUROCRIT CARE, V17, P131, DOI 10.1007/s12028-011-9621-9; National Institute of Neurological Disorders and Stroke (NINDS), 2017, COMM DAT EL TRAUM BA; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nordstrom CH, 2016, ACTA NEUROCHIR, V158, P1231, DOI 10.1007/s00701-016-2835-z; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; O'Leary R, 2016, NEW ENGL J MED, V374, P1383, DOI 10.1056/NEJMc1600339; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Peck KA, 2014, J TRAUMA ACUTE CARE, V76, P431, DOI 10.1097/TA.0000000000000107; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Prins ML, 2014, J LIPID RES, V55, P2450, DOI 10.1194/jlr.R046706; Quintard H, 2016, J NEUROTRAUM, V33, P681, DOI 10.1089/neu.2015.4057; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROPPER AH, 1991, ARCH NEUROL-CHICAGO, V48, P1166, DOI 10.1001/archneur.1991.00530230074025; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Sinclair HL, 2010, CRIT CARE, V14, DOI 10.1186/cc8220; Skoglund K, 2014, NEUROCRIT CARE, V20, P413, DOI 10.1007/s12028-013-9876-4; Skoglund K, 2012, CRIT CARE MED, V40, P216, DOI 10.1097/CCM.0b013e31822d7dbd; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; Stocchetti N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0887-8; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brand CL, 2017, J NEUROTRAUM, V34, P1, DOI 10.1089/neu.2015.4393; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Veenith TV, 2014, J CEREBR BLOOD F MET, V34, P1622, DOI 10.1038/jcbfm.2014.123; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2016, ANN NEUROL, V79, P579, DOI 10.1002/ana.24606; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wijayatilake DS, 2015, J NEUROSURG ANESTH, V27, P241, DOI 10.1097/ANA.0000000000000143; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; World Health Organization, GLOB HLT OBS DAT LIF; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	120	101	111	3	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2017	16	6					452	464		10.1016/S1474-4422(17)30118-7			13	Clinical Neurology	Neurosciences & Neurology	EU1WD	WOS:000400815800012	28504109	Green Published			2021-06-18	
J	Schallner, N; Pandit, R; LeBlanc, R; Thomas, AJ; Ogilvy, CS; Zuckerbraun, BS; Gallo, D; Otterbein, LE; Hanafy, KA				Schallner, Nils; Pandit, Rambhau; LeBlanc, Robert, III; Thomas, Ajith J.; Ogilvy, Christopher S.; Zuckerbraun, Brian S.; Gallo, David; Otterbein, Leo E.; Hanafy, Khalid A.			Microglia regulate blood clearance in subarachnoid hemorrhage by heme oxygenase-1	JOURNAL OF CLINICAL INVESTIGATION			English	Article							TRAUMATIC BRAIN-INJURY; FRACTALKINE RECEPTOR CX(3)CR1; CARBON-MONOXIDE PROTECTS; RAT-BRAIN; OXIDATIVE STRESS; LUNG INJURY; PHARMACOLOGICAL INDUCTION; INTRACEREBRAL HEMORRHAGE; INFLAMMATORY RESPONSE; PROVIDES PROTECTION	Subarachnoid hemorrhage (SAH) carries a 50% mortality rate. The extravasated erythrocytes that surround the brain contain heme, which, when released from damaged red blood cells, functions as a potent danger molecule that induces sterile tissue injury and organ dysfunction. Free heme is metabolized by heme oxygenase (HO), resulting in the generation of carbon monoxide (CO), a bioactive gas with potent immunomodulatory capabilities. Here, using a murine model of SAH, we demonstrated that expression of the inducible HO isoform (HO-1, encoded by Hmox1) in microglia is necessary to attenuate neuronal cell death, vasospasm, impaired cognitive function, and clearance of cerebral blood burden. Initiation of CO inhalation after SAH rescued the absence of microglial HO-land reduced injury by enhancing erythrophagocytosis. Evaluation of correlative human data revealed that patients with SAH have markedly higher HO-1 activity in cerebrospinal fluid (CSF) compared with that in patients with unruptured cerebral aneurysms. Furthermore, cisternal hematoma volume correlated with HO-1 activity and cytokine expression in the CSF of these patients. Collectively, we found that microglial HO-1 and the generation of CO are essential for effective elimination of blood and heme after SAH that otherwise leads to neuronal injury and cognitive dysfunction. Administration of CO may have potential as a therapeutic modality in patients with ruptured cerebral aneurysms.	[Schallner, Nils; Thomas, Ajith J.; Ogilvy, Christopher S.; Gallo, David; Otterbein, Leo E.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02140 USA; [Schallner, Nils] Univ Med Ctr Freiburg, Dept Anesthesiol & Intens Care Med, Freiburg, Germany; [Pandit, Rambhau; LeBlanc, Robert, III; Hanafy, Khalid A.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02140 USA; [Zuckerbraun, Brian S.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA; [Otterbein, Leo E.] Aston Univ, Birmingham B4 7ET, W Midlands, England	Hanafy, KA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Neurointens Care Med,Neurol, 3 Blackfan Circle, Boston, MA 02140 USA.	khanafy@bidmc.harvard.edu	Thomas, Ajith/AAX-9054-2020	Thomas, Ajith/0000-0003-4412-3152	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL076167, R01HL071797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM082830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS078048] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000566] Funding Source: NIH RePORTER; VAUS Department of Veterans Affairs [1I01BX000566-01] Funding Source: Federal RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-071797, HL-076167, R01 HL076167, R01 HL071797] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM082830] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS078048, K08NS078048] Funding Source: Medline; BLRD VA [I01 BX000566] Funding Source: Medline		Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Almeida AS, 2012, J BIOL CHEM, V287, P10761, DOI 10.1074/jbc.M111.306738; Basuroy S, 2006, AM J PHYSIOL-CELL PH, V291, pC897, DOI 10.1152/ajpcell.00032.2006; Beck K, 2010, CIRC RES, V107, P1490, DOI 10.1161/CIRCRESAHA.110.231985; Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P3784, DOI 10.1167/iovs.09-4894; Boscia F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006486; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643; Collinson EJ, 2011, J BIOL CHEM, V286, P2205, DOI 10.1074/jbc.M110.187062; D'Amico G, 2006, J CELL SCI, V119, P2291, DOI 10.1242/jcs.02914; Dallas ML, 2011, FASEB J, V25, P1519, DOI 10.1096/fj.10-173450; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Foresti R, 2013, PHARMACOL RES, V76, P132, DOI 10.1016/j.phrs.2013.07.010; Foussat A, 2000, EUR J IMMUNOL, V30, P87, DOI 10.1002/1521-4141(200001)30:1<87::AID-IMMU87>3.3.CO;2-Z; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Goebel U, 2008, ANESTHESIOLOGY, V108, P1025, DOI 10.1097/ALN.0b013e3181733115; Hanafy KA, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-83; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; HIJDRA A, 1986, NEUROLOGY, V36, P329, DOI 10.1212/WNL.36.3.329; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; King JT, 1997, NEUROIMAG CLIN N AM, V7, P659; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Kuroki M, 1998, STROKE, V29, P683, DOI 10.1161/01.STR.29.3.683; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Lin QS, 2008, FREE RADICAL BIO MED, V44, P847, DOI 10.1016/j.freeradbiomed.2007.11.012; Liu YQ, 2013, NEUROREPORT, V24, P281, DOI 10.1097/WNR.0b013e32835f2810; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Montero M, 2009, BRAIN RES, V1291, P140, DOI 10.1016/j.brainres.2009.06.097; Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228; Nakaso K, 2000, NEUROSCI LETT, V293, P49, DOI 10.1016/S0304-3940(00)01491-9; Ogawa T, 2011, J CEREBR BLOOD F MET, V31, P2231, DOI 10.1038/jcbfm.2011.87; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422; Parada E, 2013, ANTIOXID REDOX SIGN, V19, P1135, DOI 10.1089/ars.2012.4671; Rincon F, 2013, NEUROSURGERY, V73, P217, DOI 10.1227/01.neu.0000430290.93304.33; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Saleem S, 2008, STROKE, V39, P3389, DOI 10.1161/STROKEAHA.108.523480; Shimada Y, 2009, EUR J PHARMACOL, V620, P16, DOI 10.1016/j.ejphar.2009.08.009; Smith A, 2013, CLIN CHIM ACTA, V424, P231, DOI 10.1016/j.cca.2013.06.017; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; Soulet D, 2008, CURR OPIN PHARMACOL, V8, P508, DOI 10.1016/j.coph.2008.04.002; Sun MH, 2010, INVEST OPHTH VIS SCI, V51, P4798, DOI 10.1167/iovs.09-4086; Sutherland BA, 2009, NEUROSCI RES, V65, P326, DOI 10.1016/j.neures.2009.08.007; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; Tayem Y, 2014, PHARMACOL RES, V81, P1, DOI 10.1016/j.phrs.2014.01.001; Tong N, 2000, J IMMUNOL, V164, P1333, DOI 10.4049/jimmunol.164.3.1333; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Vergouwen MDI, 2011, STROKE, V42, P924, DOI 10.1161/STROKEAHA.110.597914; Vieira HLA, 2008, J NEUROCHEM, V107, P375, DOI 10.1111/j.1471-4159.2008.05610.x; Vinet J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-27; Wang HQ, 2012, NEUROTOX RES, V21, P368, DOI 10.1007/s12640-011-9292-5; Wegiel B, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.97; Wegiel B, 2014, ANTIOXID REDOX SIGN, V20, P1709, DOI 10.1089/ars.2013.5667; Wu LY, 2005, PHARMACOL REV, V57, P585, DOI 10.1124/pr.57.4.3; Yabluchanskiy A, 2012, CRIT CARE MED, V40, P544, DOI 10.1097/CCM.0b013e31822f0d64; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; Zeynalov E, 2009, NEUROTOX RES, V15, P133, DOI 10.1007/s12640-009-9014-4; Zhang F, 2012, STROKE, V43, P1390, DOI 10.1161/STROKEAHA.111.647420; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003	75	101	106	1	8	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	JUL	2015	125	7					2609	2625		10.1172/JCI78443			17	Medicine, Research & Experimental	Research & Experimental Medicine	CM3AK	WOS:000357553300011	26011640	Green Published, Green Accepted			2021-06-18	
J	Tapia, NM; Chang, A; Norman, M; Welsh, F; Scott, B; Wall, MJ; Mattox, KL; Suliburk, J				Tapia, Nicole M.; Chang, Alex; Norman, Michael; Welsh, Francis; Scott, Bradford; Wall, Matthew J., Jr.; Mattox, Kenneth L.; Suliburk, James			TEG-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penetrating trauma patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Thromboelastogram; massive transfusion protocol; penetrating trauma	FRESH-FROZEN PLASMA; BLOOD-PRODUCT RATIOS; IMPROVED SURVIVAL; CELL RATIOS; THROMBELASTOGRAPHY; THROMBOELASTOGRAPHY; COAGULOPATHY; PLATELET; OUTCOMES; IMPACT	BACKGROUND: For nearly a decade, our center performed thromboelastograms (TEGs) to analyze coagulation profiles, allowing rapid data-driven blood component therapy. After consensus recommendations for massive transfusion protocols (MTPs), we implemented an MTP in October 2009 with 1:1:1 ratio of blood (red blood cells [RBC]), plasma (fresh-frozen plasma [FFP]), and platelets. We hypothesized that TEG-directed resuscitation is equivalent to MTP resuscitation. METHODS: All patients receiving 6 units (U) or more of RBC in the first 24 hours for 21 months before and after MTP initiation in an urban Level I trauma center were examined. Demographics, mechanism of injury (MOI), Injury Severity Score (ISS), 24-hour volume of RBC, FFP, platelets, crystalloid, and 30-day mortality were compared, excluding patients with traumatic brain injuries. Variables were analyzed using Student's t-test and chi(2) or Fisher's exact test. RESULTS: For the preMTP group, there were 165 patients. In the MTP group, there were 124 patients. There were no significant differences in ISS, age, or sex. PreMTP patients with 6U or more RBC had significantly more penetrating MOI (p = 0.017), whereas preMTP patients with 10U or more RBC had similar MOIs. All patients received less crystalloid after MTP adoption (p G 0.001). There was no difference in volume of blood products or mortality in patients receiving 6U or more RBC. Blunt trauma MTP patients who received 10U or more RBC received more FFP (p = 0.02), with no change in mortality. Penetrating trauma patients who received 10U or more RBC received a similar volume of FFP; however, mortality increased from 54.1% for MTP versus 33.3% preMTP (p = 0.04). CONCLUSION: TEG-directed resuscitation is equivalent to standardizedMTP for patients receiving 6U or more RBC and for bluntMOI patients receiving 10UormoreRBC. MTP therapyworsenedmortality in penetratingMOI patients receiving 10UormoreRBC, indicating a continued need for TEG-directed therapy. A 1:1:1 strategy may not be adequate in all patients. (J Trauma Acute Care Surg. 2013;74: 378-386. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Tapia, Nicole M.; Chang, Alex; Norman, Michael; Welsh, Francis; Scott, Bradford; Wall, Matthew J., Jr.; Mattox, Kenneth L.; Suliburk, James] Baylor Coll Med, Houston, TX 77030 USA	Tapia, NM (corresponding author), 1 Baylor Plaza,Suite 404D, Houston, TX 77030 USA.	nmtapia@bcm.edu		Suliburk, James/0000-0002-6421-269X			Alam HB, 2009, J TRAUMA, V67, P856, DOI 10.1097/TA.0b013e3181b5ae75; BEAL RW, 1976, AUST NZ J SURG, V46, P309; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Carroll RC, 2009, TRANSL RES, V154, P34, DOI 10.1016/j.trsl.2009.04.001; Cinat ME, 1999, ARCH SURG-CHICAGO, V134, P964, DOI 10.1001/archsurg.134.9.964; Cothren CC, 2007, WORLD J SURG, V31, P1507, DOI 10.1007/s00268-007-9087-2; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; Davenport R, 2011, J TRAUMA, V70, P90, DOI 10.1097/TA.0b013e318202e486; DAVIS CL, 1995, J AM SOC NEPHROL, V6, P1250; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Floccard B, 2012, INJURY, V43, P26, DOI 10.1016/j.injury.2010.11.003; Frith D, 2012, CURR OPIN ANESTHESIO, V25, P229, DOI 10.1097/ACO.0b013e3283509675; Gunter OL, 2008, J TRAUMA, V65, P527, DOI 10.1097/TA.0b013e3181826ddf; Hansen Mads Koch, 2006, Ugeskr Laeger, V168, P3535; Hess JR, 2003, TRANSFUSION, V43, P1622, DOI 10.1046/j.1537-2995.2003.00576.x; Hodgetts T J, 2007, J R Army Med Corps, V153, P299; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Inaba K, 2012, TEG TRAUM CRIT CAR A; Inaba K, 2010, J AM COLL SURGEONS, V211, P573, DOI 10.1016/j.jamcollsurg.2010.06.392; Jeger V, 2011, EMERG MED INT, V2011, DOI 10.1155/2011/895674; Kashuk JL, 2008, J TRAUMA, V65, P261, DOI 10.1097/TA.0b013e31817de3e1; Kashuk JL, 2012, TRANSFUSION, V52, P23, DOI 10.1111/j.1537-2995.2011.03264.x; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; Lucas CE, 2012, J TRAUMA ACUTE CARE, V72, P821, DOI 10.1097/TA.0b013e3182484111; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Martini WZ, 2008, J TRAUMA, V65, P535, DOI 10.1097/TA.0b013e31818379a6; Miller BE, 1997, ANESTH ANALG, V85, P1196, DOI 10.1097/00000539-199712000-00003; OWEN CA, 1987, MAYO CLIN PROC, V62, P761, DOI 10.1016/S0025-6196(12)62328-3; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Plotkin AJ, 2008, J TRAUMA, V64, pS64, DOI 10.1097/TA.0b013e318160772d; Repine TB, 2006, J TRAUMA, V60, pS59, DOI 10.1097/01.ta.0000219013.64168.b2; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Shore-Lesserson L, 1999, ANESTH ANALG, V88, P312, DOI 10.1097/00000539-199902000-00016; Sisak K, 2012, ANZ J SURG, V82, P161, DOI 10.1111/j.1445-2197.2011.05967.x; Spoerke N, 2011, J TRAUMA, V71, pS380, DOI 10.1097/TA.0b013e318227f1c5; Tieu BH, 2007, WORLD J SURG, V31, P1055, DOI 10.1007/s00268-006-0653-9; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; WILSON RF, 1971, J TRAUM, V11, P275, DOI 10.1097/00005373-197104000-00001; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	40	101	104	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					378	385		10.1097/TA.0b013e31827e20e0			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	108UH	WOS:000316321200009	23354228				2021-06-18	
J	Woo, SK; Kwon, MS; Ivanov, A; Gerzanich, V; Simard, JM				Woo, Seung Kyoon; Kwon, Min Seong; Ivanov, Alexander; Gerzanich, Volodymyr; Simard, J. Marc			The Sulfonylurea Receptor 1 (Sur1)-Transient Receptor Potential Melastatin 4 (Trpm4) Channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; K-ATP CHANNELS; SENSITIVE POTASSIUM CHANNELS; SPINAL-CORD-INJURY; ADULT-RAT BRAIN; REACTIVE ASTROCYTES; CELLS; SUR1; STOICHIOMETRY; TRAFFICKING	The sulfonylurea receptor 1 (Sur1)-NCCa-ATP channel plays a central role in necrotic cell death in central nervous system (CNS) injury, including ischemic stroke, and traumatic brain and spinal cord injury. Here, we show that Sur1-NCCa-ATP channels are formed by co-assembly of Sur1 and transient receptor potential melastatin 4 (Trpm4). Co-expression of Sur1 and Trpm4 yielded Sur1-Trpm4 heteromers, as shown in experiments with Forster resonance energy transfer (FRET) and co-immunoprecipitation. Co-expression of Sur1 and Trpm4 also yielded functional Sur1-Trpm4 channels with biophysical properties of Trpm4 and pharmacological properties of Sur1. Co-assembly with Sur1 doubled the affinity of Trpm4 for calmodulin and doubled its sensitivity to intracellular calcium. Experiments with FRET and co-immunoprecipitation showed de novo appearance of Sur1-Trpm4 heteromers after spinal cord injury in rats. Our findings depart from the long-held view of an exclusive association between Sur1 and K-ATP channels and reveal an unexpected molecular partnership with far-ranging implications for CNS injury.	[Woo, Seung Kyoon; Kwon, Min Seong; Ivanov, Alexander; Gerzanich, Volodymyr; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Simard, JM (corresponding author), Univ Maryland, Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS060801, NS061808, HL082517, NS061934, NS072501]; Department of Veterans Affairs (Baltimore, MD)US Department of Veterans Affairs; Department of the Army [W81XWH 1010898]; Christopher and Dana Reeve Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072501, R01NS061808, R01NS061934, R01NS060801] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grants NS060801 and NS061808 (NINDS) and HL082517 (NHLBI) (to J. M. S.) and NS061934 and NS072501 (NINDS) (to V. G.). This work was also supported by grants from the Department of Veterans Affairs (Baltimore, MD), the Department of the Army (Grant W81XWH 1010898), and the Christopher and Dana Reeve Foundation (to J. M. S.). J. M. S. holds a United States patent (Number 7,285,574), "A novel non-selective cation channel in neural cells and methods for treating brain swelling." J. M. S. is a member of the scientific advisory board and holds shares in Remedy Pharmaceuticals. No support, direct or indirect, was provided to J. M. S., or for this project, by Remedy Pharmaceuticals.	Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227; Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Bryan J, 2007, PFLUG ARCH EUR J PHY, V453, P703, DOI 10.1007/s00424-006-0116-z; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2002, J BIOL CHEM, V277, P25416, DOI 10.1074/jbc.M203109200; Demion M, 2007, CARDIOVASC RES, V73, P531, DOI 10.1016/j.cardiores.2006.11.023; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; GILLIS KD, 1989, AM J PHYSIOL, V257, pC1119; Guinamard R, 2011, ADV EXP MED BIOL, V704, P147, DOI 10.1007/978-94-007-0265-3_8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Hyun YM, 2009, J IMMUNOL, V183, P359, DOI 10.4049/jimmunol.0803388; Konig P, 2006, LAB INVEST, V86, P853, DOI 10.1038/labinvest.3700443; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liu H, 2010, CIRC-CARDIOVASC GENE, V3, P374, DOI 10.1161/CIRCGENETICS.109.930867; Meissner M, 2011, TRP CHANNELS, P135; Mikhailov MV, 2001, FEBS LETT, V499, P154, DOI 10.1016/S0014-5793(01)02538-8; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; Nilius B, 2005, J BIOL CHEM, V280, P6423, DOI 10.1074/jbc.M411089200; Sala-Rabanal M, 2012, J BIOL CHEM, V287, P8746, DOI 10.1074/jbc.M111.336131; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2012, PFLUG ARCH EUR J PHY, V464, P573, DOI 10.1007/s00424-012-1166-z; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Song MY, 2010, ADV EXP MED BIOL, V661, P99, DOI 10.1007/978-1-60761-500-2_6; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Vennekens R., 2007, V179, P269; Vila-Carriles WH, 2007, FASEB J, V21, P18, DOI 10.1096/fj.06-6730hyp; Winkler M, 2009, J BIOL CHEM, V284, P6752, DOI 10.1074/jbc.M805435200; Yoshida H, 2004, J MOL CELL CARDIOL, V37, P857, DOI 10.1016/j.yjmcc.2004.05.022; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	38	101	105	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 1	2013	288	5					3655	3667		10.1074/jbc.M112.428219			13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	082NE	WOS:000314397900069	23255597	Green Published, Other Gold			2021-06-18	
J	Mayes, SD; Gorman, AA; Hillwig-Garcia, J; Syed, E				Mayes, Susan Dickerson; Gorman, Angela A.; Hillwig-Garcia, Jolene; Syed, Ehsan			Suicide ideation and attempts in children with autism	RESEARCH IN AUTISM SPECTRUM DISORDERS			English	Article						Autism; Suicide ideation; Suicide attempts	DEFIANT DISORDER DIFFERENCES; TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; ASPERGER-SYNDROME; PROCESSING SPEED; GENDER-DIFFERENCES; SPECTRUM DISORDER; ADHD SUBTYPES; RISK-FACTORS; WISC-III	Frequency of suicide ideation and attempts in 791 children with autism (1-16 years), 35 nonautistic depressed children, and 186 typical children and risk factors in autism were determined. Percent of children with autism for whom suicide ideation or attempts was rated as sometimes to very often a problem by mothers (14%) was 28 times greater than that for typical children (0.5%) but less than for depressed children (43%). For children with autism, four demographic variables (age 10 or older, Black or Hispanic, lower SES, and male) were significant risk factors of suicide ideation or attempts. The majority of children (71%) who had all four demographic risk factors had ideation or attempts. Comorbid psychological problems most highly predictive of ideation or attempts were depression, behavior problems, and teased. Almost half of children with these problems had suicide ideation or attempts. All children with autism should be screened for suicide ideation or attempts because ideation and attempts in autism are significantly higher than the norm and are present across the spectrum. This is especially important for children who have the demographic and comorbid risk factors, many of which can be targeted for intervention to reduce and prevent suicide ideation and attempts. (C) 2012 Elsevier Ltd. All rights reserved.	[Mayes, Susan Dickerson; Gorman, Angela A.; Hillwig-Garcia, Jolene; Syed, Ehsan] Penn State Coll Med, Dept Psychiat, Hershey, PA USA	Mayes, SD (corresponding author), Hershey Med Ctr, Dept Psychiat H073, 500 Univ Dr, Hershey, PA 17033 USA.	smayes@psu.edu					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bae Sejong, 2005, Arch Suicide Res, V9, P193, DOI 10.1080/13811110590904034; Bellini S., 2004, FOCUS AUTISM DEV DIS, V19, P78, DOI DOI 10.1177/10883576040190020201; Bixler EO, 2009, SLEEP, V32, P731, DOI 10.1093/sleep/32.6.731; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Brereton AV, 2006, J AUTISM DEV DISORD, V36, P863, DOI 10.1007/s10803-006-0125-y; Calhoun SL, 2005, PSYCHOL SCHOOLS, V42, P333, DOI 10.1002/pits.20067; Centers for Disease Control, 2012, SUIC PREV; Cui S, 2011, CHILD CARE HLTH DEV, V37, P692, DOI 10.1111/j.1365-2214.2010.01181.x; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; Epstein JA, 2010, ARCH SUICIDE RES, V14, P193, DOI 10.1080/13811118.2010.494130; Fleming TM, 2007, AUST NZ J PSYCHIAT, V41, P213, DOI 10.1080/00048670601050481; Gadow KD, 2005, AUTISM, V9, P392, DOI 10.1177/1362361305056079; Gadow KD, 2008, J AUTISM DEV DISORD, V38, P1710, DOI 10.1007/s10803-008-0556-8; Gadow KD, 2012, J AUTISM DEV DISORD, V42, P1353, DOI 10.1007/s10803-011-1367-x; Gould MS, 1998, J AM ACAD CHILD PSY, V37, P915, DOI 10.1097/00004583-199809000-00011; Green J, 2000, J AUTISM DEV DISORD, V30, P279, DOI 10.1023/A:1005523232106; Greening L, 2010, J YOUTH ADOLESCENCE, V39, P357, DOI 10.1007/s10964-009-9459-z; Gutierrez Peter M, 2005, Arch Suicide Res, V9, P177, DOI 10.1080/13811110590904025; Guttmann-Steinmetz S, 2009, J AUTISM DEV DISORD, V39, P976, DOI 10.1007/s10803-009-0706-7; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; Hetrick SE, 2012, CRISIS, V33, P13, DOI 10.1027/0227-5910/a000095; Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899; Hurtig T, 2009, AUTISM, V13, P583, DOI 10.1177/1362361309335719; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Karch Debra L., 2009, Morbidity and Mortality Weekly Report, V58, P1; Kim J.A., 2000, AUTISM INT J RES PRA, V4, P117, DOI DOI 10.1177/1362361300004002002; Kim Young Shin, 2008, Int J Adolesc Med Health, V20, P133; Kim YS, 2009, ARCH SUICIDE RES, V13, P15, DOI 10.1080/13811110802572098; Kim YS, 2005, PEDIATRICS, V115, P357, DOI 10.1542/peds.2004-0902; Kirchner T, 2011, ACTAS ESP PSIQUIATRI, V39, P226; Klomek AB, 2007, J AM ACAD CHILD PSY, V46, P40, DOI 10.1097/01.chi.0000242237.84925.18; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Lindgren S. D., 1987, ADV BEHAV ASSESSMENT, P57; MANJIVIONA J, 1995, J AUTISM DEV DISORD, V25, P23, DOI 10.1007/BF02178165; Mann J John, 2007, Arch Suicide Res, V11, P3, DOI 10.1080/13811110600993124; Matson JL, 2007, RES DEV DISABIL, V28, P341, DOI 10.1016/j.ridd.2005.12.004; Mattison RE, 2012, J ATTEN DISORD, V16, P138, DOI 10.1177/1087054710380188; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Mayes S.D., 2012, CHECKLIST AUTISM SPE; Mayes SD, 2004, CLIN NEUROPSYCHOL, V18, P559, DOI 10.1080/13854040490888530; Mayes SD, 2004, J DEV PHYS DISABIL, V16, P257, DOI 10.1023/B:JODD.0000032301.07550.0e; Mayes SD, 2001, J ABNORM CHILD PSYCH, V29, P263, DOI 10.1023/A:1010337916636; Mayes SD, 1999, INFANT YOUNG CHILD, V12, P90, DOI 10.1097/00001163-199910000-00011; Mayes SD, 2003, J AUTISM DEV DISORD, V33, P329, DOI 10.1023/A:1024462719081; Mayes SD, 2008, J AUTISM DEV DISORD, V38, P428, DOI 10.1007/s10803-007-0410-4; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; Mayes SD, 2006, LEARN INDIVID DIFFER, V16, P145, DOI 10.1016/j.lindif.2005.07.004; Mayes SD, 2012, RES AUTISM SPECT DIS, V6, P277, DOI 10.1016/j.rasd.2011.05.009; Mayes SD, 2012, RES AUTISM SPECT DIS, V6, P1, DOI 10.1016/j.rasd.2011.08.001; Mayes SD, 2011, J DEV PHYS DISABIL, V23, P325, DOI 10.1007/s10882-011-9231-7; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P749, DOI 10.1016/j.rasd.2010.09.002; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P474, DOI 10.1016/j.rasd.2010.06.012; Mayes SD, 2009, J ATTEN DISORD, V12, P540, DOI 10.1177/1087054708320402; Mayes SD, 2009, J AUTISM DEV DISORD, V39, P1682, DOI 10.1007/s10803-009-0812-6; Mayes SD, 2009, SLEEP MED CLIN, V4, P19, DOI 10.1016/j.jsmc.2008.12.004; Mayes SD, 2009, RES AUTISM SPECT DIS, V3, P931, DOI 10.1016/j.rasd.2009.04.002; Mayes SD, 2009, J PEDIATR PSYCHOL, V34, P328, DOI 10.1093/jpepsy/jsn083; McKeown RE, 1998, J AM ACAD CHILD PSY, V37, P612, DOI 10.1097/00004583-199806000-00011; Mikami K, 2009, GEN HOSP PSYCHIAT, V31, P163, DOI 10.1016/j.genhosppsych.2008.12.003; Miller JN, 2000, J ABNORM PSYCHOL, V109, P227, DOI 10.1037/0021-843X.109.2.227; Miller JN, 1997, J CHILD PSYCHOL PSYC, V38, P247; Murphy O, 2009, RES AUTISM SPECT DIS, V3, P474, DOI 10.1016/j.rasd.2008.09.008; Murray MJ, 2011, J AUTISM DEV DISORD, V41, P1586, DOI 10.1007/s10803-011-1178-0; Nichols S, 2000, J PEDIATR PSYCHOL, V25, P545, DOI 10.1093/jpepsy/25.8.545; Ozonoff S., 2000, AUTISM, V4, P29, DOI [DOI 10.1177/1362361300041003, 10.1177/1362361300041003]; ROTHERAMBORUS MJ, 1990, J CONSULT CLIN PSYCH, V58, P554, DOI 10.1037/0022-006X.58.5.554; Russell E, 2005, AUST NZ J PSYCHIAT, V39, P633, DOI 10.1111/j.1440-1614.2005.01637.x; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; SZATMARI P, 1995, J AM ACAD CHILD PSY, V34, P1662, DOI 10.1097/00004583-199512000-00017; Tryon P. A., 2006, FOCUS AUTISM OTHER D, V21, P2, DOI [10.1177/10883576060210010101, DOI 10.1177/10883576060210010101]; Wannan G, 1998, J ADOLESCENCE, V21, P371, DOI 10.1006/jado.1998.0162; Wichstrom L, 2000, J AM ACAD CHILD PSY, V39, P603, DOI 10.1097/00004583-200005000-00014; WING L, 1981, PSYCHOL MED, V11, P115, DOI 10.1017/S0033291700053332; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501	77	101	102	3	57	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-9467	1878-0237		RES AUTISM SPECT DIS	Res. Autism Spectr. Disord.	JAN-MAR	2013	7	1					109	119		10.1016/j.rasd.2012.07.009			11	Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation	Education & Educational Research; Psychology; Psychiatry; Rehabilitation	044WN	WOS:000311656000013					2021-06-18	
J	Xu, F; Liu, PY; Pascual, JM; Xiao, GH; Lu, HZ				Xu, Feng; Liu, Peiying; Pascual, Juan M.; Xiao, Guanghua; Lu, Hanzhang			Effect of hypoxia and hyperoxia on cerebral blood flow, blood oxygenation, and oxidative metabolism	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral metabolic rate of oxygen; cerebral venous oxygenation; hyperoxia; hypoxia	CARBON-DIOXIDE; GLUCOSE-METABOLISM; PERFUSION MRI; BOLD; HYPERCAPNIA; CALIBRATION; SATURATION; VELOCITY; NEURONS; CORTEX	Characterizing the effect of oxygen (O-2) modulation on the brain may provide a better understanding of several clinically relevant problems, including acute mountain sickness and hyperoxic therapy in patients with traumatic brain injury or ischemia. Quantifying the O-2 effects on brain metabolism is also critical when using this physiologic maneuver to calibrate functional magnetic resonance imaging (fMRI) signals. Although intuitively crucial, the question of whether the brain's metabolic rate depends on the amount of O-2 available has not been addressed in detail previously. This can be largely attributed to the scarcity and complexity of measurement techniques. Recently, we have developed an MR method that provides a noninvasive (devoid of exogenous agents), rapid (<5 minutes), and reliable (coefficient of variant, Coy <3%) measurement of the global cerebral metabolic rate of O-2 (CMRO2). In the present study, we evaluated metabolic and vascular responses to manipulation of the fraction of inspired O-2 (FiO(2)). Hypoxia with 14% FiO(2) was found to increase both CMRO2 (5.0 +/- 2.0%, N=16, P=0.02) and cerebral blood flow (CBF) (9.8 +/- 2.3%, P<0.001). However, hyperoxia decreased CMRO2 by 10.3 +/- 1.5% (P<0.001) and 16.9 +/- 2.7% (P<0.001) for FiO(2) of 50% and 98%, respectively. The CBF showed minimal changes with hyperoxia. Our results suggest that modulation of inspired O-2 alters brain metabolism in a dose-dependent manner. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1909-1918; doi:10.1038/jcbfm.2012.93; published online 27 June 2012	[Xu, Feng; Liu, Peiying; Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Xiao, Guanghua] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; [Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA	Lu, HZ (corresponding author), Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hanzhang.lu@utsouthwestern.edu	Liu, Peiying/D-7512-2017; Xu, Feng/K-7760-2015	Liu, Peiying/0000-0003-0830-5960; Xu, Feng/0000-0001-7958-3787; Pascual, Juan/0000-0002-0843-8221	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH084021, R01 NS067015, R01 AG033106]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH084021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078656, R01NS067015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042753, R01AG033106, R21AG034318] Funding Source: NIH RePORTER	This work was supported, in part, by the National Institutes of Health (R01 MH084021, R01 NS067015, and R01 AG033106).	AYRES SM, 1964, J APPL PHYSIOL, V19, P43; Baddeley H, 2000, BRIT J RADIOL, V73, P1100, DOI 10.1259/bjr.73.874.11271904; Bakker CJG, 1999, JMRI-J MAGN RESON IM, V9, P119, DOI 10.1002/(SICI)1522-2586(199901)9:1<119::AID-JMRI16>3.0.CO;2-F; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Brutus NA, 2009, NEUROCHEM RES, V34, P1219, DOI 10.1007/s11064-008-9898-z; Bulte DP, 2007, J CEREBR BLOOD F MET, V27, P69, DOI 10.1038/sj.jcbfm.9600319; Chen Y, 2009, NEUROCHEM RES, V34, P1047, DOI 10.1007/s11064-008-9873-8; Chiarelli PA, 2007, NEUROIMAGE, V37, P808, DOI 10.1016/j.neuroimage.2007.05.033; Cohen ER, 2002, J CEREBR BLOOD F MET, V22, P1042, DOI 10.1097/00004647-200209000-00002; Dean JB, 2004, J APPL PHYSIOL, V96, P784, DOI 10.1152/japplphysiol.00892.2003; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; EVANS AJ, 1993, INVEST RADIOL, V28, P109, DOI 10.1097/00004424-199302000-00004; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Guyton AC, 2005, TXB MED PHYSL; HAMBERGER A, 1963, J CELL BIOL, V16, P521, DOI 10.1083/jcb.16.3.521; HARIK SI, 1995, J APPL PHYSIOL, V79, P136; Imray C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4943; JAMIESON D, 1986, ANNU REV PHYSIOL, V48, P703, DOI 10.1146/annurev.ph.48.030186.003415; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Kolbitsch C, 2002, MAGN RESON IMAGING, V20, P535, DOI 10.1016/S0730-725X(02)00534-9; Liu PY, 2013, MAGN RESON MED, V69, P675, DOI 10.1002/mrm.24295; LOEPPKY JA, 1983, RESP PHYSIOL, V51, P167; Lu HZ, 2008, MAGN RESON MED, V60, P357, DOI 10.1002/mrm.21627; Lu HZ, 2012, MAGN RESON MED, V67, P42, DOI 10.1002/mrm.22970; Maandag NJG, 2007, P NATL ACAD SCI USA, V104, P20546, DOI 10.1073/pnas.0709515104; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MINTUN MA, 1984, J NUCL MED, V25, P177; Moller K, 2002, J CEREBR BLOOD F MET, V22, P118, DOI 10.1097/00004647-200201000-00014; Mudduluru M, 2010, NEUROCHEM RES, V35, P1003, DOI 10.1007/s11064-010-0147-x; Nishimura N, 2007, AVIAT SPACE ENVIR MD, V78, P1121, DOI 10.3357/ASEM.2177.2007; Noth U, 2008, NMR BIOMED, V21, P464, DOI 10.1002/nbm.1210; Nofzinger EA, 2002, BRAIN, V125, P1105, DOI 10.1093/brain/awf103; Richards EM, 2007, STROKE, V38, P1578, DOI 10.1161/STROKEAHA.106.473967; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Sicard KM, 2005, NEUROIMAGE, V25, P850, DOI 10.1016/j.neuroimage.2004.12.010; Silvennoinen MJ, 2003, MAGNET RESON MED, V49, P568, DOI 10.1002/mrm.10370; Smith Z. M., 2011, P INT SOC MAGN RES M; STEIN PD, 1995, CHEST, V107, P139, DOI 10.1378/chest.107.1.139; Tatarkova Z, 2011, NEUROCHEM RES, V36, P1475, DOI 10.1007/s11064-011-0473-7; Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008; Tuunanen PI, 2006, NEUROIMAGE, V30, P102, DOI 10.1016/j.neuroimage.2005.09.021; Wise RG, 2007, J CEREBR BLOOD F MET, V27, P1521, DOI 10.1038/sj.jcbfm.9600465; Xu F, 2011, J CEREBR BLOOD F MET, V31, P58, DOI 10.1038/jcbfm.2010.153; Xu F, 2009, MAGN RESON MED, V62, P141, DOI 10.1002/mrm.21994; Yezhuvath US, 2009, NMR BIOMED, V22, P779, DOI 10.1002/nbm.1392; ZANANIRI FV, 1991, J MED ENG TECHNOL, V15, P170, DOI 10.3109/03091909109023704	48	101	103	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2012	32	10					1909	1918		10.1038/jcbfm.2012.93			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	014KY	WOS:000309375800009	22739621	Green Published, Bronze			2021-06-18	
J	Kimbler, DE; Shields, J; Yanasak, N; Vender, JR; Dhandapani, KM				Kimbler, Donald E.; Shields, Jessica; Yanasak, Nathan; Vender, John R.; Dhandapani, Krishnan M.			Activation of P2X7 Promotes Cerebral Edema and Neurological Injury after Traumatic Brain Injury in Mice	PLOS ONE			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; SEVERE HEAD-INJURY; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; ATP-INDUCED RELEASE; SPINAL-CORD-INJURY; CEREBROSPINAL-FLUID; INTRACRANIAL HYPERTENSION; COGNITIVE DYSFUNCTION; AQUAPORIN-4	Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Cerebral edema, the abnormal accumulation of fluid within the brain parenchyma, contributes to elevated intracranial pressure (ICP) and is a common life-threatening neurological complication following TBI. Unfortunately, neurosurgical approaches to alleviate increased ICP remain controversial and medical therapies are lacking due in part to the absence of viable drug targets. In the present study, genetic inhibition (P2X7-/- mice) of the purinergic P2x7 receptor attenuated the expression of the pro-inflammatory cytokine, interleukin-1 beta (IL-1 beta) and reduced cerebral edema following controlled cortical impact, as compared to wild-type mice. Similarly, brilliant blue G (BBG), a clinically non-toxic P2X7 inhibitor, inhibited IL-1 beta expression, limited edemic development, and improved neurobehavioral outcomes after TBI. The beneficial effects of BBG followed either prophylactic administration via the drinking water for one week prior to injury or via an intravenous bolus administration up to four hours after TBI, suggesting a clinically-implementable therapeutic window. Notably, P2X7 localized within astrocytic end feet and administration of BBG decreased the expression of glial fibrillary acidic protein (GFAP), a reactive astrocyte marker, and attenuated the expression of aquaporin-4 (AQP4), an astrocytic water channel that promotes cellular edema. Together, these data implicate P2X7 as a novel therapeutic target to prevent secondary neurological injury after TBI, a finding that warrants further investigation.	[Kimbler, Donald E.; Shields, Jessica; Vender, John R.; Dhandapani, Krishnan M.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA USA; [Yanasak, Nathan] Georgia Hlth Sci Univ, Dept Radiol, Augusta, GA USA	Kimbler, DE (corresponding author), Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA USA.	kdhandapani@georgiahealth.edu		Dhandapani, Krishnan/0000-0001-7044-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; TriServices Nursing Research Program [HU0001-10-1-TS11]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	Financial support for this study was provided by grants from the National Institutes of Health (NS065172) and from the TriServices Nursing Research Program (HU0001-10-1-TS11). The content and views expressed herein do not necessarily represent the views of the Department of Defense, the TriServices Nursing Research Program, Uniformed Services University of the Health Sciences, or the United States Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], **DROPPED REF**; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Basso AM, 2009, BEHAV BRAIN RES, V198, P83, DOI 10.1016/j.bbr.2008.10.018; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Dhandapani KM, 2003, J BIOL CHEM, V278, P43329, DOI 10.1074/jbc.M305835200; Dhandapani KM, 2003, ENDOCRINE, V21, P59, DOI 10.1385/ENDO:21:1:59; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jiang LH, 2000, MOL PHARMACOL, V58, P82; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawamata T, 2006, ACTA NEUROCHIR SUPPL, V96, P3; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kleinschmidt JJ, 2000, NEUROLOGY, V54, P319, DOI 10.1212/WNL.54.2.319; Koo JW, 2008, P NATL ACAD SCI USA, V105, P751, DOI 10.1073/pnas.0708092105; Koo JW, 2009, CURR OPIN INVEST DR, V10, P664; Koo JW, 2009, NEUROSCI LETT, V456, P39, DOI 10.1016/j.neulet.2009.03.068; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; Latini S, 1996, NEUROCHEM INT, V28, P113, DOI 10.1016/0197-0186(95)00062-D; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Lin HW, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-15; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Norman GJ, 2010, MOL PSYCHIATR, V15, P404, DOI 10.1038/mp.2009.91; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Oprica M, 2005, BRAIN BEHAV IMMUN, V19, P223, DOI 10.1016/j.bbi.2004.07.006; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Perregaux DG, 1998, J IMMUNOL, V160, P2469; Pillai A, 2007, NEUROPSYCHOPHARMACOL; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Savers S, 2000, J NEUROTRAUM, V17, P507; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Takenouchi T, 2009, CRIT REV IMMUNOL, V29, P335, DOI 10.1615/CritRevImmunol.v29.i4.40; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wheaton P., 2011, J PSYCHOPHARMACOL; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	76	101	104	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2012	7	7							e41229	10.1371/journal.pone.0041229			10	Multidisciplinary Sciences	Science & Technology - Other Topics	975JG	WOS:000306507000083	22815977	DOAJ Gold, Green Published			2021-06-18	
J	Wright, RM; Ramesh, KT				Wright, Rika M.; Ramesh, K. T.			An axonal strain injury criterion for traumatic brain injury	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Diffuse axonal injury; Traumatic brain injury; Injury criteria; Finite element model; Diffusion tensor imaging; Anisotropic model; TBI; DAI	FINITE-ELEMENT-ANALYSIS; DYNAMIC STRETCH INJURY; MECHANICAL-PROPERTIES; WHITE-MATTER; HEAD-INJURY; CONSTITUTIVE-EQUATIONS; MODEL; TISSUE; SHEAR; TOLERANCE	Computational models are often used as tools to study traumatic brain injury. The fidelity of such models depends on the incorporation of an appropriate level of structural detail, the accurate representation of the material behavior, and the use of an appropriate measure of injury. In this study, an axonal strain injury criterion is used to estimate the probability of diffuse axonal injury (DAI), which accounts for a large percentage of deaths due to brain trauma and is characterized by damage to neural axons in the deep white matter regions of the brain. We present an analytical and computational model that treats the white matter as an anisotropic, hyperelastic material. Diffusion tensor imaging is used to incorporate the structural orientation of the neural axons into the model. It is shown that the degree of injury that is predicted in a computational model of DAI is highly dependent on the incorporation of the axonal orientation information and the inclusion of anisotropy into the constitutive model for white matter.	[Wright, Rika M.; Ramesh, K. T.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA	Ramesh, KT (corresponding author), Johns Hopkins Univ, Dept Mech Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	rika@jhu.edu; ramesh@jhu.edu	Ramesh, KT/D-5451-2009	Ramesh, KT/0000-0003-2659-4698	National Science FoundationNational Science Foundation (NSF); Center for Advanced Metallic and Ceramic Systems; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41RR15241, R01AG020012]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR015241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020012] Funding Source: NIH RePORTER	We gratefully acknowledge Dr. Susumu Mori at the Johns Hopkins University School of Medicine for providing access to the diffusion tensor imaging data used in this study. This work is supported by a National Science Foundation Graduate Research Fellowship, the Center for Advanced Metallic and Ceramic Systems, and NIH grants P41RR15241 and R01AG020012.	Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F, 1994, 38 STAPP CAR CRASH C; Billiar KL, 2000, J BIOMECH ENG-T ASME, V122, P327, DOI 10.1115/1.1287158; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Bovendeerd PHM, 2002, STAPP CAR CRASH J, V46, P1; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; ESTES MS, 1970, P 4 ASME BIOM C; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Feist F, 2009, 21 INT C ENH SAF VEH, P1; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Freed AD, 2005, BIOMECH MODEL MECHAN, V4, P100, DOI 10.1007/s10237-005-0069-8; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Holzapfel G., 2000, NONLINEAR SOLID MECH; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hurschler C, 1997, J BIOMECH ENG-T ASME, V119, P392, DOI 10.1115/1.2798284; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; KUIJPERS AHWM, 1995, J NEUROTRAUM, V12, P715, DOI 10.1089/neu.1995.12.715; LANIR Y, 1983, J BIOMECH, V16, P1, DOI 10.1016/0021-9290(83)90041-6; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Mendis K., 1992, FINITE ELEMENT MODEL; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ommaya A, 1967, 11 P STAPP CAR CRASH, P47; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Spencer AJM, 1972, DEFORMATIONS FIBRE R; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Versace J, 1971, 15 STAPP CAR CRASH C; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang HC, 2010, J NEUROTRAUM, V27, P707, DOI 10.1089/neu.2009.1071; Watanabe D, 2009, J COMPUT SCI TECHNOL, V3, P252, DOI 10.1299/jcst.3.252; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yao JF, 2008, SAFETY SCI, V46, P1103, DOI 10.1016/j.ssci.2007.06.021; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1994, 38 STAPP CAR CRASH C, P1697; Zou H, 2008, INT J CRASHWORTHINES, V13, P337, DOI 10.1080/13588260801943047	66	101	104	0	23	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	JAN	2012	11	1-2					245	260		10.1007/s10237-011-0307-1			16	Biophysics; Engineering, Biomedical	Biophysics; Engineering	891QB	WOS:000300230600019	21476072				2021-06-18	
J	von Steinbuchel, N; Wilson, L; Gibbons, H; Hawthorne, G; Hofer, S; Schmidt, S; Bullinger, M; Maas, A; Neugebauer, E; Powell, J; von Wild, K; Zitnay, G; Bakx, W; Christensen, AL; Koskinen, S; Sarajuuri, J; Formisano, R; Sasse, N; Truelle, JL				von Steinbuechel, Nicole; Wilson, Lindsay; Gibbons, Henning; Hawthorne, Graeme; Hoefer, Stefan; Schmidt, Silke; Bullinger, Monika; Maas, Andrew; Neugebauer, Edmund; Powell, Jane; von Wild, Klaus; Zitnay, George; Bakx, Wilbert; Christensen, Anne-Lise; Koskinen, Sanna; Sarajuuri, Jaana; Formisano, Rita; Sasse, Nadine; Truelle, Jean-Luc		QOLIBRI Task Force	Quality of Life after Brain Injury (QOLIBRI): Scale Development and Metric Properties	JOURNAL OF NEUROTRAUMA			English	Article						multi-national study; outcome instrument; quality of life; traumatic brain injury	COMMUNITY INTEGRATION; MULTIPLE TRAUMA; HEALTH-STATUS; OUTCOMES; MODERATE; SF-36; REHABILITATION; QUESTIONNAIRE; SATISFACTION; INSTRUMENT	The consequences of traumatic brain injury (TBI) for health-related quality of life (HRQoL) are poorly investigated, and a TBI-specific instrument has not previously been available. The cross-cultural development of a new measure to assess HRQoL after TBI is described here. An international TBI Task Force derived a conceptual model from previous work, constructed an initial item bank of 148 items, and then reduced the item set through two successive multicenter validation studies. The first study, with eight language versions of the QOLIBRI, recruited 1528 participants with TBI, and the second with six language versions, recruited 921 participants. The data from 795 participants from the second study who had complete Glasgow Coma Scale (GCS) and Glasgow Outcome Scale (GOS) data were used to finalize the instrument. The final version of the QOLIBRI consists of 37 items in six scales (see Appendix). Satisfaction is assessed in the areas of "Cognition,'' "Self,'' "Daily Life and Autonomy,'' and "Social Relationships,'' and feeling bothered by "Emotions,'' and "Physical Problems.'' The QOLIBRI scales meet standard psychometric criteria (internal consistency, alpha = 0.75-0.89, test-retest reliability, r(tt) = 0.78-0.85). Test-retest reliability (r(tt) = 0.68-0.87) as well as internal consistency (alpha = 0.81-0.91) were also good in a subgroup of participants with lower cognitive performance. Although there is one strong HRQoL factor, a six-scale structure explaining additional variance was validated by exploratory and confirmatory factor analyses, and with Rasch modeling. The QOLIBRI is a new cross-culturally developed instrument for assessing HRQoL after TBI that fulfills standard psychometric criteria. It is potentially useful for clinicians and researchers conducting clinical trials, for assessing the impact of rehabilitation or other interventions, and for carrying out epidemiological surveys.	[von Steinbuechel, Nicole; Gibbons, Henning; Sasse, Nadine] Univ Gottingen, Dept Med Psychol & Med Sociol, Gottingen, Germany; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [Hawthorne, Graeme] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Psychiat, Melbourne, Vic, Australia; [Hoefer, Stefan] Med Univ Innsbruck, Dept Med Psychol, Innsbruck, Austria; [Schmidt, Silke] Ernst Moritz Arndt Univ Greifswald, Inst Psychol, Dept Hlth & Prevent, Greifswald, Germany; [Bullinger, Monika] Univ Hosp Eppendorf, Dept Med Psychol, Hamburg, Germany; [Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Neugebauer, Edmund] Private Univ Witten Herdecke, IFOM, Cologne, Germany; [Powell, Jane] Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; [von Wild, Klaus] Univ Munster, Fac Med, Munster, Germany; [Zitnay, George] Assoc Martha Jefferson Hosp, Charlottesville, VA USA; [Bakx, Wilbert] Maastricht Univ, Maastricht, Netherlands; [Bakx, Wilbert] Hoensbroeck Rehabil Ctr, Hoensbroeck, Netherlands; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Rehabil Brain Injury, Copenhagen, Denmark; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Cognit & Memory, Copenhagen, Denmark; [Koskinen, Sanna; Sarajuuri, Jaana] Kapyla Rehabil Ctr, Helsinki, Finland; [Formisano, Rita] Rehabil Hosp, IRCCS, Santa Lucia Fdn, Rome, Italy; [Truelle, Jean-Luc] CHU Raymond Poincare, Serv Med Phys & Readapt, Garches, France	von Steinbuchel, N (corresponding author), Univ Gottingen, Dept Med Psychol & Med Sociol, Waldweg 37, Gottingen, Germany.	nvsteinbuechel@med.uni-goettingen.de	Sarajuuri, Jaana/AAD-8665-2019; Wilson, Lindsay/A-3659-2009; Hofer, Stefan/B-8393-2008; Hofer, Stefan/N-8253-2019; Wilson, Lindsay/O-8883-2019; Maas, Andrew IR/C-5584-2013	Sarajuuri, Jaana/0000-0002-6432-0295; Wilson, Lindsay/0000-0003-4113-2328; Hofer, Stefan/0000-0002-6128-3687; Hofer, Stefan/0000-0002-6128-3687; Wilson, Lindsay/0000-0003-4113-2328; Maas, Andrew IR/0000-0003-1612-1264; Koskinen, Sanna/0000-0002-3453-5084			Acquadro C, 1996, QUALITY LIFE PHARMAC, P575; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; Bond T. G., 2007, APPL RASCH MODEL, V2nd; BRANDT J, 2003, TELEPHONE INTERVIEW; Brod M, 1999, GERONTOLOGIST, V39, P25, DOI 10.1093/geront/39.1.25; BULLINGER M, 1993, QUAL LIFE RES, V2, P451, DOI 10.1007/BF00422219; Bullinger M, 2001, CURR PROB E, V16, P277; Callahan CD, 2005, REHABIL PSYCHOL, V50, P65, DOI 10.1037/0090-5550.50.1.65; Cattelani R, 2008, EUR J PHYS REHAB MED, V44, P245; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CRUM RM, 1993, JAMA-J AM MED ASSOC, V12, P2386; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; English TC, 1904, LANCET, V1, P485; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FLEISS JL, 1986, CONTROL CLIN TRIALS, V7, P267, DOI 10.1016/0197-2456(86)90034-6; Folstein M, 1988, NEUROPSY NEUROPSY BE, V1, P111; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GERIN P, 1989, THERAPIE, V44, P355; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; Hawthorne G, 2006, QUAL LIFE RES, V15, P1257, DOI 10.1007/s11136-006-0062-4; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hays R, 1988, USERS GUIDE MULTITRA; HU LT, 1999, STRUCTURAL EQUATION, V1, P55; JENNETT B, 1975, LANCET, V1, P480; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mascialino G, 2009, NEUROREHABILITATION, V24, P29, DOI 10.3233/NRE-2009-0451; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Moosbrugger H., 2007, TESTTHEORIE FRAGEBOG; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Novella JL, 2001, AGING CLIN EXP RES, V13, P362, DOI 10.1007/BF03351504; Olsson I, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-46; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; PAPULAYAN KF, 2006, ARCH PHYS MED REHAB, V87, P611; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Power M, 2005, QUAL LIFE RES, V14, P2197, DOI 10.1007/s11136-005-7380-9; Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Riemsma R P, 2001, Health Technol Assess, V5, P1; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Schmidt S, 2006, J CLIN EPIDEMIOL, V59, P587, DOI 10.1016/j.jclinepi.2005.09.012; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Smith AB, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-33; Sopena S, 2007, BRAIN INJURY, V21, P1063, DOI 10.1080/02699050701630342; Stucki G, 1997, Z RHEUMATOL, V56, P266, DOI 10.1007/s003930050041; Tazopoulou E, 2005, ACTA NEUROPSYCHOL, V1, P13; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Truelle JL, 2008, ACTA NEUROCHIR SUPPL, V101, P125; von Steinbuchel Nicole, 2006, Eur J Ageing, V3, P116, DOI 10.1007/s10433-006-0024-2; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; VONSTEINBUCHEL N, 1995, PRAVENTION REHABILIT, V7, P39; VONSTEINBUCHEL N, 2002, STUDY PROTOCOL UNPUB; Ware J. E., 1996, SF 36 HLTH SURVEY VE; WARE JE, 1995, INT J TECHNOL ASSESS, V11, P525, DOI 10.1017/S0266462300008710; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Ware JE., 1993, SF 36 HLTH SURVEY MA; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wlodarczyk JH, 2004, ARCH GERONTOL GERIAT, V39, P25, DOI 10.1016/j.archger.2003.12.004; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599	78	101	101	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1167	1185		10.1089/neu.2009.1076			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100002	20486801	Green Accepted			2021-06-18	
J	Schwarzmaier, SM; Kim, SW; Trabold, R; Plesnila, N				Schwarzmaier, Susanne M.; Kim, Seong-Woong; Trabold, Raimund; Plesnila, Nikolaus			Temporal Profile of Thrombogenesis in the Cerebral Microcirculation after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; leukocytes; mice; microcirculation; microthrombi; platelets; traumatic brain injury	CONTROLLED CORTICAL IMPACT; LEUKOCYTE-ENDOTHELIUM INTERACTIONS; BLOOD-FLOW; INTRAVASCULAR COAGULATION; HEMODYNAMIC DEPRESSION; SECONDARY EXPANSION; THROMBUS FORMATION; RATS; ISCHEMIA; CONTUSION	Traumatic brain injury (TBI) is associated with an almost immediate reduction in cerebral blood flow (CBF). Because cerebral perfusion pressure is often normal under these circumstances it was hypothesized that the reduction of post-traumatic CBF has to occur at the level of the microcirculation. The aim of the current study was to investigate whether cerebral microvessels are involved in the development of blood flow disturbances following experimental TBI. C57/BL6 mice (n = 12) were intubated and ventilated under control of end-tidal PCO2 (ETPCO2). After preparation of a cranial window and baseline recordings, the animals were subjected to experimental TBI by controlled cortical impact (CCI; 6m/sec, 0.5 mm). Vessel lumina and intravascular cells were visualized by in vivo fluorescence microscopy (IVM) using the fluorescent dyes FITC-dextran and rhodamine 6G, respectively. Vessel diameter, cell-endothelial interactions, and thrombus formation were quantified within the traumatic penumbra by IVM up to 2 h after CCI. Arteriolar diameters increased after CCI by 26.2 +/- 2.5% (mean +/- SEM, p<0.01 versus baseline), and remained at this level until the end of the observation period. Rolling of leukocytes on the cerebrovascular endothelium was observed both in arterioles and venules, while leukocyte-platelet aggregates were found only in venules. Microthrombi occluded up to 70% of venules and 33% of arterioles. The current data suggest that the immediate post-traumatic decrease in peri-contusional blood flow is not caused by arteriolar vasoconstriction, but by platelet activation and the subsequent formation of thrombi in the cerebral microcirculation.	[Schwarzmaier, Susanne M.; Kim, Seong-Woong; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dublin 2, Ireland; [Schwarzmaier, Susanne M.; Kim, Seong-Woong; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Inst Surg Res, Walter Brendel Ctr Expt Med, D-8000 Munich, Germany; [Schwarzmaier, Susanne M.; Kim, Seong-Woong; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Dept Neurosurg, Univ Munich Med Ctr Grosshadern, Munich, Germany	Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, 123 St Stephens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Plesnila, Nikolaus/T-7522-2019				ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIETRICH WD, 1980, AM J PHYSIOL, V238, pH172; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Ishikawa M, 2009, NEUROSURGERY, V64, P546, DOI 10.1227/01.NEU.0000337579.05110.F4; Kataoka H, 2004, J CEREBR BLOOD F MET, V24, P668, DOI 10.1097/01.WCB.0000117812.35136.5B; KAWAMURA S, 1990, INT J MICROCIRC, V9, P369; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kontos H A, 1981, Trans Am Clin Climatol Assoc, V92, P111; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; LEHR HA, 1994, LAB INVEST, V71, P380; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; MA YP, 1974, MICROVASC RES, V8, P1, DOI 10.1016/0026-2862(74)90059-4; Maeda T, 1997, ACT NEUR S, V70, P102; Plesnila N, 2003, NEUROSCI LETT, V345, P85, DOI 10.1016/S0304-3940(03)00396-3; Rivera J, 2009, HAEMATOL-HEMATOL J, V94, P700, DOI 10.3324/haematol.2008.003178; ROSENBLUM WI, 1963, ARCH NEUROL-CHICAGO, V9, P414, DOI 10.1001/archneur.1963.00460100102012; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SEGAWA H, 1981, ARCH NEUROL-CHICAGO, V38, P265, DOI 10.1001/archneur.1981.00510050031002; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stein SC, 2009, J NEUROTRAUM, V26, P1585, DOI [10.1089/neu.2008.0720, 10.1089/neu.2008-0720]; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Uhl E, 2000, J CEREBR BLOOD F MET, V20, P979, DOI 10.1097/00004647-200006000-00010; Vaage J, 1980, Acta Chir Scand Suppl, V499, P141; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	40	101	109	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					121	130		10.1089/neu.2009.1114			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200010	19803784				2021-06-18	
J	Temkin, NR; Corrigan, JA; Dikmen, SS; Machamer, J				Temkin, Nancy R.; Corrigan, John A.; Dikmen, Sureyya S.; Machamer, Joan			Social Functioning After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						closed TBI; employment; leisure activities; living situation; penetrating TBI; psychosocial outcome; social outcome; traumatic brain injury	MILD HEAD-INJURY; LONG-TERM DISABILITY; QUALITY-OF-LIFE; FOLLOW-UP; UNITED-STATES; 1ST YEAR; WORK; POPULATION; RECOVERY; MODERATE	Objective: To determine the relationship between adult-onset traumatic brain injury (TBI) and social functioning including employment, social relationships, independent living, recreation, functional status, and quality of life 6 months or longer after injury. Participants: Not applicable. Design: Systematic review of the published, peer-reviewed literature. Primary Measures: Not applicable. Results: Fourteen primary and 25 secondary studies were identified that allowed comparison to controls for adults who were at least 6 months post-TBI. TBI decreases the probability of employment after injury in those who were workers before their injury, lengthens the timing of their return if they do return to work, and decreases the likelihood that they will return to the same position. Those with moderate and severe TBI are clearly affected, but there was insufficient evidence of a relationship between unemployment and mild TBI. Penetrating head injury sustained in wartime is clearly associated with increased unemployment. TBI also adversely affects leisure and recreation, social relationships, functional status, quality of life, and independent living. Although there is a dose-response relationship between seventy of injury and social outcomes, there is insufficient evidence to determine at what level of severity the adverse effects are demonstrated. Conclusion: TBI clearly has adverse effects on social functioning for adults. While some consequences might arise from injuries to other parts of the body, those with moderate to severe TBI have more impaired functioning Thai do those with other injuries alone.	[Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98104 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.; Machamer, Joan] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Dikmen, Sureyya S.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA; [Corrigan, John A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Temkin, NR (corresponding author), Univ Washington, Dept Neurol Surg, Box 359924,325 9th Ave, Seattle, WA 98104 USA.	temkin@uw.edu			US Department of Veterans AffairsUS Department of Veterans Affairs	This study was supported by a contract from the US Department of Veterans Affairs to the National Academy of Sciences, Institute of Medicine.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Finkelstein EA., 2006, INCIDENCE EC BURDEN; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gerberich SG, 1997, NEUROEPIDEMIOLOGY, V16, P1, DOI 10.1159/000109665; Groswasser Z, 2002, BRAIN INJURY, V16, P681, DOI 10.1080/02699050110119835; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; JENNETT B, 1975, LANCET, V1, P480; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; McLeod A, 2004, OCCUP ENVIRON MED, V61, P414, DOI 10.1136/oem.2003.007336; Millimet DL, 2003, J ECONOMETRICS, V113, P83, DOI 10.1016/S0304-4076(02)00168-9; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Ommaya A. K., 1996, TRAUMATIC BRAIN INJU; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Walker A., 1969, HEAD INJURED MEN 15, P85; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	49	101	102	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2009	24	6					460	467		10.1097/HTR.0b013e3181c13413			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	528VW	WOS:000272476100006	19940679				2021-06-18	
J	Hanson, B; Neidenbach, P; de Boer, P; Stengel, D				Hanson, Beate; Neidenbach, Philipp; de Boer, Piet; Stengel, Dirk			Functional outcomes after nonoperative management of fractures of the proximal humerus	JOURNAL OF SHOULDER AND ELBOW SURGERY			English	Article						Proximal humeral fracture; functional treatment; Constant score; Disabilities of the Arm; Shoulder and Hand	FIXATION; EPIDEMIOLOGY; HEAD	Background: Prospective follow-up data after nonoperative treatment for fractures of the proximal humerus are scarce. We studied functional outcomes and rates of complication and failure after conservative management of these common injuries. Materials and methods: Consecutive patients aged older than 18 years presenting to the emergency department of a large district hospital with an isolated, closed proximal humeral fracture considered suitable for functional treatment by the surgeon oil charge were enrolled in a prospective, externally monitored observational study. Surgeons were free to reduce the fracture and to prescribe any type of sling or brace. Active follow-up after 12 weeks, 6, and 12 months included plain radiographs, Constant score, and Disabilities of Arm, Shoulder and Hand (DASH) score. Results: We enrolled 160 patients (118 women; mean age. 63.3 +/- 14.8 years), and 124 completed I-year follow-up. There were 85, 71, and 4 AO 11 A B, and C fractures, and 75 one-part, 60 two-part. 23 three-part, and 2 four-part and head-splitting fractures. After I year, the mean difference in Constant scores between the injured and contralateral shoulder was 8.2 (95% confidence interval [Cl] 6.0-10.4). The mean difference in 1-year DASH scores to baseline assessment was 10.2 points (95% Cl 7.3-13.1 points). The risk of delayed and nonunion was 7.0% (95% CI, 3.6%-12.3%). Four patients subsequently underwent surgical fixation, and 5 had arthroscopic subacromial decompression. Conclusion: This study may provide reference values for future investigations and stresses ceiling effects that will make it difficult to demonstrate a significant advantage of surgical over nonoperative treatment in patients with proximal humeral fractures. Level of evidence: Level 4, Prospective case series without a control group. (C) 2009 Journal of Shoulder and Elbow Surgery Board of Trustees.	[Stengel, Dirk] Unfallkrankenhaus Berlin, Dept Orthoped & Trauma Surg, Clin Res Ctr, D-12683 Berlin, Germany; [Hanson, Beate; Neidenbach, Philipp; de Boer, Piet; Stengel, Dirk] AO Clin Invest & Documentat, Dubendorf, Switzerland; [de Boer, Piet] York Dist Gen Hosp, Dept Traumatol, York, N Yorkshire, England; [Stengel, Dirk] Univ Hosp Greifswald, Berlin, Germany	Stengel, D (corresponding author), Unfallkrankenhaus Berlin, Dept Orthoped & Trauma Surg, Clin Res Ctr, Warener Str 7, D-12683 Berlin, Germany.	stengeldirk@aol.com	Stengel, Dirk/AAF-6470-2019				Barrett JA, 1999, J CLIN EPIDEMIOL, V52, P243, DOI 10.1016/S0895-4356(98)00167-X; Calvo E, 2007, J SHOULDER ELB SURG, V16, P774, DOI 10.1016/j.jse.2007.03.019; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Court-Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130; Court-Brown CM, 2001, J BONE JOINT SURG BR, V83B, P799, DOI 10.1302/0301-620X.83B6.11401; Court-Brown CM, 2002, J BONE JOINT SURG BR, V84B, P504, DOI 10.1302/0301-620X.84B4.12488; Court-Brown CM, 2004, ACTA ORTHOP SCAND, V75, P736, DOI 10.1080/00016470410004111; Fjalestad T, 2005, ARCH ORTHOP TRAUM SU, V125, P310, DOI 10.1007/s00402-005-0803-9; Frangen TM, 2007, ZBL CHIR, V132, P60, DOI 10.1055/s-2006-958639; Gradl G, 2007, ARCH ORTHOP TRAUM SU, V127, P937, DOI 10.1007/s00402-007-0425-5; Hagino H, 1999, BONE, V24, P265, DOI 10.1016/S8756-3282(98)00175-6; Handschin AE, 2008, INJURY, V39, P306, DOI 10.1016/j.injury.2007.10.011; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Keener JD, 2007, J SHOULDER ELB SURG, V16, P330, DOI 10.1016/j.jse.2006.09.006; Kollig E, 2003, ZBL CHIR, V128, P111, DOI 10.1055/s-2003-37764; Lefevre-Colau MM, 2007, J BONE JOINT SURG AM, V89A, P2582, DOI 10.2106/JBJS.F.01419; Lill H, 2001, ZBL CHIR, V126, P205, DOI 10.1055/s-2001-12495; Linhart W, 2007, J ORTHOP TRAUMA, V21, P285, DOI 10.1097/BOT.0b013e318059b5a1; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1077, DOI 10.2106/00004623-197052060-00001; Stiller J, 2005, ATHLET THER TODAY, V10, P34; van den Broek CM, 2007, ARCH ORTHOP TRAUM SU, V127, P459, DOI 10.1007/s00402-006-0250-2; Voigt C, 2007, CHIRURG, V78, P40, DOI 10.1007/s00104-006-1241-0; Zyto K, 1997, J BONE JOINT SURG BR, V79B, P412, DOI 10.1302/0301-620X.79B3.7419; Zyto K, 1998, INJURY, V29, P349, DOI 10.1016/S0020-1383(97)00211-8	24	101	113	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	1058-2746			J SHOULDER ELB SURG	J. Shoulder Elbow Surg.	JUL-AUG	2009	18	4			SI		612	621		10.1016/j.jse.2009.03.024			10	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	468JB	WOS:000267812400019	19559373				2021-06-18	
J	Bilotta, F; Caramia, R; Paoloni, FP; Delfini, R; Rosa, G				Bilotta, Federico; Caramia, Remo; Paoloni, Francesca P.; Delfini, Roberto; Rosa, Giovanni			Safety and Efficacy of Intensive Insulin Therapy in Critical Neurosurgical Patients	ANESTHESIOLOGY			English	Article; Proceedings Paper	Joint Annual Meeting of the European-Society-of-Anaesthesiology/Annual Meeting of the EAA	JUN 03-06, 2006	Madrid, SPAIN	European Soc Anaesthesiol, EAA			PLASMA-GLUCOSE CONCENTRATIONS; TRAUMATIC BRAIN-INJURY; STROKE TRIAL GIST; ILL PATIENTS; ISCHEMIC BRAIN; BLOOD-GLUCOSE; CARE-UNIT; DIABETES-MELLITUS; GLYCEMIC CONTROL; MEDICAL ICU	Background: Intensive insulin therapy to maintain blood glucose at or below 6.11 mM reduces morbidity and mortality after cardiac surgery and morbidity in medical intensive care unit (ICU) patients. The authors investigated the clinical safety and outcome effects of intensive insulin therapy compared to conventional insulin therapy in patients receiving postoperative intensive care after neurosurgical procedures. Methods: In this prospective randomized controlled trial, 483 patients undergoing elective or emergency brain surgery were prospectively and randomly assigned either to intensive insulin therapy (241 patients), receiving insulin titrated to maintain blood glucose levels within the range of 4.44-6.11 mM, or to conventional insulin therapy (242 patients), receiving insulin to maintain blood glucose levels below 11.94 mM. Primary end-point was incidence of hypoglycemia (defined as blood glucose < 2.78 mM). Efficacy measures included the length of ICU stay, infection rate, and 6 months follow-tip Glasgow outcome scale score and overall survival. Results: Hypoglycemia episodes were more frequent in patients receiving intensive insulin therapy, median (min-max): 8 (0-23) versus 3 (0-4); P < 0.0001. The length of stay in the ICU was shorter (6 vs. 8 days; P = 0.0001), and the infection rate was lower (25.7% vs. 39.3%; P = 0.0018). Glasgow outcome scale score and overall survival at 6 months were similar in the two groups. Conclusions: Intensive insulin therapy in patients admitted to a postoperative neurosurgical ICU after brain surgery is associated with iatrogenic hypoglycemia, but it can also reduce the infection rate and shorten the ICU stay.	[Bilotta, Federico] Univ Roma La Sapienza, Policlin Umberto 1, Dept Anesthesiol Crit Care & Pain Med, I-00199 Rome, Italy	Bilotta, F (corresponding author), Univ Roma La Sapienza, Policlin Umberto 1, Dept Anesthesiol Crit Care & Pain Med, Viale Somalia 81, I-00199 Rome, Italy.	bilotta@tiscali.it					Bhalla A, 2003, EUR J NEUROL, V10, P25, DOI 10.1046/j.1468-1331.2003.00504.x; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; BOYLE PJ, 1988, NEW ENGL J MED, V318, P1487, DOI 10.1056/NEJM198806093182302; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Donnan GA, 2007, LANCET NEUROL, V6, P380, DOI 10.1016/S1474-4422(07)70086-8; Egi M, 2006, ANESTHESIOLOGY, V105, P244, DOI 10.1097/00000542-200608000-00006; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gray CS, 2007, LANCET NEUROL, V6, P397, DOI 10.1016/S1474-4422(07)70080-7; Horan TC, 2004, SURVEILLANCE NOSOCOM, P1659; Kimura K, 2007, J NEUROL SCI, V255, P90, DOI 10.1016/j.jns.2007.02.005; Krinsley JS, 2007, CRIT CARE MED, V35, P2262, DOI 10.1097/01.CCM.0000282073.98414.4B; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LI PA, 1994, NEUROSCI LETT, V177, P63, DOI 10.1016/0304-3940(94)90045-0; Lukins MB, 2005, ANESTH ANALG, V100, P1129, DOI 10.1213/01.ANE.0000146943.45445.55; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Mechanick JI, 2007, CURR OPIN CLIN NUTR, V10, P193, DOI 10.1097/MCO.0b013e32802b7016; Pasternak JJ, 2004, J NEUROSURG ANESTH, V16, P122, DOI 10.1097/00008506-200404000-00003; Pittas AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/archinte.164.18.2005; Preiser JC, 2007, CRIT CARE MED, V35, pS503, DOI 10.1097/01.CCM.0000278046.24345.C7; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Thomas G, 2007, NEPHROL DIAL TRANSPL, V22, P2849, DOI 10.1093/ndt/gfm401; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Turina M, 2006, CRIT CARE MED, V34, pS291, DOI 10.1097/01.ccm.0000231887.84751.04; *U MI MED CTR, 2006, APSF NEWSL; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van den Berghe G, 2006, DIABETES, V55, P3151, DOI 10.2337/db06-0855; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vriesendorp TM, 2006, CRIT CARE MED, V34, P2714, DOI 10.1097/01.CCM.0000241155.36689.91; Vriesendorp TM, 2006, CRIT CARE MED, V34, P96, DOI 10.1097/01.CCM.0000194536.89694.06; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wass CT, 1996, MAYO CLIN PROC, V71, P801; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; Weinstein MP, 1998, J CLIN MICROBIOL, V36, P2089, DOI 10.1128/JCM.36.7.2089-2092.1998; WIDOM B, 1990, ANN INTERN MED, V112, P904, DOI 10.7326/0003-4819-112-12-904; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Yamada K, 2007, CRIT CARE, V11, DOI 10.1186/cc5953	44	101	110	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAR	2009	110	3					611	619		10.1097/ALN.0b013e318198004b			9	Anesthesiology	Anesthesiology	412OU	WOS:000263734900024	19237874	Bronze			2021-06-18	
J	Anderson, KJ; Scheff, SW; Miller, KM; Roberts, KN; Gilmer, LK; Yang, C; Shaw, G				Anderson, Kevin J.; Scheff, Stephen W.; Miller, Kelly M.; Roberts, Kelly N.; Gilmer, Lesley K.; Yang, Cui; Shaw, Gerry			The Phosphorylated Axonal Form of the Neurofilament Subunit NF-H (pNF-H) as a Blood Biomarker of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cell death; cortical contusion; neurofilaments; serum	CONTROLLED CORTICAL IMPACT; BIOCHEMICAL SERUM MARKERS; CYCLOSPORINE-A; PROTEIN-LEVELS; CLEAVED-TAU; HEAD-INJURY; DAMAGE; PROTEOLYSIS; CALPAIN; RAT	The detection of neuron-specific proteins in blood might allow quantification of the degree of neuropathology in experimental and clinical contexts. We have been studying a novel blood biomarker of axonal injury, the heavily phosphorylated axonal form of the high molecular weight neurofilament subunit NF-H (pNF-H). We hypothesized that this protein would be released from damaged and degenerating neurons following experimental traumatic brain injury (TBI) in amounts large enough to allow its detection in blood and that the levels detected would reflect the degree of injury severity. An enzyme-linked immunosorbent assay (ELISA) capture assay capable of detecting nanogram amounts of pNF-H was used to test blood of rats subjected to experimental TBI using a controlled cortical impact (CCI) device. Animals were subjected to a mild (1.0 mm), moderate (1.5 mm), or severe (2.0 mm) cortical contusion, and blood samples were taken at defined times post-injury. The assay detected the presence of pNF-H as early as 6 h post-injury; levels peaked at 24-48 h, and then slowly decreased to baseline over several days post-injury. No signal above baseline was detectable in control animals. Analysis of variance (ANOVA) showed a significant effect of lesion severity, and post hoc analysis revealed that animals given a moderate and severe contusion showed higher levels of blood pNF-H than controls. In addition, the peak levels of pNF-H detected at both 24 and 48 h post-injury correlated with the degree of injury as determined by volumetric analysis of spared cortical tissue. Relative amounts of pNF-H were also determined in different areas of the central nervous system (CNS) and were found to be highest in regions containing large-diameter axons, including spinal cord and brainstem, and lowest in the cerebral cortex and hippocampus. These findings suggest that the measurement of blood levels of pNF-H is a convenient method for assessing neuropathology following TBI.	[Anderson, Kevin J.] Univ Florida, Dept Physiol Sci, McKnight Brain Inst, Gainesville, FL 32610 USA; [Anderson, Kevin J.; Yang, Cui; Shaw, Gerry] Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; [Anderson, Kevin J.; Scheff, Stephen W.; Miller, Kelly M.; Roberts, Kelly N.; Gilmer, Lesley K.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Shaw, Gerry] EnCor Biotechnol Inc, Gainesville, FL USA	Anderson, KJ (corresponding author), Univ Florida, Dept Physiol Sci, McKnight Brain Inst, POB 100144, Gainesville, FL 32610 USA.	kanders@mbi.ufl.edu	, Gerry/X-2377-2019		Kentucky Spinal Cord and Head Injury Research Trust [5A]; Spinal Cord Research Foundation; Department of Veteran AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS39828, AG21981]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER	We would like to thank Chris Horrell for his technical assistance. This study was supported by the Kentucky Spinal Cord and Head Injury Research Trust (project no. 5A), the Spinal Cord Research Foundation, the Department of Veteran Affairs, and the NIH (grants NS39828 and AG21981).	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bush EC, 2003, BRAIN BEHAV EVOLUT, V61, P1, DOI 10.1159/000068880; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FRAHM HD, 1982, J HIRNFORSCH, V23, P375; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Hashimoto R, 1999, PSYCHIAT CLIN NEUROS, V53, P587, DOI 10.1046/j.1440-1819.1999.00610.x; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; JOHNSON GVW, 1991, NEUROCHEM RES, V16, P869, DOI 10.1007/BF00965535; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1274, DOI 10.1038/jcbfm.2008.23; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Petzold A, 2007, NEURODEGENER DIS, V4, P185, DOI 10.1159/000101843; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shaw G, 2004, BIOCHEM BIOPH RES CO, V325, P619, DOI 10.1016/j.bbrc.2004.09.223; Shaw G, 1998, NEUROFILAMENTS; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; Stroop R, 1998, ACT NEUR S, V71, P303; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Togo T, 2002, ACTA NEUROPATHOL, V104, P398, DOI 10.1007/s00401-002-0569-x	40	101	106	1	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1079	1085		10.1089/neu.2007.0488			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900004	18729720	Green Accepted, Green Published			2021-06-18	
J	Maldonado, MA; Allred, RP; Felthauser, EL; Jones, TA				Maldonado, Monica A.; Allred, Rachel P.; Felthauser, Erik L.; Jones, Theresa A.			Motor skill training, but not voluntary exercise, improves skilled reaching after unilateral ischemic lesions of the sensorimotor cortex in rats	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						exercise; rehabilitation; skilled reaching; experience-dependent plasticity	DENDRITIC STRUCTURAL PLASTICITY; FOCAL CORTICAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; ADULT SQUIRREL-MONKEYS; GROWTH-FACTOR-I; NEUROTROPHIC FACTOR; SYNAPTIC-PLASTICITY; MOVEMENT REPRESENTATIONS; SPINAL-CORD; FUNCTIONAL RECOVERY	Background and Purpose. Exercise and rehabilitative training each have been implicated in the promotion of restorative neural plasticity after cerebral injury. Because motor skill training induces synaptic plasticity and exercise increases plasticity-related proteins, we asked if exercise could improve the efficacy of training on a skilled motor task after focal cortical lesions. Methods. Female young and middle-aged rats were trained on the single-pellet retrieval task and received unilateral ischemic sensorimotor cortex lesions contralateral to the trained limb. Rats then received both, either, or neither voluntary running and/or rehabilitative training for 5 weeks beginning 5 days postlesion. Motor skill training consisted of daily practice of the impaired forelimb in a tray-reaching task. Exercised rats had free access to running wheels for 6 h/day. Reaching function was periodically probed using the single-pellet retrieval task. Results. In young adults, motor skill training significantly enhanced skilled reaching recovery compared to controls. However, exercise did not significantly enhance performance when administered alone or in combination with skill training. There was also no major benefit of exercise in older rats. Additionally, there were no effects of exercise in a measure of coordinated forelimb placement (the foot-fault test) or in immunocytochemical measures of several plasticity-related proteins in the motor cortex. Conclusions. In young and middle-aged animals, exercise did not improve motor skill training efficacy following ischemic lesions. Practicing motor skills more effectively improved recovery of these skills than did exercise. It remains possible that an alternative manner of administering exercise would be more effective.	[Maldonado, Monica A.; Felthauser, Erik L.; Jones, Theresa A.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Allred, Rachel P.; Jones, Theresa A.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA	Jones, TA (corresponding author), Univ Stn A8000, Austin, TX 78712 USA.	tjones@psy.utexas.edu	Jones, Theresa A/F-1182-2010	Jones, Theresa A/0000-0003-0906-6439	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20 RR020700, RR020700] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH064586, MH 65728, T32 MH065728, MH 64586] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31 NS059290-01A1, R01 NS056839-06, R01 NS056839, R01 NS056839-07] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR020700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH065728, R01MH064586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS059290, R01NS056839] Funding Source: NIH RePORTER		Adkins DL, 2006, J APPL PHYSIOL, V101, P1776, DOI 10.1152/japplphysiol.00515.2006; Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Adkins DL, 2004, NEUROSCIENCE, V128, P473, DOI 10.1016/j.neuroscience.2004.07.019; Adkins-Muir DL, 2003, NEUROL RES, V25, P780, DOI 10.1179/016164103771953853; Adlard PA, 2004, NEUROSCI LETT, V363, P43, DOI 10.1016/j.neulet.2004.03.058; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Allred RP, 2004, EXP NEUROL, V190, P433, DOI 10.1016/j.expneurol.2004.08.005; Barbay S, 2006, EXP BRAIN RES, V169, P106, DOI 10.1007/s00221-005-0129-4; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Bury SD, 2002, J NEUROSCI, V22, P8597; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DeBow SB, 2003, STROKE, V34, P1021, DOI 10.1161/01.STR.0000063374.89732.9F; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Ding YH, 2004, CURR NEUROVASC RES, V1, P411, DOI 10.2174/1567202043361875; Ding YH, 2006, CURR NEUROVASC RES, V3, P15, DOI 10.2174/156720206775541787; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Friel KM, 2007, NEUROREHAB NEURAL RE, V21, P51, DOI 10.1177/1545968306291851; Friel KM, 1998, SOMATOSENS MOT RES, V15, P173, DOI 10.1080/08990229870745; Fuxe K, 1997, NEUROREPORT, V8, P2623, DOI 10.1097/00001756-199707280-00040; Gharbawie OA, 2005, BEHAV BRAIN RES, V156, P125, DOI 10.1016/j.bbr.2004.05.015; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Hsu JE, 2006, EXP NEUROL, V201, P479, DOI 10.1016/j.expneurol.2006.05.003; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Jones TA, 1999, J COMP NEUROL, V414, P57; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; Kleim JA, 2002, BRAIN RES, V934, P1, DOI 10.1016/S0006-8993(02)02239-4; Klintsova AY, 2004, BRAIN RES, V1028, P92, DOI 10.1016/j.brainres.2004.09.003; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; Komitova M, 2005, EUR J NEUROSCI, V21, P2397, DOI 10.1111/j.1460-9568.2005.04072.x; KOSAR E, 1986, BRAIN RES, V379, P329, DOI 10.1016/0006-8993(86)90787-0; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Leasure JL, 2004, BEHAV BRAIN RES, V150, P83, DOI 10.1016/S0166-4328(03)00254-7; Li J, 2004, NEUROL RES, V26, P404, DOI 10.1179/016164104225016038; Markham JA, 2004, NEURON GLIA BIOL, V1, P351, DOI 10.1017/S1740925X05000219; Mattson MP, 2005, ANNU REV NUTR, V25, P237, DOI 10.1146/annurev.nutr.25.050304.092526; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; Molteni R, 2004, P NATL ACAD SCI USA, V101, P8473, DOI 10.1073/pnas.0401443101; Monfils MH, 2005, NEUROSCIENTIST, V11, P471, DOI 10.1177/1073858405278015; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144; Nudo RJ, 1996, J NEUROSCI, V16, P785; PAXINOS C, 1986, RAT BRAIN STEREOTAXI; PETERSON GM, 1951, J COMP PHYSIOL PSYCH, V44, P191, DOI 10.1037/h0060555; Ploughman M, 2005, NEUROSCIENCE, V136, P991, DOI 10.1016/j.neuroscience.2005.08.037; Ploughman M, 2007, BRAIN RES, V1150, P207, DOI 10.1016/j.brainres.2007.02.065; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Tropp J, 2001, PHYSIOL BEHAV, V73, P553, DOI 10.1016/S0031-9384(01)00487-5; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Wang RY, 2001, BRAIN RES, V922, P140, DOI 10.1016/S0006-8993(01)03154-7; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; WHISHAW IQ, 1992, BEHAV BRAIN RES, V52, P45, DOI 10.1016/S0166-4328(05)80323-7; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Woodlee MT, 2004, RESTOR NEUROL NEUROS, V22, P153; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015	71	101	103	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY-JUN	2008	22	3					250	261		10.1177/1545968307308551			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	302IM	WOS:000255962000004	18073324	Green Accepted			2021-06-18	
J	Bushnik, T; Englander, J; Wright, J				Bushnik, Tamara; Englander, Jefftey; Wright, Jerry			The experience of fatigue in the first 2 years after moderate-to-severe traumatic brain injury: A preliminary report	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; fatigue; pain; sleep; traumatic brain injury	GROWTH-HORMONE DEFICIENCY; DISABILITY RATING-SCALE; MINOR HEAD-INJURY; INVENTORY; REHABILITATION; RELIABILITY; INSTRUMENT; DEPRESSION; RECOVERY; INSOMNIA	Fatigue is a well-recognized issue for individuals with traumatic brain injury (TBI). This prospective study examined the rate and types of fatigue that are experienced by a cohort of individuals with TBI within the first 2 years, using a multidimensional fatigue scale. The impact of factors such as demographics, Injury severity indices, and concomitant psychosocial variables was also examined. Using 2 measures of overall fatigue, 16%-32% at Year 1 and 21%-34% at Year 2 reported significant levels of fatigue. Fatigue did not appear to change between 1 and 2 years post-TBI. Sleep quality was the most prevalent concomitant disturbance followed by depression and pain.	[Bushnik, Tamara; Englander, Jefftey; Wright, Jerry] Santa Clara Valley Med Ctr, Rehabil Res Ctr, No California TBI Model Syst Care, Co PI, San Jose, CA 95128 USA	Bushnik, T (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, No California TBI Model Syst Care, Co PI, 751 S Bascom Ave, San Jose, CA 95128 USA.	tamara@thi-sci.org		Bushnik, Tamara/0000-0003-3328-257X			Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Barroso Julie, 2002, J Assoc Nurses AIDS Care, V13, P66, DOI 10.1016/S1055-3290(06)60242-2; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BELZA BL, 1995, J RHEUMATOL, V22, P639; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; BUSHNIK T, 2006, 2 FED INT C TBI MARC; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; de Rijk AE, 1999, J PSYCHOSOM RES, V47, P509, DOI 10.1016/S0022-3999(99)00049-5; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FINKELMAN JM, 1994, HUM FACTORS, V36, P232; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; Furberg H, 2005, J PSYCHOSOM RES, V59, P283, DOI 10.1016/j.jpsychores.2005.05.008; Glader EL, 2002, STROKE, V33, P1327, DOI 10.1161/01.STR.0000014248.28711.D6; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Grady C, 1998, NURS RES, V47, P227, DOI 10.1097/00006199-199807000-00008; Hillier SL, 1997, BRAIN INJURY, V11, P661; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lieberman SA, 1996, J PEDIATR-US, V128, pS58, DOI 10.1016/S0022-3476(96)70013-6; Lou JS, 2001, MOVEMENT DISORD, V16, P190, DOI 10.1002/mds.1042; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Michael Kathleen, 2002, Rehabil Nurs, V27, P89; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; *NAT HOUS SURV DRU, SUBST AB MENT HLTH S; Novack T., 2000, ORIENTATION LOG; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Resnick HE, 2006, J CLIN SLEEP MED, V2, P163; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; SHARAR E, 1990, J FAM PRACTICE, V31, P257; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Taylor RR, 2002, PSYCHOSOM MED, V64, P319, DOI 10.1097/00006842-200203000-00016; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	55	101	101	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2008	23	1					17	24		10.1097/01.HTR.0000308717.80590.22			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	256HS	WOS:000252719800005	18219231				2021-06-18	
J	El Sayed, T; Mota, A; Fraternali, F; Ortiz, M				El Sayed, Tamer; Mota, Alejandro; Fraternali, Fernando; Ortiz, Michael			Biomechanics of traumatic brain injury	COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING			English	Article						Brain tissue damage; Finite deformation; Plasticity; Finite viscoelasticity; Diffuse axonal injury; Cavitation injury; Traumatic brain injury	VARIATIONAL CONSTITUTIVE MODEL; HEAD-INJURY; MECHANICAL-PROPERTIES; LARGE-DEFORMATION; TISSUE; IMPACT; FORMULATION; IMPLEMENTATION; CONCUSSION; ELASTOMERS	A biomechanical model for traumatic brain injury and soft tissue damage is presented. A variational constitutive model for soft biological tissues is utilized to reproduce axonal damage and cavitation injury through inelastic deformation. The material response is split into elastoplastic and viscoelastic components, including rate effects, shear and porous plasticity, and finite viscoelasticity. Mechanical damage of brain tissue is classified as volumetric (compression/tension) and shear-type. Finite element simulations of brain injuries are presented, examining frontal and oblique head impacts with external objects. Localization, extension, intensity and reversibility/irreversibility of tissue damage are predicted. Future directions of this work, relating mechanical damage and physiological brain dysfunction, and application to relevant medical and engineering problems are discussed. (c) 2008 Elsevier B.V. All rights reserved.	[El Sayed, Tamer; Mota, Alejandro; Ortiz, Michael] CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; [Fraternali, Fernando] Univ Salerno, Dept Civil Engn, I-84084 Fisciano, SA, Italy	Ortiz, M (corresponding author), CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA.	ortiz@aero.caltech.edu	Fraternali, Fernando/A-4237-2018	Fraternali, Fernando/0000-0002-7549-6405	Regione Campania, ItalyRegione Campania	The support of the Regione Campania, Italy, through the program "Modeling Shape, Structure and Mechanical Behavior of the Skull-Encephalon Complex" is greatly acknowledged. The authors also want to sincerely thank Davide Zuppa, graduate student at the Department of Civil Engineering of the University of Salerno, for his relevant and precious collaboration with the present work.	ADAMS JH, 1984, RECENT ADV HISTOPATH; Bergstrom JS, 2001, MECH MATER, V33, P523, DOI 10.1016/S0167-6636(01)00070-9; Brands Dave W A, 2002, Stapp Car Crash J, V46, P103; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; BRENNEN CE, 2003, 5 INT S CAV OS JAP; CARDAMONE L, 2005, ANAL NUMERICA TRAUMA; El Sayed T, 2008, J BIOMECH, V41, P1458, DOI 10.1016/j.jbiomech.2008.02.023; ELSAYED T, 2007, THESIS CALTECH; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; FUJIWARA S, 1989, FORENSIC SCI INT, V43, P159, DOI 10.1016/0379-0738(89)90132-1; Gasser TC, 2002, COMPUT MECH, V29, P340, DOI 10.1007/s00466-002-0347-6; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; HARDY WN, 1994, INT J IMPACT ENG, V15, P561, DOI 10.1016/0734-743X(94)80034-7; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; JOHNSON EAC, 2006, C2006 DIG HUM MOD DE; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; KLEIVEN S, 2002, THESIS ROYAL I TECHN; Leestma J, 1987, FORENSIC NEUROPATHOL; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller K, 2005, J BIOMECH, V38, P153, DOI 10.1016/j.jbiomech.2004.03.004; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; MILLER K, 2006, RES REPORT INTELLIGE; Nahum A. M., 1977, P 21 STAPP CAR CRASH; NUSHOLTZ GS, 1996, P NATO AGARD HEAD IM; Ogden R.W., 1984, NONLINEAR ELASTIC DE; ORTIZ M, 1992, J APPL MECH-T ASME, V59, P48, DOI 10.1115/1.2899463; Ortiz M, 1999, COMPUT METHOD APPL M, V171, P419, DOI 10.1016/S0045-7825(98)00219-9; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RODRIGES SR, 2003, BIOMECH 2003; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Thoutireddy P, 2002, INT J NUMER METH ENG, V53, P1337, DOI 10.1002/nme.337; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Weinberg K, 2005, COMP MATER SCI, V32, P588, DOI 10.1016/j.commatsci.2004.09.005; Weinberg K, 2006, COMPUT MECH, V37, P142, DOI 10.1007/s00466-005-0685-2; Yang Q, 2006, J MECH PHYS SOLIDS, V54, P401, DOI 10.1016/j.jmps.2005.08.010; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; ZHOU C, 1995, SAE N 952714, P121; Zhou C, 1995, P 39 STAPP CAR CRASH	46	101	102	0	34	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0045-7825	1879-2138		COMPUT METHOD APPL M	Comput. Meth. Appl. Mech. Eng.		2008	197	51-52					4692	4701		10.1016/j.cma.2008.06.006			10	Engineering, Multidisciplinary; Mathematics, Interdisciplinary Applications; Mechanics	Engineering; Mathematics; Mechanics	374BG	WOS:000261016600015					2021-06-18	
J	Singh, IN; Sullivan, PG; Hall, ED				Singh, Indrapal N.; Sullivan, Patrick G.; Hall, Edward D.			Peroxynitrite-mediated oxidative damage to brain mitochondria: Protective effects of peroxynitrite scavengers	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						peroxynitrite; mitochondria; penicillamine; tempol; oxidative damage	MEMBRANE-LIPID-PEROXIDATION; NITRIC-OXIDE; NITROXIDE RADICALS; MOUSE MODEL; INJURY; DYSFUNCTION; SUPEROXIDE; NITRATION; MELATONIN; MECHANISM	Peroxynitrite-mediated oxidative damage has been implicated in brain mitochondrial respiratory dysfunction after traumatic brain injury (TBI), which precedes the onset of neuronal loss. The aim of this study was to investigate the detrimental effects of the peroxynitrite donor SIN-1 (3-morpholinosydnonimine) on isolated brain mitochondria and to screen penicillamine, a stoichiometric (1:1) peroxynitrite-scavenging agent, and tempol, a catalytic scavenger of peroxynitrite-derived radicals, as antioxidant mitochondrial protectants. Exposure of the isolated mitochondria to SIN-1 caused a significant dose-dependent decrease in the respiratory control ratio and was accompanied by a significant increase in state 11 respiration, followed by significant decreases (P < 0.05) in states III and V. These functional alterations occurred together with significant increases in mitochondrial protein carbonyl (PC), lipid peroxidation-related 4-hydroxynonenal (4-HNE), and 3-nitrotyrosine (3-NT) content. Penicillamine hydrochloride (10 mu M) partially but significantly (P < 0.05) protected against SIN-1-induced decreases in states III and V. However, a 2.5 mu M concentration of tempol was able to significantly antagonize a 4-fold molar excess (10 mu M) concentration of SIN-1 as effectively as were higher tempol concentrations, consistent with the likelihood that tempol works by a catalytic mechanism. The protection of mitochondrial respiration by penicillamine and tempol occurred in parallel with attenuation of PC, 4-HNE, and 3-NT. These results indicate that SIN-1 causes mitochondrial oxidative damage and complex I dysfunction and that antioxidant compounds that target either peroxynitrite or its radicals may be effective mitochondrial protectants in the treatment of neural injury. (c) 2007 Wiley-Liss, Inc.	Univ Kentucky, Coll Med, Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Brain Injury Res Ctr, B383 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013				Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bonini MG, 2002, CHEM RES TOXICOL, V15, P506, DOI 10.1021/tx015571z; BOYER PD, 1977, ANNU REV BIOCHEM, V46, P955, DOI 10.1146/annurev.bi.46.070177.004515; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Frankel EN, 1996, J AGR FOOD CHEM, V44, P131, DOI 10.1021/jf950374p; Fujimura M, 2000, J NEUROSCI, V20, P2817; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hall ED, 1996, ACT NEUR S, V66, P107; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Hall ED, 1996, BRAIN RES, V742, P80, DOI 10.1016/S0006-8993(96)00968-7; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Lai J C, 1979, Methods Enzymol, V55, P51; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Martin H, 2005, LITHOS, V79, P1, DOI 10.1016/j.lithos.2004.04.048; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Rohn TT, 1998, BIOCHEM PHARMACOL, V56, P1371, DOI 10.1016/S0006-2952(98)00266-4; Romero N, 1999, ARCH BIOCHEM BIOPHYS, V368, P23, DOI 10.1006/abbi.1999.1272; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Yamamoto T, 2002, J NEURAL TRANSM, V109, P1, DOI 10.1007/s702-002-8232-1; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	41	101	103	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2007	85	10					2216	2223		10.1002/jnr.21360			8	Neurosciences	Neurosciences & Neurology	196XO	WOS:000248516700016	17510982				2021-06-18	
J	Catroppa, C; Anderson, VA; Morse, SA; Haritou, F; Rosenfeld, JV				Catroppa, Cathy; Anderson, Vicki A.; Morse, Sue A.; Haritou, Flora; Rosenfeld, Jeffrey V.			Children's attentional skills 5 years Post-TBI	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						attention; children; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; ACADEMIC-PERFORMANCE; EARLY-CHILDHOOD; RECOVERY; PREDICTORS; ADOLESCENTS; SEVERITY; SEQUELAE; MEMORY	Objective While a small number of research papers have reported findings on attentional deficits following pediatric traumatic brain injury (TBI), no study to date has reported findings in this area at 5 years post-TBI in very young children. This study examined attentional skills in a group of children who had sustained a mild, moderate, or severe TBI between the ages of 2 and 7 years. Methods The sample comprised 70 children, 54 of these had sustained a TBI and 16 the non-injured control group. Children were assessed 5 years post-TBI, with focus on tests of attentional ability. Results Attentional and processing speed (PS) deficits do occur and persist up to 5 years post-TBI, particularly following severe TBI in early childhood. Predictors of attentional outcomes varied depending on the component of attention investigated. Conclusions Those skills developing or emerging at time of injury (e.g., sustained attention, shifting attention, divided attention, PS) are more compromised and may not develop at a normal rate of post-injury.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Murdoch Univ, Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Murdoch, WA 6150, Australia; Univ Melbourne, Melbourne, Vic, Australia; Alfred Hosp, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Rosenfeld, Jeffrey V/B-7249-2011				Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; BETTS J, IN PRESS CHILD NEURO; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1995, TRAUMATIC HEAD INJUR; Dennis M., 1989, CLIN NEUROPSYCHOLOGY; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Goldstein FC, 1992, COGNITIVE DISORDERS; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAIL R, 1986, CHILD DEV, V57, P969, DOI 10.2307/1130372; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Manly T., 1999, TEST EVERYDAY ATTENT; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; VANZOMORON AH, 1994, CLIN NEUROPSYCHOLOGY; Wechsler D., 1991, MANUAL WECHSLER INTE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	59	101	101	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	APR	2007	32	3					354	369		10.1093/jpepsy/jsl019			16	Psychology, Developmental	Psychology	145BL	WOS:000244840200013	16840790	Green Published, Bronze			2021-06-18	
J	Landre, N; Poppe, CJ; Davis, N; Schmaus, B; Hobbs, SE				Landre, Nancy; Poppe, Christopher J.; Davis, Nancy; Schmaus, Brian; Hobbs, Susan E.			Cognitive functioning and postconcussive symptoms in trauma patients with and without mild TBI	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mild TBI; postconcussive syndrome; cognitive; neuropsychological; trauma; outcome	MINOR HEAD-INJURY; POST-CONCUSSIONAL SYNDROME; BRAIN-INJURY; CHRONIC PAIN; HIGH-SCHOOL; BASE RATES; RECOVERY; SPORTS; PSYCHOGENESIS; PHYSIOGENESIS	Although there is a large body of research on mild traumatic brain injury (MTBI), the portion that pertains to acute patients (those less than 1 month postinjury) is relatively small and yields inconsistent findings. The potential contribution of non-neurological factors, such as pain and emotional distress, to the clinical picture in this population is also lacking. To address these issues, the cognitive performance and symptom complaints of 37 hospitalized MTBI subjects were compared to those of 39 hospitalized trauma subjects, averaging 4.5 days postinjury. MTBI subjects performed significantly worse on all cognitive measures, but did not differ from trauma subjects in their report of postconcussive symptoms. Analyses also revealed that cognitive performance was unrelated to pain severity and emotional distress. Postconcussive symptoms were similarly unrelated to pain severity, but were consistently related to emotional distress. Results are discussed in terms of their etiological and treatment implications. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Lutheran Gen Hosp, Neuropsychol Serv, Park Ridge, IL 60068 USA; Ingenium Clin Res, Libertyville, IL USA; Advocate Res & Educ, Park Ridge, IL USA	Landre, N (corresponding author), Lutheran Gen Hosp, Neuropsychol Serv, Parkside Bldg,Suite 690,1775 Dempster St, Park Ridge, IL 60068 USA.	Nancy.Landre@advocatehealth.com					BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN S, 1987, NEUROBEHAVIORAL RECO; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Ferguson R.J., 1996, SOURCEBOOK PSYCHOL T; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GORDON M, 1982, GORDON DIAGNOSTIC SY; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1974, LANCET, V2, P605; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL H F, 1974, Acta Neurologica Scandinavica Supplementum, V50, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reitan RM, 1979, TRAIL MAKING TEST MA; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WARE JE, 1994, SF36 PHYS MENTAL HLT; Wechsler D., 1987, WECHSLER MEMORY SCAL; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	56	101	103	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2006	21	4					255	273		10.1016/j.acn.2005.12.007			19	Psychology, Clinical; Psychology	Psychology	067GI	WOS:000239289500002	16716563	Bronze			2021-06-18	
J	Solaroglu, I; Cahill, J; Jadhav, V; Zhang, JH				Solaroglu, I; Cahill, J; Jadhav, V; Zhang, JH			A novel neuroprotectant granulocyte-colony stimulating factor	STROKE			English	Article						granulocyte-colony stimulating factor; growth factor; neuroprotection; stem cell; stroke	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; FACTOR G-CSF; PROGENITOR CELLS; FACTOR-RECEPTOR; STEM-CELLS; BCL-2 EXPRESSION; STROKE; ACTIVATION	Background and Purpose - Granulocyte-colony stimulating factor (G-CSF) is a growth factor that orchestrates the proliferation, differentiation, and survival of hematopoietic progenitor cells. It has been used for many years in clinical practice to accelerate the recovery of patients from neutropenia after cytotoxic therapy. However, there is a growing body of evidence from experimental studies suggesting that G-CSF also has important nonhematopoietic functions in the central nervous system. Summary of Review - The presence of the G-CSF/G-CSF-receptor system in the brain and its role in neuroprotection and neural tissue repair has been investigated in many recent studies. The neuroprotective actions of G-CSF have mainly been attributed to its anti-inflammatory and antiapoptotic effects. Furthermore, it induces neurogenesis and angiogenesis and improves functional recovery. In this review, we summarize the role of G-CSF and the corresponding signal transduction pathways regulated by G-CSF in neuroprotection. Conclusions - Much additional work is needed to better understand the precise mechanisms of G-CSF - induced neuroprotection. However, there is emerging data suggesting that G-CSF is a potential new agent for neuroprotection.	Loma Linda Univ, Med Ctr, Div Neurosurg, Sch Med, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA 92354 USA	Zhang, JH (corresponding author), Loma Linda Univ, Med Ctr, Div Neurosurg, Sch Med, 11234 Anderson St,Room 2562B, Loma Linda, CA 92354 USA.	johnzhang3910@yahoo.com	Cahill, Julian/M-1916-2019; Solaroglu, Ihsan/ABF-7606-2020; Solaroglu, Ihsan/ABE-8816-2020	Cahill, Julian/0000-0003-0296-4412; Solaroglu, Ihsan/0000-0002-9472-1735	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD043120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043338, R01NS045694] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD43120] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45694, NS43338] Funding Source: Medline		ALOISI F, 1992, J IMMUNOL, V149, P2358; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BENSINGER WI, 1995, BLOOD, V85, P1655, DOI 10.1182/blood.V85.6.1655.bloodjournal8561655; Boneberg EM, 2000, BLOOD, V95, P270, DOI 10.1182/blood.V95.1.270; BUDEL LM, 1989, BLOOD, V74, P2668; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carlsson G, 2004, BRIT J HAEMATOL, V126, P127, DOI 10.1111/j.1365-2141.2004.05008.x; DEL PL, 1997, SCIENCE, V278, P687; DEMETRI GD, 1991, BLOOD, V78, P2791; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dong F, 2000, BLOOD, V95, P1656, DOI 10.1182/blood.V95.5.1656.005k29_1656_1662; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Gibson CL, 2005, J CEREBR BLOOD F MET, V25, P431, DOI 10.1038/sj.jcbfm.9600033; Gibson CL, 2005, J NEUROPATH EXP NEUR, V64, P763, DOI 10.1097/01.jnen.0000179196.10032.dd; GRIGG AP, 1995, BLOOD, V86, P4437, DOI 10.1182/blood.V86.12.4437.bloodjournal86124437; HANAZONO Y, 1990, EXP HEMATOL, V18, P1097; Hunter MG, 1998, J IMMUNOL, V160, P4979; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Katakowski M, 2003, J NEUROSCI RES, V74, P494, DOI 10.1002/jnr.10775; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kleinschnitz C, 2004, MOL BRAIN RES, V131, P73, DOI 10.1016/j.molbrainres.2004.08.011; Kocherlakota P, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e6; KOMINEKOBAYASHI M, 2005, J CEREB BLOOD F 0727; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Lee H, 2003, FASEB J, V17, P1943, DOI 10.1096/fj.03-0057fje; Lee ST, 2005, BRAIN RES, V1058, P120, DOI 10.1016/j.brainres.2005.07.076; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; Morikawa K, 2002, BRIT J HAEMATOL, V118, P296, DOI 10.1046/j.1365-2141.2002.03574.x; Park HK, 2005, BRAIN RES, V1041, P125, DOI 10.1016/j.brainres.2004.11.067; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; ROSENMAN SJ, 1995, J IMMUNOL, V154, P1888; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; SHIMODA K, 1993, J CLIN INVEST, V91, P1310, DOI 10.1172/JCI116330; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Six I, 2003, EUR J PHARMACOL, V458, P327, DOI 10.1016/S0014-2999(02)02785-1; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Stumm RK, 2002, J NEUROSCI, V22, P5865; Tehranchi R, 2003, BLOOD, V101, P1080, DOI 10.1182/blood-2002-06-1774; TIAN SS, 1994, BLOOD, V84, P1760; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Zavala F, 2002, J IMMUNOL, V168, P2011, DOI 10.4049/jimmunol.168.4.2011	61	101	106	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2006	37	4					1123	1128		10.1161/01.STR.0000208205.26253.96			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	025UJ	WOS:000236292100044	16514095	Bronze, Green Published			2021-06-18	
J	Halterman, CI; Langan, J; Drew, A; Rodriguez, E; Osternig, LR; Chou, LS; van Donkelaar, P				Halterman, CI; Langan, J; Drew, A; Rodriguez, E; Osternig, LR; Chou, LS; van Donkelaar, P			Tracking the recovery of visuospatial attention deficits in mild traumatic brain injury	BRAIN			English	Article						attention; mTBI; executive function; recovery	POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD INJURY; REACTION-TIME; CONCUSSION; CONFLICT; CORTEX; SYMPTOMS; NETWORK; SYSTEM; SPECT	The goal of the current investigation was to probe the deficits in the alerting, orienting and executive components of visuospatial attention in individuals who have recently suffered a mild traumatic brain injury (mTBI) and to assess the rate and degree of recovery for each of these components over a month post-injury. A group design was employed to assess and compare the performance of participants (12 males, 8 females; mean age: 21 +/- 1.74 years) identified with mTBI relative to control subjects matched for gender, age, height, weight and activity level. Participants performed the attentional network test, designed to isolate the constituents of attention into alerting, orienting and executive components. Reaction times (RTs) and response accuracy were the main dependent variables. The results showed that the orienting and executive components were significantly affected by mTBI immediately after the injury, whereas the alerting component was not. Furthermore, participants with mTBI recovered from the deficits in the orienting component of attention within a week of their injury, whereas the deficits in the executive component remained throughout the month post-injury. In addition, the RT cost to generate accurate compared with inaccurate responses was significantly larger in participants with mTBI than in controls, and this difference was maintained throughout the 1 month testing period. These findings indicate that the regions of the brain associated with the orienting and executive components of visuospatial attention may be most susceptible to neural damage resulting from mTBI. Moreover, the lack of recovery in the executive component indicates that the degree and time course for recovery may be regionally specific.	Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	van Donkelaar, P (corresponding author), Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.	paulvd@darkwing.uoregon.edu	Rodriguez-Torres, Erika Elizabeth/A-3843-2019	Rodriguez-Torres, Erika Elizabeth/0000-0002-7738-1863; Langan, Jeanne/0000-0003-1417-2180			Casey BJ, 2000, P NATL ACAD SCI USA, V97, P8728, DOI 10.1073/pnas.97.15.8728; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kelly JP, 1997, NEUROLOGY, V48, P581; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Nobre AC, 2004, J COGNITIVE NEUROSCI, V16, P363, DOI 10.1162/089892904322926700; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, NEUROPSYCHOLOGIA, V25, P135, DOI 10.1016/0028-3932(87)90049-2; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Sturm W, 1999, NEUROPSYCHOLOGIA, V37, P797, DOI 10.1016/S0028-3932(98)00141-9; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860; Weissman DH, 2003, NEUROIMAGE, V19, P1361, DOI 10.1016/S1053-8119(03)00167-8; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921	32	101	103	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2006	129		3				747	753		10.1093/brain/awh705			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	013TY	WOS:000235433800019	16330498	Green Published, Bronze			2021-06-18	
J	Anderson, RCE; Kan, P; Klimo, P; Brockmeyer, DL; Walker, ML; Kestle, JRW				Anderson, RCE; Kan, P; Klimo, P; Brockmeyer, DL; Walker, ML; Kestle, JRW			Complications of intracranial pressure monitoring in children with head trauma	JOURNAL OF NEUROSURGERY			English	Article						ventriculostomy; external ventricular drain; head trauma; intracranial pressure monitoring; fiberoptic monitor; children	INTRA-CRANICAL PRESSURE; VENTRICULOSTOMY-RELATED INFECTIONS; BRAIN-TISSUE PRESSURE; FIBEROPTIC DEVICE; CLINICAL-PRACTICE; AGGRESSIVE TREATMENT; RISK-FACTORS; INJURY; EXPERIENCE; MANAGEMENT	Object. Intracranial pressure (ICP) monitoring has become routine in the management of patients with traumatic brain injury (TBI). Many surgeons prefer to use external ventricular drains (EVDs) over fiberoptic monitors to measure ICP because of the added benefit of cerebrospinal fluid drainage. The purpose of this study was to examine a consecutive series of children with TBI and compare the incidence of complications after placement of an EVD, a fiberoptic intraparencyhmal monitor, or both. Methods. A retrospective chart review was conducted to identify children with TBI who met the criteria for insertion of an ICP monitor. All patients underwent head CT scanning on admission and after placement of an ICP monitor. During a 5-year period 80 children met the criteria for inclusion in the study. Eighteen children (22.5%) underwent EVD placement only, 18 (22.5%) underwent placement of a fiberoptic device only, and 44 (55%) received both. A total of 62 fiberoptic devices (48%) were inserted, and 68 EVDs (52%) were placed. Overall, there was a fourfold increased risk of complications in children who received an EVD compared with those in whom a fiberoptic monitor was placed (p = 0.004). Hemorrhagic complications were detected in 12 (17.6%) of 62 patients who received an EVD compared with four (6.5%) of 62 patients who received a fiberoptic monitor (p = 0.025). Six (8.8%) of 68 EVDs were malpositioned and required replacement; in three (50%) of these cases a hemorrhagic complication occurred. Only one infection was noted in a patient with an EVD (1.5%). Conclusions. In this retrospective cohort of pediatric patients with TBI, complication rates were significantly higher in those receiving EVDs than in those in whom fiberoptic monitors were placed. Although the majority of these complications did not entail clinical sequelae, surgeons should be aware of the different complication rates when choosing the most appropriate device for each patient.	Univ Utah, Primary Childrens Med Ctr, Dept Neurosurg, Salt Lake City, UT USA	Anderson, RCE (corresponding author), Neurol Inst, 4th Floor,710 W 168th St, New York, NY 10032 USA.	rceanderson@yahoo.com					AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; BADER MK, 1995, HEART LUNG, V24, P166, DOI 10.1016/S0147-9563(05)80012-3; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; Bochicchio M, 1996, INTENS CARE MED, V22, P1070, DOI 10.1007/BF01699230; CRUTCHFIELD JS, 1990, J NEUROSURG, V72, P482, DOI 10.3171/jns.1990.72.3.0482; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DEAN JM, 1981, NEUROSURGERY, V9, P627; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FELDMAN Z, 1993, HEAD INJURY, P247; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; Guyot LL, 1998, ACT NEUR S, V71, P47; Hader WJ, 2000, NEUROSURGERY, V46, P1149, DOI 10.1097/00006123-200005000-00025; Hammer GB, 1997, PEDIAT NEUROSURGICAL, P13; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Khan SH, 1998, ACT NEUR S, V71, P50; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; LUERSSEN TG, 1997, PEDIAT NEUROSURGICAL, P37; Lyke KE, 2001, CLIN INFECT DIS, V33, P2028, DOI 10.1086/324492; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; Piek J, 1994, Zentralbl Neurochir, V55, P48; Poca MA, 2002, J NEUROTRAUM, V19, P439, DOI 10.1089/08977150252932398; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Rossi S, 1998, ACT NEUR S, V71, P91; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; Schurer L, 1997, ACT NEUR S, V70, P296; Shapiro S, 1996, SURG NEUROL, V45, P278, DOI 10.1016/0090-3019(95)00359-2; STENAGER E, 1986, ACTA NEUROCHIR, V83, P20, DOI 10.1007/BF01420503; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; Wiesmann M, 2001, J CLIN NEUROSCI, V8, P126, DOI 10.1054/jocn.2000.0749; WINN HR, 1977, SURG NEUROL, V8, P41; YABLON JS, 1993, J CLIN MONITOR, V9, P171, DOI 10.1007/BF01617024	43	101	103	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	1		S			53	58		10.3171/ped.2004.101.2.0053			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	843QS	WOS:000223100100009	16206972				2021-06-18	
J	Hester, RL; Murphy, K; Foxe, JJ; Foxe, DM; Javitt, DC; Garavan, H				Hester, RL; Murphy, K; Foxe, JJ; Foxe, DM; Javitt, DC; Garavan, H			Predicting success: Patterns of cortical activation and deactivation prior to response inhibition	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE CORTEX; EVENT-RELATED FMRI; SUSTAINED ATTENTION; PREFRONTAL CORTEX; WORKING-MEMORY; BEHAVIORAL-INHIBITION; EXECUTIVE FUNCTIONS; DEFAULT MODE; BLOOD-FLOW	The present study investigated the relationships between attention and other preparatory processes prior to a response inhibition task and the processes involved in the inhibition itself. To achieve this, a mixed fMRI design was employed to identify the functional areas activated during both inhibition decision events and the block of trials following a visual cue introduced 2 to 7 sec prior (cue period). Preparing for successful performance produced increases in activation for both the cue period and the inhibition itself in the frontoparietal cortical network. Furthermore, preparation produced activation decreases in midline areas (insula and medial prefrontal) argued to be responsible for monitoring internal emotional states, and these cue period deactivations alone predicted subsequent success or failure. The results suggest that when cues are provided to signify the imminent requirement for behavioral control, successful performance results from a coordinated pattern of preparatory activation in task-relevant areas and deactivation of task-irrelevant ones.	Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA	Garavan, H (corresponding author), Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland.	Hugh.Garavan@tcd.ie	Murphy, Kevin/A-1581-2010; Javitt, Daniel/U-6015-2019; Hester, Robert/F-2097-2011	Murphy, Kevin/0000-0002-6516-313X; Hester, Robert/0000-0003-0982-8026; Foxe, John/0000-0002-4300-3098	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00058] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA14100] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH65350, MH63434] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH063434, R01MH065350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA014100] Funding Source: NIH RePORTER		Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Brass M, 2002, CEREB CORTEX, V12, P908, DOI 10.1093/cercor/12.9.908; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cummings JL, 2001, AGING-CLIN EXP RES, V13, P240, DOI 10.1007/BF03351482; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; Drevets WC, 1998, COGNITION EMOTION, V12, P353, DOI 10.1080/026999398379646; Fiez JA, 2001, J CLIN EXP NEUROPSYC, V23, P19, DOI 10.1076/jcen.23.1.19.1221; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Gray JR, 2002, P NATL ACAD SCI USA, V99, P4115, DOI 10.1073/pnas.062381899; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Keppel, 1991, DESIGN ANAL RES HDB; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; Konrad KN, 2000, BRAIN INJURY, V14, P859; Lawrence NS, 2003, J COGNITIVE NEUROSCI, V15, P1028, DOI 10.1162/089892903770007416; Liddle PF, 2001, HUM BRAIN MAPP, V12, P100, DOI 10.1002/1097-0193(200102)12:2<100::AID-HBM1007>3.0.CO;2-6; Luks TL, 2002, NEUROIMAGE, V17, P792, DOI 10.1006/nimg.2002.1210; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Matochik JA, 1996, BRAIN RES, V723, P23, DOI 10.1016/0006-8993(96)00177-1; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Perlstein WM, 2001, AM J PSYCHIAT, V158, P1105, DOI 10.1176/appi.ajp.158.7.1105; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rapport LJ, 2001, CLIN NEUROPSYCHOL, V15, P479, DOI 10.1076/clin.15.4.479.1878; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Sakai K, 2003, NAT NEUROSCI, V6, P75, DOI 10.1038/nn987; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Simpson JR, 2000, J COGNITIVE NEUROSCI, V12, P157, DOI 10.1162/089892900564019; Stevens J, 2002, DEV NEUROPSYCHOL, V21, P117, DOI 10.1207/S15326942DN2102_1; Talairach J., 1988, COPLANAR STEREOTAXIC; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; van Veen V, 2001, NEUROIMAGE, V14, P1302, DOI 10.1006/nimg.2001.0923; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Watanabe J, 2002, NEUROIMAGE, V17, P1207, DOI 10.1006/nimg.2002.1198; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	49	101	101	0	4	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0898-929X	1530-8898		J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	JUN	2004	16	5					776	785		10.1162/089892904970726			10	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	829FK	WOS:000222031700006	15200705	Green Accepted			2021-06-18	
J	Angelakis, E; Lubar, JF; Stathopoulou, S; Kounios, J				Angelakis, E; Lubar, JF; Stathopoulou, S; Kounios, J			Peak alpha frequency: an electroencephalographic measure of cognitive preparedness	CLINICAL NEUROPHYSIOLOGY			English	Article						electroencephalographic; peak alpha frequency; cognitive preparedness; traumatic brain injury; working memory; trait; state; resting baseline	CEREBRAL BLOOD-FLOW; QUANTITATIVE EEG; DOUBLE-BLIND; INDOMETHACIN; CAFFEINE; HYPOXIA; MEMORY	Objective: Electroencephalographic (EEG) peak alpha frequency (PAF) (measured in Hz) has been correlated to cognitive performance between healthy and clinical individuals, and among healthy individuals. PAF also varies within individuals across developmental stages, among different cognitive tasks, and among physiological states induced by administration of various substances. The present study suggests that, among other things, PAF reflects a trait or state of cognitive preparedness. Methods: Experiment 1 involved 19-channel EEG recordings from 10 individuals with traumatic brain injury (TBI) and 12 healthy matched controls, before, during, and after tasks of visual and auditory attention. Experiment 2 involved EEG recordings from 19 healthy young adults before and after a working memory task (WAIS-R Digit Span), repeated on 2 different days to measure within-individual differences. Results: Experiment 1 showed significantly lower PAF in individuals with TBI, mostly during post-task rest. Experiment 2 showed PAF during pre-task baseline to be significantly correlated with Digit Span performance of the same day but not with Digit Span performance of another day. Moreover, PAF was significantly increased after Digit Span for those participants whose PAF was lower than the sample median before the task, but not for those who had it higher. Finally, both PAF and Digit Span performance were increased during the second day. Conclusions: PAF was shown to detect both trait and state differences in cognitive preparedness, as well as to be affected by cognitive tasks. Traits are better reflected during post-task rest, whereas states are better reflected during initial resting baseline recordings. (C) 2004 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All fights reserved.	Drexel Univ, Dept Psychol, Philadelphia, PA 19102 USA; Univ Tennessee, Dept Psychol, Knoxville, TN 37996 USA	Angelakis, E (corresponding author), Drexel Univ, Dept Psychol, MS 626,245 N 15th St, Philadelphia, PA 19102 USA.	efthymis@mailcity.com			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC004818] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC04818] Funding Source: Medline		Angelakis E., 2002, Journal of Neurotherapy, V6, P5, DOI 10.1300/J184v06n02_03; Anokhin A, 1996, INTELLIGENCE, V23, P1, DOI 10.1016/S0160-2896(96)80002-X; BILLIOT K. M., 1997, J NEUROTHERAPY, V2, P20, DOI DOI 10.1300/J184V02N02_; Brunia CHM, 2001, INT J PSYCHOPHYSIOL, V43, P59, DOI 10.1016/S0167-8760(01)00179-9; Canive JM, 1998, PSYCHOPHARMACOL BULL, V34, P101; Congedo M., 2002, Journal of Neurotherapy, V6, P73, DOI 10.1300/J184v06n04_08; CONNERS CK, 1999, PRACTITIONERS GUIDE, P413; Doppelmayr MM, 1998, BRAIN TOPOGR, V11, P133, DOI 10.1023/A:1022206622348; FELDMAN RS, 1997, PRINCIPLES NEUROPSYC, P902; HEMLER RJB, 1990, METHOD FIND EXP CLIN, V12, P641; HOLM S, 1979, SCAND J STAT, V6, P65; Juhasz C, 1997, ACTA NEUROL SCAND, V96, P397; KINOSHITA T, 1990, Psychiatria et Neurologia Japonica, V92, P255; Klimesch W, 1997, INT J PSYCHOPHYSIOL, V26, P319, DOI 10.1016/S0167-8760(97)00773-3; Klimesch W., 1993, Brain Topography, V5, P241, DOI 10.1007/BF01128991; Klimesch W., 1990, J PSYCHOPHYSIOL, V4, P381; KNOTT VJ, 1988, NEUROPSYCHOBIOLOGY, V19, P54, DOI 10.1159/000118434; KOSTANDOV E, 1995, ZH VYSSH NERV DEYAT+, V45, P3; Kostyunina MB, 1998, ZH VYSSH NERV DEYAT+, V48, P213; KRAAIER V, 1992, ELECTROEN CLIN NEURO, V82, P208, DOI 10.1016/0013-4694(92)90169-I; Lindgren M, 1999, PSYCHOPHARMACOLOGY, V145, P342, DOI 10.1007/s002130051067; Lubar JF, 1999, INTRO QUANTITATIVE E, P103, DOI DOI 10.1016/B978-012243790-8/50006-7; MECHANIC D, 1975, MED CARE, V13, P189, DOI 10.1097/00005650-197503000-00001; NEWMAN F, 1992, PSYCHIAT RES-NEUROIM, V45, P105, DOI 10.1016/0925-4927(92)90004-N; Osaka M, 1999, COGNITIVE BRAIN RES, V8, P365, DOI 10.1016/S0926-6410(99)00022-1; OSAKA M, 1984, PSYCHOPHYSIOLOGY, V21, P101, DOI 10.1111/j.1469-8986.1984.tb02325.x; PASSERO S, 1995, DEMENTIA, V6, P148, DOI 10.1159/000106938; PFURTSCHELLER G, 1989, Brain Topography, V2, P3, DOI 10.1007/BF01128838; PIERLOVISI-LAVAIVRE M, 1991, Neurophysiologie Clinique, V21, P411, DOI 10.1016/S0987-7053(05)80332-6; Posthuma D, 2001, BEHAV GENET, V31, P567, DOI 10.1023/A:1013345411774; PSATTA D M, 1991, Revue Roumaine de Neurologie et Psychiatrie, V29, P9; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; SALETU B, 1984, INT J CLIN PHARM RES, V4, P95; SALETU B, 1995, INT J CLIN PHARM TH, V33, P249; Sterman MB, 2000, CLIN ELECTROENCEPHAL, V31, P45, DOI 10.1177/155005940003100111; Suldo S. M., 2001, Journal of Neurotherapy, V5, P39; Thatcher RW, 1999, INTRO QUANTITATIVE E, P29; TIFFIN P, 1995, PSYCHOPHARMACOLOGY, V121, P494, DOI 10.1007/BF02246500; VANDERWORP HB, 1991, ELECTROEN CLIN NEURO, V79, P335, DOI 10.1016/0013-4694(91)90197-C; WILSHER CR, 1994, CURRENT DIRECTIONS D; 李德明, 1996, [心理学报, Acta Psychologica Sinica], V28, P76	41	101	108	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	APR	2004	115	4					887	897		10.1016/j.clinph.2003.11.034			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	806DO	WOS:000220414800021	15003770				2021-06-18	
J	Kaups, KL; Davis, JW; Parks, SN				Kaups, KL; Davis, JW; Parks, SN			Routinely repeated computed tomography after blunt head trauma: Does it benefit patients?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma		computed tomography of the head; closed head injury; brain injury	BRAIN-INJURY; FOLLOW-UP; NONOPERATIVE MANAGEMENT; CT SCANS; HYPOTENSION; HEMORRHAGE; MODERATE; UTILITY; HEMATOMAS; CHILDREN	Background. Computed tomography of the head (HCT) is an integral part of the diagnosis and management of the patient with head injury, but the utility of repeated HCT performed solely for routine follow-up in the patient with blunt head trauma has not been defined. In the absence of clinical indications, routinely repeated HCT, even in patients with significant brain injury, does not contribute to patient care. Methods. Trauma registry records at a Level I trauma center from July 1, 1997, to June 30, 2002, were reviewed. Patients with severe blunt head injury (Abbreviated Injury Scale score greater than or equal to 3) admitted to the intensive care unit and who had a repeat HCT scan obtained for scheduled follow-up were included. Those patients with initial craniotomy, repeat HCT more than 72 hours after the initial HCT, or repeat HCT ordered for clinical indications were excluded. Data included were age, mechanism of injury, time to initial (HCT1) and repeat HCT (HCT2), indications for HCT2, and HCT findings. Additional data included Glasgow Coma Scale (GCS) score (admission and at HCT2); Injury Severity Score; occurrence of hypotension, coagulopathy, or elevated intracranial pressure (ICP); interventions made; and patient outcome. Results. Entry criteria were met in 462 patients. Most were injured in motor vehicle crashes; the average age was 36 years and the mean initial GCS score was 9. The mean time to HCT1 was 1.3 hours and the mean time to HCT2 was 22.6 hours. HCT2 showed worsening in 85 patients (18.4%), and 16 patients had interventions in response to HCT2 (repeat HCT in 8, ICP monitoring or drainage in 6, and craniotomy in 2). No patient undergoing routine repeat HCT without other clinical findings required intervention. All patients with worsening HCT findings requiring intervention had coagulopathy, hypotension, ICP elevation, or marked decrease in GCS score. Conclusion: In the absence of clinical indicators or risk factors, repeat HCT after blunt head injury does not alter patient management and is unnecessary.	Calif State Univ Fresno, Med Ctr, Dept Surg, Fresno, CA 93702 USA	Kaups, KL (corresponding author), Calif State Univ Fresno, Med Ctr, Dept Surg, 4th Floor,445 S Cedar Ave, Fresno, CA 93702 USA.	kaups@ucsfresno.edu					Allins A, 1996, AM SURGEON, V62, P883; ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; *BRAIN TRAUM FDN, 1996, GUID MAN SEV HEAD IN; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Davis KA, 1996, ARCH SURG-CHICAGO, V131, P255; Falimirski ME, 2003, J TRAUMA, V55, P1, DOI 10.1097/01.TA.0000071295.67263.A2; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HURST JM, 1992, J TRAUMA, V33, P582, DOI 10.1097/00005373-199210000-00015; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, ACT NEUR S, V81, P81; Servadei F, 2000, NEUROSURGERY, V46, P70; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Thaemert BC, 1997, J TRAUMA, V43, P748, DOI 10.1097/00005373-199711000-00003; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533	36	101	105	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2004	56	3					475	480		10.1097/01.TA.0000114304.56006.D4			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	808CM	WOS:000220547200003	15128116				2021-06-18	
J	Yune, TY; Kim, SJ; Lee, SM; Lee, YK; Oh, YJ; Kim, YC; Markelonis, GJ; Oh, TH				Yune, TY; Kim, SJ; Lee, SM; Lee, YK; Oh, YJ; Kim, YC; Markelonis, GJ; Oh, TH			Systemic administration of 17 beta-estradiol reduces apoptotic cell death and improves functional recovery following traumatic spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; BB score; bcl-2; bcl-x; caspase-3; DNA laddering; estrogen; functional recovery; lesion area; neuroprotection; spinal cord injury; TUNEL	ESTROGEN REPLACEMENT THERAPY; BETA-ESTRADIOL PROTECTS; INDUCED NEURONAL DEATH; NECROSIS-FACTOR-ALPHA; CEREBRAL-ISCHEMIA; BCL-2 EXPRESSION; GLOBAL-ISCHEMIA; MOUSE MODEL; OXIDATIVE STRESS; GLIAL APOPTOSIS	Recent evidence indicates that estrogen exerts neuroprotective effects in both brain injury and neurodegenerative diseases. We examined the protective effect of estrogen on functional recovery after spinal cord injury (SCI) in rats. 17beta-estradiol (3, 100, or 300 mug/kg) was administered intravenously 1-2 h prior to injury (pre-treatment), and animals were then subjected to a mild, weight-drop spinal cord contusion injury. Estradiol treatment significantly improved hind limb motor function as determined by the Basso-Beattie-Bresnahan (BBB) locomotor open field behavioral rating test. Fifteen to 30 days after SCI, BBB scores were significantly higher in estradiol-treated (100 mug/kg) rats when compared to vehicle-treated rats. Morphological analysis showed that lesion sizes increased progressively in either vehicle-treated or 17beta-estradiol-treated spinal cords. However, in response to treatment with 17beta-estradiol, the lesion size was significantly reduced 18-28 days after SCI when compared to vehicle-treated controls. Terminal deoxynucleotidyl transferase-mediated UTP nick-end labeling (TUNEL) staining and DNA gel electrophoresis revealed that apoptotic cell death peaked 24-48 h after injury. Also, SCI induced a marked increase in activated caspase-3 in the spinal cord, evident by 4 h after injury. However, administration of 17beta-estradiol significantly reduced the SCI-induced increase in apoptotic cell death and caspase-3 activity after SCI. Furthermore, 17beta-estradiol significantly increased expression of the anti-apoptotic genes, bcl-2 and bcl-x, after SCI while expression of the pro-apoptotic genes, bad and bax, was not affected by drug treatment. Finally, intravenous administration of 17beta-estradiol (100 mug/kg) immediately after injury (post-treatment) also significantly improved hind limb motor function 19-30 days after SCI compared to vehicle-treated controls. These data suggest that after SCI, 17beta-estradiol treatment improved functional recovery in the injured rat, in part, by reducing apoptotic cell death.	Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Korea Inst Sci & Technol, Ctr Biomed Res, Seoul 130650, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; Seoul Natl Univ, Coll Pharm, Seoul, South Korea	Oh, TH (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, 685 W Baltimore St, Baltimore, MD 21201 USA.	toh@umaryland.edu					Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Antonawich FJ, 1999, EXP NEUROL, V156, P130, DOI 10.1006/exnr.1998.7004; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; BALENTINE JD, 1978, LAB INVEST, V39, P236; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Behl C, 1997, MOL PHARMACOL, V51, P535; Callier S, 2000, SYNAPSE, V37, P245, DOI 10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chen J, 2000, J CEREBR BLOOD F MET, V20, P1033, DOI 10.1097/00004647-200007000-00002; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; CHEN J, 1998, J CEREB BLOOD FLOW M, V18, P931; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Dare E, 2000, J NEUROSCI RES, V62, P557, DOI 10.1002/1097-4547(20001115)62:4<557::AID-JNR10>3.0.CO;2-9; Disshon KA, 1997, BRAIN RES, V764, P9, DOI 10.1016/S0006-8993(97)00418-6; Dluzen DE, 2000, J NEUROCYTOL, V29, P387, DOI 10.1023/A:1007117424491; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Goodman SB, 1998, BIOL REPROD, V59, P820, DOI 10.1095/biolreprod59.4.820; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Greene K, 1997, WOMEN POLIT, V17, P17, DOI 10.1300/J014v17n03_02; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Gridley KE, 1998, MOL PHARMACOL, V54, P874; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; Henderson VW, 1996, PSYCHONEUROENDOCRINO, V21, P421, DOI 10.1016/0306-4530(95)00060-7; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; LEE SM, 2004, IN PRESS J NEUROTRAU; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li YQ, 2000, RADIAT RES, V154, P268, DOI 10.1667/0033-7587(2000)154[0268:RIAITN]2.0.CO;2; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lu AG, 2002, J CEREBR BLOOD F MET, V22, P183, DOI 10.1097/00004647-200202000-00006; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; SABOURIN JC, 1994, INT J CANCER, V59, P1, DOI 10.1002/ijc.2910590102; Sawada H, 2000, FASEB J, V14, P1202; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Schmidt R, 1996, J AM GERIATR SOC, V44, P1307, DOI 10.1111/j.1532-5415.1996.tb01400.x; SELINA CC, 1989, BRAIN RES, V482, P271; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; SHIMAZAKI K, 1994, NEUROSCI RES, V20, P95, DOI 10.1016/0168-0102(94)90026-4; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Thompson KE, 2002, ENDOCRINOLOGY, V143, P1058, DOI 10.1210/en.143.3.1058; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116; Zaulyanov LL, 1999, CELL MOL NEUROBIOL, V19, P705, DOI 10.1023/A:1006948921855; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	96	101	116	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					293	306		10.1089/089771504322972086			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600007	15115604				2021-06-18	
J	Wagner, AK; Willard, LA; Kline, AE; Wenger, MK; Bolinger, BD; Ren, DX; Zafonte, RD; Dixon, CE				Wagner, AK; Willard, LA; Kline, AE; Wenger, MK; Bolinger, BD; Ren, DX; Zafonte, RD; Dixon, CE			Evaluation of estrous cycle stage after experimental and gender on behavioral outcome traumatic brain injury	BRAIN RESEARCH			English	Article						gender; estrogen; progesterone; traumatic brain injury; spatial memory; motor function	CONTROLLED CORTICAL IMPACT; COGNITIVE RECOVERY; RECEPTOR-ALPHA; WORKING-MEMORY; CEREBRAL EDEMA; MESSENGER-RNA; PROGESTERONE; PERFORMANCE; ESTRADIOL; MODEL	Female sex hormones are acutely neuroprotective in experimental models of traumatic brain injury (TBI). Because hormonal profiles are known to vary with estrous cycle stage, the purpose of this study was to evaluate how pre-injury estrous stage affects motor and cognitive performance after experimental TBI. We also sought to compare post-injury behavioral performance in males vs. females. Under anesthesia, male (n = 18) and female (n = 35) Sprague-Dawley rats underwent either controlled cortical impact (CCI) injury (2.7 mm; 4 m/s) or sham operations. Females were grouped according to estrous stage (proestrous or non-proestrous) at the time of surgery. Motor function was assessed pre-injury and for the first 5 days after surgery using beam balance and walking tasks. Spatial memory was assessed beginning 14 days post-injury utilizing the Morris water maze (MWM) task. No significant differences were found on any task between injured females regardless of estrous cycle stage. Females performed significantly better than males on both motor tasks, but gender did not influence MWM performance. Mixed effects multivariate analysis corroborated these results by showing that pre-injury serum hormone levels had little affect on behavioral performance. The results suggest that the presence of endogenous circulating hormones, rather than hormonal status at time of injury, may confer early neuroprotection in females after TBI. The impact of early neuroprotection on later behavioral outcome and the anatomic structural specificity of hormonal neuroprotection require further study. (C) 2003 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	wagnerak@msx.upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD41399, K08HD40833] Funding Source: Medline; ODCDC CDC HHS [CCR310285-07] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD041399, K08HD040833] Funding Source: NIH RePORTER		Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Berry B, 1997, BEHAV NEUROSCI, V111, P267, DOI 10.1037/0735-7044.111.2.267; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BRYAN JM, 2001, J NEUROTRAUM, V18, P1129; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Candelario-Jalil E, 2001, NEUROSCI RES, V41, P233, DOI 10.1016/S0168-0102(01)00282-6; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fugger HN, 1998, HORM BEHAV, V34, P163, DOI 10.1006/hbeh.1998.1475; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harukuni I, 2001, BRAIN RES, V900, P137, DOI 10.1016/S0006-8993(01)02278-8; Healy SD, 1999, P ROY SOC B-BIOL SCI, V266, P2303, DOI 10.1098/rspb.1999.0923; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Rissman EF, 2002, P NATL ACAD SCI USA, V99, P3996, DOI 10.1073/pnas.012032699; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sharp PE, 1998, LAB RAT; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; Shughrue PJ, 2003, NEUROSCIENCE, V116, P851, DOI 10.1016/S0306-4522(02)00790-X; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; Williams NI, 2001, ENDOCRINOLOGY, V142, P2381, DOI 10.1210/en.142.6.2381; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	47	101	104	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 13	2004	998	1					113	121		10.1016/j.brainres.2003.11.027			9	Neurosciences	Neurosciences & Neurology	771QA	WOS:000188796500013	14725974				2021-06-18	
J	Doppenberg, EMR; Choi, SC; Bullock, R				Doppenberg, EMR; Choi, SC; Bullock, R			Clinical trials in traumatic brain injury: Lessons for the future	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article; Proceedings Paper	Perioperative Neuroprotection Symposium	SEP 13, 2003	ANNAPOLIS, MD	Univ Maryland Sch Med, Univ Maryland Sch Med, Dept Anesthesiol, Program Neurosci Neuroprotect Res Focus Grp, Univ Maryland Sch Med, Off Grad & Continuing Med Educ		neuroprotective; clinical; trials; pitfalls	KALLIKREIN-KININ SYSTEM; ACUTE SUBDURAL-HEMATOMA; CEREBRAL BLOOD-FLOW; THERAPEUTIC HYPOTHERMIA; AXONAL CHANGE; HEAD-INJURY; ISCHEMIA; GLUTAMATE; MEDIATOR; EDEMA	Thus far, none of the neuroprotective drugs that have been tested to reduce or prevent secondary ischemic brain damage have been shown clear benefit. We will attempt to identify factors that may be responsible for some of these failures. We also will give our thoughts on how to prevent these pitfalls in the usefulness and criteria for use of animal models for traumatic brain injury to depict human head injury are discussed. Clearly, mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, are more likely to show benefit in this heterogeneous patient population. Other factors, such as the effect of brain penetration, safety and tolerability of the compound, and the interface between the pharmaceutical industry and academics are a major influence in the success of these trials. Furthermore, the way trials have been analyzes in the past may not always have been be the most appropriate to show benefits. It is clear that a multi-targeted approach is necessary to address the complicated and closely related mechanisms seen after traumatic and or ischemic brain damage.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, POB 980631, Richmond, VA 23298 USA.	robulloc@mail2.vcu.edu					ADAMS JH, 1983, ACTA NEUROCHIR, V32, pS15; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; BROADDUS WC, 1996, NEUROTRAUMA; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; CHOI SC, 1996, DISCOVERIES HEAD TRA, P67; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; Drummond ME, 1987, METHODS EC EVALUATIO; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KURODA Y, 1992, NEUROSURGERY, V31, P1062, DOI 10.1227/00006123-199212000-00012; LANDOLT H, 1994, ACTA NEUROCHIR, P475; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; Marmarou A, 1996, ACT NEUR S, V66, P118; McLellan D, 1986, COMA TRAUMATIQUE, P165; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WEI EP, 1993, AM J PHYSIOL, V265, pH1439; Whitehead J., 1983, DESIGN ANAL SEQUENTI; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	31	101	102	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2004	16	1					87	94		10.1097/00008506-200401000-00019			8	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	758PR	WOS:000187659800018	14676577				2021-06-18	
J	Brehaut, JC; Miller, A; Raina, P; McGrail, KM				Brehaut, JC; Miller, A; Raina, P; McGrail, KM			Childhood behavior disorders and injuries among children and youth: A population-based study	PEDIATRICS			English	Article						methylphenidate; attention-deficit/hyperactivity disorder; behavior disorders; injury; children; database analysis	DEFICIT-HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; SCHOOL-AGE-CHILDREN; YOUNG-ADULTS; FOLLOW-UP; METHYLPHENIDATE; PRESCRIPTION; ADOLESCENTS; MEDICATION; DATABASE	Context. While an association between pediatric behavioral disorders and injuries is generally acknowledged, no studies have measured the risk for injury in the context of a large, population-based study that is free of cohort biases. Objectives. To examine the association between childhood behavior disorders ([CBDs] as indicated by prescription for methylphenidate [MPH]) and a variety of injury outcomes, and to evaluate the risk for injury among these children after controlling for known demographic correlates. Design. Population-based database analysis of all children in British Columbia (BC) under the age of 19 as of December 31, 1996; comparison of those who had been prescribed MPH and therefore placed in the CBD group (n = 16 806) and those who were not (n = 1 010 067). Demographic information collected was as follows: age, sex, measures of socioeconomic status, and region of residence. Outcome Measures. Common types of childhood injury in BC: International Classification of Diseases, Ninth Revision N-codes (fractures, open wounds, poisoning/ toxic effect, concussion, intracranial, burns) and E-codes (falls, postoperative complications, motor vehicle accidents, struck by object, adverse effects of drugs, suffocation, drowning). Data Source. BC Linked Health Data Set and the BC Triplicate Prescription Program. Results. After controlling for known demographic correlates, odds for injury was greater among those treated with MPH and presumed to have a behavioral disorder, when injury was characterized either by type (1.67; 99% confidence interval: 1.54-1.81) or cause (1.52; 99% confidence interval: 1.40-1.66) of injury. This increased risk extended to unexpected categories of injury such as postoperative complications and adverse effects of drugs. Conclusions. Children with CBDs have >1.5 times the odds of sustaining injuries of a variety of types from a variety of causes, even after controlling for known demographic correlates, than those without behavioral disorders. The risks for these children extend beyond those that might be directly associated with impulsivity and overactivity. Injury prevention strategies aimed at this group of children and youth would be beneficial. Policy-makers should account for increased risk of a wide variety of injuries in this group of children and youth.	Ottawa Hosp, Clin Epidemiol Unit, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Childrens & Womens Hlth Ctr British Columbia, Ctr Community Hlth & Hlth Evaluat Res, Vancouver, BC, Canada; Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada; British Columbia Injury Res & Prevent Unit, Vancouver, BC, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V5Z 1M9, Canada	Brehaut, JC (corresponding author), Ottawa Hosp, Clin Epidemiol Unit, Ottawa Hlth Res Inst, Civ Campus,F6-1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.		Miller, Anton/U-5719-2018	Miller, Anton/0000-0002-6509-2589			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARKLEY RA, 1993, PEDIATRICS, V92, P212; BARKLEY RA, 1990, J AM ACAD CHILD PSY, V29, P546, DOI 10.1097/00004583-199007000-00007; Barkley RA, 1996, PEDIATRICS, V98, P1089; BARKLEY RA, 2001, EC NEUROSCI, V3, P64; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; Brownell MD, 2001, CAN J PSYCHIAT, V46, P264, DOI 10.1177/070674370104600307; Bussing R, 1996, ARCH PEDIAT ADOL MED, V150, P50, DOI 10.1001/archpedi.1996.02170260054009; Chamberlayne R, 1998, CAN J PUBLIC HEALTH, V89, P270, DOI 10.1007/BF03403934; Christoffel KK, 1996, PEDIATRICS, V97, P33; Cox DJ, 2000, J NERV MENT DIS, V188, P230, DOI 10.1097/00005053-200004000-00006; DAVIDSON LL, 1987, J DEV BEHAV PEDIATR, V8, P335; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; Dulcan M, 1997, J AM ACAD CHILD PSY, V36, pS85, DOI 10.1097/00004583-199710001-00007; FARMER JE, 1995, HEALTH PSYCHOL, V14, P325, DOI 10.1037/0278-6133.14.4.325; HALPERIN JM, 1995, J CHILD PSYCHOL PSYC, V36, P1199, DOI 10.1111/j.1469-7610.1995.tb01365.x; *HLTH CAN, 1999, SURV ATT DEF HYP DIS; Hoagwood K, 2000, J AM ACAD CHILD PSY, V39, P198, DOI 10.1097/00004583-200002000-00020; HUSBAND P, 1972, ARCH DIS CHILD, V47, P396, DOI 10.1136/adc.47.253.396; Jolly B T, 1998, Ann Emerg Med, V32, P267; Kohen D E, 2000, Inj Prev, V6, P223, DOI 10.1136/ip.6.3.223; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; KRALL V, 1953, J ABNORM SOC PSYCH, V48, P99, DOI 10.1037/h0054392; KWASMAN A, 1995, ARCH PEDIAT ADOL MED, V149, P1211, DOI 10.1001/archpedi.1995.02170240029004; LeFever GB, 1999, AM J PUBLIC HEALTH, V89, P1359, DOI 10.2105/AJPH.89.9.1359; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; MANHEIMER DI, 1967, CHILD DEV, V38, P491, DOI 10.1111/j.1467-8624.1967.tb04358.x; MEYER RJ, 1963, J PEDIATR, V71, P95; Miller AR, 2001, CAN MED ASSOC J, V165, P1489; Ng E, 1993, Health Rep, V5, P179; RAPPLEY MD, 1995, ARCH PEDIAT ADOL MED, V149, P675, DOI 10.1001/archpedi.1995.02170190085015; Robison LM, 1999, CLIN PEDIATR, V38, P209, DOI 10.1177/000992289903800402; RUEL JM, 1992, CAN J PSYCHIAT, V37, P570, DOI 10.1177/070674379203700809; Safer D J, 2000, Ann Clin Psychiatry, V12, P55, DOI 10.1023/A:1009031211900; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; SHAPIRO ED, 1989, INFECT CONT HOSP EP, V10, P167, DOI 10.2307/30144323; SOUBHI H, 1999, UNINTENTIONAL INJURI; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P205, DOI 10.1111/j.1469-7610.1989.tb00235.x; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TSUANG MT, 1985, AM J PSYCHIAT, V142, P538; WEISS G, 1979, ARCH GEN PSYCHIAT, V36, P675; *WHO, 1985, INT CLASS DIS 9 REV; Zito JM, 1999, ARCH PEDIAT ADOL MED, V153, P1257, DOI 10.1001/archpedi.153.12.1257	43	101	103	1	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	FEB	2003	111	2					262	269		10.1542/peds.111.2.262			8	Pediatrics	Pediatrics	640VR	WOS:000180709100022	12563049				2021-06-18	
J	Hartings, JA; Williams, AJ; Tortella, FC				Hartings, JA; Williams, AJ; Tortella, FC			Occurrence of nonconvulsive seizures, periodic epileptiform discharges, and intermittent rhythmic delta activity in rat focal ischemia	EXPERIMENTAL NEUROLOGY			English	Article						ischemia; electroencephalography; epilepsy; nonconvulsive seizure; PLED; IRDA; MCAo; in vivo; paroxysm; rat	INTENSIVE-CARE UNIT; CONVULSIVE STATUS EPILEPTICUS; SUSTAINED POTENTIAL SHIFTS; TRAUMATIC BRAIN INJURY; CONTINUOUS EEG; ELECTROGRAPHIC SEIZURES; PAROXYSMAL DISCHARGES; SPECTRAL-ANALYSIS; MODEL; HIPPOCAMPUS	A significant proportion of neurologic patients suffer electroencephalographic (EEG) seizures in the acute phase following traumatic or ischemic brain injury, including many without overt behavioral manifestations. Although such nonconvulsive seizures may exacerbate neuropathological processes, they have received limited attention clinically and experimentally. Here we characterize seizure episodes following focal cerebral ischemia in the rat as a model for brain injury-induced seizures. Cortical EEG activity was recorded continuously from both hemispheres up to 72 h following middle cerebral artery occlusion (MCAo). Seizure discharges appeared in EEG recordings within 1 h of MCAo in 13/16 (81%) animals and consisted predominantly of generalized 1-3 Hz rhythmic spiking. During seizures animals engaged in quiet awake or normal motor behaviors, but exhibited no motor convulsant activity. Animals had a mean of 10.6 seizure episodes within 2 h, with a mean duration of 60 s per episode. On average, seizures ceased at 1 h 59 min post-MCAo in permanently occluded animals and did not occur following reperfusion at 2 h in transiently occluded animals. In addition to seizures, periodic lateralized epileptiform discharges (PLEDs) appeared over penumbral regions in the injured hemisphere while intermittent rhythmic delta activity (IRDA) recurred in the contralateral hemisphere with frontoparietal dominance. PLEDs and IRDA persisted up to 72 It in permanent MCAo animals, and early onset of the former was predictive of prolonged seizure activity. The presentation of these EEG waveforms, each with characteristic features replicating those in clinical neurologic populations, validates rat MCAo for study of acutely induced brain seizures and other neurophysiological aspects of brain injury. Published by Elsevier Science (USA).	Walter Reed Army Inst Res, Div Neurosci, Silver Spring, MD 20910 USA	Hartings, JA (corresponding author), Walter Reed Army Inst Res, Div Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.			Hartings, Jed/0000-0001-8583-3471			Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; Bergui M, 1997, J NEUROSURG, V87, P803; Borck C, 1999, J NEUROPHYSIOL, V82, P2130; CHATRIAN GE, 1964, ELECTROEN CLIN NEURO, V17, P177, DOI 10.1016/0013-4694(64)90149-X; FARIELLO RG, 1982, ELECTROEN CLIN NEURO, V54, P194, DOI 10.1016/0013-4694(82)90161-4; Garzon E, 2001, NEUROLOGY, V57, P1175, DOI 10.1212/WNL.57.7.1175; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Gross DW, 1999, CLIN NEUROPHYSIOL, V110, P1516, DOI 10.1016/S1388-2457(99)00119-4; HANDFORTH A, 1994, EPILEPSIA, V35, P876, DOI 10.1111/j.1528-1157.1994.tb02526.x; JENSEN MS, 1988, ANN NEUROL, V24, P591, DOI 10.1002/ana.410240502; JORDAN K G, 1992, Neurology, V42, P194; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Krsek P, 2001, EPILEPSIA, V42, P171, DOI 10.1046/j.1528-1157.2001.35799.x; Lipton P, 1999, PHYSIOL REV, V79, P1431; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; MARKAND ON, 1971, NEUROLOGY, V21, P975, DOI 10.1212/WNL.21.10.975; McIntosh TK, 1996, LAB INVEST, V74, P315; Meltzer CC, 2000, EPILEPSIA, V41, P193, DOI 10.1111/j.1528-1157.2000.tb00139.x; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Neufeld MY, 1999, J NEUROL SCI, V164, P56, DOI 10.1016/S0022-510X(99)00018-0; PohlmannEden B, 1996, J CLIN NEUROPHYSIOL, V13, P519, DOI 10.1097/00004691-199611000-00007; RAROQUE H G JR, 1991, Epilepsia, V32, P77; REIHER J, 1991, ELECTROEN CLIN NEURO, V78, P12, DOI 10.1016/0013-4694(91)90013-T; SCHAUL N, 1981, ARCH NEUROL-CHICAGO, V38, P690, DOI 10.1001/archneur.1981.00510110050006; SCHRAEDER PL, 1980, EPILEPSIA, V21, P647, DOI 10.1111/j.1528-1157.1980.tb04318.x; SCHWARTZ MS, 1973, BRAIN, V96, P613, DOI 10.1093/brain/96.3.613; Silbert PL, 1996, ELECTROEN CLIN NEURO, V98, P223, DOI 10.1016/0013-4694(95)00268-5; SNODGRASS SM, 1989, J CLIN NEUROPHYSIOL, V6, P159, DOI 10.1097/00004691-198904000-00003; SOMJEN GG, 1985, J NEUROPHYSIOL, V53, P1079; Striano S, 1986, Acta Neurol (Napoli), V8, P1; Sun DA, 2001, STROKE, V32, P2344, DOI 10.1161/hs1001.097242; Tortella FC, 1997, J PHARMACOL EXP THER, V282, P286; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; VESPA PM, 1997, CRIT CARE MED S, V25, pA120; WADMAN WJ, 1992, BRAIN RES, V570, P85, DOI 10.1016/0006-8993(92)90567-S; WALSH JM, 1987, EPILEPSIA, V28, P533, DOI 10.1111/j.1528-1157.1987.tb03684.x; Williams AJ, 2002, BRAIN RES, V932, P45, DOI 10.1016/S0006-8993(02)02275-8; WILLIAMS AL, 2001, SOC NEUR ABSTR, V27; WOODS L, 2001, SOC NEUR ABSTR, V27; Young G, 1988, AM J EEG TECHNOL, V28, P1; Young GB, 1996, NEUROLOGY, V47, P83	49	101	106	2	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2003	179	2					139	149	PII S0014-4886(02)00013-4	10.1016/S0014-4886(02)00013-4			11	Neurosciences	Neurosciences & Neurology	653JM	WOS:000181432100002	12618120				2021-06-18	
J	Coelho, CA				Coelho, CA			Story narratives of adults with closed head injury and non-brain-injured adults: Influence of socioeconomic status, elicitation task, and executive functioning	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						discourse; TBI; pragmatics; stories; adults	DISCOURSE PRODUCTION; COGNITION; DEFICITS; CHILDREN; MILD	Narratives were elicited in two story tasks, retelling and generation, from two groups of adults, 55 with closed head injury (CHI) and 47 non-brain-injured (NBI), recruited from rehabilitation facilities. in three northeastern states. Participants were classified, on the basis of their socioeconomic status (SES), as professional, skilled worker, or unskilled worker. Narratives were analyzed using five discourse measures at the levels of sentence production, intersentential cohesion, and story grammar. Discourse performance was then compared across groups, tasks, and SES levels. Discourse performance of the CHI group was also compared with their scores from the Wisconsin Card Sorting Test, a measure of executive functioning. results indicated that two discourse measures, distinguished the groups. The CHI participants produced significantly fewer words per T-unit and fewer T-units within episode structure than did the NBI group, which was attributed to difficulties with content organization. Performance on all five discourse measures differed for the, story retelling versus the story generation tasks for both CHI and NBI groups. All participants produced longer and more grammatically complex T-units in the story gene ration task than in story retelling. However, cohesive adequacy and story grammar were better in the story retelling task than in the story generation task. It was therefore concluded that story generation was a more challenging task than story retelling for both groups. The only significant difference noted for SES involved the measure of intersentential cohesion. The unskilled workers demonstrated poorer cohesive adequacy. than either the skilled workers or professionals, regardless of group or story task. Finally, modest correlations were noted between the discourse performance of the CHI group and scores from the Wisconsin Card Sorting lest in both story tasks.	Univ Connecticut, Dept Commun Sci, Storrs, CT 06269 USA	Coelho, CA (corresponding author), Univ Connecticut, Dept Commun Sci, U-1085,850 Bolton Rd, Storrs, CT 06269 USA.						Baddeley A. D., 1987, WORKING MEMORY; Body R., 1999, COMMUNICATION DISORD; CANNIZZARO MS, IN PRESS BRAIN INJUR; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Connor Lisa Tabor, 2000, Seminars in Speech and Language, V21, P109; Glosser G., 1990, BRAIN LANG, V40, P67; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HAGEN C, 1980, REHABILITATION HEAD; HART T, 1999, EVALUATION TREATMENT; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Heaton R., 1993, WISCONSIN CARD SORTI; HOLLINGSHEAD A, 1972, UNPUB 4 FACTOR INDEX; Hughes D., 1997, GUIDE NARRATIVE LANG; HUNT CEL, 1970, J NUCL MATER, V35, P134, DOI 10.1016/0022-3115(70)90040-1; Kertesz A., 1982, W APHASIA BATTERY; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOL ASSESSM; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Mattis S, 1976, GERIATRIC PSYCHIAT; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P583; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; Murray Laura L., 2000, Seminars in Speech and Language, V21, P153, DOI 10.1055/s-2000-7562; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Tompkins C.A., 1995, RIGHT HEMISPHERE COM; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Van Dijk T.A., 1983, STRATEGIES DISCOURSE; Winter P., 1976, BEAR FLY; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745; YORKSTON KM, 1993, CLIN APHASIOLOGY, V21, P165	40	101	103	0	10	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA	1092-4388			J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	DEC	2002	45	6					1232	1248		10.1044/1092-4388(2002/099)			17	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	631KM	WOS:000180167000014	12546490				2021-06-18	
J	Mathias, CW; Greve, KW; Bianchini, KJ; Houston, RJ; Crouch, JA				Mathias, CW; Greve, KW; Bianchini, KJ; Houston, RJ; Crouch, JA			Detecting malingered neurocognitive dysfunction using the reliable digit span in traumatic brain injury	ASSESSMENT			English	Article						response bias; malingering; forensic; neuropsychology; assessment; Wechsler Adult Intelligence Scale	NEUROPSYCHOLOGICAL ASSESSMENT; INCOMPLETE EFFORT; SCALES	This study assessed the effectiveness of Greiffenstein's Reliable Digit Span (RDS) score for the detection of malingered neurocognitive dysfunction. Participants were 54 traumatic brain injury patients referred for neuropsychological evaluation. Twenty-four met the Slick, Sherman, and Iverson criteria for at least probable malingered neurocognitive dysfunction. The control group was composed of 30 patients without external incentive and who thus did not meet the Slick criteria. All patients completed the digit span test as part of either the WAIS-R or WAIS-III. The RDS scores were calculated, and sensitivity, specificity, and predictive power were examined for several cutoffs. Classification accuracy for the RDS was excellent. Issues related to the clinical application of this technique are discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Inst Living, Hartford, CT 06106 USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu		Mathias, Charles/0000-0003-1902-673X			Axelrod B. N., 1999, J FORENSIC NEUROPSYC, V1, P15; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; DUNCAN SA, IN PRESS ASSESSMENT; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GREVE KW, IN PRESS ARCH CLIN N; Hartlage LC, 1998, CRIT ISS NE, P239; Hennekens CH, 1987, EPIDEMIOLOGY MED; Heubrock D, 1998, EUR J PSYCHOL ASSESS, V14, P211, DOI 10.1027/1015-5759.14.3.211; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; OWENS RG, 1995, AM J FORENSIC PSYCH, V13, P61; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WECHSLER ADULT INTEL; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	32	101	102	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	SEP	2002	9	3					301	308		10.1177/1073191102009003009			8	Psychology, Clinical	Psychology	588YL	WOS:000177729800009	12216787				2021-06-18	
J	Sander, AM; Caroselli, JS; High, WM; Becker, C; Neese, L; Scheibel, R				Sander, AM; Caroselli, JS; High, WM; Becker, C; Neese, L; Scheibel, R			Relationship of family functioning to progress in a post-acute rehabilitation programme following traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	28th Annual Meeting of the International-Neuropsychological-Society	FEB, 2000	DENVER, COLORADO	Int Neuropsychol Soc			DISABILITY RATING-SCALE; CLOSED-HEAD-INJURY; ASSESSMENT DEVICE; RELATIVES; CAREGIVERS; RECOVERY; RELIABILITY; PREDICTORS; COMMUNITY; VALIDITY	Primary objective: To investigate the relationship of family functioning to patients' progress in a post-acute TBI rehabilitation programme. Research design: Cohort study investigating predictors of change from admission to follow-up. Methods and procedures: Caregivers of 37 persons with severe TBI consecutively admitted to a residential post-acute rehabilitation facility completed the Family Assessment Device (FAD) within a few weeks of admission. The Disability Rating Scale (DRS) was completed upon admission and similar to1 month after discharge. FAD scores were used to predict DRS change scores after controlling for injury severity, admit FAD scores, and time from admission to follow-up. Main outcomes and results: Persons with unhealthy family functioning showed less improvement on DRS total, level of functioning (LOF), and employability (EMP) scores. Conclusions: The results emphasize that family functioning is an important variable to include in future models predicting rehabilitation outcome, and the importance of family intervention as part of the rehabilitation process.	Brain Injury Res Ctr, Inst Rehabil & Res, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Transit Learning Ctr Galveston, Galveston, TX USA	Sander, AM (corresponding author), Brain Injury Res Ctr, Inst Rehabil & Res, 2455 S Braeswood, Houston, TX 77030 USA.						BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; SANDER A, 1999, REHABILITATION ADULT, P199; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1987, ASSESSING MED REHABI, P91; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	36	101	102	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2002	16	8					649	657		10.1080/02699050210128889			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	583GP	WOS:000177399100001	12182162				2021-06-18	
J	Rees, LM; Tombaugh, TN; Boulay, L				Rees, LM; Tombaugh, TN; Boulay, L			Depression and the Test of Memory Malingering	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						depression; TOMM; affective state; memory impairment; neurological impairment; memory dysfunction	TRAUMATIC BRAIN INJURY; MINI-MENTAL STATE; NORMATIVE DATA; TOMM	Research on the Test of Memory Malingering (TOMM) [Tombaugh, T. N., 1996. The Test of Memory Malingering. Toronto, Canada: Multi-Health Systems], has consistently shown that it is sensitive to exaggerated or deliberate faking of memory impairment, but it is relatively unaffected by a wide variety of neurological impairments causing genuine memory dysfunction. However, there is little research on the effects that affective disorders have on the TOMM. The current study examined how inpatients diagnosed with major depression performed on the TOMM. Results show that the TOMM is unaffected by affective state. These results, combined with those from previous research, provide converging evidence that performance on the TOMM below a cutoff score of 45 cannot be attributable to depression, neurological impairment, age or education. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Carleton Univ, Ottawa Concuss Clin, Ottawa, ON K1S 5B6, Canada; Royal Ottawa Hosp, Ottawa, ON K1Z 7K4, Canada	Rees, LM (corresponding author), Carleton Univ, Ottawa Concuss Clin, Room B550,Loeb Bldg, Ottawa, ON K1S 5B6, Canada.						*AM PSYCH ASS APA, 1994, DIAGN STAT MAN MENT; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kaplan H., 1991, SYNOPSIS PSYCHIAT; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; OUELLETTEHUGHES N, 1991, THESIS CARLETON U OT; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; REES LM, 1996, THESIS CARLETON U OT; Rosenstein LD, 1998, NEUROPSYCHOL REV, V8, P109, DOI 10.1023/A:1025628925796; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; WEINGARTNER H, 1986, HDB CLIN MEMORY ASSE, P218	15	101	101	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2001	16	5					501	506		10.1016/S0887-6177(00)00064-0			6	Psychology, Clinical; Psychology	Psychology	443HK	WOS:000169335600006	14590163	Bronze			2021-06-18	
J	Cherry, SR				Cherry, SR			Fundamentals of positron emission tomography and applications in preclinical drug development	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article							TRAUMATIC BRAIN INJURY; RESOLUTION PET SCANNER; IMAGING SMALL ANIMALS; IN-VIVO; PHARMACOKINETIC ANALYSIS; PERFORMANCE EVALUATION; LIVING ANIMALS; REPORTER GENE; MICROPET; ONCOLOGY	Positron emission tomography (PET) is a nuclear imaging technique that can dynamically image trace amounts of positron-labeled radiopharmaceuticals in vivo. Tracer concentrations can be determined quantitatively, and by application of appropriate tracer kinetic models, the rates of a wide range of different biological processes can be measured noninvasively in humans. PET has been used as a research tool for more than 25 years and has also found clinical applications, particularly in oncology, neurological disorders, and cardiovascular disease. Recently, there has been tremendous interest in applying PET technology to in vivo small-animal imaging. Significant improvements in the imaging technology now permit a wide range of PET studies in mice and rats, using compact, relatively low-cost, dedicated small-animal PET scanners. This article reviews the fundamental basis of PET imaging and discusses the development of small-animal PET scanners and their possible application in preclinical drug development. (C) 2001 the American College of Clinical Pharmacology.	Univ Calif Los Angeles, Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Cherry, SR (corresponding author), Univ Calif Los Angeles, Sch Med, Crump Inst Mol Imaging, Box 951770, Los Angeles, CA 90095 USA.		Cherry, Simon/AAH-1000-2019	Cherry, Simon/0000-0002-0155-5644	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA069370, R01CA074036] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 74036, CA 69370] Funding Source: Medline		Adam LE, 1997, IEEE T NUCL SCI, V44, P1172, DOI 10.1109/23.596983; Beanlands R, 1996, CAN J CARDIOL, V12, P875; Bergmann SR, 1998, SEMIN NUCL MED, V28, P320, DOI 10.1016/S0001-2998(98)80036-6; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Beyer T, 2000, J NUCL MED, V41, P1369; BLOOMFIELD PM, 1995, PHYS MED BIOL, V40, P1105, DOI 10.1088/0031-9155/40/6/010; Brooks DJ, 1997, BAILLIERE CLIN NEUR, V6, P69; Budinger TF, 1998, SEMIN NUCL MED, V28, P247, DOI 10.1016/S0001-2998(98)80030-5; Burns HD, 1999, CURR OPIN CHEM BIOL, V3, P388, DOI 10.1016/S1367-5931(99)80059-3; Chatziioannou AF, 1999, J NUCL MED, V40, P1164; CHERRY SR, 1995, IEEE T NUCL SCI, V42, P1064, DOI 10.1109/23.467748; Cherry SR, 1997, IEEE T NUCL SCI, V44, P1161, DOI 10.1109/23.596981; Chugani H T, 1999, Adv Neurol, V79, P883; Correia JA, 1999, IEEE T NUCL SCI, V46, P631, DOI 10.1109/23.775590; ENGEL J, 1995, ADV NEUROL, V66, P223; Fischman AJ, 1997, DRUG METAB REV, V29, P923, DOI 10.3109/03602539709002238; Gambaccini M, 1998, NUCL INSTRUM METH A, V409, P508, DOI 10.1016/S0168-9002(97)01304-1; Gambhir SS, 2000, NEOPLASIA, V2, P118, DOI 10.1038/sj.neo.7900083; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; GUERRERO TM, 1990, IEEE T NUCL SCI, V37, P676, DOI 10.1109/23.106697; Hoffman J M, 1995, J Med Assoc Ga, V84, P125; Hoh CK, 1997, SEMIN NUCL MED, V27, P94, DOI 10.1016/S0001-2998(97)80042-6; HUANG S-C, 1986, P287; HUME SP, 1995, SYNAPSE, V21, P45, DOI 10.1002/syn.890210107; Hume SP, 1996, J NEUROSCI METH, V67, P103; Hume SP, 1998, EUR J NUCL MED, V25, P173, DOI 10.1007/s002590050211; Jeavons AP, 1999, IEEE T NUCL SCI, V46, P468, DOI 10.1109/23.775564; Kornblum HI, 2000, NAT BIOTECHNOL, V18, P655, DOI 10.1038/76509; KUDO T, 1999, J NUCL MED, V40; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Lecomte R, 1996, IEEE T NUCL SCI, V43, P1952, DOI 10.1109/23.507252; Lewellen TK, 1996, IEEE T NUCL SCI, V43, P2199, DOI 10.1109/23.531882; MacLaren DC, 1999, GENE THER, V6, P785, DOI 10.1038/sj.gt.3300877; MARRIOTT CJ, 1994, J NUCL MED, V35, P1390; McCarthy TJ, 1998, SEMIN NUCL MED, V28, P235, DOI 10.1016/S0001-2998(98)80029-9; Mielke R, 1998, J NEURAL TRANSM-SUPP, P237; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Offord SJ, 1999, J CLIN PHARMACOL, V39, p17S, DOI 10.1002/j.1552-4604.1999.tb05933.x; OLLINGER J, 1997, IEEE SIGNAL PROC MAG, P43; Phelps ME, 1986, POSITRON EMISSION TO; Pichler B, 1998, IEEE T NUCL SCI, V45, P1298, DOI 10.1109/23.682020; Qi JY, 1998, PHYS MED BIOL, V43, P1001, DOI 10.1088/0031-9155/43/4/027; Rubins DJ, 1999, J NUCL MED, V40, p261P; Schelbert H R, 1998, Curr Probl Cardiol, V23, P69, DOI 10.1016/S0146-2806(98)80011-X; Schiepers C, 1998, EUR RADIOL, V8, P1481, DOI 10.1007/s003300050579; Shao Y, 1997, IEEE T NUCL SCI, V44, P1167, DOI 10.1109/23.596982; Slates R, 1999, IEEE T NUCL SCI, V46, P565, DOI 10.1109/23.775580; Tewson TJ, 1998, SEMIN NUCL MED, V28, P221, DOI 10.1016/S0001-2998(98)80028-7; TILSLEY DWO, 1993, CANCER SURV, V17, P425; Tornai MP, 1999, J NUCL MED, V40, P1176; TORRES EM, 1995, NEUROREPORT, V6, P2017, DOI 10.1097/00001756-199510010-00016; WAGNER HN, 1983, SCIENCE, V221, P1264, DOI 10.1126/science.6604315; Weber S, 1999, IEEE T NUCL SCI, V46, P1177, DOI 10.1109/23.790853; Weber WA, 1999, STRAHLENTHER ONKOL, V175, P356, DOI 10.1007/s000660050022; Welch MJ, 2000, J NUCL MED, V41, P315; WU AM, 1999, J NUCL MED, V40	56	101	104	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	MAY	2001	41	5					482	491		10.1177/00912700122010357			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	427UW	WOS:000168424700002	11361044				2021-06-18	
J	McAllister, TW; Sparling, MB; Flashman, LA; Saykin, AJ				McAllister, TW; Sparling, MB; Flashman, LA; Saykin, AJ			Neuroimaging findings in mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; DIFFUSE AXONAL INJURY; COMPUTED-TOMOGRAPHY; TECHNETIUM-99M-HMPAO SPECT; INTRACRANIAL INJURY; CEREBRAL PERFUSION; IMAGING FINDINGS; MRI	The role of neuroimaging in the diagnosis and management of mild traumatic brain injury (TBI) is evolving. In general, the structural imaging techniques play a role in acute diagnosis and management, while the functional imaging techniques show promise for clarification of pathophysiology, symptom genesis, and mechanisms of recovery. A wide array of neuropathological processes are involved in mild TBI including changes in bone (e.g., a skull fracture), tissue density and water content (edema), blood flow, white matter integrity and pathway connectivity (diffuse axonal injury), and subtle changes in the neuronal and extracellular biochemical milieu. No single imaging technique is capable of addressing all these processes. It is, therefore, important to be aware of the advantages and limitations of the various available imaging modalities. This paper selectively reviews the pertinent literature on the structural and functional imaging in mild TBI.	Dartmouth Coll Sch Med, Sect Neuropsychiat, Lebanon, NH USA; Dartmouth Coll Sch Med, Brain Imaging Lab, Lebanon, NH USA; New Hampshire Hosp, Concord, NH USA; Def & Vet Head Injury Program, Washington, DC USA	McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Thomas.W.McAllister@Dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS40472-01] Funding Source: Medline		Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS RD, 1985, PRINCIPLES NEUROLOGY; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Alavi A, 1996, J NUCL MED, V37, P1170; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; AUERBACH SH, 1989, PHYSICAL MED REHABIL, V3, P1; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Campbell B G, 1998, Top Magn Reson Imaging, V9, P208; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gennarelli T. A., 1987, HEAD INJURY, P108; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; GEORGE J K, 1989, Journal of Nuclear Medicine, V30, P802; GODERSKY JC, 1990, ACT NEUR S, V51, P311; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAY BG, 1992, J NUCL MED, V33, P52; Greenspan S L, 1998, Magn Reson Imaging Clin N Am, V6, P53; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V37, P463; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JACOBS A, 1994, J NUCL MED, V35, P942; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENKINS A, 1986, LANCET, V2, P445; Kawamoto H, 1997, ACTA NEUROCHIR, V139, P566, DOI 10.1007/BF02751001; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN H, 1997, ARCH NEUROL-CHICAGO, V53, P88; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McAllister T., 2001, J NEUROPSYCHIATRY CL, V13, P141; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCALLISTER TW, IN PRESS NEURO IMAGE; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; NAGAMACHI S, 1995, NUCL MED COMMUN, V16, P17, DOI 10.1097/00006231-199501000-00006; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PELLICANO G, 1997, NEURORADIOLOGY, V39, pS82; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; ROPER SN, 1991, J NUCL MED, V32, P1684; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SILVERMAN IE, 1993, J NUCL MED, V34, P1447; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Tsurushima H, 1996, NEUROL SURG TOKYO, V24, P891; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0	85	101	101	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					775	791		10.1076/jcen.23.6.775.1026			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200007	11910544				2021-06-18	
J	Angeleri, F; Majkowski, J; Cacchio, G; Sobieszek, A; D'Acunto, S; Gesuita, R; Bachleda, A; Polonara, G; Krolicki, L; Signorino, M; Salvolini, I				Angeleri, F; Majkowski, J; Cacchio, G; Sobieszek, A; D'Acunto, S; Gesuita, R; Bachleda, A; Polonara, G; Krolicki, L; Signorino, M; Salvolini, I			Posttraumatic epilepsy risk factors: One-year prospective study after head injury	EPILEPSIA			English	Article						posttraumatic epilepsy; clinical; brain CT; MRI; EEG follow-up; hemosiderin	POST-TRAUMATIC EPILEPSY; SEIZURES; MODEL; POPULATION; VETERANS; EEG; MR	Purpose: Prospective evaluation of risk factors for posttraumatic epilepsy (PTE) by using clinical, EEG, and brain computed tomography (CT) data in four assessments from the head injury (HI) acute phase to 1 year later; and evaluation of the possible epileptogenic role of hemosiderin as shown by brain magnetic resonance imaging (MRI). Methods: Risk factors for PTE were evaluated by using Kaplan-Meier curves, log-rank test, and the Cox model in 137 consecutively enrolled adult inpatients. Percentage differences of patients with brain hyperintense and/or hemosiderin areas shown by MRI 1 year after HI were statistically evaluated by univariate tests considering two subgroups [e.g., patients with (PTE) and without (WLS) late seizures]. Results: The PTE subgroup included 18 patients with at least two seizures between the second and twelfth months. Kaplan-Meier curves demonstrated that Glasgow Coma Scale low score, early seizures, and single brain CT lesions are PTE risk factors, as is the development of an EEG focus 1 month after HI. No significant percentage difference was found between PTE and WLS patients with hemosiderin spots shown by MRI 1 year after HI. Conclusions: the Cox model indicates that, for HI patients with early seizures and brain CT single temporal or frontal lesions in the acute phase, the PTE risk is 8.58 and 3.43 times higher, respectively, than for those without. An EEG focus 1 month after HI is a risk factor 3.49 times higher than for patients without such EEG changes. One year after HI, a higher percentage of PTE than WLS patients had cortical MRI hyperintense areas including hemosiderin.	Univ Ancona, Inst Nervous Dis, Neurol Clin, Ancona, Italy; Univ Ancona, Serv Neuroradiol, Ancona, Italy; Dist Hosp, Dept Neurol & Epileptol, Med Ctr Postgrad Educ, Warsaw, Poland; Dist Hosp, Dept Radiol, Warsaw, Poland; Univ Ancona, Dept Epidemiol Biostat & Med Informat Technol, Ancona, Italy	Angeleri, F (corresponding author), Univ Torrette Ancona, Polo Osped, Inst Nervous Syst Dis, Via Conca 16, I-60020 Ancona, Italy.		Gesuita, Rosaria/AAU-8863-2020	krolicki, leszek/0000-0002-7117-9621; POLONARA, GABRIELE/0000-0002-2866-2749			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; CHATRIAN GE, 1990, CURRENT PRACTICE CLI, P425; COX DR, 1972, J R STAT SOC B, V34, P187; da Silva A M, 1992, Acta Neurochir Suppl (Wien), V55, P56; DALESSANDRO R, 1983, ARCH NEUROL-CHICAGO, V40, P831, DOI 10.1001/archneur.1983.04050120081022; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; Dalmady-Israel Christina, 1993, Brain Injury, V7, P263, DOI 10.3109/02699059309029679; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; FLEISS GL, 1981, STAT METHODS RATES P, P217; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GODDARD GV, 1983, TRENDS NEUROSCI, V6, P275, DOI 10.1016/0166-2236(83)90118-2; GODDARD GV, 1980, LIMBIC EPILEPSY DYSC, P107; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; HEIKKINEN ER, 1990, STEREOT FUNCT NEUROS, V54-5, P25, DOI 10.1159/000100186; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; JABBARI B, 1986, ELECTROEN CLIN NEURO, V64, P285, DOI 10.1016/0013-4694(86)90151-3; JENNETT B, 1975, EPILEPSIA, V16, P251, DOI 10.1111/j.1528-1157.1975.tb06055.x; JENNETT B, 1990, REHABILITATION ADULT, P89; Jennett B, 1975, EPILEPSY NONMISSILE; Jennett BFrankowskiR, 1990, HDB CLIN NEUROLOGY, V13, P1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAUFMAN L, 1996, PHARM PRACTICE ANAES, P70; KUZNIECKI RI, 1995, MAGNETIC RESONANCE E; LEE TE, 1990, STAT METHODS SURVIVA; MAJKOWSKI J, 1986, ACTA NEUROL SCAND, V74, P97, DOI 10.1111/j.1600-0404.1986.tb04868.x; PAGNI CA, 1990, ACT NEUR S, V50, P38; PAMPIGLIONE G, 1975, OUTCOME SEVERE DAMAG, P263; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; VILBERGER JE, 1987, NEUROSURGERY, V20, P571; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; WILLMORE LJ, 1992, NEUROL CLIN, V10, P869; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WILLMORE LJ, 1975, EXP NEUROL, V647, P280	40	101	105	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0013-9580			EPILEPSIA	Epilepsia	SEP	1999	40	9					1222	1230		10.1111/j.1528-1157.1999.tb00850.x			9	Clinical Neurology	Neurosciences & Neurology	232JJ	WOS:000082367300006	10487184	Bronze			2021-06-18	
J	Borssen, E; Holm, AK				Borssen, E; Holm, AK			Traumatic dental injuries in a cohort of 16-year-olds in northern Sweden	ENDODONTICS & DENTAL TRAUMATOLOGY			English	Article						concussion; crown fractures; dental trauma; tooth luxation	CHILDREN	The prevalence and yearly incidence of traumatic tooth injury between 1 and 16 years of age were studied in a cohort of 16-year-olds, born in 1975, and residing in the County of Vasterbotten, northern Sweden. The study comprised 3007 dental records from the public dental health service. The general distribution was 50.3% girls and 49.7% boys. The records showed that 35% of the children on one or more occasions had sustained injury to their primary or permanent dentition. The frequency was nearly twice as high for boys (64%) as for girls (36%). Twenty-five percent of the 16-year-olds had met with tooth injury more than once and this group consisted predominantly of boys. The incidence of injury episodes to primary and permanent teeth was 28 per 1000 per year. The boys had sustained trauma to their teeth most frequently when they were 4 years of age and between the ages of 8 and 11. This was also true for girls at 4 and at 9 years of age, although less evidently so. In the primary dentition, the majority of dental injuries had affected the supporting tissue of the maxillary incisors. In the permanent dentition, 75% of the traumatised teeth were upper incisors. Fractures of varying severity constituted 60% of all registered diagnoses in this dentition, followed by subluxation (19%) and concussion (11%).		Borssen, E (corresponding author), UMEA UNIV,DEPT PEDODONT,S-90187 UMEA,SWEDEN.						Andreasen J O, 1972, Int J Oral Surg, V1, P235, DOI 10.1016/S0300-9785(72)80042-5; FORSBERG CM, 1990, SWED DENT J, V14, P115; Glendor U, 1996, SWED DENT J, V20, P15; Hedegard B, 1973, Sven Tandlak Tidskr, V66, P431; Holland T, 1988, J Paediatr Dent, V4, P13; HOLM AK, 1975, COMMUNITY DENT ORAL, V3, P25, DOI 10.1111/j.1600-0528.1975.tb00275.x; JARVINEN S, 1979, ACTA ODONTOL SCAND, V37, P47, DOI 10.3109/00016357909004684; Magnusson B, 1969, Sven Tandlak Tidskr, V62, P61; OIKARINEN K, 1987, ENDOD DENT TRAUMATOL, V3, P172; RAVN JJ, 1974, COMMUNITY DENT ORAL, V2, P231, DOI 10.1111/j.1600-0528.1974.tb01658.x; Stecksen-Blicks C, 1995, Int J Paediatr Dent, V5, P143; STOCKWELL AJ, 1988, COMMUNITY DENT ORAL, V16, P294, DOI 10.1111/j.1600-0528.1988.tb01779.x	12	101	108	0	5	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0109-2502			ENDOD DENT TRAUMATOL	Endod. Dent. Traumatol.	DEC	1997	13	6					276	280					5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	YK454	WOS:A1997YK45400005	9558509				2021-06-18	
J	McKeating, EG; Andrews, PJD; Signorini, DF; Mascia, L				McKeating, EG; Andrews, PJD; Signorini, DF; Mascia, L			Transcranial cytokine gradients in patients requiring intensive care after acute brain injury	BRITISH JOURNAL OF ANAESTHESIA			English	Article						brain, injury; polypeptides, cytokines; intensive care	HEAD-INJURY; RAT-BRAIN; IL-6; INTERLEUKIN-6; ELEVATION; SEPSIS; PLASMA	After acute brain injury there may be increased intracranial production of cytokines, with activation of inflammatory cascades. We have sought to determine if a transcranial cytokine gradient was demonstrable in paired sera of 32 patients requiring intensive care after acute brain injury. The difference between concentrations of IL-1 beta, IL-6, IL-8 and TNF alpha in jugular venous and arterial serum was measured on admission, and at 24, 48 and 96 h after the primary injury. There were no differences in IL-1 beta, IL-8 or TNF alpha, but median gradients of 6.7 and 11.5 pg ml(-1) for IL-6 were demonstrated in the traumatic brain injury (n=22) and subarachnoid haemorrhage (n=10) groups, respectively (normal values in serum <4.7 pg ml(-1); P<0.001 both groups). This suggests that there is significant production of IL-6 by intracranial cells after acute brain injury. Therapy directed towards combatting the negative effects of IL-6 may potentially benefit patients who have sustained an acute brain injury.	UNIV EDINBURGH,WESTERN GEN HOSP,DEPT ANAESTHET,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV BARI,DEPT INTENS CARE,BARI,ITALY	McKeating, EG (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		mascia, Luciana/L-3039-2018				ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BELLANTI JA, 1994, PEDIATR CLIN N AM, V41, P597; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; FOEX BA, 1993, INJURY, V24, P373, DOI 10.1016/0020-1383(93)90098-Q; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HOFMAN F M, 1990, Regional Immunology, V3, P268; Lam JMK, 1996, BRIT J NEUROSURG, V10, P357; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; PATEL RT, 1994, BRIT J SURG, V81, P1306, DOI 10.1002/bjs.1800810914; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; Ronco JJ, 1996, CRIT CARE CLIN, V12, P645, DOI 10.1016/S0749-0704(05)70268-2; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Souter MJ, 1996, BRIT J ANAESTH, V76, P744; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F	25	101	103	0	0	PROF SCI PUBL	LONDON	TAVISTOCK HOUSE EAST, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	MAY	1997	78	5					520	523					4	Anesthesiology	Anesthesiology	WZ848	WOS:A1997WZ84800007	9175965				2021-06-18	
J	VINK, R; MCINTOSH, TK; WEINER, MW; FADEN, AI				VINK, R; MCINTOSH, TK; WEINER, MW; FADEN, AI			EFFECTS OF TRAUMATIC BRAIN INJURY ON CEREBRAL HIGH-ENERGY PHOSPHATES AND PH - A P-31 MAGNETIC-RESONANCE SPECTROSCOPY STUDY	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article									UNIV CALIF SAN FRANCISCO,CTR NEURAL INJURY,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MAGNET RESONANCE UNIT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143	VINK, R (corresponding author), VET ADM MED CTR,NEUROL SERV 127,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.		Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			ACKERMAN JJH, 1980, NATURE, V283, P167, DOI 10.1038/283167a0; ACKERMAN JJH, 1984, J MAGN RESON, V56, P318, DOI 10.1016/0022-2364(84)90109-4; ALBIN MS, 1969, J TRAUM, V9, P1000, DOI 10.1097/00005373-196912000-00004; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BEHAR KL, 1985, J NEUROCHEM, V44, P1045, DOI 10.1111/j.1471-4159.1985.tb08723.x; BOTTOMLEY PA, 1984, RADIOLOGY, V150, P441, DOI 10.1148/radiology.150.2.6691099; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; CADY EB, 1983, LANCET, V1, P1059; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; CHANCE B, 1978, P NATL ACAD SCI USA, V75, P4925, DOI 10.1073/pnas.75.10.4925; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; COURTEN-MYERS G M, 1985, Stroke, V16, P1016; COX DWG, 1983, BIOCHEM J, V212, P365, DOI 10.1042/bj2120365; CROCKARD A, 1980, STROKE, V11, P494, DOI 10.1161/01.STR.11.5.494; DECORPS M, 1984, FEBS LETT, V168, P1, DOI 10.1016/0014-5793(84)80195-7; DELPY DT, 1982, PEDIATRICS, V70, P310; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GADIAN DG, 1986, ABSTR SOC MAGN RES M, V5, P1109; GADIAN DG, 1982, NUCLEAR MAGNETIC RES; GONZALEZMENDEZ R, 1985, J CEREBR BLOOD F MET, V5, P512, DOI 10.1038/jcbfm.1985.77; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; GYULAI L, 1985, J BIOL CHEM, V260, P3947; HASELGROVE JC, 1985, BRAIN IMAGING BRAIN, P271; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; ISHIGE N, 1987, J NEUROSURG, V20, P848; KIM SH, 1985, J CEREBR BLOOD F MET, V5, P432, DOI 10.1038/jcbfm.1985.58; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LITT L, 1985, J CEREBR BLOOD F MET, V5, P537, DOI 10.1038/jcbfm.1985.81; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PETROFF OAC, 1984, ANN NEUROL, V16, P169, DOI 10.1002/ana.410160203; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SATO M, 1984, J CEREBR BLOOD F MET, V4, P173, DOI 10.1038/jcbfm.1984.25; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SHOUBRIDGE EA, 1982, FEBS LETT, V140, P288, DOI 10.1016/0014-5793(82)80916-2; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SWANSON PD, 1969, ARCH NEUROL-CHICAGO, V20, P653, DOI 10.1001/archneur.1969.00480120099010; THULBORN KR, 1982, J CEREBR BLOOD F MET, V2, P299, DOI 10.1038/jcbfm.1982.31; VINK R, 1987, IN PRESS ANN NY ACAD; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHIDA S, 1985, J CEREBR BLOOD F MET, V5, P490, DOI 10.1038/jcbfm.1985.75; YOUNKIN DP, 1984, ANN NEUROL, V16, P581, DOI 10.1002/ana.410160509	54	101	101	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	1987	7	5					563	571		10.1038/jcbfm.1987.106			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	K4661	WOS:A1987K466100006	3654796	Bronze			2021-06-18	
J	Giacino, JT; Katz, DI; Schiff, ND; Whyte, J; Ashman, EJ; Ashwal, S; Barbano, R; Hammond, FM; Laureys, S; Ling, GSF; Nakase-Richardson, R; Seel, RT; Yablon, S; Getchius, TSD; Gronseth, GS; Armstrong, MJ				Giacino, Joseph T.; Katz, Douglas I.; Schiff, Nicholas D.; Whyte, John; Ashman, Eric J.; Ashwal, Stephen; Barbano, Richard; Hammond, Flora M.; Laureys, Steven; Ling, Geoffrey S. F.; Nakase-Richardson, Risa; Seel, Ronald T.; Yablon, Stuart; Getchius, Thomas S. D.; Gronseth, Gary S.; Armstrong, Melissa J.			Practice guideline update recommendations summary: Disorders of consciousness Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research	NEUROLOGY			English	Article							LOCKED-IN SYNDROME; INPATIENT REHABILITATION; VEGETATIVE STATE; BRAIN-INJURY; RECOVERY; SCALE; COMA; OUTCOMES; RESPONSIVENESS; COMORBIDITIES	Objective To update the 1995 American Academy of Neurology (AAN) practice parameter on persistent vegetative state and the 2002 case definition on minimally conscious state (MCS) and provide care recommendations for patients with prolonged disorders of consciousness (DoC). Methods Recommendations were based on systematic review evidence, related evidence, care principles, and inferences using a modified Delphi consensus process according to the AAN 2011 process manual, as amended. Recommendations Clinicians should identify and treat confounding conditions, optimize arousal, and perform serial standardized assessments to improve diagnostic accuracy in adults and children with prolonged DoC (Level B). Clinicians should counsel families that for adults, MCS (vs vegetative state [VS]/unresponsive wakefulness syndrome [UWS]) and traumatic (vs nontraumatic) etiology are associated with more favorable outcomes (Level B). When prognosis is poor, long-term care must be discussed (Level A), acknowledging that prognosis is not universally poor (Level B). Structural MRI, SPECT, and the Coma Recovery Scale-Revised can assist prognostication in adults (Level B); no tests are shown to improve prognostic accuracy in children. Pain always should be assessed and treated (Level B) and evidence supporting treatment approaches discussed (Level B). Clinicians should prescribe amantadine (100-200 mg bid) for adults with traumatic VS/UWS or MCS (4-16 weeks post injury) to hasten functional recovery and reduce disability early in recovery (Level B). Family counseling concerning children should acknowledge that natural history of recovery, prognosis, and treatment are not established (Level B). Recent evidence indicates that the term chronic VS/UWS should replace permanent VS, with duration specified (Level B). Additional recommendations are included.	[Giacino, Joseph T.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Giacino, Joseph T.] Harvard Med Sch, Boston, MA USA; [Giacino, Joseph T.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Katz, Douglas I.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA; [Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Ashman, Eric J.] Bronson Methodist Hosp, Bronson Neurosci Ctr, Kalamazoo, MI USA; [Ashwal, Stephen] Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Loma Linda, CA 92350 USA; [Barbano, Richard] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14627 USA; [Hammond, Flora M.] Univ Indiana, Indiana Univ, Dept Phys Med & Rehabil, Sch Med, Indianapolis, IN USA; [Laureys, Steven] Sart Tillman Liege Univ, Coma Sci Grp GIGA Res, Liege, Belgium; [Laureys, Steven] Sart Tillman Liege Univ, Dept Neurol, Liege, Belgium; [Laureys, Steven] Univ Hosp, Liege, Belgium; [Ling, Geoffrey S. F.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Ling, Geoffrey S. F.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD USA; [Nakase-Richardson, Risa] US Dept Vet Affairs, James A Haley Vet Hosp, Tampa, FL 33612 USA; [Seel, Ronald T.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA; [Seel, Ronald T.] Virginia Commonwealth Univ, Sch Med, Ctr Rehabil Sci & Engn, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; [Yablon, Stuart] Univ Mississippi, Sch Med, Div Phys Med & Rehabil, Jackson, MS USA; [Yablon, Stuart] Methodist Rehabil Ctr, Brain Injury Program, Jackson, MS USA; [Getchius, Thomas S. D.] Heart Rhythm Soc, Washington, DC USA; [Gronseth, Gary S.] Univ Kansas, Med Ctr, Dept Neurol, Lawrence, KS 66045 USA; [Armstrong, Melissa J.] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL USA	Giacino, JT (corresponding author), Amer Acad Neurol, Minneapolis, MN 55415 USA.	guidelines@aan.com	Laureys, Steven/AAN-2097-2021; Giacino, Joseph/AAF-1952-2021; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; Giacino, Joseph/0000-0002-7916-9698; Armstrong, Melissa/0000-0002-2163-1907	American Academy of Neurology (AAN); American Congress of Rehabilitation Medicine; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services	This practice guideline was funded by the American Academy of Neurology (AAN), the American Congress of Rehabilitation Medicine, and the National Institute on Disability, Independent Living, and Rehabilitation Research. Authors who serve or served as AAN subcommittee members (E.J.A., S.A., R.B., G.S.G.) or as methodologists (M.J.A., G.S.G.), or who were AAN staff members (T.S.D.G.), were reimbursed by the AAN for expenses related to travel to subcommittee meetings where drafts of manuscripts were reviewed.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Candelieri A, 2011, J NEUROTRAUM, V28, P2013, DOI 10.1089/neu.2011.1885; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Cortese MD, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0455-5; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; Ganesh S, 2013, ARCH PHYS MED REHAB, V94, P1899, DOI 10.1016/j.apmr.2012.12.026; Giacino JT, 2018, NEUROLOGY, V91, P461, DOI 10.1212/WNL.0000000000005928; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kotchoubey B, 2014, CURR PHARM DESIGN, V20, P4239; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Lovstad M, 2010, J HEAD TRAUMA REHAB, V25, P349, DOI 10.1097/HTR.0b013e3181cec841; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Monti MM, 2015, NEUROLOGY, V84, P167, DOI 10.1212/WNL.0000000000001123; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1861, DOI 10.1016/j.apmr.2013.05.027; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Pape TLB, 2005, J REHABIL RES DEV, V42, P1, DOI 10.1682/JRRD.2004.03.0032; RADER MA, 1994, BRAIN INJURY, V8, P309, DOI 10.3109/02699059409150982; Riganello F, 2015, J NEUROTRAUM, V32, P1071, DOI 10.1089/neu.2014.3539; Schnakers C, 2015, PM&R, V7, pS270, DOI 10.1016/j.pmrj.2015.09.016; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Smart CM, 2008, NAT CLIN PRACT NEURO, V4, P448, DOI 10.1038/ncpneuro0823; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1851, DOI 10.1016/j.apmr.2013.07.003; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1877, DOI 10.1016/j.apmr.2012.12.027	40	100	102	1	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 4	2018	91	10					450	460		10.1212/WNL.0000000000005926			11	Clinical Neurology	Neurosciences & Neurology	HD2UL	WOS:000452366900017	30089618	Green Published, Bronze	Y	N	2021-06-18	
J	Mckee, CA; Lukens, JR				Mckee, Celia A.; Lukens, John R.			Emerging Roles for the Immune System in Traumatic Brain Injury	FRONTIERS IN IMMUNOLOGY			English	Article						traumatic brain injury; neuroinflammation; cytokine; inflammasome; innate immunology; neuroprotection; microglia; neurodegeneration	TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; AMYLOID PROTEIN DEPOSITION; CONTROLLED CORTICAL IMPACT; COLONY-STIMULATING FACTOR; NEURONAL CELL-DEATH; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID	Traumatic brain injury (TBI) affects an ever-growing population of all ages with long-term consequences on health and cognition. Many of the issues that TBI patients face are thought to be mediated by the immune system. Primary brain damage that occurs at the time of injury can be exacerbated and prolonged for months or even years by chronic inflammatory processes, which can ultimately lead to secondary cell death, neurodegeneration, and long-lasting neurological impairment. Researchers have turned to rodent models of TBI in order to understand how inflammatory cells and immunological signaling regulate the post-injury response and recovery mechanisms. In addition, the development of numerous methods to manipulate genes involved in inflammation has recently expanded the possibilities of investigating the immune response in TBI models. As results from these studies accumulate, scientists have started to link cells and signaling pathways to pro-and anti-inflammatory processes that may contribute beneficial or detrimental effects to the injured brain. Moreover, emerging data suggest that targeting aspects of the immune response may offer promising strategies to treat TBI. This review will cover insights gained from studies that approach TBI research from an immunological perspective and will summarize our current understanding of the involvement of specific immune cell types and cytokines in TBI pathogenesis.	[Mckee, Celia A.; Lukens, John R.] Univ Virginia, Sch Med, Dept Neurosci, Ctr Brain Immunol & Glia, Charlottesville, VA 22908 USA	Lukens, JR (corresponding author), Univ Virginia, Sch Med, Dept Neurosci, Ctr Brain Immunol & Glia, Charlottesville, VA 22908 USA.	jrl7n@virginia.edu		Lukens, John/0000-0002-6795-0866; McKee, Celia/0000-0002-5271-7877	Owens Family Foundation; University of Virginia Research and Development Committee Award	The authors apologize to authors whose work could not be referenced in this review due to space limitations. The authors also thank members of the Lukens Lab for their valuable comments on the manuscript. This work was supported by the Owens Family Foundation (JL) and the University of Virginia Research and Development Committee Award (JL).	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; [Anonymous], 2012, LANCET NEUROL, V11, P651, DOI 10.1016/S1474-4422(12)70166-7; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127; Bloom GS, 2014, JAMA NEUROL, V71, P505, DOI 10.1001/jamaneurol.2013.5847; Brickler T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6373506; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chio CC, 2014, J NEUROCHEM, V131, P816, DOI 10.1111/jnc.12971; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Di Paolo NC, 2016, NAT IMMUNOL, V17, P906, DOI 10.1038/ni.3503; Ellwardt E, 2016, TRENDS IMMUNOL, V37, P154, DOI 10.1016/j.it.2015.12.008; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Feng L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0409-2; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Frieler RA, 2015, BRAIN RES, V1624, P103, DOI 10.1016/j.brainres.2015.07.011; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Gombault A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00414; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Gustin A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130624; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hanamsagar R, 2014, J NEUROCHEM, V129, P704, DOI 10.1111/jnc.12669; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Heneka MT, 2015, NAT IMMUNOL, V16, P229, DOI 10.1038/ni.3102; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jones KJ, 2015, J NEUROIMMUNE PHARM, V10, P587, DOI 10.1007/s11481-015-9625-x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Juengst SB, 2015, J HEAD TRAUMA REHAB, V30, P207, DOI 10.1097/HTR.0000000000000031; Kang JH, 2012, J NEUROTRAUM, V29, P90, DOI 10.1089/neu.2011.1936; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Kawabori M, 2015, J NEUROSCI, V35, P3384, DOI 10.1523/JNEUROSCI.2620-14.2015; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Khorooshi R, 2010, J IMMUNOL, V185, P1258, DOI 10.4049/jimmunol.0901753; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-141; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Luheshi NM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-186; Lukens John R, 2014, Rare Dis, V2, pe27742, DOI 10.4161/rdis.27742; Lukens JR, 2014, SEMIN IMMUNOPATHOL, V36, P595, DOI 10.1007/s00281-014-0434-8; Lukens JR, 2014, P NATL ACAD SCI USA, V111, P1066, DOI 10.1073/pnas.1318688111; Lukens JR, 2013, NATURE, V498, P224, DOI 10.1038/nature12174; Lukens JR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00315; Lunny CA, 2014, J NEUROL SCI, V336, P13, DOI 10.1016/j.jns.2013.08.011; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mencl S, 2014, J NEUROIMMUNOL, V274, P125, DOI 10.1016/j.jneuroim.2014.07.010; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Probert L, 2015, NEUROSCIENCE, V302, P2, DOI 10.1016/j.neuroscience.2015.06.038; Ramirez K, 2016, CURRENT TOPICS BEHAV, P1; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Russo MV, 2015, TRENDS IMMUNOL, V36, P637, DOI 10.1016/j.it.2015.08.002; Saber M, 2017, J NEUROTRAUM, V34, P423, DOI 10.1089/neu.2016.4401; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Semple BD, 2015, NEUROBIOL DIS, V74, P263, DOI 10.1016/j.nbd.2014.12.003; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Soares HD, 1995, J NEUROSCI, V15, P8223; Song SJ, 2016, J NEUROSCI RES, V94, P409, DOI 10.1002/jnr.23714; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Szmydynger-Chodobska J, 2012, J CEREBR BLOOD F MET, V32, P93, DOI 10.1038/jcbfm.2011.111; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036; Taylor JM, 2014, NEUROBIOL AGING, V35, P1012, DOI 10.1016/j.neurobiolaging.2013.10.089; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Van Cauwenberghe C, 2016, GENET MED, V18, P421, DOI 10.1038/gim.2015.117; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Walsh JT, 2015, J CLIN INVEST, V125, P699, DOI [10.1172/JCI176210, 10.1172/JCI76210]; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang RG, 2011, GLIA, V59, P946, DOI 10.1002/glia.21167; Wang WY, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.49; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Warren SA, 2013, CAN J NEUROL SCI, V40, P168, DOI 10.1017/S0317167100013688; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yan EB, 2014, J NEUROTRAUM, V31, P618, DOI 10.1089/neu.2013.3087; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yeh FL, 2016, NEURON, V91, P328, DOI 10.1016/j.neuron.2016.06.015; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	168	100	109	0	27	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 5	2016	7								556	10.3389/fimmu.2016.00556			17	Immunology	Immunology	ED8XR	WOS:000389154700001	27994591	DOAJ Gold, Green Published			2021-06-18	
J	Kenney, K; Amyot, F; Haber, M; Pronger, A; Bogoslovsky, T; Moore, C; Diaz-Arrastia, R				Kenney, Kimbra; Amyot, Franck; Haber, Margalit; Pronger, Angela; Bogoslovsky, Tanya; Moore, Carol; Diaz-Arrastia, Ramon			Cerebral Vascular Injury in Traumatic Brain Injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic cerebral vascular injury (TCVI); Traumatic brain injury (TBI); Neurovascular unit (NVU); Cerebrovascular reactivity (CVRx); Cerebral microvasculature; Microvascular injury; Cerebral blood flow (CBF); Controlled cortical impact (CCI); Fluid percussion injury (FPI); Chronic traumatic encephalopathy (CTE); Hypercapnia; Single photon emission computed tomography (SPECT); MRI-arterial spin labeling (MRI-ASL); Susceptibility-weighted imaging (SWI); Mild TBI(mTBI); Transcranial Doppler (TCD); Functional Near InfraRed Spectroscopy (fNIRS); Hypercapnia	NEAR-INFRARED SPECTROSCOPY; BIOGENIC-AMINE CONTENT; BLOOD-FLOW; ALZHEIMERS-DISEASE; CEREBROVASCULAR REACTIVITY; MICROVASCULAR ALTERATIONS; TEMPORAL PROFILE; RISK-FACTORS; HEAD TRAUMA; TIME-COURSE	Traumatic cerebral vascular injury (TCVI) is a very frequent, if not universal, feature after traumatic brain injury (TBI). It is likely responsible, at least in part, for functional deficits and TBI-related chronic disability. Because there are multiple pharmacologic and non-pharmacologic therapies that promote vascular health, TCVI is an attractive target for therapeutic intervention after TBI. The cerebral microvasculature is a component of the neurovascular unit (NVU) coupling neuronal metabolism with local cerebral blood flow. The NVU participates in the pathogenesis of TBI, either directly from physical trauma or as part of the cascade of secondary injury that occurs after TBI. Pathologically, there is extensive cerebral microvascular injury in humans and experimental animal, identified with either conventional light microscopy or ultrastructural examination. It is seen in acute and chronic TB!, and even described in chronic traumatic encephalopathy (CTE). Non-invasive, physiologic measures of cerebral microvascular function show dysfunction after TBI in humans and experimental animal models of TBI. These include imaging sequences (MRI-ASL), Transcranial Doppler (TCD), and Near InfraRed Spectroscopy (NIRS). Understanding the pathophysiology of TCVI, a relatively under-studied component of TBI, has promise for the development of novel therapies for TBI. Published by Elsevier Inc.	[Kenney, Kimbra; Amyot, Franck; Haber, Margalit; Pronger, Angela; Bogoslovsky, Tanya; Moore, Carol; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Diaz-Arrastia, R (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	ramon.diaz-arrastia@usuhs.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Chronic Effects of Neurotrauma Consortium; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003138] Funding Source: NIH RePORTER	Work in the authors' laboratory was supported by the Center for Neuroscience and Regenerative Medicine, and by the Chronic Effects of Neurotrauma Consortium. The contents of this paper are solely the responsibility of the authors and do not represent the official views of the Department of Defense or the Center for Neuroscience and Regenerative Medicine.	ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; Atalay B, 2006, NEUROSURGERY, V59, P1102, DOI 10.1227/01.NEU.0000245605.22817.44; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Baranova AI, 2008, J NEUROSURG, V109, P502, DOI 10.3171/JNS/2008/109/9/0502; Barkai G, 2004, PSYCHIAT RES-NEUROIM, V132, P279, DOI 10.1016/j.pscychresns.2004.09.004; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Besancon E, 2008, TRENDS PHARMACOL SCI, V29, P268, DOI 10.1016/j.tips.2008.02.003; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Breteler MMB, 2000, NEUROBIOL AGING, V21, P153, DOI 10.1016/S0197-4580(99)00110-4; Castejon OJ, 2011, FOLIA NEUROPATHOL, V49, P162; Chabriat H, 2009, LANCET NEUROL, V8, P643, DOI 10.1016/S1474-4422(09)70127-9; Cherian L, 2011, J PHARMACOL EXP THER, V337, P451, DOI 10.1124/jpet.110.176602; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cohen Z, 1996, PROG NEUROBIOL, V50, P335, DOI 10.1016/S0301-0082(96)00033-0; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; Danaila L, 2013, CHIRURGIA-BUCHAREST, V108, P319; del Zoppo GJ, 2013, STROKE, V44, P263, DOI 10.1161/STROKEAHA.112.653618; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Diedler J, 2011, ANESTH ANALG, V113, P849, DOI 10.1213/ANE.0b013e3182285dc0; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ding GL, 2008, J CEREBR BLOOD F MET, V28, P1440, DOI 10.1038/jcbfm.2008.33; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Gahm C, 2000, NEUROSURGERY, V46, P169; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; Gardner A.J., 2014, BR J SPORTS MED; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Hamel E, 2006, J APPL PHYSIOL, V100, P1059, DOI 10.1152/japplphysiol.00954.2005; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; Castejon OJ, 2014, FOLIA NEUROPATHOL, V52, P10, DOI 10.5114/fn.2014.41740; Kainerstorfer JM, 2014, ACAD RADIOL, V21, P185, DOI 10.1016/j.acra.2013.10.012; Kassner Andrea, 2004, Top Magn Reson Imaging, V15, P58, DOI 10.1097/00002142-200402000-00006; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kontos H A, 1980, Adv Exp Med Biol, V131, P243; Kurland DB, 2013, PHARMACEUTICALS, V6, P1287, DOI 10.3390/ph6101287; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lecrux C, 2011, ACTA PHYSIOL, V203, P47, DOI 10.1111/j.1748-1716.2011.02256.x; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Li L, 2007, BRAIN RES, V1132, P185, DOI 10.1016/j.brainres.2006.10.098; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Marchesi VT, 2014, CELL MOL LIFE SCI, V71, P949, DOI 10.1007/s00018-013-1542-7; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; Matsumura M, 2009, J ATHEROSCLER THROMB, V16, P319, DOI 10.5551/jat.No026; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Menon DK, 2006, CURR OPIN CRIT CARE, V12, P85, DOI 10.1097/01.ccx.0000216572.19062.8f; Merzagora ACR, 2014, BRAIN IMAGING BEHAV, V8, P446, DOI 10.1007/s11682-013-9258-8; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P1354, DOI 10.1038/jcbfm.2011.43; Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P200, DOI 10.1038/jcbfm.2010.78; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Olesen J, 1971, STROKE, V2, P519, DOI 10.1161/01.STR.2.6.519; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Pifarre P, 2010, J NEUROCHEM, V112, P807, DOI 10.1111/j.1471-4159.2009.06518.x; Pronger AM, 2014, J NEUROTRAUM, V31, pA26; Puzzo D, 2009, J NEUROSCI, V29, P8075, DOI 10.1523/JNEUROSCI.0864-09.2009; Raji CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091088; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Roy C S, 1890, J Physiol, V11, P85; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; Stanimirovic DB, 2012, J CEREBR BLOOD F MET, V32, P1207, DOI 10.1038/jcbfm.2012.25; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; VILLRINGER A, 1995, CEREBROVAS BRAIN MET, V7, P240; Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015; Wang JY, 2014, NEUROBIOL DIS, V68, P91, DOI 10.1016/j.nbd.2014.04.014; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Wu HT, 2011, NEUROSURGERY, V68, P1363, DOI 10.1227/NEU.0b013e31820c06b9; Xing CH, 2012, NEUROL RES, V34, P325, DOI 10.1179/1743132812Y.0000000019; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Yu GX, 2014, J NEUROTRAUM, V31, P739, DOI 10.1089/neu.2013.3187; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320	121	100	103	2	34	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2016	275		3		SI		353	366		10.1016/j.expneurol.2015.05.019			14	Neurosciences	Neurosciences & Neurology	DB2ED	WOS:000368320200006	26048614	Bronze			2021-06-18	
J	Babikian, T; Merkley, T; Savage, RC; Giza, CC; Levin, H				Babikian, Talin; Merkley, Tricia; Savage, Ronald C.; Giza, Christopher C.; Levin, Harvey			Chronic Aspects of Pediatric Traumatic Brain Injury: Review of the Literature	JOURNAL OF NEUROTRAUMA			English	Article						academic; chronic outcomes; health outcomes; neurocognitive; pediatric brain injury	CLOSED-HEAD-INJURY; BEHAVIOR RATING INVENTORY; LATERAL FLUID PERCUSSION; CORPUS-CALLOSUM; NEUROCOGNITIVE OUTCOMES; EXECUTIVE FUNCTION; INTRACRANIAL-PRESSURE; INTELLECTUAL ABILITY; UNMYELINATED AXONS; EMOTIONAL PROSODY	Traumatic brain injury (TBI) in children, while the brain is in a state of rapid change and development, can adversely impact their development, their extended environment, and their families. The extant literature has identified several physiological, genetic, and environmental variables that predict outcomes after pediatric TBI; nonetheless, the individual course of recovery and later development of a given child is uniquely shaped by injury-related factors (e.g., nature and extent of the injury itself, the developmental status of the child) as well as a number of personal and family variables (e.g., pre-injury cognitive, genetic, and psychological status of the child, family functioning and resources, coping style). Further, the effects of a brain injury during development may or may not become evident immediately after injury depending on a number of factors. Instead, observing trajectories of development over time may allow for a better understanding of the long-term consequences in many functional domains that interest researchers, clinicians, and families. The current article reviews the chronic aspects of medical/health, cognitive/academic, emotional/behavioral, and family/social outcomes after pediatric TBI, with the goal of providing monitoring and treatment strategies for affected children and their families, as well as serving as a resource for researchers designing studies to better understand this heterogeneous population.	[Babikian, Talin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Babikian, Talin; Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA 90095 USA; [Merkley, Tricia] Barrow Neurol Inst, Dept Clin Neuropsychol, Phoenix, AZ 85013 USA; [Savage, Ronald C.] Int Pediat Brain Injury Soc, Sarasota, FL USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat & Neurosurg, Los Angeles, CA 90095 USA; [Levin, Harvey] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Babikian, T (corresponding author), Univ Calif Los Angeles, Semel Inst, 760 Westwood Plaza,Room C8-746, Los Angeles, CA 90095 USA.	tbabikian@mednet.ucla.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391			Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2010, DEV NEUROSCI-BASEL, V32, P431, DOI 10.1159/000320667; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barkovich A J, 1993, Top Magn Reson Imaging, V5, P96; Barrett LF, 2007, ANNU REV PSYCHOL, V58, P373, DOI 10.1146/annurev.psych.58.110405.085709; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Bell MA, 2004, CHILD DEV, V75, P366, DOI 10.1111/j.1467-8624.2004.00679.x; Bosnell R, 2008, DEV NEUROREHABIL, V11, P174, DOI 10.1080/17518420802289065; Bruce S., 2006, STRATEGIES MANAGING; Cacioppo JT, 1999, CURR DIR PSYCHOL SCI, V8, P133, DOI 10.1111/1467-8721.00031; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Chapman S.B., 2006, BRAIN INJ PROF, V3, P10; Choe M.C., 2014, P NAT NEUR SOC ANN M, V2014; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen J., NAT C STAT LEG ZER 3; Cook LG, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00087; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Dennis M, 2010, CORTEX, V46, P1043, DOI 10.1016/j.cortex.2009.10.008; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Durston S, 2001, J AM ACAD CHILD PSY, V40, P1012, DOI 10.1097/00004583-200109000-00009; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Finger S, 1999, J Hist Neurosci, V8, P269, DOI 10.1076/jhin.8.3.269.1824; Garth J, 1997, Pediatr Rehabil, V1, P99; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Giedd JN, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-19; Gil AM, 2003, J SCHOOL PSYCHOL, V41, P337, DOI 10.1016/S0022-4405(03)00085-2; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; Goodman B., 2013, P AM AC NEUR 65 ANN; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hammond F., 2012, BRAIN INJURY, V10, P6; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Josie KL, 2008, J HEAD TRAUMA REHAB, V23, P357, DOI 10.1097/01.HTR.0000341431.29133.a8; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lajiness-O'Neill R, 2011, APPL NEUROPSYCHOL, V18, P298, DOI 10.1080/09084282.2011.595457; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LEVIN HS, 1992, CURR OPIN NEUROL NEU, V5, P673; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Logue SF, 2014, PHARMACOL BIOCHEM BE, V123, P45, DOI 10.1016/j.pbb.2013.08.007; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; National Scientific Council on the Developing Child, 2004, 2 NAT SCI COUNC DEV; Newsome MR, 2013, J INT NEUROPSYCH SOC, V19, P911, DOI 10.1017/S1355617713000817; Newsome MR, 2012, INT J DEV NEUROSCI, V30, P255, DOI 10.1016/j.ijdevneu.2011.10.008; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Peterson RL, 2013, J HEAD TRAUMA REHAB, V28, pE1, DOI 10.1097/HTR.0b013e318263f5ba; Posner M.I., 2013, NEURAL CIRCUIT DEV F; Posner MI, 2013, TRENDS NEUROSCI EDUC, V2, P107, DOI 10.1016/j.tine.2013.09.001; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Raj SP, 2014, J PEDIATR PSYCHOL, V39, P84, DOI 10.1093/jpepsy/jst075; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Savage R.C., 2012, NEUROTRAUMA NEWSLETT; Savage R.C., 2007, P N AM BRAIN INJ SOC; Schmidt AT, 2013, BRAIN INJURY, V27, P1528, DOI 10.3109/02699052.2013.828851; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Spencer-Smith M, 2009, DEV NEUROREHABIL, V12, P279, DOI 10.3109/17518420903090701; Spitz G, 2013, BRAIN TOPOGR, V26, P648, DOI 10.1007/s10548-013-0283-0; Squire LR, 2011, ANNU REV NEUROSCI, V34, P259, DOI 10.1146/annurev-neuro-061010-113720; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; U.S. Department of Education OoSEP, 1999, 21 ANN C 1999 WASH D; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Yeates KO, 2014, CLIN PSYCHOL SCI, V2, P97, DOI 10.1177/2167702613499734; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P493, DOI 10.1017/S1355617713000398; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	121	100	100	4	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2015	32	23			SI		1849	1860		10.1089/neu.2015.3971			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CX4TW	WOS:000365694200003	26414654				2021-06-18	
J	Weissberg, I; Wood, L; Kamintsky, L; Vazquez, O; Milikovsky, DZ; Alexander, A; Oppenheim, H; Ardizzone, C; Becker, A; Frigerio, F; Vezzani, A; Buckwalter, MS; Huguenard, JR; Friedman, A; Kaufer, D				Weissberg, Itai; Wood, Lydia; Kamintsky, Lyn; Vazquez, Oscar; Milikovsky, Dan Z.; Alexander, Allyson; Oppenheim, Hannah; Ardizzone, Carolyn; Becker, Albert; Frigerio, Federica; Vezzani, Annamaria; Buckwalter, Marion S.; Huguenard, John R.; Friedman, Alon; Kaufer, Daniela			Albumin induces excitatory synaptogenesis through astrocytic TGF-beta/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction	NEUROBIOLOGY OF DISEASE			English	Article						Epilepsy; Albumin; TGF-beta; Synaptogenesis; Blood-brain barrier (BBB); Seizures; Astrocytes; Post-insult epilepsy (PIE); Post-traumatic epilepsy (PIE); ALK5	KAINIC ACID; TGF-BETA; SYNAPTIC CONNECTIVITY; FUNCTIONAL RECOVERY; CNS SYNAPTOGENESIS; SECRETED PROTEINS; VASCULAR CHANGES; CEREBRAL-CORTEX; AMPA RECEPTORS; EPILEPTOGENESIS	Post-injury epilepsy (PIE) is a common complication following brain insults, including ischemic, and traumatic brain injuries. At present, there are no means to identify the patients at risk to develop PIE or to prevent its development. Seizures can occur months or years after the insult, do not respond to anti-seizure medications in over third of the patients, and are often associated with significant neuropsychiatric morbidities. We have previously established the critical role of blood-brain barrier dysfunction in PIE, demonstrating that exposure of brain tissue to extravasated serum albumin induces activation of inflammatory transforming growth factor beta (TGF-beta) signaling in astrocytes and eventually seizures. However, the link between the acute astrocytic inflammatory responses and reorganization of neural networks that underlie recurrent spontaneous seizures remains unknown. Here we demonstrate in vitro and in vivo that activation of the astrocytic ALK5/MF+beta-pathway induces excitatory, but not inhibitory, synaptogenesis that precedes the appearance of seizures. Moreover, we show that treatment with SJN2511, a specific ALK5/TGF-beta inhibitor, prevents synaptogenesis and epilepsy. Our findings point to astrocyte-mediated synaptogenesis as a key epileptogenic process and highlight the manipulation of the TGF-beta-pathway as a potential strategy for the prevention of PIE. (C) 2015 Elsevier Inc. All rights reserved.	[Weissberg, Itai; Kamintsky, Lyn; Milikovsky, Dan Z.; Friedman, Alon] Ben Gurion Univ Negev, Dept Physiol & Cell Biol, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel; [Weissberg, Itai; Kamintsky, Lyn; Milikovsky, Dan Z.; Friedman, Alon] Ben Gurion Univ Negev, Dept Cognit & Brain Sci, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel; [Wood, Lydia; Oppenheim, Hannah; Ardizzone, Carolyn; Kaufer, Daniela] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Vazquez, Oscar; Kaufer, Daniela] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Alexander, Allyson; Buckwalter, Marion S.; Huguenard, John R.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Becker, Albert] Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; [Frigerio, Federica; Vezzani, Annamaria] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [Kaufer, Daniela] Canadian Inst Adv Res CIFAR, Program Child & Brain Dev, Toronto, ON M5G 1Z8, Canada	Friedman, A (corresponding author), Ben Gurion Univ Negev, POB 653, IL-8410501 Beer Sheva, Israel.	alonf@bgu.ac.il; danielak@berkeley.edu	Becker, Albert J/F-6248-2012; Huguenard, John/K-6429-2019; Huguenard, John/I-5016-2012; Vezzani, Annamaria/AAB-1882-2020	Huguenard, John/0000-0002-6950-1191; Huguenard, John/0000-0002-6950-1191; Vezzani, Annamaria/0000-0003-0573-6175; Milikovsky, Dan Z/0000-0002-4826-5273; Buckwalter, Marion/0000-0003-2807-2447; Kamintsky, Lyna/0000-0001-6776-0969	European UnionEuropean Commission [602102]; Israel Science FoundationIsrael Science Foundation [713/11]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1/NINDS NS066005]; German Science Foundation (DFG)German Research Foundation (DFG) [SFB TR3]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067132, R01NS090911, R01NS066005] Funding Source: NIH RePORTER	The research leading to these results has received funding from the European Union's Seventh Framework Program (FP7/2007-2013) under grant agreement no.602102 (EPITARGET, AF), the Israel Science Foundation (713/11, AF), the National Institute of Health (RO1/NINDS NS066005, DK, AF), and the German Science Foundation (DFG-SFB TR3, AF).	Abbott NJ, 2012, EPILEPSIA, V53, P1, DOI 10.1111/j.1528-1167.2012.03696.x; Allen NJ, 2012, NATURE, V486, P410, DOI 10.1038/nature11059; Aronica E, 2008, NEUROSCIENCE, V151, P272, DOI 10.1016/j.neuroscience.2007.10.036; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; Balosso S, 2008, BRAIN, V131, P3256, DOI 10.1093/brain/awn271; Bar-Klein G, 2014, ANN NEUROL, V75, P864, DOI 10.1002/ana.24147; Braganza O, 2012, EPILEPSIA, V53, P1898, DOI 10.1111/j.1528-1167.2012.03665.x; Bragin A, 2000, EPILEPSIA, V41, pS144, DOI 10.1111/j.1528-1157.2000.tb01573.x; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Cekanaviciute E, 2014, GLIA, V62, P1227, DOI 10.1002/glia.22675; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Chung WS, 2012, CURR OPIN NEUROBIOL, V22, P438, DOI 10.1016/j.conb.2011.10.003; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; Crawford DC, 2012, J NEUROSCI, V32, P13100, DOI 10.1523/JNEUROSCI.2604-12.2012; Crunelli V., 2014, NEUROSCIENTIST; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; David Y, 2009, J NEUROSCI, V29, P10588, DOI 10.1523/JNEUROSCI.2323-09.2009; deLanerolle N. C., 2012, JASPERS BASIC MECH E; Devinsky O, 2013, TRENDS NEUROSCI, V36, P174, DOI 10.1016/j.tins.2012.11.008; Diniz L.P., 2014, GLIA; Diniz LP, 2012, J BIOL CHEM, V287, P41432, DOI 10.1074/jbc.M112.380824; Elmariah SB, 2005, J NEUROSCI, V25, P3638, DOI 10.1523/JNEUROSCI.3980-04.2005; Eroglu C, 2010, NATURE, V468, P223, DOI 10.1038/nature09612; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Falo MC, 2008, J NEUROTRAUM, V25, P769, DOI 10.1089/neu.2008.0511; Feng Z, 2008, J NEUROSCI, V28, P9599, DOI 10.1523/JNEUROSCI.2589-08.2008; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Friedman A., 2012, JASPERS BASIC MECH E; Friedman A, 2009, EPILEPSY RES, V85, P142, DOI 10.1016/j.eplepsyres.2009.03.005; Frigerio F, 2012, EPILEPSIA, V53, P1887, DOI 10.1111/j.1528-1167.2012.03666.x; Ippolito D.M, 2010, JOVE J VISUAL EXP, pE2270, DOI DOI 10.3791/2270; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Kaya M, 2012, EPILEPSIA, V53, P31, DOI 10.1111/j.1528-1167.2012.03700.x; Kucukdereli H, 2011, P NATL ACAD SCI USA, V108, pE440, DOI 10.1073/pnas.1104977108; Lapilover EG, 2012, NEUROBIOL DIS, V48, P495, DOI 10.1016/j.nbd.2012.06.024; Leonoudakis D, 2008, J NEUROSCI, V28, P2119, DOI 10.1523/JNEUROSCI.5159-07.2008; Li LY, 2013, J MOL NEUROSCI, V50, P109, DOI 10.1007/s12031-012-9879-1; Liauw J, 2008, J CEREBR BLOOD F MET, V28, P1722, DOI 10.1038/jcbfm.2008.65; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Marchi N, 2014, TRENDS NEUROSCI, V37, P55, DOI 10.1016/j.tins.2013.11.002; Marco P, 1997, EXP BRAIN RES, V114, P1, DOI 10.1007/PL00005608; Marcon J, 2009, NEUROBIOL DIS, V34, P121, DOI 10.1016/j.nbd.2008.12.018; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; NUSSER Z, 1995, EUR J NEUROSCI, V7, P630, DOI 10.1111/j.1460-9568.1995.tb00667.x; Packard M, 2003, NAT REV NEUROSCI, V4, P113, DOI 10.1038/nrn1036; PONT F, 1995, NEUROSCI LETT, V184, P52, DOI 10.1016/0304-3940(94)11166-G; Raabe A, 2012, EPILEPSIA, V53, P539, DOI 10.1111/j.1528-1167.2012.03405.x; Rosenberg GA, 2012, J CEREBR BLOOD F MET, V32, P1139, DOI 10.1038/jcbfm.2011.197; Ruscher K, 2011, BRAIN, V134, P732, DOI 10.1093/brain/awq367; RUTH RE, 1984, EPILEPSIA, V25, P259, DOI 10.1111/j.1528-1157.1984.tb04185.x; SAIJA A, 1992, LIFE SCI, V51, P467, DOI 10.1016/0024-3205(92)90023-I; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schmitz AK, 2013, SEIZURE-EUR J EPILEP, V22, P144, DOI 10.1016/j.seizure.2012.10.014; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Tomkins O, 2001, CELL MOL NEUROBIOL, V21, P675, DOI 10.1023/A:1015147920283; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; van Vliet EA, 2014, NEUROBIOL DIS, V63, P74, DOI 10.1016/j.nbd.2013.11.019; Vezzani A, 2011, BRAIN BEHAV IMMUN, V25, P1281, DOI 10.1016/j.bbi.2011.03.018; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Viviani B, 2003, J NEUROSCI, V23, P8692; Yu C-V., 2014, NERUOMOL MED; ZUCKER DK, 1983, EXP NEUROL, V79, P422, DOI 10.1016/0014-4886(83)90223-6	68	100	100	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2015	78						115	125		10.1016/j.nbd.2015.02.029			11	Neurosciences	Neurosciences & Neurology	CI0IH	WOS:000354419800012	25836421	Green Accepted			2021-06-18	
J	Grayson, B; Leger, M; Piercy, C; Adamson, L; Harte, M; Neill, JC				Grayson, Ben; Leger, Marianne; Piercy, Chloe; Adamson, Lisa; Harte, Michael; Neill, Joanna C.			Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents	BEHAVIOURAL BRAIN RESEARCH			English	Article						Object recognition; Alzheimer's disease; Schizophrenia; Parkinson's disease; Autistic spectrum disorder; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; HIPPOCAMPAL CELL-PROLIFERATION; PRENATAL IMMUNE ACTIVATION; ENVIRONMENTAL RISK-FACTORS; ALZHEIMERS-DISEASE; MEMORY DEFICITS; PARKINSONS-DISEASE; VISUAL RECOGNITION	The novel object recognition test (NOR) test is a two trial cognitive paradigm that assesses recognition memory. Recognition memory is disturbed in a range of human disorders and NOR is widely used in rodents for investigating deficits in a variety of animal models of human conditions where cognition is impaired. It possesses several advantages over more complex tasks that involve lengthy training procedures and/or food or water deprivation. It is quick to administer, non-rewarded, provides data quickly, cost effective and most importantly, ethologically relevant as it relies on the animal's natural preference for novelty. A PubMed search revealed over 900 publications in rats and mice using this task over the past 3 years with 34 reviews in the past 10 years, demonstrating its increasing popularity with neuroscientists. Although it is widely used in many disparate areas of research, no articles have systematically examined this to date, which is the subject of our review. We reveal that NOR may be used to study recognition memory deficits that occur in Alzheimer's disease and schizophrenia, where research is extensive, in Parkinson's disease and Autism Spectrum Disorders (ASD) where we observed markedly reduced numbers of publications. In addition, we review the use of NOR to study cognitive deficits induced by traumatic brain injury and cancer chemotherapy, not disorders per se, but situations in which cognitive deficits dramatically reduce the quality of life for those affected, see Fig. 1 for a summary. Our review reveals that, in all these animal models, the NOR test is extremely useful for identification of the cognitive deficits observed, their neural basis, and for testing the efficacy of novel therapeutic agents. Our conclusion is that NOR is of considerable value for cognitive researchers of all disciplines and we anticipate that its use will continue to increase due to its versatility and several other advantages, as detailed in this review. (C) 2014 Elsevier B.V. All rights reserved.	[Grayson, Ben; Leger, Marianne; Piercy, Chloe; Adamson, Lisa; Harte, Michael; Neill, Joanna C.] Univ Manchester, Manchester Pharm Sch, Manchester M13 9PT, Lancs, England	Grayson, B (corresponding author), Univ Manchester, Manchester Pharm Sch, Manchester M13 9PT, Lancs, England.	Ben.grayson@manchester.ac.uk; Joanna.neill@manchester.ac.uk	neill, joanna c/L-5155-2016	neill, joanna c/0000-0002-2717-9739; Leger, Marianne/0000-0002-7811-8522; Harte, Michael/0000-0002-4702-4785			Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adler BL, 2014, NEUROBIOL AGING, V35, P793, DOI 10.1016/j.neurobiolaging.2013.10.076; Vilatela MEA, 2012, ARCH MED RES, V43, P622, DOI 10.1016/j.arcmed.2012.10.017; Ambree O, 2009, NEUROBIOL AGING, V30, P1192, DOI 10.1016/j.neurobiolaging.2007.11.010; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; ARITA I, 1990, CARCINOGENESIS, V11, P1733, DOI 10.1093/carcin/11.10.1733; Bardgett ME, 2011, NEUROBIOL LEARN MEM, V95, P64, DOI 10.1016/j.nlm.2010.10.008; Benito-Leon J, 2011, J NEUROL SCI, V310, P176, DOI 10.1016/j.jns.2011.06.054; Berlyne DE, 1950, B J PSYCHOL-GEN SECT, V41, P68, DOI 10.1111/j.2044-8295.1950.tb00262.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bhattacharya A, 2012, NEURON, V76, P325, DOI 10.1016/j.neuron.2012.07.022; Bisen-Hersh EB, 2013, CLIN CANCER RES, V19, P3008, DOI 10.1158/1078-0432.CCR-12-3764; Brown MW, 2012, NEUROPSYCHOLOGIA, V50, P3122, DOI 10.1016/j.neuropsychologia.2012.07.034; Capurro V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056870; Chao OYH, 2013, EXP NEUROL, V247, P373, DOI 10.1016/j.expneurol.2013.01.003; Chen GQ, 2000, NATURE, V408, P975; Cheng D, 2014, BEHAV BRAIN RES, V260, P111, DOI 10.1016/j.bbr.2013.11.046; Christensen TO, 2007, INT J PSYCHIAT CLIN, V11, P89, DOI 10.1080/13651500600969061; D'Agostino G, 2012, NEUROPSYCHOPHARMACOL, V37, P1784, DOI 10.1038/npp.2012.25; Dachir S, 2014, BRAIN RES, V1555, P78, DOI 10.1016/j.brainres.2014.01.044; Dalaker TO, 2011, MOVEMENT DISORD, V26, P297, DOI 10.1002/mds.23443; Davis KE, 2013, J ALZHEIMERS DIS, V33, P681, DOI 10.3233/JAD-2012-121543; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; Deprez S, 2011, HUM BRAIN MAPP, V32, P480, DOI 10.1002/hbm.21033; Dere E, 2007, NEUROSCI BIOBEHAV R, V31, P673, DOI 10.1016/j.neubiorev.2007.01.005; Dewachter I, 2002, J NEUROSCI, V22, P3445; Dickendesher TL, 2012, NAT NEUROSCI, V15, P703, DOI 10.1038/nn.3070; Didic M, 2013, DEMENT GERIATR COGN, V35, P291, DOI 10.1159/000347203; Didic M, 2010, J ALZHEIMERS DIS, V22, P1269, DOI 10.3233/JAD-2010-101257; Dodart JC, 1999, BEHAV NEUROSCI, V113, P982, DOI 10.1037/0735-7044.113.5.982; Donkin JJ, 2010, J BIOL CHEM, V285, P34144, DOI 10.1074/jbc.M110.108100; Dos Santos ACD, 2013, J NEUROSCI RES, V91, P1508, DOI 10.1002/jnr.23258; ELBeltagy M, 2010, BEHAV BRAIN RES, V208, P112, DOI 10.1016/j.bbr.2009.11.017; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ennaceur A, 1996, BEHAV BRAIN RES, V80, P9, DOI 10.1016/0166-4328(96)00006-X; Escribano L, 2010, NEUROPSYCHOPHARMACOL, V35, P1593, DOI 10.1038/npp.2010.32; FALLIS RJ, 1987, J NEUROIMMUNOL, V14, P205, DOI 10.1016/0165-5728(87)90055-5; Fardell JE, 2014, PSYCHOPHARMACOLOGY, V231, P841, DOI 10.1007/s00213-013-3301-8; Fardell JE, 2012, PSYCHOPHARMACOLOGY, V220, P183, DOI 10.1007/s00213-011-2466-2; Fernandes VS, 2012, BEHAV BRAIN RES, V231, P154, DOI 10.1016/j.bbr.2012.03.008; Fernandes VS, 2008, PROG NEURO-PSYCHOPH, V32, P1479, DOI 10.1016/j.pnpbp.2008.05.004; Filali M, 2012, BEHAV BRAIN RES, V234, P334, DOI 10.1016/j.bbr.2012.07.004; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Frydman-Marom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016564; Fukumoto H, 2010, J NEUROSCI, V30, P11157, DOI 10.1523/JNEUROSCI.2884-10.2010; GAFFAN D, 1994, EXP BRAIN RES, V99, P411; Gandal MJ, 2008, NEUROSCIENCE, V157, P95, DOI 10.1016/j.neuroscience.2008.08.060; Gerenu G, 2013, BBA-MOL BASIS DIS, V1832, P837, DOI 10.1016/j.bbadis.2013.02.018; Giovanoli S, 2014, BRAIN BEHAV IMMUN, V40, P48, DOI 10.1016/j.bbi.2014.04.005; Giovanoli S, 2013, SCIENCE, V339, P1095, DOI 10.1126/science.1228261; Giuliani A, 2013, J NEUROCHEM, V124, P613, DOI 10.1111/jnc.12136; Goes ATR, 2014, NEUROSCIENCE, V256, P61, DOI 10.1016/j.neuroscience.2013.09.042; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Gomes GM, 2013, TOXICON, V76, P23, DOI 10.1016/j.toxicon.2013.08.059; Good MA, 2007, BEHAV NEUROSCI, V121, P1180, DOI 10.1037/0735-7044.121.6.1180; Greco SJ, 2010, J ALZHEIMERS DIS, V19, P1155, DOI 10.3233/JAD-2010-1308; Green MF, 2004, BIOL PSYCHIAT, V56, P301, DOI 10.1016/j.biopsych.2004.06.023; Green MF, 1996, AM J PSYCHIAT, V153, P321; Guzman-Ramos K, 2012, LEARN MEMORY, V19, P453, DOI 10.1101/lm.026070.112; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Harris JA, 2010, J NEUROSCI, V30, P372, DOI 10.1523/JNEUROSCI.5341-09.2010; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harvey PD, 2006, DRUGS, V66, P1465, DOI 10.2165/00003495-200666110-00004; He PP, 2013, HORM BEHAV, V64, P1, DOI 10.1016/j.yhbeh.2013.04.009; Heneka MT, 2006, J NEUROSCI, V26, P1343, DOI 10.1523/JNEUROSCI.4236-05.2006; Hillen H, 2010, J NEUROSCI, V30, P10369, DOI 10.1523/JNEUROSCI.5721-09.2010; Ho SC, 2014, BEHAV BRAIN RES, V268, P177, DOI 10.1016/j.bbr.2014.04.022; Ho YJ, 2011, BEHAV BRAIN RES, V219, P280, DOI 10.1016/j.bbr.2011.01.028; Howlett DR, 2004, BRAIN RES, V1017, P130, DOI 10.1016/j.brainres.2004.05.029; Huang SM, 2006, J BIOL CHEM, V281, P17941, DOI 10.1074/jbc.M601372200; Isono T, 2013, NEUROSCI RES, V77, P180, DOI 10.1016/j.neures.2013.08.005; Janelsins MC, 2014, INT REV PSYCHIATR, V26, P102, DOI 10.3109/09540261.2013.864260; Jardanhazi-Kurutz D, 2010, NEUROCHEM INT, V57, P375, DOI 10.1016/j.neuint.2010.02.001; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Kamboh MI, 2004, ANN HUM GENET, V68, P381, DOI 10.1046/j.1529-8817.2004.00110.x; Kane MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048975; Keefe Richard S E, 2012, Handb Exp Pharmacol, P11, DOI 10.1007/978-3-642-25758-2_2; Kendall I, 2011, PSYCHOPHARMACOLOGY, V213, P413, DOI 10.1007/s00213-010-1854-3; Kesler SR, 2013, BRAIN IMAGING BEHAV, V7, P501, DOI 10.1007/s11682-013-9228-1; Knowles JK, 2013, NEUROBIOL AGING, V34, P2052, DOI 10.1016/j.neurobiolaging.2013.02.015; Korosoglou G, 2012, J MAGN RESON IMAGING, V35, P804, DOI 10.1002/jmri.22879; Laquintana V, 2009, EXPERT OPIN DRUG DEL, V6, P1017, DOI 10.1517/17425240903167942; Li XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071341; Lu P, 2009, BRIT J PHARMACOL, V157, P1270, DOI 10.1111/j.1476-5381.2009.00295.x; Luques L, 2007, EXP NEUROL, V206, P209, DOI 10.1016/j.expneurol.2007.04.007; Lyall K, 2014, INT J EPIDEMIOL, V43, P443, DOI 10.1093/ije/dyt282; Lyon L, 2012, PSYCHOPHARMACOLOGY, V220, P647, DOI 10.1007/s00213-011-2536-5; Magen I, 2012, EUR J NEUROSCI, V35, P870, DOI 10.1111/j.1460-9568.2012.08012.x; Marco EM, 2013, NEUROPHARMACOLOGY, V68, P223, DOI 10.1016/j.neuropharm.2012.08.014; Martin-Moreno AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-8; Matsuo K, 2014, J NEUROIMMUNOL, V266, P1, DOI 10.1016/j.jneuroim.2013.11.002; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; McGrath J, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-13; McIntosh AL, 2013, PSYCHOPHARMACOLOGY, V228, P31, DOI 10.1007/s00213-013-3011-2; McLean SL, 2011, EUR NEUROPSYCHOPHARM, V21, P333, DOI 10.1016/j.euroneuro.2010.06.003; Meltzer HY, 2013, INT J NEUROPSYCHOPH, V16, P2181, DOI 10.1017/S1461145713000928; Meunier J, 2013, EUR J PHARMACOL, V698, P193, DOI 10.1016/j.ejphar.2012.10.033; MEUNIER M, 1993, J NEUROSCI, V13, P5418; Meyer U, 2014, BIOL PSYCHIAT, V75, P307, DOI 10.1016/j.biopsych.2013.07.011; Middei S, 2006, GENES BRAIN BEHAV, V5, P249, DOI 10.1111/j.1601-183X.2005.00160.x; Mondie CM, 2010, BEHAV BRAIN RES, V209, P66, DOI 10.1016/j.bbr.2010.01.016; Moore H, 2010, SCHIZOPHRENIA BULL, V36, P1066, DOI 10.1093/schbul/sbq106; Mori T, 2012, J BIOL CHEM, V287, P6912, DOI 10.1074/jbc.M111.294025; Morley JE, 2012, CURR PHARM DESIGN, V18, P1123; Morris S, 2008, ANAESTHESIA, V63, P499, DOI 10.1111/j.1365-2044.2007.05432.x; Mouri A, 2007, FASEB J, V21, P2135, DOI 10.1096/fj.06-7685com; Moy SS, 2006, AM J MED GENET C, V142C, P40, DOI 10.1002/ajmg.c.30081; MUMBY DG, 1994, BEHAV NEUROSCI, V108, P11, DOI 10.1037/0735-7044.108.1.11; Murray DK, 2014, TRANSL NEURODEGENER, V3, DOI 10.1186/2047-9158-3-5; Mychasiuk R, 2012, DEV NEUROSCI-BASEL, V34, P268, DOI 10.1159/000341786; Neill JC, 2010, PHARMACOL THERAPEUT, V128, P419, DOI 10.1016/j.pharmthera.2010.07.004; O'Farrell E, 2013, CURR ONCOL REP, V15, P260, DOI 10.1007/s11912-013-0307-7; O'Grada C, 2007, HUM PSYCHOPHARM CLIN, V22, P397, DOI 10.1002/hup.861; O'Tuathaigh CMP, 2010, EUR J NEUROSCI, V31, P349, DOI 10.1111/j.1460-9568.2009.07069.x; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Ohta H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030007; Ferreira APO, 2014, PSYCHOPHARMACOLOGY, V231, P1935, DOI 10.1007/s00213-013-3336-x; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Onishi T, 2011, J NEUROCHEM, V119, P1330, DOI 10.1111/j.1471-4159.2011.07532.x; Ozawa K, 2006, BIOL PSYCHIAT, V59, P546, DOI 10.1016/j.biopsych.2005.07.031; Papaleo F, 2012, NEUROPHARMACOLOGY, V62, P1204, DOI 10.1016/j.neuropharm.2011.04.025; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Platt B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027068; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Presti-Torres J, 2007, NEUROPHARMACOLOGY, V52, P724, DOI 10.1016/j.neuropharm.2006.09.020; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Pyter LM, 2010, BRAIN BEHAV IMMUN, V24, P903, DOI 10.1016/j.bbi.2010.02.004; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Ribes D, 2012, ALZ DIS ASSOC DIS, V26, P179, DOI 10.1097/WAD.0b013e3182211ab1; Ryan D, 2013, CELL MOL LIFE SCI, V70, P2603, DOI 10.1007/s00018-013-1314-4; Sanna KG, 2011, RES AUTISM SPECT DIS, V5, P622, DOI 10.1016/j.rasd.2010.07.007; Santos JR, 2013, BEHAV BRAIN RES, V253, P68, DOI 10.1016/j.bbr.2013.06.031; Sawamoto N, 2008, BRAIN, V131, P1294, DOI 10.1093/brain/awn054; Scali C, 1997, EUR J PHARMACOL, V325, P173, DOI 10.1016/S0014-2999(97)00128-3; Scholtzova H, 2008, J NEUROSCI RES, V86, P2784, DOI 10.1002/jnr.21713; Scullion GA, 2011, NEUROPHARMACOLOGY, V60, P223, DOI 10.1016/j.neuropharm.2010.09.002; Seigers R, 2008, BEHAV BRAIN RES, V186, P168, DOI 10.1016/j.bbr.2007.08.004; Shin JH, 2011, CELL, V144, P689, DOI 10.1016/j.cell.2011.02.010; Silverman DHS, 2007, BREAST CANCER RES TR, V103, P303, DOI 10.1007/s10549-006-9380-z; Silverman JL, 2013, NEUROPHARMACOLOGY, V64, P268, DOI 10.1016/j.neuropharm.2012.07.013; Sipos E, 2007, NEUROSCIENCE, V147, P28, DOI 10.1016/j.neuroscience.2007.04.011; Sivilia S, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-44; Snowden JS, 2011, BRAIN, V134, P2478, DOI 10.1093/brain/awr189; Spilman P, 2014, BRAIN RES, V1551, P25, DOI 10.1016/j.brainres.2013.12.029; Taglialatela G, 2009, BEHAV BRAIN RES, V200, P95, DOI 10.1016/j.bbr.2008.12.034; Tessitore A, 2002, J NEUROSCI, V22, P9099, DOI 10.1523/jneurosci.22-20-09099.2002; Tong J, 2013, J NEUROTRAUM, V30, P247, DOI 10.1089/neu.2012.2493; Tsunekawa H, 2008, BEHAV BRAIN RES, V190, P224, DOI 10.1016/j.bbr.2008.03.002; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; UNGERSTEDT U, 1968, EUR J PHARMACOL, V5, P107, DOI 10.1016/0014-2999(68)90164-7; Vardy J, 2007, CRIT REV ONCOL HEMAT, V63, P183, DOI 10.1016/j.critrevonc.2007.06.001; Wang DY, 2013, J BIOL CHEM, V288, P10298, DOI 10.1074/jbc.M112.415141; Wefel JS, 2012, CURR NEUROL NEUROSCI, V12, P267, DOI 10.1007/s11910-012-0264-9; Whitwell JL, 2007, BRAIN, V130, P1777, DOI 10.1093/brain/awm112; Wolf JM, 2008, AUTISM RES, V1, P329, DOI 10.1002/aur.56; Yabuki Y, 2014, NEUROSCIENCE, V259, P126, DOI 10.1016/j.neuroscience.2013.11.051; Yamaguchi Y, 2012, J PHARMACOL SCI, V119, P160, DOI 10.1254/jphs.12036FP; Yan JJ, 2013, BIOL PHARM BULL, V36, P140, DOI 10.1248/bpb.b12-00798; Yang M, 2012, J NEUROSCI, V32, P6525, DOI 10.1523/JNEUROSCI.6107-11.2012; Yuede CM, 2009, NEUROBIOL DIS, V35, P426, DOI 10.1016/j.nbd.2009.06.002; Zhang L, 2006, BEHAV BRAIN RES, V173, P246, DOI 10.1016/j.bbr.2006.06.034; Zhang R, 2012, J ALZHEIMERS DIS, V31, P801, DOI 10.3233/JAD-2012-120151; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144; Zufferey V, 2013, BRAIN RES BULL, V94, P17, DOI 10.1016/j.brainresbull.2013.01.011	165	100	102	2	43	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAY 15	2015	285				SI		176	193		10.1016/j.bbr.2014.10.025			18	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CG2CU	WOS:000353083300017	25447293				2021-06-18	
J	Dean, PJA; Sterr, A				Dean, Philip J. A.; Sterr, Annette			Long-term effects of mild traumatic brain injury on cognitive performance	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						head injury; minor; post-concussion syndrome; cognition; neuropsychological tests	POST-CONCUSSION SYMPTOMS; DEFAULT MODE NETWORK; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION-LIKE SYMPTOMS; WORKING-MEMORY LOAD; HEAD-INJURY; FUNCTIONAL MRI; NEUROPSYCHOLOGICAL PERFORMANCE; UNIVERSITY-STUDENTS; RESTING-STATE	Although a proportion of individuals report chronic cognitive difficulties after mild traumatic brain injury (mTBI), results from behavioral testing have been inconsistent. In fact, the variability inherent to the mTBI population may be masking subtle cognitive deficits. We hypothesized that this variability could be reduced by accounting for post-concussion syndrome (PCS) in the sample. Thirty-six participants with mTBI (> 1 year post-injury) and 36 non-head injured controls performed information processing speed (Paced Visual Serial Addition Task, PVSAT) and working memory (n-Back) tasks. Both groups were split by PCS diagnosis (4 groups, all n = 18), with categorization of controls based on symptom report. Participants with mTBI and persistent PCS had significantly greater error rates on both the n-Back and PVSAT, at every difficulty level except 0-Back (used as a test of performance validity). There was no difference between any of the other groups. Therefore, a cognitive deficit can be observed in mTBI participants, even 1 year after injury. Correlations between cognitive performance and symptoms were only observed for mTBI participants, with worse performance correlating with lower sleep quality, in addition to a medium effect size association (falling short of statistical significance) with higher PCS symptoms, post-traumatic stress disorder (PTSD), and anxiety. These results suggest that the reduction in cognitive performance is not due to greater symptom report itself, but is associated to some extent with the initial injury. Furthermore, the results validate the utility of our participant grouping, and demonstrate its potential to reduce the variability observed in previous studies.	[Dean, Philip J. A.; Sterr, Annette] Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England	Dean, PJA (corresponding author), Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England.	p.dean@surrey.ac.uk		Dean, Philip/0000-0002-2362-513X	Wingate Foundation Scholarship, UK	This study was supported by a Wingate Foundation Scholarship, UK. We would like to thank Darragh O'Neill for his help in the preparation of this manuscript.	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bell BD, 1999, ARCH CLIN NEUROPSYCH, V14, P389, DOI 10.1016/S0887-6177(98)00020-1; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Erez ABH, 2009, AM J OCCUP THER, V63, P634; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Fos L A, 2000, Appl Neuropsychol, V7, P140, DOI 10.1207/S15324826AN0703_4; GILLBERG M, 1994, SLEEP, V17, P236, DOI 10.1093/sleep/17.3.236; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kemp S, 2008, J PSYCHOSOM RES, V65, P319, DOI 10.1016/j.jpsychores.2008.02.010; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Kumar S, 2005, PSYCHIAT CLIN NEUROS, V59, P466, DOI 10.1111/j.1440-1819.2005.01400.x; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moore E, 2006, PARIS REV, P117; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; NCIPC, 2003, REP C MILD TRAUM BRA; Nelson HE, 1982, NATL ADULT READING T; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; O'Jile JR, 2006, ARCH CLIN NEUROPSYCH, V21, P293, DOI 10.1016/j.acn.2006.03.003; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Pella RD, 2012, ARCH CLIN NEUROPSYCH, V27, P45, DOI 10.1093/arclin/acr090; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Ptito A, 2007, NEUROREHABILITATION, V22, P217; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sandrone S, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00261; Sandrone S, 2012, J NEUROSCI, V32, P1915, DOI 10.1523/JNEUROSCI.5637-11.2012; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107; Shum D, 2011, NEUROPSYCHOLOGIA, V49, P2156, DOI 10.1016/j.neuropsychologia.2011.02.006; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Slick D., 1997, VICTORIA SYMPTOM VAL; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Solbakk AK, 2005, J CLIN EXP NEUROPSYC, V27, P205, DOI 10.1080/13803390490515739; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Weiss D. S, 2007, CROSS CULTURAL ASSES, P218; World Health Organization, 1992, ICD 10 INT STAT CLAS; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543	104	100	106	0	78	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	FEB 12	2013	7								30	10.3389/fnhum.2013.00030			11	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	101MP	WOS:000315779400001	23408228	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Tzeng, YC; Ainslie, PN; Cooke, WH; Peebles, KC; Willie, CK; MacRae, BA; Smirl, JD; Horsman, HM; Rickards, CA				Tzeng, Y. C.; Ainslie, P. N.; Cooke, W. H.; Peebles, K. C.; Willie, C. K.; MacRae, B. A.; Smirl, J. D.; Horsman, H. M.; Rickards, C. A.			Assessment of cerebral autoregulation: the quandary of quantification	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						cerebral blood flow; autoregulation; blood vessel; circulation	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; BAROREFLEX SENSITIVITY; ARTERIAL-PRESSURE; ACUTE HYPOTENSION; HEART-RATE; TRANSCRANIAL DOPPLER; CENTRAL HYPOVOLEMIA; HUMANS; VARIABILITY	Tzeng YC, Ainslie PN, Cooke WH, Peebles KC, Willie CK, MacRae BA, Smirl JD, Horsman HM, Rickards CA. Assessment of cerebral autoregulation: the quandary of quantification. Am J Physiol Heart Circ Physiol 303: H658-H671, 2012. First published July 20, 2012; doi:10.1152/ajpheart.00328.2012.-We assessed the convergent validity of commonly applied metrics of cerebral autoregulation (CA) to determine the extent to which the metrics can be used interchangeably. To examine between-subject relationships among low-frequency (LF; 0.07-0.2 Hz) and very-low-frequency (VLF; 0.02-0.07 Hz) transfer function coherence, phase, gain, and normalized gain, we performed retrospective transfer function analysis on spontaneous blood pressure and middle cerebral artery blood velocity recordings from 105 individuals. We characterized the relationships (n = 29) among spontaneous transfer function metrics and the rate of regulation index and autoregulatory index derived from bilateral thigh-cuff deflation tests. In addition, we analyzed data from subjects (n = 29) who underwent a repeated squat-to-stand protocol to determine the relationships between transfer function metrics during forced blood pressure fluctuations. Finally, data from subjects (n = 16) who underwent step changes in end-tidal PCO2 (PETCO2) were analyzed to determine whether transfer function metrics could reliably track the modulation of CA within individuals. CA metrics were generally unrelated or showed only weak to moderate correlations. Changes in PETCO2 were positively related to coherence [LF: beta = 0.0065 arbitrary units (AU)/mmHg and VLF: beta = 0.011 AU/mmHg, both P < 0.01] and inversely related to phase (LF: beta = -0.026 rad/mmHg and VLF: beta = -0.018 rad/mmHg, both P < 0.01) and normalized gain (LF: beta = -0.042%/mmHg(2) and VLF: beta = -0.013%/ mmHg(2), both P < 0.01). However, PETCO2 was positively associated with gain (LF: beta = 0.0070 cm.s(-1.)mmHg(-2), P < 0.05; and VLF: beta = 0.014 cm.s(-1).mmHg(-2), P < 0.01). Thus, during changes in PETCO2, LF phase was inversely related to LF gain (beta = -0.29 cm.s(-1).mmHg(-1).rad(-1), P < 0.01) but positively related to LF normalized gain (beta = 1.3% mmHg(-1)/rad, P < 0.01). These findings collectively suggest that only select CA metrics can be used interchangeably and that interpretation of these measures should be done cautiously.	[Tzeng, Y. C.; Peebles, K. C.; MacRae, B. A.; Horsman, H. M.] Univ Otago, Cardiovasc Syst Lab, Wellington, New Zealand; [Ainslie, P. N.; Willie, C. K.; Smirl, J. D.] Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Cooke, W. H.; Rickards, C. A.] Univ Texas San Antonio, Dept Hlth & Kinesiol, San Antonio, TX USA	Tzeng, YC (corresponding author), Univ Otago, Cardiovasc Syst Lab, 23A Mein St,POB 7343, Wellington, New Zealand.	shieak.tzeng@otago.ac.nz		Peebles, Karen/0000-0002-9694-9127; Rickards, Caroline/0000-0002-5759-6912; Smirl, Jonathan/0000-0003-1054-0038; MacRae, Braid/0000-0003-2077-3978	New Zealand National Heart Foundation Grant [1284]; Health Research Council Grant [09/186]; United States Department of Defense Medical Research and Material Command Grant [W81XWH-11-2-0137]; Canada Research Chair and Natural Sciences and Engineering Council	The work was supported by New Zealand National Heart Foundation Grant 1284 and Health Research Council Grant 09/186, the United States Department of Defense Medical Research and Material Command Grant W81XWH-11-2-0137, and the Canada Research Chair and Natural Sciences and Engineering Council.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Ainslie PN, 2008, BRAIN RES, V1230, P115, DOI 10.1016/j.brainres.2008.07.048; Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Blockley NP, 2011, MAGN RESON MED, V65, P1278, DOI 10.1002/mrm.22719; Chacon M, 2008, PHYSIOL MEAS, V29, P1179, DOI 10.1088/0967-3334/29/10/003; Chan GSH, 2011, J APPL PHYSIOL, V110, P917, DOI 10.1152/japplphysiol.01407.2010; Claassen JAHR, 2009, J APPL PHYSIOL, V106, P153, DOI 10.1152/japplphysiol.90822.2008; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; Deegan BM, 2011, STROKE, V42, P1988, DOI 10.1161/STROKEAHA.110.605618; Edwards MR, 2002, AM J PHYSIOL-REG I, V283, pR653, DOI 10.1152/ajpregu.00452.2001; Elstad M, 2011, J HYPERTENS, V29, P1327, DOI 10.1097/HJH.0b013e328347a17a; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Gommer ED, 2008, PHYSIOL MEAS, V29, P1293, DOI 10.1088/0967-3334/29/11/005; Gommer ED, 2010, MED BIOL ENG COMPUT, V48, P1243, DOI 10.1007/s11517-010-0706-y; Hamner JW, 2010, STROKE, V41, P102, DOI 10.1161/STROKEAHA.109.557132; Hamner JW, 2004, J PHYSIOL-LONDON, V559, P965, DOI 10.1113/jphysiol.2004.066969; HOLM S, 1979, SCAND J STAT, V6, P65; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Kugler J, 1997, INT J CLIN MONIT COM, V14, P251, DOI 10.1023/A:1016927206619; La Rovere MT, 2001, CIRCULATION, V103, P2072; Lazic SE, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-5; Lewis Philip M, 2012, Acta Neurochir Suppl, V114, P141, DOI 10.1007/978-3-7091-0956-4_26; Lucas SJE, 2010, HYPERTENSION, V55, P698, DOI 10.1161/HYPERTENSIONAHA.109.146290; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; Monson KL, 2008, ANN BIOMED ENG, V36, P2028, DOI 10.1007/s10439-008-9578-9; Nishimura N, 2010, J APPL PHYSIOL, V108, P1154, DOI 10.1152/japplphysiol.00656.2009; Ogoh S, 2008, STROKE, V39, P1979, DOI 10.1161/STROKEAHA.107.510008; Ogoh S, 2010, J PHYSIOL-LONDON, V588, P365, DOI 10.1113/jphysiol.2009.180844; Ogoh S, 2009, EXERC SPORT SCI REV, V37, P123, DOI 10.1097/JES.0b013e3181aa64d7; Panerai RB, 2010, J APPL PHYSIOL, V109, P1860, DOI 10.1152/japplphysiol.00857.2010; Panerai RB, 1999, PHYSIOL MEAS, V20, P265, DOI 10.1088/0967-3334/20/3/304; Panerai RB, 2008, CARDIOVASC ENG, V8, P42, DOI 10.1007/s10558-007-9044-6; Panerai RB, 2009, CLIN AUTON RES, V19, P197, DOI 10.1007/s10286-009-0011-8; Panerai RB, 2009, PHILOS T R SOC A, V367, P1319, DOI 10.1098/rsta.2008.0264; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Pinna GD, 2002, CLIN SCI, V103, P81; Pinna GD, 2001, MED BIOL ENG COMPUT, V39, P338, DOI 10.1007/BF02345289; Reinhard M, 2003, PHYSIOL MEAS, V24, P27, DOI 10.1088/0967-3334/24/1/303; Romero SA, 2011, J APPL PHYSIOL, V110, P492, DOI 10.1152/japplphysiol.01060.2010; Rothwell PM, 2010, LANCET, V375, P938, DOI 10.1016/S0140-6736(10)60309-1; Ryan KL, 2011, J PHYSIOL-LONDON, V589, P5311, DOI 10.1113/jphysiol.2011.213074; Ryan KL, 2010, SHOCK, V33, P583, DOI 10.1097/SHK.0b013e3181cd8cbe; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; Slessarev M, 2007, J PHYSIOL-LONDON, V581, P1207, DOI 10.1113/jphysiol.2007.129395; Sorond FA, 2009, ULTRASOUND MED BIOL, V35, P21, DOI 10.1016/j.ultrasmedbio.2008.08.001; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; TRIEDMAN JK, 1993, HYPERTENSION, V21, P236, DOI 10.1161/01.HYP.21.2.236; Tu YK, 2007, STAT MED, V26, P443, DOI 10.1002/sim.2538; Tzeng YC, 2011, J PHYSIOL-LONDON, V589, P3263, DOI 10.1113/jphysiol.2011.206953; Tzeng YC, 2010, J APPL PHYSIOL, V108, P1162, DOI 10.1152/japplphysiol.01390.2009; van Beek AHEA, 2010, ULTRASOUND MED BIOL, V36, P192, DOI 10.1016/j.ultrasmedbio.2009.10.011; Wilson TE, 2006, AM J PHYSIOL-REG I, V291, pR1443, DOI 10.1152/ajpregu.00712.2005; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zhang R, 2009, J PHYSIOL-LONDON, V587, P2567, DOI 10.1113/jphysiol.2008.168302	56	100	100	0	12	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135			AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	SEP	2012	303	6					H658	H671		10.1152/ajpheart.00328.2012			14	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	009AY	WOS:000308998900003	22821992				2021-06-18	
J	Shumskaya, E; Andriessen, TMJC; Norris, DG; Vos, PE				Shumskaya, Elena; Andriessen, Teuntje M. J. C.; Norris, David G.; Vos, Pieter E.			Abnormal whole-brain functional networks in homogeneous acute mild traumatic brain injury	NEUROLOGY			English	Article							MINOR HEAD-INJURY; CONNECTIVITY; MEMORY; SCALE; DYSFUNCTION; MECHANISMS; PREDICTION; SYMPTOMS; DEFICITS; REST	Objectives: To evaluate the whole-brain resting-state networks in a homogeneous group of patients with acute mild traumatic brain injury (MTBI) and to identify alterations in functional connectivity induced by MTBI. Methods: Thirty-five patients with acute MTBI and 35 healthy control subjects, matched in age, gender, handedness, and education, underwent resting-state fMRI, susceptibility weighted imaging, neuropsychological, and postconcussive symptom assessments. We ensured the homogeneity of the patient group by limiting the injury mechanism to fronto-occipital impacts. Alterations in functional connectivity were analyzed by using data-driven independent component analysis, which is not biased by a priori region selection. Results: We found a decrease in functional connectivity within the motor-striatal network in the MTBI group. At the same time, patients showed deficits in psychomotor speed as well as in speed of information processing. We propose that although disorders in motor function after MTBI are rarely reported, injury still has an effect on motor functioning, which in its turn may also explain the reduction in speed of information processing. Further, we found a cluster of increased functional connectivity in the right frontoparietal network in the MTBI group. We suggest that this abnormal increased connectivity might reflect increased awareness to external environment and explain excessive cognitive fatigue reported by patients with MTBI. It might also underlie the physical postconcussive symptoms, such as headache and increased sensitivity to noise/light. Conclusions: We proved that whole-brain functional connectivity is altered early (within 4 weeks) after MTBI, suggesting that changes in functional networks underlie the cognitive deficits and postconcussive complaints reported by patients with MTBI. Neurology (R) 2012;79:175-182	[Shumskaya, Elena; Norris, David G.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit Neuroimaging, NL-6525 ED Nijmegen, Netherlands; [Shumskaya, Elena; Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Norris, David G.] Erwin L Hahn Inst Magnet Resonance, Essen, Germany; [Norris, David G.] Univ Twente, MIRA Inst Biomed Technol & Tech Med, NL-7500 AE Enschede, Netherlands	Shumskaya, E (corresponding author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit Neuroimaging, NL-6525 ED Nijmegen, Netherlands.	elena.shumskaya@donders.ru.nl	Norris, David G/A-1937-2010	Norris, David G/0000-0002-3699-6917	Dutch Brain Foundation (Hersenstichting Nederland) [HsN 15F07.34]; Ever Neuro Pharma	Supported by the Dutch Brain Foundation (Hersenstichting Nederland) (HsN 15F07.34).; E. Shumskaya, T. Andriessen, and D. Norris report no disclosures. P. Vos serves on a scientific advisory board and has received funding for travel and speaker honoraria from Ever Neuro Pharma. Go to Neurology.org for full disclosures.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Alberts M, 1997, Ned Tijdschr Geneeskd, V141, P1526; Arnsten AFT, 2010, TRENDS COGN SCI, V14, P365, DOI 10.1016/j.tics.2010.05.003; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beckmann C. F., 2009, NEUROIMAGE, V47, pS148, DOI [10.1016/S1053-8119(09)71511-3, DOI 10.1016/S1053-8119(09)71511-3]; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cole DM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00008; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McHugh PR, 2007, J ANXIETY DISORD, V21, P211, DOI 10.1016/j.janxdis.2006.09.003; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Spikman JM, 2010, J NEUROTRAUM, V27, P1195, DOI 10.1089/neu.2010.1277; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Van der Does A, 2002, MANUAL DUTCH VERSION; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Veer IM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00041; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zuo XN, 2010, NEUROIMAGE, V49, P1432, DOI 10.1016/j.neuroimage.2009.09.037	40	100	102	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JUL	2012	79	2					175	182		10.1212/WNL.0b013e31825f04fb			8	Clinical Neurology	Neurosciences & Neurology	971XV	WOS:000306241000017	22744656				2021-06-18	
J	Bolkvadze, T; Pitkanen, A				Bolkvadze, Tamuna; Pitkanen, Asla			Development of Post-Traumatic Epilepsy after Controlled Cortical Impact and Lateral Fluid-Percussion-Induced Brain Injury in the Mouse	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalogram; epilepsy; post-traumatic seizure; traumatic brain injury	LONG-TERM HYPEREXCITABILITY; SEIZURE SUSCEPTIBILITY; HEAD-INJURY; ELECTRICAL-STIMULATION; DENTATE GYRUS; CELL LOSS; MODEL; HIPPOCAMPUS; PENTYLENETETRAZOL; EPILEPTOGENESIS	The present study investigated the development of hyperexcitability and epilepsy in mice with traumatic brain injury (TBI) induced by controlled cortical impact (CCI) or lateral fluid-percussion injury (FPI), which are the two most commonly used experimental models of human TBI in rodents. TBI was induced with CCI to 50 (14 controls) and with lateral FPI to 45 (15 controls) C57BL/6S adult male mice. The animals were followed-up for 9 months, including three 2-week periods of continuous video-electroencephalographic (EEG) monitoring, and a seizure susceptibility test with pentylenetetrazol (PTZ). In the end, the animals were perfusion-fixed for histology. The experiment included two independent cohorts of animals. Late post-traumatic spontaneous electrographic seizures were detected in 9% of mice after CCI and 3% after lateral FPI. Eighty-two percent of mice after CCI and 71% after lateral FPI had spontaneous epileptiform spiking on EEG. In addition, 58% of mice with lateral FPI showed spontaneous epileptiform discharges. A PTZ test demonstrated increased seizure susceptibility in the majority of mice in both models, compared to control mice. There was no further progression in the occurrence of epilepsy or epileptiform spiking when follow-up was extended from 6 to 9 months. The severity of cortical or hippocampal damage did not differentiate mice with or without epileptiform activity in either model. Finally, two independent series of experiments in both injury models provided comparable data demonstrating reproducibility of the modeling. These data show that different types of impact can trigger epileptogenesis in mice. Even though the frequency of spontaneous seizures in C57BL/6S mice is low, a large majority of animals develop hyperexcitability.	[Bolkvadze, Tamuna; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uef.fi	Ritter, Stefanie L/D-9312-2012		Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE; Finnish Epilepsy Foundation	This study was supported by the Academy of Finland (AP), The Sigrid Juselius Foundation (AP), CURE (AP), and The Finnish Epilepsy Foundation (TB). We thank Drs. M. S. Grady and D.J. Watson, Department of Neurosurgery, University of Pennsylvania, Philadelphia, for their help in setting up the lateral fluid-percussionmodel in mice. We also thank Marja-Leena Hannila, M.Sc., statistician of the Faculty of Health of the University of Eastern Finland, for her help in statistical analysis.	Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bortel A, 2010, NEUROBIOL DIS, V40, P478, DOI 10.1016/j.nbd.2010.07.015; Calcagni ML, 2002, EUR J NUCL MED MOL I, V29, P1298, DOI 10.1007/s00259-002-0879-1; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; Chrzaszcz M, 2010, J NEUROTRAUM, V27, P1283, DOI 10.1089/neu.2009.1227; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dardiotis E., 2010, NEUROSURG FOCUS, V28, P9; DASILVA AM, 1990, ACT NEUR S, V50, P48; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Dudek FE, 2009, NEUROTHERAPEUTICS, V6, P319, DOI 10.1016/j.nurt.2009.01.020; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Golarai G, 2001, J NEUROSCI, V21, P8523; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Guo D., 2010, AM EP SOC ANN M; Gurkoff GG, 2009, NEUROSCIENCE, V164, P862, DOI 10.1016/j.neuroscience.2009.08.021; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Hanell A, 2010, J NEUROTRAUM, V27, P1297, DOI 10.1089/neu.2009.1255; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kazemi M, 2004, MAGN RESON IMAGING, V22, P653, DOI 10.1016/j.mri.2004.01.043; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kraus J., 2006, ACTA NEUROCHIR, V148, P255; LOSCHER W, 1991, EPILEPSY RES, V9, P1, DOI 10.1016/0920-1211(91)90041-D; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MATHERN GW, 1995, J NEUROSURG, V82, P220, DOI 10.3171/jns.1995.82.2.0220; Mora GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005759; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A., 2011, NEUROSCI LETT   0321; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schauwecker PE, 2002, PROG BRAIN RES, V135, P139; Scheid R, 2010, DTSCH ARZTEBL INT, V107, P199, DOI 10.3238/arztebl.2010.0199; Schwartzkroin PA, 2010, EPILEPSY RES, V92, P74, DOI 10.1016/j.eplepsyres.2010.08.009; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Specht CG, 2004, GENOMICS, V83, P1176, DOI 10.1016/j.ygeno.2003.12.014; Specht CG, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-11; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Toth Z, 1997, J NEUROSCI, V17, P8106; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Vezzani A, 1995, EUR J NEUROSCI, V7, P2513, DOI 10.1111/j.1460-9568.1995.tb01050.x; WIESER HG, 1979, EPILEPSIA, V20, P47, DOI 10.1111/j.1528-1157.1979.tb04775.x; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wotjak CT, 2003, TRENDS GENET, V19, P183, DOI 10.1016/S0168-9525(02)00049-5; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; YONEKAWA WD, 1980, J PHARMACOL EXP THER, V214, P589	81	100	100	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					789	812		10.1089/neu.2011.1954			24	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900009	22023672				2021-06-18	
J	Fjalestad, T; Hole, MO; Hovden, IAH; Blucher, J				Fjalestad, Tore; Hole, Margrethe O.; Hovden, Inger Anette Hynas; Blucher, Judith			Surgical Treatment With an Angular Stable Plate for Complex Displaced Proximal Humeral Fractures in Elderly Patients: A Randomized Controlled Trial	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						proximal humeral fracture; displaced; surgical treatment; conservative treatment; randomized controlled trial; functional outcome; axillary nerve injury	LOCKING COMPRESSION PLATE; 4-PART FRACTURES; INTERNAL-FIXATION; OPEN REDUCTION; CLASSIFICATIONS; RELIABILITY; 3-PART; HEAD	Objective: The objective of the study was to evaluate functional outcome, patient self-assessment, and radiographic outcome at 1 year in displaced three-and four-part proximal humeral fractures (OTA group 11-B2 and 11-C2). Design: Randomized controlled trial. Setting: Academic medical center. Patients/Participants: Fifty patients aged 60 years or older with displaced three-or four-part proximal humeral fractures and no previous shoulder injuries were randomized either to surgical treatment or to conservative closed treatment. Twenty-five patients were included in each group. Forty-eight patients completed 12-month follow-up. Two surgical patients died within 3 months. Intervention: The surgically treated group had a standardized surgical treatment with open reduction and internal fixation using an angular stable plate and cerclages. Instructed physical therapy started the third postoperative day. The conservative treatment group had a standardized nonoperative treatment that included closed reduction if displacement between the head and metaphyseal shaft fragment exceeded 50% of the diaphyseal diameter. Physical therapy started on the fifteenth postoperative day. Main Outcome Measurements: The main outcome was the mean difference in Constant score between the injured and noninjured shoulder at 12 months. The secondary outcomes were patient self-assessment (American Shoulder and Elbow Surgeons score) and radiographic ratings at 12 months. Results: At 12 months, mean Constant scores favored conservative treatment by 2.4 points (nonsignificant; P = 0.62). There was no significant difference in mean patient self-assessment. However, radiographic outcomes were significantly better for surgically treated patients. Conclusion: There is no evidence of a difference in functional outcome at 1-year follow-up between surgical treatment and conservative treatment of displaced proximal humeral fractures in elderly patients.	[Fjalestad, Tore; Blucher, Judith] Univ Oslo, Hosp Ulleval HF, Dept Orthoped, N-0514 Oslo, Norway; [Hole, Margrethe O.] Univ Oslo, Hosp Ulleval HF, Dept Physiotherapy, Div Med, N-0514 Oslo, Norway; [Hovden, Inger Anette Hynas] Univ Oslo, Hosp Ulleval HF, Neurophysiol Lab, N-0514 Oslo, Norway; [Blucher, Judith] Univ Oslo, Hosp Aker HF, Dept Radiol, N-0514 Oslo, Norway	Fjalestad, T (corresponding author), Univ Oslo, Hosp Aker HF, Dept Orthopaed, Trondheimsveien 235, N-0514 Oslo, Norway.	torfja@online.no		Hovden, Inger Anette Hynas/0000-0001-6347-3700	Helse Sor-Ost (Regional Hospital and Health Services in Norway)	Funding for this work was provided by Helse Sor-Ost (Regional Hospital and Health Services in Norway): payment of wage in a 50% occupation for a physiotherapist during the study period.	Audige L, 2004, ACTA ORTHOP SCAND, V75, P184, DOI 10.1080/00016470412331294445; Bigliani LU, 1997, TECH ORTHOP, V12, P42; Bjorkenheim JM, 2004, ACTA ORTHOP SCAND, V75, P741, DOI 10.1080/00016470410004120; Bogner R, 2008, J BONE JOINT SURG BR, V90B, P1602, DOI 10.1302/0301-620X.90B12.20269; Brunner A, 2009, J BONE JOINT SURG BR, V91B, P766, DOI 10.1302/0301-620X.91B6.22109; Conboy VB, 1996, J BONE JOINT SURG BR, V78B, P229; Constant CR, 2008, J SHOULDER ELB SURG, V17, P355, DOI 10.1016/j.jse.2007.06.022; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Fjalestad T, 2009, EUR J ORTHOP SURG TR, V19, P461, DOI 10.1007/s00590-009-0453-7; Frangen TM, 2007, ACTA ORTHOP BELG, V73, P571; Gaebler C, 2003, ACTA ORTHOP SCAND, V74, P580, DOI 10.1080/00016470310017992; Handoll HHG, 2008, COCHRANE DB SYST REV, V4; Hertel R, 2004, J SHOULDER ELB SURG, V13, P427, DOI 10.1016/j.jse.2004.01.034; Hertel R, 2005, OSTEOPOROSIS INT, V16, pS65, DOI 10.1007/s00198-004-1714-2; Hodgson SA, 2007, J SHOULDER ELB SURG, V16, P143, DOI 10.1016/j.jse.2006.06.003; King GJ, 1994, J SHOULDER ELB SURG, V3, P347; Kralinger F, 2004, J BONE JOINT SURG BR, V86B, P217, DOI 10.1302/0301-620X.86B2.14553; Lanting B, 2008, J SHOULDER ELB SURG, V17, P42, DOI 10.1016/j.jse.2007.03.016; Marsh JL, 2007, J ORTHOP TRAUMA, V21, pS1, DOI 10.1097/00005131-200711101-00001; Miranda MA, 2007, INJURY, V38, P35, DOI 10.1016/j.injury.2007.08.009; Moonot P, 2007, J BONE JOINT SURG BR, V89B, P1206, DOI 10.1302/0301-620X.89B9.18528; Nho SJ, 2007, J BONE JOINT SURG AM, V89A, P44, DOI 10.2106/JBJS.G.00648; Olsson C, 2005, ACTA ORTHOP, V76, P397, DOI 10.1080/17453670510041295; Owsley KC, 2008, J BONE JOINT SURG AM, V90A, P233, DOI 10.2106/JBJS.F.01351; Perren S M, 2005, Acta Chir Orthop Traumatol Cech, V72, P89; Resch H, 1997, J BONE JOINT SURG BR, V79B, P295, DOI 10.1302/0301-620X.79B2.6958; Ring D, 2007, INJURY, V38, P59, DOI 10.1016/j.injury.2007.08.013; Solberg BD, 2009, J BONE JOINT SURG AM, V91A, P1689, DOI 10.2106/JBJS.H.00133; Sommer C, 2003, INJURY, V34, P43, DOI 10.1016/j.injury.2003.09.024; Visser CPJ, 1999, CLIN NEUROL NEUROSUR, V101, P86, DOI 10.1016/S0303-8467(99)00011-6; Wall B, 2007, HAND CLIN, V23, P425, DOI 10.1016/j.hcl.2007.08.002; Wijgman AJ, 2002, J BONE JOINT SURG AM, V84A, P1919, DOI 10.2106/00004623-200211000-00002; Zyto K, 1998, INJURY, V29, P349, DOI 10.1016/S0020-1383(97)00211-8	33	100	105	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	FEB	2012	26	2					98	106		10.1097/BOT.0b013e31821c2e15			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	877RQ	WOS:000299200000012	21804410				2021-06-18	
J	Pan, H; Wang, HD; Wang, XL; Zhu, L; Mao, L				Pan, Hao; Wang, Handong; Wang, Xiaoliang; Zhu, Lin; Mao, Lei			The Absence of Nrf2 Enhances NF-kappa B-Dependent Inflammation following Scratch Injury in Mouse Primary Cultured Astrocytes	MEDIATORS OF INFLAMMATION			English	Article							TRAUMATIC BRAIN-INJURY; NF-E2-RELATED FACTOR-2; TNF-ALPHA; ACTIVATION; EXPRESSION; CYTOKINES; PATHWAY; SULFORAPHANE; BARRIER	It has been proved that Nrf2 depletion enhances inflammatory process through activation of NF-kappa B in the brain after TBI, but little is known about the relationship between Nrf2 and NF-kappa B in astrocytes after TBI. Hence, we used primary cultured astrocytes from either Nrf2 wildtype or knockout mice to study the influence of Nrf2 on the activation of NF-kappa B and expression of proinflammatory cytokines in a model of TBI in vitro. Primary cultured astrocytes were scratched to mimic the traumatic injury in vitro. Then the DNA-binding activity of NF-kappa B was evaluated by EMSA. The mRNA and protein levels of TNF-alpha, IL-1 beta, IL-6, and MMP9 were also evaluated. Gelatin zymography was performed to detect the activity of MMP9. The activity of NF-kappa B and expression of proinflammatory cytokines mentioned above were upregulated at 24 h after scratch. The expression and activity of MMP9 were also elevated. And such tendency was much more prominent in Nrf2 KO astrocytes than that in WT astrocytes. These results suggest that the absence of Nrf2 may induce more aggressive inflammation through activation of NF-kappa B and downstream proinflammatory cytokines in astrocytes.	[Pan, Hao; Wang, Handong; Wang, Xiaoliang; Zhu, Lin; Mao, Lei] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	hdwang_nj@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Jiangsu Provincial Key Subject [X4200722]; Jinling Hospital of Nanjing, China [2010Q017]	The authors would like to thank Dr. Geng-bao Feng for technical assistance. This work was supported by Grants from The National Natural Science Foundation of China (no. 81070974), the Jiangsu Provincial Key Subject (no. X4200722), and Jinling Hospital of Nanjing, China (no. 2010Q017). The authors alone are responsible for the content and writing of the paper.	Bethea JR, 1998, J NEUROSCI, V18, P3251; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hsu CP, 2011, EUR J CLIN INVEST, V41, P277, DOI 10.1111/j.1365-2362.2010.02405.x; Hu R, 2010, ANTIOXID REDOX SIGN, V13, P1679, DOI 10.1089/ars.2010.3276; Jeong WS, 2004, PHARM RES-DORDR, V21, P661, DOI 10.1023/B:PHAM.0000022413.43212.cf; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Jin W, 2009, J SURG RES, V157, P251, DOI 10.1016/j.jss.2008.08.003; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Kemler I, 1999, GLIA, V26, P212, DOI 10.1002/(SICI)1098-1136(199905)26:3<212::AID-GLIA3>3.3.CO;2-6; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; Pan H, 2011, NEUROCHEM RES, V36, P2434, DOI 10.1007/s11064-011-0571-6; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; Sohn Y, 2009, AM J CHINESE MED, V37, P273, DOI 10.1142/S0192415X09006849; Srinivasan D, 2004, J NEUROSCI, V24, P6482, DOI 10.1523/JNEUROSCI.5712-03.2004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Xu CJ, 2005, ONCOGENE, V24, P4486, DOI 10.1038/sj.onc.1208656; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306	29	100	105	1	16	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2012	2012								217580	10.1155/2012/217580			9	Cell Biology; Immunology	Cell Biology; Immunology	907JU	WOS:000301414400001	22529521	DOAJ Gold, Green Published			2021-06-18	
J	Dang, J; Mitkari, B; Kipp, M; Beyer, C				Dang, Jon; Mitkari, Bhimashankar; Kipp, Markus; Beyer, Cordian			Gonadal steroids prevent cell damage and stimulate behavioral recovery after transient middle cerebral artery occlusion in male and female rats	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Stroke; MCAO; Estrogen; Progesterone; Microglia; Chemokine	TRAUMATIC BRAIN-INJURY; ESTROGEN-MEDIATED NEUROPROTECTION; EXPERIMENTAL STROKE; FOCAL ISCHEMIA; SEX STEROIDS; INFLAMMATORY RESPONSE; FUNCTIONAL RECOVERY; RECEPTOR-ALPHA; ANIMAL-MODELS; TISSUE-INJURY	17 beta-Estradiol (E) and progesterone (P) are neuroprotective factors in the brain preventing neuronal death under different injury paradigms. Our previous work demonstrates that both steroids compensate neuronal damage and activate distinct neuroprotective strategies such as improving local energy metabolism and abating pro-inflammatory responses. The current study explored steroid hormone-mediated protection from brain damage and restoration of behavioral function after 1 h transient middle cerebral artery occlusion (tMCAO). Male and ovariectomized female rats were studied 24 h after stroke. Both steroid hormones reduced the cortical infarct area in males and females to a similar extent. A maximum effect of similar to 60-70% reduction of the infarct size was evident after Panda combined treatment with both hormones. No infarct protection was seen in the basal ganglia. Testing of motor and sensory behavioral revealed an equal high degree of functional recovery in all three hormone groups. Gene expression studies in the delineated penumbra revealed that estrogen receptor (ER) alpha and beta are locally up-regulated. tMCAO-mediated induction of the pro-inflammatory chemokines CCL2, CCL5 and interleukin 6 was attenuated by E and P. whereas the expression of vascular endothelial growth factor (VEGF) was fortified. Local expression of microglia/macrophage/lymphocyte markers, i.e. Iba1, CD68 and CD3, were significantly reduced in the penumbra after hormone treatment suggesting attenuation of microglia and lymphocyte attraction. These results demonstrate the neuroprotective potency of a combined treatment with E and P under ischemic conditions in both sexes and point at the regulation of chemokine-microglia/lymphocyte interactions as a supposable mechanism implicated in cell protection. (C) 2011 Elsevier Inc. All rights reserved.	[Dang, Jon; Mitkari, Bhimashankar; Kipp, Markus; Beyer, Cordian] Rhein Westfal TH Aachen, Inst Neuroanat, Fac Med, D-52074 Aachen, Germany	Beyer, C (corresponding author), Rhein Westfal TH Aachen, Inst Neuroanat, Fac Med, Wendlingweg 2, D-52074 Aachen, Germany.	cbeyer@ukaachen.de	Kipp, Markus/K-2694-2015; tao, li/G-7956-2011		Faculty of Medicine, RWTH Aachen University; B. Braun Melsungen AG (Germany)	The technical support by H. Helten is acknowledged. The work was supported by IZKF BIOMAT (C.B.) and START (M.K.) of the Faculty of Medicine, RWTH Aachen University as well as B. Braun Melsungen AG (Germany).	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Ardelt AA, 2005, STROKE, V36, P337, DOI 10.1161/01.STR.0000153795.38388.72; Arevalo M. A., 2009, BIOCHIM BIOPHYS ACTA, V1800, P1106; Arnold S, 2009, J NEUROCHEM, V110, P1, DOI 10.1111/j.1471-4159.2009.06133.x; Babcock AA, 2003, J NEUROSCI, V23, P7922; Benedek A, 2006, BRAIN RES, V1116, P159, DOI 10.1016/j.brainres.2006.07.123; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Carswell HVO, 2005, J STEROID BIOCHEM, V96, P89, DOI 10.1016/j.jsbmb.2005.02.016; Carwile E, 2009, J NEUROSCI NURS, V41, P18, DOI 10.1097/JNN.0b013e31819345f8; Chen TY, 2010, STROKE, V41, P160, DOI 10.1161/STROKEAHA.109.562850; Chiappetta O, 2007, INT REV NEUROBIOL, V82, P357, DOI 10.1016/S0074-7742(07)82019-8; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Cross AK, 1999, J NEUROSCI RES, V55, P17, DOI 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Denes A, 2010, J NEUROSCI, V30, P10086, DOI 10.1523/JNEUROSCI.1227-10.2010; Dhandapani KM, 2007, EXP GERONTOL, V42, P70, DOI 10.1016/j.exger.2006.06.032; Draca S, 2009, MED HYPOTHESES, V73, P1051, DOI 10.1016/j.mehy.2009.04.049; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Elzer JG, 2010, J CEREBR BLOOD F MET, V30, P935, DOI 10.1038/jcbfm.2009.258; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Guo JB, 2010, J CEREBR BLOOD F MET, V30, P545, DOI 10.1038/jcbfm.2009.226; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Ivanova T, 2003, J NEUROBIOL, V54, P638, DOI 10.1002/neu.10193; Johann S, 2008, J MOL NEUROSCI, V34, P177, DOI 10.1007/s12031-007-9028-4; Kajta M, 2003, ENDOCRINE, V21, P3, DOI 10.1385/ENDO:21:1:3; Kipp M, 2006, FRONT NEUROENDOCRIN, V27, P376, DOI 10.1016/j.yfrne.2006.07.001; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Liu M, 2010, MINERVA ENDOCRINOL, V35, P127; Liu MY, 2009, RESTOR NEUROL NEUROS, V27, P163, DOI 10.3233/RNN-2009-0467; Liu R, 2010, J PHARMACOL EXP THER, V332, P1006, DOI 10.1124/jpet.109.160937; Lorenz L, 2009, J NEUROENDOCRINOL, V21, P841, DOI 10.1111/j.1365-2826.2009.01903.x; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; Misiak M, 2010, BBA-BIOENERGETICS, V1797, P1178, DOI 10.1016/j.bbabio.2010.04.009; Paxinos G., 2004, RAT NERVOUS SYSTEM, VThird; PERTERFALVI A, 2009, CEREBROVASC DIS, V28, P490; Rau SW, 2003, J NEUROSCI, V23, P11420; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Schilling M, 2009, NEUROSCIENCE, V161, P806, DOI 10.1016/j.neuroscience.2009.04.025; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Singh M, 2008, FRONT BIOSCI-LANDMRK, V13, P1083, DOI 10.2741/2746; Soderstrom I, 2009, EUR J NEUROSCI, V29, P1215, DOI 10.1111/j.1460-9568.2009.06662.x; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Strom JO, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-39; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tambuyzer BR, 2009, J LEUKOCYTE BIOL, V85, P352, DOI 10.1189/jlb.0608385; Terao S, 2008, STROKE, V39, P2560, DOI 10.1161/STROKEAHA.107.513150; Toung TJ, 2004, J CEREBR BLOOD F MET, V24, P1160, DOI 10.1097/01.WCB.0000135594.13576.D2; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Trotter A, 2006, PEDIATR RES, V60, P60, DOI 10.1203/01.pdr.0000220360.77567.d8; Trotter A, 1999, J CLIN ENDOCR METAB, V84, P4531, DOI 10.1210/jc.84.12.4531; Trotter A, 2009, EARLY HUM DEV, V85, P353, DOI 10.1016/j.earlhumdev.2008.12.013; Vikman P, 2007, EXP BRAIN RES, V183, P499, DOI 10.1007/s00221-007-1062-5; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Yamada Y, 2008, CURR PHARM DESIGN, V14, P3590, DOI 10.2174/138161208786848793; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Zhang B, 2010, J IMMUNOL, V184, P4087, DOI 10.4049/jimmunol.0902339; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhang Z, 2010, NEUROPHARMACOLOGY, V58, P930, DOI 10.1016/j.neuropharm.2010.01.002; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	81	100	101	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAY	2011	25	4					715	726		10.1016/j.bbi.2011.01.013			12	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	762GN	WOS:000290463100015	21277368				2021-06-18	
J	Blaiss, CA; Yu, TS; Zhang, G; Chen, JA; Dimchev, G; Parada, LF; Powell, CM; Kernie, SG				Blaiss, Cory A.; Yu, Tzong-Shiue; Zhang, Gui; Chen, Jian; Dimchev, Georgi; Parada, Luis F.; Powell, Craig M.; Kernie, Steven G.			Temporally Specified Genetic Ablation of Neurogenesis Impairs Cognitive Recovery after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							NEURAL STEM-CELLS; ADULT HIPPOCAMPAL NEUROGENESIS; CENTRAL-NERVOUS-SYSTEM; GFP TRANSGENIC MICE; DENTATE GYRUS; SUBVENTRICULAR ZONE; EXPRESSING PROGENITORS; CELLULAR PROLIFERATION; STEM/PROGENITOR CELLS; REACTIVE ASTROCYTES	Significant spontaneous recovery occurs after essentially all forms of serious brain injury, although the mechanisms underlying this recovery are unknown. Given that many forms of brain injury such as traumatic brain injury (TBI) induce hippocampal neurogenesis, we investigated whether these newly generated neurons might play a role in recovery. By modeling TBI in transgenic mice, we determined that injury-induced newly generated neurons persisted over time and elaborated extensive dendritic trees that stably incorporated themselves throughout all neuronal layers of the dentate gyrus. When we selectively ablated dividing stem/progenitors at the time of injury with ganciclovir in a nestin-HSV-TK transgenic model, we eliminated injury-induced neurogenesis and subsequently diminished the progenitor pool. Moreover, using hippocampal-specific behavioral tests, we demonstrated that only injured animals with neurogenesis ablated at the time of injury lost the ability to learn spatial memory tasks. These data demonstrate a functional role for adult neurogenesis after brain injury and offer compelling and testable therapeutic options that might enhance recovery.	[Yu, Tzong-Shiue; Zhang, Gui; Dimchev, Georgi; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Yu, Tzong-Shiue; Zhang, Gui; Chen, Jian; Dimchev, Georgi; Parada, Luis F.; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA; [Blaiss, Cory A.; Powell, Craig M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Powell, Craig M.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA	Kernie, SG (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.Kernie@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020; Parada, luis F/B-9400-2014	Dimchev, Georgi/0000-0001-8370-6161; Powell, Craig/0000-0001-5451-2165; Kernie, Steven/0000-0003-1371-0549; Yu, Tzong-Shiue/0000-0003-4277-6213	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS048192]; Seay Endowed Fund for Research on Brain and Spinal Cord Injuries in Children; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Hartwell Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069560] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD065290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH081164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant R01 NS048192 (S.G.K.), the Seay Endowed Fund for Research on Brain and Spinal Cord Injuries in Children (S.G.K.), National Institute of Mental Health (C.M.P.), National Institute of Child Health and Human Development (C.M.P.), and The Hartwell Foundation (C.M.P.).	Aguirre A, 2004, J NEUROSCI, V24, P10530, DOI 10.1523/JNEUROSCI.3572-04.2004; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Chen J, 2009, GENESIS, V47, P122, DOI 10.1002/dvg.20465; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Duan X, 2008, CURR OPIN NEUROBIOL, V18, P108, DOI 10.1016/j.conb.2008.04.001; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Durieux PF, 2009, NAT NEUROSCI, V12, P393, DOI 10.1038/nn.2286; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Etherton MR, 2009, P NATL ACAD SCI USA, V106, P17998, DOI 10.1073/pnas.0910297106; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Goosens KA, 2001, LEARN MEMORY, V8, P148, DOI 10.1101/lm.37601; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Hellstraom NAK, 2009, STEM CELLS, V27, P634, DOI 10.1634/stemcells.2008-0732; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kokovay E, 2008, NEURON, V60, P420, DOI 10.1016/j.neuron.2008.10.025; Lagace DC, 2007, J NEUROSCI, V27, P12623, DOI 10.1523/JNEUROSCI.3812-07.2007; Lau BWM, 2009, NEUROREPORT, V20, P371, DOI 10.1097/WNR.0b013e328324edcd; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Lipp HP, 1998, CURR OPIN NEUROBIOL, V8, P272, DOI 10.1016/S0959-4388(98)80151-7; Luquet S, 2005, SCIENCE, V310, P683, DOI 10.1126/science.1115524; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Miles DK, 2008, HIPPOCAMPUS, V18, P793, DOI 10.1002/hipo.20439; Morshead CM, 2003, EUR J NEUROSCI, V18, P76, DOI 10.1046/j.1460-9568.2003.02727.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Naylor AS, 2008, P NATL ACAD SCI USA, V105, P14632, DOI 10.1073/pnas.0711128105; Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010; Onishi BKA, 2010, NEUROBIOL LEARN MEM, V93, P165, DOI 10.1016/j.nlm.2009.09.007; Powell CM, 2004, NEURON, V42, P143, DOI 10.1016/S0896-6273(04)00146-1; Pozniak CD, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-207; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richmond MA, 1999, BEHAV NEUROSCI, V113, P1189, DOI 10.1037/0735-7044.113.6.1189; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Sofroniew MV, 1999, BRAIN RES, V835, P91, DOI 10.1016/S0006-8993(99)01639-X; Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Yamaguchi M, 2000, NEUROREPORT, V11, P1991, DOI 10.1097/00001756-200006260-00037; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562	58	100	103	0	12	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 30	2011	31	13					4906	4916		10.1523/JNEUROSCI.5265-10.2011			11	Neurosciences	Neurosciences & Neurology	742JM	WOS:000288938200017	21451029	Bronze, Green Accepted, Green Published			2021-06-18	
J	Moubarik, C; Guillet, B; Youssef, B; Codaccioni, JL; Piercecchi, MD; Sabatier, F; Lionel, P; Dou, L; Foucault-Bertaud, A; Velly, L; Dignat-George, F; Pisano, P				Moubarik, Chahrazad; Guillet, Benjamin; Youssef, Bennis; Codaccioni, Jean-Laurent; Piercecchi, Marie-Dominique; Sabatier, Florence; Lionel, Pellegrini; Dou, Laetitia; Foucault-Bertaud, Alexandrine; Velly, Lionel; Dignat-George, Francoise; Pisano, Pascale			Transplanted Late Outgrowth Endothelial Progenitor Cells as Cell Therapy Product for Stroke	STEM CELL REVIEWS AND REPORTS			English	Article						Stroke; Late endothelial progenitors; Angiogenesis; Apoptosis	FOCAL CEREBRAL-ISCHEMIA; MARROW STROMAL CELLS; UMBILICAL-CORD BLOOD; TRAUMATIC BRAIN-INJURY; REDUCES INFARCT VOLUME; BONE-MARROW; BEHAVIORAL DEFICITS; VASCULAR INJURY; GROWTH-FACTOR; RAT MODEL	Endothelial progenitor cells (EPCs) seem to be a promising option to treat patients with ischemic diseases. Here, we investigated the effects of late outgrowth EPCs, or endothelial colony-forming cells (ECFCs), a recently defined homogeneous subtype of EPCs, in a rat model of transient middle cerebral artery occlusion (MCAO). Either vehicle or 4.10(6) ECFCs, isolated from human cord blood, were intravenously injected 24 h after 1 h MCAO in rats assigned to control and transplanted groups respectively. In-111-oxine-labeled ECFCs specifically homed to ischemic hemisphere and CM-Dil prelabeled ECFCs preferentially settled in the inner boundary of the core area of transplanted animals. Although incorporation of cells into neovessels was hardly detectable, ECFCs transplantation was associated with a reduction in apoptotic cell number, an increase in capillary density and a stimulation of neurogenesis at the site of injury. These effects were associated with an increase in growth factors expression in homogenates from ischemic area and may be related to the secretion by ECFCs of soluble factors that could affect apoptosis, vascular growth and neurogenesis. Microscopic examination of the ischemic hemisphere showed that ECFCs transplantation was also associated with a reduction in reactive astrogliosis. In conclusion, we demonstrated that ECFCs injected 24 h after MCAO settled in the injured area and improved functional recovery. The neurological benefits may be linked to a reduction in ischemia-induced apoptosis and a stimulation of ischemia-induced angiogenesis and neurogenesis. These findings raise perspectives for the use of ECFCs as a well-characterized cell therapy product for optimal therapeutic outcome after stroke.	[Guillet, Benjamin] Fac Pharm Marseille, INSERM, UMR 608, Lab Pharmacodynam, F-13005 Marseille, France; [Moubarik, Chahrazad; Guillet, Benjamin; Youssef, Bennis; Piercecchi, Marie-Dominique; Sabatier, Florence; Dou, Laetitia; Foucault-Bertaud, Alexandrine; Dignat-George, Francoise; Pisano, Pascale] Univ Mediterranee, INSERM, UMR 608, Fac Pharm, Marseille, France; [Codaccioni, Jean-Laurent; Lionel, Pellegrini; Velly, Lionel] CHU Timone, Dept Anesthesie Reanimat, Marseille, France; [Dignat-George, Francoise] CHU Concept, Dept Hematol, Marseille, France; [Sabatier, Florence] CHU Concept, INSERM CIC BT 510, Lab Culture & Therapie Cellulaire, Marseille, France	Guillet, B (corresponding author), Fac Pharm Marseille, INSERM, UMR 608, Lab Pharmacodynam, 27 Blvd Jean Moulin, F-13005 Marseille, France.	benjamin.guillet@pharmacie.univ-mrs.fr	guillet, benjamin A/G-2848-2013; Dou, Laetitia/Q-4963-2017; pascale, pisano/C-1733-2013; Bennis, Youssef/ABC-8816-2020; DIGNAT-GEORGE, Francoise/R-1129-2016	Dou, Laetitia/0000-0002-4594-4676; DIGNAT-GEORGE, Francoise/0000-0001-7006-4462; Bennis, Youssef/0000-0002-0186-4797			Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bechara C, 2007, MED SCI MONITOR, V13, pRA87; Bin Deng Y, 2010, NEUROL RES, V32, P148, DOI 10.1179/174313209X414434; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Codaccioni JL, 2009, ANESTHESIOLOGY, V110, P1271, DOI 10.1097/ALN.0b013e3181a1fe68; Corselli M, 2008, EXP HEMATOL, V36, P340, DOI 10.1016/j.exphem.2007.10.008; Delorme B, 2005, THROMB HAEMOSTASIS, V94, P1270, DOI 10.1160/TH05-07-0499; Di Stefano R, 2009, THROMB RES, V123, P925, DOI 10.1016/j.thromres.2008.10.013; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; DUBOWITZ V, 1985, MUSCLE BIOPSY PRACTI, P504; Fedoroff S, 1997, NEUROSCI BIOBEHAV R, V21, P187, DOI 10.1016/S0149-7634(96)00009-7; Hau S, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-30; He TR, 2005, AM J PHYSIOL-HEART C, V289, pH968, DOI 10.1152/ajpheart.01166.2004; Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jourde-Chiche N, 2009, J THROMB HAEMOST, V7, P1576, DOI 10.1111/j.1538-7836.2009.03540.x; Kooijman R, 2009, STROKE, V40, pE83, DOI 10.1161/STROKEAHA.108.528356; Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Liu XS, 2007, J NEUROSCI RES, V85, P2120, DOI 10.1002/jnr.21359; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mokudai T, 2000, STROKE, V31, P1679, DOI 10.1161/01.STR.31.7.1679; Mouw G, 2002, METAB BRAIN DIS, V17, P143, DOI 10.1023/A:1019921904378; Newcomb JD, 2006, CELL TRANSPLANT, V15, P213, DOI 10.3727/000000006783982043; Rouhl RPW, 2008, STROKE, V39, P2158, DOI 10.1161/STROKEAHA.107.507251; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Sobrino T, 2007, STROKE, V38, P2759, DOI 10.1161/STROKEAHA.107.484386; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wang CH, 2008, ARTERIOSCL THROM VAS, V28, P54, DOI 10.1161/ATVBAHA.107.147256; Wechsler L, 2009, STROKE, V40, P510, DOI 10.1161/STROKEAHA.108.526863; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081; Zhang L, 2006, EUR J HAEMATOL, V76, P1, DOI 10.1111/j.1600-0609.2005.00579.x; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	49	100	115	0	13	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1550-8943	1558-6804		STEM CELL REV REP	Stem Cell Rev. Rep.	MAR	2011	7	1					208	220		10.1007/s12015-010-9157-y			13	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	709TV	WOS:000286465200018	20526754				2021-06-18	
J	Maas, AIR; Harrison-Felix, CL; Menon, D; Adelson, PD; Balkin, T; Bullock, R; Engel, DC; Gordon, W; Langlois-Orman, J; Lew, HL; Robertson, C; Temkin, N; Valadka, A; Verfaellie, M; Wainwright, M; Wright, DW; Schwab, K				Maas, Andrew I. R.; Harrison-Felix, Cynthia L.; Menon, David; Adelson, P. David; Balkin, Tom; Bullock, Ross; Engel, Doortje C.; Gordon, Wayne; Langlois-Orman, Jean; Lew, Henry L.; Robertson, Claudia; Temkin, Nancy; Valadka, Alex; Verfaellie, Mieke; Wainwright, Mark; Wright, David W.; Schwab, Karen			Standardizing Data Collection in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						clinical studies; common data elements; data coding; data collection; standardization; traumatic brain injury	COMMON DATA ELEMENTS; RECOMMENDATIONS; MODERATE; CLASSIFICATION; RELIABILITY; VALIDITY	Collaboration among investigators, centers, countries, and disciplines is essential to advancing the care for traumatic brain injury (TBI). It is thus important that we "speak the same language.'' Great variability, however, exists in data collection and coding of variables in TBI studies, confounding comparisons between and analysis across different studies. Randomized controlled trials can never address the many uncertainties concerning treatment approaches in TBI. Pooling data from different clinical studies and high-quality observational studies combined with comparative effectiveness research may provide excellent alternatives in a cost-efficient way. Standardization of data collection and coding is essential to this end. Common data elements (CDEs) are presented for demographics and clinical variables applicable across the broad spectrum of TBI. Most recommendations represent a consensus derived from clinical practice. Some recommendations concern novel approaches, for example assessment of the intensity of therapy in severely injured patients. Up to three levels of detail for coding data elements were developed: basic, intermediate, and advanced, with the greatest level of detail attained in the advanced version. More detailed codings can be collapsed into the basic version. Templates were produced to summarize coding formats, explanation of choices, and recommendations for procedures. Endorsement of the recommendations has been obtained from many authoritative organizations. The development of CDEs for TBI should be viewed as a continuing process; as more experience is gained, refinement and amendments will be required. This proposed process of standardization will facilitate comparative effectiveness research and encourage high-quality meta-analysis of individual patient data.	[Maas, Andrew I. R.] Univ Antwerp Hosp, Antwerp, Belgium; [Harrison-Felix, Cynthia L.] Craig Hosp, Englewood, CO USA; [Menon, David] Univ Cambridge, Cambridge, England; [Adelson, P. David] Phoenix Childrens Neurosci Inst, Phoenix, AZ USA; [Balkin, Tom] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; [Bullock, Ross] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Engel, Doortje C.] Univ Heidelberg Hosp, Heidelberg, Germany; [Gordon, Wayne] Mt Sinai Sch Med, New York, NY USA; [Langlois-Orman, Jean] USA, Inst Surg Res, San Antonio, TX USA; [Lew, Henry L.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Lew, Henry L.] Virginia Commonwealth Univ, Def & Vet Brain Injury Ctr, Richmond, VA USA; [Robertson, Claudia] Baylor Coll Med, Houston, TX 77030 USA; [Temkin, Nancy] Univ Washington, Seattle, WA 98195 USA; [Valadka, Alex] Seton Brain & Spine Inst, Austin, TX USA; [Verfaellie, Mieke] Boston VA Hlth Care Syst, Boston, MA USA; [Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02118 USA; [Wainwright, Mark] Northwestern Univ, Chicago, IL 60611 USA; [Wright, David W.] Emory Univ, Sch Med, Atlanta, GA USA; [Schwab, Karen] Def & Vet Brain Injury Ctr, Washington, DC USA	Maas, AIR (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Wright, David/F-1209-2013; Maas, Andrew IR/C-5584-2013; Adelson, David/W-2083-2019	Wright, David/0000-0002-7145-9105; Maas, Andrew IR/0000-0003-1612-1264; Verfaellie, Mieke/0000-0001-5535-4584	National Institutes of Health (NIH)-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 042691]; National Institute on Disability and Rehabilitation Research; Department of Veterans AffairsUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Defense Centers of Excellence; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	The meetings and activities of the working group "Demographics and Clinical Assessment'' were supported by funding in the context of the interagency initiative towards "an integrated approach to Research in Psychological Health and Traumatic Brain Injury'' (National Institutes of Health (NIH)-NINDS; the National Institute on Disability and Rehabilitation Research; the Department of Veterans Affairs; the Defense and Veterans Brain Injury Center; and the Defense Centers of Excellence). The development of CDEs was further supported by a supplemental grant from NIH-NINDS (NS 042691). The authors greatly acknowledge the input and advice obtained from these international experts: Giuseppe Citerio (Italy), Peter Hutchinson (U.K.), Bertil Romner (Denmark), Juan Sahuquillo (Spain), Franco Servadei (Italy), and Nino Stocchetti (Italy). We are grateful to Nele Kleisz and Anne-Claire van Harderwijk for administrative support in developing the common data elements and templates, and in preparing this manuscript.	*ASS ADV AUT MED, 1990, ABBR INJ SCAL 1990 R, P15; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Jorde LB, 2004, NAT GENET, V36, pS28, DOI 10.1038/ng1435; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kompanje EJO, 2005, ACTA NEUROCHIR, V147, P633, DOI 10.1007/s00701-005-0525-3; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, INTENS CARE MED, V30, P517, DOI 10.1007/s00134-003-2142-z; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; VANLEEUWEN N, PROGNOSTIC VAL UNPUB; *WHO OMS, 2009, GLOB STAT REP ROAD S; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9	32	100	103	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					177	187		10.1089/neu.2010.1617			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700002	21162610	Green Published			2021-06-18	
J	Nyein, MK; Jason, AM; Yu, L; Pita, CM; Joannopoulos, JD; Moore, DF; Radovitzky, RA				Nyein, Michelle K.; Jason, Amanda M.; Yu, Li; Pita, Claudio M.; Joannopoulos, John D.; Moore, David F.; Radovitzky, Raul A.			In silico investigation of intracranial blast mitigation with relevance to military traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						computational models; personal protection equipment	VIRTUAL TEST FACILITY; SIMULATION; IRAQ; CARE; TBI; WAR	Blast-induced traumatic brain injury is the most prevalent military injury in Iraq and Afghanistan, yet little is known about the mechanical effects of blasts on the human head, and still less is known about how personal protective equipment affects the brain's response to blasts. In this study we investigated the effect of the Advanced Combat Helmet (ACH) and a conceptual face shield on the propagation of stress waves within the brain tissue following blast events. We used a sophisticated computational framework for simulating coupled fluid-solid dynamic interactions and a three-dimensional biofidelic finite element model of the human head and intracranial contents combined with a detailed model of the ACH and a conceptual face shield. Simulations were conducted in which the unhelmeted head, head with helmet, and head with helmet and face shield were exposed to a frontal blast wave with incident overpressure of 10 atm. Direct transmission of stress waves into the intracranial cavity was observed in the unprotected head and head with helmet simulations. Compared to the unhelmeted head, the head with helmet experienced slight mitigation of intracranial stresses. This suggests that the existing ACH does not significantly contribute to mitigating blast effects, but does not worsen them either. By contrast, the helmet and face shield combination impeded direct transmission of stress waves to the face, resulting in a delay in the transmission of stresses to the intracranial cavity and lower intracranial stresses. This suggests a possible strategy for mitigating blast waves often associated with military concussion.	[Joannopoulos, John D.] MIT, Dept Phys, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA; [Nyein, Michelle K.; Jason, Amanda M.; Yu, Li; Pita, Claudio M.; Radovitzky, Raul A.] MIT, Dept Aeronaut & Astronaut, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA; [Moore, David F.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA	Joannopoulos, JD (corresponding author), MIT, Dept Phys, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA.	joannop@mit.edu; rapa@mit.edu	Radovitzky, Raul A/A-5353-2009	Radovitzky, Raul A/0000-0001-6339-2708	Joint Improvised Explosive Device Defeat Organization through the Army Research Office; MIT Institute for Soldier Nanotechnologies	This work was supported by financial aid from the Joint Improvised Explosive Device Defeat Organization through the Army Research Office. Partial support from the MIT Institute for Soldier Nanotechnologies is also gratefully acknowledged.	ALLEY MD, 2009, BLAST LOADING EXPT D; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; CERNAK I, 2009, J CEREBR BLOOD F MET, P1; Cummings J, 2002, J SUPERCOMPUT, V23, P39, DOI 10.1023/A:1015733102520; Deiterding R, 2006, ENG COMPUT-GERMANY, V22, P325, DOI 10.1007/s00366-006-0043-9; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; *DVBIC, 2010, TBI NUMB DEP DEF NUM; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Jordan P, 2008, LECT NOTES COMPUT SC, V5242, P930, DOI 10.1007/978-3-540-85990-1_112; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Malvern L. E., 1969, INTRO MECH CONTINUOU; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Meyers MA., 1994, DYNAMIC BEHAV MAT; Moore DF, 2008, ANN NEUROL, V64, pS30; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Moss W.C., 2009, J ACOUST SOC AM, V125, P2650; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; NAKAGAWA A, 2009, ACTA NEUROCHIR SUPP, P421; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson P.A., 1972, COMPRESSIBLE FLUID D; Wadley HNG, 2010, INT J IMPACT ENG, V37, P317, DOI 10.1016/j.ijimpeng.2009.06.006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	33	100	100	1	25	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 30	2010	107	48					20703	20708		10.1073/pnas.1014786107			6	Multidisciplinary Sciences	Science & Technology - Other Topics	687ET	WOS:000284762400025	21098257	Bronze, Green Published			2021-06-18	
J	De Bonis, P; Pompucci, A; Mangiola, A; Rigante, L; Anile, C				De Bonis, Pasquale; Pompucci, Angelo; Mangiola, Annunziato; Rigante, Luigi; Anile, Carmelo			Post-Traumatic Hydrocephalus after Decompressive Craniectomy: An Underestimated Risk Factor	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; post-traumatic hydrocephalus; risk factor; traumatic brain injury	TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; MANAGEMENT	The incidence of post-traumatic hydrocephalus (PTH) has been reported to be 0.7-51.4%, and we have frequently observed the development of PTH in patients undergoing decompressive craniectomy (DC). For this reason we performed a retrospective review of a consecutive series of patients undergoing DC after traumatic brain injury (TBI). From January 2006 to December 2009, 41 patients underwent DC after closed head injury. Study outcomes focused specifically on the development of hydrocephalus after DC. Variables described by other authors to be associated with PTH were studied, including advanced age, the timing of cranioplasty, higher score on the Fisher grading system, low post-resuscitation Glasgow Coma Scale (GCS) score, and cerebrospinal fluid (CSF) infection. We also analyzed the influence of the area of craniotomy and the distance of craniotomy from the midline. Logistic regression was used with hydrocephalus as the primary outcome measure. Of the nine patients who developed hydrocephalus, eight patients (89%) had undergone craniotomy with the superior limit <25mm from the midline. This association was statistically significant (p=0.01 - Fisher's exact test). Logistic regression analysis showed that the only factor independently associated with the development of hydrocephalus was the distance from the midline. Patients with craniotomy whose superior limit was <25mm from the midline had a markedly increased risk of developing hydrocephalus (OR 17). Craniectomy with a superior limit too close to the midline can predispose patients undergoing DC to the development of hydrocephalus. We therefore suggest performing wide DCs with the superior limit >25mm from the midline.	[De Bonis, Pasquale; Pompucci, Angelo; Mangiola, Annunziato; Rigante, Luigi; Anile, Carmelo] Catholic Univ, Sch Med, Inst Neurosurg, I-00168 Rome, Italy	De Bonis, P (corresponding author), Catholic Univ, Sch Med, Inst Neurosurg, Lgo F Vito 1, I-00168 Rome, Italy.	debonisvox@gmail.com	de bonis, pasquale/K-8200-2016	de bonis, pasquale/0000-0002-9879-8940; Rigante, Luigi/0000-0003-0539-526X			Anile C, 2009, CHILD NERV SYST, V25, P325, DOI 10.1007/s00381-008-0749-7; ANILE C, 1999, EUR CONTR C ECC 99 3; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Guyot LL, 2000, NEUROL RES, V22, P25; HOCHWALD G M, 1972, Developmental Medicine and Child Neurology, V27, P65; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kaufman H H, 1978, Neurosurgery, V2, P136; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Munch E, 2000, NEUROSURGERY, V47, P315; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Phuenpathom Nakornchai, 1999, Journal of the Medical Association of Thailand, V82, P46; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; WEIFORD EC, 1949, J NEUROSURG, V6, P13, DOI 10.3171/jns.1949.6.1.0013; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	21	100	102	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1965	1970		10.1089/neu.2010.1425			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500004	20812777				2021-06-18	
J	Brady, KM; Mytar, JO; Lee, JK; Cameron, DE; Vricella, LA; Thompson, WR; Hogue, CW; Easley, RB				Brady, Ken M.; Mytar, Jennifer O.; Lee, Jennifer K.; Cameron, Duke E.; Vricella, Luca A.; Thompson, W. Reid; Hogue, Charles W.; Easley, R. Blaine			Monitoring Cerebral Blood Flow Pressure Autoregulation in Pediatric Patients During Cardiac Surgery	STROKE			English	Article						cerebrovascular pressure autoregulation; congenital heart disease; near-infrared spectroscopy; pediatrics	NEAR-INFRARED SPECTROSCOPY; CONGENITAL HEART-DISEASE; TRAUMATIC BRAIN INJURY; CARDIOPULMONARY BYPASS; PERFUSION-PRESSURE; REACTIVITY; OUTCOMES; CHILDREN	Background and Purpose-The limits of cerebral blood flow-pressure autoregulation have not been adequately defined for pediatric patients. Mean arterial blood pressure below these limits might contribute to brain injury during cardiac surgery. The purpose of this pilot study was to assess a novel method of determining the lower limits of pressure autoregulation in pediatric patients supported with cardiopulmonary bypass. Methods-A prospective, observational pilot study was conducted in children (n=54) undergoing cardiac surgery with cardiopulmonary bypass for correction of congenital heart defects. Cerebral oximetry index (COx) was calculated as a moving, linear correlation coefficient between slow waves of arterial blood pressure and cerebral oximetry measured with near-infrared spectroscopy. An autoregulation curve was constructed for each patient with averaged COx values sorted by arterial blood pressure. Results-Hypotension was associated with increased values of COx (P<0.0001). For 77% of patients, an individual estimate of lower limits of pressure autoregulation could be determined using a threshold COx value of 0.4. The mean lower limits of pressure autoregulation for the cohort using this method was 42 +/- 7 mm Hg. Conclusions-This pilot study of COx monitoring in pediatric patients demonstrates an association between hypotension during cardiopulmonary bypass and impairment of autoregulation. The COx may be useful to identify arterial blood pressure-dependent limits of cerebral autoregulation during cardiopulmonary bypass. Larger trials with neurological outcomes are indicated. (Stroke. 2010; 41:1957-1962.)	[Brady, Ken M.; Mytar, Jennifer O.; Lee, Jennifer K.; Hogue, Charles W.; Easley, R. Blaine] Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Cameron, Duke E.; Vricella, Luca A.] Johns Hopkins Univ Hosp, Div Cardiac Surg, Baltimore, MD 21287 USA; [Thompson, W. Reid] Johns Hopkins Univ Hosp, Div Pediat Cardiol, Baltimore, MD 21287 USA	Brady, KM (corresponding author), 600 N Wolfe St,Blalock 941, Baltimore, MD 21287 USA.	Kbrady5@jhmi.edu			Hartwell Foundation; Foundation for Anesthesia Education and Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL092259] Funding Source: NIH RePORTER	Supported by the Hartwell Foundation and the Foundation for Anesthesia Education and Research.	Bassan H, 2005, PEDIATR RES, V57, P35, DOI 10.1203/01.PDR.0000147576.84092.F9; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1997, NEUROSURGERY, V41, P17; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Galli KK, 2004, J THORAC CARDIOV SUR, V127, P692, DOI 10.1016/j.jtcvs.2003.09.053; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lemaire JJ, 2002, ACTA NEUROCHIR, V144, P243, DOI 10.1007/s007010200032; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Mahle WT, 2002, CIRCULATION, V106, pI109, DOI 10.1161/01.cir.0000032908.33237.b1; McKenzie ED, 2005, AM J SURG, V190, P289, DOI 10.1016/j.amjsurg.2005.05.029; Newburger JW, 2006, CIRCULATION, V113, P183, DOI 10.1161/CIRCULATIONAHA.105.594804; Pua HL, 1998, CAN J ANAESTH, V45, P960, DOI 10.1007/BF03012304; Schmoker JD, 2009, J THORAC CARDIOV SUR, V137, P459, DOI 10.1016/j.jtcvs.2008.08.022; Shillingford AJ, 2008, PEDIATRICS, V121, pE759, DOI 10.1542/peds.2007-1066; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; TAYLOR RH, 1992, ANESTH ANALG, V74, P636; Wernovsky G, 2005, CURR OPIN CARDIOL, V20, P94, DOI 10.1097/01.hco.0000153451.68212.68; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	24	100	101	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	SEP	2010	41	9					1957	1962		10.1161/STROKEAHA.109.575167			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	645YV	WOS:000281503000019	20651273	Green Accepted, Bronze			2021-06-18	
J	Pietrzak, RH; Olver, J; Norman, T; Piskulic, D; Maruff, P; Snyder, PJ				Pietrzak, Robert H.; Olver, James; Norman, Trevor; Piskulic, Danijela; Maruff, Paul; Snyder, Peter J.			A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Schizophrenia; Computerized; Executive function; Psychopharmacology; Cognition	PHASE CLINICAL-TRIALS; TEST-RETEST INTERVALS; OLDER-ADULTS; NEUROCOGNITIVE DEFICITS; STATISTICAL APPROACH; FUNCTIONAL-CAPACITY; WORKING-MEMORY; PERFORMANCE; STANDARDIZATION; CONCUSSION	This study examined the criterion and construct validity of a brief computerized cognitive test battery (CogState Schizophrenia Battery) compared to a conventional cognitive test battery recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus. The CogState and MATRICS batteries yielded comparable effect sizes in comparing patients with schizophrenia to healthy controls (Cohen's ds = -1.50 for both batteries). Moderate to large correlations were observed between CogState and MATRICS measures of processing speed, attention/vigilance, working memory, verbal and visual learning, reasoning/problem solving, and social cognition (rs = .56-.79). CogState and MATRICS composite scores also correlated strongly with scores on the University of California at San Diego (UCSD) Performance-Based Skills Assessment (UPSA; rs = .76 and .79, respectively) in patients with schizophrenia. Results of this study suggest that the CogState Schizophrenia Battery provides valid measurement of the cognitive domains nominated by the MATRICS consensus group as being important to consider in the context of pharmacological treatments for cognitive impairment in schizophrenia.	[Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Olver, James; Norman, Trevor; Piskulic, Danijela] Univ Melbourne, Sch Med, Dept Psychiat, Melbourne, Vic, Australia; [Maruff, Paul] Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; [Maruff, Paul] CogState Ltd, Melbourne, Vic, Australia; [Snyder, Peter J.] Brown Univ, Warren Alpert Med Sch, Dept Clin Neurosci, Providence, RI 02912 USA; [Snyder, Peter J.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA	Snyder, PJ (corresponding author), Rhode Isl Hosp, Off Res Adm, Aldrich Bldg,1st Floor, Providence, RI 02903 USA.	psnyder@lifespan.org	Maruff, Paul/AAD-2454-2021; Snyder, Peter J./W-2609-2019; Piskulic, Danijela/O-9092-2017; Maruff, Paul/ABA-1673-2020	Maruff, Paul/0000-0002-6947-9537; Snyder, Peter/0000-0003-0555-4654	Pfizer Global Research and DevelopmentPfizer	This research was supported in part by Pfizer Global Research and Development through the Australian P3 grants program and by CogState Ltd. Conflict of Interest Statement: Paul Maruff is employed by the company (CogState Ltd., Melbourne, Australia) that distributes the computer-based cognitive battery that was used in this study. Peter Snyder serves as a consultant to that company.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bowie CR, 2008, BIOL PSYCHIAT, V63, P505, DOI 10.1016/j.biopsych.2007.05.022; Buchanan RW, 2007, SCHIZOPHRENIA BULL, V33, P1120, DOI 10.1093/schbul/sbm083; CAIRNEY S, 2006, INFORM TECHNOLOGY IN; Cargin JW, 2007, J CLIN EXP NEUROPSYC, V29, P706, DOI 10.1080/13825580600954256; CARGIN JW, 2007, J CLIN EXP NEUROPSYC, V21, P1; Carter CS, 2007, SCHIZOPHRENIA BULL, V33, P1131, DOI 10.1093/schbul/sbm081; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, BRIT J SPORT MED, V37, P370, DOI 10.1136/bjsm.37.4.370-a; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2002, ANN THORAC SURG, V73, P2005, DOI 10.1016/S0003-4975(01)03375-6; Collie A, 2007, CONTEMP CLIN TRIALS, V28, P391, DOI 10.1016/j.cct.2006.10.010; Collie A, 2006, HUM PSYCHOPHARM CLIN, V21, P481, DOI 10.1002/hup.799; Coulston CM, 2007, SCHIZOPHR RES, V96, P169, DOI 10.1016/j.schres.2007.08.006; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P611, DOI 10.1037/0894-4105.21.5.611; Duff K, 2004, J INT NEUROPSYCH SOC, V10, P828, DOI 10.1017/S1355617704106048; Duff K, 2007, J CLIN EXP NEUROPSYC, V29, P854, DOI 10.1080/13803390601147629; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Fioravanti M, 2005, NEUROPSYCHOL REV, V15, P73, DOI 10.1007/s11065-005-6254-9; First MB., 2002, STRUCTURED CLIN INTE; Freedman R, 2008, AM J PSYCHIAT, V165, P1040, DOI 10.1176/appi.ajp.2008.07071135; Goldberg TE, 2007, ARCH GEN PSYCHIAT, V64, P1115, DOI 10.1001/archpsyc.64.10.1115; Green MF, 2004, SCHIZOPHR RES, V72, P41, DOI 10.1016/j.schres.2004.09.009; Green MF, 1996, AM J PSYCHIAT, V153, P321; Green MF, 2008, AM J PSYCHIAT, V165, P221, DOI 10.1176/appi.ajp.2007.07010089; Harvey PD, 2008, AM J PSYCHIAT, V165, P163, DOI 10.1176/appi.ajp.2007.07111810; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Hill SK, 2008, J INT NEUROPSYCH SOC, V14, P209, DOI 10.1017/S1355617708080570; Keefe RSE, 2006, NEUROPSYCHOPHARMACOL, V31, P2033, DOI 10.1038/sj.npp.1301072; Keefe RSE, 2006, J CLIN EXP NEUROPSYC, V28, P260, DOI 10.1080/13803390500360539; Kern RS, 2008, AM J PSYCHIAT, V165, P214, DOI 10.1176/appi.ajp.2007.07010043; Krabbendam L, 2005, SCHIZOPHR RES, V80, P137, DOI 10.1016/j.schres.2005.08.004; Lewis MS, 2007, ARCH CLIN NEUROPSYCH, V22, P247, DOI 10.1016/j.acn.2007.01.002; Lewis MS, 2006, ANN THORAC SURG, V81, P2097, DOI 10.1016/j.athoracsur.2006.01.044; Maruff P, 2006, PSYCHOPHARMACOLOGY, V186, P7, DOI 10.1007/s00213-006-0331-5; MARUFF P, ARCH CLIN N IN PRESS; Mathewson KJ, 2008, PSYCHOPHYSIOLOGY, V45, P936, DOI 10.1111/j.1469-8986.2008.00699.x; Matza LS, 2006, SCHIZOPHRENIA BULL, V32, P666, DOI 10.1093/schbul/sbl004; Mollica CM, 2004, HUM PSYCHOPHARM CLIN, V19, P445, DOI 10.1002/hup.624; Nelson HE, 1982, NATL ADULT READING T; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; Pantelis C, 2002, J PSYCHOSOM RES, V53, P655, DOI 10.1016/S0022-3999(02)00434-8; Patterson TL, 2001, SCHIZOPHRENIA BULL, V27, P235, DOI 10.1093/oxfordjournals.schbul.a006870; PIETRZAK RH, HUMAN PSYCH IN PRESS; Prouteau A, 2005, SCHIZOPHR RES, V77, P343, DOI 10.1016/j.schres.2005.03.001; Reichenberg A, 2007, PSYCHOL BULL, V133, P833, DOI 10.1037/0033-2909.133.5.833; Snyder AM, 2008, CHILD NEUROPSYCHOL, V14, P211, DOI 10.1080/09297040701220005; Snyder PJ, 2008, PSYCHIAT RES, V160, P316, DOI 10.1016/j.psychres.2007.07.011; SNYDER PJ, 2006, HUMAN PSYCHOPHARMACO, V20, P263; Surguladze SA, 2007, J CLIN PSYCHOPHARM, V27, P560, DOI 10.1097/jcp.0b013e31815a256c; Thomas E, 2008, NEUROPSYCHOLOGIA, V46, P2476, DOI 10.1016/j.neuropsychologia.2008.04.010	53	100	102	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2009	31	7					848	859		10.1080/13803390802592458			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	500AS	WOS:000270270000007	19142774				2021-06-18	
J	Broglio, SP; Pontifex, MB; O'Connor, P; Hillman, CH				Broglio, Steven P.; Pontifex, Mathew B.; O'Connor, Philip; Hillman, Charles H.			The Persistent Effects of Concussion on Neuroelectric Indices of Attention	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalogram (EEG); event-related potentials (ERP); mild traumatic brain injury; N2; novelty oddball; P3	CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGE FOOTBALL PLAYERS; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; PROFESSIONAL FOOTBALL; MENTAL CHRONOMETRY; AUDITORY-STIMULI; P300 COMPONENT; LEAGUE PLAYER; BRAIN-INJURY	Mild traumatic brain injuries (mTBIs) that result from participation in sports are a major public health issue affecting 1.6-3.8 million individuals annually. The injury has been postulated as transient and void of long-term consequences when rapidly diagnosed and properly managed. Emerging evidence, however, has suggested an increased risk for late life cognitive dysfunction in those with previous injuries. The purpose of this investigation was to evaluate young adults with and without a history of concussion using a standard clinical assessment and highly sensitive electrophysiological measures for persistent changes in cognitive functioning. Ninety participants (19.7 +/- 1.3 years; 44 without mTBI and 46 with previous mTBI) were evaluated using the ImPACT and event-related brain potentials (ERPs) that were recorded during a three-stimulus oddball task. Those with a history of concussion reported an average of 3.4 years post-injury. No significant differences were found between groups on the ImPACT. Significant decrements in the N2 and P3b amplitudes of the stimulus-locked ERP were noted for those with a history relative to those without a history of concussion. Although the previously concussed participants performed equal to those without injury on the clinical cognitive assessment, these findings support the notion that sport mTBI can no longer be thought of as a transient injury resulting in short-lived neurological impairment. It is not clear if these persistent deficits will manifest into clinical pathologies later in life.	[Broglio, Steven P.; Pontifex, Mathew B.; O'Connor, Philip; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA	Broglio, SP (corresponding author), 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu	Pontifex, Matthew B/A-4474-2009; Hillman, Charles/AAD-4828-2019; Hillman, Charles/A-4479-2009	Pontifex, Matthew B/0000-0001-9819-9625; Hillman, Charles/0000-0002-3722-5612	Mary Jane Neer Fund for Disability Research; University of Illinois	This project was funded by grants from the Mary Jane Neer Fund for Disability Research and the Research Board at the University of Illinois.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Donchin E., 1986, PSYCHOPHYSIOLOGY SYS, P309; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Fratiglioni L, 2007, J ALZHEIMERS DIS, V12, P11; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hillman CH, 2005, MED SCI SPORT EXER, V37, P1967, DOI 10.1249/01.mss.0000176680.79702.ce; Ilan AB, 1999, CLIN NEUROPHYSIOL, V110, P367; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; JOHNSON R, 1993, PSYCHOPHYSIOLOGY, V30, P90; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kaufman A.S., 1990, KAUFMAN BRIEF INTELL; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Knight RT, 1997, J COGNITIVE NEUROSCI, V9, P75, DOI 10.1162/jocn.1997.9.1.75; KNIGHT RT, 1984, ELECTROENCEPHALOGR C, V52, P9; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Ohman A., 2000, HDB PSYCHOPHYSIOLOGY, P533; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peters A, 2002, NEUROSCI BIOBEHAV R, V26, P733, DOI 10.1016/S0149-7634(02)00060-X; Polich J, 1997, EVOKED POTENTIAL, V104, P244, DOI 10.1016/S0168-5597(97)96139-6; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P747, DOI 10.1111/j.1469-8986.1996.tb02371.x; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P334, DOI 10.1111/j.1469-8986.1996.tb01058.x; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Ridderinkhof KR, 2000, BIOL PSYCHOL, V54, P55, DOI 10.1016/S0301-0511(00)00053-3; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; 2009, OFFLINE ANAL ACQUIRE	56	100	101	1	34	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1463	1470		10.1089/neu.2008.0766			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200003	19331519				2021-06-18	
J	Crowe, L; Babl, F; Anderson, V; Catroppa, C				Crowe, Louise; Babl, Franz; Anderson, Vicki; Catroppa, Cathy			The epidemiology of paediatric head injuries: Data from a referral centre in Victoria, Australia	JOURNAL OF PAEDIATRICS AND CHILD HEALTH			English	Article						closed head injury	TRAUMATIC BRAIN-INJURY; CHILDREN; ADOLESCENTS	Aim: Currently, there are no population-based or hospital-based studies on the full spectrum of paediatric head injuries (HIs) in Australia. We set out to provide detailed information on the incidence rates, causes and clinical management of all severities of HI in children and adolescents at an Australian tertiary referral centre using emergency department (ED) and admission data as a basis for further investigations and prevention efforts. Methods: A retrospective chart review of all children aged 0-16 years who attended the Royal Childrens Hospital (RCH), Melbourne, following a HI in 2004 was used. The cases were identified using the International Classification of Diseases 10th revision codes, and all medical records were reviewed based on a piloted data form. Information was collected on demographics, injury factors and clinical management of HIs in the hospital setting. Results: Over the 12-month period, there were 1115 children with an HI who attended the RCH ED, or were admitted. Ninety per cent were classified as mild, 8% as moderate and 3% as severe. Males and children under 3 years had the higher attendance rates. Falls, sports and motor vehicle accidents were the main HI causes. The main sport played (30%) when sustaining an HI was Australian rules football. Thirty-two per cent of children were admitted, 67% of these with mild HI. Twenty-one per cent had a radiology imaging study, most (67%) with a normal result. Conclusions: Many HI causes appear preventable, in particular, falls from heights in infants and sports safety. High rates of admission and radiology imaging of mild HI warrant further investigation.	[Crowe, Louise; Babl, Franz; Anderson, Vicki; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Crowe, Louise; Babl, Franz; Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Melbourne, Vic, Australia; [Babl, Franz] Royal Childrens Hosp, Emergency Dept, Melbourne, Vic, Australia	Crowe, L (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	louise.crowe@mcri.edu.au		Crowe, Louise/0000-0003-4619-9708			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HENDRIE D, 1998, AUST J PUBLIC HEALTH, V18, P380; Holsti M, 2005, PEDIATR EMERG CARE, V21, P639, DOI 10.1097/01.pec.0000181426.25342.a9; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MCMAHON KA, 1993, MED J AUSTRALIA, V159, P301, DOI 10.5694/j.1326-5377.1993.tb137864.x; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; NOLAN T, 1992, J PAEDIATR CHILD H, V28, P27, DOI 10.1111/j.1440-1754.1992.tb02613.x; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1992, INT CLASS DIS; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	21	100	101	4	13	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1034-4810			J PAEDIATR CHILD H	J. Paediatr. Child Health	JUN	2009	45	6					346	350		10.1111/j.1440-1754.2009.01499.x			5	Pediatrics	Pediatrics	464WJ	WOS:000267539900006	19490410				2021-06-18	
J	Randolph, C; Millis, S; Barr, WB; McCrea, M; Guskiewicz, KM; Hammeke, TA; Kelly, JP				Randolph, Christopher; Millis, Scott; Barr, William B.; McCrea, Michael; Guskiewicz, Kevin M.; Hammeke, Thomas A.; Kelly, James P.			Concussion Symptom Inventory: An Empirically Derived Scale for Monitoring Resolution of Symptoms Following Sport-Related Concussion	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Brain injury; Post-concussion; Scale	COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL TEST PROTOCOL; TRAUMATIC BRAIN-INJURY; 2ND IMPACT SYNDROME; HIGH-SCHOOL; POSTURAL STABILITY; NCAA CONCUSSION; HEAD-INJURY; RELIABILITY; PREVENTION	Self-report post-concussion symptom scales have been a key method for monitoring recovery from sport-related concussion, to assist in medical management, and return-to-play decision-making. To date, however, item selection and scaling metrics for these instruments have been based solely upon clinical judgment, and no one scale has been identified as the "gold standard". We analyzed a large set of data from existing scales obtained from three separate case-control studies in order to derive a sensitive and efficient scale for this application by eliminating items that were found to be insensitive to concussion. Baseline data from symptom checklists including a total of 27 symptom variables were collected from a total of 16,350 high school and college athletes. Follow-up data were obtained from 641 athletes who subsequently incurred a concussion. Symptom checklists were administered at baseline (preseason), immediately post-concussion, post-game, and at 1, 3, and 5 days post-injury. Effect-size analyses resulted in the retention of only 12 of the 27 variables. Receiver-operating characteristic analyses were used to confirm that the reduction in items did not reduce sensitivity or specificity. The newly derived Concussion Symptom Inventory is presented and recommended as a research and clinical tool for monitoring recovery from sport-related concussion.	[Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA; [Millis, Scott] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Barr, William B.] NYU, Sch Med, Dept Neurol, New York, NY USA; [Barr, William B.] NYU, Sch Med, Dept Psychiat, New York, NY USA; [McCrea, Michael] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI USA; [McCrea, Michael; Hammeke, Thomas A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Orthoped, Chapel Hill, NC USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA	Randolph, C (corresponding author), 1 E Erie,Suite 355, Chicago, IL 60611 USA.	crandol@lumc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Barr, William/0000-0001-7711-7758	NCAA; National Operating Committee on Standards for Athletic Equipment (NOCSAE); Center for Disease Control's National Center for Injury Prevention and Control (NPIPC); National Academy of Neuropsychology; Waukesha Memorial Hospital Foundation; National Federation of State High School Associations; NFL Charities; Green Bay Packer Foundation; Milwaukee Bucks; Herbert H. Kohl Charities; Waukesha Service Club; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [M01-RR00058]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000058] Funding Source: NIH RePORTER	This project was supported in part by funding from the NCAA, the National Operating Committee on Standards for Athletic Equipment (NOCSAE), Center for Disease Control's National Center for Injury Prevention and Control (NPIPC), National Academy of Neuropsychology, Waukesha Memorial Hospital Foundation, National Federation of State High School Associations, NFL Charities, Green Bay Packer Foundation, Milwaukee Bucks, Herbert H. Kohl Charities, Waukesha Service Club, and the Medical College of Wisconsin General Clinical Research Center (M01-RR00058 from the National Institutes of Health).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J ATHL TRAINING, V36, P297; Barth JT., 1989, MILD HEAD INJURY, P257; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HSIAO JK, 1989, ARCH GEN PSYCHIAT, V46, P664; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; LeBlanc K E, 1998, J La State Med Soc, V150, P312; Linacre J. M., 2004, INTRO RASCH MEASUREM, P258, DOI DOI 10.1891/JNUM.10.3.189.52562; Love J. A., 2003, HDB METATHESIS, V2, P296; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2001, J ATHL TRAINING, V36, P288; Rasch G., 1960, PROBABILISTIC MODELS; Zhou X.-H., 2002, STAT METHODS DIAGNOS	47	100	100	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2009	24	3					219	229		10.1093/arclin/acp025			11	Psychology, Clinical; Psychology	Psychology	483WJ	WOS:000269001900003	19549721	Green Published, Bronze			2021-06-18	
J	Preiss-Farzanegan, SJ; Chapman, B; Wong, TM; Wu, J; Bazarian, JJ				Preiss-Farzanegan, Sarah J.; Chapman, Benjamin; Wong, Tony M.; Wu, Joanne; Bazarian, Jeffrey J.			The Relationship Between Gender and Postconcussion Symptoms After Sport-Related Mild Traumatic Brain Injury	PM&R			English	Article							POST-CONCUSSION SYMPTOMS; COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; SEX-DIFFERENCES; IMPACT; QUESTIONNAIRE; IMPAIRMENT; PREDICTION; RECOVERY; LONG	Objective: The authors sought to define the relationship between gender and post-concussion symptoms (PCSx) at 3 months after sport-related mild traumatic brain injury (mTBI) and, further, to examine whether age (minors vs. adults), source of PCSx reporting (self-reported vs. proxy), previous head injury or loss of consciousness, or the sport type in which the mTBI was incurred explain any observed gender differences in PCSx. Design: Prospective nested cohort study. Setting: Regional trauma center emergency department. Patients: A total of 260 patients who presented with sport-related mTBI, as defined by American Congress of Rehabilitation Medicine criteria, began the study. The participants who lacked litigation concerning the mTBI and had participated in the follow-up assessment completed the study (n = 215). Assessment of Risk Factors: Self, proxy, and interviewer report of age, gender, previous head injury or loss of consciousness, and sport in which injury was sustained. Main Outcome Measurements: Rivermead Post Concussion Symptoms Questionnaire (RPQ). Results: Adult females are at greater risk for elevated RPQ scores (odds ratio [OR] = 2.89, 95% confidence interval [95% CI] = 1.25-6.71; P = .013) but not female minors (OR = 0.87, 95% CI = 0.45-1.71]; P = .695), as compared with male subjects. Adjustment for empirically identified confounders in each age group revealed persisting elevated risk for adult females (OR = 2.57, 95% CI = 1.09-6.08; P = .031), but not minor females (OR = 1.07, 95% CI = 0.52-2.19, P = .852). The risk associated with female gender in adults could not be explained by characteristics of the sports, such as helmeted versus not, or contact versus no contact, in which women incurred mTBIs. No sport characteristics were associated with increased risk of PCSx after mTBI. Conclusions: Adult females, but not female minors, are at increased risk for PCSx after sport-related mTBI as compared with male patients. This increased risk cannot be explained by self-report, rather than proxy report, of symptoms, previous head injury or loss of consciousness, age, or sport characteristics. Further research is needed to elucidate the processes of age-differential recovery from mild brain injury in women and on how to most effectively incorporate appropriate follow-up after emergency department evaluation.	[Preiss-Farzanegan, Sarah J.; Wu, Joanne] Univ Rochester, Med Ctr, Dept Phys Med & Rehabil, Rochester, NY 14642 USA; [Chapman, Benjamin] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA; [Wong, Tony M.] Univ Rochester, Med Ctr, Dept Neuropsychol, Dept Phys Med & Rehabil,Unity Hlth Syst, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA	Preiss-Farzanegan, SJ (corresponding author), Stanford Sports Med Ctr, 341 Galvez St, Stanford, CA 94305 USA.	Preiss18@yahoo.com		Chapman, Benjamin/0000-0002-5170-3131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS041952] Funding Source: Medline		Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Ananth CV, 1997, INT J EPIDEMIOL, V26, P1323, DOI 10.1093/ije/26.6.1323; [Anonymous], 2001, NIH PUBL; Badie H, 1992, J NEUROTRAUM, V9, P56; Bazarian JJ, 2006, RESTOR NEUROL NEUROS, V24, P163; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FEE CRA, 1988, ARCH EMERG MED, V5, P12; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Ives JC, 2007, J ATHL TRAINING, V42, P431; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McNamee R, 2005, OCCUP ENVIRON MED, V62, P500, DOI 10.1136/oem.2002.001115; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Necajauskaite Olga, 2005, Medicina (Kaunas), V41, P457; Newman SC, 2004, J CLIN EPIDEMIOL, V57, P325, DOI 10.1016/j.jclinepi.2003.07.014; *NIH, 1982, NIH PUBL; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pavalko EK, 2000, J HEALTH SOC BEHAV, V41, P91, DOI 10.2307/2676362; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004	56	100	101	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	MAR	2009	1	3					245	253		10.1016/j.pmrj.2009.01.011			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V24LF	WOS:000208411200008	19627902	Green Accepted			2021-06-18	
J	Courtney, AC; Courtney, MW				Courtney, A. C.; Courtney, M. W.			A thoracic mechanism of mild traumatic brain injury due to blast pressure waves	MEDICAL HYPOTHESES			English	Article							ARMOR BLUNT TRAUMA; TYMPANIC-MEMBRANE PERFORATION; MISSILE EXTREMITY IMPACT; CENTRAL-NERVOUS-SYSTEM; SMALL-BOWEL INJURY; INDUCED NEUROTRAUMA; IMPULSE NOISE; SHELL SHOCK; TRANSIENT; DAMAGE	The mechanisms by which blast pressure waves cause mild-to-moderate traumatic brain injury (mTBI) are an open question. Possibilities include acceleration of the head, direct passage of the blast wave via the cranium, and propagation of the blast wave to the brain via a thoracic mechanism. The hypothesis that the blast pressure wave reaches the brain via a thoracic mechanism is considered in light of ballistic and blast pressure wave research. Ballistic pressure waves, caused by penetrating ballistic projectiles or ballistic impacts to body armor, can only reach the brain via an internal mechanism and have been shown to cause cerebral effects. Similar effects have been documented when a blast pressure wave has been applied to the whole body or focused on the thorax in animal models. While vagotomy reduces apnea and bradycardia due to ballistic or blast pressure waves, it does not eliminate neural damage in the brain, suggesting that the pressure wave directly affects the brain cells via a thoracic mechanism. An experiment is proposed which isolates the thoracic mechanism from cranial mechanisms of mTBI due to blast wave exposure. Results have implications for evaluating risk of mTBI due to blast exposure and for developing effective protection. Published by Elsevier Ltd.	[Courtney, A. C.] US Mil Acad, Dept Phys, West Point, NY 10996 USA; [Courtney, M. W.] Ballist Testing Grp, West Point, NY 10996 USA	Courtney, AC (corresponding author), US Mil Acad, Dept Phys, POB 24, West Point, NY 10996 USA.	amy_courtney@post.harvard.edu; michael_courtney@alum.mit.edu		Courtney, Amy/0000-0002-1925-8736			BELLAMY RF, 1990, TXB MILITARY MED; Bhatoe HS, 2003, NEUROL INDIA, V51, P507; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Cannon L, 2001, J R Army Med Corps, V147, P87; CARROLL AW, 1978, ANN SURG, V188, P753, DOI 10.1097/00000658-197812000-00007; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1996, J TRAUMA, V40, pS148, DOI 10.1097/00005373-199603001-00032; CERNAK I, 2005, RESTORATIVE NEUROLOG, V23, P139; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cooper GJ, 1996, J TRAUMA, V40, pS105, DOI 10.1097/00005373-199603001-00024; Courtney A, 2007, BRAIN INJURY, V21, P657, DOI 10.1080/02699050701481571; COURTNEY M, EXPT OBSERVATIONS IN; COURTNEY M, 2007, METHOD TESTING HANDG; DARAIO C, 2006, PHYS REV LETT, V96, P580; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DONEY R, 2006, PHYS REV LETT, V97, P1555; Drobin D, 2007, J TRAUMA, V63, P405, DOI 10.1097/01.ta.0000236015.68105.48; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; GORANSSON AM, 1988, J TRAUMA, V28, pS204; Gryth D, 2008, J TRAUMA, V64, P1420, DOI 10.1097/TA.0b013e318054e247; Gryth D, 2007, MIL MED, V172, P1110, DOI 10.7205/MILMED.172.10.1110; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107; HARVEY EN, 1947, J EXP MED, V85, P321, DOI 10.1084/jem.85.3.321; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; JOHANSSON L, 1982, ACTA CHIR SCAND, V148, P15; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; KARMYJONES R, 1994, MIL MED, V159, P536; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; Krave U, 2005, EUR J NEUROSCI, V21, P2876, DOI 10.1111/j.1460-9568.2005.04115.x; Lai XN, 1996, J TRAUMA, V40, pS60, DOI 10.1097/00005373-199603001-00013; Lee M, 1997, J FLUID STRUCT, V11, P819, DOI 10.1006/jfls.1997.0103; Li Chao-jun, 2006, Chin J Traumatol, V9, P242; LIDEN E, 1988, J TRAUMA, V28, pS145, DOI 10.1097/00005373-198801001-00029; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUDWIG GD, 1950, J ACOUST SOC AM, V22, P862, DOI 10.1121/1.1906706; Merkle AC, 2008, J TRAUMA, V64, P1555, DOI 10.1097/TA.0b013e318160ff3a; METKER LW, 1978, TR78034 ARCSL; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Mines M, 2000, OPHTHALMOLOGY, V107, P837, DOI 10.1016/S0161-6420(00)00030-0; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Peters CE, 1990, J TRAUMA S2, V6, P308; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; PHILLIPS YY, 1990, TXB MILITARY MED; Pompei A, 2007, J SOUND VIB, V302, P925, DOI 10.1016/j.jsv.2006.12.018; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Roberts JC, 2007, J TRAUMA, V62, P1127, DOI 10.1097/01.ta.0000231779.99416.ee; Roberts JC, 2005, J TRAUMA, V58, P1241, DOI 10.1097/01.TA.0000169805.81214.DC; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; SASAKI LS, 1995, J TRAUMA, V39, P602; Sharp D, 2006, LANCET, V368, P975, DOI 10.1016/S0140-6736(06)69395-1; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Singerm E, 2008, TECHNOL REV, V111, P52; STUHMILLER JH, 2008, QUANTITATIVE PHYSL P; Sturtevant B, 1998, SADHANA-ACAD P ENG S, V23, P579, DOI 10.1007/BF02744581; SUNESON A, 1988, J TRAUMA, V28, pS197, DOI 10.1097/00005373-198801001-00041; SUNESON A, 1987, J TRAUMA, V27, P782, DOI 10.1097/00005373-198707000-00016; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; SUNESON A, 1990, J TRAUMA, V30, P281, DOI 10.1097/00005373-199003000-00006; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; SUNESON A, 1989, J TRAUMA, V29, P10, DOI 10.1097/00005373-198901000-00003; Sylvia FR, 2001, MIL MED, V166, P918; Tatic V, 1996, J TRAUMA, V40, pS94, DOI 10.1097/00005373-199603001-00022; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tien HC, 2007, J TRAUMA, V62, P762, DOI 10.1097/01.ta.0000231555.81174.9e; Toth Z, 1997, J NEUROSCI, V17, P8106; Treib J, 1996, MIL MED, V161, P61; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Velitchkov NG, 2000, J TRAUMA, V48, P169, DOI 10.1097/00005373-200001000-00035; Wang Q, 2004, J TRAUMA, V56, P604, DOI 10.1097/01.TA.0000058122.57737.0E; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Yang ZH, 1996, J TRAUMA, V40, pS81, DOI 10.1097/00005373-199603001-00019; YELVERTON JT, 1973, 3114T DNA; YLIKOSKI ME, 1995, SCAND AUDIOL, V24, P3, DOI 10.3109/01050399509042203; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	81	100	104	0	12	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	JAN	2009	72	1					76	83		10.1016/j.mehy.2008.08.015			8	Medicine, Research & Experimental	Research & Experimental Medicine	385YZ	WOS:000261850800023	18829180				2021-06-18	
J	Lannsjo, M; Af Geijerstam, JL; Johansson, U; Bring, J; Borg, J				Lannsjo, Marianne; Af Geijerstam, Jean-Luc; Johansson, Ulla; Bring, Johan; Borg, Jorgen			Prevalence and structure of symptoms at 3 months after mild traumatic brain injury in a national cohort	BRAIN INJURY			English	Article						Mild Traumatic Brain Injury; Post-concussion Symptoms; Rivermead Post-concussion Symptoms Questionnaire	POST-CONCUSSION SYNDROME; MINOR HEAD-INJURY; POSTCONCUSSION SYNDROME; DIAGNOSTIC-CRITERIA; SOCIAL SUPPORT; CHRONIC PAIN; QUESTIONNAIRE; MODERATE; EXPECTATION; RELIABILITY	Objectives: To describe symptom prevalence and structure after mild traumatic brain injury (MTBI) in a population-based cohort. Methods: Symptoms data were collected at 3 months post-MTBI by use of the Rivermead Post-concussion Symptoms Questionnaire (RPQ) at follow-up of 2602 patients attending 39 Swedish hospitals. Spearmans rank correlation analysis was used to explore correlations between symptoms and structural equation modelling (SEM) was performed by use of several fit indices to explore if data were compatible with one or more factors. Results: Questionnaires were received from 2523 (97%) patients with a mean age of 31 years (median 22, range 6-96). A majority of the respondents (56%) reported no remaining injury related symptoms, 24% reported three or more symptoms and 10% reported seven or more symptoms. All symptoms exhibited strong positive inter-relations and SEM provided strong support for a single or two factor solution. Fit indices were only slightly weaker for three and four factor solutions. Conclusions: A significant minority of patients reported multiple symptoms to persist at 3 months after MTBI. The observed structure of symptoms according to RPQ demonstrates a common factor for all symptoms, but also sub-groups of symptoms as previously suggested.	[Lannsjo, Marianne; Borg, Jorgen] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Lannsjo, Marianne; Johansson, Ulla] Uppsala Univ, Cty Council Gavleborg, Ctr Res & Dev, Uppsala, Sweden; [Af Geijerstam, Jean-Luc] Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden; [Bring, Johan] Univ Gavle, Dept Math Nat & Comp Sci, Gavle, Sweden	Lannsjo, M (corresponding author), Univ Uppsala Hosp, S-75185 Uppsala, Sweden.	marianne.lannsjo@lg.se		Lannsjo, Marianne/0000-0001-8792-3796; Borg, Jorgen/0000-0002-2372-7478	Swedish insurance company AFA; Centre for Research and Development Uppsala University/ County Council of Gavleborg	This study was supported by grants from the Swedish insurance company AFA and Centre for Research and Development Uppsala University/ County Council of Gavleborg.	af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; STALNACKE BM, 2004, THESIS UMEA U SWEDEN; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; World Health Organization, 1992, ICD 10 CLASS MENT BE	41	100	100	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	3					213	219	PII 908613182	10.1080/02699050902748356			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	406AJ	WOS:000263267100004	19205957				2021-06-18	
S	Thaut, MH; Gardiner, JC; Holmberg, D; Horwitz, J; Kent, L; Andrews, G; Donelan, B; McIntosh, GR		DallaBella, S; Kraus, N; Overy, K; Pantev, C; Snyder, JS; Tervaniemi, M; Tillmann, B; Schlaug, G		Thaut, Michael H.; Gardiner, James C.; Holmberg, Dawn; Horwitz, Javan; Kent, Luanne; Andrews, Garrett; Donelan, Beth; McIntosh, Gerald R.			Neurologic Music Therapy Improves Executive Function and Emotional Adjustment in Traumatic Brain Injury Rehabilitation	NEUROSCIENCES AND MUSIC III: DISORDERS AND PLASTICITY	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on the Neurosciences and Music III	JUN 25-28, 2008	McGill Univ, Montreal, CANADA		McGill Univ	brain injury; neurologic music therapy; cognitive rehabilitation; attention; memory; executive function; emotional adjustment	MEMORY; ATTENTION; STIMULATION; MNEMONICS; RESPONSES; CORRELATE; RECALL	This study examined the immediate effects of neurologic music therapy (NMT) on cognitive functioning and emotional adjustment with brain-injured persons. Four treatment sessions were held, during which participants were given a pre-test, participated in 30 min of NMT that focused on one aspect of rehabilitation (attention, memory, executive function, or emotional adjustment), which was followed by post-testing. Control participants engaged in a pre-test, 30 min of rest, and then a post-test. Treatment participants showed improvement in executive function and overall emotional adjustment, and lessening of depression, sensation seeking, and anxiety. Control participants improved in emotional adjustment and lessening of hostility, but showed decreases in measures of memory, positive affect, and sensation seeking.	[Thaut, Michael H.; Holmberg, Dawn; McIntosh, Gerald R.] Colorado State Univ, Ctr Biomed Res Mus, Ft Collins, CO 80523 USA; [Gardiner, James C.; Horwitz, Javan; Kent, Luanne; Andrews, Garrett; Donelan, Beth] Vet Affairs Black Hills Hlth Care Syst, Mental Hlth Serv, Ft Meade, SD USA	Thaut, MH (corresponding author), Colorado State Univ, Ctr Biomed Res Mus, Ft Collins, CO 80523 USA.	michael.thaut@colostate.edu					Baur B, 2000, NEUROCASE, V6, P415, DOI 10.1080/13554790008402712; BENNETT T, 1998, J COGN REHABIL, V16, P8; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; BICKMAN L, 1991, VANDERBILT MENTAL HL; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Campbell D.T, 1963, EXPT QUASIEXPERIMENT; Carruth EK, 1997, J MUSIC THER, V34, P165, DOI 10.1093/jmt/34.3.165; Chan AS, 1998, NATURE, V396, P128, DOI 10.1038/24075; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CLAUSSEN DW, 1997, CAN J MUSIC THER, V5, P55; Cowles A, 2003, NEUROCASE, V9, P493, DOI 10.1076/neur.9.6.493.29378; Derogatis LR., 2000, BRIEF SYMPTOM INVENT, V18; Deutsch D., 1982, MUSIC MIND BRAIN, P119; Foster NA, 2001, EXP AGING RES, V27, P215, DOI 10.1080/036107301300208664; GEFFEN GM, 1994, ARCH CLIN NEUROPSYCH, V9, P303, DOI 10.1016/0887-6177(94)90018-3; GFELLER KE, 1983, J MUSIC THER, V20, P179, DOI 10.1093/jmt/20.4.179; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; Gold C, 2004, MUSIC THERAPY PERSPE, V22, P91, DOI DOI 10.1093/MTP/22.2.91; Goldberg E, 2001, EXECUTIVE BRAIN FRON; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; GORDON WA, 1992, NEUROPSYCHOLOGY, V6, P361; Gregory D, 2002, J MUSIC THER, V39, P244, DOI 10.1093/jmt/39.4.244; HANSER SB, 1994, J GERONTOL, V49, pP265, DOI 10.1093/geronj/49.6.P265; Haslam C, 2002, NEUROCASE, V8, P453, DOI 10.1093/neucas/8.6.453; Ho YC, 2003, NEUROPSYCHOLOGY, V17, P439, DOI 10.1037/0894-4105.17.3.439; Homberg V, 2005, ACTA NEUROCHIR SUPPL, V93, P3; Hummelsheim H, 1999, CURR OPIN NEUROL, V12, P697, DOI 10.1097/00019052-199912000-00007; Iwaki T, 1997, PERCEPT MOTOR SKILL, V84, P515, DOI 10.2466/pms.1997.84.2.515; Jones M.R., 1992, COGNITIVE BASES MUSI; Klein JM, 1996, PERCEPT PSYCHOPHYS, V58, P34, DOI 10.3758/BF03205473; Kleinstauber M., 2006, J COGN REHAB, V24, P4; Knox R, 1996, CAN J REHABIL, V9, P169; Knox R, 2003, MUSIC THER PERSPECT, V21, P99, DOI [10.1093/mtp/21.2.99, DOI 10.1093/MTP/21.2.99, DOI 10.1093/mtp/21.2.99]; Levitin D., 2006, THIS IS YOUR BRAIN M; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; MCCAFFREY RJ, 1993, ARCH CLIN NEUROPSYCH, V8, P519; MCCAFFREY RJ, 1992, CLIN NEUROPSYCHOL, V6, P32, DOI DOI 10.1080/13854049208404115; MORTON LL, 1990, J MUSIC THER, V26, P58; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; O'Connor C, 2004, BRAIN COGNITION, V54, P133, DOI 10.1016/S0278-2626(03)00268-9; Parente R., 1996, RETRAINING COGNITION; Peretz I, 2005, ANNU REV PSYCHOL, V56, P89, DOI 10.1146/annurev.psych.56.091103.070225; PURDIE H, 1997, CRIT REV PHYS REHABI, V9, P205; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rimmele C T, 1987, Arch Clin Neuropsychol, V2, P353; Sloboda J. A., 1985, MUSICAL MIND COGNITI; Sohlberg M. M., 1989, ATTENTION PROCESS TR; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sturm W, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P365; STUSS DT, 1987, J CLIN EXP NEUROPSYC, V9, P131, DOI 10.1080/01688638708405353; Thaut M., 2005, RHYTHM MUSIC BRAIN S; Thaut MH, 2005, ANN NY ACAD SCI, V1060, P243, DOI 10.1196/annals.1360.017; Thaut MH, 1999, IEEE ENG MED BIOL, V18, P101, DOI 10.1109/51.752991; THAUT MH, 1999, TRAINING MANUAL NEUR; THAUT MH, 2005, MUSICAL COMMUNICATIO, P171; UNKEFER R, 2002, MUSIC THERAPY TREATM; WALLACE WT, 1994, J EXP PSYCHOL LEARN, V20, P1471, DOI 10.1037/0278-7393.20.6.1471; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; Zatorre RJ, 2001, ANN NY ACAD SCI, V930, P193, DOI 10.1111/j.1749-6632.2001.tb05734.x; Zatorre RJ, 2003, ANN NY ACAD SCI, V999, P4, DOI 10.1196/annals.1284.001; Zuckerman M., 1965, MANUAL MULTIPLE AFFE	65	100	107	3	70	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-739-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2009	1169						406	416		10.1111/j.1749-6632.2009.04585.x			11	Psychology, Developmental; Multidisciplinary Sciences; Neurosciences; Psychology; Psychology, Experimental	Psychology; Science & Technology - Other Topics; Neurosciences & Neurology	BKY88	WOS:000269652300061	19673815				2021-06-18	
J	Wu, X; Hu, J; Zhuo, LF; Fu, CW; Hui, GZ; Wang, YH; Yang, WZ; Teng, LZ; Lu, ST; Xu, GS				Wu, Xing; Hu, Jin; Zhuo, Liangfu; Fu, Chaowei; Hui, Guozhen; Wang, Yehan; Yang, Weizhong; Teng, Liangzhu; Lu, Sitin; Xu, Gengsheng			Epidemiology of traumatic brain injury in eastern China, 2004: A prospective large case study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; epidemiology; eastern China	HEAD-INJURY; UNITED-STATES; HELMET USE; NATIONAL EVALUATION; COUNTY; CARE; AGE; IMPLEMENTATION; MORTALITY; PATTERNS	Background: Traumatic brain injury (TBI) is the leading cause of death for traumatic injury, which is the fifth highest killer in China and the highest killer in adults under 40 years of age. But, there is a lack of epidemiologic data of TBI in China during the past decade. This study aimed to investigate the epidemiologic data of TBI in eastern China, based on a prospective multicenter trial. Methods: Data were collected from the 77 hospitals by standardized structured questionnaires in this region during the 1-year period (2004). Results: A total of 14,948 of cases of traumatic brain injury were identified from 77 hospitals in eastern China. There were 11,446 men (76.6%) and 3,502 women (25.4%). Male adolescents and young adults were affected more often by brain injury. Traffic accidents (60.9%), knock on head (13.4%), and falls (13.1%) were the leading causes of patients with TBI. Approximately one-thirds of the traffic-related TBI were motorcyclists, 31% were pedestrians, and 21.9% were cyclists, whereas motor vehicle occupants only counted for 14% of the cases. The distribution of head injury severity, on the basis of Glasgow Coma Scale scores, was mild in 62%, moderate in 18.1%, and severe in 20% for all cases. The traffic accidents caused the most of severe injuries, which accounted for about 70.4%. Based on Glasgow Outcome Scale assessment, 10.8% of the patients died, 2.6% were in vegetation status, 2.2 % had severe disability, 7.2% had moderate disability, and 77.3% had good recovery. And, the outcome depended on age, injury mechanism and initial Glasgow Coma Scale score. Conclusions: The prospective cohort study shows an alteration of TBI during the past decade in eastern China. It is essential to establish a standardized surveillance system of TBI incidence, risk factors, causes, and outcomes for development of new, more effective, targeted strategies to prevent TBI.	[Wu, Xing; Zhuo, Liangfu] Fudan Univ, Dept Neurosurg, Shanghai Med Sch, Huashan Hosp, Shanghai 200040, Peoples R China; [Hu, Jin] Shanghai Jiao Tong Univ, Ctr Trauma, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China; [Fu, Chaowei] Fudan Univ, Shanghai Med Coll, Dept Publ Hlth, Shanghai 200040, Peoples R China; [Hui, Guozhen] Suzhou Univ, Dept Neurosurg, First Hosp, Suzhou, Jiangsu, Peoples R China; [Wang, Yehan] Anhui Med Univ, Anhui Prov Hosp, Dept Neurosurg, Hefei, Anhui, Peoples R China; [Teng, Liangzhu] Sandong Univ, Sandong Prov Hosp, Dept Neurosurg, Sandong, Peoples R China; [Lu, Sitin] Zhejiang Univ, Second Hosp, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China	Zhuo, LF (corresponding author), Fudan Univ, Dept Neurosurg, Shanghai Med Sch, Huashan Hosp, 12 Wulumuqizhong Rd, Shanghai 200040, Peoples R China.	Lfzhou.neuro@yahoo.com.cn	Fu, Chaowei/H-7811-2013	Fu, Chaowei/0000-0003-0966-8552			Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Auman KM, 2002, AM J PUBLIC HEALTH, V92, P1352, DOI 10.2105/AJPH.92.8.1352; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CALES RH, 1985, ANN EMERG MED, V14, P853, DOI 10.1016/S0196-0644(85)80633-8; *CRTAS, 2004, CHIN ROAD TRAFF ACC; *CRTAS, 2003, CHIN ROAD TRAFF ACC; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GABELLA B, 1995, ACCIDENT ANAL PREV, V27, P363, DOI 10.1016/0001-4575(94)00079-2; [高进东 Gao Jindong], 2002, [中华创伤杂志, Chinese Journal of Traumatology], V18, P743; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Harden CL, 2003, NEUROLOGY, V61, P451, DOI 10.1212/01.WNL.0000081228.48016.44; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Hotz GA, 2002, J TRAUMA, V52, P469, DOI 10.1097/00005373-200203000-00009; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Liberman M, 2004, J TRAUMA, V56, P1330, DOI 10.1097/01.TA.0000071297.76727.8B; [刘娜 Liu Na], 2005, [中华流行病学杂志, Chinese Journal of Epidemiology], V26, P746; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; Schieber RA, 2001, PUBLIC HEALTH REP, V116, P113, DOI 10.1093/phr/116.2.113; Schwab W, 2000, J TRAUMA, V48, P30; Sethi D, 2002, J TRAUMA, V53, P508, DOI 10.1097/00005373-200209000-00019; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Sosin DM, 1996, PEDIATRICS, V98, P868; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; Valent F, 2002, J TRAUMA, V52, P745, DOI 10.1097/00005373-200204000-00023; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; Wang ZG, 1996, CHINESE MED J-PEKING, V109, P24; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6; WU D, 2006, BEIJING AUTOMOTIVE E, P5; YANG J, 1996, CHIN J TRAUMA, V12, P1996; Yang YC, 1987, CHINESE J NEUROSURGE, V3, P23; Zhang Y.Q., 1999, CHIN J TRAUMA, V15, P51; ZHU GL, 1989, CHIN J NEUROSURG S, P44; [朱佩芳 Zhu Peifang], 2002, [中华创伤杂志, Chinese Journal of Traumatology], V18, P329; 赵小纲, 2003, [中华创伤杂志, Chinese Journal of Traumatology], V19, P680; 李培, 2004, [中华创伤杂志, Chinese Journal of Traumatology], V20, P619	47	100	119	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2008	64	5					1313	1319		10.1097/TA.0b013e318165c803			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	301SH	WOS:000255915400029	18469656				2021-06-18	
J	Green, REA; Melo, B; Christensen, B; Ngo, LA; Monette, G; Bradbury, C				Green, Robin E. A.; Melo, Brenda; Christensen, Bruce; Ngo, Le-Anh; Monette, Georges; Bradbury, Cheryl			Measuring premorbid IQ in traumatic brain injury: An examination of the validity of the Wechsler Test of Adult Reading (WTAR)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							WAIS-III; INTELLIGENCE; PERFORMANCE; INDEX; NART; DEMENTIA; SUBTEST	Estimation of premorbid IQ in traumatic brain injury (TBI) is clinically and scientifically valuable because it permits the quantification of the cognitive impact of injury. This is achieved by comparing performances on tests of current ability to estimates of premorbid IQ, thereby enabling current capacity to be interpreted in light of preinjury ability. However, the validity of premorbid IQ tests that are commonly used for TBI has been questioned. In the present study, we examined the psychometric properties of a recently developed test, the Wechsler Test of Adult Reading (WTAR), which has yet to be examined for TBI. The cognitive performance of a group of 24 patients recovering from TBI (with a mean Glasgow Coma Scale score in the severely impaired range) was measured at 2 and 5 months postinjury. On both occasions, patients were administered three tests that have been used to measure premorbid IQ (the WTAR and the Vocabulary and Matrix Reasoning subtests of the Wechsler Adult Intelligence Scale 3rd Edition, WAIS-III) and three tests of current ability (Symbol Digit Modalities Test-Oral and Similarities and Block Design subtests of the WAIS-III). We found that performance significantly improved on tests of current cognitive ability, confirming recovery. In contrast, stable performance was observed on the WTAR from Assessment 1 (M = 34.25/50) to Assessment 2 (M = 34.21/50; r = .970, p < .001). Mean improvement across assessments was negligible (t = -0.086, p = .47; Cohen's d = -0.005), and minimal individual participant change was observed (modal scaled score change = 0). WTAR scores were also highly similar to scores on a demographic estimate of premorbid IQ. Thus, converging evidence-high stability during recovery from TBI and similar IQ estimates to those of a demographic equation-suggests that the WTAR is a valid measure of premorbid IQ for TBI. Where word pronunciation tests are indicated (i.e., in patients for whom English is spoken and read fluently), these results endorse the use of the WTAR for patients with TBI.	[Green, Robin E. A.; Melo, Brenda; Ngo, Le-Anh; Bradbury, Cheryl] Univ Ctr, Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Green, Robin E. A.] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; [Christensen, Bruce] McMaster Univ, Michael G DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Monette, Georges] York Univ, Dept Math & Stat, Toronto, ON, Canada	Green, REA (corresponding author), Univ Ctr, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	Green.Robin@Torontorehab.on.ca		Green, Robin/0000-0001-9451-3963			Baddeley A.D., 1992, SPEED CAPACITY LANGU; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; Bright P, 2002, J INT NEUROPSYCH SOC, V8, P847, DOI 10.1017/S1355617702860131; CIPOLOTTI L, 1995, J NEUROL NEUROSUR PS, V58, P655, DOI 10.1136/jnnp.58.6.655; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P192, DOI 10.1080/13854049708407050; Crawford JR, 2001, PSYCHOL MED, V31, P451, DOI 10.1017/S0033291701003634; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; EPPINGER MG, 1987, J CONSULT CLIN PSYCH, V55, P86, DOI 10.1037/0022-006X.55.1.86; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; Gardner H., 1993, FRAMES MIND THEORY M; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Langeluddecke PM, 2004, CLIN NEUROPSYCHOL, V18, P423, DOI 10.1080/1385404049052422; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McGurn B, 2004, NEUROLOGY, V62, P1184, DOI 10.1212/01.WNL.0000103169.80910.8B; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Newson RS, 2005, J GERONTOL B-PSYCHOL, V60, pP113, DOI 10.1093/geronb/60.3.P113; REVEN JC, 1992, MANUAL REVENS PROGRE; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; RUSSELL EW, 1980, PERCEPT MOTOR SKILL, V51, P121, DOI 10.2466/pms.1980.51.1.121; Ryan JJ, 2005, INT J NEUROSCI, V115, P129, DOI 10.1080/00207450490512704; Smith A, 1992, SYMBOL DIGIT MODALIT; SPEARMAN C, 2004, AM J PSYCHOL, V13, P671; STERNBERG RJ, 1983, COGNITION, V15, P1, DOI 10.1016/0010-0277(83)90032-X; SWEET JJ, 1990, PSYCHOL ASSESSMENT J, V2, P41; TEASDALE G, 1974, LANCET, V2, P81; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Tombaugh TN, 1996, TEST MEMORY MALINGER; VANDERPLOEG RD, 1994, CLIN GUIDE NEUROPSYC; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yuspeh RL, 1998, APPL NEUROPSYCHOL, V5, P149, DOI 10.1207/s15324826an0503_6	40	100	101	0	17	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2008	30	2					163	172		10.1080/13803390701300524			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	264UY	WOS:000253317100005	18213530				2021-06-18	
J	Maikos, JT; Elias, RAI; Shreiber, DI				Maikos, Jason T.; Elias, Ragi A. I.; Shreiber, David I.			Mechanical properties of dura mater from the rat brain and spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						constitutive modeling; injury biomechanics; spinal cord injury; tissue mechanics; traumatic brain injury; viscoelasticity	CEREBROSPINAL-FLUID; IN-VITRO; INJURY; FIBROBLASTS; TENSION; TISSUE; MODEL; DEFORMATION; GLYCEROL; VIVO	The dura mater is the outermost and most substantial meningial layer of central nervous system (CNS) tissue that acts as a protective membrane for the brain and spinal cord. In animal models of traumatic brain injury and spinal cord injury, mechanical insults are often delivered directly to the dura to injure the underlying tissue. As such, including a description of the mechanical properties of dura mater is critical for biomechanical analyses of these models. We have characterized the mechanical response of dura mater from the rat brain and spinal cord in uniaxial tension. Testing was performed at low (0.0014 sec(-1)) and high (19.42 sec(-1)) strain rates. Both rat cranial dura and spinal dura demonstrated non-linear stress-strain responses characteristic of collagenous soft tissues. The non-linear increase in stress lagged in the spinal dura compared to the cranial dura. The slow rate data was fit to a one-term Ogden hyperelastic constitutive law, and significant differences were observed for the stiffness, G, and the parameter, alpha, which nominally introduces non-linearity. High strain rate stress-relaxation tests were performed to 10% strain, which was held for 10 sec. The relaxation was fit to a four-term Prony series exponential decay. Cranial dura and spinal dura demonstrated similar overall relaxation, but significant differences were identified in the distribution of the relaxation over the Prony series parameters, which demonstrated that cranial dura tended to relax faster. Polarized light microscopy revealed that the structural entities of spinal dura were aligned in the axial direction, whereas cranial dura did not demonstrate a preferential alignment. This was confirmed qualitatively with Masson's Tri-chrome and Verhoeff's Van Gieson staining for collagen and elastin, which also indicated greater elastin content for the spinal dura than for the cranial dura.	[Maikos, Jason T.; Elias, Ragi A. I.; Shreiber, David I.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA	Shreiber, DI (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	shreiber@rci.rutgers.edu		Shreiber, David/0000-0001-8248-419X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR 221744-01] Funding Source: Medline		Berkowitz ED, 1998, REV AM HIST, V26, P620; Bilston LE, 1996, ANN BIOMED ENG, V24, P67; Carpenter PW, 2003, J BIOMECH ENG-T ASME, V125, P857, DOI 10.1115/1.1634281; D'Addario M, 2003, J BIOL CHEM, V278, P53090, DOI 10.1074/jbc.M309027200; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Federspil PA, 2003, LARYNGOSCOPE, V113, P465, DOI 10.1097/00005537-200303000-00014; Fiford RJ, 2005, J BIOMECH, V38, P1509, DOI 10.1016/j.jbiomech.2004.07.009; FRISEN M, 1969, J BIOMECH, V2, P13, DOI 10.1016/0021-9290(69)90037-2; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Guertin PA, 2005, SPINAL CORD, V43, P459, DOI 10.1038/sj.sc.3101754; Haimann MCJ, 1998, J ANAT, V192, P99; He YL, 2004, CONNECT TISSUE RES, V45, P28, DOI 10.1080/03008200490278124; Ichihara K, 2001, J NEUROTRAUM, V18, P361, DOI 10.1089/08977150151071053; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Linninger AA, 2007, IEEE T BIO-MED ENG, V54, P291, DOI 10.1109/TBME.2006.886853; Loth F, 2001, J BIOMECH ENG-T ASME, V123, P71, DOI 10.1115/1.1336144; MCGARVEY KA, 1984, BIOMATERIALS, V5, P109, DOI 10.1016/0142-9612(84)90011-5; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; PARK JB, 1984, BIOMATERIALS SCI ENG; PATIN DJ, 1993, ANESTH ANALG, V76, P535; Petroll WM, 2004, INVEST OPHTH VIS SCI, V45, P3466, DOI 10.1167/iovs.04-0361; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Runza M, 1999, ANESTH ANALG, V88, P1317, DOI 10.1097/00000539-199906000-00022; Spicer MA, 2004, NEUROSURGERY, V54, P783, DOI 10.1227/01.NEU.0000114139.16118.F2; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; Taylor Z, 2004, J BIOMECH, V37, P1263, DOI 10.1016/j.jbiomech.2003.11.027; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Vandenabeele F, 1996, J ANAT, V189, P417; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; VIIDIK A, 1968, Journal of Biomechanics, V1, P3, DOI 10.1016/0021-9290(68)90032-8; Weed LH, 1938, J ANAT, V72, P181; Young W, 2002, PROG BRAIN RES, V137, P231; Yuan Q, 1998, SPINE, V23, P1677, DOI 10.1097/00007632-199808010-00012	39	100	103	2	34	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2008	25	1					38	51		10.1089/neu.2007.0348			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	258IJ	WOS:000252861300004	18355157				2021-06-18	
J	Chen, XR; Besson, VC; Palmier, B; Garcia, Y; Plotkine, M; Marchand-Leroux, C				Chen, Xiao Ru; Besson, Valerie C.; Palmier, Bruno; Garcia, Yannick; Plotkine, Michel; Marchand-Leroux, Catherine			Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						fenofibrate; neuroinflammation; oxidative stress; peroxisome proliferator-activated receptor alpha; traumatic brain injury	ACTIVATED-RECEPTOR-ALPHA; NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; INFLAMMATORY RESPONSES; SELECTIVE-INHIBITION; MOUSE MODEL; GLUTATHIONE; MATRIX-METALLOPROTEINASE-9; NEUROPROTECTION; PEROXYNITRITE	We previously demonstrated that fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, reduced the neurological deficit, the edema and the cerebral lesion induced by traumatic brain injury (TBI). In order to elucidate these beneficial effects, in the present study, we investigated, in the same TBI model, fenofibrate's effects on the inflammation and oxidative stress. Male Sprague Dawley rats were randomized in four groups: non-operated, sham-operated, TBI + vehicle, TBI + fenofibrate. TBI was induced by lateral fluid percussion of the temporoparietal cortex. Rats were given fenofibrate (50 mg/kg) or its vehicle (water containing 0.2% methylcellulose), p.o. 1 and 6 h after brain injury. A neurological assessment was done 24 h after TBI, then rats were killed and the brain COX2, MMP9 expression, GSx, GSSG levels were determined. The same schedule of treatment was used to evaluate the effect of fenofibrate on immunohistochemistry of 3NT, 4HNE and iNOS at 24 h post-injury. Our results showed that fenofibrate promotes neurological recovery by exerting anti-inflammatory effect evidenced by a decrease in iNOS, COX2 and MMP9 expression. In addition, fenofibrate showed anti-oxidant effect demonstrated by a reduction of markers of oxidative stress: loss of glutathione, glutathione oxidation ratio, 3NT and 4HNE staining. Our data suggest that PPAR alpha activation could mediate pleiotropic effects and strengthen that it could be a promising therapeutic strategy for TBI.	Univ Paris 05, Pharmacol Lab, UPRES EA 2510, Fac Pharm,Lab Pharmacol Circulat Cerebrale, F-75006 Paris, France	Besson, VC (corresponding author), Univ Paris 05, Pharmacol Lab, UPRES EA 2510, Fac Pharm,Lab Pharmacol Circulat Cerebrale, 4 Ave Observ, F-75006 Paris, France.	valerie.besson@univ-paris5.fr	BESSON, VALERIE/AAZ-9989-2020; besson, valerie C/L-7388-2017; MARCHAND-LEROUX, Catherine/L-7453-2017	BESSON, VALERIE/0000-0002-1491-2380; besson, valerie C/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			Arnaiz SL, 1995, BBA-MOL BASIS DIS, V1272, P175; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chew LJ, 2006, MENT RETARD DEV D R, V12, P105, DOI 10.1002/mrdd.20102; Collino M, 2006, FREE RADICAL BIO MED, V41, P1619, DOI 10.1016/j.freeradbiomed.2006.09.013; Cuzzocrea S, 2004, LAB INVEST, V84, P1643, DOI 10.1038/labinvest.3700185; Delayre-Orthez C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-91; Deplanque D, 2003, J NEUROSCI, V23, P6264; Duval C, 2004, ARCH MAL COEUR VAISS, V97, P665; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Genovese T, 2005, EXP NEUROL, V194, P267, DOI 10.1016/j.expneurol.2005.03.003; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hooper DC, 2000, FASEB J, V14, P691; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Inoue H, 2003, NEUROSCI LETT, V352, P203, DOI 10.1016/j.neulet.2003.09.001; Inoue I, 2001, METABOLISM, V50, P3, DOI 10.1053/meta.2001.19415; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Lee JH, 2005, NEUROREPORT, V16, P829; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Ogata T, 2004, J AM COLL CARDIOL, V43, P1481, DOI 10.1016/j.jacc.2003.11.043; OUK T, 2005, J CEREB BLOOD FLO S1, V26, pS59; Pahan K, 2002, J BIOL CHEM, V277, P45984, DOI 10.1074/jbc.M200250200; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rival Y, 2004, DNA CELL BIOL, V23, P283, DOI 10.1089/104454904323090912; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Toyama T, 2004, BIOCHEM BIOPH RES CO, V324, P697, DOI 10.1016/j.bbrc.2004.09.110; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Xu JH, 2005, J NEUROSCI RES, V81, P403, DOI 10.1002/jnr.20518; Zhang JW, 1997, J NEUROSCI METH, V76, P15, DOI 10.1016/S0165-0270(97)00065-4	46	100	105	2	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1119	1131		10.1089/neu.2006.0216			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200004	17610352				2021-06-18	
J	Griffith, RW; Humphrey, DR				Griffith, Ronald W.; Humphrey, Donald R.			Long-term gliosis around chronically implanted platinum electrodes in the Rhesus macaque motor cortex	NEUROSCIENCE LETTERS			English	Article						microelectrode; glial scar; astrocyte; microglia; primate	DEEP BRAIN-STIMULATION; ASTROCYTES; ATTACHMENT; EXPRESSION; OUTGROWTH; SURFACES; INJURY; CELLS; CNS	Chronically implanted microelectrodes have been an important tool used by neuroscientists for many years and are critical for the development of neural prostheses designed to restore function after traumatic central nervous system (CNS) injury. It is well established that a variety of mammals, including non-human primates (NHP), tolerate noble metal electrodes in the cortex for extended periods of time, but little is known about the long-term effects of electrode implantation at the cellular level. While data from rodents have clearly shown gliosis around such implants, there have been difficulties in demonstrating these reactions in NHP. Glial reactions are to be expected in NHP, since any trauma to the mammalian CNS is believed to result in the formation of a glial scar consisting of reactive astrocytes and microglia around the injury site. Because a glial scar can potentially affect the quality of recordings or stimulations from implanted electrodes, it is important to determine the extent of gliosis around implants in NHP. We studied the response of cortical glial cells to chronic electrode implantation in the motor cortices of Rhestis macaques (Macaca mulatta) after 3 months and 3 years duration. Antibodies specific for astrocytes and microglia were used to detect the presence of glial reactions around electrode implant sites. Reactive glia were found within the cortical neuropil surrounding the chronically implanted noble metal electrodes. Reactive gliosis persisted over the time periods studied and demonstrates the importance of developing strategies to minimize this event, even around noble metal implants. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Emory Univ, Sch Med, Dept Physiol, Whitehead Biomed Res Ctr, Atlanta, GA 30322 USA	Griffith, RW (corresponding author), Emory Univ, Sch Med, Dept Physiol, Whitehead Biomed Res Ctr, Suite 605S,615 Michael St, Atlanta, GA 30322 USA.	ronald.griffith@emory.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40437] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040437] Funding Source: NIH RePORTER		AGNEW WF, 1993, NEUROSCIENCE, V52, P45, DOI 10.1016/0306-4522(93)90180-N; Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001; Donoghue JP, 2002, NAT NEUROSCI, V5, P1085, DOI 10.1038/nn947; DONOGHUE JP, 2004, CLIN NEUROPHYSIOL, V57, P593; DUSART I, 1991, NEUROSCIENCE, V45, P541, DOI 10.1016/0306-4522(91)90269-T; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GARRISON CJ, 1994, EXP NEUROL, V129, P237, DOI 10.1006/exnr.1994.1165; GILMORE SA, 1990, GLIA, V3, P342, DOI 10.1002/glia.440030505; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; Griffith R, 1996, J COMP NEUROL, V371, P362; Griffith R, 2000, EXP NEUROL, V161, P297, DOI 10.1006/exnr.1999.7257; Haberler C, 2000, ANN NEUROL, V48, P372, DOI 10.1002/1531-8249(200009)48:3<372::AID-ANA12>3.3.CO;2-S; HERRERA DG, 1992, BRAIN RES, P293; Humphrey D. R., 1997, Society for Neuroscience Abstracts, V23, P1556; Kam L, 2002, BIOMATERIALS, V23, P511, DOI 10.1016/S0142-9612(01)00133-8; Kam L, 1999, BIOMATERIALS, V20, P2343, DOI 10.1016/S0142-9612(99)00163-5; Kam L, 2001, BIOMATERIALS, V22, P1049, DOI 10.1016/S0142-9612(00)00352-5; Kennedy PR, 2004, IEEE T NEUR SYS REH, V12, P339, DOI 10.1109/TNSRE.2004.834629; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Oka J, 2000, NEUROSCI RES, V36, P93, DOI 10.1016/S0168-0102(99)00106-6; Otto SR, 2002, J NEUROSURG, V96, P1063, DOI 10.3171/jns.2002.96.6.1063; Park MC, 2004, J NEUROPHYSIOL, V92, P2968, DOI 10.1152/jn.00649.2003; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; PUDENZ RH, 1977, BRAIN BEHAV EVOLUT, V14, P103, DOI 10.1159/000125578; Rauschecker JP, 2002, SCIENCE, V295, P1025, DOI 10.1126/science.1067796; STENSAAS SS, 1978, ACTA NEUROPATHOL, V41, P145, DOI 10.1007/BF00689766; StJohn PM, 1997, J NEUROSCI METH, V75, P171, DOI 10.1016/S0165-0270(97)00069-1; Suner S, 2005, IEEE T NEUR SYS REH, V13, P524, DOI 10.1109/TNSRE.2005.857687; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; Turner AMP, 2000, J BIOMED MATER RES, V51, P430, DOI 10.1002/1097-4636(20000905)51:3<430::AID-JBM18>3.0.CO;2-C; Turner JL, 2000, J NEUROCHEM, V74, pS82; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Vitek JL, 2004, MOVEMENT DISORD, V19, P907, DOI 10.1002/mds.20137; YUEN TGH, 1995, BIOMATERIALS, V16, P951, DOI 10.1016/0142-9612(95)93121-S	36	100	100	0	16	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 2	2006	406	1-2					81	86		10.1016/j.neulet.2006.07.018			6	Neurosciences	Neurosciences & Neurology	087XH	WOS:000240775600016	16905255				2021-06-18	
J	Ziino, C; Ponsford, J				Ziino, Carlo; Ponsford, Jennie			Selective attention deficits and subjective fatigue following traumatic brain injury	NEUROPSYCHOLOGY			English	Article						brain injury; fatigue; attention	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; REACTION-TIME; SCALE; VALIDITY; ANXIETY	The present study aimed to investigate the relationship between subjective fatigue and selective attention deficits following traumatic brain injury (TBI). Forty-six participants with mild-severe TBI and 46 healthy controls completed fatigue scales (Visual Analogue Scale - Fatigue, Fatigue Severity Scale [FSS] and Causes of Fatigue Questionnaire [COF]), and attentional measures including subtests from the Test of Everyday Attention, and the Complex Selective Attention Task (C-SAT). TBI participants reported greater fatigue on the FSS and COF, performed more slowly on attentional measures, and made more errors on the C-SAT. After controlling for anxiety and depression, fatigue was significantly correlated with performance only on the C-SAT. Findings suggest a relationship between subjective fatigue and impairment on tasks requiring higher order attentional processes.	Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia	Ziino, C (corresponding author), Monash Univ, Dept Psychol, Clayton Campus,POB 17, Clayton, Vic 3800, Australia.	Carlo.Ziino@med.monash.edu.au					Annett J, 2002, ERGONOMICS, V45, P966, DOI 10.1080/00140130210166951; AVIES DR, 1984, VARIEITES ATTENTION, P395; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Caci H, 2003, PSYCHIAT RES, V118, P89, DOI 10.1016/S0165-1781(03)00044-1; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Ferraccioli G, 1996, J RHEUMATOL, V23, P1539; Harter M, 2001, DISABIL REHABIL, V23, P737; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; NELSON HE, 1994, NATL ADULT READING T; NORMAN A, 1986, CONSCIOUSNESS SELF R, V4; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, P241; POSNER MI, 1971, PSYCHOL REV, V78, P391, DOI 10.1037/h0031333; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; ROA V, 2002, CURRENT TREATMENT OP, V4, P77; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Smith A., 1973, SYMBOL DIGIT MODALIT; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Sturm W, 2001, NEUROIMAGE, V14, pS76, DOI 10.1006/nimg.2001.0839; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SUSS DT, 1986, FRONTAL LOBES; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; VANZOMEREN AH, 1987, NEUROBEHAVIOURAL REC; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	50	100	101	0	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2006	20	3					383	390		10.1037/0894-4105.20.3.383			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	047UN	WOS:000237904300013	16719631				2021-06-18	
J	Howe, JA; Inness, EL; Venturini, A; Williams, JI; Verrier, MC				Howe, J. A.; Inness, E. L.; Venturini, A.; Williams, J. I.; Verrier, M. C.			The Community Balance and Mobility Scale - a balance measure for individuals with traumatic brain injury	CLINICAL REHABILITATION			English	Article							HEAD-INJURY; SWAY; WALKING; GAIT	Objective: To provide evidence for the validity and reliability of a new outcome measure of balance, the Community Balance and Mobility Scale, developed for the ambulatory individual with traumatic brain injury. Design: A validity and reliability study. Setting: Acute care, in- and outpatient rehabilitation and day hospital settings. Subjects: Two convenience samples (n = 36, 32) of ambulatory patients with traumatic brain injury. Main measures: The content and construct validity, test-retest, inter- and intra-rater reliability and internal consistency of the Community Balance and Mobility Scale. Results: Content validity was demonstrated by the involvement of patients with traumatic brain injury (n = 7) and clinicians (n = 17) in the process of item generation and by physical therapists' ratings of item relevance. Further support is the correlation of the Community Balance and Mobility Scale scores with physical therapists' global balance ratings of the patient (r = 0.62). Construct validity was supported by the ability of the measure to differentiate between patients along the continuum of care and also by comparisons with maximal walking velocity (r= 0.64). Patients who scored greater than or less than 50 on the balance measure demonstrated significantly different Community Integration Questionnaire scores (P = 0.004). The Community Balance and Mobility Scale demonstrated intraclass correlation coefficients (ICCs) of 0.977, 0.977, 0.975 and Cronbach's alpha of 0.96 for intra-, inter-, test-retest reliability and internal consistency, respectively. Conclusion: The Community Balance and Mobility Scale is a valid and reliable outcome measure for the ambulatory individual with traumatic brain injury.	Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; Univ Toronto, Fac Med, Dept Phys Therapy, Toronto, ON, Canada; Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON, Canada	Howe, JA (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	howe.jo-anne@torontorehab.on.ca		Inness, Elizabeth L./0000-0002-9217-4619			Altman D, 1991, PRACTICAL STAT MED R; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERG K, 1989, Physiotherapy Canada, V41, P304; Colton T., 1974, STAT MED; Dean S, 2000, PSYCHOL REP, V86, P653, DOI 10.2466/pr0.2000.86.2.653; FLEISS JL, 1978, PSYCHOMETRIKA, V43, P259, DOI 10.1007/BF02293867; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Hillier SL, 1997, BRAIN INJURY, V11, P661; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NIECHWIEJSZWEDO E, 2006, IN PRESS GAIT POSTUR; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; OBERG T, 1993, J REHABIL RES DEV, V30, P210; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Willems D, 1996, PHYSIOTHER CAN, V48, P179; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WONG P, 1999, BRAIN INJURY, V7, P283	23	100	101	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.		2006	20	10					885	895		10.1177/0269215506072183			11	Rehabilitation	Rehabilitation	098YG	WOS:000241559100005	17008340				2021-06-18	
J	Statler, KD; Alexander, H; Vagni, V; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM				Statler, KD; Alexander, H; Vagni, V; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM			Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats	JOURNAL OF NEUROTRAUMA			English	Article						analgesia; benzodiazepine; controlled cortical impact; isoflurane; ketamine; narcotic; propofol; sedation	CEREBRAL-BLOOD-FLOW; PROPOFOL INFUSION; ENDOGENOUS OPIOIDS; NITROUS-OXIDE; ISOFLURANE ANESTHESIA; FOREBRAIN ISCHEMIA; GLOBAL-ISCHEMIA; KETAMINE; FENTANYL; NEUROPROTECTION	Isoflurane is commonly used in experimental traumatic brain injury (TBI), both before and early after injury, yet it is rarely used clinically. Narcotics and benzodiazepines are frequently used after injury in clinical TBI. We compared seven anesthetic/sedative agents applied after injury in the controlled cortical impact model: diazepam, fentanyl, isoflurane, ketamine, morphine, pentobarbital, and propofol. Our objective was to provide insight into the relative degrees of neuroprotection provided by these agents in a standard model of TBI. We hypothesized that the choice of anesthetic/sedative early after experimental TBI critically impacts outcome and that the agents most commonly used clinically may be less neuroprotective than isoflurane. Rats treated with isoflurane had the best cognitive recovery (p < 0.05) and hippocampal neuronal survival (p < 0.05). Conversely, rats treated with ketamine had the most hippocampal neuronal death (p < 0.05). Morphine or propofol, two agents commonly used clinically, were associated with the poorest motor function on post-trauma day 1-5 (p < 0.05). Our data support beneficial effects of isoflurane early after experimental TBI. Our data suggest that the early post-TBI use of isoflurane, despite practical logistical issues, could potentially provide clinical benefits in TBI-versus other commonly used sedatives or analgesics. Furthermore, the choice of post-injury sedation and analgesia could have important implications on attempts to translate novel therapies from bench to field or bedside.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Statler, KD (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	kim.statler@hsc.utah.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P50NS030318, P20NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		Bayona NA, 2004, ANESTHESIOLOGY, V100, P1151, DOI 10.1097/00000542-200405000-00017; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; BRAY RJ, 1995, ANAESTHESIA, V50, P94, DOI 10.1111/j.1365-2044.1995.tb04544.x; Cannon ML, 2001, J NEUROSURG, V95, P1053, DOI 10.3171/jns.2001.95.6.1053; CARLSSON C, 1981, ANESTHESIOLOGY, V54, P488, DOI 10.1097/00000542-198106000-00008; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CORRIGALL WA, 1980, BRAIN RES, V192, P227, DOI 10.1016/0006-8993(80)91022-7; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Elsersy H, 2004, ANESTHESIOLOGY, V100, P1160, DOI 10.1097/00000542-200405000-00018; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539-200302000-00041; Ergun R, 2002, NEUROSURG REV, V25, P95, DOI 10.1007/s101430100171; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FISHBACK AS, 1995, NEUROSURGERY, V37, P969, DOI 10.1227/00006123-199511000-00017; FRENK H, 1983, BRAIN RES REV, V6, P197, DOI 10.1016/0165-0173(83)90039-5; Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023; Gilron I, 1999, ANESTH ANALG, V89, P128, DOI 10.1097/00000539-199907000-00022; Grasshoff C, 2002, ANESTH ANALG, V95, P920, DOI 10.1213/01.ANE.0000025705.93185.09; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; HERNANDEZ MJ, 1978, STROKE, V9, P150, DOI 10.1161/01.STR.9.2.150; Hill GE, 1998, ANESTH ANALG, V87, P1015, DOI 10.1097/00000539-199811000-00006; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kang TM, 2002, ANN PHARMACOTHER, V36, P1453; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; KISSIN I, 1987, CAN J ANAESTH, V34, P146, DOI 10.1007/BF03015332; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kofke WA, 1996, ANESTH ANALG, V83, P141, DOI 10.1097/00000539-199607000-00025; LARSSON JE, 1994, BRIT J ANAESTH, V73, P692, DOI 10.1093/bja/73.5.692; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; Lingamaneni R, 2003, BRIT J ANAESTH, V90, P199, DOI 10.1093/bja/aeg040; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; McNamara RK, 1997, PHARMACOL BIOCHEM BE, V56, P383, DOI 10.1016/S0091-3057(96)00237-7; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; MURR R, 1993, ANESTH ANALG, V77, P898; Nagase K, 2003, J NEUROSURG ANESTH, V15, P98, DOI 10.1097/00008506-200304000-00006; Neff SPW, 1997, ANAESTH INTENS CARE, V25, P581; Nemoto E M, 1983, Am J Emerg Med, V1, P175, DOI 10.1016/0735-6757(83)90086-4; Nikolaishvili L S, 2004, Neurosci Behav Physiol, V34, P467, DOI 10.1023/B:NEAB.0000022631.46176.6b; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATEL PM, 1993, J CEREB BLOOD FLOW M, pS685; Proescholdt M, 2001, BRAIN RES, V904, P245, DOI 10.1016/S0006-8993(01)02465-9; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHIU GK, 1983, CRIT CARE MED, V11, P452, DOI 10.1097/00003246-198306000-00013; SHIU GK, 1981, J NEUROCHEM, V37, P1448, DOI 10.1111/j.1471-4159.1981.tb06314.x; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2003, BRAIN RES, V994, P37, DOI 10.1016/j.brainres.2003.09.042; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; WERNER C, 1993, ANESTH ANALG, V76, P971; Yang CCH, 1996, AM J PHYSIOL-HEART C, V270, pH575	65	100	103	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2006	23	1					97	108		10.1089/neu.2006.23.97			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	009GP	WOS:000235100100008	16430376				2021-06-18	
J	Lynch, JR; Wang, H; Mace, B; Leinenweber, S; Warner, DS; Bennett, ER; Vitek, MP; McKenna, S; Laskowitz, DT				Lynch, JR; Wang, H; Mace, B; Leinenweber, S; Warner, DS; Bennett, ER; Vitek, MP; McKenna, S; Laskowitz, DT			A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury	EXPERIMENTAL NEUROLOGY			English	Article						apolipoprotein E; brain inflammation; closed head injury	MICROGLIAL ACTIVATION; MIMETIC PEPTIDES; GENOTYPE; MODEL; APOE; RAT; EXCITOTOXICITY; DEFICITS; MOTOR	Although apolipoprotein E4 (APOE4) was initially identified as a susceptibility gene for the development of Alzheimer's disease, the presence of the APOE4 allele is also associated with poor outcome after acute brain injury. One mechanism by which apoE may influence neurological outcome is by downregulating the neuroinflammatory response. Because it does not readily cross the blood-brain barrier, the apoE holoprotein has limited therapeutic potential. We demonstrate that a single intravenous injection of a small peptide derived from the apoE receptor binding region crosses the blood-brain barrier and significantly improves histological and functional outcomes after traumatic brain injury (TBI). The development of an apoE-based intervention represents a novel therapeutic strategy in the management of acute brain injury. (C) 2004 Elsevier Inc. All rights reserved.	Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Multidisciplinary Neurpprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Univ N Carolina, Dept Anesthesiol Pediat Crit Care, Chapel Hill, NC 27516 USA; Cognosci Inc, Res Triangle Pk, NC 27709 USA	Lynch, JR (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Neurol, 227E Bryan Res Bldg,Box 2900, Durham, NC 27710 USA.	lynch004@duke.edu		Vitek, Michael/0000-0001-8140-8048	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG022230] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1K08AG022230-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R21NS4487-01, 1R01NS368087] Funding Source: Medline		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Leung CHS, 2002, STROKE, V33, P548, DOI 10.1161/hs0202.102326; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Schauwecker PE, 1998, EXP NEUROL, V149, P87, DOI 10.1006/exnr.1997.6679; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	25	100	110	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2005	192	1					109	116		10.1016/j.expneurol.2004.11.014			8	Neurosciences	Neurosciences & Neurology	899LZ	WOS:000227147200012	15698624				2021-06-18	
J	Jellinger, KA				Jellinger, KA			Head injury and dementia	CURRENT OPINION IN NEUROLOGY			English	Article						Alzheimer's disease; amyloid deposition; dementia; experimental models; genetic factors; traumatic brain injury; tau pathology	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E POLYMORPHISM; LONG-TERM ACCUMULATION; ALZHEIMERS-DISEASE; RISK-FACTOR; PSYCHIATRIC-DISORDERS; CEREBROSPINAL-FLUID; EARLY ADULTHOOD; BETA-SECRETASE	Purpose of review The link between head injury and dementia/Alzheimer's disease is controversial. This review discusses some recent epidemiological, human autopsy and experimental studies on the relationship between traumatic head injury and dementia. Recent findings Recent epidemiological studies have shown that head injury is a risk factor for the development of dementia/Alzheimer's disease, whereas others have not. After experimental brain trauma the long-term accumulation of amyloid P peptide suggests that neurodegeneration is influenced by apolipoprotein E epsilon4, and after human brain injury both amyloid beta peptide deposition and tau pathology are seen, even in younger patients. Amyloid beta peptide levels in the cerebrospinal fluid and the overproduction of beta amyloid precursor protein in humans and animals after traumatic brain injury are increased. Repeated mild head trauma in both animals and humans accelerates amyloid beta peptide accumulation and cognitive impairment. Retrospective autopsy data support clinical studies suggesting that severe traumatic brain injury with long-lasting morphological residuals are a risk factor for the development of dementia/ Alzheimer's disease. The influence of the apolipoprotein E genotype on the prognosis of traumatic brain injury is under discussion. Summary Although epidemiological studies and retrospective autopsy data provide evidence that a later cognitive decline may occur after severe traumatic brain injury, the relationship between dementia after head/brain trauma and apolipoprotein E status is still ambiguous. Both human postmortem and experimental studies showing apolipoprotein beta deposition and tau pathology after head injury support the link between traumatic brain injury and dementia, and further studies are warranted to clarify this relationship.	Inst Clin Neurobiol, A-1070 Vienna, Austria	Jellinger, KA (corresponding author), Inst Clin Neurobiol, Kenyongasse 18, A-1070 Vienna, Austria.	kurt.jellinger@univie.ac.at					Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; ALSARRAJ ST, 2004, J NEUROL NEUROSUR PS, V63, P234; ATTEMS J, 2004, 7 VIENN INT C GER VI; Barnett C, 2003, INT J GERIATR PSYCH, V18, P88, DOI 10.1002/gps.728; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bramlett HM, 2003, EXP NEUROL, V184, P27, DOI 10.1016/S0014-4886(03)00401-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Golden Z, 2003, INT J NEUROSCI, V113, P869, DOI 10.1080/00207450390200927; Gottlieb S, 2000, BRIT MED J, V321, P1100; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hinkebein JH, 2003, BRAIN INJURY, V17, P1035, DOI 10.1080/0269905031000110490; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horner Arlene, 2002, AACN Clin Issues, V13, P73, DOI 10.1097/00044067-200202000-00008; Hy LX, 2000, NEUROLOGY, V55, P198, DOI 10.1212/WNL.55.2.198; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Leon-Carrion J, 2002, NEUROREHABILITATION, V17, P115; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ohashi Masahiro, 2004, Nihon Rinsho, V62 Suppl, P285; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Ubis JIQ, 2003, ACTAS ESP PSIQUIATRI, V31, P353; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2004, NEUROBIOL AGING S1, V25, pP2; Wilson JTL, 2003, J NEUROL NEUROSUR PS, V74, P841, DOI 10.1136/jnnp.74.7.841; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0	56	100	105	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2004	17	6					719	723		10.1097/00019052-200412000-00012			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	878XY	WOS:000225682000011	15542981				2021-06-18	
J	Herbertsson, P; Josefsson, PO; Hasserius, R; Besjakov, J; Nyqvist, F; Karlsson, MK				Herbertsson, P; Josefsson, PO; Hasserius, R; Besjakov, J; Nyqvist, F; Karlsson, MK			Fractures of the radial head and neck treated with radial head excision	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							TERM-FOLLOW-UP; MASON TYPE-II; INTERNAL-FIXATION; CLOSED FRACTURE; ELBOW; DISLOCATIONS; RESECTION	Background: The reported long-term outcomes of the treatment of radial head and neck fractures with excision of the radial head have been mixed. The purpose of the present study was to evaluate the long-term outcomes of primary or delayed radial head excision for the treatment of these fractures. Methods: Sixty-one individuals (mean age, forty-four years) with thirty-nine Mason type-II, ten Mason type-III, and twelve Mason type-IV fractures were evaluated subjectively, objectively, and radiographically at a mean of eighteen years (range, eleven to thirty-three years) after treatment. Forty-three fractures were treated with primary radial head excision, and the remaining eighteen were treated with delayed radial head excision at a median of five months (range, one to 238 months) after the injury. Results: At the time Of follow-up, twenty-eight individuals had no symptoms, twenty-seven had occasional elbow pain, and six had daily pain. Four individuals with daily pain had had a Mason type-IV fracture. The range of motion of the formerly injured upper extremities was slightly less than that of the uninjured upper extremities in terms of flexion (139degrees +/- 11degrees compared with 142degrees +/- 8degrees), extension (-7degrees +/- 12degrees compared with -1degrees +/- 6degrees), and supination (77degrees +/- 20degrees compared with 85degrees +/- 10degrees) (all p < 0.01). A higher percentage of formerly injured elbows than uninjured elbows had cysts, sclerosis, and osteophytes (73% compared with 7%; p < 0.001), but none had a reduced joint space. No differences were found between the outcomes for individuals treated with a primary radial head excision and those for individuals treated with a delayed excision. Conclusions: Following a displaced radial head or neck fracture, excision of the radial head often leads to a good or fair result. We found no differences in outcome between primary and delayed radial head excisions following a Mason type-II, III, or IV fracture. The outcomes are associated with the type of fracture, with Mason type-IV fractures having the worst results, rather than with the timing of the radial head excision (primary or delayed). Level of Evidence: Therapeutic study, Level III-2 (retrospective cohort study). See Instructions to Authors for a complete description of levels of evidence.	Malmo Univ Hosp, Dept Orthopaed, SE-20502 Malmo, Sweden; Malmo Univ Hosp, Dept Radiol, SE-20502 Malmo, Sweden	Herbertsson, P (corresponding author), Malmo Univ Hosp, Dept Orthopaed, SE-20502 Malmo, Sweden.	par.herbertsson@skane.se; peo.josefsson@skane.se; ralph.hasserius@skane.se; jack.besjakov@skane.se; caroline.karlsson@skane.se; magnus.karlsson@orto.mas.lu.se					ARNER O, 1957, Acta Chir Scand, V112, P115; BAKALIM G, 1970, ACTA ORTHOP SCAND, V41, P320, DOI 10.3109/17453677008991518; BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; BROBERG MA, 1987, CLIN ORTHOP RELAT R, P109; COLEMAN DA, 1987, J BONE JOINT SURG AM, V69A, P385; Conn J, 1961, J TRAUMA, V1, P248; ESSER RD, 1995, J ORTHOP TRAUMA, V9, P318, DOI 10.1097/00005131-199509040-00008; GOLDBERG I, 1986, J BONE JOINT SURG AM, V68A, P675, DOI 10.2106/00004623-198668050-00006; HELFERICH H, 1899, FRACTURES DISLOCATIO, P96; Herbertsson P, 2004, J BONE JOINT SURG AM, V86A, P569, DOI 10.2106/00004623-200403000-00016; HERBERTSSON P, 2003, ANN M SWED SOC ORTH; Ikeda M, 2000, ACTA ORTHOP SCAND, V71, P191, DOI 10.1080/000164700317413184; JOHNSTON G W, 1962, Ulster Med J, V31, P51; JOSEFSSON PO, 1984, J BONE JOINT SURG AM, V66A, P927, DOI 10.2106/00004623-198466060-00014; KNIGHT DJ, 1993, J BONE JOINT SURG BR, V75, P572; Malmvik J, 2003, J PEDIATR ORTHOP B, V12, P63, DOI 10.1097/00009957-200301000-00012; MASON ML, 1954, BRIT J SURG, V42, P123, DOI 10.1002/bjs.18004217203; MIKIC ZD, 1983, CLIN ORTHOP RELAT R, P220; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; MORREY BF, 1979, J BONE JOINT SURG AM, V61, P63, DOI 10.2106/00004623-197961010-00012; Murray RC, 1940, BRIT J SURG, V28, P106, DOI 10.1002/bjs.18002810911; Odelberg-Johnson G, 1924, ACTA RADIOL, V3, P45, DOI 10.3109/00016922409133476; POULSEN JO, 1974, ACTA ORTHOP SCAND, V45, P66, DOI 10.3109/17453677408989123; RADIN EL, 1966, J BONE JOINT SURG AM, VA 48, P1055, DOI 10.2106/00004623-196648060-00003; Ring D, 2002, J BONE JOINT SURG AM, V84A, P1811, DOI 10.2106/00004623-200210000-00011; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; STEPHEN IBM, 1981, ACTA ORTHOP SCAND, V52, P409, DOI 10.3109/17453678109050121; Watson-Jones R., 1941, FRACTURES OTHER BONE, P336; Wilson PD, 1933, SURG GYNECOL OBSTET, V56, P335	29	100	104	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	SEP	2004	86A	9					1925	1930		10.2106/00004623-200409000-00010			6	Orthopedics; Surgery	Orthopedics; Surgery	852ZJ	WOS:000223795200010	15342754				2021-06-18	
J	Yogev-Falach, M; Amit, T; Bar-Am, O; Youdim, MBH				Yogev-Falach, M; Amit, T; Bar-Am, O; Youdim, MBH			The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing	FASEB JOURNAL			English	Article						mitogen-activated protein kinase; Alzheimer's disease	CLOSED-HEAD INJURY; MAO-B INHIBITOR; ENDOGENOUS NEUROTOXIN; BETA-PROTEIN; ALZHEIMERS-DISEASE; CHOLINESTERASE; APOPTOSIS; N-METHYL(R)SALSOLINOL; RIVASTIGMINE; PEPTIDE	Rasagiline [N-propargyl-(1R)-aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor exerts neuroprotective and antiapoptotic effects against a variety of insults in cell cultures and in vivo and has finished its phase III clinical trials for Parkinson's disease. In the present study, we show that rasagiline (1 and 10 muM) significantly protected rat PC12 cells against beta-amyloid (Abeta(1-42)) toxicity. In addition, rasagiline significantly increased (approximately threefold) the secretion of the nonamyloidogenic soluble form of the amyloid precursor protein (sAPPalpha) from SH-SY5Y neuroblastoma and PC12 cells. The increase of sAPPa. was dose-dependent and was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-9790 (100 muM), suggesting that the effect is mediated via alpha-secretase activity. Rasagiline-induced sAPPa. release was significantly reduced by the inhibitors of protein kinase C (PKC), GF109203X, and ERK mitogen-activated protein kinase (MAPK) PD98059. Moreover, rasagiline dose dependently (0.1-10 muM) increased the phosphorylation of p44 and p42 MAPK, which was abolished by PD98059 (30 muM) and GF109203X (2.5 muM). By comparing the actions of rasagiline with those of its S-isomer TVP1022, which is not an MAO inhibitor, we have been able to demonstrate that MAO-B inhibition is not a prerequisite for either sAPPalpha-induced release or ERK phosphorylation. In addition, structure-activity relationship among rasagiline-related compounds suggests the crucial role of the propargyl moiety in these molecules, because propargylamine itself significantly induced the secretion of sAPPa. and increased MAPK phosphorylation with similar potency to that of rasagiline and its derivatives.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Neurodegenerat Dis, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Pharmacol, NPF Ctr Neurodegenerat Dis, IL-31096 Haifa, Israel	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Neurodegenerat Dis, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il					Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akao Y, 2002, NEUROSCI LETT, V326, P105, DOI 10.1016/S0304-3940(02)00332-4; Akao Y, 1999, NEUROSCI LETT, V267, P153, DOI 10.1016/S0304-3940(99)00361-4; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Desai A, 2001, Expert Opin Pharmacother, V2, P653, DOI 10.1517/14656566.2.4.653; Finberg J P, 1999, Adv Neurol, V80, P495; Grant SM, 1999, NEUROREPORT, V10, P41, DOI 10.1097/00001756-199901180-00008; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; KIEBURTZ K, 2001, PARK RELAT DISORD S, V60; Kim KS., 1988, NEUROSCI RES COMMUN, V2, P121; Lamb HM, 2001, PHARMACOECONOMICS, V19, P303, DOI 10.2165/00019053-200119030-00008; Lu DC, 2000, NAT MED, V6, P397; Maruyama W, 2002, J NEURAL TRANSM, V109, P467, DOI 10.1007/s007020200038; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; Maruyama W, 2001, J NEURAL TRANSM, V108, P11, DOI 10.1007/s007020170093; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Moreira PI, 2002, J NEUROSCI RES, V69, P257, DOI 10.1002/jnr.10282; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015; Rabey JM, 2000, CLIN NEUROPHARMACOL, V23, P324, DOI 10.1097/00002826-200011000-00005; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Speiser Z, 1999, J NEURAL TRANSM, V106, P593, DOI 10.1007/s007020050182; Tatton WG, 2002, J PHARMACOL EXP THER, V301, P753, DOI 10.1124/jpet.301.2.753; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.0.CO;2-Z; WEINSTOCK M, 2000, J NEURAL TRANSM-SUPP, V60, pS157; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim M B, 1991, J Neural Transm Suppl, V34, P61; Youdim MBH, 2002, MECH AGEING DEV, V123, P1081, DOI 10.1016/S0047-6374(01)00391-8; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 2003, IN PRESS BIOCH PHARM	44	100	102	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2325	+		10.1096/fj.03-0078fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	WOS:000186343300004	14525944				2021-06-18	
J	Zhang, L; Abreu, BC; Seale, GS; Masel, B; Christiansen, CH; Ottenbacher, KJ				Zhang, L; Abreu, BC; Seale, GS; Masel, B; Christiansen, CH; Ottenbacher, KJ			A virtual reality environment for evaluation of a daily living skill in brain injury rehabilitation: Reliability and validity	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	78th Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	OCT 25-26, 2001	TUCSON, AZ			brain injuries; outcomes assessment (health care); rehabilitation; virtual systems	HEAD-INJURY; COGNITIVE REHABILITATION; FUTURE; ADULTS	Objective: To establish the stability and validity of information collected in a virtual reality environment from persons with traumatic brain injury (TBI). Design: Prospective correlation design to, examine 3-week test-retest results for equivalence reliability between computer- simulated and natural environments. Setting: A residential rehabilitation center for brain injury, Participants: fifty-four consecutive patients with TBI who received comprehensive rehabilitation services and who were at different stages of recovery Intervention: An immersive virtual kitchen was developed in which a meal preparation task involving multiple steps was performed. The subjects completed meal preparation both in a virtual reality kitchen and an actual kitchen twice over a 3-week period. Main Outcome Measures: Time and errors on task completion using virtual reality assessment, actual kitchen performance (analogous to the virtual reality environment), occupational therapy (OT) evaluation, and neuropsychologic tests. Results: The stability of performance using the simulated virtual environment was estimated with-intraclass correlation coefficients (ICCs). The ICC value for total performance, based on all steps involved in the meal preparation task, was .76 (P<.01). The construct validity of the simulated environment was examined by correlatin. 9 performance in the virtual environment with that in the actual kitchen (r=.63, P<.01), the OT evaluation (r=.30, P=.05 for meal preparation; r=.40, P=.01 for cognitive subskills), and neuropsychologic tests (r=.56, P<.01 for the full-scale intelligence quotient [IQ]; r=.40, P<.01 for the verbal IQ; r=.56, P<.01 for the performance IQ). Finally, a multiple regression analysis revealed that the virtual reality environment test was a good predictor for the actual assessment kitchen (beta=35, P=.01). Conclusion; The virtual reality system showed adequate reliability and validity as a method of assessment in persons with brain injury. (C) 2603 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Texas, Med Branch, Div Rehabil Sci, Sch Allied Hlth Sci, Galveston, TX 77555 USA; Transit Learning Ctr, Galveston, TX USA	Ottenbacher, KJ (corresponding author), Univ Texas, Med Branch, Div Rehabil Sci, Sch Allied Hlth Sci, 301 Univ Blvd, Galveston, TX 77555 USA.	kottenba@utmb.edu	, Charles/V-6218-2019	Ottenbacher, Kenneth/0000-0001-5990-3982; Christiansen, Charles/0000-0003-0542-1042	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG017638] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [3R01AG17638] Funding Source: Medline		Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Andreae MH, 1996, BMJ-BRIT MED J, V312, P4, DOI 10.1136/bmj.312.7022.4; BOND MR, 1991, PSYCHIAT CLOSED HEAD, P148; *BRAIN INJ ASS INC, WHO WE AR VIS STAT; BRICKENKAMP R, 1981, CONCENTRATION ENDURA; Brown D., 1995, ABILITY, V15, P24; CHAMBERLIN M, 1995, TRAUMATIC BRAIN INJU; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Christiansen C, 1996, J MED VIRTUAL REALIT, V1, P6; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; INMAN DP, 1995, P VIRT REAL PERS DIS, P57; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jennett B, 1981, MANAGEMENT HEAD INJU; KENYON RV, 1995, ANN BIOMED ENG, V23, P445, DOI 10.1007/BF02584444; KOZAK JJ, 1993, ERGONOMICS, V36, P777, DOI 10.1080/00140139308967941; LOFTIN RB, 1995, IEEE COMPUT GRAPH, V15, P31, DOI 10.1109/38.403825; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; NEISTADT ME, 1994, AM J OCCUP THER, V48, P431, DOI 10.5014/ajot.48.5.431; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Passig D, 2001, CYBERPSYCHOL BEHAV, V4, P681, DOI 10.1089/109493101753376623; Portney LG., 1993, FDN CLIN RES APPL PR, V3rd; REGAN EC, 1994, AVIAT SPACE ENVIR MD, V65, P527; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Rose FD, 2000, ERGONOMICS, V43, P494, DOI 10.1080/001401300184378; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; SATAVA RM, 1992, MINIM INVASIV THER, V1, P357; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; WANN JP, 1993, BAILLIERE CLIN NEUR, V2, P15; Wechsler D., 1939, MEASUREMENT ADULT IN; Whyte J, 1993, REHABILITATION MED P, P825; Witmer BG, 1996, INT J HUM-COMPUT ST, V45, P413, DOI 10.1006/ijhc.1996.0060; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	35	100	107	1	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2003	84	8					1118	1124		10.1016/S0003-9993(03)00203-X			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	709LQ	WOS:000184627000004	12917848				2021-06-18	
J	Bryant, RA; Moulds, ML; Nixon, RVD				Bryant, RA; Moulds, ML; Nixon, RVD			Cognitive behaviour therapy of acute stress disorder: a four-year follow-up	BEHAVIOUR RESEARCH AND THERAPY			English	Article						acute stress disorder; PTSD; cognitive behaviour therapy	2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN INJURY; INTERVIEW; SCALE	The aim of this study was to index the long-term benefits of early provision of cognitive behavior therapy to trauma survivors with acute stress disorder. Civilian trauma survivors (n = 80) with acute stress disorder were randomly allocated to either cognitive behavior therapy (CBT) or supportive counseling (SC) - 69 completed treatment, and 41 were assessed four years post-treatment for post-traumatic stress disorder (PTSD) with the Clinician Administered PTSD Scale. Two CBT patients (8%) and four SC patients (25%) met PTSD criteria at four-year follow-up. Patients who received CBT reported less intense PTSD symptoms, and particularly less frequent and less avoidance symptoms, than patients who received SC. These findings suggest that early provision of CBT in the initial month after trauma has long-term benefits for people who are at risk of developing PTSD. (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Moulds, Michelle/B-2928-2010; Bryant, Richard/AAA-6479-2019; Nixon, Reginald/A-6095-2015	Bryant, Richard/0000-0002-9607-819X; Nixon, Reginald/0000-0003-1507-8428; Moulds, Michelle/0000-0001-7064-4248			BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLANCHARD EB, 1997, CRASH ASSESSMENT TRE; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Ehlers A, 1995, Behav Cogn Psychother, V23, P217, DOI 10.1017/S135246580001585X; Foa EB, 2000, J CLIN PSYCHIAT, V61, P43; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; SPEILBERGER CD, 1983, MANUAL STATE TRAIT A	16	100	103	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967			BEHAV RES THER	Behav. Res. Ther.	APR	2003	41	4					489	494		10.1016/S0005-7967(02)00179-1			6	Psychology, Clinical	Psychology	662LT	WOS:000181948800008	12643970				2021-06-18	
J	Sun, MC; Honey, CR; Berk, C; Wong, NLM; Tsui, JKC				Sun, MC; Honey, CR; Berk, C; Wong, NLM; Tsui, JKC			Regulation of aquaporin-4 in a traumatic brain injury model in rats	JOURNAL OF NEUROSURGERY			English	Article						aquaporin; brain edema; brain injury; trauma	INSENSITIVE WATER CHANNEL; MESSENGER-RNA EXPRESSION; FOCAL CEREBRAL-ISCHEMIA; GLIAL-CELLS; EDEMA; ASTROCYTES; PROTEIN; IMMUNOLOCALIZATION; LOCALIZATION; TISSUES	Object. Aquaporin-4 (AQP4) plays a significant role in the regulation of brain water homeostasis. In this study the authors investigated the regulation of AQP4 following a focal cortical contusion injury in rats. Methods. Thirty-three adult male Wistar rats received a focal cortical contusion of the parietal cortex. An additional nine rats underwent a craniectomy, but no trauma was inflicted (sham injury). Animals were killed 1, 4, and 24 hours later. The rat brains were examined for water content by comparing the wet and dry weights of each hemisphere. Aquaporin-4 messenger (m)RNA was measured by reverse transcription-polymerase chain reaction. A ratio of AQP4 mRNA expression in the lesioned hemisphere compared with that in the contralateral control hemisphere was calculated for each animal at the injury site (parietal cortex) and at sites adjacent to (occipital cortex) and distant from the injury (frontal pole cortex). Brain edema was significantly increased at the injury site. The expression of AQP4 mRNA was significantly increased at the injury site, significantly decreased adjacent to the injury site, and not significantly different at a site distant from the injury. The magnitude of AQP4 mRNA upregulation at the injured parietal cortex correlated with the degree of downregulation in the adjacent occipital cortex. Conclusions. Data from this study demonstrate that an upregulation of AQP4 occurs at the site of traumatic brain injury and that a downregulation of this molecule occurs adjacent to the site of injury. Understanding the physiology of AQP4 and its regulation following brain injury may allow for the development of novel treatments for cerebral edema that accompanies head injury.	Univ British Columbia, Div Neurosurg, Dept Med, Vancouver, BC V5Z 4E5, Canada; Univ British Columbia, Ctr Neurodegenerat Disorders, Vancouver, BC V5Z 4E5, Canada; Cardinal Tien Hosp, Taipei, Taiwan; Fu Jen Catholic Univ, Taipei, Taiwan	Honey, CR (corresponding author), Univ British Columbia, Div Neurosurg, Dept Med, Suite 325,700 W 10th Ave, Vancouver, BC V5Z 4E5, Canada.	chris.honey@telus.net					Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Baskaya MK, 1997, NEUROSURGERY, V40, P364; Baumgart E, 1997, HISTOCHEM CELL BIOL, V108, P185, DOI 10.1007/s004180050160; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUCKER TB, 1976, HDB CLIN NEUROLOGY, V25, P9; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Jackson PS, 1997, PEDIATR NEUROSURG, V27, P286, DOI 10.1159/000121272; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nakahama K, 1999, GLIA, V25, P240, DOI 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.3.CO;2-3; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Stewart-Wallace AM, 1939, BRAIN, V62, P426, DOI 10.1093/brain/62.4.426; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Venero JL, 1999, NEUROSCIENCE, V94, P239, DOI 10.1016/S0306-4522(99)00182-7; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246	30	100	126	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2003	98	3					565	569		10.3171/jns.2003.98.3.0565			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	653WW	WOS:000181460900017	12650429				2021-06-18	
J	Hawley, CA				Hawley, CA			Reported problems and their resolution following mild, moderate and severe traumatic brain injury amongst children and adolescents in the UK	BRAIN INJURY			English	Article							HEAD-INJURIES; CHILDHOOD; SEQUELAE; OUTCOMES; SCALE	Primary objectives : To examine the problems reported by families of children who have suffered traumatic brain injury (TBI), and how these differ from problems reported by control families. To identify those problems most likely to resolve over time, and to examine information and follow-up requirements. Design, methods and procedures : The families of 97 children with mild (49), moderate (19) and severe (29) TBI, aged 5-15 at injury, were interviewed and assessed at a mean of 2.29 years post-injury and compared with 31 healthy controls. A structured questionnaire was used to collect information on problems pre- and post-TBI. Initially, respondents reported problems spontaneously, and were subsequently prompted using a checklist of problem categories. Problems of behaviour and emotion were measured using the Vineland Adaptive Behaviour Scales (VABS) and the Hospital Anxiety and Depression Scale (HADS). Main outcomes and results : Following the TBI, 83 children (85.6%) received no therapeutic input, 74 families (76.3%) had unmet information needs, particularly regarding long-term consequences. At first interview, 1097 problems were reported by the TBI group. Behavioural and school problems were frequently reported by all TBI groups, significantly more than controls (pless than or equal to0.001). On the VABS, approximately two thirds of children with TBI exhibited significant maladaptive behaviours, significantly more than controls (p=0.002). Children in the mild and moderate/severe groups were significantly more anxious than controls on the HADS (p=0.04). At 12 month follow-up, there were no significant differences in problem resolution between the TBI groups: 498 (53.9%) problems remained unchanged and 75 (8.1%) had worsened. Physical problems were most likely to resolve. Conclusions : Parents should be given information and support following their child's TBI, children should be routinely followed-up by health professionals and their needs assessed. It was found that children with TBI may be at risk of anxiety, yet few parents reported this as a particular concern. Future research should examine the relationship between anxiety and TBI.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England	Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HAWLEY CA, IN PRESS BRAIN INJUR; *HOUS COMM SEL COM, 2001, 3 REP HEAD INJ REH; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Parmelee D X, 1989, Psychiatr Med, V7, P11; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; Sparrow S., 1984, VINELAND ADAPTIVE BE; STILWELL J, 1998, REPORT NATL TRAUMATI; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	100	102	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	2					105	129		10.1080/0269905021000010131			25	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LL	WOS:000180284700002	12519639				2021-06-18	
J	Faden, AI				Faden, AI			Neuroprotection and traumatic brain injury: theoretical option or realistic proposition	CURRENT OPINION IN NEUROLOGY			English	Article						traumatic brain injury; neuroprotection; apoptosis; necrosis; trial design	APOPTOTIC CELL-DEATH; IN-VITRO; NEURONAL APOPTOSIS; HEAD-INJURY; FEMALE RATS; ACTIVATION; EXPRESSION; SUSCEPTIBILITY; VULNERABILITY; CONTRIBUTES	Purpose of review Preclinical studies have shown that treatment to limit secondary cell damage can significantly improve outcome after traumatic brain injury. In contrast, neuroprotection trials in human traumatic brain injury have failed to convincingly demonstrate therapeutic benefit. Recent literature has begun to address this discrepancy between preclinical and clinical trials. Recent findings Perhaps the most important recent observations relate to the potential role of apoptosis in secondary brain injury. Because apoptosis peaks more than 24 h after injury, concepts about the therapeutic window for traumatic brain injury treatment have changed. Apoptosis and necrosis are in delicate balance and inhibition of one cell death pathway may enhance the other. This raises questions about the ultimate effectiveness of treatment strategies directed toward a single injury mechanism. In contrast to clinical head injury, which reflects a complex multifactorial disorder, animal models are generally designed to address only a single injury component and are performed in genetically inbred animals of a single sex. Moreover, animal studies usually employ pretreatment or early posttreatment administration, examine moderate rather than severe injury, fail to examine brain drug levels or treatment optimization, and do not use an intent-to-treat methodology. Summary Recognition of these methodological differences between animal and human studies has led to new trial design proposals. For clinical studies, there should be better stratification of patients, a focus on moderate injury and earlier treatment, and larger sample sizes. Animal experiments should better parallel clinical studies and address therapeutic window and treatment optimization. Recognition of multiple cell death pathways should lead to new treatment strategies - including both combination drug treatment and drugs that affect multiple components of the secondary injury cascade.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW,Room EP-12, Washington, DC 20057 USA.	fadena@georgetown.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119, R01NS036537] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 36537-04, R01 NS 41119-02] Funding Source: Medline		Allen JW, 1999, FASEB J, V13, P1875; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cerami A, 2002, NEPHROL DIAL TRANSPL, V17, P8, DOI 10.1093/ndt/17.suppl_1.8; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1996, NEUROTRAUMA, P1479; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Glazner GW, 2000, J NEUROSCI, V20, P3641; Golarai G, 2001, J NEUROSCI, V21, P8523; Grotta J, 2002, STROKE, V33, P306, DOI 10.1161/str.33.1.306; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; KNOBLACH S, 2000, SOC NEUROSCIENCE, V26, P2300; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lees KR, 2002, STROKE, V33, P308, DOI 10.1161/str.33.1.308; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Mukhin A, 1996, J NEUROSCI, V16, P6012; Peterson DA, 2002, CURR OPIN PHARMACOL, V2, P34, DOI 10.1016/S1471-4892(01)00118-7; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Povlishock JT., 1996, NEUROTRAUMA, P1325; Qiu JH, 2002, J NEUROSCI, V22, P3504; RINK A, 1995, AM J PATHOL, V147, P1575; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; TEASDALE G, 1990, ACT NEUR S, V51, P315; Temple MD, 2001, HEAD TRAUMA, P87; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	49	100	105	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2002	15	6					707	712		10.1097/00019052-200212000-00008			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	627VD	WOS:000179956100008	12447109				2021-06-18	
J	Radelet, MA; Lephart, SM; Rubinstein, EN; Myers, JB				Radelet, MA; Lephart, SM; Rubinstein, EN; Myers, JB			Survey of the injury rate for children in community sports	PEDIATRICS			English	Article						first aid training; injury risk; injury prevention; gender differences	PREVENTION	Objective. To determine the baseline injury rate for children ages 7 to 13 participating in community organized baseball, softball, soccer, and football. Methods. In this observational cohort study, 1659 children were observed during 2 seasons of sports participation in an urban area. Data were collected by coaches using an injury survey tool designed for the study. A reportable injury was defined as one requiring on-field evaluation by coaching staff, or causing a player to stop participation for any period of time, or requiring first aid during an event. Logistic regression analyses were done within and across sports for injury rates, game versus practice injury frequencies, and gender differences where appropriate. Results. The injury rates, calculated per 100 athlete exposures during total events (games plus practices), were: baseball, 1.7; softball, 1.0; soccer, 2.1; and football, 1.5. The injury rates for baseball and football were not significantly different. Across sports, contusions were the most frequent type of injury. Contact with equipment was the most frequent method of injury, except in football where contact with another player was the most frequent method. In baseball, 3% of all injuries reported were considered serious (fracture, dislocation, concussion); in soccer, 1% were considered serious; and in football, 14% were considered serious. The frequency of injury per team per season (FITS), an estimation of injury risk, was 3 for baseball and soccer, 2 for softball, and 14 for football for total events. For all sports, there were more game than practice injuries; this difference was significant except for softball. There were no significant gender differences in soccer for injury rates during total events. Conclusions. Given the classification of football as a collision sport, the high number of exposures per player, the FITS score, and the percentage of injuries considered serious, youth football should be a priority for injury studies. Health professionals should establish uniform medical coverage policies for football even at this age level. Recommendations for Modifications. Injury surveillance for youth sports is gaining momentum as an important step toward formulating injury prevention methods. However, establishing patterns of injuries, taking preventive measures, and evaluating equipment and coaching modifications may take years. In addition to the objective findings of this study, our direct observations of community sports through 2 seasons showed areas where immediate modifications could reduce injury risk. The first recommendation is that youth sports leagues provide and require first aid training for coaches. Training could be done by sports medicine professionals and include recognition and immediate response to head, neck, and spine injuries, as well as heat-related illnesses. The second recommendation is that youth sports leagues have clear, enforceable return to play guidelines for concussions, neck and back injuries, fractures, and dislocations. The third recommendation is that baseball and softball leagues consider the injury prevention potential of face guards on batting helmets.	Univ Pittsburgh, Neuromuscular Res Lab, Pittsburgh, PA 15203 USA; Univ Pittsburgh, Off Measurements & Evaluat Teaching, Pittsburgh, PA 15203 USA	Lephart, SM (corresponding author), Univ Pittsburgh, Neuromuscular Res Lab, 3200 S Water St, Pittsburgh, PA 15203 USA.	neurolab@pitt.edu					AARON DJ, 1977, EXERCISE SPORT SCI R, V25, P391; Andersen JC, 2002, J ATHL TRAINING, V37, P99; Anderson SJ, 2000, PEDIATRICS, V105, P659, DOI 10.1542/peds.105.3.640; ARNHEIM D, 1999, ESSENTIALS ATHLETIC; Beachy G, 1997, AM J SPORT MED, V25, P675, DOI 10.1177/036354659702500515; BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; Buckley Steven L., 1994, Current Opinion in Pediatrics, V6, P80, DOI 10.1097/00008480-199402000-00014; CANTU RC, 1995, CLIN SPORT MED, V14, P517; deLoes M, 1997, SPORTS MED, V24, P172, DOI 10.2165/00007256-199724030-00005; Finch CF, 1997, SPORTS MED, V24, P157, DOI 10.2165/00007256-199724030-00002; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; GOLDBERG B, 1984, PHYSICIAN SPORTSMED, V128, P122; GROLLMAN LF, 1995, J ATHLETIC TRAININ S, pS39; Hergenroeder AC, 1998, PEDIATRICS, V101, P1057, DOI 10.1542/peds.101.6.1057; *INT FED SPORTS ME, 1998, SID; Janda DH, 1997, SPORTS MED, V24, P169, DOI 10.2165/00007256-199724030-00004; Koester MC, 2000, J ATHL TRAINING, V35, P466; LEVY MI, 1988, AM J SPORT MED, V16, pS132; Lindenfeld T N, 1988, Am J Sports Med, V16 Suppl 1, pS69; MAFFULLI N, 1995, SPORTS MED, V19, P137, DOI 10.2165/00007256-199519020-00005; Marchi AG, 1999, ARCH DIS CHILD, V81, P324, DOI 10.1136/adc.81.4.324; Meeuwisse WH, 1997, SPORTS MED, V24, P184, DOI 10.2165/00007256-199724030-00008; MICHELI LJ, 1995, CLIN SPORT MED, V14, P727; Mills D, 1998, AM J NURS, V98, P58; Mueller FO, 2001, PHYSICIAN SPORTSMED, V29, P41, DOI 10.3810/psm.2001.07.874; OUTERBRIDGE AR, 1995, CLIN SPORT MED, V14, P503; Patel DR, 2000, MED CLIN N AM, V84, P983, DOI 10.1016/S0025-7125(05)70270-4; PERRIELLO VA, 2000, CONT PEDIAT, V2, P132; Powell J W, 1988, Am J Sports Med, V16 Suppl 1, pS134; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; ROEMMICH JN, 1995, CLIN SPORT MED, V14, P483; Stanitski CL, 1997, CLIN SPORT MED, V16, P613, DOI 10.1016/S0278-5919(05)70045-4; Twellaar M, 1996, AM J SPORT MED, V24, P528, DOI 10.1177/036354659602400419; vanMechelen W, 1997, SPORTS MED, V24, P176, DOI 10.2165/00007256-199724030-00006; vanMechelen W, 1997, SPORTS MED, V24, P164, DOI 10.2165/00007256-199724030-00003; Wallace R B, 1988, Am J Sports Med, V16 Suppl 1, pS22; Washington RL, 2001, PEDIATRICS, V107, P782; Weaver NL, 1999, MED SCI SPORT EXER, V31, P176, DOI 10.1097/00005768-199901000-00027; Wells Michael J., 1995, Journal of Athletic Training, V30, P249; Zito M, 1983, J Orthop Sports Phys Ther, V5, P20	40	100	100	0	21	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2002	110	3							e28	10.1542/peds.110.3.e28			11	Pediatrics	Pediatrics	589MN	WOS:000177762900001	12205278	Bronze, Green Published			2021-06-18	
J	Raghupathi, R; Margulies, SS				Raghupathi, R; Margulies, SS			Traumatic axonal injury after closed head injury in the neonatal pig	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; head injury; infants; subarachnoid hematoma; white matter	PERCUSSION BRAIN INJURY; FLUID-PERCUSSION; CORTICAL IMPACT; DEVELOPING RAT; IMMATURE RAT; DAMAGE; MODEL; NEUROPATHOLOGY; CHILDREN; AGE	Closed head injury is the leading cause of morbidity and mortality in infants and children, and results in pathologies such as diffuse axonal injury (DAI) and subarachnoid hematoma (SAH). To better understand the mechanical environment associated with closed head injury in the pediatric population, animal models that include salient features of human infant brain must be utilized. Based on detailed information regarding the parallels between brain development in the pig and the human, the 3-5-day-old piglet was used to represent the infant at less than 3 months of age. Anesthetized piglets (n = 7) were subjected to rapid, inertial (nonimpact) rotation of the head about its axial plane and sacrificed at 6 h postinjury. Immediately following injury, five of seven piglets were apneic, with an absence of pupillary and pain reflexes. All piglets exhibited severe coma immediately postinjury, but recovered by sacrifice time. Blood was present on the surface of the frontal lobes, cerebellum, and brainstem, and subarachnoid hemorrhage was evident in the frontal cortex. In six of seven brain-injured piglets, accumulation of the 68-kDa neurofilament protein was evident in contiguous axons (swollen) and occasionally in disconnected axons (axonal bulbs), suggestive of traumatic axonal injury (TAI). Mapping of the regional pattern of TAI revealed injured axons predominantly in central and peripheral white matter tracts in the frontal and temporal lobes and in the midbrain. The number of injured axons was equivalent in both hemispheres, and did not correlate to the load applied to the head. Together, these data demonstrate that rapid rotation of the piglet head without impact results in SAH and TAI, similar to that observed in children following severe brain trauma.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 105D Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS39679, NS41561] Funding Source: Medline; ODCDC CDC HHS [R49-CCR312712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, R01NS039679] Funding Source: NIH RePORTER		ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Conti AC, 1998, J NEUROSCI, V18, P5663; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Fisher M D, 1997, Crit Care Nurs Q, V20, P36; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOEHNER PJ, 1994, STROKE, V25, P2060, DOI 10.1161/01.STR.25.10.2060; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; LOWENHIELM P, 1975, J BIOMECH, V8, P351, DOI 10.1016/0021-9290(75)90069-X; LUERSSEN TG, 1991, CONC PED N, V11, P87; MADSEN FF, 1990, ACTA NEUROCHIR, V105, P150, DOI 10.1007/BF01670000; MADSEN FF, 1987, ACTA NEUROCHIR WIEN, V102, P65; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Ommaya AK, 1967, 11 STAPP CAR CRASH C, P73; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Villablanca JR, 2000, NEUROSCIENCE, V95, P625; YOSHIKAWA T, 1968, ATLAS BRAINS DOMESTI, V5, P1	42	100	102	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2002	19	7					843	853		10.1089/08977150260190438			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	577JL	WOS:000177057700004	12184854				2021-06-18	
J	Marsh, NV; Kersel, DA; Havill, JH; Sleigh, JW				Marsh, NV; Kersel, DA; Havill, JH; Sleigh, JW			Caregiver burden during the year following severe traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; SOCIAL-ADJUSTMENT; FAMILY; RELATIVES; STRESS; MEMBERS	Fifty-two primary caregivers of people with a severe traumatic brain injury (TBI) were assessed at 6-months and 1-year postinjury. Caregiver appraisal of the person with TBI's physical, cognitive, emotional, behavioural, and social functioning was assessed. Caregiver psychosocial functioning and levels of subjective and objective burden were also assessed. Some aspects of the difficulties reported for the people with TBI remained stable, while others increased in frequency, over time. At 6-months postinjury, approximately one third of caregivers reported clinically significant symptoms of anxiety and depression, and poor social adjustment. By 1-year postinjury, the prevalence of anxiety and depression remained the same, although only one-quarter continued to report poor social adjustment. There was some evidence of adaptation by caregivers, as the frequency with which various types of objective burden were reported remained stable, while the distress caused by these decreased in the first year postinjury. It appears that the impact on caregivers of physical impairment is comparatively short-lived and that caregivers learn some practical ways to manage the behavioural problems of the people with TBI. Despite this, over time the person with TBI's behavioural and cognitive problems begins to play a larger role in the level of distress experienced by the caregiver. However, it is the person with TBI's social isolation that has a stable and consistent role in the experience of subjective burden for primary caregivers in the first year postinjury.	Univ Waikato, Dept Psychol, Hamilton, New Zealand; Univ Glasgow, Dept Psychol Med, Glasgow, Lanark, Scotland; Waikato Hosp, Intens Care Unit, Hamilton, New Zealand	Marsh, NV (corresponding author), Univ Teesside, Sch Hlth & Social Care, Middlesbrough TS1 3BA, Cleveland, England.		Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			Acorn S., 1993, CANADIAN J REHABILIT, V7, P149; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; JENNETT B, 1975, LANCET, V1, P480; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KNIGHT RG, 1984, J CLIN PSYCHOL, V40, P751, DOI 10.1002/1097-4679(198405)40:3<751::AID-JCLP2270400320>3.0.CO;2-Y; Kosciulek JF, 1999, BRAIN INJURY, V13, P245, DOI 10.1080/026990599121610; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Livingston MG., 1990, REHABILITATION ADULT, P225; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MARSH NV, 1999, BRAIN DAM B, P175; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A., 1972, REHABILITATION, V38, P33; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; RAPE RN, 1992, REHABIL PSYCHOL, V37, P3, DOI 10.1037/h0079094; Smith L.M., 1995, FAMILY SUPPORT PROGR; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; STEVENSON C, 1999, BRAIN IMPAIRMENT REH, P133; Tabachnick BG, 2013, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Walker A E, 1972, Scand J Rehabil Med, V4, P5; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; WEISSMAN MM, 1978, J NERV MENT DIS, V166, P317, DOI 10.1097/00005053-197805000-00002; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111	35	100	103	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	4					434	447		10.1076/jcen.24.4.434.1030			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	568ZJ	WOS:000176574600003	12187457				2021-06-18	
J	Chatzipanteli, K; Yanagawa, Y; Marcillo, AE; Kraydieh, S; Yezierski, RP; Dietrich, WD				Chatzipanteli, K; Yanagawa, Y; Marcillo, AE; Kraydieh, S; Yezierski, RP; Dietrich, WD			Posttraumatic hypothermia reduces polymorphonuclear leukocyte accumulation following spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; inflammation; MPO; rat; spinal cord injury	TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; LIPID-PEROXIDATION; REPERFUSION INJURY; AMINO-ACIDS; ISCHEMIA; NEUTROPHIL; PROTECTION; DAMAGE; INFILTRATION	The present study addresses the effects of moderate posttraumatic hypothermia (32 degrees C) on the temporal and regional profile of polymorphonuclear leukocyte (PMNL) accumulation after traumatic spinal cord injury (SCI). We hypothesized that posttraumatic hypothermia would reduce the degree of inflammation by reducing PMNL infiltration. Rats underwent moderate spinal cord injury at T10 using the NYU impactor device. In the first study, the temporal profile of myeloperoxidase (MPO) activity (a marker of neutrophil accumulation) under normothermic (37 degrees C) conditions was determined. The animals were allowed to survive for 3 or 24 h, or 3 or 7 days after SCI. Spinal cords were dissected into five segments rostral and caudal to the injury site. Additional animals were studied for the immunocytochemical visualization of MPO. In the second study, rats were sacrificed at 24 h after a monitoring period of normothermia (36.5 degrees C/3 h) or hypothermia (32.4 degrees C/3 h) with their controls. In the time course studies, MPO enzymatic activity was significantly increased at 3 and 24 h within the traumatized T10 segment compared to controls. MPO activity was also increased at 3 h within the rostral T8 and T9 segments and caudal T11 and T12 segments compared to controls. At 24 h after trauma, MPO activity remained elevated within both the rostral and caudal segments compared to control. By 3 days, the levels of MPO activity were reduced compared to the 24-h values but remained significantly different from control. Neutrophils that exhibited MPO immunoreactivity were seen at 6 and 24 h, with a higher number at 3 days. PMNLs were located within the white and gray matter of the lesion and both rostral and caudal to the injury site. Post-traumatic hypothermia reduced MPO activity at 24 h in the injured spinal cord segment, compared to normothermic values. The results of this study indicate that a potential mechanism by which hypothermia improves outcome following SCI is by attenuating posttraumatic inflammation.	Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, 1600 NW 10th Ave R-48, Miami, FL 33136 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51; ALLEN BT, 1994, J VASC SURG, V19, P332, DOI 10.1016/S0741-5214(94)70108-3; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 1998, J NEUROSCI, V18, P3251; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLIGHT AR, 1992, J NEUROTRAUM, V9, P147, DOI 10.1089/neu.1992.9.147; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Dietrich WD, 1996, NEUROTRAUMA, P1491; DOBRINA A, 1994, EUR J NEUROSCI, V6, P712; Farooque M, 1999, NEUROREPORT, V10, P131, DOI 10.1097/00001756-199901180-00024; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GOSS JR, 1996, J NEUROTRAUM, V13, P809; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Green B A, 1973, Surg Forum, V24, P436; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HARLAN JM, 1987, SEMIN THROMB HEMOST, V13, P434, DOI 10.1055/s-2007-1003520; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699; HEROLD JA, 1994, J THORAC CARDIOV SUR, V107, P536, DOI 10.1016/S0022-5223(12)70100-9; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; Ishikawa T, 1999, CELL MOL NEUROBIOL, V19, P199, DOI 10.1023/A:1006973026514; IWASA K, 1989, FREE RADICAL BIO MED, V6, P599, DOI 10.1016/0891-5849(89)90067-1; Kakinohana M, 1999, ANESTHESIOLOGY, V90, P789, DOI 10.1097/00000542-199903000-00022; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marsala M, 1997, J NEUROSCI METH, V74, P97, DOI 10.1016/S0165-0270(97)02270-X; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; Matsumoto M, 1997, ANESTHESIOLOGY, V86, P1120, DOI 10.1097/00000542-199705000-00016; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; NAKAKIMURA K, 1997, ANESTHESIOLOGY, V86, P1120; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P467, DOI 10.1111/j.1600-0404.1988.tb03689.x; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; PUCHALA E, 1977, EXP NEUROL, V55, P1, DOI 10.1016/0014-4886(77)90155-8; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROSOMOFF HL, 1985, ARCH NEUROL-CHICAGO, V13, P337; SAGANOVA K, 1994, EXP NEUROL, V130, P337, DOI 10.1006/exnr.1994.1212; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SIEMIONOW M, 1993, J HAND SURG-AM, V18A, P963, DOI 10.1016/0363-5023(93)90384-F; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; Svensson LG, 1999, ANN THORAC SURG, V67, P1935, DOI 10.1016/S0003-4975(99)00395-1; TABAYASHI K, 1993, ANN THORAC SURG, V56, P494, DOI 10.1016/0003-4975(93)90885-L; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VANICKY I, 1993, J NEUROSURG, V79, P736, DOI 10.3171/jns.1993.79.5.0736; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WISSELINK W, 1994, J VASC SURG, V19, P788, DOI 10.1016/S0741-5214(94)70003-6; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; ZHANG XD, 1994, IEEE PARALL DISTRIB, V2, P3	70	100	101	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2000	17	4					321	332		10.1089/neu.2000.17.321			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302LA	WOS:000086365500005	10776915				2021-06-18	
J	Schwartz, MF; Buxbaum, LJ; Montgomery, MW; Fitzpatrick-DeSalme, E; Hart, T; Ferraro, M; Lee, SS; Coslett, HB				Schwartz, MF; Buxbaum, LJ; Montgomery, MW; Fitzpatrick-DeSalme, E; Hart, T; Ferraro, M; Lee, SS; Coslett, HB			Naturalistic action production following right hemisphere stroke	NEUROPSYCHOLOGIA			English	Article						right hemisphere stroke; naturalistic action; supervisory attention; neglect; resource capacity	SUSTAINED ATTENTION; CEREBRAL ACTIVATION; VISUAL NEGLECT; BRAIN-DAMAGE; LATERALITY; DOMINANCE; BEHAVIOR; SYSTEM	An unselected group of right hemisphere, semi-acute stroke patients (n = 30) was run on a laboratory test of naturalistic action production and was found to commit errors of action at a higher rate than what was previously reported for recovering head injury patients [Schwartz et al., Naturalistic action impairment in closed head injury. Neuropsychology, 1997, 8, 59-72]. There were strong similarities in how these two patient groups responded to variations in task demands and in the pattern of errors they produced. Hemispatial biases were evident in the errors of right hemisphere patients with neglect but not those without neglect; and neglect patients also many errors that were unrelated to the spatial layout. We argue that a non-specific resource limitation - which might translate as reduced arousal or effort - is central to the breakdown of naturalistic action production after brain damage, and right hemisphere patients are especially vulnerable to this resource limitation and its behavioral consequences. (C) 1998 Elsevier Science Ltd. All rights reserved.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Philadelphia, PA 19122 USA; American Univ, Washington, DC 20016 USA	Schwartz, MF (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	mschwar@vm.temple.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS31824] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031824] Funding Source: NIH RePORTER		ALLPORT A, 1993, ATTENTION PERFORMANC, V14; Baars BJ., 1992, EXPT SLIPS HUMAN ERR; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; Buxbaum LJ, 1995, NEUROCASE, V1, P3, DOI 10.1080/13554799508402342; BUXBAUM LJ, IN PRESS COGNITIVE N; Cooper R, 1997, PROCEEDINGS OF THE NINETEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P131; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; GAINOTTI G, 1990, J NEUROL NEUROSUR PS, V53, P422, DOI 10.1136/jnnp.53.5.422; GLISKY EL, 1986, J CLIN EXPT NEUROPSY, V8, P293; HALLIGAN PW, 1992, J NEUROL NEUROSUR PS, V55, P1060, DOI 10.1136/jnnp.55.11.1060; HEILMAN KM, 1979, NEUROPSYCHOLOGIA, V17, P315, DOI 10.1016/0028-3932(79)90077-0; HEILMAN KM, 1972, NEUROLOGY, V22, P660, DOI 10.1212/WNL.22.6.660; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; HEILMAN KM, 1977, ADV NEUROL, V15, P93; Kahneman D., 1973, ATTENTION EFFORT; Kleinbaum D.G., 1978, APPL REGRESSION ANAL; NAVON D, 1984, PSYCHOL REV, V91, P216, DOI 10.1037/0033-295X.91.2.216; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Pocock SJ, 1983, CLIN TRIALS PRACTICA; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; REASON JT, 1982, ABSENT MINDED PSYCHO; ROBERTSON I, 1992, INT J NEUROSCI, V62, P45; ROBERTSON I, 1989, NEUROPSYCHOLOGIA, V27, P157, DOI 10.1016/0028-3932(89)90168-1; Robertson I. H., 1994, TEST EVERYDAY ATTENT; ROBERTSON IH, 1994, CORTEX, V30, P199, DOI 10.1016/S0010-9452(13)80193-1; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Robertson MM, 1997, CRIT REV NEUROBIOL, V11, P1; Schwartz M. F., 1997, APRAXIA NEUROPSYCHOL, P269; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz MF, 1995, ANN NY ACAD SCI, V769, P321, DOI 10.1111/j.1749-6632.1995.tb38148.x; SCHWARTZ MF, 1993, J HEAD TRAUMA REHAB, V8, P59, DOI DOI 10.1097/00001199-199303000-00007; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; Shallice T., 1988, NEUROPSYCHOLOGY MENT; *STAT U NEW YORK B, 1993, GUID US UN DAT SET M; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; WEINTRAUB S, 1987, ARCH NEUROL-CHICAGO, V44, P621, DOI 10.1001/archneur.1987.00520180043014; Wickens C.D., 1984, VARIETIES ATTENTION, P63, DOI 10.1038/s41598-020-80452-5; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; Wilson B.A., 1996, BADS BEHAV ASSESSMEN; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	49	100	100	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JAN	1999	37	1					51	66					16	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	148TL	WOS:000077548900007	9920471				2021-06-18	
J	Ewing-Cobbs, L; Fletcher, JM; Levin, HS; Iovino, I; Miner, ME				Ewing-Cobbs, L; Fletcher, JM; Levin, HS; Iovino, I; Miner, ME			Academic achievement and academic placement following traumatic brain injury in children and adolescents: A two-year longitudinal study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; READING-DISABILITY; PERFORMANCE; SEVERITY; SEQUELAE; RECOVERY; COHORT; PREVALENCE; COGNITION; MEMORY	Prospective, longitudinal follow-up of academic status following pediatric traumatic brain injury (TBI) identified that patients with severe TBI (n = 33) obtained significantly lower reading recognition, spelling, and arithmetic scores than those with mild to moderate TBI (n = 28). Independent of injury severity, adolescents scored lower than children on computational arithmetic and reading comprehension subtests. Although all achievement scores increased significantly from the baseline evaluation to 6 months after the injury, no further change was noted from 6 months to 2 years. Despite average achievement test scores by 2 years after TBI, 79% of the severely injured patients had either failed a grade or received special educational assistance. Traditional achievement tests may be insensitive to posttraumatic academic deficits.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Dept Clin Serv Neurobehav Resources, Houston, TX USA; Ohio State Univ, Sch Med, Dept Neurol Surg, Columbus, OH 43210 USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,2400 Univ Ctr Tower, Houston, TX 77030 USA.	lewing@pedl.med.uth.tmc.edu	Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [29462, 27597, 21889] Funding Source: Medline		BARNES MA, IN PRESS DEV NEUROPS; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; BIJUR PE, 1990, PEDIATRICS, V86, P337; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Dunn L. M., 1970, PEABODY INDIVIDUAL A; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; EWINGCOBBS L, 1996, J INT NEUROPSYCH SOC, V2, P39; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V57, P1; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HARNADEK MCS, 1994, J LEARN DISABIL, V27, P144, DOI 10.1177/002221949402700303; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; HOLLINGSHEAD AB, 1958, 2 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jastak J., 1978, WIDE RANGE ACHIEVEME; Jastak S, 1984, WIDE RANGE ACHIEVEME; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1985, 2 EUR S DEV NEUR; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; Shurtleff H. A., 1988, J PSYCHOEDUCATIONAL, V6, P298, DOI 10.1177/073428298800600313; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	48	100	100	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1998	20	6					769	781		10.1076/jcen.20.6.769.1109			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	204RQ	WOS:000080778300001	10484689				2021-06-18	
J	Paniak, C; Toller-Lobe, G; Durand, A; Nagy, J				Paniak, C; Toller-Lobe, G; Durand, A; Nagy, J			A randomized trial of two treatments for mild traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; POSTCONCUSSIVE SYMPTOMS; CONCUSSION	The purpose of this study was to compare an education-oriented single session treatment (SS) for mild traumatic brain injury (MTBI) to a more extensive assessment, education, and treatment-as-needed intervention (TAN). Participants were 111 adults with MTBI who were recruited from consecutive admissions to two hospital emergency wards. They were randomly assigned to either the SS or TAN modality. The groups did not differ on any demographic, injury-related, or questionnaire variable when first seen within 3 weeks of injury. The groups generally improved a similar amount and did not differ from each other on any symptom-related, functional, or vocational variables 3-4 months alter their baseline session. Patient satisfaction ratings with services provided were also similar for the two groups. Brief educational intervention given soon after MTBI appears to be adequate for most MTBI survivors.	Glenrose Rehabil Hosp, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada	Paniak, C (corresponding author), Glenrose Rehabil Hosp, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; Bennett T L, 1997, Appl Neuropsychol, V4, P55, DOI 10.1207/s15324826an0401_7; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; BOLLA KI, 1991, ARCH NEUROL-CHICAGO, V48, P61, DOI 10.1001/archneur.1991.00530130069022; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KAY T, 1986, UNSEEN INJURY MINOR; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Kraus Jess F., 1994, P3; KRAUS JF, 1989, MILD HEAD INJURY, P8; MATEER CA, 1992, REHABILITATION POSTC, P143; MAX W, 1991, J HEAD TRAUMA REHAB, V6, P79; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; NOVACEK MJ, 1988, PHYLOGENY CLASSIFICA, V2, P31; PANIAK C, 1992, DISS ABSTR INT, V52, P6093; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; TRAHAN DE, 1998, J INT NEUROPSYCH SOC, V4, P8; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; WARE JE, 1988, MED CARE, V26, P393, DOI 10.1097/00005650-198804000-00008; WARE JE, 1992, SF 36 HLTH SURVEY MA; Willer B., 1993, BRAIN INJURY REHABIL, P355	41	100	101	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1998	12	12					1011	1023		10.1080/026990598121927			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	150BW	WOS:000077643400002	9876861				2021-06-18	
J	Spain, DA; Richardson, JD; Polk, HC; Bergamini, TM; Wilson, MA; Miller, FB				Spain, DA; Richardson, JD; Polk, HC; Bergamini, TM; Wilson, MA; Miller, FB			Venous thromboembolism in the high-risk trauma patient: Do risks justify aggressive screening and prophylaxis?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	56th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 19-21, 1996	HOUSTON, TX	Amer Assoc Surg Trauma			CAVA FILTER INSERTION; PULMONARY-EMBOLISM; SUBCUTANEOUS HEPARIN; MULTIPLE TRAUMA; THROMBOSIS; EFFICACY; PREVENTION; INJURY	Objective: Deep venous thrombosis (DVT) and pulmonary embolism (PE) are considered to be a major source of morbidity and mortality among trauma patients, Several reports have identified high-risk patients with recommendations for management ranging from frequent duplex scanning to placement of prophylactic inferior vena cava (IVC) filters, We reviewed our experience with a large trauma population to determine whether such approaches are justified. Methods: We analyzed 2,868 consecutive trauma admissions over 22 months and identified 280 patients (10%) in high-risk groups who survived greater than or equal to 48 hours: (1) severe closed head injury with mechanical ventilation greater than or equal to 72 hours, (2) closed head injury with lower extremity fractures, (3) spinal column/cord injury, (4) combined pelvic and lower extremity fractures, and (5) major infrarenal venous injuries, The remaining nonthermal injury patients constituted the low-risk group. Results: There were 280 high-risk patients, 213 of whom (76%) received prophylaxis with compression therapy, There were 12 cases of DVT (5%) with four nonfatal PE (1.4%), Six patients (2%) had therapeutic IVC filters inserted and only one patient had prophylactic placement. There were 38 deaths in this group, attributable primarily to severe closed head injury or spine injuries, and none were caused by PE, In the 2,249 low-risk patients, there were three cases of DVT (0.1%,p < 0.05 vs, high risk) and no PE (p < 0.05 vs, high risk). Conclusions: Although these patients were at increased risk for thromboembolic events, the overall incidence of DVT was still extremely low with no apparent PE deaths, In our patient population, aggressive screening and prophylactic IVC filters would not have benefited 95% of ''high-risk'' patients without DVT and would not have prevented any deaths, We could not identify any population, except perhaps venous injuries, where such expensive and potentially harmful maneuvers seemed justified. Our experience with DVT and PE does not support either aggressive screening or prophylactic IVC filters as the standards of care.	VET ADM MED CTR, LOUISVILLE, KY USA	Spain, DA (corresponding author), UNIV LOUISVILLE, DEPT SURG, LOUISVILLE, KY 40292 USA.						ALEXANDER JJ, 1994, AM J SURG, V168, P102, DOI 10.1016/S0002-9610(94)80045-6; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Britt LD, 1996, AM J SURG, V172, P13, DOI 10.1016/S0002-9610(96)00079-7; BURNS GA, 1993, J TRAUMA, V35, P405, DOI 10.1097/00005373-199309000-00012; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; FAUNO P, 1994, J BONE JOINT SURG AM, V76A, P1814, DOI 10.2106/00004623-199412000-00007; FERRIS EJ, 1993, RADIOLOGY, V188, P851, DOI 10.1148/radiology.188.3.8351361; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; HARRIS EJ, 1995, J VASC SURG, V22, P606, DOI 10.1016/S0741-5214(95)70047-1; HEPARIN RD, 1994, J BONE JOINT SURG AM, V76, P1174; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; KUDSK KA, 1989, AM J SURG, V158, P515, DOI 10.1016/0002-9610(89)90182-7; LEACH TA, 1994, AM SURGEON, V60, P292; NAPOLITANO LM, 1995, J TRAUMA, V39, P651, DOI 10.1097/00005373-199510000-00006; Owings John T., 1995, Journal of Trauma, V39, P159; Patton JH, 1996, J TRAUMA, V41, P231, DOI 10.1097/00005373-199608000-00006; Piotrowski JJ, 1996, AM J SURG, V172, P210, DOI 10.1016/S0002-9610(96)00154-7; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; Rosenthal D, 1994, Cardiovasc Surg, V2, P52; SCHMIDT U, 1992, J TRAUMA, V33, P312, DOI 10.1097/00005373-199208000-00023; UPCHURCH GR, 1995, AM SURGEON, V61, P749; WILSON JT, 1994, NEUROSURGERY, V35, P234, DOI 10.1227/00006123-199408000-00008; WINCHELL RJ, 1994, J TRAUMA, V37, P600, DOI 10.1097/00005373-199410000-00013	28	100	102	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1997	42	3					463	467		10.1097/00005373-199703000-00014			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	WR152	WOS:A1997WR15200025	9095114				2021-06-18	
J	Waterloo, K; Ingebrigtsen, T; Romner, B				Waterloo, K; Ingebrigtsen, T; Romner, B			Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury	ACTA NEUROCHIRURGICA			English	Article						head injury; protein S-100; cognitive dysfunction	FIBRILLARY ACIDIC PROTEIN; HUMAN CEREBROSPINAL-FLUID; NEURON-SPECIFIC ENOLASE; CENTRAL NERVOUS-SYSTEM; RECOVERY; IMPAIRMENT; CONCUSSION; DEFICITS; ANTIGEN; DAMAGE	Protein S-100 is a calcium binding protein, synthetized in astroglial cells in all parts of the central nervous system (CNS). We have previously reported high serum levels of protein S-100 in patients after minor head injury (MHI). A battery of conventional and computerized neuropsychological measures was administered to two groups of MHI patients. Neuropsychological outcome at 12 months postinjury was examined in a group of 7 patients with increased serum levels of protein S-100 after MHI and 7 age- and sex-matched controls without detectable S-100 in serum after MHI. Our results demonstrate no overall cognitive dysfunction in either of the two groups. Our findings indicate specific dysfunction on measures of reaction time, attention and speed of information processing for the S-100 group. Posttraumatic depression does not explain the neuropsychological differences between the groups. These findings support that increased serum levels of protein S-100 may be of predictive and prognostic value for longlasting neurocognitive abnormalities after minor head injury. Presence of S-100 in serum may indicate the presence of diffuse brain damage. Our results suggest that information processing measures in computerized neuropsychological assessment are more sensitive for detecting small signs of neurocognitive abnormalities after MHI than conventional test batteries.	UNIV TROMSO HOSP, DEPT NEUROSURG, N-9038 TROMSO, NORWAY; UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN	Waterloo, K (corresponding author), UNIV TROMSO HOSP, DEPT NEUROL, N-9038 TROMSO, NORWAY.			Ingebrigtsen, Tor/0000-0001-5966-9786			AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; AURELL A, 1989, J NEUROL SCI, V89, P157, DOI 10.1016/0022-510X(89)90017-8; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Edna T H, 1987, J Oslo City Hosp, V37, P41; FAGNART OC, 1988, CLIN CHEM, V34, P1387; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; GRONWALL D, 1974, LANCET, V2, P2605; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; KATO K, 1982, BIOMED RES-TOKYO, V3, P24; KELLY R, 1981, J ROY SOC MED, V74, P242; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Levin HS, 1989, MILD HEAD INJURY; LEVIN HS, 1992, J TRAUMA, V33, P385; LEZAK MD, 1995, NEUROPSYCHIOLOGICAL; LEZAK MD, 1989, CLIN NEUROSCIENCE, V7; MICHETTI F, 1980, J NEUROL SCI, V44, P259, DOI 10.1016/0022-510X(80)90133-1; MICHETTI F, 1979, NEUROSCI LETT, V11, P171, DOI 10.1016/0304-3940(79)90122-8; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER EN, 1991, NEUROLOGY, V41, P1608, DOI 10.1212/WNL.41.10.1608; MILLER EN, 1993, CALIFORNIA COMPUTERI; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SINDIC CJM, 1982, J NEUROL NEUROSUR PS, V45, P1130, DOI 10.1136/jnnp.45.12.1130; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANGORP WG, 1994, NEUROLOGY, V44, P929, DOI 10.1212/WNL.44.5.929; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WECHSLER D, 1987, MANUAL MEMORY SCALE; Wetzel JW, 1984, CLIN HDB DEPRESSION; Wolfson D., 1993, HALSTEAD REITAN NEUR	46	100	103	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1997	139	1					26	31		10.1007/BF01850864			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WF448	WOS:A1997WF44800010	9059708				2021-06-18	
J	Crawford, S; Wenden, FJ; Wade, DT				Crawford, S; Wenden, FJ; Wade, DT			The Rivermead head injury follow up questionnaire: A study of a new rating scale and other measures to evaluate outcome after head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury follow up; head injury assessment questionnaire; outcome	SEQUELAE; SYMPTOMS	Objective-To develop and evaluate a short (10 item) simple measure of outcome mainly for use with patients with mild to moderate head injuries. Design-Two studies on patients at three and six months after injury, comparing different methods of administration (two raters and postal questionnaire), and comparing ratings with other assessments. Subjects-Forty three patients seen three months after injury and 46 seen six months after injury: both groups had head injuries covering a range of severity from minor to severe. Main outcome measures-Differences between ratings in different groups of patients (Mann-Whitney U test); differences in ratings using different methods of administration (Wilcoxon signed rank test); and correlations between ratings from the same patient (Spearman r). Results-The sum total ratings were consistent between raters and between methods (postal questionnaire v face to face interview) with no evidence of selective bias between raters or methods. Ratings on individual items were also reasonably consistent. The sum total ratings varied as anticipated between groups divided by clinical judgement of recovery and patient assessment of recovery, and related as expected to the extent of post;concussion symptomatology. The 10 items included covered the most important problem areas reported by patients. Conclusion-The Rivermead head injury follow up questionnaire (RHFUQ) is a short, simple, adequately reliable, and valid measure of outcome, across the entire range of severity, but particularly after mild to moderate head injury.		Crawford, S (corresponding author), RIVERMEAD REHABIL CTR,OXFORD HEAD INJURY SERV,ABINGDON RD,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442			BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Collin C, 1988, Int Disabil Stud, V10, P61; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fleiss JL, 1981, STATISTICAL METHODS; HAWTHORNE VM, 1975, SCOT MED J, V1, P23; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MOSS NEG, 1994, CLIN REHABIL, V8, P149; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff RM, 1986, J HEAD TRAUMA REHAB, V1, P43; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; *WORK PART REP MED, 1988, MAN TRAUM BRAIN INJ; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	20	100	100	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1996	60	5					510	514		10.1136/jnnp.60.5.510			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	UJ915	WOS:A1996UJ91500007	8778254	Bronze, Green Published			2021-06-18	
J	Nilsson, P; Laursen, H; Hillered, L; Hansen, AJ				Nilsson, P; Laursen, H; Hillered, L; Hansen, AJ			Calcium movements in traumatic brain injury: The role of glutamate receptor-operated ion channels	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calcium ion-selective microelectrode; 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[F]quinoxaline; glutamate; MK-801; rat; traumatic brain injury	SPREADING DEPRESSION; RAT-BRAIN; AMINO-ACIDS; ISCHEMIA; ACCUMULATION; POTASSIUM; CONTUSION; BREAKDOWN; BARRIER	Ion-selective microelectrodes were used to study acute effects of N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) receptor blockade on posttraumatic calcium disturbances. An autoradiographic technique with Ca-45(2+) was used to study calcium disturbances at 8, 24, and 72 h. Compression contusion trauma of the cerebral cortex was produced by a 21-g weight dropped from a height of 35 cm onto a piston that compressed the brain 2 mm. Pre- and posttrauma interstitial [Ca2+] ([Ca2+](e)) concentrations were measured in the perimeter, i.e., the shear stress zone (SSZ) and in the central region (CR) of the trauma site. For the [Ca2+](e) studies the animals were divided into controls and groups pretreated with dizocilipine maleate (MK-801) or with 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[F]quinoxaline (NBQX). In all groups, [Ca2+](e) decreased from pretrauma values of approximately 1 mM to posttraumatic values of 0.1 mM in both the CR and the SSZ. This was followed by a slow restitution toward pretraumatic levels during the 2-h observation period. There was no significant difference in recovery pattern between controls and pretreated animals. Accumulation of Ca-45(2+) and serum proteins was seen in the entire SSZ, while neuronal necrosis was confined to a narrow band within the SSZ. The CR was unaffected apart from occasional eosinophilic neurons and showed no accumulation of Ca-45(2+). Posttraumatic treatment with MK-801 or NBQX had no obvious effect on neuronal injury in the SSZ. We conclude that (a) acute [Ca2+](e) disturbances in compression contusion brain trauma are not affected by blockade of NMDA or AMPA receptors, (b) C-45(2+) accumulation in the SSZ reflects mainly protein accumulation due to blood-brain barrier breakdown rather than cell death, and (c) acute cellular Ca2+ overload per se does not seem to be a major determinant of cell death after cerebral trauma in our model.	UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN; UNIV COPENHAGEN,INST NEUROPATHOL,COPENHAGEN,DENMARK; NOVO NORDISK AS,DIV PHARMACEUT,MALOV,DENMARK							CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; HANSEN AJ, 1988, NEUROCHEM PATHOL, V9, P195; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NELLGARD B, 1992, ACTA PHYSIOL SCAND, V146, P497, DOI 10.1111/j.1748-1716.1992.tb09451.x; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1992, J NERUOTRAUMA, V9, pS1	25	100	100	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1996	16	2					262	270		10.1097/00004647-199603000-00011			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	TW393	WOS:A1996TW39300011	8594058	Bronze			2021-06-18	
J	Anderson, CV; Bigler, ED; Blatter, DD				Anderson, CV; Bigler, ED; Blatter, DD			Frontal lobe lesions, diffuse damage, and neuropsychological functioning in traumatic brain-injured patients	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CARD SORTING TEST; AXONAL INJURY; ATROPHY	This study quantified lesion volume in relation to damage location and executive functioning in traumatic brain-injured (TBI) patients. Magnetic resonance (MR) scans of 68 TBI patients were analyzed by taking volumetric measures of lesion sites. Patients were grouped according the presence/absence of frontal lobe lesions. Measures of frontal lesion volume were studied as predictors for outcome on designated tests of executive functioning (Halstead Category Test and Wisconsin Card Sorting Test). Results showed no significant differences in level of deficit between groups. In addition, no significant differences were found between groups on other tests of neuropsychological functioning (Trail Making Test, Parts A and B, and Wechsler Adult Intelligence Scale-Revised). These results suggest that tests that are traditionally used to detect ''frontal lobe'' damage may not be adequate for distinguishing specific frontal lobe dysfunction, and do not add anything unique about frontal lobe integrity and neuropsychological functioning in TBI patients.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,PROVO,UT 84602; LATTER DAY ST HOSP,SALT LAKE CITY,UT 84143							ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; ARNETT PA, 1994, NEUROLOGY, V44, P420, DOI 10.1212/WNL.44.3_Part_1.420; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P279, DOI 10.1016/0887-6177(88)90020-0; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; BIGLER ED, 1994, FUNCTIONAL NEUROIMAG, P121; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; CULLUM CM, 1990, TRAUMATIC BRAIN INJU, P129; Damasio H., 1989, LESION ANAL NEUROPSY; DeFilippis NA, 1979, BOOKLET CATEGORY TES; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GOLDBERG E, 1994, J NEUROPSYCH CLIN N, V6, P371; GOLDBERG E, 1995, J CLIN EXT NEUROPSYC, V17, P192; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRATTAN LM, 1994, NEUROPSY NEUROPSY BE, V7, P251; Gronwall D., 1990, HEAD INJURY FACTS; Gurdjian ES, 1975, IMPACT HEAD INJURY; Halstead WC, 1947, BRAIN INTELLIGENCE; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton R. K, 1981, WISCONSIN CARD SORTI; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; Hellman S. G., 1992, INT J METH PSYCH RES, V2, P151; HOM J, 1990, J CLIN EXP NEUROPSYC, V12, P644, DOI 10.1080/01688639008401008; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Loong J., 1990, WISCONSIN CARD SORTI; LOONG J, 1990, COMPUTERIZED CATEGOR; MALLOY PF, 1994, J NEUROPSYCH CLIN N, V6, P399; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RASBAND W, 1993, IMAGE 1 52 COMPUTER; Reitan R., 1985, NEUROANATOMY NEUROPA; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; Reitan RM., 1985, HALSTEAD REITAN NEUR; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; ROSENTHAL M, 1993, TRAUMATIC BRAIN INJU; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; *SOC NEUR, 1990, BRAIN FACTS PRIM BRA; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; SULLIVAN EV, 1993, PSYCHIAT RES, V46, P175, DOI 10.1016/0165-1781(93)90019-D; VANDENBROEK MD, 1993, BRIT J CLIN PSYCHOL, V32, P333; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; Wetzel L., 1987, SHORT CATEGORY TEST; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29	58	100	102	0	15	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1995	17	6					900	908		10.1080/01688639508402438			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	TM776	WOS:A1995TM77600009	8847395				2021-06-18	
J	RUDGE, JS; PASNIKOWSKI, EM; HOLST, P; LINDSAY, RM				RUDGE, JS; PASNIKOWSKI, EM; HOLST, P; LINDSAY, RM			CHANGES IN NEUROTROPHIC FACTOR EXPRESSION AND RECEPTOR ACTIVATION FOLLOWING EXPOSURE OF HIPPOCAMPAL NEURON ASTROCYTE COCULTURES TO KAINIC ACID	JOURNAL OF NEUROSCIENCE			English	Article						BRAIN-DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; SIGNAL TRANSDUCTION; EPILEPSY; ISCHEMIA; EXCITOTOXICITY; RECEPTOR REGULATION	NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; ADULT-RAT BRAIN; VASOACTIVE-INTESTINAL-PEPTIDE; MOUSE ASTROGLIAL CELLS; REGIONAL DISTRIBUTION; PRIMARY CULTURES; NGF; SECRETION; SURVIVAL	Neurotrophic factor expression in the adult mammalian CNS is largely neuronal. However, upon traumatic injury reactive astrocytes express a number of neurotrophic factors including ciliary neurotrophic factor (CNTF), fibroblast growth factor (FGF), and NGF. In this study, we examined whether the upregulation of neurotrophic factors in reactive astrocytes and cultured astrocytes is a consequence of separation from their neuronal counterparts, and whether neurotrophic factor levels can be regulated by placing astrocytes into coculture with neurons. We show that reintroduction of rat hippocampal neurons to rat hippocampal astrocytes in vitro leads to a time dependent downregulation in astrocytes of the neurotrophic factors CNTF, NGF, and neurotrophin 3 (NT-3). In contrast, brain-derived neurotrophic factor (BDNF) mRNA, which is only expressed in neurons in these cultures is slightly increased. Once neurotrophic factor levels in cocultures had reached a steady state in the neuron/glia cocultures, we initiated a traumatic event with the excitotoxin kainic acid. BDNF protein was rapidly upregulated within 24 hr after lesion, whereas CNTF protein upregulation was delayed reaching maximal levels by 3 d. Despite the endogenous upregulation of both of these trophic factors, no activation of their respective receptors, as measured by tyrosine phosphorylation, was detectable following kainate administration. However, following addition of exogenous CNTF at any time point up to 24 hr after kainate administration, the beta components of the CNTF receptor (LIFR beta and gp130) could be phosphorylated. Furthermore, although activation of neuronal LIFR beta and gp130 by exogenous CNTF declined during the period of neuronal death, these receptors reappeared on astrocytes and could be activated by CNTF. in contrast, phosphorylation of TrkB by exogenous BDNF was undetectable by 24 hr and could not be reactivated after this point. These data suggest that the intimate association of astrocytes and neurons in the CNS serves to suppress astrocyte-derived neurotrophic factor expression and that neuronal loss leads to a derepression of neurotrophic factor synthesis in astrocytes. However, the upregulation of endogenous BDNF and CNTF observed after excitotoxic lesion in this culture model are insufficient to activate signal transduction and protect against neuronal loss.		RUDGE, JS (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.						ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; ALTAR CA, 1992, J NEUROCHEM, V59, P2167; ASADA H, 1995, J NEUROSCI RES, V40, P22, DOI 10.1002/jnr.490400104; AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CARROLL P, 1993, GLIA, V9, P176, DOI 10.1002/glia.440090303; CONDORELLI DF, 1994, J NEUROCHEM, V63, P509; FERRARA N, 1988, BRAIN RES, V462, P223, DOI 10.1016/0006-8993(88)90550-1; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; FURUKAWA S, 1987, BIOCHEM BIOPH RES CO, V147, P1048, DOI 10.1016/S0006-291X(87)80176-6; GASSER UE, 1990, J NEUROSCI, V10, P1276; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061, DOI 10.1073/pnas.92.6.2061; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, 1993, J NEUROSCI, V13, P3394; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KNUSEL B, 1994, J NEUROSCI, V14, P1542; LASEK RJ, 1977, J CELL BIOL, V74, P501, DOI 10.1083/jcb.74.2.501; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LU B, 1991, J NEUROSCI, V11, P318; MANTHORPE M, 1986, ASTROCYTES, P315; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; NIETOSAMPEDRO M, 1983, J NEUROSCI, V3, P2219; NORRIS JG, 1993, J NEUROIMMUNOL, V45, P137; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; Rudge J. S., 1993, ASTROCYTES PHARM FUN, P267; RUDGE JS, 1994, EUR J NEUROSCI, V6, P218, DOI 10.1111/j.1460-9568.1994.tb00264.x; RUDGE JS, 1992, EUR J NEUROSCI, V4, P459, DOI 10.1111/j.1460-9568.1992.tb00896.x; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; RUDGE JS, 1995, IBRO ABSTR, P147; SCHOOLTINK H, 1992, FEBS LETT, V314, P280, DOI 10.1016/0014-5793(92)81489-9; SHAO YP, 1994, GLIA, V11, P147, DOI 10.1002/glia.440110209; SOFRONIEW MV, 1990, SCIENCE, V247, P338, DOI 10.1126/science.1688664; SORG O, 1991, BRAIN RES, V563, P227, DOI 10.1016/0006-8993(91)91538-C; SORG O, 1992, J NEUROSCI, V12, P4923; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VARON SS, 1979, NEUROSCI RES PROG B, V17, P6; VIGE X, 1992, BRAIN RES, V591, P345, DOI 10.1016/0006-8993(92)91718-T; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; YAMAKUNI T, 1987, FEBS LETT, V223, P117, DOI 10.1016/0014-5793(87)80520-3; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1992, J NEUROSCI, V12, P4793	65	100	100	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT	1995	15	10					6856	6867					12	Neurosciences	Neurosciences & Neurology	TB904	WOS:A1995TB90400048	7472443				2021-06-18	
J	HEINEMANN, AW; WHITENECK, GG				HEINEMANN, AW; WHITENECK, GG			RELATIONSHIPS AMONG IMPAIRMENT, DISABILITY, HANDICAP, AND LIFE SATISFACTION IN PERSONS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; FOLLOW-UP	Four regional brain injury centers sun eyed 758 individuals with loss of consciousness from head trauma who were living in the community. Relationships among demographic characteristics, severity of impairment, severity of disability, extent of handicap, and life satisfaction were assessed with multiple regression. While the demographic and impairment variables were relatively weak predictors of disability, the combination of these variables was a much stronger predictor of handicap. In turn, 13% of the adjusted variance in life satisfaction was accounted for by these variables. These results support the World Health Organization model of impairment, disability, and handicap and suggest that efforts to remediate disability have a direct benefit in reducing handicap and enhancing life satisfaction.	NORTHWESTERN UNIV,SCH MED,DEPT PHYS MED & REHABIL,CHICAGO,IL 60611; CRAIG HOSP,ENGLEWOOD,CO 80110	HEINEMANN, AW (corresponding author), REHABIL INST CHICAGO,REHABIL SERV EVALUAT UNIT,CHICAGO,IL 60611, USA.		Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326			BROWN SC, 1993, J DISABIL POLICY STU, V4, P57; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; HALL MK, 1993, J HEAD TRAUMA REHABI, V8, P60; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LINACRE JM, 1991, BIGSTEPS RASCH PROGR; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MENTER RR, 1991, PARAPLEGIA, V29, P613, DOI 10.1038/sc.1991.90; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; RASCH G, 1990, PROBABILISTIC MODELS; RINTALA DH, 1993, MAY AM SPIN INJ ASS; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WHITENECK GG, 1994, JUN ANN M AM C REH M; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLER BS, 1993, BRAIN INJURY REHABIL; World Health Organization, 1980, INT CLASS IMP DIS HA; Wright B.D., 1982, RATING SCALE ANAL	24	100	101	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1995	10	4					54	63		10.1097/00001199-199508000-00006			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RN010	WOS:A1995RN01000006					2021-06-18	
J	BORZOTTA, AP; PENNINGS, J; PAPASADERO, B; PAXTON, J; MARDESIC, S; BORZOTTA, R; PARROTT, A; BLEDSOE, F				BORZOTTA, AP; PENNINGS, J; PAPASADERO, B; PAXTON, J; MARDESIC, S; BORZOTTA, R; PARROTT, A; BLEDSOE, F			ENTERAL VERSUS PARENTERAL-NUTRITION AFTER SEVERE CLOSED-HEAD INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	24th Annual Meeting of the Western-Trauma-Association	FEB 27-MAR 04, 1994	CRESTED BUTTE, CO	W TRAUMA ASSOC			BRAIN INJURY; METABOLIC RESPONSE; PATIENT; BENEFITS; TRAUMA	We measured energy expenditure (MREE) and nitrogen excretion (UUN) in patients with severe head injury randomized to early parenteral (TPN, n = 21) or jejunal (ENT, n = 27) feeding with identical formulations. The MREE rose to 2400 +/- 531 kcal/day in both groups and remained at 135% +/- 26% to 146% +/- 42% of predicted energy expenditure over 4 weeks. Nitrogen excretion peaked the second week at 33.4 +/- 10 (TPN) and 31.2 +/- 7.5 (ENT) g N/day. Both routes were equally effective at meeting nutritional goals (1.2 x MREE, 2.5 g protein/kg/day intake, stabilized albumin and transferrin levels). Infections were equally frequent: 1.86 episodes/TPN patient versus 1.89 episodes/ENT patient. While patient charges were much greater for TPN, the hospital costs were similar for TPN and ENT support regimens. These findings show that patients with head injuries are hypermetabolic for weeks, that only 27% are capable of spontaneously eating nutritional requirements by discharge, and that either TPN or ENT support is equally effective when prescribed according to individual measurements of MREE and nitrogen excretion.		BORZOTTA, AP (corresponding author), LEGACY EMANUEL HOSP & HLTH CTR,TRAUMA SERV,2801 N GANTENBEIN AVE,PORTLAND,OR 97227, USA.						ADAMS S, 1986, J TRAUMA, V26, P882, DOI 10.1097/00005373-198610000-00004; BOUZARTH NF, 1972, SURG GYNECOL OBSTET, V126, P995; BRANSON R D, 1990, Respiratory Care, V35, P640; CERRA F, 1987, ANN SURG, V205, P282, DOI 10.1097/00000658-198703000-00011; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; MOORE EE, 1986, J TRAUMA, V26, P874, DOI 10.1097/00005373-198610000-00003; NORTON JA, 1987, J NEUROSURG, V67, P846; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; OTT L, 1989, NUTRITION, V5, P75; PHILLIPS R, 1988, J NEUROSURG, V68, P62; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; VANE DW, 1982, J PEDIATR SURG, V17, P960, DOI 10.1016/S0022-3468(82)80475-2; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	25	100	100	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1994	37	3					459	468		10.1097/00005373-199409000-00022			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	PG534	WOS:A1994PG53400023	8083910				2021-06-18	
J	SCHALEN, W; MESSETER, K; NORDSTROM, CH				SCHALEN, W; MESSETER, K; NORDSTROM, CH			COMPLICATIONS AND SIDE-EFFECTS DURING THIOPENTONE THERAPY IN PATIENTS WITH SEVERE HEAD-INJURIES	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						BARBITURATE THERAPY; HEAD INJURY; INTENSIVE CARE COMPLICATIONS; SIDE EFFECTS	DOSE BARBITURATE THERAPY; CEREBRAL BLOOD-FLOW; INTRACRANIAL HYPERTENSION; AGGRESSIVE TREATMENT; PRESSURE; BRAIN; ANESTHESIA; METABOLISM; PNEUMONIA; NUTRITION	This study reports all complications and side effects occurring in 38 patients with severe traumatic brain lesions treated with barbiturate coma because of a dangerous increase in intracranial pressure. The treatment was induced by intravenous infusion of thiopentone (5-11 mg.kg-1) followed by a continuous infusion of 4-8 mg.kg-1.h-1. The subsequent rate of thiopentone infusion was governed by the level of the intracranial pressure with the intention of keeping ICP below 20 mmHg (2.7 kPa). The duration of treatment was 1-15 days. Arterial hypotension occurred in 58%, hypokalemia in 82%, respiratory complications in 76%, infections in 55%, hepatic dysfunction in 87% and renal dysfunction in 47% of the patients. Twenty patients survived. Mortality in 17 patients was caused by an untreatable increase in intracranial pressure. In one patient complications due to barbiturate treatment may have contributed to the fatal outcome. In none of the other cases were the noted complications and side effects associated with any permanent symptoms or dysfunctions.	UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT ANESTHESIOL, S-22185 LUND, SWEDEN							BECKER KE, 1978, ANESTHESIOLOGY, V49, P197, DOI 10.1097/00000542-197809000-00009; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; BREIVIK H, 1978, CRIT CARE MED, V6, P228, DOI 10.1097/00003246-197807000-00004; CARLSSON C, 1975, Acta Anaesthesiologica Scandinavica Supplementum, V57, P7; CHAPMAN AG, 1978, ANESTHESIOLOGY, V48, P175, DOI 10.1097/00000542-197803000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; DAUCH WA, 1989, J NEUROSURG, V70, P862, DOI 10.3171/jns.1989.70.6.0862; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; ESPERSEN F, 1981, J INFECT DIS, V144, P19, DOI 10.1093/infdis/144.1.19; FERRER CFS, 1987, BRAIN RES, V411, P304; FORBES AR, 1979, ANESTH ANALG, V58, P387; GOLDBERG LI, 1985, CIRCULATION, V72, P245, DOI 10.1161/01.CIR.72.2.245; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; HARP JR, 1985, BASIS PRACTICE NEURO, P83; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LAMBERT JR, 1985, JPEN-PARENTER ENTER, V9, P501, DOI 10.1177/0148607185009004501; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARIN J, 1981, J NEUROSURG, V54, P521, DOI 10.3171/jns.1981.54.4.0521; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MESSETER K, 1972, ACTA PHYSIOL SCAND, V85, P174, DOI 10.1111/j.1748-1716.1972.tb05248.x; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; NORDBY HK, 1984, ACTA NEUROCHIR, V72, P157, DOI 10.1007/BF01406868; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; NORDSTROM CH, 1978, STROKE, V9, P335, DOI 10.1161/01.STR.9.4.335; NORDSTROM CH, 1990, 41ST P ANN M SCAND N; PIATT JH, 1984, NEUROSURGERY, V15, P427, DOI 10.1227/00006123-198409000-00023; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON JFR, 1986, JPEN-PARENTER ENTER, V10, P172, DOI 10.1177/0148607186010002172; ROCKOFF MA, 1979, ANN NEUROL, V6, P194, DOI 10.1002/ana.410060303; SATO M, 1989, RESUSCITATION, V17, P233, DOI 10.1016/0300-9572(89)90039-7; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SELTZER JL, 1980, BRIT J ANAESTH, V52, P527, DOI 10.1093/bja/52.5.527; SMITH AL, 1972, ANESTHESIOLOGY, V36, P378, DOI 10.1097/00000542-197204000-00015; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603; TRAEGER SM, 1983, CRIT CARE MED, V11, P697, DOI 10.1097/00003246-198309000-00005; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383	46	100	100	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	1992	36	4					369	377		10.1111/j.1399-6576.1992.tb03483.x			9	Anesthesiology	Anesthesiology	HR870	WOS:A1992HR87000014	1595344				2021-06-18	
J	MCINTOSH, TK; FADEN, AI; BENDALL, MR; VINK, R				MCINTOSH, TK; FADEN, AI; BENDALL, MR; VINK, R			TRAUMATIC BRAIN INJURY IN THE RAT - ALTERATIONS IN BRAIN LACTATE AND PH AS CHARACTERIZED BY H-1 AND P-31 NUCLEAR-MAGNETIC-RESONANCE	JOURNAL OF NEUROCHEMISTRY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; GRIFFITH UNIV,SCH SCI,BRISBANE,AUSTRALIA	MCINTOSH, TK (corresponding author), VET ADM MED CTR,CTR NEURAL INJURY 127,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM34690-02A1] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [902269] Funding Source: Medline		ACKERMAN JJH, 1984, J MAGN RESON, V56, P318, DOI 10.1016/0022-2364(84)90109-4; ALBIN MS, 1969, J TRAUM, V9, P1000, DOI 10.1097/00005373-196912000-00004; BAX A, 1979, J MAGN RESON, V35, P167, DOI 10.1016/0022-2364(79)90088-X; BECKER DP, 1985, CENTRAL NERVOUS SYST, P229; BENDALL MR, 1986, B MAGN RESON, V8, P17; BENDALL MR, 1984, BIOMEDICAL MAGNETIC, P99; BERGER JP, 1979, LACTATE ACUTE CONDIT, P115; BLENNOW G, 1977, ACTA PHYSIOL SCAND, V100, P126, DOI 10.1111/j.1748-1716.1977.tb05929.x; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; COLLINS RC, 1970, AM J PHYSIOL, V218, P943; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DEWITT DS, 1980, SOC NEUR ABSTR, V6, P80; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; DUFFY TE, 1975, J NEUROCHEM, V24, P925, DOI 10.1111/j.1471-4159.1975.tb03657.x; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; GULATI SC, 1980, ACTA NEUROCHIR, V53, P39, DOI 10.1007/BF02074519; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; HANSTOCK CC, 1987, IN PRESS J CEREB BLO; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HETHERINGTON HP, 1985, P NATL ACAD SCI USA, V82, P3115, DOI 10.1073/pnas.82.10.3115; HETHERINGTON HP, 1984, J MAGN RESON, V65, P348; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; HORE PJ, 1983, J MAGN RESON, V55, P293; HOWSE DC, 1974, AM J PHYSIOL, V227, P1444; ISHIGE M, 1986, P SOC MAG RESON MED, V4, P1355; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; KING LR, 1974, J NEUROSURG, V40, P617, DOI 10.3171/jns.1974.40.5.0617; KOGURE K, 1980, BRAIN, V97, P104; KUSHMERICK MJ, 1985, AM J PHYSIOL, V248, pC542; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; MACMILLAN V, 1973, J NEUROCHEM, V21, P1283, DOI 10.1111/j.1471-4159.1973.tb07582.x; MCINTOSH TK, 1987, UNPUB NEUROSCIENCE; MCINTOSH TK, 1987, IN PRESS AM J PHYSL; MYERS RE, 1979, ADV PERINATAL NEUROL, P88; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; PETROFF OAC, 1986, ANN NEUROL, V20, P185, DOI 10.1002/ana.410200203; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PRITCHARD JW, 1986, ANN REV NEUROSCI, V9, P61; REHNCRONA S, 1980, ACTA PHYSIOL SCAND, V110, P435, DOI 10.1111/j.1748-1716.1980.tb06692.x; ROOS A, 1981, PHYSIOL REV, V61, P296; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; ROTHMAN DL, 1984, P NATL ACAD SCI-BIOL, V81, P6330, DOI 10.1073/pnas.81.20.6330; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIESJO BK, 1972, J NEUROCHEM, V19, P2483, DOI 10.1111/j.1471-4159.1972.tb01308.x; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; THULBORN KR, 1982, J CEREBR BLOOD F MET, V2, P299, DOI 10.1038/jcbfm.1982.31; VINK R, 1987, IN PRESS J CEREB BLO; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHIDA S, 1985, J CEREBR BLOOD F MET, V5, P490, DOI 10.1038/jcbfm.1985.75	60	100	100	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	1987	49	5					1530	1540					11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	K4248	WOS:A1987K424800029	3668537				2021-06-18	
J	Villapol, S; Loane, DJ; Burns, MP				Villapol, Sonia; Loane, David J.; Burns, Mark P.			Sexual dimorphism in the inflammatory response to traumatic brain injury	GLIA			English	Article						cytokine; inflammation; microglia; sex-differences; trauma	MICROGLIAL ACTIVATION; ISCHEMIC-INJURY; FEMALE RATS; ESTROGEN; GENDER; NEURODEGENERATION; NEUROPROTECTION; EXPRESSION; NEUROINFLAMMATION; PROGESTERONE	The activation of resident microglial cells, alongside the infiltration of peripheral macrophages, are key neuroinflammatory responses to traumatic brain injury (TBI) that are directly associated with neuronal death. Sexual disparities in response to TBI have been previously reported; however it is unclear whether a sex difference exists in neuroinflammatory progression after TBI. We exposed male and female mice to moderate-to-severe controlled cortical impact injury and studied glial cell activation in the acute and chronic stages of TBI using immunofluorescence and in situ hybridization analysis. We found that the sex response was completely divergent up to 7 days postinjury. TBI caused a rapid and pronounced cortical microglia/macrophage activation in male mice with a prominent activated phenotype that produced both pro- (IL-1 beta and TNF alpha) and anti-inflammatory (Arg1 and TGF beta) cytokines with a single-phase, sustained peak from 1 to 7 days. In contrast, TBI caused a less robust microglia/macrophage phenotype in females with biphasic pro-inflammatory response peaks at 4 h and 7 days, and a delayed anti-inflammatory mRNA peak at 30 days. We further report that female mice were protected against acute cell loss after TBI, with male mice demonstrating enhanced astrogliosis, neuronal death, and increased lesion volume through 7 days post-TBI. Collectively, these findings indicate that TBI leads to a more aggressive neuroinflammatory profile in male compared with female mice during the acute and subacute phases postinjury. Understanding how sex affects the course of neuroinflammation following brain injury is a vital step toward developing personalized and effective treatments for TBI.	[Villapol, Sonia; Burns, Mark P.] Georgetown Univ, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20057 USA; [Loane, David J.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Dept Anesthesiol, Baltimore, MD 21201 USA	Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg EG11,3970 Reservoir Rd NW, Washington, DC 20057 USA.	mpb37@georgetown.edu	Villapol, Sonia/D-1949-2014	Loane, David/0000-0003-0393-3503; Burns, Mark P/0000-0003-4750-2000; Villapol, Sonia/0000-0002-6174-4113	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS067417, R01NS082308, R03NS095038]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS095038, R03NS067417, R01NS081068, R01NS082308] Funding Source: NIH RePORTER	NIH grants, Grant numbers: R01NS067417 (M.P. Burns), R01NS082308 (D.J. Loane), and R03NS095038 (S. Villapol)	Acaz-Fonseca E, 2015, GLIA, V63, P1966, DOI 10.1002/glia.22867; Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Ayoub AE, 2003, J NEUROSCI, V23, P7759; Bansal V, 2003, CURR OPIN CLIN NUTR, V6, P223, DOI 10.1097/00075197-200303000-00012; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Caplan HW, 2017, J NEUROSCI RES, V95, P509, DOI 10.1002/jnr.23854; Castellano B, 2016, ADV EXP MED BIOL, V949, P147, DOI 10.1007/978-3-319-40764-7_7; Choi S, 2009, ASN NEURO, V1, DOI 10.1042/AN20090009; Cohen M, 2014, EMBO J, V33, P2906, DOI 10.15252/embj.201489293; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Crain JM, 2013, J NEUROSCI RES, V91, P1143, DOI 10.1002/jnr.23242; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; Dimayuga FO, 2005, J NEUROIMMUNOL, V161, P123, DOI 10.1016/j.jneuroim.2004.12.016; Dotson AL, 2015, J NEUROIMMUNOL, V278, P289, DOI 10.1016/j.jneuroim.2014.11.020; Doyle HH, 2017, J NEUROSCI, V37, P3202, DOI 10.1523/JNEUROSCI.2906-16.2017; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Engler-Chiurazzi E. B., 2016, PROGR NEURO IN PRESS; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Fleiss B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-70; GLENN JA, 1992, J ANAT, V180, P109; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Harry GJ, 2008, EXPERT OPIN DRUG MET, V4, P1265, DOI 10.1517/17425255.4.10.1265 ; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Jin X., 2012, PLOS ONE, V7; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; McCullough LD, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/s13293-014-0015-5; Mirza MA, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0251-6; Mishra SK, 2017, MOL CELL NEUROSCI, V78, P25, DOI 10.1016/j.mcn.2016.11.008; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Moore CS, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000080; Morganti J. M., 2016, PLOS ONE, V11; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093650; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ohsawa K, 2011, GLIA, V59, P1793, DOI 10.1002/glia.21238; Ohsawa K, 2010, GLIA, V58, P790, DOI 10.1002/glia.20963; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rice RA, 2017, GLIA, V65, P931, DOI 10.1002/glia.23135; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Sawada M, 2000, J CEREBR BLOOD F MET, V20, P112, DOI 10.1097/00004647-200001000-00015; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Selenica MLB, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-86; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Srinivasan D, 2004, J NEUROSCI, V24, P6482, DOI 10.1523/JNEUROSCI.5712-03.2004; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Tam WY, 2014, SCI REP-UK, V4, DOI 10.1038/srep07279; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Tucker LB, 2017, J NEUROTRAUM, V34, P890, DOI 10.1089/neu.2016.4508; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Vegeto E, 2001, J NEUROSCI, V21, P1809, DOI 10.1523/JNEUROSCI.21-06-01809.2001; Villapol S, 2015, BRAIN, V138, DOI 10.1093/brain/awv172; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Villapol S, 2013, EXP NEUROL, V250, P353, DOI 10.1016/j.expneurol.2013.10.008; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052	77	99	100	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	SEP	2017	65	9					1423	1438		10.1002/glia.23171			16	Neurosciences	Neurosciences & Neurology	FA5IL	WOS:000405476300003	28608978	Green Accepted			2021-06-18	
J	Mesia, R; Henke, M; Fortin, A; Minn, H; Ancona, ACY; Cmelak, A; Markowitz, AB; Hotte, SJ; Singh, S; Chan, ATC; Merlano, MC; Skladowski, K; Zhang, A; Oliner, KS; VanderWalde, A; Giralt, J				Mesia, Ricard; Henke, Michael; Fortin, Andre; Minn, Heikki; Yunes Ancona, Alejandro Cesar; Cmelak, Anthony; Markowitz, Avi B.; Hotte, Sebastien J.; Singh, Simron; Chan, Anthony T. C.; Merlano, Marco C.; Skladowski, Krzysztof; Zhang, Alicia; Oliner, Kelly S.; VanderWalde, Ari; Giralt, Jordi			Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial	LANCET ONCOLOGY			English	Article							OROPHARYNGEAL CANCER; HUMAN-PAPILLOMAVIRUS; RADIATION; RADIOTHERAPY; CISPLATIN; CETUXIMAB; RECURRENT	Background Panitumumab is a fully human monoclonal antibody that targets EGFR. We aimed to compare chemoradiotherapy plus panitumumab with chemoradiotherapy alone in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck. Methods In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 41 sites in nine countries worldwide. Patients aged 18 years and older with stage III, IVa, or IVb, previously untreated, measurable (>= 10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (2:3) by an independent vendor to open-label chemoradiotherapy (three cycles of cisplatin 100 mg/m(2)) or panitumumab plus chemoradiotherapy (three cycles of intravenous panitumumab 9.0 mg/kg every 3 weeks plus cisplatin 75 mg/m(2)) using stratified randomisation with a block size of five. All patients received 70 Gy to gross tumour and 50 Gy to areas at risk for subclinical disease with standard fractionation. The primary endpoint was local-regional control at 2 years, analysed in all randomised patients who received at least one dose of their assigned protocol-specific treatment (chemotherapy, radiation, or panitumumab). The trial is closed and this is the final analysis. This trial is registered with ClinicalTrials.gov, number NCT00500760. Findings Between Oct 26, 2007, and March 26, 2009, 153 patients were enrolled and 150 received treatment (63 in the chemoradiotherapy group and 87 in the panitumumab plus chemoradiotherapy group). Local-regional control at 2 years was 68% (95% CI 54-78) in the chemoradiotherapy group and 61% (50-71) in the panitumumab plus chemoradiotherapy group. The most frequent grade 3-4 adverse events were dysphagia (17 [27%] of 63 patients in the chemoradiotherapy group vs 35 [40%] of 87 in the panitumumab plus chemoradiotherapy group), mucosal inflammation (15 [24%] vs 48 [55%]), and radiation skin injury (eight [13%] vs 27 [31%]). Serious adverse events were reported in 20 (32%) of 63 patients in the chemoradiotherapy group and in 37 (43%) of 87 patients in the panitumumab plus chemo radio therapy group. Interpretation In patients with locally advanced squamous-cell carcinoma of the head and neck, the addition of panitumumab to standard fractionation radiotherapy and cisplatin did not confer any benefit, and the role of EGFR inhibition in these patients needs to be reassessed.	[Mesia, Ricard] Inst Catala Oncol ICO Hosp, Barcelona, Spain; [Henke, Michael] Univ Freiburg Klinikum, Freiburg, Germany; [Fortin, Andre] Ctr Hosp Univ Quebec, Hotel Dieu Quebec, Quebec City, PQ, Canada; [Minn, Heikki] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland; [Yunes Ancona, Alejandro Cesar] Unidad Oncol Serv Salud Estado Puebla, Puebla, Mexico; [Cmelak, Anthony] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Markowitz, Avi B.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Hotte, Sebastien J.] Juravinski Canc Ctr, Hamilton, ON, Canada; [Singh, Simron] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada; [Chan, Anthony T. C.] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China; [Merlano, Marco C.] Oncol Med ASOS Croce E Carle, Cuneo, Italy; [Skladowski, Krzysztof] Inst M Sklodowskiej Curie, Ctr Onkol, Gliwice, Poland; [Zhang, Alicia; Oliner, Kelly S.; VanderWalde, Ari] Amgen Inc, Thousand Oaks, CA USA; [Giralt, Jordi] Hosp Valle De Hebron, Barcelona, Spain; [Giralt, Jordi] Univ Autonoma Barcelona, Bellaterra, Spain	Mesia, R (corresponding author), Inst Catala Oncol, Dept Med Oncol, Head & Neck Oncol Clin Res Program, Granvia Hosp 199-203, Lhospitalet Llobregat 08908, Spain.	rmesia@iconcologia.net	Chan, Anthony Tak Cheung/R-3940-2018; de Sagredo, Jordi Giralt Lopez/J-1873-2018	Chan, Anthony Tak Cheung/0000-0002-6912-8091; de Sagredo, Jordi Giralt Lopez/0000-0002-1840-5159; Skladowski, Krzysztof/0000-0002-0554-6171; Minn, Heikki/0000-0002-5878-4333	AmgenAmgen	This study was funded by Amgen. We thank the study staff, and the patients and their families, for their contributions to this study. We also acknowledge Jennifer Gansert (Amgen) for her contributions to the study design and protocol development, and James Ziobro for assistance with the writing of this manuscript (funded by Amgen).	Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Ang K, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.5507; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2011, P AM SOC CLIN ONCO S, V29, P5500; [Anonymous], 2012, NATL COMPREHENSIVE C; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; BRITTAIN E, 1982, BIOMETRICS, V38, P1003, DOI 10.2307/2529880; Gillison ML, 2012, VACCINE, V30, pF34, DOI 10.1016/j.vaccine.2012.05.070; Gillison ML, 2012, J CLIN ONCOL, V30, P2102, DOI 10.1200/JCO.2011.38.4099; Giralt J, 2015, LANCET ONCOL; Gregoire Vincent, 2003, Rays, V28, P217; Kruser TJ, 2008, INT J RADIAT ONCOL, V72, P534, DOI 10.1016/j.ijrobp.2008.06.1490; Melkane AE, 2014, HEAD NECK-J SCI SPEC, V36, P257, DOI 10.1002/hed.23302; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Rivera F, 2009, EXPERT REV ANTICANC, V9, P1421, DOI 10.1586/ERA.09.113; Robinson M, 2010, ORAL ONCOL, V46, P492, DOI 10.1016/j.oraloncology.2010.02.013; Vermorken JB, 2013, LANCET ONCOL, V14, P697, DOI 10.1016/S1470-2045(13)70181-5; Wirth LJ, 2010, ANN ONCOL, V21, P342, DOI 10.1093/annonc/mdp477	19	99	101	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	FEB	2015	16	2					208	220		10.1016/S1470-2045(14)71198-2			13	Oncology	Oncology	CA3YR	WOS:000348841700037	25596660				2021-06-18	
J	Bass, C; Halligan, P				Bass, Christopher; Halligan, Peter			Factitious disorders and malingering: challenges for clinical assessment and management	LANCET			English	Article							MEDICALLY UNEXPLAINED SYMPTOMS; CHRONIC REGIONAL PAIN; MINOR HEAD-INJURY; MUNCHAUSENS-SYNDROME; COMPENSATION NEUROSIS; PERFORMANCE VALIDITY; ETHICAL IMPLICATIONS; RISK-FACTORS; ILLNESS; LITIGATION	Compared with other psychiatric disorders, diagnosis of factitious disorders is rare, with identification largely dependent on the systematic collection of relevant information, including a detailed chronology and scrutiny of the patient's medical record. Management of such disorders ideally requires a team-based approach and close involvement of the primary care doctor. As deception is a key defining component of factitious disorders, diagnosis has important implications for young children, particularly when identified in women and health-care workers. Malingering is considered to be rare in clinical practice, whereas simulation of symptoms, motivated by financial rewards, is regarded as more common in medicolegal settings. Although psychometric investigations (eg, symptom validity testing) can inform the detection of illness deception, such tests need support from converging evidence sources, including detailed interview assessments, medical notes, and relevant non-medical investigations. A key challenge in any discussion of abnormal health-care-seeking behaviour is the extent to which a person's reported symptoms are considered to be a product of choice, or psychopathology beyond volitional control, or perhaps both. Clinical skills alone are not typically sufficient for diagnosis or to detect malingering. Medical education needs to provide doctors with the conceptual, developmental, and management frameworks to understand and deal with patients whose symptoms appear to be simulated. Central to the understanding of factitious disorders and malingering are the explanatory models and beliefs used to provide meaning for both patients and doctors. Future progress in management will benefit from an increased appreciation of the contribution of non-medical factors and a greater awareness of the conceptual and clinical findings from social neuroscience, occupational health, and clinical psychology.	[Bass, Christopher] John Radcliffe Hosp, Dept Psychol Med, Oxford OX3 9DU, England; [Halligan, Peter] Cardiff Univ, Sch Psychol, Cardiff CF10 3AX, S Glam, Wales	Bass, C (corresponding author), John Radcliffe Hosp, Dept Psychol Med, Oxford OX3 9DU, England.	christopher.bass@oxfordhealth.nhs.uk	Halligan, Peter W/A-1669-2010	Halligan, Peter W/0000-0003-2784-6690			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, V5th; Angell M, 2011, NEW YORK REV BOOKS, V58, P14; Aronoff Gerald M, 2007, Pain Pract, V7, P178, DOI 10.1111/j.1533-2500.2007.00126.x; ASHER R, 1951, LANCET, V260, P339; BARSKY AJ, 1983, AM J PSYCHIAT, V140, P273; BASS C, 1995, J PSYCHOSOM RES, V39, P403, DOI 10.1016/0022-3999(94)00157-Z; Bass C, 2014, LANCET; Bass C, 2009, NEW OXFORD TXB PSYCH, P1049; Bass C, 2007, J ROY SOC MED, V100, P81, DOI 10.1258/jrsm.100.2.81; Bass C, 2013, PERSONAL MENT HEALTH, V7, P80, DOI 10.1002/pmh.1223; Bass C, 2011, BRIT J PSYCHIAT, V199, P113, DOI 10.1192/bjp.bp.109.074088; Berry DTR, 2010, PSYCHOL INJ LAW, V3, P295, DOI 10.1007/s12207-010-9087-7; Binder LM, 2012, CLIN NEUROPSYCHOL, V26, P116, DOI 10.1080/13854046.2011.633563; Breting L. G., 2013, MILD TRAUMATIC BRAIN, P145; British Psychological Society (BPS), 2009, ASS EFF CLIN TEST CO; Burke FD, 2008, J HAND SURG-EUR VOL, V33E, P103, DOI 10.1177/1753193408087230; BURKETT BG, 1998, STOLEN VALOR VIETNAM; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA., 2013, MILD TRAUMATIC BRAIN, P101; Cassidy JD, 2011, INJURY, V42, P428, DOI 10.1016/j.injury.2010.11.027; Chafetz M, 2013, ARCH CLIN NEUROPSYCH, V28, P633, DOI 10.1093/arclin/act038; Creed F, 2011, MED UNEXPLAINED SYMP, P1, DOI DOI 10.1017/CBO9780511977862; Crittenden P., 2011, ASSESSING ADULT ATTA; Croft P., 2010, CHRONIC PAIN EPIDEMI, P3; Cunningham JM, 2011, PSYCHOSOMATICS, V52, P185, DOI 10.1016/j.psym.2010.11.005; de Asla R, 2011, J BONE JOINT SURG AM, V93, p[e116, 1], DOI DOI 10.2106/JBJS.K; DeWitt DE, 2010, MED J AUSTRALIA, V192, P55, DOI 10.5694/j.1326-5377.2010.tb03411.x; DeWitt DE, 2009, MED J AUSTRALIA, V191, P213, DOI 10.5694/j.1326-5377.2009.tb02755.x; Drob SL, 2009, J AM ACAD PSYCHIATRY, V37, P98; Dyer C, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3226; Eastwood S, 2008, PSYCHOTHER PSYCHOSOM, V77, P209, DOI 10.1159/000126072; Ehrlich S, 2008, PSYCHOSOMATICS, V49, P392, DOI 10.1176/appi.psy.49.5.392; Eisendrath S, 1996, SPECTRUM FACTITIOUS, P65; Eisendrath SJ, 2004, PSYCHOSOMATICS, V45, P350, DOI 10.1176/appi.psy.45.4.350; Eisendrath SJ, 2002, J AM ACAD PSYCHIATRY, V30, P391; Eisendrath SJ, 1996, SPECTRUM FACTITIOUS, P195; Eisendrath SJ, 2008, ANN PLAS SURG, V60, P64, DOI 10.1097/SAP.0b013e318049cc41; Farnfield Steve, 2010, Clin Child Psychol Psychiatry, V15, P313, DOI 10.1177/1359104510364315; Fehnel CR, 2006, AM J PSYCHIAT, V163, P547, DOI 10.1176/appi.ajp.163.3.547-a; Feldman MD, 2006, INT J CLIN PRACT, V60, P1675, DOI 10.1111/j.1742-1241.2006.00975.x; Ferrari R, 2011, J NEUROL NEUROSUR PS, V82, P826, DOI 10.1136/jnnp.2010.213520; Ferrari R, 2012, J RHEUMATOL, V39, P655, DOI 10.3899/jrheum.110970; FINK P, 1992, J PSYCHOSOM RES, V36, P125, DOI 10.1016/0022-3999(92)90021-S; Fliege H, 2007, PSYCHOSOMATICS, V48, P60, DOI 10.1176/appi.psy.48.1.60; Ganis G, 2009, SOC NEUROSCI, V4, P465, DOI 10.1080/17470910802507660; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gieler U, 2004, DERMATOL PSYCHOSOM, V5, P93; Goebel RA, 2012, COMPLEX REGIONAL PAI; Goldstein AB, 1998, INT J PSYCHIAT MED, V28, P221, DOI 10.2190/8LRP-5YTD-3VP2-3HC6; Granacher R, 2008, CLIN ASSESSMENT MALI, P145; Green P., 2013, MILD TRAUMATIC BRAIN, P73; Green P., 2005, GREENS WORD MEMORY T; Greiffenstein M, 2005, LEG CRIMINOL PSYCHOL, V10, P1; Greiffenstein M, 2013, CLIN NEUROPSYCHOL, V27, P138, DOI 10.1080/13854046.2012.722686; Greve K. W., 2012, COPING PSYCHIAT PSYC, P587, DOI DOI 10.1093/MED:PSYCH/9780195174113.003.0026; Greve KW, 2013, CLIN NEUROPSYCHOL, V27, P108, DOI 10.1080/13854046.2012.739646; Greve KW, 2009, ARCH PHYS MED REHAB, V90, P1117, DOI 10.1016/j.apmr.2009.01.018; Hadeed V, 1998, ANN INTERN MED, V129, P73, DOI 10.7326/0003-4819-129-1-199807010-00027; Hall RCW, 2007, J FORENSIC SCI, V52, P717, DOI 10.1111/j.1556-4029.2007.00434.x; Hall RCW, 2006, GEN HOSP PSYCHIAT, V28, P525, DOI 10.1016/j.genhosppsych.2006.08.011; Hall RCW, 2012, J AM ACAD PSYCHIATRY, V40, P390; Hallett M, 2010, J CLIN NEUROSCI, V17, P959, DOI 10.1016/j.jocn.2009.11.021; Halligan P, 2003, MALINGERING ILLNESS, P3; Halligan P., 2011, PSYCHOGENIC MOVEMENT, P120; Hamilton JC, 2013, PSYCHOSOMATICS, V54, P142, DOI 10.1016/j.psym.2012.08.013; Hamilton JM, 2009, JOURNALISM'S ROVING EYE: A HISTORY OF AMERICAN FOREIGN REPORTING, UPDATED EDITION, P27; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoertel N, 2012, PSYCHIAT RES, V200, P1077, DOI 10.1016/j.psychres.2012.05.004; Holm LW, 2008, PLOS MED, V5, P760, DOI 10.1371/journal.pmed.0050105; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2006, APPL NEUROPSYCHOL, V13, P77, DOI 10.1207/s15324826an1302_3; Iverson Grant L, 2007, Pain Pract, V7, P94, DOI 10.1111/j.1533-2500.2007.00116.x; Johnson-Greene D, 2013, CLIN NEUROPSYCHOL, V27, P148, DOI 10.1080/13854046.2012.733732; Jung B, 2007, PAIN MED, V8, P433, DOI 10.1111/j.1526-4637.2007.00315.x; Kanaan RAA, 2010, HIST HUM SCI, V23, P68, DOI 10.1177/0952695109357128; Kanaan RAA, 2010, PSYCHOSOMATICS, V51, P47, DOI 10.1176/appi.psy.51.1.47; Kapfhammer HP, 1998, NERVENARZT, V69, P401, DOI 10.1007/s001150050289; Kendell R, 2003, AM J PSYCHIAT, V160, P4, DOI 10.1176/appi.ajp.160.1.4; Kozlowska Kasia, 2007, Clin Child Psychol Psychiatry, V12, P487, DOI 10.1177/1359104507080977; Krahn LE, 2003, AM J PSYCHIAT, V160, P1163, DOI 10.1176/appi.ajp.160.6.1163; Krahn LE, 2008, PSYCHOSOMATICS, V49, P277, DOI 10.1176/appi.psy.49.4.277; Lamberty G. J., 2008, UNDERSTANDING SOMATI; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2004, DIFFERENTIAL DIAGNOSIS IN ADULT NEUROPSYCHOLOGICAL ASSESSMENT, P243; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; LIBOW JA, 1995, CHILD ABUSE NEGLECT, V19, P1131, DOI 10.1016/0145-2134(95)00073-H; Lucire Y., 2003, CONSTRUCTING RSI BEL; Mailis-Gagnon A, 2008, CLIN J PAIN, V24, P176, DOI 10.1097/AJP.0b013e31815ca278; Main CJ, 1998, SPINE, V23, P2367, DOI 10.1097/00007632-199811010-00025; McCullumsmith CB, 2011, PSYCHIAT CLIN N AM, V34, P621, DOI 10.1016/j.psc.2011.05.013; MECHANIC D, 1961, AM SOCIOL REV, V26, P51, DOI 10.2307/2090512; MENDELSON G, 1995, J PSYCHOSOM RES, V39, P695, DOI 10.1016/0022-3999(94)00154-W; Merckelbach H, 2012, CLIN NEUROPSYCHOL, V26, P1217, DOI 10.1080/13854046.2012.710252; Merten T, 2013, PSYCHOL INJ LAW, V6, P122, DOI 10.1007/s12207-013-9155-x; Merten T, 2009, PSYCHOL INJ LAW, V2, P284, DOI 10.1007/s12207-009-9057-0; MILLER H, 1972, LANCET, V1, P580; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mohandas P, 2013, BRIT J DERMATOL, V169, P600, DOI 10.1111/bjd.12416; Morel K. R., 2010, DIFFERENTIAL DIAGNOS; Nicholas MK, 2011, PHYS THER, V91, P737, DOI 10.2522/ptj.20100224; Nimnuan C, 2000, QJM-INT J MED, V93, P21, DOI 10.1093/qjmed/93.1.21; O'Connor EA, 2013, J HAND SURG-AM, V38A, P1590, DOI 10.1016/j.jhsa.2013.04.047; Ochoa JL, 2010, J NEUROPSYCH CLIN N, V22, P278, DOI 10.1176/appi.neuropsych.22.3.278; Pankratz L, 1998, PATIENTS WHO DECEIVE; Pearce JMS, 2005, SPINAL CORD, V43, P263, DOI 10.1038/sj.sc.3101709; Pearce S, 2010, J MED ETHICS, V36, P831, DOI 10.1136/jme.2010.035865; Peebles R, 2005, CLIN PEDIATR, V44, P237, DOI 10.1177/000992280504400307; Petrie KJ, 2012, CURR DIR PSYCHOL SCI, V21, P60, DOI 10.1177/0963721411429456; Poole CJM, 2010, OCCUP MED-OXFORD, V60, P127, DOI 10.1093/occmed/kqp170; Raab S, 2005, MAFIA LEADER WHO FEI; REICH P, 1983, ANN INTERN MED, V99, P240, DOI 10.7326/0003-4819-99-2-240; Resnick P, 2008, CLIN ASSESSMENT MALI, P109; Rief W, 2004, J PSYCHOSOM RES, V57, P367, DOI 10.1016/j.jpsychores.2004.02.015; Rief W, 2003, J PSYCHOSOM RES, V54, P405, DOI 10.1016/S0022-3999(02)00401-4; Robertson MD, 2009, MED J AUSTRALIA, V191, P217, DOI 10.5694/j.1326-5377.2009.tb02756.x; Rogers R, 1990, Bull Am Acad Psychiatry Law, V18, P323; Rogers R, 2009, LAW HUMAN BEHAV, V33, P213, DOI 10.1007/s10979-008-9145-9; Ronson G, 2009, LEADING FRONT; Rosen GM, 2007, J ANXIETY DISORD, V21, P201, DOI 10.1016/j.janxdis.2006.09.011; Salmon P, 2007, PATIENT EDUC COUNS, V67, P246, DOI 10.1016/j.pec.2007.03.008; Singh HP, 2006, J HAND SURG-BRIT EUR, V31B, P611, DOI 10.1016/j.jhsb.2006.08.009; Spence SA, 2004, PHILOS T R SOC B, V359, P1755, DOI 10.1098/rstb.2004.1555; Stone J, 2012, J NEUROL NEUROSUR PS, V83, P67, DOI 10.1136/jnnp-2011-300125; Suchy Y, 2012, CLIN NEUROPSYCHOL, V26, P1296, DOI 10.1080/13854046.2012.722230; Sullivan K., 2007, J FORENSIC NEUROPSYC, V4, P49, DOI DOI 10.1300/J151V04N04_04; Sullivan MJL, 2012, CLIN J PAIN, V28, P484, DOI 10.1097/AJP.0b013e3182527d13; Sweet JJ, 2013, J EXP PSYCHOPATHOL, V4, P6, DOI 10.5127/jep.022311; Tombaugh TN, 1996, TEST MEMORY MALINGER; Torres L, 2012, PSYCHOL INJ LAW, V5, P1, DOI 10.1007/s12207-012-9118-7; TRIVERS R, 2011, DECEIT SELF DECEPTIO; Tyrer P, 1999, J PSYCHOSOM RES, V46, P177, DOI 10.1016/S0022-3999(98)00072-5; Van Dinter TG, 2009, AM J MED, V122, pE4, DOI 10.1016/j.amjmed.2009.03.035; Vranceanu AM, 2011, J HAND THER, V24, P118, DOI 10.1016/j.jht.2010.12.002; Vranceanu AM, 2009, J BONE JOINT SURG AM, V91A, P2014, DOI 10.2106/JBJS.H.01512; Vrij A., 2008, DETECTING LIES DECEI; Wade DT, 2007, CLIN REHABIL, V21, P291, DOI 10.1177/0269215507077799; Wade DT, 2004, BMJ-BRIT MED J, V329, P1398, DOI 10.1136/bmj.329.7479.1398; Wade DT, 2003, CLIN REHABIL, V17, P349, DOI 10.1191/0269215503cr619ed; Walters GD, 2009, J CLIN EXP NEUROPSYC, V31, P584, DOI 10.1080/13803390802363728; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; World Health Organization, 1992, ICD 10 CLASS MENT BE	142	99	102	0	49	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	2014	383	9926					1422	1432		10.1016/S0140-6736(13)62186-8			11	Medicine, General & Internal	General & Internal Medicine	AG3LI	WOS:000335318400028	24612861				2021-06-18	
J	Boussi-Gross, R; Golan, H; Fishlev, G; Bechor, Y; Volkov, O; Bergan, J; Friedman, M; Hoofien, D; Shlamkovitch, N; Ben-Jacob, E; Efrati, S				Boussi-Gross, Rahav; Golan, Haim; Fishlev, Gregori; Bechor, Yair; Volkov, Olga; Bergan, Jacob; Friedman, Mony; Hoofien, Dan; Shlamkovitch, Nathan; Ben-Jacob, Eshel; Efrati, Shai			Hyperbaric Oxygen Therapy Can Improve Post Concussion Syndrome Years after Mild Traumatic Brain Injury - Randomized Prospective Trial	PLOS ONE			English	Article							EMISSION COMPUTED-TOMOGRAPHY; CYSTIC-FIBROSIS PATIENTS; FLUID-PERCUSSION INJURY; ACUTE ISCHEMIC-STROKE; MINOR HEAD-INJURY; DEAD-SEA; LOW-ALTITUDE; NEUROPSYCHOLOGICAL DEFICITS; MITOCHONDRIAL-FUNCTION; CEREBRAL OXYGENATION	Traumatic brain injury (TBI) is the leading cause of death and disability in the US. Approximately 70-90% of the TBI cases are classified as mild, and up to 25% of them will not recover and suffer chronic neurocognitive impairments. The main pathology in these cases involves diffuse brain injuries, which are hard to detect by anatomical imaging yet noticeable in metabolic imaging. The current study tested the effectiveness of Hyperbaric Oxygen Therapy (HBOT) in improving brain function and quality of life in mTBI patients suffering chronic neurocognitive impairments.	[Boussi-Gross, Rahav; Fishlev, Gregori; Bechor, Yair; Bergan, Jacob; Friedman, Mony; Efrati, Shai] Assaf Harofeh Med Ctr, Inst Hyperbar Med, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel; Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel; [Golan, Haim; Volkov, Olga; Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Golan, Haim; Volkov, Olga] Assaf Harofeh Med Ctr, Inst Nucl Med, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel] Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel; [Hoofien, Dan] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Hoofien, Dan] Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; [Shlamkovitch, Nathan] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel] Rice Univ, Ctr Theoret Biol Phys, Houston, TX USA; [Ben-Jacob, Eshel; Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Ben-Jacob, E (corresponding author), Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel.	eshel@rice.edu; efratishai@013.net	Golan, Haim/K-2831-2019		Assaf-Harofeh medical center; Tauber Family Foundation; Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University	The study was supported by the research fund of Assaf-Harofeh medical center, by the Tauber Family Foundation and by the Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University. None of the supporting bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abinader EG, 1999, AM J CARDIOL, V83, P250, DOI 10.1016/S0002-9149(98)00829-7; Vilela DSA, 2008, ACTA OTO-LARYNGOL, V128, P1048, DOI 10.1080/00016480701827525; ANDERSON DC, 1991, STROKE, V22, P1137, DOI 10.1161/01.STR.22.9.1137; Austin D, 1998, LANCET, V351, P1815, DOI 10.1016/S0140-6736(05)78781-X; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Calvert JW, 2007, NEUROL RES, V29, P132, DOI 10.1179/016164107X174156; Cao H, 2013, EXP THER MED, V5, P1609, DOI 10.3892/etm.2013.1043; Catafau AM, 1998, PSYCHIAT RES-NEUROIM, V83, P67, DOI 10.1016/S0925-4927(98)00031-6; Chang CC, 2009, J NEUROTRAUM, V26, P1263, DOI 10.1089/neu.2008-0619; Chen ZQ, 2008, NEURAL REGEN RES, V3, P117; Cifu DX, 2013, J HEAD TRAUMA REHABI; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collet JP, 2001, LANCET, V357, P582, DOI 10.1016/S0140-6736(00)04054-X; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; de Frias CM, 2003, J GERONTOL B-PSYCHOL, V58, pP12, DOI 10.1093/geronb/58.1.P12; Doniger GM, 2007, MINDSTREAMS VALIDITY; Doniger GM, 2007, MINDSTREAMS COMPUTER; Doniger GM, 2007, CONSTRUCT VALIDITY M; Doniger GM, 2012, GUIDE MINDSTREAMS NO; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Falk B, 2006, PEDIATR PULM, V41, P234, DOI 10.1002/ppul.20342; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gabizon I, 2011, ISR MED ASSOC J, V13, P402; Glisky EL, 2004, SCI PRACT NEUROPSYCH, P100; Goldbart AD, 2007, ISR MED ASSOC J, V9, P806; Golden Z, 2006, DISABIL REHABIL, V28, P1379, DOI 10.1080/09638280600638364; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; GOLDING F C, 1960, Br J Ind Med, V17, P167; Gunther A, 2005, EUR J NEUROSCI, V21, P3189, DOI 10.1111/j.1460-9568.2005.04151.x; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Imai K, 2006, NEUROL MED-CHIR, V46, P373, DOI 10.2176/nmc.46.373; Insel Thomas R, 2010, Sci Am, V302, P44; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; James PB, 2001, LANCET, V357, P2052, DOI 10.1016/S0140-6736(00)05137-0; JASZCZAK RJ, 1979, PHYS MED BIOL, V24, P1123, DOI 10.1088/0031-9155/24/6/003; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KOCHANEK PM, 2007, BRAIN INJURY MED PRI, P81; Kramer MR, 1998, CHEST, V113, P571, DOI 10.1378/chest.113.3.571; Kuffler DP, 2011, P R HEALTH SCI J, V30, P35; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Lo CP, 2007, EUR J NEUROL, V14, P777, DOI 10.1111/j.1468-1331.2007.01854.x; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mychaskiw G, 2013, J NEUROTRAUMA; Mychaskiw Ii G, 2012, J NEUROTRAUMA; Neubauer RA, 1998, NEUROL RES, V20, pS33; Neubauer RA, 2000, HYPERBARIC OXYGEN TH; NIGHOGHOSSIAN N, 1995, STROKE, V26, P1369, DOI 10.1161/01.STR.26.8.1369; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Posner MI, 2007, COGN AFFECT BEHAV NE, V7, P391, DOI 10.3758/CABN.7.4.391; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rusyniak DE, 2003, STROKE, V34, P571, DOI 10.1161/01.STR.0000050644.48393.D0; SCOVILLE WB, 1973, ACTA NEUROCHIR, V28, P251, DOI 10.1007/BF01405644; Sohlberg M. M., 2001, COGNITIVE REHABILITA; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Vila JF, 2005, UNDERSEA HYPERBAR M, V32, P341; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549; Yang YJ, 2008, UNDERSEA HYPERBAR M, V35, P113; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	83	99	105	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2013	8	11							e79995	10.1371/journal.pone.0079995			18	Multidisciplinary Sciences	Science & Technology - Other Topics	255RX	WOS:000327258600052	24260334	DOAJ Gold, Green Published			2021-06-18	
J	Elbin, RJ; Kontos, AP; Kegel, N; Johnson, E; Burkhart, S; Schatz, P				Elbin, R. J.; Kontos, Anthony P.; Kegel, Nate; Johnson, Eric; Burkhart, Scott; Schatz, Philip			Individual and Combined Effects of LD and ADHD on Computerized Neurocognitive Concussion Test Performance: Evidence for Separate Norms	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						ADHD; LD; Computerized neurocognitive testing; ImPACT	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY DISORDER; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; LEARNING-DISABILITIES; HIGH-SCHOOL; NEUROPSYCHOLOGICAL PERFORMANCE; EXECUTIVE FUNCTIONS; POSITION STATEMENT	Decreased neurocognitive performance in individuals with self-reported attention deficit hyperactivity disorder(ADHD) and learning disability (LD) is well documented in the neuropsychological research literature. Previous studies employing paper-and-pencil neurocognitive assessments report lower performance in individuals with ADHD and LD. The purpose of the current study was to examine the influence of a self-reported diagnosis of LD, ADHD, and combined LD/ADHD on baseline computerized neurocognitive testing (CNT) used for the concussion assessment. Results revealed athletes with a self-reported diagnosis of LD, ADHD, and/or combined LD/ADHD demonstrated lower performance on baseline CNT and reported larger numbers of symptoms than did control athletes without these diagnoses. These findings provide evidence for the development of separate normative data for athletes with LD, ADHD, and LD/ADHD diagnoses on CNT batteries commonly used for concussion management.	[Elbin, R. J.; Kontos, Anthony P.; Kegel, Nate; Johnson, Eric; Burkhart, Scott] Univ Pittsburgh, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15260 USA; [Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Elbin, RJ (corresponding author), UPMC Ctr Sport Med, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	rje13@pitt.edu		Kontos, Anthony/0000-0002-3749-4310			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barkley R. A., 2003, ATTENTION DEFICIT HY; Barkley RA, 2003, BRAIN DEV-JPN, V25, P77, DOI 10.1016/S0387-7604(02)00152-3; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bauermeister JJ, 2007, J CHILD PSYCHOL PSYC, V48, P831, DOI 10.1111/j.1469-7610.2007.01750.x; Biederman J, 2006, PSYCHOL MED, V36, P167, DOI 10.1017/S0033291705006410; Biederman J, 2008, J CLIN PSYCHIAT, V69, P1150, DOI 10.4088/JCP.v69n0715; Birchwood J, 2012, J ADOLESCENCE, V35, P225, DOI 10.1016/j.adolescence.2010.08.011; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; DENCKLA MB, 1991, J CHILD NEUROL, V6, pS44, DOI 10.1177/0883073891006001S06; DuPaul GJ, 2001, J LEARN DISABIL-US, V34, P370, DOI 10.1177/002221940103400412; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Glass K, 2011, ADHD-ATTEND DEFICIT, V3, P29, DOI 10.1007/s12402-010-0042-y; Gross-Tsur V, 2006, DEV MED CHILD NEUROL, V48, P901, DOI 10.1017/S0012162206001976; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hoffman JB, 2000, CHILD ADOL PSYCH CL, V9, P647; IBM Corporation, 2012, IBM SPSS STAT WIND V; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jakobson A, 2007, J LEARN DISABIL-US, V40, P194, DOI 10.1177/00222194070400030101; Johnson DE, 2001, ARCH CLIN NEUROPSYCH, V16, P587; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Mayes SD, 2000, J LEARN DISABIL-US, V33, P417, DOI 10.1177/002221940003300502; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; MCGEE R, 1991, J AM ACAD CHILD PSY, V30, P224, DOI 10.1097/00004583-199103000-00010; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Merikangas KR, 2010, PEDIATRICS, V125, P75, DOI 10.1542/peds.2008-2598; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Penttila Jani, 2011, Duodecim, V127, P1433; Purvis KL, 1997, J ABNORM CHILD PSYCH, V25, P133, DOI 10.1023/A:1025731529006; Putukian M, 2011, CLIN J SPORT MED, V21, P392, DOI 10.1097/JSM.0b013e3182262eb1; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Seidman LJ, 2006, CLIN PSYCHOL REV, V26, P466, DOI 10.1016/j.cpr.2006.01.004; Seidman LJ, 1995, J CHILD PSYCHOL PSYC, V36, P1459, DOI 10.1111/j.1469-7610.1995.tb01675.x; Seidman LJ, 1997, J CONSULT CLIN PSYCH, V65, P150, DOI 10.1037/0022-006X.65.1.150; Seidman LJ, 2001, NEUROPSYCHOLOGY, V15, P544, DOI 10.1037/0894-4105.15.4.544; Seidman LJ, 2006, NEUROPSYCHOLOGY, V20, P166, DOI 10.1037/0894-4105.20.2.166; Seidman LJ, 2005, DEV NEUROPSYCHOL, V27, P79, DOI 10.1207/s15326942dn2701_4; Silver CH, 2008, ARCH CLIN NEUROPSYCH, V23, P217, DOI 10.1016/j.acn.2007.09.006; Skirrow C, 2009, EXPERT REV NEUROTHER, V9, P489, DOI [10.1586/ern.09.2, 10.1586/ERN.09.2]; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Tsushima William T, 2008, Hawaii Med J, V67, P93; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Willcutt EG, 2001, J ABNORM PSYCHOL, V110, P157, DOI 10.1037//0021-843X.1001.1.157; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	55	99	99	1	26	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2013	28	5					476	484		10.1093/arclin/act024			9	Psychology, Clinical; Psychology	Psychology	186CN	WOS:000322019600009	23608188	Bronze, Green Published			2021-06-18	
J	Goodrich, GS; Kabakov, AY; Hameed, MQ; Dhamne, SC; Rosenberg, PA; Rotenberg, A				Goodrich, Grant S.; Kabakov, Anatoli Y.; Hameed, Mustafa Q.; Dhamne, Sameer C.; Rosenberg, Paul A.; Rotenberg, Alexander			Ceftriaxone Treatment after Traumatic Brain Injury Restores Expression of the Glutamate Transporter, GLT-1, Reduces Regional Gliosis, and Reduces Post-Traumatic Seizures in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						epilepsy; glia cell response to injury; immunoblots; recovery; traumatic brain injury	CEREBRAL-CORTEX; INDUCTION; EPILEPSY; LOCALIZATION; MECHANISMS; TERMINALS; GLT1A	Excessive extracellular glutamate after traumatic brain injury (TBI) contributes to excitotoxic cell death and likely to posttraumatic epilepsy. Glutamate transport is the only known mechanism of extracellular glutamate clearance, and glutamate transporter 1 (GLT-1) is the major glutamate transporter of the mammalian brain. We tested, by immunoblot, in the rat lateral fluid percussion injury TBI model whether GLT-1 expression is depressed in the cortex after TBI, and whether GLT-1 expression after TBI is restored after treatment with ceftriaxone, a well-tolerated b-lactam antibiotic previously shown to enhance GLT-1 expression in noninjured animals. We then tested whether treatment with ceftriaxone mitigates the associated regional astrogliosis, as reflected by glial fibrillary acid protein (GFAP) expression, and also whether ceftriaxone treatment mitigates the severity of post-traumatic epilepsy. We found that 7 days after TBI, GLT-1 expression in the ipsilesional cortex was reduced by 29% (n = 7/group; p < 0.01), relative to the contralesional cortex. However, the loss of GLT-1 expression was reversed by treatment with ceftriaxone (200 mg/kg, daily, intraperitoneally). We found that ceftriaxone treatment also decreased the level of regional GFAP expression by 43% in the lesioned cortex, relative to control treatment with saline (n = 7 per group; p < 0.05), and, 12 weeks after injury, reduced cumulative post-traumatic seizure duration (n = 6 rats in the ceftriaxone treatment group and n = 5 rats in the saline control group; p < 0.001). We cautiously conclude that our data suggest a potential role for ceftriaxone in treatment of epileptogenic TBI.	[Goodrich, Grant S.; Kabakov, Anatoli Y.; Hameed, Mustafa Q.; Dhamne, Sameer C.; Rosenberg, Paul A.; Rotenberg, Alexander] Harvard Univ, Sch Med, Dept Neurol, Boston Childrens Hosp, Boston, MA 02115 USA; [Hameed, Mustafa Q.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Neurosurg, Boston, MA USA	Rotenberg, A (corresponding author), Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02215 USA.	alexander.rotenberg@childrens.harvard.edu	Hameed, Mustafa/G-3677-2014	Hameed, Mustafa/0000-0003-4004-5564; Rosenberg, Paul/0000-0002-5185-1118	Department of Defense (DoD) Defense Medical Research and Development Program Basic Research Award [PT090716]; Citizens United for Research in Epilepsy;  [NS066019]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS066019] Funding Source: NIH RePORTER	This work was supported by the Department of Defense (DoD) Defense Medical Research and Development Program Basic Research Award (PT090716; to A.R. and A.Y.K.), Citizens United for Research in Epilepsy (CURE; to A.R.), and NS066019 (to P.A.R.). The authors thank Drs. Roman Gersner and David Zurakowski for their advice related to statistical analysis of EEG data.	Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Berger UV, 2005, J COMP NEUROL, V492, P78, DOI 10.1002/cne.20737; Chen WZ, 2004, J NEUROSCI, V24, P1136, DOI 10.1523/JNEUROSCI.1586-03.2004; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DeSilva TM, 2009, J NEUROSCI, V29, P7898, DOI 10.1523/JNEUROSCI.6129-08.2009; Furness DN, 2008, NEUROSCIENCE, V157, P80, DOI 10.1016/j.neuroscience.2008.08.043; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Lai PC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-69; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; Lewerenz J, 2009, J NEUROCHEM, V111, P332, DOI 10.1111/j.1471-4159.2009.06347.x; Li TF, 2012, GLIA, V60, P83, DOI 10.1002/glia.21250; Luo P, 2011, BRAIN RES BULL, V85, P313, DOI 10.1016/j.brainresbull.2011.05.004; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntyre DC, 2007, EPILEPSIA, V48, P30, DOI 10.1111/j.1528-1167.2007.01398.x; Melone M, 2009, GLIA, V57, P108, DOI 10.1002/glia.20744; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Sari Y, 2009, J NEUROSCI, V29, P9239, DOI 10.1523/JNEUROSCI.1746-09.2009; Seifert G, 2010, BRAIN RES REV, V63, P212, DOI 10.1016/j.brainresrev.2009.10.004; Shaw FZ, 2007, J NEUROPHYSIOL, V97, P238, DOI 10.1152/jn.00340.2006; Shaw FZ, 2004, J NEUROPHYSIOL, V91, P63, DOI 10.1152/jn.00487.2003; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099	32	99	102	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2013	30	16					1434	1441		10.1089/neu.2012.2712			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	199JB	WOS:000322989500007	23510201	Green Published			2021-06-18	
J	Mysliwiec, V; Gill, J; Lee, H; Baxter, T; Pierce, R; Barr, TL; Krakow, B; Roth, BJ				Mysliwiec, Vincent; Gill, Jessica; Lee, Hyunhwa; Baxter, Tristin; Pierce, Roslyn; Barr, Taura L.; Krakow, Barry; Roth, Bernard J.			Sleep Disorders in US Military Personnel A High Rate of Comorbid Insomnia and Obstructive Sleep Apnea	CHEST			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH DISORDERS; DAYTIME SLEEPINESS; FIRE EVACUEES; IRAQ; VETERANS; DISTURBANCE; NIGHTMARES; DEPLOYMENT	Background: Sleep disturbances are among the most common symptoms of military personnel who return from deployment. The objective of our study was to determine the presence of sleep disorders in US military personnel referred for evaluation of sleep disturbances after deployment and examine associations between sleep disorders and service-related diagnoses of depression, mild traumatic brain injury, pain, and posttraumatic stress disorder (PTSD). Methods: This was a cross-sectional study of military personnel with sleep disturbances who returned from combat within 18 months of deployment. Sleep disorders were assessed by clinical evaluation and polysomnogram with validated instruments to diagnose service-related illnesses. Results: Of 110 military personnel included in our analysis, 97.3% were men (mean age, 33.6 +/- 8.0 years; mean BMI, 30.0 +/- 4.3 kg/m(2)), and 70.9% returned from combat within 12 months. Nearly one-half (47.3%) met diagnostic criteria for two or more service-related diagnoses. Sleep disorders were diagnosed in 88.2% of subjects; 11.8% had a normal sleep evaluation and served as control subjects. Overall, 62.7% met diagnostic criteria for obstructive sleep apnea (OSA) and 63.6% for insomnia. The exclusive diagnoses of insomnia and OSA were present in 25.5% and 24.5% of subjects, respectively; 38.2% had comorbid insomnia and OSA. Military personnel with comorbid insomnia and OSA were significantly more likely to meet criteria for depression (P < .01) and PTSD (P < .01) compared with control subjects and those with OSA only. Conclusions: Comorbid insomnia and OSA is a frequent diagnosis in military personnel referred for evaluation of sleep disturbances after deployment. This diagnosis, which is difficult to treat, may explain the refractory nature of many service-related diagnoses.	[Mysliwiec, Vincent; Baxter, Tristin; Pierce, Roslyn; Roth, Bernard J.] Madigan Army Med Ctr, Tacoma, WA 98431 USA; [Gill, Jessica; Lee, Hyunhwa] NIH, Bethesda, MD 20892 USA; [Barr, Taura L.] W Virginia Univ, Morgantown, WV 26506 USA; [Barr, Taura L.] Robert Wood Johnson Fdn, Morgantown, WV USA; [Krakow, Barry] Maimonides Sleep Arts & Sci Ltd, Sleep & Human Hlth Inst, Albuquerque, NM USA	Mysliwiec, V (corresponding author), Madigan Army Med Ctr, Dept Pulm Crit Care & Sleep Med, 9040A Fitzsimmons Ave, Tacoma, WA 98431 USA.	vincent.mysliwiec.mil@mail.mil	Gill, Gill M/Q-2020-2017	Lee, Hyunhwa/0000-0002-5625-3141	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855]; intramural department of the National Institutes of Health, National Institute of Nursing Research; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000029, ZIANR000027] Funding Source: NIH RePORTER	This study was supported, in part, by the Center for Neuroscience and Regenerative Medicine [Grant 60855]. Funding support was provided by the intramural department of the National Institutes of Health, National Institute of Nursing Research (to Drs Gill and Lee).	Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889; Al-Jawder SE, 2012, SLEEP BREATH, V16, P295, DOI 10.1007/s11325-011-0513-1; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; American Congress of Rehabilitation Medicine, DEF MILD TRAUM BRAIN; [Anonymous], 2010, MED SURVEILLANCE MON, V17, P12; Armed Forces Health Surveillance Center, 2010, MSMR, V17, P8; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Britt TW, 2007, MIL MED, V172, P157, DOI 10.7205/MILMED.172.2.157; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Chung KF, 2005, RESPIRATION, V72, P460, DOI 10.1159/000087668; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Collen JF, 2012, J CLIN SLEEP MED, V8, P667, DOI 10.5664/jcsm.2260; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; FERRER CF, 1995, AVIAT SPACE ENVIR MD, V66, P571; Frayne SM, 2011, J GEN INTERN MED, V26, P33, DOI 10.1007/s11606-010-1497-4; Guilleminault C, 2008, SLEEP, V31, P1527, DOI 10.1093/sleep/31.11.1527; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iber C, 2007, AASM MANUAL SCORING; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Joint Mental Health Advisory Team 7 (J-MHAT 7), OP END FREED 2010; Krakow B, 2004, J TRAUMA STRESS, V17, P257, DOI 10.1023/B:JOTS.0000029269.29098.67; Krakow B, 2002, J NERV MENT DIS, V190, P442, DOI 10.1097/00005053-200207000-00004; Krakow B, 2001, CHEST, V120, P1923, DOI 10.1378/chest.120.6.1923; Krakow B, 2000, J PSYCHOSOM RES, V49, P291, DOI 10.1016/S0022-3999(00)00147-1; Krakow B, 2001, BIOL PSYCHIAT, V49, P948, DOI 10.1016/S0006-3223(00)01087-8; Krakow Barry, 2002, Sleep Breath, V6, P189; Krakow BJ, 2002, J CLIN PSYCHIAT, V63, P673, DOI 10.4088/JCP.v63n0804; Krell Suzanne B, 2005, Sleep Breath, V9, P104, DOI 10.1007/s11325-005-0026-x; Lettieri CJ, 2005, J CLIN SLEEP MED, V1, P381; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; Luyster FS, 2010, J CLIN SLEEP MED, V6, P196; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Miller NL, 2010, SLEEP, V33, P1623, DOI 10.1093/sleep/33.12.1623; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Peppard PE, 2013, SLEEP, V36, P7, DOI 10.5665/sleep.2284; Persson HE, 1996, CHEST, V109, P645, DOI 10.1378/chest.109.3.645; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Ryan CM, 2005, J APPL PHYSIOL, V99, P2440, DOI 10.1152/japplphysiol.00772.2005; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Sharafkhaneh A, 2005, SLEEP, V28, P1405, DOI 10.1093/sleep/28.11.1405; Sinnott C, 2005, DIABETES CARE, V28, P1534, DOI 10.2337/diacare.28.6.1534; Smith S, 2004, SLEEP MED, V5, P449, DOI 10.1016/j.sleep.2004.03.005; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; STOOHS RA, 1993, NEW ENGL J MED, V328, P1279, DOI 10.1056/NEJM199304293281714; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Wickwire EM, 2010, CHEST, V137, P1449, DOI 10.1378/chest.09-1485; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Yang CM, 2011, J PSYCHOSOM RES, V70, P355, DOI 10.1016/j.jpsychores.2010.12.005; Younes M, 2004, AM J RESP CRIT CARE, V169, P623, DOI 10.1164/rccm.200307-1023OC	60	99	100	0	26	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0012-3692	1931-3543		CHEST	Chest	AUG	2013	144	2					549	557		10.1378/chest.13-0088			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	199UQ	WOS:000323021400030	23681455	Green Published			2021-06-18	
J	Topjian, AA; Gutierrez-Colina, AM; Sanchez, SM; Berg, RA; Friess, SH; Dlugos, DJ; Abend, NS				Topjian, Alexis A.; Gutierrez-Colina, Ana M.; Sanchez, Sarah M.; Berg, Robert A.; Friess, Stuart H.; Dlugos, Dennis J.; Abend, Nicholas S.			Electrographic Status Epilepticus Is Associated With Modality and Worse Short-Term Outcome in Critically Ill Children	CRITICAL CARE MEDICINE			English	Article						electroencephalographic monitoring; nonconvulsive seizure; outcome; pediatric; seizure; status epilepticus	NONCONVULSIVE STATUS EPILEPTICUS; INTENSIVE-CARE-UNIT; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; TRAUMATIC BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; NEONATAL SEIZURES; EEG PATTERNS; PREDICTION; ELECTROENCEPHALOGRAPHY; ARREST	Objectives: Electrographic seizures and electrographic status epilepticus are common in critically ill children. We aimed to determine whether electrographic seizures and electrographic status epilepticus are associated with higher mortality or worse short-term neurologic outcome. Design: Prospective observational study. Setting: PICU of a tertiary children's hospital. Patients: Non-neonatal children admitted to a PICU with acute encephalopathy underwent continuous electroencephalographic monitoring. Electroencephalographs were scored as 1) no seizures, 2) electrographic seizures, or 3) electrographic status epilepticus. Covariates included age, acute neurologic disorder category, prior neurodevelopmental status, sex, and electroencephalographic background category. Outcomes were mortality and worsening of pediatric cerebral performance category from preadmission to PICU discharge. Chi-square analysis, Fisher's exact test, and multivariable logistic regression were used to evaluate the associations between electrographic seizures or electrographic status epilepticus and mortality or short-term neurologic outcome, using odds ratios and 95% confidence intervals. Interventions: None. Main Results: Two hundred children underwent continuous electroencephalographic monitoring. Eighty-four (42%) had seizures, which were categorized as electrographic seizures in 41 (20.5%) and electrographic status epilepticus in 43 (21.5%). Thirty-six subjects (18%) died, and 88 subjects (44%) had pediatric cerebral performance category worsening. In multivariable analysis, electrographic status epilepticus was associated with an increased risk of mortality (odds ratio 5.1; 95% confidence interval 1.4, 18; p = 0.01) and pediatric cerebral performance category worsening (odds ratio 17.3; 95% confidence interval 3.7, 80; p < 0.001), whereas electrographic seizures were not associated with an increased risk of mortality (odds ratio 1.3; 95% confidence interval 0.3, 5.1; p = 0.74) or pediatric cerebral performance category worsening (odds ratio 1.2; 95% confidence interval 0.4, 3.9; p = 0.77). Conclusions: Electrographic status epilepticus, but not electrographic seizures, is associated with mortality and worse short-term neurologic outcome in critically ill children with acute encephalopathy. (Crit Care Med 2013; 41:215-223)	[Topjian, Alexis A.; Berg, Robert A.; Friess, Stuart H.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Gutierrez-Colina, Ana M.; Sanchez, Sarah M.; Dlugos, Dennis J.; Abend, Nicholas S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Abend, NS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA.	abend@email.chop.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K12HD047349, U01HL094345, 5K08NS064051, K23NS076550]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS064051, K23NS075363, K23NS076550] Funding Source: NIH RePORTER	Dr. Topjian received grant support from NIH 5K12HD047349 and U01HL094345. Dr. Friess received grant support from NIH 5K08NS064051. Dr. Abend received grant support from NIH K23NS076550.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Alehan FK, 2001, J CHILD NEUROL, V16, P484, DOI 10.1177/088307380101600704; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; CHELIOUT-HERAUT F, 1991, Neurophysiologie Clinique, V21, P121, DOI 10.1016/S0987-7053(05)80066-8; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; CLANCY RR, 1988, EPILEPSIA, V29, P256, DOI 10.1111/j.1528-1157.1988.tb03715.x; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Greiner HM, 2012, PEDIATRICS, V129, pE748, DOI 10.1542/peds.2011-2067; Hauf M, 2009, AM J NEURORADIOL, V30, P693, DOI 10.3174/ajnr.A1456; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Kessler SK, 2011, NEUROCRIT CARE, V14, P37, DOI 10.1007/s12028-010-9450-2; Mandel R, 2002, J PEDIATR-US, V141, P45, DOI 10.1067/mpd.2002.125005; McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506; McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; Nash KB, 2011, NEUROLOGY, V76, P556, DOI 10.1212/WNL.0b013e31820af91a; Nishisaki A, 2007, PEDIATR CRIT CARE ME, V8, P10, DOI 10.1097/01.pcc.0000256621.63135.4b; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; PAMPIGLI.G, 1968, LANCET, V1, P1261; Pampiglione G, 1978, Ann N Y Acad Sci, V315, P281, DOI 10.1111/j.1749-6632.1978.tb50346.x; Pisani F, 2007, NEUROLOGY, V69, P2177, DOI 10.1212/01.wnl.0000295674.34193.9e; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; RamachandranNair R, 2005, PEDIATR NEUROL, V33, P345, DOI 10.1016/j.pediatrneurol.2005.05.007; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Scher MS, 2003, PEDIATR NEUROL, V28, P277, DOI 10.1016/S0887-8994(02)00621-5; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; TASKER RC, 1988, ARCH DIS CHILD, V63, P895, DOI 10.1136/adc.63.8.895; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Wusthoff CJ, 2011, J CHILD NEUROL, V26, P724, DOI 10.1177/0883073810390036; Young GB, 1996, NEUROLOGY, V47, P83	41	99	101	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2013	41	1					215	223		10.1097/CCM.0b013e3182668035			9	Critical Care Medicine	General & Internal Medicine	065LR	WOS:000313150300024	23164815	Green Accepted			2021-06-18	
J	Liu, AL; Margaill, I; Zhang, SD; Labombarda, F; Coqueran, B; Delespierre, B; Liere, P; Marchand-Leroux, C; O'Malley, BW; Lydon, JP; De Nicola, AF; Sitruk-Ware, R; Mattern, C; Plotkine, M; Schumacher, M; Guennoun, R				Liu, Ailing; Margaill, Isabelle; Zhang, Shaodong; Labombarda, Florencia; Coqueran, Berard; Delespierre, Brigitte; Liere, Philippe; Marchand-Leroux, Catherine; O'Malley, Bert W.; Lydon, John P.; De Nicola, Alejandro F.; Sitruk-Ware, Regine; Mattern, Claudia; Plotkine, Michel; Schumacher, Michael; Guennoun, Rachida			Progesterone Receptors: A Key for Neuroprotection in Experimental Stroke	ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; NEUROACTIVE STEROIDS; INFARCT VOLUME; SPINAL-CORD; MICE; NEUROSTEROIDS; OCCLUSION; ISCHEMIA; QUANTIFICATION	Progesterone receptors (PR) are expressed throughout the brain. However, their functional significance remains understudied. Here we report a novel role of PR as crucial mediators of neuroprotection using a model of transient middle cerebral artery occlusion and PR knockout mice. Six hours after ischemia, we observed a rapid increase in progesterone and 5 alpha-dihydroprogesterone, the endogenous PR ligands, a process that may be a part of the natural neuroprotective mechanisms. PR deficiency, and even haploinsufficiency, increases the susceptibility of the brain to stroke damage. Within a time window of 24 h, PR-dependent signaling of endogenous brain progesterone limits the extent of tissue damage and the impairment of motor functions. Longer-term improvement requires additional treatment with exogenous progesterone and is also PR dependent. The potent and selective PR agonist Nestorone is also effective. In contrast to progesterone, levels of the neurosteroid allopregnanolone, which modulates gamma-aminobutyric acid type A receptors, did not increase after stroke, but its administration protected both wild-type and PR-deficient mice against ischemic damage. These results show that 1) PR are linked to signaling pathways that influence susceptibility to stroke, and 2) PR are direct key targets for both endogenous neuroprotection and for therapeutic strategies after stroke, and they suggest a novel indication for synthetic progestins already validated for contraception. Although allopregnanolone may not be an endogenous neuroprotective agent, its administration protects the brain against ischemic damage by signaling mechanisms not involving PR. Collectively, our data clarify the relative roles of PR and allopregnanolone in neuroprotection after stroke. (Endocrinology 153: 3747-3757, 2012)	[Liu, Ailing; Zhang, Shaodong; Delespierre, Brigitte; Liere, Philippe; Schumacher, Michael; Guennoun, Rachida] Inst Natl Sante & Rech Med, Unite Mixte Rech 788, F-94276 Le Kremlin Bicetre, France; [Liu, Ailing; Zhang, Shaodong; Delespierre, Brigitte; Liere, Philippe; Schumacher, Michael; Guennoun, Rachida] Univ Paris 11, F-94276 Le Kremlin Bicetre, France; [Margaill, Isabelle; Coqueran, Berard; Marchand-Leroux, Catherine; Plotkine, Michel] Univ Paris 05, Pharmacol Circulat Cerebrale EA4475, F-75006 Paris, France; [Labombarda, Florencia; De Nicola, Alejandro F.] Univ Buenos Aires, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; [Labombarda, Florencia; De Nicola, Alejandro F.] Univ Buenos Aires, Dept Human Biochem, RA-1428 Buenos Aires, DF, Argentina; [O'Malley, Bert W.; Lydon, John P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Sitruk-Ware, Regine] Rockefeller Univ, Populat Council, Ctr Biomed Res, New York, NY 10065 USA; [Mattern, Claudia] M&P Pharma AG, CH-6370 Stans, Switzerland	Guennoun, R (corresponding author), Inst Natl Sante & Rech Med, Unite Mixte Rech 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	rachida.guennoun@inserm.fr	Guennoun, Rachida/F-2420-2011; Margaill, Isabelle/ABA-4362-2020; MARCHAND-LEROUX, Catherine/L-7453-2017; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Margaill, Isabelle/0000-0002-7941-6644; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Schumacher, Michael/0000-0001-6117-5371	Institut National de la Sante et de la Recherche Medicale (INSERM), University Paris-Sud; Barrus Foundation; University Paris-Sud; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD008188, R01HD007857] Funding Source: NIH RePORTER	This work was supported by Institut National de la Sante et de la Recherche Medicale (INSERM), University Paris-Sud, a cooperative program between the Governments of France and Argentina (INSERM/CONICET), and by the Barrus Foundation. A. L. was beneficiary of a postdoctoral fellowship from University Paris-Sud. M. S. is the beneficiary of an Interface Program of INSERM and the Assistance Publique-Hopitaux de Paris.	Attardi BJ, 2010, MOL CELL ENDOCRINOL, V328, P16, DOI 10.1016/j.mce.2010.06.010; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Blaustein JD, 2008, ENDOCRINOLOGY, V149, P2737, DOI 10.1210/en.2008-0395; Conneely OM, 2002, RECENT PROG HORM RES, V57, P339, DOI 10.1210/rp.57.1.339; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gofflot F, 2007, CELL, V131, P405, DOI 10.1016/j.cell.2007.09.012; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Krebs CJ, 2000, P NATL ACAD SCI USA, V97, P12816, DOI 10.1073/pnas.97.23.12816; Kumar N, 2000, STEROIDS, V65, P629, DOI 10.1016/S0039-128X(00)00119-7; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Langmade SJ, 2006, P NATL ACAD SCI USA, V103, P13807, DOI 10.1073/pnas.0606218103; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Liere P, 2009, J LIPID RES, V50, P2430, DOI 10.1194/jlr.M900162-JLR200; Liu L, ENDOCRINOLOGY, V151, P5782; Liu MY, 2009, RESTOR NEUROL NEUROS, V27, P163, DOI 10.3233/RNN-2009-0467; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez AD, 2006, MEASURING GLOBAL BUR; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Mani SK, 1997, HORM BEHAV, V31, P244, DOI 10.1006/hbeh.1997.1393; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; PARSONS B, 1982, J NEUROSCI, V2, P1446; Peinnequin Andre, 2004, BMC Immunology, V5, P1, DOI 10.1186/1471-2172-5-3; PFAFF DW, 1983, SCIENCE, V219, P808, DOI 10.1126/science.6297008; Reddy DS, 2005, NEUROPHARMACOLOGY, V48, P14, DOI 10.1016/j.neuropharm.2004.09.002; Rupprecht R, 1996, EUR J PHARMACOL, V303, P227, DOI 10.1016/0014-2999(96)00036-2; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schifilliti D, 2010, CNS DRUGS, V24, P893, DOI 10.2165/11584760-000000000-00000; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Thomas P, 2008, FRONT NEUROENDOCRIN, V29, P292, DOI 10.1016/j.yfrne.2008.01.001; Tureyen K, 2004, J NEUROSCI METH, V139, P203, DOI 10.1016/j.jneumeth.2004.04.029; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	48	99	101	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	AUG	2012	153	8					3747	3757		10.1210/en.2012-1138			11	Endocrinology & Metabolism	Endocrinology & Metabolism	977JD	WOS:000306652400022	22635678	Bronze, Green Published			2021-06-18	
J	Burlew, CC; Biffl, WL; Moore, EE; Barnett, CC; Johnson, JL; Bensard, DD				Burlew, Clay Cothren; Biffl, Walter L.; Moore, Ernest E.; Barnett, Carlton C.; Johnson, Jeffrey L.; Bensard, Denis D.			Blunt cerebrovascular injuries: Redefining screening criteria in the era of noninvasive diagnosis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 14-17, 2011	Chicago, IL	Amer Assoc Surg Trauma		Cerebrovascular injury; carotid artery injury; vertebral artery injury; trauma; antithrombotics; screening criteria; guidelines	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CAROTID ARTERIAL INJURIES; VASCULAR NECK INJURIES; TRAUMA; OUTCOMES; ASSOCIATION; ACCURACY; IMPROVES	BACKGROUND: Screening for blunt cerebrovascular injuries (BCVIs) and early treatment has virtually eliminated injury-related strokes. Screening protocols developed in the 1990s captured similar to 80% of ultimately identified BCVI. With the availability of noninvasive diagnosis with computed tomographic angiography, broader indications for screening seem warranted. The purpose of this study was to identify injury patterns of patients with BCVI that are not currently recommended screening criteria. METHODS: Our prospective BCVI database, initiated in 1997, was queried through December 2010. Indications for screening, injury mechanism, and outcomes were analyzed. Patients younger than 18 years were excluded. RESULTS: During the 14-year study period, 585 BCVIs were identified in 418 patients (66% men; age, 40 years +/- 0.7 years). Eighty-three (20%) patients with BCVI did not have standard screening criteria; 66% were asymptomatic at diagnosis. Injury patterns in these patients included mandible fracture (27 patients), complex skull fractures (21 patients), traumatic brain injury with thoracic trauma (6 patients), scalp degloving (6 patients), and great vessel or cardiac injuries (4 patients). Other injuries (11 patients) and no injuries (8 patients) were identified in the remainder. Of the 307 asymptomatic patients who received antithrombotic treatment, one patient suffered stroke (0.3%) and one patient a transient ischemic attack (0.3%). CONCLUSIONS: A significant number of patients suffering BCVI are not captured by current screening guidelines. Screening for BCVI should be considered in patients with mandible fractures, complex skull fractures, traumatic brain injury with thoracic injuries, scalp degloving, and thoracic vascular injuries. (J Trauma. 2012; 72: 330-337. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Burlew, Clay Cothren] Denver Hlth Med Ctr, Dept Surg, Denver, CO 80204 USA; Univ Colorado, Sch Med, Denver, CO USA	Burlew, CC (corresponding author), Denver Hlth Med Ctr, Dept Surg, 777 Bannock St,MC 0206, Denver, CO 80204 USA.	clay.cothren@dhha.org					Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Cook A, 2011, J TRAUMA, V71, P114, DOI 10.1097/TA.0b013e31821c350f; Cothren CC, 2007, SURGERY, V141, P76, DOI 10.1016/j.surg.2006.04.005; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2005, AM J SURG, V190, P845, DOI 10.1016/j.amsurg.2005.08.007; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; CRISSEY MM, 1974, SURGERY, V75, P543; DAVIS JW, 1990, J TRAUMA, V30, P1514, DOI 10.1097/00005373-199012000-00013; DiCocco JM, 2011, J AM COLL SURGEONS, V212, P549, DOI 10.1016/j.jamcollsurg.2010.12.035; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Eastman AL, 2009, J TRAUMA, V67, P551, DOI 10.1097/TA.0b013e3181b84408; Emmett KP, 2011, J TRAUMA, V70, P1058, DOI 10.1097/TA.0b013e318213f849; Fabian TC, 2002, ANN SURG, V235, P706; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FABIAN TC, 1990, J TRAUMA, V30, P953, DOI 10.1097/00005373-199008000-00003; Fleck SK, 2011, NEUROSURGERY, V69, P615, DOI 10.1227/NEU.0b013e31821a8701; Flint L, 2011, J AM COLL SURGEONS, V212, P557; Hipp A, 2008, EUR J EMERG MED, V15, P134, DOI 10.1097/MEJ.0b013e328270367d; Jones TS, 2011, AM J SURG; KRAJEWSKI LP, 1980, ANN SURG, V191, P341, DOI 10.1097/00000658-198003000-00014; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McKevitt EC, 2002, J TRAUMA, V53, P472, DOI 10.1097/00005373-200209000-00013; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; MOKRI B, 1988, J NEUROSURG, V68, P189, DOI 10.3171/jns.1988.68.2.0189; Parikh AA, 1997, J AM COLL SURGEONS, V185, P80, DOI 10.1016/S1072-7515(01)00886-9; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Sliker CW, 2008, AM J ROENTGENOL, V190, P790, DOI 10.2214/AJR.07.2378; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Utter GH, 2006, J AM COLL SURGEONS, V203, P838, DOI 10.1016/j.jamcollsurg.2006.08.003	39	99	99	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2012	72	2					330	337		10.1097/TA.0b013e31823de8a0			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	898ZN	WOS:000300781000021	22327974				2021-06-18	
J	Miyai, I; Sonoda, S; Nagai, S; Takayama, Y; Inoue, Y; Kakehi, A; Kurihara, M; Ishikawa, M				Miyai, Ichiro; Sonoda, Shigeru; Nagai, Shota; Takayama, Yuko; Inoue, Yukiko; Kakehi, Atsuo; Kurihara, Masaki; Ishikawa, Makoto			Results of New Policies for Inpatient Rehabilitation Coverage in Japan	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						inpatient rehabilitation facility; rehabilitation outcome; stroke; medical insurance	EARLY SUPPORTED DISCHARGE; STROKE UNIT; MULTIDISCIPLINARY REHABILITATION; BENEFIT; MORTALITY; RECOVERY; PROGRAM; LENGTH; STAY; TIME	Background. A new interdisciplinary postacute rehabilitation unit, the Kaifukuki (convalescent) rehabilitation ward (KRW), has been incorporated into the Japanese medical insurance system since 2000. More than 57 000 beds (45 beds per 100 000 population) are currently available nationwide. The maximal coverage for therapy sessions increased from 2 to 3 hours per day, 7 days a week, in 2006. Objective. To investigate how changes in policy affected rehabilitation outcomes of KRWs in a retrospective cohort study of 87 917 patients over 10 years. Results. The mean (standard deviation) age of the patients was 73.0 (13.8) years, and 55.4% were women. Diagnoses included stroke (47.9%); orthopedic diseases, including hip fracture (35.2%); and traumatic brain and spinal cord injury (5.4 %). Onset-admission interval (OAI) was 31.5 (18.6) days, length of stay was 75.9 (46.1) days, and 69.1% were discharged home. Daily therapy time was 79.4 (34.5) minutes. Admission/discharge scores of the Barthel Index and the Functional Independence Measure were 49.3 (31.0)/70.4 (31.9) and 75.3 (31.2)/91.7 (31.8), respectively. Year-by-year comparison revealed that older age, greater initial disability, and shorter OAI were coupled with a higher dose of rehabilitative interventions and a higher rate of home discharge. Longitudinal data from a cohort of hospitals implied a small but significant dose-dependent effect of hours of therapy on rehabilitation outcome after stroke. Conclusions. Although the organization of KRWs is in flux as the system of hospitals grows, results over the past 8 years suggest that changes in national insurance policies are affecting the quantity and organization of rehabilitation interventions and improvement in patient outcomes.	[Miyai, Ichiro] Morinomiya Hosp, Neurorehabil Res Inst, Joto Ku, Osaka 5360025, Japan; [Miyai, Ichiro; Sonoda, Shigeru; Nagai, Shota; Takayama, Yuko; Kurihara, Masaki; Ishikawa, Makoto] Kaifukuki Rehabil Ward Assoc, Annual Survey Comm, Tokyo, Japan; [Sonoda, Shigeru] Fujita Hlth Univ, Tsu, Mie, Japan; [Nagai, Shota] Kinjo Univ, Haku San, Ishikawa, Japan; [Takayama, Yuko] Ukai Rehabil Hosp, Aichi, Japan; [Inoue, Yukiko; Kakehi, Atsuo] Natl Inst Publ Hlth, Saitama, Japan; [Kurihara, Masaki] Nagasaki Rehabil Hosp, Nagasaki, Japan; [Ishikawa, Makoto] Hatsudai Rehabil Hosp, Tokyo, Japan	Miyai, I (corresponding author), Morinomiya Hosp, Neurorehabil Res Inst, Joto Ku, 2-1-88 Morinomiya, Osaka 5360025, Japan.	webeo@ga2.so-net.ne.jp	Sonoda, Shigeru/V-9529-2019	Sonoda, Shigeru/0000-0001-7491-5308			Indredavik B, 1999, STROKE, V30, P917, DOI 10.1161/01.STR.30.5.917; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; Indredavik B, 2000, STROKE, V31, P2989, DOI 10.1161/01.STR.31.12.2989; JORGENSEN HS, 1995, STROKE, V26, P1178, DOI 10.1161/01.STR.26.7.1178; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Langhorne P, 2005, LANCET, V365, P501; Langhorne P, 2001, STROKE, V32, P268, DOI 10.1161/01.STR.32.1.268; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; MAHONEY F I, 1965, Md State Med J, V14, P61; Miyai I, 1998, J NEUROL REHABIL, V12, P95; Ottenbacher KJ, 2004, JAMA-J AM MED ASSOC, V292, P1687, DOI 10.1001/jama.292.14.1687; Shelton FDAP, 2001, NEUROREHAB NEURAL RE, V15, P229, DOI 10.1177/154596830101500311; Sonoda S, 2004, AM J PHYS MED REHAB, V83, P88, DOI 10.1097/01.PHM.0000107481.69424.E1; Stuart M, 2009, NEUROREHAB NEURAL RE, V23, P726, DOI 10.1177/1545968309332734; Thorsen AM, 2005, STROKE, V36, P297, DOI 10.1161/01.STR.0000152288.42701.a6; Yagura H, 2005, CEREBROVASC DIS, V20, P258, DOI 10.1159/000087708; Yagura H, 2003, ARCH PHYS MED REHAB, V84, P1687, DOI 10.1053/S0003-9993(03)00286-7	21	99	100	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL-AUG	2011	25	6					540	547		10.1177/1545968311402696			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	774KL	WOS:000291384200006	21451116				2021-06-18	
J	Zweifel, C; Castellani, G; Czosnyka, M; Helmy, A; Manktelow, A; Carrera, E; Brady, KM; Hutchinson, PJA; Menon, DK; Pickard, JD; Smielewski, P				Zweifel, Christian; Castellani, Gianluca; Czosnyka, Marek; Helmy, Adel; Manktelow, Anne; Carrera, Emmanuel; Brady, Kenneth M.; Hutchinson, Peter J. A.; Menon, David K.; Pickard, John D.; Smielewski, Peter			Noninvasive Monitoring of Cerebrovascular Reactivity with Near Infrared Spectroscopy in Head-Injured Patients	JOURNAL OF NEUROTRAUMA			English	Article						cerebrovascular pressure reactivity; near infrared spectroscopy; optimal arterial blood pressure; optimal cerebral perfusion pressure; cerebrovascular pressure reactivity; total hemoglobin reactivity	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; BLOOD-PRESSURE; AUTOREGULATION	Monitoring of cerebrovascular pressure reactivity (PRx) has diagnostic and prognostic value in head-injured patients, but requires invasive monitoring of intracranial pressure (ICP). Near infrared spectroscopy (NIRS) is a noninvasive method that is suitable for continuous detection of cerebral blood volume changes. We compared a NIRS-based index of cerebrovascular reactivity, called total hemoglobin reactivity (THx), against standard measurements of PRx in a prospective observational study. Forty patients with closed-head injury were monitored daily with arterial blood pressure (ABP), ICP, and a NIRS-based total hemoglobin index. PRx and THx were calculated as the moving correlation coefficients using 5-min time windows between 10-sec averaged values of ICP and ABP, and total hemoglobin index and ABP, respectively. A total of 120 recordings were performed between the median first (IQR 0.75-2) and fourth (IQR 2-6) day after head injury, giving a total duration of 1760 hours. PRx and THx demonstrated a significant association across averaged individual recordings (r=0.49, p<0.0001), and across patients (r=0.56, p=0.0002). Assessment of optimal cerebral perfusion pressure (CPP) and ABP using THx was possible in about 50% of recordings, and showed a significant agreement with the optimal CPP and ABP assessed with PRx. THx may be of diagnostic value to optimize therapy oriented toward restoration and continuity of cerebrovascular reactivity, especially in patients for whom direct ICP monitoring is not feasible.	[Zweifel, Christian; Castellani, Gianluca; Czosnyka, Marek; Helmy, Adel; Carrera, Emmanuel; Hutchinson, Peter J. A.; Pickard, John D.; Smielewski, Peter] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Manktelow, Anne; Menon, David K.] Univ Cambridge, Sch Clin, Dept Anaesthet, Cambridge, England; [Zweifel, Christian] Univ Basel Hosp, Dept Neurosurg, CH-4031 Basel, Switzerland; [Castellani, Gianluca] Fdn Policlin San Matteo, Dept Anaesthesia & Crit Care, Pavia, Italy; [Brady, Kenneth M.] Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA	Zweifel, C (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, Dept Clin Neurosci, Level 4,A Block, Cambridge CB2 2QQ, England.	zweifelch@gmx.ch	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carrera, Emmanuel/0000-0003-0045-5382; Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research, Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; NIHRNational Institute for Health Research (NIHR); Swiss National Science Foundation, Bern, SwitzerlandSwiss National Science Foundation (SNSF) [PBBSP3-125550, PASSMP3-124262]; Academy of Medical Science Health Foundation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0802251, G0601025] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, ACF-2006-14-004] Funding Source: researchfish	This work was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), the Medical Research Council (grants G0600986 and G9439390), and NIHR Senior Investigator Awards (to J.D.P. and D.K.M.); and also by the Swiss National Science Foundation (PBBSP3-125550 to C.Z. and PASSMP3-124262 to E.C.), Bern, Switzerland. E.C. was additionally supported by the SICPA Foundation, Lausanne, Switzerland. P.J.A.H. is supported by an Academy of Medical Science Health Foundation Senior Surgical Scientific Fellowship.	Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Balestreri M, 2005, ACT NEUR S, V95, P25; BARZO P, 1993, NEUROSURGERY, V32, P611; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; HARRIS DN, 1993, LANCET, V342, P586, DOI 10.1016/0140-6736(93)91412-F; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Lee JS, 2009, STROKE, V40, pE131; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Menon DK, 2004, ANAESTHESIA, V59, P785, DOI 10.1111/j.1365-2044.2004.03800.x; Ragauskas A, 2005, ACTA NEUROCHIR SUPPL, V95, P367; Schmidt B, 1997, STROKE, V28, P2465, DOI 10.1161/01.STR.28.12.2465; Smielewski P, 2005, ACT NEUR S, V95, P43; Soul JS, 2007, PEDIATR RES, V61, P467, DOI 10.1203/pdr.0b013e31803237f6; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Tofteng F, 2004, METAB BRAIN DIS, V19, P207, DOI 10.1023/B:MEBR.0000043970.34533.04; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Yoshitani K, 2007, ANESTHESIOLOGY, V106, P458, DOI 10.1097/00000542-200703000-00009; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	23	99	99	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1951	1958		10.1089/neu.2010.1388			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500002	20812789				2021-06-18	
J	Muller, F; Simion, A; Reviriego, E; Galera, C; Mazaux, JM; Barat, M; Joseph, PA				Muller, Francois; Simion, Audrey; Reviriego, Elsa; Galera, Cedric; Mazaux, Jean-Michel; Barat, Michel; Joseph, Pierre-Alain			Exploring theory of mind after severe traumatic brain injury	CORTEX			English	Article						Theory of mind; Empathy; Head injury; Social cognition	VENTROMEDIAL PREFRONTAL CORTEX; HIGH-FUNCTIONING AUTISM; EMOTION RECOGNITION; ASPERGER-SYNDROME; SOCIAL COMMUNICATION; NONVERBAL TASK; EMPATHY; ATTRIBUTION; INTENTIONS; COGNITION	Previous studies have reported a dissociation between social behavioral impairments after severe traumatic brain injury (TBI) and relatively preserved performances in traditional tasks that investigate cognitive abilities. Theory of mind (ToM) refers to the ability to make inferences about other's mental states and use them to understand and predict others' behavior. We tested a group of 15 patients with severe TBI and 15 matched controls on a series of four verbal and non-verbal ToM tasks: the faux pas test, the first-order and second-order false belief task, the character intention task and the Reading the Mind in the Eyes Test. Participants with severe TBI were also compared to controls on non-ToM inference tasks of indirect speech act from the Montreal Evaluation of Communication (M.E.C.) Protocol and empathy (Davis Interpersonal Reactivity Index - I.R.I.) and tests for executive functions. Subjects with TBI performed worse than control subjects on all ToM tasks, except the first-order false belief task. The findings converge with previous evidence for ToM deficit in TBI and dissociation between ToM and executive functions. We show that ToM deficit is probably distinct from other aspects of social cognition like empathy and pragmatic communication skills. (C) 2009 Elsevier Srl. All rights reserved.	[Muller, Francois; Simion, Audrey; Reviriego, Elsa; Mazaux, Jean-Michel; Barat, Michel; Joseph, Pierre-Alain] CHU Pellegrin, Serv Med Phys & Readaptat, F-33076 Bordeaux, France; [Galera, Cedric] Ctr Hosp Charles Perrens, Serv Univ Psychiat Enfant & Adolescent, Bordeaux, France	Muller, F (corresponding author), CHU Pellegrin, Serv Med Phys & Readaptat, F-33076 Bordeaux, France.	fmuller.gassies@ugecamaq.fr	Galera, Cedric/T-4896-2019	GALERA, CEDRIC/0000-0003-0549-9608			Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; BACH L, 1998, COGNITIVE NEUROPSYCH, V3, P139; Bach LJ, 2000, COGN NEUROPSYCHIATRY, V5, P175, DOI DOI 10.1080/13546800050083520; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; BRUYER R., 1995, ARCH PSYCHOL, V63, P257; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Joanette Y., 2004, PROTOCOLE MONTREAL E; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Perner J, 1999, TRENDS COGN SCI, V3, P337, DOI 10.1016/S1364-6613(99)01362-5; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Russell J, 1999, J CHILD PSYCHOL PSYC, V40, P859, DOI 10.1111/1469-7610.00504; Sarfati Y, 1997, SCHIZOPHR RES, V25, P199, DOI 10.1016/S0920-9964(97)00025-X; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T, 2001, BRAIN, V124, P247, DOI 10.1093/brain/124.2.247; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Spinella M, 2005, BIOL PSYCHOL, V70, P175, DOI 10.1016/j.biopsycho.2004.01.005; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Vollm BA, 2006, NEUROIMAGE, V29, P90, DOI 10.1016/j.neuroimage.2005.07.022; WECHSLER DA, 1987, STANDARDIZED MEMORY; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wolfson D., 1993, HALSTEAD REITAN NEUR	53	99	100	0	54	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	OCT	2010	46	9					1088	1099		10.1016/j.cortex.2009.08.014			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	659JA	WOS:000282561600004	19828142				2021-06-18	
J	Yu, SJ; Kaneko, Y; Bae, E; Stahl, CE; Wang, Y; van Loveren, H; Sanberg, PR; Borlongan, CV				Yu, Seongjin; Kaneko, Yuji; Bae, Eunkyung; Stahl, Christine E.; Wang, Yun; van Loveren, Harry; Sanberg, Paul R.; Borlongan, Cesar V.			Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits	BRAIN RESEARCH			English	Article						Head injury; Cortical damage; Locomotor and cognitive behaviors; Animal model	THERAPEUTIC STRATEGY; UNITED-STATES; CELL THERAPY; TRANSPLANTATION; STROKE; VOLUME; DEATH	The clinical presentation of traumatic brain injury (TBI) involves either mild, moderate, or severe injury to the head resulting in long-term and even permanent disability. The recapitulation of this clinical scenario in animal models should allow examination of the pathophysiology of the trauma and its treatment. To date, only a few studies have demonstrated TBI animal models encompassing the three levels of trauma severity. Thus, in the present study we characterized in mice and rats both brain histopathologic and behavioral alterations across a range of injury magnitudes arising from mild, moderate, and severe TBI produced by controlled cortical impact injury technique. Here, we replicated the previously observed TBI severity-dependent brain damage as revealed by 2,3,5-triphenyltetrazolium chloride staining (severe > moderate > mild) in rats, but also extended this pattern of histopathologic changes in mice. Moreover, we showed severity-dependent abnormalities in locomotor and cognitive behaviors in TBI-exposed rats and mice. Taken together, these results support the use of rodent models of TBI as a sensitive platform for investigations of the injury-induced neurostructural and behavioral deficits, which should serve as key outcome parameters for testing experimental therapeutics. (C) 2009 Elsevier B.V. All rights reserved.	[van Loveren, Harry; Sanberg, Paul R.; Borlongan, Cesar V.] Univ S Florida, Dept Neurosurg, Tampa, FL 33612 USA; [Yu, Seongjin; Kaneko, Yuji; Bae, Eunkyung; Borlongan, Cesar V.] Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; [Stahl, Christine E.] Dwight D Eisenhower Army Med Ctr, Dept Internal Med, Augusta, GA 30905 USA; [Wang, Yun] NIDA, Neural Protect & Regenerat Sect, NIH, Baltimore, MD 21224 USA	Borlongan, CV (corresponding author), Univ S Florida, Dept Neurosurg, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Kaneko, Yuji/J-6447-2012	Borlongan, Cesar/0000-0002-2966-9782	NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [ZIADA000461, ZIADA000429] Funding Source: NIH RePORTER		Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Borlongan CV, 2008, REGEN MED, V3, P249, DOI 10.2217/17460751.3.3.249; Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091; Chuck Y, 2008, MILD TRAUMATIC BRAIN; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gerlai R, 2000, BEHAV BRAIN RES, V108, P63, DOI 10.1016/S0166-4328(99)00130-8; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang Y, 2001, STROKE, V32, P775, DOI 10.1161/01.STR.32.3.775; Xia CF, 2006, HYPERTENSION, V47, P752, DOI 10.1161/01.HYP.0000214867.35632.0e; Yasuhara T, 2008, REJUV RES, V11, P201, DOI 10.1089/rej.2007.0608; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu GL, 2004, BRAIN RES, V1015, P50, DOI 10.1016/j.brainres.2004.04.055	31	99	100	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 1	2009	1287						157	163		10.1016/j.brainres.2009.06.067			7	Neurosciences	Neurosciences & Neurology	489XR	WOS:000269460100016	19573519				2021-06-18	
J	Kumar, R; Gupta, RK; Husain, M; Chaudhry, C; Srivastava, A; Saksena, S; Rathore, RKS				Kumar, Raj; Gupta, Rakesh K.; Husain, Mazhar; Chaudhry, Chaynika; Srivastava, Arti; Saksena, Sona; Rathore, Ram K. S.			Comparative evaluation of corpus callosum DTI metrics in acute mild and moderate traumatic brain injury: Its correlation with neuropsychometric tests	BRAIN INJURY			English	Article						Mild and moderate TBI; diffuse axonal injury; corpus callosum; radial and axial diffusivity; neuropsychological test	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; TENSOR IMAGING DETECTS; WHITE-MATTER INJURY; WALLERIAN DEGENERATION; HEPATIC-ENCEPHALOPATHY; ISCHEMIC-STROKE; SPINAL-CORD; MRI; CHILDREN	Primary objective: To look for differences in vulnerability of corpus callosum (CC) in patients of mild and moderate traumatic brain injury (TBI) in the acute stage using quantitative diffusion tensor imaging (DTI) and to correlate these with neuropsychometric tests (NPT) done at 6 months post-injury. Research design, methods and procedures: Conventional MRI, DTI and NPT were performed on 83 patients (moderate TBI, n = 57; mild TBI, n = 26) within 5-14 days after TBI. Thirty-three age- and sex-matched healthy controls were also included for comparison. Results: Significantly decreased fractional anisotropy (FA) in genu and splenium; significantly increased radial diffusivity (RD) values in genu, midbody and splenium with significant increase in mean diffusivity (MD) and a decrease in axial diffusivity (AD) only in genu, respectively, in patients with moderate TBI compared to healthy controls were observed. However, in moderate TBI, significantly decreased FA was found only in genu compared to mild TBI. Moderate TBI showed poor NPT scores compared to mild TBI, but this did not reach statistical significance. Conclusions: It is concluded that DTI abnormalities in the regions of CC were more in patients with moderate TBI compared to mild TBI and this was associated with relatively poor neuropsychological outcome 6 months post-injury.	[Gupta, Rakesh K.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, MR Sect, Lucknow 226014, Uttar Pradesh, India; [Kumar, Raj; Husain, Mazhar] Chhatrapati Shahuji Maharaj Med Univ, Dept Neurosurg, Lucknow, Uttar Pradesh, India; [Rathore, Ram K. S.] Indian Inst Technol, Dept Math & Stat, Kanpur 208016, Uttar Pradesh, India	Gupta, RK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, MR Sect, Lucknow 226014, Uttar Pradesh, India.	rgupta@sgpgi.ac.in			Indian Council of Medical ResearchIndian Council of Medical Research (ICMR) [5/4-5/13/Neuro/2004-NCD-1]; Indian Council of Medical Research, New Delhi, IndiaIndian Council of Medical Research (ICMR)	Part of the study was supported by Indian Council of Medical Research (Grant No. 5/4-5/13/Neuro/2004-NCD-1). Raj Kumar and Sona Saksena acknowledge the financial assistance from the Indian Council of Medical Research, New Delhi, India.	ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barkovich AJ, 2005, J INHERIT METAB DIS, V28, P311, DOI 10.1007/s10545-005-5952-z; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Batchelor PG, 2003, MAGN RESON MED, V49, P1143, DOI 10.1002/mrm.10491; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; COOPER PR, 2000, NEUROBEHAVIORAL SEQU, P525; Das A, 2001, J GASTROEN HEPATOL, V16, P531, DOI 10.1046/j.1440-1746.2001.02487.x; DELANEY KA, 2000, HEAD INJURY, P41; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; DHIMAN RK, 1995, J GASTROEN HEPATOL, V10, P14, DOI 10.1111/j.1440-1746.1995.tb01041.x; EISENBERG HM, 1987, NEUROBEHAVIORAL RECO, P13; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; Fogel Barry S., 1994, P413; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; IIZUKA H, 1989, STROKE, V20, P1396, DOI 10.1161/01.STR.20.10.1396; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LAMPERT PW, 1966, AM J PATHOL, V49, P1139; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2006, 24 ANN NAT NEUR SOC; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCLELLAN DR, 1990, COMA EMERGING PATIEN, P389; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Plylar P A, 1989, J Neurosci Nurs, V21, P353; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; PURWAR A, P ISMRM 2006, P325; Ramalingaswamy P., 1974, MANUAL INDIAN ADAPTA, P2; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schiff ND, 2006, J HEAD TRAUMA REHAB, V21, P388, DOI 10.1097/00001199-200609000-00003; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Thomalla G, 2005, J NEUROL NEUROSUR PS, V76, P266, DOI 10.1136/jnnp.2004.046375; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Valadka AB, 1996, NEUROTRAUMA, P119; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	75	99	100	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					675	685	PII 912685693	10.1080/02699050903014915			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600012	19557571				2021-06-18	
J	Nutt, JG; Gunzler, SA; Kirchhoff, T; Hogarth, P; Weaver, JL; Krams, M; Jamerson, B; Menniti, FS; Landen, JW				Nutt, John G.; Gunzler, Steven A.; Kirchhoff, Trish; Hogarth, Penelope; Weaver, Jerry L.; Krams, Michael; Jamerson, Brenda; Menniti, Frank S.; Landen, Jaren W.			Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism	MOVEMENT DISORDERS			English	Article						Parkinson's disease; levodopa; dysminesia; NR2B subunit selective glutamate antagonist; CP-101.606; amnesia; dissociation	LESIONED MARMOSET MODEL; TRAUMATIC BRAIN-INJURY; ANTIPARKINSONIAN ACTIONS; RECEPTOR ANTAGONIST; DOUBLE-BLIND; L-DOPA; DISEASE; SUBUNITS; MILD; RATS	Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101.606 on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101.606 reduced the maximum severity of levodopa-induced dyskinesia similar to 30% but neither dose improved Parkinsonism. CP-101.606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects. (C) 2008 Movement Disorder Society.	[Nutt, John G.; Gunzler, Steven A.; Kirchhoff, Trish; Hogarth, Penelope] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Weaver, Jerry L.; Krams, Michael; Menniti, Frank S.; Landen, Jaren W.] Pfizer Global Res & Dev, Groton, CT USA; [Jamerson, Brenda] Campbell Univ, Sch Pharm, VA Med Ctr, Ctr Geriatr Res Educ & Clin, Morrisville, NC USA; [Jamerson, Brenda] Campbell Univ, Sch Pharm, Dept Clin Res, Morrisville, NC USA	Nutt, JG (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, OP 32,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	nuttj@ohsu.edu		Menniti, Frank/0000-0003-2612-9534; Gunzler, Steven/0000-0003-2635-9022	Pfizer Global Research and DevelopmentPfizer; Oregon Clinical and Translational Research Institute [UL1-RR024140]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021062] Funding Source: NIH RePORTER	We thank the subjects for their voluntary participation in a demanding protocol. This project was funded by a grant from Pfizer Global Research and Development and support from the Oregon Clinical and Translational Research Institute, grant UL1-RR024140.	Blanchet PJ, 1999, J PHARMACOL EXP THER, V290, P1034; Bullock MR, 1999, ANN NY ACAD SCI, V890, P51, DOI 10.1111/j.1749-6632.1999.tb07980.x; Calon F, 2003, NEUROBIOL DIS, V14, P404, DOI 10.1016/j.nbd.2003.07.003; Chase TN, 2003, NEUROTOX RES, V5, P139, DOI 10.1007/BF03033378; Chazot P L, 2000, Curr Opin Investig Drugs, V1, P370; CHENARD BL, 1995, J MED CHEM, V38, P3138, DOI 10.1021/jm00016a017; Dunah AW, 2000, MOL PHARMACOL, V57, P342; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GREENAMYRE JT, 1994, ANN NEUROL, V35, P655, DOI 10.1002/ana.410350605; HADJ TA, 2004, NEUROBIOL DIS, V15, P171; Hallett PJ, 2005, NEUROPHARMACOLOGY, V48, P503, DOI 10.1016/j.neuropharm.2004.11.008; Hurley MJ, 2005, EUR J NEUROSCI, V21, P3240, DOI 10.1111/j.1460-9568.2005.04169.x; KLOCKGETHER T, 1990, ANN NEUROL, V28, P539, DOI 10.1002/ana.410280411; Loftis JM, 2003, PHARMACOL THERAPEUT, V97, P55, DOI 10.1016/S0163-7258(02)00302-9; Loschmann PA, 2004, EXP NEUROL, V187, P86, DOI 10.1016/j.expneurol.2004.01.018; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323; Metman LV, 1997, NEUROLOGY, V49, P711, DOI 10.1212/WNL.49.3.711; Nash JE, 1999, EXP NEUROL, V155, P42, DOI 10.1006/exnr.1998.6963; Nash JE, 2004, EXP NEUROL, V188, P471, DOI 10.1016/j.expneurol.2004.05.004; Nash JE, 2000, EXP NEUROL, V165, P136, DOI 10.1006/exnr.2000.7444; Newcomer JW, 2001, HIPPOCAMPUS, V11, P529, DOI 10.1002/hipo.1069; NUTT JG, 1984, NEW ENGL J MED, V311, P193; NUTT JG, 1984, NEW ENGL J MED, V310, P483, DOI 10.1056/NEJM198402233100802; *PFIZ GLOB RES DEV, 2004, INV BROCH CP 101 606; Steece-Collier K, 2000, EXP NEUROL, V163, P239, DOI 10.1006/exnr.2000.7374; vanHilten JJ, 1997, CLIN NEUROPHARMACOL, V20, P402, DOI 10.1097/00002826-199710000-00004; VANLAAR T, 1993, CLIN NEUROL NEUROSUR, V95, P231, DOI 10.1016/0303-8467(93)90128-4; Wessell RH, 2004, NEUROPHARMACOLOGY, V47, P184, DOI 10.1016/j.neuropharm.2004.03.011; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428	32	99	100	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.	OCT 15	2008	23	13					1860	1866		10.1002/mds.22169			7	Clinical Neurology	Neurosciences & Neurology	368DL	WOS:000260601400010	18759356	Green Accepted			2021-06-18	
J	Deng-Bryant, Y; Singh, IN; Carrico, KM; Hall, ED				Deng-Bryant, Ying; Singh, Indrapal N.; Carrico, Kimberly M.; Hall, Edward D.			Neuroprotective effects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calpain; controlled cortical impact; neurodegeneration; oxidative damage; peroxynitrite; tempol	INDUCED AXONAL INJURY; CLOSED-HEAD INJURY; OXIDATIVE DAMAGE; MITOCHONDRIAL-MEMBRANE; LIPID-PEROXIDATION; NITROXIDE RADICALS; CALPAIN; NEURODEGENERATION; DEGRADATION; MICE	We examined the ability of tempol, a catalytic scavenger of peroxynitrite (PN)-derived free radicals, to reduce cortical oxidative damage, mitochondrial dysfunction, calpain-mediated cytoskeletal (alpha-spectrin) degradation, and neurodegeneration, and to improve behavioral recovery after a severe (depth 1.0mm), unilateral controlled cortical impact traumatic brain injury (CCI-TBI) in male CF-1 mice. Administration of a single 300 mg/kg intraperitoneal dose of tempol 15 mins after TBI produced a complete suppression of PN-mediated oxidative damage (3-nitrotyrosine, 3NT) in injured cortical tissue at 1 h after injury. Identical tempol dosing maintained respiratory function and attenuated 3NT in isolated cortical mitochondria at 12 h after injury, the peak of mitochondrial dysfunction. Multiple dosing with tempol (300 mg/kg intraperitoneally at 15 mins, 3, 6, 9, and 12 h) also suppressed alpha-spectrin degradation by 45% at its 24 h post-injury peak. The same dosing regimen improved 48 h motor function and produced a significant, but limited (17.4%, P < 0.05), decrease in hemispheric neurodegeneration at 7 days. These results are consistent with a mechanistic link between PN-mediated oxidative damage to brain mitochondria, calpain-mediated proteolytic damage, and neurodegeneration. However, the modest neuroprotective effect of tempol suggests that multitarget combination strategies may be needed to interfere with posttraumatic secondary injury to a degree worthy of clinical translation.	[Hall, Edward D.] Univ Kentucky, Spinal Cord & Brain Injuiry Res Ctr, Chandler Med Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Chandler Med Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Spinal Cord & Brain Injuiry Res Ctr, Chandler Med Ctr, B483 Biomed & Biol Sci Bldg,741 S Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1P30 NS051220, 1R01 NS046566] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS046566] Funding Source: NIH RePORTER		Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Behringer W, 2002, J CEREBR BLOOD F MET, V22, P105, DOI 10.1097/00004647-200201000-00013; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Faddis BT, 1997, J NEUROSCI, V17, P951; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; Giulivi C, 2003, FREE RADICAL BIO MED, V34, P397, DOI 10.1016/S0891-5849(02)01298-4; Grune T, 1997, FASEB J, V11, P526; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Kamatari M, 2002, FREE RADICAL RES, V36, P1115, DOI 10.1080/1071576021000028352; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141; Krishna MC, 1996, J BIOL CHEM, V271, P26026, DOI 10.1074/jbc.271.42.26026; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Povlishock JT, 1999, ACT NEUR S, V73, P15; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	33	99	100	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2008	28	6					1114	1126		10.1038/jcbfm.2008.10			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	304NR	WOS:000256116700005	18319733	Bronze			2021-06-18	
J	Liu, CL; Chen, S; Dietrich, D; Hu, BR				Liu, Cindy L.; Chen, Shaoyi; Dietrich, Dalton; Hu, Bingren R.			Changes in autophagy after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ATG12-ATG5; autophagy; LC3-ATG8-APG8; lysosome; traumatic brain injury; ubiquitin	TRANSIENT CEREBRAL-ISCHEMIA; NEURODEGENERATIVE DISEASE; PROTEIN AGGREGATION; HYPOXIA-ISCHEMIA; CELL-DEATH; MECHANISMS; SYSTEM; LC3; MITOCHONDRIA; STORAGE	Autophagy is the chief machinery for bulk degradation of superfluous or aberrant cytoplasmic components. This study used the rat moderate fluid percussion injury model to investigate whether the autophagy pathway plays a key role after traumatic brain injury (TBI). Induction of autophagy is manifested by accumulation of autophagosomes (APs), observable under transmission electron microscopy (EM). Two hallmarks of autophagy, i. e., the microtubule-associated protein light chain 3 (LC3)-II and the autophagy-related gene (ATG) 12-ATG5 conjugates, were explored by biochemical and confocal microscopic analyses of brain tissues. Under EM, both APs and autolysosomes were markedly accumulated in neurons from 4 h onward after TBI. Western blot analysis showed that ATG12-ATG5 conjugate was markedly redistributed during 5 to 15 days in brain tissues after TBI. LC3-II conjugate was initially unchanged but was drastically upregulated from 24 h onward in the pre-AP-containing fraction after TBI. LC-3 immunostaining was mainly located in living neurons under confocal microscopy. These results clearly show that the autophagy pathway is persistently activated after TBI. Because the autophagy pathway is the chief machinery for bulk elimination of aberrant cell components, we propose that activation of this pathway serves as a protective mechanism for maintaining cellular homeostasis after TBI.	[Liu, Cindy L.; Chen, Shaoyi; Hu, Bingren R.] Univ Miami, Sch Med, Dept Neurol, Neurochem Lab Brain Injury, Miami, FL 33136 USA; [Dietrich, Dalton] Univ Miami, Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Dietrich, Dalton] Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Hu, BR (corresponding author), Univ Miami, Sch Med, Dept Neurol, Neurochem Lab Brain Injury, POB 16960, Miami, FL 33136 USA.	cliu@med.Miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040407, R56NS036810, R01NS036810, R29NS036810, P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040407-08, NS040407, P50 NS030291, R01 NS036810, R29 NS036810, NS030291, NS36810, R01 NS040407, R56 NS036810] Funding Source: Medline		Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Chu CT, 2006, J NEUROPATH EXP NEUR, V65, P423, DOI 10.1097/01.jnen.0000229233.75253.be; Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hu BR, 1998, J NEUROSCI, V18, P625; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; HU BR, 2006, IN PRESS HDB NEUROCH, V23; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kiselyov K, 2007, AUTOPHAGY, V3, P259, DOI 10.4161/auto.3906; Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a; Klionsky DJ, 2005, CURR BIOL, V15, pR282, DOI 10.1016/j.cub.2005.04.013; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; LAI Y, 2007, J CEREB BLOOD F 0905; Liu CL, 2005, NEUROSCIENCE, V134, P1273, DOI 10.1016/j.neuroscience.2005.05.015; Martinez A, 1999, PLANT J, V19, P97, DOI 10.1046/j.1365-313X.1999.00504.x; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Moore MN, 2006, MAR ENVIRON RES, V62, pS420, DOI 10.1016/j.marenvres.2006.04.055; Nishino Ichizo, 2006, Semin Pediatr Neurol, V13, P90, DOI 10.1016/j.spen.2006.06.004; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; PONTEN U, 1973, J NEUROCHEM, V21, P1121, DOI 10.1111/j.1471-4159.1973.tb07566.x; SIESJO BK, 1995, J NEUROSURG ANESTH, V7, P47, DOI 10.1097/00008506-199501000-00009; Swanson MS, 2006, J IMMUNOL, V177, P4945, DOI 10.4049/jimmunol.177.8.4945; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	33	99	102	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2008	28	4					674	683		10.1038/sj.jcbfm.9600587			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	280GS	WOS:000254414500002	18059433	Green Accepted, Bronze			2021-06-18	
J	Nagamoto-Combs, K; Mcneal, DW; Morecraft, RJ; Combs, CK				Nagamoto-Combs, Kumi; Mcneal, David W.; Morecraft, Robert J.; Combs, Colin K.			Prolonged microgliosis in the rhesus monkey central nervous system after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						microglia; motor cortex; motor recovery; spinal cord; stroke	TRKB NEUROTROPHIN RECEPTORS; OUTGROWTH IN-VITRO; RAT SPINAL-CORD; TRUNCATED TRKB; KAINIC ACID; ARM REPRESENTATION; MULTIPLE-SCLEROSIS; NONHUMAN-PRIMATES; MOTOR CORTEX; RECOVERY	Impaired fine motor functions after traumatic brain injury (TBI) in humans and non-human primates often continue to improve months after injury. To initiate a series of studies in the primate model designed to investigate possible involvement of microglia/macrophage in the long-term recovery processes, changes in these cells were studied in the rhesus monkey central nervous system at 1, 6, and 12 months after a combined unilateral lesion of the arm area of the primary motor cortex and arm area of the lateral premotor cortex. Immunohistological studies showed profound CD68 immunoreactivity in the lesion area and the contralateral lateral corticospinal tract in the spinal cord at all time points, demonstrating that microglia/macrophage remain reactive at the sites of injury and axonal degeneration/survival for at least 12 months. We also observed marked increases in brain-derived neurotrophic factor (BDNF) and its receptor subtypes, TrkB[gp145] and TrkB[TK-], around the cortical lesion site after 6-month survival. Similar increases were also observed in the spinal cord, although it was less apparent for TrkB[gp145]. Double-labeling revealed that a sub-population of CD68-immunoreacitve microglia/macrophage co-expressed BDNF in the cortex and spinal cord, and also TrkB[gp145] or TrkB[TK-] in the spinal cord. In contrast, cytokine expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6) at these time intervals was less prominent, suggesting that immediate inflammatory responses had subsided. These results demonstrate that microglia/macrophage undergo prolonged activation after TBI in the non-human primate brain and express BDNF and its receptors, suggesting their tropic/trophic roles in the long-term recovery processes.	Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA; Univ S Dakota, Sch Med, Div Basic Biomed Sci, Vermillion, SD USA	Nagamoto-Combs, K (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 504 Hamline St, Neurosci Bldg, Grand Forks, ND 58202 USA.	ccombs@medicine.nodak.edu	Nagamoto-Combs, Kumi/AAN-6697-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS046367, R01NS046367] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 046367] Funding Source: Medline		Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Asami T, 2006, BIOCHEM BIOPH RES CO, V344, P941, DOI 10.1016/j.bbrc.2006.03.228; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 2002, EUR J NEUROSCI, V15, P826, DOI 10.1046/j.1460-9568.2002.01914.x; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; BECK KD, 1993, J NEUROSCI, V13, P4001; Butefisch CM, 2006, NEUROL SCI, V27, pS18, DOI 10.1007/s10072-006-0540-z; Cagnin A, 2001, BRAIN, V124, P2014, DOI 10.1093/brain/124.10.2014; Carmichael ST, 2003, NEUROSCIENTIST, V9, P64, DOI 10.1177/1073858402239592; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Darling WG, 2006, J NEUROSCI METH, V154, P38, DOI 10.1016/j.jneumeth.2005.11.013; Eide FF, 1996, J NEUROSCI, V16, P3123; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Fryer RH, 1997, EXP NEUROL, V148, P616, DOI 10.1006/exnr.1997.6699; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Goutan E, 1998, MOL BRAIN RES, V59, P154, DOI 10.1016/S0169-328X(98)00156-9; Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Kasahara K, 2006, SPINE, V31, P2059, DOI 10.1097/01.brs.0000231893.21964.f2; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; King VR, 2000, EXP NEUROL, V165, P327, DOI 10.1006/exnr.2000.7480; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Mack CL, 2003, J NEUROIMMUNOL, V144, P68, DOI 10.1016/j.jneuroim.2003.08.032; Malcangio M, 2003, TRENDS PHARMACOL SCI, V24, P116, DOI 10.1016/S0165-6147(03)00025-7; Morecraft RJ, 2004, J COMP NEUROL, V469, P37, DOI 10.1002/cne.10980; Morecraft RJ, 2002, BRAIN, V125, P176, DOI 10.1093/brain/awf011; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; Morecraft RJ, 2007, J COMP NEUROL, V504, P149, DOI 10.1002/cne.21438; Morecraft RJ, 2007, J COMP NEUROL, V500, P134, DOI 10.1002/cne.21165; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Nudo Randolph J, 2006, NeuroRx, V3, P420; NUDO RJ, 1992, J NEUROSCI, V12, P2918; Nudo RJ, 1999, CURR OPIN NEUROBIOL, V9, P740, DOI 10.1016/S0959-4388(99)00027-6; Panagis L, 2005, EUR J NEUROSCI, V21, P2305, DOI 10.1111/j.1460-9568.2005.04046.x; Pizzimenti MA, 2007, J NEUROPHYSIOL, V98, P1015, DOI 10.1152/jn.00354.2007; Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983; Salie R, 2005, INT J DEV NEUROSCI, V23, P587, DOI 10.1016/j.ijdevneu.2005.07.003; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Shelton FDAP, 2001, STROKE, V32, P107, DOI 10.1161/01.STR.32.1.107; Smith ME, 2001, MICROSC RES TECHNIQ, V54, P81, DOI 10.1002/jemt.1123; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sun W, 2003, MOL CELL NEUROSCI, V24, P875, DOI 10.1016/S1044-7431(03)00219-7; Suzuki H, 2001, NEUROSCI LETT, V312, P95, DOI 10.1016/S0304-3940(01)02198-X; Tanaka R, 2003, NEUROSCIENCE, V117, P531, DOI 10.1016/S0306-4522(02)00954-5; Taub Edward, 2003, Phys Med Rehabil Clin N Am, V14, pS77, DOI 10.1016/S1047-9651(02)00052-9; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Wenzelburger R, 2005, BRAIN, V128, P64, DOI 10.1093/brain/awh317; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Wong JYF, 1997, EXP NEUROL, V148, P83, DOI 10.1006/exnr.1997.6670; Zhang JM, 2003, EXP NEUROL, V183, P469, DOI 10.1016/S0014-4886(03)00222-X	64	99	102	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1719	1742		10.1089/neu.2007.0377			24	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500005	18001202				2021-06-18	
J	Styrke, J; Stalnacke, BM; Sojka, P; Bjornstig, U				Styrke, Johan; Stalnacke, Britt-Marie; Sojka, Peter; Bjornstig, Ulf			Traumatic brain injuries in a well-defined population: Epidemiological aspects and severity	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; head trauma; traumatic brain injury	CT-SCAN; HEAD; MILD	The aim was to describe epidemiological and medical aspects of 449 cases of traumatic brain injury (TBI) from a well-defined geographical area with a population of 137,000 inhabitants. An episode of disturbed consciousness was a prerequisite for inclusion in the study. The incidence of TBI was 354/100,000 inhabitants. Median age was 23 years, range 0-91 years; 55% were men and 45% were women; 33% children 0-14 years, 50% adults 15-64 years, and 17% elderly persons 65-91 years old. Severity classification was based on Glasgow Coma Scale (GCS) on arrival; mild TBI 97% (GCS 13-15), moderate 1% (GCS 9-12), and severe 2% ( GCS 3-8). The most common injury events were falls (55%) and vehicle-related events (30%). The percentage of falls was high among children and elderly persons but among adults vehicle-related injury events were also prominent. At least 17% of all patients were under the influence of alcohol, especially adult male bicyclists. CT was performed on 163 cases (36%) revealing 34 cases with intracranial hemorrhage (ICH) which is 21% of the examined or 8% of all the injured. The rate of ICH increased with increasing age (from 3% among children to 17% among the elderly persons) and also increased with decreasing GCS from 6% in the group of mild TBI to 60% among those with severe TBI. Attention should be directed to acute management of mild TBI in order to detect potentially dangerous ICH as well as to preventive actions against falls and vehicle related accidents.	Umea Univ, Dept Surg & Perioperat Sci, Div Surg, Umea, Sweden; Umea Univ, Dept Community Med & Rehabil, Umea, Sweden	Styrke, J (corresponding author), Umea Univ, Dept Surg & Perioperat Sci, Div Surg, Umea, Sweden.	jonste00@student.umu.se	Styrke, Johan/AAE-1193-2021				Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; BJORNSTIG K, 2006, VEHICLE RELATED INJU; BJORNSTIG U, 1992, J TRAUMA, V33, P887; Bordignon KC, 2002, ARQ NEURO-PSIQUIAT, V60, P204, DOI 10.1590/S0004-282X2002000200004; BORG BM, 2000, 153 SWEED COUNC TECH; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BYLUND PO, 2001, P ASS ADV AUT MED C, V45, P1; BYLUND PO, 1996, J TRAFFIC MED, V24, P27; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; *COMM TRAUM, 2004, ADV TRAUM LIF SUPP D; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; EVANS L, 2000, CRASH PREV INJ CONTR, V2, P111; EWANUELSON I, 2003, ACTA NEUROL SCAND, V108, P332; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; HONKANEN R, 1977, SCAND J SOC MED, V5, P91, DOI 10.1177/140349487700500207; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Krafft Maria, 2006, Traffic Inj Prev, V7, P125, DOI 10.1080/15389580500509278; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; *NAT BOARD HLTH WE, 1997, INT STAT CLASS DIS R; *NAT CTR INJ CONTR, 2003, REP C MILD TRAUM BRA; Nordstrom C H, 2005, Acta Neurochir Suppl, V95, P475; Paden M., 2002, INJURY LEADING CAUSE; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; von Wild KRH, 2005, ACTA NEUROCHIR SUPPL, V93, P15; Wahlberg T, 1995, Lakartidningen, V92, P658; WAHLBERG T, 1994, HJARNSKAKINGETIOLOGI; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	39	99	100	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2007	24	9					1425	1436		10.1089/neu.2007.0266			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	214ZT	WOS:000249777600002	17892405				2021-06-18	
J	Haider, AH; Efron, DT; Haut, ER; DiRusso, SM; Sullivan, T; Cornwell, EE				Haider, Adil H.; Efron, David T.; Haut, Elliott R.; DiRusso, Stephen M.; Sullivan, Thomas; Cornwell, Edward E., III			Black children experience worse clinical and functional outcomes after traumatic brain injury: An analysis of the national pediatric trauma registry	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		racial disparities; pediatric traumatic brain injury; functional outcomes	RACIAL DISPARITIES; SEVERITY SCORE; MORTALITY; INDEPENDENCE	Background. Recent studies suggest racial disparities in the treatment and outcomes of children with traumatic brain injury (TBI). This study aims to identify race-based clinical and functional outcome differences among pediatric TBI patients in a national database. Methods: A total of 41,122 patients (ages 2-16 years) who were included in the National Pediatric Trauma Registry (from 1996-2001) were studied. TBI was categorized by Relative Head Injury Severity Score (RHISS) and patients with moderate to severe TBI were included. Individual race groups were compared with white as the majority group. Differences between races in functional outcomes at discharge in three domains-speech, locomotion, and feeding-were determined using multiple logistic regression. Cases were adjusted for age, sex, severity of head injury (using RHISS), severity of injury (using New Injury Severity Score and Pediatric Trauma Score), premorbidities, mechanism, and injury intent. Results: A total of 7,778 children had moderate or severe TBI with or without associated injuries. All races had similar demographics. Hispanics (n = 1,041) had outcomes comparable to whites (n = 4,762). Black children (n = 1,238) had significantly increased premorbidities, penetrating trauma, and violent intent. They also had higher unadjusted mortality and longer mean intensive care unit and floor stays. After adjustment, there was no difference in the odds of death between black and white children. However, black patients were more likely to be discharged to an inpatient rehabilitation facility and had increased odds of possessing a functional deficit at discharge for all three domains studied. Conclusion: Black children with traumatic brain injury have worse clinical and functional outcomes at discharge when compared with equivalently injured white children.	Johns Hopkins Sch Med, Dept Surg, Div Trauma, Baltimore, MD 21287 USA; New York Med Coll, Dept Surg, Valhalla, NY 10595 USA; St Barnabas Hosp, Dept Surg, Bronx, NY USA	Haider, AH (corresponding author), Johns Hopkins Sch Med, Dept Surg, Div Trauma, 600 N Wolfe St,Blalock 688, Baltimore, MD 21287 USA.	ahaider1@jhmi.edu	Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X			Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; DREXLER M, DISPARITIES BODY POL; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; *I MED NAT AC, 2002, UN TREATM CONFR RAC; Krause JS, 2006, J SPINAL CORD MED, V29, P17, DOI 10.1080/10790268.2006.11753852; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Msall ME, 1993, PHYS MED REHAB CLIN, V4, P517; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Slover J, 2005, J PEDIATR ORTHOPED, V25, P717, DOI 10.1097/01.bpo.0000184835.79345.0e; Sperle PA, 1997, AM J OCCUP THER, V51, P35, DOI 10.5014/ajot.51.1.35; Sullivan T, 2003, J TRAUMA, V55, P1083, DOI 10.1097/01.TA.0000102175.58306.2A; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TAN CP, 2004, N Z MED J, P117; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	16	99	100	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2007	62	5					1259	1262		10.1097/TA.0b013e31803c760e			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	168OF	WOS:000246533200037	17495733				2021-06-18	
J	Meffre, D; Pianos, A; Liere, P; Eychenne, B; Cambourg, A; Schumacher, M; Stein, DG; Guennoun, R				Meffre, D.; Pianos, A.; Liere, P.; Eychenne, B.; Cambourg, A.; Schumacher, M.; Stein, D. G.; Guennoun, R.			Steroid profiling in brain and plasma of male and pseudopregnant female rats after traumatic brain injury: Analysis by gas chromatography/mass spectrometry	ENDOCRINOLOGY			English	Article							PERIPHERAL BENZODIAZEPINE-RECEPTOR; MEMBRANE PROGESTIN RECEPTOR; SPINAL-CORD-INJURY; MASS-SPECTROMETRY; NEUROACTIVE STEROIDS; GABA(A) RECEPTOR; NERVOUS-SYSTEM; DEVELOPMENTAL REGULATION; IMMOBILIZATION STRESS; NADPH-P450 REDUCTASE	Steroids in brain arise from the peripheral endocrine glands and local synthesis. In traumatic brain injury ( TBI), the endogenous circulating hormones at the time of injury are important for neuroprotection. In particular, pseudopregnant females recover better than males from TBI. We investigated the effect of pseudopregnancy and TBI on steroid levels in plasma and in three brain regions ( within, adjacent, and distal to the lesion site), 6 and 24 h after prefrontal cortex injury. The following steroids were analyzed by gas chromatography/ mass spectrometry: pregnenolone, progesterone, 5 alpha-dihydroprogesterone, 3 alpha, 5 alpha-tetrahydroprogesterone, 3 beta, 5 alpha-tetrahydroprogesterone, dehydroepiandrosterone, Delta(4)-androstenedione, testosterone, 5 alpha-dihydrotestosterone, 3 alpha, 5 alpha-tetrahydrotestosterone, 3 beta, 5 alpha-tetrahydrotestosterone, and 17 beta-estradiol. Corticosterone was assayed in plasma to account for stress in the rats. We found different steroid profiles in brain and plasma of male and pseudopregnant female rats and specific profile changes after TBI. In sham-operated pseudopregnant females, much higher levels of progesterone, 5 alpha-dihydroprogesterone, 3 alpha, 5 alpha-tetrahydroprogesterone, and 3 beta, 5 alpha-tetrahydroprogesterone were measured in both brain and plasma, compared with sham-operated males. Plasma levels of corticosterone were high in all groups, indicating that the surgeries induced acute stress. Six hours after TBI, the levels of pregnenolone, progesterone, and 5 alpha-dihydroprogesterone increased, and those of testosterone decreased in male brain, whereas levels of 5 alpha-dihydroprogesterone and 3 beta, 5 alpha-tetrahydroprogesterone increased in brain of pseudopregnant female rats. Plasma levels of 5 alpha-dihydroprogesterone did not change after TBI, suggesting a local activation of the 5 alpha-reduction pathway of progesterone in both male and pseudopregnant female brain. The significant increase in neurosteroid levels in the male brain after TBI is consistent with their role in neuroprotection. In pseudopregnant females, high levels of circulating progestagens may provide protection against TBI.	INSERM, UMR788, F-94276 Le Kremlin Bicetre, France; Univ Paris 11, F-94276 Le Kremlin Bicetre, France; Emory Univ, Brain Res Lab, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Guennoun, R (corresponding author), INSERM, UMR788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	guennoun@kb.inserm.fr	Guennoun, Rachida/F-2420-2011; Stein, Donald/AAJ-5139-2020; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371; MEFFRE, Delphine/0000-0002-9204-2245	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N540825, 1R01N538664] Funding Source: Medline		ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Auchus RJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P134, DOI 10.1016/S0003-9861(02)00491-5; Backstrom T, 2005, EUR J PHARMACOL, V512, P15, DOI 10.1016/j.ejphar.2005.01.049; Barbaccia ML, 1996, NEUROENDOCRINOLOGY, V63, P166, DOI 10.1159/000126953; Barbaccia ML, 2001, INT REV NEUROBIOL, V46, P243; BARNEA A, 1990, ENDOCRINOLOGY, V127, P500, DOI 10.1210/endo-127-1-500; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Belelli D, 2002, NEUROPHARMACOLOGY, V43, P651, DOI 10.1016/S0028-3908(02)00172-7; BILLIAR RB, 1975, BRAIN RES, V94, P99, DOI 10.1016/0006-8993(75)90880-X; Bixo M, 1997, BRAIN RES, V764, P173, DOI 10.1016/S0006-8993(97)00455-1; CHENEY DL, 1995, J NEUROSCI, V15, P4641; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; Dong E, 2001, P NATL ACAD SCI USA, V98, P2849, DOI 10.1073/pnas.051628598; Ebner MJ, 2006, ENDOCRINOLOGY, V147, P179, DOI 10.1210/en.2005-1065; FINK G, 1991, J STEROID BIOCHEM, V40, P123, DOI 10.1016/0960-0760(91)90175-5; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; Garcia-Ovejero D, 2005, BRAIN RES REV, V48, P273, DOI 10.1016/j.brainresrev.2004.12.018; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; GARLAND HO, 1987, J ENDOCRINOL, V113, P435, DOI 10.1677/joe.0.1130435; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Guennoun R, 2003, CONTRO ISSU CLIM MED, P57; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Higashi T, 2005, STEROIDS, V70, P1, DOI 10.1016/j.steroids.2004.08.001; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Huang C, 2000, ALZHEIMERS REP, V3, P275; JAMBART S, 1980, ACTA ENDOCRINOL-COP, V93, P264, DOI 10.1530/acta.0.0930264; KARAVOLAS HJ, 1990, CIBA F SYMP, V153, P22; Kostic T, 1998, J STEROID BIOCHEM, V66, P51, DOI 10.1016/S0960-0760(98)00003-X; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lacor P, 1999, BRAIN RES, V815, P70, DOI 10.1016/S0006-8993(98)01105-6; Lacor P, 1996, NEUROSCI LETT, V220, P61, DOI 10.1016/S0304-3940(96)13187-6; Lambert JJ, 1996, CELL MOL NEUROBIOL, V16, P155, DOI 10.1007/BF02088174; LEE SC, 1994, BRAIN INJURY, V8, P571; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Lundstrom U.S., 2003, WATER AIR SOIL POLLU, V3, P5; Maric D, 1996, J STEROID BIOCHEM, V58, P351, DOI 10.1016/0960-0760(96)00044-1; MARTINI L, 1993, J STEROID BIOCHEM, V47, P195, DOI 10.1016/0960-0760(93)90075-8; Marwah A, 2001, J CHROMATOGR B, V757, P333, DOI 10.1016/S0378-4347(01)00171-2; MCEWEN BS, 1981, SCIENCE, V211, P1303, DOI 10.1126/science.6259728; MCEWEN BS, 1994, HORM BEHAV, V28, P396, DOI 10.1006/hbeh.1994.1036; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Micevych PE, 2007, ENDOCRINOLOGY, V148, P782, DOI 10.1210/en.2006-0774; Mills CD, 2005, MOL CELL NEUROSCI, V30, P228, DOI 10.1016/j.mcn.2005.07.010; NAFTOLIN F, 1994, J REPROD MED, V39, P257; NORMINGTON K, 1992, J BIOL CHEM, V267, P19548; ORR TE, 1994, J ANDROL, V15, P302; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Rupprecht R, 1996, J STEROID BIOCHEM, V56, P163, DOI 10.1016/0960-0760(95)00233-2; Safarinejad MR, 2001, UROLOGY, V58, P671, DOI 10.1016/S0090-4295(01)01353-X; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; Selmin O, 1996, CARCINOGENESIS, V17, P2609, DOI 10.1093/carcin/17.12.2609; SHET MS, 1994, ARCH BIOCHEM BIOPHYS, V311, P402, DOI 10.1006/abbi.1994.1255; Shu PY, 2003, J CHROMATOGR B, V783, P93, DOI 10.1016/S1570-0232(02)00520-2; Sierra A, 2003, EUR J NEUROSCI, V18, P1458, DOI 10.1046/j.1460-9568.2003.02872.x; Sinchak K, 2003, DEV NEUROSCI-BASEL, V25, P343, DOI 10.1159/000073511; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; Soma KK, 2005, ENDOCRINOLOGY, V146, P4386, DOI 10.1210/en.2005-0569; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Toran-Allerand CD, 2005, ENDOCRINOLOGY, V146, P3843, DOI 10.1210/en.2004-1616; Vallee M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841; Verleye M, 2005, PHARMACOL BIOCHEM BE, V82, P712, DOI 10.1016/j.pbb.2005.11.013; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang MD, 2002, J NEUROSCI, V22, P3366; WELSCHEN R, 1975, J ENDOCRINOL, V64, P37, DOI 10.1677/joe.0.0640037; WRIGHT DW, IN PRESS ANN EMERG M; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	79	99	101	0	11	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	MAY	2007	148	5					2505	2517		10.1210/en.2006-1678			13	Endocrinology & Metabolism	Endocrinology & Metabolism	158RG	WOS:000245810600062	17303653	Bronze			2021-06-18	
J	Staffa, G; Nataloni, A; Compagnone, C; Servadei, F				Staffa, G.; Nataloni, A.; Compagnone, C.; Servadei, F.			Custom made cranioplasty prostheses in porous hydroxy-apatite using 3D design techniques: 7 years experience in 25 patients	ACTA NEUROCHIRURGICA			English	Article						skull defect; ceramic; porous hydroxy-apatite; cranioplasty	POSTTRAUMATIC INTRACRANIAL HYPERTENSION; TRAUMATIC BRAIN-INJURY; QUICK-SETTING MATERIAL; CRANIAL BONE DEFECTS; DECOMPRESSIVE CRANIECTOMY; CEMENT CRANIOPLASTY; CERAMIC IMPLANTS; CRANIOFACIAL SKELETON; TECHNICAL NOTE; SKULL DEFECTS	Background. None of the materials currently used to reconstruct skull defects is fully satisfactory. Their biological and physical properties are very different to those of natural bone. Solid state, high porosity hydroxyapatite (HA) seems to be a good support for bone regeneration within the prostheses, enabling integration of the heterologous material with low post-implant infective risk. Materials and methods. A model of the cranium of each patient was made in epoxy resin by stereolithography. The prosthesis was built on this model using a ceramic sintering process. In each case, an exact copy of the missing bone flap was obtained (curvature, dimensions, margins, irregularities and thickness). The porosity obtained is the same as that of the spongy bone of the skull with interconnected macropores (> 150 mu m) to promote osteoblast migration into the prosthetic core. In The Neurosurgery Division of Cesena, 26 cranioplasty prostheses have been implanted with this technique in 7 years (from 1998 to 2004). No particular criteria were pre-established, but the main indications for use of ceramic prostheses were complex and/or extended (surface > 25 cm(2)) post-surgery craniolacuna and/or previous unsuccessful procedures due to rejection, infection or bone flap reabsorption. Results. Twenty-five patients were included in this study. A clinical check-up and 3D CT (mean follow-up 30 months, range 12-79) always showed an excellent aesthetic result. No cases of infection, rejection or spontaneous prosthesis fragmentation were found. The surgical procedure was simpler and shorter than for other described procedures. Conclusions. Bioceramic porous hydroxy-apatite prosthesis have been demonstrated as a valid alternative to traditional cranioplasty techniques both aesthetically and in terms of absence of infections/rejections. Principal limitations for the use of HA prostheses are the need for stereolithography process, the poor malleability of the material and the high cost.	Presidio Osped, Div Neurotraumatol, I-47023 Cesena, Italy; Ceram Faenza, Div Biomed, Faenza, Italy; Intens Care Unit, Presidio Osped Bufalini, Cesena, Italy	Staffa, G (corresponding author), Presidio Osped, Div Neurotraumatol, Via Ghirotti 286, I-47023 Cesena, Italy.	gstaffa@ausl-cesena.emr.it		Compagnone, Christian/0000-0001-9951-5503; Servadei, Franco/0000-0002-3595-3464			Agner C, 2003, MINIM INVAS NEUROSUR, V46, P186; Arriaga MA, 2002, OTOLARYNG HEAD NECK, V126, P512, DOI 10.1067/mhn.2002.124436; Artico M, 2003, SURG NEUROL, V60, P71, DOI 10.1016/S0090-3019(03)00031-4; Boyde A, 1999, BONE, V24, P579, DOI 10.1016/S8756-3282(99)00083-6; Bruce JN, 2003, J NEUROSURG, V98, P1203, DOI 10.3171/jns.2003.98.6.1203; Bryant KJ, 2003, J AM VET MED ASSOC, V223, P67, DOI 10.2460/javma.2003.223.67; Chen TM, 2002, ANN PLAS SURG, V49, P272, DOI 10.1097/00000637-200209000-00006; Choi SH, 1998, PEDIATR NEUROSURG, V29, P324, DOI 10.1159/000028747; COCCHI R, 1999, BIOCERAMICS, P57; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Costantino PD, 2000, OTOLARYNG HEAD NECK, V123, P409, DOI 10.1067/mhn.2000.107679; COSTANTINO PD, 1992, PLAST RECONSTR SURG, V90, P174, DOI 10.1097/00006534-199290020-00003; DAVOLIO F, 2001, ATT CONV NAZ RIC CRA, P69; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Denissen H, 2000, J PERIODONTOL, V71, P272, DOI 10.1902/jop.2000.71.2.272; Ducic J, 2002, J ORAL MAXIL SURG, V60, P272, DOI 10.1053/joms.2002.30575; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; Eppley BL, 2003, J CRANIOFAC SURG, V14, P209, DOI 10.1097/00001665-200303000-00014; Eppley BL, 2003, J CRANIOFAC SURG, V14, P85, DOI 10.1097/00001665-200301000-00015; FABBRI M, 1995, BIOMATERIALS, V16, P225, DOI 10.1016/0142-9612(95)92121-L; FABBRI M, 1995, 4 EUR CER, V8, P109; GLADSTONE HB, 1995, OTOLARYNG CLIN N AM, V28, P381; Gosain AK, 1997, J CRANIOFAC SURG, V8, P506, DOI 10.1097/00001665-199711000-00017; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hobar PC, 2003, PLAST RECONSTR SURG, V111, P1667, DOI 10.1097/01.PRS.0000054752.72999.DB; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; JOFFE JM, 1992, BRIT J NEUROSURG, V6, P343, DOI 10.3109/02688699209023793; Johnson PJ, 2000, OTOLARYNG HEAD NECK, V123, P515, DOI 10.1067/mhn.2000.105182; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; Komolafe E O, 2003, West Afr J Med, V22, P35; Kubo S, 2002, NEUROSURGERY, V51, P1094, DOI 10.1097/00006123-200210000-00046; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Marcacci M, 1999, CALCIFIED TISSUE INT, V64, P83, DOI 10.1007/s002239900583; Mastrogiacomo M, 2005, Orthod Craniofac Res, V8, P277, DOI 10.1111/j.1601-6343.2005.00350.x; MENABUE L, 1992, BIOMATERIALI, P107; Miyake H, 2000, NEUROSURGERY, V46, P414, DOI 10.1097/00006123-200002000-00028; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Munch E, 2000, NEUROSURGERY, V47, P315; Nakagawa S, 2003, NEUROL MED-CHIR, V43, P120, DOI 10.2176/nmc.43.120; Narayan D, 2002, NEUROSURG CLIN N AM, V13, P505, DOI 10.1016/S1042-3680(02)00022-0; NATALONI A, 2000, ATT 13 INT S CER MED, P881; NATALONI A, 2000, ATT 6 M SEM CER CELL, P198; NATALONI A, 2001, CERAMICA ACTA, V13, P102; Ono I, 1999, PLAST RECONSTR SURG, V104, P339, DOI 10.1097/00006534-199908000-00003; ONO I, 1993, PLAST RECONSTR SURG, V92, P819, DOI 10.1097/00006534-199392050-00007; OSBORN JF, 1989, Z MATERIAL, P2; Ozerdem OR, 2002, ANN PLAS SURG, V49, P127; Park HK, 2002, BIOMED SCI INSTRUM, V38, P429; Pompili A, 1998, J NEUROSURG, V89, P236, DOI 10.3171/jns.1998.89.2.0236; Saringer W, 2002, ACTA NEUROCHIR, V144, P1193, DOI 10.1007/s00701-002-0995-5; Verheggen R, 2001, ACTA NEUROCHIR, V143, P919, DOI 10.1007/s007010170022; Vories A, 2001, Ear Nose Throat J, V80, P29; Wang Jing, 2002, Hunan Yi Ke Da Xue Xue Bao, V27, P187; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025; Yap C, 2002, BRIT J NEUROSURG, V16, P523, DOI 10.1080/0268869021000030951	56	99	100	1	17	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	FEB	2007	149	2					161	170		10.1007/s00701-006-1078-9			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	132UV	WOS:000243968800012	17242849				2021-06-18	
J	Catena, RD; van Donkelaar, P; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan			Cognitive task effects on gait stability following concussion	EXPERIMENTAL BRAIN RESEARCH			English	Article						concussion; cognition; dual-task; attention; gait	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; CENTER-OF-MASS; DIVIDED ATTENTION; FOOTBALL PLAYERS; RECOVERY; COLLEGIATE; BALANCE; WALKING; DIFFICULTY	The purpose of this study was to determine how two different types of concurrent tasks affect gait stability in patients with concussion and how balance is maintained. Fourteen individuals suffering from a grade II concussion and 14 matched controls performed a single task of level walking and two types of concurrent tasks during level walking: a discrete reaction time task and a continuous sequential question and answer task. Common gait spatial/temporal measurements, whole-body center of mass motion, and the center of pressure trajectory were recorded. Concussed individuals demonstrated differences in gait while performing single-task level walking and while being challenged with a more difficult secondary task compared to normal controls. Concussed individuals adopted a slower, more conservative gait strategy to maintain stability, but still exhibited signs of instability with center of mass deviations in the coronal plane increasing by 13% during the question and answer dual-task and 26% more than control subjects. Trends of attentional deficits were present with the question and answer task, while the reaction time task seemed to help concussed individuals be more alert to their gait and stability. Recommendations for a sensitive testing protocol of deficits following concussion are explained.	1240 Univ Oregon, Mot Anal Lab, Dept Human Physiol, Eugene, OR 97403 USA; Univ Oregon, Eye Hand Lab, Dept Human Physiol, Eugene, OR 97403 USA	Chou, LS (corresponding author), 1240 Univ Oregon, Mot Anal Lab, Dept Human Physiol, Eugene, OR 97403 USA.	chou@uoregon.edu		Catena, Robert/0000-0001-9128-1343	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR021735, CCR023203] Funding Source: Medline		BARDY BG, 1991, PERCEPT MOTOR SKILL, V72, P915, DOI 10.2466/PMS.72.3.915-926; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bowen A, 2001, AGE AGEING, V30, P319, DOI 10.1093/ageing/30.4.319; Brown LA, 1999, J GERONTOL A-BIOL, V54, pM165, DOI 10.1093/gerona/54.4.M165; BRUKNER P, 2001, CLIN SPORTS MED; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Cock J, 2003, BRAIN INJURY, V17, P561, DOI 10.1080/0269905031000088306; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DEJONG R, 1995, ACTA PSYCHOL, V90, P287, DOI 10.1016/0001-6918(95)00036-T; EBERSBACH G, 1995, PERCEPT MOTOR SKILL, V81, P107, DOI 10.2466/pms.1995.81.1.107; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Godefroy O, 2002, NEUROPSYCHOLOGIA, V40, P2234, DOI 10.1016/S0028-3932(02)00109-4; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Haggard P, 2000, J NEUROL NEUROSUR PS, V69, P479, DOI 10.1136/jnnp.69.4.479; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Kahneman D., 1973, ATTENTION EFFORT; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; Kelly JP, 1997, NEUROLOGY, V48, P581; Krauss JK, 1997, MOVEMENT DISORD, V12, P428, DOI 10.1002/mds.870120326; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; PASHLER H, 1990, J EXP PSYCHOL HUMAN, V16, P826, DOI 10.1037/0096-1523.16.4.826; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vallis LA, 2004, EXP BRAIN RES, V157, P94, DOI 10.1007/s00221-003-1824-7; VANDONKELAAR P, 2006, IN PRESS EXERCISE SP, V34; VANDONKELAAR P, 2005, IN PRESS BRAIN INJUR; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; Winter D.A., 1990, BIOMECHANICS MOTOR C, V2nd; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	40	99	100	0	12	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	JAN	2007	176	1					23	31		10.1007/s00221-006-0596-2			9	Neurosciences	Neurosciences & Neurology	144HQ	WOS:000244787500003	16826411				2021-06-18	
J	Stalnacke, BM				Stalnacke, B.-M.			Community integration, social support and life satisfaction in relation to symptoms 3 years after mild traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; brain concussion; community integration; life satisfaction; post-concussion symptoms; depression; post-traumatic stress disorder	QUALITY-OF-LIFE; POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEURON-SPECIFIC ENOLASE; FOLLOW-UP; EVENT SCALE; HOROWITZS IMPACT; SERUM-LEVELS; ACUTE-PHASE	Primary objective: To investigate the relation between psychosocial functioning ( community integration, life satisfaction and social support) and symptoms ( post-concussion, post-traumatic stress and depression) in persons with mild traumatic brain injury ( MTBI) 3 years after the trauma. Methods: Population-based follow-up study of 163 patients. At follow-up, an assessment of community integration, social support, life satisfaction and symptoms was made. Results: Total score of Community Integration Questionnaire ( CIQ) was negatively correlated to total score of the Rivermead Post-Concussion Symptoms Questionnaire ( RPQ, r=- 0.270, p < 0.001) and to total score of the Beck Depression Inventory ( BDI, r=- 0.332, p < 0.001). Life satisfaction ( LiSat- 11) was negatively correlated to the RPQ ( r=- 0.459, p < 0.001), to total score of the Impact of Event Scale ( IES, r=- 0.365, p < 0.001) and to the BDI ( r=- 0.642, p < 0.001). Low levels of life satisfaction were common at follow-up. Conclusions: A large proportion of the individuals with MTBI experienced both psychosocial difficulties, with low levels of life satisfaction in particular and symptoms ( post- concussion, post- traumatic stress and depression) 3 years after trauma. Since the possibility of pre-injury factors contributing to the condition at follow-up cannot be ruled out, the study indicates that all these factors should be taken into consideration in the management of persons with MTBI.	Umea Univ, Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, SE-90185 Umea, Sweden	Stalnacke, BM (corresponding author), Umea Univ, Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	stalnacke@rehabmed.umu.se					Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beck A.T., 1996, BDI BECK DEPRESSION; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Fleming J, 1999, BRAIN INJURY, V13, P417; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1126/science.3399889; Johansson U, 2003, BRAIN INJURY, V17, P991, DOI 10.1080/0269905031000110508; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; KARLSSON J, 1995, J CLIN EPIDEMIOL, V48, P817, DOI 10.1016/0895-4356(94)00196-W; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kinsella G, 1989, Int Disabil Stud, V11, P9; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Saeki S, 2006, J REHABIL MED, V38, P333, DOI 10.1080/16501970600780245; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Sundin EC, 2003, PSYCHOSOM MED, V65, P870, DOI 10.1097/01.PSY.0000084835.46074.F0; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	64	99	99	1	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	9					933	942		10.1080/02699050701553189			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600005	17729046				2021-06-18	
J	Heitger, MH; Jones, RD; Dalrymple-Alford, JC; Frampton, CM; Ardagh, MW; Anderson, TJ				Heitger, Marcus H.; Jones, Richard D.; Dalrymple-Alford, John C.; Frampton, Chris M.; Ardagh, Michael W.; Anderson, Tim J.			Motor deficits and recovery during the first year following mild closed head injury	BRAIN INJURY			English	Article						closed head injury; recovery; saccades; oculomotor smooth pursuit; upper-limb	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYMPTOMS; POSITRON-EMISSION-TOMOGRAPHY; CORTICAL CONTROL; TECHNETIUM-99M-HMPAO SPECT; NEUROIMAGING FINDINGS; COMPUTED-TOMOGRAPHY; WORKING-MEMORY; EYE-MOVEMENT; DAMAGE	Objective: This study examined motor impairments over 1 year following mild closed head injury (CHI). It is the first study to serially assess long-term oculomotor and upper-limb visuomotor function following mild head trauma. Methods: Thirty-seven patients with mild CHI and 37 matched controls were compared at 1 week, 3 months and 6 months and 31 available pairs at 12 months post-injury on measures of saccades, oculomotor smooth pursuit, upper-limb visuomotor function and neuropsychological performance. Symptomatic recovery was sampled using the Rivermead Postconcussion Symptoms Questionnaire. Results: At 1 week, the group with CHI reported high levels of post-concussional symptoms and exhibited prolonged saccade latencies, increased directional errors, decreased saccade accuracy and impaired fast sinusoidal smooth pursuit concomitant with increased arm movement reaction time, decreased arm movement speed and decreased motor accuracy on upper-limb visuomotor tracking tasks. Neuropsychological testing identified deficits only in verbal learning and speed of processing while attention, short-term/working memory and general cognitive performance were preserved. At 3 and 6 months, the group with CHI continued to show deficits on several oculomotor and upper-limb visuomotor measures in combination with some deficits on verbal learning and improved, yet abnormal, levels of post-concussional symptoms. At 12 months, the group with CHI had no cognitive impairment but residual deficits in eye and arm motor function and continued to show elevated levels of post-concussional symptoms. Conclusions: The findings indicate that multiple motor systems are measurably impaired up to 12 months following mild CHI and that instrumented motor assessment may provide sensitive and objective markers of cerebral dysfunction during recovery from mild head trauma independent of neuropsychological assessment and patient self-report.	Van Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand; Christchurch Hosp, Dept Med Phys & Bioengn, Christchurch, New Zealand; Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; Christchurch Hosp, Dept Emergency, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand	Heitger, MH (corresponding author), Van Veer Inst Parkinsons & Brain Res, 16 St Asaph St, Christchurch, New Zealand.	marcus.heitger@chmeds.ac.nz		Jones, Richard/0000-0003-2287-3358			Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ANDERSON TJ, 1994, BRAIN, V117, P1073, DOI 10.1093/brain/117.5.1073; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; *CDCP NAT CTR INJ, 1999, TRAUM BRAIN INJ US R; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; Ellermann JM, 1998, J MAGN RESON, V131, P272, DOI 10.1006/jmre.1998.1379; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRAY BG, 1992, J NUCL MED, V33, P52; Graziano MSA, 2002, NEURON, V36, P349, DOI 10.1016/S0896-6273(02)01003-6; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PACED AUDITORY SERIA; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HAGGARD P, 1995, J NEUROL NEUROSUR PS, V58, P433, DOI 10.1136/jnnp.58.4.433; Hamzei F, 2002, EXP BRAIN RES, V146, P273, DOI 10.1007/s00221-002-1139-0; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Hills EC, 1998, BRAIN INJURY, V12, P69, DOI 10.1080/026990598122872; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jacobs A, 1996, J NUCL MED, V37, P1605; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jones R D, 1981, Int Rehabil Med, V3, P71; JONES RD, 2000, BIOMEDICAL ENG HDB, P1; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1989, MILD HEAD INJURY, P8; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mallinson AI, 1998, AM J OTOL, V19, P809; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Muir S. R., 2003, Australasian Physical & Engineering Sciences in Medicine, V26, P18; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Pierrot-Deseilligny C, 2003, PROG BRAIN RES, V142, P3; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; Reitan RM, 2003, ARCH CLIN NEUROPSYCH, V18, P11, DOI 10.1016/S0887-6177(01)00177-9; REULEN JPH, 1988, MED BIOL ENG COMPUT, V26, P20, DOI 10.1007/BF02441823; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOLOGI; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; SIETSEMA JM, 1993, AM J OCCUP THER, V47, P19, DOI 10.5014/ajot.47.1.19; Smith A., 1973, SYMBOL DIGIT MODALIT; Spreen O., 1991, COMPENDIUM NEUROPSYC; SWAINE BR, 1992, ARCH PHYS MED REHAB, V73, P55; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Umile EM, 1998, BRAIN INJURY, V12, P577; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Williams IM, 1997, J CLIN NEUROSCI, V4, P186, DOI 10.1016/S0967-5868(97)90072-2; Wrightson P, 1998, NEW ZEAL MED J, V111, P99	71	99	99	0	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					807	824		10.1080/02699050600676354			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300004	17060148				2021-06-18	
J	Ji, ZS; Mullendorff, K; Cheng, IH; Miranda, RD; Huang, YD; Mahley, RW				Ji, ZS; Mullendorff, K; Cheng, IH; Miranda, RD; Huang, YD; Mahley, RW			Reactivity of apolipoprotein E4 and amyloid beta peptide - Lysosomal stability and neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; ONSET ALZHEIMER-DISEASE; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; PRECURSOR PROTEIN; CELL-DEATH; E GENOTYPE; ENDOCYTIC PATHWAY; TRANSPORT PROTEIN	We previously demonstrated that apolipoprotein E4 (apoE4) potentiates lysosomal leakage and apoptosis induced by amyloid beta (A beta) peptide in cultured Neuro-2a cells and hypothesized that the low pH of lysosomes accentuates the conversion of apoE4 to a molten globule, inducing reactive intermediates capable of destabilizing cellular membranes. Here we report that neutralizing lysosomal pH with bafilomycin or NH4Cl abolished the apoE4 potentiation of A beta-induced lysosomal leakage and apoptosis in Neuro-2a cells. Consistent with these results, apoE4 at acidic pH bound more avidly to phospholipid vesicles and disrupted them to a greater extent than at pH 7.4. Comparison of "Arctic" mutant A beta, which forms multimers, and GM6 mutant A beta, which remains primarily monomeric, showed that aggregation is essential for apoE4 to potentiate A beta-induced lysosomal leakage and apoptosis. Both apoE4 and A beta 1-42 had to be internalized to exert these effects. Blocking the low density lipoprotein receptor-related protein with small interfering RNA abolished the enhanced effects of apoE4 and A beta on lysosomes and apoptosis. In cultured Neuro-2a cells, A beta 1-42 increased lysosome formation to a greater extent in apoE3- or apoE4-transfected cells than in Neo-transfected cells, as shown by immunostaining for lysosome-associated membrane protein 1. Similarly, in transgenic mice expressing apoE and amyloid precursor protein, hippocampal neurons displayed increased numbers of lysosomes. Thus, apoE4 and A beta 1-42 may work in concert in neurons to increase lysosome formation while increasing the susceptibility of lysosomal membranes to disruption, release of lysosomal enzymes into the cytosol, and neuronal degeneration.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	rmahley@gladstone.ucsf.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022074] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR18928] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG022074] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS046465] Funding Source: Medline		Arelin K, 2002, MOL BRAIN RES, V104, P38, DOI 10.1016/S0169-328X(02)00203-6; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Buttini M, 1999, J NEUROSCI, V19, P4867; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Cheng IH, 2004, NAT MED, V10, P1190, DOI 10.1038/nm1123; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; Demattos RB, 2004, J MOL NEUROSCI, V23, P255, DOI 10.1385/JMN:23:3:255; Ditaranto K, 2001, NEUROBIOL DIS, V8, P19, DOI 10.1006/nbdi.2000.0364; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Holtzman DM, 2004, J MOL NEUROSCI, V23, P247, DOI 10.1385/JMN:23:3:247; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Irizarry MC, 2004, J NEUROCHEM, V90, P1132, DOI 10.1111/j.1471-4159.2004.02581.x; Ji Y, 2003, NEUROSCIENCE, V122, P305, DOI 10.1016/j.neuroscience.2003.08.007; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jordan J, 1998, J NEUROSCI, V18, P195; Kaback M M, 1977, Prog Clin Biol Res, V18, P267; Kane MD, 1999, J NEUROCHEM, V72, P1939, DOI 10.1046/j.1471-4159.1999.0721939.x; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Karageorgos LE, 1997, EXP CELL RES, V234, P85, DOI 10.1006/excr.1997.3581; Klug GMJA, 2003, EUR J BIOCHEM, V270, P4282, DOI 10.1046/j.1432-1033.2003.03815.x; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lacomblez L, 2002, NEUROLOGY, V58, P1112, DOI 10.1212/WNL.58.7.1112; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Li YJ, 2002, AM J HUM GENET, V70, P985, DOI 10.1086/339815; Lin HJ, 2001, ANAL BIOCHEM, V294, P118, DOI 10.1006/abio.2001.5155; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 2001, METABOLIC MOL BASES, V2, P2835; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nacmias B, 2004, NEUROSCI LETT, V367, P379, DOI 10.1016/j.neulet.2004.06.039; Narita M, 1997, J NEUROCHEM, V69, P1904; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Nilsson LNG, 2004, NEUROBIOL AGING, V25, P1153, DOI 10.1016/j.neurobiolaging.2003.12.011; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Nixon RA, 2001, J ALZHEIMERS DIS, V3, P97, DOI 10.3233/JAD-2001-3114; Panas M, 1999, J NEUROL, V246, P574, DOI 10.1007/s004150050406; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Permanne B, 1997, BIOCHEM BIOPH RES CO, V240, P715, DOI 10.1006/bbrc.1997.7727; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Srinivasan R, 2003, J MOL BIOL, V333, P1003, DOI 10.1016/j.jmb.2003.09.001; Stenh C, 2002, NEUROREPORT, V13, P1857, DOI 10.1097/00001756-200210280-00005; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Su Y, 2001, BRAIN RES, V893, P287, DOI 10.1016/S0006-8993(00)03322-9; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; Tsuang DW, 2002, ARCH NEUROL-CHICAGO, V59, P1622, DOI 10.1001/archneur.59.10.1622; Van Everbroeck B, 2001, NEUROSCI LETT, V313, P69, DOI 10.1016/S0304-3940(01)02264-9; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wurth C, 2002, J MOL BIOL, V319, P1279, DOI 10.1016/S0022-2836(02)00399-6; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Ye CP, 2003, NEUROBIOL DIS, V13, P177, DOI 10.1016/S0969-9961(03)00068-8; Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6	77	99	100	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2683	2692		10.1074/jbc.M506646200			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	006XT	WOS:000234931800034	16298992	Other Gold			2021-06-18	
J	Thornton, M; Marshall, S; McComas, J; Finestone, H; McCormick, A; Sveistrup, H				Thornton, M; Marshall, S; McComas, J; Finestone, H; McCormick, A; Sveistrup, H			Benefits of activity and virtual reality based balance exercise programmes for adults with traumatic brain injury: Perceptions of participants and their caregivers	BRAIN INJURY			English	Article						virtual reality; self-efficacy; self-concept; physiotherapy; balance confidence; community integration	CONFIDENCE ABC SCALE; PHYSICAL-ACTIVITY; PEOPLE; REHABILITATION; METAANALYSIS; AWARENESS; RECOVERY; OUTCOMES; FALLS; LIFE	Objective: To explore multi-dimensional benefits of exercise participation perceived by adults with traumatic brain injury (TBI) and their caregivers. Methods: Adults (n = 27, aged 18 - 66) with moderate or severe TBI 6 months or more earlier participated in focus groups following 6 weeks of an activity-based (ABE) or a virtual reality (VR) delivered balance exercise programme. Family members and care providers participated in separate focus groups. Perceptions related to programme participation as well as balance confidence and lower extremity function were extracted from focus group verbatim and quantitative scales, respectively. Outcomes: Benefits in three domains, psychosocial, physical and programme, were identified from transcription and analyses of focus group verbatim. Improvements were noted in balance confidence and function in both groups. Substantially greater enthusiasm and knowledge was expressed by participants in the VR group and their caregivers. Conclusions: Both exercise programmes offered benefits in addition to improved balance. The VR participants had greater improvements on quantitative measures and provided more comments expressing enjoyment and improved confidence. Applications in terms of community reintegration and quality of life are discussed.	Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada; Sisters Char Ottawa Hlth Serv, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Toronto, ON, Canada	Sveistrup, H (corresponding author), Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	hsveist@uottawa.ca					Allison L., 1999, NEUROLOGY REPORT, V23, P13, DOI DOI 10.1097/01253086-199923010-00010; Binkley JM, 1999, PHYS THER, V79, P371; Blair SN, 1996, J AM GERIATR SOC, V44, P599, DOI 10.1111/j.1532-5415.1996.tb01450.x; Carter ND, 2001, SPORTS MED, V31, P427, DOI 10.2165/00007256-200131060-00003; Cattaneo D, 2001, CYBERPSYCHOL BEHAV, V4, P687, DOI 10.1089/109493101753376632; *CDC, 2003, TRAUM BRAIN INJ US R; *CDC, 2003, WHAT IS BRAIN INJ; CONDELUCI A, 1990, BRAIN INJURY, V6, P543; Dunn AL, 2001, MED SCI SPORT EXER, V33, pS587, DOI 10.1097/00005768-200106001-00027; Durgin CJ, 2000, J HEAD TRAUMA REHAB, V15, P1195, DOI 10.1097/00001199-200012000-00002; EMERSON EB, 1985, AM J MENT DEF, V90, P277; Etnier JL, 1997, J SPORT EXERCISE PSY, V19, P249, DOI 10.1123/jsep.19.3.249; Finch E., 2002, PHYS REHABILITATION; FOUGEYROLLAS P, 1995, DISABIL REHABIL, V17, P145, DOI 10.3109/09638289509166709; Fougeyrollas P, 1998, QUEBEC CLASSIFICATIO; Gettman L R, 1983, Phys Sportsmed, V11, P56, DOI 10.1080/00913847.1983.11708657; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Hillier SL, 1997, BRAIN INJURY, V11, P661; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Kennedy MRT, 2001, BRAIN INJURY, V15, P469, DOI 10.1080/02699050120517; KIZONY R, 2003, USING VIDEO PROJECTE, P82; Lord S, 1994, Aust J Physiother, V40, P83, DOI 10.1016/S0004-9514(14)60454-2; Man DWK, 2003, BRAIN INJURY, V17, P775, DOI 10.1080/0269905031000088577; MAZZEO RS, 2004, PHYS SPORTSMEDICINE, V27, P115; Miller WC, 2002, PHYS THER, V82, P856, DOI 10.1093/ptj/82.9.856; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Myers AM, 1998, J GERONTOL A-BIOL, V53, pM287, DOI 10.1093/gerona/53A.4.M287; Myers AM, 1996, J GERONTOL A-BIOL, V51, pM37, DOI 10.1093/gerona/51A.1.M37; *NAT CTR CHRON DIS, 2003, MORBIDITY MORTALITY, V49, P420; NORAEU L, 2000, DISABILITY REHABILIT, V22, P170; PATLA AE, 1992, CAN J PUBLIC HEALTH, V83, pS29; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Reid D, 2002, CYBERPSYCHOL BEHAV, V5, P559, DOI 10.1089/109493102321018204; Rose DJ, 2002, J AGING PHYS ACTIV, V10, P207, DOI 10.1123/japa.10.2.207; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; Skelton DA, 2001, AGE AGEING, V30, P33, DOI 10.1093/ageing/30.suppl_4.33; Skelton Dawn A., 1999, Physiotherapy Theory and Practice, V15, P105, DOI 10.1080/095939899307801; Stratford PW, 2000, PHYSIOTHER CAN, V52, P97; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Tennsledt S, 1998, J GERONTOL B-PSYCHOL, V53, pP384, DOI 10.1093/geronb/53B.6.P384; THORNTON M, 2004, P CAN PHYS ASS NAT C; Tillerson JL, 2002, NEUROSCIENTIST, V8, P574, DOI 10.1177/1073858402238516; van Gool CH, 2003, AGE AGEING, V32, P81, DOI 10.1093/ageing/32.1.81; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Weiss PL, 2003, CYBERPSYCHOL BEHAV, V6, P335, DOI 10.1089/109493103322011650; WILLER B, 2004, BRAIN INJURY REHABIL, P355	50	99	103	2	33	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2005	19	12					989	1000		10.1080/02699050500109944			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZA	WOS:000233269700005	16263641				2021-06-18	
J	Sanchez, B; Waxman, K; Jones, T; Conner, S; Chung, R; Becerra, S				Sanchez, B; Waxman, K; Jones, T; Conner, S; Chung, R; Becerra, S			Cervical spine clearance in blunt trauma: Evaluation of a computed tomography-based protocol	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	75th Annual Meeting of the Pacific-Coast-Surgical-Associaton	FEB 15-16, 2004	Maui, HI	Pacific Coast Surg Assoc		cervical spine; cervical spine clearance; blunt trauma; spiral computed tomographic scan	RADIOGRAPHY; CT; FRACTURES; INJURIES	Background. Prompt identification of cervical spine injuries has been a critical issue in trauma management. In 1998, the authors developed a new protocol to evaluate cervical spines in blunt trauma. This protocol relies on clinical clearance for appropriate patients and helical computed tomography instead of plain radiographs for patients who cannot be clinically cleared. The authors then prospectively collected data on all cervical spine evaluations to assess the sensitivity and specificity of their approach. Methods Any patient without clinical evidence of neurologic injury, alcohol or drug intoxication, or distracting injury underwent cervical spine evaluation by clinical examination. Patients who did not meet these criteria underwent helical computed tomographic scanning of the entire cervical spine. For patients who had neurologic deficits, a magnetic resonance image was obtained. If the patient was not evaluable secondary to coma, the computed tomographic scan was without abnormality, and the patient was moving all four extremities at arrival in the emergency department, the cervical spine was cleared, and spinal precautions were removed. Data were collected for all patients admitted to Santa Barbara Cottage Hospital trauma service between 1999 and 2002. The authors selected for analysis patients with blunt trauma and further identified those with closed head injuries (Glasgow Coma Scale score < 15 and loss of consciousness). In addition, all blunt cervical spine injuries were reviewed. Results. During the period of study, 2,854 trauma patients were admitted, of whom 2,603 (91%) had blunt trauma. Of these, 1,462 (56%) had closed head injuries. One hundred patients (7% of patients admitted for blunt trauma) had cervical spine or spinal cord injuries, of which 99 were identified by the authors' protocol. Only one injury was not appreciated in a patient with syringomyelia. Fifteen percent of patients with spinal cord injury had no radiographic abnormality; all of these patients presented with neurologic deficits. The sensitivity for detecting cervical spine injury was thus 99%, and the specificity was 100%. The risk of missing a cervical spine injury in these blunt trauma patients was 0.04%. The authors missed no spine injuries in patients with head injuries. Conclusions. The use of the authors' protocol resulted in excellent sensitivity and specificity in detecting cervical spine injuries. In addition, it allowed early removal of spinal precautions.	Santa Barbara Cottage Hosp, Dept Surg, Santa Barbara, CA 93102 USA; Santa Barbara Cottage Hosp, Dept Neurosurg, Santa Barbara, CA 93102 USA	Waxman, K (corresponding author), Santa Barbara Cottage Hosp, Dept Surg, POB 689, Santa Barbara, CA 93102 USA.	kwaxman@sbch.org					Amar AP, 1999, J AM COLL SURGEONS, V188, P550, DOI 10.1016/S1072-7515(99)00013-7; Barba CA, 2001, J TRAUMA, V51, P652, DOI 10.1097/00005373-200110000-00005; Berne JD, 1999, J TRAUMA, V47, P896, DOI 10.1097/00005373-199911000-00014; Besman A, 2003, AM SURGEON, V69, P1010; Blackmore CC, 1999, RADIOLOGY, V212, P117, DOI 10.1148/radiology.212.1.r99jl08117; BOROCK EC, 1991, J TRAUMA, V31, P1001, DOI 10.1097/00005373-199107000-00021; Crim JR, 2001, SEMIN ULTRASOUND CT, V22, P283, DOI 10.1016/S0887-2171(01)90023-X; Diaz JJ, 2003, J TRAUMA, V55, P658, DOI 10.1097/01.TA.0000088120.99247.4A; Hanson JA, 2002, AM J ROENTGENOL, V178, P1261, DOI 10.2214/ajr.178.5.1781261; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; MARION D, PRACTICE PARAMETERS; Novelline RA, 1999, RADIOLOGY, V213, P321, DOI 10.1148/radiology.213.2.r99nv01321; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; RAVICHANDRAN G, 1982, BRIT MED J, V284, P953, DOI 10.1136/bmj.284.6320.953; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; Sheridan R, 2003, J TRAUMA, V55, P665, DOI 10.1097/01.TA.0000048094.38625.B5; Weisskopf M, 2001, EUR SPINE J, V10, P250, DOI 10.1007/s005860000208; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006	19	99	103	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2005	59	1					179	183		10.1097/01.TA.0000171449.94650.81			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	956ZN	WOS:000231339000039	16096560				2021-06-18	
J	Olsson, A; Csajbok, L; Ost, M; Hoglund, K; Nylen, K; Rosengren, L; Nellgard, B; Blennow, K				Olsson, A; Csajbok, L; Ost, M; Hoglund, K; Nylen, K; Rosengren, L; Nellgard, B; Blennow, K			Marked increase of beta-amyloid((1-42)) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury	JOURNAL OF NEUROLOGY			English	Article						Alzheimer's disease; amyloid precursor protein; beta-amyloid; cerebrospinal fluid; traumatic brain injury	ALZHEIMERS-DISEASE; HEAD-INJURY; AXONAL INJURY; BETA-PROTEIN; ALPHA-SECRETASE; DOWNS-SYNDROME; PEPTIDE 1-42; PLASMA; APP; ACCUMULATION	Severe traumatic brain injury (TBI) may result in widespread damage to axons, termed diffuse axonal injury. Alzheimer's disease (AD) is characterised by synaptic and axonal degeneration together with senile plaques (SP). SP are mainly composed of aggregated beta-amyloid (Abeta), which are peptides derived from the amyloid precursor protein (APP). Apart from TBI in itself being considered a risk factor for AD, severe head injury seems to initiate a cascade of molecular events that are also associated with AD. We have therefore analysed the 42 amino acid forms of Abeta (Abeta((1-42))) and two soluble forms of APP (alpha-sAPP and sssAPP) in ventricular cerebrospinal fluid (VCSF) and Abeta((1-42)) in plasma from 28 patients in a serial samples 0-11 days after TBI. The levels of alpha-sAPP, ss-sAPP and Abeta((1-42)) were determined using ELISA assays. After TBI, there was a significant stepwise increase in VCSF-Abeta((1-42)) up to 1173 % from day 0-1 to day 5-6 and in VCSF-beta-sAPP up to 2033 % increase from day 0-1 to day 7-11. There was also a slight but significant increase of VCSF-beta-sAPP from day 0-1 to day 5-6 and day 7-11. By contrast, the plasma- Abeta((1-42)) level is unchanged after injury. The marked increase in VCSFAbeta(( 1-42)) implies that increased Abeta expression may occur as a secondary phenomenon after TBI with axonal damage. The unchanged level of plasma-Abeta((1-42)) in contrast to the marked increase in VCSF-Abeta((1-42)) after severe TBI, supports the suggestion that plasma Abeta((1-42)) does not reflect Abeta metabolism in the central nervous system (CNS).	Sahlgrens Univ Hosp, Inst Clin Neurosci Sect, SE-43180 Molndal, Sweden; Sahlgrens Univ Hosp, Dept Anaesthesia & Intens Care Med, SE-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden	Olsson, A (corresponding author), Sahlgrens Univ Hosp, Inst Clin Neurosci Sect, SE-43180 Molndal, Sweden.	Annika.Olsson@neuro.gu.se	Ost, Martin/AAY-5827-2020; Hoglund, Kina/I-8451-2012	Hoglund, Kina/0000-0002-1213-9953; Rosengren, Lars/0000-0003-0505-8896			Blennow K, 2000, J NEURAL TRANSM, V107, P1065, DOI 10.1007/s007020070052; De Strooper B, 2000, J CELL SCI, V113, P1857; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Graham DI, 1996, ACT NEUR S, V66, P96; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matsubara E, 1999, ANN NEUROL, V45, P537, DOI 10.1002/1531-8249(199904)45:4<537::AID-ANA20>3.0.CO;2-2; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayeux R, 1999, ANN NEUROL, V46, P412, DOI 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; Olsson A, 2003, EXP NEUROL, V183, P74, DOI 10.1016/S0014-4886(03)00027-X; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Tamaoka A, 1996, J NEUROL SCI, V141, P65, DOI 10.1016/0022-510X(96)00143-8; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364	43	99	105	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	JUL	2004	251	7					870	876		10.1007/s00415-004-0451-y			7	Clinical Neurology	Neurosciences & Neurology	838CU	WOS:000222691600014	15258792				2021-06-18	
J	Mickeviciene, D; Schrader, H; Obelieniene, D; Surkiene, D; Kunickas, R; Stovner, LJ; Sand, T				Mickeviciene, D; Schrader, H; Obelieniene, D; Surkiene, D; Kunickas, R; Stovner, LJ; Sand, T			A controlled prospective inception cohort study on the post-concussion syndrome outside the medicolegal context	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						concussion; post-concussion syndrome; post-traumatic headache	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; SYMPTOMS; EXPECTATION	In an earlier historical cohort study on the post-concussion syndrome (PCS) in Lithuania, a country in which there are few confounding factors, the validity of this condition as a disease entity could not be confirmed. In order to register the post-traumatic symptoms, the influence of sociodemographic factors, and the effect of expectation on these symptoms more reliably, we performed a controlled prospective study. Three hundred subjects with concussion were followed up with repeated questionnaires for 1 year. For each study subject, a sex- and age-matched control person with minor non-head injury was identified. These controls received similar questionnaires. Headache both after 3 months and after 1 year did not differ significantly between the head-injured participants and the non-head-injured controls. Several other symptoms attributed to PCS did not differ significantly between the groups after 3 months. After 1 year the vast majority of symptoms did not differ significantly. Exceptions were slightly significant differences concerning memory problems, concentration problems, dizziness and tiredness. These differences were insignificant when analysing symptoms in unmarried and/or people with lower education, separately. No relationship between cognitive dysfunction and the severity of concussion was found. Although the possibility of a mild organic brain injury cannot be completely ruled out, our results cast doubt on the validity of PCS as a useful clinical entity, at least for head injuries with loss of consciousness for <15 min. Sociodemographic factors and expectation seem to influence reporting of symptoms after concussion.	Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, N-7006 Trondheim, Norway; Red Cross Hosp, Dept Neurol, Kaunas, Lithuania; Med Univ Clin, Dept Neurol, Kaunas, Lithuania; Red Cross Hosp, Emergency Ward, Dept Traumatol, Kaunas, Lithuania	Schrader, H (corresponding author), Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, N-7006 Trondheim, Norway.	harald.schrader@medisin.ntnu.no		Obelieniene, Diana/0000-0002-7356-7150; Schrader, Harald/0000-0001-9975-1960			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BINDER LM, 1990, J CLIN EXP NEUROPSYC, V12, P45; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; WHO World Health Organization, 1978, ICD 9 CLASS MENT BEH	14	99	99	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	JUN	2004	11	6					411	419		10.1111/j.1468-1331.2004.00816.x			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	824NS	WOS:000221693900008	15171738				2021-06-18	
J	Raghupathi, R; Mehr, MF; Helfaer, MA; Margulies, SS				Raghupathi, R; Mehr, MF; Helfaer, MA; Margulies, SS			Traumatic axonal injury is exacerbated, following repetitive closed head injury in the neonatal pig	JOURNAL OF NEUROTRAUMA			English	Article						children; mild head injury; neurofilament; white matter	SHAKEN-BABY SYNDROME; PERCUSSION BRAIN-INJURY; FLUID-PERCUSSION; COGNITIVE IMPAIRMENT; IMMATURE RAT; MODEL; NEUROPATHOLOGY; INFANTS; VULNERABILITY; BEHAVIOR	Inflicted brain injury is associated with widespread traumatic axonal injury (TAI) and subdural hematoma and is the leading cause of death in infants and children. Anesthetized 3-5-day-old piglets were subjected to either a single (n = 5) or double (n = 6, 15 min apart) rapid (< 15 msec), non-impact, axial rotations of the head. Peak rotational velocities (averaging 172 rad/sec for single and 138 rad/sec for double loads) were lower than those utilized to induce severe injuries (240-260 rad/sec; Raghupathi and Margulies, 2002). At 6 h post-injury, brains were evaluated for the presence TAI using immunohistochemistry for the 200-kDa neurofilament protein (NF200). Accumulation of NF200 was observed in both contiguous (swellings) and in disconnected axons (axon bulbs) predominantly in central deep and peripheral subcortical white matter regions in the frontal, temporal, and parietal lobes of all injured piglets. Although the density of injured axons did not significantly increase after two rotational loads, the distribution of injured axons shifted from a few foci (2.2 +/- 2.3 per animal) with 1-2 swellings/bulbs following a single rotation to significantly more foci (14.7 +/- 11.9), and additional foci (2.5 +/- 1.9) containing 3 or more axon swellings/bulbs following two rotational loads. The density and distribution of injured axons following a single mild rotation were significantly reduced compared with those obtained previously following a single more severe rotational load. Collectively, these data are indicative of the graded response of the immature brain to rotational load magnitude, and importantly, the vulnerability to repeated, mild, non-impact loading conditions.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 105D Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	margulies@seas.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, R01NS039679] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS41561, R01-NS39679] Funding Source: Medline; ODCDC CDC HHS [R49-CCR312712] Funding Source: Medline		Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; HYMEL KP, 1998, CHILD MALTREATMENT, V3, P116, DOI DOI 10.1177/1077559598003002006; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LUERSSEN TG, 1991, CONC PED N, V11, P87; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Marin-Padilla M, 2002, ACTA NEUROPATHOL, V103, P321, DOI 10.1007/s00401-001-0470-z; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; YOSHIKAWA T, 1968, ATLAS BRAINS DOMESTI, P1	31	99	100	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					307	316		10.1089/089771504322972095			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600008	15115605				2021-06-18	
J	Hawley, CA; Ward, AB; Long, J; Owen, DW; Magnay, AR				Hawley, CA; Ward, AB; Long, J; Owen, DW; Magnay, AR			Prevalence of traumatic brain injury amongst children hospital in one health district: a population-based admitted to study	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							HEAD-INJURY; ADOLESCENTS; INFANTS	There is a dearth of information regarding the prevalence of brain injury, serious enough to require hospital admission, amongst children in UK. In North Staffordshire, a register of all children admitted with traumatic brain injury (TBI) has been maintained since 1992 presenting an opportunity to investigate the incidence of TBI within the region in terms of age, cause of injury, injury severity and social deprivation. The register contains details of 1553 children with TBI, two-thirds of whom are male. This population-based study shows that TBI is most prevalent amongst children from families living in more deprived areas, however, social deprivation was not related to the cause of injury. Each year, 280 per 100,000 children are admitted for greater than or equal to24 h with a TBI, of these 232 will have a mild brain injury, 25 moderate, 17 severe, and 2 will die. The incidence of moderate and severe injuries is higher than previous estimates. Children under 2 years of age account for 18.5% of all TBIs, usually due to falls, being dropped or non-accidental injuries (NAIs). Falls account for 60% of TBIs in the under 5 years. In the 10-15 age group road traffic accidents (RTAs) were the most common cause (185, 36.7%). These findings will help to plan health services and target accident prevention initiatives more accurately. (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent ST6 7AG, Staffs, England; Univ Warwick, Ctr Res Ethn Relat, Coventry CV4 7AL, W Midlands, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England	Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.		Hawley, Carol/AAG-3830-2019				*BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; *HOUS COMM SEL COM, 2001, 3 HOUS COMM SEL COMM; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MILLER JD, 1990, REHABILITATION ADULT; *N STAFF HLTH AUTH, 1994, HLTH N STAFF ANN REP; Parmelee D X, 1989, Psychiatr Med, V7, P11; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO	14	99	101	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAY	2003	34	4					256	260	PII S0020-1383(02)00193-6	10.1016/S0020-1383(02)00193-6			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	668KR	WOS:000182290300003	12667776				2021-06-18	
J	Barr, WB				Barr, WB			Neuropsychological testing of high school athletes - Preliminary norms and test-retest indices	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						sports injury; concussion; test reliability; traumatic brain injury; sex differences; adolescents	TRAUMATIC BRAIN INJURY; MILD HEAD-INJURY; FOOTBALL PLAYERS; SEX-DIFFERENCES; CONCUSSION; SPORTS; RELIABILITY; PERFORMANCE; COLLEGIATE; MATURATION	This study provides preliminary norms and test-retest indices on a brief battery of neuropsychological tests administered to a sample of 60 male and 40 female high school athletes. Forty-eight subjects completed retesting 8 weeks later. Analyses of baseline scores indicate that girls outperform boys on selected measures of processing speed and executive functions [Wechsler Adult Intelligence Scale-III (WAIS-III) Digit Symbol, Trails B, and Controlled Oral Word Association Test (COWAT)]. Test-retest reliability was low and varied widely among the tests. There were no gender differences in test-retest reliability. Reliable Change Indices (RCIs) were computed on the test-retest data for use in clinical interpretation. These preliminary results indicate that caution should be used in interpreting neuropsychological test data from high school athletes. The current findings indicate that separate norms for boys and girls are warranted. Caution should be used in interpreting discrepancies from baseline scores as a result of what may turn out to be poor test-retest reliability in this population. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	NYU, Sch Med, Comprehens Epilepsy Ctr, New York, NY 10016 USA	Barr, WB (corresponding author), NYU, Sch Med, Comprehens Epilepsy Ctr, Rivergate 4th Floor,560 1st Ave, New York, NY 10016 USA.	william.barr@med.nyu.edu		Barr, William/0000-0001-7711-7758			Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT., 1989, MILD HEAD INJURY, P257; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benton AL, 1978, MULTILINGUAL APHASIA; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; COHEN J, 1994, AM PSYCHOL, V49, P997, DOI 10.1037/0003-066X.49.12.997; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Franzen MD, 1999, SPORTS-RELATED CONCUSSION, P171; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halpern DF, 1997, AM PSYCHOL, V52, P1091, DOI 10.1037/0003-066X.52.10.1091; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JENSEN AR, 1983, PERS INDIV DIFFER, V4, P223, DOI 10.1016/0191-8869(83)90029-6; Kaufman A. S., 1990, ASSESSING ADOLESCENT; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, SPORTS-RELATED CONCUSSION, P75; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SANDERS B, 1986, DEV PSYCHOL, V22, P199, DOI 10.1037/0012-1649.22.2.199; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Spreen O., 1998, COMPENDIUM NEUROPSYC; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Vanderploeg RD, 2000, CLIN NEUROPSYCHOL, V14, P318, DOI 10.1076/1385-4046(200008)14:3;1-P;FT318; WABER DP, 1976, SCIENCE, V192, P572, DOI 10.1126/science.1257795; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	39	99	99	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2003	18	1					91	101	PII S0887-6177(01)00185-8	10.1016/S0887-6177(01)00185-8			11	Psychology, Clinical; Psychology	Psychology	645RJ	WOS:000180992000009	14591481				2021-06-18	
J	Stocchetti, N; Rossi, S; Zanier, ER; Colombo, A; Beretta, L; Citerio, G				Stocchetti, N; Rossi, S; Zanier, ER; Colombo, A; Beretta, L; Citerio, G			Pyrexia in head-injured patients admitted to intensive care	INTENSIVE CARE MEDICINE			English	Article						antipyretic therapy; brain injury; cerebral perfusion pressure; Pyrexia; intracranial pressure	TRAUMATIC BRAIN INJURY; ACUTE CEREBRAL-DAMAGE; INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; CORE TEMPERATURE; BODY-TEMPERATURE; MILD HYPOTHERMIA; HYPERTHERMIA; FEVER; ISCHEMIA	Objectives: (a) To quantify the occurrence of pyrexia during the first week after head injury; (b) to elucidate the relationships between pyrexia and neurological severity, length of stay in the ICU, intracranial hypertension, and cerebral perfusion pressure (CPP); and (c) to describe the effects of antipyretic. therapy on temperature, intracranial pressure (ICP) and CPP. Design and setting: Multicenter retrospective observational study in three ICUs in the Milan area. Patients: 110 patients with traumatic brain injury. Measurements and results: Eighty patients suffered pyrexia, defined as an external temperature higher than 38degreesC or internal temperature higher than 38.4degreesC. Occurrence and duration of pyrexia were associated with the degree of neurological impairment and with prolonged ICU stay. In patients with normal perimesencephalic cisterns the episodes of in-creased ICP were more frequent in febrile cases. Various antipyretic therapies were used in 66 patients. Pharmacological treatment was slightly effective (mean temperature reduction 0.58 +/- 0.7degreesC) but caused a significant drop in CPP (6.5 +/- 12.5 mmHg). Conclusions: Pyrexia is extremely frequent in the acute phase after head injury. Its incidence is higher in more severe cases and is correlated with a longer ICU stay. It may affect ICP, but its contribution is difficult to assess when other major causes of increased intracranial volume are present. Antipyretic therapy is poorly effective for controlling body temperature and may be deleterious for CPP.	Osped Maggiore, Policlin IRCCS, I-3520122 Milan, Italy; Neurorianimaz Osped S Raffaele, Milan, Italy; Terapia Intens Osped S Gerardo, Monza, Italy	Stocchetti, N (corresponding author), Osped Maggiore, Policlin IRCCS, Via S Sforza, I-3520122 Milan, Italy.		Stocchetti, Nino/O-7444-2017; Zanier, Elisa/AAA-8095-2020; Citerio, Giuseppe/B-1839-2015	Stocchetti, Nino/0000-0003-3250-6834; Citerio, Giuseppe/0000-0002-5374-3161; Zanier, Elisa/0000-0002-3011-8718; Rossi, Sandra/0000-0002-9963-8121			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Circiumaru B, 1999, INTENS CARE MED, V25, P668, DOI 10.1007/s001340050928; CLASEN RA, 1974, J NEUROSURG, V41, P576, DOI 10.3171/jns.1974.41.5.0576; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cormio M, 2000, INTENS CARE MED, V26, P552, DOI 10.1007/s001340051203; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Fallis WM, 2002, AM J CRIT CARE, V11, P38, DOI 10.4037/ajcc2002.11.1.38; Fulbrook P, 1993, Intensive Crit Care Nurs, V9, P217, DOI 10.1016/S0964-3397(05)80002-3; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marik PE, 2000, CHEST, V117, P855, DOI 10.1378/chest.117.3.855; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MELLERGARD P, 1994, ACTA NEUROCHIR, P485; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; NIERMAN DM, 1991, CRIT CARE MED, V19, P818, DOI 10.1097/00003246-199106000-00015; Ozveri ES, 1999, INTENS CARE MED, V25, P1155, DOI 10.1007/s001340051028; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; Reglodi D, 2000, EXP NEUROL, V163, P399, DOI 10.1006/exnr.2000.7367; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Robinson J, 1998, CAN J ANAESTH, V45, P317, DOI 10.1007/BF03012021; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; TAKAGI K, 1994, AM J PHYSIOL-HEART C, V267, pH1770; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	41	99	104	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	NOV	2002	28	11					1555	1562		10.1007/s00134-002-1513-1			8	Critical Care Medicine	General & Internal Medicine	641HL	WOS:000180739300006	12415441				2021-06-18	
J	Berger, C; Schabitz, WR; Georgiadis, D; Steiner, T; Aschoff, A; Schwab, S				Berger, C; Schabitz, WR; Georgiadis, D; Steiner, T; Aschoff, A; Schwab, S			Effects of hypothermia on excitatory amino acids and metabolism in stroke patients - A microdialysis study	STROKE			English	Article						cerebral metabolism; excitatory amino acids; hypothermia; microdialysis; stroke	CEREBRAL-ARTERY INFARCTION; IN-VIVO MICRODIALYSIS; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; HUMAN BRAIN; EXTRACELLULAR GLUTAMATE; MODERATE HYPOTHERMIA; INTENSIVE-CARE; HEAD-INJURY; ISCHEMIA	Background and Purpose-The objective of this study was to assess the effect of therapeutic moderate hypothermia on excitatory amino acids and metabolism by applying cerebral microdialysis in patients suffering from space-occupying middle cerebral artery infarction. Methods-This was an open, prospective, observational study of 12 patients undergoing moderate hypothermia (33 C) as rescue therapy for large, life-threatening middle cerebral artery infarction. Microdialysis probes were placed concomitantly with intracranial pressure (ICP) measuring devices in the frontal lobe of the infarcted and/or noninfarcted hemisphere. Using the CMA 600 Microdialysis Autoanalyzer, we analyzed glutamate, glycerol, pyruvate, and lactate. Results-According to follow-up cranial CT scans, 3 different compartments of microdialysis measurements could be defined. First, noninfarcted brain tissue had stable dialysate concentrations but a significant effect of hypothermia on glutamate (2.6 versus 3.6 mumol/L), lactate (1.8 versus 3 mmol/L), and pyruvate (50 versus 95.8 mumol/L). Second, measurements from peri-infarct tissue had a significant effect of hypothermia on glutamate (4.8 versus 12.6 mumol/L), glycerol (58 versus 82 mumol/L), lactate (0.7 versus 1.3 mmol/L), and pyruvate (13.3 versus 36.8 mumol/L). Third, dialysate concentrations obtained from irreversibly damaged tissue were excessive for glutamate (453 mumol/L), glycerol (1187 mumol/L), lactate (12 mumol/L), and pyruvate (4 mumol/L). In this extreme compartment, no effect of hypothermia was observed. Conclusions-Cerebral microdialysis is a safe and feasible bedside method for neurochemical monitoring indicating normal brain tissue, potentially salvageable brain tissue, and irreversibly damaged areas in stroke. We could demonstrate that hypothermia decreases glutamate, glycerol, lactate, and pyruvate in the "tissue at risk" area of the infarct but not within the infarct core. Thus, future treatment strategies for life-threatening stroke should be guided by close neurochemical monitoring.	Heidelberg Univ, Neurol Klin, Dept Neurol, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany	Berger, C (corresponding author), Heidelberg Univ, Neurol Klin, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	christian_berger@med.uni-heidelberg.de	Steiner, Thorsten/A-7391-2014				Berger C, 1999, STROKE, V30, P460, DOI 10.1161/01.STR.30.2.460; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Goodman JC, 1996, ACT NEUR S, V67, P37; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HerreraMarschitz M, 1996, J NEUROCHEM, V66, P1726; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2000, NEUROSURGERY, V46, P201; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LARSEN M, 1994, BRAIN RES, V663, P335, DOI 10.1016/0006-8993(94)91282-3; Mendelowitsch A, 1996, ACT NEUR S, V67, P48; Mendelowitsch A, 1998, ACTA NEUROCHIR, V140, P349, DOI 10.1007/s007010050108; Mendelowitsch A, 1998, J NEUROL NEUROSUR PS, V64, P611, DOI 10.1136/jnnp.64.5.611; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nakashima K, 1996, ANESTHESIOLOGY, V85, P161, DOI 10.1097/00000542-199607000-00022; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Nilsson OG, 1996, ACT NEUR S, V67, P45; Obrenovitch TP, 1996, ACT NEUR S, V66, P50; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Schneweis S, 2001, STROKE, V32, P1863, DOI 10.1161/01.STR.32.8.1863; Schwab S, 1996, NEUROLOGY, V47, P393, DOI 10.1212/WNL.47.2.393; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1998, ACT NEUR S, V71, P131; Shuaib A, 1996, ACT NEUR S, V67, P53; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	34	99	108	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2002	33	2					519	524		10.1161/hs0102.100878			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	518AX	WOS:000173644900019	11823663	Bronze			2021-06-18	
J	Ginis, I; Jaiswal, R; Klimanis, D; Liu, H; Greenspon, J; Hallenbeck, JM				Ginis, I; Jaiswal, R; Klimanis, D; Liu, H; Greenspon, J; Hallenbeck, JM			TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappa B transactivation: The role of NF-kappa B association with p300 adaptor	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						astrocytes; stress adaptation; tolerance; tumor necrosis factor; NF-kappa B; p300 adapter protein; protein kinase A	TUMOR-NECROSIS-FACTOR; SUPEROXIDE-DISMUTASE GENE; ACTIVATED PROTEIN-KINASE; INTERCELLULAR-ADHESION MOLECULE-1; SIGNAL-REGULATED KINASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; BETA-PEPTIDE TOXICITY; CREB-BINDING PROTEIN; C-ZETA	Preconditioning with sublethal ischemia results in natural tolerance to ischemic stress, where multiple mediators of ischemic damage are simultaneously counteracted. Tumor necrosis factor alpha (TNF-alpha) has been implicated in development of ischemic tolerance. Using cellular models of ischemic tolerance, we have demonstrated that an effector of TNF-alpha-induced preconditioning is ceramide, a sphingolipid messenger in TNF-alpha signaling. TNF-alpha/ceramide-induced preconditioning protected cultured neurons against ischemic death and cultured astrocytes against proinflammatory effects of TNF-alpha. TNF-alpha activates a transcription factor NF-kappaB that binds promoters of multiple genes, thus ensuring pleiotropic effects of TNF-alpha. We describe here a mechanism that allows selective suppression of TNF-alpha/NF-kappaB-induced harmful genes in preconditioned cells while preserving cytoprotective responses. We demonstrate that in astrocytes activation of an adhesion molecule ICAM-1 by TNF-alpha is regulated through association of the phosphorylated p65 subunit of NF-kappaB with an adapter protein, p300, and that in preconditioned cells p65 remains unphosphorylated and ICAM-1 transcription is inhibited. However, TNF-alpha-activated transcription of a protective enzyme, MnSOD, does not depend on p300 and does not become inhibited in preconditioned cells. This new understanding of TNF-alpha-induced adaptation to ischemic stress and inflammation could suggest novel avenues for clinical intervention during ischemic and inflammatory diseases.	NINCDS, Mol Biol Lab, Stroke Branch, NIH, Bethesda, MD 20892 USA	Ginis, I (corresponding author), NINCDS, Mol Biol Lab, Stroke Branch, NIH, 36 Convent Dr,MSC 4092,Bldg 36,Room 3C12, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002924, Z01NS002924] Funding Source: NIH RePORTER		Andjelkovic AV, 2000, J LEUKOCYTE BIOL, V68, P545; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Chen Y, 2001, J CEREBR BLOOD F MET, V21, P34, DOI 10.1097/00004647-200101000-00005; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/0304-3940(96)13116-5; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Furuya K, 2001, J CEREBR BLOOD F MET, V21, P226, DOI 10.1097/00004647-200103000-00006; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171; Ginis I, 2000, MOL MED, V6, P1028, DOI 10.1007/BF03402054; GINIS I, 1997, AM J PHYSIOL, V41, pC295; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Keller JN, 1998, J NEUROSCI, V18, P687; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kyrkanides S, 1999, J NEUROIMMUNOL, V95, P95, DOI 10.1016/S0165-5728(98)00270-7; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; Lee SJ, 1998, J NEUROIMMUNOL, V92, P196, DOI 10.1016/S0165-5728(98)00209-4; LIU J, 1994, J BIOL CHEM, V269, P3047; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; O'Connor TM, 2000, QJM-INT J MED, V93, P323, DOI 10.1093/qjmed/93.6.323; Pahan K, 1999, J NEUROCHEM, V73, P513, DOI 10.1046/j.1471-4159.1999.0730513.x; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Schneider A, 1999, NAT MED, V5, P554; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shibayama M, 1996, J NEUROTRAUM, V13, P801, DOI 10.1089/neu.1996.13.801; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zimmermann C, 2001, BRAIN RES, V895, P59, DOI 10.1016/S0006-8993(01)02028-5	67	99	113	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2002	22	2					142	152		10.1097/00004647-200202000-00002			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	517KB	WOS:000173608700002	11823712	Bronze			2021-06-18	
J	Dikmen, S; Machamer, J; Temkin, N				Dikmen, S; Machamer, J; Temkin, N			Mild head injury: Facts and artifacts	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							RECOVERY; CONCUSSION; DEFICITS	While most would agree that mild traumatic brain injury (TBI) is associated with early neuropsychological problems, disagreement exists regarding their persistence and whether they are the cause of the disabilities experienced by some people. The aim of this study was to examine how the criteria used to define mild TBI and how the pre-injury characteristics of people affect their neuropsychological outcome. A total of 157 unselected hospitalized cases with Glasgow Coma Scale scores of 13-15 and 109 trauma controls were prospectively recruited and administered a number of cognitive measures at 1 month and 12 months after injury. The results indicated early impairments that decreased with time and the stringency of the definition of 'mild' TBI. The contribution of demographics was usually significant and often stronger than the mild TBI effect. Subtle variation of the demographics of the brain injured or the comparison subjects can be sufficient to mimic or mask mild brain injury effects.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Dikmen, S (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	dikmen@u.washington.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS005304] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS05304] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19643] Funding Source: Medline		Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; GRONWALL D, 1974, LANCET, V2, P605; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1955, MANUAL WECHSLER ADUL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfson D., 1993, HALSTEAD REITAN NEUR	28	99	99	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					729	738		10.1076/jcen.23.6.729.1019			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200003	11910540				2021-06-18	
J	Silver, CH				Silver, CH			Ecological validity of neuropsychological assessment in childhood traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; brain injury; child; validity	EXECUTIVE FUNCTIONS SCALE; CLOSED-HEAD-INJURY; ACADEMIC PLACEMENT; CHILDREN; SEVERITY; RECOVERY; MEMORY	Empirical investigation of the degree to which testing predicts children's real-world functioning following traumatic brain injury (TBI) is sparse. This article reviews the research in neuropsychology, which offers only moderate correlations between test scores and everyday functioning. This line of research is hindered by several methodological issues: difficulty translating performance on standardized testing into real-world capacities, measurement of real-world functioning, developmental factors, and the influence of intervening variables in the natural environment. Ecologically valid assessment may require multiple data sources. More research is needed to respond effectively to questions about children's everyday functioning after traumatic brain injury.	Univ Texas, SW Med Ctr, Dallas, TX USA	Silver, CH (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX USA.						Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Acker MB, 1990, NEUROPSYCHOLOGY EVER, P19; *AHCPR, 2000, AHCPR PUBL; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BRUININKS RH, 1985, WOODCOCKJOHNSON PSYC; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; Chelune G. J, 1986, NEUROPSYCHOLOGY HDB, P489; Clark E, 1999, SCHOOL PSYCHOL REV, V28, P242; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Franzen M.D., 1996, ECOLOGICAL VALIDITY, P91; Goldstein G, 1996, ECOLOGICAL VALIDITY, P75; Goulden LG, 1997, ARCH CLIN NEUROPSYCH, V12, P326, DOI 10.1093/arclin/12.4.326; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HARTLAGE LC, 1996, ECOLOGICAL VALIDITY, P301; Isquith PK, 1999, CLIN NEUROPSYCHOL, V13, P222; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLESGES RC, 1983, CLIN NEUROPSYCHOLOGY, V1, P28; KOLB B, 1995, BRAIN PLASTICITY BEH, P67; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Molho CE, 1997, ARCH CLIN NEUROPSYCH, V12, P370, DOI 10.1093/arclin/12.4.370a; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Papero PH, 1997, J HEAD TRAUMA REHAB, V12, P51, DOI 10.1097/00001199-199706000-00006; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIZZO AA, 1999, J INT NEUROPSYCH SOC, V5, P125; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Williams JM, 1996, ECOLOGICAL VALIDITY, P129; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; WILSON BA, 1993, J CLIN EXP NEUROPSYC, V15, P474, DOI 10.1080/01688639308402572; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P159; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9	46	99	100	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2000	15	4					973	988		10.1097/00001199-200008000-00002			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	340DK	WOS:000088517700002	10876170				2021-06-18	
J	Clinchot, DM; Bogner, J; Mysiw, WJ; Fugate, L; Corrigan, J				Clinchot, DM; Bogner, J; Mysiw, WJ; Fugate, L; Corrigan, J			Defining sleep disturbance after brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; sleep; fatigue	HEAD-INJURY; NARCOLEPSY	Sleep disorders are a relatively common occurrence after brain injury. Sleep disturbances often result in a poor daytime performance and a poor individual sense of well-being. Unfortunately, there has been minimal attention paid to this common and often disabling sequela of brain injury. This study attempts to define and to correlate the incidence and type of sleep disturbances that occur after brain injury. Consecutive admissions to a rehabilitation unit were used to create a longitudinal database designed to predict long-term outcomes for individuals who suffered a brain injury. Fifty percent of subjects had difficulty sleeping. Sixty-four percent described waking up too early, 25% described sleeping more than usual, and 45% described problems falling asleep. Eighty percent of subjects reporting sleep problems also reported problems with fatigue. Logistic regression analysis revealed the following: the more severe the brain injury the less likely the subject would be to have a sleep disturbance; subjects who had sleep disturbances were more likely to have problems with fatigue; females were more likely to have trouble with sleep. This study demonstrates the substantial prevalence of sleep disturbances after brain injury. It underscores the relationship between sleep disorders and perception of fatigue. It also underscores the need for clinicians to strive for interventional studies to look at the treatment of sleep and fatigue problems after brain injury.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Clinchot, DM (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Sanguansri, Luz/B-6630-2011; Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011	Sanguansri, Luz/0000-0003-1908-7604; Clinchot, Daniel/0000-0002-2810-7227			ANSELL BJ, 1989, W NEURO SENSORY STIM; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BILLIARD M, 1986, SLEEP, V9, P149, DOI 10.1093/sleep/9.1.149; CLINCHOT DM, 1993, HEARSAY J OHIO SPEEC, V8, P4; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DRAKE ME, 1986, NEUROLOGY, V36, P867, DOI 10.1212/WNL.36.6.867; GEORGE B, 1981, NEUROCHIRURGIE, V27, P35; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; HARDA M, 1976, KUMAMOTO MED J, V29, P110; HARTMANN E, 1973, PSYCHOSOMATICS, V14, P95; JONES HS, 1968, ELECTROEN CLIN NEURO, V24, P378, DOI 10.1016/0013-4694(68)90199-5; JOUVET M, 1969, SCIENCE, V163, P32, DOI 10.1126/science.163.3862.32; JOUVET M, 1967, PHYSIOL REV, V47, P117; Landau-Ferey J, 1981, Rev Electroencephalogr Neurophysiol Clin, V11, P116, DOI 10.1016/S0370-4475(81)80042-1; LOOMIS ALFRED L., 1935, SCIENCE, V81, P597, DOI 10.1126/science.81.2111.597; MARKAND ON, 1976, NEUROLOGY, V26, P769, DOI 10.1212/WNL.26.8.769; MCCUBBIN H, 1987, FAMILY ASSESSMENT IN, P203; MEDDIS R, 1973, ELECTROEN CLIN NEURO, V35, P213, DOI 10.1016/0013-4694(73)90180-6; PARSONS LC, 1981, NURS RES, V31, P260; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Reitan RM., 1985, HALSTEAD REITAN NEUR; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Willer B., 1993, BRAIN INJURY REHABIL, P355	30	99	102	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	1998	77	4					291	295		10.1097/00002060-199807000-00006			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	109VQ	WOS:000075344900005	9715917				2021-06-18	
J	Knight, RG; Devereux, R; Godfrey, HPD				Knight, RG; Devereux, R; Godfrey, HPD			Caring for a family member with a traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; SOCIAL SUPPORT; CAREGIVER BURDEN; RELATIVES; STRESS; APPRAISAL	The responses to a questionnaire on subjective burden are reported for 52 primary caregivers of a group of persons with traumatic brain injuries sustained an average of 6 years previously. The aim of the study was to examine satisfaction with social support, perception of coping skills, and appraisal of symptoms as predictors of strain in the carer;. A range of responses, both positive and negative, to the work of caring for a relative with a head injury was reported. A high prevalence rate of emotional and behavioural changes in the persons with head injuries was found and the amount of distress caused by these symptoms was found to be predictive of burden. The other factor important in predicting burden was the carers' ratings of their satisfaction with their ability to cope with the work of caregiving. Social support, injury severity, and the demographic characteristics of the persons with head injury and their carer; were not significant predictor;. Depression in the carers was also investigated and the variable most predictive of elevated depression scores was coping satisfaction. These findings reinforce the importance of strengthening carers coping resources in rehabilitation work with head injured persons and their families.	Univ Otago, Dept Psychol, Dunedin, New Zealand	Knight, RG (corresponding author), Univ Otago, Dept Psychol, Box 56, Dunedin, New Zealand.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS WP, 1986, LETT APPL MICROBIOL, V2, P1, DOI 10.1111/j.1472-765X.1986.tb01502.x; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; COCKERILL R, 1990, J REHABIL, V56, P41; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FOLKMAN S, 1994, J CONSULT CLIN PSYCH, V62, P746, DOI 10.1037/0022-006X.62.4.746; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; Knight RG, 1997, BEHAV RES THER, V35, P373, DOI 10.1016/S0005-7967(96)00107-6; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/0090-5550.39.4.215; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Smith L.M., 1995, FAMILY SUPPORT PROGR; TOSELAND RW, 1992, GERONTOLOGIST, V32, P382, DOI 10.1093/geront/32.3.382; Zarit S., 1985, HIDDEN VICTIMS ALZHE	34	99	104	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1998	12	6					467	481		10.1080/026990598122430			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZU400	WOS:000074193300003	28925744				2021-06-18	
J	Giacino, JT; Zasler, ND; Katz, DI; Kelly, JP; Rosenberg, JH; Filley, CM				Giacino, JT; Zasler, ND; Katz, DI; Kelly, JP; Rosenberg, JH; Filley, CM			Development of practice guidelines for assessment and management of the vegetative and minimally conscious states	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						minimally conscious state; practice guidelines; rehabilitation; traumatic brain injury; vegetative state	INJURED PATIENTS	The Aspen Neurobehavioral Conference was convened as a venue to consider interactions of mind and brain with regard to health and disease. The primary purpose of the conference was to provide a forum for discussion and scientific collaboration, particularly in areas marked by uncertainty and controversy, with eventual dissemination of conclusions. One of the selected topics for the inaugural session of the conference concerned the development of guidelines for evaluation and management of the vegetative and minimally conscious states. The purpose of this article is to acquaint neurorehabilitation specialists with the unique approach to consensus-based guideline development utilized at the Aspen Conference and to summarize the proceedings of the Aspen Workgroup on the Vegetative and Minimally Conscious States conducted since 1994.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHYS MED & REHABIL, PISCATAWAY, NJ 08854 USA; NATL NEUROREHABIL CONSORTIUM INC, RICHMOND, VA USA; CONCUSS CARE CTR VIRGINIA, RICHMOND, VA USA; BRAINTREE REHABIL HOSP, TRAUMAT HEAD INJURY PROGRAM, TBI PROGRAM, BRAINTREE, MA USA; BRAINTREE REHABIL HOSP, TRAUMAT HEAD INJURY PROGRAM, STROKE PROGRAM, BRAINTREE, MA USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; NORTHWESTERN UNIV, SCH MED,DEPT REHABIL,REHABIL INST CHICAGO, BRAIN INJURY PROGRAM, CHICAGO, IL USA; NORTHWESTERN UNIV, SCH MED,DEPT NEUROL,REHABIL INST CHICAGO, BRAIN INJURY PROGRAM, CHICAGO, IL 60611 USA; SO CALIF PERMANENTE MED GRP, DEPT NEUROL, SAN DIEGO, CA 92120 USA; UNIV COLORADO, HLTH SCI CTR, DEPT NEUROL, DENVER, CO 80262 USA	Giacino, JT (corresponding author), JFK JOHNSON REHABIL INST, CTR HEAD INJURIES, COGNIT REHABIL PROGRAM, 2048 OAK TREE RD, EDISON, NJ 08820 USA.		Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ANSELL BJ, 1995, ARCH PHYS MED REHAB, V76, P726, DOI 10.1016/S0003-9993(95)80526-5; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; DiPasquale MC, 1996, J HEAD TRAUMA REHAB, V11, P9, DOI 10.1097/00001199-199612000-00004; Elovic E, 1996, NEUROREHABILITATION, V6, P57, DOI 10.3233/NRE-1996-6107; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; HALL M E, 1992, Brain Injury, V6, P435, DOI 10.3109/02699059209008139; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; KANNO T, 1987, PACE, V10, P207, DOI 10.1111/j.1540-8159.1987.tb05949.x; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Plum F, 1982, DIAGNOSIS STUPOR COM; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; Timmons M, 1987, J HEAD TRAUMA REHAB, V2, P64; Tsubokawa T, 1990, Brain Inj, V4, P315; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112	27	99	106	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1997	12	4					79	89		10.1097/00001199-199708000-00008			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XP104	WOS:A1997XP10400008					2021-06-18	
J	Becker, R; Alberti, O; Bauer, BL				Becker, R; Alberti, O; Bauer, BL			Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury	JOURNAL OF NEUROLOGY			English	Article						intrathecal infusion; baclofen; supraspinal spasticity; cerebral palsy; implantable pump	SPINAL-CORD; CEREBRAL-PALSY; ORIGIN	Severe spinal spasticity has been shown to be a good indication for continuous intrathecal baclofen infusion (CIBI), but then is only limited experience with this treatment in patients with supraspinal spasticity. Eighteen patients with severe spasticity from traumatic or hypoxic brain injury were treated with CIBI. In all patients spasticity could be reduced significantly. The mean Ashworth score was reduced from 4.5 to 2.33 and the mean Spasm frequency score from 2.16 to 0.94. This reduction of spasticity led to a marked pain reduction. Nursing, perineal care and mobilization became much easier. The complication rate was low. In this series we saw one infection in the pump pocket, one epileptic seizure after a bolus application of baclofen and one spinal catheter displacement. The results are similar to those reported from series of patients with spinal spasticity and correspond to the limited experience we have so far with supraspinal spasticity patients. To prevent limb contractures CIBI should be performed as soon as the patient is in a stable clinical condition after brain injury. Further prospective clinical trials will be necessary to obtain more experience with patients suffering from supraspinal spasticity.		Becker, R (corresponding author), UNIV MARBURG HOSP, DEPT NEUROSURG, BALDINGERSTR, D-35033 MARBURG, GERMANY.						Abbott R, 1991, NEUROSURGERY SPASTIC, P215; ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; BITTIGER H, 1989, TREATING SPASTICITY : PHARMACOLOGICAL ADVANCES, P20; BOISSON D, 1991, NEUROSURGERY SPASTIC, P59; BROSETA J, 1990, STEREOT FUNCT NEUROS, V54-5, P147, DOI 10.1159/000100205; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; DAVIDOFF RA, 1985, ANN NEUROL, V17, P107, DOI 10.1002/ana.410170202; DRALLE D, 1985, LANCET, V2, P1003; Feldman RG, 1980, SPASTICITY DISORDERE, P41; KNUTSSON E, 1974, J NEUROL SCI, V23, P473, DOI 10.1016/0022-510X(74)90163-4; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; MATHE JF, 1991, NEUROSURGERY SPASTIC, P63; MERTENS P, 1991, NEUROSURGERY SPASTIC, P119; MULLER H, 1992, DEV MED CHILD NEUROL, V34, P739; Muller H., 1988, LOCAL SPINAL THERAPY, P223; NANCE P, 1995, CAN J NEUROL SCI, V22, P22, DOI 10.1017/S0317167100040452; OCHS G, 1989, J NEUROL NEUROSUR PS, V52, P933, DOI 10.1136/jnnp.52.8.933; OTSUKA M, 1980, J EXP BIOL, V89, P201; PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302; PENN RD, 1985, LANCET, V2, P125; PENN RD, 1988, ANN NY ACAD SCI, V531, P157, DOI 10.1111/j.1749-6632.1988.tb31822.x; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1984, LANCET, V1, P1078; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Rifici C, 1994, Funct Neurol, V9, P29; SINDOU M, 1991, NEUROSURGERY SPASTIC, P211; Zieglgansberger W, 1988, LOCAL SPINAL THERAPY, P37; Zierski J, 1988, Acta Neurochir Suppl (Wien), V43, P94	30	99	104	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	MAR	1997	244	3					160	166		10.1007/s004150050067			7	Clinical Neurology	Neurosciences & Neurology	WL933	WOS:A1997WL93300004	9050956				2021-06-18	
J	Hill, SJ; Barbarese, E; McIntosh, TK				Hill, SJ; Barbarese, E; McIntosh, TK			Regional heterogeneity in the response of astrocytes following traumatic brain injury in the adult rat	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						blood-brain barrier; Cajal's gold sublimate; fluid percussion; glial fibrillary acidic protein; S100 protein; vimentin	FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; S-100 PROTEIN; VIMENTIN; FLUID; CELLS; IMMUNOFLUORESCENCE; PHOSPHORYLATION; PROLIFERATION; INTERLEUKIN-1	The regional distribution and temporal appearance of astrocytes expressing glial fibrillary acidic protein (GFAP), S100 protein, and vimentin were determined in a nonpenetrating lateral fluid percussion (LFP) brain injury model. Following injury, reactive astrocytes were observed in the subcortical white matter tracts as early as 1 day, in the hippocampus and injured cortex by 3 days, and in the thalamus by 1 week. Reactive astrocytes in the injured cortex, subcortical white matter tracts, and CA3 region of the hippocampus were all vimentin positive at 1 month post-injury. These astrocytes had a distinct morphology characterized by an enlarged cell body and long intertwined processes. In contrast, reactive astrocytes in the thalamic nuclei never expressed vimentin, and displayed an enlarged cell body with thick shortened processes. An increase in S100 protein was detected in all reactive astrocytes following LFP brain injury. Quantitative assessment of GFAP, S100, and vimentin polypeptides confirmed the immunohistochemical evaluation. Our data indicate that although astrogliosis mirrors the spatial pattern of post-traumatic neuronal cell loss, the expression of vimentin and the cellular morphology of the cells were regionally distinct, suggesting that astrogliosis may be modulated by factors present in the post-traumatic brain.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104; UNIV CONNECTICUT,CTR HLTH,DEPT NEUROL,FARMINGTON,CT 06030					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019943] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NSRO126818, NSPO1088003, NS19943] Funding Source: Medline		BARGER SW, 1992, J BIOL CHEM, V267, P9689; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; CALVO JL, 1990, BRAIN RES, V532, P355, DOI 10.1016/0006-8993(90)91784-E; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; CIESIELSKITRESKA J, 1988, J NEUROCYTOL, V17, P79, DOI 10.1007/BF01735380; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GUILIAN D, 1989, Journal of Neuroscience, V9, P4416; GUILIAN D, 1988, J NEUROSCI, V8, P2485; GUILIAN D, 1985, SCIENCE, V228, P497; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HICKS RR, IN PRESS BRAIN RES; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; POLVISHOCK JT, 1994, J NEUROTRAUM, V11, P723; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOARES HD, 1996, IN PRESS J NEUROSCI; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THOMPSON SW, 1966, SELECTED HISTOCHEMIC, P814; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; VAUGHN JE, 1969, J COMP NEUROL, V131, P143; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	40	99	103	1	4	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	1996	55	12					1221	1229		10.1097/00005072-199612000-00005			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	VW890	WOS:A1996VW89000006	8957445	Bronze			2021-06-18	
J	MENDEZ, MF				MENDEZ, MF			THE NEUROPSYCHIATRIC ASPECTS OF BOXING	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						BOXING; PUGILISM; DEMENTIA PUGILISTICA; PUNCH DRUNK; HEAD TRAUMA; CHRONIC TRAUMATIC ENCEPHALOPATHY; CLOSED HEAD INJURY; CONCUSSION; POST-CONCUSSION SYNDROME	CHRONIC BRAIN-DAMAGE; ACTIVE AMATEUR BOXERS; DEMENTIA-PUGILISTICA; HEAD-INJURY; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; PROFESSIONAL BOXERS; COMPUTED-TOMOGRAPHY; LEAD; CT	Objective: To review the neuropsychiatry of boxing. Method: This update considers the clinical, neuropsychological, diagnostic, neurobiological, and management aspects of boxing-related brain injury. Results: Professional boxers with multiple bouts and repeated head blows are prone to chronic traumatic encephalopathy (CTE). Repeated head blows produce rotational acceleration of the brain, diffuse axonal injury, and other neuropathological features. CTE includes motor changes such as tremor, dysarthria, and parkinsonism; cognitive changes such as mental slowing and memory deficits; and psychiatric changes such as explosive behavior, morbid jealousy, pathological intoxication, and paranoia. Screening with neuropsychological tests and neuroimaging may help predict those boxers at risk for CTE. Conclusions: Boxing results in a spectrum of CTE ranging from mild, nonprogressive motor changes to dementia pugilistica. Recent emphasis on safety in the ring, rehabilitation techniques, and other interventions do not eliminate the risk for CTE. For this reason, there is an active movement to ban boxing.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	MENDEZ, MF (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR, NEUROBEHAV UNIT 691116AF, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA.						ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P348; BRAYNE CEG, 1982, LANCET, V2, P1308; BRETON F, 1990, BIOL PSYCHOL, V31, P57, DOI 10.1016/0301-0511(90)90078-B; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; CHARNAS L, 1990, JAMA-J AM MED ASSOC, V264, P1532, DOI 10.1001/jama.264.12.1532; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CORSELLIS JAN, 1989, BRIT MED J, V298, P318; COWART VS, 1989, JAMA-J AM MED ASSOC, V261, P14, DOI 10.1001/jama.261.1.14; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; ENZENAUER RW, 1989, JAMA-J AM MED ASSOC, V261, P1463, DOI 10.1001/jama.261.10.1463; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HEILBRONNER RL, 1991, AM J SPORT MED, V19, P376, DOI 10.1177/036354659101900409; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; JORDAN BD, 1985, MED SCI SPORT EXER, V17, P212, DOI 10.1249/00005768-198504000-00142; KASTE M, 1982, LANCET, V2, P1186; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P2483, DOI 10.1001/jama.255.18.2483; MACPHERSON P, 1988, NEURORADIOLOGY, V30, P506, DOI 10.1007/BF00339691; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET, V2, P795; MCCOWN IA, 1979, PHYSICIAN SPORTSMED, V7, P75; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; MICHALS ML, 1993, J CLIN PSYCHOPHARM, V13, P198; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; PEARCE JMS, 1984, BRIT MED J, V288, P933, DOI 10.1136/bmj.288.6421.933-a; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; RICHARDS NG, 1984, NEUROLOGY, V34, P1485, DOI 10.1212/WNL.34.11.1485; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1988, LANCET, V2, P1456; RODRIGUEZ G, 1983, LANCET, V2, P858; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; Sironi V A, 1982, J Neurosurg Sci, V26, P165; SPILLANE JD, 1962, BRIT MED J, P1205; STILLER JW, 1985, PSYCHIAT CLIN N AM, V8, P339; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; UHL GR, 1982, ANN NEUROL, V12, P99; UNTERHARNSCHEID.FJ, 1975, HDB CLIN NEUROLOGY, V23, P531; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; 1983, JAMA-J AM MED ASSOC, V249, P254	75	99	102	1	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2174	1541-3527		INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1995	25	3					249	262		10.2190/CUMK-THT1-X98M-WB4C			14	Psychiatry	Psychiatry	TF010	WOS:A1995TF01000003	8567192				2021-06-18	
J	MCINTOSH, TK; YU, T; GENNARELLI, TA				MCINTOSH, TK; YU, T; GENNARELLI, TA			ALTERATIONS IN REGIONAL BRAIN CATECHOLAMINE CONCENTRATIONS AFTER EXPERIMENTAL BRAIN INJURY IN THE RAT	JOURNAL OF NEUROCHEMISTRY			English	Article						BRAIN INJURY; CATECHOLAMINES; FLUID; PERCUSSION; RAT	SENSORIMOTOR CORTEX INJURY; TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL BLOOD-FLOW; CORTICAL INJURY; STRIATAL DOPAMINE; SELECTIVE LESIONS; BEAM-WALKING; HEAD-INJURY; CIRCULATING CATECHOLAMINES; CEREBELLAR NOREPINEPHRINE	Although activation of brain catecholaminergic: systems has been implicated in the cerebrovascular and metabolic changes during subarachnoid hemorrhage, cerebral ischemia, cortical ablation, and cortical freeze lesions, little is known of the response of regional brain catecholamine systems to traumatic brain injury. The present study was designed to characterize the temporal changes in concentrations of norepinephrine (NE), dopamine (DA), and epinephrine (E) in discrete brain regions following experimental fluid-percussion traumatic brain injury in rats. Anesthetized rats were subjected to fluid-percussion brain injury of moderate severity (2.2-2.3 atm) and killed at 1 h, 6 h, 24 h, 1 week, and 2 weeks postinjury (n = 6 per timepoint). Control animals (surgery and anesthesia without injury) were killed at identical timepoints (n = 6 per timepoint). Tissue concentrations of NE, DA, and E were evaluated using HPLC. Following brain injury, an acute decrease was observed in DA concentrations in the injured cortex (p < 0.05) at 1 h postinjury, which persisted up to 2 weeks postinjury. Striatal concentrations of DA were significantly increased (p < 0.05) only at 6 h postinjury. Hypothalamic concentrations of DA and NE increased significantly beginning al 1 h postinjury (p < 0.05 and p < 0.05, respectively) and persisted up to 24 h for DA (p < 0.05) and 1 week (p < 0.05) for NE. These data suggest that acute alterations occur in regional concentrations of brain catecholamines following brain trauma, which may persist for prolonged periods postinjury.		MCINTOSH, TK (corresponding author), UNIV PENN, DIV NEUROSURG, CNS INJURY LAB, 105 HAYDEN HALL, 240 S 33RD ST, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, P01NS008803, P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline		ADACHI N, 1991, J NEUROCHEM, V57, P61, DOI 10.1111/j.1471-4159.1991.tb02099.x; BENFENATI F, 1989, BRAIN RES, V498, P376, DOI 10.1016/0006-8993(89)91120-7; BLOOMQUIST P, 1985, NEUROSCI LETT, V58, P353; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1985, EXP NEUROL, V89, P479, DOI 10.1016/0014-4886(85)90107-4; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; BUCHWEITZ E, 1982, J PHARMACOL EXP THER, V223, P322; BURKE RE, 1991, DEV BRAIN RES, V58, P171, DOI 10.1016/0165-3806(91)90003-2; BUSTO R, 1985, ANN NEUROL, V18, P329, DOI 10.1002/ana.410180310; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CALDERINI G, 1978, BRAIN RES, V157, P303, DOI 10.1016/0006-8993(78)90032-X; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CROWDER JM, 1983, EUR J PHARMACOL, V343, P352; CVEJIC V, 1980, ACTA NEUROPATHOL, V51, P71, DOI 10.1007/BF00688852; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DELANGEN CDJ, 1980, BRAIN RES, V185, P399; DELGADO TJ, 1986, J CEREBR BLOOD F MET, V6, P600, DOI 10.1038/jcbfm.1986.107; ESCHUN G, 1992, SURG NEUROL, V37, P101, DOI 10.1016/0090-3019(92)90184-O; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; FEENEY DM, 1988, PHARM APPROACHES TRE, P78; FINKLESTEIN S, 1983, BRAIN RES, V271, P279, DOI 10.1016/0006-8993(83)90290-1; GAUDET R, 1978, J NEUROCHEM, V30, P751, DOI 10.1111/j.1471-4159.1978.tb10781.x; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GORDON K, 1990, J NEUROCHEM, V54, P605, DOI 10.1111/j.1471-4159.1990.tb01914.x; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HARIK SI, 1986, NEUROLOGY, V36, P971, DOI 10.1212/WNL.36.7.971; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; JENNETT B, 1981, CONT NEUROLOGY SERIE, V20; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JOHNSTON MV, 1983, ANN NEUROL, V13, P511, DOI 10.1002/ana.410130507; KOBAYASHI H, 1985, EXPERIENTIA, V41, P427, DOI 10.1007/BF01966140; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; LANGFITT TW, 1966, HEAD INJURY, P172; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P146; LYNCH MA, 1986, NEUROPHARMACOLOGY, V25, P493, DOI 10.1016/0028-3908(86)90173-5; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; MARTIN JB, 1990, CLIN NEUROENDOCRINOL; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYAUCHI Y, 1989, J NEUROCHEM, V53, P408, DOI 10.1111/j.1471-4159.1989.tb07349.x; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PALAZZOLO DL, 1990, J CHROMATOGR, V518, P258, DOI 10.1016/S0021-9673(01)93185-1; PALKOVITZ M, 1988, MAP GUIDE MICRODISSE; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; RICHARDSON DJ, 1993, J HELMINTHOL SOC W, V60, P128, DOI 10.1111/j.1471-4159.1993.tb05830.x; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROBINSON RG, 1975, NATURE, V255, P332, DOI 10.1038/255332a0; Romhanyi R, 1990, J NEUROTRAUM, V9, P164; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STANTON PK, 1989, EXP BRAIN RES, V77, P517; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SVENDGAARD NA, 1987, J CEREBR BLOOD F MET, V7, P21, DOI 10.1038/jcbfm.1987.4; SVENDGAARD NA, 1986, J CEREBR BLOOD F MET, V6, P650, DOI 10.1038/jcbfm.1986.120; Tandian D, 1990, J NEUROTRAUM, V9, P174; VEINOT JP, 1987, EXP NEUROL, V97, P207, DOI 10.1016/0014-4886(87)90295-0; WEAVER MS, 1988, SOC NEUR ABSTR, V14, P1451; WEISS HR, 1988, EUR J PHARMACOL, V148, P107, DOI 10.1016/0014-2999(88)90459-1; WOODWARD DJ, 1979, FED PROC, V38, P2109; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875	79	99	102	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	1994	63	4					1426	1433					8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	PH202	WOS:A1994PH20200029	7931293				2021-06-18	
J	KIRBY, RL; ACKROYDSTOLARZ, SA; BROWN, MG; KIRKLAND, SA; MACLEOD, DA				KIRBY, RL; ACKROYDSTOLARZ, SA; BROWN, MG; KIRKLAND, SA; MACLEOD, DA			WHEELCHAIR-RELATED ACCIDENTS CAUSED BY TIPS AND FALLS AMONG NONINSTITUTIONALIZED USERS OF MANUALLY PROPELLED WHEELCHAIRS IN NOVA-SCOTIA	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						WHEELCHAIRS; EPIDEMIOLOGY; SAFETY; REHABILITATION	PREVENTION; INJURIES	The purpose of this study was to document what proportion of noninstitutionalized users of manually propelled wheelchairs are affected by wheelchair-related accidents caused by tips and falls, determine the nature and severity of the resulting injuries, and, by comparison with an unaffected group, identify factors associated with the risk of such accidents. We administered a postal questionnaire to as many as possible of the estimated 2055 members of the target population in the province of Nova Scotia. Among the 577 appropriate respondents, 57.4% reported they had completely tipped over or fallen from their wheelchairs at least once, and 66.0% reported having partially tipped. Of the falls and tips that were reported, 46.3% were forward in direction, 29.5% backward and 24.2% sideways. Many of the accidents occurred outdoors or on ramps. A total of 292 injuries were reported by 272 (47.1%) respondents. Most of the injuries (84.3%) were minor (e.g., abrasions, contusions, lacerations and sprains). Of the 15.8% of injuries that were serious, the most common were fractures (10.6%) and concussions (2.7%). Factors that appear to be associated with an increased risk of accidents and injuries included younger age, male gender, paraplegia or spina bifida as the reason for wheelchair use, having had a wheelchair prescribed, some wheelchair features (lightweight, camber, adjustable rear-axle positions, a knapsack), daily use of a wheelchair, propelling the chair with both hands, use of the wheelchair for recreation, use of a sideways transfer (without a transfer board) and doing repairs themselves or having them done by the dealer. Factors associated with a decreased risk include multiple sclerosis, stroke or arthritis as the reason for wheelchair use, attendant propulsion and the use of a one-person assist for transfers. The results of this study, that wheelchair-related accidents caused by tips and falls are very common, that serious injuries are not unusual and that there is a pattern of risk factors, should be useful to wheelchair users, clinicians, manufacturers and regulatory bodies.	DALHOUSIE UNIV,NOVA SCOTIA REHABIL CTR,DEPT EPIDEMIOL & COMMUNITY HLTH,HALIFAX,NS,CANADA	KIRBY, RL (corresponding author), DALHOUSIE UNIV,NOVA SCOTIA REHABIL CTR,DEPT MED,DIV PHYS MED & REHABIL,1341 SUMMER ST,HALIFAX B3H 4K4,NS,CANADA.						BATAVIA A I, 1990, Journal of Rehabilitation Research and Development, V27, P425, DOI 10.1682/JRRD.1990.10.0425; BECKER D G, 1991, Journal of Emergency Medicine, V9, P115, DOI 10.1016/0736-4679(91)90314-6; Bennett L, 1987, J Rehabil Res Dev, V24, P81; BLOOMQUIST LE, 1986, PHYSICIAN SPORTSMED, V14, P97; BREED AL, 1986, DEV MED CHILD NEUROL, V24, P366; CALDER CJ, 1990, AM J PHYS MED REHAB, V69, P184, DOI 10.1097/00002060-199008000-00003; CURTIS KA, 1985, PARAPLEGIA, V23, P170, DOI 10.1038/sc.1985.29; Dillman D.A., 1978, MAIL TELEPHONE SURVE; DUDLEY NJ, 1992, CLIN REHABIL, V7, P9; Fenwick D., 1977, WHEELCHAIRS THEIR US; GRAY B, 1992, DEV MED CHILD NEUROL, V34, P589; HAYS RM, 1985, ARCH PHYS MED REHAB, V66, P709; Hunter J, 1987, Int J Rehabil Res, V10, P77; KAUZLARICH JJ, 1981, WHEELCHAIR MOBILITY, P55; KETTLE M, 1992, CLIN REHABIL, V6, P67, DOI DOI 10.1177/026921559200600109; KIRBY RL, 1992, 7TH P WORLD C ISPO, P257; KIRBY RL, 1990, ASSISTIVE TECHNOLOGY, V2, P59; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LOANE TD, 1985, ARCH PHYS MED REHAB, V66, P174; MARWICK DP, 1975, SAMPLE SURVEY THEORY; Mion L C, 1989, Rehabil Nurs, V14, P17; NILSEN R, 1985, PARAPLEGIA, V23, P152, DOI 10.1038/sc.1985.26; NOTTAGE WM, 1981, CLIN ORTHOPAEDICS, V155, P65; PAULSON SM, 1983, ARCH PHYS MED REHAB, V64, P180; PLATTS EA, 1974, P ROY SOC MED, V67, P414, DOI 10.1177/003591577406700532; REED RL, 1993, ARCH PHYS MED REHAB, V74, P101; UMMAT S, 1994, AM J PHYS MED REHAB, V73, P163, DOI 10.1097/00002060-199406000-00004; WOODWARD CA, 1983, GUIDE QUESTIONNAIRE; 1982, STATISTICAL ABSTRACT, P115; 1991, NOVA SCOTIA FACT BOO; 1988, HLTH ACTIVITY LIMITA; 1992, PEOPLE DISABILITIES	32	99	100	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP-OCT	1994	73	5					319	330		10.1097/00002060-199409000-00004			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	PL292	WOS:A1994PL29200003	7917161				2021-06-18	
J	RIVARA, JB; JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, HA; LIAO, SQ				RIVARA, JB; JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, HA; LIAO, SQ			FAMILY FUNCTIONING AND INJURY SEVERITY AS PREDICTORS OF CHILD FUNCTIONING ONE-YEAR FOLLOWING TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; ENVIRONMENT; ADOLESCENTS; ADAPTATION; ADJUSTMENT; ILLNESS; MODEL		UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROSURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,STAT & EPIDEMIOL RES CORP,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,SEATTLE,WA 98195; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,SEATTLE,WA 98195				Shurtleff, Hillary/0000-0003-0959-2842	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Achenbach TM, 1986, MANUAL TEACHERS REPO; ASARNOW RF, 1991, J PED PSYCHOL, V16, P545; BILLINGS AG, 1987, HEALTH PSYCHOL, V6, P343, DOI 10.1037/0278-6133.6.4.343; BLACK P, 1969, LATE EFFECTS HEAD IN; BORROW ES, 1985, DIABETES CARE, V2, P146; BRESLAU N, 1985, J ABNORM CHILD PSYCH, V13, P199, DOI 10.1007/BF00910642; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; HAUSER ST, 1985, FAM RELAT, V34, P99, DOI 10.2307/583762; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JACOBSON MS, 1986, PEDIATRICS, V77, P236; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JOHNSON SB, 1988, J CHILD PSYCHOL PSYC, V29, P729; KUPST M J, 1982, Journal of Pediatric Psychology, V7, P157; MCCLEAN WE, 1992, J PEDIATR PSYCHOL, V2, P159; McCubbin HI, 1980, FAMILY ASSESSMENT RE; Miller R. G., 1981, SIMULTANEOUS STAT IN; Moos R. H., 1974, SOCIAL CLIMATE SCALE; MRAZEK D, 1985, 32ND P ANN M AM AC C; MURCH RL, 1989, J PEDIATR PSYCHOL, V14, P193, DOI 10.1093/jpepsy/14.2.193; PERROTT SB, 1991, DEV NEUROPSYCHOL, V1, P69; PLESS IB, 1972, INT J EPIDEMIOL, V1, P271, DOI 10.1093/ije/1.3.271; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RJ, 1990, J PEDIATR PSYCHOL, V1, P3; UNGERER JA, 1988, PEDIATRICS, V81, P195; VARNI JW, 1989, PEDIATRICS, V84, P323; VARNI JW, 1988, HEALTH PSYCHOL, V7, P421, DOI 10.1037/0278-6133.7.5.421; WERTLIEB D, 1986, J PEDIATR PSYCHOL, V4, P463	32	99	99	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1993	74	10					1047	1055		10.1016/0003-9993(93)90060-N			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	MB216	WOS:A1993MB21600007	8215855				2021-06-18	
J	ISHIGE, N; PITTS, LH; HASHIMOTO, T; NISHIMURA, MC; BARTKOWSKI, HM				ISHIGE, N; PITTS, LH; HASHIMOTO, T; NISHIMURA, MC; BARTKOWSKI, HM			EFFECT OF HYPOXIA ON TRAUMATIC BRAIN INJURY IN RATS .1. CHANGES IN NEUROLOGICAL FUNCTION, ELECTROENCEPHALOGRAMS, AND HISTOPATHOLOGY	NEUROSURGERY			English	Article									UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL SURG,EDITORIAL OFF,1360 9TH AVE,SUITE 210,SAN FRANCISCO,CA 94143							BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BOSE B, 1984, BRAIN RES, V311, P385, DOI 10.1016/0006-8993(84)90106-9; CHIAPPA KH, 1979, STROKE, V10, P381, DOI 10.1161/01.STR.10.4.381; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GURDJIAN E, 1940, AM J PHYSL, V156, P149; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; KATSURADA K, 1973, SURGERY, V73, P191; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; LEVINE JE, 1979, NEW ENGL J MED, V301, P109; LEVY WJ, 1980, ANESTHESIOLOGY, V53, P223, DOI 10.1097/00000542-198009000-00009; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1965, BIOPHYSIK, V2, P230; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P1; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; Miller J D, 1980, Adv Neurol, V28, P413; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NELSON LR, 1976, NEURAL TRAUMA, P297; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; RAMPIL IJ, 1983, ANESTH ANALG, V62, P186; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1982, HEAD INJURY BASIC CL, P103; SAUNDERS D, 1981, BRIT J ANAESTH, V53, P1, DOI 10.1093/bja/53.1.1; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	35	99	99	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1987	20	6					848	853		10.1227/00006123-198706000-00005			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	H8835	WOS:A1987H883500004	3614563				2021-06-18	
J	Rashid, B; Destrade, M; Gilchrist, MD				Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.			Mechanical characterization of brain tissue in simple shear at dynamic strain rates	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Diffuse axonal injury (DAI); Ogden; Mooney-Rivlin; Traumatic brain injury (TBI); Homogeneous; Viscoelastic; Relaxation	VISCOELASTIC PROPERTIES; CONSTITUTIVE MODEL; IN-VIVO; BEHAVIOR; INJURY; DEFORMATION; STRETCH; IMPLEMENTATION; COMPRESSION; ELASTICITY	During severe impact conditions, brain tissue experiences a rapid and complex deformation, which can be seen as a mixture of compression, tension and shear. Diffuse axonal injury (DAI) occurs in animals and humans when both the strains and strain rates exceed 10% and 10/s, respectively. Knowing the mechanical properties of brain tissue in shear at these strains and strain rates is thus of particular importance, as they can be used in finite element simulations to predict the occurrence of brain injuries under different impact conditions. However, very few studies in the literature provide this information. In this research, an experimental setup was developed to perform simple shear tests on porcine brain tissue at strain rates <= 120/s. The maximum measured shear stress at strain rates of 30, 60, 90 and 120/s was 1.15+/-0.25 kPa, 1.34+/-0.19 kPa, 2.19+/-0.225 kPa and 2.52+/-0.27 kPa, (mean +/- SD), respectively at the maximum amount of shear, K=1. Good agreement of experimental, theoretical (Ogden and Mooney-Rivlin models) and numerical shear stresses was achieved (p=0.7866-0.9935). Specimen thickness effects (2.0-10.0 mm thick specimens) were also analyzed numerically and we found that there is no significant difference (p=0.9954) in the shear stress magnitudes, indicating a homogeneous deformation of the specimens during simple shear tests. Stress relaxation tests in simple shear were also conducted at different strain magnitudes (10-60% strain) with the average rise time of 14 ms. This allowed us to estimate elastic and viscoelastic parameters (initial shear modulus, mu=4942.0 Pa, and Prony parameters: g(1)=0.520, g(2)=0.3057, tau(1)=0.0264 s, and tau(2)=0.011 s) that can be used in FE software to analyze the non-linear viscoelastic behavior of brain tissue. This study provides new insight into the behavior in finite shear of brain tissue under dynamic impact conditions, which will assist in developing effective brain injury criteria and adopting efficient countermeasures against traumatic brain injury. (C) 2013 Elsevier Ltd. All rights reserved.	[Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland; [Destrade, Michel] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland	Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland.	badar.rashid@ucdconnect.ie; michel.destrade@nuigalway.ie; michael.gilchrist@ucd.ie	Destrade, Michel/O-5825-2019	Destrade, Michel/0000-0002-6266-1221	Irish Research Council for Science, Engineering and Technology (IRCSET), IrelandIrish Research Council for Science, Engineering and Technology; Irish Research Council (IRC)Irish Research Council for Science, Engineering and Technology	The authors thank Dr. John D. Finan of Columbia University for his valuable input regarding implementation of the non-linear viscoelastic model. This work was supported for the first author by a Postgraduate Research Scholarship awarded in 2009 by the Irish Research Council for Science, Engineering and Technology (IRCSET), Ireland, and for the second author, by a New Foundations award from the Irish Research Council (IRC).	ANDERSON R, 2000, THESIS U ADELAIDE S; Arbogast K., 1995, 952716 SAE; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands D.W.A., 2000, P WAM2000 ASME S CRA; BRANDS D. W. A., 2000, P STAPP CAR CRASH C, V44, P249; Brands D.W.A., 1999, P 43 STAPP CAR CRASH, P313; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Claessans M., 1997, P 41 STAPP CAR CRASH, P315, DOI DOI 10.4271/973338; Claessens M., 1997, THESIS EINDHOVEN U T; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Destrade M, 2012, INT J NONLIN MECH, V47, P210, DOI 10.1016/j.ijnonlinmec.2011.05.008; Destrade M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2979869; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; ESTES MS, 1970, 70BHF13 ASME; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Fung Y., 1993, BIOMECHANICS MECH PR; FUNG YC, 1979, AM J PHYSIOL, V237, pH620; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532; Funk JR, 2000, J BIOMECH ENG-T ASME, V122, P15, DOI 10.1115/1.429623; Garo A, 2007, BIORHEOLOGY, V44, P51; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gennarelli T.A., 1972, STAPP CAR CRASH J, P296; Gent AN, 1996, RUBBER CHEM TECHNOL, V69, P59, DOI 10.5254/1.3538357; Hirakawa K, 1981, No To Shinkei, V33, P1057; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Holzapfel G., 2008, NONLINEAR SOLID MECH; HORGAN CO, 1995, SIAM REV, V37, P53, DOI 10.1137/1037003; Horgan CO, 2001, P ROY SOC A-MATH PHY, V457, P1999, DOI 10.1098/rspa.2001.0798; Horgan CO, 2011, P ROY SOC A-MATH PHY, V467, P760, DOI 10.1098/rspa.2010.0288; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laksari K, 2012, J BIOMECH, V45, P642, DOI 10.1016/j.jbiomech.2011.12.023; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; Lippert SA, 2004, BIORHEOLOGY, V41, P681; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Meaney D.F., 1990, P INT C BIOM IMP IRC; Merodio J, 2005, INT J NONLIN MECH, V40, P213, DOI 10.1016/j.ijnontinmec.2004.05.003; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; MOONEY M, 1964, J APPL PHYS, V35, P23, DOI 10.1063/1.1713076; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ogden R., 1997, NONLINEAR ELASTIC DE; Ogden RW, 2004, COMPUT MECH, V34, P484, DOI 10.1007/s00466-004-0593-y; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Ommaya AK, 1966, P 10 STAPP CAR CRASH, V10, P314; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rashid B, 2012, P I MECH ENG P-J SPO, V226, P170, DOI 10.1177/1754337112436900; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tamura A., 2008, J BIOMECH SCI ENG, V3, P263, DOI DOI 10.1299/JBSE.3.263; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Trexler MM, 2011, J MECH BEHAV BIOMED, V4, P1920, DOI 10.1016/j.jmbbm.2011.06.008; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Zhang L, 2001, Stapp Car Crash J, V45, P369	81	98	101	0	47	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	DEC	2013	28				SI		71	85		10.1016/j.jmbbm.2013.07.017			15	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	269IH	WOS:000328234500008	23973615				2021-06-18	
J	Leddy, JJ; Cox, JL; Baker, JG; Wack, DS; Pendergast, DR; Zivadinov, R; Willer, B				Leddy, John J.; Cox, Jennifer L.; Baker, John G.; Wack, David S.; Pendergast, David R.; Zivadinov, Robert; Willer, Barry			Exercise Treatment for Postconcussion Syndrome: A Pilot Study of Changes in Functional Magnetic Resonance Imaging Activation, Physiology, and Symptoms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						exercise; fMRI; physiology; postconcussion syndrome	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; VOLUNTARY EXERCISE; UP-REGULATION; HEAD-INJURY; RECOVERY; RELIABILITY; MRI; ABNORMALITIES; VALIDATION	Purpose: To compare functional magnetic resonance imaging (fMRI) activation patterns during a cognitive task, exercise capacity, and symptoms in postconcussion syndrome (PCS) patients who received exercise treatment (n = 4) with a PCS placebo stretching group (n = 4) and a healthy control group (n = 4). Methods: Subjects completed a math processing task during fMRI and an exercise treadmill test before (time 1) and after approximately 12 weeks (time 2). Exercise subjects performed aerobic exercise at 80% of the heart rate (HR) attained on the treadmill test, 20 minutes per day with an HR monitor at home, 6 days per week. The program was modified as the HR for symptom exacerbation increased. Results: At time 1, there was no difference in fMRI activation between the 2 PCS groups but healthy controls had significantly greater activation in the posterior cingulate gyrus, lingual gyrus, and cerebellum versus all PCS subjects (P < .05, corrected for multiple comparisons). At time 2, exercise PCS did not differ from healthy controls whereas placebo stretching PCS had significantly less activity in the cerebellum (P < .05 corrected) and in the anterior cingulate gyrus and thalamus (P < .001, uncorrected) versus healthy controls. At time 2, exercise PCS achieved a significantly greater exercise HR (P < .001) and had fewer symptoms (P < .0004) than placebo stretching PCS. Cognitive performance did not differ by group or time. Conclusions: Controlled aerobic exercise rehabilitation may help restore normal cerebral blood flow regulation, as indicated by fMRI activation, in PCS patients. The PCS symptoms may be related to abnormal cerebral blood flow regulation.	[Leddy, John J.; Baker, John G.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14260 USA; [Leddy, John J.; Baker, John G.] SUNY Buffalo, Univ Sports Med, Buffalo, NY 14260 USA; [Cox, Jennifer L.; Zivadinov, Robert] SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Dept Neurol, Buffalo, NY 14260 USA; [Baker, John G.; Wack, David S.] SUNY Buffalo, Dept Nucl Med, Buffalo, NY 14260 USA; [Pendergast, David R.] SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA	Leddy, JJ (corresponding author), Univ Sports Med, 160 Farber Hall SUNY, Buffalo, NY 14214 USA.	leddy@buffalo.edu	Zivadinov, Robert/Q-2054-2019	Zivadinov, Robert/0000-0002-7799-1485	University at Buffalo; Robert Rich Family Foundation; Buffalo Sabres Foundation	The authors acknowledge the assistance of the Buffalo Neuroimaging Analysis Center (BNAC), located in the Jacobs Neurological Institute (JNI) at the Buffalo General Hospital, for performing the fMRI studies for this project. Dr Leddy received funding from the University at Buffalo Interdisciplinary Research Development Fund. Drs Willer and Leddy received funding from the Robert Rich Family Foundation and the Buffalo Sabres Foundation.	ACSM's Guidelines for Exercise Testing and Prescription, 2006, ACSMS GUID EX TEST P; Baillieux H, 2008, CLIN NEUROL NEUROSUR, V110, P763, DOI 10.1016/j.clineuro.2008.05.013; Bonte FJ, 2004, J NUCL MED, V45, P771; Brys M, 2003, AM J PHYSIOL-HEART C, V285, pH1048, DOI 10.1152/ajpheart.00062.2003; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Chein JM, 2011, NEUROIMAGE, V54, P550, DOI 10.1016/j.neuroimage.2010.07.067; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Doering TJ, 1998, AM J PHYS MED REHAB, V77, P490, DOI 10.1097/00002060-199811000-00006; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Kozlowski KF, 2007, NEUROREHABILITATION, V22, P191; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Matsuda H, 2007, AM J NEURORADIOL, V28, P731; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Saalmann YB, 2009, CURR OPIN NEUROBIOL, V19, P408, DOI 10.1016/j.conb.2009.05.007; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Short P, 2007, ARCH CLIN NEUROPSYCH, V22, pS63, DOI 10.1016/j.acn.2006.10.012; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039	29	98	100	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					241	249		10.1097/HTR.0b013e31826da964			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900001	23249769				2021-06-18	
J	Mannix, R; Meehan, WP; Mandeville, J; Grant, PE; Gray, T; Berglass, J; Zhang, J; Bryant, J; Rezaie, S; Chung, JY; Peters, NV; Lee, C; Tien, LW; Kaplan, DL; Feany, M; Whalen, M				Mannix, Rebekah; Meehan, William P.; Mandeville, Joseph; Grant, Patricia E.; Gray, Tory; Berglass, Jacqueline; Zhang, Jimmy; Bryant, John; Rezaie, Shervin; Chung, Joon Yong; Peters, Nicholas V.; Lee, Christopher; Tien, Lee W.; Kaplan, David L.; Feany, Mel; Whalen, Michael			Clinical Correlates in an Experimental Model of Repetitive Mild Brain Injury	ANNALS OF NEUROLOGY			English	Article							APOLIPOPROTEIN-E; MOUSE MODEL; ALZHEIMERS-DISEASE; HEAD-INJURY; A-BETA; COGNITIVE PERFORMANCE; TRANSGENIC MICE; DEFICITS; E4; SUSCEPTIBILITY	ObjectiveAlthough there is growing awareness of the long-term cognitive effects of repetitive mild traumatic brain injury (rmTBI; eg, sports concussions), whether repeated concussions cause long-term cognitive deficits remains controversial. Moreover, whether cognitive deficits depend on increased amyloid deposition and tau phosphorylation or are worsened by the apolipoprotein E4 allele remains unknown. Here, we use an experimental model of rmTBI to address these clinical controversies. MethodsA weight drop rmTBI model was used that results in cognitive deficits without loss of consciousness, seizures, or gross or microscopic evidence of brain damage. Cognitive function was assessed using a Morris water maze (MWM) paradigm. Immunostaining and enzyme-linked immunosorbent assay (ELISA) were used to assess amyloid deposition and tau hyperphosphorylation. Brain volume and white matter integrity were assessed by magnetic resonance imaging (MRI). ResultsMice subjected to rmTBI daily or weekly but not biweekly or monthly had persistent cognitive deficits as long as 1 year after injuries. Long-term cognitive deficits were associated with increased astrocytosis but not tau phosphorylation or amyloid (by ELISA); plaques or tangles (by immunohistochemistry); or brain volume loss or changes in white matter integrity (by MRI). APOE4 was not associated with worse MWM performance after rmTBI. InterpretationWithin the vulnerable time period between injuries, rmTBI produces long-term cognitive deficits independent of increased amyloid or tau phosphorylation. In this model, cognitive outcome is not influenced by APOE4 status. The data have implications for the long-term mental health of athletes who suffer multiple concussions. Ann Neurol 2013;74:65-75	[Mannix, Rebekah; Meehan, William P.; Berglass, Jacqueline; Zhang, Jimmy] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah; Meehan, William P.; Mandeville, Joseph; Grant, Patricia E.; Feany, Mel; Whalen, Michael] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P.] Sports Concuss Clin, Div Sports Med, Boston, MA USA; [Meehan, William P.] Micheli Ctr Sports Injury Prevent, Boston, MA USA; [Mandeville, Joseph; Grant, Patricia E.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Grant, Patricia E.] Childrens Hosp Boston, Dept Radiol, Boston, MA 02115 USA; [Gray, Tory; Bryant, John; Rezaie, Shervin; Chung, Joon Yong; Peters, Nicholas V.; Lee, Christopher; Whalen, Michael] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Gray, Tory; Bryant, John; Rezaie, Shervin; Chung, Joon Yong; Peters, Nicholas V.; Lee, Christopher; Whalen, Michael] Massachusetts Gen Hosp, Neurosci Ctr, Charlestown, MA 02129 USA; [Tien, Lee W.; Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Boston, MA 02111 USA; [Feany, Mel] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Mannix, R (corresponding author), Childrens Hosp Boston, 300 Longwood Ave, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu; MWhalen@Partners.org	Mannix, Rebekah/AAD-8702-2020	Feany, Mel/0000-0003-0315-7970; Chung, Joon Yong/0000-0002-3980-2065	NFL; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128-06]; Charles Hood Foundation; NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075226]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075226] Funding Source: NIH RePORTER	This study was supported by the NFL Charities Medical Grant (R. M., W. P. M., M. W.), NICHD T32HD040128-06 (W. P. M.), Charles Hood Foundation (R. M.), and NIH National Institute of Neurological Disorders and Stroke R21NS075226 (M. W.).	Barreto GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027881; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Cai YM, 2012, ANESTHESIOLOGY, V116, P84, DOI 10.1097/ALN.0b013e31823da7a2; Callaway JK, 2012, EUR J ANAESTH, V29, P239, DOI 10.1097/EJA.0b013e32835103c1; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Collie A, 2004, NEUROLOGY, V63, P2460, DOI 10.1212/WNL.63.12.2460; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.02.928; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Khuman J MWI, 2009, 2 JOINT S INT NAT NE, VSanta Barbara, CA; Kida K, 2012, RESUSCITATION, V83, P1292, DOI 10.1016/j.resuscitation.2012.02.020; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Oddo S, 2006, J BIOL CHEM, V281, P39413, DOI 10.1074/jbc.M608485200; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134	45	98	98	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2013	74	1					65	75		10.1002/ana.23858			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	282UH	WOS:000329198600009	23922306	Green Accepted			2021-06-18	
J	Wiggins, A; Austerberry, R; Morrison, D; Ho, KM; Honeybul, S				Wiggins, Anthony; Austerberry, Richard; Morrison, David; Ho, Kwok M.; Honeybul, Stephen			Cranioplasty With Custom-Made Titanium Plates-14 Years Experience	NEUROSURGERY			English	Article						Autologous cranioplasty; Complications; Decompressive craniectomy; Neurotrauma; Titanium cranioplasty	CONTAINING COLLAGEN IMPLANT; SURGICAL SITE INFECTION; MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE CRANIECTOMY; HYDROXYAPATITE CEMENT; LOCAL APPLICATION; SUBARACHNOID HEMORRHAGE; GRAFT INFECTION; HEAD; COMPLICATIONS	BACKGROUND: There is no consensus on which material is best suited for repair of cranial defects. OBJECTIVE: To investigate the outcomes following custom-made titanium cranioplasty. METHODS: The medical records for all patients who had titanium cranioplasty at 2 major neurosurgical centers in Western Australia were retrieved and analyzed for this retrospective cohort study. RESULTS: Altogether, 127 custom-made titanium cranioplasties on 113 patients were included. Two patients had 3 titanium cranioplasties and 10 patients had 2. Infected bone flap (n = 61, 54%), either from previous craniotomy or autologous cranioplasty, and contaminated bone flap (n = 16, 14%) from the initial injury were the main reasons for requiring titanium cranioplasty. Complications attributed to titanium cranioplasty were common (n = 33, 29%), with infection being the most frequent complication (n = 18 patients, 16%). Complications were, on average, associated with an extra 7 days of hospital stay (interquartile range 2-17). The use of titanium as the material for the initial cranioplasty (P = .58), the presence of skull fracture(s) (P > .99) or scalp laceration(s) (P = .32) at the original surgery, and proven local infection before titanium cranioplasty (P = .78) were not significantly associated with an increased risk of infection. Infection was significantly more common after titanium cranioplasty for large defects (hemicraniectomy [39%] and bifrontal craniectomy [28%]) than after cranioplasty for small defects (P = .04). CONCLUSION: Complications after using titanium plate for primary or secondary cranioplasty were common (29%) and associated with an increased length of hospital stay. Infection was a major complication (16%), and this suggested that more vigorous perioperative infection prophylaxis is needed for titanium plate cranioplasty.	[Wiggins, Anthony; Honeybul, Stephen] Royal Perth Hosp, Dept Neurosurg, Perth, WA, Australia; [Austerberry, Richard; Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Morrison, David] Royal Perth Hosp, Dept Med Engn & Phys, Perth, WA, Australia; [Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Wiggins, A (corresponding author), Royal Perth Hosp, Dept Neurosurg, Wellington St, Perth Cbd, WA 6000, Australia.	anwiggins77@hotmail.com	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004; Morrison, David/0000-0003-1305-035X			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agner C, 2003, MINIM INVAS NEUROSUR, V46, P186; Asano Y, 1993, No To Shinkei, V45, P1145; Bartlett P, 2009, BRIT J ORAL MAX SURG, V47, P238, DOI 10.1016/j.bjoms.2008.08.022; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Brett-Major DM, 2008, MIL MED, V173, P697, DOI 10.7205/MILMED.173.7.697; Burstein FD, 2006, PLAST RECONSTR SURG, V118, P482, DOI 10.1097/01.prs.0000234811.48147.64; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; CHANDLER CL, 1994, BRIT J NEUROSURG, V8, P409, DOI 10.3109/02688699408995107; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chiarini L, 2004, J CRANIO MAXILL SURG, V32, P5, DOI 10.1016/j.jcms.2003.08.005; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Day RE, 2012, BRIT J ORAL MAX SURG, V50, P376, DOI 10.1016/j.bjoms.2011.05.001; DILEK H, 1953, Turk Tip Cemiy Mecm, V19, P281; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Eppley BL, 2003, J CRANIOFAC SURG, V14, P209, DOI 10.1097/00001665-200303000-00014; Eufinger H, 1998, PLAST RECONSTR SURG, V102, P300, DOI 10.1097/00006534-199808000-00002; Fathi AR, 2008, J CRANIOFAC SURG, V19, P777, DOI 10.1097/SCS.0b013e31816b1b2a; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Friedman C D, 2000, Arch Facial Plast Surg, V2, P124, DOI 10.1001/archfaci.2.2.124; Gilardino MS, 2009, PLAST RECONSTR SURG, V123, P983, DOI 10.1097/PRS.0b013e318199f6ad; Goh RCW, 2010, J PLAST RECONSTR AES, V63, P1479, DOI 10.1016/j.bjps.2009.08.010; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2011, J TRAUMA, V71, P1637, DOI 10.1097/TA.0b013e31823a08f1; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S., 2012, RECONSTRUCTING DEFEC; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hussain ST, 2012, INT J SURG, V10, pS5, DOI 10.1016/j.ijsu.2012.05.015; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Inoue Akira, 1995, Neurologia Medico-Chirurgica, V35, P804; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Joffe J, 1999, BRIT J NEUROSURG, V13, P576, DOI 10.1080/02688699943088; Kakar V, 2009, BRIT J NEUROSURG, V23, P147, DOI 10.1080/02688690902756702; Kamyszek T, 2001, Mund Kiefer Gesichtschir, V5, P233, DOI 10.1007/s100060100317; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; Knaepler H, 2012, INT J SURG, V10, pS15, DOI 10.1016/j.ijsu.2012.05.020; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Kunze E, 1998, ACT NEUR S, V71, P16; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Matic DB, 2004, J CRANIOFAC SURG, V15, P415, DOI 10.1097/00001665-200405000-00012; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Miller JP, 2009, J NEUROSURG, V110, P247, DOI 10.3171/2008.6.17605; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; Muller A, 2003, J CRANIOFAC SURG, V14, P899; Nagayama K, 2002, NEUROL SURG TOKYO, V30, P165; Pankratiev BE, 1933, ANN SURG, V97, P321, DOI 10.1097/00000658-193303000-00001; Poetker DM, 2004, OTOL NEUROTOL, V25, P604, DOI 10.1097/00129492-200407000-00031; Raja SG, 2012, INT J SURG, V10, pS10, DOI 10.1016/j.ijsu.2012.05.018; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tokoro K, 1989, Neurol Med Chir (Tokyo), V29, P196, DOI 10.2176/nmc.29.196; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANGOOL AV, 1985, J MAXILLOFAC SURG, V13, P2, DOI 10.1016/S0301-0503(85)80005-9; Verret DJ, 2005, OTOLARYNG HEAD NECK, V133, P897, DOI 10.1016/j.otohns.2005.09.001; VITERBO F, 1995, J CRANIOFAC SURG, V6, P80, DOI 10.1097/00001665-199501000-00019; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; WOODHALL B, 1945, ANN SURG, V121, P649, DOI 10.1097/00000658-194505000-00009; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	74	98	106	1	24	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2013	72	2					248	256		10.1227/NEU.0b013e31827b98f3			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	073HP	WOS:000313734400041	23149967				2021-06-18	
J	Huber, BR; Meabon, JS; Martin, TJ; Mourad, PD; Bennett, R; Kraemer, BC; Cernak, I; Petrie, EC; Emery, MJ; Swenson, ER; Mayer, C; Mehic, E; Peskind, ER; Cook, DG				Huber, Bertrand R.; Meabon, James S.; Martin, Tobin J.; Mourad, Pierre D.; Bennett, Raymond; Kraemer, Brian C.; Cernak, Ibolja; Petrie, Eric C.; Emery, Michael J.; Swenson, Erik R.; Mayer, Cynthia; Mehic, Edin; Peskind, Elaine R.; Cook, David G.			Blast Exposure Causes Early and Persistent Aberrant Phospho- and Cleaved-Tau Expression in a Murine Model of Mild Blast-Induced Traumatic Brain Injury	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Blast-induced neurotrauma; brain trauma; cerebellum; mitochondrial oxidative stress; neurodegeneration; tauopathy	HEAD-INJURY; CASPASE ACTIVATION; MOUSE MODEL; ENCEPHALOPATHY; DISEASE; STRESS; HYPERPHOSPHORYLATION; OVERPRESSURE; AFGHANISTAN; INVOLVEMENT	Mild traumatic brain injury (mTBI) is considered the 'signature injury' of combat veterans that have served during the wars in Iraq and Afghanistan. This prevalence of mTBI is due in part to the common exposure to high explosive blasts in combat zones. In addition to the threats of blunt impact trauma caused by flying objects and the head itself being propelled against objects, the primary blast overpressure (BOP) generated by high explosives is capable of injuring the brain. Compared to other means of causing TBI, the pathophysiology of mild-to-moderate BOP is less well understood. To study the consequences of BOP exposure in mice, we employed a well-established approach using a compressed gas-driven shock tube that recapitulates battlefield-relevant open-field BOP. We found that 24 hours post-blast a single mild BOP provoked elevation of multiple phospho- and cleaved-tau species in neurons, as well as elevating manganese superoxide-dismutase (MnSOD or SOD2) levels, a cellular response to oxidative stress. In hippocampus, aberrant tau species persisted for at least 30 days post-exposure, while SOD2 levels returned to sham control levels. These findings suggest that elevated phospho- and cleaved-tau species may be among the initiating pathologic processes induced by mild blast exposure. These findings may have important implications for efforts to prevent blast-induced insults to the brain from progressing into long-term neurodegenerative disease processes.	[Huber, Bertrand R.; Petrie, Eric C.; Mayer, Cynthia; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Northwest Network Mental Illness Res Educ & Clin, Seattle, WA USA; [Meabon, James S.; Petrie, Eric C.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Meabon, James S.; Martin, Tobin J.; Kraemer, Brian C.; Cook, David G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA; [Mourad, Pierre D.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Mourad, Pierre D.] Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA; [Mourad, Pierre D.; Mehic, Edin] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Bennett, Raymond] Baker Engn & Risk Consultants, San Antonio, TX USA; [Kraemer, Brian C.; Cook, David G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA; [Cernak, Ibolja] Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2M7, Canada; [Emery, Michael J.; Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; [Swenson, Erik R.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA USA; [Cook, David G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA	Cook, DG (corresponding author), 1660 S Columbian Way, Seattle, WA 98108 USA.	dgcook@u.washington.edu		Petrie, Eric/0000-0003-1188-6321; Ibolja, Cernak/0000-0003-3214-698X	Department of Veterans Affairs Office of Research and Development Medical Research ServiceUS Department of Veterans Affairs; University of Washington Friends of Alzheimer's Research; University of Washington Royalty Research FundUniversity of Washington; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 AG000258]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000258, P50AG005136] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002619] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (DGC, ERP, BCK), University of Washington Friends of Alzheimer's Research (DGC, ERP), University of Washington Royalty Research Fund (DGC); Northwest Network Mental Illness Research, Education and Clinical Center (ERP), Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (BRH); NIH T32 AG000258 (JSM); None of the authors have financial or other potential conflicts of interest regarding this report.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Belmont PJ, 2012, J TRAUMA ACUTE CARE, V73, P3, DOI 10.1097/TA.0b013e318250bfb4; Bowen I G, 1967, Fission Prod Inhal Proj, P1; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2000, MAGNESIUM RES, V13, P29; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Goldstein L.E., 2012, SCI TRANSL MED, V4; Hosek B, 2011, NEW ENGL J MED; Jaffe DH, 2010, ANN SURG, V251, P138, DOI 10.1097/SLA.0b013e3181b5d7ab; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meabon JS, 2012, J HISTOCHEM CYTOCHEM, V60, P139, DOI 10.1369/0022155411430095; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Spires-Jones TL, 2008, J NEUROSCI, V28, P862, DOI 10.1523/JNEUROSCI.3072-08.2008; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wood GW, 2013, INJURY PREV, V19, P19, DOI 10.1136/injuryprev-2011-040277; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025	47	98	99	0	26	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877			J ALZHEIMERS DIS	J. Alzheimers Dis.		2013	37	2					309	323		10.3233/JAD-130182			15	Neurosciences	Neurosciences & Neurology	217EA	WOS:000324338400006	23948882	Green Accepted			2021-06-18	
J	Menge, T; Zhao, YH; Zhao, J; Wataha, K; Gerber, M; Zhang, JH; Letourneau, P; Redell, J; Shen, L; Wang, J; Peng, ZL; Xue, H; Kozar, R; Cox, CS; Khakoo, AY; Holcomb, JB; Dash, PK; Pati, S				Menge, Tyler; Zhao, Yuhai; Zhao, Jing; Wataha, Kathryn; Gerber, Michael; Zhang, Jianhu; Letourneau, Phillip; Redell, John; Shen, Li; Wang, Jing; Peng, Zhalong; Xue, Hasen; Kozar, Rosemary; Cox, Charles S., Jr.; Khakoo, Aarif Y.; Holcomb, John B.; Dash, Pramod K.; Pati, Shibani			Mesenchymal Stem Cells Regulate Blood-Brain Barrier Integrity Through TIMP3 Release After Traumatic Brain Injury	SCIENCE TRANSLATIONAL MEDICINE			English	Article							TISSUE INHIBITOR; VASCULAR-PERMEABILITY; MODEL; EXPRESSION; SECRETION; APOPTOSIS; LUNG	Mesenchymal stem cells (MSCs) may be useful for treating a variety of disease states associated with vascular instability including traumatic brain injury (TBI). A soluble factor, tissue inhibitor of matrix metalloproteinase-3 (TIMP3), produced by MSCs is shown to recapitulate the beneficial effects of MSCs on endothelial function and to ameliorate the effects of a compromised blood-brain barrier (BBB) due to TBI. Intravenous administration of recombinant TIMP3 inhibited BBB permeability caused by TBI, whereas attenuation of TIMP3 expression in intravenously administered MSCs blocked the beneficial effects of the MSCs on BBB permeability and stability. MSCs increased circulating concentrations of soluble TIMP3, which blocked vascular endothelial growth factor-A-induced breakdown of endothelial cell adherens junctions in vitro and in vivo. These findings elucidate a potential molecular mechanism for the beneficial effects of MSCs on the BBB after TBI and demonstrate a role for TIMP3 in the regulation of BBB integrity.	[Menge, Tyler; Wataha, Kathryn; Pati, Shibani] Blood Syst Res Inst, San Francisco, CA 94118 USA; [Zhao, Yuhai; Gerber, Michael; Letourneau, Phillip; Peng, Zhalong; Kozar, Rosemary; Holcomb, John B.] Univ Texas Houston, Hlth Sci Ctr, Dept Surg, Houston, TX 77030 USA; [Zhao, Yuhai; Gerber, Michael; Letourneau, Phillip; Peng, Zhalong; Kozar, Rosemary; Holcomb, John B.] Univ Texas Houston, Hlth Sci Ctr, Ctr Translat Injury Res, Houston, TX 77030 USA; [Zhao, Jing; Redell, John; Dash, Pramod K.] Univ Texas Houston, Hlth Sci Ctr, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Zhang, Jianhu; Shen, Li; Wang, Jing] Univ Texas Houston, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Houston, Hlth Sci Ctr, Dept Pediat Surg, Houston, TX 77030 USA; [Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Houston, Hlth Sci Ctr, Inst Mol Med, Houston, TX 77030 USA; [Khakoo, Aarif Y.] Amgen Inc, San Francisco, CA 94080 USA; [Pati, Shibani] Univ Calif San Francisco, San Francisco, CA 94118 USA	Pati, S (corresponding author), Blood Syst Res Inst, San Francisco, CA 94118 USA.	spati@bloodsystems.org		holcomb, john/0000-0001-8312-9157; Dash, Pramod/0000-0001-6746-1002	Mission Connect; Texas Institute for Rehabilitation and Research; Bentsen Foundation, Houston, TX; National Heart, Lung, and Blood Institute K18 award [K18HL102256-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K18HL102256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This work is funded in part by Mission Connect; the Texas Institute for Rehabilitation and Research; the Bentsen Foundation, Houston, TX; and National Heart, Lung, and Blood Institute K18 award (K18HL102256-01).	Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Black RA, 2004, NAT GENET, V36, P934, DOI 10.1038/ng0904-934; Block GJ, 2009, STEM CELLS, V27, P670, DOI [10.1634/stemcells.stemcells.2008-0742, 10.1002/stem.20080742]; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gill SE, 2010, AM J PATHOL, V176, P64, DOI 10.2353/ajpath.2010.090158; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376; Kaur I, 2010, P NATL ACAD SCI USA, V107, pE112, DOI 10.1073/pnas.1007476107; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; KISHNANI NS, 1995, MATRIX BIOL, V14, P479, DOI 10.1016/0945-053X(95)90005-5; Koyama Junji, 2007, Kobe J Med Sci, V53, P199; Kwak HI, 2009, MATRIX BIOL, V28, P470, DOI 10.1016/j.matbio.2009.07.007; Lee JK, 2008, NEUROBIOL DIS, V30, P174, DOI 10.1016/j.nbd.2008.01.004; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Matthay MA, 2010, CRIT CARE MED, V38, pS569, DOI 10.1097/CCM.0b013e3181f1ff1d; Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Picinich SC, 2007, EXPERT OPIN BIOL TH, V7, P965, DOI 10.1517/14712598.7.7.965; Pounds S, 2003, BIOINFORMATICS, V19, P1236, DOI 10.1093/bioinformatics/btg148; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858	27	98	100	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	NOV 21	2012	4	161							161ra150	10.1126/scitranslmed.3004660			11	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	041UO	WOS:000311426900003	23175708	Green Accepted			2021-06-18	
J	Wang, HK; Lin, SH; Sung, PS; Wu, MH; Hung, KW; Wang, LC; Huang, CY; Lu, K; Chen, HJ; Tsai, KJ				Wang, Hao-Kuang; Lin, Sheng-Hsiang; Sung, Pi-Shan; Wu, Ming-Hsiu; Hung, Kuo-Wei; Wang, Liang-Chao; Huang, Chih-Yuan; Lu, Kang; Chen, Han-Jung; Tsai, Kuen-Jer			Population based study on patients with traumatic brain injury suggests increased risk of dementia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							AMYLOID-BETA DYNAMICS; ALZHEIMERS-DISEASE; HEAD-INJURY; PARKINSONS-DISEASE; PREVALENCE; ONSET; TAIWAN; AGE	Objective The relationship between traumatic brain injury (TBI) and the risk of dementia remains controversial. This population based study was designed to estimate and compare the risk of dementia in TBI and non-TBI individuals during the 5 year period after TBI. Methods This study was a retrospective cohort study. Data were obtained from the Longitudinal Health Insurance Database 2000. We included 44 925 patients receiving ambulatory or hospital care and 224 625 non-TBI patients; patients were matched for sex, age and year of index use of healthcare. Patients < 15 years of age and those admitted to the intensive care unit were excluded. Each individual was studied for 5 years to identify the subsequent development of dementia. Data were analysed by Cox proportional hazard regression. Results During the 5 year follow-up period, 1196 TBI (2.66%) and 224 625 non-TBI patients (1.53%) patients developed dementia. During the 5 year follow-up period, TBI was independently associated with a 1.68 (range 1.57-1.80) times greater risk of dementia after adjusting for sociodemographic characteristics and selected comorbidities. Conclusions The findings of this study suggest an increased risk of dementia among individuals with TBI. We suggest the need for more intensive medical monitoring and health education in individuals with TBI.	[Wang, Hao-Kuang; Lin, Sheng-Hsiang; Sung, Pi-Shan; Wu, Ming-Hsiu; Hung, Kuo-Wei; Wang, Liang-Chao; Huang, Chih-Yuan; Tsai, Kuen-Jer] Natl Cheng Kung Univ, Inst Clin Med, Tainan 704, Taiwan; [Wang, Hao-Kuang; Lu, Kang; Chen, Han-Jung] I Shou Univ, E Da Hosp, Dept Neurosurg, Kaohsiung, Taiwan; [Sung, Pi-Shan] Natl Cheng Kung Univ, Dept Neurol, Tainan 704, Taiwan; [Wu, Ming-Hsiu] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Hung, Kuo-Wei] Yuans Gen Hosp, Dept Neurol, Kaohsiung, Taiwan; [Wang, Liang-Chao; Huang, Chih-Yuan] Natl Cheng Kung Univ Hosp, Dept Surg, Neurosurg Serv, Tainan 70428, Taiwan	Tsai, KJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Tainan 704, Taiwan.	kjtsai@mail.ncku.edu.tw	Tsai, Kuen-Jer/B-9393-2009	Tsai, Kuen-Jer/0000-0002-2170-9735			Almeida OP, 2012, EUR HEART J, V33, P1769, DOI 10.1093/eurheartj/ehr467; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Chiang CJ, 2007, AM J GERIAT PSYCHIAT, V15, P762, DOI 10.1097/JGP.0b013e318050c98f; Chien IC, 2004, PSYCHIAT SERV, V55, P691, DOI 10.1176/appi.ps.55.6.691; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hung C C, 1991, J Formos Med Assoc, V90, P1227; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Kung WM, 2011, INJURY, V42, P940, DOI 10.1016/j.injury.2010.09.019; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Levy G, 2002, MOVEMENT DISORD, V17, P250, DOI 10.1002/mds.10086; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mizrahi EH, 2011, AM J ALZHEIMERS DIS, V26, P623, DOI 10.1177/1533317511432733; Mura E, 2010, CURR PHARM DESIGN, V16, P672, DOI 10.2174/138161210790883723; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rossor MN, 2010, LANCET NEUROL, V9, P793, DOI 10.1016/S1474-4422(10)70159-9; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Savva GM, 2009, NEW ENGL J MED, V360, P2302, DOI 10.1056/NEJMoa0806142; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SWAAB DF, 1994, J NEUROENDOCRINOL, V6, P681, DOI 10.1111/j.1365-2826.1994.tb00635.x; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Turner MR, 2010, J NEUROL SCI, V288, P45, DOI 10.1016/j.jns.2009.10.010; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; Wancata J, 2007, AM J GERIAT PSYCHIAT, V15, P1034, DOI 10.1097/JGP.0b013e31813c6b6c; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61	41	98	98	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2012	83	11					1080	1085		10.1136/jnnp-2012-302633			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	020MG	WOS:000309813600010	22842203				2021-06-18	
J	Meehan, WP; Zhang, J; Mannix, R; Whalen, MJ				Meehan, William P., III; Zhang, Jimmy; Mannix, Rebekah; Whalen, Michael J.			Increasing Recovery Time Between Injuries Improves Cognitive Outcome After Repetitive Mild Concussive Brain Injuries in Mice	NEUROSURGERY			English	Article						Cell death; Concussion; Mice; Mild traumatic brain injury; Morris water maze; Repeated traumatic brain injury; Sport-related concussion	FLUID-PERCUSSION INJURY; CEREBRAL CONCUSSION; UNITED-STATES; HEAD-INJURIES; BLOOD-FLOW; SPORTS; PERFORMANCE; FOOTBALL; IMPACT; RATS	BACKGROUND: Although previous evidence suggests that the cognitive effects of concussions are cumulative, the effect of time interval between repeat concussions is largely unknown. OBJECTIVE: To determine the effect of time interval between repeat concussions on the cognitive function of mice. METHODS: We used a weight-drop model of concussion to subject anesthetized mice to 1, 3, 5, or 10 concussions, each a day apart. Additional mice were subjected to 5 concussions at varying time intervals: daily, weekly, and monthly. Morris water maze performance was measured 24 hours, 1 month, and 1 year after final injury. RESULTS: After 1 concussion, injured and sham-injured mice performed similarly in the Morris water maze. As the number of concussions increased, injured mice performed worse than sham-injured mice. Mice sustaining 5 concussions either 1 day or 1 week apart performed worse than sham-injured mice. When 5 concussions were delivered at 1-month time intervals, no difference in Morris water maze performance was observed between injured and sham-injured mice. After a 1-month recovery period, mice that sustained 5 concussions at daily and weekly time intervals continued to perform worse than sham-injured mice. One year after the final injury, mice sustaining 5 concussions at a daily time interval still performed worse than sham-injured mice. CONCLUSION: When delivered within a period of vulnerability, the cognitive effects of multiple concussions are cumulative, persistent, and may be permanent. Increasing the time interval between concussions attenuates the effects on cognition. When multiple concussions are sustained by mice daily, the effects on cognition are long term.	[Meehan, William P., III] Harvard Univ, Sch Med, Childrens Hosp Boston, Sports Concuss Clin,Div Sports Med,Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III; Mannix, Rebekah] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med,Dept Med, Boston, MA 02115 USA; [Meehan, William P., III; Mannix, Rebekah] Harvard Univ, Sch Med, Childrens Hosp Boston, Brain Injury Ctr, Boston, MA 02115 USA; [Meehan, William P., III; Zhang, Jimmy; Mannix, Rebekah; Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Boston, MA 02114 USA; [Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Boston, MA USA	Meehan, WP (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Sports Concuss Clin,Div Sports Med,Dept Orthoped, 319 Longwood Ave, Boston, MA 02115 USA.	concussion.sportsmed@childrens.harvard.edu; mwhalen@partners.org	Mannix, Rebekah/AAD-8702-2020		NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040128-06]; National Football League Charities; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447, 1R21NS075226]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075226, R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from the NICHD T32 HD040128-06 (Dr Meehan), National Football League Charities (Drs Meehan, Mannix, and Whalen), and NINDS 5RO1NS047447 (Dr Whalen) and 1R21NS075226 (Dr Whalen). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRONWALL D, 1975, LANCET, V2, P995; Holbourn AHS, 1943, LANCET, V2, P438; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x	43	98	98	0	27	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2012	71	4					885	891		10.1227/NEU.0b013e318265a439			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	010TO	WOS:000309117200045	22743360	Bronze, Green Published			2021-06-18	
J	Meehan, WP; d'Hemecourt, P; Collins, CL; Comstock, RD				Meehan, William P., III; d'Hemecourt, Pierre; Collins, Christy L.; Comstock, R. Dawn			Assessment and Management of Sport-Related Concussions in United States High Schools	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						athletic injuries; athletic trainer; medical personnel; computed tomography; neuropsychological testing	CHRONIC TRAUMATIC ENCEPHALOPATHY; SEX-DIFFERENCES; CONTACT-SPORTS; BRAIN-INJURY; SYMPTOMS; EPIDEMIOLOGY; RISK	Background: Little existing data describe which medical professionals and which medical studies are used to assess sport-related concussions in high school athletes. Purpose: To describe the medical providers and medical studies used when assessing sport-related concussions. To determine the effects of medical provider type on timing of return to play, frequency of imaging, and frequency of neuropsychological testing. Study Design: Descriptive epidemiology study. Methods: All concussions recorded by the High School Reporting Information Online (HS RIO) injury surveillance system during the 2009 to 2010 academic year were included. chi 2 analyses were conducted for categorical variables. Fisher exact test was used for nonparametric data. Logistic regression analyses were used when adjusting for potential confounders. Statistical significance was considered for P < .05. Results: The HS RIO recorded 1056 sport-related concussions, representing 14.6% of all injuries. Most (94.4%) concussions were assessed by athletic trainers (ATs), 58.8% by a primary care physician. Few concussions were managed by specialists. The assessment of 21.2% included computed tomography. Computerized neuropsychological testing was used for 41.2%. For 50.1%, a physician decided when to return the athlete to play; for 46.2%, the decision was made by an AT. After adjusting for potential confounders, no associations between timing of return to play and the type of provider (physician vs AT) deciding to return the athlete to play were found. Conclusion: Concussions account for nearly 15% of all sport-related injuries in high school athletes. The timing of return to play after a sport-related concussion is similar regardless of whether the decision to return the athlete to play is made by a physician or an AT. When a medical doctor is involved, most concussions are assessed by primary care physicians as opposed to subspecialists. Computed tomography is obtained during the assessment of 1 of every 5 concussions occurring in high school athletes.	[Meehan, William P., III; d'Hemecourt, Pierre; Collins, Christy L.; Comstock, R. Dawn] Childrens Hosp, Sports Concuss Clin, Div Sports Med, Boston, MA 02115 USA	Meehan, WP (corresponding author), Childrens Hosp, Sports Concuss Clin, Div Sports Med, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations (NFHS); National Operating Committee on Standards for Athletic Equipment (NOCSAE); EyeBlack; DonJoy Orthotics; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172, R49CE000674] Funding Source: NIH RePORTER	The Research Institute at Nationwide Children's Hospital, Columbus, Ohio. One or more of the authors has declared the following potential conflict of interest or source of funding: The content of this work was funded in part by the Centers for Disease Control and Prevention (CDC) grants #R49/CE000674-01 and #R49/CE001172-01. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the CDC. The authors also acknowledge the generous research funding contributions of the National Federation of State High School Associations (NFHS), the National Operating Committee on Standards for Athletic Equipment (NOCSAE), EyeBlack, and DonJoy Orthotics. This study was supported by the National Institutes of Health (NIH) T32 Award to Dr Meehan (T32 HD040128-06A1).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brody AS, 2007, PEDIATRICS, V120, P677, DOI 10.1542/peds.2007-1910; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Farace E, 2000, Neurosurg Focus, V8, pe6; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Foreman Megan, 2010, State Legis, V36, P28; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; PRESS A, 2010, NFL NEWS        1213; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; RICKERSON J, 2010, CONCUSSION LAWS; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHWARZ A, 2009, NY TIMES        1220; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WAXENBERG R, 2009, ATHLETIC TRAINERS FI	36	98	98	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2011	39	11					2304	2310		10.1177/0363546511423503			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	838KG	WOS:000296287900003	21969181	Green Accepted			2021-06-18	
J	Whiteneck, GG; Dijkers, MP; Heinemann, AW; Bogner, JA; Bushnik, T; Cicerone, KD; Corrigan, JD; Hart, T; Malec, JF; Millis, SR				Whiteneck, Gale G.; Dijkers, Marcel P.; Heinemann, Allen W.; Bogner, Jennifer A.; Bushnik, Tamara; Cicerone, Keith D.; Corrigan, John D.; Hart, Tessa; Malec, James F.; Millis, Scott R.			Development of the Participation Assessment With Recombined Tools-Objective for Use After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injury, chronic; Interpersonal relations; Outcome assessment, health care; Psychometrics; Questionnaires; Rehabilitation; Reproducibility of results; Role; Social adjustment	DISABILITY RATING-SCALE; COMMUNITY INTEGRATION QUESTIONNAIRE; PORTLAND ADAPTABILITY INVENTORY; GALVESTON ORIENTATION; HEAD-INJURY; AMNESIA TEST; OUTCOMES; REHABILITATION; VALIDITY; SATISFACTION	Whiteneck GG, Dijkers MP, Heinemann AW, Bogner JA, Bushnik T, Cicerone KD, Corrigan JD, Hart T, Malec JF, Millis SR. Development of the Participation Assessment With Recombined Tools Objective for use after traumatic brain injury. Arch Phys Med Rehabil 2011;92:542-51. Objective: To develop a new measure, the Participation Assessment With Recombined Tools Objective (PART-O), based on items from 3 participation instruments. Design: Instrument development based on survey research. Setting: Community. Participants: Adults (N=400) with traumatic brain injury (TBI) 1 to 15 years postinjury, recruited from 8 TBI Model Systems (TBIMS). Interventions: None. Main Outcome Measure: Community Integration Questionnaire version 2; Participation Objective, Participation Subjective; Craig Handicap Assessment and Reporting Technique; PART-O. Results: Using Rasch rating scale analysis to evaluate the psychometric properties of participation items drawn from 3 instruments, a set of 24 items was developed that covered a broad range of participation content and formed a measure with person separation of 2.47, person reliability of .86, item spread of 4.25 logits, item separation of 11.36, and item reliability of .99. Items were well targeted on the sample with only 1 item misfitting. The PART-O showed expected relationships with measures of impairment, activity limitations, and subjective well-being. Conclusions: The 24-item PART-O is an acceptable measure of objective participation for persons with moderate and severe TBI. It has been adopted as the measure of participation in the TBIMS.	[Whiteneck, Gale G.] Craig Hosp, Englewood, CO 80113 USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Bogner, Jennifer A.; Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Bushnik, Tamara] NYU, Rusk Inst Rehabil Med, Langone Med Ctr, New York, NY USA; [Cicerone, Keith D.] JFK Johnson Rehabil Inst, Edison, NJ USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Millis, Scott R.] Wayne State Univ, Sch Med, Detroit, MI USA	Whiteneck, GG (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	gale@craig-hospital.org	Corrigan, John D./E-2921-2011; Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326; Bushnik, Tamara/0000-0003-3328-257X; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research [H133A020510, H133A070022]; New York TBIMS [H1331020501, H133A070033]; Ohio Regional TBIMS [H133A020503, H133A070029]; Northern California TBIMS [H133A020524, H133A070038]; JFK Johnson Rehabilitation Institute TBIMS [H133A020518, H133A070030]; Moss TBIMS [H133A020505, H133A070040]; Rehabilitation Research and Training Center on the Community Integration of Individuals With Traumatic Brain Injury [H133B30038]; Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness [H133B040032]	Supported by the National Institute on Disability and Rehabilitation Research through Traumatic Brain Injury Model System (TBIMS) awards to the Rocky Mountain Regional Brain Injury System (grant nos. H133A020510, H133A070022); New York TBIMS (grant nos. H1331020501, H133A070033); Ohio Regional TBIMS (grant nos. H133A020503, H133A070029); Northern California TBIMS (grant nos. H133A020524, H133A070038); JFK Johnson Rehabilitation Institute TBIMS (grant nos. H133A020518, H133A070030); The Moss TBIMS (grant nos. H133A020505, H133A070040); Rehabilitation Research and Training Center on the Community Integration of Individuals With Traumatic Brain Injury (grant no. H133B30038); and Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness (grant no. H133B040032).	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BOAKE C, SUPERVISION RATING S; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bond T.G., 2001, APPL RASCH MODEL FUN; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers M, 2009, ARCH PHYS MED REHAB, V90, pe39, DOI DOI 10.1016/j.apmr.2009.08.123; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Frey KL, 2007, BRAIN INJURY, V21, P513, DOI 10.1080/02699050701311026; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Green J, 2001, DISABIL REHABIL, V23, P670, DOI 10.1080/09638280110045382; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hart T, 2010, J HEAD TRAUMA REHAB, V25, P339, DOI 10.1097/HTR.0b013e3181c7e60b; Heinemann AW, 2011, ARCH PHYS MED REHAB, V92, P564, DOI 10.1016/j.apmr.2010.07.220; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Linacre J M, 1999, J Outcome Meas, V3, P103; Linacre J.M., USERS GUIDE WINSTEPS; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; *NAT DAT STAT CTR, SYLL; Nouri F. M., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Resnik L, 2009, ARCH PHYS MED REHAB, V90, P856, DOI 10.1016/j.apmr.2008.11.010; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, pR5, DOI 10.1097/00001199-199602000-00001; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wade D T, 1985, Int Rehabil Med, V7, P176; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wiersma D, 1996, SOC PSYCH PSYCH EPID, V31, P101, DOI 10.1007/BF00785755; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2001, INT CLASS FUNCT DIS; Wright B.D., 1982, RATING SCALE ANAL; Wright BD, 1996, RASCH MEASUREMENT T, V10, P509; Wright J, 2000, DISABILITY RATING SC; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	69	98	98	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2011	92	4					542	551		10.1016/j.apmr.2010.08.002			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	743VT	WOS:000289047500004	21367393				2021-06-18	
J	Sauerbeck, A; Gao, JX; Readnower, R; Liu, M; Pauly, JR; Bing, GY; Sullivan, PG				Sauerbeck, Andrew; Gao, Jianxin; Readnower, Ryan; Liu, Mei; Pauly, James R.; Bing, Guoying; Sullivan, Patrick G.			Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Pioglitazone; Mitochondria; Inflammation; Microglia; Cortical lesion; Cortical impact; Contusion; PPAR; Peroxisome proliferator-activated receptor	ACTIVATED-RECEPTOR-GAMMA; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; PPAR-ALPHA AGONIST; NF-KAPPA-B; CELL-DEATH; OXIDATIVE STRESS; MOUSE MODEL; DOPAMINERGIC NEURODEGENERATION	Following traumatic brain injury (TBI) there is significant neuropathology which includes mitochondrial dysfunction, loss of cortical gray matter, microglial activation, and cognitive impairment. Previous evidence has shown that activation of the peroxisome proliferator-activated receptors (PPARs) provide neuroprotection following traumatic brain and spinal injuries. In the current study we hypothesized that treatment with the PPAR ligand Pioglitazone would promote neuroprotection following a rat controlled cortical impact model of TBI. Animals received a unilateral 1.5 mm controlled cortical impact followed by administration of Pioglitazone at 10 mg/kg beginning 15 min after the injury and subsequently every 24h for 5 days. Beginning 1 day after the injury there was significant impairment in mitochondrial bioenergetic function which was attenuated by treatments with Pioglitazone at 15 min and 24 h ( p< 0.05). In an additional set of animals, cognitive function was assessed using the Morris Water Maze (MWM) and it was observed that over the course of 4 days of testing the injury produced a significant increase in both latency ( p< 0.05) and distance ( p< 0.05) to the platform. Animals treated with Pioglitazone performed similarly to sham animals and did not exhibit any impairment in MWM performance. Sixteen days after the injury tissue sections through the lesion site were quantified to determine the size of the cortical lesion. Vehicle-treated animals had an average lesion size of 5.09 +/- 0.73 mm(3) and treatment with Pioglitazone significantly reduced the lesion size by 55% to 2.27 +/- 0.27 mm(3) ( p< 0.01). Co-administration of the antagonist T0070907 with Pioglitazone blocked the protective effect seen with administration of Pioglitazone by itself. Following the injury there was a significant increase in the number of activated microglia in the area of the cortex adjacent to the site of the lesion ( p< 0.05). Treatment with Pioglitazone prevented the increase in the number of activated microglia and no difference was observed between sham and Pioglitazone-treated animals. From these studies we conclude that following TBI Pioglitazone is capable ameliorating multiple aspects of neuropathology. These studies provide further support for the use of PPAR ligands, specifically Pioglitazone, for neuroprotection. (C) 2010 Elsevier Inc. All rights reserved.	[Sauerbeck, Andrew; Readnower, Ryan; Liu, Mei; Bing, Guoying; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Sauerbeck, Andrew; Readnower, Ryan; Pauly, James R.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA; [Gao, Jianxin] Shandong Univ, Sch Med, Dept Physiol, Jinan 250012, Shandong, Peoples R China	Sullivan, PG (corresponding author), BBSRB, 741 S Limestone St,Room 475, Lexington, KY 40536 USA.	Adsaue2@uky.edu; gaojx@sdu.edu.cn; rdread2@uky.edu; mei.liu@uky.edu; jim.pauly@uky.edu; guoying.bing@uky.edu; patsull@uky.edu		Bing, Guoying/0000-0003-0609-8152	National Institutes of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [R01 NS48191, R01 NS062993, P30 NS051220, 5 T32 AG000242]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, R01NS062993, P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health, U.S. Public Health Service grants R01 NS48191, R01 NS062993 (P.G.S.), P30 NS051220, 5 T32 AG000242, and funding from the Kentucky Spinal Cord and Head Injury Research Trust. The authors would like to thank Andrea Sebastian and Deann Hopkins for technical assistance.	Allahtavakoli M, 2009, BRAIN RES, V1271, P121, DOI 10.1016/j.brainres.2009.03.040; Arimoto T, 2003, NEUROBIOL DIS, V12, P35, DOI 10.1016/S0969-9961(02)00017-7; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Bernardo A, 2006, CURR PHARM DESIGN, V12, P93, DOI 10.2174/138161206780574579; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; BRAISSANT, 1996, ENDOCRINOLOGY, V137, P354; Breidert T, 2002, J NEUROCHEM, V82, P615, DOI 10.1046/j.1471-4159.2002.00990.x; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; Collino M, 2006, FREE RADICAL BIO MED, V41, P579, DOI 10.1016/j.freeradbiomed.2006.04.030; Cristiano L, 2001, J NEUROCYTOL, V30, P671, DOI 10.1023/A:1016525716209; CULLINGFORD IE, 1998, DISTRIBUTION, V70, P1366; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Dehmer T, 2004, J NEUROCHEM, V88, P494, DOI 10.1046/j.1471-4159.2003.02210.x; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Drew PD, 2006, NEUROCHEM INT, V49, P183, DOI 10.1016/j.neuint.2006.04.003; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Feng D, 2008, J INT MED RES, V36, P783, DOI 10.1177/147323000803600421; GILMER LK, 2009, J NEUROTRAUMA; Guan YF, 2002, DRUG NEWS PERSPECT, V15, P147, DOI 10.1358/dnp.2002.15.3.840011; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Heneka MT, 2000, J NEUROSCI, V20, P6862, DOI 10.1523/JNEUROSCI.20-18-06862.2000; Heneka MT, 1999, J NEUROIMMUNOL, V100, P156, DOI 10.1016/S0165-5728(99)00192-7; Hunter RL, 2008, NEUROSCI LETT, V432, P198, DOI 10.1016/j.neulet.2007.12.019; Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x; HUNTER RL, 2007, CURR NEUROPHARMACOL; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Jiang CY, 1998, NATURE, V391, P82; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007; Kiaei M, 2008, PPAR RES, V2008, DOI 10.1155/2008/418765; Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5; Liberatore GT, 1999, NAT MED, V5, P1403; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Miglio G, 2009, NEUROCHEM INT, V55, P496, DOI 10.1016/j.neuint.2009.05.001; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Ou ZS, 2006, BRAIN RES, V1096, P196, DOI 10.1016/j.brainres.2006.04.062; Paddock ML, 2007, P NATL ACAD SCI USA, V104, P14342, DOI 10.1073/pnas.0707189104; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Pershadsingh HA, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-3; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Risner ME, 2006, PHARMACOGENOMICS J, V6, P246, DOI 10.1038/sj.tpj.6500369; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Sakamoto J, 2000, BIOCHEM BIOPH RES CO, V278, P704, DOI 10.1006/bbrc.2000.3868; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; SOOD V, 2000, TECHNOL THER, V2, P429; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sun H, 2008, INT J DEV NEUROSCI, V26, P505, DOI 10.1016/j.ijdevneu.2008.01.009; Sundararajan S, 2006, NEUROCHEM INT, V49, P136, DOI 10.1016/j.neuint.2006.03.020; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Vijitruth R, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-6; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wiley SE, 2007, P NATL ACAD SCI USA, V104, P5318, DOI 10.1073/pnas.0701078104; Xing B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-4; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Young PW, 1998, J PHARMACOL EXP THER, V284, P751	84	98	99	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2011	227	1					128	135		10.1016/j.expneurol.2010.10.003			8	Neurosciences	Neurosciences & Neurology	708NF	WOS:000286367800018	20965168	Green Accepted			2021-06-18	
J	Kozai, TDY; Marzullo, TC; Hooi, F; Langhals, NB; Majewska, AK; Brown, EB; Kipke, DR				Kozai, T. D. Y.; Marzullo, T. C.; Hooi, F.; Langhals, N. B.; Majewska, A. K.; Brown, E. B.; Kipke, D. R.			Reduction of neurovascular damage resulting from microelectrode insertion into the cerebral cortex using in vivo two-photon mapping	JOURNAL OF NEURAL ENGINEERING			English	Article							TRAUMATIC BRAIN INJURY; MULTIPHOTON MICROSCOPY; BLOOD-FLOW; NEURAL INTERFACES; CALCIUM SIGNALS; TISSUE; MICRODIALYSIS; EDEMA; PROBE; RAT	Penetrating neural probe technologies allow investigators to record electrical signals in the brain. The implantation of probes causes acute tissue damage, partially due to vasculature disruption during probe implantation. This trauma can cause abnormal electrophysiological responses and temporary increases in neurotransmitter levels, and perpetuate chronic immune responses. A significant challenge for investigators is to examine neurovascular features below the surface of the brain in vivo. The objective of this study was to investigate localized bleeding resulting from inserting microscale neural probes into the cortex using two-photon microscopy (TPM) and to explore an approach to minimize blood vessel disruption through insertion methods and probe design. 3D TPM images of cortical neurovasculature were obtained from mice and used to select preferred insertion positions for probe insertion to reduce neurovasculature damage. There was an 82.8 +/- 14.3% reduction in neurovascular damage for probes inserted in regions devoid of major (> 5 mu m) sub-surface vessels. Also, the deviation of surface vessels from the vector normal to the surface as a function of depth and vessel diameter was measured and characterized. 68% of the major vessels were found to deviate less than 49 mu m from their surface origin up to a depth of 500 mu m. Inserting probes more than 49 mu m from major surface vessels can reduce the chances of severing major sub-surface neurovasculature without using TPM.	[Kozai, T. D. Y.; Marzullo, T. C.; Langhals, N. B.; Kipke, D. R.] Univ Michigan, Coll Engn, Dept Biomed Engn, Neural Engn Lab, Ann Arbor, MI 48109 USA; [Hooi, F.] Univ Michigan, Coll Engn, Dept Biomed Engn, Basic Radiol Sci Div, Ann Arbor, MI 48109 USA; [Majewska, A. K.] Univ Rochester, Sch Med & Dent, Dept Neurobiol & Anat, Rochester, NY 14642 USA	Kozai, TDY (corresponding author), Univ Michigan, Coll Engn, Dept Biomed Engn, Neural Engn Lab, Ann Arbor, MI 48109 USA.	tkozai@umich.edu; dkipke@umich.edu	Langhals, Nicholas/C-2123-2008; Kozai, Takashi/I-2214-2012	Langhals, Nicholas/0000-0003-0644-9020; Kozai, Takashi/0000-0002-2507-3295; Majewska, Ania/0000-0002-2167-6849	Center for Neural Communication Technology, National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41 EB002030]; National Institutes of Health (NEI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY019277]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY019277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS076401] Funding Source: NIH RePORTER	The authors would like to thank Badri Roysam for helpful project discussions, Anna Devor for helpful two-photon vascular imaging discussions and Paras Patel for assistance characterizing neurovasculature. This research is supported by Center for Neural Communication Technology, a P41 Resource Center funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB, P41 EB002030) and supported by the National Institutes of Health (NEI; EY019277), Burroughs Wellcome Fund Career Award in the Biomedical sciences, Fellowship from the Alfred P Sloan Foundation, the Whitehall Foundation, Department of Defense Era of Hope Scholar Award and Pew Scholar in the Biomedical Sciences Award.	Abdul-Karim MA, 2003, MICROVASC RES, V66, P113, DOI 10.1016/S0026-2862(03)00039-6; Azemi E, 2008, ACTA BIOMATER, V4, P1208, DOI 10.1016/j.actbio.2008.02.028; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Biran R, 2005, EXP NEUROL, V195, P115, DOI 10.1016/j.expneurol.2005.04.020; Bjornsson CS, 2006, J NEURAL ENG, V3, P196, DOI 10.1088/1741-2560/3/3/002; Bolan PJ, 2006, NEUROIMAGE, V32, P62, DOI 10.1016/j.neuroimage.2006.03.027; CAMP DM, 1992, J NEUROCHEM, V58, P1706, DOI 10.1111/j.1471-4159.1992.tb10044.x; Chaigneau E, 2003, P NATL ACAD SCI USA, V100, P13081, DOI 10.1073/pnas.2133652100; Chauhan VP, 2009, BIOPHYS J, V97, P330, DOI 10.1016/j.bpj.2009.03.064; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dorr A, 2007, NEUROIMAGE, V35, P1409, DOI 10.1016/j.neuroimage.2006.12.040; Dunn KW, 2008, ILAR J, V49, P66, DOI 10.1093/ilar.49.1.66; DUVERNOY HM, 1981, BRAIN RES BULL, V7, P519, DOI 10.1016/0361-9230(81)90007-1; EDELL DJ, 1992, IEEE T BIO-MED ENG, V39, P635, DOI 10.1109/10.141202; GOLDSMITH JD, 1995, HEARING RES, V83, P80, DOI 10.1016/0378-5955(94)00193-T; Grill WM, 2009, ANNU REV BIOMED ENG, V11, P1, DOI 10.1146/annurev-bioeng-061008-124927; Groothuis DR, 1998, BRAIN RES, V803, P218, DOI 10.1016/S0006-8993(98)00572-1; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Helmchen F, 2008, METHOD ENZYMOL, V444, P231, DOI 10.1016/S0076-6879(08)02810-3; Holson RR, 1998, BRAIN RES, V808, P182, DOI 10.1016/S0006-8993(98)00816-6; House Paul A, 2006, Neurosurg Focus, V20, pE4; Johnson MD, 2007, J NEUROSCI METH, V160, P276, DOI 10.1016/j.jneumeth.2006.09.023; Johnson Matthew D, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P3178; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kipke DR, 2008, J NEUROSCI, V28, P11830, DOI 10.1523/JNEUROSCI.3879-08.2008; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Kozai TDY, 2009, J NEUROSCI METH, V184, P199, DOI 10.1016/j.jneumeth.2009.08.002; Lauwers F, 2008, NEUROIMAGE, V39, P936, DOI 10.1016/j.neuroimage.2007.09.024; Lee H, 2005, J NEURAL ENG, V2, P81, DOI 10.1088/1741-2560/2/4/003; Levene MJ, 2004, J NEUROPHYSIOL, V91, P1908, DOI 10.1152/jn.01007.2003; Lowery RL, 2009, DEV NEUROBIOL, V69, P674, DOI 10.1002/dneu.20735; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Majewska A, 2000, PFLUG ARCH EUR J PHY, V441, P398, DOI 10.1007/s004240000435; Majewska A, 2000, J NEUROSCI, V20, P1722; McConnell GC, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/5/056003; McIntosh TK, 1996, LAB INVEST, V74, P315; NADAL A, 1995, P NATL ACAD SCI USA, V92, P1426, DOI 10.1073/pnas.92.5.1426; Nadal A, 1998, J PHYSIOL-LONDON, V509, P711, DOI 10.1111/j.1469-7793.1998.711bm.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nishimura N, 2007, P NATL ACAD SCI USA, V104, P365, DOI 10.1073/pnas.0609551104; Purcell EK, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/2/026005; Rohatgi P, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.4.FOCUS0983; SCHMIDT EM, 1976, EXP NEUROL, V52, P496, DOI 10.1016/0014-4886(76)90220-X; Schwartz AB, 2006, NEURON, V52, P205, DOI 10.1016/j.neuron.2006.09.019; Seymour JP, 2007, BIOMATERIALS, V28, P3594, DOI 10.1016/j.biomaterials.2007.03.024; Shen YF, 2004, ANAL CHEM, V76, P1134, DOI 10.1021/ac034869m; Subbaroyan J, 2005, J NEURAL ENG, V2, P103, DOI 10.1088/1741-2560/2/4/006; Svoboda K, 2006, NEURON, V50, P823, DOI 10.1016/j.neuron.2006.05.019; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Tyrrell JA, 2005, MICROVASC RES, V70, P165, DOI 10.1016/j.mvr.2005.08.005; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	58	98	99	2	15	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	1741-2560	1741-2552		J NEURAL ENG	J. Neural Eng.	AUG	2010	7	4			SI				046011	10.1088/1741-2560/7/4/046011			12	Engineering, Biomedical; Neurosciences	Engineering; Neurosciences & Neurology	627KP	WOS:000280038600015	20644246	Green Accepted			2021-06-18	
J	Smilek, D; Carriere, JSA; Cheyne, JA				Smilek, Daniel; Carriere, Jonathan S. A.; Cheyne, J. Allan			Failures of sustained attention in life, lab, and brain: Ecological validity of the SART	NEUROPSYCHOLOGIA			English	Article						Sustained attention; SART; Cognitive failures; Cognitive Failures Questionnaire (CFQ); Attention failures; Traumatic brain injury; Attention-Related Cognitive Errors Scale (ARCES)	DEFICIT-HYPERACTIVITY-DISORDER; RESPONSE VARIABILITY; EVERYDAY ATTENTION; ADHD; ERROR; MIND; TASK; PERFORMANCE; AWARENESS; CHILDREN	The Sustained Attention to Response Task (SART) is a widely used tool in cognitive neuroscience increasingly employed to identify brain regions associated with failures of sustained attention. An important claim of the SART is that it is significantly related to real-world problems of sustained attention such as those experienced by TB! and ADHD patients. This claim is largely based on its association with the Cognitive Failures Questionnaire (CFQ), but recently concerns have been expressed about the reliability of the SART-CFQ association. Based on a review of the literature, meta-analysis of prior research, and analysis of original data, we conclude that, across studies sampling diverse populations and contexts, the SART is reliably associated with the CFQ. The CFQ-SART relation also holds for patients with TBI. We note, however, conceptual limitations of using the CFQ which was designed as a measure of general cognitive failures, to validate the SART, which was specifically designed to assess sustained attention. To remedy this limitation, we report on associations between the SART and a specific Attention-Related Cognitive Errors Scale (ARCES) and a Mindful Awareness of Attention Scale-Lapses Only (MAAS-LO). (C) 2010 Elsevier Ltd. All rights reserved.	[Smilek, Daniel] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada	Smilek, D (corresponding author), Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada.	dsmilek@uwaterloo.ca			Natural Sciences and Engineering Research Council (NSERC) of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC); NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by a research grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada awarded to DS and a graduate scholarship from NSERC awarded to JSAC. All authors contributed equally to this work.	Bellgrove MA, 2005, NEUROPSYCHOLOGIA, V43, P1847, DOI 10.1016/j.neuropsychologia.2005.03.011; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Bellgrove MA, 2006, CORTEX, V42, P838, DOI 10.1016/S0010-9452(08)70426-X; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Cheyne D. O., 2009, NCM ANN M WAIK HAW A; Cheyne JA, 2009, COGNITION, V111, P98, DOI 10.1016/j.cognition.2008.12.009; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Dockree PM, 2007, EUR J NEUROSCI, V25, P900, DOI 10.1111/j.1460-9568.2007.05324.x; Dockree PM, 2005, NEUROIMAGE, V27, P587, DOI 10.1016/j.neuroimage.2005.05.044; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Fassbender C, 2006, J PSYCHOPHYSIOL, V20, P286, DOI 10.1027/0269-8803.20.4.286; Field AP, 2001, PSYCHOL METHODS, V6, P161, DOI 10.1037//1082-989X.6.2.161; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Hunter J.E., 2004, METHODS METAANALYSIS; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Kingstone A, 2003, CURR DIR PSYCHOL SCI, V12, P176, DOI 10.1111/1467-8721.01255; Kingstone A, 2008, BRIT J PSYCHOL, V99, P317, DOI 10.1348/000712607X251243; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T, 2004, NEUROPSYCHOL REHABIL, V14, P89, DOI 10.1080/09602010343000110; Mullins C, 2005, J AM ACAD CHILD PSY, V44, P169, DOI 10.1097/00004583-200502000-00009; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Reason J.T., 1979, ASPECTS CONSCIOUSNES, V1, P67; REASON JT, 1977, ADULT LEARNING; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Smallwood J, 2008, J COGNITIVE NEUROSCI, V20, P458, DOI 10.1162/jocn.2008.20037; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Van der Linden D, 2005, WORK STRESS, V19, P23, DOI 10.1080/02678370500065275; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Zordan L, 2008, BRAIN COGNITION, V66, P57, DOI 10.1016/j.bandc.2007.05.005	41	98	98	2	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JUL	2010	48	9					2564	2570		10.1016/j.neuropsychologia.2010.05.002			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	634ID	WOS:000280573300016	20452366				2021-06-18	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			Vitamin E Protects Against Oxidative Damage and Learning Disability After Mild Traumatic Brain Injury in Rats	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; hippocampus; learning; BDNF; vitamin E	LONG-TERM POTENTIATION; NEUROTROPHIC FACTOR; SYNAPTIC-TRANSMISSION; SYNAPSIN-I; COGNITIVE FUNCTION; SPATIAL MEMORY; DENTATE GYRUS; FAT DIET; PLASTICITY; MICE	Background. Reactive oxygen species induce neuronal damage, and their role in reducing synaptic plasticity and function is beginning to be understood. Vitamin E is a potent reactive oxygen species scavenger, which has the potential to reduce oxidative damage encountered after traumatic brain injury (TBI). Brain-derived neurotrophic factor (BDNF) can facilitate synaptic function and support learning by modulating the CaMKII system, synapsin I, and cAMP-response element-binding protein (CREB). The elevation of superoxide dismutase (SOD) and Sir2 (silent information regulator 2) play an important role in resistance to oxidative stress. Objective. We examined the possibility that vitamin E supplemented in the diet may help counteract the effects of TBI on the molecular substrates underlying synaptic plasticity and cognitive function in the hippocampus. Methods. Rats were fed a regular diet with or without 500 IU/kg of vitamin E for 4 weeks (n = 6-8 per group) before a mild fluid percussion injury (FPI) was performed. Results. FPI increased protein oxidation as evidenced by elevated levels of protein carbonyls and reduced levels of SOD and Sir2. In addition, FPI resulted in poor performance in the Morris water maze, which was accompanied by reduced levels of BDNF and its downstream effectors on synaptic plasticity, synapsin I, CREB, and CaMKII. Supplementation of vitamin E in the diet counteracted all the observed effects of FPI. Conclusions. These results suggest that vitamin E dietary supplementation can protect the brain against the effects of mild TBI on synaptic plasticity and cognition, using molecular systems associated with the maintenance of long-term plasticity, such as BDNF and Sir2.	[Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA USA	Gomez-Pinilla, F (corresponding author), Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 50465]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465] Funding Source: NIH RePORTER	This study was supported by NIH award NS 50465.	BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; Bolton MM, 2000, PROG BRAIN RES, V128, P203; BROCK TO, 1987, J NEUROSCI, V7, P931; Cao L, 2009, NEUROSCIENCE, V161, P73, DOI 10.1016/j.neuroscience.2009.02.059; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Erol FS, 2004, NEUROSURG REV, V27, P65, DOI 10.1007/s10143-003-0291-8; Ferri P, 2003, J NEUROCYTOL, V32, P1155, DOI 10.1023/B:NEUR.0000021909.84327.e8; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fukui K, 2002, ANN NY ACAD SCI, V959, P275, DOI 10.1111/j.1749-6632.2002.tb02099.x; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Gonzalez-Polo RA, 2003, J NEUROCHEM, V84, P305, DOI 10.1046/j.1471-4159.2003.01520.x; HARA H, 1990, BRAIN RES, V510, P335, DOI 10.1016/0006-8993(90)91386-U; Joseph JA, 1998, J NEUROSCI, V18, P8047; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kelly A, 2003, J NEUROSCI, V23, P5354; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Linnarsson S, 1997, EUR J NEUROSCI, V9, P2581, DOI 10.1111/j.1460-9568.1997.tb01687.x; Mishima K, 2003, NEUROSCI LETT, V337, P56, DOI 10.1016/S0304-3940(02)01293-4; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mu JS, 1999, BRAIN RES, V835, P259, DOI 10.1016/S0006-8993(99)01592-9; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Sherwood NT, 1999, J NEUROSCI, V19, P7025, DOI 10.1523/JNEUROSCI.19-16-07025.1999; Steffenach HA, 2002, P NATL ACAD SCI USA, V99, P3194, DOI 10.1073/pnas.042700999; Sugaya K, 1996, J NEUROSCI, V16, P3427; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062; Veinbergs I, 2000, EUR J NEUROSCI, V12, P4541, DOI 10.1111/j.1460-9568.2000.01308.x; WANG T, 1995, J NEUROSCI, V15, P4796; Wilson IA, 2004, J NEUROSCI, V24, P3870, DOI 10.1523/JNEUROSCI.5205-03.2004; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002	45	98	101	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAR	2010	24	3					290	298		10.1177/1545968309348318			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	556JI	WOS:000274586500009	19841436	Green Accepted			2021-06-18	
J	Chapman, LA; Wade, SL; Walz, NC; Taylor, HG; Stancin, T; Yeates, KO				Chapman, Leah A.; Wade, Shari L.; Walz, Nicolay C.; Taylor, H. Gerry; Stancin, Terry; Yeates, Keith O.			Clinically Significant Behavior Problems During the Initial 18 Months Following Early Childhood Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; early childhood; behavior problems	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; FAMILY ASSESSMENT DEVICE; LONG-TERM OUTCOMES; YOUNG-CHILDREN; HEAD-INJURY; SOCIAL COMPETENCE; PREDICTORS; RECOVERY; SKILLS; RELIABILITY	Objective: This study looked at the emergence of clinically significant problems in behavior, executive function skills, and social competence during the initial 18 months following traumatic brain injury (TBI) in young, children relative to a cohort of children with orthopedic injuries (OI) and the environmental factors that predict difficulties postinjury, Participants: Children. ages 3-7 years, hospitalized for severe TBI, moderate TBI. or OI were seen shortly after their injury (M = 40 days) and again 6 months, 12 months, and 18 months postinjury. Design: Behavioral parent self-reports, demographic data. family functioning reports, and home environment reports were collected at injury baseline and each time point postinjury. Results: Results suggest that. compared with the 01 group. the severe TBI group developed significantly more externalizing behavior problems and executive function problems following injury that persisted through the 18-month follow-up. Minimal social competence difficulties appeared at the 18-month follow-up, suggesting a possible pattern of emerging deficits rather than a recovery over time. Conclusions: Predictors of the emergence of clinically significant problems included permissive parenting, family dysfunction. and low socioeconomic status. The findings are similar to those found in school-age children.	[Walz, Nicolay C.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; [Chapman, Leah A.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Div Dev & Behav Pediat & Pediat Psychol, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Div Psychol, Columbus, OH 43210 USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA	Chapman, LA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Behav Med & Clin Psychol, 333 Burnet Ave, Cincinnati, OH 45229 USA.	chapmala@email.uc.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR026314-01, UL1 RR026314] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729, R01 HD042729-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR026314] Funding Source: NIH RePORTER		Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Arroyos-Jurado E, 2000, J SCHOOL PSYCHOL, V38, P571, DOI 10.1016/S0022-4405(00)00053-4; Bayer JK, 2006, J APPL DEV PSYCHOL, V27, P542, DOI 10.1016/j.appdev.2006.08.002; BRADLEY RH, 1984, DEV PSYCHOL, V20, P315, DOI 10.1037/0012-1649.20.2.315; Burnham K. P., 2002, MODEL SELECTION INFE; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Caldwell B. M., 1984, HOME OBSERVATION MEA; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; DeaterDeckard K, 1997, PSYCHOL INQ, V8, P161, DOI 10.1207/s15327965pli0803_1; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gelman A., 2004, TEXTS STAT SCI BAYES; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Merrell K.W., 2002, PRESCHOOL KINDERGART; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos R, 1994, LIFE STRESSORS SOCIA; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Querido JG, 2002, J CLIN CHILD ADOLESC, V31, P272, DOI 10.1207/S15374424JCCP3102_12; Robinson C. C., 1996, BIENN C INT SOC STUD; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Taylor H. G., J HEAD TRAU IN PRESS; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	43	98	98	4	131	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2010	55	1					48	57		10.1037/a0018418			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	563NJ	WOS:000275139000006	20175634	Green Accepted			2021-06-18	
J	Rao, V; Rosenberg, P; Bertrand, M; Salehinia, S; Spiro, J; Vaishnavi, S; Rastogi, P; Noll, K; Schretlen, DJ; Brandt, J; Cornwell, E; Makley, M; Miles, QS				Rao, Vani; Rosenberg, Paul; Bertrand, Melaine; Salehinia, Saeed; Spiro, Jennifer; Vaishnavi, Sandeep; Rastogi, Pramit; Noll, Kathy; Schretlen, David J.; Brandt, Jason; Cornwell, Edward; Makley, Michael; Miles, Quincy Samus			Aggression After Traumatic Brain Injury: Prevalence and Correlates	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							OVERT AGGRESSION; HEAD-INJURY; POPULATION; AGITATION; BEHAVIOR; SCALE; ONSET	Aggression after traumatic brain injury (TBI) is common but not well defined. Sixty-seven participants with first-time TBI were evaluated for aggression within 3 months of injury. The prevalence of aggression was found to be 28.4%, predominantly verbal aggression. Post-TBI aggression was associated with new-onset major depression (p=0.02), poorer social functioning (p=0.04), and increased dependency in activities of daily living (p=0.03), but not with a history Of substance abuse or adult/childhood behavioral problems. Implications of the study include early screening for aggression, evaluation for depression, and consideration of psychosocial support in aggressive patients. (The journal of Neuropsychiatry and Clinical Neurosciences 2009; 21:420-429)	[Rao, Vani] Johns Hopkins Univ, Div Neuropsychiat & Geriatr Psychiat, Dept Psychiat, Johns Hopkins Sch Med, Baltimore, MD 21224 USA; [Vaishnavi, Sandeep] Alexian Bros Behav Hlth Hosp, Div Neuropsychiat, Alexian Neurosci Inst, Chicago, IL USA; [Noll, Kathy] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; [Schretlen, David J.; Brandt, Jason] Johns Hopkins Sch Med, Div Med Psychol, Dept Psychiat, Baltimore, MD USA; [Cornwell, Edward] Howard Univ, Coll Med, Dept Surg, Washington, DC USA; [Makley, Michael] Univ Maryland, Kernan Hosp, Baltimore, MD 21201 USA	Rao, V (corresponding author), Johns Hopkins Univ, Div Neuropsychiat & Geriatr Psychiat, Dept Psychiat, Johns Hopkins Sch Med, 5300 Alpha Commons Dr,4th Floor 444, Baltimore, MD 21224 USA.	vrao@jhmi.edu		Brandt, Jason/0000-0001-7381-6244	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 066894]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH085142, K23MH066894] Funding Source: NIH RePORTER	This study was supported by grant K23 MH 066894 from the NIMH. The abstract was presented at the 2008 annual neuropsychiatry conference in Savannah, Georgia.	Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Benedict R., 1997, BRIEF VISUOSPATIAL M; BOWMAN M, 1997, BRAIN IMPAIRMENT IMP, P116; Brandt J., 2001, HOPKINS VERBAL LEARN; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Diaz F G, 1995, Med Law, V14, P131; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Eaton WW, 2008, ARCH GEN PSYCHIAT, V65, P513, DOI 10.1001/archpsyc.65.5.513; First MB., 1997, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Garno JL, 2008, BIPOLAR DISORD, V10, P285, DOI 10.1111/j.1399-5618.2007.00489.x; Golden J. C., 1978, STROOP COLOR WORD TE; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Greve KW, 2001, BRAIN INJURY, V15, P255; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hellings JA, 2005, J NEUROPSYCH CLIN N, V17, P29, DOI 10.1176/appi.neuropsych.17.1.29; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kafantaris V, 1996, J NEUROPSYCH CLIN N, V8, P186; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Lyketsos CG, 1999, J AM GERIATR SOC, V47, P487, DOI 10.1111/j.1532-5415.1999.tb07245.x; MCNIEL DE, 1991, AM J PSYCHIAT, V148, P1317; Nelson HE, 1982, NATL ADULT READING T; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; ROBINSON RG, 1985, AM J PSYCHIAT, V142, P1424; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; Schretlen D., 1996, BRIEF TEST ATTENTION; Silver J M, 1991, J Neuropsychiatry Clin Neurosci, V3, pS22; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Sloane PD, 2004, J AM GERIATR SOC, V52, P1795, DOI 10.1111/j.1532-5415.2004.52501.x; Spreen O., 1977, NEUROSENSORY CTR COM; Spreen O, 1969, NEUROSENSORY CTR COM; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81; Weissman MM, 2000, ARCH GEN PSYCHIAT, V57, P675, DOI 10.1001/archpsyc.57.7.675; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	46	98	99	0	17	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2009	21	4					420	429					10	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	526RR	WOS:000272311300009	19996251	Green Accepted			2021-06-18	
J	Roe, C; Sveen, U; Alvsaker, K; Bautz-Holter, E				Roe, Cecilie; Sveen, Unni; Alvsaker, Kristin; Bautz-Holter, Erik			Post-concussion symptoms after mild traumatic brain injury: influence of demographic factors and injury severity in a 1-year cohort study	DISABILITY AND REHABILITATION			English	Article						Mild traumatic brain injury; post concussion symptoms; injury severity; drop-out	MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; POSTCONCUSSION-SYNDROME; FOLLOW-UP; BASE-RATE; QUESTIONNAIRE; EPIDEMIOLOGY; SENSITIVITY; POPULATION; PREDICTORS	Purpose. To assess the prevalence and variation of post-concussion symptoms within the first year after mild traumatic brain injury (TBI), and explore the association between injury severity, demographic factors and symptoms. Methods. Prospective study of patients with mild TBI followed up at 3, 6 and 12 months (N = 96 included, n = 52 attending all follow-ups). Sociodemographic factors, injury mechanisms and impact of injury (Glasgow Coma Scale score, Abbreviated Injury Severity Score (AIS), Injury Severity Score) were recorded at inclusion. Symptoms were reported in the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) at the follow-ups. The sumscore of all symptoms in RPQ was calculated for each subject. Scores were also calculated separately for the cognitive, physical and behavioural symptoms. Results. Twenty-nine subjects met the post-concussion syndrome criteria at 3 months, and 22 patients at 6 and 12 months. The cognitive symptoms were more prominent than the physical and behavioural symptoms. The cognitive and physical symptoms were associated with AIS for the head injury at 3 months, but not at 12 months. Considerable individual variability in the symptom pattern was found, and the subjects who attended only the 3-months follow-up reported a lower level of symptoms than those attending all follow-ups. Conclusions. Persistence of symptoms was a considerable problem even I year after the injury, with cognitive symptoms dominating. More severe AIS scores were associated with a higher level of cognitive and physical symptoms at 3 months, but not at later follow-ups. Strategies to prevent and treat these symptoms should be focussed in clinical practice.	[Roe, Cecilie; Sveen, Unni; Alvsaker, Kristin; Bautz-Holter, Erik] Ullevaal Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway; [Roe, Cecilie; Bautz-Holter, Erik] Univ Oslo, Fac Med, N-0316 Oslo, Norway	Roe, C (corresponding author), Ullevaal Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	cecilie.roe@ulleval.no					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chan RCK, 2005, BRAIN INJURY, V19, P1117, DOI 10.1080/026990500150088; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Edna T H, 1987, J Oslo City Hosp, V37, P101; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fenton GW, 1996, CLIN ELECTROENCEPHAL, V27, P174; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Steingrimsdottir OA, 2004, PAIN, V110, P130, DOI 10.1016/j.pain.2004.03.016; TEASDALE G, 1974, LANCET, V2, P81; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; *WHO, 1981, ICD 10 CLASS; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	51	98	98	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2009	31	15					1235	1243		10.1080/09638280802532720			9	Rehabilitation	Rehabilitation	473MX	WOS:000268212200003	19116810				2021-06-18	
J	Chen, G; Shi, JX; Hang, CH; Me, WY; Liu, J; Liu, XM				Chen, Gang; Shi, Ji Xin; Hang, Chun Hua; Me, Weiying; Liu, Jian; Liu, Xiaoming			Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: A potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO)	NEUROSCIENCE LETTERS			English	Article						erythropoietin; traumatic brain injury; cerebral inflammation	NF-KAPPA-B; EXPRESSION; ISCHEMIA; APOPTOSIS; BARRIER; EDEMA	Erythropoietin (EPO) has recently been shown to have a neuroprotective effect in animal models of traumatic brain injury (TBI). However, the precise mechanisms remain unclear. Cerebral inflammation plays an important role in the pathogenesis of secondary brain injury after TBI. We, therefore, tried to analyze how recombinant human erythropoietin (rhEPO) might effect the inflammation-related factors common to TBI: nuclear factor kappa B (NF-kappa B), interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and intercellular adhesion molecule-1 (ICAM- 1) in a rat TBI model. Male rats were given 0 or 5000 units/kg injections of rhEPO I It post-injury and on days 1, 2 and 3 after surgery. Brain samples were extracted at 3 days after trauma. We measured NF-kappa B by electrophoretic mobility shift assay (EMSA); IL-1 beta, TNF-alpha and IL-6 by enzyme-linked immunosorbent assay (ELISA); ICAM- I by immunohistochemistry; brain edema by wet/dry method; blood-brain barrier (BBB) permeability by Evans blue extravasation and cortical apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method. We found that NF-kappa B, pro-inflammatory cytokines and ICAM-1 were increased in all injured animals. In animals given rhEPO post-TBI, NF-kappa B, IL-1 beta, TNF-alpha and ICAM-I were decreased in comparison to vehicle-treated animals. Measures of IL-6 showed no change after rhEPO treatment. Administration of rhEPO reduced brain edema, BBB permeability and apoptotic cells in the injured brain. In conclusion, post-TBI rhEPO administration may attenuate inflammatory response in the injured rat brain, and this may be one mechanism by which rhEPO improves outcome following TBI. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; Nanjing Univ, Sch Med, Jinling Hosp, Dept Anaesthesiol, Nanjing 210002, Jiangsu, Peoples R China	Chen, G (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	nju_neurosurgery@163.com		Chen, Gang/0000-0002-0758-1907			Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beaumont A, 2002, ACT NEUR S, V81, P217; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Conti AC, 1998, J NEUROSCI, V18, P5663; Erbayraktar S, 2006, MOL MED, V12, P74, DOI 10.2119/2006-00042.Erbayraktar; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Keswani SC, 2004, NEUROSCI LETT, V371, P102, DOI 10.1016/j.neulet.2004.08.080; Liu XM, 2006, LIFE SCI, V78, P2255, DOI 10.1016/j.lfs.2005.09.053; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Okutan O, 2007, J CLIN NEUROSCI, V14, P364, DOI 10.1016/j.jocn.2006.01.022; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Spandou E, 2004, NEUROSCI LETT, V366, P24, DOI 10.1016/j.neulet.2004.05.032; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Vink R, 2003, ACT NEUR S, V86, P257; Xie WY, 2006, NEUROSCI LETT, V393, P255, DOI 10.1016/j.neulet.2005.09.077; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yidirim E, 2005, J TRAUMA, V58, P1252, DOI 10.1097/01.TA.0000169803.09482.F8; Yu YP, 2005, NEUROSCI LETT, V387, P5, DOI 10.1016/j.neulet.2005.07.008	32	98	103	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 2	2007	425	3					177	182		10.1016/j.neulet.2007.08.022			6	Neurosciences	Neurosciences & Neurology	224ET	WOS:000250431000009	17825990				2021-06-18	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			Omega-3 fatty acids supplementation restores mechanisms that maintain brain Homeostasis in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; omega-3 fatty acids; oxidative stress; Sir2 alpha	TRANSCRIPTION FACTOR FOXO3A; LIFE-SPAN EXTENSION; CALORIE RESTRICTION; SACCHAROMYCES-CEREVISIAE; SIRT1 DEACETYLASE; OXIDATIVE STRESS; NAD; SIR2-ALPHA; NEURONS; PATHWAY	Traumatic brain injury TBI) produces a state of vulnerability that reduces the brain capacity to cope with secondary insults. The silent information regulator 2 (Sir2) has been implicated with maintaining genomic stability and cellular homeostasis under challenging situation. Here we explore the possibility that the action of Sir2 alpha (mammalian Sir2) in the brain can extend to serve neuronal plasticity. We provide novel evidence showing that mild TBI reduces the expression of Sir2a in the hippocampus, in proportion to increased levels of protein oxidation. In addition, we show that dietary supplementation of omega-3 fatty acids that ameliorates protein oxidation was effective to reverse the reduction of Sir2a level in injured rats. Given that oxidative stress is a subproduct of dysfunctional energy homeostasis, we measured AMP-activated protein kinase (AMPK) and phosphorylated-AMPK (p-AMPK) to have an indication of the energy status of cells. Hippocampal levels of total and phosphorylated AMPK were reduced after TBI and levels were normalized by omega-3 fatty acts supplements. Further, we found that TBI reduced ubiquitous mitochondrial creatine kinase (uMtCK), an enzyme implicated in the energetic regulation of Ca2+-pumps and in the maintenance of Ca2+ -homeostasis. Omega-3 fatty acids supplements normalized the levels of uMtCK after lesion. Furthermore, we found that the correlation between Sir2a and AMPK or p-AMPK was disrupted by TBI, but restored by omega-3 fatty acids supplements. Our results suggest that TBI may compromise neuronal protective mechanisms by involving the action of Sir2a. In addition, results show the capacity of omega-3 fatty acids to counteract some of the effects of TBI by normalizing levels of molecular systems associated with energy homeostasis.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 48804] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [50465] Funding Source: Medline		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Guarente L, 2000, GENE DEV, V14, P1021; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Sinclair D, 2005, NAT GENET, V37, P339, DOI 10.1038/ng0405-339; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EUR J NEUROSCI, V23, P2573, DOI 10.1111/j.1460-9568.2006.04807.x	17	98	100	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2007	24	10					1587	1595		10.1089/neu.2007.0313			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	227HZ	WOS:000250649100005	17970622				2021-06-18	
J	Newcombe, VFJ; Williams, GB; Nortje, J; Bradley, PG; Harding, SG; Smielewski, P; Coles, JP; Maiya, B; Gillard, JH; Hutchinson, PJ; Pickard, JD; Carpenter, TA; Menon, DK				Newcombe, V. F. J.; Williams, G. B.; Nortje, J.; Bradley, P. G.; Harding, S. G.; Smielewski, P.; Coles, J. P.; Maiya, B.; Gillard, J. H.; Hutchinson, P. J.; Pickard, J. D.; Carpenter, T. A.; Menon, D. K.			Analysis of acute traumatic axonal injury using diffusion tensor imaging	BRITISH JOURNAL OF NEUROSURGERY			English	Article						traumatic axonal injury (TAI); traumatic brain injury (TBI); diffusion tensor imaging (DTI); magnetic resonance imaging (MRI)	WHITE-MATTER INJURY; CLOSED-HEAD INJURY; BRAIN-INJURY; PRACTICAL SCALE; MRI; SEVERITY; SCORE; NEUROPATHOLOGY; DISCONNECTION; COEFFICIENT	Traumatic axonal injury (TAI) contributes significantly to mortality and morbidity following traumatic brain injury (TBI), but is poorly characterized by conventional imaging techniques. Diffusion tensor imaging (DTI) may provide better detection as well as insights into the mechanisms of white matter injury. DTI data from 33 patients with moderate-to-severe TBI, acquired at a median of 32 h postinjury, were compared with data from 28 age-matched controls. The global burden of whole brain white matter injury (GB(WMI)) was quantified by measuring the proportion of voxels that lay below a critical fractional anisotropy (FA) threshold, identified from control data. Mechanisms of change in FA maps were explored using an Eigenvalue analysis of the diffusion tensor. When compared with controls, patients showed significantly reduced mean FA (P < 0.001) and increased apparent diffusion coefficient (ADC; p = 0.017). GB(WMI) was significantly greater in patients than in controls (p < 0.01), but did not distinguish patients with obvious white matter lesions seen on structural imaging. It predicted classification of DTI images as head injury with a high degree of accuracy. Eigenvalue analysis showed that reductions in FA were predominantly the result of increases in radial diffusivity (p < 0.001). DTI may help quantify the overall burden of white matter injury in TBI and provide insights into underlying pathophysiology. Eigenvalue analysis suggests that the early imaging changes seen in white matter are consistent with axonal swelling rather than axonal truncation. This technique holds promise for examining disease progression, and may help define therapeutic windows for the treatment of diffuse brain injury.	Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Univ Div Anaesthesia, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Radiol, Cambridge, England	Williams, GB (corresponding author), Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Box 65,Hills Rd, Cambridge CB2 2QQ, England.	gbwlOOO@wbic.cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938; Newcombe, Virginia/0000-0001-6044-9035	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0601025, G9439390, G0600986] Funding Source: Medline		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BENNETT M, 1995, IRISH MED J, V88, P59; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Graham DI, 2005, NEUROPSYCHOL REHABIL, V15, P198, DOI 10.1080/09602010443000452; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1975, LANCET, V1, P480; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kawamata T, 2002, ACTA NEUROCHIR SUPPL, V81, P281; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MEDA SA, 2006, P INT SOC MAG RESON, V14, P2712; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Papadakis NG, 1999, J MAGN RESON, V137, P67, DOI 10.1006/jmre.1998.1673; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Schaefer P W, 2000, Top Magn Reson Imaging, V11, P300, DOI 10.1097/00002142-200010000-00006; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Smith RB, 2002, NEUROREHABILITATION, V17, P3; TEASDALE G, 1974, LANCET, V2, P81; WAGNER DP, 1984, MED DECIS MAKING, V4, P297, DOI 10.1177/0272989X8400400305; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	37	98	99	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	AUG	2007	21	4					340	348		10.1080/02688690701400882			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	207JJ	WOS:000249247100007	17676452				2021-06-18	
J	Hessen, E; Nestvold, K; Anderson, V				Hessen, Erik; Nestvold, Knut; Anderson, Vicki			Neuropsychological function 23 years after mild traumatic brain injury: A comparison of outcome after paediatric and adult head injuries	BRAIN INJURY			English	Article						mild head injury; TBI; cognitive deficits; neuropsychological impairment	WORKING-MEMORY; CHILDREN; CHILDHOOD; MODERATE; CLASSIFICATION; CONSEQUENCES; EPIDEMIOLOGY; ADOLESCENTS; TOMOGRAPHY; IMPAIRMENT	Primary objective: To the authors' knowledge no study comparing very long-term neuropsychological outcome after mild paediatric and adult traumatic brain injury ( TBI) has been published. The primary objective of this study was to compare neuropsychological outcome 23 years after mainly mild paediatric and adult TBI. Research design: The study was a neuropsychological follow-up 23 years after a prospective head injury study conducted at a Norwegian public hospital. Methods and procedures: One hundred and nineteen patients were assessed with a comprehensive neuropsychological test battery. Of these, 45 were paediatric TBI and 74 were adult TBI. Main outcomes and results: Both the paediatric and adult groups obtained scores in the normal range. In the paediatric group significant relationships were found between head injury severity and current neuropsychological function. The most important predictors of poor outcome were length of post-traumatic amnesia ( PTA) and a combination of PTA and EEG pathology within 24 hours of injury. No influence of pre- and post-injury risk factors on current neuropsychological function was evident. Conclusions: The findings indicate that children sustaining complicated mild TBI may be more vulnerable to development of chronic mild neuropsychological dysfunction than adults sustaining similar head injuries.	Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway; Univ Melbourne, Melbourne, Vic, Australia	Hessen, E (corresponding author), Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway.	erik.hessen@nevropsykologi.no					*AET NORW, 2006, SUBJ DIS BEN NORW; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; DOLAN RJ, 1994, PSYCHOL MED, V24, P849, DOI 10.1017/S0033291700028944; Duus B R, 1991, Ugeskr Laeger, V153, P2111; Egeland J., 2005, J NORWEGIAN PSYCHOL, V42, P99; Egeland J, 2006, CLIN NEUROPSYCHOL, V20, P716, DOI 10.1080/13854040500351008; ENGVIK H, 1978, WECHSLER ADULT INTEL; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; EVANS RW, 1992, NEUROL CLIN, V10, P815; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; GIMSE R, 1995, WECHSLER MEMORY SCAL; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Heaton R.K., 1991, COMPREHENSIVE NORMS; Hessen E, 2006, EPILEPSIA, V47, P1870, DOI 10.1111/j.1528-1167.2006.00830.x; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hux K, 2000, J COMMUN HEALTH, V25, P47, DOI 10.1023/A:1005140918066; JENNETT B, 1975, LANCET, V1, P480; Johnson David A, 2003, Pediatr Rehabil, V6, P103, DOI 10.1080/1363849031000166730; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lund C, 2005, ANN THORAC SURG, V80, P2126, DOI 10.1016/j.athoracsur.2005.06.012; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Miller L, 1996, J COGNITIVE REHABILI, V14, P8; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reitan RM., 1985, HALSTEAD REITAN NEUR; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; *STAT NORW, 2001, LEV ED PERS 16 YEARS; Statistics Norway, 2004, LEV ED PERS 16 YEARS; Tellier A, 1999, BRAIN INJURY, V13, P463; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1999, MILD HEAD INJURY; ZAKZANIS KK, 1999, MILD TRAUMATIC BRAIN, P163	65	98	98	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	9					963	979		10.1080/02699050701528454			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600008	17729049				2021-06-18	
J	Leddy, JJ; Kozlowski, K; Fung, M; Pendergast, DR; Willer, B				Leddy, John J.; Kozlowski, Karl; Fung, Michael; Pendergast, David R.; Willer, Barry			Regulatory and autoregulatory physiological dysfunction as a primary characteristic of post concussion syndrome: Implications for treatment	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; CEREBRAL-BLOOD-FLOW; PROFESSIONAL FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; PHYSICAL-ACTIVITY; POSTCONCUSSIVE SYMPTOMS; EXERCISE WITHDRAWAL	Although most patients with concussion recover within days to weeks, a small but significant minority develop persistent signs and symptoms of post-concussion syndrome (PCS). The standard treatments of PCS, rest and cognitive adaptation, have limited effectiveness. PCS patients are advised not to exercise because of the concern for symptom exacerbation. Prolonged rest, however, leads to deconditioning (especially in athletes) and may cause secondary effects including depressive symptoms. Concussion is associated with metabolic and physiological changes in the brain and in other organ systems (for example, autonomic function of the heart and altered cerebral autoregulation, sleep, and circadian rhythms). We propose that PCS results from ongoing central and systemic physiologic regulatory dysfunction after traumatic brain injury (TBI) and we further propose that this physiologic dysfunction may be reduced or alleviated by individualized controlled sub-symptom threshold aerobic exercise rehabilitation.	SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Publ Hlth & Hlth Prof, Buffalo, NY 14260 USA	Leddy, JJ (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, 160 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	leddy@buffalo.edu	Kozlowski, Karl/H-5253-2019				Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Barnes DE, 2003, J AM GERIATR SOC, V51, P459, DOI 10.1046/j.1532-5415.2003.51153.x; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berlin AA, 2006, PSYCHOSOM MED, V68, P224, DOI 10.1097/01.psy.0000204628.73273.23; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Brys M, 2003, AM J PHYSIOL-HEART C, V285, pH1048, DOI 10.1152/ajpheart.00062.2003; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Cayen B, 2002, BRAIN INJURY, V16, P397, DOI 10.1080/02699050110103931; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doering TJ, 1998, AM J PHYS MED REHAB, V77, P490, DOI 10.1097/00002060-199811000-00006; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Ford ES, 2002, EPIDEMIOLOGY, V13, P561, DOI 10.1097/00001648-200209000-00012; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giza CC, 2001, J ATHL TRAINING, V36, P228; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GOLDING EM, 1998, AM J PHYSIOL, V275, pR1287; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GROSS PM, 1980, J APPL PHYSIOL, V48, P213; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamilton MT, 2004, EXERC SPORT SCI REV, V32, P161; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Humm JL, 1999, EXP NEUROL, V157, P349, DOI 10.1006/exnr.1999.7061; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P1; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; King ML, 1997, BRAIN INJURY, V11, P445; Koch A, 2005, CLIN AUTON RES, V15, P83, DOI 10.1007/s10286-005-0249-8; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kraus Jess F., 1994, P3; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; MCARDLE WD, 1996, EXERCISE PHYSL ENERG, P393; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; North T C, 1990, Exerc Sport Sci Rev, V18, P379; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1461, DOI 10.1152/ajpheart.00948.2004; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Scully D, 1998, BRIT J SPORT MED, V32, P111, DOI 10.1136/bjsm.32.2.111; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Solomon GS, 2007, J NEUROPSYCH CLIN N, V19, P195, DOI 10.1176/appi.neuropsych.19.2.195; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Vissing J, 1996, J CEREBR BLOOD F MET, V16, P729, DOI 10.1097/00004647-199607000-00025; Weinstein AA, 2007, MED SCI SPORT EXER, V39, P735, DOI 10.1249/mss.0b013e31802f590c; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Youngstedt SD, 2005, CLIN SPORT MED, V24, P355, DOI 10.1016/j.csm.2004.12.003; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	79	98	99	1	19	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					199	205					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800006	17917170				2021-06-18	
J	Wagner, AK; Sokoloski, JE; Ren, D; Chen, X; Khan, AS; Zafonte, RD; Michael, AC; Dixon, CE				Wagner, AK; Sokoloski, JE; Ren, D; Chen, X; Khan, AS; Zafonte, RD; Michael, AC; Dixon, CE			Controlled cortical impact injury affects dopaminergic transmission in the rat striatum	JOURNAL OF NEUROCHEMISTRY			English	Article						dopamine; dopamine transporter; fast scan cyclic voltammetry; kinetics; rotational behavior; traumatic brain injury	TRAUMATIC BRAIN-INJURY; VESICULAR MONOAMINE TRANSPORTER; CAUDATE-PUTAMEN; METHYLPHENIDATE TREATMENT; TYROSINE-HYDROXYLASE; NUCLEUS-ACCUMBENS; RAPID REGULATION; COCAINE; EXPRESSION; CORTEX	The therapeutic benefits of dopamine (DA) agonists after traumatic brain injury (TBI) imply a role for DA systems in mediating functional deficits post-TBI. We investigated how experimental TBI affects striatal dopamine systems using fast scan cyclic voltammetry (FSCV), western blot, and d-amphetamine-induced rotational behavior. Adult male Sprague-Dawley rats were injured by a controlled cortical impact (CCI) delivered unilaterally to the parietal cortex, or were naive controls. Amphetamine-induced rotational behavior was assessed 10 days post-CCI. Fourteen days post-CCI, animals were anesthetized and underwent FSCV with bilateral striatal carbon fiber microelectrode placement and stimulating electrode placement in the medial forebrain bundle (MFB). Evoked DA overflow was assessed in the striatum as the MFB was electrically stimulated at 60 Hz for 10 s. In 23% of injured animals, but no naive animals, rotation was observed with amphetamine administration. Compared with naives, striatal evoked DA overflow was lower for injured animals in the striatum ipsilateral to injury (p < 0.05). Injured animals exhibited a decrease in V-max (52% of naive, p < 0.05) for DA clearance in the hemisphere ipsilateral to injury compared with naives. Dopamine transporter (DAT) expression was proportionally decreased in the striatum ipsilateral to injury compared with naive animals (60% of naive, p < 0.05), despite no injury-related changes in vesicular monoamine transporter or D-2 receptor expression (DRD2) in this region. Collectively, these data appear to confirm that the clinical efficacy of dopamine agonists in the treatment of TBI may be related to disruptions in the activity of subcortical dopamine systems.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS40125] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125] Funding Source: NIH RePORTER		BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; Bergstrom BP, 2001, J NEUROSCI METH, V106, P15, DOI 10.1016/S0165-0270(00)00372-1; Bezard E, 2003, J NEUROSCI, V23, P10999; Cai GP, 2002, J PHARMACOL EXP THER, V302, P1105, DOI 10.1124/jpet.102.036673; Canales JJ, 2002, BRAIN, V125, P2353, DOI 10.1093/brain/awf239; Copland D, 2003, J INT NEUROPSYCH SOC, V9, P1041, DOI 10.1017/S1355617703970081; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1027, DOI 10.1017/S1355617703970068; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Dixon C. E., 1999, Society for Neuroscience Abstracts, V25, P313; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Frey K, 1997, EUR J PHARMACOL, V334, P273, DOI 10.1016/S0014-2999(97)01152-7; Garris PA, 1997, BRAIN RES, V753, P225, DOI 10.1016/S0006-8993(97)00003-6; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; Gulley JM, 2003, EUR J PHARMACOL, V479, P139, DOI 10.1016/j.ejphar.2003.08.064; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HEFTI F, 1980, PHARMACOL BIOCHEM BE, V12, P185, DOI 10.1016/0091-3057(80)90353-6; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; JONES SR, 1995, J NEUROCHEM, V64, P2581; Jones SR, 1996, PSYCHOPHARMACOLOGY, V126, P331, DOI 10.1007/BF02247384; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kilbourn MR, 1996, NUCL MED BIOL, V23, P467, DOI 10.1016/0969-8051(96)00023-6; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KLINE AE, 2001, MO CL BI CC, V2, P267; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kulagina NV, 2001, NEUROSCIENCE, V102, P121, DOI 10.1016/S0306-4522(00)00480-2; Kumer SC, 1996, J NEUROCHEM, V67, P443; MAY LJ, 1989, BRAIN RES, V487, P311, DOI 10.1016/0006-8993(89)90835-4; Michael DJ, 1999, J PHARMACEUT BIOMED, V19, P33, DOI 10.1016/S0731-7085(98)00145-9; MOKRY J, 1995, PHYSIOL RES, V44, P143; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rebec GV, 1997, NEUROSCIENCE, V76, P707, DOI 10.1016/S0306-4522(96)00382-X; Runnels PL, 1999, ANAL CHEM, V71, P2782, DOI 10.1021/ac981279t; Sabeti J, 2002, J NEUROSCI METH, V121, P41, DOI 10.1016/S0165-0270(02)00229-7; SACHS C, 1975, BRAIN RES, V99, P277, DOI 10.1016/0006-8993(75)90029-3; VanderBorght T, 1995, EUR J PHARMACOL, V294, P577; Venton BJ, 2003, J NEUROCHEM, V87, P1284, DOI 10.1046/j.1471-4159.2003.02109.x; WAGNER AK, 2005, IN PRESS GENDER ENV; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; WIGHTMAN RM, 1990, BRAIN RES REV, V15, P135, DOI 10.1016/0165-0173(90)90015-G; WIGHTMAN RM, 1988, NEUROSCIENCE, V25, P513, DOI 10.1016/0306-4522(88)90255-2; Wilson JM, 1996, J NEUROSCI, V16, P3507; WILSON JM, 1994, J NEUROSCI, V14, P2966; Wu Q, 2001, J NEUROSCI METH, V112, P119, DOI 10.1016/S0165-0270(01)00459-9; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Yang H, 1998, J NEUROCHEM, V71, P684; Zahniser NR, 2004, NEUROPHARMACOLOGY, V47, P80, DOI 10.1016/j.neuropharm.2004.07.010; Zhou Y, 2001, BRAIN RES, V917, P127, DOI 10.1016/S0006-8993(01)02935-3; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982; 2005, J NEUROCHEM, V95, P457	63	98	100	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2005	95	2					457	465		10.1111/j.1471-4159.2005.03382.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	968DU	WOS:000232142900016	16190869				2021-06-18	
J	Engstrom, M; Polito, A; Reinstrup, P; Romner, B; Ryding, E; Ungerstedt, U; Nordstrom, CH				Engstrom, M; Polito, A; Reinstrup, P; Romner, B; Ryding, E; Ungerstedt, U; Nordstrom, CH			Intracerebral microdialysis in severe brain trauma: the importance of catheter location	JOURNAL OF NEUROSURGERY			English	Article						microdialysis; brain trauma; penumbra zone	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; INTERSTITIAL GLYCEROL; ENERGY-METABOLISM; VOLUME REGULATION; ISCHEMIA; GLUTAMATE; THERAPY; PRINCIPLES	Object. Intracerebral microdialysis has attracted increasing interest as a monitoring technique during neurological/neurosurgical intensive care. The purpose of this study was to compare cerebral energy metabolism, an indicator of secondary excitotoxic injury and cell membrane degradation close to focal traumatic lesions ("penumbra zones") and in remote and apparently intact brain regions of the ipsilateral and contralateral hemispheres. Methods. The study included 22 consecutive patients with a mean age 44 17 years and an estimated postresuscitation Glasgow Coma Scale motor score less than 5. Altogether 40 microdialysis catheters with radiopaque.tips were inserted. Two catheters could not be localized on postoperative computerized tomography (CT) scans and were excluded from the analysis. The perfusates were analyzed at the patient's bedside for levels of glucose, pyruyate, lactate, glutamate, and glycerol with the aid of a CMA 600 Analyzer. The positions of eight (22%) of the 36 catheters were reclassified after a review of findings on CT scans. Except for pyruvate the values of all biochemical variables and the lactate/pyruvate (L/P) ratio were significantly different in the penumbra zone when compared with mean values found in "normal" tissue ipsilateral to the parenchymal damage and in contralateral normal tissue (p < 0.001). In the penumbra zone a slow normalization of the UP ratio and levels of glutamate and glycerol were observed. In normal tissue these parameters remained within normal limits. Conclusions. Data obtained from intracerebral microdialysis can be correctly interpreted only if the locations of the catheters as they relate to focal brain lesions are visualized. A "biochemical penumbra zone" surrounds focal traumatic brain lesions. It remains to be proven whether therapeutic interventions can protect the penumbra zone from permanent damage.	Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Anesthesia & Intens Care, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Neurophysiol, S-22185 Lund, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden	Nordstrom, CH (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.	carl-henrik.nordstrom@neurokir.lu.se					ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; Ederoth P, 2004, BRIT J CLIN PHARMACO, V57, P427, DOI 10.1046/j.1365-2125.2003.02032.x; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJA, 2002, ACT NEUR S, V81, P359; JORGENSEN MB, 1982, ACTA NEUROL SCAND, V66, P536; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Nordstrom Carl-Henrik, 2003, Neurosurg Focus, V15, pE5; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; NORDSTROM CH, 1978, J NEUROCHEM, V30, P479, DOI 10.1111/j.1471-4159.1978.tb06553.x; NORDSTROM CH, 1996, BRAIN PROTECTION SEV, P117; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robinson BH, 2000, PEDIATR RES, V48, P581, DOI 10.1203/00006450-200011000-00004; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Stahl N, 2003, ACTA NEUROL SCAND, V108, P211, DOI 10.1034/j.1600-0404.2003.00095.x; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	33	98	100	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2005	102	3					460	469		10.3171/jns.2005.102.3.0460			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	911PR	WOS:000228017200010	15796380				2021-06-18	
J	Ehrenreich, H; Aust, C; Krampe, H; Jahn, H; Jacob, S; Herrmann, M; Siren, AL				Ehrenreich, H; Aust, C; Krampe, H; Jahn, H; Jacob, S; Herrmann, M; Siren, AL			Erythropoietin: Novel approaches to neuroprotection in human brain disease	METABOLIC BRAIN DISEASE			English	Article; Proceedings Paper	3rd International Hannover Conference on Hepatic Encephalopathy	MAY 31-AUG 21, 2003	Bremen, GERMANY	Solvay Pharmacut GmbH		EPO; stroke; schizophrenia; treatment; regeneration	PERMANENT CEREBRAL-ISCHEMIA; IN-VITRO; SCHIZOPHRENIA; RECEPTOR; DISORDER; PROTECTS; HYPOXIA; NEUROGENESIS; EXPRESSION; NEURONS	With the increased life expectancy in western industrialized countries, the incidence and prevalence of brain diseases dramatically increased. Stroke and a wide spectrum of neuropsychiatric illnesses such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic head injury, and schizophrenia all lead to severe disability. However, targeted effective therapies for treatment of these diseases are lacking. Even more frustrating is the fact that we do not yet clearly understand the basic mechanisms underlying the disease processes in these conditions. We propose a hypothesis of loss of neuronal function via a final common deleterious pathway in this clinically very heterogeneous disease group. This review presents a novel neuroprotective concept for treatment of brain disease: Erythropoietin (EPO). EPO is a natural body-own-protein hormone that has been used for treatment of anemia for more than a decade. The neuroprotective approach using EPO in brain disease represents a totally new frontier. The "Gottingen EPO-stroke trial" represents the first effective use in man of a neuroprotective therapy in an acute brain disease while the experimental EPO therapy to combat cognitive decline in patients with schizophrenia will be introduced as an example of a neuroprotective strategy for a chronic brain disease.	Max Planck Inst Expt Med, Clin Neurosci Lab, D-37075 Gottingen, Germany; Univ Bremen, Dept Neuropsychol & Behav Neurobiol, D-2800 Bremen 33, Germany	Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Clin Neurosci Lab, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Siren, Anna-Leena/AAE-1374-2019; Herrmann, Manfred/H-3931-2011	Siren, Anna-Leena/0000-0002-2217-0081; Herrmann, Manfred/0000-0003-1872-8406; Ehrenreich, Hannelore/0000-0001-8371-5711			Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Aydin A, 2003, BRAIN DEV-JPN, V25, P494, DOI 10.1016/S0387-7604(03)00039-1; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bohlius Julia F., 2002, Blood, V100, P3430; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Campana WM, 2001, FASEB J, V15, P1804, DOI 10.1096/fj.00-0857fje; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chattopadhyay A, 2000, BIOCHEM PHARMACOL, V59, P419, DOI 10.1016/S0006-2952(99)00277-4; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Ehrenreich H, 2001, EUR ARCH PSY CLIN N, V251, P149, DOI 10.1007/s004060170034; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Genc S, 2002, NEUROSCI LETT, V321, P73, DOI 10.1016/S0304-3940(02)00041-1; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Hafner H, 2000, EUR ARCH PSY CLIN N, V250, P271, DOI 10.1007/s004060070001; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Jelkmann W., 2000, Current Pharmaceutical Biotechnology, V1, P11, DOI 10.2174/1389201003379068; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Kilts CD, 2001, BIOL PSYCHIAT, V50, P845, DOI 10.1016/S0006-3223(01)01286-0; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; Kraepelin E., 1919, DEMENTIA PRAECOX PAR; Kremen WS, 2001, BIOL PSYCHIAT, V50, P453, DOI 10.1016/S0006-3223(01)01099-X; Kuhn HG, 2001, EUR ARCH PSY CLIN N, V251, P152, DOI 10.1007/s004060170035; Lewczuk P, 2000, NEUROREPORT, V11, P3485, DOI 10.1097/00001756-200011090-00017; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Lieberman JA, 1999, BIOL PSYCHIAT, V46, P729, DOI 10.1016/S0006-3223(99)00147-X; Lipska BK, 2000, NEUROPSYCHOPHARMACOL, V23, P223, DOI 10.1016/S0893-133X(00)00137-8; Magavi SS, 2000, NATURE, V405, P951; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Marenco S, 2000, DEV PSYCHOPATHOL, V12, P501, DOI 10.1017/S0954579400003138; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; McGlashan TH, 2000, ARCH GEN PSYCHIAT, V57, P637, DOI 10.1001/archpsyc.57.7.637; Mielke R, 1998, ALZ DIS ASSOC DIS, V12, pS29; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Prass K, 2003, STROKE, V34, P1981, DOI 10.1161/01.STR.0000080381.76409.B2; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sasaki R, 2001, NEWS PHYSIOL SCI, V16, P110; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2001, EUR ARCH PSY CLIN N, V251, P179, DOI 10.1007/s004060170038; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Stuckmann I, 2003, DEV BIOL, V255, P334, DOI 10.1016/S0012-1606(02)00078-7; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wu H, 1999, DEVELOPMENT, V126, P3597; Yu XB, 2002, DEVELOPMENT, V129, P505	65	98	106	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	DEC	2004	19	3-4					195	206		10.1023/B:MEBR.0000043969.96895.3c			12	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	860EO	WOS:000224325500005	15554415				2021-06-18	
J	Villarreal, PM; Monje, F; Junquera, LM; Mateo, J; Morillo, AJ; Gonzalez, C				Villarreal, PM; Monje, F; Junquera, LM; Mateo, J; Morillo, AJ; Gonzalez, C			Mandibular condyle fractures: Determinants of treatment and outcome	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							OPEN REDUCTION; FOLLOW-UP; CHILDREN	Purpose: The objective of this study was to analyze the principal variables that determine the choice of the method of treatment and the outcome in condylar fractures. Materials and Methods: We conducted a retrospective analysis of 104 mandibular condyle fractures to analyze and determine the relation between the principal clinical variables and the postoperative results. All patients underwent a clinic-radiologic investigation focusing on fracture remodeling, evolution, dental occlusion, and symmetry of the mandible. We analyzed the influence of the preoperative clinical variables (level of fracture, treatment, postoperative physical therapy, displacement and dislocation, comminution, loss of ramus height, patient age, gender, etiology, occlusion, status of dentition, and presence of facial and mandibular fractures) over the postoperative results and outcome. Results: The principal factors that determined the treatment decision were the level of the fracture and the degree of displacement. The level of the fracture influenced the degree of preoperative coronal and sagittal displacement (neck fractures had greater medial and anterior displacement than head and subcondylar fractures) and the treatment applied. The functional improvement obtained by open methods was greater than that obtained by closed treatment. Open treatment increased the incidence of postoperative condylar deformities and mandibular asymmetry. Conclusion: The variables that influenced the method of treatment and predicted the prognosis are the level of fracture, degree and direction of displacement of the fractured segments, age, medical status of the patient, concomitant injuries, and status of dentition. (C) 2004 American Association of Oral and Maxillofacial Surgeons.	Hosp Cabuenes, Dept Oral & Maxillofacial Surg, Gijon, Spain; Hosp Infanta Cristina, Dept Oral & Maxillofacial Surg, Badajoz, Spain; Hosp Cent Asturias, Dept Oral & Maxillofacial Surg, Oviedo, Spain	Villarreal, PM (corresponding author), C Monte Auseva 12 4 B, Oviedo 33012, Spain.	pedrovillarreal@eresmas.com		MONJE, FLORENCIO/0000-0003-0184-3758			Bos RRM, 1999, BRIT J ORAL MAX SURG, V37, P87; BUCHBINDER D, 1993, J ORAL MAXIL SURG, V51, P1174, DOI 10.1016/S0278-2391(10)80285-X; Choi BH, 1997, INT J ORAL MAX SURG, V26, P344, DOI 10.1016/S0901-5027(97)80794-1; Choi BH, 2001, J ORAL MAXIL SURG, V59, P734, DOI 10.1053/joms.2001.24283; DAHLSTROM L, 1989, INT J ORAL MAX SURG, V18, P18, DOI 10.1016/S0901-5027(89)80009-8; Ellis E, 1999, J ORAL MAXIL SURG, V57, P1307, DOI 10.1016/S0278-2391(99)90867-4; Ellis E, 2000, J ORAL MAXIL SURG, V58, P27, DOI 10.1016/S0278-2391(00)80010-5; HAYWARD JR, 1993, J ORAL MAXIL SURG, V51, P57, DOI 10.1016/S0278-2391(10)80391-X; HOOPES JE, 1970, PLAST RECONSTR SURG, V46, P357, DOI 10.1097/00006534-197010000-00005; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; RAVEH J, 1989, J ORAL MAXIL SURG, V47, P120, DOI 10.1016/S0278-2391(89)80100-4; SOREL B, 1998, ORAL MAXILLOFAC SURG, V10, P541; SPIESSL B, 1972, RECONSTRUCTION SURGERY AND TRAUMATOLOGY, V13, P124; TAKENOSHITA Y, 1990, J ORAL MAXIL SURG, V48, P1191, DOI 10.1016/0278-2391(90)90535-A; Thoren H, 2001, J ORAL MAXIL SURG, V59, P768, DOI 10.1053/joms.2001.23369; XIEN Z, 1991, J ORAL MAXIL SURG, V49, P1181, DOI 10.1016/0278-2391(91)90414-H; YAMAOKA M, 1994, BRIT J ORAL MAX SURG, V32, P77, DOI 10.1016/0266-4356(94)90131-7; ZIDE MF, 1983, J ORAL MAXIL SURG, V41, P89, DOI 10.1016/0278-2391(83)90214-8	18	98	105	1	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	FEB	2004	62	2					155	163		10.1016/j.joms.2003.08.010			9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	768MT	WOS:000188547300006	14762747				2021-06-18	
J	Servadei, F; Begliomini, C; Gardini, E; Giustini, M; Taggi, F; Kraus, J				Servadei, F; Begliomini, C; Gardini, E; Giustini, M; Taggi, F; Kraus, J			Effect of Italy's motorcycle helmet law on traumatic brain injuries	INJURY PREVENTION			English	Article							HEAD-INJURY; FATALITIES; CRASHES; CALIFORNIA; ACCIDENTS; PATTERNS; DRIVERS; RIDERS; DEATHS	Objectives: To evaluate the impact of a revised Italian motorcycle-moped-scooter helmet law on crash brain injuries. Design: A pre-post law evaluation of helmet use and traumatic brain injury (TBI) occurrence from 1999 to 2001. Setting: Romagna region, northeastern Italy, with a 2000 resident population of 983 534 persons. Participants: Motorcycle-moped rider survey for helmet use compliance and all residents in the region admitted to the Division of Neurosurgery of the Maurizio Bufalini Hospital in Cesena, Italy for TBI. Outcome measures: Helmet use compliance and change in TBI admissions and type(s) of brain lesions. Results: Helmet use increased from an average of less than 20% to over 96%. A comparison of TBI incidence in the Romagna region shows that there was no significant variation before and after introduction of the revised helmet law, except for TBI admissions for motorcycle-moped crashes where a 66% decrease was observed. In the same area TBI admissions by age group showed that motorcycle mopeds riders aged 14-60 years sustained significantly fewer TBIs. The rate of TBI admissions to neurosurgery decreased by over 31% and epidural hematomas almost completely disappeared in crash injured moped riders. Conclusions: The revised Italian mandatory helmet law, with police enforcement, is an effective measure for TBI prevention at all ages.	Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy; Osped Gen Provinciale M Bufalini, Div Neurosurg, I-47023 Cesena, Italy; Italian Natl Hlth Inst, Rome, Italy; Univ Calif Los Angeles, WHO, Collaborating Ctr Neurotrauma, So Calif Injury Prevent Res Ctr, Los Angeles, CA 90024 USA	Servadei, F (corresponding author), Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy.		BEGLIOMINI, CHIARA/D-1516-2014; Giustini, Marco/Q-3166-2017	BEGLIOMINI, CHIARA/0000-0001-7433-0414; Giustini, Marco/0000-0003-2691-1956; Servadei, Franco/0000-0002-3595-3464			BEGG DJ, 1994, ACCIDENT ANAL PREV, V26, P157, DOI 10.1016/0001-4575(94)90085-X; BJORNSTIG UL, 1985, ACTA CHIR SCAND, V151, P577; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; CLARKE JA, 1995, DISABIL REHABIL, V17, P377, DOI 10.3109/09638289509166725; DALL G, 1983, S AFR MED J, V64, P16; EVANS L, 1988, ACCIDENT ANAL PREV, V20, P447, DOI 10.1016/0001-4575(88)90043-7; Falope I A, 1991, West Afr J Med, V10, P187; Ferrando J, 2000, Inj Prev, V6, P184, DOI 10.1136/ip.6.3.184; GIUSTINI M, 2001, P 57 C TRAFF INJ RIV, P152; HOLUBOWYCZ OT, 1995, J STUD ALCOHOL, V56, P513, DOI 10.15288/jsa.1995.56.513; KRAUS JF, 1988, B NEW YORK ACAD MED, V64, P788; KRAUS JF, 1991, AM J PUBLIC HEALTH, V81, P172, DOI 10.2105/AJPH.81.2.172; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LaTorre G, 2002, EUR J PUBLIC HEALTH, V12, P99, DOI 10.1093/eurpub/12.2.99; PLASENCIA A, 1995, ACCIDENT ANAL PREV, V27, P591, DOI 10.1016/0001-4575(95)00007-M; Romano P, 1991, J HEAD TRAUMA REHAB, V6, P21; RUTLEDGE R, 1993, ACCIDENT ANAL PREV, V25, P347, DOI 10.1016/0001-4575(93)90028-U; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; SHANKAR BS, 1992, ACCIDENT ANAL PREV, V24, P385, DOI 10.1016/0001-4575(92)90051-J; SOOD S, 1988, J TRAUMA, V28, P530, DOI 10.1097/00005373-198804000-00021; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; TAGGI F, 1988, LANCET, V1, P182; Wang YC, 1995, CHINESE MED J, V55, P50; WATSON G, 1980, AM J PUBLIC HEALTH, V71, P297	25	98	102	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047			INJURY PREV	Inj. Prev.	SEP	2003	9	3					257	260		10.1136/ip.9.3.257			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	719QK	WOS:000185214900013	12966016	Green Published, Bronze			2021-06-18	
J	Bedard, M; Felteau, M; Mazmanian, D; Fedyk, K; Klein, R; Richardson, J; Parkinson, W; Minthorn-Biggs, MB				Bedard, M; Felteau, M; Mazmanian, D; Fedyk, K; Klein, R; Richardson, J; Parkinson, W; Minthorn-Biggs, MB			Pilot evaluation of a mindfulness-based intervention to improve quality of life among individuals who sustained traumatic brain injuries	DISABILITY AND REHABILITATION			English	Article							STRESS REDUCTION INTERVENTION; BECK DEPRESSION INVENTORY; CLOSED-HEAD-INJURY; PEER SUPPORT; CHRONIC PAIN; COMMUNITY INTEGRATION; ANXIETY DISORDERS; FAMILY MEMBERS; FOLLOW-UP; REHABILITATION	Primary objective: To examine the potential efficacy of a mindfulness-based stress reduction approach to improve quality of life in individuals who have suffered traumatic brain injuries. Research design: Pre-post design with drop-outs as controls. Methods and procedures: We recruited individuals with mild to moderate brain injuries, at least 1 year post-injury. We measured their quality of life, psychological status, and function. Results of 10 participants who completed the programme were compared to three drop-outs with complete data. Experimental intervention: The intervention was delivered in 12-weekly group sessions. The intervention relied on insight meditation, breathing exercises, guided visualization, and group discussion. We aimed to encourage a new way of thinking about disability and life to bring a sense of acceptance, allowing participants to move beyond limiting beliefs. Main outcomes and results: The treatment group mean quality of life (SF-36) improved by 15.40 (SD = 9.08) compared to - 1.67 (SD = 16.65; p = 0.036) for controls. Improvements on the cognitive-affective domain of the Beck Depression Inventory II (BDI-II) were reported (p = 0.029), while changes in the overall BDI-II (p = 0.059) and the Positive Symptom Distress Inventory of the SCL-90R (p = 0.054) approached statistical significance. Conclusions: The intervention was simple, and improved quality of life after other treatment avenues for these participants were exhausted.	Lakehead Univ, Dept Psychol, Thunder Bay, ON P7B 5E1, Canada; Lakehead Psychiat Hosp, Thunder Bay, ON, Canada; Lakehead Univ, Canadian Parapleg Assoc, Thunder Bay, ON P7B 5E1, Canada; McMaster Univ, Hamilton, ON L8S 4L8, Canada	Bedard, M (corresponding author), Lakehead Univ, Dept Psychol, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.			Richardson, Julie Anne/0000-0001-6356-0492			Astin JA, 1997, PSYCHOTHER PSYCHOSOM, V66, P97, DOI 10.1159/000289116; Beck A. T., 1996, BECK DEPRESSION INVE; BECK AT, 1988, BECK SCALE SUICIDAL; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Brazil K, 1992, Int J Rehabil Res, V15, P93, DOI 10.1097/00004356-199206000-00001; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Davidson L, 1999, CLIN PSYCHOL-SCI PR, V6, P165, DOI 10.1093/clipsy/6.2.165; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Derogatis L.R., 1994, SCL 90 R ADM SCORING, V3rd; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Dunn J, 1999, J COMMUNITY APPL SOC, V9, P13, DOI 10.1002/(SICI)1099-1298(199901/02)9:1<13::AID-CASP488>3.0.CO;2-F; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Frosch S, 1997, BRAIN INJURY, V11, P891; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; Gosling J, 1999, BRAIN INJURY, V13, P785; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hopman WM, 2000, CAN MED ASSOC J, V163, P265; Kabat-Zinn J, 1998, PSYCHOSOM MED, V60, P625, DOI 10.1097/00006842-199809000-00020; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; KOLB DA, 1984, EXPT LEARNING EXPERI; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Leon-Carrion J, 1998, INT J NEUROSCI, V94, P75, DOI 10.3109/00207459808986440; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; MASSION AO, 1995, MED HYPOTHESES, V44, P39, DOI 10.1016/0306-9877(95)90299-6; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MILLER JJ, 1995, GEN HOSP PSYCHIAT, V17, P192, DOI 10.1016/0163-8343(95)00025-M; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Thurman DJ, 1996, WESTERN J MED, V165, P192; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; WARE JE, 2001, SF 36 PHYSICAL MENTA; Watanabe Y, 2001, DISABIL REHABIL, V23, P370; Whisman MA, 2000, J CLIN PSYCHOL, V56, P545, DOI 10.1002/(SICI)1097-4679(200004)56:4<545::AID-JCLP7>3.0.CO;2-U; Wilson BA, 1998, CURR OPIN NEUROBIOL, V8, P281, DOI 10.1016/S0959-4388(98)80152-9; Wilson ME, 1999, PSYCHIATR REHABIL J, V22, P239, DOI 10.1037/h0095238; Woischneck D, 1997, NEUROL RES, V19, P305, DOI 10.1080/01616412.1997.11740817	73	98	98	3	42	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1464-5165			DISABIL REHABIL	Disabil. Rehabil.	JUL 8	2003	25	13					722	731		10.1080/0963828031000090489			10	Rehabilitation	Rehabilitation	695YH	WOS:000183857600004	12791557				2021-06-18	
J	Kobori, N; Clifton, GL; Dash, PK				Kobori, N; Clifton, GL; Dash, PK			Altered expression of novel genes in the cerebral cortex following experimental brain injury	MOLECULAR BRAIN RESEARCH			English	Article						microarray; traumatic brain injury; real-time PCR; mRNA	CORTICAL IMPACT INJURY; NERVE GROWTH-FACTOR; MESSENGER-RNA; AMYLOID-BETA; C-FOS; NEUROTROPHIC FACTOR; CELL-GROWTH; RAT-BRAIN; PROTEIN; TRANSTHYRETIN	Damage to the cerebral cortex results in neurological impairments such as motor, attention, memory and executive dysfunctions. To examine the molecular mechanisms contributing to these deficits, mRNA expression was profiled using high-density cDNA microarray hybridization after experimental cortical impact injury in mice. The mRNA levels at 2 h 6 h, 24 h, 3 days and 14 days after injury were compared with those of control animals. This revealed 86 annotated genes and 24 expression sequence tags (ESTs) as being differentially expressed with a 1.5-fold or greater change. Quantitative real-time PCR analysis was used to independently verify these results for selected genes. Seven functional classes of genes were found to be altered following injury, including transcription factors, signal transduction genes and inflammatory proteins. While a few of these genes have been previously reported to be differentially regulated following injury, the most of the genes have not been previously implicated in traumatic brain injury (TBI) pathophysiology. For example, consistent with previous reports, the transcription factor c-jun and the neurotrophic factor bdnf mRNA levels were altered as a result of TBI. Among the novel genes, the mRNA levels for the high mobility group protein I (hmg-1), the regulator of G-protein signaling 2 (rgs-2), the transforming growth factor P inducible early growth response (tieg), the inhibitor of DNA binding 3 (id3), and the heterogeneous nuclear ribonucleoprotein H (hnrnp h) were changed following injury. The functional significance of these genes in neurite outgrowth, neuronal regeneration, and plasticity following injury are discussed. (C) 2002 Published by Elsevier Science B.V.	Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Neurobiol, Houston, TX 77255 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Anat, Houston, TX 77255 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Neurobiol, POB 20708, Houston, TX 77255 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327, R01NS035457] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, P050NS23327] Funding Source: Medline		Brown AJP, 2001, EMBO J, V20, P3177, DOI 10.1093/emboj/20.12.3177; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Cavallaro S, 2001, EUR J NEUROSCI, V13, P1809, DOI 10.1046/j.0953-816x.2001.01543.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou DKH, 2001, J NEUROCHEM, V77, P120, DOI 10.1046/j.1471-4159.2001.00209.x; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; DASH PK, 1995, J NEUROSCI, V15, P2030; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Haaland KY, 2000, BRAIN, V123, P2306, DOI 10.1093/brain/123.11.2306; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; HERBERT J, 1986, NEUROLOGY, V36, P900, DOI 10.1212/WNL.36.7.900; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Hermsdorfer J, 2001, NEUROIMAGE, V14, P149, DOI 10.1006/nimg.2001.0796; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Ingi T, 1998, J NEUROSCI, V18, P7178; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Katano H, 1998, BRAIN RES, V800, P69, DOI 10.1016/S0006-8993(98)00493-4; Klein BS, 2000, CYTOGENET CELL GENET, V88, P218, DOI 10.1159/000015554; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Merched A, 1998, FEBS LETT, V425, P225, DOI 10.1016/S0014-5793(98)00234-8; Mills JC, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e72; Mirnics K, 2001, TRENDS NEUROSCI, V24, P479, DOI 10.1016/S0166-2236(00)01862-2; Moore AN, 1999, NEUROSCIENCE, V94, P405, DOI 10.1016/S0306-4522(99)00288-2; Nag S, 1996, J NEUROPATH EXP NEUR, V55, P880, DOI 10.1097/00005072-199608000-00003; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; SCHLINGENSIEPEN KH, 1994, CELL MOL NEUROBIOL, V14, P487, DOI 10.1007/BF02088833; Schwarzman AL, 1996, CIBA F SYMP, V199, P146; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tsuzuki K, 2000, NEUROSCI LETT, V281, P171, DOI 10.1016/S0304-3940(00)00834-X; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02; Wolffe AP, 1999, NAT GENET, V22, P215, DOI 10.1038/10267; Yamazaki K, 2001, J NEUROL, V248, P235, DOI 10.1007/s004150170234; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41	55	98	103	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	AUG 15	2002	104	2					148	158	PII S0169-328X(02)00331-5	10.1016/S0169-328X(02)00331-5			11	Neurosciences	Neurosciences & Neurology	602WW	WOS:000178528300007	12225869				2021-06-18	
J	Kiening, KL; van Landeghem, FKH; Schreiber, S; Thomale, UW; von Deimling, A; Unterberg, AW; Stover, JF				Kiening, KL; van Landeghem, FKH; Schreiber, S; Thomale, UW; von Deimling, A; Unterberg, AW; Stover, JF			Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats	NEUROSCIENCE LETTERS			English	Article						Astrocytes; traumatic brain injury; water channel; cortical perfusion	WATER; EXPRESSION; GLUTAMATE; HYPOXANTHINE	The cerebral Aquaporin-4 (AQP4) water channel is suggested to be involved in brain edema formation aggravated by reduced cerebral blood flow early after traumatic brain injury (TBI). Therefore, the temporal profile of brain edema formation, AQP4 expression, and cortical perfusion were investigated following focal TBI in rats. Brain edema was maximal by 24 h. Concurrently, AQP4 protein expression was decreased in both hemispheres, being more pronounced in the traumatized hemisphere (-50%) 48 h after trauma. Cortical perfusion was only decreased in the ipsilateral cortex (-40%) between 4 and 8 h after trauma, reaching baseline values at 24 h. Globally reduced AQP4 expression following induction of a focal contusion coincides with edema development and seems to be independent of changes in cortical perfusion. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Humboldt Univ, Virchow Med Ctr, Charite, Inst Neuropathol, D-13353 Berlin, Germany; Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, D-13353 Berlin, Germany	Stover, JF (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	stover@mail.med.upenn.edu	von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X			CUEVAS P, 1985, ANAT EMBRYOL, V172, P171, DOI 10.1007/BF00319599; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kobayashi H, 2001, NEUROSCI LETT, V297, P163, DOI 10.1016/S0304-3940(00)01705-5; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Sato S, 2000, ACTA NEUROCHIR SUPPL, V76, P239; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Stroop R, 1998, ACT NEUR S, V71, P303; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140	17	98	130	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 17	2002	324	2					105	108	PII S0304-3940(02)00180-5	10.1016/S0304-3940(02)00180-5			4	Neurosciences	Neurosciences & Neurology	555KK	WOS:000175793100005	11988338				2021-06-18	
J	McPherson, K; Headrick, L; Moss, F				McPherson, K; Headrick, L; Moss, F			Working and learning together: good quality care depends on it, but how can we achieve it?	QUALITY IN HEALTH CARE			English	Article						interprofessional education; multiprofessional learning; teamwork	TRAUMATIC BRAIN-INJURY; INTERPROFESSIONAL EDUCATION; STROKE CARE; REHABILITATION; IMPROVE; INTERVENTION; TEAMWORK; EFFICACY; VIEW; PAIN	Educating healthcare professionals is a key issue in the provision of quality healthcare services, and interprofessional education (IPE) has been proposed as a means of meeting this challenge. Evidence that collaborative working can be essential for good clinical outcomes underpins the real need to find out how best to develop a work force that can work together effectively. We identify barriers to mounting successful IPE programmes, report on recent educational initiatives that have aimed to develop collaborative working, and discuss the lessons learned. To develop education strategies that really prepare learners to collaborate we must: agree on the goals of IPE, identify effective methods of delivery, establish what should be learned when, attend to the needs of educators and clinicians regarding their own competence in interprofessional work, and advance our knowledge by robust evaluation using both qualitative and quantitative approaches. We must ensure that our education strategies allow students to recognise, value, and engage with the difference arising from the practice of a range of health professionals. This means tackling some long held assumptions about education and identifying where it fosters norms and attitudes that interfere with collaboration or fails to engender interprofessional knowledge and skill. We need to work together to establish education strategies that enhance collaborative working along with profession specific skills to produce a highly skilled, proactive, and respectful work force focused on providing safe and effective health for patients and communities.	Univ Southampton, Sch Hlth Profess & Rehabil Sci, Southampton SO17 1BJ, Hants, England; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ London, Univ Coll London Hosp, London, England	McPherson, K (corresponding author), Univ Southampton, Sch Hlth Profess & Rehabil Sci, Southampton SO17 1BJ, Hants, England.	kmcpherson@wnmeds.ac.nz		McPherson, Kath/0000-0003-0487-8497			ANNENDALE SJ, 2000, J INTERPROFESSIONAL, V14, P161; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; Baker G R, 1998, Qual Manag Health Care, V6, P1; BALDWIN DC, 1998, MISSION MANAGEMENT N; Balestreire J J, 1998, Qual Manag Health Care, V6, P31; BARR H, 2000, INTERPROFESSIONAL ED, P1; Barrett H., 2000, EVALUATION INTERPROF, P1; BEHRINGER BA, 1994, CATALYSTS INTERDISCI, P43; Boaden N, 2000, MED EDUC, V34, P921, DOI 10.1046/j.1365-2923.2000.00794.x; Brennan A, 1997, Br J Nurs, V6, P697; Campbell JK, 1999, BRIT MED J, V318, P1272; Campbell NC, 1996, J PUBLIC HEALTH MED, V18, P478, DOI 10.1093/oxfordjournals.pubmed.a024548; Centre for the Advancement of Interprofessional Education (CAIPE), 1997, CAIPE B, V13, P19; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CLEGHORN GD, 2000, J INTERPROF CARE, V14, P147; Committee on Quality of Health Care in America Institute of Medicine, 2001, CROSS QUAL CHASM NEW; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; *COUNC GRAD MED ED, 2000, COLL ED ENS PAT SAF, P9; Curley C, 1998, MED CARE, V36, pAS4, DOI 10.1097/00005650-199808001-00002; Dafoe W, 1997, CAN MED ASSOC J, V156, P527; *DEP HLTH, 2000, HLTH SERV ALL TAL DE; Department of Health, 2000, NHS PLAN PLAN INV PL; DIFABIO RP, 1995, PHYS THER, V75, P865, DOI 10.1093/ptj/75.10.865; Finch J, 2000, BRIT MED J, V321, P1138, DOI 10.1136/bmj.321.7269.1138; Firth-Cozens J, 2001, QUAL HEALTH CARE, V10, P65, DOI 10.1136/qhc.10.2.65; FULGINITI VA, 1994, CATALYSTS INTERDISCI, P7; GUILLILAND K, 2001, INTERDISCIPLINARY UN; Hackman J.R., 1990, GROUPS WORK THOSE DO; Hammick M, 2000, MED TEACH, V22, P461, DOI 10.1080/01421590050110713; Headrick LA, 1998, BRIT MED J, V316, P771, DOI 10.1136/bmj.316.7133.771; Headrick LA, 1996, JOINT COMM J QUAL IM, V22, P149, DOI 10.1016/S1070-3241(16)30217-6; HEADRICK LA, 2000, LEARNING IMPROVE COM, P77; HEALTH CARE FIN. ADMIN, 2000, MAT SERV REF DOC, P9; *INT PROF ED COLL, 1999, GUID ACC TEACH LEARN; *JA HARTF FDN, 2000, JA HARTF FDN ANN REP; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; Katz Warren A., 1998, American Journal of Medicine, V105, p2S, DOI 10.1016/S0002-9343(98)00068-0; KNAPP ML, 2000, J INTERPROF CARE, V14, P119, DOI DOI 10.1080/713678558; KOHN LT, 2000, ERR HUMAN BUILDING S; KOPPEL I, 2001, ISSUES INTERDISCIPLI, V3, P41; Langhorne P, 2001, STROKE, V32, P268, DOI 10.1161/01.STR.32.1.268; Maugeri FS, 1998, EUR HEART J, V19, P466; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; Munin MC, 1998, JAMA-J AM MED ASSOC, V279, P847, DOI 10.1001/jama.279.11.847; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Opie A, 1998, QUAL HEALTH RES, V8, P188, DOI 10.1177/104973239800800204; OPIE A, 2000, THINKING TEAMS THINK; OPIE A, 1999, HLTH SOC AOTEAROA NZ, P181; Papps E., 1997, DOCTORING CHILDBIRTH; PARKER DL, 1997, ACAD MED, P451; Pierce-Bulger M, 2001, Qual Manag Health Care, V9, P40; Roberts C, 2000, MED TEACH, V22, P386; RUBENSTEIN LZ, 1991, J AM GERIATR SOC S, V39, P8; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Smith BH, 1999, FAM PRACT, V16, P475, DOI 10.1093/fampra/16.5.475; STEIN LI, 1967, ARCH GEN PSYCHIAT, V16, P699; Wilcock M, 2000, J INTERPROF CARE, V14, P111; WILLIAMS PC, 1999, CATALYSTS INTERDISCI, P79; ZWARENSTEIN M, 2000, COCHRANE LIBR	59	98	98	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0963-8172			QUAL HEALTH CARE	Qual. Health Care	DEC	2001	10			2			46	53					8	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	506KF	WOS:000172969100009					2021-06-18	
J	McCrea, M				McCrea, M			Standardized mental status assessment of sports concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain injuries; brain concussion; athletic injuries; neuropsychologic tests	MILD HEAD-INJURY; FOOTBALL PLAYERS; MANAGEMENT; RECOVERY	Neurocognitive status is often considered the domain of neurologic functioning most sensitive to change following concussion, but the effects are often subtle and difficult to detect on routine clinical examination. Recent efforts have focused on the development of brief, standardized methods of mental status assessment for use by sports medicine clinicians to quantify the acute neurocognitive effects of concussion and objectively track postinjury recovery. Research has demonstrated the reliability, validity, and sensitivity of these measures in detecting concussion in athletes and providing empirical data for consideration in the context of other examination findings, neuropsychologic test data, and neuroimaging results. Standardized measures of mental status and other postconcussive symptoms are valuable tools to assist clinicians in the assessment and management of concussion, but should nut be used as a replacement for medical evaluation or viewed as a stand-alone means for determining readiness to return to competition after injury.	Waukesha Mem Hosp, Neuropsychol Serv, Waukesha, WI 53188 USA; Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA	McCrea, M (corresponding author), Waukesha Mem Hosp, Neuropsychol Serv, 721 Amer Ave,Suite 501, Waukesha, WI 53188 USA.						Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BARR W, IN PRESS J INT NEURO; Barth JT., 1989, MILD HEAD INJURY, P257; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; *COL MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; COLLINS MW, 1999, JAMA-J AM MED ASSOC, P2282; FARRARA M, IN PRESS J ATHLETIC; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KUTNER KC, 1998, NATL ACAD NEUROPSYCH, V5, P19; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 1996, STANDARDIZED ASSESSM; McCrea M., 2000, STANDARDIZED ASSESSM; *NAT ATHL TRAIN AS, 1994, P MILD BRAIN INJ SUM; ONATE JA, 2000, J ATHL TRAINING, V35, pS54; Pottinger LS, 1999, ARCH CLIN NEUROPSYCH, V14, P39, DOI 10.1093/arclin/14.1.39a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; RIEMANN BL, 1999, J SPORT REHABIL, V8, P1; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1996, NEUROTRAUMA, P23; TEASDALE G, 1974, LANCET, V2, P81; TEIN SC, 1996, NEUROTRAUMA, P31; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863	46	98	98	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2001	11	3					176	181		10.1097/00042752-200107000-00008			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	454YG	WOS:000169998900007	11495322				2021-06-18	
J	Lichtman, SW; Seliger, G; Tycko, B; Marder, K				Lichtman, SW; Seliger, G; Tycko, B; Marder, K			Apolipoprotein E and functional recovery from brain injury following postacute rehabilitation	NEUROLOGY			English	Article							FATAL HEAD-INJURY; ALZHEIMERS-DISEASE; INDEPENDENCE MEASURE; E POLYMORPHISM; ASSOCIATION; DEPOSITION; EPSILON-4; ETIOLOGY; ALLELE	Objective: APOE epsilon4 has been associated with late-onset familial and sporadic AD and delayed recovery from head injury. The authors examined the relationship between functional recovery of patients with head injury and the APOE alleles. Methods: Thirty-one patients with head injury who had completed the Acute Neurorehabilitation Program at Helen Hayes Hospital were evaluated for presence of APOE epsilon4 and assessed for recovery based on Functional Independence Measures (FIM). Results: Analysis of covariance (using coma days as the covariate to control for differences in initial severity of injury between subjects with and without APOE epsilon4) revealed a significant difference for both total FIM and motor FIM scores between the subjects with and without APOE epsilon4. Specifically, there were lower scores for total FIM (df = 30; F = 3.341; p = 0.05) and motor FIM (df = 30; F = 4.189; p = 0.026) in APOE epsilon4 carriers, No difference was found for the cognitive portion of the FIM. Conclusions: The data suggest that the presence of the lipoprotein APOE epsilon4 adversely affects rehabilitation outcome for traumatic brain injury survivors.	Helen Hayes Hosp, Dept Internal Med, W Haverstraw, NY 10993 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Internal Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Inst, New York, NY 10032 USA	Lichtman, SW (corresponding author), Helen Hayes Hosp, Dept Internal Med, Route 9W, W Haverstraw, NY 10993 USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG08702] Funding Source: Medline		Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; *CTR FUNCT ASS RES, 1990, GUID US UN DAT SET M; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1996, ACT NEUR S, V66, P96; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P253; HIXSON JE, 1990, J LIPID RES, V31, P545; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KAMBOH MI, 1995, HUM BIOL, V67, P195; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Nicoll JAR, 1996, NEUROPATH APPL NEURO, V22, P515, DOI 10.1111/j.1365-2990.1996.tb01128.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; STOREY E, 1995, MED J AUSTRALIA, V163, P256, DOI 10.5694/j.1326-5377.1995.tb124564.x; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Zunarelli E, 1996, NEUROREPORT, V8, P45, DOI 10.1097/00001756-199612200-00010	26	98	104	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	NOV 28	2000	55	10					1536	1539		10.1212/WNL.55.10.1536			4	Clinical Neurology	Neurosciences & Neurology	376DR	WOS:000165443400019	11094110				2021-06-18	
J	Rose, C; Michalak, A; Pannunzio, M; Chatauret, N; Rambaldi, A; Butterworth, RF				Rose, C; Michalak, A; Pannunzio, M; Chatauret, N; Rambaldi, A; Butterworth, RF			Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure	HEPATOLOGY			English	Article							ACUTE HEPATIC-FAILURE; AMINO-ACIDS; TOTAL HEPATECTOMY; CEREBRAL EDEMA; BODY-TEMPERATURE; ENCEPHALOPATHY; INJURY; AMMONIA; HYPERAMMONEMIA; MICRODIALYSIS	Mild hypothermia is effective in the prevention of brain edema associated with cerebral ischemia and traumatic brain injury. Brain edema is also a serious complication of acute liver failure (ALF), To assess the effectiveness of hypothermia in ALF, groups of rats were subjected to hepatic devascularization (portacaval anastomosis, followed 48 hours later by hepatic artery ligation), and body temperatures were maintained at either 35 degrees C (hypothermic) or 37 degrees C (normothermic). Mild hypothermia resulted in a significant delay in the onset of severe encephalopathy and in reduction of brain water content compared with normothermic ALF rats (control [n = 8] 80.22%; ALF-37 degrees C [n = 8] 81.74%; ALF-35 degrees C [n = 8] 80.48% [P <.01 compared with ALF-37 degrees C]). This protective effect was accompanied by a significant reduction of cerebrospinal fluid (CSF) (but not plasma) ammonia concentrations (CSF ammonia: control: 0.05 mg/dL; ALF-37 degrees C: 1.01 mg/dL; ALF-35 degrees C: 0.07 mg/dL, P <.01. compared with ALF-37 degrees C). In vivo cerebral microdialysis studies revealed that mild hypothermia resulted in a significant reduction of extracellular glutamate concentrations in the brains of rats with ALF (control: 1.06 mu mol/L; ALF37 degrees C: 2.74 mu mol/L; ALF-35 degrees C: 1.49 mu mol/L [:P <.01 compared with ALF-37 degrees C]). These findings suggest that: 1) mild hypothermia is an effective approach to the prevention of the central nervous system consequences of experimental ALF; and that 2) the beneficial effect of hypothermia is mediated via mechanisms involving reduced blood-brain. transfer of ammonia and/or reduction of extracellular brain glutamate concentrations. Mild hypothermia may be an effective approach to delay the onset of brain edema in patients with ALF awaiting liver transplantation.	Univ Montreal, Ctr Hosp, Neurosci Res Unit, Montreal, PQ, Canada	Butterworth, RF (corresponding author), Hop St Luc, CHUM, Neurosci Res Unit, 1058 St Denis St, Montreal, PQ H2X 3J4, Canada.	buterwr@medclin.umontreal.ca	Rose, Christopher F/F-1105-2010; Rambaldi, Alessandro/M-6172-2019	Rose, Christopher F/0000-0001-9854-6834; Rambaldi, Alessandro/0000-0002-3739-7502			BLEI AT, 1991, HEPATOLOGY, V13, P376, DOI 10.1016/0270-9139(91)92455-H; BOSMAN DK, 1992, J NEUROCHEM, V59, P591, DOI 10.1111/j.1471-4159.1992.tb09410.x; BRUSILOW SW, 1985, GENETIC METABOLIC DI, P140; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUTTERWORTH RF, 1992, MOL NEUROPHARMACOL, V2, P229; Butterworth RF, 1997, HEPATOLOGY, V25, P1032, DOI 10.1002/hep.510250440; CHAN H, IN PRESS NEUROCHEM I; CHODOBSKI A, 1986, J NEUROSURG, V65, P86, DOI 10.3171/jns.1986.65.1.0086; Clemmesen JO, 1999, HEPATOLOGY, V29, P648, DOI 10.1002/hep.510290309; Cordoba J, 1996, SEMIN LIVER DIS, V16, P271, DOI 10.1055/s-2007-1007240; Cordoba J, 1999, GASTROENTEROLOGY, V116, P686, DOI 10.1016/S0016-5085(99)70191-5; DEKNEGT RJ, 1994, J HEPATOL, V20, P19, DOI 10.1016/S0168-8278(05)80462-3; DIENST SG, 1961, J LAB CLIN MED, V58, P149; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; GANZ R, 1989, METAB BRAIN DIS, V4, P213, DOI 10.1007/BF01000297; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; HOLMIN T, 1983, EUR J CLIN INVEST, V13, P215, DOI 10.1111/j.1365-2362.1983.tb00090.x; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; JENKINS JG, 1987, BRIT MED J, V294, P337, DOI 10.1136/bmj.294.6568.337; KNECHT K, 1997, NEUROSCI LETT, V25, P1032; LANIER WL, 1995, J NEUROSURG ANESTH, V7, P216, DOI 10.1097/00008506-199507000-00021; LEE SH, 1961, SURGERY, V50, P668; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; MANS AM, 1979, J NEUROCHEM, V32, P285, DOI 10.1111/j.1471-4159.1979.tb00350.x; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; Michalak A, 1996, HEPATOLOGY, V24, P908, DOI 10.1002/hep.510240425; Michalak A, 1997, HEPATOLOGY, V25, P631, DOI 10.1002/hep.510250323; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; NORENBERG MD, 1994, ACTA NEUROCHIR, P24; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PEIGNOUX M, 1982, CLIN SCI, V62, P273, DOI 10.1042/cs0620273; RAO VLR, 1995, J NEUROCHEM, V65, P1221; Roberts DRD, 1999, CLIN TRANSPLANT, V13, P545, DOI 10.1034/j.1399-0012.1999.130617.x; ROZGA J, 1993, LANCET, V342, P898, DOI 10.1016/0140-6736(93)91947-K; SCHENKER S, 1962, J LAB CLIN MED, V60, P291; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; SWAIN MS, 1992, HEPATOLOGY, V16, P1028, DOI 10.1002/hep.1840160428; TAKAHASHI H, 1991, AM J PHYSIOL, V281, pH826; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Vogels BAPM, 1997, HEPATOLOGY, V25, P820, DOI 10.1002/hep.510250406	42	98	103	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	APR	2000	31	4					872	877		10.1053/he.2000.5923			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	299JH	WOS:000086195000009	10733542				2021-06-18	
J	Albensi, BC; Knoblach, SM; Chew, BGM; O'Reilly, MP; Faden, AI; Pekar, JJ				Albensi, BC; Knoblach, SM; Chew, BGM; O'Reilly, MP; Faden, AI; Pekar, JJ			Diffusion and high resolution MRI of traumatic brain injury in rats: Time course and correlation with histology	EXPERIMENTAL NEUROLOGY			English	Article						magnetic resonance imaging; traumatic brain injury; diffusion; fluid-percussion; edema; blood-brain barrier	CLOSED-HEAD INJURY; CEREBRAL-ISCHEMIA; WATER DIFFUSION; T2-WEIGHTED MRI; FOCAL ISCHEMIA; RESONANCE; STROKE; SPECTROSCOPY; DISRUPTION; EVOLUTION	Although widely employed in studies of cerebral ischemia, the use of diffusion-weighted imaging (DWI) for traumatic brain injury (TBI) has been both limited and primarily confined to the first few hours after injury. Therefore, the present study examined the temporal evolution of magnetic resonance imaging (MRI) signal changes from hours to weeks after moderate fluid-percussion TBI in rats. We used isotropic diffusion along three directions and high resolution (HR) spin-echo pulse sequences to visualize DWI and HR MRI changes, respectively. Late changes were compared to histopathological and neurological outcome. A significant decrease (P < 0.05) in the apparent diffusion coefficients (ADC) below preinjury levels was found in the left cortex and left hippocampus (ipsilateral to injury) at 1-2 h post-TBI. At 2 weeks post-TBI, ADCs were significantly elevated (P < 0.05) above preinjury levels in both carter and hippocampus. Regions of hypo- and hyperintensity detected in HR MRI scans also showed evidence of tissue damage by histological evaluation. Neurological assessment indicated that such changes were observed at a level of injury which produced moderate impairment 2 weeks after the insult. These results indicate that alterations in DWI and HR MRI signals occur both early (hours) and late (weeks) after lateral fluid-percussion injury. Furthermore, the study showed that DWI was sensitive to MR signal change at 1-2 h post TBI (in select ROIs), whereas HR scans showed MR signal change primarily at later time points (3-4 h and later). Moreover, regions which demonstrate late changes are associated with histological damage and neurological impairment. The study demonstrates the utility of MRI to detect early changes, in some cases, that are predictive of long lasting damage verified histologically. (C) 2000 Academic Press.	Georgetown Univ, Inst Cognit & Computat Sci, Washington, DC 20007 USA	Albensi, BC (corresponding author), Warner Lambert Parke Davis, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Albensi, Benedict C/F-7304-2010; Albensi, Benedict/AAJ-2359-2021	Albensi, Benedict/0000-0002-7884-9261; Pekar, James/0000-0002-9830-0655			Albensi BC, 1998, INVEST RADIOL, V33, P377, DOI 10.1097/00004424-199807000-00001; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BOSE B, 1988, STROKE, V19, P28, DOI 10.1161/01.STR.19.1.28; Brown M S, 1995, J Neuroimaging, V5, P23; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVIS D, 1994, MAGNET RESON MED, V31, P454, DOI 10.1002/mrm.1910310416; GENTRY LR, 1994, RADIOLOGY, V191, P1; GILL R, 1995, J CEREBR BLOOD F MET, V15, P1, DOI 10.1038/jcbfm.1995.1; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HOEHNBERLAGE M, 1995, MAGN RESON MED, V34, P824, DOI 10.1002/mrm.1910340607; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; KAUPPINEN RA, 1993, TRENDS NEUROSCI, V16, P88, DOI 10.1016/0166-2236(93)90129-A; LO EH, 1994, MAGN RESON IMAGING, V12, P403, DOI 10.1016/0730-725X(94)92533-X; MATSUMOTO K, 1995, AM J NEURORADIOL, V16, P1107; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINEMATSU K, 1992, STROKE, V23, P1304, DOI 10.1161/01.STR.23.9.1304; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; MOSELEY M, 1988, MAGNETIC RESONANCE I; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; PAN Y, 1995, J NEUROL SCI, V131, P128, DOI 10.1016/0022-510X(95)00103-9; Pierce AR, 1997, J CEREBR BLOOD F MET, V17, P183, DOI 10.1097/00004647-199702000-00008; PIERPAOLI C, 1993, RADIOLOGY, V189, P439, DOI 10.1148/radiology.189.2.8210373; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; TAKAHASHI M, 1993, MAGNET RESON MED, V30, P485, DOI 10.1002/mrm.1910300411; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; Verheul H. B., 1992, Brain Topography, V5, P171, DOI 10.1007/BF01129046; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; WARACH S, 1995, NEUROSCIENTIST, V1, P221	33	98	107	0	9	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2000	162	1					61	72		10.1006/exnr.2000.7256			12	Neurosciences	Neurosciences & Neurology	297KX	WOS:000086083000006	10716889				2021-06-18	
J	Ewing-Cobbs, L; Prasad, M; Kramer, L; Louis, PT; Baumgartner, J; Fletcher, JM; Alpert, B				Ewing-Cobbs, L; Prasad, M; Kramer, L; Louis, PT; Baumgartner, J; Fletcher, JM; Alpert, B			Acute neuroradiologic findings in young children with inflicted or noninflicted traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						child abuse; shaken baby syndrome; brain injury; infants; children; neuroimaging	SHAKEN BABY SYNDROME; HEAD-INJURY; COMPUTED-TOMOGRAPHY; IMPACT SYNDROME; ABUSED-CHILD; INFANTS; COMA; SCALE; MECHANISMS; AGE	Acute CT/MRI findings were examined in a prospective, longitudinal study of 60 children 0-6 years of age hospitalized for moderate to severe traumatic brain injury (TBI). TBI was categorized as either inflicted (n=31) or noninflicted (n=29). Glasgow Coma Scale scores and perinatal history were comparable in both groups. Acute CT/MRI studies were visually inspected by a radiologist blind to group membership. Compared with the noninflicted TBI group, the inflicted TBI group had significantly elevated rates of subdural interhemispheric and convexity hemorrhages as well as signs of pre-existing brain abnormality, including cerebral atrophy, subdural hygroma, and ex vacuo ventriculomegaly. Intraparenchymal hemorrhage, shear injury, and skull fractures were more frequent after noninflicted TBI. Subarachnoid hemorrhage and infarct/edema occurred with comparable frequency in both groups. Characteristic acute neuroimaging findings of inflicted TBI included multiple extraaxial hemorrhages in addition to the mild atrophy, subdural hygromas, and ventriculomegaly that suggest prior brain abnormality.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,Suite 2431, Houston, TX 77030 USA.	lewing@pedl.med.uth.tmc.edu	Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR-02558] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [29462] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BRODY BA, 1987, J NEUROPATH EXP NEUR, V46, P283, DOI 10.1097/00005072-198705000-00005; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; GENNARELLI TA, 1985, NEUROSURGERY; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; GROSSMAN RI, 1994, NEURORADIOLOGY REQUI, P149; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MCCLELLAND CQ, 1980, CHILD BRAIN, V7, P225; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MESERVY CJ, 1987, AM J ROENTGENOL, V149, P173, DOI 10.2214/ajr.149.1.173; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Shugerman RP, 1996, PEDIATRICS, V97, P664; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; TEASDALE G, 1974, LANCET, V2, P81; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	38	98	99	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JAN	2000	16	1					25	33		10.1007/s003810050006			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	275VH	WOS:000084840500006	10672426				2021-06-18	
J	Newell, KL; Boyer, P; Gomez-Tortosa, E; Hobbs, W; Hedley-Whyte, ET; Vonsattel, JP; Hyman, BT				Newell, KL; Boyer, P; Gomez-Tortosa, E; Hobbs, W; Hedley-Whyte, ET; Vonsattel, JP; Hyman, BT			alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						alpha-synuclein; axonal spheroids; axonal swellings; diffuse axonal injury; Hallervorden-Spatz syndrome; Lewy body; neuroaxonal dystrophy	AMYLOID PRECURSOR PROTEIN; MULTIPLE SYSTEM ATROPHY; HALLERVORDEN-SPATZ SYNDROME; LEWY BODY DISEASE; GLIAL CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; NEURODEGENERATIVE DISORDERS; ALZHEIMERS-DISEASE; BODIES; DEMENTIA	The primary neuroaxonal dystrophies (NAD), which include infantile NAD and Hallervorden-Spatz syndrome (HSS), an characterized by dystrophic terminal axons and axonal swellings. Lewy bodies have been found in some cases. In Parkinson disease (PD) and dementia with Lewy bodies (DLB), Lewy bodies and neurites display prominent alpha-synuclein immunoreactivity. We examined 2 cases of HSS and 4 cases of infantile NAD with alpha-synuclein immunohistochemistry to test the hypothesis that these disorders with similar morphological findings might share a biochemical phenotype. Furthermore, we compared them to 8 cases of secondary or physiologic NAD of various causes and 2 cases of recent traumatic head injury. alpha-Synuclein positive neuronal cytoplasmic inclusions, including Lewy bodies, and neurites were numerous in 1 HSS and 1 infantile NAD case. In addition, axonal spheroids were immunostained in all 6 cases of primary NAD, 5 cases of secondary NAD, and 2 cases of recent head injury. Axonal spheroids were faintly stained in the 3 physiologic NAD cases. alpha-Synuclein positive axonal swellings may suggest a mechanism, such as axonal injury, leading to the neuronal cytoplasmic accumulation of alpha-synuclein in NAD and other disorders.	Harvard Univ, Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA	Newell, KL (corresponding author), Massachusetts Gen Hosp E, Alzheimers Dis Res Unit, 149 13th St,Room 6604B, Charlestown, MA 02129 USA.		Hedley-Whyte, E Tessa/AAJ-9975-2021	Hedley-Whyte, E Tessa/0000-0002-1687-8905	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05134] Funding Source: Medline		ALBERCA R, 1987, J NEUROL NEUROSUR PS, V50, P1665, DOI 10.1136/jnnp.50.12.1665; ANTOINE JC, 1985, REV NEUROL-FRANCE, V141, P806; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Baba M, 1998, AM J PATHOL, V152, P879; COCHRAN E, 1991, AM J PATHOL, V139, P485; DEFENDINI R, 1973, J NEUROL SCI, V20, P7, DOI 10.1016/0022-510X(73)90114-7; DOOLING EC, 1974, ARCH NEUROL-CHICAGO, V30, P70, DOI 10.1001/archneur.1974.00490310072012; EIDELBERG D, 1987, BRAIN, V110, P993, DOI 10.1093/brain/110.4.993; Ellison D, 1998, NEUROPATHOLOGY; GAYTANGARCIA S, 1990, CLIN NEUROPATHOL, V9, P136; GOMEZTORTOSA E, IN PRESS NEUROLOGY; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; HEDLEYWHYTE ET, 1968, NEUROLOGY, V18, P891, DOI 10.1212/WNL.18.9.891; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; LOWE J, 1997, GREENFIELDS NEUROPAT, V2, P336; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PARK BE, 1975, NEUROLOGY, V25, P1172, DOI 10.1212/WNL.25.12.1172; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; ROZDILSKY B, 1971, ACTA NEUROPATHOL, V17, P331, DOI 10.1007/BF00685019; Seitelberger F., 1971, ACTA NEUROPATHOLOGY, V5, P17; Seitwelberger F, 1986, HDB CLIN NEUROLOGY, V5, P391; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; SUGIYAMA H, 1993, CLIN NEUROPATHOL, V12, P147; Takeda A, 1998, AM J PATHOL, V152, P367; Taylor TD, 1996, NAT GENET, V14, P479, DOI 10.1038/ng1296-479; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; WILLIAMSON K, 1982, ANN NEUROL, V11, P335, DOI 10.1002/ana.410110403	35	98	98	0	2	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	1999	58	12					1263	1268		10.1097/00005072-199912000-00007			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	267JU	WOS:000084355500007	10604751	Bronze			2021-06-18	
J	Werring, DJ; Clark, CA; Barker, GJ; Miller, DH; Parker, GJM; Brammer, MJ; Bullmore, ET; Giampietro, VP; Thompson, AJ				Werring, DJ; Clark, CA; Barker, GJ; Miller, DH; Parker, GJM; Brammer, MJ; Bullmore, ET; Giampietro, VP; Thompson, AJ			The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in a traumatic injury of the internal capsule	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						magnetic resonance imaging; brain mapping; motor recovery	HUMAN-BRAIN; STROKE; CORTEX; MRI	Objectives-Recovery from focal motor pathway lesions may be associated with a functional reorganisation of cortical motor areas. Previous studies of the relation between structural brain damage and the functional consequences have employed MRI and CT, which provide Limited structural information. The recent development of diffusion tensor imaging (DTI) now provides quantitative measures of fibre tract integrity and orientation. The objective was to use DTI and functional MRI (fMRI) to determine the mechanisms underlying the excellent recovery found after a penetrating injury to the right capsular region. Methods-DTI and fMRI were performed on the patient described; DTI was performed on five normal controls. Results-The injury resulted in a left hemiplegia which resolved fully over several weeks. When studied 18 months later there was no pyramidal weakness, a mild hemidystonia, and sensory disturbance. fMRI activation maps showed contralateral primary and supplementary motor cortex activation during tapping of each hand; smaller ipsilateral primary motor areas were activated by the recovered hand only. DTI disclosed preserved structural integrity and orientation in the posterior capsular limb by contrast with the disrupted structure in the anterior limb on the injured side. Conclusions-The findings suggest that the main recovery mechanism was a preservation of the integrity and orientation of pyramidal tract fibres. The fMRI studies do not suggest substantial reorganisation of the motor cortex, although ipsilateral pathways may have contributed to the recovery. The initial deficit was probably due to reversible local factors including oedema and mass effect; permanent damage to fibre tracts in the anterior capsular limb may account for the persistent sensory deficit. This study shows for the first time the potential value of combining fMRI and DTI together to investigate mechanisms of recovery and persistent deficit in an individual patient.	Neurol Inst, NMR Res Unit, London, England; Inst Psychiat, Brain Image Anal Unit, London, England	Thompson, AJ (corresponding author), Univ London, Dept Clin Neurol, Neurol Inst, Queen Sq, London WC1N 3BG, England.		Clark, Chris/C-9853-2009; Parker, Geoffrey J.M./Y-6269-2019; Giampietro, Vincent P/D-1279-2011; Barker, Gareth J/C-9616-2009; Brammer, Michael J/B-7128-2012; Werring, David J/D-4741-2009; Werring, David/Q-8435-2019; Bullmore, Ed/C-1706-2012; Thompson, Alan J/C-2654-2008	Parker, Geoffrey J.M./0000-0003-2934-2234; Giampietro, Vincent P/0000-0002-9381-8201; Barker, Gareth J/0000-0002-5214-7421; Brammer, Michael J/0000-0001-9800-2052; Werring, David J/0000-0003-2074-1861; Werring, David/0000-0003-2074-1861; Bullmore, Ed/0000-0002-8955-8283; Thompson, Alan J/0000-0002-4333-8496			Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Brammer MJ, 1997, MAGN RESON IMAGING, V15, P763, DOI 10.1016/S0730-725X(97)00135-5; Bullmore E, 1996, MAGN RESON MED, V35, P261, DOI 10.1002/mrm.1910350219; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Danziger N, 1996, BRAIN, V119, P1835, DOI 10.1093/brain/119.6.1835; FEINBERG DA, 1987, RADIOLOGY, V163, P793, DOI 10.1148/radiology.163.3.3575734; FRIES W, 1993, BRAIN, V116, P369, DOI 10.1093/brain/116.2.369; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; PIERPAOLI C, 1997, P 5 ANN M ISMRM VANC, P1741; Prichard JW, 1997, NEUROLOGY, V48, P797, DOI 10.1212/WNL.48.4.797; RAO SM, 1995, NEUROLOGY, V45, P919, DOI 10.1212/WNL.45.5.919; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; Talairach J., 1988, COPLANAR STEREOTAXIC; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; WERRING DJ, 1998, IN PRESS J NEUROLNEU	24	98	104	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	1998	65	6					863	869		10.1136/jnnp.65.6.863			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	146FK	WOS:000077418200011	9854962	Bronze, Green Published			2021-06-18	
J	McCarron, MO; Muir, KW; Weir, CJ; Dyker, AG; Bone, I; Nicoll, JAR; Lees, KR				McCarron, MO; Muir, KW; Weir, CJ; Dyker, AG; Bone, I; Nicoll, JAR; Lees, KR			The apolipoprotein E epsilon 4 allele and outcome in cerebrovascular disease	STROKE			English	Article						apolipoproteins; stroke outcome	CEREBRAL AMYLOID ANGIOPATHY; CORONARY HEART-DISEASE; E POLYMORPHISM; ISCHEMIC STROKE; DEFICIENT MICE; HEMORRHAGE; INJURY; APOE; RISK; RAT	Background and Purpose-Polymorphism of the apolipoprotein E gene (APOE) may influence outcome after traumatic brain injury and intracerebral hemorrhage, with the epsilon 4 allele being associated with poorer prognosis. We investigated APOE allele distribution in acute stroke and the effect of the epsilon 4 allele on outcome. Methods-APOE genotypes were determined in 714 stroke patients: 640 ischemic stroke and 74 intracerebral hemorrhage patients. The survival effect of the epsilon 4 allele was assessed with the use of a stratified log-rank test. A Cox proportional hazards regression model was used to estimate the independent effect of epsilon 4 dose (0, 1, or 2) on survival, and logistic regression was used to determine the effect on 3-month outcome (good if alive at home, poor if in care or dead). Results-Allele distribution matched the general population with no difference between the ischemic and hemorrhagic groups. Survival in the entire cohort was unaffected by epsilon 4 dose. Improved survival with increasing epsilon 4 dose was found in the ischemic group (relative hazard=0.76 per allele; P=0.04). If transient ischemic attacks were excluded, a trend for improved survival persisted (P=0.06). With intracerebral hemorrhage, a trend was seen toward reduced survival with epsilon 4 (P=0.07, log-rank test). Three-month outcome in the ischemic group was unaffected by epsilon 4 dose, and a trend toward poorer outcome with epsilon 4 was Seen for intracerebral hemorrhage (P=0.10). Conclusions-The APOE epsilon 4 allele had divergent effects on survival and outcome in ischemic and hemorrhagic strokes in this population The reported adverse effect on patients with intracerebral hemorrhage was supported. The favorable survival effect on ischemic stroke patients requires further study.	So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland	Nicoll, JAR (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland.	JARN1H@clinmed.gla.ac.uk	Muir, Keith W/A-7670-2011; Nicoll, James/I-9253-2017	Muir, Keith W/0000-0001-9535-022X; Nicoll, James/0000-0002-9444-7246; Weir, Christopher/0000-0002-6494-4903			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Basun H, 1996, STROKE, V27, P1310, DOI 10.1161/01.STR.27.8.1310; CORIA F, 1995, STROKE, V26, P2375; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Dyker AG, 1997, BMJ-BRIT MED J, V314, P1584, DOI 10.1136/bmj.314.7094.1584; Ferrucci L, 1997, STROKE, V28, P2410, DOI 10.1161/01.STR.28.12.2410; Ford I, 1995, J CLIN EPIDEMIOL, V48, P1441; Greenberg SM, 1996, NEW ENGL J MED, V335, P189, DOI 10.1056/NEJM199607183350308; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Greenberg SM, 1996, STROKE, V27, P1333, DOI 10.1161/01.STR.27.8.1333; Greenberg SM, 1997, ANN NEUROL, V41, P701, DOI 10.1002/ana.410410604; Hachinski V, 1996, ARCH NEUROL-CHICAGO, V53, P303, DOI 10.1001/archneur.1996.00550040031011; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALARIA RN, 1995, LANCET, V346, P1424, DOI 10.1016/S0140-6736(95)92437-X; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KENDRICK S, 1993, HLTH B EDINB, V51, P1; KERVINEN K, 1994, ATHEROSCLEROSIS, V105, P89, DOI 10.1016/0021-9150(94)90011-6; Kessler C, 1997, ARTERIOSCL THROM VAS, V17, P2880, DOI 10.1161/01.ATV.17.11.2880; KUUSISTO J, 1995, ARTERIOSCL THROM VAS, V15, P1280, DOI 10.1161/01.ATV.15.9.1280; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; MAHIEUX F, 1990, STROKE S1, V21, P115; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; McCarron MO, 1998, NEUROSCI LETT, V247, P45, DOI 10.1016/S0304-3940(98)00286-9; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Muir KW, 1996, STROKE, V27, P1817, DOI 10.1161/01.STR.27.10.1817; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Puttfarcken PS, 1997, J NEUROCHEM, V68, P760; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303; WENHAM PR, 1991, LANCET, V41, P479	47	98	98	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0039-2499			STROKE	Stroke	SEP	1998	29	9					1882	1887		10.1161/01.STR.29.9.1882			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	115FA	WOS:000075651800024	9731613	Bronze			2021-06-18	
J	Brown, M; Vandergoot, D				Brown, M; Vandergoot, D			Quality of life for individuals with traumatic brain injury: Comparison with others living in the community	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED-HEAD-INJURY; OF-LIFE; FOLLOW-UP; SATISFACTION; DISABILITY; REHABILITATION; PREDICTORS; PEOPLE; DISABLEMENT; IMPAIRMENT	Objectives: To provide a conceptual overview of approaches to quality of life (QOL) measurement and an extensive review of research relating to QOL after TBI; to document subjective QOL of individuals with traumatic brain injury (TBI); to explore how subjective QOL differs for people with TBI in comparison to individuals with no disability (ND) and those with spinal cord injury (SCI); and to document the perceptions of unmet important needs and the relationship between such perceptions and subjective QOL. Design: Interview-based data focusing on current perceptions of QOL and unmet important needs, obtained from individuals with TBI, SCI, or ND. Covariance and partial regression analyses were used to explore group differences and to document relationships between variables. Setting: Individuals drawn from diverse communities across New York State. participants: TBI group: 430 individuals who identified themselves as having TBI; SCI group: 101 individuals with spinal cord injury; ND group: 187 people who identified themselves as having no disability. Participants were recruited through recruitment ads in general circulation newspapers and newsletters and through contacting a wide variety of community agencies. Main Outcome Measures: Two summary QOL indicators: a Global QOL Measure based on two items tapping the individual's emotion-based view of QOL, and a summary score adapted from Flanagan's Scale of Needs, reflecting the individual's perceptions of total unmet important needs. Results: Both summary QOL indicators were correlated with demographic characteristics. Unmet important needs were stronger in the TBI group than in the SCI and ND groups. Most areas of unmet important need were moderately correlated with the summary QOL indicators. Analyses of covariance showed that severity of injury was a more powerful modulator of post-TBI QOL judgments than the mere fact of TBI. For example, those with the most severe injury (ie, loss of consciousness [LOC] >1 month) rated their QOL similar to that in the ND group, whereas individuals who had experienced only a brief LOC (<20 minutes) viewed their QOL as significantly lower than that in the ND and SCI groups and lower than other TBI severity subgroups. Conclusions: This exploration of subjective QOL strengthens the argument that after TBI, the insider's reaction to injury varies greatly within the population Thus, severity of injury strongly affects perceptions of QOL. The use of a multimethod approach for exploring the reactions and perceptions of QOL has proven useful in this study.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA; Ctr Essential Management Serv, Jericho Turnpike, NY USA	Brown, M (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.						ALEXANDER JL, 1981, ARCH PHYS MED REHAB, V62, P261; Allison PJ, 1997, SOC SCI MED, V45, P221, DOI 10.1016/S0277-9536(96)00339-5; Andrews F. M., 1976, SOCIAL INDICATORS WE; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; BRICKMAN P, 1978, J PERS SOC PSYCHOL, V36, P917, DOI 10.1037/0022-3514.36.8.917; BROWN M, 1988, REHABIL PSYCHOL, V33, P173, DOI 10.1037//0090-5550.33.3.173; Brown M, 1983, Annu Rev Rehabil, V3, P93; BROWN M, IN PRESS MT SINAI J; BROWN M, UNPUB PREDICTORS QUA; BROWN M, 1980, REHABILITATION CLIEN; BROWN MM, 1983, DISS ABSTR INT B, V43, P2314; BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604; BURCKHARDT CS, 1993, J RHEUMATOL, V20, P475; CASSILETH BR, 1982, J AM ACAD DERMATOL, V7, P742, DOI 10.1016/S0190-9622(82)70155-0; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; CONDELUCI A, 1992, Brain Injury, V6, P543, DOI 10.3109/02699059209008151; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DECKER SD, 1985, AM J OCCUP THER, V39, P740, DOI 10.5014/ajot.39.11.740; DENNIS RE, 1993, EXCEPT CHILDREN, V59, P499, DOI 10.1177/001440299305900603; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; FUHRER MJ, 1997, ASSESSING MED REHABI; GOLEMBIEWSKI RT, 1976, J APPL BEHAV SCI, V12, P133, DOI 10.1177/002188637601200201; GORDON WA, REHABILITATION ADULT; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; IRWIN PH, 1982, SOC INDIC RES, V10, P187, DOI 10.1007/BF00302510; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LAUVER D, 1993, RES NURS HEALTH, V16, P385, DOI 10.1002/nur.4770160510; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; LEZAK MD, 1990, TRAUMATIC BRAIN INJU; MCKENNELL AC, 1983, J COMMUNITY PSYCHOL, V11, P98, DOI 10.1002/1520-6629(198304)11:2<98::AID-JCOP2290110204>3.0.CO;2-E; Millis S R, 1994, Int J Neurosci, V79, P165; MINAIRE P, 1993, VITAL HLTH STAT, V5, P9; Montgomery H, 1996, SCAND J REHABIL MED, V28, P233; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; Ormel J, 1997, SOC SCI MED, V45, P1051, DOI 10.1016/S0277-9536(97)00032-4; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAMUND B, 1988, SCAND J PSYCHOL, V29, P137, DOI 10.1111/j.1467-9450.1988.tb00783.x; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON JP, 1977, AM USE TIME SOCIAL S; ROGERSON RJ, 1995, SOC SCI MED, V41, P1373, DOI 10.1016/0277-9536(95)00122-N; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; *SAS I, 1992, SAS STAT SOFTW REL 6; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SIOSTEEN A, 1990, PARAPLEGIA, V28, P476, DOI 10.1038/sc.1990.64; STAMBROOK M, 1990, CAN J SURG, V33, P115; STENSMAN R, 1985, SCAND J REHABIL MED, V17, P87; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; SZALAI A, 1972, USE TIME; TENNANT A, 1995, ANN RHEUM DIS, V54, P439, DOI 10.1136/ard.54.6.439; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Warren L, 1996, J REHABIL RES DEV, V33, P404; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WRIGHT BA, 1960, PHYSICAL DISABILITY	70	98	98	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1998	13	4					1	23		10.1097/00001199-199808000-00002			23	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DZ	WOS:000075366000002	9651236				2021-06-18	
J	Mesenge, C; Margaill, I; Verrecchia, C; Allix, M; Boulu, RG; Plotkine, M				Mesenge, C; Margaill, I; Verrecchia, C; Allix, M; Boulu, RG; Plotkine, M			Protective effect of melatonin in a model of traumatic brain injury in mice	JOURNAL OF PINEAL RESEARCH			English	Article						head injury; melatonin; free radicals	EXPERIMENTAL HEAD-INJURY; LIPID-PEROXIDATION; NITRIC-OXIDE; INDUCED SEIZURES; DAMAGE; RAT; SUPEROXIDE; RADICALS	The pineal hormone melatonin has recently been shown to exert neuroprotective activity in a variety of experimental neuropathologies in which free radicals are involved. This neuroprotective effect has been attributed to the antioxidant properties of melatonin. Considering that free radicals also play a deleterious role in traumatic brain injury (TBI), the purpose of the present study was to determine whether melatonin would have a beneficial effect in this pathology. Head injury was induced in mice and the neurological deficit was evaluated at 24 hr by a grip test. In this model, the free radical scavenger, alpha-phenyl-tert-butyl-nitrone (2 x 100 mg/ kg, i.p.) given 5 min and repeated at 4 hr after TBI was neuroprotective. Melatonin(l.25 mg/kg, i.p.) given 5 min and repeated at i, 2, and 3 hr after head trauma also significantly reduced the neurological deficit. This beneficial effect was not due to melatonin-induced hypothermia since repeated treatment with melatonin did not modify the colonic temperature of mice. This study shows that melatonin exerts a beneficial effect on the neurological deficit induced by traumatic brain injury in mice. The mechanisms of this neuroprotection remains to be established, and more particularly, the contribution of the antioxidant activity of melatonin.	Univ Rene Descartes, Pharmacol Lab, F-75270 Paris 06, France	Mesenge, C (corresponding author), Univ Rene Descartes, Pharmacol Lab, 4 Ave Observ, F-75270 Paris 06, France.		MARCHAND-LEROUX, Catherine/L-7453-2017; Margaill, Isabelle/ABA-4362-2020	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Margaill, Isabelle/0000-0002-7941-6644			ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; Antolin I, 1996, FASEB J, V10, P882; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; Escames G, 1997, NEUROSCI LETT, V230, P147, DOI 10.1016/S0304-3940(97)00498-9; Gilad E, 1997, LIFE SCI, V60, P169; Giusti P, 1996, FASEB J, V10, P891; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; LEBARS D, 1991, NUCL MED BIOL, V18, P357; Manev H, 1996, FASEB J, V10, P1546; McIntosh TK, 1996, LAB INVEST, V74, P315; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Norlund JJ, 1977, J CLIN ENDOCR METAB, V45, P768; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; PIERREFICHE G, 1995, EXP GERONTOL, V30, P213, DOI 10.1016/0531-5565(94)00036-3; POZO D, 1994, LIFE SCI, V55, P455; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter R J, 1997, Adv Pharmacol, V38, P103; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; REITER RJ, 1981, ENDOCRINOLOGY, V109, P1796; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Tan D-X, 1993, ENDOCR J, V1, P57; Verrecchia C, 1995, ADV NEUROIMMUNOL, V5, P359, DOI 10.1016/0960-5428(95)00023-2; Yamamoto H, 1996, J PINEAL RES, V21, P108, DOI 10.1111/j.1600-079X.1996.tb00277.x; Yamamoto HA, 1996, NEUROSCI LETT, V207, P89, DOI 10.1016/0304-3940(96)12493-9	37	98	101	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0742-3098			J PINEAL RES	J. Pineal Res.	AUG	1998	25	1					41	46		10.1111/j.1600-079X.1998.tb00384.x			6	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	ZY668	WOS:000074647200007	9694403				2021-06-18	
J	Valadka, AB; Goodman, JC; Gopinath, SP; Uzura, M; Robertson, CS				Valadka, AB; Goodman, JC; Gopinath, SP; Uzura, M; Robertson, CS			Comparison of brain tissue oxygen tension to microdialysis-based measures of cerebral ischemia in fatally head-injured humans	JOURNAL OF NEUROTRAUMA			English	Article						brain tissue oxygen tension; glucose; head injury; ischemia; microdialysis; oxygen; traumatic brain injury	EXTRACELLULAR POTASSIUM; CULTURED ASTROCYTES; CELL-DAMAGE; LACTATE; RELEASE; GLUTAMATE; METABOLISM; MECHANISMS; ELEVATION; PRESSURE	This study investigated the relationship between brain tissue oxygen tension (PbtO(2)) and cerebral microdialysate concentrations of several compounds in five patients with refractory intracranial hypertension after severe head injury. The following substances were assayed: lactate and glucose; the excitatory amino acids glutamate and aspartate; and the cations potassium, calcium, and magnesium. Glucose concentrations did not correlate with PbtO(2), but lactate increased as PbtO(2) decreased. The lactate/glucose ratio exhibited a close relationship to PbtO(2), increasing sharply only when oxygen tension reached zero. Although glucose and oxygen eventually reached very low levels and zero, respectively, in these fatally head-injured patients, the terminal decrease in PbtO(2) slightly preceded that of glucose in four of the five patients. This time lag is the cause of the poor correlation between glucose and PbtO(2). Glutamate and aspartate concentrations both demonstrated a close relationship to PbtO(2), with sharp increases not occurring until PbtO(2) was zero. Concentrations of these amino acids exhibited a similar pattern in response to decreasing glucose concentrations. Potassium concentrations began increasing at a PbtO(2) of 35 mm Hg, which is not generally considered indicative of hypoxia. Sharper increases began occurring once PbtO(2) dropped below 15 mm Hg, with a slight rise in the minimum potassium concentrations recorded at these low PbtO(2) values. Calcium and magnesium concentrations did not vary in response to PbtO(2). In summary, the most robust biochemical indicators of cerebral anoxia were elevations in the lactate/glucose ratio and in the concentrations of lactate and of the excitatory amino acids glutamate and aspartate. Furthermore, the fact that glucose concentrations continue to decrease for a short period after oxygen levels reach zero suggests that cells continue to utilize glucose anaerobically for such functions as maintenance of cellular integrity, with collapse of the cell membrane as evidenced by increases of extracellular glutamate and aspartate not occurring until both oxygen and glucose concentrations reach zero.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	Valadka, AB (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Ste 944, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; BULLOCK R, 1992, J NEUROTRAUMA S2, V9, P443; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; FLECKENSTEIN W, 1996, 1 C CER OX ROTT FEBR; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GOODMAN JC, 1997, 15 ANN NAT NEUR S NE; GOODMAN JC, 1997, ISNM 2 NEUR MON INT; GOODMAN JC, 1995, NEUROCHEMICAL MONITO, P78; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HOEHNER TJ, 1987, AM J EMERG MED, V5, P19, DOI 10.1016/0735-6757(87)90283-X; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; JUURLINK BHJ, 1992, NEUROREPORT, V3, P1135, DOI 10.1097/00001756-199212000-00026; KATAYAMA Y, 1991, BRAIN RES, V567, P57, DOI 10.1016/0006-8993(91)91435-4; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1995, NEUROCHEMICAL MONITO, P3; KAWAMATA T, 1995, NEUROCHEMICAL MONITO, P72; KELLEHER JA, 1995, NEUROCHEM RES, V20, P785, DOI 10.1007/BF00969690; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Landolt H, 1996, EUR J ANAESTH, V13, P269, DOI 10.1046/j.1365-2346.1996.00975.x; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; Linde R, 1996, ACT NEUR S, V66, P15; LUNDGREN J, 1991, J CEREBR BLOOD F MET, V11, P587, DOI 10.1038/jcbfm.1991.108; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; SHAPIRA Y, 1989, Neurological Research, V11, P169; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; VALADKA AB, 1998, IN PRESS CRIT CARE M; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1996, J NEUROCHEM, V66, P2477; WALZ W, 1988, GLIA, V1, P366, DOI 10.1002/glia.440010603; WALZ W, 1988, NEUROSCI LETT, V86, P296, DOI 10.1016/0304-3940(88)90499-5; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	41	98	101	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1998	15	7					509	519		10.1089/neu.1998.15.509			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZY374	WOS:000074614700005	9674554				2021-06-18	
J	Tate, RL; McDonald, S; Lulham, JM				Tate, RL; McDonald, S; Lulham, JM			Incidence of hospital-treated traumatic brain injury in an Australian community	AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH			English	Article							HEAD; EPIDEMIOLOGY	This paper reports findings from an incidence study of head trauma in a defined population. In the North Coast Health Region of NSW, 1,259 subjects with head trauma were admitted to hospitals in a 12-month period in 1988. Direct examination of the medical records confirmed brain injury in only 413 of these cases, corresponding to an annual incidence of approximately 100/100,000 resident population. Although most injuries (62.2%) were mild, 38% were serious (either moderate, 20.3%, or severe, 13.6%; and 3.9% died after admission to hospital). Severe brain injury represented an annual incidence of 12/100,000 resident population. Road traffic accidents accounted for a higher proportion of injuries in the severe group in comparison with the other injury groups. Methodological issues involved in case ascertainment of brain injury are discussed.	Univ Sydney, Dept Psychol A16, Sydney, NSW 2006, Australia; Univ New S Wales, Kensington, NSW 2033, Australia	Tate, RL (corresponding author), Univ Sydney, Dept Psychol A16, Sydney, NSW 2006, Australia.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			CARADOCDAVIES TH, 1995, NEUROEPIDEMIOLOGY, V14, P199, DOI 10.1159/000109797; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; JENNETT J, 1981, MANAGEMENT HEAD INJU; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LYLE DM, 1990, COMMUNITY HEALTH ST, V14, P118; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SELECKI BR, 1981, INJURIES HEAD SPINE; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; TEASDALE G, 1974, LANCET, V2, P81; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013	13	98	99	0	2	PUBLIC HEALTH ASSOC AUSTRALIA INC	CURTIN	PO BOX 319, CURTIN, ACT 2600, AUSTRALIA	1326-0200			AUST NZ J PUBL HEAL	Aust. N. Z. Publ. Health	JUN	1998	22	4					419	423		10.1111/j.1467-842X.1998.tb01406.x			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	ZX372	WOS:000074508900003	9659765				2021-06-18	
J	Hausmann, EHS; Berman, NEJ; Wang, YY; Meara, JB; Wood, GW; Klein, RM				Hausmann, EHS; Berman, NEJ; Wang, YY; Meara, JB; Wood, GW; Klein, RM			Selective chemokine mRNA expression following brain injury	BRAIN RESEARCH			English	Article						chemokine; cytokine; mRNA; brain injury; cortical lesion	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MONOCYTE CHEMOATTRACTANT PROTEIN-1; NECROSIS-FACTOR-ALPHA; INTRACEREBRAL INJECTION; INFLAMMATORY RESPONSE; CYTOKINE FAMILY; GROWTH-FACTOR; MOUSE UTERUS; GENE ENCODES	Injury in non-neuronal tissues stimulates chemokine expression leading to recruitment of inflammatory cells responsible for orchestration of repair processes. The signals involved in directing repair of damage to the brain are less well understood. We hypothesized that following brain injury, chemokines are expressed and regulate the rate and pattern of inflammatory cell accumulation. The two chemokine subfamilies are alpha(alpha)-chemokines, which primarily function as neutrophil chemoattractants, and the beta(beta)chemokines, which function primarily as monocyte chemoattractants. We assessed alpha and beta chemokine mRNA expression patterns and leukocyte accumulation following a cerebral cortical lesion. Cortical lesions were produced with and without addition of endotoxin, Escherichia coli lipopolysaccharide (LPS), which stimulates cytokine expression. We studied the expression of the beta-chemokines: monocyte chemoattractant protein (gene product JE; MCP-1/JE), macrophage inflammatory protein-1 alpha and beta (MIP-1 alpha and MIP-1 beta), and the regulated upon activation normal T expressed and secreted chemokine (RANTES) as well as the alpha-chemokines: interferon-gamma-inducible protein (IP-10) and N51/KC (KC; a murine homologue of MIP-2). Changes in gene expression were analyzed by northern analysis at different time points following injury. Leukocyte and macrophage densities were analyzed by immunohistochemistry at the same time intervals. All chemokines were elevated following cortical injury/endotoxin. MCP-1 and MIP-1 alpha were elevated at 2 h and peaked 6 h, MIP-1 beta peaked at 6 h, but declined more rapidly than MCP-1 or MIP-1 alpha, and IP-10 peaked at 6 h and showed the most rapid decline. KC was elevated at 1 h, and peaked at 6 h following LPS. RANTES was elevated at 1 h and achieved a plateau level between 6 and 18 h, then declined. In contrast, sterile injuries produced in the absence of endotoxin only induced the mRNA of the beta-chemokine MCP-1, and its expression was delayed compared to the cortical injury/endotoxin group. The presence of chemokine message as early as 1 h indicates that expression of this class of molecules is an early response in the repair process following traumatic brain injury. Macrophage/microglia accumulation occurred more rapidly, activated microglia further from the lesion border, and more cells accumulated in cortical injury/endotoxin than in cortical lesions produced under sterile conditions. Thus, there was a positive correlation between beta-chemokine expression and the number of beta-chemokine responsive cells (i.e. microglia) accumulating in injury sites. This is the first comprehensive study using a panel of chemokine probes and specific marcophage/microglial markers to study in vivo activation of the brain following injury. Our data show that the brain is capable of expression of multiple chemokine genes upon appropriate stimulation (e.g. LPS-treatment). The gradient of microglial activation is consistent with physical damage stimulating release of chemokines that diffuse from the injury site. These data strongly suggest that chemokines are instrumental in the initiation of repair processes following brain injury. (C) 1998 Elsevier Science B.V.	Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA	Klein, RM (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	rklein@kumc.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH038399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P60AG014635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R03AA010412] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA10412] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1P60AG14635-01] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH38399] Funding Source: Medline		ALLEN RW, 1987, J BIOL CHEM, V262, P649; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; ASHWELL K, 1991, DEV BRAIN RES, V58, P1, DOI 10.1016/0165-3806(91)90231-7; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BARBUL A, 1995, OTOLARYNG CLIN N AM, V28, P955; BOZIC CR, 1995, J IMMUNOL, V154, P6048; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE M, 1993, J REPROD FERTIL, V97, P83, DOI 10.1530/jrf.0.0970083; DIPIETRO LA, 1995, SHOCK, V4, P233, DOI 10.1097/00024382-199510000-00001; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Glabinski AR, 1995, BRAIN BEHAV IMMUN, V9, P315, DOI 10.1006/brbi.1995.1030; HAUSMANN EHS, 1994, INFECT IMMUN, V62, P3625, DOI 10.1128/IAI.62.9.3625-3632.1994; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; IMAMOTO K, 1977, J COMP NEUROL, V174, P255, DOI 10.1002/cne.901740205; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; KIM JS, 1995, J NEUROIMMUNOL, V56, P127, DOI 10.1016/0165-5728(94)00138-E; KWON BS, 1987, P NATL ACAD SCI USA, V84, P2896, DOI 10.1073/pnas.84.9.2896; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; MALE D, 1990, J NEUROIMMUNOL, V30, P161, DOI 10.1016/0165-5728(90)90100-2; MATSUMOTO Y, 1992, J NEUROIMMUNOL, V37, P23, DOI 10.1016/0165-5728(92)90152-B; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MonteroMenei CN, 1996, BRAIN RES, V724, P55, DOI 10.1016/0006-8993(96)00268-5; MOUMDJIAN RA, 1991, BRAIN RES, V547, P223, DOI 10.1016/0006-8993(91)90965-X; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1992, NEUROPATH APPL NEURO, V18, P454, DOI 10.1111/j.1365-2990.1992.tb00811.x; Peterson PK, 1997, J INFECT DIS, V175, P478, DOI 10.1093/infdis/175.2.478; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; RANSOHOFF RM, 1993, FASEB J, V7, P592; ROBINSON AP, 1986, IMMUNOLOGY, V57, P231; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1994, CYTOKINE HDB, P419; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; Sun DM, 1997, J NEUROSCI RES, V48, P192; Tani M, 1996, J CLIN INVEST, V98, P529, DOI 10.1172/JCI118821; Taub D D, 1994, Ther Immunol, V1, P229; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; WATTS RG, 1989, NEUROSURGERY, V25, P202, DOI 10.1227/00006123-198908000-00008; WIDMER U, 1991, J IMMUNOL, V146, P4031; WOOD GW, 1992, DEV BIOL, V152, P336, DOI 10.1016/0012-1606(92)90140-C; XIE DC, 1995, J NEUROCYTOL, V24, P435, DOI 10.1007/BF01181605	56	98	99	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 30	1998	788	1-2					49	59		10.1016/S0006-8993(97)01160-8			11	Neurosciences	Neurosciences & Neurology	ZM870	WOS:000073584600007	9554951				2021-06-18	
J	Cicerone, KD; Tanenbaum, LN				Cicerone, KD; Tanenbaum, LN			Disturbance of social cognition after traumatic orbitofrontal brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; PREFRONTAL CORTEX; BEHAVIOR; IMPAIRMENTS; DEFICITS	A patient with traumatic orbitomedial frontal lobe damage demonstrated good neurocognitive recovery but a lasting, profound disturbance of emotional regulation and social cognition. initial neuropsychological findings included a complete anosmia, mildly reduced fluency and disturbed motor regulation. The impairments of fluency and motor regulation resolved, and formal measures of ''frontal lobe'' functioning were generally intact. However, she remained impaired on tasks requiring the interpretation of social situations, which mirrored her impairment in real life functioning. This disturbance in social cognition appeared related to difficulty appreciating and integrating the relatively subtle social and emotional cues required for the appropriate interpretation of events. The patient's presentation represents an intermediate position between patients with profound neurobehavioral deficits and patients with impaired real-life social cognition despite intact neuropsychological performance following orbitofrontal damage. Variations in the orbitofrontal behavioral syndrome may be related to extent of lesion, time post injury and the course of recovery in different patients. (C) 1997 National Academy of Neuropsychology.	JFK MED CTR,NEW JERSEY NEUROSCI INST,EDISON,NJ	Cicerone, KD (corresponding author), JFK JOHNSON REHABIL INST,2048 OAK TREE RD,EDISON,NJ 08820, USA.						BARBAS H, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P35; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P279, DOI 10.1016/0887-6177(88)90020-0; BRAZZELLI M, 1994, CORTEX, V30, P27, DOI 10.1016/S0010-9452(13)80323-1; Bryant B. R., 1991, SCHOLASTIC ABILITIES; BUTTER C M, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P525; CANCELLIERE AEB, 1990, BRAIN COGNITION, V13, P133, DOI 10.1016/0278-2626(90)90046-Q; CURRIE J, 1991, ARCH NEUROL-CHICAGO, V48, P644, DOI 10.1001/archneur.1991.00530180102024; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Damasio H., 1989, LESION ANAL NEUROPSY; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Grace J, 1992, FRONTAL LOBE PERSONA; HEBB DO, 1945, ARCH NEURO PSYCHIATR, V54, P10, DOI 10.1001/archneurpsyc.1945.02300070020002; KLING A, 1976, BRAIN BEHAV EVOLUT, V13, P216, DOI 10.1159/000123811; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; LEZAK MD, 1994, NEUROPSYCHOLOGICAL A; LHERMITTE F, 1986, ANN NEUROL, V19, P335, DOI 10.1002/ana.410190405; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; MESULAM MM, 1986, ANN NEUROL, V19, P320, DOI 10.1002/ana.410190403; O'Sullivan M., 1976, 4 FACTOR TESTS SOCIA; Orrison Jr. WW, 1995, ATLAS BRAIN FUNCTION; Robinson L J, 1991, Arch Clin Neuropsychol, V6, P27, DOI 10.1016/0887-6177(91)90019-6; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Ruff R. M., 1988, RUFF FIGURAL FLUENCY; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SERGENT J, 1994, LOCALIZATION NEUROIM, P473; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Spivack, 1975, MANUAL MEANS ENDS PR; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608	36	98	99	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1997	12	2					173	188		10.1016/S0887-6177(96)00022-4			16	Psychology, Clinical; Psychology	Psychology	WV548	WOS:A1997WV54800009	14588429	Bronze			2021-06-18	
J	Lahz, S; Bryant, RA				Lahz, S; Bryant, RA			Incidence of chronic pain following traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; SEVERITY	Objective: To index the frequency of reported chronic pain in patients with traumatic brain injury (TBI). Design: A case series study was conducted on consecutive patients with TBI. Setting: TBI patients were recruited from an adult tertiary care center brain injury clinic. Patients: A consecutive sample of 132 patients who attended a brain injury rehabilitation center after TBI. The sample included 53 mild and 79 moderate/severe TBI patients. Outcome Measures: Patients were administered a protocol that indexed pain site, frequency, severity, and duration. Results: Chronic pain was reported by 58% of mild TBI and 52% of moderate/severe TBI patients. Headaches were the most commonly reported pain problem. Chronic headaches were reported by 47% of mild TBI patients and 34% of moderate/severe TBI patients. Neck/shoulder, back, upper limb, and lower limb pain were reported similarly by mild and moderate/severe TBI patients. Conclusions: Findings indicate that chronic pain is a significant problem in mild and moderate/severe TBI patients. More effective diagnosis of TBI patients with chronic pain may facilitate rehabilitation of these patients. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV NEW S WALES,SCH PSYCHOL,SYDNEY,NSW 2052,AUSTRALIA; WESTMEAD HOSP,BRAIN INJURY REHABIL UNIT,WESTMEAD,NSW 2145,AUSTRALIA			Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			ANDERSON JM, 1990, ARCH PHYS MED REHAB, V71, P703; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BRYANT RA, 1993, PAIN, V52, P379; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HORN IJ, 1990, REHABILITATION ADULT, P107; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; TEASDALE G, 1974, LANCET, V2, P81; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; UOMOTO JM, 1990, KRUSENS HDB PHYSICAL, P1252; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	14	98	98	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1996	77	9					889	891		10.1016/S0003-9993(96)90275-0			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	VG419	WOS:A1996VG41900008	8822679				2021-06-18	
J	Hall, ED				Hall, ED			Inhibition of lipid peroxidation in central nervous system trauma and ischemia	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	Satellite Symposium on Normal and Pathological Brain Iron	SEP 17, 1994	NIAGARA FALLS, NY			antioxidant; cerebral ischemia; head injury; lipid peroxidation; subarachnoid hemorrhage; tirilazad mesylate	NONGLUCOCORTICOID 21-AMINOSTEROID U74006F; CHRONIC CEREBRAL VASOSPASM; SPINAL-CORD INJURY; SUBARACHNOID HEMORRHAGE; ARTERY OCCLUSION; PRIMATE MODEL; U-74006F; EDEMA; RATS; METHYLPREDNISOLONE	A novel group of compounds, the 21-aminosteroids (''lazaroids''), have been designed that are potent inhibitors of oxygen free radical-induced, iron-catalyzed lipid peroxidation (LP) in microvascular and nervous tissue. One of these, tirilazad mesylate (U-74006F), has been selected for clinical evaluation as a cerebroprotective agent. In vitro studies suggest that tirilazad exerts its antioxidant activity by multiple mechanisms including: increasing membrane stability, scavenging of lipid peroxyl radicals, reducing LP-induced arachidonic acid release, decreased formation or scavenging of hydroxyl radicals, and maintenance of the levels of endogenous vitamin E. The major site of action appears to be the blood-brain barrier based upon its known localization in cerebrovascular endothelium and numerous studies showing an attenuation of subarachnoid hemorrhage (SAH), injury, and ischemia-induced blood-brain barrier permeability. Tirilazad has demonstrated neuroprotective efficacy in multiple preclinical models of spinal cord and head injury, SAH, and focal cerebral ischemia, as measured by a decrease in cerebral vasospasm, blood-brain barrier compromise, post-traumatic ischemia, edema, ischemic neuronal necrosis and infarction, and improved neurological recovery. This efficacy is correlated with a reduction in markers of oxygen radical-induced LP. Phase III clinical trials are currently ongoing in spinal cord and head injury, SAH, and ischemic stroke. Initial results from a European/Australian/New Zealand trial in SAH have shown a significant decrease in mortality and an increase in the incidence of good recovery.		Hall, ED (corresponding author), UPJOHN CO, CENT NERVOUS SYST DIS RES, KALAMAZOO, MI 49001 USA.		Hall, Edward D/F-8930-2013				ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; Anderson DK, 1991, J NEUROTRAUM, V8, P187, DOI 10.1089/neu.1991.8.187; ASANO T, 1991, CRIT REV NEUROSURG, V1, P361; AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; BECK T, 1991, BRAIN RES, V560, P159, DOI 10.1016/0006-8993(91)91226-Q; BOISVERT DP, 1991, J CEREB BLOOD FLO S2, V11, pS135; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER J M, 1989, Drugs of the Future, V14, P143; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Dimlich R V, 1990, Adv Neurol, V52, P365; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1988, EXP NEUROL, V102, P244, DOI 10.1016/0014-4886(88)90100-8; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1991, STROKE, V22, P361, DOI 10.1161/01.STR.22.3.361; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Holtz A, 1991, J NEUROTRAUM, V8, P239, DOI 10.1089/neu.1991.8.239; KANAMARU K, 1991, J NEUROSURG, V74, P454, DOI 10.3171/jns.1991.74.3.0454; KANAMARU K, 1990, NEUROSURGERY, V27, P29, DOI 10.1227/00006123-199007000-00004; KARKI A, 1994, ACTA NEUROCHIR, P310; KASSELL NF, 1996, IN PRESS J NEUROSURG; MATHEWS WR, 1992, J MOL CELL CARDIO S3, V24, P517; MATSUI T, 1994, NEUROSURGERY, V34, P1035, DOI 10.1227/00006123-199406000-00012; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MORI E, 1995, CEREBROVASC DIS, V5, P342, DOI 10.1159/000107880; PARK CK, 1994, BRAIN RES, V645, P157; Raub TJ, 1993, J DRUG TARGET, V1, P269, DOI 10.3109/10611869308996085; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SILVIA RC, 1987, NEUR ABST, V13, P1499; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STEINKE DE, 1989, NEUROSURGERY, V24, P179, DOI 10.1227/00006123-198902000-00005; TAKESHIMA R, 1994, STROKE, V25, P670, DOI 10.1161/01.STR.25.3.670; VOLLMER DG, 1989, SURG NEUROL, V31, P190, DOI 10.1016/0090-3019(89)90115-8; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; YOUNG W, 1988, STROKE, V19, P1013, DOI 10.1161/01.STR.19.8.1013; ZUCCARELLO M, 1989, STROKE, V20, P367, DOI 10.1161/01.STR.20.3.367; ZUCCARELLO M, 1989, J NEUROSURG, V71, P98, DOI 10.3171/jns.1989.71.1.0098	43	98	99	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	DEC	1995	134			S			79	83		10.1016/0022-510X(95)00211-J			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	TT811	WOS:A1995TT81100011	8847548				2021-06-18	
J	COWEN, TD; MEYTHALER, JM; DEVIVO, MJ; IVIE, CS; LEBOW, J; NOVACK, TA				COWEN, TD; MEYTHALER, JM; DEVIVO, MJ; IVIE, CS; LEBOW, J; NOVACK, TA			INFLUENCE OF EARLY VARIABLES IN TRAUMATIC BRAIN INJURY ON FUNCTIONAL INDEPENDENCE MEASURE SCORES AND REHABILITATION LENGTH OF STAY AND CHARGES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; COMA SCALE	Objective: To determine the relationship between early variables (initial Glasgow Coma Scale [GCS] scores, computed tomography [CT] findings, presence of skeletal trauma, age, length of acute hospitalization) and outcome variables (Functional Independence Measure [FIM] scores, rehabilitation length of stay [LOS], rehabilitation charges) in traumatic brain injury (TBI). Design: Inception cohort. Setting: University tertiary care rehabilitation center. Patients: 91 patients with TBI. interventions: Inpatient rehabilitation. Main Outcome Measures: FIM, rehabilitation LOS, and rehabilitation charges. Results: Patients in the severely impaired (GCS = 3 to 7) group showed significantly lower (p = .01) mean admission and discharge motor scores (21.26, 39.83) than patients in the mildly impaired (GCS = 13 to 15) group (38.86, 55.29). Cognitive scores were also significantly lower (p < .01) in the severely impaired group on admission (26.73 vs 54.14) and discharge (42.28 vs 66.48). These findings continued to be statistically significant (p < .01) after regression analysis accounted for the other early variables previously listed. Regression analysis also illustrated that longer acute hospitalization LOS was independently associated with significantly lower admission motor (p < .01) and cognitive (p = .05) scores, and significantly higher (p = .01) rehabilitation charges. Patients with CT findings of intracranial bleed with skull fracture had longer total LOS (70.88 vs 43.08 days; p < .05), rehabilitation LOS (30.01 vs 19.68 days; p < .10), and higher rehabilitation charges ($43,346 vs $25,780; p (.05). Paradoxically, those patients in a motor vehicle crash with an extremity bone fracture had significantly higher (p = .002; p = .04 after regression analysis) FIM cognitive scores on admission (48.30 vs 27.28) and discharge (64.74 vs 45.78) than those without a fracture. Finally, data available on rehabilitation admission were used to predict discharge outcomes. The percentage of explained variance for each outcome variable is as follows: discharge FIM motor score, 69.5%; discharge FIM cognitive score, 71.2%; rehabilitation LOS, 54.1%; rehabilitation charges, 61.1%. The most powerful predictor of LOS and charges was the admission FIM motor score (p < .001), followed by CT findings (p = .02) and age (p = .04). Conclusion: Information readily available on rehabilitation admission, particularly the FIM motor score, may be useful in predicting discharge FIM scores as well as utilization of medical rehabilitation resources. Earlier transfer to rehabilitation may result in higher functional status and lower rehabilitation charges, as well as lower acute hospitalization charges. The presence of extremity fractures encountered during a motor vehicle crash is associated with a more favorable outcome in TBI as evidenced by higher discharge FIM cognitive scores. (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV ALABAMA,BIRMINGHAM MED CTR,DEPT PHYS MED & REHABIL,BIRMINGHAM,AL							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; Granger CV, 1986, GUIDE USE UNIFORM DA; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TEASDALE G, 1974, LANCET, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237	19	98	100	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1995	76	9					797	803		10.1016/S0003-9993(95)80542-7			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	RU994	WOS:A1995RU99400001	7668948				2021-06-18	
J	YOUNGJOHN, JR; BURROWS, L; ERDAL, K				YOUNGJOHN, JR; BURROWS, L; ERDAL, K			BRAIN-DAMAGE OR COMPENSATION NEUROSIS - THE CONTROVERSIAL POST-CONCUSSION SYNDROME	CLINICAL NEUROPSYCHOLOGIST			English	Article							MINOR HEAD-INJURY; DIGIT RECOGNITION TEST; MILD CONCUSSION; IMPAIRMENT; MEMORY; TRAUMA; SYMPTOMS; DEFICITS	Neuropsychological evaluations were performed on 55 consecutive patients with persisting post-concussion syndrome (PCS). All were in litigation or were pursuing/receiving financial compensation for their injuries. No PCS patients who were not in litigation or compensated were referred over the 2-year span of the study. Many patients had deficits on neuropsychological testing. However, 15% of the patients were shown to be unconsciously or consciously motivated to do poorly on the Portland Digit Recognition Test (PDRT) and 33% fell below the cut-offs suggesting poor motivation reported by previous investigators. Only 28% of the PCS patients performed at or above the levels of patients with documented brain damage, established by previous investigators. When an additional measure of cooperation was considered (the Dot Counting Test), 48% of all patients had questionable motivation during testing. The average MMPI-2 profile of the entire PCS group suggested the presence of somatization and functional overlay. The PCS group's average MMPI-2 T scores on scales Hs and Hy were well above the average MMPI T scores of patients with proven brain damage reported by previous investigators. These results suggest that the predominant causes of persisting PCS after minor or mild head injury in many patients are likely to be functional rather than organic.	ARIZONA STATE UNIV,SCOTTSDALE,AZ 85251							Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; AUERBACH AH, 1967, DIS NERV SYST, V28, P110; Barth JT., 1989, MILD HEAD INJURY, P257; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1992, ARCH CLIN NEUROPSYCH, V7, P155, DOI 10.1016/0887-6177(92)90009-C; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1993, CLIN NEUROPSYCHOL, V7, P104, DOI DOI 10.1080/13854049308401892; BURKE J M, 1990, Brain Injury, V4, P223, DOI 10.3109/02699059009026171; Butcher JN, 1989, MANUAL ADM SCORING M; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; FAUST E, 1988, PROFESSIONAL PSYCHOL, V14, P508; FAUST E, 1988, J CONSULT CLIN PSYCH, V5, P578; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GREIFFENSTEIN MF, 1994, FEB INT NEUR SOC ANN; GRONWALL D, 1974, LANCET, V2, P605; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Hathaway S. R., 1989, MINNESOTA MULTIPHASI; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; KAY T, 1992, REHABILITATION POST, P109; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER B, 1992, REHABILITATION POST, P169; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MILLER H, 1972, LANCET, V1, P445; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Reitan RM., 1985, HALSTEAD REITAN NEUR; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; ROMANO JL, 1992, REHABILITATION POST, P193; SNOW WG, 1992, FEB INT NEURO SOC AN; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; WYLIE TF, 1990, INT NEUROPSYCHOLOGIC; YOUNG E, 1991, NEW STATESMAN SOC, V4, P29; 1978, MENTAL DISORDERS GLO	47	98	98	1	14	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	1995	9	2					112	123		10.1080/13854049508401593			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	QV547	WOS:A1995QV54700002					2021-06-18	
J	JORGE, RE; ROBINSON, RG; ARNDT, S				JORGE, RE; ROBINSON, RG; ARNDT, S			ARE THERE SYMPTOMS THAT ARE SPECIFIC FOR DEPRESSED MOOD IN PATIENTS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							STROKE	This study examined the specificity of vegetative and psychological symptoms of depression among 66 patients with acute traumatic brain injury followed over 1 year. The median frequencies of vegetative and psychological symptoms among patients with depressed mood were 3 and 3. These frequencies were three times the respective rates among nondepressed patients. Although change in self-attitude and subjective anergia distinguished depressed from nondepressed patients throughout the 1-year follow-up, some symptoms, such as early awakening and difficulty concentrating, distinguished groups only after 6 months. If diagnostic criteria for major depression were modified to include only specific symptoms of depression, the standard (i.e., unmodified) DSM-III-R still had a 100% sensitivity and 94% specificity at the initial evaluation and 80% and 100%, respectively, at 1 year. There were almost no patients with depressive symptoms without a depressed mood (i.e., ''masked'' depressions). These findings suggest that DSM-III-R criteria for major depression are useful, even in an acute head-injured population, but also suggest that the nature of posttraumatic brain injury depressive disorder may change over time.		JORGE, RE (corresponding author), UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242, USA.		Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021	Arndt, Stephan/0000-0003-0783-8204; 	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 000163, MH 40355] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS151178] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER		CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DAVIDSON J, 1986, BRIT J PSYCHIAT, V148, P442, DOI 10.1192/bjp.148.4.442; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JORGE R, IN PRESS J AFFECTIVE; JORGE RE, IN PRESS J NEUROPSYC; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Prigatano G. P., 1991, AWARENESS DEFICIT BR; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; Sartorius N, 1974, MEASUREMENT CLASSIFI; STARKSTEIN SE, 1990, J NEUROL NEUROSUR PS, V53, P869, DOI 10.1136/jnnp.53.10.869; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; 1987, DIAGNOSTIC STATISTIC	17	98	98	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	FEB	1993	181	2					91	99		10.1097/00005053-199302000-00004			9	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	KL710	WOS:A1993KL71000004	8426177				2021-06-18	
J	Lin, C; Chao, HL; Li, Z; Xu, XP; Liu, YL; Hou, LJ; Liu, N; Ji, J				Lin, Chao; Chao, Honglu; Li, Zheng; Xu, Xiupeng; Liu, Yinlong; Hou, Lijun; Liu, Ning; Ji, Jing			Melatonin attenuates traumatic brain injury-induced inflammation: a possible role for mitophagy	JOURNAL OF PINEAL RESEARCH			English	Article						inflammation; melatonin; mitophagy; traumatic brain injury	SUBARACHNOID HEMORRHAGE; PARKINSONS-DISEASE; NLRP3 INFLAMMASOME; INTRACEREBRAL HEMORRHAGE; POSSIBLE INVOLVEMENT; ALZHEIMERS-DISEASE; CELL-DEATH; AUTOPHAGY; ACTIVATION; PATHWAY	Melatonin functions as a crucial mediator of sterile neuroinflammation; however, the underlying mechanisms remain poorly understood. Dysfunctional mitochondria, a main source of reactive oxygen species, are impacted in inflammation activation. This study aimed to examine the effect of melatonin on inflammation via elimination of damaged mitochondria after controlled cortical impact, an invivo model of traumatic brain injury (TBI). Here, we demonstrated that inhibition of mitophagy, the selective degradation of damaged mitochondria by autophagy, markedly enhanced inflammation induced by TBI. Melatonin treatment activated mitophagy through the mTOR pathway, then to attenuate TBI-induced inflammation. Furthermore, treatment with melatonin significantly ameliorated neuronal death and behavioral deficits after TBI, while 3-methyladenine reversed this effect by inhibiting mitophagy. Taken together, these results highlight a role for melatonin in protecting against TBI-triggered immunopathology, which is accomplished by negatively regulating inflammation activation and IL-1 secretion via the autophagy of damaged mitochondria.	[Lin, Chao; Chao, Honglu; Li, Zheng; Xu, Xiupeng; Liu, Yinlong; Liu, Ning; Ji, Jing] Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing, Jiangsu, Peoples R China; [Hou, Lijun] Second Mil Med Univ, Dept Neurosurg, Changzheng Hosp, Shanghai, Peoples R China	Ji, J (corresponding author), Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing, Jiangsu, Peoples R China.	jijing@njmu.edu.cn			Jiangsu Innovation Project, China Scholarship Council [201508320270]; Jiangsu Province's Key Discipline of Medicine [XK201117]; Jiangsu Provincial Initiative Program for Excellency Disciplines, Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471269, 81300998]	This study was supported by Jiangsu Innovation Project, China Scholarship Council (201508320270);Jiangsu Province's Key Discipline of Medicine (XK201117); the Jiangsu Provincial Initiative Program for Excellency Disciplines, Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); National Natural Science Foundation of China (81471269 and 81300998).	Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Carloni S, 2014, J PINEAL RES, V57, P192, DOI 10.1111/jpi.12156; Chen JY, 2014, J PINEAL RES, V57, P340, DOI 10.1111/jpi.12173; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Cheung RTF, 2006, J PINEAL RES, V41, P337, DOI 10.1111/j.1600-079X.2006.00372.x; Cheung RTF, 2003, J PINEAL RES, V34, P153, DOI 10.1034/j.1600-079X.2003.00034.x; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi SI, 2013, J PINEAL RES, V54, P361, DOI 10.1111/jpi.12039; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Dragicevic N, 2011, J PINEAL RES, V51, P75, DOI 10.1111/j.1600-079X.2011.00864.x; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Jabir MS, 2015, AUTOPHAGY, V11, P166, DOI 10.4161/15548627.2014.981915; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kaur C, 2013, J PINEAL RES, V54, P190, DOI 10.1111/jpi.12016; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Li Q, 2014, BIOCHEM BIOPH RES CO, V444, P182, DOI 10.1016/j.bbrc.2014.01.032; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lupfer C, 2013, NAT IMMUNOL, V14, P480, DOI 10.1038/ni.2563; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Naseem Mehar, 2014, ScientificWorldJournal, V2014, P586270, DOI 10.1155/2014/586270; Netea-Maier RT, 2016, AUTOPHAGY, V12, P245, DOI 10.1080/15548627.2015.1071759; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Patki G, 2011, PHARMACOL BIOCHEM BE, V99, P704, DOI 10.1016/j.pbb.2011.06.026; Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014; Pi HF, 2015, AUTOPHAGY, V11, P1037, DOI 10.1080/15548627.2015.1052208; Rosales-Corral SA, 2012, J PINEAL RES, V52, P167, DOI 10.1111/j.1600-079X.2011.00937.x; Rudnitskaya EA, 2015, BIOGERONTOLOGY, V16, P303, DOI 10.1007/s10522-014-9547-7; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Su LY, 2015, AUTOPHAGY, V11, P1745, DOI 10.1080/15548627.2015.1082020; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tapias V, 2010, J NEUROSCI RES, V88, P420, DOI 10.1002/jnr.22201; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wang XQ, 2014, NAT IMMUNOL, V15, P1126, DOI 10.1038/ni.3015; Wang Z, 2013, J PINEAL RES, V55, P399, DOI 10.1111/jpi.12087; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xi G, 2002, ACT NEUR S, V81, P253; Yildirim FB, 2014, NEUROCHEM INT, V79, P1, DOI 10.1016/j.neuint.2014.09.005; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Yuan BQ, 2015, J NEUROIMMUNOL, V287, P71, DOI 10.1016/j.jneuroim.2015.08.002; Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162; Zhang ZR, 2013, J IMMUNOL, V190, P3517, DOI 10.4049/jimmunol.1202628; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	54	97	100	2	23	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	SEP	2016	61	2					177	186		10.1111/jpi.12337			10	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	DS6OK	WOS:000380901300005	27117839				2021-06-18	
J	Weiner, MW; Veitch, DP; Aisen, PS; Beckett, LA; Cairns, NJ; Cedarbaum, J; Donohue, MC; Green, RC; Harvey, D; Jack, CR; Jagust, W; Morris, JC; Petersen, RC; Saykin, AJ; Shaw, L; Thompson, PM; Toga, AW; Trojanowski, JQ				Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; Beckett, Laurel A.; Cairns, Nigel J.; Cedarbaum, Jesse; Donohue, Michael C.; Green, Robert C.; Harvey, Danielle; Jack, Clifford R.; Jagust, William; Morris, John C.; Petersen, Ronald C.; Saykin, Andrew J.; Shaw, Leslie; Thompson, Paul M.; Toga, Arthur W.; Trojanowski, John Q.		Alzheimer's Dis Neuroimaging Initi	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Data-sharing; Amyloid phenotyping; Clinical trial biomarkers; Tau imaging; AD biomarker signature; Worldwide ADNI	MILD COGNITIVE IMPAIRMENT; TENSOR-BASED MORPHOMETRY; GENOME-WIDE ASSOCIATION; CEREBROSPINAL-FLUID BIOMARKERS; POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER HYPERINTENSITIES; MULTITASK FEATURE-SELECTION; BETA-AMYLOID MEASURES; NORMAL OLDER-ADULTS; HIPPOCAMPAL VOLUME	Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods: We searched for ADNI publications using established methods. Results: ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and posttraumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion: ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.	[Weiner, Michael W.; Veitch, Dallas P.] Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Aisen, Paul S.] Univ Calif San Francisco, Dept Neurosci, San Francisco, CA 94143 USA; [Beckett, Laurel A.; Harvey, Danielle] Univ Calif Davis, Div Biostat, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Cairns, Nigel J.] Washington Univ, Sch Med, Dept Neurol, Knight Alzheimers Dis Res Ctr, St Louis, MO 63110 USA; [Cairns, Nigel J.; Morris, John C.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Cedarbaum, Jesse] Biogen Idec Inc, Neurol Early Clin Dev, Cambridge, MA USA; [Donohue, Michael C.] Univ Calif San Diego, Div Biostat & Bioinformat, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA; [Green, Robert C.] Brigham & Womens Hosp, Div Genet, Dept Med, Boston, MA 02115 USA; [Green, Robert C.] Harvard Univ, Sch Med, Boston, MA USA; [Jack, Clifford R.] Mayo Clin, Dept Radiol, Rochester, MN USA; [Jagust, William] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Jagust, William] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Saykin, Andrew J.] Indiana Univ, Dept Med & Mol Genet, Sch Med, Indianapolis, IN 46204 USA; [Shaw, Leslie] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Thompson, Paul M.] Univ So Calif, Imaging Genet Ctr, Inst Neuroimaging & Informat, Marina Del Rey, CA USA; [Toga, Arthur W.] Univ So Calif, Keck Sch Med, Lab Neuroimaging, Inst Neuroimaging & Informat, Los Angeles, CA 90033 USA; [Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Res, Perelman Sch Med, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Inst Aging, Perelman Sch Med, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Alzheimers Dis Core Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Udall Parkinsons Res Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA	Weiner, MW (corresponding author), Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA.	michael.weiner@ucsf.edu	Harvey, Danielle/A-5496-2017; Cairns, Nigel/AAB-9713-2020; Jack, Clifford R/F-2508-2010; Thompson, Paul M/C-4194-2018; Jagust, William/ABE-6426-2020; Saykin, Andrew/A-1318-2007	Cairns, Nigel/0000-0001-9858-3344; Jack, Clifford R/0000-0001-7916-622X; Thompson, Paul M/0000-0002-4720-8867; Saykin, Andrew/0000-0002-1376-8532; Veitch, Dallas/0000-0002-9918-0640	NIH - National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5U01AG024904-10]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108, UL1TR002529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG024904, R01AG040060, P30AG010124, P30AG010129] Funding Source: NIH RePORTER	This work was supported by NIH grant 5U01AG024904-10 funded by the National Institute on Aging to Dr Michael Weiner.	Aisen PS, 2011, NEUROLOGY, V76, P280, DOI 10.1212/WNL.0b013e318207b1b9; Apostolova LG, 2010, NEUROBIOL AGING, V31, P1284, DOI 10.1016/j.neurobiolaging.2010.05.003; Arai H, 2010, TOHOKU J EXP MED, V221, P87, DOI 10.1620/tjem.221.87; ARRIAGADA PV, 1992, NEUROLOGY, V42, P1681, DOI 10.1212/WNL.42.9.1681; Barnes J, 2013, NEUROBIOL AGING, V34, P1996, DOI 10.1016/j.neurobiolaging.2013.02.003; Beckett LA, 2010, ALZHEIMERS DEMENT, V6, P257, DOI 10.1016/j.jalz.2010.03.002; BIERER LM, 1995, ARCH NEUROL-CHICAGO, V52, P81, DOI 10.1001/archneur.1995.00540250089017; Bis JC, 2012, NAT GENET, V44, P545, DOI 10.1038/ng.2237; Boccardi M, 2015, ALZHEIMERS DEMENT, V11, P184, DOI 10.1016/j.jalz.2013.03.001; Boyes RG, 2008, NEUROIMAGE, V39, P1752, DOI 10.1016/j.neuroimage.2007.10.026; Bracoud L., 2013, CLIN TRIALS ALZH DIS; Buchhave P, 2012, ARCH GEN PSYCHIAT, V69, P98, DOI 10.1001/archgenpsychiatry.2011.155; Cardoso MJ, 2013, MED IMAGE ANAL, V17, P671, DOI 10.1016/j.media.2013.02.006; Carmichael O, 2010, ARCH NEUROL-CHICAGO, V67, P1370, DOI 10.1001/archneurol.2010.284; Caroli A, 2010, NEUROBIOL AGING, V31, P1263, DOI 10.1016/j.neurobiolaging.2010.04.024; Carrillo MC, 2012, ALZHEIMERS DEMENT, V8, P337, DOI 10.1016/j.jalz.2012.04.007; Cedarbaum JM, 2013, ALZHEIMERS DEMENT, V9, pS45, DOI 10.1016/j.jalz.2011.11.002; Chen KW, 2011, NEUROIMAGE, V56, P52, DOI 10.1016/j.neuroimage.2011.01.049; Chen KW, 2010, NEUROIMAGE, V51, P654, DOI 10.1016/j.neuroimage.2010.02.064; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Chou YY, 2010, NEUROBIOL AGING, V31, P1386, DOI 10.1016/j.neurobiolaging.2010.05.001; Chou YY, 2009, NEUROIMAGE, V46, P394, DOI 10.1016/j.neuroimage.2009.02.015; Clarkson MJ, 2009, NEUROIMAGE, V47, P1506, DOI 10.1016/j.neuroimage.2009.05.045; Crane PK, 2012, BRAIN IMAGING BEHAV, V6, P502, DOI 10.1007/s11682-012-9186-z; Cuingnet R, 2011, NEUROIMAGE, V56, P766, DOI 10.1016/j.neuroimage.2010.06.013; Davatzikos C, 2009, BRAIN, V132, P2026, DOI 10.1093/brain/awp091; De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179; Doecke JD, 2012, ARCH NEUROL-CHICAGO, V69, P1318, DOI 10.1001/archneurol.2012.1282; Donohue MC, 2014, ALZHEIMERS DEMENT, V10, pS400, DOI 10.1016/j.jalz.2013.10.003; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Ellis KA, 2010, ALZHEIMERS DEMENT, V6, P291, DOI 10.1016/j.jalz.2010.03.009; Evans MC, 2010, EUR RADIOL, V20, P674, DOI 10.1007/s00330-009-1581-5; Fennema-Notestine C, 2009, HUM BRAIN MAPP, V30, P3238, DOI 10.1002/hbm.20744; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fodero-Tavoletti MT, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt240; Fox NC, 2011, NEUROIMAGE, V57, P15, DOI 10.1016/j.neuroimage.2011.01.077; Frisoni GB, 2011, ALZHEIMERS DEMENT, V7, P171, DOI 10.1016/j.jalz.2010.06.007; Frisoni GB, 2010, ALZHEIMERS DEMENT, V6, P280, DOI 10.1016/j.jalz.2010.03.005; Furney SJ, 2011, MOL PSYCHIATR, V16, P1130, DOI 10.1038/mp.2010.123; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Grill JD, 2013, NEUROBIOL AGING, V34, P62, DOI 10.1016/j.neurobiolaging.2012.03.006; Gunter JL, 2009, MED PHYS, V36, P2193, DOI 10.1118/1.3116776; Guo LH, 2013, EUR ARCH PSY CLIN N, V263, P325, DOI 10.1007/s00406-012-0349-0; Guzman Vanessa A, 2013, Alzheimers Dement, V9, pS124, DOI 10.1016/j.jalz.2012.11.009; Habeck C, 2012, BRAIN IMAGING BEHAV, V6, P568, DOI 10.1007/s11682-012-9208-x; Haight TJ, 2013, JAMA NEUROL, V70, P1039, DOI 10.1001/jamaneurol.2013.1878; Han MR, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-90; Han SD, 2012, BRAIN IMAGING BEHAV, V6, P610, DOI 10.1007/s11682-012-9177-0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hill DLG, 2014, ALZHEIMERS DEMENT, V10, P421, DOI 10.1016/j.jalz.2013.07.003; Hobart J, 2013, ALZHEIMERS DEMENT, V9, pS10, DOI 10.1016/j.jalz.2012.08.006; Hobart J, 2013, ALZHEIMERS DEMENT, V9, pS4, DOI 10.1016/j.jalz.2012.08.005; Holland D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047739; Holland D, 2012, HUM BRAIN MAPP, V33, P2586, DOI 10.1002/hbm.21386; Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803; Hostage CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054483; Hua X, 2013, NEUROIMAGE, V66, P648, DOI 10.1016/j.neuroimage.2012.10.086; Hua X, 2008, NEUROIMAGE, V43, P458, DOI 10.1016/j.neuroimage.2008.07.013; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Jack CR, 2011, ARCH NEUROL-CHICAGO, V68, P1526, DOI 10.1001/archneurol.2011.183; Jack CR, 2010, BRAIN, V133, P3336, DOI 10.1093/brain/awq277; Jack CR, 2010, ALZHEIMERS DEMENT, V6, P212, DOI 10.1016/j.jalz.2010.03.004; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062; Jagust WJ, 2009, NEUROLOGY, V73, P1193, DOI 10.1212/WNL.0b013e3181bc010c; Jagust WJ, 2010, ALZHEIMERS DEMENT, V6, P221, DOI 10.1016/j.jalz.2010.03.003; Jahanshad N, 2013, P NATL ACAD SCI USA, V110, P4768, DOI 10.1073/pnas.1216206110; Jedynak BM, 2012, NEUROIMAGE, V63, P1478, DOI 10.1016/j.neuroimage.2012.07.059; Johnstone D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034341; Kang JH, 2013, JAMA NEUROL, V70, P1277, DOI 10.1001/jamaneurol.2013.3861; Kang JH, 2012, METHODS, V56, P484, DOI 10.1016/j.ymeth.2012.03.023; Karch CM, 2015, BIOL PSYCHIAT, V77, P43, DOI 10.1016/j.biopsych.2014.05.006; Karow DS, 2010, RADIOLOGY, V256, P932, DOI 10.1148/radiol.10091402; Khachaturian AS, 2014, ALZHEIMERS DEMENT, V10, pS90, DOI 10.1016/j.jalz.2014.05.1085; Khachaturian ZS, 2000, ANN NY ACAD SCI, V924, P184; Kim S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070269; Klein G, 2015, COMP ASSESSMENT SUVR; Klein G., 2013, ALZH ASS INT C BOST; Klein G., 2014, CLIN TRIALS ALZH DIS; Klein G., 2015, 12 INT C ALZH PARK D; Korecka M, 2014, J ALZHEIMERS DIS, V41, P441, DOI 10.3233/JAD-132489; Korff A, 2013, J ALZHEIMERS DIS, V36, P679, DOI 10.3233/JAD-130458; Kozauer N, 2013, NEW ENGL J MED, V368, P1169, DOI 10.1056/NEJMp1302513; Kruggel F, 2010, NEUROIMAGE, V49, P2123, DOI 10.1016/j.neuroimage.2009.11.006; Lakatos A, 2010, NEUROBIOL AGING, V31, P1355, DOI 10.1016/j.neurobiolaging.2010.04.031; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Landau SM, 2013, J NUCL MED, V54, P70, DOI 10.2967/jnumed.112.109009; Landau SM, 2011, NEUROBIOL AGING, V32, P1207, DOI 10.1016/j.neurobiolaging.2009.07.002; Leow AD, 2009, NEUROIMAGE, V45, P645, DOI 10.1016/j.neuroimage.2009.01.004; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Leung KK, 2013, NEUROLOGY, V80, P648, DOI 10.1212/WNL.0b013e318281ccd3; Leung KK, 2011, NEUROIMAGE, V55, P1091, DOI 10.1016/j.neuroimage.2010.12.067; Leung KK, 2010, NEUROIMAGE, V51, P1345, DOI 10.1016/j.neuroimage.2010.03.018; Liu F, 2013, LECT NOTES COMPUT SC, V8149, P308, DOI 10.1007/978-3-642-40811-3_39; Liu F, 2014, NEUROIMAGE, V84, P466, DOI 10.1016/j.neuroimage.2013.09.015; Liu YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055246; LLANO DA, 2010, ALZ DIS ASSOC DIS, V25, P73; Llano DA, 2013, ALZ DIS ASSOC DIS, V27, P233, DOI 10.1097/WAD.0b013e31826d597a; Lo RY, 2012, NEUROLOGY, V79, P1349, DOI 10.1212/WNL.0b013e31826c1b9d; Lo RY, 2011, ARCH NEUROL-CHICAGO, V68, P1257, DOI 10.1001/archneurol.2011.123; Lowe VJ, 2013, NEUROLOGY, V80, P2130, DOI 10.1212/WNL.0b013e318295d6cf; Marek K., 2011, PROG NEUROBIOL, V95, P629, DOI DOI 10.1016/J.PNEUROBIO.2011.09.005; Maruyama M, 2013, NEURON, V79, P1094, DOI 10.1016/j.neuron.2013.07.037; McDonald CR, 2012, NEUROBIOL AGING, V33, P242, DOI 10.1016/j.neurobiolaging.2010.03.015; Mintun M., 2013, ALZHEIMERS DEMENTIA, V9, pP842; Mormino EC, 2009, BRAIN, V132, P1310, DOI 10.1093/brain/awn320; Morra JH, 2009, NEUROIMAGE, V45, pS3, DOI 10.1016/j.neuroimage.2008.10.043; Mouiha A, 2012, J ALZHEIMERS DIS, V30, P91, DOI 10.3233/JAD-2012-111367; Mueller SG, 2005, NEUROIMAG CLIN N AM, V15, P869, DOI 10.1016/j.nic.2005.09.008; Murphy KR, 2013, NEUROIMAGE, V78, P474, DOI 10.1016/j.neuroimage.2013.04.048; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Ness S, 2012, NAT REV DRUG DISCOV, V11, P655, DOI 10.1038/nrd3822; Nettiksimmons J, 2010, NEUROBIOL AGING, V31, P1419, DOI 10.1016/j.neurobiolaging.2010.04.025; Nettiksimmons J, 2014, ALZHEIMERS DEMENT, V10, P511, DOI 10.1016/j.jalz.2013.09.003; Nettiksimmons J, 2013, PSYCHOL AGING, V28, P191, DOI 10.1037/a0031063; Nho K, 2013, MOL PSYCHIATR, V18, P781, DOI [10.1038/mp.2013.81, 10.1038/mp.2013.24]; Nir T, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P1405, DOI 10.1109/ISBI.2012.6235831; Nir TM, 2013, NEUROIMAGE-CLIN, V3, P180, DOI 10.1016/j.nicl.2013.07.006; O'Bryant SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028092; Okamura N, 2014, BRAIN, V137, P1762, DOI 10.1093/brain/awu064; Okamura N, 2013, J NUCL MED, V54, P1420, DOI 10.2967/jnumed.112.117341; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; Petersen RC, 1996, ANN NY ACAD SCI, V802, P58, DOI 10.1111/j.1749-6632.1996.tb32599.x; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2013, ANN NEUROL, V74, P199, DOI 10.1002/ana.23931; Potkin SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006501; Provenzano FA, 2013, JAMA NEUROL, V70, P455, DOI 10.1001/jamaneurol.2013.1321; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; Rajagopalan P, 2013, NEW ENGL J MED, V369, P1565, DOI 10.1056/NEJMc1306509; Ramanan VK, 2014, MOL PSYCHIATR, V19, P351, DOI 10.1038/mp.2013.19; Ramanan VK, 2012, BRAIN IMAGING BEHAV, V6, P634, DOI 10.1007/s11682-012-9196-x; Rammohan K., 2014, 6 COOP M CONS MULT S; Randall C, 2013, FRONT BIOSCI-LANDMRK, V18, P1150, DOI 10.2741/4170; Rhinn H, 2013, NATURE, V500, P45, DOI 10.1038/nature12415; Ridge PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079771; Risacher SL, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00011; Risacher SL, 2010, NEUROBIOL AGING, V31, P1401, DOI 10.1016/j.neurobiolaging.2010.04.029; Roche F., 2013, ALZH ASS INT C WASH; Roche F., 2014, ALZH ASS INT C COP D; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Schott JM, 2010, NEUROBIOL AGING, V31, P1452, DOI 10.1016/j.neurobiolaging.2010.04.011; Schott JM, 2010, ANN NEUROL, V68, P825, DOI 10.1002/ana.22315; Schuff N, 2009, BRAIN, V132, P1067, DOI 10.1093/brain/awp007; Schuff N, 2012, NEUROBIOL AGING, V33, P845, DOI 10.1016/j.neurobiolaging.2010.07.012; Shaw LM, 2011, ACTA NEUROPATHOL, V121, P597, DOI 10.1007/s00401-011-0808-0; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Shen L, 2014, BRAIN IMAGING BEHAV, V8, P183, DOI 10.1007/s11682-013-9262-z; Shen L, 2010, NEUROIMAGE, V53, P1051, DOI 10.1016/j.neuroimage.2010.01.042; Shin J, 2008, NEUROIMAGE, V43, P236, DOI 10.1016/j.neuroimage.2008.07.022; Spampinato MV, 2011, RADIOLOGY, V258, P843, DOI 10.1148/radiol.10100307; Sperling RA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007941; Sperling RA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002609; Stein JL, 2012, NAT GENET, V44, P552, DOI 10.1038/ng.2250; Stein JL, 2010, NEUROIMAGE, V53, P1160, DOI 10.1016/j.neuroimage.2010.02.032; Stricker NH, 2012, BRAIN IMAGING BEHAV, V6, P599, DOI 10.1007/s11682-012-9171-6; Swaminathan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050640; Toga AW, 2010, ALZHEIMERS DEMENT, V6, P247, DOI 10.1016/j.jalz.2010.03.001; Toledo JB, 2015, JAMA NEUROL, V72, P571, DOI 10.1001/jamaneurol.2014.4829; Toledo JB, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-65; Toledo JB, 2013, ACTA NEUROPATHOL, V126, P683, DOI 10.1007/s00401-013-1148-z; Trzepacz PT, 2014, NEUROBIOL AGING, V35, P143, DOI 10.1016/j.neurobiolaging.2013.06.018; Vemuri P, 2009, NEUROLOGY, V73, P287, DOI 10.1212/WNL.0b013e3181af79e5; Vemuri P, 2009, NEUROLOGY, V73, P294, DOI 10.1212/WNL.0b013e3181af79fb; Vemuri P, 2010, ANN NEUROL, V67, P308, DOI 10.1002/ana.21953; Villemagne VL, 2014, ALZHEIMERS DEMENT, V10, pS254, DOI 10.1016/j.jalz.2014.04.013; Villemagne VL, 2014, EUR J NUCL MED MOL I, V41, P816, DOI 10.1007/s00259-013-2681-7; Weigand SD, 2011, ALZHEIMERS DEMENT, V7, P133, DOI 10.1016/j.jalz.2010.08.230; Weiner Michael W, 2015, Alzheimers Dement, V11, pe1, DOI 10.1016/j.jalz.2014.11.001; Weiner MW, 2014, ALZHEIMERS DEMENT, V10, pS226, DOI 10.1016/j.jalz.2014.04.005; Weiner MW, 2013, ALZHEIMERS DEMENT, V9, P445, DOI [10.1016/j.jalz.2013.05.1769, 10.1016/j.jalz.2013.03.005]; Weiner Michael W, 2012, Alzheimers Dement, V8, pS1, DOI 10.1016/j.jalz.2011.09.172; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007; Westman E, 2012, NEUROIMAGE, V62, P229, DOI 10.1016/j.neuroimage.2012.04.056; Wilhelm EE, 2014, JAMA-J AM MED ASSOC, V311, P1201, DOI 10.1001/jama.2014.850; Wolz R, 2014, ALZHEIMERS DEMENT, V10, P430, DOI 10.1016/j.jalz.2013.09.014; Wolz R, 2010, NEUROIMAGE, V52, P109, DOI 10.1016/j.neuroimage.2010.04.006; Wolz R, 2010, NEUROIMAGE, V49, P1316, DOI 10.1016/j.neuroimage.2009.09.069; Wu X, 2010, J NEUROSCI METH, V192, P277, DOI 10.1016/j.jneumeth.2010.07.030; Wyman BT, 2013, ALZHEIMERS DEMENT, V9, P332, DOI 10.1016/j.jalz.2012.06.004; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Yang XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047406; Young AL, 2014, BRAIN, V137, P2564, DOI 10.1093/brain/awu176; Yu P, 2014, NEUROBIOL AGING, V35, P808, DOI 10.1016/j.neurobiolaging.2013.09.039; Zhang DQ, 2012, NEUROIMAGE, V59, P895, DOI 10.1016/j.neuroimage.2011.09.069; Zhang DQ, 2011, NEUROIMAGE, V55, P856, DOI 10.1016/j.neuroimage.2011.01.008	189	97	101	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUL	2015	11	7					865	884		10.1016/j.jalz.2015.04.005			20	Clinical Neurology	Neurosciences & Neurology	CN1RS	WOS:000358198400014	26194320	Green Accepted			2021-06-18	
J	Ransom, DM; Vaughan, CG; Pratson, L; Sady, MD; McGill, CA; Gioia, GA				Ransom, Danielle M.; Vaughan, Christopher G.; Pratson, Lincoln; Sady, Maegan D.; McGill, Catherine A.; Gioia, Gerard A.			Academic Effects of Concussion in Children and Adolescents	PEDIATRICS			English	Article							SPORT	OBJECTIVE: The aim of this work is to study the nature and extent of the adverse academic effects faced by students recovering from concussion. METHOD: A sample of 349 students ages 5 to 18 who sustained a concussion and their parents reported academic concerns and problems (eg, symptoms interfering, diminished academic skills) on a structured school questionnaire within 4 weeks of injury. Postconcussion symptoms were measured as a marker of injury severity. Results were examined based on recovery status (recovered or actively symptomatic) and level of schooling (elementary, middle, and high school). RESULTS: Actively symptomatic students and their parents reported higher levels of concern for the impact of concussion on school performance (P < .05) and more school-related problems (P < .001) than recovered peers and their parents. High school students who had not yet recovered reported significantly more adverse academic effects than their younger counterparts (P < .05). Greater severity of postconcussion symptoms was associated with more school-related problems and worse academic effects, regardless of time since injury (P < .001). CONCLUSIONS: This study provides initial evidence for a concussion's impact on academic learning and performance, with more adverse effects reported by students who had not yet recovered from the injury. School-based management with targeted recommendations informed by postinjury symptoms may mitigate adverse academic effects, reduce parent and student concerns for the impact of the injury on learning and scholastic performance, and lower the risk of prolonged recovery for students with active postconcussion symptoms.	[Ransom, Danielle M.; Vaughan, Christopher G.; Sady, Maegan D.; McGill, Catherine A.; Gioia, Gerard A.] Childrens Natl Hlth Syst, Washington, DC USA; [Ransom, Danielle M.; Vaughan, Christopher G.; Sady, Maegan D.; McGill, Catherine A.; Gioia, Gerard A.] George Washington Univ, Sch Med, Washington, DC USA; [Pratson, Lincoln] E Carolina Univ, Brody Sch Med, Greenville, NC USA	Gioia, GA (corresponding author), Childrens Natl Hlth Syst, Div Neuropsychol, 15425 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	ggioia@childrensnational.org					Gioia GA, 2016, J CHILD NEUROL, V31, P93, DOI 10.1177/0883073814555604; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McAvoy K, 2009, REAP BENEFITS GOOD C; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008	10	97	97	0	19	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2015	135	6					1043	1050		10.1542/peds.2014-3434			8	Pediatrics	Pediatrics	CJ5UR	WOS:000355557400042	25963014	Bronze			2021-06-18	
J	Lingsma, HF; Yue, JK; Maas, AIR; Steyerberg, EW; Manley, GT; Cooper, SR; Dams-O'Connor, K; Gordon, WA; Menon, DK; Mukherjee, P; Okonkwo, DO; Puccio, AM; Schnyer, DM; Valadka, AB; Vassar, MJ; Yuh, EL				Lingsma, Hester F.; Yue, John K.; Maas, Andrew I. R.; Steyerberg, Ewout W.; Manley, Geoffrey T.; Cooper, Shelly R.; Dams-O'Connor, Kristen; Gordon, Wayne A.; Menon, David K.; Mukherjee, Pratik; Okonkwo, David O.; Puccio, Ava M.; Schnyer, David M.; Valadka, Alex B.; Vassar, Mary J.; Yuh, Esther L.		TRACK-TBI Investigators	Outcome Prediction after Mild and Complicated Mild Traumatic Brain Injury: External Validation of Existing Models and Identification of New Predictors Using the TRACK-TBI Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						TBI; prognostic models; validation; GOS-E	COMMON DATA ELEMENTS; HEAD-INJURY; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; PROGNOSTIC MODELS; HEALTH; PERFORMANCE; TOMOGRAPHY; RECOVERY; ALLELE	Although the majority of patients with mild traumatic brain injury (mTBI) recover completely, some still suffer from disabling ailments at 3 or 6 months. We validated existing prognostic models for mTBI and explored predictors of poor outcome after mTBI. We selected patients with mTBI from TRACK-TBI Pilot, an unselected observational cohort of TBI patients from three centers in the United States. We validated two prognostic models for the Glasgow Outcome Scale Extended (GOS-E) at 6 months after injury. One model was based on the CRASH study data and another from Nijmegen, The Netherlands. Possible predictors of 3- and 6-month GOS-E were analyzed with univariate and multi-variable proportional odds regression models. Of the 386 of 485 patients included in the study (median age, 44 years; interquartile range, 27-58), 75% (n=290) presented with a Glasgow Coma Score (GCS) of 15. In this mTBI population, both previously developed models had a poor performance (area under the receiver operating characteristic curve, 0.49-0.56). In multivariable analyses, the strongest predictors of lower 3- and 6-month GOS-E were older age, pre-existing psychiatric conditions, and lower education. Injury caused by assault, extracranial injuries, and lower GCS were also predictive of lower GOS-E. Existing models for mTBI performed unsatisfactorily. Our study shows that, for mTBI, different predictors are relevant as for moderate and severe TBI. These include age, pre-existing psychiatric conditions, and lower education. Development of a valid prediction model for mTBI patients requires further research efforts.	[Lingsma, Hester F.; Steyerberg, Ewout W.] Univ Med Ctr, Erasmus Med Ctr, Rotterdam, Netherlands; [Yue, John K.; Manley, Geoffrey T.; Cooper, Shelly R.; Mukherjee, Pratik; Vassar, Mary J.; Yuh, Esther L.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Yue, John K.; Manley, Geoffrey T.; Cooper, Shelly R.; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Cooper, Shelly R.; Mukherjee, Pratik; Yuh, Esther L.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Med Ctr, Neurotrauma Clin Trials Ctr, Pittsburgh, PA USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge CB2 2QQ, England; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Cooper, Shelly/0000-0003-0026-6688; Schnyer, David/0000-0002-7472-2853; Mukherjee, Pratik/0000-0001-7473-7409	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC2 NS0694909, RC2 NS069409-02S1]; Department of DefenseUnited States Department of Defense [USAMRAA W81XWH-13-1-0441]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was supported by the National Institutes of Health (grant nos. RC2 NS0694909 [to G.T.M.] and RC2 NS069409-02S1 [to G.T.M.]) and the Department of Defense (USAMRAA W81XWH-13-1-0441; to G.T.M.). Registry: ClinicalTrials.gov Identifier NCT01565551.	Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polinder S, 2008, ACCIDENT ANAL PREV, V40, P182, DOI 10.1016/j.aap.2007.05.001; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	39	97	97	1	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					83	94		10.1089/neu.2014.3384			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700002	25025611	Green Published			2021-06-18	
J	Meehan, WP; Mannix, R; Monuteaux, MC; Stein, CJ; Bachur, RG				Meehan, William P., III; Mannix, Rebekah; Monuteaux, Michael C.; Stein, Cynthia J.; Bachur, Richard G.			Early symptom burden predicts recovery after sport-related concussion	NEUROLOGY			English	Article							COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROTRACTED RECOVERY; PROLONGED RECOVERY; SEVERITY; AGE	Objective:To identify independent predictors of and use recursive partitioning to develop a multivariate regression tree predicting symptom duration greater than 28 days after a sport-related concussion.Methods:We conducted a prospective cohort study of patients in a sports concussion clinic. Participants completed questionnaires that included the Post-Concussion Symptom Scale (PCSS). Participants were asked to record the date on which they last experienced symptoms. Potential predictor variables included age, sex, score on symptom inventories, history of prior concussions, performance on computerized neurocognitive assessments, loss of consciousness and amnesia at the time of injury, history of prior medical treatment for headaches, history of migraines, and family history of concussion. We used recursive partitioning analysis to develop a multivariate prediction model for identifying athletes at risk for a prolonged recovery from concussion.Results:A total of 531 patients ranged in age from 7 to 26 years (mean 14.6 2.9 years). The mean PCSS score at the initial visit was 26 +/- 26; mean time to presentation was 12 +/- 5 days. Only total score on symptom inventory was independently associated with symptoms lasting longer than 28 days (adjusted odds ratio 1.044; 95% confidence interval [CI] 1.034, 1.054 for PCSS). No other potential predictor variables were independently associated with symptom duration or useful in developing the optimal regression decision tree. Most participants (86%; 95% CI 80%, 90%) with an initial PCSS score of <13 had resolution of their symptoms within 28 days of injury.Conclusions:The only independent predictor of prolonged symptoms after sport-related concussion is overall symptom burden.	[Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA; [Meehan, William P., III; Stein, Cynthia J.] Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA USA; [Meehan, William P., III; Mannix, Rebekah; Monuteaux, Michael C.; Bachur, Richard G.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Meehan, William P., III; Mannix, Rebekah] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA	Meehan, WP (corresponding author), Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA.	William.meehan@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Monuteaux, Michael C/O-5032-2018	Bachur, Richard/0000-0001-8831-014X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A]; NFL Players Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	Funded by the NIH T32 HD040128-06A (Dr. Meehan) and the NFL Players Association (Dr. Meehan).	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dawson B, 2004, STAT METHODS MULTIPL; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Sperandei S, 2013, BIOCHEM MEDICA, V24, P12; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	30	97	97	0	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 9	2014	83	24					2204	2210		10.1212/WNL.0000000000001073			7	Clinical Neurology	Neurosciences & Neurology	AW1SK	WOS:000346070000008	25381296	Green Published			2021-06-18	
J	Hsieh, CL; Niemi, EC; Wang, SH; Lee, CC; Bingham, D; Zhang, JS; Cozen, ML; Charo, I; Huang, EJ; Liu, JL; Nakamura, MC				Hsieh, Christine L.; Niemi, Erene C.; Wang, Sarah H.; Lee, Chih Cheng; Bingham, Deborah; Zhang, Jiasheng; Cozen, Myrna L.; Charo, Israel; Huang, Eric J.; Liu, Jialing; Nakamura, Mary C.			CCR2 Deficiency Impairs Macrophage Infiltration and Improves Cognitive Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; CCR2; chemotaxis; inflammation; macrophage	CHEMOKINE RECEPTOR CCR2; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; NEUROPATHIC PAIN; MOUSE MODEL; HIPPOCAMPAL NEUROGENESIS; MONOCYTE RECRUITMENT; CRANIAL IRRADIATION	Traumatic brain injury (TBI) provokes inflammatory responses, including a dramatic rise in brain macrophages in the area of injury. The pathway(s) responsible for macrophage infiltration of the traumatically injured brain and the effects of macrophages on functional outcomes are not well understood. C-C-chemokine receptor 2 (CCR2) is known for directing monocytes to inflamed tissues. To assess the role of macrophages and CCR2 in TBI, we determined outcomes in CCR2-deficient (Ccr2(-/-)) mice in a controlled cortical impact model. We quantified brain myeloid cell numbers post-TBI by flow cytometry and found that Ccr2(-/-) mice had greatly reduced macrophage numbers (similar to 80-90% reduction) early post-TBI, compared with wild-type mice. Motor, locomotor, and cognitive outcomes were assessed. Lack of Ccr2 improved locomotor activity with less hyperactivity in open field testing, but did not affect anxiety levels or motor coordination on the rotarod three weeks after TBI. Importantly, Ccr2(-/-) mice demonstrated greater spatial learning and memory, compared with wildtype mice eight weeks after TBI. Although there was no difference in the volume of tissue loss, Ccr2(-/-) mice had significantly increased neuronal density in the CA1-CA3 regions of the hippocampus after TBI, compared with wild-type mice. These data demonstrate that Ccr2 directs the majority of macrophage homing to the brain early after TBI and indicates that Ccr2 may facilitate harmful responses. Lack of Ccr2 improves functional recovery and neuronal survival. These results suggest that therapeutic blockade of CCR2-dependent responses may improve outcomes following TBI.	[Hsieh, Christine L.; Niemi, Erene C.; Wang, Sarah H.; Nakamura, Mary C.] San Francisco VA Med Ctr, Immunol Sect, San Francisco, CA 94121 USA; [Lee, Chih Cheng; Bingham, Deborah; Liu, Jialing] San Francisco VA Med Ctr, Dept Neurol Surg, San Francisco, CA 94121 USA; [Zhang, Jiasheng; Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv, San Francisco, CA 94121 USA; [Cozen, Myrna L.] San Francisco VA Med Ctr, Ctr Liver, San Francisco, CA 94121 USA; [Hsieh, Christine L.; Niemi, Erene C.; Wang, Sarah H.; Cozen, Myrna L.; Charo, Israel; Nakamura, Mary C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Lee, Chih Cheng; Bingham, Deborah; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Zhang, Jiasheng; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Charo, Israel] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA	Hsieh, CL (corresponding author), San Francisco VA Med Ctr, Immunol Sect, 4150 Clement St,111-R Bldg 2,Room 500, San Francisco, CA 94121 USA.	Christine.Hsieh@ucsf.edu	Huang, Eric J./AAH-7997-2019; Liu, Jialing/A-8627-2012; Nakamura, Mary/ABI-2887-2020	Huang, Eric J./0000-0002-5381-3801; Liu, Jialing/0000-0003-4420-4382; Nakamura, Mary C./0000-0001-8127-9426	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Career Development Award-2US Department of Veterans Affairs; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and DevelopmentUS Department of Veterans Affairs; Russell/Engelman Center for Arthritis Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL102475] Funding Source: NIH RePORTER	The authors thank Ruby Gribi of the San Francisco VA Flow Cytometry core, Ivy Hsieh and Sherry Kamiya of the San Francisco VA Cell Imaging core for their dedication and contributions to this project. This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Career Development Award-2 to CLH. MCN is supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Merit Award and by the Russell/Engelman Center for Arthritis Research. With tremendous gratitude, we acknowledge Dr. William E. Seaman for helpful discussions and an insightful review of this manuscript.	Abbadie C, 2003, P NATL ACAD SCI USA, V100, P7947, DOI 10.1073/pnas.1331358100; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Belarbi K, 2013, CANCER RES, V73, P1201, DOI 10.1158/0008-5472.CAN-12-2989; Bonecchi R, 2009, FRONT BIOSCI-LANDMRK, V14, P540, DOI 10.2741/3261; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bose S, 2013, ARCH PHARM RES, V36, P1039, DOI 10.1007/s12272-013-0161-z; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Daley JM, 2010, J LEUKOCYTE BIOL, V87, P59, DOI 10.1189/jlb.0409236; Derecki NC, 2011, BRAIN BEHAV IMMUN, V25, P379, DOI 10.1016/j.bbi.2010.11.009; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Dulawa SC, 1999, J NEUROSCI, V19, P9550; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Fan Y, 2007, EUR J NEUROSCI, V25, P38, DOI 10.1111/j.1460-9568.2006.05269.x; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Geissmann F, 2010, NAT REV IMMUNOL, V10, P453, DOI 10.1038/nri2784; Gomez CR, 2005, CURR OPIN IMMUNOL, V17, P457, DOI 10.1016/j.coi.2005.07.013; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Greter M, 2013, GLIA, V61, P121, DOI 10.1002/glia.22408; Hammond MD, 2014, J NEUROSCI, V34, P3901, DOI 10.1523/JNEUROSCI.4070-13.2014; Hong SM, 2007, EXP NEUROL, V206, P24, DOI 10.1016/j.expneurol.2007.03.028; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lam TI, 2013, NEUROREHAB NEURAL RE, V27, P889, DOI 10.1177/1545968313491003; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leuschner F, 2011, NAT BIOTECHNOL, V29, P1005, DOI 10.1038/nbt.1989; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Manville J, 2007, J MOL NEUROSCI, V31, P95, DOI 10.1385/JMN/31:02:95; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Melik-Parsadaniantz S, 2008, J NEUROIMMUNOL, V198, P62, DOI 10.1016/j.jneuroim.2008.04.022; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Naert G, 2011, J NEUROSCI, V31, P6208, DOI 10.1523/JNEUROSCI.0299-11.2011; Niemi JP, 2013, J NEUROSCI, V33, P16236, DOI 10.1523/JNEUROSCI.3319-12.2013; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Potts Mathew B, 2006, NeuroRx, V3, P143; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Quinones MP, 2005, J MOL MED, V83, P672, DOI 10.1007/s00109-005-0637-5; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Schall TJ, 2011, NAT REV IMMUNOL, V11, P355, DOI 10.1038/nri2972; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Semple BD, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-67; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Sinopoli KJ, 2012, INT J DEV NEUROSCI, V30, P207, DOI 10.1016/j.ijdevneu.2011.08.006; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sonoda KH, 2011, ACTA OPHTHALMOL, V89, pE180, DOI 10.1111/j.1755-3768.2010.01953.x; Suh SW, 2005, DIABETES, V54, P1452, DOI 10.2337/diabetes.54.5.1452; Suh SW, 2003, J NEUROSCI, V23, P10681; Tran PB, 2007, J COMP NEUROL, V500, P1007, DOI 10.1002/cne.21229; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; White FA, 2009, MOL INTERV, V9, P188, DOI 10.1124/mi.9.4.7; Willenborg S, 2012, BLOOD, V120, P613, DOI 10.1182/blood-2012-01-403386; Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186; Zhang J, 2007, J NEUROSCI, V27, P12396, DOI 10.1523/JNEUROSCI.3016-07.2007; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Zweemer AJM, 2013, MOL PHARMACOL, V84, P551, DOI 10.1124/mol.113.086850	80	97	98	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2014	31	20					1677	1688		10.1089/neu.2013.3252			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AP8BF	WOS:000342302200001	24806994	Green Published			2021-06-18	
J	Sabirzhanov, B; Zhao, ZR; Stoica, BA; Loane, DJ; Wu, JF; Borroto, C; Dorsey, SG; Faden, AI				Sabirzhanov, Boris; Zhao, Zaorui; Stoica, Bogdan A.; Loane, David J.; Wu, Junfang; Borroto, Carlos; Dorsey, Susan G.; Faden, Alan I.			Downregulation of miR-23a and miR-27a following Experimental Traumatic Brain Injury Induces Neuronal Cell Death through Activation of Proapoptotic Bcl-2 Proteins	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; Bcl-2 proteins; microRNA; neuroprotection; traumatic brain injury	DNA-DAMAGE; IN-VIVO; POLY(ADP-RIBOSE) POLYMERASE; BH3-ONLY PROTEINS; INDUCED APOPTOSIS; CYTOCHROME-C; PROBE LEVEL; EXPRESSION; P53; MICRORNA	MicroRNAs (miRs) are small noncoding RNAs that negatively regulate gene expression at the post-transcriptional level. To identify miRs that may regulate neuronal cell death after experimental traumatic brain injury (TBI), we profiled miR expression changes during the first several days after controlled cortical impact (CCI) in mice. miR-23a and miR-27a were rapidly downregulated in the injured cortex in the first hour after TBI. These changes coincided with increased expression of the proapoptotic Bcl-2 family members Noxa, Puma, and Bax. In an etoposide-induced in vitro model of apoptosis in primary cortical neurons, miR-23a and miR-27a were markedly downregulated as early as 1 h after exposure, before the upregulation of proapoptotic Bcl-2 family molecules. Administration of miR-23a and miR-27a mimics attenuated etoposide-induced changes in Noxa, Puma, and Bax, reduced downstream markers of caspase-dependent (cytochrome c release and caspase activation) and caspase-independent (apoptosis-inducing factor release) pathways, and limited neuronal cell death. In contrast, miRs hairpin inhibitors enhanced etoposide-induced neuronal apoptosis and caspase activation. Importantly, administration of miR-23a and miR-27a mimics significantly reduced activation of Puma, Noxa, and Bax as well as attenuated markers of caspase-dependent and -independent apoptosis after TBI. Furthermore, miR-23a and miR-27a mimics significantly attenuated cortical lesion volume and neuronal cell loss in the hippocampus after TBI. These findings indicate that post-traumatic decreases in miR-23a and miR-27a contribute to neuronal cell death after TBI by upregulating proapoptotic Bcl-2 family members, thus providing a novel therapeutic target.	[Sabirzhanov, Boris; Zhao, Zaorui; Stoica, Bogdan A.; Loane, David J.; Wu, Junfang; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Sabirzhanov, Boris; Zhao, Zaorui; Stoica, Bogdan A.; Loane, David J.; Wu, Junfang; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA; [Borroto, Carlos; Dorsey, Susan G.] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA; [Dorsey, Susan G.; Faden, Alan I.] Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA	Sabirzhanov, B (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, 655 W Baltimore St,Room 6-010, Baltimore, MD 21201 USA.	bsabirzhanov@anes.umm.edu; bstoica@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS061839-05, R01 NR012686]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR012686] Funding Source: NIH RePORTER	This work was supported by NIH Grants RO1 NS061839-05 to A.I.F. and R01 NR012686 to S.G.D. We thank Shruti Kabadi, Marie Hanscom, Marta Lipinski, and Chinmoy Sarkar for expert technical assistance.	Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; GENTLEMAN R, 2005, BIOINFORMATICS COMPU; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Guo Z, 2013, J DERMATOL SCI, V69, P68, DOI 10.1016/j.jdermsci.2012.10.014; Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jimenez-Mateos EM, 2013, NEUROSCIENCE, V238, P218, DOI 10.1016/j.neuroscience.2013.02.027; Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kole AJ, 2011, GENE DEV, V25, P125, DOI 10.1101/gad.1975411; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pietrzak M, 2011, J NEUROCHEM, V117, P1033, DOI 10.1111/j.1471-4159.2011.07279.x; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sabirzhanov B, 2012, J NEUROCHEM, V123, P542, DOI 10.1111/j.1471-4159.2012.07927.x; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Shamas-Din A, 2011, BBA-MOL CELL RES, V1813, P508, DOI 10.1016/j.bbamcr.2010.11.024; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stappert L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059011; Steckley D, 2007, J NEUROSCI, V27, P12989, DOI 10.1523/JNEUROSCI.3400-07.2007; Stoica BA, 2005, MOL CELL NEUROSCI, V29, P355, DOI 10.1016/j.mcn.2005.02.009; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Vousden KH, 2005, SCIENCE, V309, P1685, DOI 10.1126/science.1118232; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yan HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055276; Yang XK, 2012, REPRODUCTION, V144, P235, DOI 10.1530/REP-11-0371; Ziu MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014724	58	97	100	1	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 23	2014	34	30					10055	10071		10.1523/JNEUROSCI.1260-14.2014			17	Neurosciences	Neurosciences & Neurology	AO0LV	WOS:000341001600022	25057207	Green Published, Bronze			2021-06-18	
J	Zanier, ER; Pischiutta, F; Riganti, L; Marchesi, F; Turola, E; Fumagalli, S; Perego, C; Parotto, E; Vinci, P; Veglianese, P; D'Amico, G; Verderio, C; De Simoni, MG				Zanier, Elisa R.; Pischiutta, Francesca; Riganti, Loredana; Marchesi, Federica; Turola, Elena; Fumagalli, Stefano; Perego, Carlo; Parotto, Emanuela; Vinci, Paola; Veglianese, Pietro; D'Amico, Giovanna; Verderio, Claudia; De Simoni, Maria-Grazia			Bone Marrow Mesenchymal Stromal Cells Drive Protective M2 Microglia Polarization After Brain Trauma	NEUROTHERAPEUTICS			English	Article						Traumatic brain injury; Microglia; Macrophages; Mesenchymal stromal cells; Immunomodulation	SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; STEM-CELLS; ALTERNATIVE ACTIVATION; MACROPHAGE PLASTICITY; FUNCTIONAL RECOVERY; RESIDENT MICROGLIA; SURFACE EXPRESSION; PHENOTYPE MARKERS	Microglia/macrophages (M) are major contributors to postinjury inflammation, but they may also promote brain repair in response to specific environmental signals that drive classic (M1) or alternative (M2) polarization. We investigated the activation and functional changes of M in mice with traumatic brain injuries and receiving intracerebroventricular human bone marrow mesenchymal stromal cells (MSCs) or saline infusion. MSCs upregulated Ym1 and Arginase-1 mRNA (p < 0.001), two M2 markers of protective M polarization, at 3 and 7 d postinjury, and increased the number of Ym1(+) cells at 7 d postinjury (p < 0.05). MSCs reduced the presence of the lysosomal activity marker CD68 on the membrane surface of CD11b-positive M (p < 0.05), indicating reduced phagocytosis. MSC-mediated induction of the M2 phenotype in M was associated with early and persistent recovery of neurological functions evaluated up to 35 days postinjury (p < 0.01) and reparative changes of the lesioned microenvironment. In vitro, MSCs directly counteracted the proinflammatory response of primary murine microglia stimulated by tumor necrosis factor-alpha + interleukin 17 or by tumor necrosis factor-alpha + interferon-gamma and induced M2 proregenerative traits, as indicated by the downregulation of inducible nitric oxide synthase and upregulation of Ym1 and CD206 mRNA (p < 0.01). In conclusion, we found evidence that MSCs can drive the M transcriptional environment and induce the acquisition of an early, persistent M2-beneficial phenotype both in vivo and in vitro. Increased Ym1 expression together with reduced in vivo phagocytosis suggests M selection by MSCs towards the M2a subpopulation, which is involved in growth stimulation and tissue repair.	[Zanier, Elisa R.; Pischiutta, Francesca; Marchesi, Federica; Fumagalli, Stefano; Perego, Carlo; Parotto, Emanuela; Veglianese, Pietro; De Simoni, Maria-Grazia] Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, I-20156 Milan, Italy; [Riganti, Loredana; Turola, Elena; Verderio, Claudia] CNR, Inst Neurosci, I-20129 Milan, Italy; [Riganti, Loredana; Turola, Elena] Univ Milan, Dept Biotechnol & Translat Med, I-20129 Milan, Italy; [Fumagalli, Stefano] IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy; [Parotto, Emanuela] Univ Padua, Inst Anesthesia & Intens Care, I-35128 Padua, Italy; [Vinci, Paola; D'Amico, Giovanna] Clin Pediat Univ Milano Bicocca, Osped San Gerardo, Fdn MBBM, Ctr Ric Tettamanti, I-20900 Monza, Italy; [Verderio, Claudia] Humanitas Clin & Res Ctr, I-20089 Milan, Italy	De Simoni, MG (corresponding author), Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, I-20156 Milan, Italy.	c.verderio@in.cnr.it; desimoni@marionegri.it	Perego, Carlo/AAA-6513-2020; Vinci, Paola/AAF-4454-2020; Pischiutta, Francesca/AAA-7927-2020; D'Amico, Giovanna/AAL-3334-2020; De Simoni, Maria Grazia/I-6021-2012; Veglianese, Pietro/AAA-7394-2020; Veglianese, Pietro/R-1871-2019; Zanier, Elisa/AAA-8095-2020; verderio, claudia/K-4415-2016	Perego, Carlo/0000-0002-0259-0003; Pischiutta, Francesca/0000-0002-7151-0812; D'Amico, Giovanna/0000-0001-7809-7269; De Simoni, Maria Grazia/0000-0001-6695-5297; Veglianese, Pietro/0000-0002-0183-9428; Elena, Turola/0000-0002-1810-8648; verderio, claudia/0000-0001-7216-5873; Fumagalli, Stefano/0000-0003-3598-6263; Zanier, Elisa/0000-0002-3011-8718	Progetto ricerca finalizzataMinistry of Health, ItalyMinistry of Health Italy - Ricerca Finalizzata (MOH-RF) [FR-CCM-2008-1248388, FISM2012/R/17]; association "Esserci con Cate per i Bimbi"	This work was supported by Progetto ricerca finalizzata FR-CCM-2008-1248388 and FISM2012/R/17 to C. V. We thank Professor Maria Pia Abbracchio and Dr. Davide Lecca, 20133 University of Milan, for useful discussions; and Ilaria Prada (IN CNR, Milan) for assistance with some of the experiments. We also thank the association "Esserci con Cate per i Bimbi", which supported this work.	Babcock AA, 2003, J NEUROSCI, V23, P7922; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bonilla C, 2009, BRAIN INJURY, V23, P760, DOI 10.1080/02699050903133970; Butovsky O, 2007, MOL CELL NEUROSCI, V35, P490, DOI 10.1016/j.mcn.2007.04.009; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Cho HH, 2009, CELL PHYSIOL BIOCHEM, V24, P511, DOI 10.1159/000257495; Christie KJ, 2013, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00070; CURTIS R, 1991, EUR J NEUROSCI, V3, P876, DOI 10.1111/j.1460-9568.1991.tb00099.x; Dander E, 2012, LEUKEMIA, V26, P1681, DOI 10.1038/leu.2011.384; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Franquesa M, 2013, TRANSPLANTATION, V96, P234, DOI 10.1097/TP.0b013e318298f9fa; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; HOLNESS CL, 1993, BLOOD, V81, P1607; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim YJ, 2009, GLIA, V57, P13, DOI 10.1002/glia.20731; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Madinier A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008101; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; MICKLEM K, 1989, BRIT J HAEMATOL, V73, P6, DOI 10.1111/j.1365-2141.1989.tb00210.x; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Neher JJ, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00027; Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Riglar DT, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2449; Sarnowska A, 2009, EXP NEUROL, V215, P317, DOI 10.1016/j.expneurol.2008.10.023; Sato A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-65; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shechter R, 2013, J PATHOL, V229, P332, DOI 10.1002/path.4106; Si Y, 2010, J CLIN INVEST, V120, P1192, DOI 10.1172/JCI40310; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Stein VM, 2007, J VET MED A, V54, P314, DOI 10.1111/j.1439-0442.2007.00926.x; Travaglione S, 2002, TOXICOL IN VITRO, V16, P405, DOI 10.1016/S0887-2333(02)00028-0; Verderio C, 2012, ANN NEUROL, V72, P610, DOI 10.1002/ana.23627; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Zanier ER, 2013, CNS NEUROSCI THER, V19, P695, DOI 10.1111/cns.12128; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba	60	97	104	2	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JUL	2014	11	3					679	695		10.1007/s13311-014-0277-y			17	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AN1VR	WOS:000340372400021	24965140	Green Published			2021-06-18	
J	Hong, YT; Veenith, T; Dewar, D; Outtrim, JG; Mani, V; Williams, C; Pimlott, S; Hutchinson, PJA; Tavares, A; Canales, R; Mathis, CA; Klunk, WE; Aigbirhio, FI; Coles, JP; Baron, JC; Pickard, JD; Fryer, TD; Stewart, W; Menon, DK				Hong, Young T.; Veenith, Tonny; Dewar, Deborah; Outtrim, Joanne G.; Mani, Vaithianadan; Williams, Claire; Pimlott, Sally; Hutchinson, Peter J. A.; Tavares, Adriana; Canales, Roberto; Mathis, Chester A.; Klunk, William E.; Aigbirhio, Franklin I.; Coles, Jonathan P.; Baron, Jean-Claude; Pickard, John D.; Fryer, Tim D.; Stewart, William; Menon, David K.			Amyloid Imaging With Carbon 11-Labeled Pittsburgh Compound B for Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							HEAD-INJURY; PROTEIN DEPOSITION; ALZHEIMERS-DISEASE; TERM SURVIVORS; BETA; ACCUMULATION; PATHOLOGY; PLAQUES; AXONS; PRESENILIN-1	OBJECTIVES To image amyloid deposition in patients with traumatic brain injury (TBI) using carbon 11-labeled Pittsburgh Compound B ([C-11] PiB) positron emission tomography (PET) and to validate these findings using tritium-labeled PiB ([H-3] PiB) autoradiography and immunocytochemistry in autopsy-acquired tissue. DESIGN, SETTING, AND PARTICIPANTS In vivo PET at tertiary neuroscience referral center and ex vivo immunocytochemistry of autopsy-acquired brain tissue from a neuropathology archive. [C-11] PiB PET was used to image amyloid deposition in 11 controls (median [range] age, 35 [24-60] years) and in 15 patients (median [range] age, 33 [21-50] years) between 1 and 361 days after a TBI. [H-3] PiB autoradiography and immunocytochemistry for beta-amyloid (A beta) and beta-amyloid precursor protein in brain tissue were obtained from separate cohorts of 16 patients (median [range] age, 46 [21-70] years) who died between 3 hours and 56 days after a TBI and 7 controls (median [range] age, 61 [29-71] years) who died of other causes. MAIN OUTCOMES AND MEASURES We quantified the [C-11] PiB distribution volume ratio and standardized uptake value ratio in PET images. The distribution volume ratio and the standardized uptake value ratio were measured in cortical gray matter, white matter, and multiple cortical and white matter regions of interest, as well as in striatal and thalamic regions of interest. We examined [H-3] PiB binding and A beta and beta-amyloid precursor protein immunocytochemistry in autopsy-acquired brain tissue. RESULTS Compared with the controls, the patients with TBI showed significantly increased [C-11] PiB distribution volume ratios in cortical gray matter and the striatum (corrected P <.05 for both), but not in the thalamus or white matter. Increases in [C-11] PiB distribution volume ratios in patients with TBI were seen across most cortical subregions, were replicated using comparisons of standardized uptake value ratios, and could not be accounted for by methodological confounders. Autoradiography revealed [H-3] PiB binding in neocortical gray matter, in regions where amyloid deposition was demonstrated by immunocytochemistry; white matter showed A beta and beta-amyloid precursor protein by immunocytochemistry, but no [H-3] PiB binding. No plaque-associated amyloid immunoreactivity or [H-3] PiB binding was seen in cerebellar gray matter in autopsy-acquired tissue from either controls or patients with TBI, although 1 sample of cerebellar tissue from a patient with TBI showed amyloid angiopathy in meningeal vessels. CONCLUSIONS AND RELEVANCE [C-11] PiB shows increased binding following TBI. The specificity of this binding is supported by neocortical [H-3] PiB binding in regions of amyloid deposition in the postmortem tissue of patients with TBI. [C-11] PiB PET could be valuable in imaging amyloid deposition following TBI.	[Hong, Young T.; Canales, Roberto; Aigbirhio, Franklin I.; Baron, Jean-Claude; Pickard, John D.; Fryer, Tim D.; Menon, David K.] Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; [Veenith, Tonny; Outtrim, Joanne G.; Mani, Vaithianadan; Williams, Claire; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Dewar, Deborah; Tavares, Adriana] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland; [Pimlott, Sally; Stewart, William] Univ Glasgow, Glasgow, Lanark, Scotland; [Pimlott, Sally; Stewart, William] So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland; [Hong, Young T.; Hutchinson, Peter J. A.; Canales, Roberto; Aigbirhio, Franklin I.; Baron, Jean-Claude; Pickard, John D.; Fryer, Tim D.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA; [Mathis, Chester A.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA; [Klunk, William E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Klunk, William E.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Baron, Jean-Claude] Univ Paris 05, INSERM, U894, Sorbonne Paris Cite, Paris, France	Menon, DK (corresponding author), Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Box 93, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Veenith, Tonny/AAI-3067-2020; Pimlott, Sally L/F-8098-2010	Veenith, Tonny/0000-0002-4125-8804; Pimlott, Sally L/0000-0002-8396-3392; Klunk, William/0000-0001-5512-0251; Stewart, William/0000-0003-2199-2582; baron, jean-claude/0000-0002-5264-2588; Outtrim, Joanne/0000-0001-8118-6430; Tavares, Adriana/0000-0001-7505-9144	National Institute for Health Research Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research Council (United Kingdom)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [RG46503]; Academy of Medical SciencesAcademy of Medical Sciences (AMS);  [P50 AG005133];  [R37 AG025516];  [P01 AG025204]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G1000183B, G1002277, G0001354, G0001354B, G0900903] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RF1AG025516, P50AG005133, P01AG025204, R37AG025516] Funding Source: NIH RePORTER	This study was supported by the Neuroscience Theme of the National Institute for Health Research Cambridge Biomedical Research Centre. Drs Menon and Pickard are supported by National Institute for Health Research Senior Investigator awards. Dr Hutchinson is supported by funding from the Academy of Medical Sciences. Radiochemistry development of [<SUP>11</SUP>C] PiB was supported by grant RG46503 from the Medical Research Council (United Kingdom). Data collection in controls was undertaken by funding awarded to Dr Baron by the National Institute for Health Research Cambridge Biomedical Research Centre. Dr Klunk is supported by the following grants: P50 AG005133, R37 AG025516, P01 AG025204.	Cairns NJ, 2009, ARCH NEUROL-CHICAGO, V66, P1557, DOI 10.1001/archneurol.2009.279; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Devanand DP, 2010, J GERIATR PSYCH NEUR, V23, P185, DOI 10.1177/0891988710363715; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fodero-Tavoletti MT, 2009, J NUCL MED, V50, P198, DOI 10.2967/jnumed.108.057984; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Herholz K, 2011, LANCET NEUROL, V10, P667, DOI 10.1016/S1474-4422(11)70123-5; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2012, ACTA NEUROPATHOL, V123, P433, DOI 10.1007/s00401-012-0943-2; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klunk WE, 2007, J NEUROSCI, V27, P6174, DOI 10.1523/JNEUROSCI.0730-07.2007; Landt J, 2011, ARCH NEUROL-CHICAGO, V68, P890, DOI 10.1001/archneurol.2011.36; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; LUCY LB, 1974, ASTRON J, V79, P745, DOI 10.1086/111605; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mintun MA, 2006, NEUROLOGY, V67, P446, DOI 10.1212/01.wnl.0000228230.26044.a4; Morris JC, 2010, ANN NEUROL, V67, P122, DOI 10.1002/ana.21843; RICHARDSON WH, 1972, J OPT SOC AM, V62, P55, DOI 10.1364/JOSA.62.000055; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rosen RF, 2010, ACTA NEUROPATHOL, V119, P221, DOI 10.1007/s00401-009-0583-3; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Stankoff B, 2011, ANN NEUROL, V69, P673, DOI 10.1002/ana.22320; Villemagne VL, 2009, ARCH NEUROL-CHICAGO, V66, P1537, DOI 10.1001/archneurol.2009.285; Whitaker Chastity, 2003, J Alzheimers Dis, V5, P491; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Younkin S G, 1997, Rinsho Shinkeigaku, V37, P1099; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	37	97	99	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JAN	2014	71	1					23	31		10.1001/jamaneurol.2013.4847			9	Clinical Neurology	Neurosciences & Neurology	301YH	WOS:000330567700005	24217171	Green Accepted, Bronze			2021-06-18	
J	Kroshus, E; Daneshvar, DH; Baugh, CM; Nowinski, CJ; Cantu, RC				Kroshus, Emily; Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.; Cantu, Robert C.			NCAA concussion education in ice hockey: an ineffective mandate	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Ice hockey	CHRONIC TRAUMATIC ENCEPHALOPATHY; SOCIAL-SCIENCES THEORIES; FOOTBALL PLAYERS; INJURY; SPORT; KNOWLEDGE; BRAIN; STATEMENT; CONSENSUS; EFFICACY	Background/aim Despite concussion education being increasingly mandated by states and sports leagues, there has been limited evaluation of what education is in fact effective. The National Collegiate Athletic Association (NCAA) currently mandates that institutions provide concussion education, without specifying content or delivery. The present study evaluated the effectiveness of this general mandate, as enacted for male collegiate ice hockey teams within one conference of competition. Methods In a prospective cohort design, 146 players from 6 male collegiate ice hockey teams in one Division 1 conference completed written surveys before and after receiving their institution-determined concussion education. Knowledge, attitudes, perceived norms and behavioural intention were assessed using validated measures. Education content and delivery was assessed by open-ended responses and consultation with team athletic trainers. Results All teams received concussion education material; however, content and delivery varied. Rates of material recall differed by delivery format. Considering all teams together, there were no significant improvements in knowledge and only a very small decrease in intention to continue playing while experiencing symptoms of a concussion. Pre-education and post-education, there were significant between-team differences in attitudes towards concussion reporting and behavioural intention. Conclusions The NCAA's general education mandate was divergently enacted; it did not significantly change the constructs of interest nor did it mitigate the pre-education team differences in these constructs. Existing educational materials should be evaluated, theory and evidence-driven materials developed, and mandates extended to, at a minimum, recommend materials found to be effective in changing concussion-reporting behaviour.	[Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Kroshus, Emily; Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Boston, MA USA; [Baugh, Christine M.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA	Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave,Kresge Bldg 172, Boston, MA 02115 USA.	emk329@mail.harvard.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513	National Collegiate Athletic Association (NCAA)	National Collegiate Athletic Association (NCAA) 2012-2013 Graduate Student Research Grant.	Ajzen I., 1980, UNDERSTANDING ATTITU, V278; Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Foundation TNAoN Association NAT, 2010, CONC SPORTS; Gielen AC, 2003, EPIDEMIOL REV, V25, P65, DOI 10.1093/epirev/mxg004; Glasgow RE, 2003, AM J PUBLIC HEALTH, V93, P1261, DOI 10.2105/AJPH.93.8.1261; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; NCAA, 2012, CONC FACT SHEET STUD; NCAA, 2011, 2011 12 NCAA SPORTS; NFL, 2012, LYST LAW OV; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Saldana J., 2016, CODING MANUAL QUALIT; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Talavage TM, 2012, NEUROIMAGE, V62, P641, DOI 10.1016/j.neuroimage.2012.01.006; Trifiletti LB, 2005, HEALTH EDUC RES, V20, P298, DOI 10.1093/her/cyg126; Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	52	97	98	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					135	U146		10.1136/bjsports-2013-092498			7	Sport Sciences	Sport Sciences	276KK	WOS:000328749000016	23956336				2021-06-18	
J	Tajiri, N; Acosta, SA; Shahaduzzaman, M; Ishikawa, H; Shinozuka, K; Pabon, M; Hernandez-Ontiveros, D; Kim, DW; Metcalf, C; Staples, M; Dailey, T; Vasconcellos, J; Franyuti, G; Gould, L; Patel, N; Cooper, D; Kaneko, Y; Borlongan, CV; Bickford, PC				Tajiri, Naoki; Acosta, Sandra A.; Shahaduzzaman, Md; Ishikawa, Hiroto; Shinozuka, Kazutaka; Pabon, Mibel; Hernandez-Ontiveros, Diana; Kim, Dae Won; Metcalf, Christopher; Staples, Meaghan; Dailey, Travis; Vasconcellos, Julie; Franyuti, Giorgio; Gould, Lisa; Patel, Niketa; Cooper, Denise; Kaneko, Yuji; Borlongan, Cesar V.; Bickford, Paula C.			Intravenous Transplants of Human Adipose-Derived Stem Cell Protect the Brain from Traumatic Brain Injury-Induced Neurodegeneration and Motor and Cognitive Impairments: Cell Graft Biodistribution and Soluble Factors in Young and Aged Rats	JOURNAL OF NEUROSCIENCE			English	Article						aging; brain injury; stem cell	LONG NONCODING RNAS; CONTROLLED CORTICAL IMPACT; NEURAL STEM; CONDITIONED MEDIUM; PARKINSONS-DISEASE; TISSUE INHIBITOR; PROGENITOR CELLS; THERAPY; ADULT; DIFFERENTIATION	Traumatic brain injury (TBI) survivors exhibit motor and cognitive symptoms from the primary injury that can become aggravated over time because of secondary cell death. In the present in vivo study, we examined the beneficial effects of human adipose-derived stem cells (hADSCs) in a controlled cortical impact model of mild TBI using young (6 months) and aged (20 months) F344 rats. Animals were transplanted intravenously with 4 X 10(6) hADSCs (Tx), conditioned media (CM), or vehicle (unconditioned media) at 3 h after TBI. Significant amelioration of motor and cognitive functions was revealed in young, but not aged, Tx and CM groups. Fluorescent imaging in vivo and ex vivo revealed 1,1' dioactadecyl-3-3-3',3'-tetramethylindotricarbocyanine iodide-labeled hADSCs in peripheral organs and brain after TBI. Spatiotemporal deposition of hADSCs differed between young and aged rats, most notably reduced migration to the aged spleen. Significant reduction in cortical damage and hippocampal cell loss was observed in both Tx and CM groups in young rats, whereas less neuroprotection was detected in the aged rats and mainly in the Tx group but not the CM group. CM harvested from hADSCs with silencing of either NEAT1 (nuclear enriched abundant transcript 1) or MALAT1 (metastasis associated lung adenocarcinoma transcript 1), long noncoding RNAs (lncRNAs) known to play a role in gene expression, lost the efficacy in our model. Altogether, hADSCs are promising therapeutic cells for TBI, and lncRNAs in the secretome is an important mechanism of cell therapy. Furthermore, hADSCs showed reduced efficacy in aged rats, which may in part result from decreased homing of the cells to the spleen.	[Tajiri, Naoki; Acosta, Sandra A.; Shahaduzzaman, Md; Ishikawa, Hiroto; Shinozuka, Kazutaka; Pabon, Mibel; Hernandez-Ontiveros, Diana; Kim, Dae Won; Metcalf, Christopher; Staples, Meaghan; Dailey, Travis; Vasconcellos, Julie; Franyuti, Giorgio; Kaneko, Yuji; Borlongan, Cesar V.; Bickford, Paula C.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; [Tajiri, Naoki] Univ S Florida, Morsani Coll Med, Sch Phys Therapy & Rehabil Sci, Tampa, FL 33612 USA; [Shahaduzzaman, Md; Gould, Lisa; Patel, Niketa; Cooper, Denise; Bickford, Paula C.] James A Haley Vet Affairs Hosp, Res Serv, Tampa, FL 33612 USA; [Hernandez-Ontiveros, Diana; Gould, Lisa; Borlongan, Cesar V.; Bickford, Paula C.] Univ S Florida, Morsani Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33612 USA; [Patel, Niketa; Cooper, Denise] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA	Borlongan, CV (corresponding author), Univ S Florida, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Denise.cooper@va.gov; ykaneko@health.usf.edu; cborlong@health.usf.edu; pbickfor@health.usf.edu	Borlongan, Cesar/I-5696-2012; Bickford, Paula C/J-5970-2012	Borlongan, Cesar/0000-0002-2966-9782; Bickford, Paula C/0000-0001-9657-7725; Patel, Niketa A./0000-0003-4811-8596; Shinozuka, Kazutaka/0000-0002-6435-4460; Ishikawa, Hiroto/0000-0003-0760-7203; Franyuti Kelly, Giorgio Alberto/0000-0002-7173-7339	National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke Grant [1R01NS071956-01]; Department of Defense GrantUnited States Department of Defense [W81XWH1110634]; James and Esther King Foundation for Biomedical Research Program Grant [1KG01-33966]; SanBio; Celgene Cellular TherapeuticsCelgene Corporation; KM Pharmaceutical Consulting LLC; NeuralStem; Veterans Affairs Medical Research ServiceUS Department of Veterans Affairs; NIH/National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1PO1AG-04418-27, 1R01 AG044919]; Michael J. Fox Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG004418, R01AG044919] Funding Source: NIH RePORTER	C.V.B. is supported by National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke Grant 1R01NS071956-01, Department of Defense Grant W81XWH1110634, James and Esther King Foundation for Biomedical Research Program Grant 1KG01-33966, SanBio, Celgene Cellular Therapeutics, KM Pharmaceutical Consulting LLC and NeuralStem. P.C.B. is supported by Veterans Affairs Medical Research Service, NIH/National Institute on Aging Grants 1PO1AG-04418-27 and 1R01 AG044919, and the Michael J. Fox Foundation.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002; Baek SJ, 2011, EXP MOL MED, V43, P596, DOI 10.3858/emm.2011.43.10.069; Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Bjugstad KB, 2008, EXP NEUROL, V211, P362, DOI 10.1016/j.expneurol.2008.01.025; Blaber SP, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-172; Boddington Sophie, 2008, J Vis Exp, DOI 10.3791/686; Bond CS, 2009, J CELL BIOL, V186, P637, DOI 10.1083/jcb.200906113; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Borlongan CV, 1998, NEUROREPORT, V9, P3615, DOI 10.1097/00001756-199811160-00012; Carlson ME, 2007, AGING CELL, V6, P371, DOI 10.1111/j.1474-9726.2007.00286.x; Cho YJ, 2012, J NEUROSCI RES, V90, P1794, DOI 10.1002/jnr.23063; Clarkson ED, 2001, DRUG AGING, V18, P773, DOI 10.2165/00002512-200118100-00006; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Darkazalli A, 2012, HISTOL HISTOPATHOL, V27, P1255, DOI 10.14670/HH-27.1255; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Detante O, 2009, CELL TRANSPLANT, V18, P1369, DOI 10.3727/096368909X474230; Egashira Y, 2012, BRAIN RES, V1461, P87, DOI 10.1016/j.brainres.2012.04.033; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox AH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000687; Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hawkins BE, 2013, BRAIN RES, V1496, P28, DOI 10.1016/j.brainres.2012.12.027; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Ibrahim AG, 2009, EXP NEUROL, V215, P142, DOI 10.1016/j.expneurol.2008.09.023; Ikegame Y, 2011, CYTOTHERAPY, V13, P675, DOI 10.3109/14653249.2010.549122; Isacson O, 2001, PARKINSONISM RELAT D, V7, P205, DOI 10.1016/S1353-8020(00)00059-6; Jang YY, 2011, MOL IMAGING, V10, P111, DOI 10.2310/7290.2010.00046; Katsuda T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01197; Kim WS, 2007, J DERMATOL SCI, V48, P15, DOI 10.1016/j.jdermsci.2007.05.018; Lee P, 2012, EXP NEUROL, V234, P50, DOI 10.1016/j.expneurol.2011.12.016; Lefebvre JS, 2012, AGING CELL, V11, P732, DOI 10.1111/j.1474-9726.2012.00836.x; Lendeckel S, 2004, J CRANIO MAXILL SURG, V32, P370, DOI 10.1016/j.jcms.2004.06.002; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Liu YP, 2009, ACTA NEUROPATHOL, V117, P469, DOI 10.1007/s00401-009-0516-1; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; McDonald KG, 2011, IMMUN AGEING, V8, DOI 10.1186/1742-4933-8-1; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Mizuno H, 2012, STEM CELLS, V30, P804, DOI 10.1002/stem.1076; Muraoka K, 2008, J NEUROSURG, V108, P149, DOI 10.3171/JNS/2008/108/01/0149; Naganuma T, 2013, RNA BIOL, V10, P456, DOI 10.4161/rna.23547; Nakagawa S, 2012, CELL MOL LIFE SCI, V69, P3027, DOI 10.1007/s00018-012-0973-x; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Ribeiro CA, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt109; Sasaki YTF, 2009, P NATL ACAD SCI USA, V106, P2525, DOI 10.1073/pnas.0807899106; Singer NG, 2011, ANNU REV PATHOL-MECH, V6, P457, DOI 10.1146/annurev-pathol-011110-130230; SOLANTO MV, 1984, PSYCHOL BULL, V95, P387; Spadaro Paola A., 2012, Frontiers in Genetics, V3, P132, DOI 10.3389/fgene.2012.00132; Sugiyama T, 2011, NEUROSURGERY, V68, P1036, DOI 10.1227/NEU.0b013e318208f891; Sun J, 2012, CELLS TISSUES ORGANS, V196, P510, DOI 10.1159/000339245; Ushiki T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011114; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035; Yang M, 2003, CELL MOL NEUROBIOL, V23, P851, DOI 10.1023/A:1025017423102; Yao J, 2012, REJUV RES, V15, P495, DOI 10.1089/rej.2012.1325; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang B, 2012, CELL REP, V2, P111, DOI 10.1016/j.celrep.2012.06.003	69	97	102	0	24	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JAN 1	2014	34	1					313	326		10.1523/JNEUROSCI.2425-13.2014			14	Neurosciences	Neurosciences & Neurology	282NE	WOS:000329177800030	24381292	Green Published, Bronze			2021-06-18	
J	Jadischke, R; Viano, DC; Dau, N; King, AI; McCarthy, J				Jadischke, Ron; Viano, David C.; Dau, Nathan; King, Albert I.; McCarthy, Joe			On the accuracy of the Head Impact Telemetry (HIT) System used in football helmets	JOURNAL OF BIOMECHANICS			English	Article						HIT system; Football helmets; Head acceleration; Measurement errors; Head/helmet contact pressure; Hybrid III dummy; Volunteer testing	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; CONCUSSION; PERFORMANCE; ACCELERATION; PLAYERS	On-field measurement of head impacts has relied on the Head Impact Telemetry (HIT) System, which uses helmet mounted accelerometers to determine linear and angular head accelerations. HIT is used in youth and collegiate football to assess the frequency and severity of helmet impacts. This paper evaluates the accuracy of HIT for individual head impacts. Most HIT validations used a medium helmet on a Hybrid III head. However, the appropriate helmet is large based on the Hybrid III head circumference (58 cm) and manufacturer's fitting instructions. An instrumented skull cap was used to measure the pressure between the head of football players (n=63) and their helmet. The average pressure with a large helmet on the Hybrid III was comparable to the average pressure from helmets used by players. A medium helmet on the Hybrid III produced average pressures greater than the 99th percentile volunteer pressure level. Linear impactor tests were conducted using a large and medium helmet on the Hybrid III. Testing was conducted by two independent laboratories. HIT data were compared to data from the Hybrid III equipped with a 3-2-2-2 accelerometer array. The absolute and root mean square error (RMSE) for HIT were computed for each impact (n=90). Fifty-five percent (n=49) had an absolute error greater than 15% while the RMSE was 59.1% for peak linear acceleration. (C) 2013 Elsevier Ltd. All rights reserved.	[Jadischke, Ron; Viano, David C.; Dau, Nathan; King, Albert I.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Jadischke, Ron; McCarthy, Joe] McCarthy Engn Inc, Windsor, ON N9C 4E4, Canada	King, AI (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA.	king@rrb.eng.wayne.edu			Department of Biomedical Engineering of Wayne State University; NFL	The first series of tests was supported by the Department of Biomedical Engineering of Wayne State University. The authors would like to express gratitude to Dr. Cindy Bir for the use the Sports Biomechanics Lab. The authors also appreciate the efforts of Chris Withnall and Michael Wonnacott at Biokinetics & Associates, Ltd., Ottawa, Canada, for their testing of the HIT in the second test series, which was sponsored by the NFL. Dr. Viano was co-chair of the MTBI Committee at the NFL during the second series of tests. The testing reported in this paper was designed to independently evaluate the HIT system, using a new method of determining the proper size of helmets used by football players. All testing were completed by December 2010.	Armstrong S., 1992, INT J FORECASTING, V8, P69; Backaitis S.H. Mertz H.J., 1994, SAE BOOK; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J., 2007, 51 ANN P ASS ADV AUT, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hyndman RJ, 2006, INT J FORECASTING, V22, P679, DOI 10.1016/j.ijforecast.2006.03.001; Jadischke R., 2012, THESIS WAYNE STATE U; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Viano D.C., 2012, BRAIN INJURY MED; Viano D.C., 2011, COMP HIT HELMET SYST; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	23	97	97	0	40	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	SEP 3	2013	46	13					2310	2315		10.1016/j.jbiomech.2013.05.030			6	Biophysics; Engineering, Biomedical	Biophysics; Engineering	225NL	WOS:000324969500030	23891566				2021-06-18	
J	Lipton, ML; Kim, N; Park, YK; Hulkower, MB; Gardin, TM; Shifteh, K; Kim, M; Zimmerman, ME; Lipton, RB; Branch, CA				Lipton, Michael L.; Kim, Namhee; Park, Young K.; Hulkower, Miriam B.; Gardin, Tova M.; Shifteh, Keivan; Kim, Mimi; Zimmerman, Molly E.; Lipton, Richard B.; Branch, Craig A.			Robust detection of traumatic axonal injury in individual mild traumatic brain injury patients: Intersubject variation, change over time and bidirectional changes in anisotropy	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury (mTBI); MRI; Diffusion tensor imaging (DTI); Traumatic axonal injury (TAI); Image processing and analysis	TENSOR IMAGING DETECTS; WHITE-MATTER INTEGRITY; MOUSE MODEL; EXECUTIVE DYSFUNCTION; REGISTRATION; MODERATE; DAMAGE; ABNORMALITIES; PATHOGENESIS; IMPAIRMENT	To identify and characterize otherwise occult inter-individual spatial variation of white matter abnormalities across mild traumatic brain injury (mTBI) patients. After informed consent and in compliance with Health Insurance Portability and Accountability Act (HIPAA), Diffusion tensor imaging (DTI) was performed on a 3.0 T MR scanner in 34 mTBI patients (19 women; 19-64 years old) and 30 healthy control subjects. The patients were imaged within 2 weeks of injury, 3 months after injury, and 6 months after injury. Fractional anisotropy (FA) images were analyzed in each patient. To examine white matter diffusion abnormalities across the entire brain of individual patients, we applied Enhanced Z-score Microstructural Assessment for Pathology (EZ-MAP), a voxelwise analysis optimized for the assessment of individual subjects. Our analysis revealed areas of abnormally low or high FA (voxel-wise P-value < 0.05, cluster-wise P-value < 0.01(corrected for multiple comparisons)). The spatial pattern of white matter FA abnormalities varied among patients. Areas of low FA were consistent with known patterns of traumatic axonal injury. Areas of high FA were most frequently detected in the deep and subcortical white matter of the frontal, parietal, and temporal lobes, and in the anterior portions of the corpus callosum. The number of both abnormally low and high FA voxels changed during follow up. Individual subject assessments reveal unique spatial patterns of white matter abnormalities in each patient, attributable to inter-individual differences in anatomy, vulnerability to injury and mechanism of injury. Implications of high FA remain unclear, but may evidence a compensatory mechanism or plasticity in response to injury, rather than a direct manifestation of brain injury.	[Lipton, Michael L.; Kim, Namhee; Park, Young K.; Hulkower, Miriam B.; Gardin, Tova M.; Branch, Craig A.] Yeshiva Univ, Gruss Magnet Resonance Res Ctr, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Lipton, Michael L.; Kim, Namhee; Branch, Craig A.] Yeshiva Univ, Dept Radiol, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Lipton, Michael L.] Yeshiva Univ, Dept Psychiat & Behav Sci, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Lipton, Michael L.] Yeshiva Univ, Dominick P Purpura Dept Neurosci, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Kim, Mimi; Lipton, Richard B.] Yeshiva Univ, Dept Epidemiol & Populat Hlth, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Zimmerman, Molly E.; Lipton, Richard B.] Yeshiva Univ, Saul R Korey Dept Neurol, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Branch, Craig A.] Yeshiva Univ, Dept Physiol & Biophys, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Lipton, Michael L.; Gardin, Tova M.; Shifteh, Keivan] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA	Lipton, ML (corresponding author), Yeshiva Univ, Gruss Magnet Resonance Res Ctr, Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	michael.lipton@einstein.yu.edu	Lipton, Richard B/B-5060-2011				Ardekani BA, 2005, J NEUROSCI METH, V142, P67, DOI 10.1016/j.jneumeth.2004.07.014; ARDEKANI BA, 1995, J COMPUT ASSIST TOMO, V19, P615, DOI 10.1097/00004728-199507000-00022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler E. D, 2012, BRAIN IMAGING BEHAV; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kim N., 2011, ISMRM 19 ANN M EXH M; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lim KO, 2006, AM J PSYCHIAT, V163, P2008, DOI 10.1176/appi.ajp.163.11.2008; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Muller HP, 2009, MAGN RESON IMAGING, V27, P324, DOI 10.1016/j.mri.2008.07.003; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K, 2010, JHU MNI SS ATLAS; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Poupon C, 2000, NEUROIMAGE, V12, P184, DOI 10.1006/nimg.2000.0607; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rosenbaum S. B., 2012, BRAIN IMAGING BEHAV; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton M. E., 2012, BRAIN IMAGING BEHAV; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Wang SL, 2009, CANCER RES, V69, P1190, DOI 10.1158/0008-5472.CAN-08-2661	50	97	101	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557			BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		329	342		10.1007/s11682-012-9175-2			14	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900012	22684769				2021-06-18	
J	Nishijima, DK; Offerman, SR; Ballard, DW; Vinson, DR; Chettipally, UK; Rauchwerger, AS; Reed, ME; Holmes, JF				Nishijima, Daniel K.; Offerman, Steven R.; Ballard, Dustin W.; Vinson, David R.; Chettipally, Uli K.; Rauchwerger, Adina S.; Reed, Mary E.; Holmes, James F.		CREST Network	Immediate and Delayed Traumatic Intracranial Hemorrhage in Patients With Head Trauma and Preinjury Warfarin or Clopidogrel Use	ANNALS OF EMERGENCY MEDICINE			English	Article							NEW-ORLEANS CRITERIA; BRAIN-INJURY; ANTICOAGULATED PATIENTS; COMATOSE PATIENTS; CT; MORTALITY; HEMATOMA; RISK; RULE; COMPLICATIONS	Study objective: Patients receiving warfarin or clopidogrel are considered at increased risk for traumatic intracranial hemorrhage after blunt head trauma. The prevalence of immediate traumatic intracranial hemorrhage and the cumulative incidence of delayed traumatic intracranial hemorrhage in these patients, however, are unknown. The objective of this study is to address these gaps in knowledge. Methods: A prospective, observational study at 2 trauma centers and 4 community hospitals enrolled emergency department (ED) patients with blunt head trauma and preinjury warfarin or clopidogrel use from April 2009 through January 2011. Patients were followed for 2 weeks. The prevalence of immediate traumatic intracranial hemorrhage and the cumulative incidence of delayed traumatic intracranial hemorrhage were calculated from patients who received initial cranial computed tomography (CT) in the ED. Delayed traumatic intracranial hemorrhage was defined as traumatic intracranial hemorrhage within 2 weeks after an initially normal CT scan result and in the absence of repeated head trauma. Results: A total of 1,064 patients were enrolled (768 warfarin patients [72.2%] and 296 clopidogrel patients [27.8%]). There were 364 patients (34.2%) from Level I or II trauma centers and 700 patients (65.8%) from community hospitals. One thousand patients received a cranial CT scan in the ED. Both warfarin and clopidogrel groups had similar demographic and clinical characteristics, although concomitant aspirin use was more prevalent among patients receiving clopidogrel. The prevalence of immediate traumatic intracranial hemorrhage was higher in patients receiving clopidogrel (33/276, 12.0%; 95% confidence interval [Cl] 8.4% to 16.4%) than patients receiving warfarin (37/724, 5.1%; 95% Cl 3.6% to 7.0%), relative risk 2.31 (95% Cl 1.48 to 3.63). Delayed traumatic intracranial hemorrhage was identified in 4 of 687 (0.6%; 95% Cl 0.2% to 1.5%) patients receiving warfarin and 0 of 243 (0%; 95% Cl 0% to 1.5%) patients receiving clopidogrel. Conclusion: Although there may be unmeasured confounders that limit intergroup comparison, patients receiving clopidogrel have a significantly higher prevalence of immediate traumatic intracranial hemorrhage compared with patients receiving warfarin. Delayed traumatic intracranial hemorrhage is rare and occurred only in patients receiving warfarin. Discharging patients receiving anticoagulant or antiplatelet medications from the ED after a normal cranial CT scan result is reasonable, but appropriate instructions are required because delayed traumatic intracranial hemorrhage may occur. [Ann Emerg Med. 2012;59:460-468.]	[Nishijima, Daniel K.; Holmes, James F.] UC Davis Sch Med, Dept Emergency Med, Sacramento, CA USA; [Offerman, Steven R.] Kaiser Permanente, S Sacramento Med Ctr, Sacramento, CA USA; [Ballard, Dustin W.] Kaiser Permanente, San Rafael Med Ctr & Med Off, San Rafael, CA USA; [Vinson, David R.] Kaiser Permanente, Sacramento Med Ctr & Med Off, Sacramento, CA USA; [Chettipally, Uli K.] Kaiser Permanente, S San Francisco Med Ctr & Med Off, San Francisco, CA USA; [Rauchwerger, Adina S.; Reed, Mary E.] Kaiser Permanente, Div Res, Oakland, CA USA	Nishijima, DK (corresponding author), UC Davis Sch Med, Dept Emergency Med, Sacramento, CA USA.	daniel.nishijima@ucdmc.ucdavis.edu	Vinson, David R/AAK-3227-2020	Vinson, David R/0000-0001-6559-1858; Rauchwerger, Adina/0000-0002-6329-6836	Garfield Memorial Fund (Kaiser Permanente); Mentored Clinical Research Training Program Award [K30, KL2]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024146]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024146] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This work was supported by the Garfield Memorial Fund (Kaiser Permanente). Dr. Nishijima was supported through a Mentored Clinical Research Training Program Award (K30 and KL2), grant UL1 RR024146 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The Garfield Memorial Fund, NCRR, and NIH had no role in the design and conduct of the study, in the analysis or interpretation of the data, or in the preparation of the data.	Quintero-Gonzalez JA, 2010, INVEST CLIN, V51, P269; [Anonymous], HEAD INJ TRIAG ASS I; Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; Claudia C, 2011, J TRAUMA, V70, P906, DOI 10.1097/TA.0b013e3182031ab7; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Coimbra R, 2005, J TRAUMA, V59, P374, DOI 10.1097/01.ta.000174728.46883.a4; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hensrud DD, 1999, MAYO CLIN PROC, V74, P443; IMS, TOP 20 GLOB PROD 201; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Major J, 2009, EMERG MED J, V26, P871, DOI 10.1136/emj.2008.068643; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Ostini R, 2008, PHARMACOEPIDEM DR S, V17, P1077, DOI 10.1002/pds.1638; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; POON WS, 1992, NEUROSURGERY, V30, P681; Quinn J, 2008, WEST J EMERG MED, V9, P6; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Virjo I, 2010, SCAND J PRIM HEALTH, V28, P237, DOI 10.3109/02813432.2010.514138; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	40	97	97	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUN	2012	59	6					460	468		10.1016/j.annemergmed.2012.04.007			9	Emergency Medicine	Emergency Medicine	959HA	WOS:000305302300005	22626015	Green Accepted			2021-06-18	
J	Kimpara, H; Iwamoto, M				Kimpara, Hideyuki; Iwamoto, Masami			Mild Traumatic Brain Injury Predictors Based on Angular Accelerations During Impacts	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Traumatic brain injury; Acceleration; Rotation; Injury; Injury criterion; Finite Element model; Head; Brain	AXONAL INJURY; HEAD IMPACTS; TOLERANCE; FOOTBALL; CONCUSSION; STRAIN	Although Head Injury Criterion (HIC) is an effective criterion for head injuries caused by linear acceleration such as skull fractures, no criteria for head injuries caused by rotational kinematics has been accepted as effective so far. This study proposed two criteria based on angular accelerations for Traumatic Brain Injury (TBI), which we call Rotational Injury Criterion (RIC) and Power Rotational Head Injury Criterion (PRHIC). Concussive and non-concussive head acceleration data obtained from football head impacts were utilized to develop new injury criteria. A well-validated human brain Finite Element (FE) model was employed to find out effective injury criteria for TBI. Correlation analyses were performed between the proposed criteria and FE-based brain injury predictors such as Cumulative Strain Damage Measure (CSDM), which is defined as the percent volume of the brain that exceeds a specified first principal strain threshold, proposed to predict Diffuse Axonal Injury (DAI) which is one of TBI. The RIC was significantly correlated with the CSDMs with the strain thresholds of less than 15% (R > 0.89), which might predict mild TBI. In addition, PRHIC was also strongly correlated with the CSDMs with the strain thresholds equal to or greater than 20% (R > 0.90), which might predict more severe TBI.	[Kimpara, Hideyuki; Iwamoto, Masami] Toyota Cent Res & Dev Labs Inc, Vehicle Safety & Biomech Lab, Nagakute, Aichi 4801192, Japan	Kimpara, H (corresponding author), Toyota Cent Res & Dev Labs Inc, Vehicle Safety & Biomech Lab, 41-1 Yokomichi, Nagakute, Aichi 4801192, Japan.	h-kimpara@mosk.tytlabs.co.jp	Kimpara, Hideyuki/W-9542-2019	Kimpara, Hideyuki/0000-0001-6441-6062	THUMS(TM)	The THUMS (TM) has been developed by Toyota Central R&D Labs., Inc. (TCRDL) and Toyota Motor Corporation (TMC) in conjunctions with the Wayne State University (WSU). The authors work for TCRDL which has a financial interest in the THUMS (TM). However, there is no financial interest in the basic ideas of this study regarding RIC and PRHIC.	Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Dokko Y., 2003, P 18 INT TECHN C ENH; Donnelly B. R., 1983, P 27 STAPP CAR CRASH; Ewing C. L., 1975, P 19 STAPP CAR CRASH; Feist F., 2009, P 21 INT TECHN C ENH, P15; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Gadd CW, 1966, P 10 STAPP CAR CRASH; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hertz E, 1993, 37 ANN P ASS ADV AUT, P303; Kimpara H., 2011, INT J AUTOMOT ENG, V2, P13; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; King A.I., 2003, P INT RES C BIOM IMP; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LOWENHIELM P, 1974, Z RECHTSMED, V75, P131, DOI 10.1007/BF02114709; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Nahum A. M., 1977, P 21 STAPP CAR CRASH; NAKAHIRA Y, 2000, P IRCOBI C, P147; Newman J A, 2000, Stapp Car Crash J, V44, P215; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; Patrick L. M., 1963, P 7 STAPP CAR CRASH, P483; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PRASAD P, 1985, 851246 SAE; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts E.G., 2011, 22 INT TECHN C ENH S; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tamura A, 2007, STAPP CAR CRASH JO, V51, P139; Thibault L. E., 1985, 10 INT TECHN C EXP S; Trosseille X., 1992, P 36 STAPP CAR CRASH; Versace J., 1971, REV SEVERITY INDEX; VIANO DC, 1999, CRASH PREV INJ CONTR, V1, P35; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261	37	97	99	0	31	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		114	126		10.1007/s10439-011-0414-2			13	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700011	21994065				2021-06-18	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			The Salutary Effects of DHA Dietary Supplementation on Cognition, Neuroplasticity, and Membrane Homeostasis after Brain Trauma	JOURNAL OF NEUROTRAUMA			English	Article						brain-derived neurotrophic factor; plasticity; Sir2; superoxide dismutase; traumatic brain injury	LONG-TERM POTENTIATION; PROTEIN-KINASE-II; DOCOSAHEXAENOIC ACID; NEUROTROPHIC FACTOR; MOUSE MODEL; PHOSPHOLIPID DEGRADATION; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; NEURITE OUTGROWTH	The pathology of traumatic brain injury (TBI) is characterized by the decreased capacity of neurons to metabolize energy and sustain synaptic function, likely resulting in cognitive and emotional disorders. Based on the broad nature of the pathology, we have assessed the potential of the omega-3 fatty acid docosahexaenoic acid (DHA) to counteract the effects of concussive injury on important aspects of neuronal function and cognition. Fluid percussion injury (FPI) or sham injury was performed, and rats were then maintained on a diet high in DHA (1.2% DHA) for 12 days. We found that DHA supplementation, which elevates brain DHA content, normalized levels of brain-derived neurotrophic factor (BDNF), synapsin I (Syn-1), cAMP-responsive element-binding protein (CREB), and calcium/calmodulin-dependent kinase II (CaMKII), and improved learning ability in FPI rats. It is known that BDNF facilitates synaptic transmission and learning ability by modulating Syn-I, CREB, and CaMKII signaling. The DHA diet also counteracted the FPI-reduced manganese superoxide dismutase (SOD) and Sir2 (a NAD+-dependent deacetylase). Given the involvement of SOD and Sir2 in promoting metabolic homeostasis, DHA may help the injured brain by providing resistance to oxidative stress. Furthermore, DHA normalized levels of calcium-independent phospholipase A2 (iPLA2) and syntaxin-3, which may help preserve membrane homeostasis and function after FPI. The overall results emphasize the potential of dietary DHA to counteract broad and fundamental aspects of TBI pathology that may translate into preserved cognitive capacity.	[Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465]	This study was supported by NIH award NS50465.	Adasme T, 2011, P NATL ACAD SCI USA, V108, P3029, DOI 10.1073/pnas.1013580108; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calon F, 2005, EUR J NEUROSCI, V22, P617, DOI 10.1111/j.1460-9568.2005.04253.x; Cansev M, 2007, NEUROSCIENCE, V148, P421, DOI 10.1016/j.neuroscience.2007.06.016; Cesca F, 2010, PROG NEUROBIOL, V91, P313, DOI 10.1016/j.pneurobio.2010.04.006; Chytrova G, 2010, BRAIN RES, V1341, P32, DOI 10.1016/j.brainres.2009.05.018; Darios F, 2006, NATURE, V440, P813, DOI 10.1038/nature04598; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Elgersma Y, 2004, J NEUROSCI, V24, P8410, DOI 10.1523/JNEUROSCI.3622-04.2004; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; FAROOQUI AA, 1994, INT REV NEUROBIOL, V36, P267, DOI 10.1016/S0074-7742(08)60306-2; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fornasiero EF, 2010, CELL MOL LIFE SCI, V67, P1383, DOI 10.1007/s00018-009-0227-8; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hashimoto M, 2002, J NEUROCHEM, V81, P1084, DOI 10.1046/j.1471-4159.2002.00905.x; HASHIMOTO M, 2011, J PHARM SCI IN PRESS; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Homayoun P, 1997, J NEUROCHEM, V69, P199; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kenney JW, 2008, MOL NEUROBIOL, V38, P101, DOI 10.1007/s12035-008-8037-9; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Martel MA, 2006, EUR J NEUROSCI, V23, P505, DOI 10.1111/j.1460-9568.2005.04565.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Pillay NS, 2005, ANN NY ACAD SCI, V1056, P450, DOI 10.1196/annals.1352.021; Riedel G, 1999, NAT NEUROSCI, V2, P898; Sajikumar S, 2011, P NATL ACAD SCI USA, V108, P2551, DOI 10.1073/pnas.1016849108; Sato T, 2007, EUR J PHARMACOL, V560, P36, DOI 10.1016/j.ejphar.2007.01.011; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Tanaka JI, 2008, SCIENCE, V319, P1683, DOI 10.1126/science.1152864; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Wang SW, 2011, J NEUROSCI, V31, P7275, DOI 10.1523/JNEUROSCI.6476-10.2011; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wolf MJ, 1995, FEBS LETT, V377, P358, DOI 10.1016/0014-5793(95)01371-7; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002	44	97	98	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2113	2122		10.1089/neu.2011.1872			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500012	21851229	Green Published			2021-06-18	
J	Hart, T; Brenner, L; Clark, AN; Bogner, JA; Novack, TA; Chervoneva, I; Nakase-Richardson, R; Arango-Lasprilla, JC				Hart, Tessa; Brenner, Lisa; Clark, Allison N.; Bogner, Jennifer A.; Novack, Thomas A.; Chervoneva, Inna; Nakase-Richardson, Risa; Arango-Lasprilla, Juan Carlos			Major and Minor Depression After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Rehabilitation	GLASGOW OUTCOME SCALE; NATIONAL COMORBIDITY SURVEY; HEAD-INJURY; PARTICIPATION ASSESSMENT; SERVICE UTILIZATION; SYSTEMATIC BIAS; 1ST YEAR; MILD; COMMUNITY; SYMPTOMS	Hart T, Brenner L, Clark AN, Bogner JA, Novack TA, Chervoneva I, Nakase-Richardson R, Arango-Lasprilla JC. Major and minor depression after traumatic brain injury. Arch Phys Med Rehabil 2011;92:1211-9. Objective: To examine minor as well as major depression at 1 year posttraumatic brain injury (TB!), with particular attention to the contribution of depression severity to levels of societal participation. Design: Observational prospective study with a 2-wave longitudinal component. Setting: Inpatient rehabilitation centers, with 1-year follow up conducted primarily by telephone. Participants: Persons with TBI (N=1570) enrolled in the TBI Model System database and followed up at I-year postinjury. Interventions: Not applicable. Main Outcome Measures: FIM, Patient Health Questionnaire-9, Participation Assessment with Recombined Tools-Objective, Glasgow Outcome Scale-Extended, and the Satisfaction With Life Scale. Results: Twenty-two percent of the sample reported minor depression, and 26% reported major depression at 1-year post-TBI. Both levels of depression were associated with sex (women), age (younger), preinjury mental health treatment and substance abuse, and cause of injury (intentional). There was a monotonic dose-response relationship between severity of depression and all 1-year outcomes studied, including level of cognitive and physical disability, global outcome, and satisfaction with life. With other predictors controlled, depression severity remained significantly associated with the level of societal participation at 1-year post-TBI. Conclusions: Minor depression may be as common as major depression after TBI and should be taken seriously for its association to negative outcomes related to participation and quality of life. Findings suggest that, as in other populations, minor and major depression are not separate entities, but exist on a continuum. Further research should determine whether people with TBI traverse between the 2 diagnoses as in other patient groups.	[Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Brenner, Lisa] Univ Colorado, Sch Med, VISN Mental Illness 19, Denver, CO USA; [Brenner, Lisa] Craig Hosp, Denver, CO USA; [Clark, Allison N.] Baylor Coll Med, Houston, TX 77030 USA; [Clark, Allison N.] TIRR Mem Hermann, Houston, TX USA; [Bogner, Jennifer A.] Ohio State Univ, Columbus, OH 43210 USA; [Novack, Thomas A.] Univ Alabama, Birmingham, AL USA; [Chervoneva, Inna] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Nakase-Richardson, Risa] Univ S Florida, Tampa, FL USA; [Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Richmond, VA USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu	Brenner, Lisa A./AAG-2442-2019		National Institute on Disability and Rehabilitation Research [H133A070040, H133A070039, H133A070022, H133A070029, H133A070036, H133A070043]	Supported by the National Institute on Disability and Rehabilitation Research (grant nos. H133A070040, H133A070039, HI33A070022, H133A070029, H133A070036, and H133A070043).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cuijpers P, 2004, J AFFECT DISORDERS, V79, P71, DOI 10.1016/S0165-0327(02)00348-8; Cuijpers P, 2007, CLIN PSYCHOL REV, V27, P318, DOI 10.1016/j.cpr.2006.11.001; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2003, PSYCHOSOMATICS, V44, P161; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Howland RH, 2008, PSYCHOTHER PSYCHOSOM, V77, P384, DOI 10.1159/000151519; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Judd LL, 1997, J AFFECT DISORDERS, V45, P5, DOI 10.1016/S0165-0327(97)00055-4; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kessler RC, 1997, J AFFECT DISORDERS, V45, P19, DOI 10.1016/S0165-0327(97)00056-6; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEVIN HS, 1997, BEHAV NEUROLOGY NEUR, P479; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Rapaport MH, 2002, AM J PSYCHIAT, V159, P637, DOI 10.1176/appi.ajp.159.4.637; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; SKODOL AE, 1994, ARCH GEN PSYCHIAT, V51, P542; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; United States Department of Health and Human Services, 1998, NAT HOUS SURV DRUG A; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wagner HR, 2000, PSYCHOL MED, V30, P1377, DOI 10.1017/S0033291799002998; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	59	97	98	0	32	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2011	92	8					1211	1219		10.1016/j.apmr.2011.03.005			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	803WL	WOS:000293612800004	21807140				2021-06-18	
J	Smits, M; Houston, GC; Dippel, DWJ; Wielopolski, PA; Vernooij, MW; Koudstaal, PJ; Hunink, MGM; van der Lugt, A				Smits, Marion; Houston, Gavin C.; Dippel, Diederik W. J.; Wielopolski, Piotr A.; Vernooij, Meike W.; Koudstaal, Peter J.; Hunink, M. G. Myriam; van der Lugt, Aad			Microstructural brain injury in post-concussion syndrome after minor head injury	NEURORADIOLOGY			English	Article						Craniocerebral trauma; Post-concussion syndrome; Diffusion tensor imaging; Magnetic resonance imaging; Cognition disorder	DIFFUSE AXONAL INJURY; POSTCONCUSSION SYNDROME; NEUROPSYCHOLOGICAL DEFICITS; CEREBRAL MICROBLEEDS; WORKING-MEMORY; SYMPTOMS; LESIONS; PREDICTORS; MRI; NEUROPATHOLOGY	After minor head injury (MHI), post-concussive symptoms commonly occur. The purpose of this study was to correlate the severity of post-concussive symptoms in MHI patients with MRI measures of microstructural brain injury, namely mean diffusivity (MD) and fractional anisotropy (FA), as well as the presence of microhaemorrhages. Twenty MHI patients and 12 healthy controls were scanned at 3 T using diffusion tensor imaging (DTI) and high-resolution gradient recalled echo (HRGRE) T2*-weighted sequences. One patient was excluded from the analysis because of bilateral subdural haematomas. DTI data were preprocessed using Tract Based Spatial Statistics. The resulting MD and FA images were correlated with the severity of post-concussive symptoms evaluated with the Rivermead Postconcussion Symptoms Questionnaire. The number and location of microhaemorrhages were assessed on the HRGRE T2*-weighted images. Comparing patients with controls, there were no differences in MD. FA was decreased in the right temporal subcortical white matter. MD was increased in association with the severity of post-concussive symptoms in the inferior fronto-occipital fasciculus (IFO), the inferior longitudinal fasciculus and the superior longitudinal fasciculus. FA was reduced in association with the severity of post-concussive symptoms in the uncinate fasciculus, the IFO, the internal capsule and the corpus callosum, as well as in the parietal and frontal subcortical white matter. Microhaemorrhages were observed in one patient only. The severity of post-concussive symptoms after MHI was significantly correlated with a reduction of white matter integrity, providing evidence of microstructural brain injury as a neuropathological substrate of the post-concussion syndrome.	[Smits, Marion; Wielopolski, Piotr A.; Vernooij, Meike W.; Hunink, M. G. Myriam; van der Lugt, Aad] Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol Hs 224, NL-3000 CA Rotterdam, Netherlands; [Houston, Gavin C.] GE Healthcare, Appl Sci Lab, sHertogenbosch, Netherlands; [Dippel, Diederik W. J.; Koudstaal, Peter J.] Erasmus MC Univ Med Ctr Rotterdam, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. Myriam] Erasmus MC Univ Med Ctr Rotterdam, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. Myriam] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Smits, M (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol Hs 224, POB 2040, NL-3000 CA Rotterdam, Netherlands.	marion.smits@erasmusmc.nl	Smits, Marion/E-4795-2011; Vernooij, Meike Willemijn/E-4061-2016; Smits, Marion/AAB-3985-2019; Dippel, Diederik/AAJ-2192-2020	Smits, Marion/0000-0001-5563-2871; Dippel, Diederik/0000-0002-9234-3515; Houston, Graeme/0000-0002-9786-7975			Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, P623; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Rauscher A, 2005, MAGNET RESON MED, V54, P87, DOI 10.1002/mrm.20520; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; RUECKERT D, 2007, IMAGE REGISTRATIONT; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Vernooij MW, 2008, NEUROLOGY, V70, P1208, DOI 10.1212/01.wnl.0000307750.41970.d9; Vernooij MW, 2008, RADIOLOGY, V248, P272, DOI 10.1148/radiol.2481071158; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	68	97	99	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	AUG	2011	53	8					553	563		10.1007/s00234-010-0774-6			11	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	794IS	WOS:000292889500001	20924757	Green Published, Other Gold			2021-06-18	
J	Emmanouilidou, E; Elenis, D; Papasilekas, T; Stranjalis, G; Gerozissis, K; Ioannou, PC; Vekrellis, K				Emmanouilidou, Evangelia; Elenis, Dimitris; Papasilekas, Themis; Stranjalis, Georgios; Gerozissis, Kyriaki; Ioannou, Penelopi C.; Vekrellis, Kostas			Assessment of alpha-Synuclein Secretion in Mouse and Human Brain Parenchyma	PLOS ONE			English	Article							AMYLOID-BETA DYNAMICS; FLUORO-JADE-C; PARKINSONS-DISEASE; CEREBROSPINAL-FLUID; INTRACEREBRAL MICRODIALYSIS; HUMAN PLASMA; LEWY BODIES; IN-VIVO; NEURONS; MICE	Genetic, biochemical, and animal model studies strongly suggest a central role for alpha-synuclein in the pathogenesis of Parkinson's disease. alpha-synuclein lacks a signal peptide sequence and has thus been considered a cytosolic protein. Recent data has suggested that the protein may be released from cells via a non-classical secretory pathway and may therefore exert paracrine effects in the extracellular environment. However, proof that alpha-synuclein is actually secreted into the brain extracellular space in vivo has not been obtained. We developed a novel highly sensitive ELISA in conjugation with an in vivo microdialysis technique to measure alpha-synuclein in brain interstitial fluid. We show for the first time that alpha-synuclein is readily detected in the interstitial fluid of both alpha-synuclein transgenic mice and human patients with traumatic brain injury. Our data suggest that alpha-synuclein is physiologically secreted by neurons in vivo. This interstitial fluid pool of the protein may have a role in the propagation of synuclein pathology and progression of Parkinson's disease.	[Emmanouilidou, Evangelia; Vekrellis, Kostas] Acad Athens, Biomed Res Fdn, Div Basic Neurosci, Athens, Greece; [Elenis, Dimitris; Ioannou, Penelopi C.] Univ Athens, Dept Chem, GR-10680 Athens, Greece; [Papasilekas, Themis; Stranjalis, Georgios] Univ Athens, Evaggelismos Gen Hosp, Dept Neurosurg, Athens, Greece; [Gerozissis, Kyriaki] CNRS, Ctr Neurosci, UMR 8195, F-91405 Orsay, France; [Gerozissis, Kyriaki] Univ Paris 11, UMR 8195, Orsay, France; [Gerozissis, Kyriaki] Univ Paris 11, INSERM, F-91405 Orsay, France	Emmanouilidou, E (corresponding author), Acad Athens, Biomed Res Fdn, Div Basic Neurosci, Athens, Greece.	vekrellis@bioacademy.gr		Ioannou, Penelope/0000-0002-2595-1385	Michael J. Fox Foundation; MEFOPA FP7	This work was supported by a Rapid Innovation Response Award from the Michael J. Fox Foundation to EE and KV. Partial support was obtained from MEFOPA FP7. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbour R, 2008, NEURODEGENER DIS, V5, P55, DOI 10.1159/000112832; Bian GL, 2007, BRAIN RES, V1150, P55, DOI 10.1016/j.brainres.2007.02.078; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Chaurasia CS, 2007, PHARM RES, V24, P1014, DOI 10.1007/s11095-006-9206-z; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Danzer KM, 2011, FASEB J, V25, P326, DOI 10.1096/fj.10-164624; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; DYKSTRA KH, 1992, J NEUROCHEM, V58, P931, DOI 10.1111/j.1471-4159.1992.tb09346.x; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; EMMANOUILIDOU E, J NEUROSCI, V30, P6838; Engstrom ER, 2001, EPILEPSY RES, V43, P135, DOI 10.1016/S0920-1211(00)00191-1; GEROZISSIS K, 1993, BRAIN RES, V611, P258, DOI 10.1016/0006-8993(93)90511-K; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; HANSEN C, 2011, J CLIN INVEST; Hillman J, 2006, ACTA NEUROCHIR, V148, P319, DOI 10.1007/s00701-005-0670-8; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Kordower JH, 2008, MOVEMENT DISORD, V23, P2303, DOI 10.1002/mds.22369; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Lindberger M, 2001, EPILEPSIA, V42, P256, DOI 10.1046/j.1528-1157.2001.26600.x; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Mollenhauer B, 2008, EXP NEUROL, V213, P315, DOI 10.1016/j.expneurol.2008.06.004; Moussa CEH, 2004, NEUROSCI LETT, V371, P239, DOI 10.1016/j.neulet.2004.09.004; Ohrfelt A, 2009, NEUROSCI LETT, V450, P332, DOI 10.1016/j.neulet.2008.11.015; Olanow CW, 2004, LANCET NEUROL, V3, P496, DOI 10.1016/S1474-4422(04)00827-0; Perrin RJ, 2003, NEUROSCI LETT, V349, P133, DOI 10.1016/S0304-3940(03)00781-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; Roodveldt C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013481; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; SOTIRIOU E, NEUROBIOL AGING, V31, P2103; Specht CG, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-11; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Su XM, 2008, NEUROBIOL AGING, V29, P1690, DOI 10.1016/j.neurobiolaging.2007.04.006; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; TOKUDA T, NEUROLOGY, V75, P1766; Tokuda T, 2006, BIOCHEM BIOPH RES CO, V349, P162, DOI 10.1016/j.bbrc.2006.08.024; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODS SC, 1977, AM J PHYSIOL, V233, pE331	48	97	98	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2011	6	7							e22225	10.1371/journal.pone.0022225			9	Multidisciplinary Sciences	Science & Technology - Other Topics	793HP	WOS:000292811300049	21779395	DOAJ Gold, Green Published			2021-06-18	
J	Bohmer, AE; Oses, JP; Schmidt, AP; Peron, CS; Krebs, CL; Oppitz, PP; D'Avila, TT; Souza, DO; Portela, LV; Stefani, MA				Boehmer, Ana Elisa; Oses, Jean Pierre; Schmidt, Andre Prato; Peron, Cleiton Schweister; Krebs, Claudio Liss; Oppitz, Paulo Petry; D'Avila, Thiago Torres; Souza, Diogo Onofre; Portela, Luis Valmor; Stefani, Marco Antonio			Neuron-Specific Enolase, S100B, and Glial Fibrillary Acidic Protein Levels as Outcome Predictors in Patients With Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Glial fibrillary acidic protein; Neuron-specific enolase; Outcome; S100B	SERUM S-100B PROTEIN; SEVERE HEAD-INJURY; BIOCHEMICAL MARKERS; DAMAGE; S-100-BETA; DIAGNOSIS; RELEASE; CSF	BACKGROUND: The availability of markers able to provide an early insight related to prognostic and functional outcome of patients with traumatic brain injury (TBI) are limited. OBJECTIVE: The relationship of clinical outcome with CSF neuron-specific enolase (NSE), S100B and glial fibrillary acidic protein (GFAP) levels in patients with severe TBI was investigated. METHODS: Twenty patients with severe TBI (7 days at unit care) and controls were studied. Patients were grouped according to the outcome: (1) nonsurvival (n = 5): patients who died; (2) survival A (n = 15): CSF sampled between 1st and 3rd day from patients who survived after hospital admission; and (3) survival B (n = 7): CSF sampled between 4th and 7th day from patients who survived after hospital admission and were maintained with intraventricular catheter up to 7 days. RESULTS: Up to 3 days, S100B and NSE levels (ng/mL) were significantly elevated in the nonsurvival compared with survival A group (S100: 12.45 +/- 5.46 vs 5.64 +/- 3.36; NSE: 313.20 +/- 45.51 vs 107.80 +/- 112.10). GFAP levels did not differ between groups. In the survival B group S100B, GFAP, and NSE levels were still elevated compared with control (4.59 +/- 2.19, 2.48 +/- 2.55, and 89.80 +/- 131.10, respectively). To compare S100B and NSE for the prediction of nonsurvival and survival patients we performed receiver operating characteristic curves. At admission, CSF NSE level predicts brain death more accurately than S100B. CONCLUSION: Early elevations (up to 3 days) of S100B and NSE secondary to severe TBI predict deterioration to brain death. However, this feature was more prominently associated with NSE than S100B.	[Boehmer, Ana Elisa; Schmidt, Andre Prato; Souza, Diogo Onofre; Portela, Luis Valmor] Univ Fed Rio Grande do Sul, Dept Biochem, ICBS, Alegre, RS, Brazil; [Oses, Jean Pierre] Univ Catolica Pelotas, Dept Psychol, Pelotas, RS, Brazil; [Peron, Cleiton Schweister; Krebs, Claudio Liss; Oppitz, Paulo Petry] Hosp Cristo Redentor, Porto Alegre, RS, Brazil; [D'Avila, Thiago Torres; Stefani, Marco Antonio] Hosp Clnicas Porto Alegre, Porto Alegre, RS, Brazil	Portela, LV (corresponding author), Ave Ramiro Barcelos,2600 Anexo, BR-90035003 Porto Alegre, RS, Brazil.	roskaportela@gmail.com	Souza, Diogo O/J-8894-2014; Schmidt, Andre P/E-4652-2012; Oses, Jean Pierre/E-2534-2013; STEFANI, MARCO ANTONIO/C-3993-2013; Portela, Luis V/I-3410-2014	Souza, Diogo O/0000-0002-4322-0404; STEFANI, MARCO ANTONIO/0000-0002-4728-8764; Oses, Jean Pierre/0000-0002-2012-273X	FAPERGSFundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS); PPSUS; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); CNPQConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); IBNET; INCTen	This research was supported by FAPERGS, PPSUS, CAPES, CNPQ, IBNET and INCTen. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Busnello JV, 2006, LIFE SCI, V78, P3013, DOI 10.1016/j.lfs.2005.11.028; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazzini GS, 2009, RESUSCITATION, V80, P144, DOI 10.1016/j.resuscitation.2008.08.024; Oses JP, 2004, BRAIN RES BULL, V64, P237, DOI 10.1016/j.brainresbull.2004.07.006; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Puvanachandra P, 2008, SALUD PUBLICA MEXICO, V50, pS3; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Tramontina F, 2007, J NEUROSCI METH, V162, P282, DOI 10.1016/j.jneumeth.2007.01.001; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977	27	97	113	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2011	68	6					1624	1630		10.1227/NEU.0b013e318214a81f			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	760CK	WOS:000290299700065	21368691				2021-06-18	
J	Martinez, JA; Zhang, ZQ; Svetlov, SI; Hayes, RL; Wang, KK; Larner, SF				Martinez, Juan A.; Zhang, Zhiqun; Svetlov, Stanislav I.; Hayes, Ronald L.; Wang, Kevin K.; Larner, Stephen F.			Calpain and caspase processing of caspase-12 contribute to the ER stress-induced cell death pathway in differentiated PC12 cells	APOPTOSIS			English	Article						ER stress; Thapsigargin; Unfolded protein response; Calpain; Caspase; PC12 cells	ENDOPLASMIC-RETICULUM STRESS; MITOCHONDRIAL PERMEABILITY TRANSITION; UNFOLDED PROTEIN RESPONSE; INTRINSIC PATHWAY; APOPTOTIC CELLS; NEURONAL APOPTOSIS; II-SPECTRIN; CROSS-TALK; ACTIVATION; THAPSIGARGIN	Neuronal cell death after traumatic brain injury, Alzheimer's disease and ischemic stroke may in part be mediated through endoplasmic reticulum (ER) stress and unfolded protein response (UPR). UPR results in induction of molecular chaperone GRP78 and the ER-resident caspase-12, whose activation has been proposed to be mediated by calpain and caspase processing, although their relative contribution remains unclear. In this study we induced ER stress with thapsigargin (TG), and determined the activation profile of calpain-2, caspase-3, caspase-7, and caspase-12 by analyses of protein levels, corresponding substrates and breakdown products (BDP). Specific calpain and caspase activity was assessed by analysis of alpha II-spectrin BDP of 145 kDa (SBDP145), BDP of 150 kDa (SBDP150) and BDP of 120 kDa (SBDP120). Decrease in pro-calpain-2 protein and increased SBDP145 levels by 3 h after TG treatment indicated early calpain activity. Active caspase-7 (p20) increase occurred after 8 h, followed by concomitant up-regulation of active caspase-3 and SBDP120 after 24 h. In vitro digestion experiments supported that SBDP120 was exclusively generated by active caspase-3 and validated that kinectin and co-chaperone p23 were calpain and caspase-7 substrates, respectively. Pro-caspase-12 protein processing by the specific action of calpain and caspase-3/7 was observed in a time-dependent manner. N-terminal pro-domain processing of pro-caspase-12 by calpain generated a 38 kDa fragment, while caspase-3/7 generated a 35 kDa fragment. Antibody developed specifically against the caspase-3/7 C-terminal cleavage site D(341) detected the presence of large subunit (p20) containing 23 kDa fragment that increased after 24 h of TG treatment. Significant caspase-12 enzyme activity was only detected after 24 h of TG treatment and was completely inhibited by caspase 3/7 inhibitor DEVD-fmk and partially by calpain inhibitor SNJ-1945. ER-stress-induced cell death pathway in TG-treated PC12 cells was characterized by up-regulation of GRP-78 and processing and activation of caspase-12 by the orchestrated proteolytic activity of calpain-2 and caspase-3/7.	[Martinez, Juan A.; Zhang, Zhiqun; Svetlov, Stanislav I.; Hayes, Ronald L.; Wang, Kevin K.; Larner, Stephen F.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA	Martinez, JA (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	jmartinez@banyanbio.com; sflarner@banyanbio.com		Wang, Kevin/0000-0002-9343-6473	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS051431]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051431] Funding Source: NIH RePORTER	This work was supported by NIH Grant R01NS051431 to R. L. H. Dr. K. K. W. Wang and Dr. R. L. Hayes hold equity in Banyan Biomarkers, Inc. (Alachua, FL), a company commercializing the brain injury biomarker technology.	Baumgartner HK, 2009, J BIOL CHEM, V284, P20796, DOI 10.1074/jbc.M109.025353; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Freeze HH, 2007, CURR MOL MED, V7, P389, DOI 10.2174/156652407780831548; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Harriman JF, 2002, CELL DEATH DIFFER, V9, P734, DOI 10.1038/sj.cdd.4401029; Harwood SM, 2005, ANN CLIN BIOCHEM, V42, P415, DOI 10.1258/000456305774538238; Hiroi T, 2005, PHARMACOGENOMICS J, V5, P102, DOI 10.1038/sj.tpj.6500296; Hoppe V, 2004, FEBS LETT, V576, P277, DOI 10.1016/j.febslet.2004.09.012; Jang M, 2007, BIOCHEM BIOPH RES CO, V363, P388, DOI 10.1016/j.bbrc.2007.08.183; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Korfali N, 2004, J BIOL CHEM, V279, P1030, DOI 10.1074/jbc.M306277200; Korge P, 1999, EUR J BIOCHEM, V265, P273, DOI 10.1046/j.1432-1327.1999.00724.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lee W, 2005, APOPTOSIS, V10, P407, DOI 10.1007/s10495-005-0814-6; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Machleidt T, 1998, FEBS LETT, V436, P51, DOI 10.1016/S0014-5793(98)01095-3; Mao WK, 2006, AM J PHYSIOL-CELL PH, V290, pC1373, DOI 10.1152/ajpcell.00369.2005; Masud A, 2007, J BIOL CHEM, V282, P14132, DOI 10.1074/jbc.M700077200; Momoi T, 2004, J CHEM NEUROANAT, V28, P101, DOI 10.1016/j.jchemneu.2004.05.008; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Muruganandan S, 2006, TOXICOL SCI, V94, P118, DOI 10.1093/toxsci/kfl084; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Shimoke K, 2005, NEUROSCI LETT, V389, P124, DOI 10.1016/j.neulet.2005.07.030; Shirasaki Y, 2005, BIOORGAN MED CHEM, V13, P4473, DOI 10.1016/j.bmc.2005.04.059; Stegh AH, 2008, P NATL ACAD SCI USA, V105, P10703, DOI 10.1073/pnas.0712034105; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tran H, 2002, J CELL SCI, V115, P2031; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Truettner JS, 2009, BRAIN RES, V1249, P9, DOI 10.1016/j.brainres.2008.10.032; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Voccoli V, 2007, BRAIN RES, V1147, P1, DOI 10.1016/j.brainres.2007.01.145; Walsh JG, 2008, P NATL ACAD SCI USA, V105, P12815, DOI 10.1073/pnas.0707715105; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	49	97	104	0	10	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1360-8185			APOPTOSIS	Apoptosis	DEC	2010	15	12					1480	1493		10.1007/s10495-010-0526-4			14	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	688HL	WOS:000284840300008	20640600				2021-06-18	
J	Warner, MA; Youn, TS; Davis, T; Chandra, A; de la Plata, CM; Moore, C; Harper, C; Madden, CJ; Spence, J; McColl, R; Devous, M; King, RD; Diaz-Arrastia, R				Warner, Matthew A.; Youn, Teddy S.; Davis, Tommy; Chandra, Alvin; de la Plata, Carlos Marquez; Moore, Carol; Harper, Caryn; Madden, Christopher J.; Spence, Jeffrey; McColl, Roderick; Devous, Michael; King, Richard D.; Diaz-Arrastia, Ramon			Regionally Selective Atrophy After Traumatic Axonal Injury	ARCHIVES OF NEUROLOGY			English	Article							MAGNETIC-RESONANCE IMAGES; CORPUS-CALLOSUM ATROPHY; VOXEL-BASED MORPHOMETRY; SURFACE-BASED ANALYSIS; BRAIN-INJURY; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; LONGITUDINAL CHANGES; DIFFUSION-TENSOR; CEREBRAL ATROPHY	Objectives: To determine the spatial distribution of cortical and subcortical volume loss in patients with diffuse traumatic axonal injury and to assess the relationship between regional atrophy and functional outcome. Design: Prospective imaging study. Longitudinal changes in global and regional brain volumes were assessed using high-resolution magnetic resonance imaging-based morphometric analysis. Setting: Inpatient traumatic brain injury unit. Patients or Other Participants: Twenty-five patients with diffuse traumatic axonal injury and 22 age- and sex-matched controls. Main Outcome Measure: Changes in global and regional brain volumes between initial and follow-up magnetic resonance imaging were used to assess the spatial distribution of posttraumatic volume loss. The Glasgow Outcome Scale-Extended score was the primary measure of functional outcome. Results: Patients underwent substantial global atrophy with mean whole-brain parenchymal volume loss of 4.5% (95% confidence interval, 2.7%-6.3%). Decreases in volume (at a false discovery rate of 0.05) were seen in several brain regions including the amygdala, hippocampus, thalamus, corpus callosum, putamen, precuneus, postcentral gyrus, paracentral lobule, and parietal and frontal cortices, while other regions such as the caudate and inferior temporal cortex were relatively resistant to atrophy. Loss of whole-brain parenchymal volume was predictive of long-term disability, as was atrophy of particular brain regions including the inferior parietal cortex, pars orbitalis, pericalcarine cortex, and supramarginal gyrus. Conclusion: Traumatic axonal injury leads to substantial posttraumatic atrophy that is regionally selective rather than diffuse, and volume loss in certain regions may have prognostic value for functional recovery.	[Warner, Matthew A.; Davis, Tommy; Chandra, Alvin; Moore, Carol; Harper, Caryn; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA; [Spence, Jeffrey] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [McColl, Roderick; Devous, Michael] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez] Univ Dallas, Ctr Brain Hlth, Dallas, TX USA; [Youn, Teddy S.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [King, Richard D.] Univ Utah, Dept Neurol, Salt Lake City, UT USA	Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ramon.diaz-arrastia@utsouthwestern.edu	Youn, Teddy Si/ABH-9887-2020; Youn, Teddy Si/N-1535-2017; Youn, Teddy/AAM-7705-2020	Youn, Teddy Si/0000-0002-7325-1148; Diaz-Arrastia, Ramon/0000-0001-6051-3594; McColl, Roderick/0000-0001-7022-100X	Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); National Institutes of Health National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; US Department of EducationUS Department of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827] Funding Source: NIH RePORTER	This study was supported by a Clinical Research Fellowship through the Doris Duke Charitable Foundation (Mr Warner and Dr Youn), grants R01 HD48179 and U01 HD42652 from the National Institutes of Health National Institute of Child Health and Human Development (Dr Diaz-Arrastia), and grant H133 A020526 from the US Department of Education (Dr Diaz-Arrastia).	Agosta F, 2009, P NATL ACAD SCI USA, V106, P2018, DOI 10.1073/pnas.0812697106; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Basso M, 2006, PSYCHIAT RES-NEUROIM, V146, P251, DOI 10.1016/j.pscychresns.2006.01.007; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Holland D, 2009, P NATL ACAD SCI USA, V106, P20954, DOI 10.1073/pnas.0906053106; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McDonald CR, 2008, EPILEPSY RES, V79, P130, DOI 10.1016/j.eplepsyres.2008.01.006; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Pengas G, 2009, J NEUROIMAGING, V19, P37, DOI 10.1111/j.1552-6569.2008.00246.x; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Scahill RI, 2002, P NATL ACAD SCI USA, V99, P4703, DOI 10.1073/pnas.052587399; Shiino A, 2008, DEMENT GERIATR COGN, V26, P175, DOI 10.1159/000151241; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Tae WS, 2008, NEURORADIOLOGY, V50, P569, DOI 10.1007/s00234-008-0383-9; Teipel SJ, 2006, J NEUROL, V253, P794, DOI 10.1007/s00415-006-0120-4; Teipel SJ, 2003, NEUROBIOL AGING, V24, P85, DOI 10.1016/S0197-4580(02)00044-1; Teipel SJ, 2002, ARCH NEUROL-CHICAGO, V59, P243, DOI 10.1001/archneur.59.2.243; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; Wang PJ, 2006, NEUROBIOL AGING, V27, P1613, DOI 10.1016/j.neurobiolaging.2005.09.035; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yamauchi H, 2000, J NEUROL NEUROSUR PS, V69, P623, DOI 10.1136/jnnp.69.5.623	39	97	98	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	NOV	2010	67	11					1336	1344		10.1001/archneurol.2010.149			9	Clinical Neurology	Neurosciences & Neurology	676RQ	WOS:000283935300011	20625067	Bronze, Green Accepted			2021-06-18	
J	Dawson, HN; Cantillana, V; Jansen, M; Wang, H; Vitek, MP; Wilcock, DM; Lynch, JR; Laskowitz, DT				Dawson, H. N.; Cantillana, V.; Jansen, M.; Wang, H.; Vitek, M. P.; Wilcock, D. M.; Lynch, J. R.; Laskowitz, D. T.			LOSS OF TAU ELICITS AXONAL DEGENERATION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE	NEUROSCIENCE			English	Article						Tau; APP; axonal degeneration; spheroids; head injury; immunization	PROGRESSIVE SUPRANUCLEAR PALSY; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; A-BETA-PEPTIDE; TRAUMATIC BRAIN-INJURY; TRANSGENIC MICE; HEAD-INJURY; FRONTOTEMPORAL DEMENTIA; CORTICOBASAL DEGENERATION; STEREOLOGICAL ESTIMATION	A central issue in the pathogenesis of tauopathy is the question of how tau protein dysfunction leads to neurodegeneration. We have previously demonstrated that the absence of tau protein is associated with destabilization of microtubules and impaired neurite outgrowth (Dawson et al., 2001; Rapoport et al., 2002). We now hypothesize that the absence of functional tau protein may render the central nervous system more vulnerable to secondary insults such as the overexpression of mutated beta amyloid precursor protein (APP) and traumatic brain injury. We therefore crossed tau knockout mice (Dawson et al., 2001) to mice overexpressing a mutated human APP (APP(670,671), A(SW)) (Hsiao et al., 1996) and created a mouse model (A(sw)/mTau(-/-)) that provides evidence that the loss of tau function causes degeneration of neuronal processes. The overexpression of APP(670,671) in tau knockout mice, elicits the extensive formation of axonal spheroids. While spheroids are only found associated with A beta plaques in mice expressing APP(670,671) on an endogenous mouse tau background (Irizarry et al., 1997), A(sw)/mTau(-/-) mice have spheroids not only surrounding A beta plaques but also in white matter tracks and in the neuropil. Plaque associated and neuropil dystrophic neurites and spheroids are prominent features of Alzheimer's disease (Masliah et al., 1993; Terry, 1996; Stokin et al., 2005), and our current data suggests that loss of tau function may lead to neurodegeneration. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.	[Dawson, H. N.; Cantillana, V.; Jansen, M.; Wang, H.; Vitek, M. P.; Wilcock, D. M.; Laskowitz, D. T.] Duke Univ, Div Neurol, Durham, NC 27710 USA; [Vitek, M. P.] Cognosci Inc, Res Triangle Pk, NC 27709 USA; [Lynch, J. R.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53266 USA	Dawson, HN (corresponding author), Duke Univ, Div Neurol, Durham, NC 27710 USA.	dawso009@mc.duke.edu	Wilcock, Donna M/J-7517-2016	Vitek, Michael/0000-0001-8140-8048	Alzheimer's AssociationAlzheimer's Association [II3-02-4160]; Institute for Study of Aging/ADDF [261102.01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08-AG22230-03]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG022230] Funding Source: NIH RePORTER	This work was supported in part by Alzheimer's Association Grant II3-02-4160 HND, Institute for Study of Aging/ADDF 261102.01 DTL and NIH K08-AG22230-03 JRL. We thank Dr. Anyang Sun for providing his expertise in axonal degeneration. We thank Dr. Van Nostram's laboratory for performing A beta the elisa.	Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Black MM, 1996, J NEUROSCI, V16, P3601; Brendza RP, 2003, NEUROBIOL AGING, V24, P1071, DOI 10.1016/j.neurobiolaging.2003.04.008; Brendza RP, 2003, J COMP NEUROL, V456, P375, DOI 10.1002/cne.10536; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Crawley JN, 2000, WHATS WRONG MY MOUSE; Dai JP, 2002, BRAIN RES, V948, P138, DOI 10.1016/S0006-8993(02)03152-9; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; Dawson HN, 2001, J CELL SCI, V114, P1179; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; Dikranian K, 2001, NEUROBIOL DIS, V8, P359, DOI 10.1006/nbdi.2001.0411; Dixit R, 2008, SCIENCE, V319, P1086, DOI 10.1126/science.1152993; DRUBIN DG, 1984, J CELL BIOL, V98, P1090, DOI 10.1083/jcb.98.3.1090; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Goedert M, 1999, AM J PATHOL, V154, P1, DOI 10.1016/S0002-9440(10)65242-X; Gomez-Ramos P, 2007, J ALZHEIMERS DIS, V11, P53; Gordon MN, 2001, NEUROBIOL AGING, V22, P377, DOI 10.1016/S0197-4580(00)00249-9; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hernandez F, 2007, CELL MOL LIFE SCI, V64, P2219, DOI 10.1007/s00018-007-7220-x; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; JONES RSG, 1993, TRENDS NEUROSCI, V16, P58, DOI 10.1016/0166-2236(93)90018-H; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Katsuse O, 2003, ACTA NEUROPATHOL, V106, P251, DOI 10.1007/s00401-003-0728-8; Kempf M, 1996, J NEUROSCI, V16, P5583; Kobayashi DT, 2005, GENES BRAIN BEHAV, V4, P173, DOI 10.1111/j.1601-183X.2005.00124.x; Kosaka Satoru, 2004, Osaka City Medical Journal, V50, P19; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Long JM, 1998, J NEUROSCI METH, V84, P101, DOI 10.1016/S0165-0270(98)00100-9; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Mandelkow EM, 2003, NEUROBIOL AGING, V24, P1079, DOI 10.1016/j.neurobiolaging.2003.04.007; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; Miao JT, 2005, J NEUROSCI, V25, P6271, DOI 10.1523/JNEUROSCI.1306-05.2005; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Morris HR, 2003, NEUROLOGY, V61, P102, DOI 10.1212/01.WNL.0000072325.27824.A5; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Qing H, 2008, J EXP MED, V205, P2781, DOI 10.1084/jem.20081588; Rademakers R, 2004, HUM MUTAT, V24, P277, DOI 10.1002/humu.20086; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Stokin GB, 2008, HUM MOL GENET, V17, P3474, DOI 10.1093/hmg/ddn240; Takahashi T, 1997, ACTA NEUROPATHOL, V94, P294, DOI 10.1007/s004010050707; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Togo T, 2002, ACTA NEUROPATHOL, V104, P398, DOI 10.1007/s00401-002-0569-x; Vershinin M, 2008, TRAFFIC, V9, P882, DOI 10.1111/j.1600-0854.2008.00741.x; Vershinin M, 2007, P NATL ACAD SCI USA, V104, P87, DOI 10.1073/pnas.0607919104; Villain N, 2008, J NEUROSCI, V28, P6174, DOI 10.1523/JNEUROSCI.1392-08.2008; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Wirths O, 2006, ACTA NEUROPATHOL, V111, P312, DOI 10.1007/s00401-006-0041-4; Wirths O, 2004, J NEUROCHEM, V91, P513, DOI 10.1111/j.1471-4159.2004.02737.x; Wirths O, 2008, NEUROBIOL AGING, V29, P891, DOI 10.1016/j.neurobiolaging.2006.12.004; Wozniak DF, 1996, BRAIN RES, V707, P165, DOI 10.1016/0006-8993(95)01230-3; Zhukareva V, 2001, ANN NEUROL, V49, P165, DOI 10.1002/1531-8249(20010201)49:2<165::AID-ANA36>3.0.CO;2-3	87	97	98	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	AUG 11	2010	169	1					516	531		10.1016/j.neuroscience.2010.04.037			16	Neurosciences	Neurosciences & Neurology	621LB	WOS:000279579200052	20434528	Green Accepted			2021-06-18	
J	Kou, ZF; Wu, Z; Tong, KA; Holshouser, B; Benson, RR; Hu, JN; Haacke, EM				Kou, Zhifeng; Wu, Zhen; Tong, Karen A.; Holshouser, Barbara; Benson, Randall R.; Hu, Jiani; Haacke, E. Mark			The Role of Advanced MR Imaging Findings as Biomarkers of Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; diffusion tensor imaging (DTI); magnetic resonance imaging (MRI); MR spectroscopy (MRS); MR spectroscopy imaging (MRSI); neuroimaging; susceptibility-weighted imaging (SWI); traumatic brain injury (TBI)	DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; WHITE-MATTER INJURY; FUNCTIONAL CONNECTIVITY; PROTON MRS; MILD; CHILDREN; TIME; MODERATE; MEMORY	Treatment of traumatic brain injury (TBI) requires proper classification of the pathophysiology. Clinical classifiers and conventional neuroimaging are limited in TBI detection, outcome prediction, and treatment guidance. Advanced magnetic resonance imaging (MRI) techniques such as susceptibility weighted imaging, diffusion tensor imaging, and magnetic resonance spectroscopic imaging are sensitive to microhemorrhages, white matter injury, and abnormal metabolic activities, respectively, in brain injury. In this article, we reviewed these 3 advanced MRI methods and their applications in TBI and report some new findings from our research. These MRI techniques have already demonstrated their potential to improve TBI detection and outcome prediction. As such, they have demonstrated the capacity of serving as a set of biomarkers to reveal the heterogeneous and complex nature of brain injury in a regional and temporal manner. Further longitudinal studies using advanced MRI in a synergistic approach are expected to provide insight in understanding TBI and imaging implications for treatment.	[Hu, Jiani; Haacke, E. Mark] Wayne State Univ, Sch Med, Dept Radiol, MR Res Facil, Detroit, MI 48201 USA; [Tong, Karen A.; Holshouser, Barbara] Loma Linda Univ, Med Ctr, Dept Radiol, Loma Linda, CA USA; [Wu, Zhen; Haacke, E. Mark] McMaster Univ, Sch Biomed Engn, Hamilton, ON, Canada; [Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Benson, Randall R.] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA	Haacke, EM (corresponding author), Wayne State Univ, Sch Med, Dept Radiol, MR Res Facil, 3990 John R St, Detroit, MI 48201 USA.	nmrimaging@aol.com			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NIH 62983] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Alessandri B, 1999, ACT NEUR S, V75, P25; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Chastain C, 2006, J INVEST MED, V54, pS142; CHRISTMAN CW, 1980, NEUROSCI LETT, V20, P227, DOI 10.1016/0304-3940(80)90151-2; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GATTU R, 2008, P INT SOC MAGN RES M; GATTU R, 2009, P INT SOC MAGN RES M; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Grossman RI, 2003, NEURORADIOLOGY; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.0.CO;2-6; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kou Z., 2007, P JOINT ANN M ISMRM; KOU Z, 2008, P INT SOC MAGN RES M; Kou Z., 2008, CLIN MR NEUROIMAGING; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schuff N, 2001, MAGN RESON MED, V45, P899, DOI 10.1002/mrm.1119; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2002, ACT NEUR S, V81, P373; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Soher BJ, 2000, MAGN RESON IMAGING, V18, P1159, DOI 10.1016/S0730-725X(00)00212-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale E., 1997, HEAD INJURY, P167; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; WU Z, 2010, J MAGN RESO IN PRESS; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yoon SJ, 2005, CLIN REHABIL, V19, P209, DOI 10.1191/0269215505cr813oa; Zhang H, 2001, CLIN CHEM, V47, P1458; ZHEN W, 2009, THESIS MCMASTER U HA	82	97	100	1	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					267	282		10.1097/HTR.0b013e3181e54793			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900005	20611045				2021-06-18	
J	Siman, R; Toraskar, N; Dang, A; McNeil, E; McGarvey, M; Plaum, J; Maloney, E; Grady, MS				Siman, Robert; Toraskar, Nikhil; Dang, Antony; McNeil, Elizabeth; McGarvey, Micheal; Plaum, Justin; Maloney, Eileen; Grady, M. Sean			A Panel of Neuron-Enriched Proteins as Markers for Traumatic Brain Injury in Humans	JOURNAL OF NEUROTRAUMA			English	Article						14-3-3; biomarker panel; calpain; necrosis; neurofilament; traumatic brain injury; UCH-L1	TISSUE-PLASMINOGEN ACTIVATOR; SPECTRIN BREAKDOWN PRODUCTS; CEREBROSPINAL-FLUID; CALPAIN-I; AXONAL DAMAGE; NEUROBIOCHEMICAL MARKERS; MONOCLONAL-ANTIBODIES; BIOCHEMICAL MARKERS; SURROGATE MARKERS; TEMPORAL PROFILE	Surrogate markers have enormous potential for contributing to the diagnosis, prognosis, and therapeutic evaluation of acute brain damage, but extensive prior study of individual candidates has not yielded a biomarker in widespread clinical practice. We hypothesize that a panel of neuron-enriched proteins measurable in cerebrospinal fluid (CSF) and blood should vastly improve clinical evaluation and therapeutic management of acute brain injuries. Previously, we developed such a panel based initially on the study of protein release from degenerating cultured neurons, and subsequently on rodent models of traumatic brain injury (TBI) and ischemia, consisting of 14-3-3 beta, 14-3-3 zeta, three distinct phosphoforms of neurofilament H, ubiquitin hydrolase L1, neuron-specific enolase, alpha-spectrin, and three calpain- and caspase-derived fragments of alpha-spectrin. In the present study, this panel of 11 proteins was evaluated as CSF and serum biomarkers for severe TBI in humans. By quantitative Western blotting and sandwich immunoassays, the CSF protein levels were near or below the limit of detection in pre-surgical and most normal pressure hydrocephalus (NPH) controls, but following TBI nine of the 11 were routinely elevated in CSF. Whereas different markers peaked coordinately, the time to peak varied across TBI cases from 24-96 h post-injury. In serum, TBI increased all four members of the marker panel for which sandwich immunoassays are currently available: a calpain-derived NH2-terminal alpha-spectrin fragment and the three neurofilament H phosphoforms. Our results identify neuron-enriched proteins that may serve as a panel of CSF and blood surrogate markers for the minimally invasive detection, management, mechanistic, and therapeutic evaluation of human TBI.	[Siman, Robert; Toraskar, Nikhil; Dang, Antony; McNeil, Elizabeth; Plaum, Justin; Maloney, Eileen; Grady, M. Sean] Univ Penn, Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [McGarvey, Micheal] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA	Siman, R (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS048234]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048234] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (grant NS048234 to R. S.).	Agren-Wilsson A, 2007, ACTA NEUROL SCAND, V116, P333, DOI 10.1111/j.1600-0404.2007.00890.x; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; DAY INM, 1992, BIOCHEM SOC T, V20, P637, DOI 10.1042/bst0200637; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Foussas SG, 2007, HEART, V93, P952, DOI 10.1136/hrt.2005.084954; Gloeckner SF, 2008, J ALZHEIMERS DIS, V14, P17; GOODMAN SR, 1987, BRAIN RES BULL, V18, P787, DOI 10.1016/0361-9230(87)90217-6; Grubb NR, 2007, HEART, V93, P1268, DOI 10.1136/hrt.2006.091314; Harwood SM, 2005, ANN CLIN BIOCHEM, V42, P415, DOI 10.1258/000456305774538238; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Konstantinopoulos PA, 2008, NAT CLIN PRACT ONCOL, V5, P577, DOI 10.1038/ncponc1178; Lawrence EJ, 2005, RESUSCITATION, V64, P383, DOI 10.1016/j.resuscitation.2004.07.016; McKeating EG, 1998, ACT NEUR S, V71, P117; Morrow David A, 2007, Circulation, V115, pe356; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROL NEUROSUR PS, V76, P206, DOI 10.1136/jnnp.2004.043315; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rosen H, 2004, J NEUROL SCI, V221, P19, DOI 10.1016/j.jns.2004.03.003; Ross JS, 2008, ONCOLOGIST, V13, P477, DOI 10.1634/theoncologist.2007-0248; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Tanaka Y, 2007, BRAIN RES, V1154, P194, DOI 10.1016/j.brainres.2007.03.085; TEEPKER M, 2008, HEADACHE IN PRESS; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Williams R.C. Jr, 1983, Cell and Muscle Motility, V3, P41; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Xu JL, 2001, BRAIN RES, V898, P171, DOI 10.1016/S0006-8993(01)02156-4; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	55	97	100	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1867	1877		10.1089/neu.2009.0882			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600002	19811094	Green Published			2021-06-18	
J	Anderson, V; Brown, S; Newitt, H; Holle, H				Anderson, Vicki; Brown, Sandra; Newitt, Held; Holle, Hannah			Educational, Vocational, Psychosocial, and Quality-of-Life Outcomes for Adult Survivors of Childhood Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						child; education; long-term outcomes; qualify of life; traumatic brain injury; vocation	HEAD-INJURY; BEHAVIOR PROBLEMS; FOLLOW-UP; MILD; CHILDREN; REHABILITATION; TBI; AGE	Objective: To examine long-term outcomes from child traumatic brain injury (TBI) and relevance of injury severity. Design: A retrospective cross-sectional design. Participants: One hundred and twenty-four young adult survivors of childhood TBI (81 men), aged 18 to 30 years at evaluation (mean = 23.5, SD = 2.9), with injury on average 13.7 years prior to evaluation divided according to injury severity: mild (n = 60), moderate (n = 27), and severe (n = 37). Main Measures: Questionnaires assessed educational and employment status, psychosocial function, and quality-of-life issues. Results: Functional difficulties persisted into adulthood. Injury severity was a particularly strong predictor of long-term outcomes, with environmental factors playing a less consistent role. Survivors of severe TBI were particularly vulnerable, demonstrating global impairment: poorer school performance, employment difficulties, poor quality of life, and increased risk of mental health problems. Mild and moderate TBI were more benign, although lower educational attainment and employment status were identified, and moderate TBI was associated with late developing mental health issues. Conclusions: Traumatic brain injury is a lifelong problem, compromising the individual's capacity to meet developmental expectations across a wide range of functional domains.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic 3052, Australia; [Anderson, Vicki; Brown, Sandra] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Newitt, Held; Holle, Hannah] Univ Melbourne, Melbourne, Vic, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Melbourne, Vic 3052, Australia.						Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; *AUSTR BUR STAT, DIS LONG TERM HLTH C; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Daniel A. E., 1983, POWER PRIVILEGE PRES; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER EJ, 1995, RECEPTOR CHANNEL, V3, P21; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Kieslich M, 2001, DISABIL REHABIL, V23, P665; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; MAX J, 1997, J AM ACAD CHILD ADOL, V36, P83; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Nybo T, 1999, BRAIN INJURY, V13, P759; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; VIGNOLO G, 1980, ITAL J NEUROL, V2, P65; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	32	97	97	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2009	24	5					303	312		10.1097/HTR.0b013e3181ada830			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	509WG	WOS:000271049300001	19858964				2021-06-18	
J	Bansal, V; Costantini, T; Kroll, L; Peterson, C; Loomis, W; Eliceiri, B; Baird, A; Wolf, P; Coimbra, R				Bansal, Vishal; Costantini, Todd; Kroll, Lauren; Peterson, Carrie; Loomis, William; Eliceiri, Brian; Baird, Andrew; Wolf, Paul; Coimbra, Raul			Traumatic Brain Injury and Intestinal Dysfunction: Uncovering the Neuro-Enteric Axis	JOURNAL OF NEUROTRAUMA			English	Article						intestinal permeability; tight junctions; traumatic brain injury	FACTOR-KAPPA-B; INFLAMMATORY RESPONSE; BARRIER DYSFUNCTION; TIGHT JUNCTIONS; TNF-ALPHA; MICE; BLOOD; PERMEABILITY; EXPRESSION; APOPTOSIS	Traumatic brain injury (TBI) can lead to several physiologic complications including gastrointestinal dysfunction. Specifically, TBI can induce an increase in intestinal permeability, which may lead to bacterial translocation, sepsis, and eventually multi-system organ failure. However, the exact mechanism of increased intestinal permeability following TBI is unknown. We hypothesized that expression of tight junction protein ZO-1 and occludin, responsible for intestinal architectural and functional integrity, will decrease following TBI and increase intestinal permeability. BALB/c mice underwent a weight drop TBI model following anesthesia. Brain injury was confirmed by a neurologic assessment and gross brain pathology. Six hours following injury, FITC-dextran (25 mg 4.4 kDa FITC-dextran) was injected into the intact lumen of the isolated ileum. Intestinal permeability was measured in plasma 30 min following injection, by using spectrophotometry to determine plasma FITC-dextran concentrations. Whole ileum extracts were used to measure expression of tight junction proteins ZO-1 and occludin by Western blot. TBI caused a significant increase in intestinal permeability (110.0 mu g/mL +/- 22.2) compared to sham animals (29.4 mu g/mL +/- 9.7) 6 h after injury (p = 0.016). Expression of ZO-1 was decreased by 49% relative to sham animals (p < 0.02), whereas expression of occludin was decreased by 73% relative to sham animals (p < 0.001). An increase in intestinal permeability corresponds with decreased expression of tight junction proteins ZO-1 and occludin following TBI. Expression of intestinal tight junction proteins may be an important factor in gastrointestinal dysfunction following brain injury.	[Bansal, Vishal; Costantini, Todd; Kroll, Lauren; Peterson, Carrie; Loomis, William; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Wolf, Paul] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA	Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020; Peterson, Carrie/AAF-8586-2021; tao, li/G-7956-2011	Coimbra, Raul/0000-0002-3759-6851; Peterson, Carrie/0000-0002-8448-4633; Baird, Andrew/0000-0003-0027-9905; Eliceiri, Brian/0000-0003-1811-1916	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL073396, R01 HL073396-08] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20 GM078421, P20 GM078421-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL073396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Chen G, 2008, INFLAMM RES, V57, P57, DOI 10.1007/s00011-007-7101-7; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fuentes JM, 2006, CLIN VACCINE IMMUNOL, V13, P281, DOI 10.1128/CVI.13.2.281-288.2006; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Han XN, 2004, AM J PHYSIOL-GASTR L, V286, pG126, DOI 10.1152/ajpgi.00231.2003; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kemp CD, 2008, AM SURGEON, V74, P866; Ma B, 2007, ANAT HISTOL EMBRYOL, V36, P62, DOI 10.1111/j.1439-0264.2006.00741.x; Mazzon E, 2006, SHOCK, V25, P515, DOI 10.1097/01.shk.0000209556.31457.e7; Mazzon E, 2008, AM J PHYSIOL-GASTR L, V294, pG1268, DOI 10.1152/ajpgi.00014.2008; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Wu Z, 2008, NEUROBIOL DIS, V32, P543, DOI 10.1016/j.nbd.2008.09.002; Zeissig S, 2007, GUT, V56, P61, DOI 10.1136/gut.2006.094375; Zeissig S, 2004, GUT, V53, P1295, DOI 10.1136/gut.2003.036632	30	97	106	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1353	1359		10.1089/neu.2008.0858			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900018	19344293	Green Published			2021-06-18	
J	Donkin, JJ; Nimmo, AJ; Cernak, I; Blumbergs, PC; Vink, R				Donkin, James J.; Nimmo, Alan J.; Cernak, Ibolja; Blumbergs, Peter C.; Vink, Robert			Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cerebral edema; neurogenic inflammation; neuropeptides	SPINAL-CORD ASTROCYTES; NEUROGENIC INFLAMMATION; MAGNESIUM-DEFICIENCY; TIME-COURSE; RECEPTOR; RATS; TACHYKININ; VASODILATATION; PATHOBIOLOGY; ANTAGONIST	Brain edema and swelling is a critical factor in the high mortality and morbidity associated with traumatic brain injury (TBI). Despite this, the mechanisms associated with its development are poorly understood and interventions have not changed in over 30 years. Although neuropeptides and neurogenic inflammation have been implicated in peripheral edema formation, their role in the development of central nervous system edema after brain trauma has not been investigated. This study examines the role of the neuropeptide, substance P (SP), in the development of edema and functional deficits after brain trauma in rats. After severe diffuse TBI in adult male rats, neuronal and perivascular SP immunoreactivity were increased markedly. Perivascular SP colocalized with exogenously administered Evans blue, supporting a role for SP in vascular permeability. Inhibition of SP action by administration of the neurokinin-1 (NK1) antagonist, N-acetyl-L-tryptophan, at 30 mins after trauma attenuated vascular permeability and edema formation. Administration of the NK1 antagonist also improved both motor and cognitive neurologic outcomes. These findings suggest that SP release is integrally linked to the increased vascular permeability and edema formation after brain trauma, and that treatment with an NK1 receptor antagonist reduces edema and improves neurologic outcome. Journal of Cerebral Blood Flow & Metabolism (2009) 29, 1388-1398; doi: 10.1038/jcbfm.2009.63; published online 13 May 2009	[Donkin, James J.; Nimmo, Alan J.; Vink, Robert] Univ Adelaide, Discipline Pathol, Adelaide, SA 5005, Australia; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA; [Blumbergs, Peter C.; Vink, Robert] Hanson Inst Ctr Neurol Dis, Adelaide, SA, Australia	Vink, R (corresponding author), Univ Adelaide, Discipline Pathol, Adelaide, SA 5005, Australia.	Robert.Vink@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Nimmo, Alan/0000-0002-0718-7934; Ibolja, Cernak/0000-0003-3214-698X			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Astrop A., 2000, ESTIMATING GLOBAL RO; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GAUMANN DM, 1990, NEUROSCIENCE, V39, P761, DOI 10.1016/0306-4522(90)90259-7; HAFSTROM I, 1989, J RHEUMATOL, V16, P1033; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Kaya M, 2001, CAN J PHYSIOL PHARM, V79, P793, DOI 10.1139/cjpp-79-9-793; Kramer JH, 1997, J MOL CELL CARDIOL, V29, P97, DOI 10.1006/jmcc.1996.0255; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lin RCS, 1995, NEUROREPORT, V7, P310, DOI 10.1097/00001756-199512290-00074; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; Malcangio M, 2000, EUR J NEUROSCI, V12, P397, DOI 10.1046/j.1460-9568.2000.00946.x; MARRIOTT D, 1991, ADV PROSTAG THROMB L, V21, P739; McIntosh TK, 1996, LAB INVEST, V74, P315; NEWBOLD P, 1995, BRIT J PHARMACOL, V114, P570, DOI 10.1111/j.1476-5381.1995.tb17177.x; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Palma C, 1997, GLIA, V21, P183, DOI 10.1002/(SICI)1098-1136(199710)21:2<183::AID-GLIA2>3.0.CO;2-8; PERSSON MG, 1991, EUR J PHARMACOL, V205, P295, DOI 10.1016/0014-2999(91)90913-B; POTHOULAKIS C, 1994, P NATL ACAD SCI USA, V91, P947, DOI 10.1073/pnas.91.3.947; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; Saria A, 1999, EUR J PHARMACOL, V375, P51, DOI 10.1016/S0014-2999(99)00259-9; SARIA A, 1984, BRIT J PHARMACOL, V82, P217, DOI 10.1111/j.1476-5381.1984.tb16461.x; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stumm RK, 2001, J NEUROSCI, V21, P798; Towler PK, 1998, NEUROREPORT, V9, P1513, DOI 10.1097/00001756-199805110-00049; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; WEGLICKI WB, 1992, AM J PHYSIOL, V263, pR734; WOIE K, 1993, CIRC RES, V73, P839, DOI 10.1161/01.RES.73.5.839; YONEHARA N, 1987, J PHARMACOL EXP THER, V242, P1071; Yu ZF, 1997, NEUROREPORT, V8, P2117, DOI 10.1097/00001756-199707070-00006	42	97	100	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2009	29	8					1388	1398		10.1038/jcbfm.2009.63			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	477JO	WOS:000268515500004	19436311	Green Accepted, Bronze			2021-06-18	
J	Gironda, RJ; Clark, ME; Ruff, RL; Chait, S; Craine, M; Walker, R; Scholten, J				Gironda, Ronald J.; Clark, Michael E.; Ruff, Robert L.; Chait, Sari; Craine, Michael; Walker, Robyn; Scholten, Joel			Traumatic Brain Injury, Polytrauma, and Pain: Challenges and Treatment Strategies for the Polytrauma Rehabilitation	REHABILITATION PSYCHOLOGY			English	Article						pain; headache; polytrauma; traumatic brain injury; postconcussive syndrome; posttraumatic stress disorder	OPERATIONS ENDURING FREEDOM; TENSION-TYPE HEADACHE; SPINAL MANIPULATION; IRAQI-FREEDOM; OLDER-ADULTS; MIGRAINE; VETERANS; SLEEP; NIGHTMARES; EXPERIENCE	Problem: Chronic pain conditions are common sequelae of traumatic brain injury (TBI). Unfortunately, the incidence of TBI among personnel deployed for Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) is significant, and there is growing evidence that ongoing pain, particularly headaches, will be a primary concern for these individuals. Objective: This article synthesizes empirical data from civilian and veteran populations and clinical experience with OEF/OIF personnel with polytrauma to provide recommendations for the assessment and treatment of chronic pain among those with TBI. Conclusions: ne available data signal the need for the incorporation of early and aggressive pain management strategies into existing treatment models. Challenges to providing effective pain management for OEF/OIF veterans are numerous and include comorbid cognitive, medical, and emotional impairments that complicate readjustment to civilian life. It is likely that the problem of polytrauma pain and associated comorbid conditions such as posttraumatic stress disorder and postconcussive syndrome will require the development of integrated approaches to clinical care which bridge traditional subspecialty divisions. A proposed model of treatment is presented.	[Gironda, Ronald J.; Clark, Michael E.; Walker, Robyn] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Clark, Michael E.] Univ S Florida, Coll Med, Dept Neurol, Tampa, FL 33620 USA; [Ruff, Robert L.] Case Western Reserve Univ, Neurol Serv, Cleveland, OH 44106 USA; [Ruff, Robert L.] Case Western Reserve Univ, Cleveland Funct Elect Stimulat Ctr, Louis Stokes VA Med Ctr, Cleveland, OH 44106 USA; [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; [Chait, Sari] James A Haley Vet Hosp, Res & Dev Serv, Tampa, FL USA; [Chait, Sari] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Craine, Michael] Univ Colorado, Sch Med, Hlth Psychol Sect, VA Eastern Colorado Hlth Care Syst, Boulder, CO 80309 USA; [Craine, Michael] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Boulder, CO 80309 USA; [Scholten, Joel] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL USA; [Scholten, Joel] Univ S Florida, Coll Med, Div Phys Med & Rehabil, Tampa, FL 33620 USA	Gironda, RJ (corresponding author), James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv 116A, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Ronald.Gironda@va.gov					ANDREWS EE, 2009, J PAIN S1, V10, P74; Ashina M, 2004, CEPHALALGIA, V24, P161, DOI 10.1111/j.1468-2982.2003.00644.x; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Aurora SK, 2007, CEPHALALGIA, V27, P1442, DOI 10.1111/j.1468-2982.2007.01502.x; Baker A, 1996, Perspectives, V20, P4; Bendtsen L, 2000, CEPHALALGIA, V20, P486, DOI 10.1046/j.1468-2982.2000.00070.x; Bigal ME, 2008, HEADACHE, V48, P1157, DOI 10.1111/j.1526-4610.2008.01217.x; Bigal ME, 2009, PAIN, V142, P179, DOI 10.1016/j.pain.2009.01.013; Black JA, 2004, PAIN, V108, P237, DOI 10.1016/j.pain.2003.12.035; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; BOLINE PD, 1995, J MANIP PHYSIOL THER, V18, P148; Bove G, 1998, JAMA-J AM MED ASSOC, V280, P1576, DOI 10.1001/jama.280.18.1576; Breslau N, 2003, NEUROLOGY, V60, P1308, DOI 10.1212/01.WNL.0000058907.41080.54; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Chibnall JT, 2001, PAIN, V92, P173, DOI 10.1016/S0304-3959(00)00485-1; Clark ME, 2004, PAIN MED, V5, P333, DOI 10.1111/j.1526-4637.2004.04059.x; CLARK ME, 2009, NAT VA PAIN MAN C E; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; Coppola G, 2007, Cephalalgia, V27, P1427, DOI 10.1111/j.1468-2982.2007.01500.x; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Daly CM, 2005, MIL MED, V170, P513, DOI 10.7205/MILMED.170.6.513; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; Dierks MR, 2007, ANN PHARMACOTHER, V41, P1013, DOI 10.1345/aph.1H588; Edna T H, 1987, J Oslo City Hosp, V37, P41; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Feldt K S, 2000, Pain Manag Nurs, V1, P13, DOI 10.1053/jpmn.2000.5831; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Ferrell BA, 2000, CLIN GERIATR MED, V16, P853, DOI 10.1016/S0749-0690(05)70048-3; Ferrell BA, 1995, J PAIN SYMPTOM MANAG, V10, P591, DOI 10.1016/0885-3924(95)00121-2; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; Follett PL, 2004, J NEUROSCI, V24, P4412, DOI 10.1523/JNEUROSCI.0477-04.2004; Frank MG, 2001, NEURON, V30, P275, DOI 10.1016/S0896-6273(01)00279-3; Gallagher R, 2006, J AM MED DIR ASSOC, V7, P432, DOI 10.1016/j.jamda.2006.04.010; Garcia-Monco JC, 2007, CEPHALALGIA, V27, P920, DOI 10.1111/j.1468-2982.2007.01367.x; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Hadjistavropoulos T, 2000, CLIN J PAIN, V16, P54, DOI 10.1097/00002508-200003000-00009; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Hains BC, 2005, BRAIN, V128, P2359, DOI 10.1093/brain/awh623; Hargreaves RJ, 1999, CAN J NEUROL SCI, V26, pS12, DOI 10.1017/S0317167100000147; Herr K, 2006, J PAIN SYMPTOM MANAG, V31, P170, DOI 10.1016/j.jpainsymman.2005.07.001; Herr KA, 2001, CLIN GERIATR MED, V17, P457, DOI 10.1016/S0749-0690(05)70080-X; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLROYD KA, 1990, PAIN, V42, P1, DOI 10.1016/0304-3959(90)91085-W; Huffman Jeff C, 2007, Dialogues Clin Neurosci, V9, P29; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Jha SK, 2005, J NEUROSCI, V25, P9266, DOI 10.1523/JNEUROSCI.2722-05.2005; Kalra M, 2003, J VASC SURG, V38, P215, DOI 10.1016/S0741-5214(03)00331-8; Kaniecki R, 2003, JAMA-J AM MED ASSOC, V289, P1430, DOI 10.1001/jama.289.11.1430; Kaniecki R, 2004, STANDARDS CARE HEADA, P40; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; Koltyn KF, 1998, BRIT J SPORT MED, V32, P20, DOI 10.1136/bjsm.32.1.20; Kovach CR, 1999, J PAIN SYMPTOM MANAG, V18, P412, DOI 10.1016/S0885-3924(99)00094-9; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LANDY S, 2004, STANDARDS CARE HEADA, P27; LEEDHAM CS, 1993, MIL MED, V158, P508; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; LEW HL, J REHABILIT IN PRESS; MATHEW N, 2004, STANDARDS CARE HEADA, P73; *MIL TBI TASK FORC, 2007, REP MIL TBI TASK FOR; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Montagna P, 2000, CEPHALALGIA, V20, P3, DOI 10.1046/j.1468-2982.2000.00003.x; Morello R, 2007, PAIN, V133, P87, DOI 10.1016/j.pain.2007.03.007; Mulleners WM, 2001, HEADACHE, V41, P565, DOI 10.1046/j.1526-4610.2001.041006565.x; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Penzien DB, 2002, APPL PSYCHOPHYS BIOF, V27, P163, DOI 10.1023/A:1016247811416; Ramadan NM, 2007, HEADACHE, V47, pS52, DOI 10.1111/j.1526-4610.2007.00677.x; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; *ROYAL COLL PHYS B, 2007, CONC GUID GOOD PRACT, V8; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; RUOFF G, 2004, STANDARDS CARE HEADA, P53; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sandor PS, 2007, CEPHALALGIA, V27, P1440, DOI 10.1111/j.1468-2982.2007.01501.x; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Stankewitz A, 2007, CEPHALALGIA, V27, P1454, DOI 10.1111/j.1468-2982.2007.01503.x; Stolee P, 2005, J AM GERIATR SOC, V53, P319, DOI 10.1111/j.1532-5415.2005.53121.x; Stoudemire A, 1984, Psychiatr Med, V2, P211; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Veterans Health Administration, 2006, VHA HDB 2A, P1; WALKER RL, 2009, POSTDEPLOYMENT UNPUB; Walker RL, 2008, NAT M VA HLTH SERV R; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Waxman SG, 2006, TRENDS NEUROSCI, V29, P207, DOI 10.1016/j.tins.2006.02.003; Weiner D, 1996, PAIN, V67, P461, DOI 10.1016/0304-3959(96)03150-8; Weiner DK, 2002, PERSISTENT PAIN IN OLDER ADULTS: INTERDISCIPLINARY GUIDE FOR TREATMENT, P18; Young James A, 2007, Phys Med Rehabil Clin N Am, V18, P145, DOI 10.1016/j.pmr.2006.11.008; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007; ZOROYA G, 2006, CTR WAR RELATED BRAI	97	97	97	0	14	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					247	258		10.1037/a0016906			12	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	488SW	WOS:000269371100002	19702423				2021-06-18	
J	Laufer, J; Zhang, E; Raivich, G; Beard, P				Laufer, Jan; Zhang, Edward; Raivich, Gennadij; Beard, Paul			Three-dimensional noninvasive imaging of the vasculature in the mouse brain using a high resolution photoacoustic scanner	APPLIED OPTICS			English	Article; Proceedings Paper	Biomedical Topical Meeting	MAR 16-20, 2008	St Petersburg, FL	Opt Soc Amer			IN-VIVO; TOMOGRAPHY	The application of a novel photoacoustic imaging instrument based on a Fabry-Perot polymer film sensing interferometer to imaging the small animal brain is described. This approach provides a convenient backward mode sensing configuration that offers the prospect of overcoming the limitations of existing piezoelectric based detection schemes for small animal brain imaging. Noninvasive images of the vasculature in the mouse brain were obtained at different wavelengths between 590 and 889 nm, showing that the cerebral vascular anatomy can be visualized with high contrast and spatial resolution to depths up to 3.7 mm. It is considered that the instrument has a role to play in characterizing small animal models of human disease and injury processes such as stroke, epilepsy, and traumatic brain injury. (C) 2009 Optical Society of America	[Laufer, Jan; Zhang, Edward; Raivich, Gennadij; Beard, Paul] UCL, Dept Med Phys & Bioengn, London WC1E 6BT, England; [Raivich, Gennadij] UCL, Ctr Perinatal Brain Res, London WC1E 6BT, England	Beard, P (corresponding author), UCL, Dept Med Phys & Bioengn, Gower St, London WC1E 6BT, England.	pbeard@medphys.ucl.ac.uk	Raivich, Gennadij/A-6770-2011; Raivich, Gennadij/AAL-7229-2021	Laufer, Jan/0000-0002-9688-8993			Allen TJ, 2006, OPT LETT, V31, P3462, DOI 10.1364/OL.31.003462; [Anonymous], 1994, 608251 BS EN, P1; Balaban R S, 2001, ILAR J, V42, P248; BEARD PC, 2001, Patent No. 03039364; Cherry SR, 2004, PHYS MED BIOL, V49, pR13, DOI 10.1088/0031-9155/49/3/R01; Cope M., 1991, APPL NEAR INFRARED S; De La Zerda A, 2008, NAT NANOTECHNOL, V3, P557, DOI 10.1038/nnano.2008.231; Fang H, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.184501; Gamelin J, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2907157; Gibson AP, 2005, PHYS MED BIOL, V50, pR1, DOI 10.1088/0031-9155/50/4/R01; Hillman EMC, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2789693; Kostli KP, 2001, PHYS MED BIOL, V46, P1863, DOI 10.1088/0031-9155/46/7/309; Kruger Robert A, 2003, Mol Imaging, V2, P113, DOI 10.1162/153535003322331993; Lamont M, 2006, ELECTRON LETT, V42, P187, DOI 10.1049/el:20064135; Laufer J, 2007, PHYS MED BIOL, V52, P141, DOI 10.1088/0031-9155/52/1/010; Li ML, 2008, P IEEE, V96, P481, DOI 10.1109/JPROC.2007.913515; Lythgoe MF, 2003, BRIT MED BULL, V65, P235, DOI 10.1093/bmb/65.1.235; MASLOV K, 2007, P SPIE, V6437; Song KH, 2006, OPT LETT, V31, P2453, DOI 10.1364/OL.31.002453; STEIN EW, 2008, P SPIE, V6856; Wang L., 2007, BIOMEDICAL OPTICS PR; Wang LV, 2008, IEEE J SEL TOP QUANT, V14, P171, DOI 10.1109/JSTQE.2007.913398; Wang XD, 2004, OPT LETT, V29, P730, DOI 10.1364/OL.29.000730; Wang XD, 2003, OPT LETT, V28, P1739, DOI 10.1364/OL.28.001739; Wang XD, 2003, NAT BIOTECHNOL, V21, P803, DOI 10.1038/nbt839; Yang S, 2007, MED PHYS, V34, P3294, DOI 10.1118/1.2757088; Zhang E, 2008, APPL OPTICS, V47, P561, DOI 10.1364/AO.47.000561; ZHANG EZ, 2007, P SPIE, V6437; Zhang QZ, 2008, PHYS MED BIOL, V53, P1921, DOI 10.1088/0031-9155/53/7/008	29	97	100	0	18	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	1559-128X	2155-3165		APPL OPTICS	Appl. Optics	APR 1	2009	48	10					D299	D306		10.1364/AO.48.00D299			8	Optics	Optics	436VH	WOS:000265443700034	19340121				2021-06-18	
J	Rivera, PA; Elliott, TR; Berry, JW; Grant, JS				Rivera, Patricia A.; Elliott, Timothy R.; Berry, Jack W.; Grant, Joan S.			Problem-solving training for family caregivers of persons with traumatic brain injuries: A randomized controlled trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; caregivers; problem-solving; randomized controlled trials; rehabilitation	STROKE SURVIVORS; PHYSICAL HEALTH; INITIAL YEAR; INTERVENTION; THERAPY; STRESS; MODEL; PREDICTORS; ADJUSTMENT; DEPRESSION	Objective: To test the hypothesis that a problem-solving training program Would lower depression, health complaints. and burden, and increase well-being reported by community-residing family caregivers of persons with traumatic brain injuries (TBIs). Design: Randomized controlled trial. Setting: General community. Participants: Of the 180 people who expressed interest in the Study, 113 did not meet eligibility criteria. A consenting sample of family caregivers were randomized into a problem-solving training group (4 men, 29 women; average age, 5 1.3y) or an education-only control group (34 women, average age, 50.8y). Care recipients included 26 men and 7 women in the intervention group (average age, 36.5y) and 24 men and 10 women in the control group (average age, 37.2y). Intervention: Problem-solving training based oil the 9 D'Zurilla and Nezu social problem-solving model was provided to caregivers in the intervention group in 4 in-home sessions and 8 telephone follow-up calls over the course of their year-long participation. Control group participants received written educational materials and telephone calls at set intervals throughout their 12 months of participation. Main Outcome Measures: Caregiver depression, health complaints, well-being, and social problem-solving abilities. Results: Hierarchical linear models revealed caregivers receiving problem-solving training reported significant decreases in depression, health complaints, and in dysfunctional problem-solving styles over time. No effects were observed oil caregiver well-being, burden, or Constructive problem-solving styles. Conclusions: Problem-solving training provided in file home appears to be effective in alleviating distress and in decreasing dysfunctional problem-solving styles among family caregivers of persons with TBI. Methodologic limitations and the implications for interventions and future research are discussed.	[Rivera, Patricia A.] Birmingham VAMC, Birmingham, AL 35233 USA; [Elliott, Timothy R.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA; [Berry, Jack W.] Univ Alabama Birmingham, Injury Control Res Ctr, Birmingham, AL USA; [Grant, Joan S.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA	Rivera, PA (corresponding author), Birmingham VAMC, 700 19th St S, Birmingham, AL 35233 USA.	patricia.rivera@va.gov	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714; Grant, Joan/0000-0001-6000-4060	National Institute for Disability and Rehabilitation Research [H133A02050]; U.S. Department of health and Human Services, Centers for Disease Control and Prevention - National Center for Injury Prevention [R49/CE000191]; National Institute oil Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD07420]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007420, R01HD037661] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER	Supported by the National Institute for Disability and Rehabilitation Research (grant no. H133A02050) by the U.S. Department of health and Human Services, Centers for Disease Control and Prevention - National Center for Injury Prevention (grant no. R49/CE000191). and by the National Institute oil Child Health and Human Development (grant no. T32 HD07420).	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Bucher JA, 1999, J PSYCHOSOC ONCOL, V16, P73, DOI 10.1300/J077v16n03_05; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Dreer LE, 2007, REHABIL PSYCHOL, V52, P351, DOI 10.1037/0090-5550.52.3.351; Dzurilla T.J., 2004, SOCIAL PROBLEM SOLVI, P11, DOI DOI 10.1037/10805-001; DZurilla T. J., 2002, SOCIAL PROBLEM SOLVI; ELLIOTT T, 2008, BIENNIAL REV COUNSEL, V1; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Elliott TR, 2000, COGNITIVE BEHAV INTE, P309; Ellis C, 2007, EJC SUPPL, V5, P8, DOI 10.1016/S1359-6349(07)71715-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; Grant JS, 2006, ARCH PHYS MED REHAB, V87, P343, DOI 10.1016/j.apmr.2005.09.019; Grant JS, 2004, REHABIL PSYCHOL, V49, P172, DOI 10.1037/0090-5550.49.2.172; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Hayes AM, 2007, CLIN PSYCHOL REV, V27, P715, DOI 10.1016/j.cpr.2007.01.008; Hedeker D, 1999, J EDUC BEHAV STAT, V24, P70, DOI 10.3102/10769986024001070; Houts PS, 1996, PATIENT EDUC COUNS, V27, P63, DOI 10.1016/0738-3991(95)00790-3; Johnson MO, 2006, HEALTH PSYCHOL, V25, P355, DOI 10.1037/0278-6133.25.3.355; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Laurenceau JP, 2007, CLIN PSYCHOL REV, V27, P682, DOI 10.1016/j.cpr.2007.01.007; Lipsey M.W., 2001, APPL SOCIAL RES METH, V49; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Lui MHL, 2005, STROKE, V36, P2514, DOI 10.1161/01.STR.0000185743.41231.85; Malouff JM, 2007, CLIN PSYCHOL REV, V27, P46, DOI 10.1016/j.cpr.2005.12.005; Miller EA, 2007, HEALTH POLICY, V82, P133, DOI 10.1016/j.healthpol.2006.09.011; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; Nezu AM, 2004, BEHAV THER, V35, P1, DOI 10.1016/S0005-7894(04)80002-9; Nezu AM, 2003, J CONSULT CLIN PSYCH, V71, P1036, DOI 10.1037/0022-006X.71.6.1036; OBERST MT, 1989, CANCER NURS, V12, P209; Pennebaker J.W., 1982, PSYCHOL PHYS SYMPTOM; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perri MG, 2001, J CONSULT CLIN PSYCH, V69, P722, DOI 10.1037/0022-006X.69.4.722; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Rivera P, 2003, TOP SPINAL CORD INJ, V9, P53, DOI [DOI 10.1310/G82F-BR2R-T69L-3QX8, 10.1310/G82F-BR2R-T69L-3QX8]; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Rivera PA, 2006, J CLIN PSYCHOL MED S, V13, P431, DOI 10.1007/s10880-006-9043-6; Sahler OJZ, 2005, J CONSULT CLIN PSYCH, V73, P272, DOI 10.1037/0022-006X.73.2.272; *STAT U NEW YORK B, 1996, GUID US UN DAT SET M; Tucker JA, 2006, ADDICTION, V101, P918, DOI 10.1111/j.1360-0443.2006.01396.x; UITENBROEK DG, SISA FISHER 2 5 2000; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375	52	97	98	0	32	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					931	941		10.1016/j.apmr.2007.12.032			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900020	18452743	Green Accepted			2021-06-18	
J	Kim, J; Avants, B; Patel, S; Whyte, J; Coslett, BH; Pluta, J; Detre, JA; Gee, JC				Kim, Junghoon; Avants, Brian; Patel, Sunil; Whyte, John; Coslett, Branch H.; Pluta, John; Detre, John A.; Gee, James C.			Structural consequences of diffuse traumatic brain injury: A large deformation tensor-based morphometry study	NEUROIMAGE			English	Article						traumatic brain injury; atrophy; tensor-based morphometry; diffeomorphic; magnetic resonance imaging	VOXEL-BASED MORPHOMETRY; REGIONAL SPATIAL NORMALIZATION; BLUNT HEAD-INJURY; VEGETATIVE STATE; CORPUS-CALLOSUM; COMPUTATIONAL ANATOMY; UNITED-STATES; 3D PATTERN; NEUROPATHOLOGY; MATTER	Traumatic brain injury (TBI) is one of the most common causes of long-term disability. Despite the importance of identifying neuropathology in individuals with chronic TBI, methodological challenges posed at the stage of inter-subject image registration have hampered previous voxel-based MRI studies from providing a clear pattern of structural atrophy after TBI. We used a novel symmetric diffeomorphie image normalization method to conduct a tensor-based morphometry (TBM) study of TBI. The key advantage of this method is that it simultaneously estimates an optimal template brain and topology preserving deformations between this template and individual subject brains. Detailed patterns of atrophies are then revealed by statistically contrasting control and subject deformations to the template space. Participants were 29 survivors of TBI and 20 control subjects who were matched in terms of age, gender, education, and ethnicity. Localized volume losses were found most prominently in white matter regions and the subcortical nuclei including the thalamus, the midbrain, the corpus callosum, the mid- and posterior cingulate cortices, and the caudate. Significant voxel-wise volume loss clusters were also detected in the cerebellum and the frontal/temporal neocortices. Volume enlargements were identified largely in ventricular regions. A similar pattern of results was observed in a subgroup analysis where we restricted our analysis to the 17 TBI participants who had no macroscopic focal lesions (total lesion volume >1.5 cm(3)). The current study confirms, extends, and partly challenges previous structural MRI studies in chronic TBI. By demonstrating that a large deformation image registration technique can be successfully combined with TBM to identify TBI-induced diffuse structural changes with greater precision, our approach is expected to increase the sensitivity of future studies examining brain-behavior relationships in the TBI population. (c) 2007 Elsevier Inc. All rights reserved.	[Kim, Junghoon; Patel, Sunil; Whyte, John] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; [Avants, Brian; Detre, John A.; Gee, James C.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Coslett, Branch H.; Detre, John A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Pluta, John; Detre, John A.] Univ Penn, Ctr Funct Imaging, Philadelphia, PA 19104 USA; [Whyte, John] Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA	Kim, J (corresponding author), Albert Einstein Healthcare Network, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	kimj@einstein.edu	Kim, Junghoon/A-6669-2012; Kim, Junghoon John/I-6702-2019	Kim, Junghoon John/0000-0001-5729-8993; avants, brian/0000-0002-4212-3362; Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD039621-01, R24 HD039621, R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS045839-01, P30NS045839, P30 NS045839] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 1998, HUM BRAIN MAPP, V6, P348, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<348::AID-HBM4>3.3.CO;2-G; Avants B, 2005, ALZ DIS ASSOC DIS, V19, pS25, DOI 10.1097/01.wad.0000183083.14939.82; Avants B, 2004, NEUROIMAGE, V23, pS139, DOI 10.1016/j.neuroimage.2004.07.010; AVANTS BB, IN PRESS MED IMAGE A; Avants BB, 2006, MED IMAGE ANAL, V10, P397, DOI 10.1016/j.media.2005.03.005; Bermudez P, 2001, NEUROIMAGE, V13, P1121, DOI 10.1006/nimg.2001.0772; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BIGLER ED, 2005, TXB TRAUMATIC BRAIN, P79, DOI DOI 10.1007/S00417-005-0003-X; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Brambati SM, 2007, NEUROIMAGE, V35, P998, DOI 10.1016/j.neuroimage.2007.01.028; Cardenas VA, 2007, NEUROIMAGE, V34, P879, DOI 10.1016/j.neuroimage.2006.10.015; Chau W, 2005, NEUROIMAGE, V25, P408, DOI 10.1016/j.neuroimage.2004.12.007; Chiang MC, 2007, NEUROIMAGE, V34, P44, DOI 10.1016/j.neuroimage.2006.08.030; Chung MK, 2001, NEUROIMAGE, V14, P595, DOI 10.1006/nimg.2001.0862; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; Davatzikos C, 2001, NEUROIMAGE, V14, P1361, DOI 10.1006/nimg.2001.0937; Davatzikos C, 1996, J COMPUT ASSIST TOMO, V20, P88, DOI 10.1097/00004728-199601000-00017; Dubb A, 2005, ACAD RADIOL, V12, P3, DOI 10.1016/j.acra.2004.06.009; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gaser C, 1999, NEUROIMAGE, V10, P107, DOI 10.1006/nimg.1999.0458; Gaser C, 2001, NEUROIMAGE, V13, P1140, DOI 10.1006/nimg.2001.0771; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kochunov P, 2001, J COMPUT ASSIST TOMO, V25, P805, DOI 10.1097/00004728-200109000-00023; Kochunov P, 2005, HUM BRAIN MAPP, V24, P325, DOI 10.1002/hbm.20090; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lee AD, 2007, NEUROIMAGE, V34, P924, DOI 10.1016/j.neuroimage.2006.09.043; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Mai J.K., 2004, ATLAS HUMAN BRAIN; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miller MI, 2002, ANNU REV BIOMED ENG, V4, P375, DOI 10.1146/annurev.bioeng.4.092101.125733; Miller MI, 2004, NEUROIMAGE, V23, pS19, DOI 10.1016/j.neuroimage.2004.07.021; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Romanski LM, 1997, J COMP NEUROL, V379, P313; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Senjem ML, 2005, NEUROIMAGE, V26, P600, DOI 10.1016/j.neuroimage.2005.02.005; Studholme C, 2004, NEUROIMAGE, V21, P1387, DOI 10.1016/j.neuroimage.2003.12.009; Talairach J., 1988, COPLANAR STEREOTAXIC; Thirion J P, 1998, Med Image Anal, V2, P243, DOI 10.1016/S1361-8415(98)80022-4; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Van Essen DC, 2001, VISION RES, V41, P1359, DOI 10.1016/S0042-6989(01)00045-1; Woods RP, 2003, NEUROIMAGE, V18, P769, DOI 10.1016/S1053-8119(03)00019-3; YOO T, 2003, INSIGHT IMAGES PRINC; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	64	97	99	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	FEB 1	2008	39	3					1014	1026		10.1016/j.neuroimage.2007.10.005			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	255XN	WOS:000252691800011	17999940	Green Accepted			2021-06-18	
J	Schnakers, C; Majerus, S; Giacino, J; Vanhaudenhuyse, A; Bruno, MA; Boly, M; Moonen, G; Damas, P; Lambermont, B; Lamy, M; Damas, F; Ventura, M; Laureys, S				Schnakers, Caroline; Majerus, Steve; Giacino, Joseph; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Boly, Melanie; Moonen, Gustave; Damas, Pierre; Lambermont, Bernard; Lamy, Maurice; Damas, Francois; Ventura, Manfredi; Laureys, Steven			A French validation study of the Coma Recovery Scale-Revised (CRS-R)	BRAIN INJURY			English	Article						vegetative state; minimally conscious state; neurobehavioural; closed head injury	SENSORY MODALITY ASSESSMENT; MINIMALLY CONSCIOUS STATE; WESSEX HEAD-INJURY; VEGETATIVE STATE; REHABILITATION TECHNIQUE; MISDIAGNOSIS; DIAGNOSIS; ACCURACY; MATRIX	Primary objective: The aim of the present study was to explore the concurrent validity, inter-rater agreement and diagnostic sensitivity of a French adaptation of the Coma Recovery Scale-Revised (CRS-R) as compared to other coma scales such as the Glasgow Coma Scale (GCS), the Full Outline of UnResponsiveness scale (FOUR) and the Wessex Head Injury Matrix (WHIM). Research design: Multi-centric prospective study. Method and procedures: To test concurrent validity and diagnostic sensitivity, the four behavioural scales were administered in a randomized order in 77 vegetative and minimally conscious patients. Twenty-four clinicians with different professional backgrounds, levels of expertise and CRS-R experience were recruited to assess inter-rater agreement. Main outcomes and results: Good concurrent validity was obtained between the CRS-R and the three other standardized behavioural scales. Inter-rater reliability for the CRS-R total score and sub-scores was good, indicating that the scale yields reproducible findings across examiners and does not appear to be systematically biased by profession, level of expertise or CRS-R experience. Finally, the CRS-R demonstrated a significantly higher sensitivity to detect MCS patients, as compared to the GCS, the FOUR and the WHIM. Conclusion: The results show that the French version of the CRS-R is a valid and sensitive scale which can be used in severely brain damaged patients by all members of the medical staff.	[Schnakers, Caroline; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Boly, Melanie; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Majerus, Steve] Univ Liege, Dept Cognit Sci, B-4000 Liege, Belgium; [Giacino, Joseph] New Jersey Neurosci Inst, Edison, NJ USA; [Boly, Melanie; Moonen, Gustave; Laureys, Steven] Univ Sart Tilman, Ctr Hosp, Dept Neurol, Liege, Belgium; [Damas, Pierre; Lambermont, Bernard; Lamy, Maurice] Univ Sart Tilman, Ctr Hosp, Dept Intens Care, Liege, Belgium; [Damas, Francois] Citadelle Reg Hosp Liege, Dept Intens Care, Liege, Belgium; [Ventura, Manfredi] Univ Libre Bruxelles, CTR Neurorehabil Ctr, Brussels, Belgium	Schnakers, C (corresponding author), Univ Liege, Ctr Rech Cyclotron, Sart Tilman,B30, B-4000 Liege, Belgium.	c.schnakers@student.ulg.ac.be	Ventura, Manfredi/AAG-9123-2019; Vanhaudenhuyse, Audrey/AAP-2455-2020; Giacino, Joseph/AAF-1952-2021; Majerus, Steve/D-4678-2009; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011	Giacino, Joseph/0000-0002-7916-9698; Laureys, Steven/0000-0002-3096-3807; Boly, Melanie/0000-0001-9584-0907; Majerus, Steve/0000-0002-8206-8097	Belgian Federal Public Service for Public Health; Belgian 'Fonds National de la Recherche Scientifique' (FNRS)Fonds de la Recherche Scientifique - FNRS; 'Centre Hospitalier' of the University of LiegeUniversity of Liege	This study was supported by funds from the Belgian Federal Public Service for Public Health, Belgian 'Fonds National de la Recherche Scientifique' (FNRS), 'Centre Hospitalier' of the University of Liege, French Speaking Community of Belgium Concerted Research Action, the J. S. McDonnell Foundation, the European Commission, Mind Science Foundation, TX. SL, SM and MB are, respectively, Senior Research Associate, Research Associate, and Research Fellow at the FNRS. CS is funded by the 'Fonds Leon Fredericq' (University of Liege) and the FNRS.	Andrews K, 2005, NEUROPSYCHOL REHABIL, V15, P461, DOI 10.1080/09602010443000326; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; JAGGER J, 1983, LANCET, V2, P97; LANDIS JR, 1977, BIOMETRICS, V33, P174; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Majerus S, 2000, NEUROPSYCHOL REHABIL, V10, P167, DOI 10.1080/096020100389237; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; TEASDALE G, 1974, LANCET, V2, P81; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606	23	97	103	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	10					786	792		10.1080/02699050802403557			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	347MJ	WOS:000259145400009	18787989				2021-06-18	
J	Kharatishvili, I; Immonen, R; Grohn, O; Pitkanen, A				Kharatishvili, Irina; Immonen, Riikka; Grohn, Olli; Pitkanen, Asla			Quantitative diffusion MRI of hippocampus as a surrogate marker for post-traumatic epileptogenesis	BRAIN			English	Article						traumatic brain injury; magnetic resonance imaging; surrogate marker; post-traumatic epilepsy; video-EEG monitoring	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; FIBER SYNAPTIC REORGANIZATION; CLOSED-HEAD INJURY; WEIGHTED MR; STATUS EPILEPTICUS; WATER-DIFFUSION; DENTATE GYRUS; TIME-COURSE; SPONTANEOUS SEIZURES	The need to use animal models to develop imaging markers that could be linked to electrophysiological abnormalities in epilepsy and able to predict epileptogenicity in human studies is widely acknowledged. This study aimed to investigate the value of early magnetic resonance imaging (MRI) in predicting the long-term increased seizure susceptibility in the clinically relevant model of post-traumatic epilepsy (PTE). Moderate traumatic brain injury (TBI) was induced by lateral fluid-percussion in two groups of adult rats (34 injured, 16 controls). In Experiment 1, MRI follow-up was performed using a 4.7 T magnet at 3 h, 3 days, 9 days, 23 days, 2 months, 3 months and 6 months after TBI. T2 and 1/3 of the trace of the diffusion tensor (D-av) were quantified from a single slice using a fast spin-echo sequence. In Experiment 2, MRI was performed at 7 and 11 months post-injury. In both groups, seizure susceptibility was tested by injecting a single dose of pentylenetetrazol at 12 months post-injury. Electrographic and behavioural responses were monitored for 1 h. Total number of spikes, total number of epileptiform discharges (EDs) and latency to first spike were measured. Finally, the severity of mossy fibre sprouting was evaluated. In both experiments, EEG parameters such as total number of spikes or EDs proved to be reliable indicators of increased seizure susceptibility in injured animals when compared to controls (P < 0.05). In the hippocampus ipsilateral to TBI, D-av correlated with these EEG parameters at both early (3 h), and chronic (23 days, 2, 3, 6, 7 and 11 months) time points after TBI, as well as with the density of mossy fibre sprouting. These results for the first time demonstrate that quantitative diffusion MRI can serve as a tool to facilitate prediction of increased seizure susceptibility in a clinically relevant model of human PTE.	Univ Kuopio, Inst Mol Sci, FI-70211 Kuopio, Finland; Univ Kuopio, Epilepsy Res Grp, FI-70211 Kuopio, Finland; Univ Kuopio, Biomed NMR Res Grp, FI-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-70211 Kuopio, Finland; Univ Kuopio, Dept Neurosci, FI-70211 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Kuopio, Inst Mol Sci, PO Box 1627, FI-70211 Kuopio, Finland.	asla.pitkanen@uku.fi					Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Assaf BA, 2003, AM J NEURORADIOL, V24, P1857; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Bragin A, 1999, EPILEPSIA, V40, P1210, DOI 10.1111/j.1528-1157.1999.tb00849.x; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Diehl B, 2005, EPILEPSY RES, V65, P137, DOI 10.1016/j.eplepsyres.2005.05.007; Diehl B, 2001, EPILEPSIA, V42, P21, DOI 10.1046/j.1528-1157.2001.19500.x; Diehl B, 1999, EPILEPSIA, V40, P1667, DOI 10.1111/j.1528-1157.1999.tb02056.x; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Duncan JS, 2002, EPILEPSY RES, V50, P131, DOI 10.1016/S0920-1211(02)00075-X; Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339; Ebisu T, 1996, MAGNET RESON MED, V36, P821, DOI 10.1002/mrm.1910360604; Elmer E, 1997, NEUROREPORT, V8, P1193, DOI 10.1097/00001756-199703240-00027; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GOLARAI G, 1992, BRAIN RES, V593, P257, DOI 10.1016/0006-8993(92)91316-7; Golarai G, 2001, J NEUROSCI, V21, P8523; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOUSER CR, 1990, J NEUROSCI, V10, P267; Hufnagel A, 2003, EPILEPSIA, V44, P54, DOI 10.1046/j.1528-1157.2003.07802.x; Hugg JW, 1999, NEUROLOGY, V53, P173, DOI 10.1212/WNL.53.1.173; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Kantarci K, 2002, NEUROLOGY, V58, P1745, DOI 10.1212/WNL.58.12.1745; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kim JA, 2001, AM J NEURORADIOL, V22, P1149; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Lee JH, 2004, ACTA NEUROL SCAND, V110, P53, DOI 10.1111/j.1600-0404.2004.00261.x; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Longo BM, 1998, EPILEPSY RES, V32, P172, DOI 10.1016/S0920-1211(98)00049-7; LOSCHER W, 1991, EPILEPSY RES, V8, P171, DOI 10.1016/0920-1211(91)90062-K; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marks MP, 1996, RADIOLOGY, V199, P403, DOI 10.1148/radiology.199.2.8668785; MASON CR, 1972, EPILEPSIA, V13, P663, DOI 10.1111/j.1528-1157.1972.tb04401.x; Mathern GW, 1998, J NEUROSCI RES, V54, P734, DOI 10.1002/(SICI)1097-4547(19981215)54:6<734::AID-JNR2>3.0.CO;2-P; MATHERN GW, 1995, J NEUROSURG, V82, P211, DOI 10.3171/jns.1995.82.2.0211; Mathern GW, 1996, EPILEPSY RES, V26, P151, DOI 10.1016/S0920-1211(96)00052-6; MATHERN GW, 1995, J NEUROSURG, V82, P220, DOI 10.3171/jns.1995.82.2.0220; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; NAKASU Y, 1995, AM J NEURORADIOL, V16, P1185; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Pitkanen A, 2007, EPILEPSIA, V48, P13, DOI 10.1111/j.1528-1167.2007.01063.x; REPRESA A, 1993, HIPPOCAMPUS, V3, P257, DOI 10.1002/hipo.450030303; Rugg-Gunn FJ, 2002, LANCET, V359, P1748, DOI 10.1016/S0140-6736(02)08615-4; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sloviter RS, 2006, J COMP NEUROL, V494, P944, DOI 10.1002/cne.20850; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Sloviter RS, 1999, EPILEPSIA, V40, pS34, DOI 10.1111/j.1528-1157.1999.tb00876.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Swinyard E.A., 1989, ANTIEPILEPTIC DRUGS, P85; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Thivard L, 2005, NEUROIMAGE, V28, P682, DOI 10.1016/j.neuroimage.2005.06.045; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Toth Z, 1997, J NEUROSCI, V17, P8106; Velisek L, 2006, MODELS OF SEIZURES AND EPILEPSY, P127, DOI 10.1016/B978-012088554-1/50013-X; Wang Y, 1996, EPILEPSIA, V37, P1000, DOI 10.1111/j.1528-1157.1996.tb00539.x; Wieshmann UC, 1999, MAGN RESON IMAGING, V17, P29, DOI 10.1016/S0730-725X(98)00153-2; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Yoo SY, 2002, AM J NEURORADIOL, V23, P809; ZHONG J, 1993, MAGN RESON MED, V30, P241, DOI 10.1002/mrm.1910300214; Zhong JH, 1997, MAGN RESON MED, V37, P1, DOI 10.1002/mrm.1910370102	93	97	97	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	DEC	2007	130		12				3155	3168		10.1093/brain/awm268			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	236WX	WOS:000251335200012	18055492				2021-06-18	
J	Buttram, SDW; Wisniewski, SR; Jackson, EK; Adelson, PD; Feldman, K; Bayir, H; Berger, RP; Clark, RSB; Kochanek, PM				Buttram, Sandra D. W.; Wisniewski, Stephen R.; Jackson, Edwin K.; Adelson, P. David; Feldman, Keri; Bayir, Hulya; Berger, Rachel P.; Clark, Robert S. B.; Kochanek, Patrick M.			Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: Effects of moderate hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						children; head trauma; inflicted childhood neurotrauma; interleukin; Luminex	GROWTH-FACTOR PRODUCTION; RAT-BRAIN; CRYPTOCOCCUS-NEOFORMANS; INFLAMMATORY RESPONSE; BARRIER FUNCTION; HEAD TRAUMA; EXPRESSION; INTERLEUKIN-10; CHILDREN; SERUM	This study performed a comprehensive analysis of cerebrospinal fluid (CSF) cytokine levels after severe traumatic brain injury (TBI) in children using a multiplex bead array assay and to evaluate the effects of moderate hypothermia on cytokine levels. To this end, samples were collected during two prospective randomized controlled trials of therapeutic moderate hypothermia in pediatric TBI. Thirty-six children with severe TBI ( Glasgow Coma Scale [GCS] score of <= 8) and 10 children with negative diagnostic lumbar punctures. All children with TBI had continuous monitoring of intracranial pressure and CSF drainage via an intraventricular catheter. Moderate hypothermia (32-33 degrees C) was maintained for 48 h in 17 patients, and they were slowly re-warmed at 48-72 h. A multiplex bead array assay was used to analyze serial CSF samples (< 18 h, 24 +/- 6 h, 48 +/- 6 h, and 72 +/- 6 h) for 21 pro-and anti-inflammatory cytokines and chemokines. Interleukin (IL)-8 and transforming growth factor beta were measured by enzyme-linked immunosorbant assay (ELISA). There was a strong correlation ( Spearman correlation coefficient = 0.92, p < 0.001) between multiplex assay and ELISA for IL-8. Pro-inflammatory IL-1 beta, -6 and -12p70, anti-inflammatory IL-10 and chemokines IL-8 and MIP-1 alpha were increased after TBI compared to controls, p < 0.05; however, there was no association between cytokines and age, gender, initial GCS, or outcome. Hypothermia did not attenuate the increases in CSF cytokine levels after TBI versus normothermia. This investigation confirmed that the multiplex bead array assay is a useful method to measure CSF cytokine levels. Severe TBI in infants and children induces increases in pro- and anti-inflammatory cytokines and chemokines. It is the first clinical report of increased levels of MIP-1 alpha after TBI in any patient population and the most comprehensive assessment of cytokines after TBI to date. Moderate therapeutic hypothermia did not attenuate the increase in CSF cytokine levels in children after TBI.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009	NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000005] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-34884, NS 30318] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN B, 2004, JHEP, V12, P57; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Clausen BH, 2005, NEUROSCIENCE, V132, P879, DOI 10.1016/j.neuroscience.2005.01.031; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; Decken K, 1998, INFECT IMMUN, V66, P4994, DOI 10.1128/IAI.66.10.4994-5000.1998; Du WY, 2003, INFECT IMMUN, V71, P3947, DOI 10.1128/IAI.71.7.3947-3953.2003; Galasso JM, 2000, NEUROSCIENCE, V101, P737, DOI 10.1016/S0306-4522(00)00399-7; Hans VHJ, 1999, NEUROREPORT, V10, P409; HART BA, 2005, J IMMUNOL, V175, P4761, DOI DOI 10.4049/JIMMUN0L.175.7.4761; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hulse RE, 2004, J NEUROSCI METH, V136, P87, DOI 10.1016/j.jneumeth.2003.12.023; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Juric DM, 2001, INT J DEV NEUROSCI, V19, P675, DOI 10.1016/S0736-5748(01)00044-2; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; Kim KY, 2003, INVERSE PROBL ENG, V11, P1, DOI 10.1080/1068276021000014705; Kleinschek MA, 2006, J IMMUNOL, V176, P1098, DOI 10.4049/jimmunol.176.2.1098; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Martins TB, 2002, AM J CLIN PATHOL, V118, P346; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Nozari A, 2006, CIRCULATION, V113, P2690, DOI 10.1161/CIRCULATIONAHA.106.613349; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Prabhakar U, 2002, J IMMUNOL METHODS, V260, P207, DOI 10.1016/S0022-1759(01)00543-9; Rosler A, 1998, J NEUROL SCI, V157, P82, DOI 10.1016/S0022-510X(98)00061-6; Sato M, 2003, PEDIATRICS, V112, P1103, DOI 10.1542/peds.112.5.1103; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHORE PM, 2003, PEDIAT CRIT CARE SA, V4, P413; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985	55	97	100	0	15	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1707	1717		10.1089/neu.2007.0349			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500004	18001201				2021-06-18	
J	Deng, Y; Thompson, BM; Gao, X; Hall, ED				Deng, Ying; Thompson, Brian M.; Gao, Xiang; Hall, Edward D.			Temporal relationship of peroxymtrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						peroxynitrite; oxidative damage; calpain; cytoskeletal degradation; neurodegeneration; controlled cortical impact (CCI); TBI	NITRIC-OXIDE SYNTHASE; EXPERIMENTAL HEAD-INJURY; CONTROLLED CORTICAL IMPACT; LIPID-PEROXIDATION; MITOCHONDRIAL DYSFUNCTION; PEROXYNITRITE REACTIONS; NEURONAL DEGENERATION; TYROSINE NITRATION; NERVOUS-SYSTEM; MOUSE MODEL	We assessed the temporal and spatial characteristics of PN-induced oxidative damage and its relationship to calpain-mediated cytoskeletal degradation and neurodegeneration in a severe unilateral controlled cortical impact (CCI) traumatic brain injury (TBI) model. Quantitative temporal time course studies were performed to measure two oxidative damage markers: 3-nitrotyrosine (3NT) and 4-hydroxynonenal (4HNE) at 30 min, 1, 3, 6, 12, 24, 48, 72 h and 7 days after injury in ipsilateral cortex of young adult male CF- I mice. Secondly, the time course of Ca++-activated, calpain-mediated proteolysis was also analyzed using quantitative western-blot measurement of breakdown products of the cytoskeletal protein alpha-spectrin. Finally, the time course of neurodegeneration was examined using de Olmos silver staining. Both oxidative damage markers increased in cortical tissue immediately after injury (30 min) and elevated for the first 3-6 h before returning to baseline. In the immunostaining study, the PN-selective marker, 3NT, and the lipid peroxidation marker, 4HNE, were intense and overlapping in the injured cortical tissue. alpha-Spectrin breakdown products, which were used as biomarker for calpain-mediated cytoskeletal degradation, were also increased after injury, but the time course lagged behind the peak of oxidative damage and did not reach its maximum until 24 h post-injury. In turn, cytoskeletal degradation preceded the peak of neurodegeneration which occurred at 48 h post-injury. These studies have led us to the hypothesis that PN-mediated oxidative damage is an early event that contributes to a compromise of Ca++ homeostatic mechanisms which causes a massive Ca++ overload and calpain activation which is a final common pathway that results in post-traumatic neurodegeneration. (C) 2007 Elsevier Inc. All rights reserved.	Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,B383 Biomed & Biol Sci Res Bld, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS046566-01A1, P30 NS051220, P30 NS051220-02, R01 NS046566-04, R01 NS046566, R01 NS046566-03, P30 NS051220-019005, R01 NS046566-02, P30 NS051220-029005, P30 NS051220-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566, P30NS051220] Funding Source: NIH RePORTER		ARRIGONI E, 1991, NEUROCHEM RES, V16, P483; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BENUCK M, 1992, BRAIN RES, V596, P296, DOI 10.1016/0006-8993(92)91560-2; Bicker G, 2001, ARCH INSECT BIOCHEM, V48, P100, DOI 10.1002/arch.1062; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; Chiueh CC, 1999, ANN NY ACAD SCI, V890, P301, DOI 10.1111/j.1749-6632.1999.tb08007.x; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Dawson VL, 1996, P SOC EXP BIOL MED, V211, P33; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Gahm C, 2000, NEUROSURGERY, V46, P169; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 2003, FREE RADICAL BIO MED, V34, P397, DOI 10.1016/S0891-5849(02)01298-4; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Hall ED, 1997, J NEUROSCI METH, V76, P115, DOI 10.1016/S0165-0270(97)00089-7; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALLIWELL B, 1999, OXFORD SCI PUBLICATI; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mohanakumar KP, 1998, J CHEM NEUROANAT, V14, P195, DOI 10.1016/S0891-0618(98)00032-5; Mori T, 1998, ACT NEUR S, V71, P120; Murphy MP, 1998, GEN PHARMACOL, V31, P179, DOI 10.1016/S0306-3623(97)00418-7; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Okabe E, 2000, ANTIOXID REDOX SIGN, V2, P47, DOI 10.1089/ars.2000.2.1-47; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh LN, 2006, J NEUROTRAUM, V23, P991; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Vicente S, 2006, J NEUROSCI RES, V84, P78, DOI 10.1002/jnr.20853; Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Whiteman M, 2004, FASEB J, V18, P1395, DOI 10.1096/fj.03-1096fje; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Zhou F, 2001, J CLIN NEUROSCI, V8, P561, DOI 10.1054/jocn.2001.0980	72	97	103	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2007	205	1					154	165		10.1016/j.expneurol.2007.01.023			12	Neurosciences	Neurosciences & Neurology	166TO	WOS:000246403400018	17349624	Green Accepted			2021-06-18	
J	Cernich, A; Reeves, D; Sun, WY; Bleiberg, J				Cernich, Alison; Reeves, Dennis; Sun, Wenyu; Bleiberg, Joseph			Automated Neuropsychological Assessment Metrics sports medicine battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						brain concussion; athletic injuries; neuropsychology; psychometric	MINOR HEAD-INJURY; STANDARDIZED ASSESSMENT; BRAIN-INJURY; CONCUSSION; RECOVERY; PERFORMANCE; GUIDELINES; RETURN; TESTS; COLLEGIATE	This paper describes the development and ongoing validation of the ANAM-sports medicine battery (ASMB) for use in concussion surveillance and management. A review of previous research utilizing the ASMB highlights current issues in concussion surveillance including: tracking cognitive recovery, effect of previous concussion history on acute concussion presentation, and clinical decision making using computerized measures. ASMB interpretation using reliable change indices or impairment indices is highlighted. Future development of the ASMB is discussed as it relates to interpretation of ASMB, development of appropriate norms, and defining adequate baseline assessment. This includes the definition of practice effects, the effects of maturation on test performance and definition of adequate baseline assessment that clearly defines a subject's normal cognitive performance level. ASMB is ready for cautious introduction into clinical practice for use by neuropsychologists with experience in both sports concussion and computerized testing. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Natl Rehabil Hosp, Clinvest Inc, Springfield, MO USA	Cernich, A (corresponding author), Baltimore Vet Affairs Med Ctr, BT 116 MH, Baltimore, MD 21201 USA.	Alison.cernich@va.gov					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT., 1989, MILD HEAD INJURY, P257; Benton AL, 1978, MULTILINGUAL APHASIA; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BLEIBERG J, 2002, COMPUTERIZED NEUROPS; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Cameron KL, 1999, J ATHL TRAINING, V34, P34; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CDC: Center for Disease Control, 2006, TRAUM BRAIN INJ US E; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DELIS C, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P232; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GOLDEN C, 1978, STROOP COLOR WORLD T; GRONWALL D, 1974, LANCET, V2, P1452; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead WC., 1947, BRAIN INTELLIGENCE Q; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JASTAK S, 1984, WIDE RANGE ACHEIVEME; KANE R, 1996, 8 HOUR CE WORKSH AM; KANE R, 1997, 8 HOUR CE WORKSH AM; KANE R, 1995, 8 HOUR CE WORKSH AM; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOVE MR, 2002, IMPACT CONCUSSION MA; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MEYERS JL, 2003, RES DESIGN STAT ANAL; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; *NAT SAF KIDS CAMP, 2003, INJ FACTS RECR INJ; PETERSON LR, 1959, J EXP PSYCHOL, V10, P12; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; REITAN R, 1985, HALSTEAD REITAN NEUR, P1; ROEBUCKSPENCER TM, IN PRESS ARCH CLIN N; Schretlen D, 1997, BRIEF TEST ATTENTION; WARDEN D, 2003, 55 ANN M AM AC NEUR; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Woodard J, 2002, J INT NEUROPSYCH SOC, V8, P175	68	97	97	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2007	22	1		S			S101	S114		10.1016/j.acn.2006.10.008			14	Psychology, Clinical; Psychology	Psychology	161DZ	WOS:000245995900010	17118625	Bronze			2021-06-18	
J	Stulemeijer, M; van der Werf, S; Bleijenberg, G; Biert, J; Brauer, J; Vos, PE				Stulemeijer, Maja; van der Werf, Sieberen; Bleijenberg, Gijs; Biert, Jan; Brauer, Jolanda; Vos, Pieter E.			Recovery from mild traumatic brain injury - A focus on fatigue	JOURNAL OF NEUROLOGY			English	Article						mild traumatic brain injury; fatigue; outcome studies	MINOR HEAD-INJURY; PATIENT COMPLAINTS; SYMPTOMS; STROKE; REHABILITATION; RELIABILITY; DEPRESSION; EXPERIENCE; SEQUELAE	Background. Fatigue is one of the most frequently reported symptoms after Mild Traumatic Brain Injury (MTBI). To date, systematic and comparative studies on fatigue after MTBI are scarce, and knowledge on causal mechanisms is lacking. Objectives To determine the severity of fatigue six months after MTBI and its relation to outcome. Furthermore, to test whether injury indices, such as Glasgow Coma Scale scores, are related to higher levels of fatigue. Methods Postal questionnaires were sent to a consecutive group of patients with an MTBI and a minor-injury control group, aged 18-60, six months after injury. Fatigue severity was measured with the Checklist Individual Strength. Postconcussional symptoms and limitations in daily functioning were assessed using the Rivermead Post Concussion Questionnaire and the SF-36. Results A total of 299 out of 618 eligible (response rate 52%) MTBI patients and 287 out of 482 eligible (response rate 60%) minor-injury patients returned the questionnaire. Ninety-five MTBI patients (32%) and 35 control patients (12%) were severely fatigued. Severe fatigue was highly associated with the experience of other symptoms, limitations in physical and social functioning, and fatigue related problems like reduced activity. Of various trauma severity indices, nausea and headache experienced on the ED were significantly related to higher levels of fatigue at six months. Conclusions In conclusion, one third of a large sample of MTBI patients experiences severe fatigue six months after injury, and this experience is associated with limitations in daily functioning. Our finding that acute symptoms and mechanism of injury rather than injury severity indices appear to be related to higher levels of fatigue warrants further investigation.	Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Expert Ctr Chron Fatigue, Med Ctr, Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Surg, Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands	Stulemeijer, M (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	M.Stulemeijer@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Bleijenberg, Gijs/E-6984-2010; Biert, J./L-4200-2015				Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; EVANS RW, 1992, NEUROL CLIN, V10, P815; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kalkman J, 2002, NEUROMUSCULAR DISORD, V12, P779; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; STALNACKE B, 2004, THESIS U UMEA, P35; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Werf SP, 2001, EUR NEUROL, V45, P28, DOI 10.1159/000052085; Vercoulen J. H, 1999, GEDRAGSTHERAPIE, V32, P31; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; WHO World Health Organization, 1978, ICD 9 CLASS MENT BEH	30	97	97	0	14	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	AUG	2006	253	8					1041	1047		10.1007/s00415-006-0156-5			7	Clinical Neurology	Neurosciences & Neurology	086FR	WOS:000240659700010	16708266				2021-06-18	
J	Gibbons, HM; Dragunow, M				Gibbons, Hannah M.; Dragunow, Mike			Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide	BRAIN RESEARCH			English	Article						microglia; nitric oxide; co-culture; microglial-neuronal interaction; hypothermia	TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; INTERFERON-GAMMA; DOPAMINERGIC NEURODEGENERATION; INTERLEUKIN-10 PRODUCTION; INFLAMMATORY MECHANISMS; MODERATE HYPOTHERMIA; NEUROBLASTOMA-CELLS	Microglial cells play a major role in the pathogenesis of many neurological diseases by exacerbating neuronal and non-neuronal cell death, but the mechanisms involved are unclear. To investigate the microglial-neuronal interactions, we used the murine BV-2 microglial cell line and the human neuronal-like SK-N-SH neuroblastoma cell line in a co-culture system that enabled proximity-dependent interaction and communication, a trans-well system that allowed proximity-independent communication through diffusible molecules only, and a conditioned media system through which no proximity-dependent interactions or cell-to-cell communication is possible. Activation of BV-2 cells with lipopolysaccharide and interferon-gamma (LPS/IFN-gamma) decreased viability of the BV-2 cells alone and in co-cultures with SK-N-SH cells, but not SK-N-SH cells grown alone. In contrast, activation of BV-2 cells in the trans-well and conditioned media system did not have any effect on the viability of SK-N-SH cells, suggesting that microglia must be in close proximity to the neural cells to elicit cytotoxicity. To determine the molecules involved in proximity-dependent cell death, inhibitors of microglial activation were investigated. Only the specific inducible nitric oxide synthase (iNOS) inhibitor S-methylisothiourea, and hypothermia, which is known to suppress microglial NOS expression, prevented cell death after LPS/IFN-gamma activation. These results suggest that activated microglia release nitric oxide that is, at least partially, responsible for proximity-dependent micro glial-mediated neural toxicity. (c) 2006 Elsevier B.V. All rights reserved.	Univ Auckland, Dept Pharmacol & Clin Pharmacol, Signal Transduct Lab, Auckland, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand	Dragunow, M (corresponding author), Univ Auckland, Dept Pharmacol & Clin Pharmacol, Signal Transduct Lab, Private Bag 92019, Auckland, New Zealand.	m.dragunow@auckland.ac.nz					Acarin L, 2002, J NEUROSCI RES, V68, P745, DOI 10.1002/jnr.10261; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Biagas Katherine V., 1998, Current Opinion in Pediatrics, V10, P271, DOI 10.1097/00008480-199806000-00009; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Broholm H, 2004, ACTA NEUROL SCAND, V109, P261, DOI 10.1111/j.1600-0404.2004.00207.x; Chao CC, 1997, NEUROREPORT, V8, P3163, DOI 10.1097/00001756-199709290-00031; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Choi SH, 2003, J NEUROSCI, V23, P5877; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Egger T, 2003, BIOCHEM J, V370, P459, DOI 10.1042/BJ20021358; Eskes C, 2003, J NEUROSCI RES, V71, P583, DOI 10.1002/jnr.10508; Flavin MP, 1997, NEUROSCIENCE, V80, P437, DOI 10.1016/S0306-4522(97)00078-X; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; He Y, 2003, J NEUROCHEM, V86, P1338, DOI 10.1046/j.1471-4159.2003.01938.x; Hill KE, 2004, J NEUROIMMUNOL, V151, P171, DOI 10.1016/j.jneuroim.2004.02.005; Hoozemans JJM, 2002, BRAIN RES, V951, P218, DOI 10.1016/S0006-8993(02)03164-5; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Jana M, 2005, FREE RADICAL BIO MED, V38, P655, DOI 10.1016/j.freeradbiomed.2004.11.021; Jeohn GH, 2000, BRAIN RES, V880, P173, DOI 10.1016/S0006-8993(00)02737-2; Jeohn GH, 2000, MOL BRAIN RES, V79, P18, DOI 10.1016/S0169-328X(00)00081-4; Katsuse O, 2003, NEUROPATHOLOGY, V23, P9, DOI 10.1046/j.1440-1789.2003.00483.x; Klegeris A, 1999, NEUROPHARMACOLOGY, V38, P1017, DOI 10.1016/S0028-3908(99)00014-3; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; Lee P, 2003, NEUROSCI LETT, V349, P33, DOI 10.1016/S0304-3940(03)00697-9; Lee P, 2001, BRAIN RES, V892, P380, DOI 10.1016/S0006-8993(00)03257-1; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.00216.x; Luth HJ, 2002, BRAIN RES, V953, P135, DOI 10.1016/S0006-8993(02)03280-8; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Munch G, 2003, EXP BRAIN RES, V150, P1, DOI 10.1007/s00221-003-1389-5; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108; Nicotera P, 1997, TRENDS PHARMACOL SCI, V18, P189, DOI 10.1016/S0165-6147(97)90619-2; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Paludan SR, 2000, J LEUKOCYTE BIOL, V67, P18; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Saha RN, 2003, J NEUROCHEM, V86, P1057, DOI 10.1046/j.1471-4159.2003.01942.x; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Si QS, 1998, BRAIN RES, V812, P97, DOI 10.1016/S0006-8993(98)00954-8; Simpson KL, 1998, J CLIN ENDOCR METAB, V83, P4332, DOI 10.1210/jc.83.12.4332; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sugaya K, 1997, NEUROREPORT, V8, P2241, DOI 10.1097/00001756-199707070-00030; Taylor EL, 2003, CELL DEATH DIFFER, V10, P418, DOI 10.1038/sj.cdd.4401152; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Uryu S, 2002, BRAIN RES, V946, P298, DOI 10.1016/S0006-8993(02)02898-6; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Walton MR, 2000, J NEUROIMMUNOL, V104, P109, DOI 10.1016/S0165-5728(99)00262-3; Watters JJ, 2002, J BIOL CHEM, V277, P9077, DOI 10.1074/jbc.M104385200; Wong A, 2001, BRAIN RES, V920, P32, DOI 10.1016/S0006-8993(01)02872-4; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Yoshikawa M, 1999, MULT SCLER J, V5, P126, DOI 10.1191/135245899678847194; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhao WH, 2004, J NEUROPATH EXP NEUR, V63, P964, DOI 10.1093/jnen/63.9.964; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zujovic V, 2003, METHODS, V29, P345, DOI 10.1016/S1046-2023(02)00358-4	72	97	112	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 21	2006	1084						1	15		10.1016/j.brainres.2006.02.032			15	Neurosciences	Neurosciences & Neurology	049XO	WOS:000238051300001	16564033				2021-06-18	
J	Gilbert, A; Pivato, G; Kheiralla, T				Gilbert, A; Pivato, G; Kheiralla, T			Long-term results of primary repair of brachial plexus lesions in children	MICROSURGERY			English	Article							SURGICAL-TREATMENT; BIRTH PALSY	The results of brachial plexus reconstruction in adults are poor, despite the sophistication of the various methods used. However, the same methods used in neonates after obstetrical brachial plexus injury will give far better results. because of the shorter distance, stronger potential of regeneration, and capacity of brain adaptation. Complete paralyses, associated root ruptures, and avulsions are very severe, and the end results cannot be evaluated before the end of growth. Although the end results show that the shoulder and elbow do not do as well as in upper-type lesions, the results at the level of the hand are encouraging, showing 75% with useful function after 8 years, even in patients with avulsion injuries of the lower roots. These results demonstrate the value of the early exploration and repair of the obstetric plexus. We also review our series of traumatic brachial plexus palsy in children. The results are poorer than in neonates, where may be related, in part, to a greater percentage of associated lesions in these patients. (c) 2006 Wiley-Liss, Inc.	Inst Main, F-75016 Paris, France	Gilbert, A (corresponding author), Inst Main, 6 Sq Jouvenet, F-75016 Paris, France.	agilbert@wanadoo.fr					ALNOT JY, 1977, REV CHIR ORTHOP, V63, P5; ALQUATTAN MM, 1994, J HAND SURG-BRIT, V19, P673; Boome R, 2000, GROWING HAND DIAGNOS, P653; DAUBIGNE RM, 1967, REV CHI RORTHOP, V53, P23; DUMONTIER C, 1990, Annales de Chirurgie de la Main et du Membre Superieur, V9, P351, DOI 10.1016/S0753-9053(05)80508-3; El-Gammal TA, 2003, MICROSURG, V23, P14, DOI 10.1002/micr.10084; Erb W, 1874, NATURHIST MED VER HE, V2, P130; GILBERT A, 1984, CHIRURGIE, V110, P70; GILBERT A, 1991, CLIN ORTHOP RELAT R, P39; HAERLE M, 2003, J PEDIATR ORTHOPED, V23, P1; KAWABATA H, 1987, CLIN ORTHOP RELAT R, P233; KENNEDY B, 1903, BRIT MED J, V1, P298; Klumpke A, 1885, REV MED-PARIS, V5, P591; Narakas A, 1982, Ann Chir Main, V1, P101, DOI 10.1016/S0753-9053(82)80066-5; Rigault P, 1969, Rev Chir Orthop Reparatrice Appar Mot, V55, P125; SEDEL L, 1977, REV CHIR ORTHOP, V63, P651; TASSIN JL, 1984, PARALYSIES OBSTETRIC; TERZIS JK, 1986, HAND CLIN, V2, P773	18	97	104	0	2	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0738-1085			MICROSURG	Microsurgery		2006	26	4					334	342		10.1002/micr.20248			9	Surgery	Surgery	050FG	WOS:000238072300018	16634084				2021-06-18	
J	Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M				Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M			Human marrow stromal cell treatment provides long-lasting benefit after traumatic brain injury in rats	NEUROSURGERY			English	Article						functional improvement; human marrow stromal cells; traumatic brain injury	ADULT RATS; STEM-CELLS; FUNCTIONAL RECOVERY; TRANSPLANTATION; NEUROTROPHINS; DIFFERENTIATION; EXPRESSION; SURVIVAL; THERAPY; MODEL	OBJECTIVE: This study was designed to investigate the effects of human bone marrow stromal cell (hMSC) administration in rats for 3 months after traumatic brain injury (TBI). METHODS: Adult male Wistar rats (n = 60) were injured with controlled cortical impact and divided into four groups. The three treatment groups (n = 10 each) were injected with 2 X 10(6), 4 X 10(6), and 8 X 10(6) hMSCs, respectively, intravenously, whereas the control group (n = 30) received phosphate-buffered saline. All injections were performed 1 day after injury into the tail veins of rats. Neurological functional evaluation of animals was performed before and after injury by use of Neurological Severity Scores. Animals were sacrificed 3 months after TBI, and brain sections were stained by immunohistochernistry. RESULTS: Statistically significant improvement in functional outcome was observed in all three treatment groups compared with control values (P < 0.05). This benefit was visible 14 days after TBI and persisted until 3 months (end of trial). There was no difference in functional outcome among the three treatment groups. Histological analysis showed that hMSCs were present in the lesion boundary zone at 3 months with all three doses tested. CONCLUSION: hMSCs injected in rats after TBI survive until 3 months and provide long-lasting functional benefit. Functional improvement may be attributed to stimulation of endogenous neurorestorative functions such as neurogenesis and synaptogenesis.	Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259, P01NS042345] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS042345-01A20002, P01 NS042345, R01 NS042259-04] Funding Source: Medline		Borlongan CV, 1996, NEUROL RES, V18, P297; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MEMBERG SP, 1995, MOL CELL NEUROSCI, V6, P323, DOI 10.1006/mcne.1995.1025; Newman MP, 2000, NEUROSCIENCE, V99, P343, DOI 10.1016/S0306-4522(00)00194-9; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Postmantur R., 1997, NEUROSCIENCE, V77, P765; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Song S, 2004, EXP NEUROL, V185, P191, DOI 10.1016/j.expneurol.2003.09.003; VESELY DL, 1992, RENAL PHYSIOL BIOCH, V15, P23; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	26	97	104	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2005	57	5					1026	1030		10.1227/01.NEU.0000181369.76323.50			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	982PF	WOS:000233173400044	16284572	Green Accepted			2021-06-18	
J	Knoblach, SM; Alroy, DA; Nikolaeva, M; Cernak, I; Stoica, BA; Faden, AI				Knoblach, SM; Alroy, DA; Nikolaeva, M; Cernak, I; Stoica, BA; Faden, AI			Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; calpain; caspase; necrosis; maitotoxin; apoptosis	CORTICAL IMPACT INJURY; SH-SY5Y NEUROBLASTOMA-CELLS; APOPTOSIS-INDUCING FACTOR; CYTOCHROME-C RELEASE; NEURONAL APOPTOSIS; DNA FRAGMENTATION; SPECTRIN PROTEOLYSIS; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; TEMPORAL PROFILE	In studies designed to evaluate the therapeutic window for treatment of traumatic brain injury, the caspase 3 inhibitor z-DEVD-fmk improved neurologic function and reduced lesion volumes when administered at I but not at 4, 8, or 24 hours after injury. Moreover, neither caspase 3 nor PARP, a caspase 3 substrate, were cleaved in injured, untreated cortex from I to 72 hours after injury. Few cortical neurons expressed active caspase 3 or were TUNEL positive from 6 to 24 hours after injury, and TUNEL staining was primarily Type I (necrotic). Nissl staining revealed extensive neuronal necrosis in the injured cortex from 6 to 24 hours after impact. Considered together, these data suggested that z-DEVD-fmk may reduce neuronal necrosis, so we used an in vitro model of necrotic cell death induced by maitotoxin to test this further and explore the potential mechanism(s) involved. Z-DEVD-fmk (1 nM-100 muM) significantly attenuated maitotoxin induced neuronal cell death and markedly reduced expression of the 145 kD calpain-mediated alpha-spectrin breakdown product after maitotoxin injury. Neither the 120 kD caspase-mediated a-spectrin cleavage product nor cathepsin B were expressed after maitotoxin injury. In a cell free assay, z-DEVD-fmk reduced hydrolysis of casein by purified calpain I. Finally, z-DEVD-fmk reduced expression of the 145 kD calpain-mediated a-spectrin cleavage fragment after traumatic brain injury in vivo. These data suggest that neuroprotection by z-DEVD-fmk may, in part, reflect inhibition of calpain-related necrotic cell death.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA	Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, EP16 New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	sknob101@georgetown.edu	STOICA, BOGDAN/H-9782-2013; Cernak, Ibolja/A-6399-2008	STOICA, BOGDAN/0000-0002-2501-6434; Ibolja, Cernak/0000-0003-3214-698X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS36527] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036527] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chen J, 1998, J NEUROSCI, V18, P4914; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Inoue J, 2003, J MED CHEM, V46, P868, DOI 10.1021/jm0201924; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; KUTTY RK, 1989, TOXICOL APPL PHARM, V101, P1, DOI 10.1016/0041-008X(89)90206-8; LEGRAND AM, 1984, J MOL CELL CARDIOL, V16, P663, DOI 10.1016/S0022-2828(84)80630-6; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGinnis KM, 2003, NEUROCHEM INT, V42, P517, DOI 10.1016/S0197-0186(02)00078-5; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Volbracht C, 1999, MOL MED, V5, P477; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	69	97	99	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2004	24	10					1119	1132		10.1097/01.WCB.0000138664.17682.32			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	859YP	WOS:000224304600006	15529012	Bronze			2021-06-18	
J	Slaughter, B; Fann, JR; Ehde, D				Slaughter, B; Fann, JR; Ehde, D			Traumatic brain injury in a county jail population: prevalence, neuropsychological functioning and psychiatric disorders	BRAIN INJURY			English	Article							SUBSTANCE-ABUSE; HEAD-INJURY; REHABILITATION; OFFENDERS; ATTENTION; BEHAVIOR; SYSTEM; TRIAL	Primary objective : To determine the prevalence of traumatic brain injury (TBI) among inmates in a county jail population. Research design : Cross-sectional, observational study. Methods and procedures : A standardized interview was used to determine prevalence of TBI in 69 randomly selected inmates. To examine cognitive and emotional differences between subjects with and without recent TBI, neuropsychological tests and structured psychiatric diagnostic interviews were conducted with 50 subjects (the first 25 with TBI and the first 25 without TBI in the prior year). Results : Sixty (87.0%) reported TBI over their lifetime; 25 (36.2%) reported TBI in the prior year. The latter group had significantly worse anger and aggression scores and had a trend towards poorer cognitive test results and a higher prevalence of psychiatric disorders than the group without TBI in the prior year. Conclusion : This study suggests the need for increased attention to TBI and its cognitive, behavioural and psychiatric sequelae in jail populations.	Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Fann, JR (corresponding author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.		Ehde, Dawn/K-1883-2016	Ehde, Dawn/0000-0002-9555-2347			Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Basso MR, 2000, CLIN NEUROPSYCHOL, V14, P325, DOI 10.1076/1385-4046(200008)14:3;1-P;FT325; BECK AJ, 2000, US DEP JUSTICE BUREA; Benton A., 1994, MULTILINGUAL APHASIA; Braverman SE, 1999, BRAIN INJURY, V13, P405; Ditton P.P., 1999, MENTAL HLTH TREATMEN; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; HATZITASKOS P, 1994, JUVENILE FAM COURT J, V45, P29; IVERSON GL, 1993, CRIM JUSTICE BEHAV, V20, P347, DOI 10.1177/0093854893020004003; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAKOWSKI MI, 1989, J PSYCHIAT RES, V23, P57, DOI 10.1016/0022-3956(89)90017-4; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lamb HR, 1998, PSYCHIATR SERV, V49, P483, DOI 10.1176/ps.49.4.483; Lamb HR, 1999, PSYCHIATR SERV, V50, P907, DOI 10.1176/ps.50.7.907; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAIURO RD, 1987, J INTERPERS VIOLENCE, V2, P166, DOI DOI 10.1177/088626087002002003; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Metzner JL, 1998, TREATMENT OF OFFENDERS WITH MENTAL DISORDERS, P211; Metzner JL, 1993, CRIM BEHAV MENT HEAL, V3, P252, DOI DOI 10.1002/CMB.1993.3.4.252; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; *PIERC COUNT DET C, 1999, AUG 1999 JAIL CENS R; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SILVER JM, 1985, INT DRUG THERAPY NEW, V20, P9; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wechsler D., 1987, WECHSLER MEMORY SCAL	34	97	97	1	25	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2003	17	9					731	741		10.1080/0269905031000088649			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691ML	WOS:000183610000001	12850940				2021-06-18	
J	Levin, HS				Levin, HS			Neuroplasticity following non-penetrating traumatic brain injury	BRAIN INJURY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD-INJURY; WORKING-MEMORY; LANGUAGE-DEVELOPMENT; CORPUS-CALLOSUM; CHILDREN; APHASIA; RECOVERY; INVOLVEMENT; PLASTICITY	The primary objective of this review is to examine the methodology and evidence for neuroplasticity operating in recovery from traumatic brain injury (TBI), as compared with previous findings in patients sustaining perinatal and infantile focal vascular lesions. The evidence to date indicates that the traditional view of enhanced reorganization of function after early focal brain lesions might apply to early focal brain lesions, but does not conform with studies of early severe diffuse brain injury. In contrast to early focal vascular lesions, young age confers no advantage in the outcome of severe diffuse brain injury. Disruption of myelination could potentially alter connectivity, a suggestion which could be confirmed through diffusion tensor imaging (DTI). Initial reports of DTI in TBI patients support the possibility that this technique can demonstrate alterations in white matter connections which are not seen on conventional magnetic resonance imaging (MRI) and might change over time or with interventions. Preliminary functional MRI studies of TBI patients indicate alterations in the pattern of brain activation, suggesting recruitment of more extensive cortical regions to perform tasks which stress computational resources. Functional MRI, coupled with DTI and possibly other imaging modalities holds the promise of elucidating mechanisms of neuroplasticity and repair following TBI.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 6560 Fannin St,Box 67, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042772, R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42772, NS21889] Funding Source: Medline		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Bates E, 1997, DEV NEUROPSYCHOL, V13, P275, DOI 10.1080/87565649709540682; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; DENNIS M, 1975, BRAIN LANG, V2, P472, DOI 10.1016/S0093-934X(75)80084-8; FELDMAN HM, 1992, BRAIN LANG, V42, P89, DOI 10.1016/0093-934X(92)90058-M; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Kennard MA, 1936, AM J PHYSIOL, V115, P138; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Levin HS, 1996, ARCH NEUROL-CHICAGO, V53, P88, DOI 10.1001/archneur.1996.00550010108024; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mitrushina M., 1999, HDB NORMATIVE DATA N; Musso M, 1999, BRAIN, V122, P1781, DOI 10.1093/brain/122.9.1781; PAPANICOLAOU AC, 1988, ARCH NEUROL-CHICAGO, V45, P1025, DOI 10.1001/archneur.1988.00520330117020; Rosenzweig MR, 1999, CHANGING NERVOUS SYSTEM, P25; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Schallert T, 2000, CEREBRAL REORGANIZAT, P145; Stiles J, 1996, BRAIN COGNITION, V31, P46, DOI 10.1006/brcg.1996.0024; STILES J, IN PRESS J INT NEURO; Teuber H., 1974, NEUROSCIENCES 3 STUD, P71; Vicari S, 2000, CORTEX, V36, P31, DOI 10.1016/S0010-9452(08)70834-7; Warburton E, 1999, J NEUROL NEUROSUR PS, V66, P155, DOI 10.1136/jnnp.66.2.155; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; WOODS BT, 1979, ANN NEUROL, V6, P405, DOI 10.1002/ana.410060505; WOODS BT, 1980, NEUROPSYCHOLOGIA, V18, P65, DOI 10.1016/0028-3932(80)90084-6	35	97	99	2	20	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2003	17	8					665	674		10.1080/0269905031000107151			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500004	12850951				2021-06-18	
J	Chang, EF; Wong, RJ; Vreman, HJ; Igarashi, T; Galo, E; Sharp, FR; Stevenson, DK; Noble-Haeusslein, LJ				Chang, EF; Wong, RJ; Vreman, HJ; Igarashi, T; Galo, E; Sharp, FR; Stevenson, DK; Noble-Haeusslein, LJ			Heme oxygenase-2 protects against lipid peroxidation-mediated cell loss and impaired motor recovery after traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						heme oxygenase-2; traumatic brain injury; lipid peroxidation; oxidative stress; controlled cortical impact; heme-oxygenase-1	CONTROLLED CORTICAL IMPACT; CARBON-MONOXIDE; OXIDATIVE STRESS; DIFFERENTIAL EXPRESSION; CEREBRAL-ISCHEMIA; TIME-COURSE; BILIRUBIN; GENE; ANTIOXIDANT; ASTROCYTES	After traumatic brain injury (TBI), substantial extracellular heme is released from hemoproteins during hemorrhage and cell injury. Heme oxygenase (HO) isozymes are thought to detoxify the pro-oxidant heme to the potent antioxidant, bilirubin. HO-1, the inducible isozyme, is expressed in glial populations after injury and may play a protective role. However, the role of HO-2, the predominant and constitutively expressed isozyme in the brain, remains unclear after TBI. We used a controlled cortical impact injury model to determine the extent and mechanism of damage between HO-2 knock-out (KO) (-/-) and wild-type (WT) (+/+) mice. The specific cellular and temporal expressions of HO-2 and HO-1 were characterized by immunocytochemistry and Western blots. HO-2 was immunolocalized in neurons both before and after TBI, whereas HO-1 was highly upregulated in glia only after TBI. HO activity determined by gas chromatography using brain sonicates from injured HO-2 KO mice was significantly less than that of HO-2 wild types, despite the induction of HO-1 expression after TBI. Cell loss was significantly greater in KO mice in areas including the cortex, the CA3 region of hippocampus, and the lateral dorsal thalamus. Furthermore, motor recovery after injury, as measured by the rotarod assay and an inclined beam-walking task, was compromised in the KO mice. Finally, brain tissue from injured HO-2 KO mice exhibited decreased ability to reduce oxidative stress, as measured with an Fe2+/ascorbic acid-mediated carbon monoxide generation assay for lipid peroxidation susceptibility. These findings demonstrate that HO-2 expression protects neurons against TBI by reducing lipid peroxidation via the catabolism of free heme.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Program Neurosci, Cincinnati, OH 45267 USA	Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.	noblelj@itsa.ucsf.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS041256] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 41256, R21 NS041256] Funding Source: Medline		Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; Conti AC, 1998, J NEUROSCI, V18, P5663; Dennery PA, 2000, CURR TOP CELL REGUL, V36, P181; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dore S, 1999, ANN NY ACAD SCI, V890, P167, DOI 10.1111/j.1749-6632.1999.tb07991.x; Dore S, 2000, NEUROSCIENCE, V99, P587, DOI 10.1016/S0306-4522(00)00216-5; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; EWING JF, 1993, J NEUROCHEM, V61, P1015, DOI 10.1111/j.1471-4159.1993.tb03615.x; Ewing JF, 1997, BRAIN RES PROTOC, V1, P165, DOI 10.1016/S1385-299X(96)00027-X; Ferris CD, 1999, NAT CELL BIOL, V1, P152; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FOX GB, 2001, METH NE FRO NEUROSCI, P27; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; GOPINATHAN V, 1994, FEBS LETT, V349, P197, DOI 10.1016/0014-5793(94)00666-0; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; IMAI K, 1990, CHEM PHARM BULL, V38, P258; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Li XQ, 2000, PAIN, V86, P75, DOI 10.1016/S0304-3959(00)00238-4; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557; Maines MD, 1996, BRAIN RES, V722, P83, DOI 10.1016/0006-8993(96)00184-9; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; Patel BN, 2002, J NEUROSCI, V22, P6578; Platt JL, 1998, NAT MED, V4, P1364, DOI 10.1038/3947; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Povlishock J T, 1992, Hum Cell, V5, P345; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2002, NEUROSCIENCE, V113, P985, DOI 10.1016/S0306-4522(02)00243-9; Rouault TA, 2001, PEDIATR NEUROL, V25, P130, DOI 10.1016/S0887-8994(01)00260-0; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Takahashi M, 2000, NEURON, V28, P461, DOI 10.1016/S0896-6273(00)00125-2; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Vreman HJ, 1998, CAN J PHYSIOL PHARM, V76, P1057; VREMAN HJ, 1988, J CHROMATOGR-BIOMED, V427, P315, DOI 10.1016/0378-4347(88)80134-8; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; WONG RJ, 2000, ACTA HAEMATOL, V103, P4309; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; Zufall F, 1997, J NEUROSCI, V17, P2703	56	97	99	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAY 1	2003	23	9					3689	3696					8	Neurosciences	Neurosciences & Neurology	675MX	WOS:000182700100016	12736340				2021-06-18	
J	Savola, O; Hillbom, M				Savola, O; Hillbom, M			Early predictors of post-concussion symptoms in patients with mild head injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						mild head injury; post-concussion symptoms; protein S-100B	S-100 PROTEIN MEASUREMENTS; TRAUMATIC BRAIN INJURY; POSTCONCUSSION SYMPTOMS; EPIDEMIOLOGY; INTOXICATION; MODERATE; ALCOHOL; DAMAGE; WORK	A small proportion of patients with mild head injury (MHI) develop post-concussion symptoms (PCSs). We searched simple measures for the early detection of patients who are probable to develop PCSs. We recorded signs and symptoms, history of previous diseases, medications, and lifestyle factors and measured serum protein S-100B on admission in a series of 172 consecutive MHI patients admitted into the emergency room of a general hospital. A modified Rivermead Post-Concussion Symptoms Questionnaire was used to identify the patients with and without PCSs 1 month after the injury. We identified 37 patients with MHI who developed PCSs (22%). Odds ratios (OR) and 95% confidence intervals (CI) after adjustment for possible confounding variables were calculated by logistic regression. Independent early risk factors for PCSs in the MHI patients were skull fracture (OR 8.0, 95% CI 2.6-24.6), serum protein S-100B greater than or equal to 0.50 mug/l (OR 5.5, 95% CI 1.6-18.6), dizziness (OR 3.1, 95% CI 1.2-8.0), and headache (OR 2.6, 95% CI 1.0-6.5). Serum protein S-100B proved to be a specific, but not sensitive predictor of PCSs. The presence of skull fracture, elevated serum protein S-100B, dizziness, and headache may help the emergency room physician to identify patients at risk of PCSs and to refer them for further examination and follow-up.	Oulu Univ Hosp, Dept Neurol, FIN-90029 Oulu, Finland	Hillbom, M (corresponding author), Oulu Univ Hosp, Dept Neurol, Box 25, FIN-90029 Oulu, Finland.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; DACEY RG, 1986, J NEUROSURG, V65, P302; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DICMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P315; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	35	97	100	0	7	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	MAR	2003	10	2					175	181		10.1046/j.1468-1331.2003.00552.x			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	649VZ	WOS:000181229800009	12603294				2021-06-18	
J	Sugawara, T; Lewen, A; Gasche, Y; Yu, FS; Chan, PH				Sugawara, T; Lewen, A; Gasche, Y; Yu, FS; Chan, PH			Overexpression of SOD1 protects vulnerable motor neurons after spinal cord injury by attenuating mitochondrial cytochrome c release	FASEB JOURNAL			English	Article						superoxide dismutase; superoxide; reactive oxygen species; caspase-9	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; CASPASE-3 APOPTOTIC CASCADE; CUZN-SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; GLIAL APOPTOSIS; UP-REGULATION; MOUSE MODEL	Defective Cu,Zn-superoxide dismutase (SOD1) is responsible for some types of amyotrophic lateral sclerosis, and ventral horn motor neurons (VMN) have been shown to die through a mitochondria-dependent apoptotic pathway after chronic exposure to high levels of reactive oxygen species (ROS). VMN are also selectively vulnerable to mild spinal cord injury (SCI); however, the involvement of SOD1, ROS, and apoptosis in their death has not been clarified. Mild compression SCI was induced in SOD1-overexpressing transgenic rats and wild-type littermates. Superoxide production, mitochondrial release of cytochrome c, and activation of caspase-9 were examined, and apoptotic DNA injury was also characterized. In the wild-type animals, increased superoxide production, mitochondrial release of cytochrome c, and cleaved caspase-9 were observed exclusively in VMN after SCI. Subsequently, a majority of VMN (75%) selectively underwent delayed apoptotic cell death. Transgenic animals showed less superoxide production, mitochondrial cytochrome c release, and caspase-9 activation, resulting in death of only 45% of the VMN. These results suggest that the ROS-initiated mitochondrial signaling pathway possibly plays a pivotal role in apoptotic VMN death after SCI and that increased levels of SOD1 in VMN reduce oxidative stress, thereby attenuating the activation of the pathway and delayed cell death.	Stanford Univ, Neurosurg Labs, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Program Neurosci, Sch Med, Stanford, CA 94305 USA	Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, Dept Neurosurg, Sch Med, 1201 Welch Rd,MSLS P314, Stanford, CA 94305 USA.	phchan@leland.stanford.edu	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Yu, Fengshan/0000-0001-8620-3084			Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Buki A, 2000, J NEUROSCI, V20, P2825; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chan PH, 1996, ADV NEUROL, V71, P271; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 1997, J NEUROSCI, V17, P9172; Copin JC, 2001, FASEB J, V15, P525, DOI 10.1096/fj.00-0330com; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; Enari M, 1998, NATURE, V391, P43; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guegn C, 2001, J NEUROSCI, V21, P6569; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P1690, DOI 10.1097/00004647-200012000-00008; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Launey T, 1998, BRAIN RES, V781, P148, DOI 10.1016/S0006-8993(97)01225-0; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XZ, 1997, J NEUROSCI, V17, P5395; Murakami K, 1998, J NEUROSCI, V18, P205; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan WH, 1999, J NEUROSCI, V19, P3649; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RINK A, 1995, AM J PATHOL, V147, P1575; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSS IB, 1993, NEUROSURGERY, V33, P470; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; SUGAWARA T, 2002, IN PRESS J NEUROSCI; Terro F, 1998, BRAIN RES, V809, P319, DOI 10.1016/S0006-8993(98)00883-X; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; vonEuler M, 1997, EXP NEUROL, V145, P502, DOI 10.1006/exnr.1997.6481; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	53	97	98	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1997	+		10.1096/fj.02-0251fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	WOS:000179167600024	12368231				2021-06-18	
J	Doig, E; Fleming, J; Tooth, L				Doig, E; Fleming, J; Tooth, L			Patterns of community integration 2-5 years post-discharge from brain injury rehabilitation	BRAIN INJURY			English	Article							QUALITY-OF-LIFE; CLOSED-HEAD-INJURY; QUESTIONNAIRE; DISABILITIES; IMPAIRMENTS; EMPLOYMENT; RETURN; SCALE; WORK	Outcome after traumatic brain injury (TBI) is characterized by a high degree of variability which has often been difficult to capture in traditional outcome studies. The purpose of this study was to describe patterns of community integration 2-5 years after TBI. Participants were 208 patients admitted to a Brain Injury Rehabilitation Unit between 1991-1995 in Brisbane, Australia. The design comprised retrospective data collection and questionnaire follow-up by mail. Mean follow-up was 3.5 years. Demographic, injury severity and functional status variables were retrieved from hospital records. Community integration was assessed using the Community Integration Questionnaire (CIQ), and vocational status measured by a self administered questionnaire. Data was analysed using cluster analysis which divided the data into meaningful subsets. Based on the CIQ subscale scores of home, social and productive integration, a three cluster solution was selected, with groups labelled as working (n = 78), balanced (n = 46) and poorly integrated (n = 84). Although 38% of the sample returned to a high level of productive activity and 22% achieved a balanced lifestyle, overall community integration was poor for the remainder. This poorly integrated group had more severe injury characterized by longer periods of acute care and post-traumatic amnesia (PTA) and greater functional disability on discharge. These findings have implications for service delivery prior to and during the process of reintegration after brain injury.	Princess Alexandra Hosp, Brain Injury Rehabil Unit, Brisbane, Qld, Australia; Univ Queensland, Dept Occupat Therapy, Brisbane, Qld, Australia; Univ Queensland, Dept Social & Prevent Med, Brisbane, Qld, Australia	Doig, E (corresponding author), Princess Alexandra Hosp, Brain Injury Rehabil Unit, Brisbane, Qld, Australia.	emmahdoig@optusnet.com.au	Fleming, Jennifer M/B-4436-2011; Doig, Emmah/AAG-6674-2021; Tooth, Leigh/F-2769-2010	Doig, Emmah/0000-0002-7020-053X; Tooth, Leigh/0000-0002-1569-934X			Bickenbach JE, 1999, SOC SCI MED, V48, P1173, DOI 10.1016/S0277-9536(98)00441-9; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BODIAM C, BRIT J OCCUPATIONAL, V62, P123; BONTKE CF, 1990, COMMUNITY INTEGRATIO, P3; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fleming J, 1999, BRAIN INJURY, V13, P417; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HAIR JF, 1992, MULTIVAR DATA ANAL, P265; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Millis S R, 1994, Int J Neurosci, V79, P165; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OTTENBACHER KJ, 1988, ARCH PHYS MED REHAB, V69, P170; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stilwell P, 1998, CLIN REHABIL, V12, P521, DOI 10.1191/026921598673761855; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; TABACHNICK BG, 1996, USING MULTIVARIATE S, P57; TATE RL, 1988, P INT PERSP BRAIN IN, P415; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1994, BRAIN INJURY REHABIL, P355; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS JH, 1991, GERONTOLOGIST, V31, P84, DOI 10.1093/geront/31.1.84	49	97	97	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2001	15	9					747	762		10.1080/02699050110034343			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400001	11516344				2021-06-18	
J	Nochi, M				Nochi, M			Reconstructing self-narratives in coping with traumatic brain injury	SOCIAL SCIENCE & MEDICINE			English	Article						traumatic brain injury; rehabilitation counseling; adjustment; self-image	TIME PERSPECTIVE; DISABILITY; DISEASE; PEOPLE	This study examined qualitative data from ten individuals with traumatic brain injuries (TBI) who fell at ease with their current situations. An analysis based on the grounded theory method revealed that one's experience of coping or adjustment to the disability was represented as narratives about him or herself. Each one with TBI reconstructed certain self-narratives in coping with their changed self-images and daily lives. The common narratives were classified into five categories: "the self better than others," "the grown self," "the recovering self" ''the self living hen and now," and "the protesting self." These self-narratives reflected renewed ways to view the selves, which were conceptualized to be intact "in spite of TBI" or to be worthwhile "because of TBI." The informants achieved this conceptualization by managing their perspectives on time or on space. This classification will serve as a framework for rehabilitation practice and for future research. (C) 2000 Elsevier Science Ltd. All rights reserved.	Teikyo Univ, Dept Psychol, Hachioji, Tokyo 1920395, Japan	Nochi, M (corresponding author), Teikyo Univ, Dept Psychol, 359 Otsuka, Hachioji, Tokyo 1920395, Japan.						ANDERSSON SI, 1992, SCAND J PSYCHOL, V33, P289, DOI 10.1111/j.1467-9450.1992.tb00918.x; BOGDAN R, 1994, SOCIAL MEANING MENT; Bogdan R. C., 1998, QUALITATIVE RES ED I; BRUNER J, 1986, ACTUAL MIND POSSIBLE; Caplan G., 1964, PRINCIPLES PREVENTIV; Capps L., 1995, CONSTRUCTING PANIC D; Charmaz K., 1991, GOOD DAYS BAD DAYS S; CORBIN J, 1990, Z SOZIOL, V19, P418, DOI 10.1007/BF00988593; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; DEJONG G, 1979, ARCH PHYS MED REHAB, V60, P435; Dembo T., 1975, REHABIL PSYCHOL, V22, P1; ELLIOTT TR, 1991, J PERS SOC PSYCHOL, V61, P608, DOI 10.1037/0022-3514.61.4.608; Gergen K. J., 1994, REALITIES RELATIONSH; GERGEN KJ, 1991, THERAPY SOCIAL CONST; Glaser B. G., 1967, DISCOVERY GROUNDED T; HERMANS HJM, 1992, AM PSYCHOL, V47, P23, DOI 10.1037/0003-066X.47.1.23; Herrmann M, 1997, DISABIL REHABIL, V19, P6, DOI 10.3109/09638289709166439; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Hoskins M, 1996, J COUNS DEV, V74, P243, DOI 10.1002/j.1556-6676.1996.tb01860.x; JOHNSON CN, 1990, CHILD DEV, V61, P962, DOI 10.1111/j.1467-8624.1990.tb02834.x; Karp D. A., 1996, SPEAKING SADNESS DEP; Kelley P, 1996, SOCIAL WORK TREATMEN, P461; LENNINGS CJ, 1992, J CLIN PSYCHOL, V48, P510, DOI 10.1002/1097-4679(199207)48:4<510::AID-JCLP2270480412>3.0.CO;2-M; Lewin K., 1951, FIELD THEORY SOCIAL; MAHON NE, 1994, PERCEPT MOTOR SKILL, V79, P395, DOI 10.2466/pms.1994.79.1.395; Miller L., 1993, PSYCHOTHERAPY BRAIN; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; NOSEK MA, 1998, REHABILITATION COUNS, P107; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Richardson L., 1990, WRITING STRATEGIES R; RUSSELL RA, 1981, REHABIL LIT, V42, P330; Sarbin T. R., 1986, NARRATIVE PSYCHOL ST; Shmotkin D., 1991, J GERONTOL B-PSYCHOL, V46, P243; Wasley D, 1998, PERCEPT MOTOR SKILL, V86, P1402, DOI 10.2466/pms.1998.86.3c.1402; White M., 1990, NARRATIVE MEANS THER; *WHO, 1986, A29INFDOC1 WHO	38	97	98	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	DEC	2000	51	12					1795	1804		10.1016/S0277-9536(00)00111-8			10	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	379DF	WOS:000165625100007	11128267				2021-06-18	
J	Diringer, MN; Yundt, K; Videen, TO; Adams, RE; Zazulia, AR; Deibert, E; Aiyagari, V; Dacey, RG; Grubb, RL; Powers, WJ				Diringer, MN; Yundt, K; Videen, TO; Adams, RE; Zazulia, AR; Deibert, E; Aiyagari, V; Dacey, RG; Grubb, RL; Powers, WJ			No reduction in cerebral metabolism as a result of early moderate hyperventilation following severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; cerebral metabolism; positron emission tomography; hyperventilation; brain injury	POSITRON EMISSION TOMOGRAPHY; BLOOD-FLOW; HEAD-INJURY; INTRAVENOUS (H2O)-O-15; O-15 RADIOTRACERS; COMATOSE PATIENTS; CARBON-DIOXIDE; ISCHEMIA; HUMANS; VOLUME	Object. Hyperventilation has been used for many years in the management of patients with traumatic brain injury (TBI). Concern has been raised that hyperventilation could lead to cerebral ischemia; these concerns have been magnified by reports of reduced cerebral blood flow (CBF) early after severe TBI. The authors tested the hypothesis that moderate hyperventilation induced early after TBI would not produce a reduction in CBF severe enough to cause cerebral energy failure (CBF that is insufficient to meet metabolic needs). Methods. Nine patients were studied a mean of 11.2 +/- 1.6 hours (range 8-14 hours) after TBI occurred. The patients' mean Glasgow Coma Scale score was 5.6 +/- 1.8 and their mean age 27 +/- 9 years; eight of the patients were male. Intracranial pressure (ICP), mean arterial blood pressure, and jugular venous oxygen content were monitored and cerebral perfusion pressure was maintained at a level higher than 70 mm Hg by using vasopressors when needed. Measurements of CBF, cerebral blood volume (CBV), cerebral metabolic rate for oxygen (CMRO2), oxygen extraction fraction (OEF), and cerebral venous oxygen content (CvO(2)) were made before and after 30 minutes of hyperventilation to a PaCO2 of 30 +/- 2 mm Hg. Ten age-matched healthy volunteers were used as normocapnic controls. Global CBF, CBV, and CvO(2) did not differ between the two groups, but in the TBI patients CMRO2 and OEF were reduced (1.59 +/- 0.44 ml/100 g/minute [p < 0.01] and 0.31 +/- 0.06 [p < 0.0001], respectively). During hyperventilation, global CBF decreased to 25.5 +/- 8.7 ml/100 g/minute (p < 0.0009), CBV fell to 2.8 +/- 0.56 ml/100 g (p < 0.001), OEF rose to 0.45 +/- 0.13 (p < 0.02), and CvO(2) fell to 8.3 +/- 3 vol% (p < 0.02); CMRO2 remained unchanged. Conclusions. The authors conclude that early, brief, moderate hyperventilation does not impair global cerebral metabolism in patients with severe TBI and, thus, is unlikely to cause further neurological injury. Additional studies are needed to assess focal changes, the effects of more severe hyperventilation, and the effects of hyperventilation in the setting of increased ICP.	Washington Univ, Sch Med, Dept Neurol & Neurol Surg, Dept Radiol, St Louis, MO USA; Washington Univ, Sch Med, Neurol Neurosurg Intens Care Unit, St Louis, MO USA	Diringer, MN (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035966, P50NS035966] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35966] Funding Source: Medline		ALTMAN DI, 1993, PEDIATRICS, V92, P99; ALTMAN DI, 1991, J NUCL MED, V32, P1738; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; *JOINT SECT TRAUM, 1995, GUID MAN SEV HEAD IN; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTIN WRW, 1987, J CEREBR BLOOD F MET, V7, P421, DOI 10.1038/jcbfm.1987.85; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MILLER K, 1995, AKTUEL UROL, V26, P1, DOI 10.1055/s-2008-1057840; MINTUN MA, 1984, J NUCL MED, V25, P177; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; RAICHLE ME, 1983, J NUCL MED, V24, P790; SPARGO PM, 1985, ANAESTHESIA, V40, P901, DOI 10.1111/j.1365-2044.1985.tb11057.x; TEASDALE G, 1974, LANCET, V2, P81; VANRIJEN PC, 1989, MAGN RESON MED, V10, P182, DOI 10.1002/mrm.1910100204; VIDEEN TO, 1987, J CEREBR BLOOD F MET, V7, P513, DOI 10.1038/jcbfm.1987.97; WIENHARD K, 1994, J COMPUT ASSIST TOMO, V18, P110, DOI 10.1097/00004728-199401000-00023; WILSON DA, 1985, CIRC RES, V56, P596, DOI 10.1161/01.RES.56.4.596; YOUNG WL, 1989, ANESTH ANALG, V68, P712	33	97	100	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2000	92	1					7	13		10.3171/jns.2000.92.1.0007			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	268ZP	WOS:000084451500002	10616076				2021-06-18	
J	Buki, A; Koizumi, H; Povlishock, JT				Buki, A; Koizumi, H; Povlishock, JT			Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	2nd Conference of Cellular and Molecular Treatments of Neurological Diseases (CMT)	OCT, 1998	CAMBRIDGE, MASSACHUSETTS			traumatic brain injury; axonal injury; hypothermia; calpain; spectrin; calcium; cytoskeleton	SPINAL-CORD INJURY; SEVERE HEAD-INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; EXPERIMENTAL BRAIN INJURY; ISCHEMIC NEURONAL INJURY; TRANSIENT FOCAL ISCHEMIA; MILD HYPOTHERMIA; FOREBRAIN ISCHEMIA; AMINO-ACIDS; AXOLEMMAL PERMEABILITY	Traumatic brain injury (TBI) in animals and man generates widespread axonal injury characterized by focal axolemmal permeability changes, induction of calpain-mediated proteolysis, and neurofilament sidearm modification associated with neurofilament compaction (NFC) evolving to axonal disconnection. Recent observations have suggested that moderate hypothermia is neuroprotective in several models of TBI. Nevertheless, the pathway by which hypothermia prevents traumatic axonal injury (TAI) is still a matter of debate. The present study was conducted to evaluate the effects of moderate, early posttraumatic hypothermia on calpain-mediated spectrin proteolysis (CMSP), implicated in the pathogenesis of TAT. Using moderate (32 degrees C) hypothermia of 90 min duration without rewarming, the density of CMSP immunoreactive/damaged axons was quantified via LM analysis in vulnerable brain stem fiber tracts of hypothermic and normothermic rats subjected to impact acceleration TBI (90 min postinjury survival). To assess the influence of posthypothermic rewarming, a second group of animals was subjected to 90 min of hypothermia followed by 90 min of rewarming to normothermic levels when CMSP was analyzed to detect if any purported CMSP prevention persisted (180 min postinjury survival). Additionally, to determine if this protection translated into comparable cytoskeletal protection in the same foci showing decreased CMSP, antibodies targeting altered/compacted NF subunits were also employed. Moderate hypothermia applied in the acute postinjury period drastically reduced the number of damaged axons displaying CMSP at both time points and significantly reduced NFC immunoreactivity at 180 min postinjury. These results suggest that the neuroprotective effects of hypothermia in TBI are associated with the inhibition of axonal/cytoskeletal damage. (C) 1999 Academic Press.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Univ Pecs, Sch Med, Dept Neurosurg, H-7624 Pecs, Hungary; Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi 755, Japan	Buki, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA.		Buki, Andras/B-1960-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kataoka K, 1996, MOL CHEM NEUROPATHOL, V28, P191, DOI 10.1007/BF02815222; KNOXDUBOIS CY, 1999, J NEUROTRAUM, V15, P877; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KOIZUMI H, 1999, IN PRESS BRAIN RES; LEE VMY, 1987, J NEUROSCI, V7, P3474; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mariame B, 1996, BIOTECHNIQUES, V21, P18; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Takata T, 1997, NEUROSCI LETT, V227, P41, DOI 10.1016/S0304-3940(97)00296-6; TAKIGI K, 1994, AM J PHYSIOL, V267, pH1770; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; ZAGON IS, 1986, J NEUROSCI, V6, P2977; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	73	97	98	0	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	1999	159	1					319	328		10.1006/exnr.1999.7139			10	Neurosciences	Neurosciences & Neurology	237FM	WOS:000082644700031	10486200				2021-06-18	
J	Humm, JL; Kozlowski, DA; Bland, ST; James, DC; Schallert, T				Humm, JL; Kozlowski, DA; Bland, ST; James, DC; Schallert, T			Use-dependent exaggeration of brain injury: Is glutamate involved?	EXPERIMENTAL NEUROLOGY			English	Article						use-dependent; sensorimotor cortex; MK-801; NMDA receptor; glutamate; recovery of function; forelimb use	CENTRAL-NERVOUS-SYSTEM; SENSORIMOTOR CORTEX LESIONS; TASK-SPECIFIC PRACTICE; CORTICAL CELL-CULTURE; NMDA RECEPTOR; NEUROTOXICITY INVITRO; FUNCTIONAL RECOVERY; NEOCORTICAL DAMAGE; NEURONAL INJURY; MOTOR RECOVERY	Extreme overreliance on the impaired forelimb following unilateral lesions of the forelimb representation area of the rat sensorimotor cortex (FL-SMC) leads to exaggeration of the initial cortical injury. Glutamate has repeatedly been implicated in the secondary processes leading to neuronal death following traumatic insult, chiefly because of the neuroprotective properties of excitatory amino acid antagonists in a variety of animal models of brain injury. The present study investigated the possibility that NMDA receptor-mediated processes are involved in use-dependent exaggeration of neuronal injury. Rats were fitted with one-sleeved casts that immobilized the intact forelimb for the first 7 days following FL-SMC lesion, a procedure previously shown to result in use-dependent exaggeration of injury and more severe and persistent limb-use deficits. In the present investigation, administration of MK-801 (1 mg/kg ip once daily on alternate days) during the casting period spared neural tissue surrounding the lesion and enhanced functional recovery of the impaired forelimb. These results suggest a role for NMDA receptor-mediated processes in use-dependent exaggeration of injury. (C) 1999 Academic Press.	Univ Texas, Dept Psychol, Austin, TX 78712 USA; Univ Texas, Inst Neurosci, Austin, TX 78712 USA	Humm, JL (corresponding author), Univ Texas, Dept Psychol, Mezes 330, Austin, TX 78712 USA.	humm@mail.utexas.edu		Bland, Sondra/0000-0002-5790-089X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023964] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 23964] Funding Source: Medline		ANGEL A, 1975, J PHYSIOL-LONDON, V248, P465, DOI 10.1113/jphysiol.1975.sp010984; BARTH TM, 1990, STROKE S3, V21, P1; BIELENBERG GW, 1991, BRAIN RES, V552, P338, DOI 10.1016/0006-8993(91)90101-Z; BLAND ST, 1997, SOC NEUR ABSTR, V23; BOXER PA, 1990, STROKE, V21, P47; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P357; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAY J, 1991, PHARMACOL BIOCHEM BE, V38, P723, DOI 10.1016/0091-3057(91)90233-R; DERYCK M, 1992, BRAIN RES, V573, P44; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIMAGL U, 1990, BRAIN RES, V527, P62; FINGER S, 1982, PHYSIOL BEHAV, V29, P73, DOI 10.1016/0031-9384(82)90368-7; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; FOSTER AC, 1988, J NEUROSCI, V8, P4745; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1993, STROKE, V24, pI84; GOLDSTEIN LB, 1992, BRAIN RES, V580, P129, DOI 10.1016/0006-8993(92)90936-4; GOLDSTEIN LB, 1993, J NEUROSCI METH, V48, P35, DOI 10.1016/S0165-0270(05)80005-6; GOLDSTEIN LB, 1995, BRAIN RES, V674, P167, DOI 10.1016/0006-8993(95)00021-H; HARGREAVES EL, 1992, BEHAV BRAIN RES, V47, P23, DOI 10.1016/S0166-4328(05)80249-9; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Keefe KA, 1996, J COMP NEUROL, V367, P165, DOI 10.1002/(SICI)1096-9861(19960401)367:2<165::AID-CNE1>3.0.CO;2-3; KIRK RE, 1965, EXPT DESIGN PROCEDUR; KOCHHAR A, 1988, ARCH NEUROL-CHICAGO, V45, P148, DOI 10.1001/archneur.1988.00520260034016; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; Kozlowski DA, 1997, BRAIN RES, V763, P159, DOI 10.1016/S0006-8993(97)00377-6; LEVERE TE, 1980, PHYSIOL PSYCHOL, V8, P297, DOI 10.3758/BF03337462; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; MICHAELS RL, 1990, J NEUROSCI, V10, P283; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Ogden R, 1917, PSYCHOBIOLOGY, V1, P33, DOI [10.1037/h0074814, DOI 10.1037/H0074814]; OSTENDORF CG, 1981, J AM PHYS THER ASSOC, V61, P1022; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; ROYET JP, 1991, PROG NEUROBIOL, V37, P433, DOI 10.1016/0301-0082(91)90009-P; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SAPONJIC RM, 1995, RESTOR NEUROL NEUROS, V8, P205, DOI 10.3233/RNN-1995-8406; Schallert T, 1998, RESTORATIVE NEUROLOGY, P91; SCHALLERT T, 1990, CAN J PSYCHOL, V44, P276, DOI 10.1037/h0084244; Schallert T, 1997, ADV NEUROL, V73, P229; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1997, BEHAV BRAIN RES, V89, P51, DOI 10.1016/S0166-4328(97)00049-1; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THANOS S, 1993, J NEUROSCI, V13, P455; UYLINGS HBM, 1986, J NEUROSCI METH, V18, P19, DOI 10.1016/0165-0270(86)90111-1; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; WEBSTER HH, 1991, SOMATOSENS MOT RES, V8, P327, DOI 10.3109/08990229109144756; Whishaw IQ, 1996, BEHAV BRAIN RES, V77, P135, DOI 10.1016/0166-4328(95)00209-X; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	62	97	106	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	1999	157	2					349	358		10.1006/exnr.1999.7061			10	Neurosciences	Neurosciences & Neurology	202LD	WOS:000080653000012	10364446				2021-06-18	
J	Snow, P; Douglas, J; Ponsford, J				Snow, P; Douglas, J; Ponsford, J			Conversational discourse abilities following severe traumatic brain injury: a follow-up study	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; BEHAVIORAL-ASSESSMENT; SOCIAL-INTERACTION; RECOVERY; DAMAGE; POPULATION; DISORDER; DEFICITS; PROFILE	The major aim of this study was to describe the conversational abilities of a group of severely injured TBI speakers, at a minimum of 2 years post-injury. The association between conversational impair ment and (a) selected measures of executive function and (b) psychosocial handicap was also examined. Twenty-four members of the group of 26 severely injured TBI speakers who had initially been assessed between 3 and 6 months post-injury were reviewed at a minimum of 2 years post-injury (mean = 2 years, 10 months). At initial assessment, TBI speakers were compared with non-TBI orthopaedic patients and with a group of university students. At follow-up, however, they were compared only with the orthopaedic patients. Conversational assessment was carried out using a modified form of Damico's Clinical Discourse Analysis. As a group, the TBI speakers' conversational abilities did not improve over time. There was, however, at subgroup (n = 8) of speakers who did improve, and these could be distinguished by greater initial severity of injury and a significantly longer period of speech-language pathology intervention than the speakers who either remained the same or worsened over time. Modest associations between conversational discourse skills and measures of executive function and a measure of psychosocial handicap were identified. These findings indicate that disruptions in conversation persist into the longer term. More assiduous efforts may need to be made to (a) identify subtle discourse changes in the early months after injury and (b) engage TBI speakers in speech-language pathology services. Such services are also required over a longer time frame, in community-based models of service provision.	La Trobe Univ, Sch Human Commun Sci, Melbourne, Vic, Australia; Bethesda Hosp, Dept Psychol, Melbourne, Vic, Australia	Snow, P (corresponding author), La Trobe Univ, Fac Hlth Sci, Sch Human Commun Sci, Bundoora, Vic 3083, Australia.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ARMSTRONG EM, 1987, CLIN APHASIOLOGY, P210; BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; BIELIAUSKAS LA, 1993, J CLIN EXP NEUROPSYC, V15, P119, DOI 10.1080/01688639308407223; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BOAKE C, 1996, AM J PHYSICAL MED RE, V75, P1; BODY R, 1996, INT PERSPECTIVES TRA, P221; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; BOWDEN SC, 1994, AUST PSYCHOL, V29, P34, DOI 10.1080/00050069408257317; Brooks D N, 1979, Int Rehabil Med, V1, P166; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P767; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CANAVAN AGM, 1985, J NEUROL NEUROSUR PS, V48, P1049, DOI 10.1136/jnnp.48.10.1049; COEHLO CA, 1991, ARCH PHYSICAL MED RE, V72, P465; COEHLO CA, 1991, J HEAD TRAUMA REHAB, V6, P92; COEHLO CA, 1991, BRAIN INJURY, V5, P381; COEHLO CA, 1993, CLIN APHASIOLOGY, V21, P183; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Damico JS, 1985, COMMUNICATION SKILLS, P165; DAMICO JS, 1991, COMMUNICATION SKILLS, P125; DAVISON G, 1994, ABNORMAL PSYCHOL EXP; DEPOMPEI R, 1988, J HEAD TRAUMA REHAB, V3, P13; DOYLE PJ, 1996, AM J SPEECH-LANG PAT, V5, P53, DOI DOI 10.1044/1058-0360.0503.53; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [DOI 10.1007/BF02214959, 10.1007/BF02214959]; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; GURNS S, 1994, BRAIN INJURY, V8, P413, DOI 10.3109/02699059409150993; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; Hagen C, 1981, TOP LANG DIS, V1, P73; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HALL JW, 1982, LARYNGOSCOPE, V92, P883; Hannay HJ, 1996, J HEAD TRAUMA REHAB, V11, P41, DOI 10.1097/00001199-199612000-00007; HARTLEY L, 1989, J SPEECH LANGUAGE PA, V13, P51; Hartley L. L., 1995, COGNITIVE COMMUNICAT; JENNETT B, 1975, LANCET, V1, P480; JORDAN F, 1990, AUSTR J HUMAN COMMUN, V18, P69; KEPPELL G, 1991, DESIGN ANAL RES HDB; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milton S. B., 1986, CLIN NEUROPSYCHOLOGY, P223, DOI [10.1007/978-1-4613-2291-7_11, DOI 10.1007/978-1-4613-2291-7_11]; MILTON SB, 1988, J HEAD TRAUMA REHAB, V3, P1; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pang D, 1985, HEAD INJURY REHABILI, P3; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; PODOSHIN L, 1975, ARCH OTOLARYNGOL, V101, P15; Ponsford J., 1995, TRAUMATIC BRAIN INJU, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO G, 1986, NEUROPSYCHOL REHABIL, P143; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; Prigatano GP, 1995, PSYCHOL ASSESSMENT, V7, P396; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Ruff R, 1991, COGNITIVE REHABILITA, P23; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; SBORDONE RJ, 1991, COGNITIVE REHABILITA, P105; SCHUKNECHT HF, 1969, ANN OTO RHINOL LARYN, V78, P253, DOI 10.1177/000348946907800205; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; Snow P, 1995, TRAUMATIC BRAIN INJU, P33; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VanLancker D, 1997, BRAIN LANG, V57, P1, DOI 10.1006/brln.1997.1850; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, UNPUB SCORING GUIDEL; WHITENECK GG, 1992, GUIDE USE CHART; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; YLVISAKER M, 1985, CLIN MANAGEMENT NEUR, P243	94	97	98	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	1998	12	11					911	935		10.1080/026990598121981			25	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	143NR	WOS:000077262300002	9839026				2021-06-18	
J	Smirnova, IV; Zhang, SX; Citron, BA; Arnold, PM; Festoff, BW				Smirnova, IV; Zhang, SX; Citron, BA; Arnold, PM; Festoff, BW			Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons	JOURNAL OF NEUROBIOLOGY			English	Article						thrombin; apoptosis; protease; motor neuron; neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; CRMA-INHIBITABLE PROTEASE; PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; NEURITE RETRACTION; GRANZYME-B; NEXIN-I; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ACTIN POLYMERIZATION; SYMPATHETIC NEURONS	Apoptosis, often also termed "programmed cell death," occurs in normal development in the brain and spinal cord. Important to concepts of disease and potential intervention is the exciting finding that apoptosis is also found after neurotrauma and in a number of neurodegenerative diseases. Although the precise mechanism of neuronal cell loss remains unknown, much emphasis has been placed recently on the activation of cell death protease cascades within the cell. How these cascades may be activated, especially from extracellular influences, is currently poorly understood. Thrombin, the multifunctional coagulation protease, is an early phase modulator at sites of tissue injury and has been shown to induce cell death in neurons by an apoptotic mechanism by activating its receptor, PAR-I. Using a model motor neuronal cell Line, NSC19, which me have shown undergoes apoptosis after treatment with classic apoptosis inducers such as the topoisomerase inhibitors camptothecin and etoposide, me unambiguously found that nanomolar thrombin induced characteristic signs of apoptosis, Strikingly, endonucleolysis was accompanied by an increase in caspase-3-like activity in cellular extracts, which correlated with both detection of caspase-induced signature cleavage of the cortical cytoskeleton component nonerythroid spectrin (alpha-fodrin) and identification of increased accessibility of a caspase cleavage domain, using an antibody (Ab127) made against a synthetic peptide KGDEVD. Demonstrating that thrombin activation of death proteases was linked to cell death, we were able to inhibit thrombin-induced apoptosis by using a caspase family inhibitor, benzyloxy-carbonyl-Asp-(oMe)-flouromethyl ketone (Boc-D-FMK). These novel results demonstrate that thrombin serves as an extracellular "death signal" to activate intracellular protease pathways. These pathways lead to apoptotic cell death and can be modulated by inhibiting caspase activity downstream to PAR-1. (C) 1998 John Wiley & Sons, Inc.*	Vet Affairs Med Ctr, Neurobiol Res Lab 151R, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; Univ Kansas, Med Ctr, Dept Surg Neurosurg, Kansas City, KS 66103 USA	Festoff, BW (corresponding author), Vet Affairs Med Ctr, Neurobiol Res Lab 151R, 4801 Linwood Blvd, Kansas City, MO 64128 USA.						Adjei PN, 1996, J CLIN INVEST, V98, P2588, DOI 10.1172/JCI119078; ALEXIANU ME, 1994, J NEUROCHEM, V63, P2365; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1997, J NEUROSCI, V17, P553; BEECHER KL, 1994, J NEUROSCI RES, V37, P108, DOI 10.1002/jnr.490370115; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cb.09.110193.000331; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Bozyczko-Coyne D., 1996, Society for Neuroscience Abstracts, V22, P566; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; CHOU SM, 1998, IN PRESS J NEUROLOG; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Didier M, 1996, J NEUROSCI, V16, P2238; Donovan FM, 1997, J NEUROSCI, V17, P5316; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; EHRENGRUBER MU, 1995, FEBS LETT, V372, P161, DOI 10.1016/0014-5793(95)00880-I; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ELLIOTT JL, 1995, NEUROREPORT, V6, P449, DOI 10.1097/00001756-199502000-00011; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FENTON JW, 1989, SEMIN THROMB HEMOST, V15, P265, DOI 10.1055/s-2007-1002718; FENTON JW, 1991, HAEMOSTASIS, V21, P27; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FESTOFF BW, 1980, MED HYPOTHESES, V6, P121, DOI 10.1016/0306-9877(80)90078-X; Festoff BW, 1996, J NEUROBIOL, V30, P255, DOI 10.1002/(SICI)1097-4695(199606)30:2<255::AID-NEU7>3.0.CO;2-4; Festoff BW, 1996, SEMIN THROMB HEMOST, V22, P267, DOI 10.1055/s-2007-999018; FESTOFF BW, 1990, NATO ASI SERIES A, V191, P360; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HANTAI D, 1988, REV NEUROL, V144, P680; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; INCE P, 1993, NEUROPATH APPL NEURO, V19, P291, DOI 10.1111/j.1365-2990.1993.tb00443.x; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; JOSEPH R, 1993, MOL BRAIN RES, V17, P70, DOI 10.1016/0169-328X(93)90074-Y; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; KRUEGER BK, 1995, J NEUROSCI, V15, P3366; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Mukasa T, 1997, BIOCHEM BIOPH RES CO, V231, P770, DOI 10.1006/bbrc.1996.6002; Mundle SD, 1995, ANTICANCER RES, V15, P1895; NAKAJIMA M, 1994, BRAIN RES, V641, P350, DOI 10.1016/0006-8993(94)90165-1; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; ONISHI Y, 1993, BIOCHIM BIOPHYS ACTA, V1175, P147, DOI 10.1016/0167-4889(93)90017-J; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Smirnova IV, 1996, J NEUROCHEM, V67, P2188; SMIRNOVA IV, 1997, IN PRESS SPINE; SMIRNOVA IV, 1996, AM SOC CELL BIOL ABS, V7, P1115; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Srinivasan A, 1996, J NEUROSCI, V16, P5654; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	86	97	100	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0022-3034			J NEUROBIOL	J. Neurobiol.	JUL	1998	36	1					64	80		10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8			17	Neurosciences	Neurosciences & Neurology	ZW508	WOS:000074418000006	9658339				2021-06-18	
J	Hoffman, SW; Moore, S; Ellis, EF				Hoffman, SW; Moore, S; Ellis, EF			Isoprostanes: Free radical-generated prostaglandins with constrictor effects on cerebral arterioles	STROKE			English	Article						brain injuries; cerebral circulation; cerebral ischemia; lipid peroxidation; oxygen radical; rats	EXPERIMENTAL HEAD-INJURY; LOW-DENSITY-LIPOPROTEIN; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; BRAIN INJURY; F2-ISOPROSTANE; RECEPTOR; RATS; ANTAGONIST; EXISTENCE	Background and Purpose Isoprostanes are generated by cyclooxygenase-independent free radical attack of arachidonic acid and are potent constrictors of the peripheral vasculature. Traumatic brain injury stimulates oxygen radical production and is associated with cerebral blood flow reduction. However, no specific vasoconstrictor has been identified as the cause of posttraumatic blood flow reduction. The purpose of this study was to determine whether isoprostanes constrict cerebral arterioles. Methods The effects of 10(-9) to 10(-5) mol/L 8-iso-prostaglandin F-2 alpha (8-iso-PGF(2 alpha)), S-iso-prostaglandin E(2) (8-isol-PGE(2)), and prostaglandin F-2 alpha (PGF(2 alpha)) on pial arteriolar diameter were measured in anesthetized rats using a closed cranial window and in vivo microscopy. Results All prostanoids produced vasoconstriction. Of these, 8-iso-PGF(2 alpha) produced the greatest vasoconstriction (34% +/- 2), followed by 8-iso-PGE(2) (25% +/- 4) and PGF(2 alpha) (20% +/- 2). After six cerebrospinal fluid washouts of the cranial window, both 8-iso-PGF(2 alpha),- and 8-iso-PGE(2)-treated vessels remained slightly constricted, whereas the PGF(2a)-treated vessels returned to control diameter, Coapplication of the semiselective thromboxane A(2)/prostaglandin H-2 receptor antagonist SQ29548 completely blocked the vasoconstriction induced by 8-iso-PGF(2a) and 8-iso-PGE(2). Conclusions Isoprostanes are potent constrictors of cerebral arterioles and appear to act at a receptor that is similar to the thromboxane A(2)/prostaglandin H-2 receptor. Isoprostanes may play a role in the reduction of cerebral blood flow that occurs after brain injury and subsequent oxygen radical production.		Hoffman, SW (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, POB 980613, 410 N 12TH ST, RICHMOND, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-07288, NS-27214] Funding Source: Medline		AWAD JA, 1993, J BIOL CHEM, V268, P4161; BAEZ S, 1966, J APPL PHYSIOL, V21, P229; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Caron M J, 1991, Neurosurg Clin N Am, V2, P483; CHAN KH, 1993, ACTA NEUROCHIR, P81; CLARK WM, 1995, DRUGS, V50, P971, DOI 10.2165/00003495-199550060-00005; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; FADEL MM, 1995, SURG NEUROL, V43, P52, DOI 10.1016/0090-3019(95)80038-I; FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619; FUKUNAGA M, 1993, BIOCHEM BIOPH RES CO, V195, P507, DOI 10.1006/bbrc.1993.2075; GAETANI P, 1994, NEUROCHEM RES, V19, P839, DOI 10.1007/BF00967453; GOPAUL NK, 1994, BIOCHEM BIOPH RES CO, V200, P338, DOI 10.1006/bbrc.1994.1453; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LONGMIRE AW, 1994, PROSTAGLANDINS, V48, P247, DOI 10.1016/0090-6980(94)90011-6; MAYHAN WG, 1992, AM J PHYSIOL, V262, pH539; McIntosh TK, 1996, LAB INVEST, V74, P315; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P28; Mohler ER, 1996, BIOCHEM BIOPH RES CO, V225, P915, DOI 10.1006/bbrc.1996.1272; MOORE KP, 1995, CIRC RES, V77, P335, DOI 10.1161/01.RES.77.2.335; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; ROBERTS LJ, 1995, ADV PROSTAG THROMB L, V23, P219; ROSENBLUM WI, 1975, STROKE, V6, P293, DOI 10.1161/01.STR.6.3.293; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; Smith D H, 1995, New Horiz, V3, P562; SUZUKI S, 1994, ACTA NEUROCHIR, V131, P184, DOI 10.1007/BF01808610; WAGERLE LC, 1990, CIRC RES, V66, P824, DOI 10.1161/01.RES.66.3.824; WHITE RP, 1982, PHARMACOL THERAPEUT, V18, P313, DOI 10.1016/0163-7258(82)90035-3	39	97	100	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	1997	28	4					844	849		10.1161/01.STR.28.4.844			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	WR454	WOS:A1997WR45400031	9099206				2021-06-18	
J	Boake, C				Boake, C			Supervision rating scale: A measure of functional outcome from brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; REHABILITATION RESEARCH; CLINICAL-TRIALS; DISABILITY; RELIABILITY; COMMUNITY	Objective: To introduce a new outcome rating scale, the Supervision Rating Scale (SRS), which measures the level of supervision that a patient receives from caregivers. The SRS rates level of supervision on a 13-point ordinal scale that can optionally be grouped into five ranked categories (Independent, Overnight Supervision, Part-Time Supervision, Full-Time Indirect Supervision, and Full-Time Direct Supervision). Design: Descriptive correlational study of the scale's interrater reliability and criterion-related validity. Setting: Brain injury program of a freestanding rehabilitation hospital. Patients: Referred case series of 114 patients with moderate to severe traumatic brain injury (mean time postinjury = 3.8 years) who resided in the community or a nonhospital facility. Intervention: None. Main Outcome Measures: Functional outcome as measured by the Disability Rating Scale (DRS), Glasgow Outcome Scale (GOS), type of living arrangement, and independence in self-care and instrumental activities of daily living (ADL). Results: SRS ratings showed consistent relationships with type of living arrangement and with independence in self-care and instrumental ADL. SRS ratings were also strongly associated with ratings on the DRS and GOS. Interrater reliability of the SRS was evaluated in a subsample of 19 patients and found to be satisfactory (intraclass correlation = .86, weighted kappa = .64). Conclusions: The results suggest that the SRS should have sufficient reliability and validity to serve as a measure of functional outcome from brain injury. Because SRS ratings are based on observed behaviors, the SRS may have a smaller subjective component as compared to the DRS and GOS. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	UNIV TEXAS,SCH MED,DEPT PHYS MED & REHABIL,HOUSTON,TX; INST REHABIL RES,HOUSTON,TX							ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Boake C., 1990, COMMUNITY INTEGRATIO, P115; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Condeluci A., 1992, J HEAD TRAUMA REHAB, V7, P37; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Credner L, 1930, Z GESAMTE NEUROL PSY, V126, P721, DOI 10.1007/BF02864129; DILLER L, 1987, REHABILITATION OUTCO, P209; DODDARD D, 1988, J NEUROL NEUROSUR PS, V51, P833; Fillenbaum G.G., 1988, MULTIDIMENSIONAL FUN; Fleiss JL, 1981, STATISTICAL METHODS; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HAFFEY W, 1989, MODELS BRAIN INJURY, P205; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; JONES ML, 1992, J INSUR MED, V4, P186; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; McDowell I., 1987, MEASURING HLTH GUIDE; NOSEK MA, 1987, REHABILITATION OUTCO, P71; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; OTTENBACHER KJ, 1993, AM J PHYS MED REHAB, V72, P266, DOI 10.1097/00002060-199310000-00003; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SHEIKH K, 1986, ARCH PHYS MED REHAB, V67, P245; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; WADE DT, 1993, MEASUREMENT NEUROLOG; WAGNER KA, 1986, NEUROTRAUMA TREATMEN, V1, P213; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583	38	97	97	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1996	77	8					765	772		10.1016/S0003-9993(96)90254-3			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	VA965	WOS:A1996VA96500005	8702369				2021-06-18	
J	Feldman, Z; Gurevitch, B; Artru, AA; Oppenheim, A; Shohami, E; Reichenthal, E; Shapira, Y				Feldman, Z; Gurevitch, B; Artru, AA; Oppenheim, A; Shohami, E; Reichenthal, E; Shapira, Y			Effect of magnesium given 1 hour after head trauma on brain edema and neurological outcome	JOURNAL OF NEUROSURGERY			English	Article						head injury; brain edema; neurological outcome; magnesium; rat	EXCITATORY AMINO-ACIDS; VOLTAGE-DEPENDENT BLOCK; NERVOUS-SYSTEM INJURY; GLUTAMATE NEUROTOXICITY; BARRIER PERMEABILITY; ACTIVATED CHANNELS; CEREBRAL EDEMA; RATS; BLOOD; NEURONS	Excitatory amino acids (EAA), mainly glutamate and aspartate, are released in excessive amounts from terminals of ischemic or traumatically injured neurons. These excessive levels of EAAs initiate a cascade of events believed to lead to secondary delayed damage to the surrounding brain. The N-methyl-D-aspartate receptor antagonists MK-801 and ketamine are reported to suppress excessive EAA release and to attenuate the development of focal brain edema following neuronal injury. Magnesium is also reported to work at the postsynaptic receptor to reduce the neurotoxic effect of glutamate. The present study was undertaken to examine the effect of postinjury treatment with Mg++ on brain edema and neurological outcome after traumatic brain injury. Sixty-nine rats that survived halothane anesthesia and closed head trauma (CHT) were randomly assigned to one of seven experimental groups: sham, CHT, and CHT with administration of Mg++ 1 hour postinjury. At 48 hours, brain tissue Mg++ concentration (calculated from optical density using a standard curve) was significantly increased compared to baseline levels (10.06 +/- 2.44 mg/g vs. 6.83 +/- 0.81 mg/g, p < 0.01 calculated by one-way analysis of variance). Also at 48 hours postinjury, brain tissue specific gravity in the contused hemisphere of Mg++-treated rats was significantly greater than that in the contused hemisphere of untreated rats, indicating attenuation of brain edema formation by Mg++. The neurological severity score (NSS) of rats treated with Mg++ improved significantly at both 18 and 48 hours, compared to baseline values obtained 1 hour after CHT but prior to administration of Mg++ (11.2 +/- 2.5 vs. 15.2 +/- 4.1, p = 0.03; and 12.3 +/- 6.1 vs. 17.3 +/- 3.6, p = 0.004, respectively). In the untreated groups, the NSS at 18 and 48 hours was not significantly different from baseline values (that is, no neurological improvement). The present study indicates that postinjury treatment with Mg++ attenuates brain edema formation and improves neurological outcome after experimental CHT.	SOROKA MED CTR,DEPT NEUROSURG,IL-84101 BEER SHEVA,ISRAEL; SOROKA MED CTR,DEPT ANESTHESIOL,IL-84101 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,BEER SHEVA,ISRAEL; UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA 98195; HADASSAH MED CTR,DEPT ANESTHESIOL,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL							ALEXANDER SC, 1975, BLOOD FLOW METABOLIS; ARTRU AA, 1988, J CEREBR BLOOD F MET, V8, P750, DOI 10.1038/jcbfm.1988.123; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CLARK AF, 1980, J BIOL CHEM, V255, P6556; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FELDMAN Z, 1995, J NEUROSURG, V83, P1060, DOI 10.3171/jns.1995.83.6.1060; FISCHER S, 1993, EUR J PHARMACOL, V232, P121, DOI 10.1016/0014-2999(93)90736-2; FORSTER A, 1978, ANESTHESIOLOGY, V49, P26, DOI 10.1097/00000542-197807000-00008; GARFINKEL L, 1985, Magnesium, V4, P60; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GJEDDE A, 1980, J NEUROCHEM, V35, P1382, DOI 10.1111/j.1471-4159.1980.tb09013.x; GUMERLOCK MK, 1990, NEUROSURGERY, V26, P268, DOI 10.1227/00006123-199002000-00014; HANNAN CJ, 1988, 4 COLL BIOL SCI BLOO, V529, P172; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; JOHNSON JW, 1990, BIOPHYS J, V57, P1085, DOI 10.1016/S0006-3495(90)82626-6; KOHMURA E, 1990, J CEREBR BLOOD F MET, V10, P877, DOI 10.1038/jcbfm.1990.144; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, SYNAPSE, V6, P179, DOI 10.1002/syn.890060210; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; NEMOTO EM, 1978, ANESTHESIOLOGY, V49, P170, DOI 10.1097/00000542-197809000-00004; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PASHAYAN AG, 1988, ANESTHESIOLOGY REV, V15, P30; PATEL AJ, 1988, BRAIN RES, V450, P378, DOI 10.1016/0006-8993(88)91579-X; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROTHE F, 1993, NEUROREPORT, V4, P205, DOI 10.1097/00001756-199302000-00023; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SAGE JI, 1979, J NEUROCHEM, V33, P963, DOI 10.1111/j.1471-4159.1979.tb09930.x; SAIJA A, 1989, NEUROPHARMACOLOGY, V28, P997, DOI 10.1016/0028-3908(89)90202-5; SCHETTINI A, 1979, BRIT J ANAESTH, V51, P1117, DOI 10.1093/bja/51.12.1117; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1993, EUR J ANAESTH, V10, P155; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1989, PROSTAG LEUKOTR ESS, V36, P49, DOI 10.1016/0952-3278(89)90162-2; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; SHOHAMI E, 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P103; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; STEWART PA, 1988, BRAIN RES, V443, P12, DOI 10.1016/0006-8993(88)91593-4; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; WOLF G, 1991, NEUROSCIENCE, V43, P31, DOI 10.1016/0306-4522(91)90413-I	69	97	102	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1996	85	1					131	137		10.3171/jns.1996.85.1.0131			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	UT668	WOS:A1996UT66800020	8683262				2021-06-18	
J	KIRKPATRICK, PJ; SMIELEWSKI, P; CZOSNYKA, M; MENON, DK; PICKARD, JD				KIRKPATRICK, PJ; SMIELEWSKI, P; CZOSNYKA, M; MENON, DK; PICKARD, JD			NEAR-INFRARED SPECTROSCOPY USE IN PATIENTS WITH HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article						NEAR-INFRARED SPECTROSCOPY; HEAD INJURY; MULTIMODALITY MONITORING; CEREBRAL OXYGENATION	VENOUS OXYGEN-SATURATION; CEREBRAL BLOOD-FLOW; NEWBORN-INFANTS; BRAIN INJURY; TISSUE	A multimodality recording system was used in 14 ventilated patients with closed head injury to assess the potential use of near-infrared spectroscopy (NIRS) in the neurointensive care unit. Signals of intracranial pressure, cerebral perfusion pressure, peripheral oxygen saturation, jugular venous saturation, and NIRS-derived changes in the chromophores of oxy- and deoxyhemoglobin were digitized and recorded. After a review of 886 hours of continuous monitoring, 376 hours were considered free from artifact and were entered for final analysis. In nine of the patients 38 events were recorded that demonstrated clear changes in cerebral perfusion pressure accompanied by hemodynamic changes in middle cerebral artery flow velocity (transcranial Doppler) and cortical perfusion (laser Doppler flowmetry). Near-infrared spectroscopy showed correlated changes in 37 events (97%) whereas jugular venous saturation monitoring registered only 20 (53%). There was associated peripheral oxygen desaturation in eight cases (21%), intracranial hypertension in 10 (26%), and cerebral hyperemia in eight (21%). The remaining 12 events (32%) appeared to be complex changes of uncertain origin. Iatrogenic factors were identified as causative in 14 cases (37%). The potential application of NIRS in adults and the importance of using multiple parameter recording systems in the interpretation of cerebral events are discussed.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT NEUROSURG, CAMBRIDGE, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT ANAESTHESIA, CAMBRIDGE, ENGLAND				Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; COPE M, 1988, MED BIOL ENG COMPUT, V26, P289, DOI 10.1007/BF02447083; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1992, J NEUROSURG, V77, P975; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; ELWELL CE, 1992, ADV EXP MED BIOL, V317, P235; ELWELL CE, 1994, ADV EXP MED BIOL, V345, P619; Ferrari M, 1986, Adv Exp Med Biol, V200, P213; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HAMPSON NB, 1990, J APPL PHYSIOL, V69, P907; HOSHI Y, 1993, NEUROSCI LETT, V150, P5, DOI 10.1016/0304-3940(93)90094-2; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; KATO T, 1993, J CEREBR BLOOD F MET, V13, P516, DOI 10.1038/jcbfm.1993.66; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; KIRKPATRICK PJ, 1995, J NEUROSURG, V82, P756, DOI 10.3171/jns.1995.82.5.0756; KIRKPATRICK PJ, 1995, STROKE, V26, P722; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TEASDALE G, 1974, LANCET, V2, P81; VANDERZEE P, 1992, ADV EXP MED BIOL, V316, P143; WYATT JS, 1986, LANCET, V2, P1063, DOI 10.1016/S0140-6736(86)90467-8	30	97	97	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	1995	83	6					963	970		10.3171/jns.1995.83.6.0963			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TG914	WOS:A1995TG91400002	7490639				2021-06-18	
J	MOORE, AD; STAMBROOK, M				MOORE, AD; STAMBROOK, M			COGNITIVE MODERATORS OF OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY - A CONCEPTUAL-MODEL AND IMPLICATIONS FOR REHABILITATION	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; SPINAL-CORD INJURY; STAGE RENAL-DISEASE; CHRONIC ILLNESS; HEALTH LOCUS; CT SCAN; DEPRESSION; HELPLESSNESS; ATTRIBUTIONS; PREDICTORS	This paper presents a conceptual model describing the relationships between quality of life outcomes following traumatic brain injury (TBI), coping patterns, and beliefs regarding self-efficacy to assist health-care professionals in understanding the complexity of social and psychological sequelae of TBI. The model hypothesizes that long-lasting cognitive, behavioural, emotional psychiatric, and interpersonal after-effects of TBI may create a real life 'learned helplessness' with consequent deficits in coping, and altered locus of control beliefs. As a result, TBI patients are at risk for developing self-limiting belief systems about their effectiveness in altering significant events that may result in over-generalizing the effects that TBI has in their day-to-day lives. Subsequently, a feedback loop may be set up where their beliefs in not being able to influence outcomes are not tested, life chances are further restricted, outcomes are suboptimal, and quality of life is reduced. The clinical and theoretical implications of this model are discussed, and an expanded model with future research directions is suggested.	UNIV MANITOBA,HLTH SCI CLIN RES CTR,MANITOBA ADOLESCENT TREATMENT CTR,DEPT PSYCHIAT & MED,WINNIPEG,MB,CANADA	MOORE, AD (corresponding author), MANITOBA ADOLESCENT TREATMENT CTR,HLTH SCI CLIN RES CTR,SOC MANITOBANS DISABIL,WINNIPEG,MB R3A 1MS,CANADA.						ABRAMSON LY, 1989, PSYCHOL REV, V96, P358, DOI 10.1037/0033-295X.96.2.358; ABRAMSON LY, 1978, J ABNORM PSYCHOL, V87, P49, DOI 10.1037/0021-843X.87.1.49; ALLOY LB, 1988, BRIT J CLIN PSYCHOL, V27, P5, DOI 10.1111/j.2044-8260.1988.tb00749.x; Beck A. T., 1967, DEPRESSION CLIN EXPT; Beck AT., 1979, COGNITIVE THEORY DEP; BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BERROL S, 1989, MILD MODERATE HEAD I, P135; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS N, 1984, CLOSED HEAD INJURY P, P44; BULMAN RJ, 1977, J PERS SOC PSYCHOL, V35, P351, DOI 10.1037/0022-3514.35.5.351; BUTLER RW, 1988, PROF PSYCHOL-RES PR, V19, P536, DOI 10.1037/0735-7028.19.5.536; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Cooper PR, 1987, HEAD INJURY, P313; CRISSON JE, 1988, PAIN, V35, P147, DOI 10.1016/0304-3959(88)90222-9; DEVINS GM, 1981, J ABNORM PSYCHOL, V90, P531, DOI 10.1037/0021-843X.90.6.531; DEVINS GM, 1986, INT J PSYCHIAT MED, V16, P151; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1989, MILD HEAD INJURY, P229; FARID BT, 1988, J STUD ALCOHOL, V49, P375, DOI 10.15288/jsa.1988.49.375; FELTON BJ, 1987, PSYCHOL AGING, V2, P164, DOI 10.1037/0882-7974.2.2.164; FELTON BJ, 1984, SOC SCI MED, V10, P889; FIEFEL H, 1987, PSYCHOSOM MED, V49, P616; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P992, DOI 10.1037/0022-3514.50.5.992; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FORREST DV, 1987, AM PSYCHIATRIC PRESS, P387; FRANK RG, 1987, J CONSULT CLIN PSYCH, V55, P727; FRANK RG, 1989, PARAPLEGIA, V27, P250, DOI 10.1038/sc.1989.37; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOUVIER D, 1986, NEUROPSYCHOLOGY HDB, P278; Gronwall D, 1989, MILD HEAD INJURY, P153; HAWRYLUK GA, 1989, CANADIAN PSYCHOL, V30, P235; KASSUM DA, 1984, CAN J SURG, V27, P64; Kolb B, 1985, FUNDAMENTALS HUMAN N; KREFTING L, 1990, SOC SCI MED, V30, P859, DOI 10.1016/0277-9536(90)90213-C; Lazarus R.S., 1984, STRESS APPRAISAL COP; LEFCOURT HM, 1981, RES LOCUS CONTROL CO, V2, P253; LEVENSON H, 1974, J PERS ASSESS, V38, P377, DOI 10.1080/00223891.1974.10119988; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; Levin HS, 1989, MILD HEAD INJURY; LEVIN HS, 1989, MILD MODERATE HEAD I, P153; LEVIN HS, 1990, NOV M NAT AC NEUR RE; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LOWERY BJ, 1987, NURS RES, V36, P88; LOWERY BJ, 1984, NURS RES, V34, P82; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MCGLASHAN TH, 1975, ARCH GEN PSYCHIAT, V32, P1269; MCGLASHAN TH, 1981, AM J PSYCHIAT, V138, P797; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McNair DM, 1971, EITS MANUAL PROFILE; Miller WG, 1986, NEUROPSYCHOLOGY HDB, P347; Moore A D, 1994, NeuroRehabilitation, V4, P122, DOI 10.3233/NRE-1994-4208; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; Moore A. D., 1990, PSYCHOL ASSESSMENT, V2, P98, DOI [10.1037/1040-3590.2.1.98, DOI 10.1037/1040-3590.2.1.98]; MOORE AD, 1991, NEUROPSYCHOL REHABIL, V1, P185, DOI DOI 10.1080/09602019108520164; MOORE AD, 1993, CANADIAN J REHABILIT, V6, P89; MOORE AD, 1989, THESIS U MANITOBA WI; Moore AD, 1994, CAN J REHABIL, V4, P122; NICASSIO PM, 1985, J RHEUMATOL, V12, P462; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; OHARA C, 1988, COGNITIVE REHABILITA, V6, P26; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PETERS LC, 1988, CANADIAN J REHABI S4, V1, P60; PETERSON C, 1982, COGNITIVE THER RES, V6, P287, DOI 10.1007/BF01173577; ROLLAND JS, 1987, CHANGING FAMILY LIFE, P453; ROSENBAUM M, 1977, J CLIN PSYCHOL, V33, P672, DOI 10.1002/1097-4679(197707)33:3<672::AID-JCLP2270330314>3.0.CO;2-3; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Seligman M., 1975, HELPLESSNESS; SHADISH WR, 1981, J CONSULT CLIN PSYCH, V49, P297, DOI 10.1037/0022-006X.49.2.297; SILVER JM, 1987, AM PSYCHIAT PRESS HD, P179; SOLOMON Z, 1989, BRIT J CLIN PSYCHOL, V28, P131, DOI 10.1111/j.2044-8260.1989.tb00823.x; SOSKIS DA, 1969, J NERV MENT DIS, V149, P443, DOI 10.1097/00005053-196912000-00001; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; STAMBROOK M, 1990, CAN J SURG, V33, P115; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; STAMBROOK M, 1989, CANADIAN J REHABILIT, V3, P87; STAMBROOK M, 1988, CANADIAN J REHABI S4, V1, P74; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; TATE RL, 1987, SCAND J REHABIL MED, V19, P19; TAYLOR SE, 1984, J PERS SOC PSYCHOL, V46, P489, DOI 10.1037/0022-3514.46.3.489; TAYLOR SE, 1989, HLTH PSYCHOL; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VINEY LL, 1982, J PSYCHOSOM RES, V26, P595, DOI 10.1016/0022-3999(82)90075-7; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; WARNER R, 1989, AM J ORTHOPSYCHIAT, V59, P398, DOI 10.1111/j.1939-0025.1989.tb01675.x; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WISE TN, 1988, J PSYCHOSOM RES, V26, P247; 1987, DIAGNOSTIC STATISTIC	99	97	98	0	12	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1995	9	2					109	130		10.3109/02699059509008185			22	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QN628	WOS:A1995QN62800001	7787832				2021-06-18	
J	REGAN, RF; CHOI, DW				REGAN, RF; CHOI, DW			THE EFFECT OF NMDA, AMPA/KAINATE, AND CALCIUM-CHANNEL ANTAGONISTS ON TRAUMATIC CORTICAL NEURONAL INJURY IN CULTURE	BRAIN RESEARCH			English	Article						CALCIUM; CELL CULTURE; CEREBRAL CORTEX; EXCITOTOXICITY; GLUTAMATE; HEAD TRAUMA; NEUROTOXICITY	EXCITATORY AMINO-ACIDS; SPINAL-CORD INJURY; BRAIN INJURY; GLUTAMATE NEUROTOXICITY; CELL-CULTURE; RECEPTOR; BLOCKADE; EXCITOTOXICITY; INVITRO	A traumatic insult was delivered to murine cortical neuronal and glial cell cultures by tearing the cell layer with a stylet in a grid pattern. Consistent with prior observations, neurons adjacent to a tear developed immediate swelling, and then went on to degenerate over the next several hours. Delivery of multiple tears produced enough cell death that measurable levels of lactate dehydrogenase accumulated in the bathing medium 24 h later, correlating well with the extent of cell death as assessed by Trypan blue exclusion and cell counts. 50-75% of this trauma-induced cell death was blocked by the NMDA receptor antagonist MK-801. 10-100 mu M CNQX also attenuated neuronal degeneration, but this neuroprotective effect was likely due to attenuation of NMDA receptor-mediated toxicity, since the more specific AMPA/kainate antagonist NBQX was ineffective. CNQX also did not augment the protective effect of MK-801. High concentrations of nimodipine or nifedipine produced modest neuroprotective effects; either dihydropyridine when combined with MK-801 reduced injury more than MK-801 alone. These results suggest that traumatic neuronal death in this in vitro model is mediated in part by excessive activation of NMDA receptors, and in part by mechanisms sensitive to high concentrations of dihydropyridines, but not by AMPA/kainate receptors.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110	REGAN, RF (corresponding author), THOMAS JEFFERSON UNIV,DEPT SURG,DIV EMERGENCY MED,1020 WALNUT ST,RM 239,THOMPSON BLDG,PHILADELPHIA,PA 19107, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026907] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26907] Funding Source: Medline		BIRCH PJ, 1988, EUR J PHARMACOL, V156, P177, DOI 10.1016/0014-2999(88)90163-X; Cannon WB, 1901, AM J PHYSIOL, V6, P91; CARVALHO CAM, 1986, J NEUROCHEM, V47, P1774, DOI 10.1111/j.1471-4159.1986.tb13088.x; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRANDSEN A, 1989, J NEUROCHEM, V53, P297, DOI 10.1111/j.1471-4159.1989.tb07327.x; GARTHWAITE G, 1986, NEUROSCI LETT, V66, P193, DOI 10.1016/0304-3940(86)90189-8; GOLDBERG M P, 1988, Society for Neuroscience Abstracts, V14, P745; GOLDBERG M P, 1991, Neurology, V41, P390; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; JONES SW, 1990, J NEUROSCI, V10, P2261; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KOH J, 1991, BRAIN RES, V548, P318, DOI 10.1016/0006-8993(91)91140-V; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1990, J NEUROSCI, V10, P693; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; REGAN R F, 1991, Society for Neuroscience Abstracts, V17, P722; REGAN RF, 1991, ANN EMERG MED, V20, P478; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; UEMATSU D, 1991, NEUROLOGY, V41, P88, DOI 10.1212/WNL.41.1.88; WALSH MP, 1988, BIOCHEM PHARMACOL, V37, P1569, DOI 10.1016/0006-2952(88)90020-2; WEISS JH, 1990, SCIENCE, V247, P1474, DOI 10.1126/science.2157282; YAMIKAMI I, 1989, J CEREB BLOOD FLOW M, V9, P117; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; ZERNIG G, 1990, TRENDS PHARMACOL SCI, V11, P38, DOI 10.1016/0165-6147(90)90040-F	37	97	101	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JAN 7	1994	633	1-2					236	242		10.1016/0006-8993(94)91544-X			7	Neurosciences	Neurosciences & Neurology	MQ949	WOS:A1994MQ94900030	7907934				2021-06-18	
J	ERB, DE; POVLISHOCK, JT				ERB, DE; POVLISHOCK, JT			AXONAL DAMAGE IN SEVERE TRAUMATIC BRAIN INJURY - AN EXPERIMENTAL-STUDY IN CAT	ACTA NEUROPATHOLOGICA			English	Article										ERB, DE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,BOX 709,MCV STN,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-07288, NS-12587, NS-20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R01NS020193, P01NS012587] Funding Source: NIH RePORTER		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Berman AL, 1968, BRAIN STEM CAT CYTOA; CAJAL SRY, 1928, DEGENERATION REGENER, P599; FRIEDE RL, 1970, BRAIN RES, V19, P165, DOI 10.1016/0006-8993(70)90432-4; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRIFFIN JW, 1977, J NEUROPATH EXP NEUR, V36, P214, DOI 10.1097/00005072-197703000-00002; GROSS GW, 1983, J NEUROSCI, V3, P1979; HIGGINS ML, 1980, J NEUROSCI METH, V3, P83; MARTINEZ AJ, 1970, BRAIN RES, V19, P183, DOI 10.1016/0006-8993(70)90433-6; OCHS S, 1982, AXOPLASMIC TRANSPORT, P221; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Tomlinson B, 1970, J CLIN PATHOL S4, V23, P154	23	97	99	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.		1988	76	4					347	358		10.1007/BF00686971			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	P6118	WOS:A1988P611800003	2459896				2021-06-18	
J	ISHIGE, N; PITTS, LH; BERRY, I; CARLSON, SG; NISHIMURA, MC; MOSELEY, ME; WEINSTEIN, PR				ISHIGE, N; PITTS, LH; BERRY, I; CARLSON, SG; NISHIMURA, MC; MOSELEY, ME; WEINSTEIN, PR			THE EFFECT OF HYPOXIA ON TRAUMATIC HEAD-INJURY IN RATS - ALTERATIONS IN NEUROLOGIC FUNCTION, BRAIN EDEMA, AND CEREBRAL BLOOD-FLOW	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article									UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT RADIOL,SAN FRANCISCO,CA 94143				BERRY, Isabelle/0000-0002-0886-3252			ASATO R, 1983, STROKE, V14, P191, DOI 10.1161/01.STR.14.2.191; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; BAKER RN, 1971, J NEUROPATH EXP NEUR, V30, P668, DOI 10.1097/00005072-197110000-00010; Bazan N G, 1980, Adv Neurol, V28, P197; Blasberg R G, 1980, Adv Neurol, V28, P255; BRANTZAWADZKI M, 1984, AM J NEURORADIOL, V5, P125; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CORALES RL, 1980, INTRACRANIAL PRESSUR, V6, P280; CROCKARD A, 1980, STROKE, V11, P487; CROCKARD A, 1982, HEAD INJURY BASIC CL, P159; CRUZ J, 1985, APR ANN M AM ASS NEU, P195; CUTLER RWP, 1964, ARCH NEUROL-CHICAGO, V11, P225, DOI 10.1001/archneur.1964.00460210003001; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DICK AR, 1980, INTRACRANIAL PRESSUR, V4, P261; DUCKER TB, 1968, J NEUROSURG, V28, P112, DOI 10.3171/jns.1968.28.2.0112; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FREI HJ, 1973, ACTA NEUROCHIR, V29, P15, DOI 10.1007/BF01414613; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GILDENBERG PL, 1985, TRAUMA CENTRAL NERVO, P79; GO KG, 1974, EXP NEUROL, V42, P332, DOI 10.1016/0014-4886(74)90030-2; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, NEUROSURGERY, V20, P840; KATSURADA K, 1973, SURGERY, V73, P191; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEVINE JE, 1979, NEW ENGL J MED, V301, P109; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1984, BRAIN EDEMA, P88; Miller J D, 1980, Adv Neurol, V28, P413; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; OBRIST WD, 1983, INTRACRANIAL PRESSUR, V5, P491; Pickel VM., 1981, NEUROANATOMICAL TRAC, P483; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1980, CEREBRAL MICROVASCUL, P227; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; REULEN HJ, 1973, ACTA NEUROCHIR, V29, P29, DOI 10.1007/BF01414614; SCHUIER FJ, 1980, STROKE, V11, P593, DOI 10.1161/01.STR.11.6.593; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SYMON L, 1979, STROKE, V10, P1184; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; TORNHEIM PA, 1975, EXPT MODEL HEAD INJU, P123; VANUITERT RL, 1978, STROKE, V9, P67, DOI 10.1161/01.STR.9.1.67; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Weisman SJ, 1939, SURGERY, V6, P722; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; YAMAGUCHI M, 1976, STROKE, V7, P77, DOI 10.1161/01.STR.7.1.77	61	97	98	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	1987	7	6					759	767		10.1038/jcbfm.1987.131			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	L4589	WOS:A1987L458900012	3693431	Bronze			2021-06-18	
J	Fann, JR; Ribe, AR; Pedersen, HS; Fenger-Gron, M; Christensen, J; Benros, ME; Vestergaard, M				Fann, Jesse R.; Ribe, Anette Riisgaard; Pedersen, Henrik Schou; Fenger-Gron, Morten; Christensen, Jakob; Benros, Michael Eriksen; Vestergaard, Mogens			Long-term risk of dementia among people with traumatic brain injury in Denmark: a population-based observational cohort study	LANCET PSYCHIATRY			English	Article							ALZHEIMER-DISEASE; ASSOCIATION; ENCEPHALOPATHY; DEATH; ONSET	Background Traumatic brain injury (TBI) has been associated with increased risk of dementia; however, large-scale studies with long follow-up have been scarce. We investigated the association between TBI, including severity and number of TBIs, and the subsequent long-term risk of dementia. Methods We did a nationwide population-based observational cohort study in Denmark using information on citizens from national registries. We used the Danish Civil Registration System to establish a population-based cohort consisting of all people born in Denmark who were living in the country on Jan 1, 1995, and who were at least 50 years old at some point during follow-up (between 1999 and 2013). We obtained information on TBIs from the Danish National Patient Register (NPR), and obtained information on dementia by combining data recorded in the NPR, the Danish Psychiatric Central Register, and the Danish National Prescription Registry (DNPR). The long-term risk of dementia after TBI was established using survival analysis. We used three prespecified models for each of the three analyses: different time periods since the TBI, multiple TBIs, and sex. The first model adjusted for sociodemographic factors, the second model added medical and neurological comorbidities, and the third added psychiatric comorbidities. Findings We used data from a cohort of 2 794 852 people for a total of 27 632 020 person-years (mean 9.89 years per patient) at risk of dementia. 132 093 individuals (4.7%) had at least one TBI during 1977-2013, and 126 734 (4.5%) had incident dementia during 1999-2013. The fully adjusted risk of all-cause dementia in people with a history of TBI was higher (hazard ratio [HR] 1.24, 95% CI 1.21-1.27) than in those without a history of TBI, as was the specific risk of Alzheimer's disease (1.16, 1.12-1.22). The risk of dementia was highest in the first 6 months after TBI (HR 4.06, 3. 79-4.34) and also increased with increasing number of events (1.22, 1.19-1.25 with one TBI to 2.83, 2.14-3.75 with five or more TBIs). Furthermore, TBI was associated with a higher risk of dementia (1.29, 1.26-1.33) in people with TBI than in individuals with a non-TBI fracture not involving the skull or spine. The younger a person was when sustaining a TBI, the higher the HRs for dementia when stratified by time since TBI. Interpretation TBI was associated with an increased risk of dementia both compared with people without a history of TBI and with people with non-TBI trauma. Greater efforts to prevent TBI and identify strategies to ameliorate the risk and impact of subsequent dementia are needed.	[Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Ribe, Anette Riisgaard; Pedersen, Henrik Schou; Fenger-Gron, Morten; Vestergaard, Mogens] Aarhus Univ, Res Unit Gen Practice, Dept Publ Hlth, Aarhus, Denmark; [Ribe, Anette Riisgaard; Pedersen, Henrik Schou; Fenger-Gron, Morten; Vestergaard, Mogens] Aarhus Univ, Sect Gen Med Practice, Dept Publ Hlth, Aarhus, Denmark; [Christensen, Jakob] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark; [Benros, Michael Eriksen] Copenhagen Univ Hosp, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark	Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.	fann@uw.edu	Benros, Michael Eriksen/N-5868-2016	Benros, Michael Eriksen/0000-0003-4939-9465; Fenger-Gron, Morten/0000-0002-6354-5871; Christensen, Jakob/0000-0002-9385-6435	Lundbeck FoundationLundbeckfonden	Lundbeck Foundation.	Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Carlson KF, 2013, BRAIN INJURY, V27, P640, DOI 10.3109/02699052.2013.771795; Carstensen B, 2011, SCAND J PUBLIC HEALT, V39, P58, DOI 10.1177/1403494811404278; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2016, NEURODEGENER DIS MAN, V6, P417, DOI 10.2217/nmt-2016-0017; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Deckers K, 2015, INT J GERIATR PSYCH, V30, P234, DOI 10.1002/gps.4245; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Institute of Medicine, 2009, GULF WAR HLTH, V7; Julien J, 2017, ANN PHYS REHABIL MED, V60, P347, DOI 10.1016/j.rehab.2017.03.009; Katon W, 2015, JAMA PSYCHIAT, V72, P612, DOI 10.1001/jamapsychiatry.2015.0082; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Mors O, 2011, SCAND J PUBLIC HEALT, V39, P54, DOI 10.1177/1403494810395825; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Orlovska S, 2014, AM J PSYCHIAT, V171, P463, DOI 10.1176/appi.ajp.2013.13020190; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Phung TKT, 2010, DEMENT GERIATR COGN, V29, P146, DOI 10.1159/000269933; Phung TKT, 2009, DEMENT GERIATR COGN, V27, P534, DOI 10.1159/000223664; Raj R, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002316; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Skrbo A, 1999, Med Arh, V53, P57; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Yang Z, 2013, NEW ENGL J MED, V369, P489, DOI 10.1056/NEJMc1305541	43	96	96	2	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2215-0374			LANCET PSYCHIAT	Lancet Psychiatry	MAY	2018	5	5					424	431		10.1016/S2215-0366(18)30065-8			8	Psychiatry	Psychiatry	GE1VD	WOS:000431004000022	29653873		Y	N	2021-06-18	
J	Covassin, T; Moran, R; Elbin, RJ				Covassin, Tracey; Moran, Ryan; Elbin, R. J.			Sex Differences in Reported Concussion Injury Rates and Time Loss From Participation: An Update of the National Collegiate Athletic Association Injury Surveillance Program From 2004-2005 Through 2008-2009	JOURNAL OF ATHLETIC TRAINING			English	Article						epidemiology; traumatic brain injuries; sports	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL SPORTS; STATES HIGH-SCHOOL; UNITED-STATES; GENDER-DIFFERENCES; RISK-FACTORS; EPIDEMIOLOGY; SYMPTOMS; SYSTEM	Context: Epidemiologic studies have identified differences in concussion incidence between the sexes. However, few authors to date have updated injury rates (IRs) and time loss between male and female concussed athletes. Objective: To examine sex differences in IRs and time loss in concussed National Collegiate Athletic Association (NCAA) athletes. Design: Descriptive epidemiologic study. Setting: National Collegiate Athletic Association athletics. Patients or Other Participants: A total of 1702 concusssed NCAA athletes, consisting of 903 females and 779 males participating in soccer, basketball, ice hockey, lacrosse, softball, or baseball over a 5-year period from 2004-2005 through 2008-2009. Main Outcome Measure(s): Using the NCAA Injury Surveillance Program, athletic trainers reported concussions, athlete-exposures (AEs), and time loss across 10 NCAA sports. An IR is the number of injuries in a particular category divided by the number of AEs in that category. Results: During the study period, 1702 concussions were reported during 4 170 427 AEs for an overall total of 5.47 per 10 000 AEs. In sex-comparable sports, females had a 1.4 times higher overall concussion IR than males (IRs = 4.84 and 3.46, respectively), with greater rates in women's baseball/softball, basketball, ice hockey, and soccer than men. Female soccer and basketball players also displayed more time loss after concussion compared with male basketball and soccer players. Conclusions: Female athletes sustained a higher rate of concussion and, in all sports except lacrosse, had greater time loss from concussion than male athletes. Additional research is needed on sex differences in time loss after concussions.	[Covassin, Tracey; Moran, Ryan] Michigan State Univ, 105 IM Sports Circle, E Lansing, MI 48824 USA; [Elbin, R. J.] Univ Arkansas, Fayetteville, AR 72701 USA	Covassin, T (corresponding author), Michigan State Univ, 105 IM Sports Circle, E Lansing, MI 48824 USA.	covassin@msu.edu					Cheng Y, 2009, NEUROSCIENCE, V158, P713, DOI 10.1016/j.neuroscience.2008.10.026; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dragoo JL, 2012, AM J SPORT MED, V40, P990, DOI 10.1177/0363546512442336; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Esposito G, 1996, J NUCL MED, V37, P559; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 2001, J ATHL TRAINING, V36, P307; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Roos KG, 2015, AM J SPORT MED, V43, P1790, DOI 10.1177/0363546515580790; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	22	96	96	1	23	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2016	51	3					189	194		10.4085/1062-6050-51.3.05			6	Sport Sciences	Sport Sciences	DK2PB	WOS:000374755800001	26950073	Green Published, Bronze			2021-06-18	
J	Ager, RR; Davis, JL; Agazaryan, A; Benavente, F; Poon, WW; LaFerla, FM; Blurton-Jones, M				Ager, Rahasson R.; Davis, Joy L.; Agazaryan, Andy; Benavente, Francisca; Poon, Wayne W.; LaFerla, Frank M.; Blurton-Jones, Mathew			Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss	HIPPOCAMPUS			English	Article						Alzheimer's disease; neural stem cells; immune suppression; transplantation; therapeutic	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; A-BETA; MICROGLIAL ACTIVATION; AMYLOID HYPOTHESIS; MOUSE MODEL; MICE; DIFFERENTIATE; TRANSPLANTS	Alzheimer's disease (AD) is the most prevalent age-related neurodegenerative disorder, affecting over 35 million people worldwide. Pathologically, AD is characterized by the progressive accumulation of -amyloid (A) plaques and neurofibrillary tangles within the brain. Together, these pathologies lead to marked neuronal and synaptic loss and corresponding impairments in cognition. Current treatments, and recent clinical trials, have failed to modify the clinical course of AD; thus, the development of novel and innovative therapies is urgently needed. Over the last decade, the potential use of stem cells to treat cognitive impairment has received growing attention. Specifically, neural stem cell transplantation as a treatment for AD offers a novel approach with tremendous therapeutic potential. We previously reported that intrahippocampal transplantation of murine neural stem cells (mNSCs) can enhance synaptogenesis and improve cognition in 3xTg-AD mice and the CaM/Tet-DTA model of hippocampal neuronal loss. These promising findings prompted us to examine a human neural stem cell population, HuCNS-SC, which has already been clinically tested for other neurodegenerative disorders. In this study, we provide the first evidence that transplantation of research grade HuCNS-SCs can improve cognition in two complementary models of neurodegeneration. We also demonstrate that HuCNS-SC cells can migrate and differentiate into immature neurons and glia and significantly increase synaptic and growth-associated markers in both 3xTg-AD and CaM/Tet-DTA mice. Interestingly, improvements in aged 3xTg-AD mice were not associated with altered A or tau pathology. Rather, our findings suggest that human NSC transplantation improves cognition by enhancing endogenous synaptogenesis. Taken together, our data provide the first preclinical evidence that human NSC transplantation could be a safe and effective therapeutic approach for treating AD. (c) 2014 The Authors. Hippocampus Published by Wiley Periodicals, Inc.	[Ager, Rahasson R.; Davis, Joy L.; Agazaryan, Andy; Poon, Wayne W.; LaFerla, Frank M.; Blurton-Jones, Mathew] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA 92697 USA; [Davis, Joy L.; Agazaryan, Andy; Benavente, Francisca; LaFerla, Frank M.; Blurton-Jones, Mathew] Univ Calif Irvine, Sue & Bill Gross Stem Cell Res Ctr, Irvine, CA 92697 USA; [Poon, Wayne W.; LaFerla, Frank M.; Blurton-Jones, Mathew] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA	Blurton-Jones, M (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA.	mblurton@uci.edu	Ager, Rahasson/I-6280-2019	Ager, Rahasson/0000-0003-1306-4321; Blurton-Jones, Mathew/0000-0002-7770-7157; Poon, Wayne/0000-0003-0625-3968	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG029378, AG16573]; California Institute for Regenerative Medicine (CIRM)California Institute for Regenerative Medicine [DR2A-05416, TG2-01152]; Alzheimer's AssociationAlzheimer's Association [NIRG 12-242-550]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG029378, P50AG016573] Funding Source: NIH RePORTER	Grant sponsor: National Institutes of Health (NIH); Grant numbers: AG029378 and AG16573; Grant sponsor: California Institute for Regenerative Medicine (CIRM) (to M.B.J.); Grant numbers: DR2A-05416 (to M.B.J. and F.M.L); TG2-01152 (to R.R.A.); Grant sponsor: Alzheimer's Association; Grant numbers: NIRG 12-242-550 (to M.B.J.).	Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Anderson AJ, 2011, REGEN MED, V6, P367, DOI [10.2217/RME.11.22, 10.2217/rme.11.22]; Baglietto-Vargas D, 2010, J ALZHEIMERS DIS, V21, P119, DOI 10.3233/JAD-2010-100066; Bakondi B, 2009, MOL THER, V17, P1938, DOI 10.1038/mt.2009.185; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BENOWITZ LI, 1981, J NEUROSCI, V1, P300; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Burns A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b158; Cattaneo A, 2008, J ALZHEIMERS DIS, V15, P255; Citron M, 2010, NAT REV DRUG DISCOV, V9, P387, DOI 10.1038/nrd2896; Connor B, 1997, MOL BRAIN RES, V49, P71, DOI 10.1016/S0169-328X(97)00125-3; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; DiCarlo G, 2001, NEUROBIOL AGING, V22, P1007, DOI 10.1016/S0197-4580(01)00292-5; Dorph-Petersen KA, 2001, J MICROSC-OXFORD, V204, P232, DOI 10.1046/j.1365-2818.2001.00958.x; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Freeman TB, 2000, P NATL ACAD SCI USA, V97, P13877, DOI 10.1073/pnas.97.25.13877; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Gupta N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004373; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Helene J, 2003, BEHAV BRAIN RES, V143, P177, DOI 10.1016/S0166-4328(03)00032-9; Herber DL, 2007, J NEUROIMMUNE PHARM, V2, P222, DOI 10.1007/s11481-007-9069-z; Hong HS, 2010, J ALZHEIMERS DIS, V22, P97, DOI 10.3233/JAD-2010-100261; KALIL K, 1986, J NEUROSCI, V6, P2563; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kiskinis E, 2010, J CLIN INVEST, V120, P51, DOI 10.1172/JCI40553; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Luo J, 2008, BRAIN RES BULL, V76, P464, DOI 10.1016/j.brainresbull.2007.12.005; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x; Mendez I, 2005, BRAIN, V128, P1498, DOI 10.1093/brain/awh510; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Naimi S, 1996, EXP NEUROL, V137, P15, DOI 10.1006/exnr.1996.0002; NarisawaSaito M, 1996, NEUROREPORT, V7, P2925, DOI 10.1097/00001756-199611250-00024; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003; Pearl JI, 2011, CELL STEM CELL, V8, P309, DOI 10.1016/j.stem.2011.01.012; Qin S, 2004, ACTA NEUROPATHOL, V107, P209, DOI 10.1007/s00401-003-0800-4; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Rosenkranz K, 2012, CELL TISSUE RES, V348, P429, DOI 10.1007/s00441-012-1401-0; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schubert D, 2012, FUTURE MED CHEM, V4, P1681, DOI [10.4155/FMC.12.109, 10.4155/fmc.12.109]; Selden NR, 2013, J NEUROSURG-PEDIATR, V11, P643, DOI 10.3171/2013.3.PEDS12397; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shimada IS, 2011, J CELL BIOCHEM, V112, P374, DOI 10.1002/jcb.22963; Sze CI, 1997, J NEUROPATH EXP NEUR, V56, P933, DOI 10.1097/00005072-199708000-00011; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tate CC, 2010, CELL TRANSPLANT, V19, P973, DOI 10.3727/096368910X494885; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Uchida N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004371; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Wimo A, 2010, WORLD ALZHEIMER REPO; Yamasaki TR, 2007, J NEUROSCI, V27, P11925, DOI 10.1523/JNEUROSCI.1627-07.2007; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Yu DY, 2006, BIOL CHEM, V387, P977, DOI 10.1515/BC.2006.121; Zahs KR, 2010, TRENDS NEUROSCI, V33, P381, DOI 10.1016/j.tins.2010.05.004	64	96	100	2	46	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus	JUL	2015	25	7					813	826		10.1002/hipo.22405			14	Neurosciences	Neurosciences & Neurology	CL2YA	WOS:000356812700005	25530343	Green Published, Other Gold, Green Accepted			2021-06-18	
J	Marshall, S; Bayley, M; McCullagh, S; Velikonja, D; Berrigan, L; Ouchterlony, D; Weegar, K				Marshall, Shawn; Bayley, Mark; McCullagh, Scott; Velikonja, Diana; Berrigan, Lindsay; Ouchterlony, Donna; Weegar, Kelly			Updated clinical practice guidelines for concussion/mild traumatic brain injury and persistent symptoms	BRAIN INJURY			English	Article						Concussion; diagnosis; guideline recommendations; management; mild traumatic brain injury; persistent post-concussive symptoms	HEAD-INJURY; YOUNG-PEOPLE; POSTCONCUSSION SYNDROME; FOLLOW-UP; MILD; DISABILITY; ADULTS; SPORT; TRIAL	Objective: To introduce a set of revised guidelines for the management of mild traumatic brain injury (mTBI) and persistent symptoms following concussive injuries. Quality of evidence: The Guidelines for Mild Traumatic Brain Injury and Persistent Symptoms were made available in March 2011 based on literature and information up to 2008. A search for new clinical practice guidelines addressing mTBI and a systematic review of the literature evaluating treatment of persistent symptoms was conducted. Healthcare professionals representing a range of disciplines from Canada and abroad attended a consensus conference to revise the original guidelines in light of new evidence. Main message: A modified Delphi process was used to create 96 recommendations addressing the diagnosis and management of mTBI and persistent symptoms, including post-traumatic headache, sleep disturbances, mental health disorders, cognitive difficulties, vestibular and vision dysfunction, fatigue and return to activity/work/school. Numerous resources, tools and treatment algorithms were also included to aid implementation of the recommendations. Conclusion: The revised clinical practice guideline reflects the most current evidence and is recommended for use by clinicians who provide care to people who experience PPCS following mTBI.	[Marshall, Shawn; Weegar, Kelly] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Marshall, Shawn] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Bayley, Mark] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada; [Bayley, Mark] Univ Toronto, Dept Med, Toronto, ON, Canada; [McCullagh, Scott; Velikonja, Diana] Hamilton Hlth Sci, Hamilton, ON, Canada; [McCullagh, Scott; Velikonja, Diana] McMaster Univ, Dept Pscyhiatry, Hamilton, ON, Canada; [Berrigan, Lindsay] St Francis Xavier Univ, Antigonish, NS B2G 1C0, Canada; [Ouchterlony, Donna] St Michaels Hosp, Toronto, ON M5B 1W8, Canada	Marshall, S (corresponding author), Ottawa Hosp Rehabil Ctr, 505 Smyth Rd, Ottawa, ON K1H 8M2, Canada.	smarshall@ottawahospital.on.ca	Meijer, Anna/K-5118-2016	Bayley, Mark/0000-0001-7860-9463	Ontario Neurotrauma Foundation	The authors report no conflicts of interest. The Ontario Neurotrauma Foundation initiated and funded the development of the original and updated guidelines. The project team independently managed the development and production of the guideline and, thus, editorial independence is retained.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; [Anonymous], 2011, AANN ARN CLIN PRACT; Bajor LA, 2011, HARVARD REV PSYCHIAT, V19, P240, DOI 10.3109/10673229.2011.614483; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Fann J, 2011, J NEUROTRAUM, V26, P2383; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; Forbes D, 2010, J TRAUMA STRESS, V23, P537, DOI 10.1002/jts.20565; Gilworth G, 2008, J REHABIL MED, V40, P334, DOI 10.2340/16501977-0169; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gulli C., 2011, CONCUSSIONS UNTOLD S; Hilton M, 2004, COCHRANE DB SYST REV, V2; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kane L., 2013, TORONTO STAR    0723; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Linstone HA., 1975, DELPHI METHOD TECHNI; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marshall S, 2013, GUIDELINES CONCUSSIO; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Marshall S, 2012, CAN FAM PHYSICIAN, V58, pE128; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Mihoces G., 2013, US TODAY; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; New South Wales Ministry of Health, 2011, AD TRAUM CLIN PRACT; New South Wales Motor Accident Authority, 2008, GUID MILD TRAUM BRAI; New Zealand Guidelines Group, 2007, TRAUM BRAIN INJ DIAG; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ouellet M, 2012, BRAIN INJURY MED PRI; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rabinowitz AR, 2014, ANNU REV PSYCHOL, V65, P301, DOI 10.1146/annurev-psych-010213-115103; Rapoport MJ, 2010, J CLIN PSYCHIAT, V71, P1125, DOI 10.4088/JCP.09m05086blu; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Scottish Intercollegiate Guidelines Network, 2009, EARL MAN PAT HEAD IN; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Stergiou-Kita M, 2012, J OCCUP REHABIL, V22, P166, DOI 10.1007/s10926-011-9332-2; Susskind O, 2010, J REHABILITATION RES, V49, P17; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Workplace Safety and Insurance Board of Ontario, 2012, MILD TRAUM BRAIN INJ; Zollman FS, 2012, J HEAD TRAUMA REHAB, V27, P135, DOI 10.1097/HTR.0b013e3182051397	58	96	97	1	42	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2015	29	6					688	700		10.3109/02699052.2015.1004755			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CL8RL	WOS:000357241700003	25871303				2021-06-18	
J	Giralt, J; Trigo, J; Nuyts, S; Ozsahin, M; Skladowski, K; Hatoum, G; Daisne, JF; Ancona, ACY; Cmelak, A; Mesia, R; Zhang, A; Oliner, KS; VanderWalde, A				Giralt, Jordi; Trigo, Jose; Nuyts, Sandra; Ozsahin, Mahmut; Skladowski, Krzysztof; Hatoum, Georges; Daisne, Jean-Francois; Yunes Ancona, Alejandro Cesar; Cmelak, Anthony; Mesia, Ricard; Zhang, Alicia; Oliner, Kelly S.; VanderWalde, Ari			Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial	LANCET ONCOLOGY			English	Article							CHEMOTHERAPY; CANCER; RADIATION; CISPLATIN; CETUXIMAB	Background We aimed to compare panitumumab, a fully human monoclonal antibody against EGFR, plus radiotherapy with chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck. Methods In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 22 sites in eight countries worldwide. Patients aged 18 years and older with stage III, IVa, or IVb, previously untreated, measurable (>= 10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (2: 3) by an independent vendor to open-label chemoradiotherapy (two cycles of cisplatin 100 mg/m 2 during radiotherapy) or to radiotherapy plus panitumumab (three cycles of panitumumab 9 mg/kg every 3 weeks administered with radiotherapy) using a stratified randomisation with a block size of five. All patients received 70-72 Gy to gross tumour and 54 Gy to areas of subclinical disease with accelerated fractionation radiotherapy. The primary endpoint was local-regional control at 2 years, analysed in all randomly assigned patients who received at least one dose of their assigned protocol-specific treatment (chemotherapy, radiation, or panitumumab). The trial is closed and this is the final analysis. This study is registered with ClinicalTrials.gov, number NCT00547157. Findings Between Nov 30, 2007, and Nov 16, 2009, 152 patients were enrolled, and 151 received treatment (61 in the chemoradiotherapy group and 90 in the radiotherapy plus panitumumab group). Local-regional control at 2 years was 61% (95% CI 47-72) in the chemoradiotherapy group and 51% (40-62) in the radiotherapy plus panitumumab group. The most frequent grade 3-4 adverse events were mucosal inflammation (25 [40%] of 62 patients in the chemoradiotherapy group vs 37 [42%] of 89 patients in the radiotherapy plus panitumumab group), dysphagia (20 [32%] vs 36 [40%]), and radiation skin injury (seven [11%] vs 21 [24%]). Serious adverse events were reported in 25 (40%) of 62 patients in the chemoradiotherapy group and in 30 (34%) of 89 patients in the radiotherapy plus panitumumab group. Interpretation Panitumumab cannot replace cisplatin in the combined treatment with radiotherapy for unresected stage III-IVb squamous-cell carcinoma of the head and neck, and the role of EGFR inhibition in locally advanced squamous-cell carcinoma of the head and neck needs to be reassessed.	[Giralt, Jordi] Hosp Valle De Hebron, Barcelona, Spain; [Giralt, Jordi] Univ Autonoma Barcelona, Bellaterra, Spain; [Trigo, Jose] Hosp Virgen de la Victoria, Malaga, Spain; [Nuyts, Sandra] Univ Hosp Gasthuisberg, Leuven, Belgium; [Ozsahin, Mahmut] CHU Vaudois, CH-1011 Lausanne, Switzerland; [Skladowski, Krzysztof] Inst M Sklodowskiej Curie, Ctr Onkol, Gliwice, Poland; [Hatoum, Georges] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Daisne, Jean-Francois] Clin St Elizabeth, Namur, Belgium; [Yunes Ancona, Alejandro Cesar] Unidad Oncol Serv Salud Estado Puebla, Puebla, Mexico; [Cmelak, Anthony] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Mesia, Ricard] Inst Catala Oncol ICO Hosp, Barcelona, Spain; [Zhang, Alicia; Oliner, Kelly S.; VanderWalde, Ari] Amgen Inc, Thousand Oaks, CA USA	Giralt, J (corresponding author), Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Radiat Oncol, P Vall dHebron 119-129, Barcelona 08035, Spain.	jgiralt@vhebron.net	de Sagredo, Jordi Giralt Lopez/J-1873-2018; nuyts, sandra/U-8254-2019	de Sagredo, Jordi Giralt Lopez/0000-0002-1840-5159; Daisne, Jean-Francois/0000-0001-8584-4189; nuyts, sandra/0000-0002-5540-4796; Skladowski, Krzysztof/0000-0002-0554-6171	AmgenAmgen	This study was funded by Amgen. We thank the study staff, and the patients and their families, for their contributions to this study. We also thank Jennifer Gansert (Amgen) for her contributions to the study design and protocol development, and to James Ziobro for assistance with the writing of this manuscript (funded by Amgen).	Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2011, P AM SOC CLIN ONCO S, V29, P5500; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Bourhis J, 2012, LANCET ONCOL, V13, P145, DOI 10.1016/S1470-2045(11)70346-1; BRITTAIN E, 1982, BIOMETRICS, V38, P1003, DOI 10.2307/2529880; Gregoire V, 2010, ANN ONCOL, V21, pv184, DOI 10.1093/annonc/mdq185; Kruser TJ, 2008, INT J RADIAT ONCOL, V72, P534, DOI 10.1016/j.ijrobp.2008.06.1490; Lefebvre JL, 2013, J CLIN ONCOL, V31, P853, DOI 10.1200/JCO.2012.42.3988; Mesia R, 2015, LANCET ONCOL; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Vermorken JB, 2013, LANCET ONCOL, V14, P697, DOI 10.1016/S1470-2045(13)70181-5; Yang BB, 2010, CLIN PHARMACOKINET, V49, P729, DOI 10.2165/11535970-000000000-00000	17	96	99	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	FEB	2015	16	2					221	232		10.1016/S1470-2045(14)71200-8			12	Oncology	Oncology	CA3YR	WOS:000348841700038	25596659				2021-06-18	
J	Wang, XQ; Campos, CR; Peart, JC; Smith, LK; Boni, JL; Cannon, RE; Miller, DS				Wang, Xueqian; Campos, Christopher R.; Peart, John C.; Smith, Lindsay K.; Boni, Jessica L.; Cannon, Ronald E.; Miller, David S.			Nrf2 Upregulates ATP Binding Cassette Transporter Expression and Activity at the Blood-Brain and Blood-Spinal Cord Barriers	JOURNAL OF NEUROSCIENCE			English	Article						ABC transporters; blood-brain barrier; drug delivery; NF-kappa B; P-glycoprotein; p53	P-GLYCOPROTEIN EXPRESSION; XENOBIOTIC EFFLUX TRANSPORTERS; PLACEBO-CONTROLLED PHASE-3; MULTIPLE-SCLEROSIS; ENDOTHELIAL-CELLS; DEFENSE PATHWAY; ORAL BG-12; INJURY; ACTIVATION; MICE	Activation of nuclear factor E2-related factor-2 (Nrf2), a sensor of oxidative stress, is neuroprotective in animal models of cerebral ischemia, traumatic brain injury, subarachnoid hemorrhage, and spinal cord injury. We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2]. Dosing rats with SFN increased protein expression of all three transporters in brain capillaries and decreased by 50% brain accumulation of the P-glycoprotein substrate verapamil. Exposing rat or mouse brain capillaries to SFN increased P-glycoprotein, Bcrp, and Mrp2 transport activity and protein expression; SFN increased P-glycoprotein activity in mouse spinal cord capillaries. Inhibiting transcription or translation abolished upregulation of P-glycoprotein activity. No such effects were seen in brain capillaries from Nrf2-null mice, indicating Nrf2 dependence. Nrf2 signaled indirectly to increase transporter activity/expression. The p53 inhibitor pifithrin abolished the SFN-induced increase in transporter activity/expression, and the p53-activator nutlin-3 increased P-glycoprotein activity. SFN did not alter P-glycoprotein transport activity in brain and spinal cord capillaries from p53-null mice. Inhibitors of p38 MAPK and nuclear factor kappa B (NF-kappa B) blocked the effects of SFN and nutlin-3 on P-glycoprotein activity. These results implicate Nrf2, p53, and NF-kappa B in the upregulation of P-glycoprotein, Bcrp, and Mrp2 at blood-CNS barriers. They imply that the barriers are tightened selectively (efflux transporter upregulation) by oxidative stress, providing increased neuroprotection, but also reduced penetration of many therapeutic drugs.	[Wang, Xueqian; Campos, Christopher R.; Peart, John C.; Smith, Lindsay K.; Boni, Jessica L.; Cannon, Ronald E.; Miller, David S.] NIEHS, Lab Toxicol & Pharmacol, NIH, Res Triangle Pk, NC 27709 USA	Miller, DS (corresponding author), NIEHS, Lab Toxicol & Pharmacol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	miller@niehs.nih.gov			Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ZIAES080048, ZIAES080060] Funding Source: NIH RePORTER	This work was supported by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health.	Agarwal S, 2011, CURR PHARM DESIGN, V17, P2793, DOI 10.2174/138161211797440186; Aleksunes LM, 2007, TOXICOL PATHOL, V35, P459, DOI 10.1080/01926230701311344; Aleksunes LM, 2012, DRUG METAB DISPOS, V40, P1366, DOI 10.1124/dmd.112.045112; Alfieri A, 2011, J PHYSIOL-LONDON, V589, P4125, DOI 10.1113/jphysiol.2011.210294; Bauer B, 2004, MOL PHARMACOL, V66, P413; Bauer B, 2008, J CEREBR BLOOD F MET, V28, P1222, DOI 10.1038/jcbfm.2008.16; Bauer B, 2008, MOL PHARMACOL, V73, P1444, DOI 10.1124/mol.107.041210; Bauer B, 2006, MOL PHARMACOL, V70, P1212, DOI 10.1124/mol.106.023796; Campos CR, 2012, J CEREBR BLOOD F MET, V32, P1559, DOI 10.1038/jcbfm.2012.47; Cannon RE, 2012, P NATL ACAD SCI USA, V109, P15930, DOI 10.1073/pnas.1203534109; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Chen WM, 2012, ANTIOXID REDOX SIGN, V17, P1670, DOI 10.1089/ars.2012.4674; Cho HY, 2007, FREE RADICAL BIO MED, V42, P433, DOI 10.1016/j.freeradbiomed.2006.11.021; Copple IM, 2012, ADV PHARMACOL, V63, P43, DOI 10.1016/B978-0-12-398339-8.00002-1; Copple Ian M, 2010, Handb Exp Pharmacol, P233, DOI 10.1007/978-3-642-00663-0_9; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Felix RA, 2002, J NEUROCHEM, V80, P64, DOI 10.1046/j.0022-3042.2001.00660.x; Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Hartz AMS, 2004, MOL PHARMACOL, V66, P387, DOI 10.1124/mol.104.001503; Hawkins BT, 2010, J NEUROSCI, V30, P1417, DOI 10.1523/JNEUROSCI.5103-09.2010; Klaassen CD, 2005, CURR DRUG METAB, V6, P309, DOI 10.2174/1389200054633826; Li B, 2012, EXP DIABETES RES, DOI 10.1155/2012/216512; Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386; Maher JM, 2005, DRUG METAB DISPOS, V33, P956, DOI 10.1124/dmd.105.003798; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Miller DS, 2010, TRENDS PHARMACOL SCI, V31, P246, DOI 10.1016/j.tips.2010.03.003; Miller DS, 2000, MOL PHARMACOL, V58, P1357; Nwaozuzu OM, 2003, J NEUROCHEM, V87, P1043, DOI 10.1046/j.1471-4159.2003.02061.x; Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014; Rotblat B, 2012, ONCOTARGET, V3, P1272; Schneider G, 2011, BBA-REV CANCER, V1815, P90, DOI 10.1016/j.bbcan.2010.10.003; SCHRAMM U, 1995, AM J PHYSIOL-RENAL, V268, pF46; Vurusaner B, 2012, FREE RADICAL BIO MED, V52, P7, DOI 10.1016/j.freeradbiomed.2011.09.035; Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216; Wang XL, 2012, J NEUROTRAUM, V29, P936, DOI 10.1089/neu.2011.1922; Wang XQ, 2013, FASEB J, V27, P1167, DOI 10.1096/fj.12-218495; Wang XQ, 2011, FASEB J, V25, P644, DOI 10.1096/fj.10-169227; Wang XQ, 2010, MOL PHARMACOL, V78, P376, DOI 10.1124/mol.110.063685; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhao B, 2006, J BIOCHEM MOL TOXIC, V20, P103, DOI 10.1002/jbt.20126; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065	43	96	99	0	16	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 18	2014	34	25					8585	8593		10.1523/JNEUROSCI.2935-13.2014			9	Neurosciences	Neurosciences & Neurology	AK5FD	WOS:000338449200019	24948812	Green Published, Bronze			2021-06-18	
J	Geurts, M; Macleod, MR; Kollmar, R; Kremer, PHC; van der Worp, HB				Geurts, Marjolein; Macleod, Malcolm R.; Kollmar, Rainer; Kremer, Philip H. C.; van der Worp, H. Bart			Therapeutic Hypothermia and the Risk of Infection: A Systematic Review and Meta-Analysis	CRITICAL CARE MEDICINE			English	Article						hypothermia; infection; respiratory tract infections; sepsis; temperature; urinary tract infections	TRAUMATIC BRAIN-INJURY; HOSPITAL CARDIAC-ARREST; ACUTE ISCHEMIC-STROKE; NORMOTHERMIC CARDIOPULMONARY BYPASS; MILD HYPOTHERMIA; SURGERY; COMPLICATIONS; SAFETY; TRIAL; THROMBOLYSIS	Objective: Observational studies suggest that infections are a common complication of therapeutic hypothermia. We performed a systematic review and meta-analysis of randomized trials to examine the risk of infections in patients treated with hypothermia. Data Sources: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were systematically searched for eligible studies up to October 1, 2012. Study Selection: We included randomized controlled clinical trials of therapeutic hypothermia induced in adults for any indication, which reported the prevalence of infection in each treatment group. Data Extraction: For each study, we collected information about the baseline characteristics of patients, cooling strategy, and infections. Data Synthesis: Twenty-three studies were identified, which included 2,820 patients, of whom 1,398 (49.6%) were randomized to hypothermia. Data from another 31 randomized trials, involving 4,004 patients, could not be included because the occurrence of infection was not reported with sufficient detail or not at all. The risk of bias in the included studies was high because information on the method of randomization and definitions of infections lacked in most cases, and assessment of infections was not blinded. In patients treated with hypothermia, the prevalence of all infections was not increased (rate ratio, 1.21 [95% CI, 0.95-1.54]), but there was an increased risk of pneumonia and sepsis (risk ratios, 1.44 [95% CI, 1.10-1.90]; 1.80 [95% CI, 1.04-3.10], respectively). Conclusion: The available evidence, subject to its limitations, strongly suggests an association between therapeutic hypothermia and the risk of pneumonia and sepsis, whereas no increase in the overall risk of infection was observed. All future randomized trials of hypothermia should report on this important complication.	[Geurts, Marjolein; Kremer, Philip H. C.; van der Worp, H. Bart] Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Macleod, Malcolm R.] Univ Edinburgh, Dept Clin Neurosci, Ctr Clin Brain Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Kollmar, Rainer] Klinikum Darmstadt, Klin Neurol & Neurogeriatrie, Darmstadt, Germany	Geurts, M (corresponding author), Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Neurol & Neurosurg, Utrecht, Netherlands.	m.geurts-2@umcutrecht.nl	Geurts, Marjolein/AAP-4148-2020; Macleod, Malcolm Robert/B-2052-2010	Macleod, Malcolm Robert/0000-0001-9187-9839	Dutch Heart FoundationNetherlands Heart Foundation [2010B239, 2010T075]; FP7 for EuroHYP-1; 7th Framework Programme European Union; Chest Heart and Stroke Scotland [Res09/A121] Funding Source: researchfish	Dr. Geurts is supported by grant (2010B239) from the Dutch Heart Foundation. Dr. Macleod received grant support from FP7 for EuroHYP-1 and is employed by the University of Edinburgh. Dr. Kollmar consulted for Zoll and received support for travel from Zoll, Bard, and Elvido. Dr. van der Worp received grant support from the Dutch Heart Foundation (2010T075 and 2010B239) and 7th Framework Programme European Union. Drs. Geurts and van der Worp are the coordinator and principal investigator, respectively, of the ongoing randomized phase II cooling trial COOLIST (NTR 2616), and Drs. Macleod, Kollmar, and van der Worp are coprincipal investigators of the randomized phase III cooling trial EuroHYP-1. Dr. Kremer has disclosed that he does not have any potential conflicts of interest.	Arrich J, 2012, COCHRANE DATABASE SY, V9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bi M, 2011, CLIN NEUROL NEUROSUR, V113, P768, DOI 10.1016/j.clineuro.2011.08.010; Boldt J, 1996, J CARDIOTHOR VASC AN, V10, P342, DOI 10.1016/S1053-0770(96)80094-2; Boodhwani M, 2007, J THORAC CARDIOV SUR, V134, P1443, DOI 10.1016/j.jtcvs.2007.08.016; Boodhwani M, 2009, ANN THORAC SURG, V87, P489, DOI 10.1016/j.athoracsur.2008.10.078; Broessner G, 2010, STROKE, V41, P2969, DOI 10.1161/STROKEAHA.110.591933; Broessner G, 2009, CRIT CARE MED, V37, P1886, DOI 10.1097/CCM.0b013e31819ffd7f; Chouhan RS, 2006, J ANAESTH CLIN PHARM, V22, P21; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; Den Hertog HM, 2009, COCHRANE DATABASE SY, V1; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Gotberg M, 2010, CIRC-CARDIOVASC INTE, V3, P400, DOI 10.1161/CIRCINTERVENTIONS.110.957902; Grimm M, 2000, EUR J CARDIO-THORAC, V18, P270, DOI 10.1016/S1010-7940(00)00510-8; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hindman BJ, 1999, NEUROSURGERY, V44, P23, DOI 10.1097/00006123-199901000-00009; Holzer M, 2002, NEW ENGL J MED, V346, P549; Honore PM, 2001, CRIT CARE MED, V29, P1903, DOI 10.1097/00003246-200110000-00009; Jacobs S, 2007, COCHRANE DATABASE SY, V4; Jarrah S, 2011, NEUROCRIT CARE, V14, P382, DOI 10.1007/s12028-011-9506-y; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lee HC, 2010, WORLD NEUROSURG, V74, P654, DOI 10.1016/j.wneu.2010.06.019; Li LR, 2012, COCHRANE DATABASE SY, V2; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Mongardon N, 2011, CRIT CARE MED, V39, P1359, DOI 10.1097/CCM.0b013e3182120b56; Nathan HJ, 2004, J THORAC CARDIOV SUR, V127, P1270, DOI 10.1016/j.jtcvs.2003.07.018; Nielsen N, 2011, INTENS CARE MED, V37, pS28; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Stone GW, 2011, AM J CARDIOL, V108, P741, DOI 10.1016/j.amjcard.2011.04.026; Sydenham E, 2009, COCHRANE DATABASE SY, P2; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tsai MS, 2005, INTENS CARE MED, V31, P621, DOI 10.1007/s00134-005-2612-6; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Weber UJ, 2008, THESIS U COPENHAGEN; Xiao GG, 2013, EMERG MED J, V30, P91, DOI 10.1136/emermed-2012-201120	53	96	101	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2014	42	2					231	242		10.1097/CCM.0b013e3182a276e8			12	Critical Care Medicine	General & Internal Medicine	291WS	WOS:000329863400018	23989182				2021-06-18	
J	Camarillo, DB; Shull, PB; Mattson, J; Shultz, R; Garza, D				Camarillo, David B.; Shull, Pete B.; Mattson, James; Shultz, Rebecca; Garza, Daniel			An Instrumented Mouthguard for Measuring Linear and Angular Head Impact Kinematics in American Football	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; mTBI; Brain; Angular velocity; Linear acceleration; Translational acceleration; Angular acceleration; Rotational velocity; Gyroscope	TRAUMATIC BRAIN-INJURY; ACCELERATION; CONCUSSION; COLLEGIATE; EPIDEMIOLOGY; SYSTEM	The purpose of this study was to evaluate a novel instrumented mouthguard as a research device for measuring head impact kinematics. To evaluate kinematic accuracy, laboratory impact testing was performed at sites on the helmet and facemask for determining how closely instrumented mouthguard data matched data from an anthropomorphic test device. Laboratory testing results showed that peak linear acceleration (r (2) = 0.96), peak angular acceleration (r (2) = 0.89), and peak angular velocity (r (2) = 0.98) measurements were highly correlated between the instrumented mouthguard and anthropomorphic test device. Normalized root-mean-square errors for impact time traces were 9.9 +/- A 4.4% for linear acceleration, 9.7 +/- A 7.0% for angular acceleration, and 10.4 +/- A 9.9% for angular velocity. This study demonstrates the potential of an instrumented mouthguard as a research tool for measuring in vivo impacts, which could help uncover the link between head impact kinematics and brain injury in American football.	[Camarillo, David B.; Shull, Pete B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Mattson, James; Shultz, Rebecca; Garza, Daniel] Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA	Camarillo, DB (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	dcamarillo@stanford.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1UL1 RR025744]; Lucile Packard Foundation for Children's Health; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB017611] Funding Source: NIH RePORTER	The authors would like to thank X2Impact for donation of devices and equipment required for laboratory testing. This work was supported in part by the NIH Clinical and Translational Science Award 1UL1 RR025744 for the Stanford Center for Clinical and Translational Education and Research (Spectrum) and by the Lucile Packard Foundation for Children's Health.	Abramowitz M, 1965, HDB MATH FUNCTIONS F, V55; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Craig M. J., 2007, THESIS WAYNE STATE U; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Higgins M, 2007, J ATHL TRAINING, V42, P5; Holbourn AHS, 1943, LANCET, V2, P438; Kang YS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4005427; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2009, 00108M10 NOCSAE DOC; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; NOCSAE, 2006, 08104M04 NOCSAE DOC; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Society of Automotive Engineers, 2007, J2111 SAE; Walker Jr L. B., 1973, P STAPP CAR CRASH C; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029	31	96	96	1	66	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2013	41	9					1939	1949		10.1007/s10439-013-0801-y			11	Engineering, Biomedical	Engineering	209EJ	WOS:000323736800015	23604848	Green Accepted			2021-06-18	
J	Claassen, J; Perotte, A; Albers, D; Kleinberg, S; Schmidt, JM; Tu, B; Badjatia, N; Lantigua, H; Hirsch, LJ; Mayer, SA; Connolly, ES; Hripcsak, G				Claassen, Jan; Perotte, Adler; Albers, David; Kleinberg, Samantha; Schmidt, J. Michael; Tu, Bin; Badjatia, Neeraj; Lantigua, Hector; Hirsch, Lawrence J.; Mayer, Stephan A.; Connolly, E. Sander; Hripcsak, George			Nonconvulsive Seizures after Subarachnoid Hemorrhage: Multimodal Detection and Outcomes	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL; ELECTROGRAPHIC SEIZURES; STATUS EPILEPTICUS; TISSUE HYPOXIA; SPREADING DEPOLARIZATION; EEG PATTERNS; CARE; PRESSURE; BLOOD	ObjectiveSeizures have been implicated as a cause of secondary brain injury, but the systemic and cerebral physiologic effects of seizures after acute brain injury are poorly understood. MethodsWe analyzed intracortical electroencephalographic (EEG) and multimodality physiological recordings in 48 comatose subarachnoid hemorrhage patients to better characterize the physiological response to seizures after acute brain injury. ResultsIntracortical seizures were seen in 38% of patients, and 8% had surface seizures. Intracortical seizures were accompanied by elevated heart rate (p = 0.001), blood pressure (p < 0.001), and respiratory rate (p < 0.001). There were trends for rising cerebral perfusion pressure (p = 0.03) and intracranial pressure (p = 0.06) seen after seizure onset. Intracortical seizure-associated increases in global brain metabolism, partial brain tissue oxygenation, and regional cerebral blood flow (rCBF) did not reach significance, but a trend for a pronounced delayed rCBF rise was seen for surface seizures (p = 0.08). Functional outcome was very poor for patients with severe background attenuation without seizures and best for those without severe attenuation or seizures (77% vs 0% dead or severely disabled, respectively). Outcome was intermediate for those with seizures independent of the background EEG and worse for those with intracortical only seizures when compared to those with intracortical and scalp seizures (50% and 25% death or severe disability, respectively). InterpretationWe replicated in humans complex physiologic processes associated with seizures after acute brain injury previously described in laboratory experiments and illustrated differences such as the delayed increase in rCBF. These real world physiologic observations may permit more successful translation of laboratory research to the bedside. Ann Neurol 2013;74:53-64	[Claassen, Jan; Schmidt, J. Michael; Badjatia, Neeraj; Lantigua, Hector; Mayer, Stephan A.] Columbia Univ, Div Crit Care Neurol, Dept Neurol, New York, NY 10032 USA; [Claassen, Jan; Tu, Bin; Hirsch, Lawrence J.] Columbia Univ, Comprehens Epilepsy Ctr, Dept Neurol, New York, NY 10032 USA; [Claassen, Jan; Badjatia, Neeraj; Mayer, Stephan A.; Connolly, E. Sander] Columbia Univ, Dept Neurosurg, New York, NY 10032 USA; [Perotte, Adler; Albers, David; Kleinberg, Samantha; Hripcsak, George] Columbia Univ, Dept Biomed Informat, Coll Phys & Surg, New York, NY 10032 USA	Claassen, J (corresponding author), Columbia Univ, Div Crit Care Neurol, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.	jc1439@columbia.edu	Claassen, Jan/AAA-5451-2020	Perotte, Adler/0000-0002-6695-0282; Hirsch, Lawrence/0000-0002-6333-832X; Schmidt, J. Michael/0000-0001-8141-2944	National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024156]; National Library of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01 LM006910]; Training in Biomedical Informatics at Columbia University [T15 LM007079]; Charles A. Dana Foundation; National Science Foundation for the Computing Research Association [1019343]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007079, R01LM006910] Funding Source: NIH RePORTER	This publication was made possible by a Grant entitled "Impact of Electrographic Seizures and Periodic Epileptiform Patterns on Neuronal Function and Outcome in Brain Injured Patients" (UL1 RR024156; J.C.) from the National Center for Research Resources (NCRR), a component of the NIH, and NIH Roadmap for Medical Research. Information on the NCRR is available at the NCRR website. Information on re-engineering the clinical research enterprise can be obtained from the NIH Roadmap website. Additional support for this work included grants from the National Library of Medicine, ("Discovering and applying knowledge in clinical databases" [R01 LM006910; G.H., D.A.] and "Training in Biomedical Informatics at Columbia University" [T15 LM007079; G.H., A.P.]), the Charles A. Dana Foundation (S.A.M.), and the National Science Foundation for the Computing Research Association CIFellows project (#1019343; S.K.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCRR, NIH, National Science Foundation, or Dana Foundation.	Bahar S, 2006, NEUROREPORT, V17, P499, DOI 10.1097/01.wnr.0000209010.78599.f5; Baumgartner C, 2001, EPILEPTIC DISORD, V3, P103; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Carrera E, 2010, J NEUROL NEUROSUR PS, V81, P793, DOI 10.1136/jnnp.2009.174425; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Czosnyka M, 2003, ACT NEUR S, V86, P581; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Drislane FW, 1999, J CLIN NEUROPHYSIOL, V16, P323, DOI 10.1097/00004691-199907000-00004; Fried R, 2000, LECT NOTES COMPUT SC, V1933, P67; Frykholm P, 2004, ACTA NEUROL SCAND, V109, P25, DOI 10.1034/j.1600-0404.2003.00174.x; Geneslaw AS, 2011, J CEREBR BLOOD F MET, V31, P1394, DOI 10.1038/jcbfm.2011.16; Helbok R, 2011, STROKE, V42, P1534, DOI 10.1161/STROKEAHA.110.604488; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hripcsak G, 2011, J AM MED INFORM ASSN, V18, pI109, DOI 10.1136/amiajnl-2011-000463; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Imhoff M, 1998, INTENS CARE MED, V24, P1305, DOI 10.1007/s001340050767; Iyer VN, 2009, CRIT CARE MED, V37, P3024, DOI 10.1097/CCM.0b013e3181b08ac7; Jones PA, 2003, PHYSIOL MEAS, V24, P201, DOI 10.1088/0967-3334/24/1/315; Kaplan PW, 2005, NEUROLOGIST, V11, P348, DOI 10.1097/01.nrl.0000162954.76053.d2; Kirkman MA, 2011, J CEREBR BLOOD F MET, V31, P2135, DOI 10.1038/jcbfm.2011.124; Ko SB, 2011, ARCH NEUROL-CHICAGO, V68, P1323, DOI 10.1001/archneurol.2011.240; Komotar RJ, 2009, NEUROSURGERY, V64, P397, DOI 10.1227/01.NEU.0000338946.42939.C7; la Fougere C, 2009, EPILEPSY BEHAV, V15, P50, DOI 10.1016/j.yebeh.2009.02.025; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Losiniecki A, 2010, CURR TREAT OPTION NE, V12, P142, DOI 10.1007/s11940-010-0063-z; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McIntosh N, 2002, CLIN MED, V2, P349, DOI 10.7861/clinmedicine.2-4-349; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Stuart RM, 2010, NEUROCRIT CARE, V12, P188, DOI 10.1007/s12028-010-9330-9; Su IC, 2009, ACTA NEUROCHIR, V151, P1631, DOI 10.1007/s00701-009-0517-9; Suh M, 2005, J NEUROSCI, V25, P68, DOI 10.1523/JNEUROSCI.2823-04.2005; Suh M, 2006, MOL NEUROBIOL, V33, P181, DOI 10.1385/MN:33:3:181; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; van der Bilt IAC, 2009, NEUROLOGY, V72, P635, DOI 10.1212/01.wnl.0000342471.07290.07; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721; Zerbet A, 2003, COMMUN STAT-THEOR M, V32, P573, DOI 10.1081/STA-120018552; Zhang SH, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006778.pub2; Zhao MR, 2011, J NEUROSCI, V31, P13292, DOI 10.1523/JNEUROSCI.2597-11.2011	59	96	97	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2013	74	1					53	64		10.1002/ana.23859			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	282UH	WOS:000329198600008	23813945	Green Accepted			2021-06-18	
J	Register-Mihalik, JK; Linnan, LA; Marshall, SW; McLeod, TCV; Mueller, FO; Guskiewicz, KM				Register-Mihalik, Johna K.; Linnan, Laura A.; Marshall, Stephen W.; McLeod, Tamara C. Valovich; Mueller, Frederick O.; Guskiewicz, Kevin M.			Using theory to understand high school aged athletes' intentions to report sport-related concussion: Implications for concussion education initiatives	BRAIN INJURY			English	Article						Brain injury; care seeking; sports	FOOTBALL PLAYERS; ACHIEVEMENT GOALS; HEALTH; KNOWLEDGE; ATTITUDES; SOCCER; INJURY; COACH; PERCEPTIONS; PERFORMANCE	Objective: To assess the influence of psychosocial determinants from the Theory of Reasoned Action and Planned Behaviour (TRA/TPB) on concussion-reporting intentions. Methods: The present study employed the TRA/TPB to develop a cross-sectional survey to examine contributors to intention to report concussion symptoms. High school athletes (n = 167, age = 15.7 +/- 1.4) completed this survey. The TRA/TPB constructs of attitude (perceptions about concussion reporting), subjective norm (perception of important social referents beliefs about concussion reporting), perceived behavioural control (perceived control over concussion reporting) and intention to report concussion symptoms served as the independent variables. Linear regression models were used to predict intention to report concussion symptoms. Binomial regression models were used to predict concussion-reporting behaviours from intention. Results: Direct attitude, subjective norm and direct perceived behavioural control were all associated with intention to report concussion. Intention was associated with decreased prevalence of participating in practices and games while symptomatic from concussion. Conclusions: Favourable attitudes toward reporting and social referents' beliefs have the greatest impact on intention to report concussion symptoms. Reporting intention may not always be an indicator of concussion-reporting behaviours. Concussion education initiatives should focus on improving attitudes and beliefs among athletes, coaches and parents to promote better care-seeking behaviours among young athletes.	[Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, Raleigh, NC 27610 USA; [Register-Mihalik, Johna K.; Mueller, Frederick O.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Linnan, Laura A.] Univ N Carolina, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; [McLeod, Tamara C. Valovich] AT Still Univ, Athlet Training Program, Mesa, AZ USA	Register-Mihalik, JK (corresponding author), WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, 3024 New Bern Ave,Suite G01, Raleigh, NC 27610 USA.	jmihalik@wakemed.org	McLeod, Tamara/AAU-9435-2020	Guskiewicz, Kevin/0000-0002-8682-2130; Register-Mihalik, Johna/0000-0002-4229-4743; Marshall, Stephen/0000-0002-2664-9233	National Football League Charities Medical Research Grant	This study was funded by a National Football League Charities Medical Research Grant.	Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Bayer JK, 1997, AUST NZ J PSYCHIAT, V31, P504, DOI 10.3109/00048679709065072; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Fishbein M., 1975, BELIEF ATTITUDE INTE; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hall-Lande JA, 2007, ADOLESCENCE, V42, P265; Johnston, 2004, CONSTRUCTING QUESTIO; Jowett S, 2006, BRIT J SOC PSYCHOL, V45, P617, DOI 10.1348/014466605X58609; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Malinauskas R, 2008, J SPORT MED PHYS FIT, V48, P107; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Murnaghan DA, 2013, PSYCHOL HEALTH, V25, P925; Nattiv A, 1997, CLIN J SPORT MED, V7, P262, DOI 10.1097/00042752-199710000-00004; Ommundsen Y, 2005, J SPORT SCI, V23, P977, DOI 10.1080/02640410500127975; Ommundsen Y, 2006, CLIN J SPORT MED, V16, P522, DOI 10.1097/01.jsm.0000248845.39498.56; PENDER NJ, 1986, NURS RES, V35, P15; Raudsepp L, 2010, PERCEPT MOTOR SKILL, V110, P3, DOI 10.2466/PMS.110.1.3-18; Register-Mihalik J, 2013, J ATHLETIC IN PRESS, P48; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Silsupadol P, 2009, ARCH PHYS MED REHAB, V90, P381, DOI 10.1016/j.apmr.2008.09.559; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Valovich McLeod TC, 2010, ATHLETIC TRAINING SP, V2, P219, DOI DOI 10.3928/19425864-20100630-02; Van Voorhees BW, 2006, SOC PSYCH PSYCH EPID, V41, P746, DOI 10.1007/s00127-006-0091-x; Van-Yperen NW, 1999, SCAND J MED SCI SPOR, V9, P358, DOI 10.1111/j.1600-0838.1999.tb00257.x; White SA, 2004, SCAND J MED SCI SPOR, V14, P57, DOI 10.1111/j.1600-0838.2003.00314.x; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	33	96	96	5	54	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					878	886		10.3109/02699052.2013.775508			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200015	23789865				2021-06-18	
J	Henry, LC; Tremblay, S; Leclerc, S; Khiat, A; Boulanger, Y; Ellemberg, D; Lassonde, M				Henry, Luke C.; Tremblay, Sebastien; Leclerc, Suzanne; Khiat, Abdesselam; Boulanger, Yvan; Ellemberg, Dave; Lassonde, Maryse			Metabolic changes in concussed American football players during the acute and chronic post-injury phases	BMC NEUROLOGY			English	Article						MRI spectroscopy; sports concussion; recovery; metabolism	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; COMPUTED-TOMOGRAPHY; N-ACETYLASPARTATE; SPORTS CONCUSSION; CELL-VOLUME; RAT-BRAIN	Background: Despite negative neuroimaging findings many athletes display neurophysiological alterations and post-concussion symptoms that may be attributable to neurometabolic alterations. Methods: The present study investigated the effects of sports concussion on brain metabolism using H-1-MR Spectroscopy by comparing a group of 10 non-concussed athletes with a group of 10 concussed athletes of the same age (mean: 22.5 years) and education (mean: 16 years) within both the acute and chronic post-injury phases. All athletes were scanned 1-6 days post-concussion and again 6-months later in a 3T Siemens MRI. Results: Concussed athletes demonstrated neurometabolic impairment in prefrontal and motor (M1) cortices in the acute phase where NAA:Cr levels remained depressed relative to controls. There was some recovery observed in the chronic phase where Glu:Cr levels returned to those of control athletes; however, there was a pathological increase of m-I:Cr levels in M1 that was only present in the chronic phase. Conclusions: These results confirm cortical neurometabolic changes in the acute post-concussion phase as well as recovery and continued metabolic abnormalities in the chronic phase. The results indicate that complex pathophysiological processes differ depending on the post-injury phase and the neurometabolite in question.	[Henry, Luke C.; Tremblay, Sebastien; Ellemberg, Dave; Lassonde, Maryse] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada; [Leclerc, Suzanne; Ellemberg, Dave] Univ Montreal, Dept Kinesiol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ, Canada; [Khiat, Abdesselam; Boulanger, Yvan] Univ Montreal, Dept Radiol, Montreal, PQ, Canada; [Khiat, Abdesselam; Boulanger, Yvan] Hop St Luc, Montreal, PQ H2X 1P1, Canada	Henry, LC (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, CP 6128, Montreal, PQ H3C 3J7, Canada.	luke.henry@umontreal.ca		Tremblay, Sebastien/0000-0001-6251-9797	CIHRCanadian Institutes of Health Research (CIHR); FRSQFonds de la Recherche en Sante du Quebec	This study was funded by CIHR grants to LCH, DE, and ML and an FRSQ award to ST.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Angelie E, 2001, AM J NEURORADIOL, V22, P119; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BABIKIAN T, 2006, J MAGN RESON IMAGING; Barr M., 2005, HUMAN NERVOUS SYSTEM; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.med.44.1.289; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jenkins BG, 1999, CURR OPIN NEUROL, V12, P753, DOI 10.1097/00019052-199912000-00016; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; Kandel E, 2000, PRINCIPLES NEUROSCIE; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lang F, 1998, PHYSIOL REV, V78, P247; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEVIN H, 2010, J NEUROTRAUMA; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; LOHR JW, 1988, LIFE SCI, V43, P271, DOI 10.1016/0024-3205(88)90317-7; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Payen JF, 2005, ANN FR ANESTH, V24, P522, DOI 10.1016/j.annfar.2005.03.005; Petroff OAC, 2003, NEUROLOGY, V60, P1646, DOI 10.1212/01.WNL.0000068020.85450.8B; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shutter L, 2006, J HEAD TRAUMA REHAB, V21, P334, DOI 10.1097/00001199-200607000-00005; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; TAYLOR DL, 1994, J NEUROCHEM, V62, P2349; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; WU TC, 2010, J NEUROTRAUMA; Yoon SJ, 2005, CLIN REHABIL, V19, P209, DOI 10.1191/0269215505cr813oa; CONCUSSION	101	96	98	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	AUG 23	2011	11								105	10.1186/1471-2377-11-105			10	Clinical Neurology	Neurosciences & Neurology	821UM	WOS:000294999900001	21861906	DOAJ Gold, Green Published			2021-06-18	
J	[Anonymous]				[Anonymous]			Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGE; CT	Objective To assess the effect of tranexamic acid (which reduces bleeding in surgical patients and reduces mortality due to bleeding in trauma patients) on intracranial haemorrhage in patients with traumatic brain injury. Methods A nested, randomised, placebo controlled trial. All investigators were masked to treatment allocation. All analyses were by intention to treat. Patients 270 adult trauma patients with, or at risk of, significant extracranial bleeding within 8 hours of injury, who also had traumatic brain injury. Interventions Patients randomly allocated to tranexamic acid (loading dose 1 g over 10 minutes, then infusion of 1 g over 8 hours) or matching placebo. Main outcome measures Intracranial haemorrhage growth (measured by computed tomography) between hospital admission and then 24-48 hours later, with adjustment for Glasgow coma score, age, time from injury to the scans, and initial haemorrhage volume. Results Of the 133 patients allocated to tranexamic acid and 137 allocated to placebo, 123 (92%) and 126 (92%) respectively provided information on the primary outcome. All patients provided information on clinical outcomes. The mean total haemorrhage growth was 5.9 ml (SD 26.8) and 8.1 mL (SD 29.2) in the tranexamic acid and placebo groups respectively (adjusted difference -3.8 mL (95% confidence interval -11.5 to 3.9)). New focal cerebral ischaemic lesions occurred in 6 (5%) patients in the tranexamic acid group versus 12 (9%) in the placebo group (adjusted odds ratio 0.51 (95% confidence interval 0.18 to 1.44)). There were 14 (11%) deaths in the tranexamic acid group and 24 (18%) in the placebo group (adjusted odds ratio 0.47 (0.21 to 1.04)). Conclusions This trial shows that neither moderate benefits nor moderate harmful effects of tranexamic acid in patients with traumatic brain injury can be excluded. However, the analysis provides grounds for further clinical trials evaluating the effect of tranexamic acid in this population.				IBIS, NEUROCRITICOS/C-1805-2016	Al-Shahi Salman, Rustam/0000-0002-2108-9222; Prieto-Merino, David/0000-0001-5001-0061	UK NIHRNational Institute for Health Research (NIHR); PfizerPfizer; BUPA Foundation; J P Moulton Charitable Foundation; UK Health Technology Assessment programmeNational Institute for Health Research (NIHR) [06/303/20]; UK MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Scottish Funding Council through the SINAPSE Collaboration (Scottish Imaging Network, A Platform for Scientific Excellence); Scottish Funding Council; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002605, G108/613] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [09/102/01] Funding Source: researchfish	The CRASH-2 study was funded by the UK NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foundation. This sub-study was funded by the UK Health Technology Assessment programme (06/303/20). Rustam Al-Shahi Salman was funded by a UK MRC clinician scientist fellowship. Joanna Wardlaw was funded by the Scottish Funding Council through the SINAPSE Collaboration (Scottish Imaging Network, A Platform for Scientific Excellence).; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: the submitted work was funded by the UK Health Technology Assessment programme (06/303/20), Rustam Al-Shahi Salman was funded by a UK MRC clinician scientist fellowship, Joanna Wardlaw was funded by the Scottish Funding Council; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Baigent C, 2010, OXFORD TXB MED, P31, DOI [10.1093/med/9780199204854.003.020303_update_002, DOI 10.1093/MED/9780199204854.003.020303_UPDATE_002]; Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cordoba G, 2010, BMJ-BRIT MED J, V341, pc3920; Edwards P, 2005, LANCET, V365, P1957; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Henry DA, 2007, COCHRANE DB SYST REV, V17; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Perel P, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-72; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; ROOS YB, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001245, 10.1002/14651858.CD001245]; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stein SC, 2007, INDIAN J MED RES, V125, P186; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WARDLAW JM, 1994, AM J NEURORADIOL, V15, P1933	22	96	97	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2011	343								d3795	10.1136/bmj.d3795			11	Medicine, General & Internal	General & Internal Medicine	788QD	WOS:000292458600002	21724564	Green Published, Green Accepted, Other Gold			2021-06-18	
J	Nunnally, ME; Jaeschke, R; Bellingan, GJ; Lacroix, J; Mourvillier, B; Rodriguez-Vega, GM; Rubertsson, S; Vassilakopoulos, T; Weinert, C; Zanotti-Cavazzoni, S; Buchman, TG				Nunnally, Mark E.; Jaeschke, Roman; Bellingan, Geoffrey J.; Lacroix, Jacques; Mourvillier, Bruno; Rodriguez-Vega, Gloria M.; Rubertsson, Sten; Vassilakopoulos, Theodoros; Weinert, Craig; Zanotti-Cavazzoni, Sergio; Buchman, Timothy G.			Targeted temperature management in critical care: A report and recommendations from five professional societies	CRITICAL CARE MEDICINE			English	Article						temperature; consensus; cardiac arrest; targeted temperature management; hypothermia	TRAUMATIC BRAIN-INJURY; MILD HYPOTHERMIA THERAPY; HOSPITAL CARDIAC-ARREST; WHOLE-BODY HYPOTHERMIA; MODERATE HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; CLINICAL-TRIAL; COMATOSE SURVIVORS; PERINATAL ASPHYXIA; PHASE-II	Objective: Representatives of five international critical care societies convened topic specialists and a nonexpert jury to review, assess, and report on studies of targeted temperature management and to provide clinical recommendations. Data Sources: Questions were allocated to experts who reviewed their areas, made formal presentations, and responded to questions. Jurors also performed independent searches. Sources used for consensus derived exclusively from peer-reviewed reports of human and animal studies. Study Selection: Question-specific studies were selected from literature searches; jurors independently determined the relevance of each study included in the synthesis. Conclusions and Recommendations: 1) The jury opines that the term "targeted temperature management" replace "therapeutic hypothermia." 2) The jury opines that descriptors (e. g., "mild") be replaced with explicit targeted temperature management profiles. 3) The jury opines that each report of a targeted temperature management trial enumerate the physiologic effects anticipated by the investigators and actually observed and/or measured in subjects in each arm of the trial as a strategy for increasing knowledge of the dose/duration/response characteristics of temperature management. This enumeration should be kept separate from the body of the report, be organized by body systems, and be made without assertions about the impact of any specific effect on the clinical outcome. 4) The jury STRONGLY RECOMMENDS targeted temperature management to a target of 32 degrees C-34 degrees C as the preferred treatment (vs. unstructured temperature management) of out-of-hospital adult cardiac arrest victims with a first registered electrocardiography rhythm of ventricular fibrillation or pulseless ventricular tachycardia and still unconscious after restoration of spontaneous circulation (strong recommendation, moderate quality of evidence). 5) The jury WEAKLY RECOMMENDS the use of targeted temperature management to 33 degrees C-35.5 degrees C (vs. less structured management) in the treatment of term newborns who sustained asphyxia and exhibit acidosis and/or encephalopathy (weak recommendation, moderate quality of evidence). (Crit Care Med 2011; 39:1113-1125)	[Buchman, Timothy G.] Emory Ctr Crit Care, Atlanta, GA USA; [Jaeschke, Roman] McMaster Univ, Hamilton, ON, Canada; [Bellingan, Geoffrey J.] Univ Coll London Hosp, London, England; [Lacroix, Jacques] Univ Montreal, Montreal, PQ, Canada; [Mourvillier, Bruno] Hop Bichat Claude Bernard, F-75877 Paris 18, France; [Rodriguez-Vega, Gloria M.] Univ Dist Hosp, San Juan, PR USA; [Rubertsson, Sten] Uppsala Univ, Dept Surg Sci Anesthesiol & Intens Care, Uppsala, Sweden; [Vassilakopoulos, Theodoros] Evangelismos Med Ctr, Athens, Greece; [Weinert, Craig] Univ Minnesota, Minneapolis, MN USA; [Zanotti-Cavazzoni, Sergio] Cooper Univ Hosp, Camden, NJ USA; [Nunnally, Mark E.] Univ Chicago, Chicago, IL 60637 USA	Buchman, TG (corresponding author), Emory Ctr Crit Care, Atlanta, GA USA.	tbuchma@emory.edu		Buchman, Timothy/0000-0001-7350-5921			Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Callaway CW, 2008, CRIT CARE MED, V36, P2607, DOI 10.1097/CCM.0b013e318184443b; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; D'Cruz BJ, 2005, BRAIN RES, V1064, P108, DOI 10.1016/j.brainres.2005.09.052; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Hamann GF, 2004, STROKE, V35, P764, DOI 10.1161/01.STR.0000116866.60794.21; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kollmar R, 2009, NEUROCRIT CARE, V10, P173, DOI 10.1007/s12028-008-9162-z; Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289; Lee SM, 2009, J CEREBR BLOOD F MET, V29, P1589, DOI 10.1038/jcbfm.2009.81; LEHOT JJ, 1992, CHEST, V102, P106, DOI 10.1378/chest.102.1.106; Lin ZL, 2006, J PERINATOL, V26, P180, DOI 10.1038/sj.jp.7211412; Linares G, 2009, CRIT CARE MED, V37, pS243, DOI 10.1097/CCM.0b013e3181aa5de1; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Robertson NJ, 2008, LANCET, V372, P801, DOI 10.1016/S0140-6736(08)61329-X; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Smrcka M, 2005, ACT NEUR S, V95, P273; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub4; Takaoka S, 1996, NEUROSCI LETT, V218, P25, DOI 10.1016/S0304-3940(96)13112-8; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tohyama Y, 1998, EXP BRAIN RES, V122, P333, DOI 10.1007/s002210050521; Tokutomi T, 2007, NEUROSURGERY, V61, P256, DOI [10.1227/01.NEU.00000038737.13185.C4, 10.1227/01.neu.0000279221.38257.1a]; Tomasevic G, 1999, NEUROSCIENCE, V90, P781, DOI 10.1016/S0306-4522(98)00484-9; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van Hemelrijck A, 2005, EUR J NEUROSCI, V22, P1327, DOI 10.1111/j.1460-9568.2005.04331.x; Varon J, 2008, CHEST, V133, P1267, DOI 10.1378/chest.07-2190; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner S, 2003, BRAIN RES, V984, P63, DOI 10.1016/S0006-8993(03)03088-9; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; Wang Wei-ping, 2005, Chin J Traumatol, V8, P54; Whalen MJ, 1997, ACT NEUR S, V70, P260; Yenari MA, 2000, BRAIN RES, V885, P208, DOI 10.1016/S0006-8993(00)02942-5; Yenari M, 2008, STROKE, V39, P2910, DOI 10.1161/STROKEAHA.108.514471; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; Zhou WH, 2002, ACTA PHARMACOL SIN, V23, P64	75	96	102	2	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2011	39	5					1113	1125		10.1097/CCM.0b013e318206bab2			13	Critical Care Medicine	General & Internal Medicine	752CX	WOS:000289667000026	21187745				2021-06-18	
J	Prevost, TP; Balakrishnan, A; Suresh, S; Socrate, S				Prevost, Thibault P.; Balakrishnan, Asha; Suresh, Subra; Socrate, Simona			Biomechanics of brain tissue	ACTA BIOMATERIALIA			English	Article						Brain tissue mechanics; Nonlinear dynamic behavior; Visco-hyperelastic; Bulk response; High rate	ELASTIC-PLASTIC DEFORMATION; FINITE-ELEMENT-ANALYSIS; CENTRAL-NERVOUS-SYSTEM; MECHANICAL-PROPERTIES; CONSTITUTIVE MODEL; PORCINE LIVER; IN-VIVO; STRAIN; BEHAVIOR; SHEAR	The dynamic behavior of porcine brain tissue, obtained from a series of in vitro observations and experiments, is analyzed and described here with the aid of a large strain, nonlinear, viscoelastic constitutive model. Mixed gray and white matter samples excised from the superior cortex were tested in unconfined uniaxial compression within 15 h post mortem. The test sequence consisted of three successive load-unload segments at strain rates of 1, 0.1 and 0.01 s(-1), followed by stress relaxation (n = 25). The volumetric compliance of the tissue was assessed for a subset of specimens (n = 7) using video extensometry techniques. The tissue response exhibited moderate compressibility, substantial nonlinearity, hysteresis, conditioning and rate dependence. A large strain kinematics nonlinear viscoelastic model was developed to account for the essential features of the tissue response over the entire deformation history. The corresponding material parameters were obtained by fitting the model to the measured conditioned response (axial and volumetric) via a numerical optimization scheme. The model successfully captures the observed complexities of the material response in loading, unloading and relaxation over the entire range of strain rates. The accuracy of the model was further verified by comparing model predictions with the tissue response in unconfined compression at higher strain rate (10 s(-1)) and with literature data in uniaxial tension. The proposed constitutive framework was also found to be adequate to model the loading response of brain tissue in uniaxial compression over a wider range of strain rates (0.01-3000 s(-1)), thereby providing a valuable tool for simulations of dynamic transients (impact, blast/shock wave propagation) leading to traumatic brain injury. (c) 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Suresh, Subra; Socrate, Simona] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Prevost, Thibault P.; Suresh, Subra] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Balakrishnan, Asha; Suresh, Subra] MIT, Dept Mech Engn, Cambridge, MA 02139 USA	Socrate, S (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ssocrate@mit.edu	Suresh, Subra/B-8289-2008	Suresh, Subra/0000-0002-6223-6831	US Army Research Office, through the MIT Institute for Soldier Nanotechnologies [W911NF-07-D-0004]; Joint Improvised Explosive Devices Defeat Organization [W911NF-07-1-0035]; Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France); Singapore-MIT Alliance for Research and Technology CentreSingapore-MIT Alliance for Research & Technology Centre	The authors acknowledge the support of the US Army Research Office, through the MIT Institute for Soldier Nanotechnologies (W911NF-07-D-0004) and the Joint Improvised Explosive Devices Defeat Organization (W911NF-07-1-0035), and that of Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France). Partial support for this work was also obtained from the Computational Systems Biology Programme of the Singapore-MIT Alliance and from the Interdisciplinary Research Group on Infectious Diseases, funded by the Singapore-MIT Alliance for Research and Technology Centre. The authors are grateful to Professor Wayne Chen from Purdue University for providing the high rate tissue data. There is no conflict of interest to be reported.	ANAND L, 1979, J APPL MECH-T ASME, V46, P78, DOI 10.1115/1.3424532; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; ARRUDA EM, 1993, J MECH PHYS SOLIDS, V41, P389, DOI 10.1016/0022-5096(93)90013-6; Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Balakrishnan A, 2008, EXP MECH, V48, P549, DOI 10.1007/s11340-007-9087-z; BALAKRISHNAN A, 2007, THESIS MIT CAMBRIDGE; BASSER PJ, 1992, MICROVASC RES, V44, P143, DOI 10.1016/0026-2862(92)90077-3; Bergstrom JS, 2001, MECH MATER, V33, P523, DOI 10.1016/S0167-6636(01)00070-9; BERNICK K, 2009, P ASME 2009 SUMM BIO; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Biot MA, 1941, J APPL PHYS, V12, P155, DOI 10.1063/1.1712886; BOYCE MC, 1989, J MECH PHYS SOLIDS, V37, P647, DOI 10.1016/0022-5096(89)90033-1; Brands Dave W A, 2002, Stapp Car Crash J, V46, P103; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Chui C, 2007, MED BIOL ENG COMPUT, V45, P99, DOI 10.1007/s11517-006-0137-y; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Criscione JC, 2002, COMPUT STRUCT, V80, P1895, DOI 10.1016/S0045-7949(02)00208-0; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; El Sayed T, 2008, J BIOMECH, V41, P1458, DOI 10.1016/j.jbiomech.2008.02.023; ESTES MS, 1970, MECH ENG, V92, P58; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fang MR, 2005, NEUROSIGNALS, V14, P102, DOI 10.1159/000086292; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gardel ML, 2006, P NATL ACAD SCI USA, V103, P1762, DOI 10.1073/pnas.0504777103; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Guillaume A, 1997, J BIOMECH, V30, P383, DOI 10.1016/S0021-9290(96)00153-4; Holzapfel G., 2000, NONLINEAR SOLID MECH; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Jordan P, 2009, J MECH BEHAV BIOMED, V2, P192, DOI 10.1016/j.jmbbm.2008.08.006; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kohandel M, 2006, MED ENG PHYS, V28, P449, DOI 10.1016/j.medengphy.2005.01.005; Lagarias JC, 1998, SIAM J OPTIMIZ, V9, P112, DOI 10.1137/S1052623496303470; LEE EH, 1969, J APPL MECH, V36, P1, DOI 10.1115/1.3564580; Lodish H., 2007, MOL CELL BIOL; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Mulliken AD, 2006, INT J SOLIDS STRUCT, V43, P1331, DOI 10.1016/j.ijsolstr.2005.04.016; Nicholson C, 2001, REP PROG PHYS, V64, P815, DOI 10.1088/0034-4885/64/7/202; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; PAMIDI MR, 1978, J BIOMECH ENG-T ASME, V100, P44, DOI 10.1115/1.3426188; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Peters GWM, 1997, BIORHEOLOGY, V34, P127, DOI 10.1016/S0006-355X(97)00009-7; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Shreiber DI, 2009, BIOMECH MODEL MECHAN, V8, P311, DOI 10.1007/s10237-008-0137-y; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; WALSH EK, 1977, AM J PHYSIOL, V232, pR27; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	72	96	98	0	68	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JAN	2011	7	1					83	95		10.1016/j.actbio.2010.06.035			13	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	687RJ	WOS:000284795300007	20603231				2021-06-18	
J	Kishk, NA; Gabr, H; Hamdy, S; Afifi, L; Abokresha, N; Mahmoud, H; Wafaie, A; Bilal, D				Kishk, Nirmeen A.; Gabr, Hala; Hamdy, Sherif; Afifi, Lamia; Abokresha, Noha; Mahmoud, Hayam; Wafaie, Ahmed; Bilal, Dalia			Case Control Series of Intrathecal Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Chronic Spinal Cord Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						mesenchymal stem cell; spinal cord injury; SSEP	STROMAL CELLS; TRANSPLANTATION; REHABILITATION; BRAIN	Background: Autologous bone marrow mesenchymal cells that include stem cells (MSCs) are a clinically attractive cellular therapy option to try to treat severe spinal cord injury (SCI). Objective: To study the possible value of MSCs injected intrathecally to enhance rehabilitation. Methods: This case control, convenience sample included 64 patients, at a mean of 3.6 years after SCI. Forty-four subjects received monthly intrathecal autologous MSCs for 6 months and 20 subjects, who would not agree to the procedures, served as controls. All subjects received rehabilitation therapies 3 times weekly. Subjects were evaluated at entry and at 12 months after completing the 6-months intervention. By the ASIA Impairment Scale, ASIA grading of completeness of injury, Ashworth Spasticity Scale, Functional Ambulation Classification, and bladder and bowel control questionnaire. Results: No differences were found in baseline measures and descriptors between the MSC group and control group. Although a higher percentage of the MSC group increased motor scores by 1-2 points and changed from ASIA A to B, no significant between-group improvements were found in clinical measures. Adverse effects of cells included spasticity and, in 24 out of the 43 patients developed neuropathic pain. One subject with a history of post-infectious myelitis developed encephalomyelitis after her third injection. Conclusion: Autologus MSCs may have side effects and may be contraindicated in patients with a history of myelitis. Their utility in treating chronic traumatic SCI needs further study in pre-clinical models and in randomized controlled trials before they should be offered to patients.	[Kishk, Nirmeen A.; Hamdy, Sherif; Abokresha, Noha] Cairo Univ, Dept Neurol, Cairo, Egypt; [Gabr, Hala] Cairo Univ, Dept Clin Pathol, Cairo, Egypt; [Afifi, Lamia] Cairo Univ, Clin Neurophysiol Unit, Cairo, Egypt; [Wafaie, Ahmed] Cairo Univ, Dept Radiol, Cairo, Egypt; [Bilal, Dalia] Cairo Univ, Natl Canc Inst, Dept Biostat & Epidemiol, Cairo, Egypt	Abokresha, N (corresponding author), Cairo Univ, Kaser Al Aini Hosp, Cairo, Egypt.	nhtaha@yahoo.com	Abokrysha, Noha/AAG-1693-2020; Mahmoud, Hayam/C-1452-2019	Abokrysha, Noha/0000-0002-3857-8698; Mahmoud, Hayam/0000-0002-9352-4916; Wafaie, Ahmed/0000-0003-3089-9240; kishk, nirmeen/0000-0003-4410-7814; Gabr, Hala/0000-0003-0262-8558			Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Akiyama Y, 2002, J NEUROSCI, V22, P6623; American Spinal Injury Association, 1984, STAND NEUR CLASS SPI; Bakshi A, 2006, J NEUROTRAUM, V23, P55, DOI 10.1089/neu.2006.23.55; Blesch A, 2002, BRAIN RES BULL, V57, P833, DOI 10.1016/S0361-9230(01)00774-2; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Callera F, 2007, STEM CELLS DEV, V16, P461, DOI 10.1089/scd.2007.0083; CHAE WP, 2009, INT J STEM CELLS, V2, P59; Dobkin BH, 2007, STROKE, V38, P832, DOI 10.1161/01.STR.0000248408.49398.9c; Dobkin BH, 2010, NEUROREHAB NEURAL RE, V24, P7, DOI 10.1177/1545968309354457; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Geffner LF, 2008, CELL TRANSPLANT, V17, P1277, DOI 10.3727/096368908787648074; HOLDEN MK, 1986, PHYS THER, V66, P1530, DOI 10.1093/ptj/66.10.1530; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; Kadoya K, 2009, NEURON, V64, P165, DOI 10.1016/j.neuron.2009.09.016; LEVIT K, 1997, AM OCC THER ASS ANN; Lima C, 2010, NEUROREHAB NEURAL RE, V24, P10, DOI 10.1177/1545968309347685; MAHONEY FI, 1994, PHYS REHABILITATION, P198; Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Zhang J, 2008, J NEUROSCI RES, V86, P1501, DOI 10.1002/jnr.21617	26	96	102	1	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	OCT	2010	24	8					702	708		10.1177/1545968310369801			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	657RH	WOS:000282429500003	20660620				2021-06-18	
J	Bailes, JE; Mills, JD				Bailes, Julian E.; Mills, James D.			Docosahexaenoic Acid Reduces Traumatic Axonal Injury in a Rodent Head Injury Model	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; docosahexaenoic acid; omega-3 fatty acids; traumatic axonal injury	POLYUNSATURATED FATTY-ACIDS; SPINAL-CORD-INJURY; BRAIN-INJURY; CELL-DEATH; OMEGA-3-FATTY-ACIDS; APOPTOSIS; SUPPLEMENTATION; INFLAMMATION; MECHANISMS; PLASMA	Traumatic brain injury (TBI) remains the most common cause of death in persons under age 45 in the Western world. Recent evidence from animal studies suggests that supplementation with omega-3 fatty acids (O3FA) improves functional outcomes following focal neural injury. The purpose of this study is to determine the benefits of DHA supplementation following diffuse axonal injury in rats. Four groups of 10 adult male Sprague-Dawley rats were subjected to an impact acceleration injury and then received 30 days of supplementation with either 10 mg/kg/d or 40 mg/kg/d of docosahexaenoic acid (DHA). Serum fatty acid levels were determined from the isolated plasma phospholipids prior to injury and at the end of the 30 days of DHA supplementation. Following sacrifice, brainstem white matter tracts underwent fluorescent immunohistochemical processing for labeling of beta-amyloid precursor protein (APP), a marker of axonal injury. Dietary supplementation with either 10 mg/kg/d or 40 mg/kg/d of DHA for 30 days results in significantly (p < 0.05) increased DHA serum levels of 123% and 175% over baseline, respectively. Immunohistochemical analysis reveals significantly (p < 0.05) decreased numbers of APP-positive axons in animals receiving dietary supplementation with DHA, 26.1 (SD 5.3) for 10 mg/kg/d, and 19.6 (SD 4.7) for 40 mg/kg/d axons per mm(2), versus 147.7 (SD 7.1) axons in unsupplemented animals. Sham-injured animals had 6.4 (SD 13.9) APP positive axons per mm(2). Dietary supplementation with DHA increases serum levels in a dose-dependent manner. DHA supplementation significantly reduces the number of APP-positive axons at 30 days post-injury, to levels similar to seen those in uninjured animals. DHA is safe, affordable, and readily available worldwide to potentially reduce the burden of TBI.	[Bailes, Julian E.; Mills, James D.] W Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA	Bailes, JE (corresponding author), W Virginia Univ, Dept Neurosurg, Sch Med, POB 9183, Morgantown, WV 26506 USA.	jbailes@hsc.wvu.edu			Martek, Inc.; Martek Biosciences, Inc.	This work was supported by a grant from Martek, Inc. The authors would like to recognize Rebecca Kessler for assistance with manuscript preparation.; This work was financially supported by Martek Biosciences, Inc., for which Dr. Bailes serves as a consultant.	Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Brossard N, 1996, AM J CLIN NUTR, V64, P577; Buki A, 2000, J NEUROSCI, V20, P2825; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; Carver JD, 2001, BRAIN RES BULL, V56, P79, DOI 10.1016/S0361-9230(01)00551-2; Danthi SJ, 2005, BIOCHEM BIOPH RES CO, V327, P485, DOI 10.1016/j.bbrc.2004.12.033; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Emsley R, 2003, CNS DRUGS, V17, P1081, DOI 10.2165/00023210-200317150-00003; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; Hovda DA, 2007, CRIT CARE MED, V35, P663, DOI 10.1097/01.CCM.0000254442.66789.52; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Lang-Lazdunski L, 2003, J VASC SURG, V38, P564, DOI 10.1016/S0741-5214(03)00473-7; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTINEZ M, 1994, WORLD REV NUTR DIET, V75, P70; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; Mills JD, 2003, J BIOMED OPT, V8, P347, DOI 10.1117/1.1584443; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sarsimaz M, 2003, NEUROSCI RES COMMUN, V33, P114, DOI 10.1002/nrc.10087; Schlanger S, 2002, EPILEPSIA, V43, P103, DOI 10.1046/j.1528-1157.2002.13601.x; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Songur A, 2004, PROG NEURO-PSYCHOPH, V28, P693, DOI 10.1016/j.pnpbp.2004.05.006; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Vidgren HM, 1997, LIPIDS, V32, P697, DOI 10.1007/s11745-997-0089-x; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029	47	96	97	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1617	1624		10.1089/neu.2009.1239			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500008	20597639				2021-06-18	
J	Wu, TC; Wilde, EA; Bigler, ED; Yallampalli, R; McCauley, SR; Troyanskaya, M; Chu, ZL; Li, XQ; Hanten, G; Hunter, JV; Levin, HS				Wu, Trevor C.; Wilde, Elisabeth A.; Bigler, Erin D.; Yallampalli, Ragini; McCauley, Stephen R.; Troyanskaya, Maya; Chu, Zili; Li, Xiaoqi; Hanten, Gerri; Hunter, Jill V.; Levin, Harvey S.			Evaluating the Relationship between Memory Functioning and Cingulum Bundles in Acute Mild Traumatic Brain Injury Using Diffusion Tensor Imaging	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; learning and memory; magnetic resonance imaging; pediatric brain injury; traumatic brain injury	AXONAL INJURY; ABNORMALITIES; DEPRESSION	Compromised memory functioning is one of the commonly reported cognitive sequelae seen following mild traumatic brain injury (mTBI). Diffusion tensor imaging (DTI) has been shown to be sufficiently sensitive at detecting early microstructural pathological alterations after mTBI. Given its location and shape, the cingulate, which is comprised of the cingulate gyrus (gray matter) and cingulum bundles (white matter), is selectively vulnerable to mTBI. In this study we examined the integrity of cingulum bundles using DTI, and the relationship between cingulum bundles and memory functioning. Twelve adolescents with mTBI and 11 demographically-matched healthy controls were studied. All participants with mTBI had a Glasgow Coma Scale score of 15, and were without intracranial findings on CT scan. Brain scans were performed on average 2.92 days post-injury, and all participants were administered the Verbal Selective Reminding Test (VSRT), an episodic verbal learning and memory task. Participants with mTBI had a significantly lower apparent diffusion coefficient (ADC) bilaterally than controls (p<0.001). Despite the marginal significance of the group difference in fractional anisotropy (FA), the effect size between groups was moderate (d=0.66). Cognitively, healthy controls performed better than the TBI group on immediate and delayed recall; however, the difference did not reach statistical significance. In the mTBI group, FA of the left cingulum bundle was significantly correlated with 30-min delayed recall (r = -0.56, p = 0.05). A marginally significant correlation was found between ADC of the left cingulum bundle and the total words of immediate recall (r = 0.59, p = 0.07). No significant correlation was found between DTI metrics and memory functioning for the control group. These preliminary findings indicate that cingulate injury likely contributes to the cognitive sequelae seen during the early phase post-mTBI.	[Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Wilde, Elisabeth A.; Yallampalli, Ragini; McCauley, Stephen R.; Troyanskaya, Maya; Li, Xiaoqi; Hanten, Gerri; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; Yallampalli, Ragini; McCauley, Stephen R.; Troyanskaya, Maya; Li, Xiaoqi; Hanten, Gerri; Levin, Harvey S.] Phys Med & Rehabil Alliance Baylor Coll Med, Houston, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol & Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurol Neurosurg & Pediat, Houston, TX 77030 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	ewilde@bcm.edu			National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS056202]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke grant no. P01 NS056202. We would also like to acknowledge the generous support by Mission Connect of the TIRR Foundation (The Institute for Rehabilitation and Research).	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Behrens TEJ, 2009, SCIENCE, V324, P1160, DOI 10.1126/science.1169694; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Christensen TA, 2008, NEUROREPORT, V19, P1101, DOI 10.1097/WNR.0b013e3283060a9d; CHU Z, 2009, AM J NEURORADIO 1203; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Ebert D, 1996, BIOL PSYCHIAT, V39, P1044, DOI 10.1016/0006-3223(95)00320-7; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gean A, 1994, IMAGING HEAD TRAUMA; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; NETSCH T, 2001, INT C COMP VIS; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rushworth MFS, 2008, NAT NEUROSCI, V11, P389, DOI 10.1038/nn2066; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zago L, 2008, NEUROPSYCHOLOGIA, V46, P2403, DOI 10.1016/j.neuropsychologia.2008.03.001	36	96	96	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					303	307		10.1089/neu.2009.1110			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800002	19877826	Green Published			2021-06-18	
J	Wojcik, BE; Stein, CR; Bagg, K; Humphrey, RJ; Orosco, J				Wojcik, Barbara E.; Stein, Catherine R.; Bagg, Karen; Humphrey, Rebecca J.; Orosco, Jason			Traumatic Brain Injury Hospitalizations of US Army Soldiers Deployed to Afghanistan and Iraq	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article								Background: Traumatic brain injury (TBI) is a life-altering condition that has affected many of our soldiers returning from war. In the current conflicts, the improvised explosive device (IED) has greatly increased the potential for soldiers to sustain a TBI. This study's objective was to establish benchmark admission rates for U.S. Army soldiers with TBIs identified during deployment to Iraq and Afghanistan. Methods: The study population consisted of U.S. Army soldiers deployed to Iraq and Afghanistan from September 11, 2001, through September 30,2007. Population data were merged with admission data to identify hospitalizations during deployment. Using the international Barell Injury Diagnosis Matrix, TBI-related admissions were categorized into Type 1 (the most severe), Type 2, and Type 3 (the least severe). All analyses were performed in 2008. Results: Of the 2898 identified TBI inpatient episodes of care, 46% were Type 1, 54% were Type 2, and less than 1% were Type 3. Over-65% of Type 1 injuries resulted from explosions, while almost half of all TBIs were non-battle-related. Overall TBI admission rates were 24.6 for Afghanistan and 41.8 for Iraq per 10,000 soldier-years. TBI hospitalization rates rose over time for both campaigns, although U.S. Army soldiers in Iraq experienced 1.7 times higher rates overall and 2.2 times higher Type 1 admission rates than soldiers in Afghanistan. The TBI-related proportion of all injury hospitalizations showed an ascending trend. Conclusions: Future surveillance of TBI hospitalization rates is needed to evaluate the effectiveness of implementation of preventive measures. (Am J Prev Med 2010;38(1S):S108 -S116) Published by Elsevier Inc. on behalf of American journal of Preventive Medicine	[Wojcik, Barbara E.; Stein, Catherine R.; Bagg, Karen; Humphrey, Rebecca J.] USA, Med Dept Ctr & Sch, Ctr Army, Med Dept Strateg Studies, Ft Sam Houston, TX USA; [Orosco, Jason] Lockheed Martin Corp, Bethesda, MD USA	Wojcik, BE (corresponding author), CASS, 1608 Stanley Rd,Suite 47, Ft Sam Houston, TX 78234 USA.	barbara.wojcik@amedd.army.mil					ABBOTT CA, 2009, 09002 RP CTR ARM MED; [Anonymous], 2008, MILD TRAUM BRAIN INJ; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; CAJIGAL S, 2007, NEUROLOGY, V7, P21; *CDC, INT COLL EFF ICE INJ; CDC. National Center for Health Statistics, BAR INJ DIAGN MATR C; *CDCP, 2006, FACTS TRAUM BRAIN IN; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; HARBEN J, 2008, TRAUMATIC BRAIN INJU; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JAFFEE MS, 2009, COMMUNICATION    WIN, P1; JONES BH, 1999, MIL MED, V164, pS633; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; SUTTON LK, 2009, DCOE ACTION, V2, P2; Tanielian T, 2008, INVISIBLE WOUNDS WAR; *TRAUM BRAIN INJ T, 2007, REP SURG GEN; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WARDEN DL, 1996, J NEUROTRAUM, V40, P211; 2008, MED SURVEILL MON REP, V15, P2; 2007, MED SURVEILL MON REP, V14, P2	24	96	99	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	JAN	2010	38	1		1			S108	S116		10.1016/j.amepre.2009.10.006			9	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	541KM	WOS:000273413900011	20117583				2021-06-18	
J	Allard, CB; Scarpelini, S; Rhind, SG; Baker, AJ; Shek, PN; Tien, H; Fernando, M; Tremblay, L; Morrison, LJ; Pinto, R; Rizoli, SB				Allard, Christopher B.; Scarpelini, Sandro; Rhind, Shawn G.; Baker, Andrew J.; Shek, Pang N.; Tien, Homer; Fernando, Michael; Tremblay, Lorraine; Morrison, Laurie J.; Pinto, Ruxandra; Rizoli, Sandro B.			Abnormal Coagulation Tests Are Associated With Progression of Traumatic Intracranial Hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Intracerebral hemorrhage; Traumatic brain injury; INR; PTT; Platelet count	PROTHROMBIN COMPLEX CONCENTRATE; ACUTE INTRACEREBRAL HEMORRHAGE; ACTIVATED FACTOR-VII; BRAIN-INJURY; HEAD TRAUMA; ANTICOAGULATION; REVERSAL; COAGULOPATHY; HEMATOMA; THROMBOCYTOPENIA	Background: Intracranial hemorrhage (ICH) is common in traumatic brain injury (TBI) and a major determinant of death and disability. ICH commonly increases in size and coagulopathy has been implicated in such progression. We investigated the association between coagulopathy diagnosed by routine laboratory tests and ICH progression. Methods: Subgroup post hoc analysis from a randomized controlled trial including adult patients with blunt severe TBI (Glasgow Coma Scale score <= 8) and repeat computerized tomography scans in 48 hours. Coagulopathy was defined as international normalized ratio >= 1.3, activated partial thromboplastin time >= 35, or platelet count (PLT) <= 100 x 10(9)/L any time in the first 24 hours. Progression was any size increase or new ICH. TBI-associated coagulopathy was investigated measuring soluble tissue factor (TF) and D-dimer. Results: The ICH progressed in 37 of 72 patients (51%), in 80% if any abnormal laboratory test (coagulopathic patients) versus 36% in noncoagulopathic (p = 0.0004). Abnormal international normalized ratio (odds ratio [OR] 4.09; 95% confidence interval [CI] = 1.29-12.95; p = 0.017), PLT (OR 12.59; 95% CI = 1.52-108.57; p = 0.019), head Abbreviated Injury Scale(AIS)(OR = 1.82; 95% CI = 1.15-2.88; p = 0.011) were significantly associated with progression (univariate analysis). In a multiple logistic regression, only head AIS (OR = 1.81; 95% CI 1.10-2.98; p = 0.0198)and PLT (OR = 11.8; 95% CI = 1.38-101.23; p = 0.024) correlated with progression. All patients with abnormal partial thromboplastin time experienced progression. ICH progression carried a 5-fold higher odds of death; 32% with progression died versus 8.6% without. Age, head AIS, Injury Severity Score, and D-dimer were also associated with mortality. Tissue factor was not associated with progression or mortality. Conclusion: This study demonstrates an association between coagulopathy, diagnosed by routine laboratorial tests in the first 24 hours, with ICH progression; and ICH progression with mortality in patients with severe TBI. The causal relationship between coagulopathy and ICH progression will require further studies.	[Allard, Christopher B.; Scarpelini, Sandro; Tien, Homer; Fernando, Michael; Tremblay, Lorraine; Pinto, Ruxandra; Rizoli, Sandro B.] Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON M4N 3M5, Canada; [Allard, Christopher B.; Scarpelini, Sandro; Tien, Homer; Fernando, Michael; Tremblay, Lorraine; Pinto, Ruxandra; Rizoli, Sandro B.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Rhind, Shawn G.; Shek, Pang N.] Def Res & Dev Canada, Toronto, ON, Canada; [Morrison, Laurie J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Prehosp & Transport Med Res Program, Toronto, ON M5B 1W8, Canada	Rizoli, SB (corresponding author), 2075 Bayview Ave,Suite H1-71, Toronto, ON M4N 3M5, Canada.	sandro.rizoli@sunnybrook.ca	morrison, laurie J/A-6325-2012; Scarpelini, Sandro/H-7063-2012	morrison, laurie J/0000-0001-8369-9774; Scarpelini, Sandro/0000-0001-5727-3913; Rhind, Shawn/0000-0003-2300-0620			Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009; Dickneite G, 2007, THROMB RES, V119, P643, DOI 10.1016/j.thromres.2006.05.011; Dzik WH, 2007, TRANSFUSION MED, V17, P367, DOI 10.1111/j.1365-3148.2007.00795.x; Eikelboom JW, 2003, BLOOD COAGUL FIBRIN, V14, P713, DOI 10.1097/00001721-200312000-00004; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; FRANKE CL, 1992, J NEUROL NEUROSUR PS, V55, P653, DOI 10.1136/jnnp.55.8.653; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jones J, 1999, VOX SANG, V77, P239, DOI 10.1046/j.1423-0410.1999.77402391.x; Levi M, 2007, CRIT CARE MED, V35, P2191, DOI 10.1097/01.CCM.0000281468.94108.4B; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; MAY AK, 1997, AM SURGEON, V63, P223; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; Riess HB, 2007, THROMB RES, V121, P9, DOI 10.1016/j.thromres.2007.02.009; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; SERVADEI F, 1995, NEUROSURGERY, V37, P906; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Vanderschueren S, 2000, CRIT CARE MED, V28, P1871, DOI 10.1097/00003246-200006000-00031; Vaslef SN, 2002, J TRAUMA, V53, P291, DOI 10.1097/00005373-200208000-00017; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	30	96	113	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2009	67	5					959	967		10.1097/TA.0b013e3181ad5d37			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	518XO	WOS:000271729500011	19901655				2021-06-18	
J	Grossetete, M; Phelps, J; Arko, L; Yonas, H; Rosenberg, GA				Grossetete, Mark; Phelps, Jeremy; Arko, Leopold; Yonas, Howard; Rosenberg, Gary A.			ELEVATION OF MATRIX METALLOPROTEINASES 3 AND 9 IN CEREBROSPINAL FLUID AND BLOOD IN PATIENTS WITH SEVERE TRAUMATIC BRAIN INJURY	NEUROSURGERY			English	Article						Cerebrospinal fluid; Matrix metalloproteinases; Traumatic brain injury; Ventriculostomy	SPONTANEOUS INTRACEREBRAL HEMORRHAGE; GENE KNOCK-OUT; MULTIPLE-SCLEROSIS; BACTERIAL-MENINGITIS; BARRIER DISRUPTION; MATRIX-METALLOPROTEINASE-9; EXPRESSION; NEUROINFLAMMATION; ACTIVATION; INHIBITORS	OBJECTIVE: Traumatic brain injury (TBI) causes an increase in matrix metalloproteinases (MMPs), which are associated with neuroinflammation, blood-brain barrier disruption, hemorrhage, and cell death. We hypothesized that patients with TBI have an increase in MMPs in ventricular cerebrospinal fluid (CSF) and plasma. METHODS: patients with TBI and a ventricular catheter were entered into the study. Samples of CSF and plasma were collected at the time of catheter placement and at 24 and 72 hours after admission. Seven TBI patients were entered into the study, with 6 having complete data for analysis. Only patients who had a known time of insult that fell within a 6-hour window from initial insult to ventriculostomy were accepted into the study. Control CSF came from ventricular fluid in patients undergoing shunt placement for normal pressure hydrocephalus. Both MMP-2 and MMP-9 were measured with gelatin zymography and MMP-3 with Western immunoblot. RESULTS: We found a significant elevation in the levels of the latent form of MMP-9 (92-kD) in the CSF obtained at the time of arrival (P < 0.05). Elevated levels of MMP-2 were detected in plasma at 72 hours, but not in the CSF. Using albumin from both CSF and blood, we calculated the MMP-9 index, which was significantly increased in the CSF, indicating endogenous MMP production. Western immunoblot showed elevated levels of MMP-3 in CSF at all times measured, whereas MMP-3 was not detected in the CSF of normal pressure hydrocephalus. CONCLUSION: We show that MMPs are increased in the CSF of TBI patients. Although the number of patients was small, the results were robust and clearly demonstrated increases in MMP-3 and MMP-9 in ventricular CSF in TBI patients compared with controls. Although these preliminary results will need to be replicated, we propose that MMPs may be important in blood-brain barrier opening and hemorrhage secondary to brain injury in patients.	[Grossetete, Mark; Arko, Leopold; Rosenberg, Gary A.] Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA; [Rosenberg, Gary A.] Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; [Phelps, Jeremy; Yonas, Howard] Univ New Mexico, Hlth Sci Ctr, Dept Neurosurg, Albuquerque, NM 87131 USA	Rosenberg, GA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurol, MSC 10 5620, Albuquerque, NM 87131 USA.	grosenberg@salud.unm.edu		Arko, Leopold/0000-0003-1052-5671	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS045847, RO1 NS052305]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052305, R01NS045847] Funding Source: NIH RePORTER	This study was supported by grants from University of New Mexico Health Sciences Center Clinical Translational Science Center Research Core Pilot Project Award in Clinical and Translational Research and Department of Health and Human Services/Public Health Service/Public Health Service/National Institutes of Health/National Center for Research Resources/General Clinical Research Center grant MO1RR00997 and National Institutes of Health grant to Gary A. Rosenberg, M.D. (RO1 NS045847 and RO1 NS052305). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Abilleira S, 2003, J NEUROSURG, V99, P65, DOI 10.3171/jns.2003.99.1.0065; Adair JC, 2004, STROKE, V35, pE159, DOI 10.1161/01.STR.0000127420.10990.76; Alvarez-Sabin J, 2004, STROKE, V35, P1316, DOI 10.1161/01.STR.0000126827.69286.90; Asahi M, 2001, J NEUROSCI, V21, P7724; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Langbein John H., 2006, TRAUMATIC BRAIN INJU, P1; Leppert D, 2000, CLIN INFECT DIS, V31, P80, DOI 10.1086/313922; Leppert D, 2001, BRAIN RES REV, V36, P249, DOI 10.1016/S0165-0173(01)00101-1; Liuzzi GM, 2002, MULT SCLER, V8, P222, DOI 10.1191/1352458502ms800oa; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Mun-Bryce S, 2002, BRAIN RES, V933, P42, DOI 10.1016/S0006-8993(02)02303-X; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 2002, NEUROSCIENTIST, V8, P586, DOI 10.1177/1073858402238517; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Silva Y, 2005, STROKE, V36, P86, DOI 10.1161/01.STR.0000149615.51204.0b; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	34	96	101	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2009	65	4					702	708		10.1227/01.NEU.0000351768.11363.48			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	502WY	WOS:000270492300015	19834375	Green Accepted			2021-06-18	
J	Alla, S; Sullivan, SJ; Hale, L; McCrory, P				Alla, S.; Sullivan, S. J.; Hale, L.; McCrory, P.			Self-report scales/checklists for the measurement of concussion symptoms: a systematic review	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; RETURN-TO-PLAY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL PERFORMANCE; NEUROCOGNITIVE PERFORMANCE; CEREBRAL CONCUSSION	Objective: To identify self-reported sport concussion symptom scales and to describe the psychometric properties of these identified scales. Design: Systematic review. Intervention: PubMed, Medline, CINAHL, Scopus, Web of Science, Sport Discus, PsycINFO and AMED were searched from their establishment until December 2008. The medical subject heading terms "brain concussion'', "signs or symptoms'' and "athletic injuries''. The search was limited to articles published in English. An additional search of the reference lists of the retrieved articles was conducted. Only full-text articles were considered for this study and these were retrieved to determine whether they met the inclusion criteria. Results: The initial search resulted in 421 articles, which were reduced to 290 articles after removing duplicates. The hand search resulted in 17 articles, thus giving a total of 307 articles. Full text was available for 295 articles of which 60 met the criteria for inclusion. The excluded 235 articles were case reports, reviews and guidelines on concussion management or studies that had not used a symptom scale or checklist. Conclusions: Six core scales were identified with a broad range of symptom items but with limited information on their psychometric properties. There were numerous derivative scales reported, most of which have not been methodically developed or subjected to scientific scrutiny. Despite this, they do make a contribution to the detection, assessment and return to play decisions but there is a need for the clinical user to be aware that many of these scales have "evolved'' rather than being scientifically developed.	[Alla, S.; Sullivan, S. J.; Hale, L.] Univ Otago, Ctr Physiotherapy Res, Dunedin, New Zealand; [McCrory, P.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia	McCrory, P (corresponding author), POB 93 Shoreham, Melbourne, Vic 3916, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT., 1989, MILD HEAD INJURY, P257; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce JM, 2004, NEUROLOGY, V63, P1516; Cameron KL, 1999, J ATHL TRAINING, V34, P34; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Irving DB, 2006, J SCI MED SPORT, V9, P11, DOI 10.1016/j.jsams.2006.02.004; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; JANUSZ J, 2004, BRIT J SPORT MED, V36, P659; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LECLERC S, 2004, ASSESSMENT CONCUSSIO; Lovell M.R., 2004, TRAUMATIC BRAIN INJU; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Lovell MR., 2000, IMPACT IMMEDIATE POS; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P69; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Meyer A, 1904, AM J INSANITY, V60, P373, DOI 10.1176/ajp.60.3.373; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Patel AV, 2007, J ATHL TRAINING, V42, P66; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2004, NEUROSURGERY, V55, P303; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; RANDOLPH C, 2006, CONCUSSION SYMPTOM I; RECKASE MD, 2000, HDB PSYCHOL ASSESSME, P43; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOL AS; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Thompson B., 2004, EXPLORATORY CONFIRMA; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	102	96	96	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I3	I12		10.1136/bjsm.2009.058339			10	Sport Sciences	Sport Sciences	450YO	WOS:000266438100002	19433422				2021-06-18	
J	Barr, RG; Barr, M; Fujiwara, T; Conway, J; Catherine, N; Brant, R				Barr, Ronald G.; Barr, Marilyn; Fujiwara, Takeo; Conway, Jocelyn; Catherine, Nicole; Brant, Rollin			Do educational materials change knowledge and behaviour about crying and shaken baby syndrome? A randomized controlled trial	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; AGE-RELATED INCIDENCE; SLEEP POSITION; PERPETRATOR; INFANTS; TRIGGER; CURVE; POWER	Background: Shaken baby syndrome often occurs after shaking in response to crying bouts. We questioned whether the use of the educational materials from the Period of PURPLE Crying program would change maternal knowledge and behaviour related to shaking. Methods: We performed a randomized controlled trial in which 1279 mothers received materials from the Period of PURPLE Crying program or control materials during a home visit by a nurse by 2 weeks after the birth of their child. At 5 weeks, the mothers completed a diary to record their behaviour and their infants' behaviour. Two months after giving birth, the mothers completed a telephone survey to assess their knowledge and behaviour. Results: The mean score (range 0-100 points) for knowledge about infant crying was greater among mothers who received the PURPLE materials (63.8 points) than among mothers who received the control materials (58.4 points) (difference 5.4 points, 95% confidence interval [CI] 4.1 to 6.5 points). The mean scores were similar for both groups for shaking knowledge and reported maternal responses to crying, inconsolable crying and self-talk responses. Compared with mothers who received control materials, mothers who received the PURPLE materials reported sharing information about walking away if frustrated more often (51.5% v. 38.5%, difference 13.0%, 95% CI 6.9% to 19.2%), the dangers of shaking (49.3% v. 36.4%, difference 12.9%, 95% CI 6.8% to 19.0%), and infant crying (67.6% v. 60.0%, difference 7.6%, 95% CI 1.7% to 13.5%). Walking away during inconsolable crying was significantly higher among mothers who received the PURPLE materials than among those who received control materials (0.067 v. 0.039 events per day, rate ratio 1.7, 95% CI 1.1 to 2.6). Interpretation: The receipt of the Period of PURPLE Crying materials led to higher maternal scores for knowledge about infant crying and for some behaviours considered to be important for the prevention of shaking. (Clinical-Trials. gov trial register no. NCT00175422.)	[Barr, Ronald G.; Fujiwara, Takeo; Catherine, Nicole] Univ British Columbia, Child & Family Res Inst, Ctr Community Child Hlth Res, Vancouver, BC V6H 3V4, Canada; [Barr, Ronald G.; Fujiwara, Takeo] Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1M9, Canada; [Brant, Rollin] Univ British Columbia, Dept Stat, Vancouver, BC V5Z 1M9, Canada; [Barr, Marilyn; Conway, Jocelyn] BC Childrens Hosp, Prevent Shaken Baby Syndrome BC, Vancouver, BC, Canada; [Barr, Marilyn] Natl Ctr Shaken Baby Syndrome, Ogden, UT USA	Barr, RG (corresponding author), Univ British Columbia, Child & Family Res Inst, Ctr Community Child Hlth Res, 4480 Oak St,L408, Vancouver, BC V6H 3V4, Canada.	rbarr@cw.bc.ca		Brant, Rollin/0000-0002-8026-2451	British Columbia Ministry of Children and Family Development; British Columbia Children's Hospital; Human Early Learning Partnership; Child and Family Research Institute es; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21790593] Funding Source: KAKEN	This study was supported by the British Columbia Ministry of Children and Family Development, the British Columbia Children's Hospital, the Human Early Learning Partnership, and a Child and Family Research Institute establishment grant to Ronald Barr. None of the funding agencies had any role in the design and conduct of the study; the collection, management, analysis and interpretation of the data; or the preparation, review or approval of the manuscript.	[Anonymous], 2001, Paediatr Child Health, V6, P663; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr R. G., 1997, RONNICLOG BABYS DAY; Barr R. G., 2006, ENCY EARLY CHILDHOOD, P1; Barr R. G., 1985, BABYS DAY DIARY; Barr R.G, 2004, PERIOD PURPLE CRYING; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Barr RG, 2005, J DEV BEHAV PEDIATR, V26, P14; BARR RG, 1989, PEDIATRICS, V84, P514; BARR RG, 1988, ARCH DIS CHILD, V63, P380, DOI 10.1136/adc.63.4.380; BARR RG, 1990, DEV MED CHILD NEUROL, V32, P356; BARR RG, PEDIATRICS IN PRESS; Barr RG, 2000, HDB DEV PSYCHOPATHOL, P327; Brewster AL, 1998, CHILD ABUSE NEGLECT, V22, P91, DOI 10.1016/S0145-2134(97)00132-4; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; CALINOIU N, 1998, DIARY INDICES PACIFI; *CAN PED SOC, 2002, SAF TIPS PAR; Catherine NLA, 2008, J DEV BEHAV PEDIATR, V29, P508, DOI 10.1097/DBP.0b013e31818d0c0c; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cummings P, 2001, INJURY CONTROL, P64; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; DIAS MS, 2003, AAP NEWS         JUL, P16; *FORCE4 PROD LTD, 1992, CHILD SAF LEARN KEEP; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; *HLTH CAN CAN PED, 1999, BACK SLEEP; HUNZIKER UA, 1986, PEDIATRICS, V77, P641; Kairys SW, 2001, PEDIATRICS, V108, P206; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KLEVENS J, 2003, INFLICTED CHILDHOOD, P269; Kramer MS, 2001, JAMA-J AM MED ASSOC, V286, P322, DOI 10.1001/jama.286.3.322; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; Layzer J. I., 2001, NATL EVALUATION FAMI, VA; Lazoritz S, 1997, CHILD ABUSE NEGLECT, V21, P1009, DOI 10.1016/S0145-2134(97)00061-6; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LEHTONEN L, 1998, PACIFIER USE INFANTS; Little R, 2002, STAT ANAL MISSING DA, V2nd; Majnemer A, 2006, J PEDIATR-US, V149, P623, DOI 10.1016/j.jpeds.2006.05.009; *NAT I CHILD HLTH, 1999, BACK SLEEP SUDD INF; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Soltis J, 2004, BEHAV BRAIN SCI, V27, P443, DOI 10.1017/S0140525X0400010X; St James-Roberts I, 2006, PEDIATRICS, V117, pE1146, DOI 10.1542/peds.2005-2387; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STARLING SP, 1995, PEDIATRICS, V95, P259; STJAMESROBERTS I, 1993, ARCH DIS CHILD, V68, P82, DOI 10.1136/adc.68.1.82; Talvik I, 2008, ACTA PAEDIATR, V97, P782, DOI 10.1111/j.1651-2227.2008.00778.x; WILLINGER M, 1994, PEDIATRICS, V93, P814	46	96	97	0	15	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	MAR 31	2009	180	7					727	733		10.1503/cmaj.081419			7	Medicine, General & Internal	General & Internal Medicine	421MC	WOS:000264362000010	19255065	Bronze, Green Published			2021-06-18	
J	Hwang, SW; Colantonio, A; Chiu, S; Tolomiczenko, G; Kiss, A; Cowan, L; Redelmeier, DA; Levinson, W				Hwang, Stephen W.; Colantonio, Angela; Chiu, Shirley; Tolomiczenko, George; Kiss, Alex; Cowan, Laura; Redelmeier, Donald A.; Levinson, Wendy			The effect of traumatic brain injury on the health of homeless people	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							ADDICTION SEVERITY INDEX; PSYCHIATRIC-DISORDERS; RISK-FACTORS; RELIABILITY; VALIDITY; PREVALENCE; SAMPLE; MEN	Background: We sought to determine the lifetime prevalence of traumatic brain injury and its association with current health conditions in a representative sample of homeless people in Toronto, Ontario. Methods: We surveyed 601 men and 303 women at homeless shelters and meal programs in 2004-2005 (response rate 76%). We defined traumatic brain injury as any self-reported head injury that left the person dazed, confused, disoriented or unconscious. Injuries resulting in unconsciousness lasting 30 minutes or longer were defined as moderate or severe. We assessed mental health, alcohol and drug problems in the past 30 days using the Addiction Severity Index. Physical and mental health status was assessed using the SF-12 health survey. We examined associations between traumatic brain injury and health conditions. Results: The lifetime prevalence among homeless participants was 53% for any traumatic brain injury and 12% for moderate or severe traumatic brain injury. For 70% of respondents, their first traumatic brain injury occurred before the onset of homelessness. After adjustment for demographic characteristics and lifetime duration of homelessness, a history of moderate or severe traumatic brain injury was associated with significantly increased likelihood of seizures (odds ratio [OR] 3.2, 95% confidence interval [CI] 1.8 to 5.6), mental health problems (OR 2.5, 95% CI 1.5 to 4.1), drug problems (OR 1.6, 95% CI 1.1 to 2.5), poorer physical health status (-8.3 points, 95% CI -11.1 to -5.5) and poorer mental health status (-6.0 points, 95% CI -8.3 to -3.7). Interpretation: Prior traumatic brain injury is very common among homeless people and is associated with poorer health.	[Hwang, Stephen W.; Chiu, Shirley] St Michaels Hosp, Ctr Res Inner City Hlth, Keenan Res Ctr Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Hwang, Stephen W.; Redelmeier, Donald A.] Univ Toronto, Div Gen Internal Med, Dept Med, Toronto, ON M5S 1A1, Canada; [Tolomiczenko, George] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada; [Colantonio, Angela] Univ Toronto, Toronto Rehabil Inst, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5S 1A1, Canada; [Kiss, Alex] Sunnybrook Hlth Sci Ctr, Dept Res Design & Biostat, Toronto, ON, Canada; [Redelmeier, Donald A.] Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON, Canada; [Tolomiczenko, George] Crohns & Colitis Fdn Canada, Toronto, ON, Canada; [Cowan, Laura] St Hlth Community Nursing Fdn, Toronto, ON, Canada	Hwang, SW (corresponding author), St Michaels Hosp, Ctr Res Inner City Hlth, Keenan Res Ctr Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	hwangs@smh.toronto.on.ca	Hwang, Stephen W./D-2297-2011	Hwang, Stephen W./0000-0002-1276-1101; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Canada Research Chair in Medical Decision SciencesCanada Research Chairs; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS014129] Funding Source: NIH RePORTER	Stephen Hwang is the recipient of a New Investigator Award from the Canadian Institutes of Health Research. Donald Redelmeier is supported by the Canada Research Chair in Medical Decision Sciences.; We thank Marko Katic, Department of Research Design and Biostatistics, Sunnybrook Health Sciences Centre, for expert programming and analyses. We are grateful for collaboration with the Institute for Clinical Evaluative Sciences. The views expressed in this publication are the views of the authors and do not necessarily reflect the views of the Ontario Ministry of Health and Long-Term Care or any of the other above-named organizations.	Bremner AJ, 1996, BRIT J PSYCHIAT, V169, P434, DOI 10.1192/bjp.169.4.434; BROWN P, 2006, STREET NEEDS ASSESSM; Burt M.R., 2001, HELPING AM HOMELESS; Burt MarthaR., 1999, HOMELESSNESS PROGRAM; *CIT TO, 2003, TOR REP CARD HOUS HO; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DRAKE RE, 1995, J STUD ALCOHOL, V56, P161, DOI 10.15288/jsa.1995.56.161; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Herman DB, 1997, AM J PUBLIC HEALTH, V87, P249, DOI 10.2105/AJPH.87.2.249; Housing Family and Social Statistics Division, 2002, ETHN DIV SURV QUEST; Hwang SW, 2005, J URBAN HLTH S2, V82, pii46; Joyner LM, 1996, SUBST USE MISUSE, V31, P729, DOI 10.3109/10826089609045836; Kass F, 1990, J Neuropsychiatry Clin Neurosci, V2, P15; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KELLY G, 2007, BRAIN IMPAIR, V8, P262, DOI DOI 10.1375/BRIM.8.3.262; Kushel MB, 2003, ARCH INTERN MED, V163, P2492, DOI 10.1001/archinte.163.20.2492; Larson CO, 2002, HEALTH SERV RES, V37, P733, DOI 10.1111/1475-6773.00046; McGahan, 1986, ADDICTION SEVERITY I; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; National Center for Injury Prevention and Control, 2008, WHAT IS TRAUM BRAIN; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Robertson MJ, 1996, ANNU REV PUBL HEALTH, V17, P311; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Shinn M, 1998, AM J PUBLIC HEALTH, V88, P1651, DOI 10.2105/AJPH.88.11.1651; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Solliday-McRoy C, 2004, J NERV MENT DIS, V192, P471, DOI 10.1097/01.nmd.0000131962.30547.26; Spence S, 2004, J ROY SOC MED, V97, P375, DOI 10.1258/jrsm.97.8.375; SUSSER E, 1993, EPIDEMIOL REV, V15, P546, DOI 10.1093/oxfordjournals.epirev.a036133; Waldmann CA, 2004, HLTH HOMELESS PERSON, P237; Ware JE, 1995, SF 12 SCORE SF 12 PH; Zakrison TL, 2004, J URBAN HEALTH, V81, P596, DOI 10.1093/jurban/jth143; ZANIS DA, 1994, J SUBST ABUSE TREAT, V11, P541, DOI 10.1016/0740-5472(94)90005-1	35	96	96	0	5	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA	0820-3946			CAN MED ASSOC J	Can. Med. Assoc. J.	OCT 7	2008	179	8					779	784		10.1503/cmaj.080341			6	Medicine, General & Internal	General & Internal Medicine	353CL	WOS:000259543600015	18838453	Green Published, Bronze			2021-06-18	
J	Wymann, NME; Holzle, A; Zachariou, Z; Iizuka, T				Wymann, Nicole M. Eggensperger; Hoelzle, Alexander; Zachariou, Zacharias; Iizuka, Tateyuki			Pediatric craniofacial trauma	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							FACIAL FRACTURES; MAXILLOFACIAL FRACTURES; JAW FRACTURES; CHILDREN; SKELETON; ETIOLOGY; INJURIES; AGE; PATTERNS; NIGERIA	Purpose: Maxillofacial and skull fractures occur with concomitant injuries in pediatric trauma patients. The aim of this study was to determine the causes and distributions of maxillofacial and skull fractures as well as concomitant injuries of pediatric patients in Switzerland. Results were compared with worldwide studies. Materials and Methods: A retrospective review was conducted of 291 pediatric patients with maxillofacial and skull fractures presenting to a level-I trauma center over a 3-year span. Data concerning the mechanism of the accident and the topographic location of the injuries were analyzed. Results: The most common causes were falls (64%), followed by traffic (22%) and sports-related accidents (9%). Fifty-four percent of the fractures occurred in the skull vault and 37% in the upper and middle facial third. One third of the patients (n = 95) suffered concomitant injuries, mostly cerebral concussions (n = 94). Conclusions: The spectrum of craniofacial injuries is related to the specific developmental stage of the craniofacial skeleton. It is probable that national prevention programs will have a positive effect on reducing the incidence of falls. Standardization of studies is needed for international comparison. (C) 2008 American Association of Oral and Maxillofacial Surgeons.	[Wymann, Nicole M. Eggensperger; Hoelzle, Alexander; Iizuka, Tateyuki] Univ Bern, Dept Craniomaxillofacial Surg, Inselspital, CH-3010 Bern, Switzerland; [Zachariou, Zacharias] Univ Bern, Inselspital, Dept Pediat Surg, CH-3010 Bern, Switzerland	Wymann, NME (corresponding author), Univ Bern, Dept Craniomaxillofacial Surg, Inselspital, CH-3010 Bern, Switzerland.	nicole.eggensperger@insel.ch					ADEKEYE EO, 1980, J ORAL SURG, V38, P355; ANDERSON PJ, 1995, INJURY, V26, P47, DOI 10.1016/0020-1383(95)90552-9; Bamjee Y, 1996, BRIT J ORAL MAX SURG, V34, P298, DOI 10.1016/S0266-4356(96)90006-6; Bataineh AB, 1998, ORAL SURG ORAL MED O, V86, P31, DOI 10.1016/S1079-2104(98)90146-9; CARROLL MJ, 1987, BRIT DENT J, V163, P289, DOI 10.1038/sj.bdj.4806278; Chan J, 2004, INT J PEDIATR OTORHI, V68, P877, DOI 10.1016/j.ijporl.2004.01.021; CHIDZONGA MM, 1987, CENT AFR J MED, V33, P274; Gassner R, 2004, J ORAL MAXIL SURG, V62, P399, DOI 10.1016/j.joms.2003.05.013; GUSSACK GS, 1987, LARYNGOSCOPE, V97, P925; GUVEN O, 1992, J CRANIO MAXILL SURG, V20, P244, DOI 10.1016/S1010-5182(05)80435-4; Haug RH, 2000, ORAL SURG ORAL MED O, V90, P126, DOI 10.1067/moe.2000.107974; Holland AJA, 2001, PEDIATR EMERG CARE, V17, P157, DOI 10.1097/00006565-200106000-00002; Iida S, 2001, INT J ORAL MAX SURG, V30, P286, DOI 10.1054/ijom.2001.0056; Jaber M A, 1997, Int J Paediatr Dent, V7, P39; Jarupoonphol Vithya, 2001, Journal of the Medical Association of Thailand, V84, P1541; KILLEY HC, 1988, BANKS; Klenk G, 2003, J CRANIOFAC SURG, V14, P78, DOI 10.1097/00001665-200301000-00014; Koltai PJ, 1996, PEDIATR CLIN N AM, V43, P1253, DOI 10.1016/S0031-3955(05)70518-6; Lallier M, 1999, J PEDIATR SURG, V34, P1060, DOI 10.1016/S0022-3468(99)90564-X; LeFort R., 1901, REV CHIR PARIS, V23, P208; MCGRAW BL, 1990, ARCH OTOLARYNGOL, V116, P41; Motamedi MHK, 2003, J ORAL MAXIL SURG, V61, P61, DOI 10.1053/joms.2003.50049; Oji C, 1999, BRIT J ORAL MAX SURG, V37, P106, DOI 10.1054/bjom.1997.0083; PORTER SR, 1987, BRIT DENT J, V163, P144, DOI 10.1038/sj.bdj.4806222; POSNICK JC, 1993, J ORAL MAXIL SURG, V51, P836, DOI 10.1016/S0278-2391(10)80098-9; Qudah MA, 2002, ORAL SURG ORAL MED O, V94, P310, DOI 10.1067/moe.2002.127406; ROWE NL, 1968, J ORAL SURG, V26, P505; STARKHAMMAR H, 1982, CLIN OTOLARYNGOL, V7, P405, DOI 10.1111/j.1365-2273.1982.tb01404.x; STYLOGIANNI L, 1991, BRIT J ORAL MAX SURG, V29, P9, DOI 10.1016/0266-4356(91)90164-Z; Tan W.K.S., 1999, Annals Academy of Medicine Singapore, V28, P625; TANAKA N, 1993, J CRANIO MAXILL SURG, V21, P289, DOI 10.1016/S1010-5182(05)80349-X; THALLER SR, 1992, ANN PLAS SURG, V29, P348, DOI 10.1097/00000637-199210000-00012; VOSS R, 1982, J MAXILLOFAC SURG, V10, P146, DOI 10.1016/S0301-0503(82)80031-3; WAITE DE, 1973, PEDIATRICS, V51, P551; ZACHARIADES N, 1990, J CRANIO MAXILL SURG, V18, P151, DOI 10.1016/S1010-5182(05)80509-8; Zerfowski M, 1998, Clin Oral Investig, V2, P120, DOI 10.1007/s007840050056	36	96	98	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JAN	2008	66	1					58	64		10.1016/j.joms.2007.04.023			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	245VG	WOS:000251966300010	18083416				2021-06-18	
J	Yen, K; Loblad, KO; Scheurer, E; Ozdoba, C; Thali, MJ; Aghayev, E; Jackowski, C; Anon, J; Frickey, N; Zwygart, K; Weis, J; Dirnhofer, R				Yen, Kathrin; Loeblad, Karl-Olof; Scheurer, Eva; Ozdoba, Christoph; Thali, Michael J.; Aghayev, Emin; Jackowski, Christian; Anon, Javier; Frickey, Nathalie; Zwygart, Karin; Weis, Joachim; Dirnhofer, Richard			Post-mortem forensic neuroimaging: Correlation of MSCT and MRI findings with autopsy results	FORENSIC SCIENCE INTERNATIONAL			English	Article						CT; MRI; forensic imaging; virtopsy; post-mortem neuroradiology	MULTISLICE COMPUTED-TOMOGRAPHY; RESONANCE-IMAGING MRI; TRAUMATIC BRAIN-INJURY; CLINICAL-EXPERIENCE; VIRTUAL AUTOPSY; CT; EPIDEMIOLOGY; VIRTOPSY; VICTIMS; HEMORRHAGE	Multislice-computed tomography (MSCT) and magnetic resonance imaging (MRI) are increasingly used for forensic purposes. Based on broad experience in clinical neuroimaging, post-mortem MSCT and MRI were performed in 57 forensic cases with the goal to evaluate the radiological methods concerning their usability for forensic head and brain examination. An experienced clinical radiologist evaluated the imaging data. The results were compared to the autopsy findings that served as the gold standard with regard to common forensic neurotrauma findings such as skull fractures, soft tissue lesions of the scalp, various forms of intracranial hemorrhage or signs of increased brain pressure. The sensitivity of the imaging methods ranged from 100% (e.g., heat-induced alterations, intracranial gas) to zero (e.g., mediobasal impression marks as a sign of increased brain pressure, plaques jaunes). The agreement between MRI and CT was 69%. The radiological methods prevalently failed in the detection of lesions smaller than 3 mm of size, whereas they were generally satisfactory concerning the evaluation of intracranial hemorrhage. Due to its advanced 2D and 3D post-processing possibilities, CT in particular possessed certain advantages in comparison with autopsy with regard to forensic reconstruction. MRI showed forensically relevant findings not seen during autopsy in several cases. The partly limited sensitivity of imaging that was observed in this retrospective study was based on several factors: besides general technical limitations it became apparent that clinical radiologists require a sound basic forensic background in order to detect specific signs. Focused teaching sessions will be essential to improve the outcome in future examinations. On the other hand, the autopsy protocols should be further standardized to allow an exact comparison of imaging and autopsy data. In consideration of these facts, MRI and CT have the power to play an important role in future forensic neuropathological examination. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	Med Univ Graz, Ctr Clin Theoret Med, Dept Forens Radiol, A-8010 Graz, Austria; Univ Bern, Inst Forens Med, CH-3012 Bern, Switzerland; Univ Geneva, Dept Neuroradiol, Geneva, Switzerland; Insel Hosp Bern, Dept Radiol, Bern, Switzerland; Univ Hosp Vienna, Dept Anesthesiol & Intens Care, Vienna, Austria; Univ Bern, Dept Clin Res Magnet Resonance Spectroscopy & M, Bern, Switzerland; Rhein Westfal TH Univ, Inst Neuropathol, Aachen, Germany	Yen, K (corresponding author), Med Univ Graz, Ctr Clin Theoret Med, Dept Forens Radiol, Harrachgasse 21, A-8010 Graz, Austria.	kathrin.yen@medtini-graz.at	Weis, Joachim/G-1984-2014; Scheurer, Eva/C-6536-2011; Scheurer, Eva/AAE-6161-2019	Weis, Joachim/0000-0003-3280-6773; Scheurer, Eva/0000-0002-2742-0422; lovblad, karl-olof/0000-0003-2768-9779			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Aghayev E, 2004, NEURORADIOLOGY, V46, P559, DOI 10.1007/s00234-004-1212-4; Bardainne M, 1996, ARCH PEDIATRIE, V3, P661, DOI 10.1016/0929-693X(96)87086-2; Blamire AM, 1999, ACTA RADIOL, V40, P593, DOI 10.3109/02841859909175593; BOYKO OB, 1994, ARCH PATHOL LAB MED, V118, P219; BROGDON BG, 1998, FORENSIC RADIOLOGY; Brookes JAS, 1996, LANCET, V348, P1139, DOI 10.1016/S0140-6736(96)02287-8; DONCHIN Y, 1994, J TRAUMA, V37, P552, DOI 10.1097/00005373-199410000-00006; Englund E, 2004, J NEUROL, V251, P350, DOI 10.1007/s00415-004-0318-2; Ezawa H, 2003, PATHOL INT, V53, P865, DOI 10.1046/j.1440-1827.2003.01573.x; Griffiths PD, 2003, AM J NEURORADIOL, V24, P22; HARRIS LS, 1991, FORENSIC SCI INT, V50, P179, DOI 10.1016/0379-0738(91)90149-D; Hart BL, 1996, AM J FOREN MED PATH, V17, P217, DOI 10.1097/00000433-199609000-00008; IWAMA T, 1994, NEURORADIOLOGY, V36, P33, DOI 10.1007/BF00599191; Iwase H, 1998, FORENSIC SCI INT, V94, P9, DOI 10.1016/S0379-0738(98)00055-3; Jackowski C, 2005, J FORENSIC SCI, V50, P1175; Lovblad KO, 2006, EUR RADIOL, V16, P1253, DOI 10.1007/s00330-005-0103-3; Lovblad KO, 2000, STROKE, V31, P539, DOI 10.1161/01.STR.31.2.539; LUDWIG B, 1983, AM J NEURORADIOL, V4, P27; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; Messori A, 2003, STROKE, V34, P376, DOI 10.1161/01.STR.0000055022.86811.10; Myers JC, 1999, INT J LEGAL MED, V113, P33, DOI 10.1007/s004140050275; *NEUR GROUP MRC CF, 2004, APPL NEUROBIOL, V30, P385; Oliver J, 1999, Australas Radiol, V43, P37, DOI 10.1046/j.1440-1673.1999.00615.x; Orakcioglu B, 2005, EXP NEUROL, V193, P369, DOI 10.1016/j.expneurol.2005.01.017; OZDOBA C, 2004, AM J NEURORADIOL, V47, P411; PAPE KE, 1983, J PEDIATR-US, V102, P275, DOI 10.1016/S0022-3476(83)80543-5; Paperno S, 2005, ROFO-FORTSCHR RONTG, V177, P130, DOI 10.1055/s-2004-813735; Parizel PM, 2002, INTENS CARE MED, V28, P85, DOI 10.1007/s00134-001-1160-y; Patriquin L, 2001, J MAGN RESON IMAGING, V13, P277, DOI 10.1002/1522-2586(200102)13:2<277::AID-JMRI1040>3.0.CO;2-W; ROS PR, 1990, MAGN RESON IMAGING, V8, P303, DOI 10.1016/0730-725X(90)90103-9; SCHUMACHER M, 1983, FORTSCHR RONTG NEUEN, V139, P58, DOI 10.1055/s-2008-1055840; Schumacher M, 1985, Beitr Gerichtl Med, V43, P95; Shen W C, 1993, Gaoxiong Yi Xue Ke Xue Za Zhi, V9, P690; Stein KM, 2000, INT J LEGAL MED, V114, P15, DOI 10.1007/s004149900124; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; SUNGSTROM T, 2005, TIDSSKR NOR LAEGEFOR, V125, P1310; Thali MJ, 2003, FORENSIC SCI INT, V138, P8, DOI 10.1016/S0379-0738(03)00225-1; Thali MJ, 2003, J FORENSIC SCI, V48, P386; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; von Wild KRH, 2005, ACTA NEUROCHIR SUPPL, V93, P15; WALLACE SK, 1994, RADIOLOGY, V193, P263, DOI 10.1148/radiology.193.1.8090904; WHITBY EH, 2005, IMAGING FETUS ADJUNC; Woodward PJ, 1997, AM J ROENTGENOL, V168, P41, DOI 10.2214/ajr.168.1.8976917; Yen K, 2006, AM J NEURORADIOL, V27, P70; Yen K, 2005, INT J LEGAL MED, V119, P129, DOI 10.1007/s00414-004-0507-7; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	48	96	105	0	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	NOV 15	2007	173	1					21	35		10.1016/j.forsciint.2007.01.027			15	Medicine, Legal	Legal Medicine	220YM	WOS:000250193300004	17336008				2021-06-18	
J	Betker, AL; Desai, A; Nett, C; Kapadia, N; Szturm, T				Betker, Aimee L.; Desai, Ankur; Nett, Cristabel; Kapadia, Naaz; Szturm, Tony			Game-based exercises for dynamic short-sitting balance rehabilitation of people with chronic spinal cord and traumatic brain injuries	PHYSICAL THERAPY			English	Article							VIRTUAL-REALITY; STROKE; TECHNOLOGY; MOBILITY; THERAPY; TASK; AGE	Background and Purpose Goal-oriented, task-specific training has been shown to improve function; however, it can be difficult to maintain patient interest. This report describes a rehabilitation protocol for the maintenance of balance in a short-sitting position following spinal cord and head injuries by use of a center-of-pressure-controlled video game-based tool. The scientific justification for the selected treatment is discussed. Case Descriptions Three adults were treated: 1 young adult with spina bifida (T10 and L1-L2), 1 middle-aged adult with complete paraplegia (complete. lesion at T11-L1), and 1 middle-aged adult with traumatic brain injury. All patients used wheelchairs full-time. Outcomes The patients showed increased motivation to perform the game-based exercises and increased dynamic short-sitting balance. Discussion The patients exhibited increases in practice volume and attention span during training with the game-based tool. In addition, they demonstrated substantial improvements in dynamic balance control. These observations indicate that a video game-based exercise approach can have a substantial positive effect by improving dynamic short-sitting balance.	Univ Manitoba, Div Phys Therapy, Sch Med Rehabil, Winnipeg, MB R3E 0T6, Canada; Univ Manitoba, Dept Elect & Comp Engn, Winnipeg, MB R3T 2N2, Canada	Szturm, T (corresponding author), Univ Manitoba, Div Phys Therapy, Sch Med Rehabil, R106-771 McDermot Ave, Winnipeg, MB R3E 0T6, Canada.	ptsturm@cc.umanitoba.ca		Kapadia, Naaz/0000-0001-7999-7488			Allum JHJ, 2002, GAIT POSTURE, V16, P264, DOI 10.1016/S0966-6362(02)00011-5; Baratto L, 2002, MOTOR CONTROL, V6, P246, DOI 10.1123/mcj.6.3.246; Betker AL, 2005, P ANN INT IEEE EMBS, P2341, DOI 10.1109/IEMBS.2005.1616935; Betker AL, 2006, ARCH PHYS MED REHAB, V87, P1141, DOI 10.1016/j.apmr.2006.04.010; Betker AL, 2005, IEEE T BIO-MED ENG, V52, P345, DOI 10.1109/TBME.2004.840466; Bourbonnais D, 2002, AM J PHYS MED REHAB, V81, P890, DOI 10.1097/00002060-200212000-00002; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Cogan A., 1977, 4 ANN C SYST DEV DIS, P187; COLLINS JJ, 1995, EXP BRAIN RES, V104, P480, DOI 10.1007/BF00231982; Cunningham D, 1999, ST HEAL T, V62, P90; Douglas J, 2005, DIABETES SELF MANAG, V22, P55; Douglas J, 2005, DIABETES SELF MANAG, V22, P51; Douglas Jean, 2005, Diabetes Self Manag, V22, P47; Dozza Marco, 2005, J Neuroeng Rehabil, V2, P13, DOI 10.1186/1743-0003-2-13; Edgerton VR, 2006, J NEUROTRAUM, V23, P560, DOI 10.1089/neu.2006.23.560; Fung J, 2006, CYBERPSYCHOL BEHAV, V9, P157, DOI 10.1089/cpb.2006.9.157; GARR JH, 1998, NEUROLOGICAL REHABIL; Geiger RA, 2001, PHYS THER, V81, P995, DOI 10.1093/ptj/81.4.995; Glanz M, 1997, J ROY SOC MED, V90, P33, DOI 10.1177/014107689709000110; Harkema SJ, 2001, NEUROSCIENTIST, V7, P455, DOI 10.1177/107385840100700514; Huxham FE, 2001, AUST J PHYSIOTHER, V47, P89, DOI 10.1016/S0004-9514(14)60300-7; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Kwakkel G, 2006, DISABIL REHABIL, V28, P823, DOI 10.1080/09638280500534861; Malone T. W., 1982, P C HUM FACT COMP SY, P63; Nelson DL, 1996, AM J OCCUP THER, V50, P639, DOI 10.5014/ajot.50.8.639; Norris JA, 2005, J BIOMECH, V38, P1263, DOI 10.1016/j.jbiomech.2004.06.014; O'Connor TJ, 2000, NEUROREHAB NEURAL RE, V14, P21, DOI 10.1177/154596830001400103; Remple MS, 2001, BEHAV BRAIN RES, V123, P133, DOI 10.1016/S0166-4328(01)00199-1; Richards CL, 2004, NEUROREHAB NEURAL RE, V18, P199, DOI 10.1177/1545968304269397; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Szturm T, 1998, J VESTIBUL RES-EQUIL, V8, P381; Todorov E, 1997, J MOTOR BEHAV, V29, P147, DOI 10.1080/00222899709600829; Tsang WWN, 2004, MED SCI SPORT EXER, V36, P658, DOI 10.1249/01.MSS.0000122077.87090.2E; Webster JS, 2001, ARCH PHYS MED REHAB, V82, P769, DOI 10.1053/apmr.2001.23201; Yoo EY, 2006, CLIN REHABIL, V20, P388, DOI 10.1191/0269215506cr962oa; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91	37	96	98	2	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	OCT	2007	87	10					1389	1398		10.2522/ptj.20060229			10	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	217WA	WOS:000249976800014	17712036	Bronze			2021-06-18	
J	Zhang, ZQ; Ottens, AK; Sadasivan, S; Kobeissy, FH; Fang, T; Hayes, RL; Wang, KKW				Zhang, Zhiqun; Ottens, Andrew K.; Sadasivan, Shankar; Kobeissy, Firas H.; Fang, Tie; Hayes, Ronald L.; Wang, Kevin K. W.			Calpain-mediated collapsin response mediator protein-1,-2, and-4 proteolysis after neurotoxic and traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						calpain; CRMP; excitotoxicity; proteolysis; TBI	CULTURED HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; CELL-DEATH; NEUROBLASTOMA-CELLS; SIGNALING PATHWAYS; CEREBRAL-ISCHEMIA; NERVOUS-SYSTEM; RHO-KINASE; CRMP-2; RAT	Collapsin response mediator proteins (CRMPs) are important molecules in neurite outgrowth and axonal guidance. Within the CRMP family, CRMP-2 has been implicated in several neurological diseases (Alzheimer's, epilepsy, and ischemia). Here, we investigated the integrity of CRMPs (CRMP-1, -2, -4, -5) after in vitro neurotoxin treatment and in vivo traumatic brain injury (TBI). After maitotoxin (MTX) and NMDA treatment of primary cortical neurons, a dramatic decrease of intact CRMP-1, -2 and -4 proteins were observed, accompanied by the appearance of distinct 55-kDa and 58-kDa breakdown products (BDP) for CRMP-2 and -4, respectively. Inhibition of calpain activation prevented NMDA-induced CRMP-2 proteolysis and redistribution of CRMP-2 from the neurites to the cell body, while attenuating neurite damage and neuronal cell injury. Similarly, CRMP-1, -2, and -4 were also found degraded in rat cortex and hippocampus following controlled cortical impact (CCI), an in vivo model of TBI. The appearance of the 55-kDa CRMP-2 BDP was observed to increase, in a time-dependent manner, between 24 and 48 h in the ipsilateral cortex, and by 48 hours in the hippocampus. The observed 55-kDa CRMP-2 BDP following TBI was reproduced by in vitro incubation of naive brain lysate with activated calpain-2, but not activated caspase-3. Sequence analysis revealed several possible cleavage sites near the C-terminus of CRMP-2. Collectively, this study demonstrated that CRMP-1, -2, and -4 are degraded following both acute traumatic and neurotoxic injury. Furthermore, calpain-2 was identified as the possible proteolytic mediator of CRMP-2 following excitotoxic injury and TBI, which appears to correlate well with neuronal cell injury and neurite damage. It is possible that the calpain-mediated truncation of CRMPs following TBI may be an inhibiting factor for post-injury neurite regeneration.	Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, McKnight Brain Inst, Gainesville, FL 32610 USA	Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, POB 100256,100 W Newell Dr, Gainesville, FL 32610 USA.	kwang@psychiatry.ufl.edu	Sadasivan, Shankar/C-9620-2009; Ottens, Andrew/K-3352-2012; Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473; Ottens, Andrew/0000-0002-2118-3796	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049175-01-A1] Funding Source: Medline		Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Araujo IM, 2004, J NEUROCHEM, V91, P1322, DOI 10.1111/j.1471-4159.2004.02811.x; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Barzilai A, 2000, ADV RES NEURODEGENER, V8, P59; Bretin S, 2005, J COMP NEUROL, V486, P1, DOI 10.1002/cne.20465; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Butterfield DA, 2003, J NEUROCHEM, V86, P1313, DOI 10.1046/j.1471-4159.2003.01948.x; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Chiesa R, 1998, J NEUROCHEM, V70, P1474; Chung MA, 2005, NEUROREPORT, V16, P1647, DOI 10.1097/01.wnr.0000176520.49841.e6; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; Czech T, 2004, NEUROCHEM RES, V29, P2189, DOI 10.1007/s11064-004-7025-3; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; Fukiage C, 1997, BBA-MOL BASIS DIS, V1361, P304, DOI 10.1016/S0925-4439(97)00043-4; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Hou ST, 2006, J NEUROSCI, V26, P2241, DOI 10.1523/JNEUROSCI.4485-05.2006; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Johnston-Wilson NL, 2000, MOL PSYCHIATR, V5, P142, DOI 10.1038/sj.mp.4000696; Khawaja X, 2004, J NEUROSCI RES, V75, P451, DOI 10.1002/jnr.10869; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Kowara R, 2005, J NEUROCHEM, V95, P466, DOI 10.1111/j.1471-4159.2005.03383.x; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Liu CP, 2003, ACTA PHARMACOL SIN, V24, P1205; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Llansola M, 2000, J PHARMACOL EXP THER, V292, P870; Lopez-Picon FR, 2006, EUR J NEUROSCI, V23, P2686, DOI 10.1111/j.1460-9568.2006.04793.x; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; Mizuno N, 1998, ENDOCRINOLOGY, V139, P1429, DOI 10.1210/en.139.3.1429; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; POHORECKI R, 1990, BRAIN RES, V528, P133, DOI 10.1016/0006-8993(90)90205-P; Quach TT, 2004, MOL CELL NEUROSCI, V25, P433, DOI 10.1016/j.mcn.2003.11.006; Riss TL, 2004, ASSAY DRUG DEV TECHN, V2, P51, DOI 10.1089/154065804322966315; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Schweitzer J, 2005, GENE EXPR PATTERNS, V5, P809, DOI 10.1016/j.modgep.2005.03.009; Tahimic CGT, 2006, BIOCHEM BIOPH RES CO, V340, P1244, DOI 10.1016/j.bbrc.2005.12.132; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Weitzdoerfer R, 2001, J NEURAL TRANSM-SUPP, P95; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang Z, 2006, CELL MOL BIOL LETT, V11, P12, DOI 10.2478/s11658-006-0002-x	58	96	99	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2007	24	3					460	472		10.1089/neu.2006.0078			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	152RQ	WOS:000245379900003	17402852				2021-06-18	
J	Notebaert, AJ; Guskiewicz, KM				Notebaert, AJ; Guskiewicz, KM			Current trends in athletic training practice for concussion assessment and management	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; mild brain injury; evaluation	FOOTBALL PLAYERS; COLLEGIATE; INTERNET	Context: Athletic trainers surveyed in 1999 demonstrated little consensus on the use of concussion grading scales and return-to-play criteria. Most relied on clinical examination or symptom checklists to evaluate athletes with concussion. Objective: To investigate the current trends of certified athletic trainers in concussion assessment and management. Design: Subjects were invited to participate in a 32-question Internet survey. Setting: An Internet link to the survey was e-mailed to the subjects. Patients or Other Participants: A total of 2750 certified athletic trainers and members of the National Athletic Trainers' Association were randomly e-mailed and invited to participate. Main Outcome Measure(s): Survey questions addressed topics including years of certification, number of concussions evaluated each year, methods of assessing concussion, and guidelines used for return to play. Compliance with the recent position statement of the National Athletic Trainers' Association on sport-related concussion was also evaluated. Results: Certified athletic trainers averaged 9.9 +/- 7.3 years of certification and evaluated an average of 8.2 +/- 6.5 concussions per year. To assess concussion, 95% reported using the clinical examination, 85% used symptom checklists, 48% used the Standardized Assessment of Concussion, 18% used neuropsychological testing, and 16% used the Balance Error Scoring System. The most frequently used concussion grading scale and return-to-play guideline belonged to the American Academy of Neurology (30%). When deciding whether to return an athlete to play, certified athletic trainers most often used the clinical examination (95%), return-to-play guidelines (88%), symptom checklists (80%), and player self-report (62%). The most important tools for making a return-to-play decision were the clinical examination (59%), symptom checklists (13%), and return-to-play guidelines (12%). Only 3% of certified athletic trainers surveyed complied with the recent position statement, which advocated using symptom checklists, neuropsychological testing, and balance testing for managing sport-related concussion. Conclusions: Our findings suggest that only a small percentage of certified athletic trainers currently follow the guidelines proposed by the National Athletic Trainers' Association. Various assessment methods and tools are currently being used, but clinicians must continue to implement a combination of methods and tools in order to comply with the position statement.	Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Fetzer Gym CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; Braithwaite D, 2003, FAM PRACT, V20, P545, DOI 10.1093/fampra/cmg509; BRAY C, 2004, 1982 2003 SPORTS SPO; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; *COL MED SOC SPORT, 1994, P MILD BRAIN INJ SPO, P106; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Durand P, 2004, J AM ACAD ORTHOP SUR, V12, P191, DOI 10.5435/00124635-200405000-00007; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 2004, AM J MED SPORTS, V6, P13; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Romanelli F, 2004, PHARMACOTHERAPY, V24, P395, DOI 10.1592/phco.24.4.395.33183; Umefjord G, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e26; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; 2001, J ATHL TRAIN, V36; 2000, CLIN J SPORT MED, V11	27	96	96	0	10	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2005	40	4					320	325					6	Sport Sciences	Sport Sciences	996MO	WOS:000234178200011	16404454				2021-06-18	
J	Yoshiyama, Y; Uryu, K; Higuchi, M; Longhi, L; Hoover, R; Fujimoto, S; McIntosh, T; Lee, VMY; Trojanowski, JQ				Yoshiyama, Y; Uryu, K; Higuchi, M; Longhi, L; Hoover, R; Fujimoto, S; McIntosh, T; Lee, VMY; Trojanowski, JQ			Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model	JOURNAL OF NEUROTRAUMA			English	Article						tau protein; transgenic mouse; repetitive head injury; neurofibrillary tangles; cerebral atrophy; cognitive deficit	CONTROLLED CORTICAL IMPACT; DEMENTIA-PUGILISTICA; ALZHEIMERS-DISEASE; TAU-PROTEIN; MICE; VULNERABILITY; IRON; RAT	Traumatic brain injury (TBI) is a risk factors for Alzheimer's disease (AD), and repetitive TBI (rTBI) may culminate in dementia pugilistica (DP), a syndrome characterized by progressive dementia, parkinsonism, and the hallmark brain lesions of AD, including neurofibrillary tangles (NFTs), formed by abnormal tau filaments and senile plaques (SPs) composed of A beta fibrils. Previous study showed that mild rTBI (mrTBI) accelerated the deposition of A beta in the brains of transgenic (Tg) mice (Tg2576) that over-express human A,6 precursor proteins with the familial AD Swedish mutations (APP695swe) and model of AD-like amyloidosis. Here, we report studies of the effects of mrTBI on AD-like tau pathologies in Tg mice expressing the shortest human tau isoform (T44) subjected to mrTBI, causing brain concussion without structural brain damage to simulate injuries linked to DP. Twelve-month-old Tg T44 (n = 18) and wild-type (WT; n = 24) mice were subjected to mrTBI (four times a day, I day per week, for 4 weeks; n = 24) or sham treatment (n = 18). Histopathological analysis of mice at 9 months after mrTBI revealed that one of the Tg T44 mice showed extensive telencephalic NFT and cerebral atrophy. Although statistical analysis of neurobehavioral tests at 6 months after mrTBI did not show any significant difference in any of groups of mice, the Tg T44 mouse with extensive NFT had an exceptionally low neurobehavioral score. The reasons for the augmentation of tau pathologies in only one T44 tau Tg mouse subjected to mrTBI remain to be elucidated.	Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Natl Chiba Higashi Hosp, Chiba, Japan; IRCCS, Osped Maggiore Policlin, Neurol Intens Care Unit, Dept Anesthesia & Crit Care Med, Milan, Italy	Trojanowski, JQ (corresponding author), Ctr Neurodegenerat Dis Res, 3600 Spruce St,HUP Maloney 3rd Fl, Philadelphia, PA 19104 USA.	trojanow@mail.med.upenn.edu	Longhi, Luca/AAF-9903-2021	Longhi, Luca/0000-0001-9894-8788	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS P50-08803, NS R0140978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER		ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; Allen B, 2002, J NEUROSCI, V22, P9340; Bouras C, 1997, EUR NEUROL, V38, P53, DOI 10.1159/000112903; Casadesus G, 2004, J ALZHEIMERS DIS, V6, P165; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Ishihara T, 2001, AM J PATHOL, V158, P555, DOI 10.1016/S0002-9440(10)63997-1; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lewis J, 2000, NAT GENET, V25, P402; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Yamamoto A, 2002, J NEUROCHEM, V82, P1137; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	22	96	96	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1134	1141		10.1089/neu.2005.22.1134			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600009	16238489				2021-06-18	
J	Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J				Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J			Attentional and processing skills following traumatic brain injury in early childhood	BRAIN INJURY			English	Article						brain injury; child; sustained attention	CLOSED-HEAD-INJURY; SELECTIVE ATTENTION; PERFORMANCE; CHILDREN; PERSPECTIVE; MATURATION; TIME	Primary objective: Attentional deficits are common following TBI in adults. This study examined whether these skills are also vulnerable following early childhood injury, when such skills are rapidly developing. Research design: This study investigated attention 30 months post-TBI in pre-schoolers (n = 56) and age-matched controls (n = 26). TBI children were divided into mild, moderate and severe injury groups. Methods and procedure: Pre-injury data were collected at time of injury. Assessment of attention included the Continuous Performance Test, Wechsler Intelligence Scale and Personality Inventory for Children. Main outcomes and results: Severe TBI was associated with reduced accuracy and slowed processing, particularly on complex motor responses. Sustained attention was more intact. Parental reports indicate internalized behavioural problems and somatic complaints. Conclusions: Young children with severe TBI are at risk for severe, persisting attentional impairments. Children with mild and moderate TBI show better outcome, with pre-injury behaviour and age also predictive of attentional skills at 30 months post-injury.	Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Monash Univ, Clayton, Vic 3168, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au					Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 2001, PEDIAT NEUROPSYCHOLO; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRAIN INJURY, V14, P679; BAKKER K, 2000, PEDIAT REHABIL, V3, P149; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1995, TRAUMATIC HEAD INJUR; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINSBOURNE M, 1996, COGNITIVE NEUROSCIEN, P1321; Kraus J., 1995, TRAUMATIC HEAD INJUR, P117; Lachar D, 1992, PERSONALITY INVENTOR; LANE DM, 1982, MERRILL PALMER QUART, V28, P317; LANE DM, 1979, J EXP CHILD PSYCHOL, V28, P16, DOI 10.1016/0022-0965(79)90099-7; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T., 1999, TEACH TEST EVERYDAY; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A.F., 1996, ATTENTION MEMORY EXE, P71; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Ruff HA, 1996, ATTENTION EARLY DEV; SHEPP BE, 1987, J EXP CHILD PSYCHOL, V43, P159, DOI 10.1016/0022-0965(87)90057-9; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Sparrow S., 1984, VINELAND ADAPTIVE BE; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANDERMEERE J, 1988, J ABNORM CHILD PSYCH, V16, P641, DOI 10.1007/BF00913475; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; WALSH K, 1978, NEUROPSYCHOLOGY CLIN; Warschausky S, 1996, ARCH CLIN NEUROPSYCH, V11, P147, DOI 10.1016/0887-6177(95)00004-6; WECHSLER D, 1987, MANUAL PRESCHOOL PRI; Wechsler D., 1991, MANUAL WECHSLER INTE; Willmott C, 2000, DEV NEUROPSYCHOL, V17, P361, DOI 10.1207/S15326942DN1703_5	56	96	96	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	9					699	710		10.1080/02699050400025281			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EH	WOS:000230484600008	16195184				2021-06-18	
J	Bazarian, JJ; McClung, J; Cheng, YT; Flesher, W; Schneider, SM				Bazarian, JJ; McClung, J; Cheng, YT; Flesher, W; Schneider, SM			Emergency department management of mild traumatic brain injury in the USA	EMERGENCY MEDICINE JOURNAL			English	Article							MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; PAIN MANAGEMENT; FOLLOW-UP; EFNS	Objective: To describe the emergency department (ED) management of isolated mild traumatic brain injury (TBI) in the USA and to examine variation in care across age and insurance types. Methods: A secondary analysis of ED visits for isolated mild TBI in the National Hospital Ambulatory Medical Care Survey 1998-2000 was performed. Mild TBI was defined by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) codes for skull fracture, concussion, intracranial injury (unspecified), and head injury (unspecified). Available ED care variables were analysed by patient age and insurance categories using multivariate logistic regression. Results: The incidence of isolated mild TBI cases attending ED was 153 296 per year, or 56.4/100000 people. Of the patients with isolated mild TBI, 44.3% underwent computed tomography, 23.9% underwent other non-extremity, non-chest x rays, 17.1% received wound care and 14.1% received intravenous fluids. However, only 43.8% had an assessment of pain. Of those with documented pain, only 45.5% received analgesics in the ED. Nearly 38% were discharged without recommendations for specific follow up. Several aspects of ED care varied by age but not by insurance type. Conclusion: Substantial ED resources are devoted to the care of isolated mild TBI. The present study identified deficiencies in and variation around several important aspects of ED care. The development of guidelines specific for mild TBI could reduce variation and improve emergency care for this injury.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; Hosp Max Peralta, San Jose, Costa Rica; Univ Rochester, Med Ctr, Dept Community & Prevent Med, Rochester, NY 14642 USA	Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 K23 NS 41952-04] Funding Source: Medline		Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Centers for Disease Control and Prevention Ambulatory and Hospital Care Statistics Branch, NAT HOSP AMB MED CAR; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; FIELD MJ, 1992, NATL ACAD SCI, P1; Gutu V, 2000, J EMERG MED, V18, P7, DOI 10.1016/S0736-4679(99)00153-5; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Jay G W, 1996, J Insur Med, V27, P262; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SMEDLEY BD, 2003, UNEQUAL TREATMENT CO; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; Von Wild K, 2001, BRAIN INJURY, V15, P273; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	36	96	96	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	JUL 1	2005	22	7					473	477		10.1136/emj.2004.019273			5	Emergency Medicine	Emergency Medicine	939ZO	WOS:000230113300005	15983080	Green Published, Bronze			2021-06-18	
J	Parker, TM; Osternig, LR; Lee, HJ; van Donkelaar, P; Chou, LS				Parker, TM; Osternig, LR; Lee, HJ; van Donkelaar, P; Chou, LS			The effect of divided attention on gait stability following concussion	CLINICAL BIOMECHANICS			English	Article						traumatic brain injury; center of mass; gait; balance	TRAUMATIC BRAIN-INJURY; CENTER-OF-MASS; POSTURAL STABILITY; DYNAMIC INSTABILITY; HEAD-INJURY; MILD HEAD; BALANCE; SWAY; PERFORMANCE; MOTION	Background. The need to identify functional impairment following a brain injury is critical to prevent re-injury during the period of recovery. While many neuropsychological tests have been developed to assess cognitive performance, relatively little information on gait and dynamic stability is available on motor task performance for young adults following concussion. This study was performed to investigate the effect of divided attention following concussion on various gait variables. It was hypothesized that, when compared to uninjured controls, concussed subjects would demonstrate deficits in maintenance of dynamic stability. Methods. Ten subjects with Grade 2 concussion completed testing within 48 h of injury as well as 10 age-, height-, weight-, and activity-snatched controls. The gait protocol consisted of level walking under two conditions: (1) undivided attention (single-task) and (2) while simultaneously completing simple mental tasks (dual-task). Whole-body motion data were collected using a six-camera motion analysis system. A 13-segment biomechanical model was used to compute whole body center of mass motion and velocity. Findings. Walking with a concurrent cognitive task resulted in significant changes in gait and center of mass measurements for both groups. Concussed subjects were found to be able to conservatively adjust their whole body center of mass motion to maintain dynamic stability while walking without divided attention. However, while walking with divided attention, subjects with concussion demonstrated a significantly greater medio-lateral center of mass sway. Interpretation. These data suggest that the ability to control and maintain stability in the frontal plane during walking is diminished under divided attention in individuals following a concussion. (c) 2004 Elsevier Ltd. All rights reserved.	Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu		Lee, Heng-Ju/0000-0001-6506-4062	ODCDC CDC HHS [R49/CCR021735, CCR023203] Funding Source: Medline		Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; *AM AC NEUR, NEUROLOGY, V48, P581; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; *CDCP, 1999, EP TRAUM BRAIN INJ U; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; EBERSBACH G, 1995, PERCEPT MOTOR SKILL, V81, P107, DOI 10.2466/pms.1995.81.1.107; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Pai YC, 1997, J BIOMECH, V30, P347, DOI 10.1016/S0021-9290(96)00165-0; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RUBIN AM, 1995, AM J OTOL, V16, P216; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; Winter DA, 1990, BIOMECHANICS MOTOR C, P56; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	32	96	96	0	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0268-0033	1879-1271		CLIN BIOMECH	Clin. Biomech.	MAY	2005	20	4					389	395		10.1016/j.clinbiomech.2004.12.004			7	Engineering, Biomedical; Orthopedics; Sport Sciences	Engineering; Orthopedics; Sport Sciences	908JM	WOS:000227783300006	15737446				2021-06-18	
J	Chieregato, A; Fainardi, E; Morselli-Labate, AM; Antonelli, V; Compagnone, C; Targa, L; Kraus, J; Servadei, F				Chieregato, A; Fainardi, E; Morselli-Labate, AM; Antonelli, V; Compagnone, C; Targa, L; Kraus, J; Servadei, F			Factors associated with neurological outcome and lesion progression in traumatic subarachnoid hemorrhage patients	NEUROSURGERY			English	Article						brain contusions; head injury; lesion progression; outcome; subarachnoid hemorrhage	SEVERE HEAD-INJURY; BRAIN-INJURY; CEREBRAL VASOSPASM; MODERATE; BLOOD; SCAN; CLASSIFICATION; MANAGEMENT; HEMATOMAS; IMPACT	OBJECTIVE: Traumatic subarachnoid hemorrhage (tSAH) is a frequent finding after closed and its presence is a powerful factor associated with poor outcome. The head injuries, exact mechanism linking tSAH and an adverse outcome is poorly understood. The aim of this study was to identify the factors that may predict outcomes and changes in the computed tomographic (CT) scans of lesions in a selected population of tSAH patients. METHODS: We evaluated 141 patients admitted consecutively from January 1, 1997, to January 31, 1999, with a CT diagnosis of tSAH. The admission and 'worst" CT scans were recorded. CT scan changes were reported as "significant CT progression" (changes in the Marshall classification) or "any CT progression." The amount of subarachnoid blood was recorded using a modified Fisher classification. Outcome was assessed at 6 months after injury with the Glasgow Outcome Scale. RESULTS: Twenty-eight patients (19.9%) had an unfavorable Glasgow Outcome Scale outcome. In the univariate analysis, prognosis was significantly related to age, admission Glasgow Coma Scale score, Marshall CT classification score at admission and on the worst CT scan, amount of tSAH, and volume of the associated brain contusions. From multivariate analysis, the only factors independently related to outcome were the Glasgow Coma Scale score (P < 0.01) and size of the tSAH at admission (P < 0.001). Thirty-four patients (24.1%) had significant CT lesion progression, and 66 patients (46.8%) had some lesion progression. Patients having significant progression of the lesion had a higher risk of an unfavorable outcome (32 versus 10%; P = 0.004). Unadjusted factors predicting CT the Marshall classification progression were the Glasgow Coma Scale score at admission, the amount of subarachnoid blood, and the presence or volume of associated admission, brain contusions at admission. independent factors associated with significant CT progression were the amount of tSAH (P < 0.001) and the presence or volume of brain contusions at admission (P < 0.001). CONCLUSION: The outcome of patients with tSAH at admission is related in a logistic regression analysis to the admission Glasgow Coma Scale score and to the amount of subarachnoid blood. These patients also have a significant risk of CT progression. The amount of subarachnoid blood and the presence of associated parenchymal damage are powerful independent factors associated with CT progression, thus linking poor outcomes and CT changes.	WHO, Maurizio Bufalini Hosp, Neurotrauma Collaborating Ctr, Div Neurotraumatol, I-47023 Cesena, Italy; Maurizio Bufalini Hosp, Intens Care Unit, Cesena, Italy; St Anna Hosp, Serv Neuroradiol, Ferrara, Italy; Univ Bologna, Dept Internal Med & Gastroenterol, Alma Mater Studiorum, Bologna, Italy; Univ Calif Los Angeles, So Calif Injury Prevent Ctr, Los Angeles, CA USA	Servadei, F (corresponding author), WHO, Maurizio Bufalini Hosp, Neurotrauma Collaborating Ctr, Div Neurotraumatol, I-47023 Cesena, Italy.	fservade@ausl-cesena.emr.it		Antonelli, Vincenzo/0000-0003-4231-529X; Servadei, Franco/0000-0002-3595-3464; Morselli/Labate, Antonio Maria/0000-0001-9318-8564; Compagnone, Christian/0000-0001-9951-5503			Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chen Guangxin, 2002, Chin J Traumatol, V5, P169; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; JENNETT B, 1975, LANCET, V1, P480; KAKAIEKA A, 1997, TRAUMATIC SUBARACHNO; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Morris GF, 1997, ACTA NEUROCHIR S, V71, P382; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2000, NEUROSURGERY, V46, P70; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TAKIZAWA T, 1984, Neurologia Medico-Chirurgica, V24, P390, DOI 10.2176/nmc.24.390; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	38	96	105	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2005	56	4					671	679		10.1227/01.NEU.0000156200.76331.7A			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	915EH	WOS:000228280200007	15792505				2021-06-18	
J	Sullivan, PG; Springer, JE; Hall, ED; Scheff, SW				Sullivan, PG; Springer, JE; Hall, ED; Scheff, SW			Mitochondrial uncoupling as a therapeutic target following neuronal injury	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article; Proceedings Paper	Mitochondria and Neuroprotection Symposium	APR 16-19, 2004	Ft Lauderdale, FL			neuronal cell death; traumatic brain injury; excitotoxicity; spinal cord injury; reactive oxygen species	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM TRAUMA; AMYLOID BETA-PEPTIDE; NF-KAPPA-B; CYCLOSPORINE-A; LIPID-PEROXIDATION; OXIDATIVE STRESS; GLUTAMATE EXCITOTOXICITY; PERMEABILITY TRANSITION; IMPAIRED MITOCHONDRIAL	Mitochondrial dysfunction is a prominent feature of excitotoxic insult and mitochondria are known to play a pivotal role in neuronal cell survival and death following injury. Following neuronal injury there is a well-documented increase in cytosolic Ca2+, reactive oxygen species (ROS) production and oxidative damage. In vitro studies have demonstrated these events are dependent on mitochondrial Ca2+ cycling and that a reduction in membrane potential is sufficient to reduce excitotoxic cell death. This concept has gained additional support from experiments demonstrating that the overexpression of endogenous mitochondrial uncoupling proteins (UCP), which decrease the mitochondrial membrane potential, decreases cell death following oxidative stress. Our group has demonstrated that upregulation of UCP activity can reduce excitotoxic-mediated ROS production and cell death whereas a reduction in UCP levels increases susceptibility to neuronal injury. These findings raise the possibility that mitochondrial uncoupling could be a potential novel treatment for acute CNS injuries.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, 240 HSRB, Lexington, KY 40536 USA.	patsull@uky.edu	Hall, Edward D/F-8930-2013				Argiles JM, 2002, BIOCHEM BIOPH RES CO, V293, P1145, DOI 10.1016/S0006-291X(02)00355-8; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Billups B, 2002, J NEUROSCI, V22, P5840; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1992, J NEUROTRAUMA, V9, P1; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Choi D W, 1990, Adv Exp Med Biol, V268, P501; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; Diano S, 2000, ENDOCRINOLOGY, V141, P4226, DOI 10.1210/en.141.11.4226; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Horvath TL, 1999, J NEUROSCI, V19, P10417; Jezek P, 2002, INT J BIOCHEM CELL B, V34, P1190, DOI 10.1016/S1357-2725(02)00061-4; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Keller JN, 1997, J NEUROCHEM, V69, P273; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; Kim-Han JS, 2001, J NEUROCHEM, V79, P658, DOI 10.1046/j.1471-4159.2001.00604.x; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Maragos WF, 2003, BRAIN RES, V966, P312, DOI 10.1016/S0006-8993(02)04225-7; Mark RJ, 1997, J NEUROCHEM, V68, P255; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mattson MP, 1998, INT REV NEUROBIOL, V42, P103, DOI 10.1016/S0074-7742(08)60609-1; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pivovarova NB, 2002, J NEUROSCI, V22, P10653; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, J BIOL CHEM, V279, P20699, DOI 10.1074/jbc.M313579200; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; White RJ, 1996, J NEUROSCI, V16, P5688; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zackova M, 2002, BIOSCIENCE REP, V22, P33, DOI 10.1023/A:1016009022186	63	96	99	0	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	AUG	2004	36	4					353	356		10.1023/B:JOBB.0000041767.30992.19			4	Biophysics; Cell Biology	Biophysics; Cell Biology	854PR	WOS:000223916300016	15377871				2021-06-18	
J	Govindaraju, V; Gauger, GE; Manley, GT; Ebel, A; Meeker, M; Maudsley, AA				Govindaraju, V; Gauger, GE; Manley, GT; Ebel, A; Meeker, M; Maudsley, AA			Volumetric proton spectroscopic imaging of mild traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; AUTOMATED SPECTRAL-ANALYSIS; DIFFUSE AXONAL INJURY; HEAD-INJURY; MR SPECTROSCOPY; H-1 MRS; METABOLITES; RELAXATION; CEREBELLUM; STEM	BACKGROUND AND PURPOSE: Poor clinical outcomes without notable neuroimaging findings after mild traumatic brain injury (MTBI) suggest diffuse tissue damage and altered metabolism not observable with conventional MR imaging and CT. In this study, MTBI-associated metabolic changes were assessed over the entire brain by using volumetric proton MR spectroscopic imaging (MRSI) and the findings related to injury and outcome assessments. METHODS: Fourteen subjects with mild closed head injury (Glasgow Coma Scale [GCS] scores of 13-15) underwent structural MR imaging and proton MRSI at 1.5 T within 1 month of injury. Distributions of N-acetylaspartate (NAA), total creatine (Cr), and total choline (Cho) were mapped over a wide region of the brain, and metabolite ratios were calculated for 25 regions without MR imaging abnormalities. Results were compared with data from 13 control subjects. RESULTS: Significant changes (P <.05) were found for some, but not all, brain regions for the average values from all MTBI subjects, with reduced NAA/Cr, increased Cho/Cr, and reduced NAA/Cho. Global NAA/Cho obtained from the sum of all sampled regions in two subjects was significantly reduced. Metabolite ratios were not significantly correlated with GCS score at admission or Glasgow Outcome Scale (GOS) score at 6 months after injury, although they were weakly correlated with GOS score at discharge. CONCLUSION. These results show evidence of widespread metabolic changes following MTBI in regions that appear normal on diagnostic MR images. Although the association with injury assessment and outcome is weak, this preliminary study demonstrates the applicability of volumetric proton MRSI for evaluating diffuse injury associated with MTBI.	Univ Calif San Francisco, No Calif Inst Res & Educ, MR Spectroscopy Unit, Vet Affairs Med Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Maudsley, AA (corresponding author), Univ Miami, Sch Med, Dept Radiol, MR Ctr, 1115 NW 14th St, Miami, FL 33136 USA.			Govind, Varan/0000-0002-1205-5194; Maudsley, Andrew/0000-0001-7653-3063	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038029] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB00207] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38029] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barker PB, 2000, MAGN RESON MED, V43, P348, DOI 10.1002/(SICI)1522-2594(200003)43:3<348::AID-MRM5>3.0.CO;2-M; Barker PB, 2001, ANN NEUROL, V49, P423, DOI 10.1002/ana.90.abs; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Ebel A, 2001, MAGNET RESON MED, V46, P1072, DOI 10.1002/mrm.1301; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Graham DI, 1996, NEUROTRAUMA, P43; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.0.CO;2-6; Jacobs MA, 2001, MAGNET RESON MED, V46, P699, DOI 10.1002/mrm.1248; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mascalchi M, 2002, J MAGN RESON IMAGING, V16, P532, DOI 10.1002/jmri.10189; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NARUSE S, 1993, P ISMRM, P1485; Pearl GS, 1998, CLIN LAB MED, V18, P39; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rooney WD, 1996, MAGN RESON MED, V35, P688, DOI 10.1002/mrm.1910350510; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schuff N, 2001, MAGN RESON MED, V45, P899, DOI 10.1002/mrm.1119; Soher BJ, 1998, MAGNET RESON MED, V40, P822, DOI 10.1002/mrm.1910400607; Son BC, 2000, ACT NEUR S, V76, P13; Tedeschi G, 1996, AM J NEURORADIOL, V17, P1871; vanderToorn A, 1995, NMR BIOMED, V8, P245; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	37	96	100	0	4	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2004	25	5					730	737					8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	821ZZ	WOS:000221503500010	15140711				2021-06-18	
J	Mathias, JL; Beall, JA; Bigler, ED				Mathias, JL; Beall, JA; Bigler, ED			Neuropsychological and information processing deficits following mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; information processing; diffuse brain damage; neuropsychological performance	MINOR HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; AXONAL INJURY; CORPUS-CALLOSUM; SEQUELAE; LESIONS; DAMAGE; DISCONNECTION; SPECTROSCOPY; TOPOGRAPHY	Neuroradiological and neuropathological investigations have found evidence of diffuse brain damage in the frontal and temporal lobes, corpus callosum, and fornices in patients who have sustained a mild traumatic brain injury (TBI). However, neuropsychological assessments of these patients do not typically target many of the subtle information processing deficits that may arise from diffuse damage involving the frontotemporal regions of the brain as well as white matter pathology, including the corpus callosum. Consequently, we have a limited understanding of the deficits that may be attributable to temporary or permanent disruptions to these functional pathways. This study assessed a group of mild TBI patients (N = 40) and a matched control group (N = 40) on a number of standard neuropsychological tests of selective and sustained attention, verbal and non-verbal fluency, and verbal memory. In addition, reaction time (RT) tasks, requiring both the inter- and intra-hemi spheric processing of visual and tactile information, were used to assess the functional integrity of the tracts that are likely to be affected by diffuse damage. In the 1st month after sustaining their injury, the mild TBI group demonstrated deficits in attention, non-verbal fluency, and verbal memory. They also demonstrated slower visual and tactile RTs, with the visual RTs of mild TBI patients being more affected by increased task difficulty and the need to transfer information across the corpus callosum, than did their matched controls.	Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA	Mathias, JL (corresponding author), Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia.	jane.mathias@psychology.adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Banich M. T, 1997, NEUROPSYCHOLOGY NEUR; Banich Marie T., 1995, P427; BANICH MT, 1992, J EXP PSYCHOL HUMAN, V18, P763, DOI 10.1037/0096-1523.18.3.763; Banich MT, 1994, NEUROPSYCHOLOGY, V8, P263; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BENTIN S, 1984, NEUROPSYCHOLOGIA, V22, P601, DOI 10.1016/0028-3932(84)90024-1; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CLARKE JM, 1994, BEHAV BRAIN RES, V64, P185, DOI 10.1016/0166-4328(94)90131-7; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; CURRY LM, 1991, PHILADELPHIA HEAD IN; DAMASIO AR, 1980, J NEUROL NEUROSUR PS, V43, P351, DOI 10.1136/jnnp.43.4.351; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EVANS RW, 1985, PERCEPT MOTOR SKILL, V61, P699, DOI 10.2466/pms.1985.61.3.699; FOS LA, 1995, INT NEUR SOC AUSTR S; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GEFFEN G, 1985, NEUROPSYCHOLOGIA, V23, P497, DOI 10.1016/0028-3932(85)90004-1; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P161; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; HOPTMAN MJ, 1994, PSYCHOL BULL, V116, P195, DOI 10.1037/0033-2909.116.2.195; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JONES NR, 1997, J CLIN NEUROSCI, V4, P1; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levander MB, 1998, BRAIN INJURY, V12, P165, DOI 10.1080/026990598122791; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEWINE JD, IN PRESS J HEAD TRAU; LEWINE JD, IN PRESS BRAIN INJUR; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NELSON HE, 1991, NATL ADULT READINT T; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PANDYA DN, 1971, BRAIN RES, V32, P31, DOI 10.1016/0006-8993(71)90153-3; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robertson I. H., 1994, TEST EVERYDAY ATTENT; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schmidt M., 1996, REY AUDITORY VERBAL; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Spreen O., 1998, COMPENDIUM NEUROPSYC; STRICH SJ, 1961, LANCET, V2, P443; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	82	96	97	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2004	10	2					286	297		10.1017/S1355617704102117			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	780KA	WOS:000189378800015	15012849	Green Published			2021-06-18	
J	Wagner, AK; Bayir, H; Ren, DX; Puccio, A; Zafonte, RD; Kochanek, PM				Wagner, AK; Bayir, H; Ren, DX; Puccio, A; Zafonte, RD; Kochanek, PM			Relationships between cerebrospinal fluid markers of excitotoxicity, ischemia, and oxidative damage after severe TBI: The impact of gender, age, and hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						excitotoxicity; gender; hypothermia; ischemia; lipid peroxidation; oxidative damage; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FACTOR MESSENGER-RNA; SEVERE HEAD-INJURY; CEREBRAL-ISCHEMIA; MODERATE HYPOTHERMIA; LIPID-PEROXIDATION; GLOBAL-ISCHEMIA; BLOOD-FLOW; RAT-BRAIN; GLUTAMATE	Excitotoxicity and ischemia can result in oxidative stress after TBI. Female sex hormones are hypothesized to be neuroprotective after TBI by affecting multiple mechanisms of secondary injury, including oxidative damage, excitotoxicity and ischemia. Ca2+ mediated oxidative stress increases with age, and hypothermia is known to attenuate secondary injury. The purpose of this study was to determine if the relationship between cerebral spinal fluid (CSF) markers of excitotoxicity, ischemia, and oxidative damage are gender and age specific and the role of hypothermia in affecting these relationships. F-2-isoprostane, glutamate, and lactate/pyruvate, were assessed in CSF from adults (n = 68) with severe TBI (Glasgow coma scale [GCS] score less than or equal to 8) using ventricular CSF samples (n = 207) collected on days 1, 2, and 3 post-injury. F-2-isoprostane/glutamate and F2-isoprostane/lactate/pyruvate ratios were determined for patients at each time point. Six-month Glasgow Outcome Scores (GOS) were also obtained. Repeated measures multivariate analysis showed a significant gender effect (p < 0.002) and gender*time interaction (p = 0.012) on F-2-isoprostane/glutamate ratios. A significant gender effect (p = 0.050) and gender*time interaction (p = 0.049) was also seen with F2-isoprostane/lactate/pyruvate. Hypothermia (p = 0.001) and age (p = 0.026) significantly increased F2-isoprostane/glutamate ratios. Females had a significant inverse relationship between day 1 F2-isoprostane/glutamate ratios and GOS scores (r = -0.43; p = 0.05) as well as day 1 F-2-isoprostane/lactate/pyruvate ratio (r = -0.46; p = 0.04) and GOS scores. These results indicate that females have smaller oxidative damage loads than males for a given excitotoxic or ischemic insult and female gonadal hormones may play a role in mediating this neuroprotective effect. These results also suggest that susceptibility to glutamate mediated oxidative damage increases with age and that hypothermia differentially attenuates CSF glutamate versus F-2-isoprostane production. Gender and age differences in TBI pathophysiology should be considered when conducting clinical trials in TBI.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.	wagnerak@msx.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Bergeron R, 1996, J NEUROSCI, V16, P1193; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; ELOVIC E, 1996, MED REHABILITATION T, P1; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; FOLBERGROVA J, 1992, J CEREBR BLOOD F MET, V12, P25, DOI 10.1038/jcbfm.1992.4; Glass TF, 2002, NEUROSCI LETT, V328, P133, DOI 10.1016/S0304-3940(02)00510-4; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRANHOLM L, 1969, SCAND J CLIN LAB INV, V23, P361, DOI 10.3109/00365516909081702; Greco A, 1999, NEUROLOGY, V53, P1876, DOI 10.1212/WNL.53.8.1876; HALLSTROM A, 1989, J PHARMACOL METHOD, V22, P113; Hof PR, 2002, BRAIN RES, V928, P175, DOI 10.1016/S0006-8993(01)03345-5; Huang FP, 1998, NEUROCHEM RES, V23, P991, DOI 10.1023/A:1021088523137; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; Inder T, 2002, PEDIATR RES, V52, DOI 10.1203/01.PDR.0000020088.11295.13; JENNETT B, 1975, LANCET, V1, P480; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; LIN BW, 1992, J NEUROCHEM, V59, P2213; Love S, 1999, BRAIN PATHOL, V9, P119; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marks JD, 2000, DEV BRAIN RES, V124, P101, DOI 10.1016/S0165-3806(00)00096-1; Marks JD, 1996, DEV BRAIN RES, V97, P194, DOI 10.1016/S0165-3806(96)00149-6; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Schroder ML, 1998, ACT NEUR S, V71, P127; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Solum DT, 2002, J NEUROSCI, V22, P2650, DOI 10.1523/JNEUROSCI.22-07-02650.2002; Sonnewald U, 1997, GLIA, V21, P56, DOI 10.1002/(SICI)1098-1136(199709)21:1<56::AID-GLIA6>3.0.CO;2-#; URQUHART N, 1975, J NEUROCHEM, V24, P1071, DOI 10.1111/j.1471-4159.1975.tb03679.x; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	65	96	100	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					125	136		10.1089/089771504322778596			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200001	15000754				2021-06-18	
J	Petzold, A; Keir, G; Lim, D; Smith, M; Thompson, EJ				Petzold, A; Keir, G; Lim, D; Smith, M; Thompson, EJ			Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern	BRAIN RESEARCH BULLETIN			English	Article; Proceedings Paper	European Symposium on Laboratory Diagnosis of Brain Damage and Inflammation with New and Old Markers in Human Cerebrospinal Fluids and Blood	SEP, 2000	MARBURG AN DER LAHN, GERMANY			brain specific proteins; ICH; SAH; TBI; reference population	BRAIN-DAMAGE; NEUROBIOCHEMICAL MARKERS; PROTEIN; S-100; INJURY	S100B is an important brain specific protein for monitoring damage and activation of astrocytes. Using a straight forward, non-resource demanding in-house ELISA technique we measured S 10013 in cerebrospinal fluid (CSF) and serum in patients with traumatic brain injury (TBI) (serum), subarachnoid hemorrhage (SAH) (CSF, serum), intracranial hemorrhage (ICH) (CSF, serum), normal controls (NC) (serum) and a reference population (CSF, N = 409). The release and wash-out pattern found in CSF and serum are discussed in relation to the three main determinants for increased brain specific protein levels in body fluids: (i) total mass effect; (ii) pathology; and (iii) time effect. (C) 2003 Elsevier Science Inc. All rights reserved.	Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Surg Intens Care Unit, London, England	Thompson, EJ (corresponding author), Inst Neurol, Dept Neuroimmunol, Queen Sq, London WC1N 3BG, England.	e.thompson@ion.ucl.ac.uk	Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749			Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Cody R P, 1997, APPL STAT SAS PROGRA; Gao F, 2000, ANAESTHESIA, V55, P764, DOI 10.1046/j.1365-2044.2000.01466.x; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Massicotte EM, 1999, J NEUROSURG, V91, P80, DOI 10.3171/jns.1999.91.1.0080; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thompson EJ, 1998, MULT SCLER, V4, P5, DOI 10.1191/135245898678909169; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	11	96	100	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	AUG 15	2003	61	3					281	285		10.1016/S0361-9230(03)00091-1			5	Neurosciences	Neurosciences & Neurology	713VZ	WOS:000184879800008	12909298				2021-06-18	
J	Huang, CY; Fujimura, M; Noshita, N; Chang, YY; Chan, PH				Huang, CY; Fujimura, M; Noshita, N; Chang, YY; Chan, PH			SOD1 down-regulates NF-kappa B and c-mye expression in mice after transient focal cerebral ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						focal cerebral ischemia; free radicals; superoxide dismutase; NF-kappa B; c-Myc; Apoptosis	CUZN-SUPEROXIDE-DISMUTASE; TRAUMATIC BRAIN INJURY; DNA-BINDING ACTIVITY; TRANSGENIC MICE; NUCLEAR-FACTOR; TRANSCRIPTION FACTOR; GLOBAL-ISCHEMIA; NITRIC-OXIDE; INDUCED APOPTOSIS; HIPPOCAMPAL-NEURONS	Reactive oxygen species (ROS) are implicated in reperfusion injury after focal cerebral ischemia (FCI). Reactive oxygen species regulate activity of transcription factors like NF-kappaB. The authors investigated the role of ROS in NF-kappaB activity after FCI using transgenic mice that overexpressed human coppcr/zinc-superoxide dismutase: (SODI) and that had reduced infarction volume after FCI. Superoxide dismutase transgenic and wild-type mice were subjected to 1 hour of middle cerebral artery occlusion (MCAO) and subsequent reperfusion. Immunohistochemistry showed SODI overexpression attenuated ischemia-induced NF-kappaB p65 immunoreactivity. Colocalization of NF-kappaB and the neuronal marker, microtubule-associated proteins (MAPs), showed that NF-kappaB was up-regulated in neurons after FCI. Electrophoretic mobility shift assays showed that SOD1 overexpression reduced ischemia-induced NF-kappaB DNA binding activity. Supershift assays showed that DNA-protein complexes contained p65 and p50 subunits. Immunoreactivity of c-myc, an NF-kappaB downstream gene, was increased in the ischemic cortex and colocalized with NF-KB. Western blotting showed that SOD1 overexpression reduced NF-KB and c-Myc protein levels in the ischemic brain. Colocalization of c-Myc and TUNEL staining was observed 24 hours after FCI. The current findings provide the first evidence that SOD 1 overexpression attenuates activation of NF-kappaB after transient FCI in mice and that preventing this early activation may block expression of downstream deleterious genes like c-myc, thereby reducing ischemic damage.	Stanford Univ, Sch Med, Dept Neurol & Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA	Chan, PH (corresponding author), Stanford Univ, Neurosci Lab, MSLS,P304,1201 Welch Rd, Stanford, CA 94305 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36147, NS25372, NS14534] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036147, R01NS025372] Funding Source: NIH RePORTER		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Asanuma M, 1998, MOL BRAIN RES, V60, P305, DOI 10.1016/S0169-328X(98)00188-0; Baichwal VR, 1997, CURR BIOL, V7, P94; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bethea JR, 1998, J NEUROSCI, V18, P3251; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; CHANDNA M, 1994, J PLANT BIOCHEM BIOT, V3, P59, DOI 10.1007/BF03321950; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foo SY, 1999, TRENDS GENET, V15, P229; Fujimura M, 1999, J CEREBR BLOOD F MET, V19, P495, DOI 10.1097/00004647-199905000-00003; Fujimura M, 1999, STROKE, V30, P2408, DOI 10.1161/01.STR.30.11.2408; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kamii H, 1996, J CEREBR BLOOD F MET, V16, P1153, DOI 10.1097/00004647-199611000-00009; KAMII H, 1995, CENTRAL NERVOUS SYST, V4, P425; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kondo T, 1997, J NEUROSCI, V17, P4180; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Murakami K, 1998, J NEUROSCI, V18, P205; Murakami K, 1997, STROKE, V28, P1797, DOI 10.1161/01.STR.28.9.1797; Nakagomi T, 1996, NEUROL RES, V18, P559; Nakai M, 1999, MOL BRAIN RES, V64, P59, DOI 10.1016/S0169-328X(98)00310-6; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Namura S, 1998, J NEUROSCI, V18, P3659; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; Petito CK, 1997, J CEREBR BLOOD F MET, V17, P967, DOI 10.1097/00004647-199709000-00006; Qin ZH, 1999, J NEUROSCI, V19, P4023; Romashkova JA, 1999, NATURE, V401, P86; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Schneider A, 1999, NAT MED, V5, P554; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Stephenson D, 2000, J CEREBR BLOOD F MET, V20, P592, DOI 10.1097/00004647-200003000-00017; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	61	96	102	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2001	21	2					163	173		10.1097/00004647-200102000-00008			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	399XK	WOS:000166839400008	11176282	Bronze			2021-06-18	
J	Dupuis, F; Johnston, KM; Lavoie, M; Lepore, F; Lassonde, M				Dupuis, F; Johnston, KM; Lavoie, M; Lepore, F; Lassonde, M			Concussions in athletes produce brain dysfunction as revealed by event-related potentials	NEUROREPORT			English	Article						electrophysiology; mild traumatic brain injury; P300; sports	HEAD-INJURY PATIENTS; P300; PLAYERS	We have used event-related potentials (ERP) to assess cerebral activity following mild traumatic brain injuries in 20 college athletes practising contact sports. Concussion victims showed a striking decrease in P300 amplitude, an effect presumed to reflect alterations in attentional-cognitive processes. Moreover, the degree of impairment was strongly related to the severity of post-concussion symptoms. Our data suggest that concussions cause objectively measurable changes in the electrophysiological markers of brain activity and hence in the functions of the structures from which they originate. ERPs may thus constitute a reliable method to accurately monitor the clinical course and recovery of head injuries in athletes. NeuroReport 11:4087-4092 (C) 2000 Lippincott Williams & Wilkins.	Univ Montreal, Grp Rech & Neuropsychol Expt, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Univ Geriatrie, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3G 1A4, Canada	Lassonde, M (corresponding author), Univ Montreal, Grp Rech & Neuropsychol Expt, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Lavoie, Marc/M-4771-2019	Lavoie, Marc/0000-0002-3037-3890			[Anonymous], 1991, J CLIN NEUROPHYSIOL, V8, P200, DOI 10.1097/00004691-199104000-00007; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; COLES MGH, 1986, PSYCHOPHYSIOLOGY SYS; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Drake M E Jr, 1996, Electromyogr Clin Neurophysiol, V36, P457; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; ROCKSTROM J, 1989, SLOW CORTICAL POTENT; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21	17	96	96	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	DEC 18	2000	11	18					4087	4092		10.1097/00001756-200012180-00035			6	Neurosciences	Neurosciences & Neurology	387PU	WOS:000166131600037	11192633				2021-06-18	
J	Schumacher, PA; Siman, RG; Fehlings, MG				Schumacher, PA; Siman, RG; Fehlings, MG			Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury	JOURNAL OF NEUROCHEMISTRY			English	Article						spinal cord injury; nerve tissue proteins; neurotrauma; calpain; neurofilament; treatment	BRAIN INJURY; NEURONAL APOPTOSIS; SECONDARY INJURY; ALPHA-SPECTRIN; IMPACT TRAUMA; BLOOD-FLOW; PROTEIN; MOTOR; RATS; PROTEOLYSIS	The pathophysiology of traumatic spinal cord injury (SCI) involves abnormal activation of the neutral cysteine protease calpain I (EC 3.4.22.17). In the present study we examined the effect of the calpain inhibitor CEP-4143 on cytoskeletal protection and neurological recovery after SCI in adult rats. Microinjection of 50 mM CEP-4143 into the T7 vertebral segment 10 min before a 35-g clip compression injury resulted in inhibition of calpain activation at 2 and 4 h postinjury, as determined by western blotting for calpain I-mediated spectrin degradation, and significantly attenuated the degradation of dephosphorylated NF200 neurofilament protein at 4 and 8 h postinjury. To examine the in vivo chronic neuroprotective effects of CEP-4143, animals underwent microinjection with saline or 50 mM CEP-4143 10 min before injury, followed by weekly blinded behavioral assessments for 6 weeks. Animals receiving CEP-4143 treatment showed significant improvement over saline-treated controls on the Basso Beattie Bresnahan locomotor rating scale (p < 0.02) and inclined plane test (p < 0.05). Counts of neurons in the red nucleus retrogradely labeled by fluorogold after introduction distal to the injury site were significantly higher in CEP-4143-treated animals. Finally, morphometric assessment of the injury site by computer-assisted image analysis revealed significant tissue preservation in CEP-4143-treated animals. We conclude that the calpain antagonist CEP-4143 exhibits biochemical, behavioral, and anatomical neuroprotection following traumatic SCI.	Toronto Western Hosp, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada; Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Cephalan, Dept Biochem, W Chester, PA USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	Fehlings, MG (corresponding author), Toronto Western Hosp, Playfair Neurosci Unit, 399 Bathurst St,MCL 12-407, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; Agrawal SK, 1996, J NEUROSCI, V16, P545; Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; BALENTINE JD, 1984, J NEUROPATH EXP NEUR, V43, P500, DOI 10.1097/00005072-198409000-00005; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Barinaga M, 1996, SCIENCE, V274, P1466; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FEHLINGS MG, 1995, SPINE, V20, P2187, DOI 10.1097/00007632-199510001-00002; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; ILDAN F, 1995, NEUROSURG REV, V18, P35, DOI 10.1007/BF00416476; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Rivlin A S, 1978, Surg Neurol, V10, P38; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1994, FASEB J, V8, P814; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; TATOR CH, 1992, J NEUROTRAUM, V9, P139, DOI 10.1089/neu.1992.9.139; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; WRATHALL JR, 1994, J NEUROSCI, V14, P6598	38	96	98	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	APR	2000	74	4					1646	1655		10.1046/j.1471-4159.2000.0741646.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	295DL	WOS:000085951400036	10737623				2021-06-18	
J	Ruchholtz, S				Ruchholtz, S		Arbeitsgemeinschaft Polytrauma Deu	The trauma registry of the German Society of Trauma Surgery as a basis for interclinical quality mangement. A multicenter study of the German Society of Trauma Surgery	UNFALLCHIRURG			German	Article						Trauma Registry of the German Society of; Trauma Surgery; interclinical quality management; severe trauma	INJURY SEVERITY SCORE; MULTIPLE INJURIES; CARE; IMPROVEMENT; SYSTEM; ERRORS; AUDIT; DIRECTIONS; MANAGEMENT; MORBIDITY	Based on the "Trauma Registry" of the German Society of Trauma Surgery, an interclinical quality management (QM) system was implemented. The principles of the QM system as well as the differences in the quality of outcome and treatment are presented. The analysis uses the data on 2,069 severely injured (ISS = 22 +/- 14) patients from 20 hospitals collected prospectively and anonymously between 2/93 and 12/97. Outcome quality was analyzed by the TRISS method and Z-statistics. The Z-value of the whole series was -0.24. There were three hospitals with more than 150 patients that had a Ps value calculated by the TRISS method. Clinic A had a good (-2.49), clinic B an average (-0.3) and clinic C (3.62) an adverse Z-value. The assessment of treatment quality was performed by criteria concerning both preclinical and acute clinical phases. Clinic C had a prolonged preclinical treatment time (90 min vs 62 min in clinic A) for severely injured (ISS > 15) patients. At the same time, the preclinical intubation rate for severe thoracic trauma (AIS > 3) was lower (44 %) in clinic C than in A (62 %). With 14 min clinic A had the shortest time until basic radiological and ultrasound diagnostics were completed (X-rays of chest and pelvis and abdominal ultrasound) in cases of severe blunt trauma (ISS > 15), compared to 54 min in clinic B or 31 min in clinic C. Also, cranial computed tomography for severe traumatic brain injury (GCS < 9) was applied significantly faster in clinic A (after 36 min) than in clinic C (after 62 min). Delayed diagnoses were defined as the difference between the ISS at discharge and the ISS at completion of diagnostics in the emergency department; this criterion was met best by cli nic A with an ISS difference of two patients compared to five in clinic B and four in clinic C. The hospitals participating in the Trauma Registry receive an annual analysis of their preclinical and acute clinical performance, Thus, every hospital can analyze and improve the quality of treatment based on reliable data that show which parts of the process have to be optimized. Furthermore, the data allow a com pa risen of the average and optimal results of the whole series.	Univ Essen Gesamthsch Klinikum, Abt Unfallchirurg, D-45122 Essen, Germany	Ruchholtz, S (corresponding author), Univ Essen Gesamthsch Klinikum, Abt Unfallchirurg, Hufelandstr 55, D-45122 Essen, Germany.						*AM COLL SURG COM, 1993, RES OPT CAR INJ PAT; *ARB POL DTSCH GES, 2000, IN PRESS UNFALLCHIRU; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARDENHEUE M, 1994, UNFALLCHIRURG, V97, P230; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHAMPION HR, 1988, ADV TRAUMA, V3, P241; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; COPES WS, 1995, J TRAUMA, V38, P432, DOI 10.1097/00005373-199503000-00027; DAVIS JW, 1992, J TRAUMA, V32, P660, DOI 10.1097/00005373-199205000-00020; DRAAISMA JMT, 1989, J TRAUMA, V29, P1552; Fallon WF, 1997, J TRAUMA, V42, P810, DOI 10.1097/00005373-199705000-00010; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; HOYT DB, 1994, J TRAUMA, V36, P377, DOI 10.1097/00005373-199403000-00017; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KREIS DJ, 1986, J TRAUMA, V26, P649, DOI 10.1097/00005373-198607000-00010; NASTKOLB D, 1994, UNFALLCHIRURG, V97, P292; NASTKOLB D, 1992, UNFALLCHIRURG, V95, P59; OESTERN HJ, 1985, UNFALLCHIRURG, V88, P465; Petrie D, 1996, J TRAUMA, V41, P870, DOI 10.1097/00005373-199611000-00020; REGEL G, 1993, UNFALLCHIRURG, V96, P350; RUCHHOLTZ S, 1994, UNFALLCHIRURG, V97, P285; Ruchholtz S, 1997, UNFALLCHIRURG, V100, P859, DOI 10.1007/s001130050205; SCHMIDT U, 1992, J TRAUMA, V33, P548, DOI 10.1097/00005373-199210000-00010; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; TEASDALE G, 1974, LANCET, V2, P81; Trupka A, 1994, Eur J Emerg Med, V1, P1, DOI 10.1097/00063110-199403000-00002; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737; YATES DW, 1994, INJURY, V25, P511, DOI 10.1016/0020-1383(94)90091-4	32	96	98	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0177-5537	1433-044X		UNFALLCHIRURG	Unfallchirurg	JAN	2000	103	1					30	37		10.1007/s001130050005			8	Emergency Medicine; Surgery	Emergency Medicine; Surgery	285YW	WOS:000085416800005	10663103				2021-06-18	
J	Sabo, T; Lomnitski, L; Nyska, A; Beni, S; Maronpot, RR; Shohami, E; Roses, AD; Michaelson, DM				Sabo, T; Lomnitski, L; Nyska, A; Beni, S; Maronpot, RR; Shohami, E; Roses, AD; Michaelson, DM			Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: The allele E3 is neuroprotective whereas E4 increases fatalities	NEUROSCIENCE			English	Article						Alzheimer's disease; animal models; apolipoprotein E3; apolipoprotein E4	E-DEFICIENT MICE; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; TYPE-4 ALLELE; BETA-PROTEIN; BRAIN INJURY; AMYLOID-BETA; E GENOTYPE; APOE; NEURONS	Apolipoprotein E, the major brain lipid-binding protein, is expressed in humans as three common isoforms (E2, E3 and E4). Previous studies revealed that the allele apolipoprotein E4 is a major genetic risk factor of Alzheimer's disease and that traumatic brain injury is associated with increased risk for developing this disease. Furthermore, it has been suggested that the effects of traumatic head injury and apolipoprotein E4 in Alzheimer's disease are synergistic. To test the hypothesis that the apolipoprotein E genotype affects susceptibility to brain injury, we subjected transgenic mice, expressing either human apolipoprotein E3 or human apolipoprotein E4 on a null mouse apolipoprotein E background and apolipoprotein E-deficient knockouts, to closed head injury and compared mortality, neurological recovery and the extent of brain damage of the survivors. More than 50% of the transgenic mice expressing human apolipoprotein E4 died following closed head injury, whereas only half as many of the transgenic mice expressing human apolipoprotein E3, and of the control and apolipoprotein E-deficient mice died during this period (P < 0.02). A neurological severity score used for clinical assessment of the surviving mice up to 11 days after closed head injury revealed that the four mouse groups displayed similar severity of damage at 1 h following injury. At three and 11 days post-injury, however, the neurological severity scores of the transgenic mice expressing human apolipoprotein E3 were significantly lower than those of the other three groups whose scores were similar, indicating better recovery of the transgenic mice expressing human apolipoprotein E3. Histopathological examination of the mice performed 11 days post-injury revealed, consistent with the above neurological results, that the size of the damaged brain area of the transgenic mice expressing human apolipoprotein E3 was smaller than that of the other head-injured groups. These findings show that transgenic mice expressing human apolipoprotein E4 are more susceptible than those expressing apolipoprotein E3 to closed head injury. We suggest that this effect is due to both a protective effect of apolipoprotein E3 and an apolipoprotein E4-related pathological function. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; NIEHS, Res Triangle Pk, NC 27709 USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Glaxo Wellcome Inc, Div Res, Res Triangle Pk, NC 27709 USA; Israel Inst Biol Res, IL-70450 Ness Ziona, Israel	Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.						Basun H, 1996, STROKE, V27, P1310, DOI 10.1161/01.STR.27.8.1310; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Buttini M, 1999, J NEUROSCI, V19, P4867; Chapman J, 1999, ARCH NEUROL-CHICAGO, V56, P1484, DOI 10.1001/archneur.56.12.1484; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FRENCH LR, 1991, J EPIDEMIOL, V121, P414; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; Ignatius MJ, 1987, PROG BRAIN RES <D>, V71, P177; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; LOMNITSKI L, 2000, IN PRESS EXPL TOXIC; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Metzger RE, 1996, J NEUROPATH EXP NEUR, V55, P372, DOI 10.1097/00005072-199603000-00013; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; PROPHET EB, 1994, LAB METHODS HISTOTEC, P56; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Seliger Glenn, 1997, Neurology, V48, pA213; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SHOHAMI E, 2000, IN PRESS J MOL MED; SHOOTER AJC, 1997, JAMA-J AM MED ASSOC, V277, P818; Sorbi S., 1996, Neurology, V46, pA307; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Sun YL, 1998, J NEUROSCI, V18, P3261; Veinbergs I, 1998, NEUROSCI LETT, V249, P71, DOI 10.1016/S0304-3940(98)00399-1; Veinbergs I, 1999, NEUROSCI LETT, V265, P218, DOI 10.1016/S0304-3940(99)00243-8; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023	54	96	96	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	101	4					879	884		10.1016/S0306-4522(00)00438-3			6	Neurosciences	Neurosciences & Neurology	385BZ	WOS:000165982900008	11113336				2021-06-18	
J	Hillered, L; Persson, L				Hillered, L; Persson, L			Neurochemical monitoring of the acutely injured human brain	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION			English	Article; Proceedings Paper	XXVI Nordic Congress in Clinical Chemistry	JUN, 1998	TURKU, FINLAND			cerebral ischemia; free radicals; glutamate; glycerol; human microdialysis; hypoxanthine; lactate; microdialysis; neurointensive care; traumatic brain injury	IN-VIVO MICRODIALYSIS; CEREBRAL-ARTERY OCCLUSION; EXTRACELLULAR AMINO-ACIDS; ISCHEMIC HUMAN BRAIN; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; SUBSTRATE DELIVERY; INTENSIVE-CARE; HEAD TRAUMA; URIC-ACID	The main goal of modern neurointensive care (NIC) of patients with acute brain injury (traumatic brain injury, neurovascular disease) is to prevent additional loss of viable brain tissue due to secondary injury processes. It is generally held that secondary injury, mediated by, for example, cerebral hypoxia/ischemia and destructive molecular cascades on the cellular level, contributes significantly to the extent of brain damage after head injury and stroke. The basic concept is that improved knowledge of the secondary injury processes will lead to new therapeutic approaches in NIC. New methods by which secondary injury processes can be detected and monitored in NIC patients are therefore greatly needed. This paper describes intracerebral microdialysis as a novel approach to neurochemical monitoring of the human brain. The main objectives are (i) to monitor cortical energy metabolism in order to detect secondary ischemia and (ii) to monitor secondary injury processes, such as glutamate receptor overactivation and increased free radical production, in MC patients.	Univ Uppsala Hosp, Dept Med Sci, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden	Hillered, L (corresponding author), Univ Uppsala Hosp, Dept Med Sci, S-75185 Uppsala, Sweden.						AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Bachli H, 1996, NEUROL RES, V18, P370; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BOLANDER HG, 1989, STROKE, V20, P930, DOI 10.1161/01.STR.20.7.930; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CARLSON H, 1992, NEUROSCI LETT, V140, P30, DOI 10.1016/0304-3940(92)90674-V; DURING MJ, 1994, J NEUROCHEM, V62, P2356; DURING MJ, 1993, LANCET, V341, P1607; DURING MJ, 1992, ANN NEUROL, V32, P618, DOI 10.1002/ana.410320504; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; HAMBERGER A, 1991, EPILEPSY RES, V9, P32, DOI 10.1016/0920-1211(91)90044-G; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; HILLERED L, 1995, NEUROREPORT, V6, P1816, DOI 10.1097/00001756-199509000-00026; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; HILLERED L, 1988, NEUROSCI LETT, V95, P286, DOI 10.1016/0304-3940(88)90672-6; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; KANTHAN R, 1995, J NEUROSCI METH, V60, P151, DOI 10.1016/0165-0270(95)00006-G; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; Kanthan R, 1996, NEUROCHEM RES, V21, P563, DOI 10.1007/BF02527754; Kanthan R, 1996, NEUROSCI LETT, V209, P207, DOI 10.1016/0304-3940(96)12642-2; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; KAUR H, 1990, CHEM-BIOL INTERACT, V73, P235, DOI 10.1016/0009-2797(90)90006-9; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; Landolt H, 1996, EUR J ANAESTH, V13, P269, DOI 10.1046/j.1365-2346.1996.00975.x; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LONNROTH P, 1987, AM J PHYSIOL, pE253; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Mendelowitsch A, 1998, NEUROL RES, V20, P142; Mendelowitsch A, 1998, J NEUROL NEUROSUR PS, V64, P611, DOI 10.1136/jnnp.64.5.611; Mendelowitsch A, 1997, NEUROL RES, V19, P66; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Persson L, 1996, J NEUROSURG, V85, P984; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Robinson TE, 1991, MICRODIALYSIS NEUROS; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; RONQUIST G, 1992, ACTA NEUROCHIR, V114, P8, DOI 10.1007/BF01401106; Runnerstam M, 1997, NEUROL RES, V19, P361, DOI 10.1080/01616412.1997.11740826; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; SCHEYER RD, 1994, NEUROLOGY, V44, P1469, DOI 10.1212/WNL.44.8.1469; SCHEYER RD, 1994, EPILEPSY RES, V18, P227, DOI 10.1016/0920-1211(94)90043-4; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	57	96	97	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0036-5513	1502-7686		SCAND J CLIN LAB INV	Scand. J. Clin. Lab. Invest.		1999	59			229			9	18		10.1080/00365519950185904			10	Medicine, Research & Experimental	Research & Experimental Medicine	174JY	WOS:000079032500003	10097285				2021-06-18	
J	Paradiso, S; Robinson, RG				Paradiso, S; Robinson, RG			Gender differences in poststroke depression	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	149th Annual Meeting of the American-Psychiatric-Association	MAY 04-09, 1996	NEW YORK, NEW YORK	Amer Psychiat Assoc			TRAUMATIC BRAIN INJURY; STROKE PATIENTS; MOOD DISORDERS; INTELLECTUAL IMPAIRMENT; MYOCARDIAL-INFARCTION; SEX-DIFFERENCES; REHABILITATION; LESION; FREQUENCY; COMMUNITY	In stroke and other medical illnesses, secondary depression may be associated with different factors in women than in men. The authors examined 301 consecutive admissions for acute treatment of cerebrovascular accident for gender differences in depression, psychosocial factors, physical impairment, and lesion location. Women were twice as frequently diagnosed with major depression as men. Women with major depression had a greater frequency of left hemisphere lesions than men. In men, major depression was associated with greater impairment in activities of daily living, and greater severity of depression was associated with greater impairment in daily activities and social functioning. In women, greater severity of depression was associated with prior diagnosis of psychiatric disorder and cognitive impairment. These findings suggest a different nature of poststroke depression in men and women and may have implications for its treatment.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA	Paradiso, S (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 200 Hawkins Dr,2887 JPP, Iowa City, IA 52242 USA.	sergio-paradiso@uiowa.edu	Paradiso, Sergio/H-9052-2012; Robinson, Robert/AAF-6191-2021		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH00163, MH40355] Funding Source: Medline		AGRELL B, 1994, AGING-CLIN EXP RES, V6, P49, DOI 10.1007/BF03324213; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSEN G, 1994, ACTA PSYCHIAT SCAND, V90, P190, DOI 10.1111/j.1600-0447.1994.tb01576.x; ANGELERI F, 1993, STROKE, V24, P1478, DOI 10.1161/01.STR.24.10.1478; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; BOLLAWILSON K, 1989, AM J PSYCHIAT, V146, P627; BOROD JC, 1992, J CONSULT CLIN PSYCH, V60, P339, DOI 10.1037/0022-006X.60.3.339; BURVILL PW, 1995, BRIT J PSYCHIAT, V166, P320, DOI 10.1192/bjp.166.3.320; CASTILLO CS, 1993, J NERV MENT DIS, V181, P100, DOI 10.1097/00005053-199302000-00005; DAM H, 1989, ACTA PSYCHIAT SCAND, V80, P118, DOI 10.1111/j.1600-0447.1989.tb01312.x; DOWNHILL JE, 1994, J NERV MENT DIS, V182, P425, DOI 10.1097/00005053-199408000-00001; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GUR RC, 1995, SCIENCE, V267, P528, DOI 10.1126/science.7824953; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HERRMANN M, 1995, STROKE, V26, P850, DOI 10.1161/01.STR.26.5.850; HOUSE A, 1990, PSYCHOL MED, V20, P805, DOI 10.1017/S0033291700036497; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; MORRIS PLP, 1991, PSYCHIATRY, V54, P306; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1986, BRIT J PSYCHIAT, V148, P541, DOI 10.1192/bjp.148.5.541; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROBINSON RG, 1981, BRAIN LANG, V14, P282, DOI 10.1016/0093-934X(81)90080-8; Sartorius N, 1974, MEASUREMENT CLASSIFI; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SCHWARTZ JA, 1993, BIOL PSYCHIAT, V33, P694, DOI 10.1016/0006-3223(93)90118-W; SHARPE M, 1994, BRIT J PSYCHIAT, V164, P380, DOI 10.1192/bjp.164.3.380; SHAYWITZ BA, 1995, NATURE, V373, P607, DOI 10.1038/373607a0; SINYOR D, 1986, STROKE, V17, P1102, DOI 10.1161/01.STR.17.6.1102; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; TRAVELLA JI, 1994, INT J PSYCHIAT MED, V24, P357, DOI 10.2190/U8R0-A61Y-AKRP-T24V; WADE DT, 1987, BRIT J PSYCHIAT, V151, P200, DOI 10.1192/bjp.151.2.200; WEISSMAN MM, 1995, SCIENCE, V269, P799, DOI 10.1126/science.7638596	36	96	101	0	8	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1998	10	1					41	47		10.1176/jnp.10.1.41			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	ZD354	WOS:000072676800006	9547465				2021-06-18	
J	Bartholdi, D; Rubin, BP; Schwab, ME				Bartholdi, D; Rubin, BP; Schwab, ME			VEGF mRNA induction correlates with changes in the vascular architecture upon spinal cord damage in the rat	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						angiogenesis; CNS; lesion; X-irradiation	ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS FACTOR; RADIATION-DAMAGE; NEURITE GROWTH; OXYGEN-TENSION; TIME-COURSE; CELL-DEATH; EXPRESSION; INJURY; BRAIN	The multiple cellular and molecular processes induced by injury to the central nervous system (CNS) are still poorly understood. In the present study, we investigated the response of the vasculature and the expression of mRNA for the angiogenic vascular endothelial growth factor (VEGF) following X-irradiation of the spinal cord in the newborn and following traumatic spinal cord injury in the adult rat, Both lesion models induced changes in the density and the distribution pattern of blood vessels: while X-irradiation led to a permanent local increase in vascular density in the fibre tracts of the exposed segments, a transient local sprouting of vessels was induced upon traumatic spinal cord injury. In situ hybridization showed that an increase of VEGF mRNA anticipated and overlapped with the vascular responses in both lesion models. In addition to the temporal correlation of VEGF expression and vascular sprouting, there was a clear correlation in the spatial distribution patterns. Following X-irradiation, the expression of VEGF mRNA was restricted to the fibre tracts, precisely the areas where the changes in the vasculature were observed later on. Upon transection in the adult animal, VEGF was mainly detectable at the border of the lesion area, where the transient increase in vascular density could be observed. Interestingly, according to the type of lesion applied, astrocytes (X-irradiation) or inflammatory cells (presumably microglial cells or macrophages; traumatic lesion) are the cellular sources of VEGF mRNA, Our results strongly indicate that VEGF is crucially involved in mediating vascular changes following different types of injury in the CNS.	Univ Zurich, Brain Res Inst, CH-8029 Zurich, Switzerland	Schwab, ME (corresponding author), Univ Zurich, Brain Res Inst, August Forel Str 1, CH-8029 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016				BAKER DG, 1989, CANCER INVEST, V7, P287, DOI 10.3109/07357908909039849; BALENTINE JD, 1978, LAB INVEST, V39, P236; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Beggs J L, 1979, Adv Neurol, V22, P179; Beggs J L, 1979, Adv Neurol, V22, P191; BLAKEMORE WF, 1982, J PATHOL, V137, P273, DOI 10.1002/path.1711370402; BREIER G, 1992, DEVELOPMENT, V114, P521; CALVO W, 1987, BRIT J RADIOL, V60, P1109, DOI 10.1259/0007-1285-60-719-1109; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CLARK RAF, 1993, DERMATOL CLIN, V11, P647, DOI 10.1016/S0733-8635(18)30218-3; DIMITRIEVICH GS, 1984, RADIAT RES, V99, P511, DOI 10.2307/3576327; DUIJVESTIJN AM, 1992, LAB INVEST, V66, P459; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; GILMORE SA, 1963, J NEUROPATH EXP NEUR, V22, P294, DOI 10.1097/00005072-196304000-00008; HAYASHI N, 1983, J NEUROSURG, V58, P516, DOI 10.3171/jns.1983.58.4.0516; Hopewell J W, 1993, Recent Results Cancer Res, V130, P1; HOPEWELL JW, 1990, INT J RADIAT BIOL, V57, P751, DOI 10.1080/09553009014550911; HOPEWELL JW, 1979, NEUROPATH APPL NEURO, V5, P329, DOI 10.1111/j.1365-2990.1979.tb00633.x; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; IMPERATO EL, 1997, IN PRESS EXP NEUROL; Joo F, 1996, PROG NEUROBIOL, V48, P255, DOI 10.1016/0301-0082(95)00046-1; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOYANAGI I, 1993, NEUROSURGERY, V33, P277; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li YQ, 1996, RADIOTHER ONCOL, V39, P35, DOI 10.1016/0167-8140(96)01705-7; LOGAN A, 1992, J NEUROSCI, V12, P3828; MASTAGLIA FL, 1976, BRAIN, V99, P101, DOI 10.1093/brain/99.1.101; MILDENBERGER M, 1990, INT J RADIAT ONCOL, V18, P1051, DOI 10.1016/0360-3016(90)90440-U; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MIYOSHI Y, 1995, EXP NEUROL, V131, P69, DOI 10.1016/0014-4886(95)90009-8; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; MYERS R, 1986, BRIT J CANCER, V53, P221; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PIERCE GF, 1992, AM J PATHOL, V140, P1375; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; REZVANI M, 1995, STEM CELLS, V13, P248, DOI 10.1002/stem.5530130730; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SAKLA FB, 1969, J COMP NEUROL, V136, P237, DOI 10.1002/cne.901360209; SAVIO T, 1990, P NATL ACAD SCI USA, V87, P4130, DOI 10.1073/pnas.87.11.4130; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; Schwab ME, 1996, PHYSIOL REV, V76, P319; SCHWEGLER G, 1995, J NEUROSCI, V15, P2756; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; STURROCK RR, 1981, J ANAT, V132, P203; WALLACE MC, 1986, NEUROSURGERY, V18, P433; WHITBY DJ, 1991, DEVELOPMENT, V112, P651	57	96	99	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	DEC	1997	9	12					2549	2560		10.1111/j.1460-9568.1997.tb01684.x			12	Neurosciences	Neurosciences & Neurology	ZB439	WOS:000072461400006	9517460				2021-06-18	
J	Newcomb, JK; Kampfl, A; Posmantur, RM; Zhao, XR; Pike, BR; Liu, SJ; Clifton, GL; Hayes, RL				Newcomb, JK; Kampfl, A; Posmantur, RM; Zhao, XR; Pike, BR; Liu, SJ; Clifton, GL; Hayes, RL			Immunohistochemical study of calpain-mediated breakdown products to alpha-spectrin following controlled cortical impact injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						calpain; alpha-spectrin; traumatic brain injury; cytoskeleton; immunohistochemistry	MICROTUBULE-ASSOCIATED PROTEIN-2; TRAUMATIC BRAIN INJURY; TRANSIENT FOREBRAIN ISCHEMIA; CALCIUM-ACTIVATED PROTEASE; MIDDLE CEREBRAL-ARTERY; SPINAL-CORD INJURY; NEUROFILAMENT PROTEINS; GERBIL HIPPOCAMPUS; FODRIN PROTEOLYSIS; NEURONAL DAMAGE	This study examined the effect of unilateral controlled cortical impact on the appearance of calpain-mediated alpha-spectrin breakdown products (BDPs) in the rat cortex and hippocampus at various times following injury. Coronal sections were taken from animals at 15 min, 1 h, 3 h, 6 h, and 24 h after injury and immunolabeled with an antibody that recognizes calpain-mediated BDPs to alpha-spectrin (Roberts-Lewis et al., 1994). Sections from a separate group of rats were also taken at the same times and stained with hematoxylin and eosin. Analyses of early time points (15 min, 1 h, 3 h, and 6 h following injury) revealed alpha-spectrin BDPs in structurally intact neuronal soma and dendrites in cortex ipsilateral to site of injury that was not present in tissue from sham-injured control rats. By 24 h after injury labeling was not restricted to clearly defined neuronal structures in ipsilateral cortex, although there was an increased extent of diffuse labeling. BDPs to alpha-spectrin in axons were not detected until 24 h after injury, in contrast to the more rapid accumulation of BDPs observed in neuronal soma and dendrites. The presence of BDPs to alpha-spectrin in the cortex at the site of impact, and in the rostral and contralateral cortex, coincided with morphopathology detected by hematoxylin and eosin. alpha-Spectrin BDPs were also observed in the hippocampus ipsilateral to the injury in the absence of overt cell death. This investigation provides further evidence that calpain is activated after controlled cortical impact and could contribute to necrosis at the site of injury. The appearance of calpain-mediated BDPs at sites distal to the contusion site and in the hippocampus also suggests that calpain activation may precede and/or occur in the absence of extensive morphopathological changes.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,VIVIAN L SMITH CTR NEUROL RES,HOUSTON,TX 77030					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5PO1NS31998, R01NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER		BANIK NL, 1987, METAB BRAIN DIS, V2, P117, DOI 10.1007/BF00999722; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BLOMGREN K, 1995, BRAIN RES, V684, P136, DOI 10.1016/0006-8993(95)00398-A; BONNEKOH P, 1990, ACTA NEUROPATHOL, V80, P18, DOI 10.1007/BF00294217; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P56; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DHERMY D, 1991, BIOL CELL, V71, P249; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GUROFF G, 1964, J BIOL CHEM, V239, P149; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; KAMPFL A, 1995, NEUROSCI LETT, V194, P149, DOI 10.1016/0304-3940(95)11745-I; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KAMPFL A, 1997, IN PRESS J NEUROTRAU; KARST H, 1993, NEUROSCI LETT, V164, P154, DOI 10.1016/0304-3940(93)90880-T; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kleese W.C., 1990, INTRACELLULAR CALCIU, P3; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; MELLGREN RL, 1980, FEBS LETT, V109, P129, DOI 10.1016/0014-5793(80)81326-3; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; Neumar RW, 1996, J NEUROCHEM, V66, P421; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; NILSSON P, 1993, J CEREB BLOOD FLOW M, V13, P185; NIXON RA, 1990, J NEUROCHEM, V55, P1950, DOI 10.1111/j.1471-4159.1990.tb05781.x; NIXON RA, 1986, J NEUROSCI, V6, P1264; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POSMANTUR R, 1994, J NEUROTRAUM, V533, P11; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POSMANTUR RM, 1997, IN PRESS NEUROSCIENC; POVLISHOCK JT, 1996, IN PRESS J NEUROPATH; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Regehr Wade G., 1994, Current Opinion in Neurobiology, V4, P373, DOI 10.1016/0959-4388(94)90099-X; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; SHAPIRA Y, 1989, Neurological Research, V11, P169; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P1787, DOI 10.1093/oxfordjournals.jbchem.a133656; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WHITSON JS, 1995, BRAIN RES, V694, P213, DOI 10.1016/0006-8993(95)00745-C; WHITSON JS, 1995, NEUROSCI LETT, V197, P159, DOI 10.1016/0304-3940(95)11921-I; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; Zhao X., 1996, Society for Neuroscience Abstracts, V22, P1903; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	82	96	99	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1997	14	6					369	383		10.1089/neu.1997.14.369			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XJ836	WOS:A1997XJ83600002	9219852				2021-06-18	
J	ROBERTSON, CS; GOPINATH, SP; GOODMAN, JC; CONTANT, CF; VALADKA, AB; NARAYAN, RK				ROBERTSON, CS; GOPINATH, SP; GOODMAN, JC; CONTANT, CF; VALADKA, AB; NARAYAN, RK			SJVO(2) MONITORING IN HEAD-INJURED PATIENTS	JOURNAL OF NEUROTRAUMA			English	Article						HEAD INJURY; SJVO(2) MONITORING; SECONDARY INJURY	JUGULAR BULB CATHETERIZATION	Jugular venous oxygen saturation (SjvO(2)) measures the balance between cerebral oxygen delivery and cerebral oxygen consumption. Abnormalities that increase oxygen consumption (e.g., fever or seizures) or that decrease oxygen delivery (e.g., increased ICP, hypotension, hypoxia, hypocapnia, or anemia) can decrease SjvO(2). Measuring SjvO(2) continuously in the ICU in 177 patients with severe head injury, jugular venous desaturation (SjvO(2) < 50%) was identified at least once in 39% of the patients. Approximately half of the episodes of desaturation were due to intracranial hypertension and half were due to systemic causes. The occurrence of one or more episodes of desaturation was strongly associated with a poor outcome, suggesting that the reduction in oxygen delivery identified with the SjvO(2) monitoring contributed to the neurological injury. In the operating room, jugular venous desaturation was identified in 6 of 8 patients who were monitored during emergency evacuation of a traumatic intracranial hematoma. The lowest SjvO(2) observed was 28%. In all 8 cases, the SjvO(2) increased, from 47 +/- 10% to 63 +/- 5% after evacuation of the hematoma. Additional data supporting the hypothesis that these secondary insults identified with the SjvO(2) monitoring contribute to the patient's neurological injury come from measurement of the extracellular concentrations of lactate and excitatory amino acids in the brain using microdialysis. Lactate concentration increased from 0.9 +/- 0.3 to 2.4 +/- 0.5 mu mol/L and glutamate increased from 11.5 +/- 8.5 to 55.0 +/- 10.4 mu mol/L during 8 episodes of jugular venous desaturation in 7 of 22 patients monitored with microdialysis. SjvO(2) identifies global reductions in cerebral oxygenation due to a variety of causes, and is useful as a monitor for secondary insults in patients with severe head injury.		ROBERTSON, CS (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GOETTING MG, 1991, INTENS CARE MED, V17, P195, DOI 10.1007/BF01709876; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SENEFF MG, 1985, INTENS CARE MED, P16; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Stocchetti N, 1991, Minerva Anestesiol, V57, P319	9	96	105	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					891	896		10.1089/neu.1995.12.891			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600013	8594216				2021-06-18	
J	GOPINATH, SP; ROBERTSON, CS; CONTANT, CF; NARAYAN, RK; GROSSMAN, RG; CHANCE, B				GOPINATH, SP; ROBERTSON, CS; CONTANT, CF; NARAYAN, RK; GROSSMAN, RG; CHANCE, B			EARLY DETECTION OF DELAYED TRAUMATIC INTRACRANIAL HEMATOMAS USING NEAR-INFRARED SPECTROSCOPY	JOURNAL OF NEUROSURGERY			English	Article						NEAR-INFRARED SPECTROSCOPY; HEAD INJURY; SUBDURAL HEMATOMA; EPIDURAL HEMATOMA; INTRACEREBRAL HEMATOMA; DELAYED TRAUMATIC HEMATOMA	SEVERE HEAD-INJURY; ACUTE SUBDURAL-HEMATOMA; INTRACEREBRAL HEMATOMAS; COMPUTERIZED-TOMOGRAPHY; CEREBRAL HEMATOMAS; CT SCAN; ONSET	Delayed intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Early identification and treatment of these lesions, which appear or enlarge after the initial computerized tomography (CT) scan, may improve neurological outcome. Serial examinations using near-infrared spectroscopy (NIRS) to detect the development of delayed hematomas were performed in 167 patients. The difference in absorbance of light (Delta OD) at 760 nm between the normal and the hematoma side was measured serially during the first 3 days after injury. Twenty-seven (16%) of the patients developed a type of late hematoma: intracerebral hematoma in eight, extracerebral hematoma in six, and postoperative hematoma in 13 patients. Eighteen of the delayed hematomas caused significant mass effect and required surgical evacuation. The hematomas appeared between 2 and 72 hours after admission. In 24 of the 27 patients, a significant increase (> 0.3) in the Delta OD occurred prior to an increase in intracranial pressure, a change in the neurological examination, or a change on CT scan. A favorable outcome occurred in 67% of the patients with delayed hematomas, which suggests that early diagnosis using NIRS may allow early treatment and reduce secondary injury caused by delayed hematomas.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	GOPINATH, SP (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616, R01NS027346] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27346, P01-NS27616] Funding Source: Medline		ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; ANDREWS BT, 1988, CONT NEUROSURG, V10, P1; BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; FUKAMACHI A, 1985, ACTA NEUROCHIR, V74, P35, DOI 10.1007/BF01413274; Gentleman D, 1989, Br J Neurosurg, V3, P367, DOI 10.3109/02688698909002817; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; GOPINATH SP, 1995, IN PRESS NEUROTRAUMA; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; KLUN B, 1984, ACTA NEUROCHIR, V71, P171, DOI 10.1007/BF01401312; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; NINCHOJI T, 1984, ACTA NEUROCHIR, V71, P69, DOI 10.1007/BF01401152; PIEPMEIER JM, 1982, J TRAUMA, V22, P455, DOI 10.1097/00005373-198206000-00003; RICHARDS T, 1974, SURGERY, V75, P253; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SAKAI H, 1986, INTRACRANIAL PRESSUR, V6, P652; SAWADA Y, 1984, J NEUROL NEUROSUR PS, V47, P1125, DOI 10.1136/jnnp.47.10.1125; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	29	96	101	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1995	83	3					438	444		10.3171/jns.1995.83.3.0438			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RR001	WOS:A1995RR00100009	7666220				2021-06-18	
J	DAVIS, RL; MULLEN, N; MAKELA, M; TAYLOR, JA; COHEN, W; RIVARA, FP				DAVIS, RL; MULLEN, N; MAKELA, M; TAYLOR, JA; COHEN, W; RIVARA, FP			CRANIAL COMPUTED-TOMOGRAPHY SCANS IN CHILDREN AFTER MINIMAL HEAD-INJURY WITH LOSS OF CONSCIOUSNESS	ANNALS OF EMERGENCY MEDICINE			English	Article								Study objective: To assess the need for cranial computed tomography (CT) in the emergency department evaluation of children with Glasgow Coma Scale (GCS) score of 15 after mild head injury with loss of consciousness. Design: Retrospective case series of children aged 2 to 17 years with documented loss of consciousness after head injury from January 1, 1988, to July 31, 1992. All had a GCS score of 15 on initial ED evaluation and were further categorized according to physical examination findings, neurologic status, and whether the head injury was isolated or nonisolated. Recursive partitioning was used to identify variables predictive of the presence and absence of intracranial hemorrhage. Setting: ED in two settings: a regional tertiary care trauma center and a community children's hospital. Results: Of the 185 patients who met study criteria, 17 had evidence of depressed or basilar skull fractures on physical examination or had a ventriculoperitoneal shunt in place before head injury. In the remaining 168 patients, recursive partioning identified two variables (neurologic status and head injury type) associated with intracranial hemorrhage. Overall, 12 of 168 patients (7%) had intracranial bleeding. However, none of the 49 neurologically normal children with isolated head injury had intracranial hemorrhage (95% confidence interval, 0.0 to 6.0). Conclusion: The prevalence of intracranial hemorrhage in children with mild closed-head injury appears to vary with the presence of neurologic abnormalities and other noncranial injuries. After isolated head injury with loss of consciousness, children older than 2 years who are neurologically normal and without signs of depressed or basilar skull fracture may be discharged home from the ED without a cranial CT scan after careful physical examination alone.		DAVIS, RL (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,WJ-10,SEATTLE,WA 98195, USA.							0	96	96	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	OCT	1994	24	4					640	645		10.1016/S0196-0644(94)70273-X			6	Emergency Medicine	Emergency Medicine	PJ498	WOS:A1994PJ49800004	8092590				2021-06-18	
J	HADDAD, FS; HADDAD, GF; TAHA, J				HADDAD, FS; HADDAD, GF; TAHA, J			TRAUMATIC INTRACRANIAL ANEURYSMS CAUSED BY MISSILES - THEIR PRESENTATION AND MANAGEMENT	NEUROSURGERY			English	Article						BRAIN INJURIES; CEREBRAL ANEURYSMS; CEREBRAL ANGIOGRAPHY; CEREBRAL HEMORRHAGE; SPASM; SUBDURAL HEMATOMA	WOUNDS; ARTERY; BRAIN	Only 30 cases of traumatic intracranial aneurysm (TICA) secondary to missile injury have been reported to date. To these we add 15 more cases. Missile TICAs are often seen on a secondary branch of the middle cerebral artery and are usually accompanied by a intracerebral hematoma (80%) or by an acute subdural hematoma (26%). Fourteen of our cases were secondary to sharpnel injuries and only one was secondary to a bullet. None of the injuries was through-and-through. TICAs may enlarge in time and, seemingly inoffensive, may rupture and lead to death. All seven TICAs studied histologically proved to be false aneurysms. TICAs are best treated through trapping and excision. The outcome depends on the patient's status and level of consciousness before surgery. Indications for angiography are discussed.	MONTREAL NEUROL HOSP & INST,3801 UNIV ST,MONTREAL H3A 2B4,QUEBEC,CANADA; AMER UNIV BEIRUT,MED CTR,DEPT NEUROSURG,BEIRUT,LEBANON							AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACHRAM M, 1980, BRIT J RADIOL, V53, P1144, DOI 10.1259/0007-1285-53-636-1144; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; BANK WO, 1978, AM J ROENTGENOL, V130, P975, DOI 10.2214/ajr.130.5.975; COURVILLE C B, 1960, Bull Los Angel Neuro Soc, V25, P48; CROMPTON MR, 1966, BRIT MED J, V1, P1138, DOI 10.1136/bmj.1.5496.1138; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FIELDS WS, 1965, INTRACRANIAL ANEURYS; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FOX JL, 1983, INTRACRANIAL ANEURYS, V3, P1453; FOX JL, 1983, INTRACRANIAL ANEURYS, V1, P423; GUIBERT, 1895, ANN OCUL, V113, P314; HADDAD FS, 1978, CAN J SURG, V21, P233; HAMBI WB, 1952, INTRACRANIAL ANEURYS, P113; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; Jackson F E, 1970, J Trauma, V10, P1158, DOI 10.1097/00005373-197012000-00008; JACKSON FE, 1974, US NAVY MED, V63, P34; KAUFMAN HH, 1980, NEUROSURGERY, V6, P181, DOI 10.1227/00006123-198002000-00011; Martin E M, 1986, J Neurosci Nurs, V18, P89; MCDONALD EJ, 1976, AM J ROENTGENOL, V126, P792, DOI 10.2214/ajr.126.4.792; Meirowsky A., 1965, NEUROLOGICAL SURGERY, P103; MOORE D, 1979, SURG NEUROL, V11, P115; PAKARINEN S, 1967, ACTA NEUROL SCAND  S, V29, P1; PETTY J M, 1969, Journal of Neurosurgery, V30, P741, DOI 10.3171/jns.1969.30.6.0741; POOL JL, 1965, ANEURYSMS ARTERIOVEN, P60; RAIMONDI AJ, 1960, NEUROCHIRURGIA STUTT, V11, P219; ROBBINS JB, 1976, LARYNGOSCOPE, V86, P893, DOI 10.1288/00005537-197607000-00001; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; SALAR G, 1978, J NEUROSURG, V49, P100, DOI 10.3171/jns.1978.49.1.0100; SARWAR M, 1976, RADIOLOGY, V120, P603, DOI 10.1148/120.3.603; SCHMIDT-VANDERHEYDEN W, 1971, Archiv fuer Psychiatrie und Nervenkrankheiten, V214, P10, DOI 10.1007/BF00344623; SPETZLER RF, 1979, NEUROSURGERY, V4, P334, DOI 10.1227/00006123-197904000-00011	33	96	99	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JAN	1991	28	1					1	7					7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EP137	WOS:A1991EP13700001	1994264				2021-06-18	
J	Barnes, DE; Byers, AL; Gardner, RC; Seal, KH; Boscardin, WJ; Yaffe, K				Barnes, Deborah E.; Byers, Amy L.; Gardner, Raquel C.; Seal, Karen H.; Boscardin, W. John; Yaffe, Kristine			Association of Mild Traumatic Brain Injury With and Without Loss of Consciousness With Dementia in US Military Veterans	JAMA NEUROLOGY			English	Article							FOOTBALL-LEAGUE PLAYER; HEAD-INJURY; ALZHEIMERS-DISEASE; INCREASED RISK; ENCEPHALOPATHY; CONCUSSION; HISTORY; ONSET; AGE	IMPORTANCE Traumatic brain injury (TBI) is common in both veteran and civilian populations. Prior studies have linked moderate and severe TBI with increased dementia risk, but the association between dementia and mild TBI, particularly mild TBI without loss of consciousness (LOC), remains unclear. OBJECTIVE To examine the association between TBI severity, LOC, and dementia diagnosis in veterans. DESIGN, SETTING, AND PARTICIPANTS This cohort study of all patients diagnosed with a TBI in the Veterans Health Administration health care system from October 1, 2001, to September 30, 2014, and a propensity-matched comparison group. Patients with dementia at baseline were excluded. Researchers identified TBIs through the Comprehensive TBI Evaluation database, which is restricted to Iraq and Afghanistan veterans, and the National Patient Care Database, which includes veterans of all eras. The severity of each TBI was based on the most severe injury recorded and classified as mild without LOC, mild with LOC, mild with LOC status unknown, or moderate or severe using Department of Defense or Defense and Veterans Brain Injury Center criteria. International Classification of Diseases, Ninth Revision codes were used to identify dementia diagnoses during follow-up and medical and psychiatric comorbidities in the 2 years prior to the index date. MAIN OUTCOMES AND MEASURES Dementia diagnosis in veterans who had experienced TBI with or without LOC and control participants without TBI exposure. RESULTS The study included 178 779 patients diagnosed with a TBI in the Veterans Health Administration health care system and 178 779 patients in a propensity-matched comparison group. Veterans had a mean (SD) age of nearly 49.5 (18.2) years at baseline; 33 250 (9.3%) were women, and 259 136 (72.5%) were non-Hispanic white individuals. Differences between veterans with and without TBI were small. A total of 4698 veterans (2.6%) without TBI developed dementia compared with 10 835 (6.1%) of those with TBI. After adjustment for demographics and medical and psychiatric comobidities, adjusted hazard ratios for dementia were 2.36 (95% Cl, 2.10-2.66) for mild TBI without LOC, 2.51 (95% Cl, 2.29-2.76) for mild TBI with LOC, 3.19 ( 95% Cl, 3.05-3.33) for mild TBI with LOC status unknown, and 3.77 ( 95% Cl, 3.63-3.91) for moderate to severe TBI. CONCLUSIONS AND RELEVANCE In this cohort study of more than 350 000 veterans, even mild TBI without LOC was associated with more than a 2-fold increase in the risk of dementia diagnosis. Studies of strategies to determine mechanisms, prevention, and treatment of TBI-related dementia in veterans are urgently needed.	[Barnes, Deborah E.; Byers, Amy L.; Gardner, Raquel C.; Seal, Karen H.; Boscardin, W. John; Yaffe, Kristine] San Francisco Vet Affairs Hlth Care Syst, 4150 Clement St,151R, San Francisco, CA 94121 USA; [Barnes, Deborah E.; Byers, Amy L.; Seal, Karen H.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Barnes, Deborah E.; Byers, Amy L.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Seal, Karen H.; Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Barnes, DE (corresponding author), San Francisco Vet Affairs Hlth Care Syst, 4150 Clement St,151R, San Francisco, CA 94121 USA.	deborah.barnes@ucsf.edu			US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); US Department of Veterans AffairsUS Department of Veterans Affairs; Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095, 1I01CX001246]	This work is supported by the US Army Medical Research and Material Command, the US Department of Veterans Affairs, and the Chronic Effects of Neurotrauma Consortium (grants W81XWH-13-2-0095 and 1I01CX001246).	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; [Anonymous], 2016, SURV CAS DEF; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chu SF, 2016, ASIA-PAC J PUBLIC HE, V28, P519, DOI 10.1177/1010539516662956; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, 2010, DEF CTR EXC PSYCH HL; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; Institute of Medicine, 2008, LONG TERM CONS TRAUM, V7; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; LoBue C, 2017, CLIN NEUROPSYCHOL, V31, P85, DOI 10.1080/13854046.2016.1257069; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2016, NEUROSURG CLIN N AM, V27, P529, DOI 10.1016/j.nec.2016.05.009; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Weiner MW, 2017, NEUROLOGY, V89, P1923, DOI 10.1212/WNL.0000000000004608; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604	46	95	95	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	SEP	2018	75	9					1055	1061		10.1001/jamaneurol.2018.0815			7	Clinical Neurology	Neurosciences & Neurology	GT1EJ	WOS:000444201900005	29801145	Bronze, Green Published	Y	N	2021-06-18	
J	Ghajari, M; Hellyer, PJ; Sharp, DJ				Ghajari, Mazdak; Hellyer, Peter J.; Sharp, David J.			Computational modelling of traumatic brain injury predicts the location of chronic traumatic encephalopathy pathology	BRAIN			English	Article						computational modelling; diffusion imaging; traumatic brain injury	DIFFUSE AXONAL INJURY; DYNAMIC STRETCH INJURY; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER INJURY; COGNITIVE IMPAIRMENT; HEAD-INJURY; TOLERANCE; CONCUSSION; TISSUE; DEFORMATION	Traumatic brain injury can lead to the neurodegenerative disease chronic traumatic encephalopathy. This condition has a clear neuropathological definition but the relationship between the initial head impact and the pattern of progressive brain pathology is poorly understood. We test the hypothesis that mechanical strain and strain rate are greatest in sulci, where neuropathology is prominently seen in chronic traumatic encephalopathy, and whether human neuroimaging observations converge with computational predictions. Three distinct types of injury were simulated. Chronic traumatic encephalopathy can occur after sporting injuries, so we studied a helmet-to-helmet impact in an American football game. In addition, we investigated an occipital head impact due to a fall from ground level and a helmeted head impact in a road traffic accident involving a motorcycle and a car. A high fidelity 3D computational model of brain injury biomechanics was developed and the contours of strain and strain rate at the grey matter-white matter boundary were mapped. Diffusion tensor imaging abnormalities in a cohort of 97 traumatic brain injury patients were also mapped at the grey matter-white matter boundary. Fifty-one healthy subjects served as controls. The computational models predicted large strain most prominent at the depths of sulci. The volume fraction of sulcal regions exceeding brain injury thresholds were significantly larger than that of gyral regions. Strain and strain rates were highest for the road traffic accident and sporting injury. Strain was greater in the sulci for all injury types, but strain rate was greater only in the road traffic and sporting injuries. Diffusion tensor imaging showed converging imaging abnormalities within sulcal regions with a significant decrease in fractional anisotropy in the patient group compared to controls within the sulci. Our results show that brain tissue deformation induced by head impact loading is greatest in sulcal locations, where pathology in cases of chronic traumatic encephalopathy is observed. In addition, the nature of initial head loading can have a significant influence on the magnitude and pattern of injury. Clarifying this relationship is key to understanding the long-term effects of head impacts and improving protective strategies, such as helmet design.	[Ghajari, Mazdak] Imperial Coll London, Dyson Sch Design Engn, London SW7 2AZ, England; [Hellyer, Peter J.] Imperial Coll London, Dept Bioengn, South Kensington Campus, London SW7 2AZ, England; [Sharp, David J.] Imperial Coll London, Computat & Clin Neuroimaging Lab, Cognit & Clin Neuroimaging Lab, Div Brain Sci, London W12 0NN, England	Ghajari, M (corresponding author), Imperial Coll London, Dyson Sch Design Engn, London SW7 2AZ, England.	m.ghajari@imperial.ac.uk	Sharp, David J/A-2119-2013; Hellyer, Peter J/F-7112-2013; Lang, Steven/AAE-8102-2021	Hellyer, Peter J/0000-0002-5139-3401; Lang, Steven/0000-0003-1669-9146	Imperial College London Junior Research Fellowship; Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Imperial College NIHR Biomedical Research Centre; Sir Henry Wellcome Postdoctoral Fellowship (Wellcome Trust); National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	This work was supported by an Imperial College London Junior Research Fellowship (M.G.) and the Medical Research Council (UK). D.J.S. has a National Institute of Health Research Professorship - RP-011-048. The work was also supported by the Imperial College NIHR Biomedical Research Centre. P.J.H is funded by a Sir Henry Wellcome Postdoctoral Fellowship (Wellcome Trust).	Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; [Anonymous], 2001, COST327 EUR COMM; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Ghajari M, 2011, INT J CRASHWORTHINES, V16, P285, DOI 10.1080/13588265.2011.559798; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Hallquist J.O., 2013, LS DYNA KEYW US MAN; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Holzapfel G., 2000, NONLINEAR SOLID MECH; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; King A.I., 2003, IRCOBI C LISB PORT, P1; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Nicolle S, 2005, BIORHEOLOGY, V42, P209; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Post A, 2014, COMPUT METHOD BIOMEC, V17, P1785, DOI 10.1080/10255842.2013.766724; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; Shreiber DI, 1997, STAPP CAR CRASH J, V41, P277; Singh Anita, 2006, Stapp Car Crash J, V50, P601; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	52	95	95	4	26	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2017	140		2				333	343		10.1093/brain/aww317			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EP3XV	WOS:000397315900018	28043957	Green Published, Bronze			2021-06-18	
J	Tai, XY; Koepp, M; Duncan, JS; Fox, N; Thompson, P; Baxendale, S; Liu, JYW; Reeves, C; Michalak, Z; Thom, M				Tai, Xin You; Koepp, Matthias; Duncan, John S.; Fox, Nick; Thompson, Pamela; Baxendale, Sallie; Liu, Joan Y. W.; Reeves, Cheryl; Michalak, Zuzanna; Thom, Maria			Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections	BRAIN			English	Article						temporal lobe epilepsy; neurofibrillary tangles; tau; Alzheimer's disease; dementia	CHRONIC TRAUMATIC ENCEPHALOPATHY; DOUBLECORTIN-EXPRESSING CELLS; ALZHEIMERS-DISEASE; HIPPOCAMPAL SCLEROSIS; PATHOLOGICAL PROCESS; TDP-43 IMMUNOREACTIVITY; GENERAL-POPULATION; NEURONAL-ACTIVITY; CEREBRAL-CORTEX; MOUSE MODELS	Temporal lobe epilepsy (TLE) is associated with a high prevalence of cognitive decline. Tai et al. reveal the presence of hyperphosphorylated tau in resected temporal lobe tissue from patients with TLE. The quantity of pathological tau correlates with cognitive decline and its distribution suggests an epilepsy-related tauopathy.Temporal lobe epilepsy, the most prevalent form of chronic focal epilepsy, is associated with a high prevalence of cognitive impairment but the responsible underlying pathological mechanisms are unknown. Tau, the microtubule-associated protein, is a hallmark of several neurodegenerative diseases including Alzheimer's disease and chronic traumatic encephalopathy. We hypothesized that hyperphosphorylated tau pathology is associated with cognitive decline in temporal lobe epilepsy and explored this through clinico-pathological study. We first performed pathological examination on tissue from 33 patients who had undergone temporal lobe resection between ages 50 and 65 years to treat drug-refractory temporal lobe epilepsy. We identified hyperphosphorylated tau protein using AT8 immunohistochemistry and compared this distribution to Braak patterns of Alzheimer's disease and patterns of chronic traumatic encephalopathy. We quantified tau pathology using a modified tau score created specifically for analysis of temporal lobectomy tissue and the Braak staging, which was limited without extra-temporal brain areas available. Next, we correlated tau pathology with pre- and postoperative cognitive test scores and clinical risk factors including age at time of surgery, duration of epilepsy, history of secondary generalized seizures, history of head injury, handedness and side of surgery. Thirty-one of 33 cases (94%) showed hyperphosphorylated tau pathology in the form of neuropil threads and neurofibrillary tangles and pre-tangles. Braak stage analysis showed 12% of our epilepsy cohort had a Braak staging III-IV compared to an age-matched non-epilepsy control group from the literature (8%). We identified a mixture of tau pathology patterns characteristic of Alzheimer's disease and chronic traumatic encephalopathy. We also found unusual patterns of subpial tau deposition, sparing of the hippocampus and co-localization with mossy fibre sprouting, a feature of temporal lobe epilepsy. We demonstrated that the more extensive the tau pathology, the greater the decline in verbal learning (Spearman correlation, r = -0.63), recall (r = -0.44) and graded naming test scores (r = -0.50) over 1-year post-temporal lobe resection (P < 0.05). This relationship with tau burden was also present when examining decline in verbal learning from 3 months to 1 year post-resection (r = -0.54). We found an association between modified tau score and history of secondary generalized seizures (likelihood-ratio chi(2), P < 0.05) however there was no clear relationship between tau pathology and other clinical risk factors assessed. Our findings suggest an epilepsy-related tauopathy in temporal lobe epilepsy, which contributes to accelerated cognitive decline and has diagnostic and treatment implications.	[Tai, Xin You; Liu, Joan Y. W.; Reeves, Cheryl; Michalak, Zuzanna; Thom, Maria] UCL Inst Neurol, Div Neuropathol, Queen Sq, London WC1N 3BG, England; [Tai, Xin You; Koepp, Matthias; Duncan, John S.; Thompson, Pamela; Baxendale, Sallie; Liu, Joan Y. W.; Reeves, Cheryl; Michalak, Zuzanna; Thom, Maria] UCL Inst Neurol, Dept Clin & Expt Epilepsy, Queen Sq, London WC1N 3BG, England; [Fox, Nick] UCL Inst Neurol, Dept Neurodegenerat Dis, Dementia Res Ctr, Queen Sq, London WC1N 3BG, England	Thom, M (corresponding author), UCL, Inst Neurol, Div Neuropathol, 1st Floor,Queen Sq House,Queen Sq, London WC1N 3BG, England.; Thom, M (corresponding author), UCL, Inst Neurol, Dept Clin & Expt Epilepsy, 1st Floor,Queen Sq House,Queen Sq, London WC1N 3BG, England.	m.thom@ucl.ac.uk	Fox, Nick C/B-1319-2009; Reeves, Cheryl/M-6192-2019; Baxendale, Sallie/AAN-8312-2020	Fox, Nick C/0000-0002-6660-657X; Liu, Joan/0000-0002-0777-5189; Duncan, John S/0000-0002-1373-0681	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/JO127OX/1]; Department of Health's NIHR Biomedical Research CentresNational Institute for Health Research (NIHR); European UnionEuropean Commission [602102]; Epilepsy Society; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/J01270X/1] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0515-10000, NF-SI-0509-10161, NF-SI-0508-10123, NF-SI-0513-10134] Funding Source: researchfish	This work is supported by the Medical Research Council (grant MR/JO127OX/1). This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. Z.M. received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement EPITARGET, #602102. The Epilepsy Society Brain and Tissue Bank at UCL was funded by the Epilepsy Society.	Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Bernhardt BC, 2009, NEUROLOGY, V72, P1747, DOI 10.1212/01.wnl.0000345969.57574.f5; Black LC, 2010, EPILEPSY BEHAV, V17, P412, DOI 10.1016/j.yebeh.2010.01.006; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Braak H, 2015, BRAIN, V138, P2814, DOI 10.1093/brain/awv236; Braak H, 2013, ACTA NEUROPATHOL, V126, P631, DOI [10.1007/s00401-013-1139-0, 10.1007/s00401-013-1153-2]; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Cormack F, 2005, NEUROIMAGE, V27, P635, DOI 10.1016/j.neuroimage.2005.05.023; Dijkstra KK, 2013, J NEUROL NEUROSUR PS, V84, P379, DOI 10.1136/jnnp-2012-303141; Duyckaerts C, 2015, ACTA NEUROPATHOL, V129, P749, DOI 10.1007/s00401-015-1390-7; Elger CE, 2004, LANCET NEUROL, V3, P663, DOI 10.1016/S1474-4422(04)00906-8; Gaitatzis A, 2004, EPILEPSIA, V45, P1613, DOI 10.1111/j.0013-9580.2004.17504.x; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814; Griffith HR, 2007, EPILEPSY RES, V74, P91, DOI 10.1016/j.eplepsyres.2007.01.002; Griffith HR, 2006, EPILEPSY BEHAV, V8, P161, DOI 10.1016/j.yebeh.2005.09.004; Haneef Z, 2014, EPILEPSIA, V55, P137, DOI 10.1111/epi.12476; Helmstaedter C, 2009, BRAIN, V132, P2822, DOI 10.1093/brain/awp182; Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872; Hogh P, 2002, NEUROLOGY, V58, P298, DOI 10.1212/WNL.58.2.298; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Kandratavicius L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/960126; Lee EB, 2008, ACTA NEUROPATHOL, V115, P305, DOI 10.1007/s00401-007-0331-5; Lewis J, 2016, ACTA NEUROPATHOL, V131, P27, DOI 10.1007/s00401-015-1507-z; Lin JJ, 2007, CEREB CORTEX, V17, P2007, DOI 10.1093/cercor/bhl109; Liu RSN, 2003, ANN NEUROL, V53, P312, DOI 10.1002/ana.10463; Liu YWJ, 2008, EUR J NEUROSCI, V28, P2254, DOI 10.1111/j.1460-9568.2008.06518.x; MACKENZIE IRA, 1994, ACTA NEUROPATHOL, V87, P504; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Oyegbile TO, 2004, NEUROLOGY, V62, P1736, DOI 10.1212/01.WNL.0000125186.04867.34; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Pooler AM, 2013, EMBO REP, V14, P389, DOI 10.1038/embor.2013.15; SHENG JG, 1994, J NEUROCHEM, V63, P1872; Spillantini MG, 2013, LANCET NEUROL, V12, P609, DOI 10.1016/S1474-4422(13)70090-5; Springer JA, 1999, BRAIN, V122, P2033, DOI 10.1093/brain/122.11.2033; Srikandarajah N, 2009, EPILEPSIA, V50, P2619, DOI 10.1111/j.1528-1167.2009.02194.x; Tellez-Zenteno JF, 2005, EPILEPSIA, V46, P1955, DOI 10.1111/j.1528-1167.2005.00344.x; Thom M, 2014, NEUROPATH APPL NEURO, V40, P520, DOI 10.1111/nan.12150; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Thompson PJ, 2015, SEIZURE-EUR J EPILEP, V29, P41, DOI 10.1016/j.seizure.2015.03.017; Vuono R, 2015, BRAIN, V138, P1907, DOI 10.1093/brain/awv107; Wolfe MS, 2012, SCI CAIRO, V2012; Xiong K, 2008, EXP NEUROL, V211, P271, DOI 10.1016/j.expneurol.2008.02.003; Zhang XM, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.017.2009	47	95	97	0	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP	2016	139		9				2441	2455		10.1093/brain/aww187			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DW5WX	WOS:000383719500019	27497924	Bronze, Green Accepted, Green Published			2021-06-18	
J	Wu, LC; Nangia, V; Bui, K; Hammoor, B; Kurt, M; Hernandez, F; Kuo, C; Camarillo, DB				Wu, Lyndia C.; Nangia, Vaibhav; Bui, Kevin; Hammoor, Bradley; Kurt, Mehmet; Hernandez, Fidel; Kuo, Calvin; Camarillo, David B.			In Vivo Evaluation of Wearable Head Impact Sensors	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Head impact sensors; Traumatic brain injury; Wearable sensors; Instrumented mouthguard; Instrumented skin patch; Instrumented skull cap; High speed video; Soft tissue modeling	SKIN-MOUNTED ACCELEROMETERS; BONE MOTION; FOOTBALL; KINEMATICS; ACCELERATION; MOVEMENT; SYSTEM	Inertial sensors are commonly used to measure human head motion. Some sensors have been tested with dummy or cadaver experiments with mixed results, and methods to evaluate sensors in vivo are lacking. Here we present an in vivo method using high speed video to test teeth-mounted (mouthguard), soft tissue-mounted (skin patch), and headgear-mounted (skull cap) sensors during 6-13 g sagittal soccer head impacts. Sensor coupling to the skull was quantified by displacement from an ear-canal reference. Mouthguard displacements were within video measurement error (< 1 mm), while the skin patch and skull cap displaced up to 4 and 13 mm from the ear-canal reference, respectively. We used the mouthguard, which had the least displacement from skull, as the reference to assess 6-degree-of-freedom skin patch and skull cap measurements. Linear and rotational acceleration magnitudes were over-predicted by both the skin patch (with 120% NRMS error for , 290% for ) and the skull cap (320% NRMS error for , 500% for ). Such over-predictions were largely due to out-of-plane motion. To model sensor error, we found that in-plane skin patch linear acceleration in the anterior-posterior direction could be modeled by an underdamped viscoelastic system. In summary, the mouthguard showed tighter skull coupling than the other sensor mounting approaches. Furthermore, the in vivo methods presented are valuable for investigating skull acceleration sensor technologies.	[Wu, Lyndia C.; Bui, Kevin; Hammoor, Bradley; Kurt, Mehmet; Camarillo, David B.] Stanford Univ, Dept Bioengn, 443 Via Ortega, Stanford, CA 94305 USA; [Nangia, Vaibhav; Hernandez, Fidel; Kuo, Calvin; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Camarillo, DB (corresponding author), Stanford Univ, Dept Bioengn, 443 Via Ortega, Stanford, CA 94305 USA.	lyndiacw@stanford.edu	Kuo, Calvin/AAH-1933-2019; Wu, Lyndia/AAQ-1106-2020	Kuo, Calvin/0000-0001-8401-9136; Wu, Lyndia/0000-0002-8236-032X; Kurt, Mehmet/0000-0002-5618-0296	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; David and Lucile Packard FoundationThe David & Lucile Packard Foundation [38454]; Stanford Child Health Research Institute Transdisciplinary Initiatives Program; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB017611] Funding Source: NIH RePORTER	We thank X2 Biosystems Inc. for supplying skin patch sensors. The study was supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, David and Lucile Packard Foundation 38454, and the Stanford Child Health Research Institute Transdisciplinary Initiatives Program.	Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bouguet J. Y., CAMERA CALIBRATION T; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Christopher J. J, 2013, 2013010805 SAE; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Ewins DJ, 2000, MODAL TESTING THEORY; Funk JR, 2009, 2009010251 SAE; Heikkila J, 1997, PROC CVPR IEEE, P1106, DOI 10.1109/CVPR.1997.609468; Hernandez F., 2015, J BIOMECH IN PRESS; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Higgins M, 2007, J ATHL TRAINING, V42, P5; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; KIM W, 1993, J BIOMECH ENG-T ASME, V115, P47, DOI 10.1115/1.2895470; Knox T., 2004, 2004013538 SAE; Lucchetti L, 1998, J BIOMECH, V31, P977, DOI 10.1016/S0021-9290(98)00083-9; PELLMAN EJ, 2003, NEUROSURGERY, V53, P796; Reinschmidt C, 1997, J BIOMECH, V30, P729, DOI 10.1016/S0021-9290(97)00001-8; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Salzar R. S., 2014, 2008012978 SAE; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Shultz R, 2011, GAIT POSTURE, V34, P44, DOI 10.1016/j.gaitpost.2011.03.008; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; TRUJILLO DM, 1990, J BIOMECH ENG-T ASME, V112, P229, DOI 10.1115/1.2891176; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153; ZHANG Z, 1999, P 7 IEEE INT C COMP, V1, P666, DOI DOI 10.1109/ICCV.1999.791289	27	95	96	0	35	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	APR	2016	44	4					1234	1245		10.1007/s10439-015-1423-3			12	Engineering, Biomedical	Engineering	DI8HJ	WOS:000373741800034	26289941	Green Accepted			2021-06-18	
J	Helmy, A; Guilfoyle, MR; Carpenter, KLH; Pickard, JD; Menon, DK; Hutchinson, PJ				Helmy, Adel; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.			Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						chemokines; IL1ra; microdialysis; neuroinflammation; randomized control trial; traumatic brain injury	NEUROPROTECTION; OVEREXPRESSION; NEUTRALIZATION; MICRODIALYSIS; CYTOKINES; ANAKINRA; SYSTEM; DAMAGE; EDEMA; MICE	Traumatic brain injury (TBI) is the commonest cause of death and disability in those aged under 40 years. Interleukin-1 receptor antagonist (Lira) is an endogenous competitive antagonist at the interleukin-1 type-1 receptor (IL-1R). Antagonism at the IL-1R confers neuroprotection in several rodent models of neuronal injury (i.e., trauma, stroke and excitotoxicity). We describe a single center, phase II, open label, randomized-control study of recombinant human IL1ra (rhIL1ra, anakinra) in severe TBI, at a dose of 100 mg subcutaneously once a day for 5 days in 20 patients randomized 1:1. We provide safety data (primary outcome) in this pathology, utilize cerebral microdialysis to directly determine brain extracellular concentrations of ILI ra and 41 cytokines and chemokines, and use principal component analysis (PCA) to explore the resultant cerebral cytokine profile. Interleukin-1 receptor antagonist was safe, penetrated into plasma and the brain extracellular fluid. The PCA showed a separation in cytokine profiles after IL1ra administration. A candidate cytokine from this analysis, macrophage-derived chemoattractant, was significantly lower in the rhIL1ra-treated group. Our results provide promising data for rhIL1ra as a therapeutic candidate by showing safety, brain penetration and a modification of the neuroinflammatory response to TBI by a putative neuroprotective agent in humans for the first time.	[Helmy, Adel; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge, England; [Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge CB2 2QQ, England	Helmy, A (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	adelhelmy@cantab.net	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727	Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond Fellowship; Royal College of Surgeons of England Research Fellowship; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); National Institute for Health Research Senior Investigator Awards; National Institute for Health Research Professorship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986 ID 79068]; Beverly Sackler Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0802251, G1000183B, G9439390, G0001354, G0600986, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090, ACF-2006-14-004, NF-SI-0508-10327] Funding Source: researchfish	AH is supported by a joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (G0802251). AN and MRG are supported by Raymond and Beverly Sackler Fellowships. MRG is supported by the Royal College of Surgeons of England Research Fellowship. KLHC is supported by the National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). DKM and JDP are supported by National Institute for Health Research Senior Investigator Awards. PJAH is supported a National Institute for Health Research Professorship. Study support was provided by the Medical Research Council (Grant number G0600986 ID 79068) and the National Institute for Health Research Biomedical Research Centre, Cambridge. PJAH and JDP are directors of Technicam. AH and MRG have received specialist training in multivariate projection methods from CAMO Software AS (Oslo, Norway). PJAH and JDP are directors of Technicam.	BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; British Medical Association, 2012, BRIT NATL FORMULARY; Burdi DF, 2007, BIOORG MED CHEM LETT, V17, P3141, DOI 10.1016/j.bmcl.2007.03.030; Cadosch D, 2010, INJURY, V41, pE4, DOI 10.1016/j.injury.2009.09.001; Cahn A, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-14; Clark SR, 2008, J CEREBR BLOOD F MET, V28, P387, DOI 10.1038/sj.jcbfm.9600537; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fearnside M, 2005, HEAD INJURY PATHOPHY; Galea J, 2011, J CEREBR BLOOD F MET, V31, P439, DOI 10.1038/jcbfm.2010.103; Gong HW, 2012, MOLECULES, V17, P9961, DOI 10.3390/molecules17089961; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Mantovani A, 2000, J LEUKOCYTE BIOL, V68, P400; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010; Osborn O, 2011, CYTOKINE, V53, P311, DOI 10.1016/j.cyto.2010.11.017; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schwartz M, 2009, NEUROSCIENCE, V158, P1133, DOI 10.1016/j.neuroscience.2008.12.013; Shannon RJ, 2013, J PHARMACOKINET PHAR, V40, P343, DOI 10.1007/s10928-013-9306-4; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Weiclenbusch M, 2012, J INNATE IMMUN, V4, P463, DOI 10.1159/000336717; Yang BB, 2003, CLIN PHARMACOL THER, V74, P85, DOI 10.1016/S0009-9236(03)00094-8	38	95	98	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2014	34	5					845	851		10.1038/jcbfm.2014.23			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AG5AE	WOS:000335430700015	24569690	Green Published, Bronze			2021-06-18	
J	Rohm, M; Schneiders, M; Muller, C; Kreilinger, A; Kaiser, V; Muller-Putz, GR; Rupp, R				Rohm, Martin; Schneiders, Matthias; Mueller, Constantin; Kreilinger, Alex; Kaiser, Vera; Mueller-Putz, Gernot R.; Rupp, Ruediger			Hybrid brain-computer interfaces and hybrid neuroprostheses for restoration of upper limb functions in individuals with high-level spinal cord injury	ARTIFICIAL INTELLIGENCE IN MEDICINE			English	Article						Functional electrical stimulation; Hybrid neuroprosthesis; EEG; Hybrid brain-computer interface (BCI); Motor imagery; BCI training; Spinal cord injury; Tetraplegia	MOTOR IMAGERY; CLINICAL-EVALUATION; HAND GRASP; EEG; SYSTEM; SIGNALS; MODE	Background: The bilateral loss of the grasp function associated with a lesion of the cervical spinal cord severely limits the affected individuals' ability to live independently and return to gainful employment after sustaining a spinal cord injury (SCI). Any improvement in lost or limited grasp function is highly desirable. With current neuroprostheses, relevant improvements can be achieved in end users with preserved shoulder and elbow, but missing hand function. Objective: The aim of this single case study is to show that (1) with the support of hybrid neuroprostheses combining functional electrical stimulation (FES) with orthoses, restoration of hand, finger and elbow function is possible in users with high-level SCI and (2) shared control principles can be effectively used to allow for a brain-computer interface (BCI) control, even if only moderate BCI performance is achieved after extensive training. Patient and methods: The individual in this study is a right-handed 41-year-old man who sustained a traumatic SCI in 2009 and has a complete motor and sensory lesion at the level of C4. He is unable to generate functionally relevant movements of the elbow, hand and fingers on either side. He underwent extensive FES training (30-45 min, 2-3 times per week for 6 months) and motor imagery (MI) BCI training (415 runs in 43 sessions over 12 months). To meet individual needs, the system was designed in a modular fashion including an intelligent control approach encompassing two input modalities, namely an MI-BCI and shoulder movements. Results: After one year of training, the end user's MI-BCI performance ranged from 50% to 93% (average: 70.5%). The performance of the hybrid system was evaluated with different functional assessments. The user was able to transfer objects of the grasp-and-release-test and he succeeded in eating a pretzel stick, signing a document and eating an ice cream cone, which he was unable to do without the system. Conclusion: This proof-of-concept study has demonstrated that with the support of hybrid FES systems consisting of FES and a semiactive orthosis, restoring hand, finger and elbow function is possible in a tetraplegic end-user. Remarkably, even after one year of training and 415 MI-BCI runs, the end user's average BCI performance remained at about 70%. This supports the view that in high-level tetraplegic subjects, an initially moderate BCI performance cannot be improved by extensive training. However, this aspect has to be validated in future studies with a larger population. (C) 2013 Elsevier B.V. All rights reserved.	[Rohm, Martin; Schneiders, Matthias; Mueller, Constantin; Rupp, Ruediger] Univ Heidelberg Hosp, Spinal Cord Injury Ctr, D-69118 Heidelberg, Germany; [Kreilinger, Alex; Kaiser, Vera; Mueller-Putz, Gernot R.] Graz Univ Technol, Inst Knowledge Discovery, Lab Brain Comp Interfaces, A-8010 Graz, Austria	Rupp, R (corresponding author), Univ Heidelberg Hosp, Spinal Cord Injury Ctr Expt Neurorehabil, Schlierbacher Landstr 200A, D-69118 Heidelberg, Germany.	Ruediger.Rupp@med.uni-heidelberg.de		tete, nilesh/0000-0002-7975-4950; Muller-Putz, Gernot/0000-0002-0087-3720	European ICT Programme Project TOBI [FP7-224631]	This study is supported by the European ICT Programme Project TOBI (FP7-224631).	Alkadhi H, 2005, CEREB CORTEX, V15, P131, DOI 10.1093/cercor/bhh116; Alon G, 2003, ARCH PHYS MED REHAB, V84, P119, DOI 10.1053/apmr.2003.50073; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Blankertz B, 2010, NEUROIMAGE, V51, P1303, DOI 10.1016/j.neuroimage.2010.03.022; Cincotti F, 2008, BRAIN RES BULL, V75, P796, DOI 10.1016/j.brainresbull.2008.01.007; Crago P E, 1998, IEEE Trans Rehabil Eng, V6, P1, DOI 10.1109/86.662614; Fazel-Rezai Reza, 2012, Front Neuroeng, V5, P14, DOI 10.3389/fneng.2012.00014; GORDON T, 1994, PHYS THER, V74, P50, DOI 10.1093/ptj/74.1.50; Gourab K, 2010, CLIN NEUROPHYSIOL, V121, P2017, DOI 10.1016/j.clinph.2010.05.012; Graimann B, 2002, CLIN NEUROPHYSIOL, V113, P43, DOI 10.1016/S1388-2457(01)00697-6; Guidali M, 2011, MED BIOL ENG COMPUT, V49, P1213, DOI 10.1007/s11517-011-0809-0; Halder S, 2011, NEUROIMAGE, V55, P1779, DOI 10.1016/j.neuroimage.2011.01.021; Hentz VR, 2002, SURG REHABILITATION; Kaiser V, 2011, FRONT NEUROSCI-SWITZ, V5, DOI [10.3389/fninf.2011.00030, 10.3389/fnins.2011.00086]; Kaufmann T, 2013, CLIN NEUROPHYSIOL, V124, P893, DOI 10.1016/j.clinph.2012.11.006; Keith MW, 2002, HAND CLIN, V18, P519, DOI 10.1016/S0749-0712(02)00034-3; Kilgore KL, 2008, J HAND SURG-AM, V33A, P539, DOI 10.1016/j.jhsa.2008.01.007; Kubler A., 2011, P 5 INT BRAIN COMP I, P100; Leeb R, 2007, COMPUT INTEL NEUROSC, V2007, DOI [10.1155/2007/79642., DOI 10.1155/2007/79642]; Marino RJ., 2003, J SPINAL CORD MED, V26, pS50, DOI [10.1080/10790268.2003.11754575, DOI 10.1080/10790268.2003.11754575]; MCLACHLAN G., 2004, DISCRIMINANT ANAL ST; Moss CW, 2011, NEUROREHAB NEURAL RE, V25, P847, DOI 10.1177/1545968311410067; Muller-Putz GR, 2006, BIOMED TECH, V51, P57, DOI 10.1515/BMT.2006.011; Mulcahey MJ, 1999, SPINAL CORD, V37, P585, DOI 10.1038/sj.sc.3100889; Muller-Putz GR, 2005, NEUROSCI LETT, V382, P169, DOI 10.1016/j.neulet.2005.03.021; Neuper C, 2005, COGNITIVE BRAIN RES, V25, P668, DOI 10.1016/j.cogbrainres.2005.08.014; NSCISC, 2013, 2006 ANN STAT REP MO; Onose G, 2012, SPINAL CORD, V50, P599, DOI 10.1038/sc.2012.14; Pfurtscheller G, 2000, NEUROSCI LETT, V292, P211, DOI 10.1016/S0304-3940(00)01471-3; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; Pfurtscheller G, 2001, P IEEE, V89, P1123, DOI 10.1109/5.939829; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; PFURTSCHELLER G, 2009, COMPUT INTEL NEUROSC, DOI DOI 10.1155/2009/104180; Popovic D, 1999, ARCH PHYS MED REHAB, V80, P299, DOI 10.1016/S0003-9993(99)90141-7; Popovic MB, 2003, J REHABIL RES DEV, V40, P443, DOI 10.1682/JRRD.2003.09.0443; Rohm M., 2011, INT J BIOELECTROMAGN, V13, P127; Rupp R., 2012, C P IEEE ENG MED BIO, V183, P5; Schneiders M, 2011, INT J BIOELECTROMAGN, V13, P2; Snoek GJ, 2004, SPINAL CORD, V42, P526, DOI 10.1038/sj.sc.3101638; VANDENHONERT C, 1979, ANN BIOMED ENG, V7, P117, DOI 10.1007/BF02363130; Varoto R, 2008, ARTIF ORGANS, V32, P725, DOI 10.1111/j.1525-1594.2008.00597.x; Williams MR, 2008, IEEE T NEUR SYS REH, V16, P485, DOI 10.1109/TNSRE.2008.2006216; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; WUOLLE KS, 1994, J HAND SURG-AM, V19A, P209, DOI 10.1016/0363-5023(94)90008-6; Zhang H, 2011, IEEE INT C REH ROB; Zickler C, 2011, CLIN EEG NEUROSCI, V42, P236, DOI 10.1177/155005941104200409	46	95	103	0	62	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0933-3657	1873-2860		ARTIF INTELL MED	Artif. Intell. Med.	OCT	2013	59	2			SI		133	142		10.1016/j.artmed.2013.07.004			10	Computer Science, Artificial Intelligence; Engineering, Biomedical; Medical Informatics	Computer Science; Engineering; Medical Informatics	256DT	WOS:000327290600009	24064256				2021-06-18	
J	Wright, DW; Kellermann, A; McGuire, LC; Chen, B; Popovic, T				Wright, David W.; Kellermann, Arthur; McGuire, Lisa C.; Chen, Bin; Popovic, Tanja			CDC Grand Rounds: Reducing Severe Traumatic Brain Injury in the United States	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article							HEAD-INJURY; GUIDELINES		[Wright, David W.] Emory Univ, Sch Med, Atlanta, GA USA; [Kellermann, Arthur] RAND Corp, RAND Hlth, Santa Monica, CA USA; [McGuire, Lisa C.] CDC, Off Director, Atlanta, GA 30333 USA		lmcguire@cdc.gov	Wright, David/F-1209-2013	Wright, David/0000-0002-7145-9105			[Anonymous], 2012, TRAFF SAF FACTS 2011; CDC, 2003, REP C MILD TRAUM BRA; CDC, 2012, MMWR, V61; Center for Disease Control and Prevention, 2010, MMWR-MORBID MORTAL W, V59, P303; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Community Preventive Services Task Force, 2000, GUID COMM PREV SERV; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P619; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Marr AL., 2004, CENTRAL NERVOUS SYST; National Highway Traffic Safety Administration, 2008, EV REINST MOT HELM L; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Sander AM, 2008, J HEAD TRAUMA REHAB, V23, P271, DOI 10.1097/01.HTR.0000336839.68585.0f; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stein S. C., 1996, NEUROTRAUMA, P31; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	23	95	96	0	5	CENTERS  DISEASE CONTROL & PREVENTION	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	JUL 12	2013	62	27					549	552					4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	188GU	WOS:000322181500002	23842444				2021-06-18	
J	Strain, J; Didehbani, N; Cullum, CM; Mansinghani, S; Conover, H; Kraut, MA; Hart, J; Womack, KB				Strain, Jeremy; Didehbani, Nyaz; Cullum, C. Munro; Mansinghani, Sethesh; Conover, Heather; Kraut, Michael A.; Hart, John, Jr.; Womack, Kyle B.			Depressive symptoms and white matter dysfunction in retired NFL players with concussion history	NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; FUNCTIONAL CONNECTIVITY; PSYCHOMETRIC EVALUATION; BRAIN-INJURY; INTEGRITY; INVENTORY; FREQUENCY; DEATH	Objective: To determine whether correlates of white matter integrity can provide general as well as specific insight into the chronic effects of head injury coupled with depression symptom expression in professional football players. Method: We studied 26 retired National Football League (NFL) athletes who underwent diffusion tensor imaging (DTI) scanning. Depressive symptom severity was measured using the Beck Depression Inventory II (BDI-II) including affective, cognitive, and somatic subfactor scores (Buckley 3-factor model). Fractional anisotropy (FA) maps were processed using tract-based spatial statistics from FSL. Correlations between FA and BDI-II scores were assessed using both voxel-wise and region of interest (ROI) techniques, with ROIs that corresponded to white matter tracts. Tracts demonstrating significant correlations were further evaluated using a receiver operating characteristic curve that utilized the mean FA to distinguish depressed from nondepressed subjects. Results: Voxel-wise analysis identified widely distributed voxels that negatively correlated with total BDI-II and cognitive and somatic subfactors, with voxels correlating with the affective component (p < 0.05 corrected) localized to frontal regions. Four tract ROIs negatively correlated (p < 0.01) with total BDI-II: forceps minor, right frontal aslant tract, right uncinate fasciculus, and left superior longitudinal fasciculus. FA of the forceps minor differentiated depressed from nondepressed athletes with 100% sensitivity and 95% specificity. Conclusion: Depressive symptoms in retired NFL athletes correlate negatively with FA using either an unbiased voxel-wise or an ROI-based, tract-wise approach. DTI is a promising biomarker for depression in this population.	[Strain, Jeremy; Didehbani, Nyaz; Mansinghani, Sethesh; Conover, Heather; Kraut, Michael A.; Hart, John, Jr.] Ctr Brain Hlth, Berman Lab Learning & Memory, Dallas, TX 75235 USA; [Cullum, C. Munro; Womack, Kyle B.] Univ Texas Dallas, Dept Psychiat, Sch Behav & Brain Sci, Dallas, TX 75230 USA; [Cullum, C. Munro; Hart, John, Jr.; Womack, Kyle B.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Kraut, Michael A.] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA	Hart, J (corresponding author), Ctr Brain Hlth, Berman Lab Learning & Memory, Dallas, TX 75235 USA.	jhart@utdallas.edu	Cullum, C. Munro/AAC-2496-2019; Womack, Kyle/O-5422-2018	Cullum, C. Munro/0000-0001-9706-5465; Womack, Kyle/0000-0002-6060-9075; Didehbani, Nyaz/0000-0001-6121-5759; Mansinghani, Sethesh/0000-0001-5861-3764	BrainHealth Institute for Athletes at the Center for BrainHealth, a research center at the University of Texas at Dallas; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG030006] Funding Source: NIH RePORTER	Supported by the BrainHealth Institute for Athletes at the Center for BrainHealth, a research center at the University of Texas at Dallas, and by a National Institute on Aging grant.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bae JN, 2006, BIOL PSYCHIAT, V60, P1356, DOI 10.1016/j.biopsych.2006.03.052; Bajwa S, 2008, J NERV MENT DIS, V196, P671, DOI 10.1097/NMD.0b013e318183f86f; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Buckley TC, 2001, J SUBST ABUSE TREAT, V20, P197, DOI 10.1016/S0740-5472(00)00169-0; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Dotson VM, 2013, INT J GERIATR PSYCH, V28, P66, DOI 10.1002/gps.3791; Douaud G, 2007, BRAIN, V130, P2375, DOI 10.1093/brain/awm184; Dozois DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guo WB, 2012, PROG NEURO-PSYCHOPH, V38, P201, DOI 10.1016/j.pnpbp.2012.03.012; Hart Jr J, 2013, JAMA NEUROL, V1, P1; Huang H, 2012, NEUROBIOL AGING, V33, P2029, DOI 10.1016/j.neurobiolaging.2011.06.027; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Peng HJ, 2012, J AFFECT DISORDERS, V136, P249, DOI 10.1016/j.jad.2011.12.006; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Taylor Warren D, 2007, Neuropsychiatr Dis Treat, V3, P669; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Xu K., 2012, J PSYCHIATR NEUROSCI, V37; Yuan YG, 2007, NEUROREPORT, V18, P1845, DOI 10.1097/WNR.0b013e3282f1939f	34	95	95	0	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 2	2013	81	1					25	32		10.1212/WNL.0b013e318299ccf8			8	Clinical Neurology	Neurosciences & Neurology	304JC	WOS:000330741900009	23709590	Green Published			2021-06-18	
J	Schatz, P; Sandel, N				Schatz, Philip; Sandel, Natalie			Sensitivity and Specificity of the Online Version of ImPACT in High School and Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; neurocognitive testing; validity; ImPACT	SPORT-RELATED CONCUSSION; COUNSELING PSYCHOMETRIC ISSUES; NEUROCOGNITIVE PERFORMANCE; CLINICAL UTILITY; RECOVERY; FOOTBALL; BATTERY; INJURY	Background: The utility of postconcussion neurocognitive testing versus symptom data has been debated. The sensitivity of the desktop version of the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) tool has been documented, but psychometric properties of the recently released online version of ImPACT have yet to be fully established. Purpose: To document the sensitivity of the online ImPACT version in samples of (1) symptomatic concussed (high school and collegiate) athletes, and (2) asymptomatic concussed (high school and collegiate) athletes suspected of hiding their concussions. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 81 athletes observed to sustain a concussion by a certified athletic trainer or team physician, a finding that was confirmed with reported postconcussion symptoms, completed the ImPACT test within 3 days of injury. Data were compared with an independent sample of 81 athletes who completed preseason baseline cognitive assessments using ImPACT and who were matched (with concussed athletes) on the basis of sex, age, sport, concussion history, and absence of attention deficit hyperactivity disorder and learning disability. An independent group of 37 athletes who were also observed to sustain a concussion completed ImPACT within 3 days of injury. These athletes reported no postconcussion symptoms but were noted for suspected invalid response patterns on ImPACT (Impulse Control index >30 and Verbal Memory index <69%). The subscale data from the assessments (excluding those contributing to the aforementioned indices) were compared with a matched sample of 37 athletes who completed preseason baseline cognitive assessments in ImPACT (using the same criteria described above). Results: Data from the ImPACT online version yielded 91.4% sensitivity and 69.1% specificity. For asymptomatic athletes suspected of hiding their concussion, data from ImPACT yielded 94.6% sensitivity and 97.3% specificity. Conclusion: The online version of the ImPACT tool is a valid measure of neurocognitive performance at the acute stages of concussion, with high levels of sensitivity and specificity, even when athletes appear to be denying postconcussion symptoms.	[Schatz, Philip; Sandel, Natalie] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu			International Brain Research Foundation; Sports Concussion Center of New Jersey	One or more of the authors has declared the following potential conflict of interest or source of funding: Dr Schatz has received funding to study the effects of concussion in high school and collegiate athletes from the International Brain Research Foundation, the Sports Concussion Center of New Jersey. He has also served as a consultant to ImPACT Applications Inc.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barth JT., 1989, MILD HEAD INJURY, P257; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Randolph C, 2006, J ATHL TRAINING, V41, P138; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, PM&R, V3, pS433, DOI 10.1016/j.pmrj.2011.08.002; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Sandel NK, 2012, APPL NEUROPSYCHOL CH; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Stevens J.P, 2009, APPL MULTIVARIATE ST; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	29	95	95	0	33	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2013	41	2					321	326		10.1177/0363546512466038			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	081GY	WOS:000314307500015	23144368				2021-06-18	
J	Schmidt, JD; Register-Mihalik, JK; Mihalk, JP; Kerr, ZY; Guskiewicz, KM				Schmidt, Julianne D.; Register-Mihalik, Johna K.; Mihalk, Jason P.; Kerr, Zachary Y.; Guskiewicz, Kevin M.			Identifying Impairments after Concussion: Normative Data versus Individualized Baselines	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						NEUROCOGNITION; POSTURAL CONTROL; CONCUSSION EVALUATION; INJURY MANAGEMENT; MILD TRAUMATIC BRAIN INJURY	SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; ERROR SCORING SYSTEM; NEUROCOGNITIVE TEST-PERFORMANCE; SENSORY ORGANIZATION TEST; BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; POSTURAL STABILITY; NCAA CONCUSSION; YOUNG-ADULTS	SCHMIDT, J. D., J. K. REGISTER-MIHALIK, J. P. MIHALIK, Z. Y. KERR, and K. M. GUSKIEWICZ. Impairments after Concussion: Normative Data versus Individualized Baselines. Med. Sci. Sports Exerc., Vol. 44, No. 9, pp. 1621-1628, 2012. Purpose: This study aimed to determine whether agreement exists between baseline comparison (comparison of postconcussion scores to individualized baseline scores) and normative comparison (comparison of postconcussion scores to a normative mean) in identifying impairments after concussion. Methods: A total of 1060 collegiate student-athletes completed baseline testing as part of an ongoing clinical program. Gender-specific normative means were obtained from a subset of 673 athletes with no history of self-reported concussion, learning disabilities, or attention-deficit disorders. Concussions were later diagnosed in 258 athletes who had completed baseline testing. The athletes completed their first assessment within 10 d after injury. Athletes completed a computerized neurocognitive test (Automated Neuropsychological Assessment Metrics), postural control assessment (Sensory Organization Test), and a 15-item graded symptom checklist at baseline and again after injury. We computed two postconcussion difference scores for each outcome measure: 1) baseline difference = postconcussion score individualized baseline score and 2) normative difference = postconcussion score normative mean. Athletes were considered impaired if postconcussion difference exceeded the reliable change parameters. McNemar tests were used to assess agreement on impairment status (impaired and unimpaired) between comparison methods for each outcome measure. Results: The baseline comparison method identified 2.6 times more impairments than the normative comparison method for the Simple Reaction Time Test I (P = 0.043). The normative comparison method identified 7.6 times more impairments than the baseline comparison method for Mathematical Processing (P < 0.001). No other disagreements were observed for postural control or symptom severity. Conclusions: Our findings suggest that, when using these concussion assessment tools, clinicians may consider using normative data in lieu of individualized baseline measures. This may be especially useful to clinicians with limited resources and an inability to capture valid baselines on all athletes.	[Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, 209 Fetzer Hall,CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Kerr, Zachary/0000-0003-1423-1259; Mihalik, Jason/0000-0001-6085-8322			Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Balint S, 2009, PSYCHOL MED, V39, P1337, DOI 10.1017/S0033291708004236; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Brown CN, 2007, J ATHL TRAINING, V42, P515; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Dickin DC, 2010, CLIN J SPORT MED, V20, P278, DOI 10.1097/JSM.0b013e3181e8f8b1; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Kaminski TW, 2009, J CLIN EXP NEUROPSYC, V31, P689, DOI 10.1080/13803390802484771; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Van der Werf YD, 2011, PROG BRAIN RES, V193, P245, DOI 10.1016/B978-0-444-53839-0.00016-8; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wyrwich KW, 2000, J EVAL CLIN PRACT, V6, P39, DOI 10.1046/j.1365-2753.2000.00238.x	40	95	95	0	38	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	SEP	2012	44	9					1621	1628		10.1249/MSS.0b013e318258a9fb			8	Sport Sciences	Sport Sciences	990IQ	WOS:000307624600001	22525765				2021-06-18	
J	Zongo, D; Ribereau-Gayon, R; Masson, F; Laborey, M; Contrand, B; Salmi, LR; Montaudon, D; Beaudeux, JL; Meurin, A; Dousset, V; Loiseau, H; Lagarde, E				Zongo, Drissa; Ribereau-Gayon, Regis; Masson, Francoise; Laborey, Magali; Contrand, Benjamin; Salmi, Louis Rachid; Montaudon, Daniele; Beaudeux, Jean Louis; Meurin, Antoine; Dousset, Vincent; Loiseau, Hugues; Lagarde, Emmanuel			S100-B Protein as a Screening Tool for the Early Assessment of Minor Head Injury	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; BIOCHEMICAL SERUM MARKERS; COMPUTED-TOMOGRAPHY; EMERGENCY-DEPARTMENT; PROGNOSTIC-FACTORS; DECISION-MAKING; CLINICAL POLICY; S-100B PROTEIN; MANAGEMENT; ELIMINATION	Study objective: A computed tomography (CT) scan has high sensitivity in detecting intracranial injury in patients with minor head injury but is costly, exposes patients to high radiation doses, and reveals clinically relevant lesions in less than 10% of cases. We evaluate S100-B protein measurement as a screening tool in a large population of patients with minor head injury. Methods: We conducted a prospective observational study in the emergency department of a teaching hospital (Bordeaux, France). Patients with minor head injury (2,128) were consecutively included from December 2007 to February 2009. CT scans and plasma S100-B levels were compared for 1,560 patients. The main outcome was to evaluate the diagnostic value of the S100-B test, focusing on the negative predictive value and the negative likelihood ratio. Results: CT scan revealed intracranial lesions in 111 (7%) participants, and their median S100-B protein plasma level was 0.46 mu g/L (interquartile range [IQR] 0.27 to 0.72) versus 0.22 mu g/L (IQR 0.14 to 0.36) in the other 1,449 patients. With a cutoff of 0.12 mu g/L, traumatic brain injuries on CT were identified with a sensitivity of 99.1% (95% confidence interval [CI] 95.0% to 100%), a specificity of 19.7% (95% CI 17.7% to 21.9%), a negative predictive value of 99.7% (95% CI 98.1% to 100%), a positive likelihood ratio of 1.24 (95% CI 1.20 to 1.28), and a negative likelihood ratio of 0.04 (95% CI 0.006 to 0.32). Conclusion: Measurement of plasma S100-B on admission of patients with minor head injury is a promising screening tool that may be of help to support the clinician's decision not to perform CT imaging in certain cases of low-risk head injury. [Ann Emerg Med. 2012;59:209-218.]	[Zongo, Drissa; Ribereau-Gayon, Regis] Hop Pellegrin, Serv Urgences Adultes, F-33076 Bordeaux, France; [Masson, Francoise] Hop Pellegrin, Serv Anesthesie Reanimat, F-33076 Bordeaux, France; [Montaudon, Daniele] Hop Pellegrin, Serv Neuroradiol Diagnost & Therapeut, Biochim Lab, F-33076 Bordeaux, France; [Meurin, Antoine; Dousset, Vincent] Hop Pellegrin, Serv Neuroimagerie, F-33076 Bordeaux, France; [Loiseau, Hugues] Hop Pellegrin, Serv Neurochirurg, F-33076 Bordeaux, France; [Salmi, Louis Rachid] Ctr Hosp Univ Bordeaux, Serv Informat Med, Bordeaux, France; [Zongo, Drissa; Laborey, Magali; Contrand, Benjamin; Salmi, Louis Rachid; Lagarde, Emmanuel] Univ Bordeaux Segalan, Inst Sante Publ Epidemiol & Dev, Bordeaux, France; [Zongo, Drissa; Ribereau-Gayon, Regis; Masson, Francoise; Laborey, Magali; Contrand, Benjamin; Salmi, Louis Rachid; Lagarde, Emmanuel] INSERM, Equipe Prevent & Prise Charge Traumatismes, Unite 897, Bordeaux, France; [Beaudeux, Jean Louis] Hop Charles Foix, APHP, Biochim Lab, Paris, France	Zongo, D (corresponding author), Hop Pellegrin, Serv Urgences Adultes, F-33076 Bordeaux, France.	drissa.zongo@isped.u-bordeaux2.fr	Salmi, Louis-Rachid/T-1982-2019; Regis, RIBEREAU-GAYON/U-5423-2019; Lagarde, Emmanuel/F-7132-2013; contrand, benjamin/T-1994-2019	DOUSSET, VINCENT/0000-0003-0427-3236	INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; Reunica Group; teaching hospital of Bordeaux (PHRC)	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). This study was funded by INSERM, the Reunica Group, and the teaching hospital of Bordeaux (PHRC 2007).	af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Beaudeux J-L, 2009, Ann Pharm Fr, V67, P187, DOI 10.1016/j.pharma.2009.03.002; Ben Abdesselam O, 2003, CLIN CHEM, V49, P836, DOI 10.1373/49.5.836; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ikeda Yasuhiko, 2005, Rinsho Byori, V53, P395; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI [10.1089/neu.2009.0928, 10.1089/neu.2009-0928]; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smith-Bindman R, 2010, NEW ENGL J MED, V363, P1, DOI 10.1056/NEJMp1002530; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Springborg Jtiaocnob Bertram, 2009, Ugeskr Laeger, V171, P978; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tort ABL, 2003, CLIN BIOCHEM, V36, P629, DOI 10.1016/S0009-9120(03)00107-3; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	40	95	102	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAR	2012	59	3					209	218		10.1016/j.annemergmed.2011.07.027			10	Emergency Medicine	Emergency Medicine	905MM	WOS:000301276300010	21944878				2021-06-18	
J	Meterko, M; Baker, E; Stolzmann, KL; Hendricks, AM; Cicerone, KD; Lew, HL				Meterko, Mark; Baker, Errol; Stolzmann, Kelly L.; Hendricks, Ann M.; Cicerone, Keith D.; Lew, Henry L.			Psychometric Assessment of the Neurobehavioral Symptom Inventory-22: The Structure of Persistent Postconcussive Symptoms Following Deployment-Related Mild Traumatic Brain Injury Among Veterans	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							POST-CONCUSSION SYNDROME; CONSTRUCT-VALIDITY		[Meterko, Mark; Baker, Errol; Stolzmann, Kelly L.; Hendricks, Ann M.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Meterko, Mark; Baker, Errol; Stolzmann, Kelly L.] VA Ctr Org Leadership & Management Res, Boston, MA USA; [Meterko, Mark; Hendricks, Ann M.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Cicerone, Keith D.] JFK Johnson Rehabil Inst, Edison, NJ USA; [Lew, Henry L.] Univ Hawaii Manoa, Def & Vet Brain Injury Ctr, Honolulu, HI 96822 USA; [Lew, Henry L.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA	Meterko, M (corresponding author), VA Boston Healthcare Syst, Mail Stop 152M,150 S Huntington Ave, Boston, MA 02130 USA.	mark.meterko@va.gov			VHA HSRD [SDR 08-405]	This research was supported by VHA HSR&D grant SDR 08-405. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Brown T.A, 2006, CONFIRMATORY FACTOR, V3rd; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GUNSTAD J, 2004, J FORENSIC NEUROPSYC, V4, P33, DOI DOI 10.1300/J151V04N01_; Herman D., 1993, ANN CONV INT SOC TRA; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pett M., 2003, MAKING SENSE FACTOR; Piland SG, 2003, J ATHL TRAINING, V38, P104; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tabachnick B., 2001, USING MULTIVARIATE S; The Department of Veterans Affairs, 2000, PAIN 5 VIT SIGN TOOL; WARE JE, 1997, MULTITRAIT MULTIITEM	21	95	95	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					55	62		10.1097/HTR.0b013e318230fb17			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400006	22190009				2021-06-18	
J	Wagner, AK; McCullough, EH; Niyonkuru, C; Ozawa, H; Loucks, TL; Dobos, JA; Brett, CA; Santarsieri, M; Dixon, CE; Berga, SL; Fabio, A				Wagner, Amy K.; McCullough, Emily H.; Niyonkuru, Christian; Ozawa, Haishin; Loucks, Tammy L.; Dobos, Julie A.; Brett, Christopher A.; Santarsieri, Martina; Dixon, C. Edward; Berga, Sarah L.; Fabio, Anthony			Acute Serum Hormone Levels: Characterization and Prognosis after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						global outcome; group based trajectory analysis; sex steroids; structural equations model; traumatic brain injury	ISCHEMIA-REPERFUSION INJURY; TISSUE STROMAL CELLS; CRITICALLY-ILL; ADIPOSE-TISSUE; PITUITARY INSUFFICIENCY; GENDER-DIFFERENCES; AROMATASE-ACTIVITY; ADRENAL-RESPONSE; BINDING GLOBULIN; BLOOD-FLOW	Experimental traumatic brain injury (TBI) studies report the neuroprotective effects of female sex steroids on multiple mechanisms of injury, with the clinical assumption that women have hormonally mediated neuroprotection because of the endogenous presence of these hormones. Other literature indicates that testosterone may exacerbate injury. Further, stress hormone abnormalities that accompany critical illness may both amplify or blunt sex steroid levels. To better understand the role of sex steroid exposure in mediating TBI, we 1) characterized temporal profiles of serum gonadal and stress hormones in a population with severe TBI during the acute phases of their injury; and 2) used a biological systems approach to evaluate these hormones as biomarkers predicting global outcome. The study population was 117 adults (28 women; 89 men) with severe TBI. Serum samples (n = 536) were collected for 7 days post-TBI for cortisol, progesterone, testosterone, estradiol, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Hormone data were linked with clinical data, including acute care mortality and Glasgow Outcome Scale (GOS) scores at 6 months. Hormone levels after TBI were compared to those in healthy controls (n = 14). Group based trajectory analysis (TRAJ) was used to develop temporal hormone profiles that delineate distinct subpopulations in the cohort. Structural equations models were used to determine inter-relationships between hormones and outcomes within a multivariate model. Compared to controls, acute serum hormone levels were significantly altered after severe TBI. Changes in the post-TBI adrenal response and peripheral aromatization influenced hormone TRAJ profiles and contributed to the abnormalities, including increased estradiol in men and increased testosterone in women. In addition to older age and greater injury severity, increased estradiol and testosterone levels over time were associated with increased mortality and worse global outcome for both men and women. These findings represent a paradigm shift when thinking about the role of sex steroids in neuroprotection clinically after TBI.	[Wagner, Amy K.; McCullough, Emily H.; Niyonkuru, Christian; Ozawa, Haishin; Dobos, Julie A.; Brett, Christopher A.; Santarsieri, Martina; Dixon, C. Edward; Fabio, Anthony] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Fabio, Anthony] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA; [Loucks, Tammy L.; Berga, Sarah L.] Emory Univ, Dept Obstet & Gynecol, Atlanta, GA 30322 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Loucks, Tammy/N-8223-2019	Loucks, Tammy/0000-0001-7651-7602; Fabio, Anthony/0000-0002-6808-4939	CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR323155]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318-16]; DODUnited States Department of Defense [W81XWH-071-0701, PT073914]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	The authors acknowledge Mary Synnott for figure construction, and the UPMC Trauma Registry team and the Brain Trauma Research Center for their role in data collection. This work was supported by CDC grant # R49/CCR323155 (A. K. W., S. L. B., A. F.), DODW81XWH-071-0701, DOD PT073914 (A. K. W., A. F.), and NIH 5P01NS030318-16 to (C.E.D.).	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Beale E, 2002, GERONTOLOGY, V48, P84, DOI 10.1159/000048932; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; Burger HG, 2002, FERTIL STERIL, V77, pS3; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Constant EL, 2001, J CLIN ENDOCR METAB, V86, P3864, DOI 10.1210/jc.86.8.3864; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DESAI D, 1989, J TRAUMA, V29, P719, DOI 10.1097/00005373-198906000-00003; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Evans MJ, 2001, CLIN BIOCHEM, V34, P107, DOI 10.1016/S0009-9120(01)00196-5; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2004, ACT NEUR S, V89, P101; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fisher RA., 1922, PHILOS T R SOC LON A, V222, P309, DOI DOI 10.1098/RSTA.1922.0009; Garcia-Segura LM, 2003, PROG NEUROBIOL, V71, P31, DOI 10.1016/j.pneurobio.2003.09.005; Gasco V., 2010, PITUITARY; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Hildreth AN, 2008, J TRAUMA, V65, P573, DOI 10.1097/TA.0b013e31818255e8; HORAN MA, 1994, ANN NY ACAD SCI, V719, P285, DOI 10.1111/j.1749-6632.1994.tb56836.x; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; JENNETT B, 1975, LANCET, V1, P480; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kalantaridou SN, 2004, J REPROD IMMUNOL, V62, P61, DOI 10.1016/j.jri.2003.09.004; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Little RJA, 1987, STAT ANAL MISSING DA; Llompart-Pou JA, 2007, J ENDOCRINOL INVEST, V30, P393, DOI 10.1007/BF03346316; Llompart-Pou JA, 2008, NEUROCRIT CARE, V9, P230, DOI 10.1007/s12028-008-9115-6; LUEPRASITSAKUL P, 1990, P SOC EXP BIOL MED, V194, P337; LUEPRASITSAKUL P, 1990, STEROIDS, V55, P540, DOI 10.1016/0039-128X(90)90049-H; MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MUTHEN B, 1987, PSYCHOMETRIKA, V52, P431, DOI 10.1007/BF02294365; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nagin D., 2005, GROUP BASED MODELING; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Silverman DHS, 2011, PSYCHONEUROENDOCRINO, V36, P502, DOI 10.1016/j.psyneuen.2010.08.002; SIMPSON ER, 1981, P NATL ACAD SCI-BIOL, V78, P5690, DOI 10.1073/pnas.78.9.5690; SIMPSON ER, 1989, ENDOCR REV, V10, P136, DOI 10.1210/edrv-10-2-136; Singh S., 1997, P 5 EUR C INT TECHN, V3, P1993; Spratt DI, 2008, AM J PHYSIOL-ENDOC M, V295, pE63, DOI 10.1152/ajpendo.00472.2007; Spratt DI, 2006, AM J PHYSIOL-ENDOC M, V291, pE631, DOI 10.1152/ajpendo.00467.2005; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Sutton-Tyrrell K, 2005, CIRCULATION, V111, P1242, DOI 10.1161/01.CIR.0000157697.54255.CE; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Torpy DJ, 2007, CLIN ENDOCRINOL, V67, P161, DOI 10.1111/j.1365-2265.2007.02890.x; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; Wagner AK, 2000, ARCH PHYS MED REHAB, V81, P1267; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Wothke W, 2000, MODELING LONGITUDINAL AND MULTILEVEL DATA, P219; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yang SH, 2005, J NEUROBIOL, V62, P341, DOI 10.1002/neu.20103; Yang SH, 2002, J APPL PHYSIOL, V92, P195; Yildiz BO, 2007, REV ENDOCR METAB DIS, V8, P331, DOI 10.1007/s11154-007-9054-0	81	95	97	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					871	888		10.1089/neu.2010.1586			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600003	21488721	Green Published			2021-06-18	
J	Duhaime, AC; Gean, AD; Haacke, EM; Hicks, R; Wintermark, M; Mukherjee, P; Brody, D; Latour, L; Riedy, G				Duhaime, Ann-Christine; Gean, Alisa D.; Haacke, E. Mark; Hicks, Ramona; Wintermark, Max; Mukherjee, Pratik; Brody, David; Latour, Lawrence; Riedy, Gerard		Common Data Elements Neuroimaging; Pediat Working Grp Members	Common Data Elements in Radiologic Imaging of Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Clinical research; Clinical trials; Database; Head injury; Magnetic resonance imaging; Radiology; Rehabilitation; Traumatic brain injury	DIFFUSE AXONAL INJURY; HEAD-INJURY; CLASSIFICATION; MICROBLEEDS; CHILDREN; VOLUME; MILD	Radio logic brain imaging is the most useful means of visualizing and categorizing the location, nature, and degree of damage to the central nervous system sustained by patients with traumatic brain injury (TBI). In addition to determining acute patient management and prognosis, imaging is crucial for the characterization and classification of injuries for natural history studies and clinical trials. This article is the initial result of a workshop convened by multiple national health care agencies in March 2009 to begin to make recommendations for potential data elements dealing with specific radiologic features and definitions needed to characterize injuries, as well as specific techniques and parameters needed to optimize radiologic data acquisition. The neuroimaging work group included professionals with expertise in basic imaging research and physics, clinical neuroradiology, neurosurgery, neurology, physiatry, psychiatry, TBI research, and research database formation. This article outlines the rationale and overview of their specific recommendations. In addition, we review the contributions of various imaging modalities to the understanding of TBI and the general principles needed for database flexibility and evolution over time to accommodate technical advances.	[Duhaime, Ann-Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Gean, Alisa D.] San Francisco Gen Hosp, Dept Radiol, Brain & Spinal Cord Injury Ctr, San Francisco, CA 94110 USA; [Haacke, E. Mark] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA; [Hicks, Ramona] NIH, Repair & Plast Program, Bethesda, MD 20892 USA; [Wintermark, Max; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Mukherjee, Pratik] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA; [Brody, David] Washington Univ, Dept Neurol, St Louis, MO USA; [Latour, Lawrence] Natl Inst Neurol Disorders & Stroke, Stroke Diagnost & Therapeut Sect, Stroke Branch, Bethesda, MD USA; [Riedy, Gerard] Walter Reed Army Med Ctr, Dept Radiol, Washington, DC 20307 USA	Duhaime, AC (corresponding author), Massachusetts Gen Hosp, Wang 331,115 Parkman St, Boston, MA 02114 USA.	aduhaime@partners.org	Latour, Larry/AAH-5663-2021; Mukherjee, Pratik/A-5446-2008	Latour, Larry/0000-0001-6160-5263; Wintermark, Max/0000-0002-6726-3951; Mukherjee, Pratik/0000-0001-7473-7409			Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MARSHALL LF, 1992, J NEUROTRAUMA S, V1, pS278; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT I NEUR DIS ST, 2010, NINDS COMM DAT EL; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale E., 1997, HEAD INJURY, P167; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x	18	95	95	1	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1661	1666		10.1016/j.apmr.2010.07.238			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400005	21044709				2021-06-18	
J	Walker, PA; Shah, SK; Jimenez, F; Gerber, MH; Xue, HS; Cutrone, R; Hamilton, JA; Mays, RW; Deans, R; Pati, S; Dash, PK; Cox, CS				Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Gerber, Michael H.; Xue, Hasen; Cutrone, Rochelle; Hamilton, Jason A.; Mays, Robert W.; Deans, Robert; Pati, Shibani; Dash, Pramod K.; Cox, Charles S., Jr.			Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: Preserving the blood brain barrier via an interaction with splenocytes	EXPERIMENTAL NEUROLOGY			English	Article						Multipotent adult progenitor cells; Traumatic brain injury; Stem cells; Splenocytes; Blood brain barrier	MESENCHYMAL STEM-CELLS; BONE-MARROW; EXPERIMENTAL STROKE; TRANSPLANTATION	Recent investigation has shown an interaction between transplanted progenitor cells and resident splenocytes leading to the modulation of the immunologic response in neurological injury. We hypothesize that the intravenous injection of multipotent adult progenitor cells (MAPC) confers neurovascular protection after traumatic brain injury through an interaction with resident splenocytes, subsequently leading to preservation of the blood brain barrier. Four groups of rats underwent controlled cortical impact injury (3 groups) or sham injury (1 group). MAPC were injected via the tail vein at two doses (2*10(6) MAPC/kg or 10*10(6) MAPC/kg) 2 and 24 h after injury. Blood brain barrier permeability was assessed by measuring Evans blue dye extravasation (n = 6/group). Additionally, splenic mass was measured (n = 12/group) followed by splenocyte characterization (n = 9/group) including: cell cycle analysis (n = 6/group), apoptosis index (n = 6/group), cell proliferation (n = 6/group), and inflammatory cytokine measurements (n = 6/group). Vascular architecture was determined by immunohistochemistry (n = 3/group). Traumatic brain injury results in a decrease in splenic mass and increased blood brain barrier permeability. Intravenous infusion of MAPC preserved splenic mass and returned blood brain barrier permeability towards control sham injured levels. Splenocyte characterization indicated an increase in the number and proliferative rate of CD4+ T cells as well as an increase in IL-4 and IL-10 production in stimulated splenocytes isolated from the MAPC treatment groups. Immunohistochemistry demonstrated stabilization of the vascular architecture in the pen-lesion area. Traumatic brain injury causes a reduction in splenic mass that correlates with an increase in circulating immune cells leading to increased blood brain barrier permeability. The intravenous injection of MAPC preserves splenic mass and the integrity of the blood brain barrier. Furthermore, the co-localization of transplanted MAPC and resident CD4+ splenocytes is associated with a global increase in IL-4 and IL-10 production and stabilization of the cerebral microvasculature tight junction proteins. (C) 2010 Elsevier Inc. All rights reserved.	[Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Walker, Peter A.; Shah, Shinil K.; Gerber, Michael H.; Xue, Hasen; Pati, Shibani; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Gerber, Michael H.; Dash, Pramod K.] Univ Texas Med Sch Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Cutrone, Rochelle; Hamilton, Jason A.; Mays, Robert W.; Deans, Robert] Athersys Inc, Dept Regenerat Med, Cleveland, OH USA	Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.s.cox@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM 08 79201, M01 RR 02558]; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; Texas Emerging Technology Fund; Athersys, Inc.; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This work was supported by grants from NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; Texas Emerging Technology Fund; Athersys, Inc.	Ajmo CT, 2009, EXP NEUROL, V218, P47, DOI 10.1016/j.expneurol.2009.03.044; Boozer Sherry, 2009, J Stem Cells, V4, P17, DOI jsc.2009.4.1.17; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Harting MT, 2008, BRAIN, V131, DOI 10.1093/brain/awn142; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lim JH, 2007, J VET SCI, V8, P275, DOI 10.4142/jvs.2007.8.3.275; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; PATI S, STEM CELLS IN PRESS; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	25	95	98	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2010	225	2					341	352		10.1016/j.expneurol.2010.07.005			12	Neurosciences	Neurosciences & Neurology	654SV	WOS:000282191500014	20637752	Green Accepted			2021-06-18	
J	Hergenroeder, GW; Moore, AN; McCoy, JP; Samsel, L; Ward, NH; Clifton, GL; Dash, PK				Hergenroeder, Georgene W.; Moore, Anthony N.; McCoy, J. Philip, Jr.; Samsel, Leigh; Ward, Norman H., III; Clifton, Guy L.; Dash, Pramod K.			Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article							C-REACTIVE PROTEIN; CEREBROSPINAL-FLUID; INTERLEUKIN-6 LEVELS; TNF-ALPHA; CYTOKINE; DAMAGE; ASSOCIATION; INDUCTION; CHILDREN; RECEPTOR	Background: Increased intracranial pressure (ICP) is a serious, life-threatening, secondary event following traumatic brain injury (TBI). In many cases, ICP rises in a delayed fashion, reaching a maximal level 48-96 hours after the initial insult. While pressure catheters can be implanted to monitor ICP, there is no clinically proven method for determining a patient's risk for developing this pathology. Methods: In the present study, we employed antibody array and Luminex-based screening methods to interrogate the levels of inflammatory cytokines in the serum of healthy volunteers and in severe TBI patients (GCS <= 8) with or without incidence of elevated intracranial pressure (ICP). De-identified samples and ELISAs were used to confirm the sensitivity and specificity of IL-6 as a prognostic marker of elevated ICP in both isolated TBI patients, and polytrauma patients with TBI. Results: Consistent with previous reports, we observed sustained increases in IL-6 levels in TBI patients irrespective of their ICP status. However, the group of patients who subsequently experienced ICP >= 25 mm Hg had significantly higher IL-6 levels within the first 17 hours of injury as compared to the patients whose ICP remained <= 20 mm Hg. When blinded samples (n = 22) were assessed, a serum IL-6 cut-off of <5 pg/ml correctly identified 100% of all the healthy volunteers, a cut-off of >128 pg/ml correctly identified 85% of isolated TBI patients who subsequently developed elevated ICP, and values between these cut-off values correctly identified 75% of all patients whose ICP remained <= 20 mm Hg throughout the study period. In contrast, the marker had no prognostic value in predicting elevated ICP in polytrauma patients with TBI. When the levels of serum IL-6 were assessed in patients with orthopedic injury (n = 7) in the absence of TBI, a significant increase was found in these patients compared to healthy volunteers, albeit lower than that observed in TBI patients. Conclusions: Our results suggest that serum IL-6 can be used for the differential diagnosis of elevated ICP in isolated TBI.	[Moore, Anthony N.; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hergenroeder, Georgene W.; Ward, Norman H., III; Clifton, Guy L.] Univ Texas Houston, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; [Hergenroeder, Georgene W.] Univ Texas Houston, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; [McCoy, J. Philip, Jr.; Samsel, Leigh] NHLBI, NIH, Bethesda, MD 20892 USA	Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002; Hergenroeder, Georgene/0000-0002-6170-2191	Mission Connect/TIRR Foundation; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZICHL005905] Funding Source: NIH RePORTER	The authors thank Dr. Shibani Pati and Dr. Aarif Khakoo for their assistance in facilitating this project. We would like to thank the Memorial Hermann Hospital Neurotrauma ICU, and Trauma and EMS coders; and Elizabeth Jones, MD, Molly S. Bray, PhD, Brian McFarlin, PhD, Ian Turpin, and Madelene Ottosen, MSN RN for assistance with recruiting orthopedic patients and healthy volunteers for the study. This work was supported in part by a grant from Mission Connect/TIRR Foundation and by the Intramural Research Program of NHLBI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Basu A, 2002, J NEUROSCI, V22, P6071; BEAGLEY KW, 1992, GASTROENTEROL CLIN N, V21, P347; Bell MJ, 1997, ACT NEUR S, V70, P96; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Carlson NG, 1999, J IMMUNOL, V163, P3963; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; DASH PK, J NEUROSCI RES; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Fernandez-Real JM, 2001, J CLIN ENDOCR METAB, V86, P1154, DOI 10.1210/jc.86.3.1154; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; Hans VHJ, 1999, NEUROREPORT, V10, P409; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Jantzen JPAH, 2007, BEST PRACT RES-CLIN, V21, P517, DOI 10.1016/j.bpa.2007.09.001; John GR, 2005, GLIA, V49, P161, DOI 10.1002/glia.20109; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323; LOPPNOW H, 1989, LYMPHOKINE RES, V8, P293; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; MURPHY PG, 1995, J NEUROSCI, V15, P5130; Oto J, 2008, J ANESTH, V22, P207, DOI 10.1007/s00540-008-0639-x; PATEL RT, 1994, BRIT J SURG, V81, P1306, DOI 10.1002/bjs.1800810914; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Ringheim GE, 1995, J NEUROIMMUNOL, V63, P113, DOI 10.1016/0165-5728(95)00134-4; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stangl M, 2001, TRANSPL P, V33, P1284, DOI 10.1016/S0041-1345(00)02479-9; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; TEASDALE G, 1974, LANCET, V2, P81; The Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL AIS 20; Wetmore JB, 2008, NEPHROLOGY, V13, P593, DOI 10.1111/j.1440-1797.2008.01021.x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Yamagami H, 2004, STROKE, V35, P677, DOI 10.1161/01.STR.0000116876.96334.82; YOSHIZAKI K, 1990, Cytokine, V2, P381, DOI 10.1016/1043-4666(90)90069-6; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; ZHANG YH, 1988, J BIOL CHEM, V263, P6177; ZWEIG MH, 1993, CLIN CHEM, V39, P561	49	95	97	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 11	2010	7								19	10.1186/1742-2094-7-19			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	586BV	WOS:000276877000001	20222971	DOAJ Gold, Green Published			2021-06-18	
J	Mols, F; Denollet, J				Mols, Floortje; Denollet, Johan			Type D personality among noncardiovascular patient populations: a systematic review	GENERAL HOSPITAL PSYCHIATRY			English	Article						Type D; Personality; Social inhibition; Negative affectivity; Noncardiovascular population	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; D SCALE-16; DISTRESS; ASSOCIATION; DEPRESSION; MORTALITY; CONSTRUCT	Objective: This article reviews all available literature concerning the implications of Type D personality (the conjoint effects of negative affectivity and social inhibition) among patients with noncardiovascular conditions. Methods: Published papers were included if they studied Type D personality among noncardiovascular patient populations. Twelve articles met our inclusion criteria and were subjected to a methodological quality checklist (e.g., sample size, response rate, Type D measurement). Results: The methodological quality of the selected studies was quite good. The noncardiovascular patient populations included chronic pain, asthma, tinnitus, sleep apnea, primary care patients, vulvovaginal candidiasis, mild traumatic brain injury, vertigo, melanoma and diabetic foot syndrome. Type D personality was associated with an increased number or severity of reported health complaints, heightened the perception of negative emotions (e.g., depression and anxiety), had an adverse effect on health-related behaviors, was associated with poor adherence to treatment and significantly reduced effort to perform during diagnostic testing. Conclusion: Type D is a vulnerability factor that not only affects people with cardiovascular conditions but also those with other medical conditions. Type D was associated with poor physical and mental health status and poor self-management of the disease. Consequently, including Type D in future studies seems warranted. (C) 2010 Elsevier Inc. All rights reserved.	[Mols, Floortje; Denollet, Johan] Tilburg Univ, Dept Med Psychol, CoRPS Ctr Res Psychol Somat Dis, POB 90153, NL-5000 LE Tilburg, Netherlands	Mols, F (corresponding author), Tilburg Univ, Dept Med Psychol, CoRPS Ctr Res Psychol Somat Dis, POB 90153, NL-5000 LE Tilburg, Netherlands.	F.Mols@uvt.nl			Netherlands Organization for Scientific Research (The Hague, The Netherlands)Netherlands Organization for Scientific Research (NWO)Netherlands Government [453-04-004]	The present research was supported by a VICI grant (#453-04-004) from the Netherlands Organization for Scientific Research (The Hague, The Netherlands) awarded to Johan Denollet.	Aquarius AE, 2005, AM J CARDIOL, V96, P996, DOI 10.1016/j.amjcard.2005.05.059; Barnett MD, 2009, J CLIN PSYCHOL MED S, V16, P194, DOI 10.1007/s10880-009-9152-0; Barone S, 2008, J BEHAV MED, V31, P331, DOI 10.1007/s10865-008-9164-5; BARTELS H, 2009, PSYCHOSOMAT IN PRESS; Bartels H, 2010, OTOL NEUROTOL, V31, P11, DOI 10.1097/MAO.0b013e3181bc3dd1; Brostrom A, 2007, J SLEEP RES, V16, P439, DOI 10.1111/j.1365-2869.2007.00620.x; Chapman BP, 2007, EUR J PERSONALITY, V21, P911, DOI 10.1002/per.645; De Fruyt F, 2002, PSYCHOL HEALTH, V17, P671, DOI 10.1080/08870440290025858; De Valck CFJ, 2007, AUDIOLOGICAL MED, V5, P169; Den Oudsten BL, 2007, MOVEMENT DISORD, V22, P1528, DOI 10.1002/mds.21567; DENOLLET J, 1995, PSYCHOSOM MED, V57, P582, DOI 10.1097/00006842-199511000-00011; Denollet J, 1998, ANN BEHAV MED, V20, P209, DOI 10.1007/BF02884962; Denollet J, 2000, CIRCULATION, V102, P630, DOI 10.1161/01.CIR.102.6.630; Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49; Denollet J, 2009, PSYCHOL MED, V39, P749, DOI 10.1017/S0033291708004157; Denollet J, 1996, LANCET, V347, P417, DOI 10.1016/S0140-6736(96)90007-0; Denollet J, 1997, EUR J PERSONALITY, V11, P343, DOI 10.1002/(SICI)1099-0984(199712)11:5<343::AID-PER305>3.3.CO;2-G; Denollet J, 2008, ARCH INTERN MED, V168, P431, DOI 10.1001/archinternmed.2007.120; Denollet J, 2009, AM J CARDIOL, V103, P399, DOI 10.1016/j.amjcard.2008.09.096; Doering LV, 2004, J CARD FAIL, V10, P344, DOI 10.1016/j.cardfail.2003.10.001; Ehrstrom S, 2007, J PSYCHOSOM OBST GYN, V28, P169, DOI 10.1080/01674820601168176; KUPPER N, 2009, PSYCHOSOM M IN PRESS; MARTENS EJ, 2009, J CLIN PSYC IN PRESS; Martens EJ, 2007, J PSYCHOSOM RES, V63, P545, DOI 10.1016/j.jpsychores.2007.06.005; Molloy GJ, 2008, PSYCHOSOM MED, V70, P863, DOI 10.1097/PSY.0b013e3181842e0c; Mols F, 2005, EUR J CANCER, V41, P2613, DOI 10.1016/j.ejca.2005.05.017; Mols F, 2010, EUR J CANCER, V46, P573, DOI 10.1016/j.ejca.2009.09.016; Pedersen SS, 2004, J PSYCHOSOM RES, V57, P265, DOI 10.1016/S0022-3999(03)00614-7; Pedersen SS, 2004, J AM COLL CARDIOL, V44, P997, DOI 10.1016/j.jacc.2004.05.064; Pedersen SS, 2003, EUR J CARDIOV PREV R, V10, P241, DOI 10.1097/00149831-200308000-00005; Pedersen SS, 2008, PSYCHOSOM MED, V70, P349, DOI 10.1097/PSY.0b013e3181656540; Pedersen SS, 2006, CURR CARDIOL REV, V2, P205, DOI 10.2174/157340306778019441; Pelle AJ, 2010, INT J CARDIOL, V142, P65, DOI 10.1016/j.ijcard.2008.12.086; Schiffer AA, 2007, HEART, V93, P814, DOI 10.1136/hrt.2006.102822; Schiffer AA, 2008, EUR J HEART FAIL, V10, P922, DOI 10.1016/j.ejheart.2008.07.010; Simson U, 2008, PSYCHOTHER PSYCH MED, V58, P44, DOI 10.1055/s-2007-971001; Spindler H, 2009, INT J BEHAV MED, V16, P98, DOI 10.1007/s12529-009-9037-5; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Thomas G, 2006, FOLIA PHONIATR LOGO, V58, P250, DOI 10.1159/000093182; Whitehead DL, 2007, J PSYCHOSOM RES, V62, P419, DOI 10.1016/j.jpsychores.2006.11.005; Williams L, 2008, J PSYCHOSOM RES, V64, P63, DOI 10.1016/j.jpsychores.2007.06.008	42	95	98	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0163-8343	1873-7714		GEN HOSP PSYCHIAT	Gen. Hosp. Psych.	JAN-FEB	2010	32	1					66	72		10.1016/j.genhosppsych.2009.09.010			7	Psychiatry	Psychiatry	584OE	WOS:000276761200009	20114130				2021-06-18	
J	Dash, PK; Orsi, SA; Moore, AN				Dash, P. K.; Orsi, S. A.; Moore, A. N.			HISTONE DEACTYLASE INHIBITION COMBINED WITH BEHAVIORAL THERAPY ENHANCES LEARNING AND MEMORY FOLLOWING TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						traumatic brain injury; HDAC; Morris water maze; hippocampus; delay fear conditioning	CORTICAL IMPACT INJURY; ENVIRONMENTAL ENRICHMENT; SYNAPTIC PLASTICITY; GENE-EXPRESSION; HIPPOCAMPAL-NEURONS; COGNITIVE DEFICITS; H3 ACETYLATION; RATS; RECOVERY; METHYLATION	Traumatic brain injury (TBI) induces a number of pathological events ranging from neuronal degeneration and tissue loss to impaired neuronal plasticity and neurochemical dysregulation. In rodents, exposure of brain-injured animals to environmental enrichment has been shown to be an effective means of enhancing learning and memory post-injury. Recently, it has been discovered that environmental enrichment may enhance neuronal plasticity through epigenetic changes that involve enhanced histone acetylation, a property that can be mimicked by the use of histone deactylase (HDAC) inhibitors. We therefore evaluated the consequences of the HDAC inhibitor sodium butyrate on the learning and memory of brain-injured mice. In contrast to a previous report using a mouse neurodegeneration model, sodium butyrate (1.2 g/kg daily for four weeks) did not improve learning and memory when tested after the completion of the drug treatment paradigm. In addition, sodium butyrate administration during the reported period of neurodegeneration (days 0-5) also offered no benefit. However, when administered concurrently with training in the Morris water maze task (beginning on day 14 post-injury), sodium butyrate improved learning and memory in brain-injured mice. Interestingly, when these mice were subsequently tested in an associative fear conditioning task, an improvement was observed. Taken together, our findings indicate that HDAC inhibition may mimic some of the cognitive improvements seen following enriched environment exposure, and that the improvement is observed when the treatment is carried out current with behavioral testing. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Dash, P. K.; Orsi, S. A.; Moore, A. N.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS049160, NS053588, MH072933]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160, R01NS053588] Funding Source: NIH RePORTER	The authors would like to thank Jing Zhao, Hyung Jin Ahn, and Min Zhang for technical assistance in performing the cortical impact injury and behavioral studies. This work was supported, in part, by grants from the NIH (NS049160, NS053588, MH072933).	Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; DASH PK, 1995, J NEUROSCI, V15, P2030; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Levenson JM, 2006, J BIOL CHEM, V281, P15763, DOI 10.1074/jbc.M511767200; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Miller CA, 2008, NEUROBIOL LEARN MEM, V89, P599, DOI 10.1016/j.nlm.2007.07.016; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	28	95	97	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	SEP 29	2009	163	1					1	8		10.1016/j.neuroscience.2009.06.028			8	Neurosciences	Neurosciences & Neurology	489FD	WOS:000269404600001	19531374	Green Accepted			2021-06-18	
J	Aukema, EJ; Caan, MWA; Oudhuis, N; Majoie, CBLM; Vos, FM; Reneman, L; Last, BF; Grootenhuis, MA; Schouten-van Meeteren, AYN				Aukema, Eline J.; Caan, Matthan W. A.; Oudhuis, Nienke; Majoie, Charles B. L. M.; Vos, Frans M.; Reneman, Liesbeth; Last, Bob F.; Grootenhuis, Martha A.; Schouten-van Meeteren, Antoinette Y. N.			WHITE MATTER FRACTIONAL ANISOTROPY CORRELATES WITH SPEED OF PROCESSING AND MOTOR SPEED IN YOUNG CHILDHOOD CANCER SURVIVORS	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS			English	Article; Proceedings Paper	40th Congress Meeting of the International-Society-of-Paediatric-Oncology (SIOP)	OCT 02-06, 2008	Berlin, GERMANY	Int Soc Paediat Oncol		DTI; Children; Cancer; Neuropsychology; MTX	TRAUMATIC BRAIN-INJURY; ACUTE LYMPHOBLASTIC-LEUKEMIA; DIFFUSION-TENSOR; NEUROCOGNITIVE DEFICITS; COGNITIVE FUNCTIONS; CHILDREN; MEDULLOBLASTOMA; CHEMOTHERAPY; ADOLESCENCE; ASSOCIATION	Purpose: To determine whether childhood medulloblastoma and acute lymphoblastic leukemia (ALL) survivors have decreased white matter fractional anisotropy (WMFA) and whether WMFA is related to the speed of processing and motor speed. Methods and Materials: For this study, 17 patients (6 medulloblastoma, 5 ALL treated with high-dose methotrexate (MTX) (4 x 5 g/m(2)) and 6 with low-dose MTX (3 x 2 g/m(2))) and 17 age-matched controls participated. On a 3.0-T magnetic resonance imaging (MRI) scanner, diffusion tensor imaging (DTI) was performed, and WMFA values were calculated, including specific regions of interest (ROIs), and correlated with the speed of processing and motor speed. Results: Mean WMFA in the patient group, mean age 14 years (range 8.9 - 16.9), was decreased compared with the control group (p = 0.01), as well as WMFA in the right inferior fronto-occipital fasciliculus (IFO) (p = 0.03) and in the genu of the corpus callosum (gCC) (p = 0.01). Based on neurocognitive results, significant positive correlations were present between processing speed and WMFA in the splenium (sCC) (r = 0.53, p = 0.03) and the body of the corpus callosum (bCC) (r = 0.52, p = 0.03), whereas the right IFO WMFA was related to motor speed (r = 0.49, p < 0.05). Conclusions: White matter tracts, using a 3.0-T MRI scanner, show impairment in childhood cancer survivors, medulloblastoma survivors, and also those treated with high doses of MTX. In particular, white matter tracts in the sCC, bCC and right IFO are positively correlated with speed of processing and motor speed. (C) 2009 Elsevier Inc.	[Aukema, Eline J.; Oudhuis, Nienke; Last, Bob F.; Grootenhuis, Martha A.] Univ Amsterdam, Acad Med Ctr, Pediat Psychosocial Dept, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [Schouten-van Meeteren, Antoinette Y. N.] Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [Caan, Matthan W. A.; Majoie, Charles B. L. M.; Vos, Frans M.; Reneman, Liesbeth] Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; [Caan, Matthan W. A.; Vos, Frans M.] Delft Univ Technol, Delft, Netherlands; [Last, Bob F.] Free Univ Amsterdam, Dept Dev Psychol, Amsterdam, Netherlands	Aukema, EJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Pediat Psychosocial Dept, Emma Childrens Hosp, Meibergdreef 9,G8-224, NL-1105 AZ Amsterdam, Netherlands.	e.j.aukema@amc.uva.nl		Caan, Matthan W.A./0000-0002-5162-8880			Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Ben Bashat D, 2005, J MAGN RESON IMAGING, V21, P503, DOI 10.1002/jmri.20281; Buizer AI, 2005, PEDIATR BLOOD CANCER, V45, P281, DOI 10.1002/pbc.20397; Buizer AI, 2005, J INT NEUROPSYCH SOC, V11, P554, DOI 10.1017/S135561770505666; Butler RW, 2006, MENT RETARD DEV D R, V12, P184, DOI 10.1002/mrdd.20110; Butler RW, 2005, J PEDIATR PSYCHOL, V30, P65, DOI 10.1093/jpepsy/jsi017; Caan M, 2008, LECT NOTES COMPUT SC, V5241, P535, DOI 10.1007/978-3-540-85988-8_64; Campbell LK, 2007, PEDIATR BLOOD CANCER, V49, P65, DOI 10.1002/pbc.20860; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; GARDNER RA, 1979, J CLIN CHILD PSYCHOL, V8, P156, DOI 10.1080/15374417909532912; Giedd JN, 1999, PROG NEURO-PSYCHOPH, V23, P571; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iuvone L, 2002, CANCER-AM CANCER SOC, V95, P2562, DOI 10.1002/cncr.10999; Khong PL, 2006, J CLIN ONCOL, V24, P884, DOI 10.1200/JCO.2005.02.4505; Khong PL, 2005, RADIOLOGY, V236, P647, DOI 10.1148/radiol.2362041066; Khong PL, 2003, AM J NEURORADIOL, V24, P734; Kort W., 2005, HANDLEIDING VERANTWO; Mabbott DJ, 2006, NEUROIMAGE, V33, P936, DOI 10.1016/j.neuroimage.2006.07.024; Mangin J.F, 2001, LNCS, V2208, P186; Moleski M, 2000, ARCH CLIN NEUROPSYCH, V15, P603, DOI 10.1016/S0887-6177(99)00050-5; Moore BD, 2005, J PEDIATR PSYCHOL, V30, P51, DOI 10.1093/jpepsy/jsi016; Mulhern RK, 2001, J CLIN ONCOL, V19, P472, DOI 10.1200/JCO.2001.19.2.472; Mulrooney DA, 2008, CURR TREAT OPTION ON, V9, P51, DOI 10.1007/s11864-008-0054-4; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Nathan PC, 2007, ARCH PEDIAT ADOL MED, V161, P798, DOI 10.1001/archpedi.161.8.798; QUI D, 2007, J RAD ONCOL BIOL PHY, V69, P846; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Reddick WE, 2005, NEURO-ONCOLOGY, V7, P12, DOI 10.1215/S1152851704000079; Reddick WE, 2003, CANCER-AM CANCER SOC, V97, P2512, DOI 10.1002/cncr.11355; Ronning C, 2005, PEDIATR NEUROSURG, V41, P15, DOI 10.1159/000084860; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Villarreal G, 2004, PSYCHIAT RES-NEUROIM, V131, P227, DOI 10.1016/j.pscychresns.2004.05.002; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	35	95	97	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0360-3016	1879-355X		INT J RADIAT ONCOL	Int. J. Radiat. Oncol. Biol. Phys.	JUL 1	2009	74	3					837	843		10.1016/j.ijrobp.2008.08.060			7	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Oncology; Radiology, Nuclear Medicine & Medical Imaging	455JJ	WOS:000266754800027	19117694				2021-06-18	
J	Simpson, DM; Gracies, JM; Yablon, SA; Barbano, R; Brashear, A; Simpson, DM; Gracies, JM; Yablon, SA; Barbano, R; Brashear, A				Simpson, D. M.; Gracies, J. M.; Yablon, S. A.; Barbano, R.; Brashear, A.; Simpson, D. M.; Gracies, J. M.; Yablon, S. A.; Barbano, R.; Brashear, A.		BoNT TZD Study Team; BoNT TZD Study Team	Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TOXIN TYPE-A; DOUBLE-BLIND; INTRAMUSCULAR INJECTION; EFFICACY; SAFETY; DYSPORT(R)	Background: While spasticity is commonly treated with oral agents or botulinum neurotoxin (BoNT) injection, these treatments have not been systematically compared. Methods: This study performed a randomised, double-blind, placebo-controlled trial to compare injection of BoNT-Type A into spastic upper limb muscles versus oral tizanidine (TZD), or placebo, in 60 subjects with upper-limb spasticity due to stroke or traumatic brain injury (TBI). Wrist flexors were systematically injected, while other upper limb muscles were injected as per investigator judgement. Participants were randomised into three groups: (1) intramuscular BoNT plus oral placebo; (2) oral TZD plus intramuscular placebo; (3) intramuscular placebo plus oral placebo. The primary outcome was the difference in change in wrist flexor modified Ashworth score (MAS) between groups. Other outcome measures included MAS at elbow and finger joints, Disability Assessment Scale (DAS) and adverse events (AE). Results: BoNT produced greater tone reduction than TZD or placebo in finger and wrist flexors at week 3 (p<0.001 vs TZD; p<0.02 vs placebo) and 6 (p=0.001 vs TZD; p=0.08 vs placebo), and greater improvement in the cosmesis domain of the DAS at week 6 (p<0.01). TZD was not superior to placebo in tone reduction at either time point (p>0.09). The incidence of AE related to study treatment was higher with TZD than in the BoNT (p<0.01) or placebo groups (p=0.001). Conclusions: BoNT is safer and more effective than TZD in reducing tone and disfigurement in upper-extremity spasticity, and may be considered as first-line therapy for this disorder.	[Simpson, D. M.] Mt Sinai Med Ctr, Clin Neurophysiol Labs, Box 1052, New York, NY 10029 USA; [Gracies, J. M.] CHU Henri Mondor, F-94010 Creteil, France; [Yablon, S. A.] Univ Mississippi, Sch Med, Jackson, MS 39216 USA; [Barbano, R.] Univ Rochester, New York, NY USA; [Brashear, A.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Simpson, D. M.; Gracies, J. M.] Metropolitan Hosp Ctr, New York, NY 10029 USA; [Simpson, D. M.; Gracies, J. M.] Mt Sinai Sch Med, New York, NY USA; [Gracies, J. M.] CHU Henri Mondor, F-94010 Creteil, France; [Yablon, S. A.] Univ Mississippi, Sch Med, Jackson, MS 39216 USA; [Barbano, R.] Univ Rochester, New York, NY USA; [Brashear, A.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA	Simpson, DM (corresponding author), Mt Sinai Med Ctr, Clin Neurophysiol Labs, Box 1052, New York, NY 10029 USA.	david.simpson@mssm.edu; david.simpson@mssm.edu	Brashear, Allison/G-3853-2015		Allergan, Inc.AbbVieAllergan	DMS of Mount Sinai School of Medicine is the sponsor of the study. The study was funded by an unrestricted grant by Allergan, Inc. Allergan had no influence on the design, interpretation or reporting of the study.	Adler CH, 2000, NEUROLOGY, V55, pS9; Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Brans JWM, 1996, NEUROLOGY, V46, P1066, DOI 10.1212/WNL.46.4.1066; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; CHILDERS M, 2002, BOTULINUM TOXIN TYPE, P77; Chin TYP, 2005, J PEDIATR ORTHOPED, V25, P286, DOI 10.1097/01.bpo.0000150819.72608.86; Gelber DA, 2001, STROKE, V32, P1841, DOI 10.1161/01.STR.32.8.1841; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; GRACIES JM, ARCH PHYS M IN PRESS; Gracies JM, 2002, HDB BOTULINUM TOXIN, P221; GRACIES JM, 1997, MUSCLE NERVE       S, V6, P61; Hyman N, 2000, J NEUROL NEUROSUR PS, V68, P707, DOI 10.1136/jnnp.68.6.707; MATHIAS C J, 1989, Journal of Rehabilitation Research and Development, V26, P9; Montane E, 2004, NEUROLOGY, V63, P1357; NANCE PW, 1994, NEUROLOGY, V44, P44; Pittock SJ, 2003, CEREBROVASC DIS, V15, P289, DOI 10.1159/000069495; Richardson D, 2000, J NEUROL NEUROSUR PS, V69, P499, DOI 10.1136/jnnp.69.4.499; Sheean G, 2006, DRUG SAFETY, V29, P31, DOI 10.2165/00002018-200629010-00003; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Smith SJ, 2000, CLIN REHABIL, V14, P5, DOI 10.1191/026921500666642221; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; VANDENBERGH A, 2007, ARCH PHYS MED REHAB, V88, pE104	23	95	101	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2009	80	4					380	385		10.1136/jnnp.2008.159657			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	419SB	WOS:000264238800008	18977811	Bronze			2021-06-18	
